<SEC-DOCUMENT>0000886163-20-000025.txt : 20200227
<SEC-HEADER>0000886163-20-000025.hdr.sgml : 20200227
<ACCEPTANCE-DATETIME>20200227171825
ACCESSION NUMBER:		0000886163-20-000025
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200227
DATE AS OF CHANGE:		20200227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		20663801

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgnd-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea,d:9c8bcdb9c365455fab9e0c3ce3684173--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:lgnd="http://www.ligand.com/20191231"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF80LTEtMS0xLTA_80f7abce-4229-4266-8477-0012788a5ca7">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF81LTEtMS0xLTA_27660fbe-2d05-47b5-b738-3a84b196e735">2019</ix:nonNumeric><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF82LTEtMS0xLTA_928ab552-700f-4271-9d69-2bf45cdf315b">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGV4dHJlZ2lvbjo4ZDQ1MTMwNDE3Mjk0NTBlYWRlOGM5YTg2NmRiN2FlYl82Mg_205d6a5d-3baf-435e-87f4-d731ac93a7a3">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGV4dHJlZ2lvbjo4ZDQ1MTMwNDE3Mjk0NTBlYWRlOGM5YTg2NmRiN2FlYl82Mw_ecfa12b1-07b8-42a9-a5eb-ca2d0d60736e">--12-31</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RhYmxlOjg3OWE5NTMxNGJhYzQzZDg5OGFmYTUzZDAxNThjNDAzL3RhYmxlcmFuZ2U6ODc5YTk1MzE0YmFjNDNkODk4YWZhNTNkMDE1OGM0MDNfMS0xLTEtMS0w_70a6c102-ebf9-49bc-a760-f68b6a814ad8">12.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RhYmxlOjg3OWE5NTMxNGJhYzQzZDg5OGFmYTUzZDAxNThjNDAzL3RhYmxlcmFuZ2U6ODc5YTk1MzE0YmFjNDNkODk4YWZhNTNkMDE1OGM0MDNfMi0xLTEtMS0w_2f93776e-d45b-4136-8a42-a1eabc2ea123">2.08</ix:nonFraction><ix:nonNumeric contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2Mg_d4d29f6d-132f-4dc2-b098-95f72fab738d">three years</ix:nonNumeric><ix:nonNumeric contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE1OQ_d031b37f-7abd-4e75-9dbc-e2609faa8890">ten years</ix:nonNumeric><ix:nonNumeric contextRef="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2Mw_9a207cf4-1833-4ab3-be76-ab0fc99f1b93">six months</ix:nonNumeric><ix:nonNumeric contextRef="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2NA_8520ed79-2606-452f-a2a5-cecf6fcdf469">forty-two months</ix:nonNumeric><ix:nonNumeric contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" name="lgnd:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODE_ffef5594-a0f1-449a-ba9a-61a27ea72532">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="ice1e4b995b8f493ca3f05d0880c4ed18_I20191231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODc_303e6841-ce99-40a8-b295-685264827d3d">P7Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDYvZnJhZzplOGUzZjQ4MWRjMjY0NjQyOWZlNDcyOGIxMzFkZGNkZS90YWJsZTo4OTI1ZjQwODE3MWY0ZTdjOGNlNTJkYzY5YWEyMjEzNy90YWJsZXJhbmdlOjg5MjVmNDA4MTcxZjRlN2M4Y2U1MmRjNjlhYTIyMTM3XzItMS0xLTEtMA_5d8e2a5b-c485-4948-b8ea-a6a62c1f058e">0.0133251</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i777f42855f6b42b5815a6e77f13da34f_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDYvZnJhZzplOGUzZjQ4MWRjMjY0NjQyOWZlNDcyOGIxMzFkZGNkZS90YWJsZTo4OTI1ZjQwODE3MWY0ZTdjOGNlNTJkYzY5YWEyMjEzNy90YWJsZXJhbmdlOjg5MjVmNDA4MTcxZjRlN2M4Y2U1MmRjNjlhYTIyMTM3XzItMi0xLTEtMA_27bc89bd-ac27-4de5-8000-b947ff154de5">0.0040244</ix:nonFraction><ix:nonNumeric contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTIvZnJhZzo4YzU4ODIyOTcwMDg0NDliYjM5MTE1ZWY0MjJmMGVhOS90ZXh0cmVnaW9uOjhjNTg4MjI5NzAwODQ0OWJiMzkxMTVlZjQyMmYwZWE5XzE2NA_644d97ae-6fb7-4538-8240-8aea62cbe311">three years</ix:nonNumeric><ix:nonNumeric contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTIvZnJhZzo4YzU4ODIyOTcwMDg0NDliYjM5MTE1ZWY0MjJmMGVhOS90ZXh0cmVnaW9uOjhjNTg4MjI5NzAwODQ0OWJiMzkxMTVlZjQyMmYwZWE5XzE2NQ_4e027a84-6ba7-4386-9829-ab30502f40c3">ten years</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMS0xLTEtMA_97c79f67-2c96-48f5-9338-a9519f29e4f2">1.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMi0xLTEtMA_dda99e59-baaa-467c-bfc7-dd31d72e85dd">2.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMy0xLTEtMA_0fe598a4-0685-462d-98ea-8b581dde66db">2.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMS0xLTEtMA_79ea4123-c66a-49ec-8477-7471e848465e">2.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMi0xLTEtMA_23cbd5ab-407a-49f4-8a23-119aadd7f53f">3.0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMy0xLTEtMA_f0a3c5ef-302b-4310-97bf-dcdbc32f2600">2.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMS0xLTEtMA_e557bb29-b244-45c9-808b-b7bfb3013224">40</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMi0xLTEtMA_4c8f23ab-a4e4-4730-8035-6430bc20ca9c">33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMy0xLTEtMA_2e94d433-9b01-4390-ba82-b61d051a93e7">43</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMS0xLTEtMA_d4486ce7-eb12-4166-8c8d-54bf975c8284">49</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMi0xLTEtMA_f2f97fac-e32b-45f1-972a-efd83d8f0c18">36</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMy0xLTEtMA_44f66bf9-e1de-4890-897c-04349e6762d2">47</ix:nonFraction><ix:nonNumeric contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMS0xLTEtMA_86adeddc-2fa6-4ccc-bc4c-fda6ef4b6b85">4.6</ix:nonNumeric><ix:nonNumeric contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMi0xLTEtMA_bf3f8564-54d1-4d19-bdd7-0781cf0092c7">5.1</ix:nonNumeric><ix:nonNumeric contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMy0xLTEtMA_b8923c77-13a3-4559-8d4a-0a979a5f4186">6.5</ix:nonNumeric><ix:nonNumeric contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMS0xLTEtMA_0ff933bf-3b43-4e6d-9db7-e351c92def90">5.9</ix:nonNumeric><ix:nonNumeric contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMi0xLTEtMA_4c1c7006-f4cd-4dae-86a9-42102f515d82">5.8</ix:nonNumeric><ix:nonNumeric contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMy0xLTEtMA_f9b1acc6-ea70-4d58-a72b-e87da2d9989f">6.8</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEtMi0xLTEtMA_a69d3950-4678-49a5-afc7-7d6ffcfc138a">9.96</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEtNC0xLTEtMA_1ba2a1d4-a704-4c9b-b0a1-d7520338360d">12.81</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzItMi0xLTEtMA_70da67f6-a8b2-45a8-b765-c9482475e765">14.47</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzItNC0xLTEtMA_17dff686-47c7-4ca0-bb41-963e0e6b4d41">14.47</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzMtMi0xLTEtMA_9314ada2-f9d7-48d8-91b3-a18d2de38c39">21.92</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzMtNC0xLTEtMA_60f31d11-50c0-420d-ac3a-dbdcc2291ae3">21.92</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzQtMi0xLTEtMA_35d9b861-7e8b-4586-b032-b03f737db72d">32</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzQtNC0xLTEtMA_f9333f4f-1ef1-46dd-8567-b9069fe22fad">74.42</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzUtMi0xLTEtMA_76fbb955-f8dd-426b-968a-39a94e3fa436">85.79</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzUtNC0xLTEtMA_e76a4347-5fc2-4003-b35c-c1101e3510a8">100.38</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzYtMi0xLTEtMA_e2b9f087-c40f-4d33-b770-d21bb80fae31">101.15</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzYtNC0xLTEtMA_a6538900-b19d-4dad-9c35-7b3ca41d198f">113.76</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzctMi0xLTEtMA_034e3464-c00b-4600-9986-7a3a9adf2f21">117.97</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzctNC0xLTEtMA_455b5bb9-43e2-447a-886f-e4eac0665eab">117.97</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzgtMi0xLTEtMA_26f000ed-29a7-4a47-b7ee-dfb41fa15c5a">119.30</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzgtNC0xLTEtMA_cb52f911-3126-4e4d-8d20-9f308d413448">159.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzktMi0xLTEtMA_0cccab06-1761-4efd-a130-cfc123d79009">159.81</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzktNC0xLTEtMA_aa2bb725-b775-417d-8d55-be78f1c1aaf6">171.28</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEwLTItMS0xLTA_b66d27aa-6cbc-4596-a416-a3f31142e382">195.91</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEwLTQtMS0xLTA_ceb54b8a-3538-4551-b83c-0fcad7f27df6">195.91</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzExLTItMS0xLTA_7e33c279-2f1b-471e-8cb9-07e0978f667d">9.96</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzExLTQtMS0xLTA_ba40b462-5777-4e85-8499-c4d741b52ef2">195.91</ix:nonFraction><ix:nonNumeric contextRef="i70b9c37a13cc461ab7f396a30c812ca3_D20150901-20150930" format="ixt-sec:durwordsen" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90ZXh0cmVnaW9uOmNiMzlmZDU1NTY5NzQ1MjdhZGFmMmYzMjA0YTQyMTgwXzI4Mw_dd5ee4fc-162e-4f0d-a9ec-912163fc61d9">three years</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lgnd-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3db79f26c0544fc6a26a782c03095534_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i52984fc7f6524de3bd553513b238634b_I20200221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1845b3a0c00f4faf86884050f553c2a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675b454e2a4246a5976716630c08343b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i869489dbc2cb4d108beb10a315c6229a_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cf4dc97e05a4c57ab75939e7f4190ad_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5489d8e2a3154e579e1950596bad4e83_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5608c1b3e145d7b634848e84a0417e_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70090b4fce044e77b235ddf8a74bbb7e_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c39c6b8d84c41cca43833810fbc7ae2_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae4fa193bce41988665297c8c87cd90_I20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb933ddf4a24744b8334b58adba6068_I20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942f3b02c5b94bd68a645167798076c7_I20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52155cd9acaf404eadf5b7e3d980852d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba785669817e4bca8806263b74bbb109_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1374cff04f4a8a9e7ff2371b8b8aed_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04273cf057274bd7ba4eb19b16af0d81_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac644851be347358be4803ad12d0c11_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a9bcb91841d44d6ba7d80ded777ad08_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5aa84c1f894416941ae3fb3370a0e7_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01597458c3654e7d814509dc1fe6a346_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecf11d232574f23813a8e1cac3990ee_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352af84d1ae44bb8a22c67271354ceae_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef94475465245018ed0c204e8bd7fda_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic339114ab562486b8927a1f3fd53be85_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd33958a305462b9dded4123ec458ad_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9508f9f000dd4ad0b0d754524aee17b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b3cbeb39e14feb8ab2224143dffb5a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ef1d23069649bc84d61c935c800a92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2870d56eba64b3dbd7901fdf1a45b5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4b9c573b6e48dcb989d7ab948495c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i53e345f65cef494a89a25239fa967bbb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0def0efae44a5ea9424174e127e04f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8277e193464fc0bfc5035fabc271f6_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8112712360b5447cbcf4086b3a12a30f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97f46503b54b4c4581f7af547a5f1819_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e85343882a43ef806ab5bd3ca04f8b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3790f97128f2494d8984195c0fc58a83_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lgnd:right</xbrli:measure></xbrli:unit><xbrli:context id="i4d5cb59bf92840e6a385702bbe7c55ba_I20100131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f6da162c3e4716b198d45ef10746a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fc29cee5074164b3c15d239382aa22_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac076f1e57a4636b9b7a8d17ac9c624_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i503b6946954c46afa717c2fcf22da428_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1677d2b07ff14a8dbc63ada1e73e55b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ee583771d143e48147fc04de5f46c1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96448a01fb3f40a096e5d761e2c099b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:DianomiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2287a9c538514d76aadb3ec1766fe149_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:DianomiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id883dd6370374636a72ea85102571215_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8345e8c12e54d5aaee35fd1453902c0_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c27966fa7a47b48404cf82d0835b4b_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe93206950f4a5ca90a7c38545f68fa_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b9fd1011fc45cb824aa53afa55ee70_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25cc6cea36649299a866a8aefa35559_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7529b75a8a4febb9932e1ac827bae4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c56e43b6e44052bafac504dcd95284_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df91a43747141109e40628d6c3e1602_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0bcf32476240a69acc2df358c66283_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia434c2f1e4fd4242bc042dcec9b0f76c_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcbe0bbeae724e1d93328ffcae8742d7_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9680e99f8b49b19bbd0708cf2b886f_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa465d6d40c45fba9d4e1bdc39e4cd8_D20170531-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b84867fefc461a891bb0fd73e18725_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id365704cf3b84c6ab7c5a47ec6bdff70_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014e836b51b047e8b7d0a0a06fb58ea5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82f8b0071ba419db2fd44d139c75921_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752660ce777040a3bf4a197f34a8a7ae_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b6c33518324d248216b8fc59601e1e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd9ffdb575642bc99960b6a0f220f7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf94a70bfff4f93bc6e7bb11e783a03_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e64ad3b9590426a946af951ece864ce_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdbe7a966e324982b84d652d014786ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff65fe494c14a35b1dd9f4bd1dc538c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9612324a089e4c32998e3a6d952592f8_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146808219fd64e048cff80065bea6f1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i960ac618c48c4ce3b0502dead45bbb2a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if187e8fde5214e529fe79103581b53a1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194607164d454958b0723749de9579e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff0c9eca02e4a2f9b35491141d683f0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffdb648378694003ae22ea717992f96b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554d97702ee847d8a57c46340addad5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a2217af97e477b903d2d5d4edab90b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd04a9173f544a62859a7935f7ae3658_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d72465b58ad4e67b216c687373c6ff8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9941b5f3154326bcadc3bdd7cdd3b7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee06435e8cf54fa7aa9127b85e72920f_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f1b30e9315498090c3a5d490662303_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0993a0ffdc9416e8eae6352f6f762b9_D20070101-20071231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e2fe191ffb414da27578a719a56920_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b883a1064da430e9dc11a5b03492ca1_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36623c1d9734d28ae32c58d9b90c026_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7411d3bb032347e6a6b92e42a6d29132_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879ae176b2124f789573e2512496d9a0_D20190101-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id432212c910f45cb9fd439930be6a10c_D20190101-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d16a6431d94f848413960849cb7def_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627d466bba7d41ddbcecee653a9fcb3e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia866a9721849422ea2aa6ef8a644c3b6_I20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6365b125a6f9462a9020457fd59be296_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if127a97e90a74b089bee82f5b9537b9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="acquisition"><xbrli:measure>lgnd:acquisition</xbrli:measure></xbrli:unit><xbrli:context id="i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee653649d66402981113f680d933493_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a285f7cae6847cbb84e55f9cc40ae24_D20190723-20190723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-23</xbrli:startDate><xbrli:endDate>2019-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i063eb253ae3b4c25a99074736166eeb7_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffee5590e9a4dc7b62742af7e16dc82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814ece52582942738ba79ba1e26c7405_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-06</xbrli:startDate><xbrli:endDate>2017-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-06</xbrli:startDate><xbrli:endDate>2017-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-06</xbrli:startDate><xbrli:endDate>2017-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofcollaborationagreements"><xbrli:measure>lgnd:numberOfCollaborationAgreements</xbrli:measure></xbrli:unit><xbrli:context id="i1697e6f29f434232b75e818f4ca2eca0_I20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf89aa90cf34ae8b88f29189cdd661b_D20171006-20171006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-06</xbrli:startDate><xbrli:endDate>2017-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b00d8919174418ebe287cc12594d727_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66e23507a484f19a663af8fe0d1ac56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b560e54f4ba43f09c2f8005e045a4b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia520b2b8a01f4302905c89f3b3631aba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13f24dbd7b94cdd98bce8907218b098_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c1b7515d834b96ba399542082661b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65edf5940434c65862432001f7fca40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2641b53d2baa4c3fa22b49a8cd48329e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a384419cf554229afda13595299df80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie86a62fed86e4561b271030c70bfbe6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1065d4ab29524f959cf02e2235084e47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0795ba3ab21f49fcbe79b88fea60278d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f894f3d17b245c480e3f32580adbf3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92a6ee4b08740648c5cc02eb96d8312_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7cf3fc5e9b14c01b5883261d2ebf84e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88fbc1c8f9440599dc1210a3215a18f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee3f1bbedd04ef0a2d097ae36f3fcfb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333307bd30ca43dabd171c81f9a061c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e55472ecafa4bd8b817bfd8cea90435_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a96b9c75a6a4db4a42908340754361e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd10b3dca034733bcf105cef8c3fe1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i053fc7c14c3a4fcca4e9518b3b0aa792_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie765c2c1580b4b668660efe86db75615_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a73bc52ddbc49a0ae7ab3c3890665fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30791cf6bd640898b2c76820ef15a1f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14e95be5980439b89d0be5d5cf9c38f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3d2af9fb0b4d51a38451c771ddbcbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2210269696b54388859b9c440a7e5ffa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie876dd3bfe4948ecb026d413a211825c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a4220bf4b8433f97d84d75a7a15ec3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6148de9bc6314d7db99b0174ac32270f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4219c1edadf45ef9ebabf21e48f42bc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62d7c10b74b402c87f6a4746c4edc9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687289d5249341bea56d56f06881a316_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12332e287c1448f0ae90bd926ae81019_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88287563b1f84464879d94daa8496cb9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9166e07465648fc897dff070b433978_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240c26f07d684902a2a5a2aa13ff4522_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1db864c137e4884a0d080828544685a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50c2885177f46b9a3b8e52be036553c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62050c02be84bc68a5fe4449b65fc5c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ec9979e10e4655be2956189114b459_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440e6011a4b240eea401a947eb82807d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50232e03fcd40198b29f681ccae378c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270207e77dc041c3a631393297a9d666_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376e8b7a95ec4903a952f0e1a98b9ca6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c435e953ccb4fea8d4665b2ee78d8aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ff8fdbb91347e4bd610fe51e004636_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d8f620ea2f4486b9f6948e67e4eb7d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35fc6c1c2c364e28b41de2556a16e837_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4405cd949e5464d859260401ea0db00_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc8f1e296044e74bbcefba8f0616310_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib784ac7bf6464a7d884b4167b4e99ee0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac90e5d89444162acf3bc0b9b6480fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f4d39a9f964e3f99fac70fd3f35100_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce4b41fbdca463599bc3cef217fef45_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79709122c16343dcbc74ae3a46e989b4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088931a8204941488973e380b4de1025_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3229ad3f5f439fa27e10965c78eea1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727f5a67038e4448b546d9073616f76a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77529a8905b14bc3bc8add865edf0f75_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d2f834fa2244ceac78756b0afb44a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c826c5ec76f4cfabdff851267a7e696_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d6816bd05c485785171f05859f970c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0feee4e225cd43f6b19d270f81f68e54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1e4b995b8f493ca3f05d0880c4ed18_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>lgnd:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>lgnd:day</xbrli:measure></xbrli:unit><xbrli:context id="i9174105094b344fdaf382f6d88a00492_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69c2295fad14d86b0c1d0d33d08fd9d_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41c98ddc8ed6424e97637ef827414c85_D20181231-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bcea58a1cc45ad91cd2cfd6e88fb72_D20181001-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d47e48e8714a4a85ce5692e87edc2a_D20190815-20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-15</xbrli:startDate><xbrli:endDate>2019-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i183d237079bf442793fe6653077b02d1_I20190815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018f28bd405f4e8e80369ec4e6ebaf93_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad13e0c01d0342d4a22d93e03d73bdec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15033c4ceb44752bec11bcc6b5a4535_D20140801-20140831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44b7731c223433ebd2d48a7da02b9fd_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677af219811f4afea5707d272137352f_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4087e5834f3f43f7b9dcd9f3bc7ad89f_D20180522-20180619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d01d0ac3874584a772c93ae9343d59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad33a1fd7a4d4bb4b58891b708e03689_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic695d6dc03fe4a25b48518725b03cc3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0a208cee4646039870279eaed26fbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id951cc41dcda47b79a7837e8a9cac151_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777f42855f6b42b5815a6e77f13da34f_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9cf631831404b3ab0a176b30ff1cf61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4adf86c26c74eebbff052e6408a24bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0997e7cf40f4560bfc2d3b81a693374_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159e354578674c4980944fd7e84d264b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0f02512c784ca8a96f7587ae1fa695_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512fa91ade644f0f8d1e64336cafc646_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0f673df80c43e6ae301f9b370879d9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i187f37e52b0046fbbddd2f4c14993bbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19269a85c84b42aab38f5fac2f97aa03_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19b9a02facb489a95e3193c4f7ac238_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e8496488c64c268cd3de6924f039d0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e41a03cf4b245ecae999cdd0f89c769_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6737d944593c47919db533223783d735_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8397721ad934a4fb6b8e4182e177246_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da08223a8214656b754f9367925b52a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5e8e38535841d0a6ebe69742fcb55b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cff8def88d547cca5ed63725081c9f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92c2bb9b787480489b39a01bb366f35_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if268533fff3b4793a31072861a742a93_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44726d215cc14202aa7482a959d9f789_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29175925b83b4f7db955ba48c6e95710_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4900b9ff94548d4902c449b76d44e10_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia139119e13424a1bbb83b3bd29c3eb9f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e84a7b813d74048b025e392263824ce_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60511aae828945a397611be17e7b185e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib238a21ed8404ddeba140fd318f30bb2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82abd5a9777940b08fc61c5d462259e1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1979f3d940c419ea3a725a37ea9e014_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ebdb404a3245379c9d5860ed4ac8ba_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i391b93678af74f27899b8002cc987285_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a6da7b97a744bc9c0497857d795d5f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84123edc447641828fe3e7279992698e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia262ce3b54954a979aceac7f234989a3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c58245200747a5b667564d502af59e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164955ed1d7f4491869eb2cbafa3cc29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e964f748c5942548018f2246cc35730_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c406d933204c55979cce5e2f3e220b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f9c362671564a50b0f69033777e2901_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf7c83e118d4acf95a3663f3661d169_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14280bd3deb24f1abb91beb0987cdc1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863a470ced3a418db7a073687288d252_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b1c1acedea452c8463bc86fcb2b913_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d741a769aee4da4af5556260a102804_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53406fa840174f8093916463e6389023_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af0404808a345a382abe78ab35beb37_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da0cebd72844cccbc3578ab39bffc76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12002ca5921748508b192203c7a9d235_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903cd103982640959896b8b7ba2c6e13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd44dfbec8d944479851c647f8b7ccdc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice16507fcb4e413ea981ad6098db588e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2831464859c14cdc9755d96fcee5dab1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4872587a0b7b4d018481b6594f32290f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c0ce63eae94a5eb3fcba29f768110d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6341c256477e4429836844da17a32b5e_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf64fbf8a55e465ba26faa70a391914c_I20190123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea985b507f54962867ac2d46fb5c542_I20190911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b9c37a13cc461ab7f396a30c812ca3_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b493974b1c542688ad91b9e471e0124_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb372575aafc4ed3b9445394ffcccb29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1894d5ffb9e46e1bd0855a3f66e9ffa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4fae611a5c4181ac378c7ecc937744_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0bb7031f9647efa3364ba02afec1e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54d651574f64756a24c8e91f44996a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666408c546004c06983d164938ebb335_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f487b559ca433687df3df3c64d6816_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_1"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">_____________________________________________________________________________________________</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN180MDI5_c764b2ad-e141-406b-b7bb-530e3678bc91">10-K</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:1.817%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.183%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6Njc3NGM1ZTYwMjdlNDU4MTlkZmM1NDQwNzQ0ZTliMGYvdGFibGVyYW5nZTo2Nzc0YzVlNjAyN2U0NTgxOWRmYzU0NDA3NDRlOWIwZl8wLTAtMS0xLTEzOTI_2f4d10f2-e374-4317-a7fe-0d6bd22b8495">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">For the Fiscal Year Ended <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTkx_39c3d824-15f0-4a4b-98d9-011a1bdfd3cc">December 31, 2019</ix:nonNumeric></span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.052%;"><tr><td style="width:1.0%;"></td><td style="width:1.957%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.043%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6YWIzNjFhMDQ3MzE4NDgyYWJlYThmNmJkNTcwZGIxNmEvdGFibGVyYW5nZTphYjM2MWEwNDczMTg0ODJhYmVhOGY2YmQ1NzBkYjE2YV8wLTAtMS0xLTEzOTQ_b00f124e-c1c2-4c8d-a87b-3a81dbd5840c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;margin-top:2pt;"><span><br/></span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Commission File No.&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDc1_63b4de35-33e7-4797-b5ef-4dc43c547dfe">001-33093</ix:nonNumeric></span></div><div style="text-align:center;margin-top:2pt;"><img src="lgnd-20191231_g1.jpg" alt="lgnd-20191231_g1.jpg" style="height:100px;width:250px;"/></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNjA5_e96d2723-cd6b-480b-9bfe-a958218d7474">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.555%;"><tr><td style="width:1.0%;"></td><td style="width:64.969%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.707%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.124%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18wLTAtMS0xLTEzMDU_94f05c65-4def-4acb-9a0e-47a008625cee">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18wLTItMS0xLTEzMDc_7ac4db62-c1b8-4f76-bdfb-de2aa4e84ce5">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(IRS Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18zLTAtMS0xLTEzMTE_5ce208c9-2d6b-4650-9359-118ed268900d">3911 Sorrento Valley Boulevard, Suite 110</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM180LTAtMS0xLTE1MzE_7ddd9392-5a18-4e3c-be66-a2357fed538d">San Diego</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM181LTAtMS0xLTE1MzM_2a4e401a-6dd1-4824-9e58-3042a99320ed">CA</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM181LTItMS0xLTE1MzU_32a4b4ef-f39b-4c92-989d-fcce922ec729">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDcz_a413bd51-1a1d-4cc4-b09e-763091392b3f">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDc0_a7ad22c8-a45e-479b-a97a-845ec5dae946">550-7500</ix:nonNumeric></span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center;margin-top:2pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467%;"><tr><td style="width:1.0%;"></td><td style="width:35.519%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.402%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of Each Class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTAtMS0xLTEzNzY_83119400-2933-40ac-be17-f44eb95e4b77">Common Stock, par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTEtMS0xLTE1NDA_bd9fb10c-ba3d-4876-8f39-533a3d3a9f9f">LGND</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTEtMS0xLTEzNzg_fbc153d4-c07a-477f-8b22-324248c7d52a">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">None</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY3_5e4b2d14-d18a-4b5c-9109-15c8738149b6">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY2_760a4dbf-a09a-4a82-97de-9a8356d7a734">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">ndicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY4_867edb9e-a719-4783-b308-ed809b96a193">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY5_aa6b7d2a-84fd-4f26-8ab0-d7cbbab3a5cb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div><div style="margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.953%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.298%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.953%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.080%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.953%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.513%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.957%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTAtMS0xLTEzNzA_1f799722-0f93-4cfb-9828-b9379becb7be">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Accelerated&#160;Filer </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Non-accelerated&#160;Filer&#160;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTUtMS0xLTEzNzQ_dfbf836e-904c-4532-843a-3b43d277f402">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTEwLTEtMS0xNTQy_2ff3f3b5-1dfe-4674-94df-e95b19220d55">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;</span></div></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div><div style="text-indent:18pt;margin-top:2pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTU1_ce9b42dc-6955-4c78-8a7e-d217ccd2a8a5">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div><div style="text-indent:18pt;margin-top:2pt;"><span><br/></span></div><div style="text-indent:18pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The aggregate market value of the Registrant&#8217;s voting and non-voting stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="i3db79f26c0544fc6a26a782c03095534_I20190628" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yODkw_a127d378-b307-475d-8eea-1c330af2ff81">1.8</ix:nonFraction> billion based on the last sales price of the Registrant&#8217;s Common Stock on the Nasdaq Global Market of the Nasdaq Stock Market LLC on June&#160;28, 2019. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="text-indent:18pt;margin-top:2pt;"><span><br/></span></div><div style="text-indent:18pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">As of February&#160;21, 2020, the Registrant had <ix:nonFraction unitRef="shares" contextRef="i52984fc7f6524de3bd553513b238634b_I20200221" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18zNTAz_394aba13-c713-454d-b440-d50ad98481d1">16,505,197</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="text-indent:18pt;margin-top:2pt;"><span><br/></span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:center;margin-top:5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Portions of the Proxy Statement for the Registrant&#8217;s 2020 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2019 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div><div style="margin-top:2pt;"><span><br/></span></div><div style="text-indent:18pt;margin-top:2pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_7"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:6.211%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.866%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Part I</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_13">Business</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_16">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_16">25</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_19">36</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_22">Properties</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_22">36</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_25">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_28">37</a></span></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Part II</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_34">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_37">Selected Consolidated Financial Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_37">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;7.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_40">40</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;7A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_52">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_52">47</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;8.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_55">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_55">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;9.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_130">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_130">87</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;9A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_133">87</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_136">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_133">87</a></span></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Part III</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;10.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_142">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_142">89</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;11.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_145">Executive Compensation</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_145">89</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;12.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_148">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_148">89</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;13.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_151">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_151">89</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;14.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_154">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_154">89</a></span></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Part IV</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;15.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_160">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_160">90</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 16.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_163">Form 10</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_163">-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_163">K - Summary</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_160">90</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_166">Signatures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_166">94</a></span></div></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:23.730%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.270%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GLOSSARY OF TERMS AND ABBREVIATIONS</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Abbreviation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definition</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019 Notes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$245.0 million aggregate principal amount of convertible senior unsecured notes due 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023 Notes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$750.0 million aggregate principal amount of convertible senior unsecured notes due 2023</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AAALAC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accreditation of Laboratory Animal Care International</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ab Initio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ab Initio Biotherapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Abvivo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Abvivo, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ACOVA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ACOVA, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ADHF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acute decompensated heart failure</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aldeyra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aldeyra Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended Interest Purchase Agreement</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANDA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Abbreviated New Drug Application</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">API</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Active pharmaceutical ingredient</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aptevo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aptevo Therapeutics</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arcus </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arcus Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASCO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">American Society of Clinical Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASCT</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Autologous Stem Cell Transplantation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Standards Update </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo Med, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxter International, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BeiGene</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BeiGene Switzerland GmbH</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BendaRx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BendaRx Corp.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bexson Biomedical</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bexson Biomedical, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BMS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bristol Myers Squibb</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CStone</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CStone Pharmaceuticals (Suzhou) Co., Ltd. </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASI Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardioxyl</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardioxyl Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CI-AKI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contrast-induced acute kidney injury</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Code of Conduct</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Code of Conduct and Ethics Policy</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Coherus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Coherus Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Composition of Matter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible Note</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Convertible Promissory Note</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COPD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chronic obstructive pulmonary disease </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cormatrix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cormatrix Cardiovascular, Inc. </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cormatrix Asset Sale</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset sale from CorMatrix to Aziyo</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COSO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Committee of Sponsoring Organizations of the Treadway Commission</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CRO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract Research Organization</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal Bioscience, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulus Oncology, Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CVR</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent value right</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CyDex</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CyDex Pharmaceuticals, Inc.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:23.730%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.270%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daiichi Sankyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daiichi Sankyo Company, Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DMF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Drug Master File</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESG</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Environmental, Social and Governance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eli Lilly</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eli Lilly and Company</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ECM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Extracellular matrix</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EPA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Environmental Protection Agency</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee Stock Purchase Plan, as amended and restated</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">European Union</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exelixis </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exelixis, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FASB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FDA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Food and Drug Administration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FSGS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Focal segmental glomerulosclerosis</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GAAP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generally accepted accounting principles in the United States</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GBM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Glioblastoma</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genagon</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genagon Therapeutics AB</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GCSF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granulocyte-colony stimulating factor</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GigaGen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GigaGen, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gilead</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GPCR</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">G-protein coupled receptor</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GRA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Glucagon receptor antagonist </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HanAll</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HanAll Biopharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Harbour</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Harbour BioMed Shanghai Co., Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HBV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hepatitis B Virus</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HCC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hepatocellular Carcinoma</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hikma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hikma Pharmaceuticals PLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HNO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nitroxyl</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hovione</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hovione FarmCiencia, S.A.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Icagen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Icagen, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-Process Research and Development</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IRAK4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interleukin-1 Receptor Associated Kinase-4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IRS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intravenous</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">iMBP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">iMetabolic Biopharma Corporation </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Immunovant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Immunovant Sciences GmbH</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IND</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investigational New Drug</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kira Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kira Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KSQ Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KSQ Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LTP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liver targeting prodrug</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lundbeck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lundbeck A/S</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marinus </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marinus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MCM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mineral Coated Microparticle</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Melinta</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Melinta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck &amp; Co., Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merrimack</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merrimack Pharmaceuticals, Inc.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:23.730%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.270%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metavant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metavant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Millennium</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Millennium Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MLA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Master License Agreement</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MRSA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Methicillin-resistant Staphylococcus aureu</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NASH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-alcoholic steatohepatitis</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NDA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">New Drug Application</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NOLs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Operating Losses</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novan, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis AG</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nucorion </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nucorion Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OMT</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Open Monoclonal Technology, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ono</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Opthea</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Opthea Limited</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orange Book</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Publication identifying drug products approved by the FDA based on safety and effectiveness</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Original Interest Purchase Agreement</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par Pharmaceutical, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PFS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Progression-free Survival</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmacopeia</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmacopeia, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phoenix Tissue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phoenix Tissue Repair</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PhoreMost</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PhoreMost Limited</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PPD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Post-Partum Depression</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PSU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock unit</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">R&amp;D</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and Development</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Roivant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Roivant Sciences GMBH</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSU </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock unit</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SAGE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARM</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selective Androgen Receptor Modulator</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SEC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor Pharmaceuticals, Inc., or RODES, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis, SA</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sermonix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sermonix Pharmaceuticals, LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spectrum</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spectrum Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SQ Innovation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SQ Innovation, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sunshine Lake Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sunshine Lake Pharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda Pharmaceuticals Company Limited</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Talem </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Talem Therapeutics LLC</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax Act</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Tax Cuts and Jobs Act</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teva</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Actavis, LLC </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TG Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TG Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TR-Beta</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thyroid hormone receptor beta</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valanbio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valanbio Therapeutics, Inc.</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:23.730%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.270%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VDP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis Design Platform</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VentiRx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VentiRx Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis plc</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Verona</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Verona Pharma plc</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking Therapeutics</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vireo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vireo Health</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">WuXi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">WuXi Biologics Ireland Limited</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">WuXi Agreement</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Platform License Agreement, dated March 23, 2015, by and between Ligand and WuXi, as amended</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong Medicine Research</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X-ALD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X-linked adrenoleukodystrophy</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">xCella Biosciences</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">xCella Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila Healthcare, Ltd</span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_10"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_13"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Cautionary Note Regarding Forward-Looking Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: </span></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This report contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position, royalties and milestones under license agreements, Capitsol material sales, product development,  and product regulatory filings and approvals, and the timing thereof, as well as other statements that are not historical. You should be aware that the occurrence of any of the events discussed under the caption &#8220;Risk Factors&#8221; could negatively affect our results of operations and financial condition and the trading price of our stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">References to &#8220;Ligand Pharmaceuticals Incorporated,&#8221; &#8220;Ligand,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Partner Information</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Information regarding partnered products and programs comes from information publicly released by our partners and licensees.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Trademarks</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our trademarks, trade names and service marks referenced herein include Ligand</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Captisol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, LTP</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, LTP technology</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniAb</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniMouse</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniRat</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniFlic</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniClic</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, OmniChicken</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> , Vernalis</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, VDP</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and HepDirect</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> which are protected under applicable intellectual property laws and are our property. All other trademarks, trade names and service marks including Kyprolis</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">,</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Evomela</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Zulresso</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Minnebro</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">,</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Baxdela</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Carnexiv</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Conbriza</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Duavee</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Promacta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, SUREtechnology Platform</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Viviant</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Vivitra</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, Bryxta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and Exemptia</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">SM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to such trademarks, trade names and service marks. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:14pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Business</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. We employ research technologies such as antibody discovery technologies, structure-based drug design, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. We currently have partnerships and license agreements with over 120 pharmaceutical and biotechnology companies. Over 200 different programs are in various stages of commercialization and development and fully funded by our collaboration partners and licensees. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and PPD, among others. Our collaboration partners and licensees have programs currently in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. We have over 1,200 issued patents worldwide.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We&#160;have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies. Fully-funded programs, which we refer to as "shots on goal," are those for which our partners pay all of the development and commercialization costs. For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept and then seek partners to continue development and potential commercialization.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. We believe that focusing on discovery and early-stage drug development while benefiting from our partners&#8217; development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue consists of three primary elements: royalties from commercialized products, sale of Captisol material, and revenue from license, milestone and other service payments. In addition to discovering and developing our own proprietary drugs, we selectively pursue acquisitions to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;">2019 and Recent Major Business Highlights</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Major Transactions and Strategic Investments</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consistent with our business model, we pursued novel investments to augment our technology platforms and assets.  We acquired Ab Initio in a $12 million acquisition that brought Ligand a patented antigen technology that is synergistic with our OmniAb&#174; therapeutic antibody discovery platform. We also invested $3 million in Dianomi in exchange for equity and a royalty rights on future development programs using Dianomi&#8217;s patented Mineral Coated Microparticle (MCM) technology.  In 2019, we sold our assets and royalty rights for Promacta to Royalty Pharma for $827 million. </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 11, 2020, we announced the signing of an agreement to acquire the core assets, partnered programs and ion channel technology from Icagen for $15 million in cash. Icagen will also be entitled to receive up to an additional $25 million of cash payments based on certain revenue achievements. The transaction is subject to certain closing conditions, including a vote of Icagen stockholders, and is expected to close in April 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Corporate and Governance Highlights</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ligand&#8217;s Board of Directors is highly committed to policies and practices focused on environmental sustainability, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on such ESG policies and practices, we believe we can affect a meaningful and positive change in our community and maintain our open, collaborative corporate culture. We will continue our proactive shareholder and employee engagement in 2020.  See www.ligand.com for information about our ESG policies and practices.</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sarah Boyce joined our Board, increasing the total number of Directors to nine.  Also in 2019, two members of our Board, Nancy Gray and Sarah Boyce, were named to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">WomenInc</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;s</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Most Influential Corporate Directors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> list.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">OmniAb Technology Platform Updates</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to invest in and expand the OmniAb Technology platform, and in 2019 we launched OmniClic&#8482;, a novel next-generation common light chain OmniChicken-based discovery technology focused on bispecific antibodies.  We entered into nine new OmniAb platform license agreements in 2019 with Sanofi, Millennium/Takeda, GigaGen, Talem Therapeutics, Kira Pharma, Genagon, Ascella, Unity Biotechnology and Abvivo.  Our scientists and our partners presented data highlighting the utility of the OmniAb platform at multiple conferences throughout the year, and we published multiple papers in peer-reviewed journals.</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Development-stage OmniAb partners continue to report progress clinically; notable advancements include:</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">CStone&#8217;s CS1001, an OmniAb-derived anti-PD-L1 antibody, that demonstrated promising antitumor activity with a complete response rate of 33.3% in a Phase 2 trial in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.  CStone also announced the start of a Phase 3 trial assessing CS1001 in combination with chemotherapy for treatment of gastric or gastro-esophageal cancers.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Immunovant starting ASCEND-GO 2, a placebo-controlled Phase 2b trial evaluating OmniAb-derived IMVT-1401 in patients with Graves&#8217; ophthalmopathy. IMVT-1401 is a fully human antibody that selectively binds to and inhibits the neonatal Fc receptor.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Aptevo Therapeutics announcing positive Phase 1 data for APVO436, and GenMab highlighting clinical progress of the OmniAb-derived DuoBody-PD-L1x4-1BB.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Captisol Technology Updates</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reported the highest level of annual Captisol material sales in 2019, and we entered into new Captisol clinical use or license and supply agreements with a number of new partners, including: Millennium/Takeda; Merck KGaA, reVision Therapeutics; SQ Innovation; BendaRx;  Bexson Biomedical, Valanbio; and others.</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Kyprolis&#174; is an Amgen product that utilizes Captisol in its formulation. We earn royalties on global sales of Kyprolis and also receive revenue for material sales.   In September 2019, Amgen announced that the Phase 3 CANDOR study met its primary endpoint of progression-free survival. The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma.   In October 2019, Amgen announced a strategic collaboration with BeiGene, an oncology-focused biotechnology company with an established infrastructure in China, to expand its oncology presence in the region. Kyprolis is currently under regulatory review in China for relapsed and refractory multiple myeloma.</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">New Captisol-enabled products were launched or expanded into new geographies in 2019, with SAGE launching ZULRESSO&#8482; for the treatment of postpartum depression in the US, and CASI launching Evomela&#174; in China.</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gilead Sciences announced on January 31, 2020 that they are working closely with global health authorities to respond to the novel coronavirus (COVID-19) outbreak through the appropriate experimental use of remdesivir (GS-5734). Remdesivir is formulated with Captisol. Gilead has initiated clinical trials together with Chinese authorities in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the virus. Remdesivir was also highlighted in The New England Journal of Medicine for treating the first case of COVID-19 in the United States. We have a non-exclusive supply agreement with Gilead, and our economics are built into Captisol material sales.</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 20, 2020, we entered into a Captisol Use/Supply Agreement with China Resources Double-Crane Pharmaceuticals Co., Ltd,  (&#8220;CR Double Crane&#8221;), pursuant to which we will supply Captisol to CR Double Crane for use in preclinical and clinical studies of remdesivir to treat the 2019 novel coronavirus, 2019-nCoV. We will receive revenues based on the amount of Captisol ordered by CR Double Crane. </span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development-stage Captisol partners reported progress of programs in a variety of therapy areas, notably:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Marinus announced positive results from a Phase 2 trial of ganaxolone in Refractory Status Epilepticus.  </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Merck KGaA announced Phase 2 results for M6620, an ATR kinase inhibitor, demonstrating that addition of M6620 to gemcitabine extended PFS without added toxicity in patients with platinum-resistant cancer.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Takeda announced results of a Phase 1 proof-of-concept study of Captisol-enabled TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in individuals with narcolepsy type 1.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">SAGE announced plans for SAGE-689, a potential therapy for disorders associated with GABA hypofunction.  SAGE expects to commence a Phase 1 trial in 2020.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Vernalis Design Platform (VDP) Updates</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continued to expand our portfolio of VDP-derived partnerships during 2019, following our 2018 acquisition of Vernalis and VDP partners continued to report on development progress.  </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Verona Pharma announced positive data in a 4-week Phase 2b COPD trial with nebulized ensifentrine on top of tiotropium therapy.  The primary endpoint was met at all doses, and ensifentrine produced clinically and statistically significant improvements in lung function.  Verona intends to start Phase 3 in 2020. </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We entered a license agreement with Cumulus for VER250840, a novel, oral, Chk1 kinase inhibitor. We are eligible to receive more than $76 million of milestones and tiered royalties in the mid-to-high single digits. </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We entered into a VDP collaboration with PhoreMost and will share revenues with PhoreMost on any future licenses. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Additional Pipeline Developments     </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">                                                                                        </span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our existing pipeline of partnered programs continued to advance, with multiple partners reporting on clinical and regulatory developments.  Selected highlights include: </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Viking presented new results from a Phase 2 study of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol, and also announced the start of a Phase 2b trial in patients with biopsy-confirmed NASH.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Palvella announced that the Phase 3 pivotal portion of the seamless Phase 2/3 VALO study of PTX-022 for the treatment of patients with pachyonychia congenita had commenced.</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Retrophin announced new data from the Phase 2 DUET study, examining the impact of sparsentan on quality of life in patients with FSGS.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Sermonix started a Phase 2 trial of lasofoxifene in breast cancer, and announced grant of Fast Track Designation.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Sanofi presented positive Phase 3 data of sutimlimab in patients with cold agglutinin disease.</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Metavant informed Ligand that they no longer planned to initiate a proof-of-concept trial for RVT-1502 in Type 1 diabetes following requests from FDA for additional non-clinical studies. Metavant is evaluating its development plans for the program. </span></div><div style="text-indent:-18pt;padding-left:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Daiichi Sankyo announced the launch of MINNEBRO&#174; (esaxerenone) tablets in Japan.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Select Partner Financing Events</span></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple partners completed financing events in 2019 to fund development of Ligand-partnered programs.  Notably, CStone listed shares on the HKG and raised $266 million it is using to fund development of CS1001.  Seelos completed a reverse merger and listed on Nasdaq. In conjunction with the transaction, Seelos generated gross proceeds of $18 million to fund its pipeline.  And, Nucorion announced the closing of a $5 million Series B financing to support Phase development for its lead program, NCO-1010 for hepatitis B.  NCO-1010 utilizes Ligand&#8217;s LTP Platform&#8482; technology. Guangdong Ji-Bao Pharmaceutical Company of Guangzhou, China invested $4 million and Ligand invested $1 million in the Nucorion Series B round. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Internal Pipeline Highlights</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to invest in internal R&amp;D with the goal to secure valuable partnerships in the future.  In 2019, we announced positive top-line results from a Phase 1 trial of our internal Captisol-enabled (CE) Iohexol program. The trial achieved the primary endpoint by demonstrating pharmacokinetic bioequivalence of CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE&#8482;) after IV administration in healthy adults. CE-Iohexol injection was well tolerated, and adverse events were in line with the known safety profile of OMNIPAQUE.  We plan to submit an IND with the FDA and to initiate a Phase 2 study in the U.S. in 2020.  We also progressed five internal antibody-related programs leveraging our OmniChicken technology that we initiated in mid-2018. The programs are focused on targets for which biology is known, centered in the oncology space.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Technologies</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A variety of technology platforms that enable elements of drug discovery or development form the basis of our portfolio of fully-funded shots on goal. Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 1,200 patents issued worldwide.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">OmniAb Technologies</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">O</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ur OmniAb technology includes our OmniRat, OmniMouse, OmniFlic, OmniChicken and OmniClic technology platforms for use in discovering fully human antibodies. The OmniRat, OmniMouse, and OmniFlic platforms consist of genetically-engineered transgenic animals that produce a broadly diversified repertoire of antibodies and enable novel fully-human antibody drug discovery and development by our OmniAb partners. Fully-human OmniAb antibodies provide advantages to our partners in that fully-human antibodies have reduced immunogenicity, streamlined development timelines and costs, and accelerated novel antibody discovery. The OmniChicken and OmniClic platforms consist of genetically-engineered transgenic chickens which enable the generation of novel antibodies against targets that are not immunogenic in mammals like mice and rats. We acquired these technologies through the acquisition of OMT in January 2016 and Crystal in October 2017. As of December 31, 2019, we had entered into OmniAb platform license agreements with more than 40 collaboration partners, including 2 partners who have rights through our partnership with WuXi. Our OmniAb partners were working on approximately 180 active programs, of which 12 were in various stages of clinical trials as of December 31, 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Captisol Technology</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Captisol is our patented, uniquely-modified cyclodextrin that is specifically designed to maximize safety, while improving the solubility, stability and bioavailability of APIs. Captisol can enable faster and more efficient development paths for our partners, given its known regulatory acceptance. In addition to solid Captisol powder, we offer our partners access to cGMP manufactured aqueous Captisol concentrate. This product offering was established in 2017 to reduce cycle time and increase Captisol production capacity for large volume drug products. We maintain both Type IV and Type V DMFs with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. We also have active DMFs in Japan, China and Canada. As of December 31, 2019, Captisol-enabled drugs were being marketed in more than 70 countries, and over 40 partners had Captisol-enabled drugs in development.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Vernalis Design Platform (VDP)</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The VDP technology leverages our leadership in structure-guided drug discovery in which protein structure, drug fragment screening and modeling are integrated with medicinal chemistry to enable the rapid discovery of novel drugs. The VDP approach establishes structural information via x-ray crystallography and NMR methods and develops reliable assay systems to test biophysical, functional and cellular properties. The VDP has proven success with highly-challenging pharmaceutical targets and has generated a broad portfolio, with over 5,000 novel drug/target complexes determined and over 400 granted and pending patents. We acquired the VDP technology through our acquisition of Vernalis in October of 2018, and maintain state-of-the-art laboratories in Cambridge, UK. As of December 31, 2019, we have agreements with 10 partners for active research collaboration using VDP technology on a total of 17 active programs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">HepDirect/LTP Technology Platform</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The HepDirect platform is a first generation liver-targeting prodrug technology designed to deliver certain phosphorus-containing drugs to the liver by using a proprietary chemical modification that renders an API biologically inactive until cleaved by a liver-specific enzyme. The HepDirect&#8482; technology may improve the efficacy and/or safety of certain drugs and can be applied to marketed or new drug products to treat liver diseases or diseases caused by hemostasis imbalance of circulating molecules controlled by the liver.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our LTP platform is a broad second generation liver-targeting prodrug technology that has an activation mechanism similar to HepDirect but with broader applications and many improved features. The proprietary chemical modifications can be used with many chemical classes of drugs in addition to phosphorus-containing compounds and have multiple chemistry strategies, designed to improve flexibility and success rates.  In addition, the second generation technology eliminates the undesirable by-products released during activation of the first generation prodrugs. As of December 31, 2019, we had entered into HepDirect/LTP platform agreements with six partners, all of whom had active programs. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">SUREtechnology Platform (owned by Selexis)</span></div><div><span><br/></span></div><div style="text-indent:26.64pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We acquired economic rights to various SURE</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">technology</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Platform programs from Selexis. The SURE</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">technology</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs. As of December 31, 2019, we are entitled to certain economic rights to SUREtechnology Platform license agreements with 14 partners developing or having commercialized 23 programs.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Partners and Licensees</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have partnerships and license agreements with over 120 pharmaceutical and biotechnology companies. In addition to the table below, we also have more than 10 undisclosed partners and licensees.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:10pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:20.794%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.711%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.529%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.768%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Big Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics, continued</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biotech, continued</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AbbVie</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ABBV</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hikma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HIK</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MEI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MEIP</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AstraZeneca</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AZN</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Melinta</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MLNT</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BAX</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CADILAHC</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Menarini</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Boehringer Ingelheim</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biotech</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Meridian Labs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BMS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BMY</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ABBA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metavant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daiichi Sankyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DSKY</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ABL Bio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">298380</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merrimack</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MACK</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eli Lilly</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LLY</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Abvivo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NOVN</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4523</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aldeyra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ALDX</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novogen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NVGN</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GSK</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GSK</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMGN</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nucorion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JNJ</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arcus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RCUS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Opthea</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPT</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MRK</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asahi Kasei</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3407</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outlook</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OTLK</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck KGaA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MRK.DE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ascella </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NVS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BendaRx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phoenix Tissue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ono</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4528</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bexson Biomedical</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Precision Biologics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Otsuka</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4768</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">bluebird bio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BLUE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RTRX</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PFE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cantex</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revision </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SNY</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Celgene</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CELG</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SAGE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SAGE</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4502</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CRVS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seattle Genetics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SGEN</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Specialty Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CStone</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2616.HK</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SEEL</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acrotech</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Servier</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aytu Bioscience</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AYTU</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Curon</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sunshine Lake</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CURx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Surface</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SURF</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beloteca</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aptevo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APVO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Symphogen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Electra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Talem</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CorMatrix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exelixis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXEL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teneobio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CTI Biopharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CTIC</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Five Prime</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FRPX</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TG Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TGTX</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cuda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">F-Star</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tizona</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ferring</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genmab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GEN</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">UBX</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gloria</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2437</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genagon</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valanbio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lundbeck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LUN</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genekey Biotech</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaxxas</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proximagen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Glenmark</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GLENMARK</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vega</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GigaGen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VenBio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sermonix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gilead Sciences</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GILD</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VentiRx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shire</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SHPG</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HanAll</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9420</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Verona</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VRNA</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SQ Innovation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Harbour</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vertex</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VRTX</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teijin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TINLF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IBC Generium</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VKTX</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vireo Health</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">iMetabolic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Virtuoso</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ticker</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Immunovant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMVT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">xCella</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alvogen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">J-Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BioCad</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kira</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XTL Bio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XTLB</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Coherus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CHRS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KSQ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">WuXi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603259</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gedeon Richter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GEDSF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marinus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MRNS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zhilkang Hongyi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercial and Clinical Stage Partnered Portfolio</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a large portfolio of current and future potential revenue-generating programs, including over 200 fully-funded by our partners.  In addition to the table below, we also have more than 100 undisclosed preclinical programs.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Approved</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Therapeutic Area</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acrotech/CASI</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alvogen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Voriconazole</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen/Ono</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aytu</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tuzistra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ECM portfolio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medical device/Cardiology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nexterone</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardiovascular</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biocad</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teberif</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exelixis/Daiichi-Sankyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Minnebro</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardiovascular</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hikma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Voriconazole</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lundbeck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carnexiv</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Melinta</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxdela</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Menarini</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Frovatriptan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noxafil-IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Posaconazole</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viviant/Conbriza</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Duavee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vfend-IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SAGE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zulresso</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vivitra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bryxta/ZyBev</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exemptia</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zydus Cadila</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vortuxi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 3/Pivotal or Regulatory Submission Stage</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Therapeutic Area</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aldeyra</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reproxalap</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biocad</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BCD-066</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Blood Disorders</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CStone</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CS1001</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IBC Generium</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GNR-008</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severe and Rare</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SB206</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outlook Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ONS-5010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sparsentan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severe and Rare</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sutimlimab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Blood Disorders</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Fosphenytoin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sunshine Lake</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vilazodone</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pevonedistat</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 2</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Therapeutic Area</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cantex</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CX-01</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardioxyl/BMS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BMS986231</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cardiovascular</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CTI Biopharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tosedostat</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FYCOMPA</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gilead</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GS-5734</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gloria</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GLS010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Immunovant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMVT-1401</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">J-Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JPH-203</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marinus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ganaxalone IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merck</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">M6620</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metavant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RT-1502</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KLM465</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Blood disorders</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Trametinib</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ECF843</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Opthea</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPT-302</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTX-022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Precision Biologics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NPC-1C</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Budesonide</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aplindore</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sermonix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lasofoxifene</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VentiRx</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VTX-2337</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Verona</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ensifentrine</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VK5211</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VK2809</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VK0214</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VK0612</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pradefovir</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XTL Bio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">hCDR1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severe and Rare</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 1</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Therapeutic Area</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMG-330</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aptevo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">APVO436</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arcus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AB122</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cifordenant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CSL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CSL-324</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cuda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cudafol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">F-Star</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FS-102</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gedeon Richter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bevacizumab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gedeon Richter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RGB-03</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genekey Biotech</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PCSK-9</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genmab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gen1046</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gossamer Bio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PFK-158</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HanAll/Harbour</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HL161</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JNJ64007957</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JNJ67371244</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MEI Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ME-344</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Meridian</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ML-061</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MIK-665</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BCL-201</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phoenix Tissue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTR-01</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proximagen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CXCR4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Servier</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S55746/S64315</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Symphogen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SYM022/SYM023</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TAK-020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TAK-925</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severe and Rare</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Teva</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-IL5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Central Nervous System</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaxxas</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nanopatch</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infectious Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VentiRx Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VTX-1463</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MB07133</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cancer</span></td></tr></table></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Selected Commercial Programs</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have multiple programs under license with other companies that have products that are already being commercialized. The following programs represent components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue. For information about the royalties owed to us for these programs, see &#8220;Royalties&#8221; later in this business section.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Promacta (Novartis)</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2019, we sold our Promacta related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827.0 million in cash. See detail in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (2), Sale of Promacta License.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;   </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the sale, Promacta accounted for nearly 50% of total revenue. We are entitled to no future royalty revenue from Promacta.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Kyprolis (Amgen)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We supply Captisol to Amgen for use with Kyprolis (carfilzomib), and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand&#8217;s Captisol technology and is approved in the United States for the following:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">In combination with dexamethasone or combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.245%;"><tr><td style="width:1.0%;"></td><td style="width:23.744%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.744%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.833%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.494%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.185%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Kyprolis is also approved in multiple countries outside the U.S. and Amgen continues to invest significantly in Kyprolis to further expand its label and geography. Amgen&#8217;s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol. Our patents and applications relating to the Captisol component of Kyprolis are not expected to expire until 2033. </span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;border-left:2pt solid #000000;padding-left:1pt;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Kyprolis (Amgen)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:2pt solid #000000;border-left:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; $250 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:2pt solid #000000;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-left:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$250 to $500 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-left:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$500 to $750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:2pt solid #000;border-left:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;$750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-bottom:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:2pt solid #000;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Evomela (Acrotech and CASI)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We supply Captisol to Acrotech Biopharma for sales of Evomela in the U.S. and to CASI Pharmaceuticals for sales of Evomela in China. Evomela received market approval by the China National Medical Products Administration (NMPA). It is the only approved and commercially available melphalan product in China. Evomela is a Captisol-enabled melphalan IV formulation which is approved by the FDA for use in two indications:</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A high-dose conditioning treatment prior to ASCT in patients with multiple myeloma. </span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">For the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.</span></div><div style="padding-left:45pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China and CASI Pharmaceuticals has rights to market in China. We are eligible to receive over $50 million in potential milestone payments under this agreement and royalties on global net sales of the Captisol-enabled melphalan product. Acrotech and CASI&#8217;s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event within ten years of the commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. The agreement may be terminated by either party for an uncured material breach or unilaterally by Acrotech and CASI by prior written notice.</span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nexterone (Baxter)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement. Under the terms of the license agreement we will continue to earn milestone payments, royalties, and revenue from Captisol material sales.  We are entitled to earn royalties on sales of Nexterone through early 2033.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Zulresso (SAGE)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have a license agreement with SAGE, related to SAGE's Zulresso, a Captisol-enabled formulation of brexanolone for the treatment of PPD. SAGE announced marketing approval on March 21, 2019 for Zulresso. Under the terms of the agreement, we receive royalties and revenue from Captisol material sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Noxafil-IV (Merck)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a supply agreement with Merck related to Merck&#8217;s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use. NOXAFIL-IV is marketed in the United States, EU and Canada. In January 2020, Merck received approval in Japan for NOXAFIL-IV. We receive our commercial compensation for this program through the sale of Captisol, and we do not receive a royalty on this program.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Baxdela IV (Melinta)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Melinta&#8217;s Baxdela IV is a Captisol-enabled delafloxacin-IV that was approved for the treatment of acute bacterial skin and skin structure infections. Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic with activity against a variety of disease-causing bacteria-gram-positives, gram-negatives, atypicals and anaerobes, including quinolone-resistant MRSA. Under the terms of the agreement, we may be entitled to regulatory milestones, as well as a royalty on future sales by Melinta, and revenue from Captisol material sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pfizer is marketing bazedoxifene, a selective estrogen receptor modulator, under the brand names Viviant</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">  </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Pfizer is responsible for the marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women. Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories. Net royalties on annual net sales of Viviant/Conbriza and Duavee/Duavive are each payable to us through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Aziyo Portfolio (Aziyo)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive a share of revenue from the currently marketed Aziyo portfolio of commercial pericardial repair and CanGaroo&#174;&#160;Envelope ECM products. In addition, we have the potential to receive a share of revenue and potential milestones from the currently marketed CanGaroo&#174;&#160;ECM Envelope for cardiac implantable electronic devices.&#160;Aziyo&#8217;s products are medical devices that are designed to permit the development and regrowth of human tissue.</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Exemptia, Vivitra, Zybev and Bryxta (Zydus Cadila)</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Zydus Cadila&#8217;s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases. Zydus Cadila uses the Selexis technology platform for Exemptia. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Zydus Cadila&#8217;s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Zydus Cadila&#8217;s Bryxta and Zybev (bevacizumab biosimilar) is marketed in India for various indications. Zydus Cadila uses the Selexis technology platform for Bryxta and Zybev. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Minnebro (Exelixis)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Daiichi Sankyo announced on January 8, 2019 the receipt of marketing approval in Japan for MINNEBRO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Tablets (esaxerenone) for the treatment of hypertension. Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo for the development of esaxerenone, a mineralocorticoid receptor antagonist. Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Selected Development Stage Programs</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms, we consider particularly noteworthy. We are eligible to receive milestone payments and royalties on these programs. This list does not include all of our partnered programs. For information about the royalties owed to Ligand for these programs, see &#8220;Royalties&#8221; later in this business section. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sparsentan (Retrophin) </span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Retrophin, is developing sparsentan for orphan indications of severe kidney diseases, and has initiated a global pivotal Phase 3 clinical trial to enable an NDA filing for sparsentan for the treatment of FSGS. Additionally, Retrophin initiated a global pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare, immune complex mediated chronic glomerular disease. Certain patient groups with severely compromised renal function, including those with FSGS and IgA nephropathy, exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate. Sparsentan, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our license agreement with Retrophin, we may be entitled to receive potential milestones of over $70 million and net royalties on future worldwide sales by Retrophin. The royalty term is expected to be 10 years following the first commercial sale. Retrophin is responsible for all development costs related to the program.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%;">TR-Beta - VK2809 and VK0214 (Viking) </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.888%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Viking, is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and NASH. Viking announced positive results from its Phase 2 trial for VK2809 in hypercholesterolemia and fatty liver disease. Viking has also been granted orphan drug status by the FDA for the development of VK0214 for treatment of X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales. Our TR Beta programs partnered with Viking are subject to CVR sharing and a portion of the cash received will be paid out to CVR holders.</span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:2pt solid #000;border-left:2pt solid #000000;padding-left:1pt;border-right:2pt solid #000;padding-right:1pt;"><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">TR-Beta - VK2809 and VK0214</span><span style="background-color:rgb(255,255,255, 0.0);color:#ff6600;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> (Viking)</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; $500 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$500 to $750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-bottom:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;$750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-bottom:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:22.5pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%;">BMS-986231 (BMS)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, BMS, is conducting Phase 2 clinical trials for a Captisol-enabled second-generation prodrug that chemically breaks down to produce HNO and an inactive byproduct. HNO is thought to have a dual mode of action, by improving cardiac function and acting as a vasodilator for treating ADHF. Under the terms of the agreement, we may be entitled to development and regulatory milestones, revenue from Captisol material sales and royalties on potential future sales by BMS.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;">IMVT-1401/HL161 (Immunovant, HanAll and Harbour)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, HanAll has granted Immunovant an exclusive license for the development, manufacture and marketing of IMVT-1401 (HL161, an anti-FcRn antibody) for the treatment of pathogenic IgG-mediated autoimmune diseases in the U.S., Canada, Mexico, the EU, the United Kingdom, Switzerland, Latin America, the Middle East and North Africa. Immunovant is currently conducting a Phase 2 clinical trial in myasthenia gravis and other inflammatory diseases. Additionally, HanAll and Harbour BioMed, are collaborating to develop HL161 for similar treatment in China and Korea. HanAll retains the rights to HL161 in Korea and Harbour will control the marketing in China. As part of our agreement with HanAll, we are entitled to development and regulatory milestones and royalties on potential future sales from HanAll and sublicense revenues from Immunovant and Harbour based on amounts received by HanAll.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">SARM - VK5211 (Viking) </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.890%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Viking is also developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture. SARMs retain the beneficial properties of androgens without undesired side-effects of steroids or other less selective androgens. In the fourth quarter of 2017, Viking announced positive results from its Phase 2 trial in patients who suffered hip fracture. Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones as well as tiered royalties on potential future sales.</span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;border-left:2pt solid #000000;padding-left:1pt;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">SARM - VK5211 (Viking)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; $500 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$500 to $750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-bottom:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;$750 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.25%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-bottom:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">PTX - 022 (Palvella) </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.890%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We acquired the economic rights to PTX-022 from Palvella in December 2018.  PTX-022 is a novel, topical formulation comprising high-strength rapamycin in development to treat pachyonychia congenita (PC).  PC is a serious, chronically debilitating lifelong monogenic rare skin disease with no approved treatment.  Palvella is continuing enrollment for a pivotal Phase 2/3 clinical trial for PC and is expected to have top line data in late 2020.</span></div></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;border-left:2pt solid #000000;padding-left:1pt;border-right:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">PTX - 022 (Palvella)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; $50 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.00%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$50 to $100 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.50%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-bottom:2pt solid #000;border-left:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;$100 million</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:2pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.80%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-bottom:2pt solid #000;border-right:2pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Lasofoxifene (Sermonix) </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lasofoxifene is a selective estrogen receptor modulator for osteoporosis treatment and other diseases, discovered through the research collaboration between us and Pfizer. </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our partner, Sermonix has a license for the development of oral lasofoxifene for the United States and additional territories. Under the terms of the agreement, we are entitled to receive over $45 million in potential regulatory and commercial milestone payments as well as royalties on potential future net sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pevonedistat - TAK-924 (Millennium/Takeda) </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our partner, Millennium/Takeda is currently conducting Phase 3 trials for the development of pevonedistat for the treatment of hematological malignancies and solid tumors. Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor. Under the terms of the clinical-stage agreement, we may be entitled to over $25 million in regulatory and development milestones from Millennium/Takeda, revenue from Captisol material sales, and royalties on potential future net sales.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Ensifentrine &#8211; RPL554 (Verona)</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Verona, is currently conducting a comprehensive Phase 2 clinical trial for the development of ensifentrine as a maintenance treatment of COPD with nebulized and inhaled formulations. Verona has also completed a positive Phase 2a study evaluating ensifentrine as a treatment for cystic fibrosis. Under the terms of our agreement with Verona, we are entitled to development and regulatory milestones, including a &#163;5.0 million payment upon the first approval of any regulatory authority, and royalties on potential future sales.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">JNJ64007957 (Janssen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Janssen, is developing JNJ64007957, a BCMAxCD3 bispecific antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting two Phase 1 trials, as a single agent and in combination with daratumumab in multiple myeloma. We are entitled to earn development and regulatory milestones based on the development of JNJ64007957.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">JNJ-67371244 (Janssen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">)</span></div><div><span><br/></span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Janssen is also developing JNJ-67371244, an anti-CD33xCD3 antibody discovered in part with the OmniAb platform technology. Janssen is currently conducting a Phase I trial for cancer therapy. We are entitled to earn development and regulatory milestones based on the development of JNJ-67371244.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Ganaxalone IV (Marinus)</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Marinus, is conducting Phase 2 clinical trials with Captisol-enabled ganaxolone IV in patients with PPD and refractory status epilepticus. Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone, a GABAA receptor modulator, for use in humans. We are entitled to development and regulatory milestones, revenue from Captisol material sales, and royalties on potential future sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">APVO436 (Aptevo)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Aptevo, is currently conducting a Phase 1 trial of APVO436 for the treatment of acute myeloid leukemia.  There is a high unmet medical need for targeted immunotherapies such as APVO436, that can potentially treat patients with relapsed or refractory disease, or patients who cannot tolerate traditional chemotherapy. Under the terms of the agreement with Aptevo, we are entitled to development and regulatory milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Gen1046 (GenMab)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, GenMab, is currently conducting a Phase 1 trial of Gen1046 for use in patients with malignant solid tumors.  Under the terms of the agreement with GenMab, we are entitled to clinical and regulatory milestones and royalties on potential future sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">SYM022 and SYM023 (Symphogen)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Symphogen, is currently conducting Phase 1 trials of SYM022 and SYM023 to determine if it is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy for which no standard therapy is available.  Under the terms of the agreement with Symphogen, we are entitled to sublicense revenues, milestones and royalties on potential future net sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WuXi Partnership</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">Pursuant to the WuXi Agreement, we have granted WuXi a non-exclusive license to use our OmniRat, OmniMouse and OmniFlic platforms solely to research, develop and make antibodies, and we have agreed to use commercially reasonable efforts to deliver to WuXi animals from such platforms to support WuXi&#8217;s licensing rights under the WuXi Agreement. Further, WuXi has the right to out-license antibodies it discovers (whether for itself or at the direction of out-licensees) under the WuXi Agreement to out-licensees worldwide. We are entitled to royalties in the low single digits on net sales of products. Unless earlier terminated, the term of the WuXi Agreement shall continue indefinitely. Either party may terminate the WuXi Agreement upon specified notice of the other party's uncured material breach of the WuXi Agreement. In addition, we have the right to terminate the WuXi Agreement if WuXi or one of its out-licensees challenges the validity of one of our patents covering the platform and WuXi has the right to terminate the WuXi Agreement for convenience following a specified period after notice of termination.</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">In addition to other earlier stage programs, the following programs have been licensed pursuant to the WuXi Agreement: </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%;text-decoration: underline;">AB122/GLS010 (Arcus and Gloria)</span></div><div style="text-indent:27pt;padding-left:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">Our partner, WuXi, has outlicensed the rights to certain programs using the OmniAb technology to Arcus and Gloria.  Arcus is conducting multiple Phase 1 trials to evaluate the safety and tolerability of AB122 in subjects with advanced solid tumors. Additionally, Gloria, is conducting a Phase 2 trial in China to evaluate the efficacy and safety of GLS-010 injection in the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%;text-decoration: underline;">CS1001 (CStone)</span></div><div style="text-indent:27pt;padding-left:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;">WuXi has also outlicensed the rights to certain programs using the OmniAb technology to CStone. CStone, is currently conducting a Phase 2 trial to evaluate the efficacy and safety of CS1001 to treat patients with natural killer cell/T-cell lymphoma and classical Hodgkin&#8217;s lymphoma. Under the terms of our agreement with WuXi, we are entitled to royalties on potential future sales.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">SB206 (Novan) </span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We acquired certain economic rights to SB206 from Novan in May 2019. SB206 is a topical nitric-oxide antiviral gel for the treatment of viral skin infections, including molluscom contagiosum (MC). MC is an infection which causes skin-lesion that affects approximately 6 million people in the United States annually, with the greatest incidence in children aged one to 14 years.  In Q1 2020, Novan announced that it did not achieve statistically significant results for its primary end point from its </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Phase 3 pivotal trials of SB206 in MC. Novan continues to explore financial as well as strategic options in order to progress SB206.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:114%;">Ciforadenant &#8211; CPI-444 (Corvus)</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Corvus, is conducting a Phase 1b/2 clinical trial in patients with renal cell carcinoma and metastatic castration resistant prostate cancer to evaluate Ciforadenant, an antagonist of adenosine A2A, in combination with the immunotherapy drug atezolizumab. Positive preliminary data was presented in February at ASCO 2020 Genitourinary Cancers Symposium (ASCO-GU) and additional data will be presented at ASCO 2020 in May/June. Ciforadenant is also being evaluated in a Phase 1b/2 trial in combination with atezolizumab in patients with non-small cell lung cancer who have failed no more than two prior regimens. Under the terms of our agreement with Corvus, we are entitled to development and regulatory milestones and tiered royalties on potential future sales. The aggregate potential milestone payments from Corvus are approximately $220 million for all indications.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:93%;">Perampanel IV (Eisai)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner, Eisai, recently completed an open-label, single group assignment, multicenter, Phase 2 study in Japan to evaluate the safety and tolerability of intravenous perampanel, formulated with Captisol, as substitute for oral tablets as an adjunctive therapy in patients with partial onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures. The primary endpoint was the number of patients with adverse events and serious adverse events. We are entitled to revenue from Captisol material sales and tiered royalties on potential future sales.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:93%;">USL-311 (Proximagen)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our partner Proximagen, a wholly owned subsidiary of ACOVA, is developing USL-311, a CXCR4 antagonist, for the potential treatment of glioblastoma (GBM) and solid tumors. Proximagen is also investigating USL-311 for the potential treatment of inflammation. USL-311 is currently in a Phase 1/2 trial in patients with advanced solid tumors and relapsed/recurrent GBM. We are entitled to development and regulatory milestones and royalties on potential future sales.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:93%;">Pradefovir (Xi'an Xintong)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our Chinese licensee, Xi'an Xintong Medicine Research (following its acquisition of Chiva Pharmaceuticals), are developing pradefovir, an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. Pradefovir was developed using Ligand&#8217;s HepDirect technology. In September 2019, Xi'an Xintong Medicine Research reported positive results from a Phase 2 trial of pradefovir, showing good efficacy, safety and tolerability. At the dose of 75 mg, the reduction of DNA viral load, the percentage of no viral load detected, and HBeAg negative conversion rate were better than tenofovir disoproxil fumarate (TDF) after 24 weeks of treatment. Overall incidence of side effects was less than TDF and there was no renal or skeletal toxicity. Xi'an Xintong Medicine Research is planning for a Phase 3 trial. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:93%;">MB07133 (Xi'an Xintong)</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Chinese licensee Xi'an Xintong Medicine Research are also developing MB07133, a liver specific, HepDirect prodrug of cytarabine monophosphate, for the potential treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma.  MB07133 is currently in Phase 1 in China. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Royalties</span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have multiple programs under license with other companies that have products that are already being commercialized. In addition to the table below, we have generally described a typical Captisol and OmniAb royalty arrangement as low- to mid-single digit royalties. The following table represents substantially all of the disclosed information about our royalty arrangements:</span></div><div style="text-align:center;margin-bottom:10pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:10pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:10pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Royalty Table</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.298%;"><tr><td style="width:1.0%;"></td><td style="width:27.922%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.077%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.001%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#333399;background-color:rgb(255,255,255, 0.0);">Ligand Licenses With Tiered Royalties</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Licensee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Royalty Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Budesonide</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0% - 10.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Meloxicam</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0% - 10.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ciforadenant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mid-single digit to low-teen royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DGAT-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0% - 7.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Duavee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ensifentrine (RPL554)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Verona</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FBPase Inhibitor (VK0612)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.5% - 9.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IRAK4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TG Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0% - 9.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amgen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5% - 3.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lasofoxifene</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sermonix</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0% - 10.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mineral Coated Microparticle</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0% - 3.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-Genagon</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genagon</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0% - 6.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-GigaGen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GigaGen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mid-single digit royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-iMetabolic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">iMetabolic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt;6%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-Kira</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kira</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low to mid-single digit royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Takeda</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oral EPO</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5% - 8.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PTX-022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0% - 9.8%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RVT-1502</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metavant</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low double digit to mid-teen royalty</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARM (VK5211)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.25% - 9.25%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SB206</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novan </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0% - 10.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TR Beta (VK2809 and VK0214)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5% - 7.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viviant/Conbriza</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5% - 2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Various</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nucorion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0% - 9.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Various</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0% - 10.0%</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.298%;"><tr><td style="width:1.0%;"></td><td style="width:27.922%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.077%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.001%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#333399;background-color:rgb(255,255,255, 0.0);">Ligand Licenses With Fixed Royalties</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Licensee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#ff6600;background-color:rgb(255,255,255, 0.0);">Royalty Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-1BB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zhilkang Hongyi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AB122</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arcus</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Baxdela</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Melinta</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Fosphenytoin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sedor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CS1001</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CStone</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acrotech/CASI</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KLM465</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Novartis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.5% (6.5% in year one)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MB07133</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ME-143</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MEI Pharma</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ME-344</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MEI Pharma</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb-KSQ Therapeutics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">KSQ Therapeutics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PCSK-9</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Genekey</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pradefovir</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reproxalap</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aldeyra Therapeutics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sparsentan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Various</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gloria</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Low single digit royalty&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Zulresso</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SAGE</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contract Payments (Milestones)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our programs under license with our partners will generate contract payments to us if our partners reach certain development, regulatory and commercial milestones. The following table represents the potential maximum value of our contract payment pipeline on milestones by development stage, technology and partner (in thousands):</span></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.152%;"><tr><td style="width:1.0%;"></td><td style="width:13.527%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.527%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.576%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.527%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.527%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.042%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.527%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.347%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology*</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stage*</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner*</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $800,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $20,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Viking</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1,500,000</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Captisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $180,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $450,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$238,000</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $350,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Regulatory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $1,600,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seelos</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$139,000</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LTP/Hep Direct</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $275,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $1,200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$100,000</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NCE/Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $1,700,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corvus</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$91,000</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $3,300,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $3,300,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Xi'an Xintong</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$44,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $1,188,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt; $3,300,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">*All tables exclude our annual access fees and collaboration revenue for development work.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;">Internal Development Programs </span></div><div style="text-indent:22pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have a number of internal development or unpartnered programs focused on a wide-range of potential indications or disease. In July 2019, we announced positive top-line results from a Phase 1 clinical trial of our internal Captisol-enabled (CE) Iohexol program. The trial achieved the primary endpoint by demonstrating pharmacokinetic bioequivalence of CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE&#8482;) after IV administration in healthy adults. CE-Iohexol injection was well tolerated, and adverse events were in line with the known safety profile of OMNIPAQUE. On November 8, 2019, we presented the positive results from the Phase 1 clinical trial at ASN Kidney week 2019 in Washington D.C. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. CI-AKI is the acute impairment of renal function following intravascular administration of an iodinated contrast agent, and occurs most frequently following coronary angiography, percutaneous coronary intervention and contrast-enhanced computed tomography, especially among patients at risk of renal injury such as those with advanced age, diabetes or heart failure.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Currently no products are approved to prevent or treat CI-AKI in this setting, and therefore We believe a significant opportunity exists for a safer formulation of contrast agents. The goal is for CE-Iohexol to improve upon the limitations of existing contrast agents and enable a future partner to gain meaningful market share. We plan to submit an IND with the FDA and initiate a Phase 2 study in the U.S. in second half of 2020.</span></div><div style="text-indent:22pt;"><span><br/></span></div><div style="text-indent:22pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our primary research and development efforts are led by our teams in Emeryville, California and Cambridge, England. The following table represents internal programs eligible for further development or partnership:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:14pt;margin-bottom:17pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.619%;"><tr><td style="width:1.0%;"></td><td style="width:43.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.452%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.044%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.778%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.139%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Program</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development Stage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Targeted Indication or Disease</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Luminespib/Hsp90 Inhibitor</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAAH Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pain</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Sertraline, Oral Concentrate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depression</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Iohexol</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostics</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CCR1 Antagonist</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Busulfan</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Cetirizine Injection</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allergy</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CE-Silymarin for Topical formulation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sun damage</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLT3 Kinase Inhibitors</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GCSF Receptor Agonist</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Blood disorders</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liver Specific Glucokinase Activator</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diabetes</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-B7-H3</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-TIM3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-TIGIT</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-CD38</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chk1 Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Oncology</span></td></tr></table></div><div style="margin-top:17pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Manufacturing</span></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We contract with a third party manufacturer, Hovione, for Captisol production.  Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing and distribution operations for Captisol are performed primarily at Hovione's Portugal and Ireland facilities. We believe we maintain adequate inventory of Captisol to meet our current and future partner needs.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers.&#160;If the supply interruption continues beyond a designated period, we may terminate the agreement.&#160;In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The current term of the agreement with Hovione is through December 2024. The agreement will automatically renew for successive two year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. We have ongoing minimum purchase commitments under the agreement.</span></div><div style="margin-top:14pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Competition</span></div><div style="text-indent:24pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.</span></div><div style="text-indent:24pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. Our OmniAb antibody technology faces competition from suppliers of other transgenic animal systems that are also available for antibody drug discovery.</span></div><div style="text-indent:24pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:14pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Environmental, Health and Safety (EHS)</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards. We establish and monitor programs to reduce pollution, prevent injuries, and maintain compliance with applicable regulations. By focusing on such practices, we believe we can affect a meaningful, positive change in our community and maintain a healthy and safe environment. During 2019, our animal health facility in Emeryville, California, received accreditation from Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. We expect to continue our effort and to refine our EHS policies and practices in 2020.</span></div><div style="margin-top:14pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Government Regulation</span></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries.&#160;We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical&#160;products. These activities are subject to additional regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed products and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Item 1A. Risk Factors.&#8221;</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Patents and Proprietary Rights</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Promacta</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patents covering Promacta are owned by Novartis. During the first quarter of 2019, we sold our Promacta related intellectual property rights to RPI Finance Trust, doing business as &#8220;Royalty Pharma&#8221;. We expect no future royalty revenue from Promacta. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Kyprolis</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. Amgen has filed suit against several generic drug companies over their applications to make generic versions of Kyprolis, with a decision expected by April 2020. The type of patent protection (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">e.g</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">., composition of matter or use) for each patent listed in the Orange Book and the expiration dates for each patent listed in the Orange Book are provided in the following table.  In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.</span></div><div style="text-indent:27pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.883%;"><tr><td style="width:1.0%;"></td><td style="width:14.332%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.640%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.640%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.798%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corresponding Foreign</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Protection</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Patent No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Expiration Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patent Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration Date&#8225;</span></td></tr><tr><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,232,818</span></td><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,781,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,101,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" rowspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,417,042</span></td><td colspan="3" rowspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7/20/2026</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,781,688</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,101,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,491,704</span></td><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,781,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,101,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,737,112</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/7/2027</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,819,353</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/7/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,260,835</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/7/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261,236</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/7/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,990,155</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/7/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,108,509</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/9/2025</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,129,346</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,616,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,207,125</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,781,688</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,616,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743,720</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/8/2025</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM / Use</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,207,126</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,616,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,207,127</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,616,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM / Use</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,207,297</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,745,064</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,394,423</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,616,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/14/2025</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,493,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,517,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,511,109</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/21/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,796,134&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/21/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,675,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/21/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,081,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/21/2029</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;vertical-align:top;">&#8225;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Captisol</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Patents and pending patent applications covering Captisol and methods of making Captisol are owned by us. The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">see, e.g.,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). Other patent applications covering methods of making Captisol, if issued, potentially have terms to 2040. We have asserted U.S. Patents 8,410,077, 9,200,088, and 9,493,582 against Teva in connection with their attempt to obtain FDA approval to manufacture and sell a generic version of EVOMELA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. We also own several patents and pending patent applications covering drug products containing Captisol as a component. The type of patent protection (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">e.g</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">., composition of matter or use) and the expiration dates for several issued patents covering Captisol are provided in the following table. In addition, certain related patents and applications in the commercially important jurisdictions of Europe and Japan are listed in the following table.</span></div><div style="text-indent:27pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"><tr><td style="width:1.0%;"></td><td style="width:14.408%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.241%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.195%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.720%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Captisol</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corresponding Foreign</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Protection</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Patent No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Expiration Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patent Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration Date&#8225;</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,114,438&#160;</span></td><td rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,708,225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,141,906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,538,739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,117,940&#160;</span></td><td rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,708,225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,141,906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,538,739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/22/2025</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,629,331&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,945,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,335,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,581,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,465,432&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,049,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/19/2026</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,583,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,846,901&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,945,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,335,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,581,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,465,432&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2026</span></td></tr><tr><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,829,182&#160;</span></td><td rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,945,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,335,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,581,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,952,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,465,432&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use/MoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,617,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/8/2026</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,952,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/MoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,202,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2025</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM / Use</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,635,773&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/13/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,923,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,039,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,276,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,444,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,410,077&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/13/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,923,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,039,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,276,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,444,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"><tr><td style="width:1.0%;"></td><td style="width:14.408%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.241%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.195%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.720%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,200,088&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/13/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,923,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,039,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,276,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,444,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,750,822&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/13/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,923,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,039,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,276,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,444,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,117,951&#160;</span></td><td rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="4" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/13/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,923,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,039,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,276,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,444,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/28/2029</span></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MoM</span></td><td colspan="2" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,751,957&#160;</span></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/28/2033</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,814,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/14/2033</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,508,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/14/2033</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,493,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,517,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,323,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,517,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/MoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,040,872&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2/27/2033</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,557,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/21/2033</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:3pt;margin-bottom:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#8225;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1A. Risk Factors.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">OmniAb  </span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our OmniAb&#174; therapeutic antibody platforms, including OmniRat&#174;, OmniMouse&#174; and OmniChicken&#8482;, produce naturally optimized, fully human antibodies in animals. We have received patent protection on OmniAb antibodies and methods  in 30 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and have 56 patent applications pending in 24 countries worldwide. The patents and applications owned by us are expected to expire between 2028 and 2034 and partners are able to use the OmniAb patented technology to generate novel antibodies, which may be entitled to additional patent protection.</span></div><div style="text-indent:22pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:22pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb in OmniMouse and OmniRat</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corresponding Foreign</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Protection</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Patent No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Expiration Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patent Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration Date&#8225;</span></td></tr><tr><td colspan="3" rowspan="7" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,703,485</span></td><td colspan="3" rowspan="5" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/10/2031</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,152,880</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,336,329</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,603,323&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,823,690</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,220,827&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,388,233</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,072,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,907,157</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/30/2028</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,475,859</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4/15/2034</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,285,132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/8/2034</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"></td><td style="width:14.172%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.513%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.017%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.626%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OmniAb in OmniChicken</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corresponding Foreign</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Protection</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Patent No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Expiration Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patent Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration Date&#8225;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,030,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/23/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Europe</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,271,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/2/2029</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,415,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/2/2029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,737,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/2/2029</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,592,644&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/30/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,756,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/11/2030</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,404,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/29/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,549,538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/11/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,010,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/11/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,172,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/11/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,362,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/11/2030</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/MoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,865,462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/8/2032</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Com/MoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,644,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/7/2031</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,380,769&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/23/2032</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EU</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,713,712&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/23/2032</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,809,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/23/2032</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM/Use</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,394,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/16/2032</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CoM</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,982,062&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/16/2032</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:3pt;margin-bottom:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#8225;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Vernalis</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our acquisition of Vernalis in October 2018 provided us with a portfolio of fully-funded shots on goal, which now include RPL554, a Phase 2, novel treatment for COPD, which is partnered with Verona; Ciforadenant, a Phase 1 adenosine A2A receptor antagonist for treatment of solid tumors, partnered with Corvus; Tosedostat, an aminopeptidase inhibitor for treatment of blood cancers, partnered with Cell Therapeutics, Inc. (CTI),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">S65487, a Bcl-2 inhibitor, and S64315, an Mcl-1 inhibitor for treatment of cancers, both of which are partnered with Servier in collaboration with Novartis, and VER250840 (an oral, selective Chk1 inhibitor for treatment of cancer) partnered with Cumulus. Vernalis has a worldwide patent portfolio of over 240 granted patents and over 20 pending applications, spanning over 60 countries.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">    </span></div><div style="margin-top:14pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of February 10, 2020, we have 115 employees, of whom 86 are involved directly in scientific research and development activities. We emphasize competitive compensation, benefits, equity participation, and a positive and attractive work environment in our efforts to attract and retain qualified personnel.</span></div><div style="margin-top:14pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investor Information</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Financial and other information about us is available on our website at www.ligand.com. We make available on our website, without charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission, or SEC. You may obtain copies of these documents by visiting the SEC&#8217;s website at www.sec.gov. These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing. </span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_16"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:9.876%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.124%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RISK FACTORS</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business, including the businesses of our subsidiaries. You should also consider the other information described in this report. Additional risks not presently known to us or that we currently deem immaterial also may impair our business.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risks Related to Our Business Operations and Reliance on Third Parties:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future revenue based on Kyprolis and Evomela, as well as royalties from our other partnered products, may be lower than expected.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Substantially all of our royalty revenue is based on sales of Kyprolis by Amgen and sales of Evomela by Acrotech Biopharma. Royalties, including payments from Amgen and Acrotech Biopharma, are expected to be a substantial portion of our ongoing revenues for the foreseeable future. Any setback that may occur with respect to any of our partners' products, and in particular Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including Amgen's or Acrotech Biopharma's failure to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition. For example, we entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. The entry of generic competition for Evomela may materially and adversely affect the revenue we derive from Evomela sales. Also, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences&#8221; and litigation against one other party is awaiting a post-trial judgement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">   </span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future revenue from sales of Captisol material to our license partners may be lower than expected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from sales of Captisol material to our collaborative partners, including Amgen, represent a significant portion of our current revenues.  Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock.  Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We obtain Captisol from a sole source supplier, and if this supplier were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships.  We maintain inventory of Captisol, which has a five year shelf life, at three geographically dispersed storage locations in the United States and Europe.&#160; If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions.  While we believe we maintain adequate inventory of Captisol to meet our current and expected future partner needs, our estimates and projections for Captisol demand may be wrong and any supply interruptions could materially adversely impact our operating results.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently depend on our arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will.  If our partners discontinue sales of products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, or choose to utilize a competing product, or if we are unable to establish new licensing and marketing relationships, our financial results and growth prospects would be materially affected. Furthermore, we maintain significant accounts receivable balances with certain customers purchasing Captisol materials, which may result in the concentration of credit risk. We generally do not require any collateral from our customers to secure payment of these accounts receivable.  If any of our major customers were to default in the payment of their obligations to us, our business, operating results and cash flows could be adversely affected.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, under most of our Captisol outlicenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">purity patents and foreign equivalents, are not expected to expire until 2029 and our morphology patents and foreign equivalents, are not expected to expire until 2025, but the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States.  If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements could reduce our milestone and license fee revenue, and potential reduce future royalties.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy for developing and commercializing many of our product candidates includes entering into collaboration agreements, outlicenses, and development funding and royalty purchase agreements with corporate partners and others. These agreements give our collaboration partners significant discretion when deciding whether or not to pursue any development program. Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaboration arrangements to develop and commercialize our unpartnered assets.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our collaborators may develop products, either alone or with others that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our or our partners' programs. If product candidates are approved for marketing under our collaboration programs, revenues we receive will depend on the manufacturing, marketing and sales efforts of our collaboration partners, who generally retain commercialization rights under the collaboration agreements. Generally, our current collaboration partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaboration partners breach (for example, by not making required payments when due, or at all) or terminate their agreements with us or otherwise fail to conduct their collaboration activities successfully, including due to insolvency events, ongoing product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates. Any such dispute or litigation could delay, interrupt or terminate the collaboration research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">respect to our partnered programs, and the success of our partnered programs could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our collaboration partners terminate their collaborations with us or do not commit sufficient resources to the development, manufacture, marketing or distribution of our partnered programs, we could be required to devote additional resources to our partnered programs, seek new collaboration partners or abandon such partnered programs, all of which could reduce our revenues and otherwise have an adverse effect on our business. For example, several of our collaboration partners using our OmniAb antibody platform have terminated their contracts or substantially reduced their investment in the antibodies discovered based on the platform. Although we expect growth in the net number of partners with one more active programs based on antibodies discovered using our OmniAb platform, there can be no assurance that our partners will continue their programs or that we will be able to find new collaboration partners interested in discovering antibodies based on our OmniAb platform.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective.  We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action.  Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could adversely affect our business. The product development and clinical trials process is complex and uncertain.  For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials.  In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities.  A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials.  The FDA may also require additional clinical trials after regulatory </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approvals are received.  Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, the ability to obtain adequate supplies of the products to be tested and patient enrollment.  Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied.  Delays in patient enrollment for our or our partners&#8217; trials may result in increased costs and longer development times.  In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations.  As a result, these partners may conduct these programs more slowly or in a different manner than expected.  Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA or foreign regulatory approval in a timely manner or the FDA or foreign regulatory authority still may not grant approval.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidate discovery, early-stage development, and product reformulation programs may require substantial additional capital to complete successfully.  Our partners&#8217; development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs.  While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing.  These financings could depress our stock price.  If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our OmniAb antibody platform faces specific risks, including the fact that no product using antibodies from the platform has been approved by the FDA or similar regulatory agency.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of our collaboration partners using our OmniAb antibody platform have received approval from the FDA or similar regulatory agency to market a product discovered based on our platform. In addition, only a few of our collaboration partners&#8217; product candidates based on the platform have been tested in late stage clinical trials. If one of our OmniAb collaboration partners&#8217; product candidates fails during preclinical studies or clinical trials, our other OmniAb collaboration partners may decide to abandon product candidates using antibodies generated from the OmniAb platform, whether or not such failure is attributable to the platform. All of our OmniAb collaboration partners may terminate their programs at any time without penalty. In addition, our OmniRat and OmniFlic platforms, which we consider the most promising, are covered by six patents within the U.S. and three patents in the European Union and are subject to the same risks as our patent portfolio discussed elsewhere, including the risk that our patents may infringe on third party patent rights or that our patents may be invalidated. As of a result of these factors, the future revenue generated from this platform may be materially lower than what we currently anticipate. Further, we face significant competition from other companies selling human antibody-generating rodents, especially mice which compete with our OmniMouse platform, including the VelocImmune mouse, the AlivaMab mouse, the Trianni mouse and the Kymouse. Many of our competitors have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market competing antibody platforms.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risks Related to Intellectual Property:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others.  If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology.  We may not be able to obtain any such licenses on acceptable terms, or at all.  Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products.&#160; Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.&#160; Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.&#160; </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We permit our partners to list our patents that cover their branded products in the Orange Book. If a third party files an NDA or ANDA for a generic drug product that relies in whole or in part on studies contained in our partner&#8217;s NDA for their branded product, the third party will have the option to certify to the FDA that, in the opinion of that third party, the patents listed in the Orange Book for our partner&#8217;s branded product are invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug product. A third party certification that a new product will not infringe Orange Book-listed patents, or that such patents are invalid, is called a paragraph IV patent certification. If the third party submits a paragraph IV patent certification to the FDA, a notice of the paragraph IV patent certification must be sent to the NDA owner and the owner of the patents that are subject to the paragraph IV patent certification notice once the third-party&#8217;s NDA or ANDA is accepted for filing by the FDA. A lawsuit may then be initiated to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of the receipt of notice of a paragraph IV patent certification automatically prevents the FDA from approving the generic NDA or ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the NDA or ANDA applicant, or such shorter or longer period as the court may order. If a patent infringement lawsuit is not initiated within the required 45-day period, the third-party&#8217;s NDA or ANDA will not be subject to the 30-month stay.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Several third-parties have challenged, and additional third parties may challenge, the patents covering our partner&#8217;s branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. We may from time to time become party to litigation or other proceedings as a result of Paragraph IV certifications. For example, as a result of the settlement of one such matter, Teva will be permitted to market a generic version of Evomela</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential. Also, as noted above, Amgen has settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences&#8221; and litigation against one other party is awaiting a post-trial judgement. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we cannot assure you that all of the potentially relevant prior art information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention-relating to our and our partners&#8217; patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we or our partners may be subject to a third party pre-issuance submission of prior art to the United States Patent and Trademark Office. Even if patents do successfully issue and even if such patents cover our or our partner&#8217;s products or potential products, third parties may initiate litigation or opposition, interference, re-examination, post-grant review, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our or our partners&#8217; products and compete directly with us and our partners, without payment to us or our partners, or limit the duration of the patent protection of our and our partners&#8217; technology and products. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our partner&#8217;s products. Any adverse outcome of such litigation or other proceedings could result in one or more or our patents being held invalid or unenforceable, which could adversely affect our ability to successfully execute our business strategy and negatively impact our financial condition and results of operations. However, given the unpredictability inherent in litigation, we cannot predict or guarantee the outcome of these matters or any other litigation. Regardless of how these matters are ultimately resolved, these matters may be costly, time-consuming and distracting to our management, which could have a material adverse effect on our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection.  For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol was upheld on appeal.  In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements.  We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position.  We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us.  These agreements may be breached, and we may not have adequate remedies for any breach.  In addition, our competitors may independently discover our trade secrets.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights.  If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights.  In addition, if any of our competitors have filed patent applications in the United States which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology.  </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The validity, scope and enforceability of any patents that cover our partners&#8217; biologic product candidate can be challenged by third parties.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For biologics, the Biologics Price Competition and Innovation Act of 2009, BPCIA, provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological products. Due to the large size and complexity of biological products, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in an Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, sponsors may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our partners&#8217; ability to prevent third parties from competing with their products or product candidates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risks Related to Government Regulation and Legal Proceedings:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of the products we license to our collaboration partners and the royalties we receive will depend in large part on the extent to which coverage and reimbursement is available from government and health administration authorities, private health maintenance organizations and health insurers, and other healthcare payors. Significant uncertainty exists as to the reimbursement status of healthcare products. Healthcare payors, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products. Even if a product is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover the costs associated with the research, development, marketing and sale of the product. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any product, market acceptance and any sales could be reduced.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, legislation is implemented to reign in rising healthcare expenditures. By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted, which included a number of provisions affecting the pharmaceutical industry, including, among other things, annual, non-deductible fees on any entity that manufactures or imports some types of branded prescription drugs and increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program. Since its enactment, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict whether other legislative changes will be adopted, if any, or how such changes would affect our operations or financial condition.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our collaboration partners may be subject to federal and state healthcare laws, including fraud and abuse, false claims, physician payment transparency and health information privacy and security laws. Our operations and those of our collaboration partners are subject to various federal and state fraud and abuse laws, including, without limitation, anti-kickback, false claims and physician payment transparency statutes. These laws may impact, among other things, financial arrangements with physicians, sales, marketing and education programs and the manner in which any of those activities are implemented. In addition, we may be subject to federal and state patient privacy regulations. If our operations or those of our collaboration partners are found to be in violation of any of those laws or any other applicable governmental regulations, we or our collaboration partners may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment, exclusion from government healthcare programs or the curtailment or restructuring of operations, any of which could adversely affect our ability to operate our business and our financial condition.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners.  For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed which would result in delayed milestone revenues and materially harm our operations of business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is common in our industry, our partners and we face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates, partnered products or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and product recall or withdrawal from the market and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $10.0&#160;million annual limit. Our insurance coverage may not be sufficient to cover all of our product liability related </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expenses or losses and may not cover us for any expenses or losses we may suffer.  If we are sued for any injury caused by our product candidates, partnered products or any future products, our liability could exceed our total assets.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face risks related to handling of hazardous materials and other regulations governing environmental safety.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. Although we have secured clearance from the EPA historically, and currently are operating in material compliance with applicable EPA rules and regulations, our business could be adversely affected if we discover that we or an acquired business is not in material compliance with these rules and regulations. In the future, we may pursue the use of other surfactant substances that will require clearance from the EPA, and we may fail to obtain such clearance. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, which could adversely affect our business.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risk Related to Our Strategic Transactions:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any difficulties from strategic acquisitions could adversely affect our stock price, operating results and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired IPR&amp;D charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Other Risks:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the royalties from the sales of Kyprolis, Evomela and other products sold by our partners; </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the success of our collaboration partners&#8217; preclinical and clinical programs;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the timing of Captisol purchases for use in clinical trials and commercial products; </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our internal development programs, which may change from time to time;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">expenditures that we may incur to acquire or develop additional product candidates and platform technologies; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">future accounting pronouncements or changes in our accounting policies. </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the FASB either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued an accounting standard for revenue recognition-Accounting Standards Codification Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or ASC 606-that supersedes most current revenue recognition guidance. The guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services.  The guidance became effective in fiscal 2018. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 606, Ligand estimates and books royalties in the same quarter that our partners report the sale of the underlying product. We rely on our partners&#8217; earning releases and other information from our partners to determine the sales of our partners&#8217; products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Uncertainties in the interpretation&#160;and&#160;application of the 2017&#160;Tax&#160;Cuts&#160;and&#160;Jobs&#160;Act&#160;could materially affect our&#160;tax&#160;obligations&#160;and&#160;effective&#160;tax&#160;rate.&#160;</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2017&#160;Tax&#160;Cuts&#160;and&#160;Jobs&#160;Act&#160;(the&#160;Tax&#160;Act) was enacted on December 22, 2017, and significantly affected U.S. tax law, including by changing how the U.S. imposes tax on certain types of income of corporations and by reducing the general U.S. corporate income tax rate. The U.S. Department of Treasury has broad authority to issue regulations and interpretative guidance that may significantly impact how we will apply the law and impact our results of operations in the period issued.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Act requires certain complex computations not previously provided in U.S. tax law. As such, the application of accounting guidance for such items is currently uncertain. Further, compliance with the Tax Act and the accounting for such provisions require accumulation of certain information not previously required or regularly produced. As a result, we have provided a provisional estimate on the effect of the Tax Act in our financial statements. As additional and other regulatory guidance is issued by the applicable taxing authorities, as accounting treatment is clarified, as we perform additional analysis on the application of the law, and as we refine estimates in calculating the effect, our final analysis, which will be recorded in the period completed, may be different from our current provisional amounts, which could materially affect our tax obligations and effective tax rate.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations. </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December&#160;31, 2019, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $31.5 million and $119.1 million, respectively.  Our federal NOLs expire through </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2037 and our state NOLs begin to expire in 2028</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, if not utilized. Under the Tax Act, any federal NOLs arising in taxable years ending after December 31, 2017 will carry forward indefinitely. As of December&#160;31, 2019, we had federal and California research and development tax credit carryforwards of approximately $0.6 million and $22.9 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2038, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code) if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Furthermore, under the Tax Act, although the treatment of tax losses generated in tax years beginning before December 31, 2017 has generally not changed, tax losses generated in tax years beginning after December 31, 2017 may only offset 80% of our taxable income. This change may require us to pay federal income taxes in future years despite having potentially generated a loss for federal income tax purposes in prior years. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications.  Despite the implementation of security measures, our internal computer systems and those of our partners are vulnerable to damage from cyber-attacks, computer viruses, security breaches, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, could lead to the loss of trade secrets or other intellectual property, could lead to the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business and financial condition could be harmed.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits or we could lose key data which could cause us to curtail or cease operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Conversion of our outstanding convertible notes may result in losses, result in the dilution of existing stockholders, create downward pressure on the price of our common stock, and restrict our ability to take advantage of future opportunities.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued $750.0 million principle amount of the 2023 Notes. The sale of the 2023 Notes may affect our earnings per share figures, as accounting procedures require that we include in our calculation of earnings per share the number of shares of our common stock into which the 2023 Notes are convertible. The convertible notes may be converted into cash and shares of our common stock, if any (subject to our right or obligation to pay cash in lieu of all or a portion of such shares).  If shares of our common stock are issued to the holders of the convertible notes upon conversion, there will be dilution to our shareholders equity and the market price of our shares may decrease due to the additional selling pressure in the market. Any downward pressure on the price of our common stock caused by the sale or potential sale of shares issuable upon conversion of the convertible notes could also encourage short sales by third parties, creating additional selling pressure on our stock.  Upon the occurrence of certain circumstances, holders of the convertible notes may require us to purchase all or a portion of their notes for cash, which may require the use of a substantial amount of cash. If such cash is not available, we may be required to sell other assets or enter into alternate financing arrangements at terms that may or may not be desirable. The existence of the convertible notes and the obligations that we incurred by issuing them may restrict our ability to take advantage of certain future opportunities, such as engaging in future debt or equity financing activities. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had $750.0 million aggregate principal amount of 2023 Notes. The notes are convertible into cash, and if applicable, shares of our common stock under certain circumstances, including trading price conditions related to our common stock. Upon conversion, we are required to record a gain or loss for the difference between the fair value of the notes to be extinguished and their corresponding net carrying value. The fair value of the notes to be extinguished depends on our current incremental borrowing rate. If our incremental borrowing rate at the time of conversion is lower than the implied interest rate of the notes, we will record a loss in our consolidated statement of income during the period in which the notes are converted. </span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our investments are subject to market and credit risks that could diminish their value and these risks could be greater</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">business, financial condition, results of operations, liquidity and cash flows.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our investments are subject to risks of credit defaults and changes in market values. Periods of macroeconomic weakness or recession, heightened volatility or disruption in the financial and credit markets could increase these risks, potentially resulting in other than temporary impairment of assets in our investment portfolio. Any event reducing the estimated fair value of these securities, other than on a temporary basis, could have a material and adverse effect on our business, results of operations, financial condition, liquidity and cash flows. If our investment manager, fails to react appropriately to difficult</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">market, economic and geopolitical conditions, our investment portfolio could incur material losses.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a risk management framework in place to identify, assess and prioritize risks, including the market and credit</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">risks to which our investments are subject. As part of that framework, we test our investment portfolio based on various market</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">scenarios. Under certain stressed market scenarios, unrealized losses on our investment portfolio could lead to material</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reductions in its carrying value.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A decline in fair value below the amortized cost of a security requires management to assess whether an impairment has occurred. The decision on whether to record an impairment is determined in part by our assessment of the financial condition and prospects of a particular issuer, projections of future cash flows and recoverability of the particular security as well as management&#8217;s assertion of whether it is more likely than not that we will sell the particular security before recovery.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our charter documents and concentration of ownership may hinder or prevent change of control transactions.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership.  In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders.  Our directors and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership.  If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our stock price has been volatile and could experience a sudden decline in value.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has recently experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher share-based compensation expense.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future.  Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; comments or opinions by securities analysts or major stockholders or changed securities analysts' reports or recommendations; future sales or shorting of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, public health emergencies, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future to contribute to, increased volatility and diminished expectations for the economy and the markets. For example, the outbreak of a novel strain of coronavirus has affected the People&#8217;s Republic of China and elsewhere and has affected worldwide equity markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.</span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_19"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unresolved Staff Comments</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_22"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Properties</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our principal facilities leased as of December&#160;31, 2019, including the location and size of each facility, and their designated use. We also lease facilities in other locations. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed. </span></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:5pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:23.598%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.413%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.389%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.600%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Approximate <br/>Square Feet</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Expiration Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">San Diego, CA</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate headquarters office</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 2023</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emeryville, CA</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Office and laboratory</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 2021</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cambridge, United Kingdom</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Office and laboratory</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 2026</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_25"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (10), Commitments and Contingencies&#8212;Legal Proceedings.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_28"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mine Safety Disclosures</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_31"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_34"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></td></tr></table></div><div style="margin-top:5pt;"><span><br/></span></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221; As of February&#160;14, 2020, there were approximately 446 holders of record of the common stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents information regarding repurchases by us of our common stock during the three months ended December 31, 2019 under the stock repurchase program approved by our board of directors in September 2019, under which we may acquire up to $500 million of our common stock in open market and negotiated purchases for a period of up to three years. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:35.591%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.524%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.041%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.149%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.691%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.096%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.562%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.625%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Shares&#160;Purchased</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Average&#160;Price&#160;Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Per Share</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Shares&#160;Purchased&#160;as</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Part of Publicly</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Announced Plans or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Maximum&#160;Dollar&#160;Value&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Shares that May Yet Be</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">Purchased Under the </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Program                              </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">October 1 - October 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">408,730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 1 - November 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">625,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.74&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">625,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 1 - December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,519&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,519&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">326,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">760,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">760,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since December 31, 2019 and as of February 21, 2020, we acquired 405,527 additional shares during 2020, and the maximum dollar value of shares that may yet be purchased under the repurchase program was $290.0 million.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the 2020 Annual Meeting Proxy Statement as defined in Item 10 below.</span></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Performance Graph</span></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalizations. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Index, and of the Nasdaq Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.</span></div><div style="text-indent:24pt;text-align:right;margin-top:9pt;"><img src="lgnd-20191231_g2.jpg" alt="lgnd-20191231_g2.jpg" style="height:342px;width:684px;"/></div><div style="text-indent:6pt;text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-indent:6pt;text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Value of $100 Invested Over Time</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"><tr><td style="width:1.0%;"></td><td style="width:36.933%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.369%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.446%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.369%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.369%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.208%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.693%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.378%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2014</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2015</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12/31/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257.34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.03&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NASDAQ Composite-Total Return</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200.49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="margin-top:9pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_37"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selected Consolidated Financial Data</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following selected historical consolidated financial and other data are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and the related notes thereto appearing elsewhere herein and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Our selected statement of operations data set forth below for each of the years ended December&#160;31, 2019, 2018, 2017, 2016 and 2015 and the balance sheet data as of December&#160;31, 2019, 2018, 2017, 2016 and 2015 are derived from our consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The comparability of the information is affected by a variety of factors, including acquisitions and divestitures of businesses, issuance and repayment of debt, share-based compensation expense, and repurchases of common stock under our stock repurchase programs. In addition, the consolidated statement of operations data for each of the years ended December 31, 2017, 2016 and 2015 and the selected consolidated balance sheet data as of December 31, 2017, 2016 and 2015 set forth in the tables below do not reflect the adoption of Topic 606 and continue to be reported under the standards in effect for those periods. Additionally, the selected consolidated balance sheet data as of December 31, 2018, 2017, 2016 and 2015 set forth in the tables below do not reflect the adoption of Topic 842 regarding leases and continue to be reported under Topic 840 for those periods. The selected consolidated financial data in this section are not intended to replace our consolidated financial statements and related notes. Our historical results are not necessarily indicative of our future results.</span></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:41.215%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.914%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.773%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Statements of Operations Data:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share amounts)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material sales</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones, and other revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of material sales</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,366&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,653&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,026&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,797&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">807,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,437)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,845)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,925)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(167,337)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,009)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,675)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,327)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations including noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629,302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">227,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,380)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629,302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$629,302</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$143,321</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$12,556</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$(1,636)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$229,824</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.08)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of common shares-basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,831&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.08)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of common shares-diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,831&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:43.722%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.324%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.324%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.330%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, short-term investments, restricted cash and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,070,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">776,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">149,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital (deficit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,106,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">788,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,847)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64,076)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,109)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,494,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,260,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">503,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term obligations (excludes long-term portions of deferred revenue, net and deferred gain)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,776&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total notes payable, net (including current portion)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">638,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings (accumulated deficit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(229,197)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(400,924)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(431,127)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(429,491)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">767,232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">399,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:6pt;"><span><br/></span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_40"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;7.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_43"></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) will help readers understand our results of operations, financial condition, and cash flow. It is provided in addition to the accompanying consolidated financial statements and notes. Comparisons under this heading refer to twelve months ended December&#160;31, 2019 and 2018, respectively, unless otherwise indicated. </span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our MD&amp;A is organized as follows:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Results of Operations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Detailed discussion of our revenue and expenses for twelve months ended December&#160;31, 2019 and 2018. A comparison of our results of operations for twelve months ended December&#160;31, 2018 and 2017 can be found under &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on February 28, 2019.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Liquidity and Capital Resources.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Discussion of key aspects of our consolidated statements of cash flows, changes in our financial position, and our financial commitments.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Off-Balance Sheet Arrangements. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no off-balance sheet arrangements.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Contractual Obligations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Tabular disclosure of known contractual obligations as of December 31, 2019.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Critical Accounting Policies and Estimates. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Discussion of significant changes we believe are important to understand the assumptions and judgments underlying our consolidated financial statements.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Recent Accounting Pronouncements.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> For summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.222%;"><tr><td style="width:1.0%;"></td><td style="width:58.300%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.551%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.559%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,580)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material Sales</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,366&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones and other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,957)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(131,171)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:27pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Royalty revenue is a function of our partners' product sales and the applicable royalty rate. Promacta and Kyprolis royalty rates are under a tiered royalty rate structure with the highest being 9.4% and 3.0%, respectively. Evomela has a fixed royalty rate of 20%. On March 6, 2019, we sold all of our rights, title and interest in and to the Promacta license to RPI. Subsequent to March 6, 2019, we no longer recognize revenue related to sales of Promacta. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (2), Sale of Promacta License.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Royalty revenue decreased in 2019 as compared to 2018 driven primarily by the above mentioned sale of the Promacta license in March 2019. Material sales increased year over year in 2019 due to timing of customer purchases of Captisol for use in clinical trials and in commercialized products. The decrease in license fee, milestones and other revenues in 2019 compared to 2018 was primarily driven by a $47.0 million OmniAb platform license fee received from WuXi and $20.0 million received from Roivant upon entering into the GRA license agreement to develop and commercialize RVT-1502 (formerly named LGD-6972) during 2018, partially offset by the additional revenue generated in 2019 from our Vernalis acquisition in October 2018. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table represents royalty revenue by program:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:21.900%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.049%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.170%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.706%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.049%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.997%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.173%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019 Estimated Partner Product Sales</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Royalty Rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019 Royalty Revenue </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018 Estimated Partner Product Sales</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Royalty Rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018 Royalty Revenue </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promacta</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,173.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">980.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,540.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,345.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Costs and Expenses</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:54.158%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.170%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.410%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.239%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of material sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,072&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating costs and expenses for 2019 increased $38.3 million or 44% compared with 2018. Cost of material sales increased year over year in 2019 primarily due to higher material sales as a result of timing of customer purchases and mix of Captisol sales in 2019. Amortization of intangibles increased year over year in 2019 primarily due to the acquisitions of Vernalis in October 2018 and Ab Initio in July 2019 as well as $2.7 million of accelerated amortization of the GRA asset due to the unlikelihood of continued program development. Research and development expenses increased year over year in 2019 due to timing of internal development costs, the Vernalis acquisition, and amortization of other economic rights during 2019. General and administrative expenses increased year over year in 2019 primarily due to increased business development activities, an increase in share-based compensation and the Vernalis acquisition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1A. Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for additional discussion of the uncertainties surrounding our research and development initiatives.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other income (expense)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:59.504%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.439%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.849%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) from Viking</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,299)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(94)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,745)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48,276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,531&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,307)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense,) net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,437)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,603&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,040)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(209)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The fluctuation in the gain (loss) from Viking is driven by the changes in the fair value of the Viking common stock and warrants. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income consists primarily of interest earned on our short-term investments. The year over year increase in 2019 was due to the increase in our short-term investment balances as a result of the proceeds from the 2023 Notes financing on May 22, 2018 and the proceeds from the sale of the Promacta license in March 2019.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense includes the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2019 Notes and 2023 Notes. The year over year decrease in 2019 was primarily due to lower average debt outstanding balance as compared to the prior year. The 2019 Notes were paid off upon the maturity date in August 2019. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net, for the twelve months ended December&#160;31, 2019, consists primarily of a $5.1 million reduction in the value of our Selexis commercial license right. See additional information in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial License and Other Economic Rights.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; Other income (expense), net, for the twelve months ended December&#160;31, 2018, consists primarily of changes in the fair value of contingent liabilities associated with our Crystal and Metabasis acquisitions and net changes in derivative instrument expense associated with our convertible notes and bond hedge transactions. See additional information in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income tax expense</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:57.281%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.548%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.880%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.548%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.548%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income tax expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">796,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">623,309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(167,337)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,009)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(137,328)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629,302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">485,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Tax Rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our effective tax rate for 2019 and 2018 was 21% and 17%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In addition to state income taxes, the items below had the most significant impact on the difference between our statutory U.S. income tax rate and our effective tax rate.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2019&#160;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$1.2 million (0.1%) decrease due to the release of a valuation allowance primarily relating to research and development tax credits. </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$0.9 million (0.1%) decrease from research and development tax credits </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$0.8 million (0.1%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2018</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$8.1 million (5%) decrease due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$4.2 million (2%) decrease due to changes in valuation allowance primarily relating to capital loss carryovers and research and development tax credits. </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$3.1 million (2%) increase from expired NOLs and credits</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$2.8 million (2%) reduction from research and development tax credits </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$0.9 million (1%) increase from non-cash contingent consideration charges that are nondeductible for tax purposes</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$0.9 million (1%) increase from Section 162(m) limitation </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_46"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resource</span></div><div style="text-indent:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, we had approximately $1,011.5 million in cash, cash equivalents, and short-term investments, of which approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">y $6.8 million was held by our foreign subsidiaries. Cash and cash equivalents and short-term investments increased by $293.2 million from last year, due to factors described in the "Cash Flow Summary" below. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, which increased during 2019 primarily from the sale of the Promacta license, has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. Our short-term investments include U.S. government debt securities, investment-grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 6.0 million shares of common stock in Viking.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, we issued the 2019 Notes with aggregate principal amount of $245.0 million. During 2018, $217.7 million in principal of the 2019 Notes were converted into cash. In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued the 2023 Notes with an aggregate principal amount of $750.0 million. A portion of the proceeds from such issuance totaling $49.7 million were used to repurchase 260,000 shares of our common stock. The 2023 Notes were not convertible as of December&#160;31, 2019. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. See detail in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, our Board of Directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years. On January 23, 2019, our Board of Directors increased the share repurchase authorization by $150.0 million. The available amount under the $350.0 million repurchase plan was fully utilized during the third quarter of 2019.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $326.8 million of our common stock remained available as of December&#160;31, 2019. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchase of Equity Securities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;</span></div><div style="text-indent:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had $8.9&#160;million in fair value of contingent consideration liabilities associated with prior acquisitions to be settled in future periods.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flow Summary</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:57.435%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.778%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.778%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.542%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.783%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,336)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">466,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(423,269)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(79,179)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(485,172)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">328,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,523)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019, we generated $827 million from the sale of the Promacta license (including $14.2 million recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019), used cash for net purchases of short-term investments, used $453.0 million to repurchase our common stock, used $103.8 million to pay federal and state estimated income taxes, paid off the remaining balance of the 2019 Notes in the amount of $27.3 million, paid $12.0 million for the purchase of Novan economic rights and paid $11.8 million for the Ab Initio acquisition (net of cash acquired).</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2018, we generated cash from operations, from issuance of the 2023 Notes and associated warrants, and from issuance of common stock under employee stock plans. During the same period we used cash for investing activities, including the acquisition of commercial rights, net purchases of short-term investments, payments made to acquire Vernalis, payments to CVR holders and capital expenditures. We also used cash for financing activities, including principal payments related to conversions of the 2019 Notes, payments to purchase the bond hedge associated with the 2023 Notes, payments for taxes related to net share settlement of equity awards and to repurchase shares of our common stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, we generated cash from operations and from issuance of common stock under employee stock plans. During the same period we used cash for investing activities, including net purchases of short-term investments, payments made to acquire Crystal, payments to CVR holders and capital expenditures. We also used cash to pay taxes related to net share settlement of equity awards and to repurchase shares of our common stock.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not participate in any transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the fiscal year ended December&#160;31, 2019, we were not involved in any &#8220;off-balance sheet arrangements&#8221; within the meaning of the rules of the SEC.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease our office facilities under operating lease arrangements with varying terms through September 2026.  The agreements provide for increases in annual rents based on changes in the Consumer Price Index or fixed percentage increases of 3.0%. We had no off-balance sheet arrangements at December 31, 2019, 2018 and 2017.</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, future minimum payments due under our contractual obligations are as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:32.513%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.799%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.688%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments Due by Period</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#160;than&#160;1&#160;year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1-2&#160;years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-4&#160;years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Purchase obligations </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Notes payable </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">769,219&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752,344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating lease obligations </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,482&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-27pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">        (1)  Amounts represent our commitments under our supply agreement with Hovione for Captisol purchases.</span></div><div style="text-indent:-27pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">        (2)  Amounts represent contractual amounts due under our 2023 Notes, including interest based on the fixed rate of 0.75% per year.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-27pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">        (3)  We lease an office facility, which we have fully vacated under operating lease arrangements expiring on February 2023. We sublet the facility through the end of our lease. As of December&#160;31, 2019, we expect to receive aggregate future minimum lease payments totaling $0.9 million (non-discounted) over the duration of the sublease agreement, which are not included in the table above. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_49"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221; Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2018, we adopted ASC 606, which amends the guidance for recognition of revenue from contracts with customers using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. We apply the following five-step model in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from material sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets and Other Long-Lived Assets &#8212; Impairment Assessments</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We regularly perform reviews to determine if the carrying values of our long-lived assets are impaired. A review of identifiable intangible assets and other long-lived assets is performed when an event occurs indicating the potential for impairment. If indicators of impairment exist, we first assess the impairment evaluation and then assess the recoverability of the affected long-lived assets and compare their fair values to the respective carrying amounts if needed. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to estimate the fair value of identifiable intangible assets and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Liabilities</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2017, we acquired Crystal for total cash consideration of&#160;$27.2 million, plus contingent consideration of up to an additional&#160;$10.5 million&#160;over a&#160;five year period following the acquisition date based on certain research milestones and a portion of the payments that we receive from a specified part of the historical Crystal business. The&#160;contingent consideration&#160;is measured at fair value using an income approach valuation technique, specifically with&#160;probability&#160;weighted&#160;and discounted cash flows. The fair value of the liability is assessed at each reporting date and the change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. The fair value of the&#160;contingent&#160;consideration liability&#160;as of&#160;December&#160;31, 2019&#160;was $2.7 million.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as proceeds are received by us from the sale or partnering of any of the Metabasis drug development programs. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Changes in the fair values are reported in the statement of operations as income (decreases) or expense (increases). The carrying amount of the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See additional information in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (5), Fair Value Measurement.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">                                                                                                                                                                                          </span></div><div style="text-indent:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_52"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;7A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quantitative and Qualitative Disclosures About Market Risk</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Portfolio Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, our investment portfolio included investments in available-for-sale securities of $940.0 million and investment in Viking common stock and warrants of $58.3 million. These securities are subject to market risk and may decline in value based on market conditions.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Price Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to minimize the impact of potential dilution to our common stock upon the conversion of our then-existing 2019 Notes, we entered into convertible bond hedges covering 3,264,643 shares of our common stock. Concurrently with entering into the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants with an exercise price of approximately $125.08 per share, subject to adjustment. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We continue to have the ability to avoid settling the warrants associated with the 2019 Notes in cash after May 22, 2018. In November 2018, we repurchased a total of 525,000 warrants. As of December&#160;31, 2019, 849,292 warrants had expired, and 1,890,359 warrants remained outstanding.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">   </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our 2023 Notes include conversion and settlement provisions that are based on the price of our common stock at conversion or maturity of the notes, as applicable. As of December&#160;31, 2019, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes. See detail in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Risk</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through our licensing and business operations, together with our recent acquisition of Vernalis, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues and profit translated into U.S. dollars. Our license partners sell our products worldwide in currencies other than the U.S. dollar. Because of this, our revenues from royalty payments are subject to risk from changes in exchange rates. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We purchase Captisol from Hovione, located in Lisbon, Portugal. Payments to Hovione are denominated and paid in U.S. dollars; however, the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. The effect of an immediate 10% change in foreign exchange rates would not have a material impact on our financial condition, results of operations or cash flows. We do not currently hedge our exposures to foreign currency fluctuations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to changes in interest rates related primarily to our investment portfolio. Our investment policy and strategy are focused on the preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy. We typically invest in highly rated securities, with the primary objective of minimizing the risk of principal loss. Our investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates across all maturities would not materially impact the fair market value of the portfolio in either period. </span></div><div style="text-indent:27pt;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_55"></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;8.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Financial Statements and Supplementary Data</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_58"></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:93.161%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.839%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_61">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_64">51</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_70">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_70">52</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_73">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_73">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_76">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_76">55</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_79">55</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_82">57</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_61"></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have audited the accompanying consolidated balance sheets of Ligand Pharmaceuticals Incorporated (the Company) as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive income , stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes, (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;27, 2020 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of ASU No. 2016-02</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and the related amendments.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of ASU No. 2014-09</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for recognizing revenue due to the adoption of Accounting Standards Update (ASU) 2014-09, R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">evenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and the amendments in ASUs 2015-14, 2016-10, and 2016-12, effective January 1, 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of ASU No. 2016-01</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 3 to the consolidated financial statements, the Company changed its method of accounting for financial instruments due to the adoption of Accounting Standards Update (ASU) 2016-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, effective January 1, 2018.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the account or disclosure to which they relate.</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.066%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.446%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:81.288%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br/>Description of the Matter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Uncertain Tax Positions</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 11 to the consolidated financial statements, the Company had unrecognized income tax benefits of $29 million related to its uncertain tax positions at December 31, 2019. The Company uses judgment to (1) determine whether, based on the technical merits, a tax position is more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. Estimated tax benefits related to uncertain tax positions that are not more likely than not to be sustained are reported as unrecognized income tax benefits.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Auditing management's analysis of the Company&#8217;s uncertain tax positions and the amount of recognized tax benefit is complex and involves judgment because management&#8217;s estimate is based upon interpretations of tax laws, and legal rulings.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s controls over the Company&#8217;s accounting process related to uncertain tax positions. For example, we tested controls over management&#8217;s identification of uncertain tax positions and its application of the recognition and measurement principles, including management&#8217;s review of the inputs and calculations of recognized tax benefits.<br/><br/>Our audit procedures included, among others, testing the completeness and accuracy of the underlying data used by the Company to determine its uncertain tax positions. We involved our tax professionals to assess the technical merits of the Company&#8217;s tax positions including its consideration of relevant tax laws and current interpretations. In addition, we compared the estimated liabilities for unrecognized income tax benefits to similar positions in prior periods and assessed the historical accuracy of management&#8217;s estimates of its uncertain tax positions by comparing the estimates with the resolution of those positions as applicable. We also evaluated the adequacy of the Company&#8217;s disclosures included in Note 11 in relation to these tax matters.<br/></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of the Matter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As discussed in Note 2 to the consolidated financial statements, on March 6, 2019 the Company sold the Promacta-related rights, title and interest in and to intellectual property and related know-how for $827 million in cash. Of the total cash proceeds from the sale, $14.2 million was recorded as revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8 million was recorded to income from operations in accordance with ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets.<br/><br/>Auditing the sale of Promacta license was especially challenging as the transaction was highly complex and the conclusions involved interpretation of complex accounting standards. This transaction required the exercise of auditor judgment in evaluating management&#8217;s determination of when control passed to the customer.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over management&#8217;s process for evaluating the transaction. For example, we tested controls over management&#8217;s review of the technical assessment over the asset sale.<br/><br/>Our auditing procedures included, among others, obtaining and reading the agreements relating to the Promacta license sale and related documentation to evaluate the Company&#8217;s accounting conclusions. We performed procedures to test whether the terms of the agreement transferred all technology, rights and materials to the counter party. We vouched proceeds of the sale and that all obligations had been satisfied as of the transaction date.</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have served as the Company's auditor since 2016.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Diego, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February&#160;27, 2020</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_64"></div><div style="text-indent:36pt;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except par value)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:72.008%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.628%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.630%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cash and cash equivalents </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNC0xLTEtMS0w_131bf674-19dd-412b-9c47-a46e283c3903">71,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNC0zLTEtMS0w_200d757f-7fd3-4998-99c3-9e86ba1a2598">117,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNS0xLTEtMS0w_47c57ddf-beb4-41fc-b09e-f53f4e12dcaa">939,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNS0zLTEtMS0w_5f5e4a9e-4126-44c1-99b8-d0f37141a49e">601,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNi0xLTEtMS0w_f483fadd-00ff-490e-8c44-2cf18b2e2759">58,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNi0zLTEtMS0w_71e93bcf-34d3-47db-9c9f-349c9c604648">55,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNy0xLTEtMS0w_32c34022-b63f-46b2-8b34-aa1caa6437fe">30,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNy0zLTEtMS0w_b24b2fa0-b21e-499c-8882-c1f05930fa1a">55,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfOS0xLTEtMS0w_22d94322-902d-48a6-a4ac-6f67e365019e">7,296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfOS0zLTEtMS0w_0810913d-1b06-4e78-9bc6-437c4f7b90ed">7,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMS0xLTEtMA_fe7d3ade-e38b-44c0-ad26-554cfd17ccb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtMA_9f63d875-5a45-469f-992f-74cca1d37bb0"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtMA_a960a01f-66e5-4a26-8dd6-4c0b5ebc4526">22,576</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMS0xLTEtNTg1OA_e0cb32e6-2b82-45bc-80fd-eb8d131cfc4d">11,361</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtNTg2MA_28c6c9b2-54a8-4b27-91d1-376bb441d959">142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTEtMS0xLTEtMA_122b8462-e775-42f8-8a6f-d3eb6d2f60c4">4,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTEtMy0xLTEtMA_18b93eaf-8c3b-4166-8b04-d9b90847d6a5">11,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTItMS0xLTEtMA_0256d628-a7df-4823-8711-8a6ddf3ea57c">1,123,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTItMy0xLTEtMA_5be84c9b-a9bb-44ab-9ecb-60658cff8846">870,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTMtMS0xLTEtMA_b347a2b8-9426-4fc4-9514-1d4be5433031">25,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTMtMy0xLTEtMA_52455c76-7206-476f-8a5e-bfed1a0c2f43">46,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTUtMS0xLTEtMA_93bdb691-98c4-4c66-9b7c-2a66149c65e1">210,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTUtMy0xLTEtMA_c8c67a94-8e3d-4385-a3c5-d8147ef1fb33">219,793</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTYtMS0xLTEtMA_6dd22ffd-c61a-4533-8ca5-e0c90d4c0af6">95,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTYtMy0xLTEtMA_c72e84dd-6df9-48ce-a251-03dbb24bd6eb">86,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial license and other economic rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTctMS0xLTEtMA_bce703a8-957c-4d30-a007-816af34dfe27">20,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTctMy0xLTEtMA_e2467a61-6fd0-490d-877a-09fb31a30378">31,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMS0xLTEtMA_e1edbb94-1bdd-4b55-8040-3552cdc81d11">7,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMy0xLTEtMA_997d1782-4e8d-41fd-895a-66e7956ff631">5,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMS0xLTEtNTg2NA_51823956-d533-4557-adfe-c09b3ed917fb">10,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMy0xLTEtNTg2Ng_91d24c8e-e866-4a0b-ad45-c1f1de2a8880">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTktMS0xLTEtMA_0f53ec6a-3752-4c54-ab20-eee0c79d683b">2,357</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTktMy0xLTEtMA_1b184c16-5a3b-4780-b168-af0cc5cf3f07">471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjAtMS0xLTEtMA_23fe458c-152f-4a75-9971-d885d8065ead">1,494,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjAtMy0xLTEtMA_295e1812-8fb4-4981-aa64-d173461e9993">1,260,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjMtMS0xLTEtMA_201975a5-0f7d-4fd9-9f4d-40dcfbf1c5b2">2,420</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjMtMy0xLTEtMA_cfb8512e-e51b-4f0c-a77a-16b5361277ef">4,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjQtMS0xLTEtMA_1f8b6582-2ae3-420c-bc21-b8cd51e6def3">9,836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjQtMy0xLTEtMA_f3aea7aa-afee-4d47-946b-60727e6d2552">19,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjUtMS0xLTEtMA_7d0a81c6-27ef-4097-91f2-e9d6cef19bff">2,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjUtMy0xLTEtMA_33aca06a-94e1-4c7f-9258-dc4f7ee8e665">5,717</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue   </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjYtMS0xLTEtMA_7492c6d7-9dc3-4d59-adef-658be914321f">2,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjYtMy0xLTEtMA_9c4785a9-8c74-443b-af11-ee199647becb">3,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Derivative liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjctMS0xLTEtMA_489693f0-10dd-44b3-b66b-320a1af49139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjctMy0xLTEtMA_96274a68-ed5a-44b9-9a0f-6f4367eabe08">23,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2019 convertible senior notes, net</span></div><div style="text-indent:12pt;"><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjgtMS0xLTEtMA_11fd20f8-dfd3-43e5-baa4-cde62bd7005b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjgtMy0xLTEtMA_fd636643-8a1d-47c0-bf3f-fd0f57837308">26,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjktMS0xLTEtMA_48531a17-c40f-49e8-8fe6-c112db3303a8">17,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjktMy0xLTEtMA_5a0cda33-f33b-4339-b0f9-7b034a52a64f">82,249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023 convertible senior notes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzAtMS0xLTEtMA_603fdbdf-faf7-4a9c-b9c3-b6718ecc8dda">638,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzAtMy0xLTEtMA_ef2eaeda-6b32-420a-9e4a-44eee47e64a8">609,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzEtMS0xLTEtMA_b07867e8-a13f-4ed7-835d-b707c4b1e635">6,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LiabilityForContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzEtMy0xLTEtMA_148a6d69-46f0-4924-a0b3-deb55b7d91bc">6,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMS0xLTEtNTg3MA_31d17ab6-615c-413d-a831-eca315d3bd01">32,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMy0xLTEtNTg3Mg_06daa613-716f-4108-9ddb-32c4a05e61dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMS0xLTEtNTg3OQ_cf10e05a-bf0d-4312-a55b-0fc904e4b0bd">9,970</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMy0xLTEtNTg4MQ_3d5355e6-a374-4a32-92cd-0ff51d21510c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMS0xLTEtMA_e85d37f8-8f5d-42ed-93f5-89254d108e3c">22,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMy0xLTEtMA_2792db1a-3ac6-4cc3-bba5-2c13ed0d748a">951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMS0xLTEtMA_993726c4-d3c0-4d23-969c-dc84a06b2bb0">727,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMy0xLTEtMA_7c5533bc-c830-4275-958f-20a57c11fc73">699,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzQtMS0xLTEtMA_39b92e8d-f33a-48d1-bf2f-836d7b8a3b8d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzQtMy0xLTEtMA_506dd6af-4b41-4900-b3d1-8b420c6550ba"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTA4_0f0bb658-1c9d-4f16-9d8d-64ea70afa836"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTA4_1f8c2af1-0e75-4f32-a32a-dd2963db6886">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTE3_c4021d57-bc45-42c8-bd26-a5c994d23282"><ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTE3_f6e33ac3-545f-4bf1-a90b-dba7ba67f886">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_00654d4c-25a7-49ae-ba7f-7b1e92a65b41"><ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_1f776f9b-761f-45cc-99ba-94cb7132bc77"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_7ec69f95-86e0-42de-9a18-3520fba9b573"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_d5c882c0-f992-45c6-b748-fd241346753c">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2019 and 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMS0xLTEtMTAwOTM_fe9ff155-634a-42ee-a82f-b35d9cc5a081">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMy0xLTEtMTAwOTY_0bd94bf5-8e13-41f2-aad7-65f15c9e03b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMjA_288272f9-f775-4694-a0d6-47a5fbe87d35"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMjA_5d49be42-1df1-4917-a9e5-23f56246fe99">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMzQ_4e213de1-cc19-4c2e-843b-8679deae2d77"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMzQ_c21ebeb7-b9fb-43c8-8053-8750d6455f45">60,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNDg_469bbcde-4b91-4854-a552-5b81904b1301"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNDg_a3777c8c-971c-4cc7-866c-36965c027f79">16,823</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNjI_8a1bc324-4331-4ff2-adcd-ed4f526abf70"><ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNjI_8ccbe489-f883-4d6a-b3f6-f32d47f508cd">20,766</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMS0xLTEtMA_96671af5-f7b3-49c0-accb-46bcdb191975">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMy0xLTEtMA_3ef199d1-8609-43d6-9fbd-33a0516b172f">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMS0xLTEtMA_7028e871-0556-42a7-8201-1208b8d6e6c8">367,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMy0xLTEtMA_05ba4ed7-85e7-4669-8517-d24a8a6ae1cf">791,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzktMS0xLTEtMA_ac9e07b9-3988-4669-bc09-b8ea9a559381">216</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzktMy0xLTEtMA_47d34871-c31e-4956-9275-b20dd582b870">1,024</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDAtMS0xLTEtMA_a0db480c-04a2-4140-befc-67f7be0712b2">400,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDAtMy0xLTEtMA_8301ff43-557e-4525-afae-a6f35d8968c9">229,197</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDEtMS0xLTEtMA_1006ea54-db41-4550-a73c-593a35c84f17">767,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDEtMy0xLTEtMA_15ad1e2d-a35b-470d-930f-25136976ed59">560,914</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDQtMS0xLTEtMA_e41e159f-8a3e-4bbf-9e01-4a25de22b441">1,494,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDQtMy0xLTEtMA_8e74848a-8150-495f-af12-9c58704af5df">1,260,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to these consolidated financial statements.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_70"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share amounts)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:61.823%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.470%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.473%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy0xLTEtMS0w_ea762e07-d4fe-40aa-85e0-7eb1bb4499b9">46,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy0zLTEtMS0w_1a45c5eb-def8-4506-ae1c-c16199b7ec6d">128,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy01LTEtMS0w_63168171-c9a5-4923-85ce-fc3c571a109e">88,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material sales</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC0xLTEtMS0w_bd7cf525-f58b-4120-a3b7-1f7ed8dd79c1">31,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i675b454e2a4246a5976716630c08343b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC0zLTEtMS0w_3cfbbba8-0794-4533-ac6f-5b041d5b0562">29,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC01LTEtMS0w_d38a3785-1468-4e6f-95c3-bf94c04dfcfb">22,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones and other revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS0xLTEtMS0w_c98f41a7-3eeb-4ab3-8d93-f9787a365d18">41,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS0zLTEtMS0w_ace98bdd-86cb-4bc8-9b06-0c608f91c4b9">93,774</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS01LTEtMS0w_3ebf739a-9dde-4429-8f3c-8768ac71abc3">30,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi0xLTEtMS0w_23f06a75-f48c-44be-a7bf-a55dd1ccde12">120,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi0zLTEtMS0w_c1604332-e585-41f9-b4b2-ee547763121f">251,453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi01LTEtMS0w_7af7dff3-4891-4aaf-9ff8-20fbd918292a">141,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cost of material sales</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC0xLTEtMS0w_b5e90310-a196-436a-97e8-999e4975e495">11,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC0zLTEtMS0w_615c8b64-5b8b-442c-847d-292ad1d44f7e">6,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostDirectMaterial" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC01LTEtMS0w_47abc8c7-f646-4e04-9336-aa2dbfc0b6d6">5,366</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS0xLTEtMS0w_0981528c-90aa-4615-a35a-1bbf470f7844">16,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS0zLTEtMS0w_14c2620c-4cfd-43dd-b23f-81d7ae98a097">15,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS01LTEtMS0w_c5add2f1-f7c4-48bf-9ba0-ec159f0555b8">12,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtMS0xLTEtMA_13dc3985-0eb5-45f4-980d-3abc2fda516f">55,908</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtMy0xLTEtMA_7c1b6d04-041f-41bd-b7cf-082da34c2d6e">27,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtNS0xLTEtMA_92b599af-848c-4991-9f90-3b9ce66e2d02">26,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtMS0xLTEtMA_187e632f-b98d-4fbd-9c28-a0be11f6fba5">41,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtMy0xLTEtMA_02b82b1d-9782-4b20-93fd-d4f397901139">37,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtNS0xLTEtMA_784b6dcf-db56-43ad-84ed-c20b081f1257">28,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItMS0xLTEtMA_6fee3b66-502d-4c45-97ab-57d28fb1d810">126,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItMy0xLTEtMA_74a4a4c6-e68b-4c91-a4a2-b5ec87a6c2c5">87,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItNS0xLTEtMA_2006fa4c-46ba-465b-b2cb-c548d6255b8e">73,026</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMS0xLTEtNDE4_a7bc024a-7ef8-42de-a4dc-50227c909f9f">812,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMy0xLTEtMTA0NTU_03dd2c2a-14f7-4167-8fbc-731034916e08">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtNS0xLTEtMTA1MTI_2d46821c-a2e9-462c-a5da-a0c3fc939d43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMS0xLTEtMA_d0a4266d-278b-40bf-acfb-13a05aadd40f">807,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMy0xLTEtMA_8c86536f-e779-4609-8fa8-43f5b275d107">163,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtNS0xLTEtMA_ff64ca7b-518f-47fa-9d26-902f8c24d225">68,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) from Viking</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtMS0xLTEtMA_55128711-5661-495b-afad-13e57eb13899">2,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtMy0xLTEtMA_5e24eaac-d352-45ec-a01e-699397c336fb">50,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtNS0xLTEtMA_74377f4d-9ebd-4b9d-abdd-c00de8653a23">2,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtMS0xLTEtMA_05c8e7b4-419c-46ed-8af1-637cb3793180">28,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtMy0xLTEtMA_fe26a59d-1e83-45d0-bfb2-1728dd3a327c">13,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtNS0xLTEtMA_f64ed375-2179-4da0-aeba-0cc2aae81181">2,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctMS0xLTEtMA_b33f6d0d-4072-4a59-9275-f86a6d9f02bc">35,745</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctMy0xLTEtMA_2c311601-00be-4e00-8cf9-d2b866516aa9">48,276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctNS0xLTEtMA_856519b5-20eb-49ea-a7a2-959ed3f48446">13,460</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtMS0xLTEtMA_d1a7dd50-72f1-45fc-95b1-a438dea2a7ef">6,010</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtMy0xLTEtMA_e98ddeb2-0c61-4832-80b0-654f38e01c68">6,307</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtNS0xLTEtMA_1d36995b-6d4a-4a89-815f-4642a2836d33">2,603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktMS0xLTEtMA_ffcbe99f-ee38-4d46-a3a4-ab94e65a48b1">10,437</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktMy0xLTEtMA_4e14b220-d0a8-44f1-bdd6-cfd2ff3d3de4">9,603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktNS0xLTEtMA_f511c50d-ca57-4372-a1e4-d6e34556ddf1">10,845</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtMS0xLTEtMA_e5b47caa-5e38-419e-a3d4-4c9da94468fe">796,639</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtMy0xLTEtMA_65bf9e40-a240-47f5-a9d1-22bd66130f92">173,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtNS0xLTEtMA_15a1e18c-cb7d-4d28-88dd-384b8b6c82b8">57,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtMS0xLTEtMA_a00303e1-29dc-40a3-9f7b-d944f7721c7b">167,337</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtMy0xLTEtMA_c59f2c60-6cf8-4118-a086-055c2068becb">30,009</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtNS0xLTEtMA_601f1f0a-9b56-4e6d-9b89-9f47cf01d7fc">44,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItMS0xLTEtMA_e6944805-cef7-4c52-a176-a201d90fda1b">629,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItMy0xLTEtMA_4bfd28e5-6d4c-4d3c-b9d2-4aa6ff585dc0">143,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItNS0xLTEtMA_50e9203a-d827-44d5-93dc-11a340b97dbb">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic net income per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtMS0xLTEtMA_ad394f90-c1da-4039-b63d-16a9a22863a2">33.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtMy0xLTEtMA_25b346ff-0c8d-4b71-bdcb-02ab9bbe1ea7">6.77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtNS0xLTEtMA_1595e0d3-259f-4506-8602-d0ccdab1247f">0.60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in basic per share calculation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtMS0xLTEtNDU4_b714ee0e-3e05-436d-800c-4bcc64fd4729">18,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtMy0xLTEtNDY4_c7b1a67f-418f-4afc-9ab3-46062298ca57">21,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtNS0xLTEtNDcw_ef81a807-c7f8-4204-979f-4d6e4303fd9f">21,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted net income per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtMS0xLTEtMA_ce952db2-8223-46c9-8445-43c77f4c3532">31.85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtMy0xLTEtMA_52e7ac39-ac72-4c1e-878f-2960c791a7fe">5.96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtNS0xLTEtMA_02778382-2579-41b6-9be7-fc02c3a910a8">0.53</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in diluted per share calculation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtMS0xLTEtMA_325f618e-0042-4891-98f8-daf4173331df">19,757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtMy0xLTEtMA_8448ff89-a910-4df0-8c55-6062717f1105">24,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtNS0xLTEtMA_9aed5d65-6eaf-4eeb-b08e-d3238489b7c9">23,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:3pt;"><span><br/></span></div><div style="margin-top:3pt;"><span><br/></span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to these consolidated financial statements.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_73"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:66.281%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.813%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi0xLTEtMS0w_33fcd6dc-0a1f-4e7c-8c63-e3ebeb45bed6">629,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi0zLTEtMS0w_395c4808-20ef-4557-9d40-dfc19c84f149">143,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi01LTEtMS0w_3aadf4bc-a26e-406b-91ae-106e867cd11f">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized net gain on available-for-sale securities, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy0xLTEtMS0w_8e7c556c-84a2-47a8-bbf4-def178a34978">200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy0zLTEtMS0w_773a69c2-e7ec-4e89-9a25-d049e8be11d7">73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy01LTEtMS0w_c739c069-fe4d-4682-bcd8-72a3c6515d19">143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC0xLTEtMS0w_12175b3b-094a-4137-b2fb-a61b89929550">608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC0zLTEtMS0w_303caa37-b89f-4d7e-861e-ccb74e1b566b">921</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC01LTEtMS0w_6190d2ed-a263-459a-8807-eba8ed972640">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Less: Reclassification of net realized gains included in net income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS0xLTEtMS0w_de5406e0-2774-4f56-a306-b0704363edd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS0zLTEtMS0w_7b955b65-4b21-431a-b260-6c210cf59a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS01LTEtMS0w_3eb11f36-5512-4c60-80c5-1e5beca68acd">400</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi0xLTEtMS0w_670794bb-9c95-406a-b69b-7c9262455ed5">630,110</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi0zLTEtMS0w_91e1a56c-e312-4b3d-b74d-46b14309c3c7">142,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi01LTEtMS0w_1292fbef-d2ee-4603-9cf9-0a50e26bb801">12,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to these consolidated financial statements.</span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_76"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:32.356%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.087%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.403%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.210%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.087%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.045%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">paid-in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">capital</span></div></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">comprehensive</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">income (loss)</span></div></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">deficit</span></div></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">stockholders&#8217;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;">equity</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i869489dbc2cb4d108beb10a315c6229a_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMS0xLTEtMA_2c640e9d-248d-4543-a9a5-fb1090e59e72">20,909,301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i869489dbc2cb4d108beb10a315c6229a_I20161231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMy0xLTEtMA_18469952-02ed-4909-994b-ad10d586fc70">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8cf4dc97e05a4c57ab75939e7f4190ad_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtNS0xLTEtMA_b3520f04-719b-4bd6-ac68-626229d03307">769,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5489d8e2a3154e579e1950596bad4e83_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtNy0xLTEtMA_c9d234b4-ecb2-41e8-b1c2-d3fd31d66995">2,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idf5608c1b3e145d7b634848e84a0417e_I20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtOS0xLTEtMA_c3ffa310-a2c5-4105-ab77-f369d315ad06">431,127</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMTItMS0xLTA_8e9ead1f-279a-4334-8699-6cc62ca1d7fb">341,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtMS0xLTEtMA_f75f7698-0c49-4ca6-ac28-f42f1253a71d">253,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtNS0xLTEtMA_a872d060-e339-454b-b6dd-939dd7d77e45">5,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtMTItMS0xLTA_21fec43c-3dfc-45fc-972c-3e249189fc72">5,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Reclassification of equity component of currently redeemable convertible notes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTItNS0xLTEtMA_fd39e8c2-15ba-4ee6-a937-7602a264c890">10,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTItMTItMS0xLTA_3ea2671c-a9d8-46af-83ff-875e36c3adf2">10,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTMtNS0xLTEtMA_e6f33cf9-4652-4cb9-b096-6e5663837403">24,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTMtMTItMS0xLTA_f69f47a7-b9f8-4a69-8313-230c4b828a81">24,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtMS0xLTEtMA_e160df71-024a-456b-aa55-c28c9dba9428">14,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtNS0xLTEtMA_ce71ca33-4f68-49f9-acb4-473c8d57c6e1">1,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtMTItMS0xLTA_d8c5ccbf-5880-4001-8e02-513dbdf00a75">1,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1c39c6b8d84c41cca43833810fbc7ae2_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTUtNy0xLTEtMA_28b6c96d-893f-448e-98a3-d3d4bbe45bbd">257</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTUtMTItMS0xLTA_6bef2feb-4e32-4522-99e6-4ed2513cad63">257</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative-effect adjustment from adoption of ASU 2016-09</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idae4fa193bce41988665297c8c87cd90_I20170101" decimals="-3" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtNS0xLTEtMA_952b8f0c-69e0-4706-b0de-3f107a4f38dc">456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcb933ddf4a24744b8334b58adba6068_I20170101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtOS0xLTEtMA_6cd7878d-5bae-404a-aef8-4b7c561023af">17,647</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i942f3b02c5b94bd68a645167798076c7_I20170101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtMTItMS0xLTA_8fc1628a-bf21-4384-8c9a-5105c3dd1355">18,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52155cd9acaf404eadf5b7e3d980852d_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTctOS0xLTEtMA_db36737d-f05a-42a7-9a7f-1cf6d619f62a">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTctMTItMS0xLTA_7d380d9f-e481-438c-b72b-810746eda575">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMS0xLTEtMA_3091596e-e9a9-4ba9-8697-e00168dcb96d">21,148,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMy0xLTEtMA_7d97ffe1-06c5-4737-8645-fad23cde578a">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba785669817e4bca8806263b74bbb109_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtNS0xLTEtMA_8ffe7c28-5279-4707-893a-37c32a8b944e">798,205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc1374cff04f4a8a9e7ff2371b8b8aed_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtNy0xLTEtMA_e6af111d-ae77-47f4-8772-b06d18d89358">2,486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i04273cf057274bd7ba4eb19b16af0d81_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtOS0xLTEtMA_16a99aff-6047-41e2-a759-faaac2459f1a">400,924</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMTItMS0xLTA_3327aa53-588c-4fe3-acce-6dab116f01a1">399,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Issuance of common stock under employee stock compensation plans, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibac644851be347358be4803ad12d0c11_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktMS0xLTEtMA_96434695-5421-4b4a-8b85-2e1b2926772e">399,116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktNS0xLTEtMA_a1f3afdd-c5d2-4aea-a843-6e467b74628a">16,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktMTItMS0xLTA_297716f7-2a1a-468a-986d-e184dc913383">16,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Reclassification of equity component of currently redeemable convertible notes</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjAtNS0xLTEtMA_b02a75df-3fa4-4e06-977f-d320358d959a">18,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjAtMTItMS0xLTA_e20ca037-0a74-48cf-b872-38bf76e5d7c5">18,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Share-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjEtNS0xLTEtMA_e0f0ec79-4a90-434c-87dd-e214da61b37e">20,846</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjEtMTItMS0xLTA_2dc13e6b-5a2d-468b-80c6-62041e96df9d">20,846</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Repurchase of common stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ibac644851be347358be4803ad12d0c11_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItMS0xLTEtMA_b8e4aac9-5416-4805-8767-6317afc2812a">782,248</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItNS0xLTEtMA_652e5af1-4c8c-4e79-9d63-290cb6909bd6">127,481</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItMTItMS0xLTA_172c9713-8e8c-4fe6-a749-de64cd65f8ed">127,481</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Other comprehensive income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjMtNy0xLTEtMA_8d012e70-f3cb-437a-9f18-6c3b416f5928">73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjMtMTItMS0xLTA_f39ea132-7d0a-4474-811a-0bdc2fc7a3c8">73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Cumulative-effect adjustment from adoption of ASU 2016-01</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a9bcb91841d44d6ba7d80ded777ad08_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtNy0xLTEtMA_47a308c4-982b-48b8-baf8-e03521535743">2,662</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e5aa84c1f894416941ae3fb3370a0e7_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtOS0xLTEtMA_66af54ce-c591-4496-a332-343a90d7554b">2,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01597458c3654e7d814509dc1fe6a346_I20180101" decimals="-3" format="ixt:zerodash" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtMTItMS0xLTA_9f2f3543-b1dc-401f-98db-ffa9909ae932">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Cumulative-effect adjustment from adoption of ASU 2014-09, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ecf11d232574f23813a8e1cac3990ee_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjUtOS0xLTEtMA_bad03e6d-871c-4e6d-959b-aa3f6929127f">25,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i352af84d1ae44bb8a22c67271354ceae_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjUtMTItMS0xLTA_5f88ce62-913d-404f-99e6-442ac659729b">25,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative associated with 2019 Notes and Bond Hedge</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjYtNS0xLTEtMA_2468427f-b963-4052-bd68-26c00623ffb9">1,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjYtMTItMS0xLTA_ca191cfe-92ee-41fd-99a4-26a816928f2b">1,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on settlement of 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjctNS0xLTEtMA_cdee5b67-4f90-48cd-b296-cf6a429c2f04">3,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjctMTItMS0xLTA_96c0f1a6-fadc-426f-a6ae-1ef86a1512d7">3,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant repurchase in connection with 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjgtNS0xLTEtMA_5ae6f8f0-81de-4619-a8a4-2ce663d2600f">30,472</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjgtMTItMS0xLTA_303fc475-0b02-496c-a9c6-e76693b52ed9">30,472</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on repurchase of warrants in connection with 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjktNS0xLTEtMA_f25a6ccd-f410-4dac-b1a1-2962b5b4313e">1,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjktMTItMS0xLTA_5a805f41-be4d-4c5c-a1cd-9576cf37caec">1,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax effect on 2019 Notes transactions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtNS0xLTEtMA_86f328ec-aff2-4113-a02b-5465a31c22a8">1,680</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMTItMS0xLTA_c5ab3dac-90d5-4e85-b165-0bafcc2f2661">1,680</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative associated with 2023 Notes and Bond Hedge</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtNS0xLTEtMA_66a72cd4-71ca-4f7b-a5cb-709ef5959c4a">1,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtMTItMS0xLTA_ff14ae8b-b22b-467f-98ca-80d770a9695a">1,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant derivative  in connection with 2023 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItNS0xLTEtMA_8ce0d423-238f-4afd-96e6-1a0c790a8378">97,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMTItMS0xLTA_b4b180d7-b9f5-4077-a479-425cde2de6ec">97,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax effect for 2023 Notes transactions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtNS0xLTEtMA_5096bbbc-b4a1-459c-8c0d-5adc3ae5346b">3,181</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtMTItMS0xLTA_c07b1a59-c161-47d0-9061-5f3e59506b28">3,181</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtNy0xLTEtMA_3b91a4cd-e686-4b0d-b628-72eaf649c0cd">921</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtMTItMS0xLTA_c196f14b-c9aa-44b7-bc63-498070cc3188">921</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other tax adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtNS0xLTEtMA_4fd0dd1b-f9b5-4c63-829e-55e3a6ad36b2">183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtOS0xLTEtMA_3b357f42-7e3c-40f9-9bc7-7057852d9462">163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtMTItMS0xLTA_c0205616-9268-4454-b089-93c59bbb671e">346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtOS0xLTEtMA_bbc02d37-77d6-4e8c-b0ef-6e0b703aa76e">143,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtMTItMS0xLTA_57328a3a-b8e8-4372-858a-ae2c524e189f">143,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">Balance at December 31, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ef94475465245018ed0c204e8bd7fda_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMS0xLTEtMA_49cf8d7f-d9bd-43eb-a5bc-0a54d59a580a">20,765,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ef94475465245018ed0c204e8bd7fda_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMy0xLTEtMA_d1d0a0b4-8410-4d6b-92a9-674dc1da649b">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic339114ab562486b8927a1f3fd53be85_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNS0xLTEtMA_00f13ee8-f5f8-4446-9f1f-656fb5071041">791,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iafd33958a305462b9dded4123ec458ad_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNy0xLTEtMA_6e89f484-24b1-47fd-9625-37015eca85cb">1,024</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9508f9f000dd4ad0b0d754524aee17b2_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctOS0xLTEtMA_7f08cfc2-ed28-4344-b581-a9d79fad5b08">229,197</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMTItMS0xLTA_5f4e35cd-be2f-4741-a189-122dd705f209">560,914</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under employee stock compensation plans, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMS0xLTEtNjg3Ng_ede1d42b-528a-40d6-a26c-a8ac16b4ec4f">179,838</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtNS0xLTEtNjg4OA_a36363dd-6464-42f1-85ba-9084074f7ace">1,421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMTItMS0xLTEwNTM1_40f224d6-bf03-4886-ae1b-2e711075f797">1,421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtNS0xLTEtNjg5MQ_9c8a056f-96c5-4164-80b3-90c5500e6ed3">24,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtMTItMS0xLTEwNTM3_bb393a6b-fd05-4d23-820b-31ff8911f521">24,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMS0xLTEtNjg3OQ_a635109c-2dc7-4004-aa3f-ffc070a5ce1b">4,122,133</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMy0xLTEtNjg4NQ_88860a74-f34f-4fa1-b27b-82b5fbcb6c51">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItNS0xLTEtNjg5NA_0a5e972d-776d-4dea-85a0-20545bf864f7">448,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMTItMS0xLTEwNTM5_1a4bd047-6649-45b8-bf66-4cd648ae4f5c">448,433</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized net gain on available-for-sale securities, net of deferred tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtNy0xLTEtNjkwMA_4124fe0d-5cba-4cea-8fd5-5dcf395d361c">200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtMTItMS0xLTEwNjA2_7591eeb3-e8ad-4943-bc10-031ed81be109">200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtNy0xLTEtNjkwMw_4c44a684-dbb1-4efc-a8d2-cb26b588dd96">608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtMTItMS0xLTEwNTQx_0a6a223f-9b9a-4471-99a5-f2f1b68e7e86">608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other tax adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtNS0xLTEtNjg5Nw_953a85a0-16ad-474e-b3e3-b0e6139f8504">1,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtMTItMS0xLTEwNTQx_2aec8885-5653-4fda-95df-f678f112bece">1,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b3cbeb39e14feb8ab2224143dffb5a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtOS0xLTEtNjkwNg_050f5ac9-6d11-4ef5-8b33-9ca2f3e6ffa8">629,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtMTItMS0xLTEwNTQx_3243bfd3-9255-4c57-8af1-383746df0435">629,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMS0xLTEtMTA1MTQ_d46699ed-ca00-4bbb-9272-3c5c037de095">16,823,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMy0xLTEtMTA1MTQ_3d2f043c-fe09-4fad-8b61-9a315fc458b5">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45ef1d23069649bc84d61c935c800a92_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNS0xLTEtMTA1MTQ_3aa15158-6ec9-4872-8876-58902e99a168">367,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib2870d56eba64b3dbd7901fdf1a45b5d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNy0xLTEtMTA1MTQ_e7ee12cc-69f8-41f8-ad33-0e0ba1d2427d">216</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice4b9c573b6e48dcb989d7ab948495c0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctOS0xLTEtMTA1MTQ_e28012eb-06c7-471c-84b4-d617301e6940">400,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMTItMS0xLTEwNTE0_0db830dd-9159-4413-a434-afba03769e01">767,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to these consolidated financial statements.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_79"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:58.588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.648%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC0xLTEtMS0w_92d7029f-ee1a-44b8-ae2d-f80d944568f5">629,302</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC0zLTEtMS0w_32744d46-cdeb-452c-861b-03718b99f3a6">143,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC01LTEtMS0w_fe87a58d-9b64-44a5-9517-e82d90ddc7b5">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC0xLTEtMS03MDIx_147d01ed-9c6f-4846-8701-451ff64a2fc2">812,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC0zLTEtMS03MDI1_3c8cf9b2-66fa-4bb6-9368-21ffa93faa3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC01LTEtMS03MDI4_9f24c184-c3ab-49ac-af86-295c7fcad3a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in estimated fair value of contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS0xLTEtMS0w_23e1eb1d-163a-4f91-9d99-1451333e8bd6">30</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS0zLTEtMS0w_da328cad-a2d6-4246-af7f-441f980bc1ab">3,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS01LTEtMS0w_afe4a2ca-7039-42f3-b8e0-448fb6703508">2,580</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized gain on sale of short-term investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtMS0xLTEtMA_c16b80c6-7e58-4f9b-ab10-edb2629ae1fc">41</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtMy0xLTEtMA_94b65b2b-2da6-4ee7-8c6f-93977826b690">2,611</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtNS0xLTEtMA_55e30685-ce71-42c0-961e-5b323b92cd67">831</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtMS0xLTEtMA_076220b5-d85c-4739-a3bd-7af717081021">18,361</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtMy0xLTEtMA_342d9a2c-8e53-4587-9bc0-c10f9aca7608">12,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtNS0xLTEtMA_d69b7ff2-5cb5-4f3c-bd19-71cdef7a1bc5">10,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Gain) loss on equity investment in Viking </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItMS0xLTEtMA_d451fe15-dea9-4a40-a1c7-5f23f8b31fb3">2,888</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItMy0xLTEtMA_718f028b-a1ba-4812-be7c-193872ca2dd9">47,658</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItNS0xLTEtMA_6b5b9706-a4d3-4fcf-86ef-61414861da38">1,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Amortization/accretion of premium (discount) on investments, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtMS0xLTEtMA_0790ef77-3312-4452-ba88-bf80e40bb9eb">10,274</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtMy0xLTEtMA_76d8974a-18b8-4b54-9f34-3cc124b8ac41">5,452</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtNS0xLTEtMA_30e6de59-5555-480d-9507-0fb17227cec1">81</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and issuance fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtMS0xLTEtMA_9b16ab71-273e-4c88-ad8c-c2c683642148">29,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtMy0xLTEtMA_c6e57bd9-b894-4c77-8aa3-ba50d1405677">43,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtNS0xLTEtMA_d862a964-6e0f-4cb1-bb2b-b80258e1a9df">11,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of commercial license and other economic rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtMS0xLTEtNzA3Ng_d90292e2-dd09-4c95-ac4b-dd878430a33b">25,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtMy0xLTEtNzA4MA_19120b62-da66-4aef-8429-2f62b59b8af8">1,934</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtNS0xLTEtNzA3OA_37942908-c537-4960-a8a0-2e292004fc00">759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctMS0xLTEtMA_1f22bf61-2297-4e44-8ad3-5a7ee56be688">24,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctMy0xLTEtMA_d551a58b-a39d-46f1-bb60-b644b278dbda">20,846</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctNS0xLTEtMA_3f442455-ac20-44f0-b5bd-0763bbac6c1a">24,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtMS0xLTEtMA_8a512b3d-a329-412b-87de-1bd460f50f9e">74,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtMy0xLTEtMA_6845c236-3b8d-4c8d-aa22-08f87f78e1d0">29,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtNS0xLTEtMA_6e6d29a6-8c8a-4525-ba9e-3f8bdc141ee0">44,518</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties recorded in retained earnings upon adoption of ASC 606 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktMS0xLTEtMA_bead9a24-0b74-4a82-9edf-43f6994eb337">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktMy0xLTEtMA_bb931ae3-6a4c-4bd8-aa10-dd7958fe17a1">32,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktNS0xLTEtMA_4751ae5f-7138-4787-bbe1-8ad1a80920eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMS0xLTEtNzI0Nw_1de9a1c5-279c-4c7e-bd2a-02c2a984081d">1,456</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMy0xLTEtNzI1MA_b120e828-d150-4794-9c23-775a3e9928fc">2,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtNS0xLTEtNzI1Mw_85cf44b1-6f51-4ac4-8897-2fd01cbc7d0a">870</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMS0xLTEtMA_0a9bd300-05aa-41a9-a6a6-7bbb9d88c33a">25,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMy0xLTEtMA_1ee53fb0-ad29-4e72-9a58-e4e89aebb052">29,544</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItNS0xLTEtMA_8cc4297f-388f-450a-92fd-07e4ba7ea64e">8,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtMS0xLTEtMA_4890637a-325e-458e-b8d0-52904a931f64">2,061</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtMy0xLTEtMA_adcbccf5-5b9c-4acb-8ad6-0a657d674444">2,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtNS0xLTEtMA_9622e2aa-1315-4416-943d-be3445ff865e">843</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMS0xLTEtMA_cda48493-0c36-4f58-88ce-d2c8671efe69">6,826</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMy0xLTEtMA_4da55e04-3fdb-4124-a2a7-42743f4af21f">4,542</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtNS0xLTEtMA_097206b8-9d30-4411-9c57-61c02588710e">1,713</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMS0xLTEtOTUyNg_d9f2da77-d636-46f8-83ac-0b8448cf5711">11,219</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMy0xLTEtOTUxOQ_5dd7f259-5f23-43c6-9d64-b46681a72d6f">318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtNS0xLTEtOTUyMg_dde5d9d7-aab1-475a-898a-fb2ba5152f72">460</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other economic rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMS0xLTEtMTAwMjQ_6d6b2046-09e4-41f6-9df0-0de0b2ccdfa6">12,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMy0xLTEtMTAwMjY_24bd6b2b-d4b4-4cfb-b311-0fb333cade36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:IncreaseDecreaseInOtherEconomicRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItNS0xLTEtMTAwMjg_fc4607d8-de78-4300-a1ee-caf8597dfb92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktMS0xLTEtNzIzNg_ff377ccd-0e0e-4fac-a3e8-62fe43cd548b">2,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktMy0xLTEtNzIzOQ_30aa3040-548f-4b0e-9fde-9cda07b8b026">5,458</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktNS0xLTEtNzI0Mg_1180cc1d-2b22-4dd1-8ec6-b6126f0b9d5d">5,062</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtMS0xLTEtMA_9b099f0d-83cd-42a0-b3f3-1c475ea70c83">29,336</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtMy0xLTEtMA_ad48d719-bd70-4ce3-90e9-c07cea712055">194,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtNS0xLTEtMA_507efff2-89e4-4a11-a432-05dadc1edc8a">88,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of Promacta license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItMS0xLTEtNzE0NA_643a4736-7263-46d6-b4d7-15286cd0fbf6">812,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItMy0xLTEtNzE0Nw_82cb5cd7-814b-43b8-bf19-a273e7135f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItNS0xLTEtNzE1MA_b5a25caf-4001-4ee0-b388-51dd417427d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of commercial license rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMS0xLTEtODcyNg_b6498f89-85d2-4524-a38e-8994e6055613">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMy0xLTEtODcyMw_8627ef90-acc7-4ebe-ae47-ed51b3dd7161">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseforCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtNS0xLTEtODcyOQ_cef47b31-2e66-40fe-b1af-be528ddfe517">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cash paid for acquisition, net of cash acquired</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtMS0xLTEtMA_2a5895e7-8028-40b9-9496-88d3b701341f">11,840</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtMy0xLTEtMA_c5e7b8d4-97e2-4821-9a2f-d045a3f8440d">5,856</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtNS0xLTEtMA_652aac80-a96a-419c-90b6-d99637f068dc">26,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtMS0xLTEtMA_a8987184-db1a-493d-a1a6-8e9ec210f099">2,553</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtMy0xLTEtMA_a4f399fb-1741-4d7a-a61e-ddfbf6a2c2fb">887</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtNS0xLTEtMA_644058c6-34ea-4f29-9ca2-d711c640be62">2,156</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktMS0xLTEtMA_939468f1-403f-4504-941e-3692b64b4eb8">2,356,545</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktMy0xLTEtMA_857076c6-9de4-4f39-ac46-4b42acb9b370">1,434,255</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktNS0xLTEtMA_051bf1fc-8d56-42c4-8505-395d928e8eed">254,258</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtMS0xLTEtMA_2c82689b-6ec7-4aea-84f6-ca646254e545">535,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtMy0xLTEtMA_399761a8-1d49-457d-b715-57c8baca924d">131,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtNS0xLTEtMA_d4384ce1-9afc-42d1-ad24-c2473bb5a965">86,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMS0xLTEtMA_77562661-d2ba-428f-9d63-42b5210a9d85">1,494,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMy0xLTEtMA_35dca859-47d8-4ae4-ab01-d79345e75b78">892,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtNS0xLTEtMA_0a048527-87d8-4e18-81e2-6f81124ad8b2">109,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Proceeds from commercial license rights</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItMS0xLTEtMA_019d4879-a65c-443b-8c18-22d77cb8d230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItMy0xLTEtMA_758dc999-2260-46d6-9abf-297c860bf716">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItNS0xLTEtMA_56f77c4d-fa0e-4be5-927c-3609e5e8260c">7,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Proceeds received from repayment of Viking note receivable</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtMS0xLTEtMA_5016d61c-d48f-4cd8-ac38-c4a79ee7aab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtMy0xLTEtMA_2f8a5afd-c518-4fff-be4e-2c3e66ba0f77">3,914</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtNS0xLTEtMA_8a808cbd-33dd-4ebe-a3c4-c255e79a6543">200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMS0xLTEtNzE5MA_53222fd4-ff3b-4dda-9e10-15255213be59">1,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMy0xLTEtNzE5Mw_e52b443d-536e-4e3a-882d-03639e4862db">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtNS0xLTEtNzE5Ng_84bb022d-f104-44ef-be5d-2bd936b0286a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtMS0xLTEtMA_8c456f82-ebb7-4ca8-a463-8a7aa4f6cd54">4,669</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtMy0xLTEtMA_2c2b51b1-4b00-4215-82ae-ba1ccce7bf38">1,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtNS0xLTEtMA_f7075f22-b841-437e-a6ad-0b8c7c5fd841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtMS0xLTEtMA_05082f5d-39c1-407e-985d-1b1d48d9f203">466,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtMy0xLTEtMA_b86fda81-5927-4178-94c0-a730528f1ad2">423,269</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtNS0xLTEtMA_a56414bf-fc27-495d-92e4-f29ea6059c68">79,179</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctMS0xLTEtMA_91ee6133-5fb0-4a65-b4bd-fb7ad13c10a9">27,323</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctMy0xLTEtMA_38f89eef-18de-41d2-8302-0df95b73d127">217,674</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctNS0xLTEtMA_b1371645-038e-4b61-bd64-030e48946085">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross proceeds from issuance of 2023 Convertible Senior Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtMS0xLTEtMA_b8aed288-182e-4500-90a2-1cefe0a65c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtMy0xLTEtMA_c02e6a30-99b1-452d-be7c-2500fb8c4d74">750,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtNS0xLTEtMA_1f62f3c5-eb3c-4ec6-b371-a728b0c8cf36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktMS0xLTEtMA_2ae3694c-0b68-4959-a0f1-a95bf1b4960e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktMy0xLTEtMA_6a8cf861-fb04-45d5-8b6b-724834c6a733">16,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktNS0xLTEtMA_a5cb2348-f9e6-4038-b9be-521b0cbec9ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtMS0xLTEtMA_17620021-158c-450c-b799-c426338b2baf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtMy0xLTEtMA_c51b4726-0d0e-482b-9ea0-82033bfb95c9">90,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtNS0xLTEtMA_6cb93442-6a4c-40b6-af7c-cd141d9ff99b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of convertible bond hedge</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtMS0xLTEtMA_3fa09d0f-faff-4beb-92bb-13bb3c939a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtMy0xLTEtMA_d318c3ec-01e4-461e-b13a-162414873282">140,250</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:PurchaseOfConvertibleBondHedge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtNS0xLTEtMA_6e456214-ba0b-456d-a76d-d885de60d242">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from bond hedge settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItMS0xLTEtMA_13d5500c-fbe8-410a-a1bf-b103de223618">12,401</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItMy0xLTEtMA_1ab56191-f9a9-4cbc-a027-ce16029894e0">439,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItNS0xLTEtMA_558ba17b-7532-4a27-9aa9-c2964a03d7fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments to convert holders for bond conversion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtMS0xLTEtMA_20b31d3c-7587-4e10-98b5-8749502011cb">12,401</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtMy0xLTEtMA_f5c106b3-3df4-4f4b-8fd9-0e5f597b1fb6">439,581</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForHedgeFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtNS0xLTEtMA_89a18869-c3d6-45de-9491-9c76568d96d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net proceeds from stock option exercises and ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMS0xLTEtMA_ffc1ef5a-9e4b-4b13-8bd0-7cf928d4c60f">2,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMy0xLTEtMA_efb96c21-b83c-40e3-9a47-63ffc1c81e5a">20,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtNS0xLTEtMA_53776a9b-c6db-4969-a83e-8dc476541664">4,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Taxes paid related to net share settlement of equity awards</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtMS0xLTEtMA_efebfcdc-5330-428c-941e-3ced6453dc8a">4,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtMy0xLTEtMA_58460992-e26b-4a6f-ab44-9aac60526645">3,765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtNS0xLTEtMA_17fae675-711c-4600-9a0d-a30e61325ee6">10,074</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share repurchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtMS0xLTEtMA_65771813-554c-4862-af9f-71384df1f78a">453,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtMy0xLTEtMA_01df278c-818e-4a2a-ae24-e873d6cf87b2">122,868</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtNS0xLTEtMA_8488237c-f9de-4349-9791-2bfd1fa6ce86">1,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctMS0xLTEtMA_cf0ef9e3-b9a3-4891-879a-9ed5a6fafbc1">380</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctMy0xLTEtMA_beaa63aa-bde0-405a-8078-f7895b86d203">30,094</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctNS0xLTEtMA_7ab7fbe2-2b82-4164-8e8d-8aa83a296a6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments to CVR Holders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMS0xLTEtMA_3a2517dc-c882-4118-938f-37082d3e5fbc">3,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMy0xLTEtMA_d2b6c1c0-2f06-4a82-8067-933cfaba14a1">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtNS0xLTEtMA_8d59564b-5099-4bd9-9dcb-82ae60443ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:58.588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.648%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktMS0xLTEtMA_46324161-c3de-4bc7-8f27-c743b23282b5">485,172</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktMy0xLTEtMA_5885dd5c-b8b0-4313-8255-08d1e1fdd890">328,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktNS0xLTEtMA_11601fc2-d7c7-408c-bab3-050a43a556b8">7,523</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtMS0xLTEtMA_c06b6b57-994c-4652-b1ba-09f508111fb1">47,590</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtMy0xLTEtMA_71f383a9-21e0-4709-ada8-30958e39eddc">99,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtNS0xLTEtMA_41ee70c8-7c04-441c-963d-f95a4234289f">1,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMS0xLTEtODA4MQ_57243fdb-d43c-43b6-bed6-524b4798ad95">83</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMy0xLTEtODA4Mw_ac733b8e-dcc3-4f9b-aa67-d69881fbb6d3">215</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtNS0xLTEtODA4NQ_8968128c-5e45-4cb5-a62f-003d3a1922fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItMS0xLTEtMA_fd84b0a7-4b94-4221-8a5a-df89a39c0b07">119,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItMy0xLTEtMA_823cc5dd-2e52-4a2c-9e56-291dc41a73c3">20,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItNS0xLTEtMA_1212fc8a-ba6e-49ca-89e5-d9b99b437a89">18,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtMS0xLTEtMA_867306db-2866-4a81-839f-0ebad713204f">72,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtMy0xLTEtMA_226d7992-d5c8-4acc-995e-042593db6b06">119,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtNS0xLTEtMA_018304b6-87d2-479e-bf94-3ce442c60843">20,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid during the year:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtMS0xLTEtMA_7a2e85a0-f00c-4cb6-8a67-fb13891dcc3a">5,827</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtMy0xLTEtMA_76b28a51-54e4-4c02-845b-91137f09df15">1,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtNS0xLTEtMA_d1e4e0a6-6faa-4608-832b-ce5cea0f9a61">1,838</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctMS0xLTEtMA_7d6ddd78-c03e-4c1e-81eb-a44bb7ab8fbe">103,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctMy0xLTEtMA_e6ff4812-b6b5-4ed9-a8e3-b81b32871391">341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctNS0xLTEtMA_0ff76732-5bf6-451b-a6eb-ea2b5d517f2a">157</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash in other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMS0xLTEtODE2Mg_9fe7efc5-8e9e-4181-8d3c-722876a862cf">730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMy0xLTEtODIwOQ_3012a497-f5f8-433a-830e-5467104d1386">2,616</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtNS0xLTEtODIxNg_0df0465c-44b1-40cc-b0fe-eade02e6de59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued inventory purchases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtMS0xLTEtMA_a52c18f5-07a1-4c69-b5fd-5e5fd9e91dda">170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtMy0xLTEtMA_9c4ce64f-4e58-4992-8453-c08eb31be6c1">2,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtNS0xLTEtMA_8f596d48-09f0-4109-bcc6-90cd3565db43">1,007</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on AFS investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItMS0xLTEtMA_7a7b225c-bcf7-4dda-b72f-8b04949d5611">256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItMy0xLTEtMA_c739081f-e273-4d02-a76f-d7c6bf17b77d">48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItNS0xLTEtMA_4b089504-432a-4496-8b64-8d67a3218fc5">144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of fixed assets recorded in accounts payable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtMS0xLTEtMTMyMzE_7f55abc0-b6a2-476c-998f-2e22b4db1910">495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtMy0xLTEtMTMyMzY_95b37611-ae3e-4277-8773-2a9f3ce531a8">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtNS0xLTEtMTMyMzk_db5a8418-f63c-47b9-9bec-ebde9a4e19ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to these consolidated financial statements.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_82"></div><div style="text-align:center;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_85"></div><div style="text-indent:36pt;margin-top:14pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:14pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Unless the context requires otherwise, references in this report to &#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Ligand Pharmaceuticals Incorporated and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzI_5201a9a8-b604-48b7-8f1f-2f02e56ed285" continuedAt="ib5a746fa4bdf43149e7ba628f3f75923" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib5a746fa4bdf43149e7ba628f3f75923" continuedAt="i8e30b7ad3037434c93581d15ef41b4db"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjQ_aae531a3-9e6d-4395-8009-cbf31df32ce6" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjU_29d8e016-23d1-43ad-9079-6376d90d6955" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDM_4a223010-db64-4f67-8469-60f31118e829" continuedAt="i82a54b2dee0641ecb51267ed8f484df1" escape="true">Reclassifications</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i82a54b2dee0641ecb51267ed8f484df1">Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking warrants was reclassified from &#8220;other current assets&#8221; to &#8220;investment in Viking&#8221; in the audited consolidated balance sheet as of December 31, 2018.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDQ_f5921a20-a303-492c-8455-c47b8931cf81" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-indent:24pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTE_adb5c6dc-e67d-447b-ac30-e8d306e130d2" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Business Risk</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTM_b1464dfc-080f-47c0-b785-d4271da03fcf" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:52.678%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.624%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner A</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i53e345f65cef494a89a25239fa967bbb_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi0xLTEtMS0w_ad2929f9-a66c-49d5-9c87-645c3e3775f4">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0c0def0efae44a5ea9424174e127e04f_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi0zLTEtMS0w_db3e4a24-a532-4581-9c43-f31ae2367135">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iad8277e193464fc0bfc5035fabc271f6_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi01LTEtMS0w_16ec8d5c-6853-4ac5-b2b9-989c078ec60b">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner B</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8112712360b5447cbcf4086b3a12a30f_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy0xLTEtMS0w_9fcaeb8a-647d-4c3c-b161-56ad338ad548">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i97f46503b54b4c4581f7af547a5f1819_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy0zLTEtMS0w_02e7282b-7fe1-412d-af13-0af5848df0e5">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i36e85343882a43ef806ab5bd3ca04f8b_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy01LTEtMS0w_3f5d7d0a-39ec-4f82-91d8-b570da9181e9">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner C</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3790f97128f2494d8984195c0fc58a83_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfNC0zLTEtMS0w_fa42eba0-7062-4942-a32e-89c786532cad">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i8e30b7ad3037434c93581d15ef41b4db" continuedAt="ifd1c0a7c915c4a978b937bca08c04a72"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjY_fbe8a8d6-7075-4cad-a9b6-496f739261e7" continuedAt="i4c79d074a52c44f1a99c2b82138e0edb" escape="true">Cash Equivalents &amp; Short-term Investments</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4c79d074a52c44f1a99c2b82138e0edb">Cash equivalents consist of all investments with maturities of <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:durwordsen" name="lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjg5NA_1a1687ae-a9eb-4a6c-baa2-84d66f1a8fda">three months</ix:nonNumeric> or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method.</ix:continuation>  </span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:AllowanceForDoubtfulAccountsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTQ_6eebb4c1-41c4-4e54-9215-60a283f09735" escape="true"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms which range from 30 to 90 days. We reserve specific receivables if collectability is no longer reasonably assured. We re-evaluate such reserves on a regular basis and adjust the reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.</span></div></ix:nonNumeric><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDU_29842245-6124-4164-93c1-c1af0dd09728" continuedAt="i9854a37828a0497c8989c07fea10c197" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9854a37828a0497c8989c07fea10c197">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_005688c4-03b4-4186-a6bc-f4e12ada5cee"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_919aada0-6a4c-4e53-a54f-9673872cca2a"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_d988ff46-c053-4c91-af5a-c01b30ca9a57">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> write downs related to obsolete inventory recorded for the years ended December&#160;31, 2019, 2018 and 2017.  </span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjc_b3339588-2447-475d-8e8e-c975bdc3cf2d" escape="true"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzc_45c7d04e-58fb-46f7-91a3-3cb6a6cce268" continuedAt="i4d2c79b6701d4e18a11401f57b238c0e" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in other income (expense), net. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ifd1c0a7c915c4a978b937bca08c04a72" continuedAt="i49b0e76257894cbfbfa6c0aff38deabb"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4d2c79b6701d4e18a11401f57b238c0e">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</ix:continuation> </span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Liabilities</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfODAzMQ_aa2918a1-6dc0-4586-9760-bcb0e0525cb8">10.5</ix:nonFraction> million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="right" contextRef="i4d5cb59bf92840e6a385702bbe7c55ba_I20100131" decimals="INF" format="ixt-sec:numwordsen" name="lgnd:NumberOfContingentValueRightsIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfODU1OA_b6278794-6a91-4d97-8db3-85a51b8eeaa2">four</ix:nonFraction> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;   </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzg_5df585d6-25b7-4215-a3a7-67591cbbd24f" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2019, noting no impairment. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:CommercialLicenseRightsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjA_3c3884e8-d768-451e-899a-cdc1d998c9e8" continuedAt="i7c3cbe206c3343d28e90c2200347d287" escape="true">Commercial license and other economic rights</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i49b0e76257894cbfbfa6c0aff38deabb" continuedAt="i6b01c78459e84182bbf3a4566de4160e"><ix:continuation id="i7c3cbe206c3343d28e90c2200347d287" continuedAt="i5181e427387249c0a46ed375a327f2d5"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:ScheduleofCommercialLicenseRightsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDY_bfd69c2e-11b5-4277-a3a9-14b0e1fe9c8f" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights consist of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"></td><td style="width:71.542%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.855%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.856%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo &amp; CorMatrix</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76f6da162c3e4716b198d45ef10746a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMi0xLTEtMS0w_51a87776-dbe9-4ff1-a052-391c00c0c85d">17,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59fc29cee5074164b3c15d239382aa22_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMi0zLTEtMS0w_7821327c-dd70-433b-8c1b-35949852e8a6">17,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ac076f1e57a4636b9b7a8d17ac9c624_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMy0xLTEtMS0w_59ae37ac-946a-4fa5-bfec-0cbd933520cf">10,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i503b6946954c46afa717c2fcf22da428_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMy0zLTEtMS0w_99135142-34d7-4d06-aee2-71e1c8e1ab0b">10,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1677d2b07ff14a8dbc63ada1e73e55b0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNC0xLTEtMS0w_b188c691-6f8b-4d93-b3bd-cd9d9fdaef1c">8,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10ee583771d143e48147fc04de5f46c1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNC0zLTEtMS0w_9d3e4534-cddd-43d5-ab20-104ace780e98">8,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i96448a01fb3f40a096e5d761e2c099b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0xLTEtMS0xNzQ2_49fb88f9-0ab6-491c-9616-dcc273133c33">2,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2287a9c538514d76aadb3ec1766fe149_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0zLTEtMS0xMDc4MA_c13d6d8d-94a0-47eb-a3b4-cbbcc1dfc001">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0xLTEtMS0w_f6fd51fd-fde2-4c70-bc7a-c7c183843c47">38,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0zLTEtMS0w_e4fdf3c8-85a9-4717-ba0c-59154405b9c4">36,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization attributed to principal or research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0xLTEtMS0w_1fd31aaa-83b9-4e5f-acb0-7d220ef25f85">18,208</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0zLTEtMS0w_24cfbad8-0bc2-4470-9dad-d588f80c6dda">4,838</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNy0xLTEtMS0w_395eab8d-0f09-458a-91b9-fbcc19d927b9">20,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNy0zLTEtMS0w_c365dd7a-50db-48e7-8f83-aca286d4acff">31,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights as of December&#160;31, 2019 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id883dd6370374636a72ea85102571215_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY5NTkxMQ_7f9a01a3-119b-4a05-acf7-8b41ae1cebf5">12.0</ix:nonFraction> million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $<ix:nonFraction unitRef="usd" contextRef="ia8345e8c12e54d5aaee35fd1453902c0_I20190531" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ3MA_21d26fa0-0241-4901-80fa-b89bdc65d4e0">20.0</ix:nonFraction> million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="i22c27966fa7a47b48404cf82d0835b4b_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ4OQ_bdcd76af-6fe7-493d-95ad-4e498d0eb0cb">7.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iabe93206950f4a5ca90a7c38545f68fa_I20190531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ5Ng_3c9e6e45-2362-4a37-aec6-93941b12f130">10.0</ix:nonFraction>% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Arrangement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and reduce our asset as the funds are expended by Novan. As of December&#160;31, 2019, Novan had used up the $<ix:nonFraction unitRef="usd" contextRef="id883dd6370374636a72ea85102571215_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTczMjk3MQ_7f9a01a3-119b-4a05-acf7-8b41ae1cebf5">12.0</ix:nonFraction> million upfront payment provided by us. As such, our other economic rights related to Novan has been fully amortized as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $<ix:nonFraction unitRef="usd" contextRef="id5b9fd1011fc45cb824aa53afa55ee70_I20181231" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTIzNzk_cc9fa361-c789-4278-9cdb-8a8d734a9233">8.0</ix:nonFraction> million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congentia. In addition to the milestone payments, Palvella will pay us tiered royalties from <ix:nonFraction unitRef="number" contextRef="ic25cc6cea36649299a866a8aefa35559_I20181231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI2NzQ_608ee05a-b26e-4321-8b54-6441221ada4e">5.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1a7529b75a8a4febb9932e1ac827bae4_I20181231" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI2ODA_d327fd93-e5e8-4625-8d7a-82fc3234dec3">9.8</ix:nonFraction>% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i04c56e43b6e44052bafac504dcd95284_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:LicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI5MDc_7d82f1a6-31c6-44f3-aea9-14b4057f35a4">10.0</ix:nonFraction> million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and will reduce our asset as the funds are expended by Palvella. We will evaluate the remaining asset basis for impairment on an ongoing basis. It is anticipated that the cost basis of the asset will be reduced to zero prior to the receipt of any payments from Palvella. Therefore, we will recognize milestones and royalties as revenue when earned. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $<ix:nonFraction unitRef="usd" contextRef="i5df91a43747141109e40628d6c3e1602_D20170531-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTM2Mzk_b65cad6c-cc29-4714-b0c1-a167ba292020">10.0</ix:nonFraction> million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a <ix:nonFraction unitRef="number" contextRef="i5c0bcf32476240a69acc2df358c66283_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTM5MDk_56adc76a-b670-4d59-b99d-250c3e8ca9ac">5</ix:nonFraction>% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original <ix:nonFraction unitRef="number" contextRef="ia434c2f1e4fd4242bc042dcec9b0f76c_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQwMDY_cf8ac407-284b-44b0-9434-baa29ec659ab">20</ix:nonFraction>% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="ibcbe0bbeae724e1d93328ffcae8742d7_I20170531" decimals="INF" format="ixt:numdotdecimal" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQyMzM_bb34f4b1-a19d-4c3f-9fa2-c3bb623b92e7">10.0</ix:nonFraction> million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i6b01c78459e84182bbf3a4566de4160e" continuedAt="iddb955fcaf474198a3ad03fa5fd9b734"><ix:continuation id="i5181e427387249c0a46ed375a327f2d5"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developmental pipeline products, including the royalty rate of <ix:nonFraction unitRef="number" contextRef="ibf9680e99f8b49b19bbd0708cf2b886f_I20170531" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQ5MzE_b4866d86-37bc-4651-99a2-29d3ace7976f">5</ix:nonFraction>% on such pipeline products. The Amended Interest Purchase Agreement will terminate <ix:nonNumeric contextRef="ieaa465d6d40c45fba9d4e1bdc39e4cd8_D20170531-20170531" format="ixt-sec:duryear" name="lgnd:RoyaltyAgreementExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTUwMTY_4c0790c1-2c11-4da0-927d-beb71d02f25f">10</ix:nonNumeric> years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Receivables</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2019 is <ix:nonFraction unitRef="number" contextRef="i00b84867fefc461a891bb0fd73e18725_D20190101-20191231" decimals="2" name="lgnd:ForecastedCashFlowsEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTU1MTU_32b74630-81ad-4196-89ac-eb0960bb5209">23</ix:nonFraction>%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2019 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. We recorded a $<ix:nonFraction unitRef="usd" contextRef="id365704cf3b84c6ab7c5a47ec6bdff70_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjE5OTAyMzM1MzEyMA_105ae137-e851-450f-88c4-5f8d6bbdc69a">5.1</ix:nonFraction>&#160;million reduction in the carrying value of the Selexis asset which was reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjk_a7fd1fc5-ca5b-4478-a3df-97694f458a95" continuedAt="ibb851e42042b4f7bb262d4024a07ffad" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See additional information in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disaggregation of Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> subsection below. Our accounting policies under the new standard were applied prospectively and are noted below.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalties, License Fees and Milestones</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iddb955fcaf474198a3ad03fa5fd9b734" continuedAt="i7a40dda2113445dc8f163f7785dd3a46"><ix:continuation id="ibb851e42042b4f7bb262d4024a07ffad" continuedAt="i9adb9b2fee6c4cbcbb52c05850f18048"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Material Sales</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at prior year-end was $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfOTg5NTYwNDc0NDA1MA_5936d94d-f22e-4022-8b81-f9362ee2ae03">3.3</ix:nonFraction> million. During the twelve months ended December&#160;31, 2018, the amount recognized as revenue that was previously deferred at prior year-end was $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfOTg5NTYwNDc0NDEwNQ_87f9018d-513a-4798-bbfb-fe6ac57dc8a8">2.3</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9adb9b2fee6c4cbcbb52c05850f18048">We have revenue sharing arrangements whereby certain revenue proceeds are shared with a third party. The revenue standard requires an entity to determine whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. We received $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:RevenueRecognitionMilestoneMethodMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjM0MzI_fe4b6ea1-660d-425e-bbbf-d293b88340a9">4.6</ix:nonFraction> million royalty payments from a license partner during 2019 of which $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcyMzE3NQ_842e3577-df90-4d8e-905a-5dd5aa47a4ac">4.0</ix:nonFraction>&#160;million was paid to a third-party in-licensor. We recorded net revenue of $<ix:nonFraction unitRef="usd" contextRef="i014e836b51b047e8b7d0a0a06fb58ea5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjM1NjY_ae2f2776-ba3a-40fb-b4b1-a9e4be98ce79">0.6</ix:nonFraction> million as we believe we are an agent in the transaction. We recorded an immaterial amount due to third-party in-licensors as general and administrative expenses as we are the principal in the transaction during 2019.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE3MzE3OQ_3f96d075-eaba-4491-b91f-8c0e93acf9a8" continuedAt="i82ade95460da4859ae4c57d2a3ac70f2" escape="true">Royalty revenue for 2019, 2018 and 2017 are reported as below (in thousands):</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7a40dda2113445dc8f163f7785dd3a46" continuedAt="i0333485439624af69392e73135ead44b"><ix:continuation id="i82ade95460da4859ae4c57d2a3ac70f2"><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:38.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.654%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.274%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.397%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.548%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2018</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2017</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promacta</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82f8b0071ba419db2fd44d139c75921_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy0yLTEtMS0xMTk4Mw_55513136-7ecf-4fab-b432-b5a0971b145b">14,193</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i752660ce777040a3bf4a197f34a8a7ae_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy00LTEtMS0xMjAwNA_882ebcc9-5050-4069-a6b7-adbb25d0cbfe">99,260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48b6c33518324d248216b8fc59601e1e_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy02LTEtMS0xMjAxNQ_adf0ff9f-edc1-44ae-b661-b26b39c10f3f">62,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fd9ffdb575642bc99960b6a0f220f7e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC0yLTEtMS0xMTk5NA_39c24535-37e0-49ff-a620-35b8cc1d7da7">25,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbf94a70bfff4f93bc6e7bb11e783a03_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC00LTEtMS0xMjAwNA_89157734-0882-4b6f-bde6-b9a4124f8032">21,686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e64ad3b9590426a946af951ece864ce_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC02LTEtMS0xMjAxNQ_4021e80a-2ec9-463c-9720-e066e4f8366b">16,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifdbe7a966e324982b84d652d014786ac_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS0yLTEtMS0xMTk5NA_b669dee6-18d9-4405-921e-e86a18448be0">5,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ff65fe494c14a35b1dd9f4bd1dc538c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS00LTEtMS0xMjAwNA_c14206ec-c1e9-49dd-8136-7f8c543219db">5,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9612324a089e4c32998e3a6d952592f8_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS02LTEtMS0xMjAxNQ_d30f4b67-df9d-4c76-b361-b3b368ca64f1">7,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i146808219fd64e048cff80065bea6f1b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi0yLTEtMS0xMTk5NA_dc1bb883-4458-4b20-b12e-652ceb6f4030">2,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i960ac618c48c4ce3b0502dead45bbb2a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi00LTEtMS0xMjAwNA_cdaa7570-9f54-4c2a-b8be-ea027207bce1">1,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if187e8fde5214e529fe79103581b53a1_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi02LTEtMS0xMjAxNQ_f5813717-c657-4cfa-a59e-b4699650752d">2,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy0yLTEtMS0xMjMyOQ_7a98b21a-ca03-4e35-9dd7-28ab0f732f82">46,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy00LTEtMS0xMjMzMA_9bfb9dc5-b517-4302-b2a0-a67ffa0da55d">128,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy02LTEtMS0xMjMzMg_2a9f8d14-9f84-4f78-b4b1-7f3006062473">88,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">1) Royalty revenue for 2019 and 2018 was reported under the current revenue recognition guidance (ASC 606).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Royalty revenue for 2017 was reported under the legacy revenue recognition guidance (ASC 605).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands), which are not affected by the adoption of ASC 606:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:35.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.944%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material Sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy0yLTEtMS0w_bd7cf525-f58b-4120-a3b7-1f7ed8dd79c1">31,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i675b454e2a4246a5976716630c08343b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy00LTEtMS0w_a4608a2a-6071-42f7-a819-86791953668a">29,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy02LTEtMS0w_11bd1dab-96c5-4d33-a743-5a4abcc5cdd2">22,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones and other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;License fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i194607164d454958b0723749de9579e2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS0yLTEtMS0w_6cb3fd65-4b51-4bd2-9c71-5740c7aa3495">6,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ff0c9eca02e4a2f9b35491141d683f0_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS00LTEtMS0w_7254e4ad-e3e6-48ff-87ce-d4f84d299041">78,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffdb648378694003ae22ea717992f96b_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS02LTEtMS0w_95c348ef-51e3-4283-851d-0cb78d0419e9">13,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i554d97702ee847d8a57c46340addad5d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi0yLTEtMS0w_ec027014-12f8-443a-aab1-695502fce16c">23,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05a2217af97e477b903d2d5d4edab90b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi00LTEtMS0w_17710779-142a-48fa-b2a3-931bfa7eeb24">6,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd04a9173f544a62859a7935f7ae3658_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi02LTEtMS0w_86677d53-03ad-4e5d-965d-102a5374a669">11,093</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d72465b58ad4e67b216c687373c6ff8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy0yLTEtMS0w_b961dc1d-a554-4fb2-b0f7-ca9cc3b87b80">12,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd9941b5f3154326bcadc3bdd7cdd3b7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy00LTEtMS0w_ae3c20bd-bcd7-4c8b-bbb2-ed2f38a4e908">9,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee06435e8cf54fa7aa9127b85e72920f_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy02LTEtMS0w_6700825a-c9b9-4c16-9d78-00a035aa7479">5,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC0yLTEtMS0w_49e30556-2a72-4915-98db-a4ad4c926463">41,817</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC00LTEtMS0w_475879ba-17d5-4028-b6ad-ee8d331fe4b9">93,774</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC02LTEtMS0w_559168d3-b8e3-44c4-bff5-87a18b437326">30,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDA_b89e5376-f37f-4927-b8cc-903b366fc6e6" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjg_288dc1d5-b584-4ac6-8157-2a3777a3454f" continuedAt="i6e81f4ee83a7477684f6996274fc9feb" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6e81f4ee83a7477684f6996274fc9feb">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzM_859df81f-7ec9-4306-bb2c-70fae4491f30" continuedAt="i4420a6960cef4a4e92e0606dc120e0e9" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:45pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i0333485439624af69392e73135ead44b" continuedAt="i003cd177017b4b64ac763c72da8cb53c"><ix:continuation id="i4420a6960cef4a4e92e0606dc120e0e9" continuedAt="ie32c73ec584340a58855816bfa4ed9c1"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction unitRef="number" contextRef="i40f1b30e9315498090c3a5d490662303_I20191231" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjgyMDA_38a99079-8558-4555-ae5d-1fa987712ba0">0</ix:nonFraction>% given that except for 2007, during which we declared a cash dividend on our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie0993a0ffdc9416e8eae6352f6f762b9_D20070101-20071231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjgyOTU_124f8a32-a9ad-49ea-9c10-f76e5e13b6e5">2.50</ix:nonFraction> per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire <ix:nonNumeric contextRef="i59e2fe191ffb414da27578a719a56920_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjkwODI_2fca8384-0ab5-47d9-adc9-9c59cc9648ef">ten years</ix:nonNumeric> from the date of grant.</span></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie32c73ec584340a58855816bfa4ed9c1">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivatives</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjkzMjU_b9fcf26d-b9c4-4195-86d4-e1a1c43e3149">750.0</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjk0MDU_0d408b4b-2ec3-4a25-bc52-6b3f4aee74b0">0.75</ix:nonFraction>% per year, payable semi-annually, as further described in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our 2019 Notes, which we issued in August 2014 for $<ix:nonFraction unitRef="usd" contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMzA5NDY_bcf997a4-8b9d-4822-8194-7ed87b204b68">245.0</ix:nonFraction> million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to <ix:nonFraction unitRef="usd" contextRef="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE2OTcyMQ_0f96d7c3-231c-491d-b15c-4ffece2106fd"><ix:nonFraction unitRef="usd" contextRef="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE2OTcyMQ_7be812fe-5ba8-4f51-8f4c-7191473e4ee2">zero</ix:nonFraction></ix:nonFraction>. See detail in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDk_086c4739-6228-4570-805d-9103c34fca73" continuedAt="i3506cac3e4a8486bbc30cf5e787addb5" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i003cd177017b4b64ac763c72da8cb53c" continuedAt="i4dedf4eed77b4a5dbf7c8474935bd6c5"><ix:continuation id="i3506cac3e4a8486bbc30cf5e787addb5"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzE_658fff9c-c6ab-47ff-9da7-8f1c0553f085" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income (loss) Per Share</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzQ_bca81617-c7b0-4abd-9b23-32fd30514357" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:61.289%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.749%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi0xLTEtMS0w_b714ee0e-3e05-436d-800c-4bcc64fd4729">18,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi0zLTEtMS0w_c7b1a67f-418f-4afc-9ab3-46062298ca57">21,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi01LTEtMS0w_4700684a-aeb2-4c57-92b5-7ebb64c1d9c4">21,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC0xLTEtMS0w_5fa46a17-1eba-4840-b27b-f736fa0abe54">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC0zLTEtMS0w_befe4a02-76c2-4b05-9c72-0e70979a871b">72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC01LTEtMS0w_2eff0143-f711-4fc6-83ef-2aa1f686ac03"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC01LTEtMS0w_9da4b67d-acf6-4171-b421-b2fb8ba7c8ac">141</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS0xLTEtMS0w_862e417c-24bf-404c-bdaf-08f511fa0715">719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS0zLTEtMS0w_8bf2e12f-09f6-4771-921c-0c66660c72ca">1,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS01LTEtMS0w_6945c21a-56ed-48e9-98f6-1ba6941e4aa1"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS01LTEtMS0w_e032b521-a7e5-46ec-bdec-bada29a8a93f">1,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi0xLTEtMS0w_5a2f45bd-fe2d-4579-a1c2-94e0d0862556">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi0zLTEtMS0w_8b0085ff-b5a7-4f48-a970-d27651a886d1">1,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi01LTEtMS0w_97af1849-eb2f-4604-9170-51acce54022d">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy0xLTEtMS0w_b7ddf039-e487-413c-b975-df3bcf57ea74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy0zLTEtMS0w_ce793e47-b6d9-4f42-9864-fdde003e887a">693</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy01LTEtMS0w_1f47ab30-488b-46a0-a05a-15b777b05828"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy01LTEtMS0w_2957f5e0-ebfa-40f9-8400-e53e7eefe191">1,214</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used to compute diluted income per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC0xLTEtMS0w_465c2087-02e5-4bb4-a442-1c7a273eedc7">19,757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC0zLTEtMS0w_bb2207a1-a66b-4fcd-a903-d6ef773e4b88">24,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC01LTEtMS0w_db7cf6c3-6ac6-4810-9324-ce1fda59b2d5">23,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS0xLTEtMS0w_21532399-3f38-462f-94e2-a861368d55ce">8,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS0zLTEtMS0w_6765e738-fbde-4e2b-b4c1-ac0e5c5670aa">2,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS01LTEtMS0w_b3d919f3-c821-4db4-8a73-e591e25e94d4"><ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS01LTEtMS0w_b552faf1-3494-4b5e-9966-27076f4590e3">335</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjM_f491ab91-4cd1-4f77-b4c5-d57af5978546" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i4dedf4eed77b4a5dbf7c8474935bd6c5" continuedAt="if78805ac8ed340e39ba2b9a95703e4eb"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTA_a94f2e0b-466c-46a6-a412-b2dfebaea9fb" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Translation of Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-indent:24pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTU_f650397c-24b2-402a-b1aa-67ebc160e7dc" continuedAt="ia66f23bde2f74500a6dda73e52cf6a1a" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In 2018, the FASB issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in ASC 840,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> Leases (Topic 840),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> including its disclosure requirements, in the comparative periods presented. We adopted this standard on January 1, 2019 by applying this optional transition method. For leases with a term of 12 months or less, we elected to not recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. In addition, we elected the available package of practical expedients upon adoption, which allowed us to carry forward our historical assessment of whether existing agreements contained a lease and the classification of our existing operating leases. We did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases. We continue to report our financial position as of December 31, 2018 under Topic 840 in our audited consolidated balance sheet. The adoption of this standard update resulted in the recognition of right-of-use assets of approximately $<ix:nonFraction unitRef="usd" contextRef="id36623c1d9734d28ae32c58d9b90c026_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcxMjk5Mw_dbf5f070-5646-4bef-9534-7269a4ddfec0">5.2</ix:nonFraction> million and lease liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="id36623c1d9734d28ae32c58d9b90c026_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcxMzAxMA_4a3628a7-59dc-4269-a82e-dd736852247d">5.9</ix:nonFraction> million on our consolidated balance as of January 1, 2019, with no material impact to our consolidated statement of operations. See "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Note (6), Leases"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> for further information regarding the impact of the adoption of ASU 2016-02 on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Not Yet Adopted</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for us beginning in the first quarter of 2020, with early adoption permitted. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We will adopt this standard effective January 1, 2020, and we currently do not expect the adoption to result in a  material impact to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Goodwill Impairment Testing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Simplifying the Test for Goodwill Impairment,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. This standard is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020, and will include the required disclosure beginning in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In November 2018, the FASB issued ASU 2018-18</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if78805ac8ed340e39ba2b9a95703e4eb"><ix:continuation id="ia66f23bde2f74500a6dda73e52cf6a1a"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">recognized from contracts with customers. The new standard is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted in any interim period for entities that have adopted ASC 606. The standard should be applied retrospectively to the period when we initially adopted ASC 606. We will adopt this standard effective January 1, 2020, and do not expect the adoption will result in material impact to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_768"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">2. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzI3NDg3NzkwNzEwNjk_56fd045c-b404-4f97-916e-aa3a9152353d" continuedAt="ie98d7cec533743779e57c5e182e22f6b" escape="true">Sale of Promacta License</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="ie98d7cec533743779e57c5e182e22f6b" continuedAt="i363a6c9432c94153846d784351bf21a2"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $<ix:nonFraction unitRef="usd" contextRef="i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306" decimals="-5" format="ixt:numdotdecimal" name="lgnd:RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNDE_350eee67-75b3-4e6c-85c4-dc6b7a062d79">827.0</ix:nonFraction>&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was <ix:nonFraction unitRef="usd" contextRef="i7411d3bb032347e6a6b92e42a6d29132_I20190306" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNjA_029aa10d-803c-4fc5-8996-8ba12301b4ad">zero</ix:nonFraction>. Of the total cash proceeds from the sale, $<ix:nonFraction unitRef="usd" contextRef="i879ae176b2124f789573e2512496d9a0_D20190101-20190306" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNjY_cb67970a-60f2-4520-97eb-5d7a47d9962a">14.2</ix:nonFraction>&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $<ix:nonFraction unitRef="usd" contextRef="id432212c910f45cb9fd439930be6a10c_D20190101-20190306" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzODQ_c6af926a-1a6e-4459-8f6c-495604fc2b5a">812.8</ix:nonFraction>&#160;million was recorded to income from operations in accordance with ASC 610-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i363a6c9432c94153846d784351bf21a2">.</ix:continuation> </span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_91"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.  <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjc0ODc3OTA3NjY3Mw_eaf7a96d-87e7-480a-a752-c33bc92d7471" continuedAt="ia663b3400ca6460f92c203ba0ef15ba0" escape="true">Investment in Viking</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia663b3400ca6460f92c203ba0ef15ba0" continuedAt="if3033bfb0a444ca180f5e77988e7052c"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ownership in Viking was approximately <ix:nonFraction unitRef="number" contextRef="i42d16a6431d94f848413960849cb7def_D20190101-20191231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfODA_588250c9-f2e3-4abc-a267-119d1c49a69c">10.3</ix:nonFraction>% as of December&#160;31, 2019, and we account for it as investment in an available-for-sale security, which is measured at fair value, with changes in fair value recognized in net income.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to February 2018, we accounted for our investment in Viking under the equity method. As a result of Viking's public stock offerings, we recorded a dilution gain of $<ix:nonFraction unitRef="usd" contextRef="i627d466bba7d41ddbcecee653a9fcb3e_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseinEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfNjcx_5060365e-1ff3-42d0-8ddf-ab961b2896af">2.7</ix:nonFraction> million for the year ended December 31, 2017. These amounts were recognized in Loss from Viking in our consolidated statement of operations. Our equity ownership interest in Viking decreased during the first quarter of 2018 to approximately <ix:nonFraction unitRef="number" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="3" name="lgnd:VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfOTU3_5217b4b1-76a6-4816-9538-3f380e15d4dc">12.4</ix:nonFraction>% due to Viking's financing events in February 2018. As a result, in February 2018, we concluded that we did not exert significant influence over Viking and discontinued accounting for our investment in Viking under the equity method. Viking is considered a related party as we maintain a seat on Viking's board of directors.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and December&#160;31, 2018, we recorded our common stock in Viking at fair value of $<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIwMA_b85c6aa1-f822-461e-9894-67177ef8b70c">48.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIwOQ_9cc64fa5-d132-470c-892c-6a56ff4fea12">46.2</ix:nonFraction> million, respectively. We also have outstanding warrants to purchase <ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIyOA_3be83385-e9c2-4f23-a031-1f92e50e21ea">1.5</ix:nonFraction> million shares of Viking's common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia866a9721849422ea2aa6ef8a644c3b6_I20160430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjc1MA_8591e775-ca42-4287-872f-7e94bf2846e2">1.50</ix:nonFraction> per share. We recorded the warrants in "investment in Viking" in our consolidated balance sheets at fair value of $<ix:nonFraction unitRef="usd" contextRef="i6365b125a6f9462a9020457fd59be296_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjg2NQ_8d14be8c-e381-476b-9863-dd092d7b168e">9.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if127a97e90a74b089bee82f5b9537b9f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:InvestmentInVikingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjg3Mg_f0035d4e-4797-47eb-9caf-6a58544721da">9.3</ix:nonFraction> million at December&#160;31, 2019 and 2018, respectively. See further discussion in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (5), Fair Value Measurement.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div></ix:continuation><div><span><br/></span></div><div><ix:continuation id="if3033bfb0a444ca180f5e77988e7052c" continuedAt="ib858bd01e76d44d0b36ff1382567f6d7"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to the adoption of ASU 2016-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Overall (Subtopic 825-10), </span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib858bd01e76d44d0b36ff1382567f6d7">on January 1, 2018, we no longer account for our investment in Viking under the equity method; instead, it is measured at fair value, with changes in fair value recognized in net income (loss).</ix:continuation> </span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_94"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.  <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1Mw_759a52ab-7169-48c5-b569-7a5851b8dfbd" continuedAt="ifa5964772811403cbfda1c59abfe5597" escape="true">Business Combinations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifa5964772811403cbfda1c59abfe5597" continuedAt="idbd90811039649fc8924fed76ecedd45"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As set forth below, we completed <ix:nonFraction unitRef="acquisition" contextRef="i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="lgnd:NumberOfAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTA5OTUxMTY0MjM4Ng_090e2d5f-e574-44f9-8b0b-25e6b03c661b">three</ix:nonFraction> acquisitions from January 1, 2017 through December 31, 2019, and all were accounted for as business combinations. We applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ab Initio Acquisition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="idbd90811039649fc8924fed76ecedd45" continuedAt="i5e85531985c243b28cbcde8025aeffbe"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purchase price of $<ix:nonFraction unitRef="usd" contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMDI_1cea1e43-b9a4-4af8-a704-59d91545be19">12.0</ix:nonFraction> million included $<ix:nonFraction unitRef="usd" contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723" decimals="-4" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMTI_9dcb7db9-7182-4036-aebb-cdc03f0b304c">11.84</ix:nonFraction> million cash consideration paid upon acquisition, net of cash acquired, and $<ix:nonFraction unitRef="usd" contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723" decimals="-4" name="lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMTk_9eee0029-b876-4d77-ad18-15a9d87d2df2">0.15</ix:nonFraction> million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i4ee653649d66402981113f680d933493_D20190101-20191231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjc0ODc3OTA4NDQ2MA_510a5e2d-b770-456e-b771-16f08b4c85a1" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"></td><td style="width:77.518%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.482%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and other assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfMC0xLTEtMS00NDQ3_370c23b9-76cb-4c6a-8edf-477a42b30fcd">28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfMy0xLTEtMS00NDQ3_f9fc24c4-5840-4655-9f14-255a042ccff6">83</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNC0xLTEtMS00NDQ3_36f6a2f3-0b0c-4e14-8205-d1862739d5c4">1,609</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNi0xLTEtMS00NDQ3_eb505c55-fada-4e9f-ac53-8b172d79b5dc">7,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNy0xLTEtMS00NDQ3_59c84023-1d52-4ebf-88b9-a3cf0f298ed4">6,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNS0xLTEtMS0xMDg0Mw_366da8ab-4910-4ee0-842b-5cffaa46f75d">12,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTgxMzU_ad4438c0-776b-48e9-bc0e-edb5f065187b">12.0</ix:nonFraction>%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric contextRef="i6a285f7cae6847cbb84e55f9cc40ae24_D20190723-20190723" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTgyODc_31fcca57-3585-485c-b7dd-4e94d1bb24ef">20</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Vernalis Acquisition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, we acquired Vernalis, a structure-based drug discovery biotechnology company for $<ix:nonFraction unitRef="usd" contextRef="i063eb253ae3b4c25a99074736166eeb7_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjAw_6a5b8434-6b75-4089-8223-8eac65991bc0">43.0</ix:nonFraction> million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="idffee5590e9a4dc7b62742af7e16dc82_D20190101-20191231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU2MQ_517b35ab-f7f5-4aed-8e46-20ae535cd2b7" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"></td><td style="width:77.518%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.482%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMC0xLTEtMS0w_665546d0-b113-439c-ab59-de80bd7ce28a">34,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMS0xLTEtMS0w_59469b80-8291-4730-aac7-a608bd4f2fff">2,836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMi0xLTEtMS0w_6e260e2e-f2b8-481f-9799-22ca1edd8618">6,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMy0xLTEtMS0w_e3dcca15-8f8a-4966-a01e-1c12b9d0d426">3,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and product reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNC0xLTEtMS0w_ea3490a5-3207-4a0e-bc2b-5e90a0b8cc34">9,241</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNS0xLTEtMS0w_868ea12d-cf84-419f-abf1-4ea98c022e38">746</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNi0xLTEtMS0w_1225c331-bbbf-4472-9d91-f0e35309eef8">7,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNy0xLTEtMS0w_638ef3b1-767b-4454-897c-7de1ba52e912">5,939</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfOC0xLTEtMS0w_00d30377-21f6-4627-9e46-d6d0b666d25e">42,978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies.  These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTM0NA_52a5db4a-3dcb-43f9-99b6-38110bac6d88">34.0</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately <ix:nonNumeric contextRef="i814ece52582942738ba79ba1e26c7405_D20181001-20181031" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTQ5NQ_b94932d0-e62b-4b91-a87e-302e80bc86e6">nine years</ix:nonNumeric>.  </span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i5e85531985c243b28cbcde8025aeffbe"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Crystal Acquisition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 6, 2017, we acquired all of the assets and liabilities of Crystal. Crystal is a biotechnology company focused in avian genetics and the generation of fully-human therapeutic engineering of animals for the generation of fully-human therapeutic antibodies through its OmniChicken</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> technology. Under the terms of the agreement, we were to pay Crystal selling shareholders $<ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjMxMQ_54d3c941-fabb-4ddf-99b6-27b79763e3f0">27.2</ix:nonFraction> million in cash including a $<ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-5" format="ixt:numdotdecimal" name="lgnd:WorkingCapitalAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjMzNA_034d2fd3-9b21-4d33-81f1-7c22fcf290d3">2.2</ix:nonFraction> million working capital adjustment, and up to an additional $<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjM4OQ_e0c909bf-22af-4fd4-b7ba-21b8a2d23841">10.5</ix:nonFraction> million&#160;of cash consideration based on Crystal&#8217;s achievement of certain research and business milestones prior to December&#160;31, 2019. In addition, Crystal&#8217;s selling shareholders will receive <ix:nonFraction unitRef="number" contextRef="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006" decimals="INF" name="lgnd:RevenueRoyaltytoAcquireeShareholdersPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjU3NA_e2e469ed-0188-4442-bda1-92f4cccc44fb">10</ix:nonFraction>% of revenues realized by Ligand above&#160;$<ix:nonFraction unitRef="usd" contextRef="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006" decimals="INF" format="ixt:numdotdecimal" name="lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjYxNA_43ee8901-cf4a-48a0-9125-fbf61c32fc1d">15</ix:nonFraction> million between the closing date and December&#160;31, 2022 from&#160;existing collaboration agreements between Crystal and&#160;three&#160;of its collaborators, and Crystal&#8217;s selling shareholders will receive <ix:nonFraction unitRef="number" contextRef="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006" decimals="INF" name="lgnd:RevenueRoyaltytoAcquireeShareholdersPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjc5OQ_9feae559-ec32-46b8-ae15-793defe4e16a">20</ix:nonFraction>% of revenues above&#160;$<ix:nonFraction unitRef="usd" contextRef="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006" decimals="INF" format="ixt:numdotdecimal" name="lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjgyMA_c7696f0c-00df-4a63-a49f-cd730ac57837">1.5</ix:nonFraction> million&#160;generated between the closing date and December&#160;31, 2022 pursuant to a <ix:nonFraction unitRef="numberofcollaborationagreements" contextRef="i1697e6f29f434232b75e818f4ca2eca0_I20171006" decimals="INF" format="ixt-sec:numwordsen" name="lgnd:NumberofCollaborationAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjg5NA_3703db2f-1218-465e-950a-9f703a0cbd99">four</ix:nonFraction>th existing collaboration agreement with a large pharmaceutical company. As of December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231" decimals="-4" format="ixt:numdotdecimal" name="lgnd:CashPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjk3OQ_b2c3e75d-83dc-4d20-abce-8974abc7b0b5">0.02</ix:nonFraction> million of the initial $<ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjk5Nw_b3d8a5f8-522c-4257-9146-4ed4818d8daf">27.2</ix:nonFraction> million of cash consideration remained outstanding.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the closing of the acquisition, we recorded an $<ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-5" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMzA5NQ_eaf7769f-d5de-4a65-b448-5b6bc334343b">8.4</ix:nonFraction> million contingent liability for amounts potentially due to Crystal shareholders. The initial fair value of the liability was determined using a probability weighted income approach incorporating the estimated future cash flows from potential milestones and revenue sharing. These cash flows were then discounted to present value using discount rates based on our estimated corporate credit rating, and averaged to approximately <ix:nonFraction unitRef="number" contextRef="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006" decimals="3" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMzUxOQ_b5bb4382-e9cc-454c-aa2a-89c29c47d0de">4.6</ix:nonFraction>%. Refer to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 5 Fair Value Measurement </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for further discussion. The liability has been periodically assessed based on events and circumstances related to the underlying milestones, and any changes in fair value are recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. For additional information, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (8), Balance Sheet Account Details</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231" name="lgnd:ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1Nw_09a9ca95-5fdd-4e90-b166-c46782056353" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final aggregate acquisition consideration was determined to be $<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDEyMQ_bba8f22d-e935-4249-858a-ca06edb8a970">35.7</ix:nonFraction> million, consisting of (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"><tr><td style="width:1.0%;"></td><td style="width:77.411%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.589%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid to Crystal shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-3" format="ixt:numdotdecimal" name="lgnd:CashPaidtoAcquireBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMC0xLTEtMS0w_ded8a8a7-464f-413a-a263-fffc41f24ee6">26,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payable to Crystal Shareholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="lgnd:CashPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMS0xLTEtMS0w_3d1cc96a-64c6-4bbf-99f3-d95ee7785b89">336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMi0xLTEtMS0w_9d567600-a0bb-45bb-b3e6-a5ac30d5be98">129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMy0xLTEtMS0w_c5c776d1-2a17-4878-a2ec-63ee271bd289">8,401</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfNC0xLTEtMS0w_7a3d089b-fdda-4684-93af-9978ea9684da">35,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1MQ_5eec17c4-ef92-4f32-9455-ab0b0a5e5dd1" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMC0xLTEtMS0w_1dd1c05c-dca2-40e8-9b85-c82f056fb6cd">224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMS0xLTEtMS0w_e0c9cb3d-0200-4ad7-a9c3-02d4ba9f2a44">2,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMi0xLTEtMS0w_0fcc8c30-b709-4ebe-b3ee-95c4376c2132">201</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMy0xLTEtMS0w_cd4818b0-02d5-468f-a30e-725dd01ec0e9">589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Current liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNC0xLTEtMS0w_ed13badd-483c-429e-8650-d14c0b11f76b">354</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNS0xLTEtMS0w_e1c2a1d2-e39e-41ad-9761-3d9e02840287">4,624</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNi0xLTEtMS0w_8c8089c5-d275-4be7-b263-9b976d3ca0d8">9,503</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNy0xLTEtMS0w_a3a7e531-0424-48bf-9936-af495b860985">36,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfOC0xLTEtMS0w_17cd1086-8ac9-4abc-82ba-0bc3121343fe">10,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfOS0xLTEtMS0w_285ade63-af68-4678-9d8e-22de9fd9ed0a">35,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the core technology, or OmniChicken technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniChicken technology. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006" decimals="INF" name="lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDYzMg_e3f84f82-22b5-49ab-8b19-b7fdf81067e6">10.8</ix:nonFraction>%.  The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i8cf89aa90cf34ae8b88f29189cdd661b_D20171006-20171006" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDc1Mw_f06f0b78-b3e7-4c98-8f5f-86c2c1b52d66">20</ix:nonNumeric> years.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was $<ix:nonFraction unitRef="usd" contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDg5NA_beeafc14-ad1e-4cbe-b86e-48c058409d10">10.7</ix:nonFraction> million and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to Crystal&#8217;s potential revenue growth from combining the Crystal and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_97"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI3MQ_64af6131-d793-4e2b-a203-51248e5fec74" continuedAt="i4410955008f848a188cc311eb085c418" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4410955008f848a188cc311eb085c418" continuedAt="i581acc70981a49948f834607ffb9b2b9"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="padding-left:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI3Mg_1bbd2f73-3b76-4004-aeaf-af53c0382884" continuedAt="ibc6582720cb2438e8c6d89e3ce691a9f" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:45.128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.669%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b00d8919174418ebe287cc12594d727_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC0xLTEtMS0w_22b03f30-a3dd-4f4e-b1f7-48e1bfb347a9">939,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if66e23507a484f19a663af8fe0d1ac56_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC0zLTEtMS0w_97a941c6-2c87-4fda-8c36-122d4dbe0396">3,073</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b560e54f4ba43f09c2f8005e045a4b7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC01LTEtMS0w_98c93640-5412-4b00-9c4a-c964800770e4">936,791</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia520b2b8a01f4302905c89f3b3631aba_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC03LTEtMS0w_cf51080c-db57-4eb4-977c-82a9087bdcaf">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if13f24dbd7b94cdd98bce8907218b098_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0xLTEtMS0xMzI3Mg_62eb5ee8-f993-40c3-9660-ff843cb6b817">48,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0c1b7515d834b96ba399542082661b2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0zLTEtMS01MjQ4_a7c38d16-f499-4266-9a05-bfa84915440d">48,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if65edf5940434c65862432001f7fca40_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS01LTEtMS01MjUx_43f42b35-f77a-4cc9-8be5-2d0bdec51bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2641b53d2baa4c3fa22b49a8cd48329e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS03LTEtMS01MjU0_58cc9d5d-c68a-416d-96bd-7897fe1aecb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a384419cf554229afda13595299df80_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0xLTEtMS0w_3d7cf599-f088-448e-a46f-04dff5b7038f">9,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie86a62fed86e4561b271030c70bfbe6b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0zLTEtMS0w_0ad0def7-3638-408f-a3a2-3f193cfc0df5">9,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1065d4ab29524f959cf02e2235084e47_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS01LTEtMS0w_abd3c7fe-7dec-4d86-b437-bdddccc0f0c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0795ba3ab21f49fcbe79b88fea60278d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS03LTEtMS0w_2714d26d-e3db-4e3b-a90c-c944a5c52bd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f894f3d17b245c480e3f32580adbf3e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0xLTEtMS0w_129b3cf6-5339-4d7f-92cc-fb7ad59be822">998,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0zLTEtMS0w_1213d771-916e-428f-ae1d-9a57fb0963d4">61,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi01LTEtMS0w_2be332cb-7f09-44de-80bd-8161f20db5bf">936,791</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi03LTEtMS0w_d1430cb0-77e8-4056-90f6-6c88c93b4b06">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic92a6ee4b08740648c5cc02eb96d8312_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC0xLTEtMS0w_c0737b71-d679-46f5-a838-3ecd1eeeea6f">2,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if7cf3fc5e9b14c01b5883261d2ebf84e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC0zLTEtMS0w_917b19c3-1fdd-4387-8829-8a60d98a2a11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88fbc1c8f9440599dc1210a3215a18f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC01LTEtMS0w_11c2c16b-41e7-446f-bfe9-83e16b1488b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ee3f1bbedd04ef0a2d097ae36f3fcfb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC03LTEtMS0w_9b21fa90-e9b5-4381-99a4-1720558189fe">2,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i333307bd30ca43dabd171c81f9a061c7_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS0xLTEtMS0w_bda652bb-4dff-478d-a404-bed669fe572a">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e55472ecafa4bd8b817bfd8cea90435_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS0zLTEtMS0w_272d0598-388d-493f-a687-fd0bcd6bd704">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a96b9c75a6a4db4a42908340754361e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS01LTEtMS0w_e65aa4af-9de7-43a2-936c-52be0e90da61">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4dd10b3dca034733bcf105cef8c3fe1c_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS03LTEtMS0w_f8f823ee-2dee-48c5-83da-fa366da9e3cc">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i053fc7c14c3a4fcca4e9518b3b0aa792_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtMS0xLTEtMA_e04b988f-97c3-45c2-a92c-2cc9c2602273">5,935</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie765c2c1580b4b668660efe86db75615_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtMy0xLTEtMA_7920061c-d062-40df-a26d-4f227bfa3518">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a73bc52ddbc49a0ae7ab3c3890665fa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtNS0xLTEtMA_cd7a2f13-94ab-43de-92ae-430fb9d3a380">5,935</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id30791cf6bd640898b2c76820ef15a1f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtNy0xLTEtMA_ce197a3e-c27e-48f1-9ede-7adf5c83cab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib14e95be5980439b89d0be5d5cf9c38f_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtMS0xLTEtMA_3324602b-bd20-4fbf-8342-1c4fcbb689e1">75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e3d2af9fb0b4d51a38451c771ddbcbc_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtMy0xLTEtMA_35430515-70c7-4324-bf41-72a5b5fe2a69">75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2210269696b54388859b9c440a7e5ffa_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtNS0xLTEtMA_51b8177d-6074-4f12-9b36-19c89f143f4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie876dd3bfe4948ecb026d413a211825c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtNy0xLTEtMA_440dc110-3e34-4593-9293-1475aaa0b42e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f894f3d17b245c480e3f32580adbf3e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItMS0xLTEtMA_80cf7d9d-e808-4fe6-a211-f979e3047565">9,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItMy0xLTEtMA_e4157beb-3d87-49e7-9b64-e1858e0949f6">75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItNS0xLTEtMA_bbbe7df3-36a5-4323-b013-971379c63c7f">5,935</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItNy0xLTEtMA_9b1de086-5877-4b38-912e-558441ebd315">3,007</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:45.128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.669%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4a4220bf4b8433f97d84d75a7a15ec3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC0xLTEtMS0w_ca48bcc9-c195-4b9d-9a49-c4a92efc807f">601,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6148de9bc6314d7db99b0174ac32270f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC0zLTEtMS0w_1b9e1bbb-5e13-43ee-99b2-1a9a4ee38626">1,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4219c1edadf45ef9ebabf21e48f42bc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC01LTEtMS0w_2e08bea2-cd21-46f8-a6e5-762fdf11fbcc">599,891</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie62d7c10b74b402c87f6a4746c4edc9f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC03LTEtMS0w_0b24b8cd-b8cb-4ef2-b1ca-9dcad1095f8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i687289d5249341bea56d56f06881a316_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS0xLTEtMS0xMDg1Nw_b2adb528-ecf1-4006-9cbb-73c10709ce1b">46,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12332e287c1448f0ae90bd926ae81019_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS0zLTEtMS03NjYz_9afa174a-f6f9-4da1-bf43-abe9e189f0e9">46,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88287563b1f84464879d94daa8496cb9_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS01LTEtMS03NjY2_81b489d6-449a-4072-a64a-9dbf61aefaaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9166e07465648fc897dff070b433978_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS03LTEtMS03NjY5_b7011eba-0002-493f-bdd2-dc3005d2606f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i240c26f07d684902a2a5a2aa13ff4522_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi0xLTEtMS0w_eab394df-a8a6-4260-b56f-2d1e9088365d">9,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1db864c137e4884a0d080828544685a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi0zLTEtMS0w_9565d7c9-eb6d-4e40-b81d-418fd0e2791f">9,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if50c2885177f46b9a3b8e52be036553c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi01LTEtMS0w_1e02c3c4-2a51-415c-93ba-dd2c4eddd2fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib62050c02be84bc68a5fe4449b65fc5c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi03LTEtMS0w_7ed77d04-5fdd-4065-a0b5-fe3732d391c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39ec9979e10e4655be2956189114b459_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy0xLTEtMS0w_d33e5920-94f5-47f9-94ee-b1819addfda1">656,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i440e6011a4b240eea401a947eb82807d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy0zLTEtMS0w_29a1d079-fbdb-4492-9b6c-28ebf015a44d">56,774</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy01LTEtMS0w_695c826e-3eb2-4068-a332-a30692021c24">599,891</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy03LTEtMS0w_16fe159e-dea2-43f4-8ea6-39856e21f077">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id50232e03fcd40198b29f681ccae378c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS0xLTEtMS0w_28b7e40a-a0a7-4da7-9f95-cabf6217d524">6,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i270207e77dc041c3a631393297a9d666_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS0zLTEtMS0w_53029e4a-9e5f-472e-ab98-5f21e7ccf03f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i376e8b7a95ec4903a952f0e1a98b9ca6_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS01LTEtMS0w_ab7c89e6-3431-4f7c-b423-0876ac85ca3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c435e953ccb4fea8d4665b2ee78d8aa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS03LTEtMS0w_3dd44c8f-ac68-4f33-9ba5-e51a7fda9fa9">6,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities - Cydex</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3ff8fdbb91347e4bd610fe51e004636_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtMS0xLTEtMA_d38e7f73-be91-4498-99b2-6ebaab7318e7">514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21d8f620ea2f4486b9f6948e67e4eb7d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtMy0xLTEtMA_f73005c8-2475-4cac-a926-68fa97001a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35fc6c1c2c364e28b41de2556a16e837_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtNS0xLTEtMA_5e878d23-a912-4d0c-abd7-b3e975e13820">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4405cd949e5464d859260401ea0db00_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtNy0xLTEtMA_8cd3bbdf-42d3-4997-adb8-f211e3ce9c00">514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdc8f1e296044e74bbcefba8f0616310_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtMS0xLTEtMA_f0ae8d65-52de-4d54-a69a-a0fcca009ab8">5,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib784ac7bf6464a7d884b4167b4e99ee0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtMy0xLTEtMA_b540fcb0-f732-4c43-8b76-14c95a2a8c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ac90e5d89444162acf3bc0b9b6480fe_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtNS0xLTEtMA_f472f91c-4f97-4345-bac3-0a3c843ab0f3">5,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5f4d39a9f964e3f99fac70fd3f35100_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtNy0xLTEtMA_18a2d98d-1bd6-4124-88bb-7edaf72c1c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ce4b41fbdca463599bc3cef217fef45_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItMS0xLTEtMA_25f46257-9017-4624-a6a6-fdce598a28af">199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79709122c16343dcbc74ae3a46e989b4_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItMy0xLTEtMA_11c38ebf-6d0e-4e00-ac67-22713586d241">199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i088931a8204941488973e380b4de1025_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItNS0xLTEtMA_a1d8496b-7333-40f3-bdbb-66aed7f60f61">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b3229ad3f5f439fa27e10965c78eea1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItNy0xLTEtMA_c9a8acdf-8ba6-4875-bb8a-bdf1076945e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39ec9979e10e4655be2956189114b459_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtMS0xLTEtMA_f8373e59-c48c-40f6-a812-911935757542">12,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i440e6011a4b240eea401a947eb82807d_I20181231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtMy0xLTEtMA_f6457dc0-49ce-4170-8797-d2d9f4c1a2a5">199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtNS0xLTEtMA_7ae277be-5c86-49ba-9a08-cd44836cbcff">5,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtNy0xLTEtMA_92fe3261-0bc9-48d2-a651-c6b27b7de888">6,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1) Short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i581acc70981a49948f834607ffb9b2b9"><ix:continuation id="ibc6582720cb2438e8c6d89e3ce691a9f" continuedAt="i19ce4ad38f634a29ad5c12f87573dfee"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on black scholes value estimated by management as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;Gain (loss) from Viking&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note (3), Investment in Viking.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#8221;  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2019, we paid $<ix:nonFraction unitRef="usd" contextRef="i727f5a67038e4448b546d9073616f76a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMTA5OTUxMTYzODgwMw_37478a49-5ece-47f4-b5e9-a4fe0484f3c1">3.0</ix:nonFraction> million contingent liability on development milestones to former Crystal shareholders. At  December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i77529a8905b14bc3bc8add865edf0f75_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMTA5OTUxMTYzOTEyNQ_a819821a-3cd2-4c97-933b-2e79e295c0f5">1.8</ix:nonFraction> million of the development and regulatory milestones were considered to be achieved and will be paid to former Crystal shareholders during the first half of 2020. </span></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:continuation id="i19ce4ad38f634a29ad5c12f87573dfee">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $<ix:nonFraction unitRef="usd" contextRef="i62d2f834fa2244ceac78756b0afb44a4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNTA5OA_82150991-8de4-418e-b586-6566daf95678">375.0</ix:nonFraction> million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $<ix:nonFraction unitRef="usd" contextRef="i9c826c5ec76f4cfabdff851267a7e696_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNTIxMw_64cdf720-54d2-445d-947e-4ee9241ef80b">10.0</ix:nonFraction> million payment upon initiation of a Phase 3 clinical trial. Another Metabasis drug development program, RVT-1502, has been outlicensed to Metavant. RVT-1502 is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist or &#8220;GRA.&#8221;</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI2OQ_39cf2945-ca90-4457-83ad-337e61bbc82c" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2019 is as follows (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:81.284%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.716%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92d6816bd05c485785171f05859f970c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfNi0xLTEtMS0w_258ba189-3c29-4fce-8c2b-b6bbbd26d45b">6,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfNy0xLTEtMS0w_4c5117db-4155-4a65-bcfd-41092da691bb">3,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfOC0xLTEtMS0w_271267db-b950-40e4-bcfa-dd8db556f8d2">934</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December&#160;31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0feee4e225cd43f6b19d270f81f68e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfOS0xLTEtMS0w_328dd5bb-9328-40e5-a883-3ec13053da87">3,007</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than a reduction in the value of our Selexis commercial license right disclosed in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial license and other economic rights</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and a GRA intangible asset, there were <ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_6b3129ac-c86f-4482-99bf-bd4c4518199c"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_eea54642-dc7a-45a5-bace-5ec68ca7ba4d"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_f0104f51-bb9a-475d-9c1d-3a20bcea616f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the current fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for additional information related to the fair value.</span></div></ix:continuation><div id="i9c8bcdb9c365455fab9e0c3ce3684173_100"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.  <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzM4Nw_c658a3aa-8d53-40b3-a306-15cd265bfa5c" continuedAt="i9e1dbe75290a4d1cb9f85f36ea168f55" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9e1dbe75290a4d1cb9f85f36ea168f55"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease certain office facilities and equipment primarily under various operating leases. Our leases have remaining contractual terms up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODE_ffef5594-a0f1-449a-ba9a-61a27ea72532">seven</span> years, some of which include options to extend the leases for up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODc_303e6841-ce99-40a8-b295-685264827d3d">seven</span> years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzI3NDg3NzkwNzM5ODc_ce74165b-77ae-485f-8cb9-0d9ab5df3f7b" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:50.122%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.912%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.556%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:24.210%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzEtMS0xLTEtNTMyOA_fe44200b-5761-4a13-96b2-e186cf27616e">10,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzMtMS0xLTEtNTMyOA_8e2811a7-775f-4f2e-bd17-87f677f8ab29">1,242</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzQtMS0xLTEtNTMyOA_0289e077-b7e8-423a-84ad-4879ed4519df">9,970</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzUtMS0xLTEtMTA4ODc_b5cd6320-02f9-44ec-aebf-d0a6263e20f3">11,212</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the twelve months ended December&#160;31, 2019, we entered into several new lease agreements including our San Diego headquarter expansion, opening new Las Vegas office and a new United Kingdom office lease, which resulted an increase in lease assets and liabilities of $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseInOperatingLeaseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5MDM_73c3788c-29de-4c65-931b-426cdb878e0b">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:IncreaseDecreaseInOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5MTA_3905ed52-1264-48f8-aede-17b50a0a155b">6.0</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzI3NDg3NzkwNzM5ODg_1d3cb110-a8a5-4a2e-ac8d-d80365a92a4c" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Maturity of Operating Lease Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:74.281%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.410%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.109%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity Dates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzEtMi0xLTEtNTMyOA_31209d87-0beb-4e8d-9d88-fbf7bd7becce">1,914</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzItMi0xLTEtNTMyOA_e7454f95-1503-4cb4-96aa-9b3c4bc23fdb">2,221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzMtMi0xLTEtNTMyOA_e9ac6848-6f9a-4fb4-acaa-baa368b69261">2,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzQtMi0xLTEtNTMyOA_e2ed00d6-e068-4ab6-bb38-f0527da1c7fd">1,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzUtMi0xLTEtNTMyOA_3756c640-d7e9-42d8-87f1-6a591bcd7e3b">1,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzYtMi0xLTEtNTMyOA_631aef3c-2611-4bab-932a-07944f821c7d">3,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzctMi0xLTEtMTA4NzQ_cea0637b-85ac-457a-84d7-e1f2d2c268f1">13,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzgtMi0xLTEtNTMyOA_6fa05762-82bc-4c81-bfaf-39e39ca221bf">2,654</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzktMi0xLTEtMTA4NzQ_0aa6a53d-5bb0-4f81-9eaa-c91ef90766c0">11,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5NjU_cacd2661-390e-492c-ae52-61e40bbf2c46">6</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5NzQ_4dc56dcc-8728-4abd-8732-80c89547416f">6</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQwMTQ_47220de2-067a-4ed1-b68b-fcd774bb8fdf">1.8</ix:nonFraction> million for the twelve months ended December&#160;31, 2019. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQyNzU_3fcef12a-5824-4670-8b08-ffaa528761f7">2.1</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQyOTQ_8308157b-3732-4cc8-bb5f-436c88ee14bd">0.7</ix:nonFraction> million) for the twelve months ended December&#160;31, 2019, respectively.</span></div></ix:continuation><div id="i9c8bcdb9c365455fab9e0c3ce3684173_103"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE2MDI2_4acd0952-7189-42cc-9364-efb2f13ebef1" continuedAt="ia66ed0d50ddd4a1d95f7dcf8c99717ff" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia66ed0d50ddd4a1d95f7dcf8c99717ff" continuedAt="i539c79e0c7834161bd0f0c8cd1214755"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, we issued $<ix:nonFraction unitRef="usd" contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMQ_bcf997a4-8b9d-4822-8194-7ed87b204b68">245.0</ix:nonFraction> million aggregate principal amount of 2019 Notes, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE3NQ_ce16b1bf-656a-488a-bdc3-174b61b4f7eb">239.3</ix:nonFraction> million. The implied estimated effective rate of the liability component of the 2019 Notes was <ix:nonFraction unitRef="number" contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzI2NQ_90d0cc8c-37a8-4b19-b48a-32415d3a08d8">5.83</ix:nonFraction>%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzUyMg_36c0d214-9d43-459e-9dd8-140b1e0d194e">75.05</ix:nonFraction> per share of common stock. The notes bear cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU5NA_04287bd8-6ab6-4aaf-b192-fd2f105a4079">0.75</ix:nonFraction>% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for at least <ix:nonFraction unitRef="trading_day" contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk0NA_89e92ac8-822a-4f72-8c3e-771bdc3977f4">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMDA_f23bc31f-dd3d-418d-a00b-bbb06d33d8b5">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExOTU_0f17fb24-e5b6-45b5-ae3b-0d96f871ae41">130</ix:nonFraction>% of the conversion price on such trading day; </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) during the <ix:nonFraction unitRef="day" contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNjA_115d57bf-c637-4da4-9af9-72dd0800a7d6">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzMDk_3cb4a193-2efc-40d3-ae46-64885fe18f38">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0MjI_09c8fa29-0751-4ad2-9dd2-bd4bf0a3b07f">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $<ix:nonFraction unitRef="usd" contextRef="ia69c2295fad14d86b0c1d0d33d08fd9d_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzI5Mzg_dab17c2f-5167-40dd-9060-e3d21797eb8c">341.6</ix:nonFraction> million. In accordance with ASC 815, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the derivative was adjusted to its fair value as of December 31, 2018 to $<ix:nonFraction unitRef="usd" contextRef="i41c98ddc8ed6424e97637ef827414c85_D20181231-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzMwNjg_4872166b-51e6-4414-9d84-16cd60ef3567">23.4</ix:nonFraction> million with the resulting $<ix:nonFraction unitRef="usd" contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzMwOTA_89819ce7-4754-4d94-b1a9-0978174fa145">118.7</ix:nonFraction> million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">                                                                                                                               </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March and April 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM0Mzc_d8218202-23d8-44a5-9a23-571df2c9137a">21.8</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM3MDM_db05c320-8435-4f14-a7e0-35937c268139">31.6</ix:nonFraction> million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM4MDY_c41924ab-8f26-4d46-8668-ad6d8003d293">195.9</ix:nonFraction> million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $<ix:nonFraction unitRef="usd" contextRef="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM5MjQ_6d2840c4-a917-4d75-90fa-2ec919ad61e3">195.9</ix:nonFraction> million principal amount and the excess of conversion value over the principal amount, totaling $<ix:nonFraction unitRef="usd" contextRef="ic8bcea58a1cc45ad91cd2cfd6e88fb72_D20181001-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzQwMTU_49ff71cb-8397-4862-b3f6-a60f853129ff">439.6</ix:nonFraction> million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzQzMjk_0ec08079-5ed7-4015-9f15-9bc4e5bb94cd">3.2</ix:nonFraction> million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, we received notices for conversion of $<ix:nonFraction unitRef="usd" contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDYzOTU_7f703151-d5f0-42db-a421-8fb046a66a61">1.0</ix:nonFraction> million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $<ix:nonFraction unitRef="usd" contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0MTE_fa3a2c59-8969-400f-9274-16f731027524">1.0</ix:nonFraction> million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $<ix:nonFraction unitRef="usd" contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0MjY_51ac38cd-0438-4e25-bcd0-e8fa89405072">0.5</ix:nonFraction> million in cash.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $<ix:nonFraction unitRef="usd" contextRef="i42d47e48e8714a4a85ce5692e87edc2a_D20190815-20190815" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0NTM_d465e09c-193c-4751-8344-cccd80649668">26.3</ix:nonFraction> million principal amount and $<ix:nonFraction unitRef="usd" contextRef="i183d237079bf442793fe6653077b02d1_I20190815" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0Njk_8713ee08-c3d9-4b8c-a8f4-37d3364c0186">11.9</ix:nonFraction> million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0ODQ_ff4f449c-7c40-4534-a731-757abb0f7fbb">11.0</ix:nonFraction> million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU4MzE_7a4a8577-3f34-45fa-882c-df83608bce05">3,264,643</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i539c79e0c7834161bd0f0c8cd1214755" continuedAt="i76253c3d01fb49bdbf8fb3b4f2462516"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The convertible bond hedges had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831" decimals="INF" name="lgnd:ExercisePriceofConvertibleBondHedge" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU5MTY_430fc6a4-3db2-47f5-802d-40decad714f4">75.05</ix:nonFraction> per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $<ix:nonFraction unitRef="usd" contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PaymentsforConvertibleBondHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzY3MTU_59a079da-5cfb-4478-8c43-8f84b72a262a">48.1</ix:nonFraction> million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $<ix:nonFraction unitRef="usd" contextRef="i018f28bd405f4e8e80369ec4e6ebaf93_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyMDU_fbfc6770-d01a-4750-b653-cc3aa0dcf97a">340.0</ix:nonFraction> million and marked it to market as of December 31, 2018 to $<ix:nonFraction unitRef="usd" contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyNTk_83334f9e-d47f-4b66-93eb-3e3283046d72">22.6</ix:nonFraction> million with the resulting $<ix:nonFraction unitRef="usd" contextRef="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyODE_fbb6ff8e-1486-4e3b-aa81-a8db1b5fbb31">119.4</ix:nonFraction> million increase, net of $<ix:nonFraction unitRef="usd" contextRef="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzczMDE_53787291-1db2-4782-97f3-2f4d08268c89">471.2</ix:nonFraction> million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $<ix:nonFraction unitRef="usd" contextRef="iad13e0c01d0342d4a22d93e03d73bdec_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDc4NjM_a1de70ef-3931-41f4-b548-29a2bbd9d5bd">10.2</ix:nonFraction> million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire <ix:nonFraction unitRef="shares" contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc1NzU_46fd1052-6f56-4586-ba49-30034e913af3">3,264,643</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc2Mjc_8029f3b1-1e5a-4b86-978e-689b8bc1de95">125.08</ix:nonFraction> per share, subject to certain adjustments. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $<ix:nonFraction unitRef="usd" contextRef="if15033c4ceb44752bec11bcc6b5a4535_D20140801-20140831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc5ODg_a5ec87c1-ae35-49ba-ae61-9b4464a4d3fe">11.6</ix:nonFraction> million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants. We continue to have the ability to avoid settling the warrants associated with the 2019 Notes in cash after May 22, 2018. Accordingly, the warrants continue to be classified in additional paid in capital.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of <ix:nonFraction unitRef="shares" contextRef="ia44b7731c223433ebd2d48a7da02b9fd_D20181101-20181130" decimals="INF" format="ixt:numdotdecimal" name="lgnd:WarrantsSettled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg2Mjg_c87df07d-4a05-47f7-821a-54899de4e118">525,000</ix:nonFraction> warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#8217; equity to a derivative liability on the modification dates, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg4NDY_ca7bc328-9fc3-404b-a584-8b5243d9df30">28.3</ix:nonFraction> million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg5NTg_6960137a-7155-494a-878a-7eb33202a927">30.1</ix:nonFraction> million and recorded a $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg5NzY_ec632a3f-4a47-40d1-8be6-6cf4cb293917">1.8</ix:nonFraction> million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December 31, 2019 and 2018, <ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzgyNDYzMzcyMjU4ODg_f27c04a2-0196-43b6-b764-9276027a34e9">1,890,359</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDc4NzY_1a303165-d8e4-4aac-8094-1c74778f4540">2,739,643</ix:nonFraction> warrants remain outstanding, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzkzNDI_9fff6f5d-681d-45b5-9ff5-030ebcd82222">750</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk0MjI_d88d1350-8334-4391-a809-e1fb97396343">0.75</ix:nonFraction>% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk1ODU_e9098073-c548-4c7b-8558-173d72bbdd83">733.1</ix:nonFraction> million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk5MTQ_6e38ed1f-0377-4ae6-986b-eb6d3562e365">248.48</ix:nonFraction> per share.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least <ix:nonFraction unitRef="trading_day" contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMjQ2_eb07d7c1-bb9a-4786-a500-0a734bbc8044">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="trading_day" contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMzAy_24a46271-b5e0-491c-a01c-8e3c26e9ad51">30</ix:nonFraction> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than <ix:nonFraction unitRef="number" contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNDk3_f9c70fac-c4cd-4a98-9971-cf780297b099">130</ix:nonFraction>% of the conversion price on such trading day;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) during the <ix:nonFraction unitRef="trading_day" contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNTYx_8cbd8137-2058-4f1c-9000-1c4bae8ad195">five</ix:nonFraction> business day period immediately following any <ix:nonFraction unitRef="trading_day" contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNjEw_73a87268-4d23-4318-9bd7-783c295a6199">10</ix:nonFraction> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than <ix:nonFraction unitRef="number" contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531" decimals="INF" name="lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNzIz_21125c0e-1d67-4efe-b716-1101584ba4bc">98</ix:nonFraction>% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i76253c3d01fb49bdbf8fb3b4f2462516" continuedAt="id6e1210016144885bdff5f7f7a462388"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Embedded Derivatives</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $<ix:nonFraction unitRef="usd" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExNTM4_431c5a1b-44d2-4c9a-81aa-33b6ad66f12b">144.0</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $<ix:nonFraction unitRef="usd" contextRef="i4087e5834f3f43f7b9dcd9f3bc7ad89f_D20180522-20180619" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExOTYz_4b9214ea-8061-42be-b9fe-584d21bcd458">13.5</ix:nonFraction> million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. As of December 31, 2019, the debt discount remains and continues to be amortized to interest expense.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyMzY4_432d167a-faba-4672-bcd3-26495297fd2e">248.48</ix:nonFraction>. As of December 31, 2019, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the 2023 Notes, we incurred $<ix:nonFraction unitRef="usd" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNTQx_e61f33e7-bbd7-4edc-8032-d8e31ba2003d">16.9</ix:nonFraction> million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $<ix:nonFraction unitRef="usd" contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNzEy_6b854987-44e9-467c-8e2d-1794dd52dce2">3.2</ix:nonFraction> million was recorded as interest expense for the twelve months ended December&#160;31, 2018. The portion of these costs allocated to the liability component totaling $<ix:nonFraction unitRef="usd" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyODM2_a7896c36-73b6-4a95-9c16-561a58d3add8">13.7</ix:nonFraction> million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzMzg5_6e87d551-a0c7-40fe-a338-e66de698dbcc">3,018,327</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzNjYz_7a5d6a30-7687-4a9a-b30f-c74440571ca5">248.48</ix:nonFraction> per share and are exercisable when and if the 2023 Notes are converted. We paid $<ix:nonFraction unitRef="usd" contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="lgnd:PaymentsforConvertibleBondHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzNzQ2_178af0b4-4e88-4213-ac5d-ce46b97b803c">140.3</ix:nonFraction> million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering <ix:nonFraction unitRef="shares" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0NjMx_b5c183c5-6c14-4119-95a0-e8468e9779fb">3,018,327</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0Njgz_d18bb851-eac4-4a16-aa11-a18ab3df36ff">315.38</ix:nonFraction> per share, subject to certain adjustments. We received $<ix:nonFraction unitRef="usd" contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0NzQx_b5a6dffc-22ce-460b-b050-8d51fa215540">90.0</ix:nonFraction> million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $<ix:nonFraction unitRef="usd" contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE1Njg3_dfc4e826-5404-4689-b235-ac4261c62f17">19.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE1Njk0_2f085692-37e0-49db-988f-c80be955cfa7">7.5</ix:nonFraction> million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE2MDMw_2abb15d9-1e93-4482-b6b1-6c063e2a7797" continuedAt="i4c6cebb0576f490c807a2a1a7a6094ac" escape="true">The following table summarizes information about the equity and liability components of the 2019 Notes and 2023 Notes (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id6e1210016144885bdff5f7f7a462388"><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><ix:continuation id="i4c6cebb0576f490c807a2a1a7a6094ac"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:57.970%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.768%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.292%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2019 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95d01d0ac3874584a772c93ae9343d59_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzEtMS0xLTEtMA_78f2c0b6-9efa-415b-85b1-604ffa46a3ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzEtMy0xLTEtMA_66df80b7-b45d-4044-8f99-2de047a4cf5d">27,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95d01d0ac3874584a772c93ae9343d59_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzItMS0xLTEtMA_178bf018-aae0-4334-af00-37cb7625a9ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzItMy0xLTEtMA_5b482f9b-72f8-47d0-b1a5-d757bddc669a">893</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzMtMy0xLTEtMA_6436cfab-d467-4817-8780-50b92bac2d8f">26,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2023 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzUtMS0xLTEtMA_56b3285c-665d-46ee-8f32-25a5f3306669">750,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzUtMy0xLTEtMA_6681d760-90c6-4ea9-ac9a-4d6eba986225">750,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzYtMS0xLTEtMA_3f4b3846-a21d-482c-9d62-231e09721d3c">111,041</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzYtMy0xLTEtMA_9150f3fc-8a09-4eb0-9c41-40bd069f064a">140,136</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id951cc41dcda47b79a7837e8a9cac151_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzctMS0xLTEtMA_ea597f7c-e5c8-42db-ae94-88c79bd7de85">638,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzctMy0xLTEtMA_14920b8a-bed5-497c-9454-6a12810f93b1">609,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of equity component of 2023 Notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzgtMS0xLTEtMA_a53645a2-5aff-4aef-801e-c45bbc6954a8">101,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzgtMy0xLTEtMA_f71814d6-1fb3-44b9-9e26-e575db3f8bec">127,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id951cc41dcda47b79a7837e8a9cac151_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzktMS0xLTEtMA_2bac3a1c-962b-405b-8459-e8b280ba7523">647,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzktMy0xLTEtMA_4133bc97-6a5b-4f7f-86aa-00a72f67395a">713,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;"><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there were no events of default or violation of any covenants under our financing obligations.</span></div></ix:continuation><div id="i9c8bcdb9c365455fab9e0c3ce3684173_109"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDA_fe93370b-1ae2-4f9c-b542-79884591907a" continuedAt="i96b536f50153435babd1fce0d12cda7e" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><ix:continuation id="i96b536f50153435babd1fce0d12cda7e" continuedAt="i7c4b03294a0d485abf3368406f4b18e9"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Short-term Investments</span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDE_555a76dc-37fc-4a7a-9a96-e1f35c82bf2c" escape="true"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the various investment categories at December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">fair value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtMS0xLTEtMA_7a699109-1977-4142-a6f3-c3a7242c92e0">411,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtMy0xLTEtMA_0f5f9e9b-525a-411f-8819-2935e8de5626">188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtNS0xLTEtMA_4557f8e3-f42c-4864-8116-e14847b0c7fb">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtNy0xLTEtMA_ed1c67b4-09e2-4573-9062-fb76c96f8991">411,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtMS0xLTEtMA_8d7e8873-bd41-41c0-8308-fca39d48a656">63,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtMy0xLTEtMA_094f51c3-bda8-4c02-8a38-d60a751b325d">161</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtNS0xLTEtMA_793d265a-ab1d-4ca2-996b-717434e4ae79">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtNy0xLTEtMA_96a96fdc-ea80-4a68-9f7b-2eac49a000ce">63,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtMS0xLTEtMA_cfaf99ce-a953-4ebe-ac32-0b59c3b279f3">4,506</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtMy0xLTEtMA_222aee7a-e425-4dd0-a6f2-97e24878d668">416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtNS0xLTEtMA_176209cf-44c6-4841-bdcd-a13d54b4c9dd">1,850</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtNy0xLTEtMA_dcc9580e-0c0c-413a-b523-468ea9cc0c8c">3,072</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtMS0xLTEtMA_606b5a21-e023-4720-8b8a-961c233eb912">210,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtMy0xLTEtMA_4d802e42-a6d9-4ce5-8b20-6fa462c7fd12">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtNS0xLTEtMA_1285eca7-7ae2-426a-8515-27679b16a5c9">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtNy0xLTEtMA_88aa270a-0b51-4d56-9c83-f6c4f001888e">210,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctMS0xLTEtMA_a481c960-d26f-43e1-bd32-82838846c887">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctMy0xLTEtMA_68a4bb9f-2391-4d43-a291-c1c07a322a52">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctNS0xLTEtMA_e484c14f-f2fb-4610-9b7b-28c4d92bc570">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctNy0xLTEtMA_ce932c75-4e95-4ace-864b-bb84b4013f11">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i159e354578674c4980944fd7e84d264b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtMS0xLTEtMA_74026afc-d950-4d41-bdca-338e77b5c189">250,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i159e354578674c4980944fd7e84d264b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtMy0xLTEtMA_f567e79c-3f48-4053-8acc-46fd856b804b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i159e354578674c4980944fd7e84d264b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtNS0xLTEtMA_bd1af22f-ccbc-459f-90ba-5d8935ad4d4f">249</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i159e354578674c4980944fd7e84d264b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtNy0xLTEtMA_e1843763-3bdb-45b0-b161-1bb2ce5861b6">250,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktMS0xLTEtMA_f990702b-9df0-40f8-9bb7-19b654824c8b">941,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktMy0xLTEtMA_e9a33031-a902-4629-bdd4-91c9a0b8cbe7">933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktNS0xLTEtMA_8cf9659b-be63-4126-b05c-9b27ec026e51">2,118</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktNy0xLTEtMA_f07dfbd3-d398-4067-bf3e-e58a791b4a0c">939,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTEtMS0xLTA_0a59c5fc-18c4-4629-9650-dd3675a8e927">311,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTMtMS0xLTA_35f31fa5-a314-4e75-bf7e-bc0c07f8f28a">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTUtMS0xLTA_223f9978-8ba2-43e6-a72c-205be3498e9b">29</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTctMS0xLTA_15b2e920-4e63-4cdd-a89f-b2bc5474bb2f">311,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTEtMS0xLTA_c426b463-a12a-40ff-9bf9-ea97f95d9039">53,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTMtMS0xLTA_914e1943-7a03-489b-a842-d98193952b5d">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTUtMS0xLTA_f39074b9-a0ca-4794-be6f-74ad8f84bdf4">45</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTctMS0xLTA_95a7e26d-ccee-4230-9028-a978be99a276">53,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTEtMS0xLTA_b5928b70-c11f-48c6-87cc-cc434060066a">135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTMtMS0xLTA_ef75b9e5-77c2-4cc2-8048-1b96c49c03f7">1,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTUtMS0xLTA_53dde29f-1dad-4384-9333-60966ef79ca6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTctMS0xLTA_1b59a14d-7663-48bf-bd38-e0df2f1f9cdc">1,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTEtMS0xLTA_f7874b40-c6ee-40da-829d-738605064690">225,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTMtMS0xLTA_a12e5f62-a4d0-41c4-a9b1-b52b811c347f">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTUtMS0xLTA_21795da9-33a2-47d9-92a6-b10385f98358">76</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTctMS0xLTA_9d90e326-536a-4590-9099-f962bb055cd8">225,663</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTEtMS0xLTA_b4a3cdb8-af3b-4104-a0d4-36ea956c2c1a">7,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTMtMS0xLTA_64fe1bf4-2d14-47dd-89b5-446460fcf869">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTUtMS0xLTA_2011e68b-9319-4dd5-ba7a-4325c66ef57b">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTctMS0xLTA_e71ebde9-aab8-4a06-aae2-c885f8563119">7,973</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTEtMS0xLTA_da54f540-0ae2-4a1e-9fdc-24ed1a5d841f">2,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTMtMS0xLTA_79d660c3-5a7c-440c-9054-136f482003f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTUtMS0xLTA_abcea190-e71a-4227-ad9c-01e46035a4fd">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTctMS0xLTA_5d53dac2-921d-4efe-8858-be33b5bcf6ac">2,013</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTEtMS0xLTA_d6c180f1-e8a9-471f-91e8-74d72fee26d5">600,154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTMtMS0xLTA_0962949f-56dd-4be5-aaf6-91739ab03142">1,226</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTUtMS0xLTA_bdb35e4d-d54f-47ec-95ac-0d353485bc69">163</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTctMS0xLTA_1f57f5ad-b227-40db-b16b-da3c724e60d9">601,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDQ_64f4f53d-2134-451f-a31e-d68754a3b4f1" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:72.008%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.628%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.630%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab and office equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e41a03cf4b245ecae999cdd0f89c769_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzItMS0xLTEtMA_b0a19a90-10d2-4c32-bc31-9cd7241d14af">6,307</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6737d944593c47919db533223783d735_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzItMy0xLTEtMA_f03e804a-500e-4dce-8621-4537a056c004">4,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8397721ad934a4fb6b8e4182e177246_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzMtMS0xLTEtMA_e6a54aa3-58aa-4ba8-9fbc-2dcb0d8c57c7">2,729</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3da08223a8214656b754f9367925b52a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzMtMy0xLTEtMA_97acbc8c-c4d0-42fd-9211-0d211c332351">2,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d5e8e38535841d0a6ebe69742fcb55b_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzQtMS0xLTEtMA_f08c1937-4bed-465b-896c-f893358d981e">999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8cff8def88d547cca5ed63725081c9f3_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzQtMy0xLTEtMA_0a3d4dc2-6086-4dcb-bbc4-4fa1f3fd472c">936</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzUtMS0xLTEtMA_f79138aa-881d-4ed6-ac84-d0e60c413374">10,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzUtMy0xLTEtMA_6e6436c1-d61c-434f-9249-2a498e69bb63">7,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzYtMS0xLTEtMA_8e190f65-e023-4ca6-890c-1d8917e28e07">2,850</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzYtMy0xLTEtMA_077bbfc7-fc49-4131-b266-c0424a114679">2,165</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzctMS0xLTEtMA_a50d2742-92f8-4f91-b9a9-eba120dbf086">7,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzctMy0xLTEtMA_cb973c88-2703-40ce-bc7f-4d655e127622">5,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7c4b03294a0d485abf3368406f4b18e9" continuedAt="id07b7733a1e7483d95f37466f596b023"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY0Mw_517c0c36-72b7-4810-a5ef-d9f93520db92">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY0Nw_455b154f-b9e8-4aaa-b301-8019e810770d">0.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY1NQ_a76fca9f-ef6f-4321-b836-0065bb80e97b">0.4</ix:nonFraction> million was recognized for the twelve months ended ended December&#160;31, 2019, 2018, and 2017, respectively, and was included in operating expenses.</span></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI3NDg3NzkwNzMyMTY_6ade4d2e-8d93-496f-bfb3-1ae221eecd8f" escape="true"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:72.008%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.628%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.630%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzQtMS0xLTEtMA_4648462d-52cf-47cc-90a8-bd8d6bbd26a6">95,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzQtMy0xLTEtMA_cde8a661-08d1-4d7b-a07b-0e8dfc1eb0e2">86,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzYtMS0xLTEtMA_609bc68b-d367-41f6-95a7-a35a23acb83a">242,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic92c2bb9b787480489b39a01bb366f35_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzYtMy0xLTEtMA_54ea0cfb-56b4-4365-9010-3ef808ec0391">235,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzctMS0xLTEtMA_953de17c-2e8c-4b6b-b1ed-b107577a2474">50,203</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic92c2bb9b787480489b39a01bb366f35_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzctMy0xLTEtMA_c3f6798f-c364-4cb4-944d-7675f9c84e97">35,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if268533fff3b4793a31072861a742a93_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzgtMS0xLTEtMA_1704d68e-e5b5-4583-aa26-d40275f2810e">2,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44726d215cc14202aa7482a959d9f789_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzgtMy0xLTEtMA_cb16a63e-5c69-411f-8edd-4bd895a76295">2,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if268533fff3b4793a31072861a742a93_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzktMS0xLTEtMA_22d594a7-127a-4e3f-bf62-2887a1885dc4">1,180</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44726d215cc14202aa7482a959d9f789_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzktMy0xLTEtMA_5b74447c-b5a5-4f81-998a-6e45aaeca92a">1,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i29175925b83b4f7db955ba48c6e95710_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEwLTEtMS0xLTA_1321dbdd-1f9d-4db4-893a-97f25f342c91">29,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4900b9ff94548d4902c449b76d44e10_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEwLTMtMS0xLTA_123b26d1-f7db-4812-a4bb-4161fc95a765">29,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i29175925b83b4f7db955ba48c6e95710_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzExLTEtMS0xLTA_73c9a881-34b2-4b44-84a0-ab77970e6506">13,224</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id4900b9ff94548d4902c449b76d44e10_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzExLTMtMS0xLTA_16aa23e0-7a53-4117-ba06-c94daed7810b">11,744</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total goodwill and other identifiable intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEyLTEtMS0xLTA_a65ea29e-1b51-4113-bb63-1b2ba5281559">305,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEyLTMtMS0xLTA_18e36c3d-0faa-41b3-ba7c-75a42dd11276">306,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.</span></div></ix:nonNumeric><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzk4OA_16938e39-7610-4c99-a58e-64748b5ca343">20</ix:nonNumeric> years. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMTY_e24d8cda-52cb-41d0-96bb-75ca8aa04a9d">16.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMjA_94d64d25-6e4c-4a06-b745-846005bd86a5">15.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMjg_05b90958-f5a2-43ee-b65b-19a1b6b0d4b1">12.1</ix:nonFraction> million was recognized for the years ended December&#160;31, 2019 and 2018, and 2017, respectively. Estimated amortization expense for the years ending December&#160;31, 2020 through 2024 is $<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_2e6cff1b-d06f-4df5-88ac-bc5cdf47d476"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_5952335c-b046-498f-b077-fc7eda72cf45"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_6854faba-8d26-43cc-b441-b1c8d5738aaf"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_c702df3b-a0d8-4491-a11c-df4753d8f0b8"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_d48dd972-39d8-40cb-a1e7-a13418e029ce">14.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. For each of the years ended December&#160;31, 2019, 2018, and 2017, there was <ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_3631cb1e-ffd2-4f70-ab83-45b33a1451d0"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_54a26f81-1edd-4bb2-a5cb-94fa9441513d"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_ec9587df-f110-41e0-a28f-0534053e8193">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDU_33d035c4-bed2-434a-b9c6-731d1f2ad141" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:72.008%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.628%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.630%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzItMS0xLTEtMA_69dfeb7c-e70a-4815-836f-86b8ce502be7">1,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzItMy0xLTEtMA_57acf224-c7d3-4da9-9315-f2c0c7c6d30f">4,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzMtMS0xLTEtMA_17f29bf5-1ce0-41f0-bb73-1d8293498227">1,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzMtMy0xLTEtMA_0d6353cb-5db7-4755-983d-4baadea5fa73">942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts owed to former licensees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzQtMS0xLTEtMA_86c7fbf5-8ef7-401d-b91e-1234eea7af14">381</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzQtMy0xLTEtMA_2f59202a-25a7-4918-8079-d92c7d27165d">428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties owed to third parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzUtMS0xLTEtMA_8e282e33-f59a-4dea-be1a-83691c73b793">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzUtMy0xLTEtMA_23abd581-c520-464e-b6f6-ad9e3a2f20d0">1,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments due to broker for share repurchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="lgnd:AccruedStockRepurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzctMS0xLTEtMA_bb3f14fe-9908-41c8-9652-2bdc20daa614">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedStockRepurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzctMy0xLTEtMA_d7fd8bed-8f15-497b-9c1d-053df23ea38a">4,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Return reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzgtMS0xLTEtMA_819e3661-fc49-4540-8c46-5ab01bc280a5">3,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:AccruedSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzgtMy0xLTEtMA_ecc4250a-4e92-4670-98fa-8e8ad26a91d7">3,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzktMS0xLTEtMA_e7957013-2dc4-469c-9351-aeb327272875">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzktMy0xLTEtMA_9f5d4dd3-1d9a-4933-97f5-85c38519d0d8">1,093</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTEtMS0xLTczMDk_389020f9-8191-4bed-bfb4-4138a7183b77">1,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="lgnd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTMtMS0xLTczMTI_ced5ed44-9a00-4e7c-8d84-e6c1d046fc7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTEtMS0xLTA_fd461561-1f3c-498c-bd0c-ac1ba4d635d0">2,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTMtMS0xLTA_7e3f5055-5c51-42ab-974c-3686dadaf6bc">3,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzExLTEtMS0xLTA_c87dc6d6-c518-4a7c-a1eb-bb2d3e6ddaf0">9,836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzExLTMtMS0xLTA_d48881df-b6a2-41c3-81ab-2e3e9fae9d49">19,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id07b7733a1e7483d95f37466f596b023"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (4), Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for more information. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:ScheduleofContingentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1Mzk_b6907b47-e267-4ef1-9a67-129f327ae92a" escape="true"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:13.509%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.782%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.453%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.225%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:8.930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.010%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.231%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cydex</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia139119e13424a1bbb83b3bd29c3eb9f_I20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMS0xLTEtMA_6bb5fea5-7019-47dc-869d-41268a3ce5ba">1,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMi0xLTEtMA_30d21b3f-ecf6-4989-9839-345eda2a858b">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMy0xLTEtMA_365c0433-a605-49b3-a692-4a412e7f270d">1,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e84a7b813d74048b025e392263824ce_I20181231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtNi0xLTEtMA_5a6f1882-9beb-4ebc-a3ae-5f1351660801">514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtNy0xLTEtMA_6a987b2d-fd43-4ce3-9e01-abb3d32cf8e1">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOC0xLTEtMA_41e56f68-1aec-4e4b-b14d-843748791f8a">116</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOS0xLTEtMTA5MzA_18457750-3507-4548-8d95-74815d87ed0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60511aae828945a397611be17e7b185e_I20191231" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOS0xLTEtMA_e4bba4c5-f97a-4f24-9048-437e84587bc0">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib238a21ed8404ddeba140fd318f30bb2_I20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMS0xLTEtMA_0154c413-ef1e-4aec-9ece-76d2e19e0b7b">3,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMi0xLTEtMA_30baf226-2fe4-4475-bd16-050311192b83">3,860</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMy0xLTEtMA_dd79d703-77a2-4b0a-9ad7-38737823ad9d">5,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82abd5a9777940b08fc61c5d462259e1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItNi0xLTEtMA_11821c35-e7ae-4876-942c-22e7eb7d9286">5,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItNy0xLTEtMA_0bb75a0b-a919-4558-aea9-24c6328d7e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOC0xLTEtMA_2b263455-1ec5-49b6-ac01-51f25b208047">904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOS0xLTEtMTA5MzA_f1f55aeb-a5e8-4b45-ba8c-dc275d5f8622">520</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1979f3d940c419ea3a725a37ea9e014_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOS0xLTEtMA_2f7a1267-0e82-4854-83c9-3426b860a418">5,935</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33ebdb404a3245379c9d5860ed4ac8ba_I20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMS0xLTEtMA_716d1234-a095-4e28-a785-3abc940de7cd">8,401</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i391b93678af74f27899b8002cc987285_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMi0xLTEtMA_970ec303-9a24-4c0a-a96d-5ecedf2c4b9b">1,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i391b93678af74f27899b8002cc987285_D20180101-20181231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMy0xLTEtMA_01d5f341-98c4-4f8c-816e-bea5f9c65f6b">924</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3a6da7b97a744bc9c0497857d795d5f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtNi0xLTEtMA_34ea4105-2106-49aa-b5dc-c05be921345f">6,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtNy0xLTEtMA_6ef1e249-6742-4475-bbf6-1dad3e552726">3,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOC0xLTEtMA_34b04d09-1218-4f0f-a226-7ec03db3c6fd">818</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOS0xLTEtMTA5MzA_3c475a74-2960-406d-bca3-15a967289819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOS0xLTEtMA_99ebca5a-423e-430b-9365-9235b0187e48">2,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMS0xLTEtMA_a5a66cc7-4f17-40a4-9744-18942475ca31">13,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMi0xLTEtMA_fe3d6fb6-27e6-4e61-8b7f-be67e17420af">4,885</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMy0xLTEtMA_9adb3e59-c36f-4a8d-838c-eb436d505fc6">3,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtNi0xLTEtMA_8e36fa39-4713-4bda-b54f-e3e26852c5ee">12,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtNy0xLTEtMA_5c2fb125-1ef2-4278-9503-6d9ddb82e063">3,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOC0xLTEtMA_8764cd83-3852-4ab2-a092-66b539987b94">30</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOS0xLTEtMTA5MzA_e8302636-cc37-4158-99f1-23e563b925ed">520</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOS0xLTEtMA_98ff474b-f42e-44a9-ba11-8ce463cfd218">8,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;"><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_115"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTI_bb2726a7-a15f-4e3d-bf90-75c43b82767c" continuedAt="i97a0140b5d3e4342ac6078afa963dcf0" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i97a0140b5d3e4342ac6078afa963dcf0" continuedAt="i81132373976c49698732782ae748640b"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTM_fbd8cc2e-5e74-422e-8bce-ff99e1a63fde" escape="true"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.102%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.143%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.143%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.146%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84123edc447641828fe3e7279992698e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtMS0xLTEtMA_d174f912-8938-4b54-9cbe-b5e9df8a9043">9,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia262ce3b54954a979aceac7f234989a3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtMy0xLTEtMA_78071b3c-3c30-4cfe-8524-c56397d0e352">8,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i36c58245200747a5b667564d502af59e_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtNS0xLTEtMA_a2f736af-8926-4e3a-935c-a509bef82e7a">14,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i164955ed1d7f4491869eb2cbafa3cc29_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtMS0xLTEtMA_7faa8475-86b2-4db6-8b04-e4e5a4a49fda">14,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e964f748c5942548018f2246cc35730_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtMy0xLTEtMA_c028bd8b-80c7-442f-9af9-1b2e68e7c91f">12,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1c406d933204c55979cce5e2f3e220b_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtNS0xLTEtMA_4e20df2e-3284-4de0-8a14-ad4f7fc01a70">10,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtMS0xLTEtMA_c1569ffc-0fd7-4e91-9b5e-ca5e02f9525e">24,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtMy0xLTEtMA_138ad582-4b2c-4b53-b073-b41d375a866b">20,846</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtNS0xLTEtMA_99112b70-949c-43af-b323-b09d903e5eb4">24,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Plans</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="i8f9c362671564a50b0f69033777e2901_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI4OQ_4dcb4d4a-fe94-4ea3-b7a0-47a9d874ab3e">0.8</ix:nonFraction> million shares. As of December&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="ifaf7c83e118d4acf95a3663f3661d169_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzM0NA_6ca74006-9997-4e68-9ed4-bc00af723760">0.9</ix:nonFraction> million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTY_88190619-b771-4076-b5f9-0380f280503c" escape="true"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:48.220%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.344%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Term in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtMS0xLTEtMA_93ef1981-4927-499d-82fb-4439cba9e27f">1,736,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtMy0xLTEtMA_6ba830d2-399c-4eec-a987-dbc30cdaeb1b">66.71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtNS0xLTEtMA_fdcf3d5b-dea2-49e1-bd21-95c3b21ce75e">5.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtNy0xLTEtMA_e1c70596-271f-459e-8f1d-681734bd2257">125,858</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzItMS0xLTEtMA_caaf48a9-1052-4aec-8187-4f5e3d2eadc1">338,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzItMy0xLTEtMA_356bbb59-7323-458d-9537-9039cb7f6929">116.69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzMtMS0xLTEtMA_5102de39-4a91-4bbd-8856-a937d5312922">112,011</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzMtMy0xLTEtMA_b59b42be-e012-40c7-8d0a-347e0dd5a8a4">23.65</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzQtMS0xLTEtMA_103944fb-e424-4a47-8e2a-9a2343eb835c">6,531</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzQtMy0xLTEtMA_451edcbb-9de8-4669-ae71-9e19c42ff21b">139.37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtMS0xLTEtMA_346cd3ea-4ee4-4103-bd84-1f6996f5a3cd">1,956,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtMy0xLTEtMA_5d52bcdd-14c1-424d-a61b-55734788cd5f">77.54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtNS0xLTEtMA_0bb1ff63-fd8c-4f75-88e2-5f50085a4143">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtNy0xLTEtMA_115d1018-81bd-4b22-9cf0-4b058aca251a">72,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtMS0xLTEtMA_c31ba1db-cafb-4242-b416-dd1101bae462">1,454,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtMy0xLTEtMA_fd67e798-0c13-41c6-a2cf-48e9d2bf11c8">61.82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtNS0xLTEtMA_11d06353-1095-418c-9a33-aeb257bc65d7">4.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtNy0xLTEtMA_6c110efd-f2d3-45bd-b5d4-750862aafeb7">70,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctMS0xLTEtMA_21df61c5-85b0-4251-806d-d2633681133e">1,956,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctMy0xLTEtMA_b8a732d8-936d-4f39-8000-fe29023c9b8a">77.54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctNS0xLTEtMA_f7ce9227-b2ac-4087-b653-7e273a926ff2">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctNy0xLTEtMA_d4bcd58b-7398-4d41-8595-698a46cdd13a">72,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant-date fair value of all stock options granted during 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYyMQ_1dc10b46-c07a-49eb-ae61-dafbd212ee18">48.65</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYyNQ_2d8abf76-19b7-46ce-a8fb-9f691eb45430">58.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYzMg_0755faa0-4755-4c98-8851-d160249c76f1">53.17</ix:nonFraction> per share, respectively. The total intrinsic value of all options exercised during 2019, 2018 and 2017 was approximately $<ix:nonFraction unitRef="usd" contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc1MA_6fdb8075-c5eb-4c56-b7a1-85366e7d649a">10.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc1NA_4e48ef0a-5587-4844-b973-918d81fa3346">51.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc2MQ_30693994-f902-4a73-9e07-58a4b6a4d4d7">13.3</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i81132373976c49698732782ae748640b" continuedAt="id47728895c9c449785e854267a0064ff"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash received from options exercised, net of fees paid, in 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usd" contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg1Nw_9f97fcf7-1ca6-41b7-9a73-3cf1104358e3">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg2MQ_d6066a86-e360-4071-a53f-e17cd8ae91e9">19.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg2OA_d860c630-742b-4f57-b7a3-9334eced5aa6">4.7</ix:nonFraction> million, respectively. </span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTA_d530ee99-50ef-4f3d-801d-1481537147af" escape="true"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a further breakdown of the options outstanding as of December&#160;31, 2019:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:25.366%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.313%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.391%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.313%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.313%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.313%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.574%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range of exercise prices</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">remaining&#160; life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">in&#160;years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.96 - $12.81</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtMS0xLTEtMA_b3f35b78-0e27-48e0-a875-5a96ac44505d">195,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtMy0xLTEtMA_8da1d33c-9b55-4f5e-9562-34716e9360ed">1.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtNS0xLTEtMA_e2b639c8-7b7b-478c-b5fe-340b424bb0d1">10.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtNy0xLTEtMA_f84b5409-5c69-4807-a3d0-91525d64cee9">195,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtOS0xLTEtMA_fe07c437-3b6b-4f98-b5cf-222b0a8d20bb">10.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItMS0xLTEtMA_741cdd09-6606-4a61-a877-8d03da7b0927">212,116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItMy0xLTEtMA_224afc2f-8ded-455a-bf8b-27d9e9dc45d8">2.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItNS0xLTEtMA_f083f026-dd5f-4c3e-b62d-10507209b3f8">14.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItNy0xLTEtMA_780fa3f0-94a8-4581-9085-70bdc64adcc4">198,116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItOS0xLTEtMA_01be4fcb-9fc8-4961-b00b-eaa764a9781b">14.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtMS0xLTEtMA_20c67744-d6f7-405b-9194-9178cd1320fa">195,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtMy0xLTEtMA_42858111-bc8c-41f8-85e1-da5ce6e6ee15">3.13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtNS0xLTEtMA_205c28fb-4c61-4649-bd0a-a8dfaff87832">21.92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtNy0xLTEtMA_1bfb19d9-219a-4d9e-b553-3242f256727b">195,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtOS0xLTEtMA_79820924-5202-43b5-bef7-d934c35f863e">21.92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$32.00 - $74.42</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtMS0xLTEtMA_c9ae39e8-1e41-4fad-b75f-36134cadd7f8">374,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtMy0xLTEtMA_672f75c2-fb51-42a9-be77-548420252637">4.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtNS0xLTEtMA_b153bbb7-79f7-4149-b5b7-22fea306ac64">63.72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtNy0xLTEtMA_884294dc-e88d-4787-8aee-966a33ec78c8">374,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtOS0xLTEtMA_e4bbc923-fc2a-4a74-831d-9420039cfa5d">63.72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$85.79 - $100.38</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d741a769aee4da4af5556260a102804_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtMS0xLTEtMA_fca196e1-1292-44a8-b031-d462804a561c">301,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtMy0xLTEtMA_0fc23ef5-d479-4a0f-9c59-c205fe3fb26c">6.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2d741a769aee4da4af5556260a102804_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtNS0xLTEtMA_8cfa0ca2-4102-4b8e-9b4e-49ac4815a318">93.41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d741a769aee4da4af5556260a102804_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtNy0xLTEtMA_02a00b7a-ad89-4d0f-ae7a-2c4e4e3512ee">239,220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2d741a769aee4da4af5556260a102804_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtOS0xLTEtMA_3ec3d5f9-f700-4a0e-b8ee-89fa212ffcbf">92.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$101.15 - $113.76</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtMS0xLTEtMA_3768f49f-7413-4e0f-8183-8fd206abbea9">98,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtMy0xLTEtMA_ea6e2a5d-f359-478f-b9ca-2f477219bb3b">7.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtNS0xLTEtMA_c023b803-afa5-4c53-8cfc-bdbf8b93d85c">109.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtNy0xLTEtMA_9ba312fa-200f-4e39-8432-ddc448cce279">46,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtOS0xLTEtMA_c6e39eff-1db5-49d5-80c2-fc246d245f15">107.65</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctMS0xLTEtMA_18cddea9-1b11-4d65-a4c8-605d2559c226">272,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctMy0xLTEtMA_44420bfc-63d2-45ff-a015-301c6fcd37d2">9.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctNS0xLTEtMA_24ddde83-1aa9-479a-a965-edc0c230a3f1">117.97</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctNy0xLTEtMA_d01b7012-3e89-4a31-a834-bfe0880a96d6">56,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctOS0xLTEtMA_0a8a2524-13ac-47a4-b9b7-8baa537f978a">117.97</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$119.30 - $159.01</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtMS0xLTEtMA_30ce2f68-e693-40a9-86d3-47dc3dd23df0">282,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtMy0xLTEtMA_0dbcd1d9-3242-43c9-8bf9-674d8656395f">8.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtNS0xLTEtMA_bc2f0d6e-6326-4756-a28d-5c7a15e58965">151.55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtNy0xLTEtMA_3a6930fd-6d07-4439-b6a3-95b1986cd306">129,541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtOS0xLTEtMA_eeb28777-2061-4bac-8e23-93e8535eb521">149.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$159.81 - $171.28</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktMS0xLTEtMA_0ce93644-6717-40d0-a75c-d4a7c346fdef">7,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktMy0xLTEtMA_f8ec6344-1e05-4633-a5a9-4e165380491d">8.52</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktNS0xLTEtMA_2c7f85ba-8754-4d1e-82c8-c86c90bf29e4">166.40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktNy0xLTEtMA_303af075-2ff8-41e1-ae2d-9cde6f6a9cbb">2,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktOS0xLTEtMA_bc2b301e-d9fd-40dd-93e5-f5606796cc12">164.90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTEtMS0xLTA_cabd126e-0157-49f1-bb5e-b34622cc9d2c">17,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTMtMS0xLTA_4de63d57-be6a-4086-8f10-9a574f7c6152">8.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTUtMS0xLTA_5b242f34-3681-4583-a32c-d0dd009fb0d6">195.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTctMS0xLTA_58af4be4-97a7-4a45-adb7-91289e7ca6c9">17,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTktMS0xLTA_69bdc9dc-d90f-4696-8fda-fc10f778e49e">195.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i12002ca5921748508b192203c7a9d235_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTEtMS0xLTA_377a151c-c495-4d93-b94b-acc331a58f9e">1,956,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTMtMS0xLTA_b8cc6e86-25a1-4a4e-acfc-91da56f1f766">5.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i12002ca5921748508b192203c7a9d235_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTUtMS0xLTA_c5956973-c13b-482b-9a3a-1357951084a9">77.54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i12002ca5921748508b192203c7a9d235_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTctMS0xLTA_8535a76a-1305-4ece-9f92-1ef0983985e3">1,454,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i12002ca5921748508b192203c7a9d235_I20191231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTktMS0xLTA_73f080c6-6022-49c2-a9c0-fc9279c5a0be">61.82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNDc_5d290495-d770-4873-af47-bfbe3f282171" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"></td><td style="width:51.709%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.540%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.986%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.540%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.540%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.544%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4%-2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7%-3.0%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%-2.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40%-49%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33%-36%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43%-47%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 to 5.9 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 to 5.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 to 6.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there was $<ix:nonFraction unitRef="usd" contextRef="i903cd103982640959896b8b7ba2c6e13_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzExNDM_558f5bc7-f06b-46ba-9c0a-31023a64ae54">23.2</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEyOTc_84e00f15-e4ed-4f59-a504-e8d56d735d97">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTE_4c74306d-fd3d-41e3-8533-33ee702c3bcc" escape="true"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of our restricted stock activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514%;"><tr><td style="width:1.0%;"></td><td style="width:70.413%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.893%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.549%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibd44dfbec8d944479851c647f8b7ccdc_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzEtMS0xLTEtMA_94258295-4521-4196-b58c-b56282caa495">132,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd44dfbec8d944479851c647f8b7ccdc_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzEtMy0xLTEtMA_6bbdcba4-6a28-4cb4-b10e-b41fa0e4ce46">130.63</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzItMS0xLTEtMA_cbe68b6e-d69e-49a5-86ec-61e1dd8aeffb">118,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzItMy0xLTEtMA_2b6111d8-f0be-47ee-977c-b34ac13c5660">115.90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzMtMS0xLTEtMA_281a6dad-55f6-43c0-aa2c-f7960ff1e866">102,846</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzMtMy0xLTEtMA_a9e570f2-1e83-478b-9205-d6d0a5401b44">121.55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzQtMS0xLTEtMA_bfa971cb-976c-4a52-94d6-82521515b4c8">666</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzQtMy0xLTEtMA_0cc01f67-796f-48d4-9094-c2ab0043750f">134.36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzUtMS0xLTEtMA_f865d4c0-84b1-4e2b-8976-fa95f8e4ad8f">147,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzUtMy0xLTEtMA_39a7531c-7e8a-4d25-a025-34fd28a3dff7">125.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, unrecognized compensation cost related to non-vested stock awards amounted to $<ix:nonFraction unitRef="usd" contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE1MDQ_3e86ae7c-b30b-4c1f-b072-5b02ccb7d184">11.2</ix:nonFraction>&#160;million. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE1ODE_0f95f3d9-671d-4e85-869c-8faeb50a56e0">1.5</ix:nonNumeric> years.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, <ix:nonFraction unitRef="shares" contextRef="i2831464859c14cdc9755d96fcee5dab1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE2NDc_7e5c57fd-80ac-4d1b-ad14-71d71e1428bf">59,263</ix:nonFraction> shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to <ix:nonFraction unitRef="shares" contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE4MjM_d8896112-61ef-4dd1-8cec-defc3b36d794">1,250</ix:nonFraction> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id47728895c9c449785e854267a0064ff" continuedAt="i4328b1f7eb574410a9b632bf721ba581"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="number" contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE5ODE_26f30ac1-9e74-424c-a9e2-394fa722888a">85</ix:nonFraction>% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were <ix:nonFraction unitRef="shares" contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMjI_123c2d8e-26b8-4bcc-a43e-6e25ce7800f5">4,745</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i4872587a0b7b4d018481b6594f32290f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMjY_f14bb0c7-659a-4028-9d52-64a9ca697462">3,386</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i06c0ce63eae94a5eb3fcba29f768110d_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMzM_608fe47c-7dfb-43a1-a233-67c63c73899b">3,061</ix:nonFraction> shares issued under the ESPP in 2019, 2018 and 2017, respectively. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchases </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased <ix:nonFraction unitRef="shares" contextRef="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIzMDM_be7dc864-5280-442b-9fcc-5ac2a06fd7f0">260,000</ix:nonFraction> shares of our common stock at a cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIzNDY_d46a1fe3-1973-4b5a-81cb-17ba938a1b1e">191.14</ix:nonFraction> per share. In September 2018, the board of directors authorized us to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6341c256477e4429836844da17a32b5e_I20160930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI0MzY_19748376-e343-472b-af12-430427d41a64">200.0</ix:nonFraction> million of our common stock from time to time over a period of up to three years (the &#8220;Repurchase Program&#8221;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="icf64fbf8a55e465ba26faa70a391914c_I20190123" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI3Njc_a51e5e47-ca7d-4a20-97aa-5b8e38683f26">350.0</ix:nonFraction> million of our outstanding common stock under the Repurchase Program.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i1ea985b507f54962867ac2d46fb5c542_I20190911" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTA0_d8b6a61e-83e7-4126-8d80-79df8c897fb9">500.0</ix:nonFraction> million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $<ix:nonFraction unitRef="usd" contextRef="icf64fbf8a55e465ba26faa70a391914c_I20190123" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTIz_a51e5e47-ca7d-4a20-97aa-5b8e38683f26">350.0</ix:nonFraction> million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTQz_9a8589ec-5cb5-438e-825a-92a17819c22d">326.8</ix:nonFraction> million of our common stock remained available as of December&#160;31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4328b1f7eb574410a9b632bf721ba581">During the twelve months ended December&#160;31, 2019, 2018 and 2017, we repurchased <ix:nonFraction unitRef="shares" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxNzU_0739448d-5034-4f1b-9a68-35405f5969c7">4,122,133</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxODk_de151c5e-1095-486d-b12c-a2245ef62524">448.4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxOTM_e4daa8c1-9c79-4c54-8f03-a85b6fa042c5">782,248</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMDc_3580cba7-c72a-4cad-8dca-25c95d1ffd73">127.5</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMTU_d1883955-10de-44c4-8f69-bd6ed5c6db96">14,000</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMjk_2a8bde35-b566-43e1-8827-b1281d1a1cf9">2.0</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_121"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.  <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjEvZnJhZzo3OTI4ZmU3ZGJhNmY0MDM1YTBhMGNiYzRkYmVmYTE4Ni90ZXh0cmVnaW9uOjc5MjhmZTdkYmE2ZjQwMzVhMGEwY2JjNGRiZWZhMTg2XzI0MDY_810826d2-6e6d-4927-a8ca-92432f749022" continuedAt="i6f4eb216a8eb49c78af6c5e214b91204" escape="true">Commitment and Contingencies: Legal Proceedings</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6f4eb216a8eb49c78af6c5e214b91204" continuedAt="ia5fc2355af55483a8c088083da6d1058"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ASC 450, Contingencies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On July 27, 2018, AG Oncon, LLC, AG Ofcon, Ltd., Calamos Market Neutral Income Fund, Capital Ventures International, Citadel Equity Fund Ltd., Opti Opportunity Master Fund, Polygon Convertible Opportunity Master Fund, Wolverine Flagship Fund Trading Limited, as plaintiffs, filed a complaint in the Court of Chancery of the State of Delaware (AG Oncon, LLC v. Ligand Pharmaceuticals Inc.) alleging claims for violation of the Trust Indenture Act, breach of contract, and others against us.  On May 24, 2019, the Court granted our motion to dismiss and the Delaware Supreme Court subsequently affirmed the decision of the Court of Chancery dismissing this case with prejudice.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Teva stating that Teva had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of U.S. Patent Nos. 8,410,077 (&#8220;the &#8217;077 patent&#8221;); 9,200,088 (&#8220;the &#8217;088 patent&#8221;), or 9,493,582 (&#8220;the &#8217;582 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or will not be infringed by Teva&#8217;s ANDA product.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 20, 2017, CyDex filed a complaint against Teva in the U.S. District Court for the District of Delaware, asserting that the filing of Teva&#8217;s ANDA constitutes infringement of each of the &#8217;077 patent, the &#8217;088 patent, and the &#8217;582 patent. On March 22, 2018, Teva filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on April 12, 2018, CyDex filed an answer to Teva&#8217;s counterclaims. On October 31, 2019, CyDex, Teva, and Acrotech Biopharma L.L.C. (the holder of the NDA for EVOMELA&#174;) entered into a Confidential Settlement Agreement, settling this patent litigation. As a result of the settlement, Teva will be permitted to market a generic version of EVOMELA&#174; in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2019, CyDex received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. On July </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ia5fc2355af55483a8c088083da6d1058"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#8217;s counterclaims. On December 16, 2019, the Court entered a Scheduling Order, setting October 2, 2020, as the fact discovery cut off, March 5, 2021, as the close of expect discovery, and May 17, 2021, as the first day of a five to six day bench trial.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin's counterclaims on January 2, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 31, 2019, we received three civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned several hundred civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div></ix:continuation><div id="i9c8bcdb9c365455fab9e0c3ce3684173_124"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NTY_7d06eb6f-f171-4e9e-b68d-5598e1a5f1ec" continuedAt="i64354e13339647da8f7d10510908ce50" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i64354e13339647da8f7d10510908ce50" continuedAt="i3b42d19c2bdc445da2675f45d7a2fcee"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Act was enacted on December 22, 2017 and includes a number of changes to existing tax laws that impact us, most notably it reduces the US federal corporate tax rate from 35% to 21%, for tax years beginning after December 31, 2017. The Tax Act made modifications to allowable tax depreciation, the deductability of compensation for officers, the deductibility of meals and entertainment expenses, and the deductibility of interest expense. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NjA_a1cb91ca-a56d-404d-bccc-7c5a7c10cfc9" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:65.503%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.192%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.833%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.192%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.686%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.194%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtMS0xLTEtMA_0eb40d00-0426-409e-888a-541eeffce9d1">89,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtMy0xLTEtMA_17b9d3cc-a4fe-4b08-97dc-45f824800709">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtNS0xLTEtMA_91b79ebc-2c3c-458d-b533-38b532cf91b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtMS0xLTEtMA_881bed4b-fb8e-49d8-927c-91bb4d5790bb">3,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtMy0xLTEtMA_2857ae3f-8115-461b-ad69-48d9ba57f5c1">424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtNS0xLTEtMA_d3271067-d0f3-49d0-b6fd-cd441c17a1c9">111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtMS0xLTEtMA_0c4459ab-385e-4558-82d5-bba275eea4ba">66</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtMy0xLTEtMA_58710640-9c56-4350-8b3b-c67772266d5b">158</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtNS0xLTEtMA_82e0f6db-5e7f-42b7-8925-644ca01092d8">261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtMS0xLTEtMA_1671a909-c92b-4cc7-9af5-75db3741dc6a">92,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtMy0xLTEtMA_e78e3bd4-0471-468c-9b70-cf9151db4717">266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtNS0xLTEtMA_2554f6c6-948c-4290-b98c-96ec58349f4e">372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtMS0xLTEtMA_c73bffff-e44c-4c05-989d-f7639770dd8e">74,627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtMy0xLTEtMA_af21feac-2c3c-41a8-9b47-3fb78730ecf1">29,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtNS0xLTEtMA_3f4500fe-40fa-48ae-98c0-7b854545eee9">44,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktMS0xLTEtMA_15aa22fd-2712-4927-9e3f-84e89dc06699">202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktMy0xLTEtMA_4bded98f-d368-401b-850d-779c4a1a1300">185</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktNS0xLTEtMA_66de0fc4-a20f-4772-9f0e-abc9bd5fa197">228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTEtMS0xLTA_84284f5d-636c-4f72-8a82-127a77eb2fec">167,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTMtMS0xLTA_12b3ecc9-d50a-4ab8-b78f-0885c90e6bf3">30,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTUtMS0xLTA_43777042-d40c-40ad-938a-aca7a470443b">44,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i3b42d19c2bdc445da2675f45d7a2fcee" continuedAt="ib0351221196448c28cbfc6bea9cf13cc"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NjI_b4f72973-6fdf-4f98-acfa-3ea643567707" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:65.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.147%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.147%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.682%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.148%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItMS0xLTEtMA_09109b65-5ea6-4fae-b37d-e3be9b7c843b">167,294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItMy0xLTEtMA_adc5180d-9953-41ba-bd6a-a48ec9b2b8fc">36,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItNS0xLTEtMA_867b232c-aae5-4c45-b8b9-9fbebf9abfaa">20,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtMS0xLTEtMA_ff625fa5-76bd-4685-9c33-ec231209d9ef">2,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtMy0xLTEtMA_63bc5b16-5e94-4b18-80f9-591d3b3f3e8c">1,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtNS0xLTEtMA_d7d12347-2ec2-4281-9010-68e10aec872b">622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtMS0xLTEtMA_bea00cd2-5e79-4417-a4e1-9800ce7a6782">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtMy0xLTEtMA_d1a1cd66-4645-4057-a1a2-9e0113e2bd47">948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtNS0xLTEtMA_a9f64b83-64cc-4fdb-8af6-0b9d28fdb9e5">903</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtMS0xLTEtMA_87619a50-a212-4aa3-9ca9-63a9c55ece16">819</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtMy0xLTEtMA_37e852ab-453a-41cd-825f-ccba6b0f45ab">8,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtNS0xLTEtMA_6d7c492c-7884-414a-887b-39efd6f71c81">4,019</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FDII</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMS0xLTEtNzM3OA_2f4f1eef-7813-464f-8d82-677ff2bb44b5">402</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMy0xLTEtMTA5ODk_adc02bde-b74e-4443-9e33-c3c539d069ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtNS0xLTEtMTA5ODk_020a6d4c-8a3b-42da-bb2d-286fe6f53878">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMS0xLTEtMA_dcf631b2-6971-4b45-b85b-6a1cc2621382">879</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMy0xLTEtMA_b3947e3c-16e4-48ca-95c5-6ba0d154be18">2,758</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtNS0xLTEtMA_f5da5a53-6e7a-4998-8503-aa298239206b">2,821</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in uncertain tax positions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctMS0xLTEtMA_3ce9c546-f1be-41da-963b-757aaa002397">441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctMy0xLTEtMA_9fba0cd2-500f-4b95-a03f-bc596b6ccac4">858</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctNS0xLTEtMA_6f2affa4-cf0d-400d-85d0-1cfd9c9f9bcf">1,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate change for changes in federal or state law</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtMS0xLTEtMA_bcb13eaf-edf8-43b1-8901-3195e584230a">210</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtMy0xLTEtMA_3c771c66-0dde-4bbe-8d67-0c696b622095">178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtNS0xLTEtMA_5868410f-2002-4ada-ab5c-9fb939b556a7">32,429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktMS0xLTEtMA_7b9dec92-2ad3-4887-b025-cb59775e272c">1,193</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktMy0xLTEtMA_a2c3ee67-0953-4733-b49c-1c6d49a9a73c">4,225</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktNS0xLTEtMA_5d6d3340-79cb-43ae-b536-b0d6dd5d19db">4,169</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired NOLs and credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTEtMS0xLTA_6bfb1436-abf4-476d-be3a-b11c716f483f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTMtMS0xLTA_ad990bcc-8534-4b8a-ba97-fe2b512c9b59">3,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTUtMS0xLTA_9098aff8-0361-4471-9879-ff293b77de0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTEtMS0xLTA_5aaea13d-31d7-4511-aa7f-ef97fee464f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTMtMS0xLTA_16d7e3ec-5406-4060-b2c1-6c986cc1c384">615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTUtMS0xLTA_628478be-c6a7-477d-aac8-fff7f41d0fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTEtMS0xLTA_2c6978de-2fa5-484f-8e6e-ed7d5b77f891">621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTMtMS0xLTA_ad08402c-2446-49d6-a564-072c96ea3763">1,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTUtMS0xLTA_afdfb2e2-fdfc-48c9-bf16-99d5fe28c6b4">391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTEtMS0xLTA_da4d85a9-d137-46b3-bb8e-8e44a4e791d9">167,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTMtMS0xLTA_ad4a9f96-f2ca-43f2-a047-5fc993a23207">30,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTUtMS0xLTA_8ba34e78-4cfb-4bad-8bbf-a6b2bff7cb42">44,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2019 and 2018 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2019, 2018 and 2017. The valuation allowance increased $<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzE5NTQ_9a456730-7ee5-4302-aaa1-73a0b50f7890">136.9</ix:nonFraction> million in 2019, decreased $<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzE5NzY_e548790f-cd16-40d7-ac45-363c563ad0d6">2.5</ix:nonFraction> million in 2018 and decreased $<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIwMDE_a227a968-ea77-4e2f-8d18-358cfc869bec">8.4</ix:nonFraction> million in 2017.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzI3NDg3NzkwNzc5ODY_1e25a612-a312-4057-bb3d-6fd3726b99e1" continuedAt="i4db3f2f024924c5bb34c0f69bb8aa0fd" escape="true">Deferred tax assets (liabilities) are comprised of the following:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ib0351221196448c28cbfc6bea9cf13cc" continuedAt="i279b5fd657424d52b28ca3ea27205697"><div style="margin-bottom:6pt;"><ix:continuation id="i4db3f2f024924c5bb34c0f69bb8aa0fd"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"></td><td style="width:75.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.762%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.913%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzQtMS0xLTEtMA_fec0945e-cc33-45e2-8626-4eeaea9c9783">150,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzQtMy0xLTEtMA_4c2f9464-2117-40e8-9fba-e592d5326c2b">57,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzUtMS0xLTEtMA_be77ca28-98ef-41bd-9284-5df07e555ac6">14,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzUtMy0xLTEtMA_a1f9cc73-e47e-4e9f-ae76-291c76d70025">31,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzYtMS0xLTEtMA_bbc41c71-dfc0-47c8-bb09-e9db689a983c">419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzYtMy0xLTEtMA_80e57c4e-78aa-4fbe-b4c2-7df5a52c54ed">1,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzctMS0xLTEtMA_f7e04924-3cfd-46ea-8fb7-0508bf10dfc4">171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzctMy0xLTEtMA_04e4794c-1635-4f23-b02f-047282f5ef41">657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzgtMS0xLTEtMA_a350cf3d-2f15-4b2f-b608-c8df13403500">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzgtMy0xLTEtMA_4dbb22cd-7f90-4fe8-86f3-60383812f505">957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzExLTEtMS0xLTA_60aaae1f-673b-4f3c-8038-3d035f5726b1">17,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzExLTMtMS0xLTA_68b2ca5c-36d6-4c17-9f12-9c05334b8312">11,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEyLTEtMS0xLTA_43572b19-1d42-4074-99ed-c6790b7e4b4d">184,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEyLTMtMS0xLTA_cdb96180-0d8a-4df3-8f56-869ddc0c1a5a">102,963</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEzLTEtMS0xLTA_214a7c3f-3c86-43a6-a893-c481b2d81205">141,338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEzLTMtMS0xLTA_74bdd6b3-36d6-49f9-9e95-94e837da1e0b">4,476</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE0LTEtMS0xLTA_adc3c325-3468-4b4a-9e26-187f403bdb63">42,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE0LTMtMS0xLTA_f313bb5d-ad54-4f7c-8fe3-b5c76c9e12b0">98,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE3LTEtMS0xLTA_0a99adaa-1ba4-4065-b459-c1c9034b4367">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE3LTMtMS0xLTA_2c2302ca-9249-4f71-9913-0358029c9e33">179</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE4LTEtMS0xLTA_3cd26b56-41d6-4012-813d-a294960d5fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE4LTMtMS0xLTA_4f012b1f-d08d-4eb8-b4f1-8863948cda86">2,905</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE5LTEtMS0xLTA_838176b7-8cce-4764-a354-780214f173cd">41,664</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE5LTMtMS0xLTA_b32e4f34-3158-469d-93bd-ac25833f59a1">44,643</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified indefinite lived intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTEtMS0xLTA_10a74620-f6fb-4dd9-b95a-60eb0bce0d56">1,040</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTMtMS0xLTA_dbd22d2e-d061-4145-b3ca-9da2b9c6d859">1,759</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTEtMS0xLTA_fed0c85a-fc45-45ec-bdb8-3219913e5a04">2,937</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTMtMS0xLTA_ba23743f-01d9-432d-970a-77ba7157c7d6">2,480</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTc0Mjg_2f247a1e-d1da-4544-856b-fe43f407cbf6">3,488</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTMtMS0xLTExMDE5_979111de-b111-4fdf-ae39-1caed4dc509d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTc0MTQ_421b6f15-0e43-441b-b8dd-3b5242e0e6f3">964</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTMtMS0xLTExMDE5_835c1d9e-cf53-436b-9f21-d9c5d63864a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTA_f9ee9775-a32f-4c1d-9a89-6e81d4b5c7a7">50,111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTMtMS0xLTA_050f80d4-f2d5-454f-ada3-d9e312bdd0c3">51,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIzLTEtMS0xLTA_0417060c-04db-4a59-9e44-9d73ace5e3ad">7,329</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIzLTMtMS0xLTA_ffa72a87-4249-4165-a4cb-5274e4e52ec1">46,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="i2b493974b1c542688ad91b9e471e0124_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxMDI_b47b0438-5cb7-4170-9f58-6bf58cee2402">31.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb372575aafc4ed3b9445394ffcccb29_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxMDk_965e58b6-99c2-4e89-8985-20236f69f6bb">119.1</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2028. We also have $<ix:nonFraction unitRef="usd" contextRef="ic1894d5ffb9e46e1bd0855a3f66e9ffa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxNjg_86b1d1a8-a460-4b62-a585-9b31224c110e">0.6</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2038. We have $<ix:nonFraction unitRef="usd" contextRef="i4b4fae611a5c4181ac378c7ecc937744_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIyNjI_6bc159e9-ee94-4924-b673-e31f8edd0e2f">22.9</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="ife0bb7031f9647efa3364ba02afec1e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzgyNDYzMzcyMjAwNTY_60702799-b4c1-4c15-8fb5-b8a220c92d04">713.8</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="ia54d651574f64756a24c8e91f44996a2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzgyNDYzMzcyMjAwMzc_debdadfd-e8eb-4199-841b-5e8ddb563cd0">14.6</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date. We have a full valuation allowance against these non-U.S. tax attributes. &#160;&#160; </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2019 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NTg_6c5fca81-f937-4d7b-8569-c405570c73a9" escape="true"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2019, 2018 and 2017 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"></td><td style="width:65.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.164%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.164%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.547%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.465%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="14" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItMS0xLTEtMA_8daedd4c-63cd-424c-a68c-4bf93b775728">30,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItMy0xLTEtMA_1d4575ad-167a-402e-a706-3a200adc9031">29,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItNS0xLTEtMA_d4438552-bf48-406a-b88b-ce526546bfe7">38,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtMS0xLTEtMA_330eab64-3ce0-4275-970d-a18b0f5c378f">543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtMy0xLTEtMA_980f8d5a-8e03-4157-be9c-4b004b6f5cc0">1,247</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtNS0xLTEtMA_f5c28d5e-f6e8-439e-a556-cd38c3210ab8">1067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtMS0xLTEtMA_320559af-1585-4208-9bee-3b4a62b19c8e">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtMy0xLTEtMA_007d5af4-0fbf-4724-862f-f80c86f3769b">336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtNS0xLTEtMA_0d74d71a-522a-4f6a-bb5a-3d82244502f6">109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtMS0xLTEtMA_e56e870c-8e92-43aa-b2e5-435e394283d3">2,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtMy0xLTEtMA_a070d1a2-8cf1-4550-928b-1f00f0f7f167">657</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtNS0xLTEtMA_e5385c8d-4762-471c-bc2f-1c6326a49856">10,583</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtMS0xLTEtMA_23e87d5e-ea8e-4b2b-84ff-4970e6590ff2">28,736</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtMy0xLTEtMA_929e85a2-20dc-4034-91cd-92116fca4920">30,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtNS0xLTEtMA_dba57545-1797-45b1-bdbf-ead5db465e88">29,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i279b5fd657424d52b28ca3ea27205697"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Included in the balance of unrecognized tax benefits at December&#160;31, 2019 is $<ix:nonFraction unitRef="usd" contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzM1NjA_a2333431-104b-4c96-b128-fb9522aa7f93">27.1</ix:nonFraction> million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and December&#160;31, 2018, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2016 tax year to the present.&#160;The state income tax returns generally remain open for the 2015 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2019, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2015 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div></ix:continuation><div id="i9c8bcdb9c365455fab9e0c3ce3684173_127"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90ZXh0cmVnaW9uOjdhZmQ4NTA3ZGU3ZTQ5NjU5YTcyOThkMTI3NDVmMGRhXzM2NA_30abb94a-59dc-41ba-9ec3-3713d2608608" continuedAt="iea6839928b6e4f909e06134ae58671eb" escape="true">Summary of Unaudited Quarterly Financial Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iea6839928b6e4f909e06134ae58671eb"><ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90ZXh0cmVnaW9uOjdhZmQ4NTA3ZGU3ZTQ5NjU5YTcyOThkMTI3NDVmMGRhXzM2NQ_a571b89c-7566-4273-ad93-c228d2b73fa9" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2019 and 2018 are as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:45.128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.669%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItMS0xLTEtMA_8c8ffaa7-e088-47c7-a763-b5495904f247">43,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItMy0xLTEtMA_4a0ca207-603a-426b-b733-2864be538537">24,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItNS0xLTEtMA_f176bd78-84d1-4f2a-88e7-d42b2a711909">24,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItNy0xLTEtMA_0a6a0960-55bd-45e3-9009-2e05a983582f">27,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtMS0xLTEtMA_87c3c796-ab6d-4910-8ad9-677df354a5a7">29,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtMy0xLTEtMA_75c4deb9-dbe8-48bb-aef4-7c4318a58092">29,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtNS0xLTEtMA_69b6ec56-1388-41c2-b95a-0b410f02fefa">29,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtNy0xLTEtMA_6f70bbc0-6d2c-4a93-b817-58014437df61">37,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtMS0xLTEtMA_4842a541-e871-4047-8dfd-a899912cd1ff">176,376</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtMy0xLTEtMA_1cecd271-cce4-46fb-9873-8f7a79f54de9">3,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtNS0xLTEtMA_fcb71c29-8faa-4c5d-8ef1-085f40a148c6">4,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtNy0xLTEtMA_9c92f6e4-489c-4440-846f-94826ee3fcf8">810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtMS0xLTEtMA_7e11c500-4b56-4d35-9c5e-47c23c55ddec">666,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtMy0xLTEtMA_884bf0cc-8078-4b50-a874-e8db750404c8">14,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtNS0xLTEtMA_9edb5ab2-7a3f-41b4-a4fc-8753c5f8bbe0">15,251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtNy0xLTEtMA_4c26e320-62c5-47a9-bb6b-43b532e9952c">7,365</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTEtMS0xLTA_c5d79871-9208-46d3-8423-a0bc079ff724">32.59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTMtMS0xLTA_cae295a5-b6a1-4cb3-80be-6954568d0acd">0.74</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTUtMS0xLTA_8ad51ef5-28ea-4dc0-a5e8-115eca6a9e1d">0.81</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTctMS0xLTA_9b52d230-947e-4506-8334-519ad48d8b41">0.43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTEtMS0xLTA_28dad269-f85f-4f60-ab14-f2e1cdce1f4a">31.32</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTMtMS0xLTA_5caa6fb3-a3bd-466b-9f47-b12a0908631b">0.74</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTUtMS0xLTA_d3f3332d-05bc-4b14-978b-0a9c693a19a4">0.81</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTctMS0xLTA_297ea957-ad26-4923-acd1-ec0a9895d02e">0.43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTEtMS0xLTA_66900692-9876-4254-b152-3675ec895b47">20,447</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTMtMS0xLTA_d492a0eb-eda3-4607-badd-117efe7117f7">19,558</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTUtMS0xLTA_e1813efd-7753-4c82-81f3-585a12a02b66">18,770</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTctMS0xLTA_475fd25f-4d6a-4e58-8b30-c0651c4ba43e">17,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTEtMS0xLTA_7e464f7f-b275-4dcc-89fa-03038f2f8db9">21,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTMtMS0xLTA_8896ba2c-3395-4f31-901e-64d6dd14cf80">19,558</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTUtMS0xLTA_7e06d0af-c311-43da-9f22-c7a30dc27e0a">18,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTctMS0xLTA_decc7e47-dd27-4f96-bea3-2cd6b6ec8116">17,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;*includes pre-tax gain from sale of Promacta license of $812,797.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTEtMS0xLTA_3450ebdd-29c5-4d0c-b222-56d4895b578d">56,157</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTMtMS0xLTA_45721839-1dbb-40ec-8143-ba446dbb299b">90,043</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTUtMS0xLTA_4d4a583c-8e55-49fa-8c6e-8d6d471c3914">45,663</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTctMS0xLTA_7ede12df-2499-4d58-a214-abcbf9506a73">59,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTEtMS0xLTA_65e6fbd4-956f-4fde-b0d3-a27ee9bffcba">19,116</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTMtMS0xLTA_5e77c6df-d0ae-4c44-833a-5ab17c26e8ca">19,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTUtMS0xLTA_f422a400-1fd7-4337-82d2-75041025db02">22,301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTctMS0xLTA_24b11954-5cf5-4136-9747-05c5490eac44">26,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTEtMS0xLTA_06ceacf0-8cfe-4db4-921a-c1a82751a3da">10,033</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTMtMS0xLTA_32885a69-a718-41e9-b2e3-310cf80afb37">22,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTUtMS0xLTA_042f28a4-d925-40f3-bd94-fedf3ae7c612">11,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTctMS0xLTA_22bbf5bb-1c68-4b00-8f81-8acabb81f5b3">14,307</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTEtMS0xLTA_e20ae0ec-edc7-425a-a613-8547a7840d03">45,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTMtMS0xLTA_06055076-5264-46c9-8253-3c08f6a8b87e">73,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTUtMS0xLTA_ed22171e-b23c-4ef8-8d09-f3ffe65e4e5c">67,362</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTctMS0xLTA_ad80827d-084f-4422-99f1-c30d8034ceeb">42,482</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTEtMS0xLTA_822f3a7b-d134-4f62-a527-bc33ac99d6f7">2.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTMtMS0xLTA_874ece80-c477-41d2-9b91-8c3d9915ef11">3.45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTUtMS0xLTA_023afc0d-8a23-46f4-8cf9-ab35d3254847">3.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTctMS0xLTA_eaeca46d-29aa-4b71-a02b-cdbceed0de01">2.02</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTEtMS0xLTA_d3cca1b5-f99c-46f3-9c3a-31587bb09ab0">1.83</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTMtMS0xLTA_f2cd1efd-280e-43a8-b3f3-4e7c2d68c672">2.99</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTUtMS0xLTA_b133ebcf-7bc1-4dee-80cb-f9ccd39ec205">2.80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTctMS0xLTA_e5eb99f0-c185-4f1d-93fc-d1d0aff5576e">2.02</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTEtMS0xLTA_42c35c5f-c1fd-4982-9d45-99d10093197b">21,209</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTMtMS0xLTA_acdd5416-b7be-46cf-b076-aa41c9f13d26">21,212</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTUtMS0xLTA_94f2efcb-4533-4c77-8e6f-446056446a5c">21,148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTctMS0xLTA_f824ca97-ee1f-4674-b0bb-d2f2937029d0">21,071</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTEtMS0xLTA_6fc6cd34-f09d-42b8-a0a5-3f3a95700978">24,800</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTMtMS0xLTA_1e7db22f-dd13-489c-90b1-87e6636b5bac">24,438</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTUtMS0xLTA_e8533788-d8a5-4380-a9be-99da28113c05">24,052</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTctMS0xLTA_60e158ad-1b9a-421b-a7e4-57cd97eaa643">21,071</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_995"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13. <ix:nonNumeric contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5MzE_6b7e862a-4a6e-415e-9a72-62108f89f255" continuedAt="i90499f5fb98948c48264a2ae05bebb94" escape="true">Subsequent Event</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i90499f5fb98948c48264a2ae05bebb94">On February 11, 2020, we announced the signing of an agreement to acquire the core assets, partnered programs and ion channel technology from Icagen for $<ix:nonFraction unitRef="usd" contextRef="ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5MzM_0d9ef2ff-d262-40e5-a02e-649d58f8c2c9">15</ix:nonFraction>&#160;million in cash. Icagen will also be entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i29f487b559ca433687df3df3c64d6816_I20200211" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5NDY_be3a9684-a94a-4516-a261-ca0ed295fec5">25</ix:nonFraction>&#160;million of cash payments based on certain revenue achievements. The transaction is subject to certain closing conditions, including a vote of Icagen stockholders, and is expected to close in April 2020.</ix:continuation></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_130"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;9.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_133"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;9A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Controls and Procedures</span></td></tr></table></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(a) Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2019.</span></div><div style="text-indent:27pt;"><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(b) Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - Integrated Framework, management concluded that our internal controls over financial reporting were effective as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, has audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have audited Ligand Pharmaceuticals Incorporated&#8217;s internal control over financial reporting as of December&#160;31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Ligand Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2019, based on the COSO criteria.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2019 and 2018, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2019, and the related notes and our report dated February&#160;27, 2020 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Diego, California</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February&#160;27, 2020</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_136"></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.198%;"><tr><td style="width:1.0%;"></td><td style="width:27.430%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:68.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Information</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_139"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Part III</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_142"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;10.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Code of Conduct</span></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board of Directors has adopted a Code of Conduct and Ethics Policy (&#8220;Code of Conduct&#8221;) that applies to all officers, directors and employees. The Company will promptly disclose (1) the nature of any amendment to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our Code of Conduct that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121.</span></div><div style="text-indent:27pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The other information under Item&#160;10 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2019.&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_145"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;11.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Compensation</span></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Item&#160;11 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_148"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;12.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Item&#160;12 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_151"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;13.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Item&#160;13 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_154"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;14.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal Accountant Fees and Services</span></td></tr></table></div><div style="text-indent:27pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Item&#160;14 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2019.</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_157"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART IV</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_160"></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.850%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;15.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibits and Financial Statement Schedule</span></td></tr></table></div><div style="margin-top:5pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(a) The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="text-indent:-13.5pt;padding-left:58.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Financial statements</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:90.228%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.772%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_58">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_58">49</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_61">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_64">51</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_70">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_70">52</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_73">Consolidated Statements of Comprehensive Income </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_73">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_76">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_76">55</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_79">55</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i9c8bcdb9c365455fab9e0c3ce3684173_82">57</a></span></div></td></tr></table></div><div style="text-indent:-13.5pt;padding-left:58.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.</span></div><div style="text-indent:-13.5pt;padding-left:58.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.649%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.360%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Exhibit</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Exhibit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">File Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date of Filing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Exhibit </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Filed </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Herewith</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000122/omttransaction-mergeragree.htm">2.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agreement and Plan of Merger, dated as of December 17, 2015, by and among Ligand Pharmaceuticals Incorporated, Open Monoclonal Technology, Inc., OMT, LLC, Schrader 1 Acquisition, Inc., Schrader 2 Acquisition, Inc. and Fortis Advisors LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 18, 2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000115/exhibit21-rule27announcment.htm">2.2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rule 2.7 Announcement issued by Ligand Holdings UK Ltd., dated August 9, 2018 </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 9, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000043/ex218k3519.htm">2.3</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Financial Trust</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 5, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/0000936392-98-001000.txt">3.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Certificate of Incorporation of the Company. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-58823</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 9, 1998</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616301000008/0000886163-01-000008-0002.txt">3.2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000 </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-20720</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 29, 2001</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616304000015/ex3-6.txt">3.3</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004 </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-20720</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 5, 2004</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November&#160;19, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000157/exhibit36.htm">3.5</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of Amendment of the Amended and Restated Certification of Incorporation of the Company, dated June 19, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-8</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-233130</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 8, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000097/thirdamendedandrestatedbyl.htm">3.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000097/thirdamendedandrestatedbyl.htm">6</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Amended and Restated Bylaws of the Company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 10, 2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgndexhibi41.htm">4.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Specimen stock certificate for shares of the common stock of the Company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/exhibit41.htm">4.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/exhibit41.htm">2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indenture, dated as of May 22, 2018, between the Company and Wilmington Trust, National Association, as trustee, including the form of 0.75% Convertible Senior Notes due 2023</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh43lgnddescriptionofse.htm">4.3</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Registered Securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;">10.1#</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2002 Stock Incentive Plan (as amended and restated through June 6, 2019)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 24, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Appendix A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.649%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.360%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;">10.2#</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2002 Employee Stock Purchase Plan (as amended and restated effective June 6, 2019)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 24, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Appendix B</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000031/lgnd-ex105_optionagreement.htm">10.3#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 24, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000095013706000420/a16037orexv10w289.txt">10.4#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Stock Issuance Agreement for non-employee directors under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-131029</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January&#160;13, 2006</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan - Performance-Based RSU Form</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Executive Officer Change in Control Severance Agreement </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August&#160;22, 2007</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312508260208/dex102.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312508260208/dex102.htm">8</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312508260208/dex102.htm">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Severance Plan, dated December 20, 2008</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;24, 2008</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit109final.htm">10.9#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">10.1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">0</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January&#160;28, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm">10.1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm">1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Glucagon Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January&#160;28, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">10.1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January&#160;28, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">10.1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">3</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January&#160;31, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">10.14</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment of General Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">10.15</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment of TR Beta Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Captisol&#174; Supply Agreement, dated December&#160;20, 2002, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1st Amendment to Captisol&#174; Supply Agreement, dated July&#160;29, 2005, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.101</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">18</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2nd&#160;Amendment to Captisol&#174; Supply Agreement, dated March&#160;1, 2007, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.102</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">19</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3rd&#160;Amendment to Captisol&#174; Supply Agreement, dated January&#160;25, 2008, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.103</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4th&#160;Amendment to Captisol&#174; Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.649%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.360%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License Agreement, dated September&#160;3, 1993, between CyDex L.C. and The University of Kansas </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.105</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">10.22</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.106</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.107</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.111</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exclusive License Agreement, dated June&#160;4, 1996, between Pfizer,&#160;Inc. and The University of Kansas </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.108</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">10.2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Addendum to Nonexclusive License Agreement, dated December&#160;11, 2001, between CyDex, Inc. and Pfizer,&#160;Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10113.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment to License Agreement, dated May 12, 2006, between CyDex, Inc. and Prism Pharmaceuticals, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.113</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">28</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10114.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supply Agreement, dated March 5, 2007, between CyDex, Inc. and Prism Pharmaceuticals, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 3, 2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.114</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">29</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012310015780/f55044exv10w22.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License and Supply Agreement, dated October 12, 2005, between CyDex Pharmaceuticals, Inc. and Proteolix, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">000-28298</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 23, 2010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.22</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511214243/dex1027.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511214243/dex1027.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511214243/dex1027.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supply Agreement, dated June 13, 2011 by and between CyDex Pharmaceuticals, Inc. and Merck Sharp &amp; Dohme Corporation </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 2, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 8, 2013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 8, 2013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 1, 2013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 5, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex102.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex102.htm">5</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of August 12, 2014, between Bank of America, N.A. and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 18, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex104.htm">10.3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex104.htm">6</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of August 12, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Base Issuer Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 18, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex106.htm">7</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of August 14, 2014, between Bank of America, N.A. and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 18, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex108.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312514313479/d775802dex108.htm">38</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of August 14, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Additional Issuer Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 18, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">39</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">October 31, 2014</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">10.4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 5, 2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">10.4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.<br/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 28, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.48</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">92</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.649%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.360%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit1042n.htm">10.42&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated March 20, 2018.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312515372802/d30180dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease, dated November 3, 2015, between the Company and 3911/3931 SVB, LLC </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 10, 2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 9, 2016</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">5</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-033093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 9, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000063/finalligand-roivantgralice.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000063/finalligand-roivantgralice.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000063/finalligand-roivantgralice.htm">6</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License Agreement, dated March 5, 2018, between the Company and Roivant Sciences GmbH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 9, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex101-basebondhedgebc.htm">7</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex102-basewarrantbc.htm">8</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex103-basebondhedgedb.htm">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex104-basewarrantdb.htm">0</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">10.5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex105-basebondhedgegs.htm">1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex106-basewarrantgs.htm">2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 17, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Base Warrant Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">10.5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex107-bondhedgebc.htm">3</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex108-additionalwarrantbc.htm">4</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">10.5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex109-bondhedgedb.htm">5</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1010-additionalwarrantdb.htm">6</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1011-bondhedgegs.htm">7</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Convertible Note Hedge Transaction</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000076/ex1012-additionalwarrantgs.htm">8</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter Agreement, dated as of May 18, 2018, between Goldman Sachs &amp; Co. LLC and the Company regarding the Additional Warrant Transaction </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-00393</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a101redlineplatformlicen.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a101redlineplatformlicen.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a101redlineplatformlicen.htm">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Platform License Agreement, dated March 23, 2015, by and between Open Monoclonal Technology, Inc. and WuXi AppTec Biopharmaceuticals Co., Ltd.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 8, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">93</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.549%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.649%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.360%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1014redlineamendmentnum.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1014redlineamendmentnum.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1014redlineamendmentnum.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment Number 1 to Platform License Agreement, dated June 11, 2017, by and between Open Monoclonal Technology, Inc. and WuXi Biologics (Hong Kong) Limited (as successor-in-interest to WuXi AppTec Biopharmaceuticals Co., Ltd.)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 8, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1015redlineamendmentnum.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1015redlineamendmentnum.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000113/a1015redlineamendmentnum.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment Number 2 to Platform License Agreement, dated June 25, 2018, by and between Open Monoclonal Technology, Inc. and WuXi Biologics Ireland Limited (as successor-in-interest to WuXi Biologics (Hong Kong) Limited).</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 8, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Indemnification Agreement between the Company and each of its directors</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.60</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Indemnification Agreement between the Company and each of its officers</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.60</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-33093</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 8, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subsidiaries of the Company </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consent of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="lgnd123119exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The following financial information from our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Comprehensive Income, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-72pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;&#160;Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.</span></div><div style="text-indent:-72pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">#&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:72pt;"><span><br/></span></div><div style="padding-left:72pt;"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_163"></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.198%;"><tr><td style="width:1.0%;"></td><td style="width:27.430%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:68.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 16.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form 10-K Summary</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None</span></div><div id="i9c8bcdb9c365455fab9e0c3ce3684173_166"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">94</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:61.695%;"><tr><td style="width:1.0%;"></td><td style="width:10.796%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:85.204%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIGAND&#160;PHARMACEUTICALS&#160;INCORPORATED</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/&#160;&#160;&#160;&#160;J</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">OHN</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> L. H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">IGGINS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John L. Higgins,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date: February&#160;27, 2020 </span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:37.353%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.329%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Signature</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Date</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/s/&#160;&#160;&#160;&#160;J</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">OHN</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> L. H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">IGGINS</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John L. Higgins</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160; MATTHEW KORENBERG</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew Korenberg</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;JOHN W. KOZARICH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director and Chairman of the Board</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John W. Kozarich</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;JASON M. ARYEH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jason M. Aryeh</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;SARAH BOYCE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sarah Boyce</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;TODD C. DAVIS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Todd C. Davis</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;NANCY R. GRAY</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nancy R. Gray</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;JOHN L. LAMATTINA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John L. LaMattina</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;SUNIL PATEL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sunil Patel</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;STEPHEN L. SABBA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stephen L. Sabba</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">95</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>exh43lgnddescriptionofse.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exh43lgnddescriptionofse</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exh43lgnddescriptionofse001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exh43lgnddescriptionofse001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                                                     Exhibit 4.3                                                           DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES                  REGISTERED PURSUANT TO SECTION 12 OF THE                       SECURITIES EXCHANGE ACT OF 1934   Ligand Pharmaceuticals Incorporated (&#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221;) has one class of   securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended:   our common stock.                              Description of Common Stock    General          The following summary of the terms of our common stock does not purport to be   complete and is subject to and qualified in its entirety by reference to our Amended and Restated   Certificate of Incorporation, as amended (the &#8220;certificate of incorporation&#8221;), and the Amended   and Restated Bylaws, as amended (the &#8220;bylaws&#8221;), which are filed as exhibits to our most recent   Annual Report on Form 10-K and are incorporated by reference herein.           Under our certificate of incorporation, the total number of shares of all classes of stock   that we have authority to issue is 65,000,000, consisting of 5,000,000 shares of preferred stock,   par value $0.001 per share, and 60,000,000 shares of common stock, par value $0.001 per share.    Common Stock    Voting Rights          The holders of our common stock are entitled to one vote for each share held of record on   all matters submitted to a vote of the stockholders, including the election of directors, and do not   have cumulative voting rights. Accordingly, the holders of a majority of the shares of common   stock entitled to vote in any election of directors can elect all of the directors standing for   election, if they so choose.     Dividends          Subject to limitations under Delaware law and preferences that may be applicable to any   then outstanding preferred stock, holders of common stock are entitled to receive ratably those   dividends, if any, as may be declared by our board of directors out of legally available funds.     Liquidation           Upon our liquidation, dissolution or winding up, the holders of common stock will be   entitled to share ratably in the net assets legally available for distribution to stockholders after the   payment of all of our debts and other liabilities of our company, subject to the prior rights of any   preferred stock then outstanding.                                            1    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exh43lgnddescriptionofse002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exh43lgnddescriptionofse002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> Rights and Preferences         Holders of common stock have no preemptive or conversion rights or other subscription  rights and there are no redemption or sinking funds provisions applicable to the common stock.   Fully Paid and Nonassessable         All outstanding shares of our common stock are fully paid and nonassessable and the  shares of common stock offered hereby will be fully paid and nonassessable.    Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and  Delaware Law          Some provisions of Delaware law, our certificate of incorporation and our bylaws contain  provisions that could make the following transactions more difficult: acquisition of us by means  of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our  incumbent officers and directors. It is possible that these provisions could make it more difficult  to accomplish or could deter transactions that stockholders may otherwise consider to be in their  best interest or in our best interests, including transactions that might result in a premium over  the market price of our shares.          These provisions, summarized below, are expected to discourage coercive takeover  practices and inadequate takeover bids. These provisions are also designed to encourage persons  seeking to acquire control of us to first negotiate with our board of directors. We believe that the  benefits of increased protection of our potential ability to negotiate with the proponent of an  unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of  discouraging these proposals because negotiation of these proposals could result in an  improvement of their terms.    Undesignated Preferred Stock          The ability to authorize undesignated preferred stock makes it possible for our board of  directors to issue preferred stock with voting or other rights or preferences that could impede the  success of any attempt to change control of us. These and other provisions may have the effect of  deferring hostile takeovers or delaying changes in control or management of our company.    Requirements for Advance Notification of Stockholder Nominations and Proposals          Our bylaws establish advance notice procedures with respect to stockholder proposals  and the nomination of candidates for election as directors, other than nominations made by or at  the direction of the board of directors or a committee of the board of directors.  These provisions  could have the effect of delaying until the next stockholder meeting stockholder actions that are  favored by the holders of a majority of our outstanding voting securities.   Elimination of Stockholder Action by Written Consent          Our certificate of incorporation eliminates the right of stockholders to act by written  consent without a meeting.                                           2    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exh43lgnddescriptionofse003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exh43lgnddescriptionofse003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> Special Meetings         Our bylaws state that a special meeting of the stockholders may be called by our  president and shall be called by our president or secretary upon written request from our board of  directors or upon a written request from stockholders owning at least 10% of the entire capital  stock of the company issued and outstanding and entitled to vote.    Delaware Anti-Takeover Statute           We are subject to Section 203 of the Delaware General Corporation Law. This statute   regulating corporate takeovers prohibits a Delaware corporation from engaging in any business   combination with any interested stockholder for three years following the date that the   stockholder became an interested stockholder, unless:             &#8226;  prior to the date of the transaction, the Board approved either the business               combination or the transaction which resulted in the stockholder becoming an               interested stockholder;             &#8226;  the interested stockholder owned at least 85% of the voting stock of the               corporation outstanding at the time the transaction commenced, excluding for               purposes of determining the number of shares outstanding (a) shares owned by               persons who are directors and also officers and (b) shares owned by employee               stock plans in which employee participants do not have the right to determine               confidentially whether shares held subject to the plan will be tendered in a tender               or exchange offer; or             &#8226;  on or subsequent to the date of the transaction, the business combination is               approved by the Board and authorized at an annual or special meeting of               stockholders, and not by written consent, by the affirmative vote of at least               66 2/3% of the outstanding voting stock which is not owned by the interested               stockholder.          Section 203 defines a business combination to include:             &#8226;  any merger or consolidation involving the corporation and the interested               stockholder;             &#8226;  any sale, transfer, pledge or other disposition involving the interested stockholder               of 10% or more of the assets of the corporation;             &#8226;  subject to exceptions, any transaction that results in the issuance or transfer by the               corporation of any stock of the corporation to the interested stockholder;             &#8226;  any transaction involving the corporation that has the effect of increasing the               proportionate share of the stock of any class or series of the corporation               beneficially owned by the interested stockholder; or                                           3    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exh43lgnddescriptionofse004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exh43lgnddescriptionofse004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">          &#8226;  the receipt by the interested stockholder of the benefit of any loans, advances,               guarantees, pledges or other financial benefits provided by or through the               corporation.         In general, Section 203 defines an interested stockholder as an entity or person  beneficially owning 15% or more of the outstanding voting stock of the corporation and any  entity or person affiliated with or controlling or controlled by such entity or person.    Fair Market Value Provision           Our certificate of incorporation contains a fair market value provision that requires the   approval of the holders of 66 2/3% of our outstanding voting stock as a condition to a merger or   certain other business transactions with, or proposed by, any person that beneficially owns,   directly or indirectly, 15% or more of our voting stock (an &#8220;Interested Stockholder&#8221;), except in   cases where a majority of the Continuing Directors (as defined below) approve the transaction or   certain minimum price criteria and other procedural requirements are met. A &#8220;Continuing   Director&#8221; is (i) a director who was originally elected upon incorporation of Ligand, (ii) a director   who is not an Interested Stockholder or affiliated with an Interested Stockholder, or (iii) a   director whose nomination or election to our board of directors is recommended or approved by   a majority of the Continuing Directors. The minimum price criteria are recommended or   approved by a majority of the Continuing Directors. The minimum price criteria generally   require that, in a transaction in which stockholders are to receive payments, holders of our   common stock must receive, on the consummation date of the transaction, a value equal to the   higher of (A) the highest price paid by the Interested Stockholder for common stock during the   prior two years and (B) the highest closing sale price of common stock during the 30-day period   before (1) the announcement of the transaction or (2) the date on which the Interested   Stockholder became an Interested Stockholder, whichever is higher.  In addition, such payment   must be made in cash or in the type of consideration paid by the Interested Stockholder for the   greatest portion of its shares. Our board of directors believes that this fair market value provision   helps assure that all our stockholders will be treated similarly if certain kinds of business   transactions are effected. However, this fair market value provision may make it more difficult to   accomplish certain transactions that are opposed by the incumbent board of directors and that   could be beneficial to stockholders.    Amendment of Charter Provisions           The amendment of any of the above provisions, except for the provision making it   possible for our board of directors to issue preferred stock, would require approval by holders of   at least 66 2/3% of our then outstanding common stock.           The provisions of Delaware law, our certificate of incorporation and our bylaws could   have the effect of discouraging others from attempting hostile takeovers and, as a consequence,   they may also inhibit temporary fluctuations in the market price of our common stock that often   result from actual or rumored hostile takeover attempts. These provisions may also have the   effect of preventing changes in our management. It is possible that these provisions could make   it more difficult to accomplish transactions that stockholders may otherwise deem to be in their   best interests.                                           4    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exh43lgnddescriptionofse005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exh43lgnddescriptionofse005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> Amendment of Bylaws         The affirmative vote of the holders of at least the majority of the total voting power of all  outstanding shares of our voting stock is required for stockholders to amend our bylaws. This  provision makes it more difficult to circumvent the anti-takeover provisions of our bylaws. Our   board of directors is authorized to make, amend, supplement or repeal our bylaws; provided that   no amendment or supplement to the bylaws adopted by the board of directors may vary or   conflict with any amendment or supplement duly adopted by the stockholders.     Listing          Our common stock is listed for trading on the Nasdaq Global Market under the symbol   &#8220;LGND.&#8221;    Transfer Agent and Registrar          The transfer agent and registrar for our common stock is Computershare Trust Company   N.A.                                           5    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>exhibit109final.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2e60dc40501240b587c32b29ca9b9605_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.9</font></div><div style="text-align:center;margin-top:9pt;"><font><br></font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Amended and Restated Effective March 28, 2019) </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">I. DIRECTOR COMPENSATION </font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-employee members of the board of directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of Ligand Pharmaceuticals Incorporated (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) shall be eligible to receive cash and equity compensation effective as of March 28, 2019 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restatement Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), as set forth in this Director Compensation Policy. The cash compensation and stock awards described in this Director Compensation Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Independent Director</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) who may be eligible to receive such cash compensation or stock awards, unless such Independent Director declines the receipt of such cash compensation or stock awards by written notice to the Chairman of the Board. This Director Compensation Policy shall remain in effect until it is revised or rescinded by further action of the Board. The terms and conditions of this Director Compensation Policy shall supersede any prior cash or equity compensation arrangements between the Company and its directors. </font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:10.5pt;">Cash Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Annual Retainer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Each Independent Director shall be eligible to receive an annual retainer of $50,000 for service on the Board. In addition, an Independent Director serving as&#58; </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i.&#160;chairman of the Board shall be eligible to receive an additional annual retainer of $30,000 for such service&#59; </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ii.&#160;chairman of the Audit Committee shall be eligible to receive an additional annual retainer of $20,000 for such service&#59; </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iii.&#160;members (other than the chairman) of the Audit Committee shall be eligible to receive an additional annual retainer of $10,000 for such service&#59;</font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iv.&#160;chairman of the Compensation Committee shall be eligible to receive an additional annual retainer of $15,000 for such service&#59; </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">v.&#160;members (other than the chairman) of the Compensation Committee shall be eligible to receive an additional annual retainer of $7,500 for such service&#59; </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">vi.&#160;chairman of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $10,000 for such service&#59; and </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">vii.&#160;members (other than the chairman) of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $5,000 for such service. </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment of Cash Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Annual retainer fees shall be paid after each annual meeting of the Company&#8217;s stockholders in advance for the upcoming year of service and shall be prorated for the period of the year served for Independent Directors who are elected or appointed to the Board </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">at a time other than the date of the annual meeting of the Company&#8217;s stockholders&#59; provided, however, that an Independent Director may elect in writing prior to the date of an annual meeting to receive all or a portion of his annual retainer fee in the form of such number of fully vested shares of the Company&#8217;s common stock as is equal to (i) the amount of the annual retainer the Independent Director has elected to receive in the form of shares of the Company&#8217;s common stock, divided by (ii) the closing price per share of the Company&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) on the date of the annual meeting. Committee retainer fees shall also be paid annually after each annual meeting of the Company&#8217;s stockholders in advance for the upcoming year of service and shall be prorated for any partial quarters served for Independent Directors who serve on a committee for a partial year.</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:10.5pt;">Equity Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Independent Directors shall be granted the following stock awards. The stock awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2002 Stock Incentive Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2002 Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the same forms previously approved by the Board. </font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Initial Stock Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. A person who is initially elected or appointed to the Board on or after the Restatement Effective Date, and who was or is an Independent Director at the time of such initial election or appointment, shall be eligible to receive the following stock awards on the date of such initial election or appointment (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Stock Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;)&#58; </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i.&#160;that number of restricted stock units determined by dividing (A) $145,000, by (B) the average closing price per share of the Company&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 30-calendar day period prior to the date of grant&#59; and </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ii.&#160;that number of stock options having a value of $280,000, calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that the Company utilizes in preparation of its financial statements). </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Subsequent Stock Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. A person who is an Independent Director as of the date of each annual meeting of the Company&#8217;s stockholders and who is re-elected for another year of service as an Independent Director at such annual meeting automatically shall be eligible to receive the following stock awards on the date of each such annual meeting of the Company&#8217;s stockholders on or after the Restatement Effective Date (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Subsequent Stock Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;)&#58; </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i.&#160;that number of restricted stock units determined by dividing (A) $95,000, by (B) the average closing price per share of the Company&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 30-calendar day period prior to the date of grant&#59; and </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ii.&#160;that number of stock options having a value of $190,000, calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that the Company utilizes in preparation of its financial statements). </font></div><div style="text-indent:49.5pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An Independent Director elected for the first time to the Board at an annual meeting of stockholders shall only receive an Initial Restricted Stock grant in connection with such election, and shall not receive a Subsequent Restricted Stock grant on the date of such meeting as well. The stock awards described in this clause shall be referred to as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Subsequent Stock Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221; </font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination of Employment of Employee Directors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive any Initial Stock Awards pursuant to clause 2(a) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Stock Awards as described in clause 2(b) above. </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Vesting of Stock Awards Granted to Independent Directors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i.&#160;Initial Stock Awards granted hereunder shall vest in three (3) equal annual installments on each of the first three (3) anniversaries following the date of grant, subject to the Independent Director&#8217;s continuing service on the Board through each such vesting date. </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ii.&#160;Subsequent Stock Awards granted hereunder shall vest in full on the earlier of (A) the date of the annual meeting of the Company&#8217;s stockholders next following the grant date (it being understood that the Subsequent Stock Awards shall vest on the date of such annual meeting whether or not the Independent Director is re-elected at such meeting, so long as the Independent Director serves through such meeting) and (B) on the first anniversary of the date of grant, subject to the Independent Director&#8217;s continuing service on the Board through each such vesting date. </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iii.&#160;Any stock awards granted hereunder shall vest in full in the event of a Change in Control or a Hostile Take-Over (each as defined in the 2002 Plan) to the extent the Independent Director is serving on the Board at the time of such transaction or in the event an Independent Director ceases to serve on the Board by reason of death or Permanent Disability as defined in the 2002 Plan. </font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-9pt;padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">iv.&#160;Any unvested stock awards will be forfeited to the Company in the event an Independent Director ceases to serve on the Board prior to the vesting of such awards.</font></div><div style="padding-left:108pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">e.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effect of Termination of Board Service on Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. An Independent Director shall be able to exercise his or her stock options that were vested at the time of his or her cessation of Board service until the first to occur of (i) the third anniversary of the date of his or her cessation of Board service, or (ii) the original expiration date of the term of such stock options. </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">f.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Term of Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Each stock option granted hereunder shall have a term of ten (10) years measured from the date of grant. </font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">g.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exercise Price of Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The exercise price per share of any stock options granted hereunder shall be equal to one hundred percent (100%) of the Fair Market Value (as defined in the 2002 Plan) of the common stock on the date of grant. </font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">II. DIRECTOR STOCK OWNERSHIP GUIDELINES </font></div><div style="text-indent:49.5pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Independent Directors are expected to own and hold shares of the Company&#8217;s common stock with a value equal to three times the annual cash retainer for service as an Independent Director (without regard to any retainers paid for committee service or service as chairman of the Board). The stock ownership level should be achieved by each Independent Director on or before April 30, 2014 or, if later, within three years after the Independent Director&#8217;s first appointment to the Board. </font></div><div style="text-indent:49.5pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock that counts toward satisfaction of these guidelines include&#58; shares of common stock owned outright by the Independent Director and his or her immediate family members who share the same household, whether held individually or jointly&#59; restricted stock where the restrictions have lapsed&#59; shares acquired upon stock </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">option exercise&#59; shares purchased in the open market&#59; and shares held in trust for the benefit of the Independent Director or his or her family. Restricted stock units, which represent the right to receive shares, do not count towards satisfaction of these guidelines. Shares held in trust may be included. Due to the complexities of trust accounts, requests to include shares held in trust should be submitted to the Secretary of the Company and the Chairman of the Board will make the final decision as to whether to include those shares. </font></div><div style="text-indent:49.5pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An Independent Director will be deemed to be in compliance with these guidelines if the Fair Market Value (as defined in the 2002 Plan) of the shares of the Company&#8217;s common stock held by such Independent Director on any date prior to the deadline for his or her compliance equals or exceeds the required multiple of his or her annual cash retainer. After meeting the requirements set forth in these guidelines, any subsequent decreases in the market value of the Company&#8217;s common stock shall not be considered, so long as the Independent Director continues to hold at least the same number of shares of the Company&#8217;s common stock as he or she did when the guidelines were first met or exceeded by such Independent Director. </font></div><div style="text-indent:49.5pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The guidelines may be waived for Independent Directors, at the discretion of the Board, if compliance would create hardship or prevent an Independent Director from complying with a court order, as in the case of a divorce settlement. </font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>4
<FILENAME>lgnd123119exhibit1042n.htm
<DESCRIPTION>EX-10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if17ed8adb129402a9c42c19f8b48f219_1"></div><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CERTAIN MATERIAL (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SUBLICENSE AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">THIS SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into effective as of February 16, 2012 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, Inc. (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">PCOP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Retrophin, LLC, a limited liability company organized under the laws of Delaware and having a place of business at 330 Madison Avenue, 6th Floor, New York, NY, 10017 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Ligand and Retrophin are each referred to herein by name or individually as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;  </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Ligand has in-licensed certain patent rights and know-how rights with respect to the Licensed Compounds (as defined below) and has the right to sublicense the same&#59; </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Retrophin desires to obtain from Ligand sublicenses relating to the Licensed Compounds and Ligand desires to grant such sublicenses to Retrophin, all on the terms and conditions set forth in this Agreement&#59;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing and the mutual covenants and agreements set forth below, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Article 1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.73pt;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEFINITIONS</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The terms in this Agreement with initial letters capitalized shall have the meaning set forth below or, if not listed below, the meaning designated in places throughout this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">AAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 14.3.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the United States Food, Drug and Cosmetic Act, as amended.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Active Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of a Person means any other Person which (directly or indirectly) is controlled by, controls or is under common control with such Person.  For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) as used with respect to a Person means (i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of the votes in the election of directors or (ii) in the case of a non-</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">corporate entity, direct or indirect ownership of at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the voting securities with the power to direct the management and policies of such entity.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the initial paragraph herein and includes all Appendices attached hereto, as the same may be amended or supplemented from time to time.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Licensed Product in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient for the manufacture, distribution, use and sale of the Licensed Product in such jurisdiction in accordance with applicable Laws.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">BMS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">BMS Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  BMS Know-How shall not include </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">business day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a day other than Saturday, Sunday or any day on which commercial banks located in New York, New York are authorized or obligated by applicable Laws to close.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Combination Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercialization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercialize</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means activities directed to commercially manufacturing, obtaining pricing and reimbursement approvals, carrying out Phase 4 Trials for, marketing, promoting, distributing, importing or selling a pharmaceutical product.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercially Reasonable Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to Licensed Compounds and Licensed Products, the carrying out of Development or Commercialization activities in a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party&#58; (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (iii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Competitive Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that is </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">unless Ligand has</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall not </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, assays, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered, or developed by a Party, or has otherwise become known to a Party, or to which rights have been assigned to a Party, as well as any other information, agreements and materials that are deemed confidential or proprietary to or by a Party (including all information and materials of a Party&#8217;s customers and any other Third Party and their consultants), in each case that are disclosed by such Party to the other Party, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or communicated to the other by the disclosing Party in oral, written, graphic, or electronic form.  </font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.17</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Controlled</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Controls</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;, when used in reference to intellectual property, means the legal authority or right of a Party hereto (or any of its Affiliates) to grant a license or sublicense of intellectual property rights to another Party, or to otherwise </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.18</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Core Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the patents and patent applications that are listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto and (a) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">listed in Appendix 1 hereto </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(but in each case, only with respect to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto), (b) all </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">foregoing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, together with all </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">thereof (but in each case, only with respect to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto).</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Cover</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">,&#8221; &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Covered</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Covering</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to patent rights, that the making, using, importation, offer for sale or sale of an invention claimed in such patent rights or the conducting of an activity that, in the absence of a license under such patent rights, would infringe at least one Valid Claim of such patent rights whether present in an issued patent or in a patent application if it issued as a patent containing such claim.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means non-clinical and clinical drug development activities reasonably related to the development and submission of information to a Regulatory Authority, including toxicology, pharmacology and other discovery and pre-clinical efforts, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including, pre- and post-approval studies and specifically excluding regulatory activities directed to obtaining pricing and reimbursement approvals).  When used as a verb, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Develop</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means to engage in Development.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.21</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Licensed Product, a comprehensive, multi-year plan specifying the anticipated timing and technical details of Development activities for such Licensed Product, including the indications to be targeted, line of therapy, timelines for completing key activities, phasing of development, primary endpoints, criteria for continuing activities, study size, comparator drugs, combination drugs, timelines for data preparation and filing of regulatory submissions, toxicology and pharmacology studies and manufacturing process development and scale up.  An outline of the initial Development Plan as of the Effective Date is attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.22</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Dollar</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">$</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the lawful currency of the United States.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.23</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the initial paragraph of this Agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.24</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">EMEA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the European Agency for the Evaluation of Medicinal Products, or any successor agency thereto.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.25</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Excluded Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Dispute that concerns (a) the validity or infringement of a patent, trademark or copyright or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.26</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8220;Executive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means for Ligand, the Chief Executive Officer of Ligand (or such individual&#8217;s designee) and for Retrophin, the Chief Executive Officer of Retrophin (or such individual&#8217;s designee).  If either position is vacant or either position does not exist, then the person having the most nearly equivalent position (or such individual&#8217;s designee) shall be deemed to be the Executive of the relevant Party.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.27</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exit Transaction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means&#58; (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.28</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.29</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Field</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.30</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">First Commercial Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Licensed Product, the first sale for use or consumption by the general public of such Licensed Product in any country in the Territory after Approval of such Licensed Product has been granted, or such marketing and sale is otherwise permitted, by the Regulatory Authority of such country.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.31</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">GAAP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means generally accepted accounting principles in the United States.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.32</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">IND</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an Investigational New Drug Application, as defined in the Act, filed with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">the FDA or its foreign counterparts.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.33</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 12.3.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.34</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 12.3.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.35</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnitor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 12.3.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.36</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JNDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a New Drug Application filed with the Koseisho required for marketing approval for the applicable Licensed Product in Japan.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.37</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JNDA Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the approval of a JNDA by the Koseisho for the applicable Licensed Product in Japan.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.38</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">JNDA Filing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the submission to the Koseisho of a JNDA for the applicable Licensed Product in Japan.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.39</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.40</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Koseisho</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Japanese Ministry of Health and Welfare, or any successor agency thereto.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.41</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.42</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any agreement transferring rights with respect to any Licensed Compound or any Licensed Product by Retrophin (or an Affiliate of Retrophin) to any Third Party licensee, including any license, sublicense, co-development, co-promotion, distribution, joint venture, development and commercialization collaboration or similar transaction involving a transfer of rights with respect to a Licensed Compound or Licensed Product.  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall also include any further transfer of such rights by a Third Party licensee to any other Third Party.  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; also refers to the corresponding arrangement for the grant by Retrophin of rights back to BMS and Ligand with respect to one or more Licensed Compound(s) and Licensed Product(s) pursuant to Article 3.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.43</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Compounds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means&#58; </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.44</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Licensed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.45</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Listed Compounds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means those compounds identified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.46</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Losses and Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 12.1.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.47</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">MAA Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means approval by the EMEA of a marketing authorization application (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">MAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) filed with the EMEA for the applicable Licensed Product under the centralized European procedure.  If the centralized EMEA filing procedure is not used, MAA Approval shall be achieved upon the first Approval for the applicable Licensed Product in any two of the following countries&#58; France, Germany, Italy, Spain or the United Kingdom.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.48</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">MAA Filing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the submission to the EMEA of a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">MAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for the applicable Licensed Product under the centralized European procedure.  If the centralized EMEA filing procedure is not used, MAA Filing shall be achieved upon the first filing of a marketing authorization application for the applicable Licensed Product in any two of the following countries&#58; France, Germany, Italy, Spain or the United Kingdom.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.49</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Major Market Countries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Major Market Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.50</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">NDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a New Drug Application filed with the FDA required for marketing approval for the applicable Licensed Product in the U.S.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.51</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">NDA Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the approval of a NDA by the FDA for the applicable Licensed Product in the U.S.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.52</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">NDA Filing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the submission to the FDA of a NDA for the applicable Licensed Product.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.53</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that where any such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Net Sales shall be determined </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the case of any Combination Product sold in the Territory, Net Sales for such Combination Product shall be calculated by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Net Sales shall not include any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.54</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Orphan Licensed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Licensed Product that receives orphan drug designation from the FDA pursuant to 21 C.F.R. Part 316, or from a Regulatory Authority pursuant to a comparable rule or regulation in a foreign jurisdiction, including the orphan indications set forth in the Development Plan.  </font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.55</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (b) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and (ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.56</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Core Patent Rights and the Other Patent Rights.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.57</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture company, governmental authority, association or other entity.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.58</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Phase 2 Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a human clinical trial of a Licensed Product, the principal purpose of which is a determination of safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b), or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.  For purposes of this Agreement, &#8220;initiation of a Phase 2 Trial&#8221; for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase 2 Trial.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.59</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Phase 3 Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a human clinical trial of a Licensed Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Licensed Product, as described in 21 C.F.R. 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.  For clarity, any human clinical trial may qualify as a Phase 3 Trial if it supports Approval of a Licensed Product without the need to conduct a Phase 3 Trial.  For purposes of this Agreement, &#8220;initiation of a Phase 3 Trial&#8221; for a Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase 3 Trial.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.60</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Phase 4 Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a human clinical trial for a Licensed Product commenced after receipt of Approval in the country for which such trial is being conducted and that is conducted within the parameters of the Approval for the Licensed Product.  Phase 4 Trials may include epidemiological studies, modeling and pharmacoeconomic studies, investigator sponsored clinical trials of the Licensed Product and post-marketing surveillance studies.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.61</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Proprietary Compound of BMS or Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;  means any compound or other agent being developed or sold, (a) as of the March 27, 2006 or at any time thereafter, by BMS or its Affiliates, or their contractors or collaborators, or (b) as of the Effective Date or any time thereafter, by Ligand or its Affiliates, or their contractors or collaborators.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.62</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any national or supranational governmental authority, including the FDA, EMEA or Koseisho (i.e., the Japanese Ministry of Health and Welfare, or any successor agency thereto), that has responsibility in countries in the Territory over the Development and&#47;or Commercialization of Licensed Compounds and Licensed Products.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.63</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sublicensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Third Party to whom rights are transferred with respect to any Licensed Compound or Licensed Product, including through any license, sublicense, co-development, co-discovery, co-promotion, distribution, joint venture, </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Development and Commercialization collaboration or similar transaction between a Party (or an Affiliate of a Party) and a Third Party.  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sublicensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall also include any Third Party to whom such rights are transferred through further sublicense by a Sublicensee.  &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sublicensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall include any Third Party that is a party to a License agreement.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.64</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any country in the world.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.65</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Third Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Person other than Retrophin, Ligand and their respective Affiliates.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.66</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Title 11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in Section 13.7.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.67</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">United States</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">U.S.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the United States of America and its territories and possessions (including Puerto Rico).</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.68</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.69</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Valid Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a claim of (i) an issued and unexpired patent or a supplementary protection certificate, which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination or disclaimer, opposition procedure, nullity suit or otherwise or (ii) a pending patent application&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if a claim of a pending patent application shall not have issued within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSE GRANTS</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Rights and Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Core Patent Rights and Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms and conditions set forth in this Agreement (including the reservation of rights in Section 2.5), Ligand hereby grants to Retrophin a non-transferable (except in accordance with Section 15.4), exclusive sublicense, with the right to further sublicense in accordance with Section 2.2, under the Core Patent Rights and Know-How solely to the extent reasonably necessary to, make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms and conditions set forth in this Agreement (including the reservation of rights in Section 2.5), Ligand hereby grants to Retrophin a non-transferable (except in accordance with Section 15.4), non-exclusive sublicense, with the right to further sublicense in accordance with Section 2.2, under the Other Patent Rights solely to the extent reasonably necessary or useful to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that no rights are granted under this Section 2.1.2 (or otherwise under this Agreement) with respect to any Proprietary Compound of BMS or Ligand.  For clarification, no rights are granted under this Section 2.1.2 (or otherwise under this </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement) to co-formulate or use in combination a Licensed Compound with any Proprietary Compound of BMS or Ligand.  The rights granted by Ligand to Retrophin under this Section 2.1.2 include the right to make, have made, use (including in activities directed at the research and Development of Licensed Compounds), export and import intermediates and starting materials reasonably necessary for the manufacture of Licensed Compounds, and to practice methods reasonably necessary for the manufacture of Licensed Compounds, and to practice methods reasonably necessary for manufacturing such intermediates and starting materials, but only for the purposes of manufacturing, using, importing or exporting Licensed Compounds in the Field in the Territory.  For clarification, no rights are granted to sell or offer to sell any such intermediates or starting materials, or use such intermediates or starting materials for any purpose other than for the purposes of manufacturing Licensed Compounds. </font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sublicenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall have the right to grant sublicenses with respect to the rights licensed to Retrophin under Sections 2.1.1 and 2.1.2 to any Affiliate of Retrophin for so long as such Affiliate remains an Affiliate of Retrophin&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that (i) such Affiliate shall agree in writing to be bound by and subject to the terms and conditions of this Agreement in the same manner and to the same extent as Retrophin and (ii) Retrophin shall remain responsible for the performance of this Agreement and shall cause such Affiliate to comply with the terms and conditions of this Agreement.  In addition, Retrophin shall have the right to grant sublicenses with respect to the rights licensed to Retrophin under Sections 2.1.1 and 2.1.2 to Third Parties.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall have the right to enter into a License agreement with a Third Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to the extent any such License agreement grants rights with respect to any Licensed Compound&#58;</font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such License agreement shall be consistent with the terms and conditions of this Agreement, and shall not limit (A) Retrophin&#8217;s ability to perform its obligations under this Agreement, (B) Ligand&#8217;s rights under this Agreement, (C) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (D)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in such License agreement, the Sublicensee shall agree in writing to be bound to Retrophin by terms and conditions that are substantially similar to, or less favorable to the Sublicensee than, or otherwise allow Retrophin to fully perform the corresponding terms and conditions of this Agreement&#59;</font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such License agreement shall comply with Section 8.10.2 hereof regarding minimum royalty payments&#59; </font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">promptly after the execution of such License agreement, Retrophin shall provide a copy of such License agreement to Ligand, with financial and other confidential or proprietary commercial terms redacted consistent with the public filing of such license agreement with the Securities and Exchange Commission (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SEC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), or, if not filed with the SEC, then with financial and other confidential or proprietary commercial terms redacted (to the extent that such other commercial terms are not reasonably necessary for Ligand to determine Retrophin&#8217;s compliance with this Agreement).  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall remain responsible for the performance of this Agreement (including its obligations under Sections 5.1.1 and 6.1), the payment of all </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">payments due, making reports and keeping books and records and shall use commercially reasonable efforts to monitor such Sublicensee&#8217;s compliance with the terms of such License&#59;</font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any sublicense rights granted by Retrophin in a License (to the extent such sublicensed rights are granted to Retrophin in this Agreement) shall terminate on a country-by-country and Licensed Product-by-Licensed Product basis effective upon (i) the termination under Section 13.2 of the license from Ligand to Retrophin with respect to such sublicensed rights or (ii) the termination under Section 13.2 of the license from BMS to Ligand with respect to such sublicensed rights&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that such sublicensed rights shall not terminate if, as of the effective date of such termination by Ligand under Section 13.2 of this Agreement or BMS under Section 13.2 of the Upstream License Agreement, the Sublicensee is not in material breach of its obligations to Retrophin under its License agreement, and within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days of such termination the Sublicensee agrees in writing to be bound directly to BMS or Ligand, as the case may be, under a license agreement substantially similar to this Agreement </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as the case may be, with respect to the rights sublicensed hereunder, substituting such Sublicensee for Retrophin or Ligand, as the case may be&#59; and </font></div><div style="text-indent:108pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such Sublicensees shall have the right to grant further sublicenses with respect to the Development or Commercialization of Licensed Products, provided that such further sublicenses shall be in accordance with and subject to all of the terms and conditions of this Section 2.2.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of clarification, the preceding provisions of this Section 2.2.2 shall not apply to Licensed Compounds with respect to which Retrophin </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ligand a License.</font></div><div><font><br></font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In accordance with the foregoing, unless Ligand agrees otherwise in writing, any License shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">It shall be a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Trademark License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No right or license, express or implied, is granted to Retrophin to use any trademark, trade name, trade dress or service mark owned or Controlled by BMS, Ligand or any of their respective Affiliates.  Retrophin, at its sole cost and expense, shall be responsible for the selection, registration and maintenance of all trademarks which it employs in connection with its activities conducted pursuant to this Agreement, if any, and shall own and control such trademarks.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Implied Licenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No license or other right is or shall be created or granted hereunder by implication, estoppel or otherwise.  All such licenses and rights are or shall be granted only as expressly provided in this Agreement.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Retained Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin understands and agrees that BMS shall retain the rights specified in Section 2.5 of the Upstream License Agreement.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the Upstream License Agreement, all rights not expressly granted under Section 2.1 are reserved by Ligand and may be used by Ligand for any purpose.  Ligand expressly reserves and retains the right (i) to make, have made and use Licensed Compounds for any internal research purposes (including but not limited to for </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">purposes of screening in support of Ligand&#8217;s internal research programs), (ii) to support the filing and prosecution of patent applications, and (iii) to make, have made and use any Licensed Compound solely for use as an intermediate or starting material in the manufacture of any compound which is not a Licensed Compound.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the exclusive rights granted to Retrophin under this Article 2 and subject to the restrictions on use of Retrophin&#8217;s Confidential Information under Article 11,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For purposes of clarity, nothing in the foregoing shall be construed to reserve to Ligand the right to engage in the discovery, Development and&#47;or Commercialization of Active Compounds Covered by the Core Patent Rights exclusively licensed to Retrophin hereunder.  </font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Upstream License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding anything to the contrary in this Agreement, Retrophin understands and agrees (i) that this Agreement is subordinate to the Upstream License Agreement and the sublicense granted to Retrophin under this Agreement is limited in scope to the rights granted to Ligand in the Upstream License Agreement&#59; (ii) this Agreement may be terminated if the Upstream License Agreement is terminated (iii) it will comply with all provisions of the Upstream License Agreement relevant to its activities as a Sublicensee (as defined in the Upstream License Agreement)&#59; (iv) BMS&#8217; exercise of its rights under the Upstream License Agreement shall not constitute a breach hereunder&#59; (v) it will not take any action that would result in a breach of the Upstream License Agreement&#59; and (vi) it will cooperate with and assist Ligand to meet its obligations under the Upstream License Agreement.&#160; Retrophin acknowledges that it has been provided with a copy of the Upstream License Agreement. </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND RIGHT OF FIRST NEGOTIATION</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">BMS Right of First Negotiation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that Retrophin desires to enter into a License arrangement with respect to any Licensed Compound (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Business Opportunity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), BMS shall be granted the Right of First Negotiation set forth in Article 3 of the Upstream License Agreement.  Retrophin shall comply with the terms set forth in Sections 3.1.1 and 3.1.3-3.1.6 of the Upstream License Agreement.  For the purposes of this Section 3.1, &#8220;Pharmacopeia&#8221; shall be replaced with &#8220;Retrophin&#8221; in Sections 3.1.1 and 3,1.3-3.1.6 of the Upstream License Agreement.   </font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ligand Right of Second Negotiation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the event that Retrophin desires to enter into a Business Opportunity, before entering into negotiations with any Third Party and after following the procedure set forth in Section 3.1 above, with respect to such License, Retrophin shall notify Ligand and provide Ligand with information necessary or useful to Ligand to evaluate the proposed License arrangement (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Evaluation Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Parties shall negotiate in good faith the terms pursuant to which Ligand may obtain such Business Opportunity for a period of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following the date of such notice (such period referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ligand Negotiation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Unless otherwise agreed between the Parties, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any License agreement entered into by Retrophin with a Third Party shall be consistent with the terms and conditions of this Agreement and shall fully enable Retrophin to fully perform all of its obligations under the Agreement which will continue </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in effect.  As set forth in Section 2.2, any Sublicensee shall be bound by the terms and conditions of this Agreement in the same manner as Retrophin.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TRANSFER OF KNOW-HOW </font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Documentation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Prior to the Effective Date, Ligand has provided to Retrophin one (1) electronic or paper copy of all documents, data or other information Controlled by Ligand as of the Effective Date to the extent that such documents, data and information are (i) reasonably necessary or useful for the manufacture, Development or Commercialization of the Listed Compounds (including SAR information) and subject to the Know-How license under Section 2.1 and (ii) are reasonably available to Ligand without undue searching&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that subject to the last sentence of this Section 4.1, the foregoing shall in no event require Ligand to provide copies of manufacturing run records or laboratory notebook records&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">further provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that if Retrophin determines it needs additional documents, data or information for the manufacture, Development or Commercialization of the Licensed Compounds (including SAR information), Ligand shall use commercially reasonable efforts (at Retrophin&#8217;s cost and expense) to determine whether it has such additional information and if Ligand has such information, it shall provide such information to Retrophin at Retrophin&#8217;s cost and expense.  Such documentation shall be deemed to be the Confidential Information of Ligand and shall not be used by Retrophin for any purpose other than Development, manufacture or Commercialization of Licensed Compounds and Licensed Products in accordance with this Agreement.  Retrophin acknowledges that it has received from Ligand such documents, data and information prior to the Effective Date through access to the electronic data room established by Ligand for the Listed Compound and that Ligand has allowed Retrophin to print such documents.  Ligand shall have no obligation to reformat or otherwise alter or modify any such materials, or to create materials in electronic form, in order to provide them to Retrophin&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such information is readable by Retrophin in its current form.  Any and all such materials delivered to Retrophin pursuant to this Section 4.1 are and shall remain, as between the Parties, the sole property of Ligand.  Notwithstanding the foregoing, if at any time during the term of this Agreement Retrophin identifies particular documents, data or information (including laboratory notebook records) that are within the Know-How, but were not previously delivered to Retrophin, and that are reasonably necessary or useful for the continued manufacture, Development or Commercialization of a Licensed Compound or Licensed Product (including materials requested in connection with an audit or other inquiry by a Regulatory Authority), or are reasonably necessary or useful to support the filing and&#47;or prosecution of patent rights Covering the Licensed Compounds or Licensed Products, Ligand shall promptly provide such material to Retrophin upon request to the extent that such items are in Ligand&#8217;s possession and are available without undue searching.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall have no obligation to provide Retrophin with samples of any compounds or other materials (other than the information provided under Section 4.1) under this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that upon written request by Retrophin, Ligand will authorize in writing the transfer by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to Retrophin of all existing clinical supplies of Licensed Product and all existing supplies of the active pharmaceutical ingredient of Licensed Product (including other materials that may be provided by or for Ligand to Retrophin pursuant to this Agreement, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Transferred Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Retrophin shall be responsible for any and all fees charged by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> in connection with the transfer of the Transferred Materials to Retrophin.  Any Transferred Materials are provided &#8220;AS IS&#8221;.  Retrophin shall be fully responsible for its and its Affiliates&#8217;, Sublicensees&#8217; and </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">contractors&#8217; use, storage, handling and disposition of the Transferred Materials.  Under no circumstances shall Ligand be liable or responsible for Retrophin&#8217;s or its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of the Transferred Materials, and Retrophin assumes sole responsibility for any claims, liabilities, damages and losses that might arise as a result of Retrophin&#8217;s and its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of any Transferred Material.  Retrophin shall indemnify, defend and hold harmless Ligand and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all damages, liabilities, losses, costs and expenses (including, without limitation, reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) arising in connection with any claims, suits, proceedings, whether for money damages or equitable relief, of any kind, arising out of or relating, directly or indirectly, to Retrophin&#8217;s, or any of its Affiliates&#8217;, Sublicensees&#8217; or contractors&#8217; use, storage, handling or disposition of any Transferred Material.  Transferred Materials may only be provided to Retrophin, its Affiliates, Sublicensees and contractors.  The Transferred Materials shall be used by Retrophin solely for purposes of supporting the Development of the Licensed Compounds and Licensed Products.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEVELOPMENT</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development and Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Commercially Reasonable Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin (or its Sublicensees, as applicable) shall use sustained Commercially Reasonable Efforts to Develop at least one Licensed Compound and Licensed Product, including using Commercially Reasonable Efforts to expeditiously carry out the clinical development for the Licensed Compounds and Licensed Products (including expeditiously pursuing regulatory filings and Approvals and marketing authorizations for at least one Licensed Compound and Licensed Product) in accordance with the Development Plan.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The initial Development Plan is attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Appendix 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to the Agreement.  </font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin will provide Ligand with (a) semi-annual written development reports within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following June and December of each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and (b) quarterly telephonic development reports within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following March and September of each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in each case presenting a summary of the Development activities accomplished by Retrophin during the applicable period, including as applicable updates to the Development Plan, and significant results, information and data generated with respect to Licensed Compounds and Licensed Products.  Upon reasonable request by Ligand, Retrophin shall also meet in-person with Ligand to review Retrophin&#8217;s Development activities for the Licensed Compounds and Licensed Products.  In addition, prior to Retrophin entering into a License agreement with a Third Party, upon reasonable request by Ligand, but no more than once per </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Retrophin shall present to Ligand, at Retrophin&#8217;s facilities, summaries of (and, at the request of Ligand, with copies of) clinical protocols, investigator brochures, regulatory submissions and correspondence from regulatory agencies with respect to Licensed Compound and Licensed Product that have been prepared or received by Retrophin as of the date of such request by Ligand.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall maintain complete and accurate records of all work conducted in furtherance of the Development and Commercialization of the Licensed Compounds and Licensed Products and all material results, data and developments made in </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">conducting such activities.  Such records shall be maintained sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.  If Ligand believes in good faith that Retrophin may not be complying with its obligations under this Section 5.3, Ligand shall provide written notice thereof to Retrophin identifying the basis for Ligand&#8217;s belief, and Retrophin shall allow an independent Third Party that has expertise in reviewing the books and records and financial information, obligations and agreements of pre-clinical and clinical stage bio-technology companies, as to which Retrophin has no reasonable objection, to review such records on behalf of Ligand to verify that Retrophin is complying with this Section 5.3.  Such review shall be conducted no more frequently than once per any twelve (12) month period, at Ligand&#8217;s cost and upon reasonable advance notice at mutually agreed upon times during normal business hours&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if the independent Third Party determines that Retrophin is not in compliance with this Section 5.3 and Retrophin would owe Ligand at least 10% more in royalties or other payments, Retrophin shall reimburse Ligand for all costs and expenses related to the independent Third Party&#8217;s review.  </font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Responsibilities and Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall have sole responsibility for, and shall bear the cost of conducting, all Development with respect to the Licensed Compounds and Licensed Products.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Responsibilities and Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall be responsible for meeting the requirements of all pre-approval inspections required by any Regulatory Authorities.  Except as set forth in Section 13.4, Retrophin or its Affiliate or Sublicensee shall own all INDs, NDAs, Approvals and submissions in connection therewith and all Approvals shall be obtained by and in the name of Retrophin or its Affiliate or Sublicensee.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Subcontracting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to and without limiting Section 2.2, Retrophin may perform any activities in support of its Development or Commercialization of Licensed Compounds and Licensed Products through subcontracting to a Third Party contractor or contract service organization&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;  (a) Retrophin shall enter into an appropriate written agreement with any such Third Party subcontractor such that the subcontractor shall be bound by all applicable provisions of this Agreement to the same extent as Retrophin and such that Ligand&#8217;s rights under this Agreement and BMS&#8217; rights under the Upstream License Agreement are not adversely affected&#59; (b) any such Third Party subcontractor to whom Retrophin discloses Confidential Information of Ligand shall enter into an appropriate written agreement obligating such Third Party to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations in this Agreement&#59; (c) Retrophin will obligate such Third Party to agree in writing to assign or license (with the right to grant sublicenses) to Retrophin any inventions (and any patent rights covering such inventions) made by such Third Party in performing such services for Retrophin&#59; and (d) Retrophin shall at all times be responsible for the performance of such subcontractor.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COMMERCIALIZATION</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Retrophin Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin (or its Sublicensees, as applicable) shall use sustained Commercially Reasonable Efforts to Commercialize at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Licensed Product in the Territory, including the Major Market Countries.  Without limiting the foregoing, Retrophin shall&#58; </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">use Commercially Reasonable Efforts to obtain Approvals in a Major Market Country with respect to at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Licensed Product and to effect the First Commercial Sale thereof in such country as soon as reasonably practicable after receipt of such Approvals&#59; </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Initiation of a Phase 2 Trial for at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Licensed Compound no later than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">File for Approval for at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Orphan Licensed Product no later than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.1.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">File for Approval for at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Licensed Product other than the first Orphan Licensed Product no later than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Continued Availability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Following the First Commercial Sale of a Licensed Product in a Major Market Country in the Territory and until the expiration or termination of this Agreement, Retrophin shall use Commercially Reasonable Efforts to supply and keep such Licensed Product reasonably available to the public in such country.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marking</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Licensed Product Commercialized by Retrophin under this Agreement shall be marked (to the extent not prohibited by applicable Laws)&#58; (i) with a notice that such Licensed Product is sold under a license from BMS and Ligand and (ii) with applicable patent and other intellectual property notices relating to the Core Patent Rights in such a manner as may be required by applicable Law.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall provide Ligand with semi-annual written reports within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following the end of June and December of each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">summarizing significant commercial activities and events with respect to Licensed Products during the just ended six month period.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MANUFACTURE AND SUPPLY</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Manufacture and Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall be solely responsible at its expense for making or having made all of its requirements of the Licensed Compounds and Licensed Products.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FINANCIAL TERMS</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consideration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In partial consideration of the rights granted by Ligand to Retrophin pursuant to this Agreement, Retrophin shall make the payments to Ligand as provided for in this Article 8.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall make milestone payments to Ligand upon achievement of each of the milestone events in the amounts set forth below in Table 1.  The first milestone payment shall be payable by Retrophin to Ligand within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days of execution of the Agreement.  Notwithstanding Section 15.4 or any other provision herein, the last milestone payment shall be payable by Retrophin to Ligand upon the Closing of Retrophin&#8217;s Exit Transaction.  Subject to Section 8.2.2, the remainder of the milestone payments set forth below will be payable by Retrophin to Ligand within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days of the achievement of the specified milestone event with </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">respect to each Licensed Compound.  The milestone payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments. </font></div><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Table 1</font></div><div style="padding-left:76.5pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:72.866%;"><tr><td style="width:1.0%;"></td><td style="width:48.585%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.415%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Milestone Event</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Execution of Agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">$1.15 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">$&#91;***&#93;</font></div></td></tr></table></div><div style="text-indent:36pt;margin-bottom:11pt;"><font><br></font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that a milestone event is achieved that triggers a development milestone payment as set forth above, if the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For example, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall pay to Ligand in cash the following royalty payments on the total aggregate annual Net Sales in the Territory of all Licensed Products in a particular </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">by Retrophin, its Affiliates, and Sublicensees in the Territory&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.722%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.278%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Aggregate Annual Worldwide Net Sales of All Licensed Products in a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Royalty Rate for Licensed Products in a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Up to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Dollars ($</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">%</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">More than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Dollars ($</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">%</font></div></td></tr></table></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By way of example, in a given </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, if the aggregate annual worldwide Net Sales for all Licensed Products is $</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the royalty payment under this Section 8.3.1 would be  calculated in accordance with the following formula&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Million Dollars.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Royalties shall be payable on a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (ii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (iii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Prior to Retrophin or its Sublicensee exercising its </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">under this Section 8.3.3, Retrophin shall provide Ligand with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties shall discuss the best course of action to resolve such potential </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, provided that such discussions shall not limit or delay Retrophin&#8217;s or its Sublicensee&#8217;s right to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as set forth above, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Royalty Conditions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The royalties under Section 8.3.1 shall be subject to the following conditions&#58;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that only one royalty shall be due with respect to the same unit of Licensed Product&#59;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that no royalties shall be due upon the sale or other transfer among Retrophin, its Affiliates, or Sublicensees, but in such cases the royalty shall be due and calculated upon Retrophin&#8217;s or its Affiliate&#8217;s or Sublicensee&#8217;s Net Sales of Licensed Product to the first independent Third Party&#59; and</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">no royalties shall accrue on the disposition of Licensed Product in reasonable quantities by Retrophin, its Affiliates or Sublicensees as part of an expanded access program, as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">bona fide</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> samples, as part of Phase 4 Trials or as donations to non-profit institutions or government agencies for non-commercial purposes&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> in each case, that neither Retrophin, its Affiliate or Sublicensees receives any payment for such Licensed Product.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Manner of Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All payments to be made by Retrophin hereunder shall be made in Dollars by wire transfer of immediately available funds to such United States bank account as shall be designated by Ligand.  Late payments shall bear interest at the rate provided in Section 8.9.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sales Reports and Royalty Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  After the First Commercial Sale of a Licensed Product and during the term of this Agreement, Retrophin shall furnish to Ligand a written report, within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after the end of each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(or portion thereof, if this Agreement terminates during a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), showing the amount of royalty due for such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(or portion thereof).  Royalty payments for each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall be due at the same time as such written report for the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  With each </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Retrophin shall deliver to Ligand a full and accurate accounting to include at least the following information&#58;</font></div><div style="padding-left:81pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:81pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:81pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:81pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:81pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If no royalty or payment is due for any royalty period hereunder, Retrophin shall so report.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sales Record Audit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall keep, and shall cause each of its Affiliates, and Sublicensees, if any, to keep, full and accurate books of accounting in accordance with GAAP as may be reasonably necessary for the purpose of calculating the royalties payable to Ligand.  Such books of accounting (including those of Retrophin&#8217;s </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Affiliates, and Sublicensees, if any) shall be kept at their principal place of business and, with all necessary supporting data, shall during all reasonable times for the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">years next following the end of the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to which each shall pertain, be open for inspection at reasonable times upon written notice by Ligand and at Ligand&#8217;s sole cost, no more than once per any </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">month period, by an independent nationally recognized certified public accounting firm selected by Ligand as to which Retrophin has no reasonable objection, for the purpose of verifying royalty statements for compliance with this Agreement.  Such accountant must have agreed in writing to maintain all information learned in confidence, except as necessary to disclose to Ligand such compliance or noncompliance by Retrophin.  The results of each inspection, if any, shall be</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable for the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">period of such inspection of more than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the amount paid, Retrophin shall pay for the reasonable out-of-pocket costs of such inspection.  Any underpayments shall be paid by Retrophin within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of notification of the results of such inspection.  Any overpayments shall be fully creditable against amounts payable in subsequent payment periods or, if no such amounts become payable within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after notification of such results, shall be refunded.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Currency Exchange</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  With respect to Net Sales invoiced in Dollars, the Net Sales and the amounts due to Ligand hereunder shall be expressed in Dollars.  With respect to Net Sales invoiced in a currency other than Dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale, together with the Dollar equivalent, calculated using the arithmetic average of the spot rates on the close of business on the last Business Day of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in which the Net Sales were made.  The &#8220;closing mid-point rates&#8221; found in the &#8220;dollar spot forward against the dollar&#8221; table published by The Financial Times, or any other publication as may be agreed to by the Parties in writing, shall be used as the source of spot rates to calculate the average as defined in the preceding sentence.  All payments shall be made in Dollars.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that any withholding taxes or similar charges are levied or assessed by any taxing authority in the Territory with respect to payments made by Retrophin to Ligand under this Agreement, Retrophin shall pay such taxes or similar charges to the proper taxing authority.  Retrophin may deduct the amount of such taxes or similar charges paid by Retrophin to such taxing authority from the applicable royalties or other payment otherwise payable to Ligand, subject to the following.  Retrophin shall promptly provide Ligand with evidence of such tax payment obligation together with an original receipt for such tax payments (or a certified copy, if the original is not available) and other documentation as Ligand reasonably determines is required for the purpose of Ligand&#8217;s tax returns.  Retrophin, its Affiliates and Sublicensees shall cooperate with Ligand to enable the claiming of a reduction or exemption from withholding taxes on payments under any applicable convention on the avoidance of double taxation or similar agreement in force and shall provide to Ligand proper evidence of payments of withholding tax and assist Ligand by obtaining or providing in as far as possible the required documentation for the purpose of Ligand&#8217;s tax returns.  Retrophin&#8217;s obligation vis-a-vis the tax authorities shall remain unaffected by the provisions of this Section 8.8.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Interest Due</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Without limiting any other rights or remedies available to Ligand, Retrophin shall pay Ligand interest on any payments that are not paid on or before the date </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after the date such payments are due under this Agreement at a rate of one and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">per month or the maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.10.1&#160;In addition to the above milestone and royalty payments, Retrophin shall pay to Ligand the following </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.10.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.722%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.278%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">&#91;***&#93;</font></div></td></tr></table></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.10.3&#160;Such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to Ligand shall be due within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.10.4&#160;For purposes of this Section 8.10, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">but does not include (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS AND WARRANTIES&#59; DISCLAIMER&#59;  </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIMITATION OF LIABILITY</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party represents and warrants to the other Party that (i) it has all requisite corporate power and authority to enter into this Agreement and to perform its obligations under this Agreement, (ii) execution of this Agreement and the performance by such Party of its obligations hereunder have been duly authorized, (iii) this Agreement is legally binding and enforceable on such Party in accordance with its terms and (iv) the performance of this Agreement by it does not create a material breach or material default under any other agreement to which it is a Party.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Representations, Warranties and Covenants of Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand represents, warrants and covenants that as of the Effective Date&#58; (i) there is no litigation pending, or to the knowledge of Ligand threatened, which alleges, or any written communication alleging, that Ligand&#8217;s activities with respect to the Patent Rights or the Licensed Compounds have infringed or misappropriated any of the intellectual property rights of any Third Party, (ii) all fees (including legal fees) required to be paid by Ligand in order to maintain the Patent Rights have been paid to date, (iii) it has not previously granted, assigned, transferred, conveyed, encumbered, mortgaged, pledged, hypothesized or licensed (or granted an option to assign, transfer, convey, encumber, mortgage, pledge, hypothesize or license) its right, title and interest in the Patent Rights or the Know-How, (iv) all of its actions related to its use of the Patent Rights and Know-How and the Development and Commercialization of the Licensed Compounds and Licensed Products complied with all applicable legal requirements and complied in all material respects with all regulatory requirements (except for the actions of Ligand&#8217;s clinical research organization, Cetero Research, as to which no representations or warranties are made hereunder), (v) to the knowledge of Ligand (A) the Patent Rights and Know-How are subsisting, valid and enforceable and Ligand has not received any notice of a claim alleging that any of the Patent Rights infringes or otherwise violates any intellectual property or proprietary right of any Third Party, (B) the manufacture, Development and </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Commercialization of the Listed Compound by Ligand did not interfere with the intellectual property rights of Third Parties, (C) it has not received any notice that any Person is infringing the Patent Rights and (D) it has not received any notice that a patent application within the Patent Rights is the subject of any pending interference, opposition, cancellation, protest or other challenge or adversarial proceeding, (vi) it has complied with the terms and conditions of the Upstream License Agreement in all material respects and has the necessary right, title and power to sublicense the Patent Rights or the Know-How, (vii) it has discontinued its internal drug discovery and development programs for the Listed Compound and that it has no active internal programs for the discovery or development of the Listed Compound  and (vii) other than the Core Patent Rights, Ligand does not Control any patent(s) or patent application(s) that are reasonably necessary or useful for the Development or Commercialization of any Listed Compound or that claims the composition of matter of any Listed Compound or a method of manufacture or use of any Listed Compound.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Representations, Warranties and Covenants of Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin covenants that (i) all of its activities related to its use of the Patent Rights and Know-How, and the Development and Commercialization of the Licensed Compounds and Licensed Products, pursuant to this Agreement shall comply with all applicable legal and regulatory requirements and (ii) it shall not knowingly engage in any activities (A) that use the Patent Rights and&#47;or  Know-How in a manner that is outside the scope of the license rights granted to it hereunder or (B) that infringe the intellectual property rights of any Third Party.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin has not, directly or indirectly, offered, promised, paid, authorized or given, and will not in the future, offer, promise, pay, authorize or give, money or anything of value, directly or indirectly, to any Government Official (as defined below) or Other Covered Party (as defined below) for the purpose of&#58; (i) influencing any act or decision of the Government Official or Other Covered Party&#59; (ii) inducing the Government Official or Other Covered Party to do or omit to do an act in violation of a lawful duty&#59; (iii) securing any improper advantage&#59; or (iv) inducing the Government Official or Other Covered Party to influence the act or decision of a government or government instrumentality, in order to obtain or retain business, or direct business to, any person or entity, in any way related to this Agreement.  For purposes of this Agreement&#58; (i) &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Government Official</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any official, officer, employee or representative of&#58; (A) any federal, state, provincial, county or municipal government or any department or agency thereof&#59; (B) any public international organization or any department or agency thereof&#59; or (C) any company or other entity owned or controlled by any government&#59; and (ii) &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Covered Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any political party or party official, or any candidate for political office.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin maintains and shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, including records of payments to any third parties, Government Officials and Other Covered Parties&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.&#160; </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Anti-Corruption Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; </font></div><div style="padding-left:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In performing under this Agreement, Retrophin and its Affiliates agree to comply with all applicable anti-corruption laws, including Foreign Corrupt Practices Act of 1977, as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">FCPA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and all laws enacted to implement the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions.&#160; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any third party who represents Retrophin or its Affiliates in connection with, or who will be involved in performing, this Agreement or any related activity, shall certify to compliance with all applicable anti-corruption laws and the obligations set forth in this Section 9.3.5 prior to any involvement in this Agreement or any related activity.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin is not aware of any Government Official or Other Covered Party having any financial interest in the subject matter of this Agreement or in any way personally benefiting, directly or indirectly, from this Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">No political contributions or charitable donations shall be given, offered, promised or paid at the request of any Government Official or Other Covered Party that is in any way related to this Agreement or any related activity, without Ligand&#8217;s prior written approval.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.3.4.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the event that Retrophin violates the FCPA or any applicable anti-corruption law or breaches any provision in this Section 9.3, Ligand shall have the right to unilaterally terminate this Agreement.&#160; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclaimer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW OF SUCH PARTY OR ANY LICENSE GRANTED BY SUCH PARTY HEREUNDER, OR WITH RESPECT TO ANY COMPOUNDS, INCLUDING BUT NOT LIMITED TO THE TRANSFERRED MATERIALS, OR PRODUCTS.  FURTHERMORE, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES THAT ANY PATENT, PATENT APPLICATION, OR OTHER PROPRIETARY RIGHTS INCLUDED IN PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW LICENSED BY SUCH PARTY TO THE OTHER PARTY HEREUNDER ARE VALID OR ENFORCEABLE OR THAT USE OF SUCH PATENT RIGHTS, CONFIDENTIAL INFORMATION OR KNOW-HOW CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.</font></div><div><font><br></font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitation of Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">DAMAGES (INCLUDING CONSEQUENTIAL DAMAGES CONSISTING OF LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS) AND, IN ANY CASE, LIGAND SHALL NOT BE LIABLE IN AN AMOUNT GREATER THAN THE AMOUNTS PAID BY RETROPHIN TO LIGAND UNDER ARTICLE 8 OF THIS AGREEMENT&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">PROVIDED</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">HOWEVER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, THAT THE FOREGOING SHALL NOT APPLY TO ANY BREACH BY RETROPHIN OF THE LICENSES GRANTED TO IT UNDER THIS AGREEMENT THAT IS AN INFRINGEMENT OF PATENT RIGHTS NOT INCLUDED IN THE PATENT RIGHTS LICENSED TO RETROPHIN HEREUNDER, OR ANY BREACH BY EITHER PARTY OF THIS ARTICLE 9  OR ARTICLE 11 HEREOF.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OWNERSHIP&#59; PATENT MAINTENANCE&#59; INFRINGEMENT&#59; EXTENSIONS</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ownership of Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Inventorship of inventions conceived or reduced to practice in the course of activities performed under or contemplated by this Agreement shall be determined by application of United States patent Laws pertaining to inventorship. If such inventions are jointly invented by one or more employees, consultants or contractors of each Party, such inventions shall be jointly owned (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Invention</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and if one or more claims included in an issued patent or pending patent application which is filed in a patent office in the Territory claim such Joint Invention, such claims shall be jointly owned (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Joint Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). If such an invention is solely invented by an employee, consultant or contractor of a Party, such invention shall be owned by such Party, and any patent filed claiming such solely owned invention shall also be owned by such Party. Subject to Section 5.6 with respect to contractors, each Party shall enter into binding agreements obligating all employees, consultants and contractors performing activities under or contemplated by this Agreement, including activities related to the Patent Rights, Licensed Compounds or Licensed Products, to assign his&#47;her interest in any invention conceived or reduced to practice in the course of such activities to the Party for which such employee, consultant or contractor is providing its services. This Agreement shall be understood to be a joint research agreement in accordance with 35 U.S.C. &#167; 103(c)(3) to develop the Licensed Compounds and Licensed Products. The filing, prosecution, maintenance and enforcement of Joint Patent Rights which are Core Patent Rights shall be handled in accordance with this Article 10.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Filing, Prosecution and Maintenance of Core Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall be responsible, using outside patent counsel selected by Retrophin and acceptable to Ligand, such acceptance not to be unreasonably withheld or delayed, for the preparation, prosecution (including, without limitation, any interferences, reissue proceedings and reexaminations) and maintenance of Core Patent Rights.  Promptly following the Effective Date, the Parties shall cooperate to expeditiously transfer such responsibility for the further preparation, prosecution and maintenance of Core Patent Rights to such outside patent counsel.  Retrophin shall be responsible for all costs incurred by Retrophin with respect to such preparation, prosecution and maintenance of Core Patent Rights so long as Retrophin remains responsible for such preparation, prosecution and maintenance.  Upon request by Ligand, Retrophin (or its patent counsel) shall provide Ligand with an update of the filing, prosecution and maintenance status for each of the Core Patent Rights.  Each Party shall reasonably consult with and cooperate with the other Party with respect to the preparation, prosecution and maintenance of the Core Patent Rights reasonably prior to any deadline or action with the U.S. Patent &#38; Trademark Office or any foreign patent office, and Retrophin (or its patent counsel) shall furnish to Ligand copies of all relevant documents reasonably in advance of such consultation.  Retrophin (or its patent counsel) shall provide to Ligand </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">copies of any papers relating to the filing, prosecution or maintenance of the Core Patent Rights promptly upon their being filed or received.  Retrophin shall not knowingly take any action during prosecution and maintenance of the Core Patent Rights that would materially adversely affect them (including any reduction in claim scope), without Ligand&#8217;s prior consent, such consent not to be unreasonably withheld, conditioned or delayed.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Abandonment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Generally</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In no event will Retrophin knowingly permit any of the Core Patent Rights to be abandoned in any country in the Territory or elect not to file a new patent application claiming priority to a patent application within the Core Patent Rights either before such patent application&#8217;s issuance or within the time period required for the filing of an international (i.e., Patent Cooperation Treaty), regional (including European Patent Office) or national application, without Ligand first being given an opportunity to assume full responsibility for the continued prosecution and maintenance of such Core Patent Rights, or the filing of such new patent application.  Accordingly, Retrophin (or its patent counsel) shall provide Ligand with notice of the allowance and expected issuance date of any patent within the Core Patent Rights, or any of the aforementioned filing deadlines, and Ligand shall provide Retrophin with prompt notice as to whether Ligand desires Retrophin to file such new patent application.  In the event that Retrophin decides either (i) not to continue the prosecution or maintenance of a patent application or patent within Core Patent Rights in any country or (ii) not to file such new patent application requested to be filed by Ligand, Retrophin shall provide Ligand with notice of this decision at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days prior to any pending lapse or abandonment thereof.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ligand Option to Assume Responsibility</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall thereupon have the right, but not the obligation, to assume responsibility for all reasonably documented external costs (subject to Section 10.3.3) thereafter incurred associated with the filing and&#47;or further prosecution and maintenance of such patents and patent applications, on a patent-by-patent and country-by-country basis.  The outside patent counsel selected by Retrophin shall proceed with such filing and&#47;or further prosecution and maintenance promptly upon receipt of written notice from Ligand of its election to assume such responsibility, with such filing to occur prior to the issuance of the patent to which the application claims priority or expiration of the applicable filing deadline, as set forth above.  In the event that Ligand assumes such responsibility for such filing, prosecution and maintenance costs (subject to Section 10.3.3), upon the reasonable request by Ligand, Retrophin shall transfer the responsibility for such filing, prosecution and maintenance of such patent applications and patents to outside patent counsel selected by Ligand&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall (i) provide sufficient written notice to Ligand of any such election such that the relevant transfer shall not prejudice the filing, prosecution and&#47;or maintenance of patent rights (where possible, such notice shall be provided at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> days prior to any pending lapse or abandonment thereof)&#59; (ii) transfer or cause to be transferred to Ligand or its patent counsel the complete prosecution file for the relevant patents and patent applications, including all correspondence and filings with patent authorities with respect thereto&#59; and (iii) at the reasonable request of Ligand and without demanding any further consideration therefore, do all things necessary, proper or advisable, including without limitation the execution, acknowledgment and recordation of specific assignments, oaths, declarations and other documents on a country-by-country basis, to assist Ligand in obtaining, perfecting, sustaining and&#47;or enforcing such patent(s).  Such patent applications and patents shall </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other Core Patent Rights, as applicable.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Retrophin Responsibility for Patent Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary under this Article 10, unless the Parties otherwise agree in writing, Retrophin shall remain responsible for all costs incurred after the Effective Date with respect to preparation, prosecution and maintenance of the Core Patent Rights covering Licensed Compounds.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement of Core Patent Rights Against Infringers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement by Retrophin.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the event that Ligand or Retrophin becomes aware of a suspected infringement of any Core Patent Right exclusively licensed to Retrophin under this Agreement, such Party shall notify the other Party promptly, and following such notification, the Parties shall confer.  Retrophin shall have the right, but shall not be obligated, to bring an infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control, subject to the following.  Ligand shall reasonably assist Retrophin (at Retrophin&#8217;s expense) in any action or proceeding being prosecuted if so requested, and shall lend its name to and join as a nominal party in such actions or proceedings if reasonably requested by Retrophin or required by applicable Laws.  Ligand shall have the right to participate and be represented in any such suit by its own counsel at its own expense.  No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Core Patent Right may be entered into by Retrophin without the prior written consent of Ligand, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ligand shall have the right at its discretion to grant to Retrophin such rights (including assignment of the applicable Core Patent Rights) as may be necessary for Retrophin to exercise its rights under this Section 10.4 (including defending or enforcing any Core Patent Rights) without Ligand&#8217;s involvement.  In the event of such grant of rights (including assignment) with respect to any Core Patent Rights, such Core Patent Rights shall continue to be treated as Core Patent Rights and shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other applicable Core Patent Rights.  For purposes of clarity, election or non-election by Ligand to grant or assign rights to Retrophin under this Section 10.4.1(b) shall not limit Ligand&#8217;s obligations under Section 10.4.1(a) to reasonably assist Retrophin in any action or proceeding, or to join in such action or proceeding upon request by Retrophin if such joinder is necessary under applicable Laws for Retrophin to exercise its rights under this Section 10.4.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement by Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If Retrophin elects not to bring any action for infringement described in Section 10.4.1 and so notifies Ligand, then Ligand may bring such action at its own expense, in its own name and entirely under its own direction and control, subject to the following.  Retrophin shall reasonably assist Ligand (at Ligand&#8217;s expense) in any action or proceeding being prosecuted if so requested, and shall lend its name to such actions or proceedings if requested by Ligand or required by applicable Laws.  Retrophin shall have the right to participate and be represented in any such suit by its own counsel at its own expense.  No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Core </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Patent Right may be entered into by Ligand without the prior written consent of Retrophin, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Withdrawal</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If either Party brings an action or proceeding under this Section 10.4 and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 10.4.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.4.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Damages</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that either Party exercises the rights conferred in this Section 10.4 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If such recovery is insufficient </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If after such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any funds shall remain from such damages or other sums recovered, such funds shall be </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">under this Section 10.4&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Patent Term Extension</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand and Retrophin shall each cooperate with one another and shall use commercially reasonable efforts in obtaining patent term extension (including without limitation, any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to patent rights covering the Licensed Products.  If elections with respect to obtaining such patent term extensions are to be made, Retrophin shall have the right to make the election to seek patent term extension or supplemental protection&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> such election will be made so as to maximize the period of marketing exclusivity for the Licensed Product.  For such purpose, for all Approvals Retrophin shall provide Ligand with written notice of any expected Approval at least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days prior to the expected date of Approval, as well as notice within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> business days of receiving each Approval confirming the date of such Approval.  Notification of the receipt of an Approval shall be in accordance with Section 15.2. </font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Data Exclusivity and Orange Book Listings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.6.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With respect to data exclusivity periods (such as those periods listed in the FDA&#8217;s Orange Book (including without limitation any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001&#47;EC&#47;83, and all international equivalents), Retrophin shall use commercially reasonable efforts consistent with its obligations under applicable Law to seek, maintain and enforce all such data exclusivity periods available for the Licensed Products.  With respect to filings in the FDA Orange Book (and foreign equivalents) for issued patents for a Licensed Product, Retrophin shall, consistent with its obligations under applicable Law, list in a timely manner and maintain all applicable Core Patent Rights and other patents Controlled by Retrophin required to be filed by it, or that it is permitted to file, under applicable Law.  At least </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> days prior to an anticipated deadline for the filing of patent listing information for Core Patent Rights, Retrophin will consult with Ligand regarding the content of such filing.  In the event of a dispute between the Parties as to whether a Core Patent Right can be filed and&#47;or the content of such filing, the Parties will take expedited steps to resolve the dispute as promptly as possible, including seeking advice of an independent legal counsel to guide their decision.  Ligand shall use commercially reasonable efforts consistent with its obligations under applicable Law to provide reasonable cooperation to Retrophin in filing and maintaining such Orange Book (and foreign equivalent) listings.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.6.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Without limiting the foregoing, Ligand shall have the right at its discretion to grant to Retrophin such rights (including assignment of the applicable Core </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Patent Rights) as may be necessary for Retrophin to exercise its rights under this Section 10.6 (including seeking, maintaining and enforcing all data exclusivity periods) without Ligand&#8217;s involvement.  In the event of such grant of rights (including assignment) with respect to any Core Patent Rights, such Core Patent Rights shall continue to be treated as Core Patent Rights and shall otherwise continue to be subject to all of the terms and conditions of the Agreement in the same way as the other applicable Core Patent Rights.  For purposes of clarity, election by Ligand to grant or assign rights to Retrophin under this Section 10.6.2 shall not limit Ligand&#8217;s obligation under Section 10.6.1 to provide reasonable cooperation to Retrophin to the extent such cooperation is reasonably necessary for Retrophin in filing and maintaining such Orange Book (and foreign equivalent) listings.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notification of Patent Certification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party shall notify and provide the other Party with copies of any allegations of alleged patent invalidity, enforceability or non-infringement of a Core Patent Right pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated NDA, an application under &#167;505(b)(2) or other similar patent certification by a Third Party, and any foreign equivalent thereof.  Such notification and copies shall be provided to the other Party within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after such Party receives such certification, and shall be sent to the address set forth in Section 15.2.  In addition, upon request by Ligand, Retrophin shall provide reasonable assistance and cooperation (including, without limitation, making available to Ligand documents possessed by Retrophin that are reasonably required by Ligand and making available personnel for interviews and testimony) in any actions reasonably undertaken by Ligand to contest any such patent certification.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NONDISCLOSURE OF CONFIDENTIAL INFORMATION</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Nondisclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party agrees that, for so long as this Agreement is in effect and for a period of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">years thereafter, a Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Receiving Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) receiving or possessing Confidential Information of the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disclosing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) (or that has received any such Confidential Information from the other Party prior to the Effective Date) shall (i) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event shall the Receiving Party use less than a reasonable standard of care, (ii) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this clause (iii) shall not create or imply any rights or licenses not expressly granted hereunder).</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confidentiality of Know-How for Disclosure Purposes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  During such time as the license to the Know-How granted under Section 2.1 is in effect, solely for disclosure purposes to Third Parties, the Know-How shall be deemed to be Confidential Information of Ligand and Retrophin under Article 11, Ligand and Retrophin shall be deemed to be a Disclosing Party of the Know-How under Article 11, and Ligand and its respective Affiliates shall be deemed not to have known such Know-How prior to disclosure for the purposes of Section 11.1.2(b).  Other than for disclosure purposes to Third Parties, the Know-How shall solely be the Confidential Information of Ligand.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exceptions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The obligations in Section 11.1 shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof&#58;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder&#59;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party&#59; </font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use&#59; </font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party&#59; or</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has been independently developed after disclosure by the Disclosing Party by employees or contractors of the Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Authorized Disclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances&#58; </font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">filing or prosecuting patents&#59;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">regulatory filings&#59;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">prosecuting or defending litigation&#59;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">subject to Section 11.4, complying with applicable governmental Laws and regulations (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party&#8217;s counsel, such disclosure is necessary for such compliance&#59; and</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">disclosure (i) in connection with the performance of this Agreement and solely on a &#8220;need to know basis&#8221; to Affiliates, potential or actual collaborators (including potential Sublicensees) or employees, contractors or agents&#59; or (ii) solely on a &#8220;need to know basis&#8221; to potential or actual investment bankers, investors, lenders, or acquirers&#59; each of whom in the case of clause (i) or (ii) prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 11&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Article 11 to treat such Confidential Information as required under this Article 11.  </font></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If and whenever any Confidential Information is disclosed in accordance with this Section 11.2, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">disclosure of such information (otherwise than by breach of this Agreement).  Where reasonably possible and subject to Section 11.4, the Receiving Party shall notify the Disclosing Party of the Receiving Party&#8217;s intent to make such disclosure pursuant to paragraphs (r) through (v) of this Section 11.2 sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Terms of this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Securities Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable Laws, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing not less than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">business days prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to this Agreement and shall use reasonable efforts to obtain confidential treatment of any information concerning this Agreement that such other Party requests be kept confidential and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed.  No such notice shall be required under this Section 11.4 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the other Party hereunder or otherwise approved by the other Party.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Publication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.5.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Publication by Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand may publish or present data and&#47;or results relating to a Licensed Compound or Licensed Product in scientific journals and&#47;or at scientific conferences, subject to the prior review, comment and approval by Retrophin as follows.  Ligand shall provide Retrophin with the opportunity to review any proposed abstract, manuscript or presentation which discloses information relating to a Licensed Compound or Licensed Product by delivering a copy thereof to Retrophin no less than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days before its intended submission for publication or presentation.  Retrophin shall have twenty (20) days from its receipt of any such abstract, manuscript or presentation in which to notify Ligand in writing of any specific objections to the disclosure.  In the event Retrophin objects to the disclosure in writing within such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day period, Ligand agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the proposed disclosure and Ligand shall delete from the proposed disclosure any Retrophin Confidential Information or Know-How or the identity of any Licensed Compound or Licensed Product, or any information relating to the Licensed Compound or its improvements that could limit or jeopardize any rights of Retrophin, upon reasonable request by Retrophin.  Failure to object to the disclosure in writing within such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day period shall be deemed approval.  Once any such abstract or manuscript is accepted for publication, Ligand will provide Retrophin with a copy of the final version of the manuscript or abstract.  For clarification, this Section 11.5.1 shall not limit or restrict Ligand&#8217;s ability to publish or present publicly information on compounds which are not Licensed Compounds or Licensed Products, provided such publication or presentation does not contain Retrophin Confidential Information or identify any </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Licensed Compound or Licensed Product.  Retrophin acknowledges BMS&#8217; right to publish or otherwise publicly disclose any licensed BMS Know-How at any time.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Publication by Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin may publish or present data and&#47;or results relating to a Licensed Compound or Licensed Product in scientific journals and&#47;or at scientific conferences, subject to attribution to Ligand of any data generated by or on behalf of Ligand prior to the Effective Date as well as the prior review and comment by Ligand as follows.  Retrophin shall provide Ligand with the opportunity to review any proposed abstract, manuscript or presentation which discloses information relating to a Licensed Compound or Licensed Product by delivering a copy thereof to Ligand no less than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days before its intended submission for publication or presentation.  Ligand shall have </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days from its receipt of any such abstract, manuscript or presentation in which to notify Retrophin in writing of any specific objections to the disclosure, such objections to be limited to matters involving the disclosure of Ligand Confidential Information, or a good faith and documented concern by Ligand that such publication would otherwise result in material commercial harm to Ligand.  In the event Ligand objects to the disclosure in writing within such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day period, Retrophin agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the proposed disclosure, and Retrophin shall delete from the proposed disclosure any Ligand Confidential Information upon the reasonable request by Ligand.  The Parties agree to take all reasonable steps to address and resolve a notice of objection by Ligand within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days of receipt of such notice.  Once any such abstract or manuscript is accepted for publication, Retrophin will provide Ligand with a copy of the final version of the manuscript or abstract, a copy of which may be provided to BMS by Ligand. </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INDEMNITY</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Retrophin Indemnity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall indemnify, defend and hold harmless Ligand and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) or judgments, whether for money or equitable relief, of any kind, arising out of any claim, action, lawsuit or other proceeding brought by a Third Party (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Losses and Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) arising out of or relating, directly or indirectly, (i) to the research, Development, Commercialization (including promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, manufacture, labeling, handling or storage, or use of, or exposure to, any Licensed Compound and&#47;or any Licensed Product by or for Retrophin or any of its Affiliates, Sublicensees, agents and&#47;or contractors, (ii) to Retrophin&#8217;s (or its Affiliates&#8217; and&#47;or Sublicensees&#8217;) use and practice otherwise of the Patent Rights or Know-How, including claims based on (A) product liability, bodily injury, risk of bodily injury, death or property damage, (B) infringement or misappropriation of Third Party patents, copyrights, trademarks or other intellectual property rights or (C) the failure to comply with applicable Laws related to the matters referred to in the foregoing clauses (i) and (ii) with respect to any Licensed Compound and&#47;or any Licensed Product, or (iii) Retrophin&#8217;s gross negligence, recklessness or willful misconduct or Retrophin&#8217;s material breach of any representation, warranty or covenant set forth in this Agreement&#59; except in any such case for Losses and Claims to the extent reasonably attributable to Ligand having committed an act or acts of gross negligence, recklessness or willful </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">misconduct or having materially breached any representation or warranty set forth in this Agreement.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Ligand Indemnity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall indemnify, defend and hold harmless Retrophin and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all Losses and Claims arising out of or relating, directly or indirectly to (i) Ligand&#8217;s gross negligence, recklessness or willful misconduct or (ii) Ligand&#8217;s material breach of any representation, warranty or covenant set forth in this Agreement&#59; except in any such case for Losses and Claims to the extent reasonably attributable to Retrophin having committed an act or acts of gross negligence, recklessness or willful misconduct or having materially breached any representation or warranty set forth in this Agreement.  For the avoidance of doubt, &#8220;Ligand&#8217;s gross negligence, recklessness or willful misconduct&#8221; shall not include any acts or omissions on the part of any Third Parties, including Ligand&#8217;s clinical research organization, Cetero Research.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification Procedure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  A claim to which indemnification applies under Section 12.1 or Section 12.2 shall be referred to herein as an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.  If any Person or Persons (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) intends to claim indemnification under this Article 12, the Indemnitee shall notify the other Party (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnitor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice).  The Indemnitor shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings.  If the Indemnitor does not assume the defense of the Indemnification Claim as aforesaid, the Indemnitee may defend the Indemnification Claim but shall have no obligation to do so.  The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an adverse effect on the Indemnitee&#8217;s interests (including any rights under this Agreement or the scope or enforceability of the Patents Rights or Know-How), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld or delayed.  The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor&#8217;s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 11.</font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall, beginning with the initiation of the first clinical trial for a Licensed Product, maintain at all times thereafter during the term of the Agreement, and until the later of (i) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (ii) the date </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, comprehensive general liability insurance from a recognized, creditworthy insurance company, on a claims-made basis, with endorsements for contractual liability and product liability, and with coverage limits of not less than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The minimum level of insurance set forth herein shall not be construed to create a limit on Retrophin&#8217;s liability hereunder.  Within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following written request from Ligand, Retrophin shall furnish to Ligand a certificate of insurance </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">evidencing such coverage as of the date.  Retrophin shall use commercially reasonable efforts to cause such certificate of insurance, as well as any certificates evidencing new coverages of Retrophin, to include a provision whereby </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">written notice shall be received by Ligand prior to coverage cancellation by either Retrophin or the insurer and of any new coverage.  In the case of a cancellation of such coverage, Retrophin shall promptly provide Ligand with a new certificate of insurance evidencing that Retrophin&#8217;s coverage meets the requirements in the first sentence of this Section 12.4.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TERM AND TERMINATION</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall continue until neither Party has any obligation under this Agreement to make payments to the other Party.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination By Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Insolvency</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement, at Ligand&#8217;s sole discretion, upon delivery of written notice to Retrophin upon the filing by Retrophin in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of Retrophin or its assets, or if Retrophin is served with an involuntary petition against it in any insolvency proceeding, upon the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day after such service if such involuntary petition has not previously been stayed or dismissed, or upon the making by Retrophin of an assignment of substantially all of its assets for the benefit of its creditors.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to Section 13.2.4 below, Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement, at Ligand&#8217;s sole discretion, upon delivery of written notice to Retrophin in the event of any material breach by Retrophin of any terms and conditions of this Agreement (other than failure to use Commercially Reasonable Efforts to Develop or Commercialize the Licensed Compounds and a Licensed Product, which breach is covered under Section 13.2.3)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> such breach has not been cured within forty-five (45) days after written notice thereof is given by Ligand to Retrophin specifying the nature of the alleged breach&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that to the extent such material breach involves the failure to make a payment when due, such breach must be cured within twenty (20)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after written notice thereof is given by Ligand to Retrophin.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Failure to Use Commercially Reasonable Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to Section 13.2.4 below, Ligand shall have the right to terminate this Agreement with respect to any or all licenses granted to Retrophin pursuant to Article 2 of this Agreement on a country-by-country basis (except as otherwise set forth in this Section 13.2.3), at Ligand&#8217;s sole discretion, in the event that Retrophin (a) fails to use Commercially Reasonable Efforts (by itself or through its Affiliates or Sublicensees) to Develop and Commercialize at least one (1) Licensed Compound and Licensed Product or (b) fails to comply with the specific diligence obligations set forth in Sections 6.1.2 and 6.1.3 of this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Retrophin has not exercised such Commercially Reasonable Efforts or complied with such specific diligence obligations in the applicable </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">country or countries within sixty (60) days following written notice by Ligand.  For clarity, it is understood and acknowledged that Commercially Reasonable Efforts in the Development of a Licensed Compound or Licensed Product in a particular country may include sequential implementation of clinical trials and&#47;or intervals between clinical trials for data interpretation and clinical program planning and any period associated with such program, to the extent such implementation is consistent with the scientific, technical and commercial factors relevant to Development of such Licensed Compound or Licensed Product in such country.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disputed Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If Retrophin disputes in good faith the existence or materiality of a breach specified in a notice provided by Ligand pursuant to Section 13.2.2, or a failure to use Commercially Reasonable Efforts specified in a notice provided by Ligand pursuant to Section 13.2.3, and Retrophin provides notice to Ligand of such dispute within the applicable forty-five (45) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day or sixty (60) day period, Ligand shall not have the right to terminate this Agreement unless and until the existence of such material breach or failure by Retrophin has been determined in accordance with Article 14 and Retrophin fails to cure such breach within sixty (60)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following such determination (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within five (5) Business Days following such determination).  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  The Parties further agree that any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute shall be promptly refunded if an arbitrator or court determines pursuant to Article 14 that such payments are to be refunded by one Party to the other Party.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination for </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms of this Section 13.2.5, Ligand shall have the right to terminate this Agreement (on a country-by-country or worldwide basis, as Ligand may elect), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in the event that (a) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event the Parties are unable to reach agreement regarding whether or not a compound is a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and the Parties have not resolved such dispute through good faith discussions, such dispute will be resolved through performance of the relevant scientific determination by an independent Third Party testing provider or other scientific expert who shall be mutually and reasonably selected by both Parties.  The findings of such Third Party scientific expert with respect to such dispute shall be binding on the Parties, and the costs of such testing shall be borne by the Party whom the independent determination does not favor.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.2.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination of Upstream License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to Section 13.5.1, if the Upstream License Agreement, in whole or in part, is terminated for any reason, the corresponding rights granted to Retrophin shall be terminated effective upon termination of the Upstream License Agreement.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Retrophin may terminate this Agreement in the event of material breach by Ligand&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that such breach has not been cured within</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">sixty (60)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after written notice thereof is given by Retrophin to Ligand.  Notwithstanding the foregoing, if Ligand disputes in good faith the existence or materiality of such breach and provides notice to Retrophin of such dispute within such sixty (60)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">day period, Retrophin shall not have the right to terminate this Agreement in accordance with this Section 13.3 unless and until it has been determined in accordance with Article 14 that this Agreement was materially breached by Ligand and Ligand fails to cure such breach </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">within sixty (60)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following such determination.  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.  The Parties further agree that any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute shall be promptly refunded if an arbitrator or court determines pursuant to Article 14 that such payments are to be refunded by one Party to the other Party.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Effect of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon termination of this Agreement or any right or license pursuant to Section 13.2.1, 13.2.2, 13.2.3 or 13.2.5, the rights and obligations of the Parties shall be as set forth in this Section 13.4.</font></div><div style="text-indent:63pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Upon termination of this Agreement, either in its entirety or with respect to one or more applicable countries (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Terminated Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) pursuant to Section 13.2.1, 13.2.2, 13.2.3 or 13.2.5 hereof (the rights and obligations of the Parties as to the remaining countries of the Territory in which termination under Section 13.2.3 or 13.2.5 has not occurred, being unaffected by such termination), the following shall apply&#58;</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All amounts due or payable to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall remain due and payable.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Should Retrophin have </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Retrophin shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Should Retrophin have </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If Retrophin has the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin shall </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin hereby</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Neither Party shall be relieved of any obligation that accrued prior to the effective date of such termination or expiration.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">l)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each Party shall have the right to retain all amounts previously paid to it by the other Party, subject to any applicable determination of an arbitrator or court pursuant to Article 14.</font></div><div style="text-indent:72pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">m)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">It is understood and agreed that Ligand shall be entitled to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">as a remedy to enforce the provisions of this Section 13.4, in addition to any other remedy to which it may be entitled by applicable Law.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination by BMS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13.5.1  Any rights granted by Ligand pursuant to this Agreement shall terminate on a country-by-country and Licensed Product-by-Licensed Product basis effective upon termination under Section 13.2 of the Upstream License Agreement with respect to such sublicensed rights&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that such sublicensed rights shall not </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">terminate if, as of the effective date of such termination by BMS under Section 13.2 of the Upstream License Agreement, Retrophin is not in material breach of its obligations to Ligand under this Agreement, and within sixty (60)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days of such termination Retrophin agrees in writing to be bound directly to BMS under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder, substituting Retrophin for Ligand.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13.5.2&#160; BMS may terminate the Upstream License Agreement where (a) Retrophin or its Affiliate (alone or in collaboration with a Third Party) undertakes the clinical development of a product that contains a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">prior to the first U.S. NDA Approval being obtained for a Licensed Compound or (b) Retrophin or its Affiliate (alone or in collaboration with a Third Party) markets a product that contains a </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> years following the first U.S. NDA Approval for a Licensed Product.  </font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Scope of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as otherwise expressly provided herein, termination of this Agreement shall be as to all countries in the Territory and all Licensed Compounds and Licensed Products.</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The following provisions shall survive termination or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination&#58; Article 1 (as applicable), Article 5 (with respect to obligations arising prior to expiration or termination of this Agreement), Article 8 (with respect to obligations arising prior to expiration or termination of this Agreement), Section 9.4, Section 9.5, Section 10.1, 10.4.4 (with respect to an action, suit or proceeding commenced prior to termination), Section 10.7, Article 11, Article 12 (with respect to Losses and Claims arising from activities and breaches that take place prior to expiration or termination of this Agreement), this Section 13.6(i), Section 13.7, Article 14 and Article 15.  Termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, subject to Article 14, with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any obligation.  All other obligations shall terminate upon expiration of this Agreement.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties agree that in the event a Party becomes a debtor under Title 11 of the U.S. Code (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Title 11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), this Agreement shall be deemed to be, for purposes of Section 365(n) of Title 11, a license to rights to &#8220;intellectual property&#8221; as defined therein.  Each Party as a licensee hereunder shall have the rights and elections as specified in Title 11.  Any agreements supplemental hereto shall be deemed to be &#8220;agreements supplementary to&#8221; this Agreement for purposes of Section 365(n) of Title 11.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DISPUTE RESOLUTION&#59; ARBITRATION</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Dispute Resolution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties agree that the procedures set forth in this Section 14.1 shall be the exclusive mechanism for resolving any bona fide disputes, controversies or claims (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Disputes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) between the Parties that arise from time to time pursuant to this Agreement relating to any Party&#8217;s rights and&#47;or obligations hereunder that cannot be resolved through good faith negotiation between the Parties.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Executive Mediation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any Dispute shall first be referred to an Executive from each Party for attempted resolution by good faith negotiations.  Any such Dispute shall be submitted to such Executives no later than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days following such request by </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">either Party.  Such Executives shall attempt in good faith to resolve any such Dispute within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after submission of the Dispute.  In the event the Executives are unable to resolve the Dispute, the Parties shall otherwise negotiate in good faith and use reasonable efforts to settle.  </font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If the Parties are not able to fully settle a Dispute pursuant to Section 14.2 above, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim or subject to expedited arbitration in accordance with Section 14.4 below, shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">AAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and judgment on the arbitration award may be entered in any court having jurisdiction thereof&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Federal Rules of Evidence shall apply with regard to the admissibility of evidence in such hearing.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The arbitration shall be conducted by a panel of three persons experienced in the pre-clinical and clinical stage pharmaceutical business.  Within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> days of their appointment.  If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA.  In any case the arbitrator shall not be an Affiliate, employee, consultant, officer, director or stockholder of either Party, or otherwise have any current or previous relationship with either Party or their respective Affiliates.  The Parties shall have the right to be represented by counsel.  The place of arbitration shall be New York, NY.  All proceedings and communications shall be in English.  </font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.  Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award.  The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s compensatory damages.  Each Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except to the extent necessary to confirm an award or as may be required by Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.  In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The arbitrators shall use their commercially reasonable efforts to rule on each disputed issue within days after completion of the hearing described in Section 14.3. The determination of the arbitrators as to the resolution of any dispute shall be binding and conclusive upon all Parties. All rulings of the arbitrator shall be in writing and shall be delivered to the Parties except to the extent that the Commercial Arbitration Rules of the AAA provide otherwise. Nothing contained herein shall be construed to permit the arbitrator to award punitive, exemplary or any similar damages.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The (i) attorneys&#8217; fees of the Parties in any arbitration, (ii) fees of the arbitrator and (iii) costs and expenses of the arbitration shall be borne by the Parties in a proportion determined by the arbitrator.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.3.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For all Excluded Claims, the Parties hereby submit to the exclusive jurisdiction of the Supreme Court of the State of New York, New York County and the United States District Court for the Southern District of New York.  For clarity, each party may seek injunctive or other equitable relief for Excluded Claims in accordance with this Section 14.3.7.  Each Party agrees that service of any process, summons, notice or document by personal delivery, by registered mail, or by a recognized international express delivery service to such Party&#8217;s respective address set forth in Section 15.2 shall be effective service of process for any action, suit or proceeding in the district court or state court with respect to any matters to which it has submitted to jurisdiction in this Section 14.3.7.  Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the district court or state court, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.  Each Party hereto also hereby waives to the fullest extent permitted by applicable Laws, any right it may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement.  Each Party hereto (i) certifies that no representative, agent or attorney of the other Party has represented, expressly or otherwise, that such other Party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges that it and the other Party hereto have been induced to enter into this Agreement, as applicable, by, among other things, the mutual waivers and certifications in this Section 14.3.7.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Expedited Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Parties agree that it is important to be able to clarify any disputes regarding </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">quickly. Accordingly, if&#58; (i) Ligand </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; (ii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; or (iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> &#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; then the Parties shall resolve such dispute in accordance with this Section 14.4. Arbitration under this Section 14.4 shall be conducted in the same manner and subject to the same terms and conditions as arbitration under Section 14.3, provided that&#58; (i) the Parties shall designate in writing a single arbitrator within fifteen (15) days of written notice of the dispute&#59; (ii) the arbitrator and the Parties shall meet, and each Party shall provide to the arbitrator a written summary of all disputed issues, such Party&#8217;s position on such disputed issues and such Party&#8217;s proposed ruling on the merits of each such issue within fifteen (15) days after the designation of the arbitrator&#59; (iii) the arbitrator shall use his or her commercially reasonable efforts to rule on each disputed issue within fifteen (15) days after completion of the hearing described in Section 14.3&#59; (d) the arbitrator shall select one of the requested positions as his decision, and shall not have the authority to render any substantive decision other than to so select the position of either Ligand or Retrophin&#59; and (e) the Parties shall use good faith efforts to complete any expedited arbitration pursuant to this Section 14.4 promptly.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MISCELLANEOUS</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any notice required or permitted to be given by this Agreement shall be in writing and shall be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by first class, registered or certified mail addressed as set forth below unless changed by notice so given&#58;</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Ligand&#58;</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ligand Pharmaceuticals Incorporated</font></div><div style="padding-left:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11085 North Torrey Pines Road, Suite 300 </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">La Jolla, CA 92037</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  General Counsel</font></div><div style="text-indent:63pt;"><font><br></font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With a copy to (which shall not constitute notice hereunder)&#58;</font></div><div style="text-indent:63pt;text-align:justify;"><font><br></font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Latham &#38; Watkins LLP</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12636 High Bluff Drive, Suite 400</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">San Diego, CA 92130</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Faye H. Russell, Esq.</font></div><div style="text-indent:63pt;"><font><br></font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Retrophin&#58;</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin LLC</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">330 Madison Avenue, 6</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Floor</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, NY 10017</font></div><div style="text-indent:63pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Martin Shkreli</font></div><div style="text-indent:63pt;"><font><br></font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With a copy to (which shall not constitute notice hereunder)&#58;</font></div><div style="text-indent:63pt;text-align:justify;"><font><br></font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Katten Muchin Rosenman LLP</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">575 Madison Avenue</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, NY 10022</font></div><div style="text-indent:63pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  Evan L. Greebel, Esq.</font></div><div style="text-indent:63pt;"><font><br></font></div><div style="text-indent:63pt;"><font><br></font></div><div style="text-indent:63pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any such notice shall be deemed given on the date received.  A Party may add, delete, or change the person or address to whom notices should be sent at any time upon written notice delivered to the Party&#8217;s notices in accordance with this Section 15.2.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder (including, without limitation Sections 6.1.2 and 6.1.3 of this Agreement) if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest or intervention of any governmental authority (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the affected Party promptly notifies the other Party and further provided that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence and shall continue performance with the utmost dispatch whenever such causes are removed.  When such circumstances arise, the Parties shall negotiate in good faith any </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.</font></div><div style="text-indent:36pt;padding-left:27pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.4.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ligand may, without Retrophin&#8217;s consent, assign or transfer all of its rights and obligations hereunder, in connection with any transfer of all of the Patent Rights and Know-How, to any Affiliate of Ligand or to any Third Party (including a successor in interest)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such assignee or transferee agrees in writing to be bound by the terms of this Agreement.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.4.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Retrophin may assign or transfer all of its rights and obligations hereunder without consent to an Affiliate of Retrophin or to a successor in interest by reason of merger, consolidation or sale of all or substantially all of the assets of Retrophin&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that (i) Retrophin&#8217;s rights and obligations under this Agreement shall be assumed by its successor in interest and shall not be transferred separate from all or substantially all of its other business assets, (ii) such assignment includes all Approvals and all rights and obligations under this Agreement, (iii) such successor in interest or Affiliate shall have agreed prior to such assignment or transfer to be bound by the terms of this Agreement in writing and (iv) where this Agreement is assigned or transferred to an Affiliate, Retrophin remains responsible for the performance of this Agreement.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.4.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Subject to the foregoing, this Agreement shall inure to the benefit of and be binding on the Parties&#8217; successors and assigns.  Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Further Assurances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party agrees to do and perform all such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Waivers and Modifications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.  Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion.  No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by all Parties hereto.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Choice of Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Publicity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties agree to issue a press release regarding the execution of this Agreement, in a form to be mutually agreed upon by the Parties.  Subject to the provisions of Sections 11.2, 11.4 and 11.5, each Party agrees not to issue any other press release or public statement disclosing the existence of this Agreement or any other information relating to this Agreement, the other Party, or the transactions contemplated </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">hereby without the prior written consent of the other Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that any disclosure which is required by applicable Laws or the rules of a securities exchange, as reasonably advised by the disclosing Party&#8217;s counsel, may be made subject to the following.  The Parties agree that any such required disclosure will not contain confidential business or technical information and, if disclosure of confidential business or technical information is required by applicable Laws, the Parties will use appropriate diligent efforts to minimize such disclosure and obtain confidential treatment for any such information which is disclosed to a governmental agency.  Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release.  Except under extraordinary circumstances, or as otherwise required under applicable Laws or the rules of a securities exchange, each Party shall provide the other with an advance copy of any such announcement at least forty eight (48) hours prior to its scheduled release.  Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by applicable Laws or the rules of a securities exchange, the Party whose announcement has been reviewed shall remove any Confidential Information of the reviewing Party that the reviewing Party reasonably deems to be inappropriate for disclosure.  The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval.  Nothing in this Section 15.8 shall be construed to prohibit Retrophin or its Affiliates or Sublicensees from making a public announcement or disclosure regarding the stage of development of Licensed Products in Retrophin&#8217;s (or its Affiliates&#8217; or Sublicensees&#8217;) product pipeline or disclosing clinical trial results regarding such Licensed Products, as may be required by applicable Laws or the rules of a securities exchange, as reasonably advised by Retrophin&#8217;s (or its Affiliates&#8217; or Sublicensees&#8217;) counsel.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Relationship of the Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each Party is an independent contractor under this Agreement.  Nothing contained herein is intended or is to be construed so as to constitute Ligand and Retrophin as partners, agents or joint venturers.  Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Headings and captions are for convenience only and are not be used in the interpretation of this Agreement.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement (including all Appendices attached hereto, which are incorporated herein by reference) (i) sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto, (ii) constitutes and contains the complete, final and exclusive understanding and agreement of the Parties with respect to the subject matter herein and (iii) cancels, supersedes and terminates all prior agreements and understanding between the Parties with respect to the subject matter hereof.  For the avoidance of doubt, the confidentiality agreement entered into by Ligand and Retrophin effective as of December 11, 2011 (the &#8220;Confidentiality Agreement&#8221;) shall remain in effect with respect to all Confidential Information (as that term is defined in the Confidentiality Agreement) disclosed by the Parties that does not pertain to the subject matter of this Agreement.  All Confidential Information (as that term is defined in the Confidentiality Agreement) pertaining to the subject matter of this Agreement disclosed to Ligand by Retrophin under the Confidentiality Agreement shall be considered Confidential Information (as that term is defined in this Agreement) of Retrophin disclosed under this Agreement and shall be </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">subject to the terms and conditions of this Agreement&#59; and all Confidential Information (as that term is defined in the Confidentiality Agreement) pertaining to the subject matter of this Agreement disclosed to Retrophin by Ligand under the Confidentiality Agreement shall be considered Confidential Information (as that term is defined in this Agreement) of Ligand disclosed under this Agreement and shall be subject to the terms and conditions of this Agreement.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, whether oral or written, between the Parties other than as set forth herein.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin agrees not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control Laws.</font></div><div style="text-indent:63pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Interpretation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:81pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.14.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel.  Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.14.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;  The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221;  The word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise clearly indicated by context.</font></div><div style="text-indent:72pt;padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.14.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to any Laws herein shall be construed as referring to such Laws as from time to time enacted, repealed or amended, (c) any reference herein to any person shall be construed to include the person&#8217;s successors and assigns, (d) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, and (e) all references herein to Articles, Sections </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:9pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or Appendices, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Appendices of this Agreement.</font></div><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">* * *</font></div><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;signature page follows&#93;</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the date first set forth above.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS&#160;RETROPHIN, LLC </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INCORPORATED &#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(&#8220;Ligand&#8221;)&#160;(&#8220;Retrophin&#8221;)</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Charles Berkman&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Martin Shkreli&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Charles Berkman&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Martin Shkreli&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;   Vice President, General Counsel and&#160;Title&#58;&#160;Chief Executive Officer</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Secretary</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Appendix 1</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Core Patent Rights</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.913%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.273%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.187%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.359%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.812%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.366%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.086%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.911%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Appendix 2</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Active Compound</font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Active Compound</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a compound that </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Appendix 3</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Development Plan</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(attached hereto)</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93; &#8211; EIGHT PAGES REDACTED</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Appendix 4</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Listed Compounds</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div id="if17ed8adb129402a9c42c19f8b48f219_4"></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">AMENDMENT TO </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SUBLICENSE AGREEMENT</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">THIS AMENDMENT TO SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of December 11, 2012 (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Amendment Effective Date&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) and amends the Sublicense Agreement effective as of February 16, 2012  (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Sublicense Agreement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;PCOP&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Ligand&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Floor, New York, NY, 10017 (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Retrophin&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">).  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">WHEREAS,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">NOW THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Capitalized Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.  </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">.  Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="text-indent:36pt;padding-left:216pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#8220;Table 1</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.177%;"><tr><td style="width:1.0%;"></td><td style="width:47.306%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.694%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Milestone Event</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Execution of Agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">$1.15 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">$1.15 million (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">&#8220;Second Milestone&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">)&#59; provided, that if the Second Milestone is received by Ligand prior to December 31, 2012, Retrophin shall make an additional $150,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.3 million) (the $150,000 additional payment, an </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">&#8220;Additional Payment&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">)</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;vertical-align:top;">1</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr></table></div><div style="text-align:justify;margin-bottom:11pt;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1)&#160;If the Second Milestone and any Additional Payment is not received by Ligand on or before December 31, 2012, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of December 31, 2012 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c), (k) and (m) related to amounts then due and payable. &#8220;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">Exit Transaction Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">. Section 8.2.2 of the Agreement is amended by replacing </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">Expedited Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">Section 14.4 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#8220;The Parties agree that it is important to be able to clarify any disputes regarding </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">quickly. Accordingly, if&#58; (i) Ligand </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#59; (ii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#59; (iii) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#59; or (iv) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%;">&#91;***&#93;&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">then the Parties shall resolve such dispute in accordance with this Section 14.4. Arbitration under this Section 14.4 shall be conducted in the same manner </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">and subject to the same terms and conditions as arbitration under Section 14.3, provided that&#58; (i) the Parties shall designate in writing a single arbitrator within fifteen (15) days of written notice of the dispute&#59; (ii) the arbitrator and the Parties shall meet, and each Party shall provide to the arbitrator a written summary of all disputed issues, such Party&#8217;s position on such disputed issues and such Party&#8217;s proposed ruling on the merits of each such issue within fifteen (15) days after the designation of the arbitrator&#59; (iii) the arbitrator shall use his or her commercially reasonable efforts to rule on each disputed issue within fifteen (15) days after completion of the hearing described in Section 14.3&#59; (iv) the arbitrator shall select one of the requested positions as his decision, and shall not have the authority to render any substantive decision other than to so select the position of either Ligand or Retrophin&#59; and (v) the Parties shall use good faith efforts to complete any expedited arbitration pursuant to this Section 14.4 promptly.&#8221;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">No Other Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(a)&#160;As used in this Clause, &#8220;Related Persons and Entities&#8221; in connection with a Party means any and all past, present, and future parents, subsidiaries, affiliates, partners, owners, joint venturers, stockholders, predecessors, successors, officers, members, directors, administrators, employees, agents, representatives, consultants, attorneys, insurers, heirs, executors, assignors or assignees, retirement plans (and&#47;or their trustees) of that Party and any other person, firm, or corporation with whom that Party is now or may hereinafter be affiliated, and any of them.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(b)&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby fully and forever, knowingly, voluntarily, and irrevocably release, acquit, discharge, and promises not to sue Ligand and its Related Persons and Entities, from, without limitation, any and all claims, demands, damages, obligations, losses, causes of action, costs, expenses, attorneys&#8217; fees, judgments, liabilities, duties, debts, liens, accounts, obligations, contracts&#47;agreements, promises, representations, actions, and causes of action, other proceedings and indemnities of any nature whatsoever arising from or in any way related to&#58; (i) the quality of the medication&#59; or (ii) compliance of the medication with specifications of Governmental Authorities delivered pursuant to the Sublicense Agreement&#59; or (iii) Ligand&#8217;s conduct during diligence and negotiations leading to the Sublicense Agreement, whether accrued or contingent, secured or unsecured, negligent or intentional, known or unknown, suspected or unsuspected, and whether based on law, equity, contract, tort, statute, or other legal or equitable theory of recovery, whether mature or to mature in the future, which from the beginning of time to the date of this Amendment, Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party had, now have, or claims to have against Ligand and its Related Persons and Entities, or any other person or entity described above. </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(c)&#160;Retrophin acknowledges that it may later discover material facts in addition to, or different from, those which it now knows or believes to be true.  Retrophin further acknowledges that there may be future events, circumstances or occurrences materially different from those it knows or believes likely to occur.  It is the intention of Retrophin to fully, finally and forever settle and generally release all claims, disputes and differences described above occurring prior to the date hereof.  </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">The releases provided in this Amendment shall remain in full effect notwithstanding the discovery or existence of any such additional or different facts or occurrence of any such future events, circumstances or conditions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;"> </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(d)&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby expressly waive the benefit of any statute or rule of law that, if applied to this Amendment would otherwise exclude from its binding effect any claims described above not known by it to exist which arose prior to the signing of this Amendment.  Retrophin acknowledges that it has read and fully understands the provisions of California Civil Code section 1542, which provides as follows&#58;</font></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="padding-left:72pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Retrophin, being aware of said Code Section, hereby expressly waives, on behalf of itself and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party, any rights and benefits that they may have under section 1542 of the California Civil Code to the full extent that they may lawfully waive such rights and benefits, and shall waive any rights and benefits they may have under any other statutes or common law principles of similar effect.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(e)&#160;This Amendment and its terms, including, but not limited to, the Release set forth in this Section 4, and the execution of this Amendment, shall not be construed as an admission of liability or fault by either of the Parties.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS &#160;&#160;&#160;RETROPHIN, INC.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">INCORPORATED</font></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Matthew Foehr&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Martin Shkreli&#160;&#160;&#160;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Title&#58; Vice President, Corporate Development&#160;Title&#58; Chief Executive Officer</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; 12&#47;20&#47;12&#160;&#160;&#160;&#160;&#160;Date&#58; 12&#47;19&#47;2012</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">AMENDMENT NO. 2 TO </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SUBLICENSE AGREEMENT</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">THIS AMENDMENT NO. 2 TO SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of January 7, 2013 (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Amendment Effective Date&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012  (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Sublicense Agreement&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;PCOP&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Ligand&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;vertical-align:top;">nd</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Floor, New York, NY, 10017 (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Retrophin&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">).  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">WHEREAS,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">NOW THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Capitalized Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.  </font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">.  Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="text-indent:36pt;padding-left:216pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">&#8220;Table 1</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:72pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.177%;"><tr><td style="width:1.0%;"></td><td style="width:47.306%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.694%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Milestone Event</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Execution of Agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">$1.15 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">The earlier of (a) March 31, 2013 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:2.25pt;padding-left:9pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">$1.3 million (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">&#8220;Second Milestone&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2013, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.2 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;">&#8220;Additional Payment&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">)</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;vertical-align:top;">1</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1)&#160;If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c), (k) and (m) related to amounts then due and payable.&#8221;</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">No Other Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(a)&#160;As used in this Clause, &#8220;Related Persons and Entities&#8221; in connection with a Party means any and all past, present, and future parents, subsidiaries, affiliates, partners, owners, joint venturers, stockholders, predecessors, successors, officers, members, directors, administrators, employees, agents, representatives, consultants, attorneys, insurers, heirs, executors, assignors or assignees, retirement plans (and&#47;or their trustees) of that Party and any other person, firm, or corporation with whom that Party is now or may hereinafter be affiliated, and any of them.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(b)&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby fully and forever, knowingly, voluntarily, and irrevocably release, acquit, discharge, and promises not to sue Ligand and its Related Persons and Entities, from, without limitation, any and all claims, demands, damages, obligations, losses, causes of action, costs, expenses, attorneys&#8217; fees, judgments, liabilities, duties, debts, liens, accounts, obligations, contracts&#47;agreements, promises, representations, actions, and causes of action, other proceedings and indemnities of any nature whatsoever arising from or in any way related to the Sublicense Agreement, as amended pursuant to this Amendment,  whether accrued or contingent, secured or unsecured, negligent or intentional, known or unknown, suspected or unsuspected, and whether based on law, equity, contract, tort, statute, or other legal or equitable theory of recovery, whether mature or to mature in the future, which from the beginning of time to the date of this Amendment, Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party had, now have, or claims to have against Ligand and its Related Persons and Entities, or any other person or entity described above. </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(c)&#160;Retrophin acknowledges that it may later discover material facts in addition to, or different from, those which it now knows or believes to be true.  Retrophin further acknowledges that there may be future events, circumstances or occurrences materially different from those it knows or believes likely to occur.  It is the intention of Retrophin to fully, finally and forever settle and generally release all claims, disputes and differences described above occurring prior to the date hereof.  The releases provided in this Amendment shall remain in full effect notwithstanding the discovery or existence of any such additional or different facts or occurrence of any such future events, circumstances or conditions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;"> </font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(d)&#160;Retrophin and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party hereby expressly waive the benefit of any statute or rule of law that, if applied to this Amendment would otherwise exclude from its binding effect any claims described above not known by it to exist which arose prior to the signing of this Amendment.  Retrophin acknowledges that it has read and fully understands the provisions of California Civil Code section 1542, which provides as follows&#58;</font></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Retrophin, being aware of said Code Section, hereby expressly waives, on behalf of itself and its Affiliates and any and all officers, directors, owners, predecessors, or successors, of that Party, any rights and benefits that they may have under section 1542 of the California Civil Code to the full extent that they may lawfully waive such rights and benefits, and shall waive any rights and benefits they may have under any other statutes or common law principles of similar effect.</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;">(e)&#160;This Amendment and its terms, including, but not limited to, the Release set forth in this Section 4, and the execution of this Amendment, shall not be construed as an admission of liability or fault by either of the Parties.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS &#160;&#160;&#160;RETROPHIN, INC.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">INCORPORATED</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Charles Berkman&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Martin Shkreli&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Charles Berkman&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Martin Shkreli&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;   Vice President, General Counsel and&#160;Title&#58;&#160;Chief Executive Officer</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Secretary</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; January 7, 2013&#160;&#160;&#160;&#160;&#160;Date&#58; January 7, 2013</font></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">THIS AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of February 27, 2015 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December&#160;11, 2012 and Amendment to Sublicense Agreement dated January 7, 2013 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sublicense Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PCOP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 777 Third Avenue, 22nd Floor, New York, NY, 10017 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BACKGROUND</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Ligand and Retrophin have previously entered into the Sublicense Agreement&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Capitalized Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)&#160;Sections 6.1.2 and 6.1.4 of the Sublicense Agreement are hereby removed.</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)&#160;Section 6.1.3 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;File for Approval for at least one (1) Orphan Licensed Product (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Approval Submission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) no later than &#91;***&#93; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Filing Deadline</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; provided that if Retrophin exercises its Extension Option (as defined below), then the Filing Deadline shall become (a) &#91;***&#93; if the Approval Submission is filed pursuant to the Code of Federal Regulations Title 21, Subpart H (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Subpart H</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or (b) &#91;***&#93;, if the Approval Submission is not eligible to be filed pursuant to Subpart H.  In order to exercise the Extension Option, prior to or on &#91;***&#93; (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Extension Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Retrophin shall either (a) pay to Ligand &#91;***&#93; or (b) issue to Ligand, or ensure that Ligand receives, that number of shares of capital stock of Retrophin equal to &#91;***&#93; as determined by the average of the closing prices for such capital stock over a five (5) trading day period ending three (3) trading days before the Extension Date (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Extension Option</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Certain information (indicated by asterisks) has been</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">omitted from this document because it is not material and would</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">likely cause competitive harm to the registrant if publicly disclosed.</font></div><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development Milestone Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The third milestone event in Table 1 for $&#91;***&#93; shall be amended and restated as follows&#58; </font></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#91;***&#93;&#8221;</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.&#160;No Other Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.&#160;Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.&#160;Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font><br></font></div><div id="if17ed8adb129402a9c42c19f8b48f219_7"></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS&#160;RETROPHIN, INC.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INCORPORATED&#160;</font></div><div style="text-indent:-252pt;padding-left:252pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Matthew W. Foehr&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Steve Aselage&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;Matthew W. Foehr&#160;&#160;Name&#58;&#160;Steve Aselage</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;President&#47;COO&#160;&#160;Title&#58;&#160;CEO</font></div><div style="text-align:justify;margin-top:2pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">THIS AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of September 17, 2015 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, and Amendment No. 3 to Sublicense Agreement dated February 27, 2015 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sublicense Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PCOP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Retrophin, Inc., a corporation organized under the laws of Delaware and having a place of business at 12255 El Camino Real, San Diego, CA 92130 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BACKGROUND</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Ligand and Retrophin have previously entered into the Sublicense Agreement pursuant to which Ligand sublicensed to Retrophin rights under the License Agreement dated March 27, 2006 between PCOP and Bristol-Myers Squib Company (the &#8220;Upstream License&#8221;)&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement and the Upstream Agreement as set forth herein.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.&#160;Capitalized Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;Amendments to Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Table 1 of Section 8.2.1 of the Agreement is hereby amended in its entirety as follows&#58;</font></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="padding-left:72pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.006%;"><tr><td style="width:1.0%;"></td><td style="width:47.404%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.596%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)   Milestone Event</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)   Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)   Execution of Agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)   $1.15 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)   The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)   $1.3 million (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Second Milestone&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2012, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.35 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,00 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Additional Payment&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">1</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:center;margin-bottom:11pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:4.5pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">1</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions of Section 13.2.4 (Disputed Breach).  In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c),(k), and (m) related to amounts then due and payable.&#8221;</font></div><div style="padding-left:4.5pt;"><font><br></font></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="padding-left:76.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)&#160;Section 8.10 of the Sublicense Agreement is hereby deleted in its entirety. </font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.&#160;Consideration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall pay Ligand (i) $850,000 in consideration for the amendments set forth in this Amendment, and (ii) $150,000 for the efforts to amend the Upstream License Agreement in accordance with Section 4 of this Amendment, in each case such payment shall be non-refundable and shall be made within 5 days of execution of this Amendment by both parties.</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.&#160;Efforts to Amend Upstream License Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:4.5pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Ligand will use reasonable best efforts to obtain a waiver of Sections 3.1 and 13.2.5 by BMS for the Asia Pacific Region. &#8220;Asia Pacific Region&#8221; means Japan, China, S. Korea, Taiwan, Thailand and Vietnam.</font></div><div style="text-indent:4.5pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Ligand will use reasonable best efforts to obtain BMS&#8217; agreement to the standby license provided by Section 2.2.2(v) in which event, Section 2.2.2(v) would be amended substantially in the form of the following language&#58; </font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#8230;provided, that, that such sublicensed rights shall not terminate if, as of the effective date of termination by BMS under Section 13.2, the Sublicensee is not in material default under its license agreement with Ligand in which case Sublicensee will assume all of Ligand&#8217;s rights and obligation under this Sublicense Agreement and be bound directly to BMS substituting Sublicensee for Ligand and subject to the payment to Ligand of all royalties and milestones under the sublicense agreement to the extent they exceed payments due to BMS under this Sublicense Agreement and payment to BMS of all royalties and milestones under this Upstream Agreement.&#8221;</font></div><div style="text-indent:9pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;Ligand will use reasonable best efforts to obtain BMS&#8217;s agreement to the following amendments to the termination provisions of the Upstream Agreement.</font></div><div style="text-indent:-9pt;padding-left:81pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.&#160;Section 13.4 (b) of the Upstream Agreement amended to read as set forth below&#58;</font></div><div style="padding-left:81pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;&#91;***&#93;&#8221;</font></div><div style="text-indent:-9pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.&#160;Section 13.4(f) amended as set forth below&#58;</font></div><div style="padding-left:81pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Ligand will &#91;***&#93;.&#8221;</font></div><div style="text-indent:-11.25pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.&#160;Section 13.4(i) deleted.</font></div><div style="text-indent:9pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;For the avoidance of doubt, any such efforts by Ligand made under this Sublicense Agreement shall not require Ligand to pay BMS any fee or concede and existing rights, but rather shall solely involve the use of logic and reason to seek to persuade BMS.</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.&#160;Amendments to Sublicense Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)&#160;For the avoidance of doubt, none of the following amendments to the Sublicense Agreement are intended to cause a breach of the Upstream Agreement and any amendment that would otherwise cause such a breach shall be null and void ab initio.</font></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)&#160;Section 1 of the Sublicense Agreement is hereby amended to include the following&#58; </font></div><div style="padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.70 &#8220;Asia Pacific Region&#8221; means Japan, China, S. Korea, Taiwan, Thailand and Vietnam.&#8221;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)&#160;Section 2.2.2 (vi) is hereby revised as set forth below&#58;</font></div><div style="padding-left:76.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#8230;provided however, that such sublicensed rights shall not terminate if, as of the effective date of termination by Ligand under Article 13, the Sublicensee is not in material default under its license agreement with Retrophin in which case Sublicensee will assume all of Retrophin&#8217;s rights and obligation under this Sublicense Agreement and be bound directly to Ligand respectively substituting Sublicensee for Retrophin and subject to the payment to Retrophin of all royalties and milestones under the sublicense agreement to the extent they exceed payments due to Ligand under this Sublicense Agreement and payment to Ligand of all royalties and milestones under this Sublicense Agreement to the extent they exceed payments due to BMS under the Upstream Agreement.&#8221;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)&#160;Section 3.2 of the Sublicense Agreement is hereby amended  to include the following&#58; </font></div><div style="padding-left:76.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;3.2.4 The provisions of Sections 3.2.1 and 3.2.2 shall not apply within the Asia Pacific Region.&#8221;</font></div><div style="padding-left:76.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e)&#160;Section 13.1.1 is hereby amended to add at the beginning of the first sentence &#8220;Subject to Section 13.7&#8230;&#8221;</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f)&#160;Section 13.2.6 is hereby deleted.</font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">g)&#160;Section 13.3 is hereby amended to add prior to the first sentence&#58;</font></div><div style="padding-left:81pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Retrophin may terminate this Agreement for convenience upon &#91;***&#93; (&#91;***&#93;) days prior written notice to Ligand and all of the provisions of Section 13.4 will survive termination of this Agreement pursuant to this Section 13.3.&#8221;</font></div><div style="padding-left:81pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:76.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">h)&#160;The following amendments will be effective (i) as between Ligand and Retrophin at a time when there is no breach claimed by BMS under the Upstream Agreement, and&#47;or (ii) at any time upon BMS&#8217;s agreement to amend or waive the applicable sections of the termination provisions in the Upstream Agreement&#59;</font></div><div style="text-indent:-18pt;padding-left:112.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.&#160;Section 13.4(b) is hereby amended as set forth below&#58;</font></div><div style="padding-left:81pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#91;***&#93;&#8221;</font></div><div style="text-indent:-18pt;padding-left:112.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.&#160;Section 13.4(f) amended as set forth below&#58;</font></div><div style="padding-left:81pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Retrophin will &#91;***&#93;.&#8221;</font></div><div style="text-indent:-18pt;padding-left:112.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.&#160;Section 13.4(i) deleted.</font></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.&#160;Further Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:-18pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)&#160;Ligand further agrees that it will not, by act or omission, cause the termination of the Upstream Agreement provided however Ligand may terminate the Upstream Agreement for good cause with Retrophin&#8217;s prior written consent, not to be unreasonably withheld. Upon receipt by Ligand of any notice of default or any event that could likely lead to termination of the Upstream Agreement, Ligand will promptly notify Retrophin and work with Retrophin to effect cure of the default or concession with BMS.</font></div><div style="text-indent:-18pt;padding-left:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)&#160;To the extent BMS shall not agree to the amendments proposed in Section 4 above, Ligand will, to the extent it does not cause a default under the Upstream Agreement, work with Retrophin in good faith and without further consideration and without refund of payments made hereunder to achieve the objectives contemplated by this Amendment by making further efforts to seek agreement from BMS.</font></div><div style="padding-left:40.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.&#160;No Other Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.&#160;Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.&#160;Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Signature Page Follows</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#93;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font><br></font></div><div id="if17ed8adb129402a9c42c19f8b48f219_10"></div><div style="position:relative;width:100%;height:40.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately with</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">the Securities and Exchange Commission.</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Confidential Treatment Requested Under</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.</font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS&#160;RETROPHIN, INC. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INCORPORATED&#160;</font></div><div style="text-indent:-252pt;padding-left:252pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Charles Berkman&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Laura Clague&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Charles Berkman   &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Name&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Laura Clague&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">VP, General Counsel &#38; Secretary  &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Title&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Chief Financial Officer&#160;</font></div><div style="text-align:justify;margin-top:2pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div id="if17ed8adb129402a9c42c19f8b48f219_13"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.2</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">***Text Omitted and Filed Separately</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">with Securities and Exchange Commission</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Confidential Treatment Requested</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 of the </font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities Exchange Act of 1934, as amended.</font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT</font></div><div style="text-align:center;margin-bottom:6pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">THIS AMENDMENT NO.  5 TO SUBLICENSE AGREEMENT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is made and entered into as of March 20, 2018 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, Amendment No. 3 to Sublicense Agreement dated February 27, 2015 and Amendment No. 4 to Sublicense Agreement dated September 17, 2015 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sublicense Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN DIEGO, CA 92121</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PCOP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), a limited liability company organized under the laws of Delaware and having a place of business at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3911 SORRENTO VALLEY BOULEVARD, SUITE 110, SAN DIEGO, CA 92121</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (collectively, Ligand Pharmaceuticals Incorporated and PCOP shall be known as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Ligand</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Retrophin Inc., a corporation organized under the laws of Delaware and having a place of business AT </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO, CA  92130</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Retrophin</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BACKGROUND</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Ligand and Retrophin have previously entered into the Sublicense Agreement pursuant to which Ligand sublicensed to Retrophin rights under the License Agreement dated March 27, 2006 between PCOP and Bristol-Myers Squib Company (the &#8220;Upstream License&#8221;)&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Ligand and Retrophin desire to amend certain terms of the Sublicense Agreement as set forth herein.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual covenants contained herein, the parties, intending to be legally bound, agree as follows&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Capitalized Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The capitalized terms used herein and not otherwise defined shall have the same definitions as provided in the Sublicense Agreement.</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)&#160;Section 6.1.3 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="padding-left:90pt;text-align:justify;"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;6.1.3  File for Approval for at least one (1) Orphan Licensed Product (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Approval Submission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) no later than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">***</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#93;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Filing Deadline</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div id="if17ed8adb129402a9c42c19f8b48f219_16"></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font><br></font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:90pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="padding-left:90pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;***&#93;.</font></div><div style="padding-left:90pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)&#160;Section 8.2.1 of the Sublicense Agreement is hereby amended to read as follows&#58;</font></div><div style="padding-left:108pt;text-align:justify;"><font><br></font></div><div style="padding-left:90pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;8.2.1  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Development Milestone Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Retrophin shall make milestone payments to Ligand upon achievement of each of the milestone events in the amounts set forth below in Table 1.  The first milestone payment shall be payable by Retrophin to Ligand within thirty (30) days of execution of the Agreement.  Notwithstanding Section 15.4 or any other provision herein, the last milestone payment shall be payable by Retrophin to Ligand upon the Closing of Retrophin&#8217;s Exit Transaction.  Subject to Section 8.2.2, the remainder of the milestone payments set forth below, with the exception of the milestone payment for Initiation of the first Phase 3 Trial for the first Licensed Product, will be payable by Retrophin to Ligand within thirty (30) days of the achievement of the specified milestone event with respect to each Licensed Compound.  The milestone for Initiation of the first Phase 3 Trial for the first Licensed Product will be payable by Retrophin to Ligand within ten (10) days of the execution of Amendment No. 5 by both Parties.  The milestone payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments.</font></div><div style="padding-left:108pt;text-align:justify;"><font><br></font></div><div style="padding-left:108pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Table 1</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:49.5pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.262%;"><tr><td style="width:1.0%;"></td><td style="width:49.705%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.295%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Milestone Event</font></div></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Execution of Agreement</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">$1.15 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">The earlier of (a) December 31, 2012 or (b) initiation of the first Phase 2 Trial for a Licensed Product</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">$1.3 million (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Second Milestone</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8221;)&#59; provided, that if the Second Milestone is received by Ligand (a) prior to or on January 31, 2012, Retrophin shall make an additional $50,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.35 million), (b) after January 31, 2013 but prior to or on February 28, 2013, Retrophin shall make an additional $100,000 payment simultaneously with the payment of the Second Milestone (for an aggregate payment of $1.4 million), and (c) after February 28, 2013 but prior to or on March 31, 2013, Retrophin shall make an additional $150,000 payment of the Second Milestone (for an aggregate payment of $1.45 million) (the additional payment, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Additional Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#8221;)</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;vertical-align:top;">2</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">At or prior to Initiation of the first Phase 3 Trial for the first Licensed Product</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">$4.6 million</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #00000a;border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;padding-left:1pt;border-right:1pt solid #00000a;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:54pt;text-align:justify;margin-top:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:54pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If the Second Milestone and any Additional Payment is not received by Ligand on or before March 31, 2013, Ligand shall have the right to terminate the Agreement pursuant to Section 13.2.2 with immediate effect as of March 31, 2013 by providing written notice to Retrophin, notwithstanding (a) the cure period for the failure to make a payment when due set out in said Section 13.2.2 (Breach) or (b) the provisions to Section 13.2.4 (Disputed Breach). In addition, and for clarity, the provisions of Section 13.4 (Effect of Termination) shall be operative, including, without limitation, the provisions of subsections (c), (k), and (m) related to amounts then due and payable.&#8221;</font></div><div style="padding-left:54pt;"><font><br></font></div><div style="padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In the event that a milestone event is achieved that triggers a development milestone payment as set forth above, if the preceding milestone events have not occurred such that the previous development milestone payments have not been previously paid, all such previous development milestone payments shall become due and payable upon achievement of such milestone event.  For example, if a Phase 3 Trial is initiated that triggers a development milestone payment as set forth above without a Phase 2 Trial supporting such Phase 3 Trial being previously initiated (and consequently the applicable initiation of Phase 2 Trial milestone payment has not been previously paid to Ligand), in addition to the milestone payment for the initiation of the Phase 3 Trial, Retrophin shall also pay to Ligand the applicable milestone payment for the initiation of a Phase 2 Trial.&#8221;</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Other Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as provided herein, the Sublicense Agreement shall continue in full force and effect.</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment shall be governed by, enforced, and shall be construed in accordance with the laws of the State of New York without regard to its conflicts of law provisions.</font></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment may be executed in counter-parts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IN WITNESS WHEREOF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties have executed this Amendment to Sublicense Agreement through their duly authorized representatives to be effective as of the Amendment Effective Date.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS&#160;&#160;&#160;&#160;RETROPHIN, INC. </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INCORPORATED</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Charles S. Berkman&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">          &#160;&#160;&#160;By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Stephen Aselage&#160;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Charles S. Berkman&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  &#160;&#160;&#160;Name&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Stephen Aselage&#160;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sr. VP, General Counsel &#38; Secretary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;&#160;&#160;Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">CEO&#160;&#160;&#160;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">***Confidential Treatment Requested</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">***Confidential Treatment Requested</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>lgnd123119exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i75d1189c700a45209f038f3d5679dcfd_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 21.1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:81.250%;"><tr><td style="width:1.0%;"></td><td style="width:49.084%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.339%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.577%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ab Initio Biotherapeutics, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjacent Acquisition Co., LLC</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Glycomed Incorporated &#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">California</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allergan Ligand Retinoid Therapeutics, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Pharmaceuticals International, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Biopharmaceuticals Incorporated</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand JVR, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Pharmaceuticals UK Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United Kingdom</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ligand Pharmaceuticals (Canada) Incorporated</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canada</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seragen Incorporated</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seragen Technology, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmacopeia, LLC</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis Therapeutics, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Neurogen Corporation</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CyDex Pharmaceuticals, Inc. &#160;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Open Monoclonal Technology, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OMT I, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OMT II, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal Bioscience, Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">California</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis plc</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">England and Wales</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis (R&#38;D) Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">England and Wales</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis Group Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">England and Wales</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis Therapeutics Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis (Canada) Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canada</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis (Canada II) Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canada</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis Development Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">England and Wales</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vernalis Research Limited</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">England and Wales</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cita NeuroPharmaceuticals Inc.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canada</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>lgnd123119exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i595bca81fda8455c9f77f4cf631df935_1"></div><div style="height:40.5pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 23.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(5) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated&#59; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our reports dated February&#160;27, 2020, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December&#160;31, 2019.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="text-indent:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">San Diego, California</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February&#160;27, 2020</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:130.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>lgnd123119exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i975e565889584fd385c4537a6213abcd_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">I, John L. Higgins, certify that&#58;</font></div><div style="margin-bottom:7pt;"><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.064%;"><tr><td style="width:1.0%;"></td><td style="width:10.811%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:85.189%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">3.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">a)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">b)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">c)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">d)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">a)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">b)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58;&#160;&#160;February&#160;27, 2020</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">John L. Higgins</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>lgnd123119exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i112f68314cc74cb8a7159c8bb3cbfa5e_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">I, Matthew Korenberg, certify that&#58;</font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">3.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">a)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">b)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">c)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">d)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:2pt;text-align:right;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">a)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:72pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">b)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58;&#160;&#160;&#160;&#160;February&#160;27, 2020</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:65.064%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>lgnd123119exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6b31ac122a584d3998f0c3664e71da84_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Exhibit 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John L. Higgins, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-indent:36pt;margin-bottom:7pt;"><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.358%;"><tr><td style="width:1.0%;"></td><td style="width:7.677%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.323%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(1)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:9.556%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.434%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.966%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.044%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:2pt;padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; John L. Higgins</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">John L. Higgins</font></div><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Chief Executive Officer</font></div><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew Korenberg, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-indent:36pt;margin-bottom:7pt;"><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.198%;"><tr><td style="width:1.0%;"></td><td style="width:9.308%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.692%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(1)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.038%;"><tr><td style="width:1.0%;"></td><td style="width:9.326%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.168%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.870%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.306%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</font></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 27, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:2pt;padding-left:2pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; Matthew Korenberg</font></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Matthew Korenberg</font></div><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="padding-left:2pt;padding-right:2pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lgnd-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:lgnd="http://www.ligand.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="lgnd_AziyoMember" abstract="true" name="AziyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" abstract="false" name="MaturityPeriodOfHighlyLiquidSecuritiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_AziyoandCorMatrixMember" abstract="true" name="AziyoandCorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_AmendedESPPMember" abstract="true" name="AmendedESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ProductRoyaltyPercentage" abstract="false" name="ProductRoyaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" abstract="false" name="NonCashChangeInEstimatedFairValueOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" abstract="false" name="BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EmployeeStockPurchasePlanAbstract" abstract="true" name="EmployeeStockPurchasePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" abstract="false" name="ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" abstract="false" name="ForecastedCashFlowsEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCydexMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCydexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" abstract="false" name="AllowanceForDoubtfulAccountsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" abstract="false" name="RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationContingentValueRights" abstract="false" name="IncomeTaxReconciliationContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolMember" abstract="true" name="MaterialSalesCaptisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" abstract="false" name="DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInOtherEconomicRights" abstract="false" name="IncreaseDecreaseInOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseinEquityMethodInvestment" abstract="false" name="IncreaseDecreaseinEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_InvestmentInVikingCurrent" abstract="false" name="InvestmentInVikingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsPolicyTextBlock" abstract="false" name="CommercialLicenseRightsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_ProceedsFromCommercialLicenseRights" abstract="false" name="ProceedsFromCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" abstract="true" name="LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" abstract="false" name="AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyOtherMember" abstract="true" name="RoyaltyOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PurchaseOfConvertibleBondHedge" abstract="false" name="PurchaseOfConvertibleBondHedge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AccruedSalesReturns" abstract="false" name="AccruedSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DianomiMember" abstract="true" name="DianomiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" abstract="false" name="RevenueRecognitionMilestoneMethodMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_WorkingCapitalAdjustment" abstract="false" name="WorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" abstract="false" name="ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CashPaidtoAcquireBusiness" abstract="false" name="CashPaidtoAcquireBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" abstract="false" name="ScheduleofCommercialLicenseRightsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" abstract="false" name="IncomeTaxReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" abstract="true" name="ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" abstract="false" name="VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_PalvellaTherapeuticsIncMember" abstract="true" name="PalvellaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" abstract="true" name="LicenseFeesMilestonesAndOtherProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotes2023Member" abstract="true" name="ConvertibleSeniorNotes2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyAgreementExpirationPeriod" abstract="false" name="RoyaltyAgreementExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyEvomelaMember" abstract="true" name="RoyaltyEvomelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CorMatrixMember" abstract="true" name="CorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" abstract="true" name="CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFairValueAdjustment" abstract="false" name="DeferredTaxLiabilitiesFairValueAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VestingPeriodOneMember" abstract="true" name="VestingPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" abstract="false" name="PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_Phase3ClinicalTrialMember" abstract="true" name="Phase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" abstract="true" name="CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_SelexisMember" abstract="true" name="SelexisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceofConvertibleBondHedge" abstract="false" name="ExercisePriceofConvertibleBondHedge" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" abstract="true" name="DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AccruedStockRepurchases" abstract="false" name="AccruedStockRepurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VikingTherapeuticsInc.Member" abstract="true" name="VikingTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_TwoThousandTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" abstract="false" name="RevenueRoyaltytoAcquireeShareholdersPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" abstract="false" name="BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_PurchaseforCommercialLicenseRights" abstract="false" name="PurchaseforCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LicenseUpfrontPayment" abstract="false" name="LicenseUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHolders" abstract="false" name="PaymentsToContingentValueRightHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PromactaMember" abstract="true" name="PromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VernalisMember" abstract="true" name="VernalisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" abstract="true" name="LiabilityForContingentValueRightsCompanyMetabasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" abstract="false" name="AmortizationOfCommercialLicenseAndOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CrystalMember" abstract="true" name="CrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_NumberofCollaborationAgreements" abstract="false" name="NumberofCollaborationAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_NovanMolluscumProductsMember" abstract="true" name="NovanMolluscumProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_MilestoneMember" abstract="true" name="MilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" abstract="true" name="LiabilityForContingentValueRightsCompanyCrystalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_NumberOfAcquisitions" abstract="false" name="NumberOfAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_LicenseFeesMilestonesandProductOtherMember" abstract="true" name="LicenseFeesMilestonesandProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_RoyaltyKyprolisMember" abstract="true" name="RoyaltyKyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_RoyaltyPromactaMember" abstract="true" name="RoyaltyPromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AbInitioMember" abstract="true" name="AbInitioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ScheduleofContingentLiabilitiesTableTextBlock" abstract="false" name="ScheduleofContingentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRights" abstract="false" name="LiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" abstract="false" name="DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedInventoryPurchases" abstract="false" name="AccruedInventoryPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" abstract="true" name="ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodTwoMember" abstract="true" name="VestingPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotes2019Member" abstract="true" name="ConvertibleSeniorNotes2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CydexPharmaceuticalsIncMember" abstract="true" name="CydexPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_ContingentLiabilityRollForward" abstract="true" name="ContingentLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CashPayable" abstract="false" name="CashPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_WarrantsSettled" abstract="false" name="WarrantsSettled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_CommercialLicenseRights" abstract="false" name="CommercialLicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CurrentPortionOfLiabilityForContingentValueRights" abstract="false" name="CurrentPortionOfLiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" abstract="false" name="IncomeTaxReconciliationExpiredTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MetabasisTherapeuticsMember" abstract="true" name="MetabasisTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_LesseeOperatingLeaseRemainingLeaseTerm" abstract="false" name="LesseeOperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" abstract="false" name="DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" abstract="false" name="RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" abstract="false" name="RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeElevenMember" abstract="true" name="ExercisePriceRangeElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsIssued" abstract="false" name="NumberOfContingentValueRightsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" abstract="false" name="BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lgnd_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lgnd_CorporateShareRepurchaseAbstract" abstract="true" name="CorporateShareRepurchaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_PaymentsforConvertibleBondHedges" abstract="false" name="PaymentsforConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" abstract="false" name="ThresholdRevenueAmounttoTriggerRoyaltyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails">
        <link:definition>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
        <link:definition>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails">
        <link:definition>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
        <link:definition>2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPromactaLicense" roleURI="http://www.ligand.com/role/SaleofPromactaLicense">
        <link:definition>2110102 - Disclosure - Sale of Promacta License</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPromactaLicenseNarrativeDetails" roleURI="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails">
        <link:definition>2411407 - Disclosure - Sale of Promacta License - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinViking" roleURI="http://www.ligand.com/role/InvestmentinViking">
        <link:definition>2112103 - Disclosure - Investment in Viking</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinVikingNarrativeDetails" roleURI="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails">
        <link:definition>2413408 - Disclosure - Investment in Viking - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.ligand.com/role/BusinessCombinations">
        <link:definition>2114104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.ligand.com/role/BusinessCombinationsTables">
        <link:definition>2315302 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>2416409 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2417410 - Disclosure - Business Combinations - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAggregateAcquisitionConsiderationDetails" roleURI="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails">
        <link:definition>2418411 - Disclosure - Business Combinations - Aggregate Acquisition Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.ligand.com/role/FairValueMeasurement">
        <link:definition>2119105 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.ligand.com/role/FairValueMeasurementTables">
        <link:definition>2320303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2421412 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>2422413 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2423414 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ligand.com/role/Leases">
        <link:definition>2124106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ligand.com/role/LeasesTables">
        <link:definition>2325304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ligand.com/role/LeasesNarrativeDetails">
        <link:definition>2426415 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseAssetsandLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails">
        <link:definition>2427416 - Disclosure - Leases - Operating Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2428417 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2428417 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes">
        <link:definition>2129107 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2330305 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNarrativeDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails">
        <link:definition>2431418 - Disclosure - Convertible Senior Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails">
        <link:definition>2432419 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails">
        <link:definition>2133108 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>2334306 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInvestmentCategoriesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails">
        <link:definition>2435420 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsPropertyandEquipmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails">
        <link:definition>2436421 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>2437422 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAccruedLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails">
        <link:definition>2438423 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsContingentLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails">
        <link:definition>2439424 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ligand.com/role/StockholdersEquity">
        <link:definition>2140109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ligand.com/role/StockholdersEquityTables">
        <link:definition>2341307 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareBasedCompensationDetails" roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails">
        <link:definition>2442425 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2443426 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionPlanActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails">
        <link:definition>2444427 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityBreakdownofOptionsOutstandingDetails" roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails">
        <link:definition>2445428 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsDetails" roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails">
        <link:definition>2446429 - Disclosure - Stockholders' Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>2447430 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLegalProceedings" roleURI="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings">
        <link:definition>2148110 - Disclosure - Commitments and Contingencies: Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ligand.com/role/IncomeTaxes">
        <link:definition>2149111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ligand.com/role/IncomeTaxesTables">
        <link:definition>2350308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2451431 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2452432 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails">
        <link:definition>2453433 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>2454434 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2455435 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformation" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation">
        <link:definition>2156112 - Disclosure - Summary of Unaudited Quarterly Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformationTables" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables">
        <link:definition>2357309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails">
        <link:definition>2458436 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.ligand.com/role/SubsequentEvent">
        <link:definition>2159113 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventNarrativeDetails" roleURI="http://www.ligand.com/role/SubsequentEventNarrativeDetails">
        <link:definition>2460437 - Disclosure - Subsequent Event - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>lgnd-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13f41175-1ba1-408c-bfa2-2cacc6d77ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1516d352-70bc-4a84-ac6b-02d938d3793a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13f41175-1ba1-408c-bfa2-2cacc6d77ba5" xlink:to="loc_us-gaap_Liabilities_1516d352-70bc-4a84-ac6b-02d938d3793a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a2ab07b3-1718-4d39-a8e1-6b5ab87cb3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13f41175-1ba1-408c-bfa2-2cacc6d77ba5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a2ab07b3-1718-4d39-a8e1-6b5ab87cb3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7e3f3c3-8dba-404c-bed7-e60a519ae4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13f41175-1ba1-408c-bfa2-2cacc6d77ba5" xlink:to="loc_us-gaap_StockholdersEquity_a7e3f3c3-8dba-404c-bed7-e60a519ae4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_67ded0ee-b218-4683-91f8-2567bcf0e247" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:to="loc_us-gaap_PreferredStockValue_67ded0ee-b218-4683-91f8-2567bcf0e247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ff91c5b1-2f22-4e45-b965-aade24873fed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:to="loc_us-gaap_CommonStockValue_ff91c5b1-2f22-4e45-b965-aade24873fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_15f90633-b7d2-41ac-8ac6-602ef9026ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:to="loc_us-gaap_AdditionalPaidInCapital_15f90633-b7d2-41ac-8ac6-602ef9026ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0fbe7c50-7119-43a0-97f3-1c3361407e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0fbe7c50-7119-43a0-97f3-1c3361407e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14d59c28-4929-4ea8-a3d4-2a742b2125ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bee76938-eea1-4ada-813a-fd28e1b6d9fe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14d59c28-4929-4ea8-a3d4-2a742b2125ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b1e111c1-e2c5-4802-9a17-bb5a7e0b9338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_us-gaap_AccountsPayableCurrent_b1e111c1-e2c5-4802-9a17-bb5a7e0b9338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1aa2a2fc-4bc2-4207-bbae-d742ef112a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1aa2a2fc-4bc2-4207-bbae-d742ef112a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_6f32e3b1-2ac8-44d2-bb48-5b1bcc9b7180" xlink:href="lgnd-20191231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_6f32e3b1-2ac8-44d2-bb48-5b1bcc9b7180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_71d0b6fd-4c74-481e-baf8-b6755311e7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_71d0b6fd-4c74-481e-baf8-b6755311e7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_5c8c49d9-9184-456d-8be1-f0058e1a1e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_5c8c49d9-9184-456d-8be1-f0058e1a1e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_f96cd52c-c74d-4f36-bd5f-4cc4aacab9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79d49ec7-c4ac-4620-bd03-86f1a033d17c" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_f96cd52c-c74d-4f36-bd5f-4cc4aacab9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63e1b45c-f336-4ec5-bfc3-36ea1a410618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_us-gaap_LiabilitiesCurrent_63e1b45c-f336-4ec5-bfc3-36ea1a410618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_c57e7f0f-bd9d-4ff8-bea3-3ad93d29ac7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_c57e7f0f-bd9d-4ff8-bea3-3ad93d29ac7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_f49e91cd-d327-4b28-bc89-fc332e3d018a" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_lgnd_LiabilityForContingentValueRights_f49e91cd-d327-4b28-bc89-fc332e3d018a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_58b8e4a8-46f2-4d75-aeb9-ab1bb733d3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_58b8e4a8-46f2-4d75-aeb9-ab1bb733d3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2dc74e1-cc0c-44f8-a822-f6b1ef7748c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2dc74e1-cc0c-44f8-a822-f6b1ef7748c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_94fb604f-4252-445f-bbd0-14bbb049f05c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7dc345bf-5eb7-4c41-8228-b1fc060a9415" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_94fb604f-4252-445f-bbd0-14bbb049f05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d054932-0aba-410d-b8f9-72c37ddd80f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_AssetsCurrent_0d054932-0aba-410d-b8f9-72c37ddd80f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_49aa2445-a267-44ea-b16c-3fa5b7cf3889" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_49aa2445-a267-44ea-b16c-3fa5b7cf3889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4484c2f0-5117-4dd7-b783-6b4cc8c163e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4484c2f0-5117-4dd7-b783-6b4cc8c163e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95afb28b-3609-4bb6-9b9d-8d8cfae1c9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_Goodwill_95afb28b-3609-4bb6-9b9d-8d8cfae1c9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_4c8cf39d-42c6-4f74-b114-997cc576a5e3" xlink:href="lgnd-20191231.xsd#lgnd_CommercialLicenseRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_lgnd_CommercialLicenseRights_4c8cf39d-42c6-4f74-b114-997cc576a5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_808ce748-11e5-4087-908b-b264879e94f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_808ce748-11e5-4087-908b-b264879e94f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e7bc983f-60d3-4003-8895-d50e004d2d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e7bc983f-60d3-4003-8895-d50e004d2d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1a53c96f-0535-4170-b4ea-7e0c7e7b0d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13d0b558-7eb5-4627-bbfd-62d13cd6537d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1a53c96f-0535-4170-b4ea-7e0c7e7b0d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_449a4355-694a-45ab-bc45-630fa2d213a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_449a4355-694a-45ab-bc45-630fa2d213a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_26c4c29a-9e82-4b10-9e5a-b33dcdd36990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_ShortTermInvestments_26c4c29a-9e82-4b10-9e5a-b33dcdd36990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_649ddc65-ca14-4c8f-8787-eb70070d1982" xlink:href="lgnd-20191231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_lgnd_InvestmentInVikingCurrent_649ddc65-ca14-4c8f-8787-eb70070d1982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eba83461-c92f-4099-887c-93aa5d85a1af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eba83461-c92f-4099-887c-93aa5d85a1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b6b75105-0924-4a57-ad69-d751d2e59208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_InventoryNet_b6b75105-0924-4a57-ad69-d751d2e59208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ce48ba1b-c3b3-4479-b038-a52477013f93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ce48ba1b-c3b3-4479-b038-a52477013f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_94929979-f96c-476a-85c8-211739bc2d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_IncomeTaxesReceivable_94929979-f96c-476a-85c8-211739bc2d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_398b4d6d-6e09-4256-86e7-94168c23a741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3d694189-4a66-406f-ae0b-0019d8d90482" xlink:to="loc_us-gaap_OtherAssetsCurrent_398b4d6d-6e09-4256-86e7-94168c23a741" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa9bbc0f-803e-4396-aef0-9f5f553f453c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_bfd9026e-0936-4220-b7e4-e8089d16fce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa9bbc0f-803e-4396-aef0-9f5f553f453c" xlink:to="loc_us-gaap_GainLossOnInvestments_bfd9026e-0936-4220-b7e4-e8089d16fce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9b90cee0-4006-4aea-acd9-7049508159aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa9bbc0f-803e-4396-aef0-9f5f553f453c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9b90cee0-4006-4aea-acd9-7049508159aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2c9b27b9-6bda-4308-85a4-7e96d5ce45be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa9bbc0f-803e-4396-aef0-9f5f553f453c" xlink:to="loc_us-gaap_InterestExpense_2c9b27b9-6bda-4308-85a4-7e96d5ce45be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31d41e30-7936-49c9-a053-788359a8a71f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fa9bbc0f-803e-4396-aef0-9f5f553f453c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31d41e30-7936-49c9-a053-788359a8a71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6efcfe72-1697-4a35-96c8-e1b89db42c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6fcfe189-913e-4671-80ff-74cf5adc3789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6efcfe72-1697-4a35-96c8-e1b89db42c84" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6fcfe189-913e-4671-80ff-74cf5adc3789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ab0c1b1f-0f7e-4b3c-b58d-02b375f79087" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6efcfe72-1697-4a35-96c8-e1b89db42c84" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ab0c1b1f-0f7e-4b3c-b58d-02b375f79087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7a98bbaa-c49c-494f-b5f6-9a6739ed13fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13fd2b0e-5908-4a9c-b8c1-26cacf1fb2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7a98bbaa-c49c-494f-b5f6-9a6739ed13fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_13fd2b0e-5908-4a9c-b8c1-26cacf1fb2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_290de70c-23db-43e2-8117-be3b1a9e4f48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7a98bbaa-c49c-494f-b5f6-9a6739ed13fd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_290de70c-23db-43e2-8117-be3b1a9e4f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3d38a280-b549-4a5d-a17f-a78e548095c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1ba24ec-fa31-4dc0-a4e2-d9d972895f05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3d38a280-b549-4a5d-a17f-a78e548095c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1ba24ec-fa31-4dc0-a4e2-d9d972895f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_8e4c6150-f573-441a-9a6e-c1341a35069b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3d38a280-b549-4a5d-a17f-a78e548095c2" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_8e4c6150-f573-441a-9a6e-c1341a35069b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_69f6085f-04ad-42bc-b200-ecffb3848f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3d38a280-b549-4a5d-a17f-a78e548095c2" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_69f6085f-04ad-42bc-b200-ecffb3848f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_53c85ff4-db15-417c-a127-9709ce0a5eda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_47b8b8a4-1127-47eb-8082-544de9822814" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_53c85ff4-db15-417c-a127-9709ce0a5eda" xlink:to="loc_us-gaap_CostDirectMaterial_47b8b8a4-1127-47eb-8082-544de9822814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18eaa998-2c47-4975-9e85-6ad15fdae8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_53c85ff4-db15-417c-a127-9709ce0a5eda" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18eaa998-2c47-4975-9e85-6ad15fdae8c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_960ea05d-f4cf-40e7-8cb9-e9bc92b657e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_53c85ff4-db15-417c-a127-9709ce0a5eda" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_960ea05d-f4cf-40e7-8cb9-e9bc92b657e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_053cfb43-477c-4920-bdcd-d47f59c4340a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_53c85ff4-db15-417c-a127-9709ce0a5eda" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_053cfb43-477c-4920-bdcd-d47f59c4340a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4fd9555-e627-4f34-9a2f-7dc1475e5bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f46d150a-1fa7-4adb-bc0c-1c3f7ee89044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4fd9555-e627-4f34-9a2f-7dc1475e5bb0" xlink:to="loc_us-gaap_NetIncomeLoss_f46d150a-1fa7-4adb-bc0c-1c3f7ee89044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_48cdfec8-82dd-4c5b-9ad2-ba675dc37dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4fd9555-e627-4f34-9a2f-7dc1475e5bb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_48cdfec8-82dd-4c5b-9ad2-ba675dc37dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7094c270-d7dd-4503-b59e-35f47e8d3eda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4fd9555-e627-4f34-9a2f-7dc1475e5bb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7094c270-d7dd-4503-b59e-35f47e8d3eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ffe41f09-7916-41e4-a386-a61985e2c549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4fd9555-e627-4f34-9a2f-7dc1475e5bb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ffe41f09-7916-41e4-a386-a61985e2c549" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_96690160-5dcc-4f60-96cc-fd949def76cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_96690160-5dcc-4f60-96cc-fd949def76cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_d151dca6-d635-4a48-8937-599ff9024f87" xlink:href="lgnd-20191231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_d151dca6-d635-4a48-8937-599ff9024f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_24587c94-8abd-436f-97d0-6e944b037bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_24587c94-8abd-436f-97d0-6e944b037bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_034bd947-b5d6-42c3-a3b5-68bd08208b82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_034bd947-b5d6-42c3-a3b5-68bd08208b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a68aab3-a8ad-4e57-9291-945e4d300b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a68aab3-a8ad-4e57-9291-945e4d300b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c5814bd-0a21-453a-9c74-8c1cc64d2db4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7c5814bd-0a21-453a-9c74-8c1cc64d2db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_62036a0d-1a0d-4516-ae6b-51e436772852" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_62036a0d-1a0d-4516-ae6b-51e436772852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_2cf6c06a-6a20-437e-80ec-5774a8c29e7b" xlink:href="lgnd-20191231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_2cf6c06a-6a20-437e-80ec-5774a8c29e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_00bd3d80-16d8-410d-a863-2ba39b185505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_ShareBasedCompensation_00bd3d80-16d8-410d-a863-2ba39b185505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_61baba0e-7b5a-4d89-8ad6-e67ef6f6f065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_61baba0e-7b5a-4d89-8ad6-e67ef6f6f065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_f2c7e134-fe71-4252-b46b-45d0ab2f66cb" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_f2c7e134-fe71-4252-b46b-45d0ab2f66cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3018bd51-0734-4f2d-a1d1-bf1a15ef5d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3018bd51-0734-4f2d-a1d1-bf1a15ef5d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87c4bca6-4442-4be0-9253-7683db85290a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87c4bca6-4442-4be0-9253-7683db85290a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_04d272f7-5e63-4583-b83b-7bf67b91f420" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_04d272f7-5e63-4583-b83b-7bf67b91f420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e747841-25fe-49cb-8ef3-cc8ddba79efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e747841-25fe-49cb-8ef3-cc8ddba79efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_d1482ff2-e184-4ad3-ad09-2e6e050a522a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_d1482ff2-e184-4ad3-ad09-2e6e050a522a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_912982aa-2dd9-4d4e-aabf-d1d1998f7b67" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_912982aa-2dd9-4d4e-aabf-d1d1998f7b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_943a761b-d5bf-409a-a1f6-ef0c6295c090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_943a761b-d5bf-409a-a1f6-ef0c6295c090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_df40cba7-f912-417d-8ae6-321a512d3e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b364c7b-1598-4b09-aaf7-d947b1880434" xlink:to="loc_us-gaap_ProfitLoss_df40cba7-f912-417d-8ae6-321a512d3e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_772179ac-4828-4837-a1e0-4fc7541ecdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_772179ac-4828-4837-a1e0-4fc7541ecdd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6b0d27d5-18a9-4509-8bb4-7245586ca789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_6b0d27d5-18a9-4509-8bb4-7245586ca789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d0e91149-99b7-4bb6-9d78-56c51b994de4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d0e91149-99b7-4bb6-9d78-56c51b994de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6b6d623d-83b3-436a-a320-3b31aa6e9495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6b6d623d-83b3-436a-a320-3b31aa6e9495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge_b5b14a3c-12bb-4809-8629-e5f60b4d3b8d" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_lgnd_PurchaseOfConvertibleBondHedge_b5b14a3c-12bb-4809-8629-e5f60b4d3b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_63cabb49-4c6e-4686-889a-a926b8d8e6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_63cabb49-4c6e-4686-889a-a926b8d8e6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_0d548fea-0d7e-435e-8309-89e64b5acfd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_0d548fea-0d7e-435e-8309-89e64b5acfd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_95fa6161-67be-4264-9f7e-122c8bf9ba92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_95fa6161-67be-4264-9f7e-122c8bf9ba92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3059de07-fb62-4ef3-8a50-a0b35c96deb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3059de07-fb62-4ef3-8a50-a0b35c96deb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3c63593c-1741-4e76-83b4-faec023e4888" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3c63593c-1741-4e76-83b4-faec023e4888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_5fa133a9-8888-4351-acb1-5ac837158c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_5fa133a9-8888-4351-acb1-5ac837158c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_18943faa-7523-408f-ad6d-8b873c0c03ee" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d67db12-19d8-40c2-b44a-6e116b3196cc" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_18943faa-7523-408f-ad6d-8b873c0c03ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_621c4df8-5f1f-4f31-911e-7e084dd05599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_621c4df8-5f1f-4f31-911e-7e084dd05599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_5e0e23e3-5891-4cac-9585-677acc8166fc" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_5e0e23e3-5891-4cac-9585-677acc8166fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0057a947-3621-4d43-a829-1285a44d51a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0057a947-3621-4d43-a829-1285a44d51a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142df0ec-7954-475a-9430-cc99d7a12815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142df0ec-7954-475a-9430-cc99d7a12815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7c7f14f4-ea5a-4a25-a43b-8b8cd8d3d91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7c7f14f4-ea5a-4a25-a43b-8b8cd8d3d91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_9ba8e04a-f9d1-4125-9861-da2cde9aea87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_9ba8e04a-f9d1-4125-9861-da2cde9aea87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_753f44ba-8c34-4533-b557-4778384ddf80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_753f44ba-8c34-4533-b557-4778384ddf80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_a0dfe442-574d-4dfc-a93b-9d3d38e86588" xlink:href="lgnd-20191231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_a0dfe442-574d-4dfc-a93b-9d3d38e86588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_9613b37b-5c17-4690-9e34-8471ab2f7492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_9613b37b-5c17-4690-9e34-8471ab2f7492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_10728752-e241-4b61-b547-1dc0c8c1c5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_10728752-e241-4b61-b547-1dc0c8c1c5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_19369ab9-9a1c-4dfb-a867-00d27e484207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb435b9d-8844-4afa-a74d-fbfb29e7b000" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_19369ab9-9a1c-4dfb-a867-00d27e484207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_7848b4d8-ec6b-4063-986f-3603c4d0736b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2e340997-1f66-41b4-b2c9-1483a974654c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_7848b4d8-ec6b-4063-986f-3603c4d0736b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2e340997-1f66-41b4-b2c9-1483a974654c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1b2f2e9-5e43-43af-ab0c-d5e2aeda9418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_7848b4d8-ec6b-4063-986f-3603c4d0736b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1b2f2e9-5e43-43af-ab0c-d5e2aeda9418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1a32326-78fc-4ad9-bd71-df48fa46e6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_7848b4d8-ec6b-4063-986f-3603c4d0736b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1a32326-78fc-4ad9-bd71-df48fa46e6c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66d2b227-1219-40f4-aedb-7082364d706f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a618e550-72b0-4727-a2b2-bf5a64241aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66d2b227-1219-40f4-aedb-7082364d706f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a618e550-72b0-4727-a2b2-bf5a64241aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_32fa6667-7a63-4c86-be74-385017045f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66d2b227-1219-40f4-aedb-7082364d706f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_32fa6667-7a63-4c86-be74-385017045f2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2184e5c8-94be-4b1c-9d2e-7ebde01662d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2184e5c8-94be-4b1c-9d2e-7ebde01662d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_cf1d8a95-8ea5-4638-ad58-e55e96401870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_cf1d8a95-8ea5-4638-ad58-e55e96401870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_2a8be4d6-57c3-42d6-88b7-5297b674319d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_2a8be4d6-57c3-42d6-88b7-5297b674319d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_072e751b-bcaf-4998-952f-234486978369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_072e751b-bcaf-4998-952f-234486978369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9f86eeda-4952-4c2e-98d7-fcfcc40afd80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6420f387-9300-4f6b-834c-84208d217bf3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9f86eeda-4952-4c2e-98d7-fcfcc40afd80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicense"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicenseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinViking" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinViking"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/InvestmentinViking" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinVikingNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinations" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinations"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BusinessCombinations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1d11fc40-fba0-4ffd-b5de-ee66b209e1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1d11fc40-fba0-4ffd-b5de-ee66b209e1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_0488f0c5-c10d-4966-abd7-d283ec7c51b0" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_0488f0c5-c10d-4966-abd7-d283ec7c51b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_03da5c10-161f-4a73-8862-195953779eac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_03da5c10-161f-4a73-8862-195953779eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f6babfcd-b07c-475a-917d-1997bf77bdd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f6babfcd-b07c-475a-917d-1997bf77bdd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0f453431-43d8-419f-8c1e-cad04211b6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0f453431-43d8-419f-8c1e-cad04211b6e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_957aecb1-92e1-4e40-b6fa-43fe70a59386" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_957aecb1-92e1-4e40-b6fa-43fe70a59386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e6674149-7c08-4668-b507-744054e72eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e6674149-7c08-4668-b507-744054e72eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6bfc20ca-b1dc-4041-af66-f9290d19bf2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6bfc20ca-b1dc-4041-af66-f9290d19bf2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2b5267ab-8b52-4120-9af4-340765ef8a78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_RestructuringReserve_2b5267ab-8b52-4120-9af4-340765ef8a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_2c8cab53-2da4-4d8f-a99a-1a36144f5b78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_2c8cab53-2da4-4d8f-a99a-1a36144f5b78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a1533496-c9c1-4af3-ba72-4c46085a9b09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a1533496-c9c1-4af3-ba72-4c46085a9b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2f05040e-c80c-471e-af07-fe17c8270008" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2f05040e-c80c-471e-af07-fe17c8270008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e35dac34-0f41-403f-97c7-0318afc95dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6639f267-d2bf-4044-a4f1-6b9f67e51580" xlink:to="loc_us-gaap_Goodwill_e35dac34-0f41-403f-97c7-0318afc95dcd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAggregateAcquisitionConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20191231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesOperatingLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_64aca4a0-4022-4581-8df7-c430a30cc35b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8f34ce6-4f77-411f-80d8-b24e73c0e061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_64aca4a0-4022-4581-8df7-c430a30cc35b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8f34ce6-4f77-411f-80d8-b24e73c0e061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be5dea9d-7ae2-410c-9d46-192a3d626c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_64aca4a0-4022-4581-8df7-c430a30cc35b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be5dea9d-7ae2-410c-9d46-192a3d626c31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a964528d-2009-4b73-9b4c-172e73be5018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a964528d-2009-4b73-9b4c-172e73be5018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94b466b5-ed73-4e8a-a403-02f4594cb235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94b466b5-ed73-4e8a-a403-02f4594cb235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb4e5547-bd89-409b-8e8c-3106f228ea8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb4e5547-bd89-409b-8e8c-3106f228ea8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8eef007-ff5a-4601-a5cd-3162ba4fdc36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8eef007-ff5a-4601-a5cd-3162ba4fdc36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6d0d4fe7-5ad1-45b2-b2f2-bcc8381ede6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6d0d4fe7-5ad1-45b2-b2f2-bcc8381ede6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_20d287e5-1ddd-4068-8200-ccae02d9ff1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d23c7e3-c3b7-4174-816d-cff833c8e385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_20d287e5-1ddd-4068-8200-ccae02d9ff1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d2f5bf0-7266-4873-95a4-863b5b48e9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83d873fb-db0b-444e-b55b-dee2a3e20c36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d2f5bf0-7266-4873-95a4-863b5b48e9e2" xlink:to="loc_us-gaap_OperatingLeaseLiability_83d873fb-db0b-444e-b55b-dee2a3e20c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b7e48f45-d0f4-4ee8-9f3f-a0ab0d0bcbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d2f5bf0-7266-4873-95a4-863b5b48e9e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b7e48f45-d0f4-4ee8-9f3f-a0ab0d0bcbb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotes"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_423a2089-2daa-4eb1-af94-c9b4b6d44047" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9baa6ec0-99dd-4738-9411-ec5db1f88763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_423a2089-2daa-4eb1-af94-c9b4b6d44047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9baa6ec0-99dd-4738-9411-ec5db1f88763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8ba28200-850b-43e9-9d10-e67e16bbce92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_423a2089-2daa-4eb1-af94-c9b4b6d44047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8ba28200-850b-43e9-9d10-e67e16bbce92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e89e090-7b1c-4db4-864e-1f485445cb80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_423a2089-2daa-4eb1-af94-c9b4b6d44047" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e89e090-7b1c-4db4-864e-1f485445cb80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3eee3ac9-4773-4b6e-922d-e38ea8de1143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7b8bdacb-66d9-4880-bec0-790aaa57847b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3eee3ac9-4773-4b6e-922d-e38ea8de1143" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7b8bdacb-66d9-4880-bec0-790aaa57847b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24c8cc80-769e-4993-ba33-2b294c3df17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3eee3ac9-4773-4b6e-922d-e38ea8de1143" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_24c8cc80-769e-4993-ba33-2b294c3df17a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5cceb7d6-c40a-40df-bd1e-2d1a26da5b40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_096ee8de-cdc5-43e9-b9cf-d2a8ef826a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5cceb7d6-c40a-40df-bd1e-2d1a26da5b40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_096ee8de-cdc5-43e9-b9cf-d2a8ef826a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c4aca034-4dfa-40f5-bdcb-ff8f364d9b30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5cceb7d6-c40a-40df-bd1e-2d1a26da5b40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c4aca034-4dfa-40f5-bdcb-ff8f364d9b30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b87b389-532e-4b35-96a5-ca19cbe790c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b87b389-532e-4b35-96a5-ca19cbe790c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_10217114-df7a-4f8f-a551-a9255c2ed1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_10217114-df7a-4f8f-a551-a9255c2ed1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_78705923-ae98-47e9-9870-341939118479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_78705923-ae98-47e9-9870-341939118479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b86bab6a-2692-430f-868b-0656e95b3e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b86bab6a-2692-430f-868b-0656e95b3e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedStockRepurchases_69754d23-8130-4049-8ca9-bbefe4728abc" xlink:href="lgnd-20191231.xsd#lgnd_AccruedStockRepurchases"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_lgnd_AccruedStockRepurchases_69754d23-8130-4049-8ca9-bbefe4728abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_9ccac3ac-d933-43ce-9de7-b8474b39001e" xlink:href="lgnd-20191231.xsd#lgnd_AccruedSalesReturns"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_lgnd_AccruedSalesReturns_9ccac3ac-d933-43ce-9de7-b8474b39001e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_7e815df5-1a5a-4b5a-b6c7-18f9b6da78bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_RestructuringReserveCurrent_7e815df5-1a5a-4b5a-b6c7-18f9b6da78bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_b68ba7df-fd06-454d-a105-767d4b9954f6" xlink:href="lgnd-20191231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_lgnd_LeaseLiabilityCurrent_b68ba7df-fd06-454d-a105-767d4b9954f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3d3510ff-fd69-4076-8fe2-12ce86ee7b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7fc23e-a702-4271-8aa7-c4aa32cbbc86" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3d3510ff-fd69-4076-8fe2-12ce86ee7b65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CommitmentsandContingenciesLegalProceedings"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b986908-c544-4c76-b955-c1c34909a25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c2097d00-9129-4baf-911d-8be8cb014f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b986908-c544-4c76-b955-c1c34909a25e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c2097d00-9129-4baf-911d-8be8cb014f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_12c57d30-2838-4ac5-9500-b337c397dc44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b986908-c544-4c76-b955-c1c34909a25e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_12c57d30-2838-4ac5-9500-b337c397dc44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6e199da0-305f-48c3-a520-0648f492d0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6b986908-c544-4c76-b955-c1c34909a25e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6e199da0-305f-48c3-a520-0648f492d0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9f24e57a-d1fb-46a2-8ddc-962a7bb2f17d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dd87dc59-53c9-45b3-b90b-ed5f20185578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9f24e57a-d1fb-46a2-8ddc-962a7bb2f17d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dd87dc59-53c9-45b3-b90b-ed5f20185578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db38e606-8069-4e42-be5c-f09c637f6cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9f24e57a-d1fb-46a2-8ddc-962a7bb2f17d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db38e606-8069-4e42-be5c-f09c637f6cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5d90f1f9-270e-4188-b456-721991024595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9f24e57a-d1fb-46a2-8ddc-962a7bb2f17d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5d90f1f9-270e-4188-b456-721991024595" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1c2f107f-05fd-4c09-9f19-6b521e55cbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1c2f107f-05fd-4c09-9f19-6b521e55cbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_95c41385-a513-4f9e-a21c-71f9eb00df86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_95c41385-a513-4f9e-a21c-71f9eb00df86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_3e57c996-b6c4-4d3b-8ceb-62c3e6d9b19d" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_3e57c996-b6c4-4d3b-8ceb-62c3e6d9b19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_90883935-6094-425c-93e1-907ce659b8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_90883935-6094-425c-93e1-907ce659b8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_ad32f4bc-cf2f-433a-bee2-1d355aa31365" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_ad32f4bc-cf2f-433a-bee2-1d355aa31365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_813ecb52-628a-41c5-866a-0a7beaf27030" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_813ecb52-628a-41c5-866a-0a7beaf27030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_f764bb23-c58e-455b-8d5d-a3ef09c749fe" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_f764bb23-c58e-455b-8d5d-a3ef09c749fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2f96ec64-c88a-496c-8446-3f8d0542f13a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2f96ec64-c88a-496c-8446-3f8d0542f13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8531dfef-aafe-4a3c-b598-c87b93ea6bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8531dfef-aafe-4a3c-b598-c87b93ea6bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_060e30e5-bfa0-4672-8483-306d66c29146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_060e30e5-bfa0-4672-8483-306d66c29146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_c7c5c311-6121-4680-a02a-d5c966c374af" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_c7c5c311-6121-4680-a02a-d5c966c374af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_af9a452d-2218-4660-871e-9e70ec70ad61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d2f83343-9a82-439b-8e50-1b2214940f67" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_af9a452d-2218-4660-871e-9e70ec70ad61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_b3019e79-4fb9-43a9-ad7c-2ccb9b7bc833" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_b3019e79-4fb9-43a9-ad7c-2ccb9b7bc833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_7d79e4e5-9cf2-407e-b15c-8e873f1876c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_7d79e4e5-9cf2-407e-b15c-8e873f1876c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_af7559c0-f1f1-489a-b43e-76994be43666" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_af7559c0-f1f1-489a-b43e-76994be43666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_8cb25f76-d079-4957-9df2-add7d11f2ff2" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_8cb25f76-d079-4957-9df2-add7d11f2ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_54cba663-f135-4231-a9f3-d34470c4dd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_54cba663-f135-4231-a9f3-d34470c4dd9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2fa36d3a-ac1c-4019-b3a4-995ddfca67e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2fa36d3a-ac1c-4019-b3a4-995ddfca67e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_c06b4ec7-1872-49f4-a9cf-7eae8e76ddb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1096a1a9-2b77-4024-87df-79f8e69d11a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_c06b4ec7-1872-49f4-a9cf-7eae8e76ddb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9f5181cc-a69c-4df9-bb37-c6d70734651d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_965ef6c3-fc49-45a2-b7f4-a24422c9b1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9f5181cc-a69c-4df9-bb37-c6d70734651d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_965ef6c3-fc49-45a2-b7f4-a24422c9b1e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_607f6431-66b6-43ca-990a-c21d18941ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9f5181cc-a69c-4df9-bb37-c6d70734651d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_607f6431-66b6-43ca-990a-c21d18941ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e9706f4f-ac95-40b9-a443-806df2eef70e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e9706f4f-ac95-40b9-a443-806df2eef70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4acec124-134a-427b-888d-aa49525c23f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4acec124-134a-427b-888d-aa49525c23f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_274c4667-af7e-4bf6-99ad-6241203de75b" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_274c4667-af7e-4bf6-99ad-6241203de75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f3abcfde-b517-44fb-a421-10cb9afa0234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_f3abcfde-b517-44fb-a421-10cb9afa0234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e2054569-2a68-4010-bbd9-de112349a02e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e2054569-2a68-4010-bbd9-de112349a02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b5568402-66fb-4988-ac4d-896e99a62c08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5c985a71-9876-4d2b-8553-3331547a430b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b5568402-66fb-4988-ac4d-896e99a62c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bee054db-516f-42f8-a4d6-3d3b2fdfe9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_57da0f9f-4956-4ac6-8016-9f121ad70af7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bee054db-516f-42f8-a4d6-3d3b2fdfe9c2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_57da0f9f-4956-4ac6-8016-9f121ad70af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_27795c38-bc82-4948-92a8-95a83b112621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bee054db-516f-42f8-a4d6-3d3b2fdfe9c2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_27795c38-bc82-4948-92a8-95a83b112621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b865425c-b022-4a0b-8469-df68d2c544dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3a50d142-6a0f-45a6-830a-5b55a7594084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b865425c-b022-4a0b-8469-df68d2c544dd" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3a50d142-6a0f-45a6-830a-5b55a7594084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_14b34411-061d-4c83-9690-793287c10996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b865425c-b022-4a0b-8469-df68d2c544dd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_14b34411-061d-4c83-9690-793287c10996" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEvent" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEvent"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SubsequentEvent" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEventNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>lgnd-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended" id="ie527ce8e4d8749a596ddb79d69a5b835_3899da04-f37a-49f0-ae4c-138d498f3caf"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ieca240aa97e94d0ba8b0df88c47c7c32_054aad73-1695-4621-8535-344518b159b8"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i6e70dd4ae4eb492f85e528c629e1954f_0e673111-7c4a-40b8-aafa-ef983a6a80c9"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ia014092738754f5ebc0f39a5fd9be6a2_0a91991d-936c-45c8-b553-a69ac56889c1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7180df-56cb-49b6-aff2-88925851067f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7180df-56cb-49b6-aff2-88925851067f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_d47c119f-c0a3-4e2f-b2bf-a912a5884658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_CostDirectMaterial_d47c119f-c0a3-4e2f-b2bf-a912a5884658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cf96b841-0a0b-409b-a9f3-0d8d2e7c5adb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cf96b841-0a0b-409b-a9f3-0d8d2e7c5adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f19631ef-2195-4066-9235-169b04c3d05f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f19631ef-2195-4066-9235-169b04c3d05f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3e3a317d-336d-4b82-8353-d08dd941540d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3e3a317d-336d-4b82-8353-d08dd941540d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2e7475d9-4a35-4fa0-b979-21fa12b724b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2e7475d9-4a35-4fa0-b979-21fa12b724b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1d07e2f2-79cd-4d99-a1fd-5982ee687f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1d07e2f2-79cd-4d99-a1fd-5982ee687f8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fdc48520-6c30-4ac8-ac2e-f6d723a33875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OperatingIncomeLoss_fdc48520-6c30-4ac8-ac2e-f6d723a33875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6f541688-78a6-411b-aa6d-4424d083c61a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_GainLossOnInvestments_6f541688-78a6-411b-aa6d-4424d083c61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3108d510-c62a-40ec-b021-00e472f9d6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3108d510-c62a-40ec-b021-00e472f9d6da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b7e476ca-383f-402f-9959-f4afd941cdea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_InterestExpense_b7e476ca-383f-402f-9959-f4afd941cdea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54d8ffd0-f5e4-4780-906e-c9614a3d4eda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54d8ffd0-f5e4-4780-906e-c9614a3d4eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d4659b50-fee8-43f8-b8a2-c271dc5fbe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d4659b50-fee8-43f8-b8a2-c271dc5fbe1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dc473c4d-27b8-4b73-97b8-c647330c0274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dc473c4d-27b8-4b73-97b8-c647330c0274" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_723d3c6c-6c97-4233-9c75-38a09481adf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_723d3c6c-6c97-4233-9c75-38a09481adf6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76d790dc-845b-4eb5-a686-134b63d6f624" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_NetIncomeLoss_76d790dc-845b-4eb5-a686-134b63d6f624" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9128887a-8d00-46b6-bab0-d8ca53a47ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_EarningsPerShareBasic_9128887a-8d00-46b6-bab0-d8ca53a47ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7f132b3-041a-4322-90b4-599a55c1b904" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7f132b3-041a-4322-90b4-599a55c1b904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_46492422-716e-416a-9973-06dee132ff8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_46492422-716e-416a-9973-06dee132ff8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64a05b76-352c-42bc-b84a-18b338e8f3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64a05b76-352c-42bc-b84a-18b338e8f3b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:to="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_114ef52c-a1f6-4a3e-a207-4382573673b5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:to="loc_srt_ProductsAndServicesDomain_114ef52c-a1f6-4a3e-a207-4382573673b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:to="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_53a10077-cc5b-4c98-a0c1-08277c6353d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_us-gaap_RoyaltyMember_53a10077-cc5b-4c98-a0c1-08277c6353d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_ead50c0f-4b6c-449c-a8fa-ed5ee0496fa1" xlink:href="lgnd-20191231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_ead50c0f-4b6c-449c-a8fa-ed5ee0496fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_952060b4-7703-4349-b743-de777a0b516a" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesandProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_952060b4-7703-4349-b743-de777a0b516a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="i393017408b2546e6a0af8374b5403436_146a6da7-568b-4e13-bf84-ec29c0666641"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="iba03d90551f94c2c99d938057605455b_265847a7-8a19-4421-b050-b0a687c8f82c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4e376b25-d0a0-40ed-9523-9aa606e25706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_SharesOutstanding_4e376b25-d0a0-40ed-9523-9aa606e25706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_54790fa6-0069-4eff-8a66-d59671a960d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_54790fa6-0069-4eff-8a66-d59671a960d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c9625b8e-b3c7-4f2b-987b-8e58568cea6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c9625b8e-b3c7-4f2b-987b-8e58568cea6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ffd806eb-22ec-4a25-a02a-99accb982c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ffd806eb-22ec-4a25-a02a-99accb982c4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_72c1077c-36c5-470d-ad79-75703861fb68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_72c1077c-36c5-470d-ad79-75703861fb68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b6df279-7588-43ad-a1d2-8d8b549fbffe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b6df279-7588-43ad-a1d2-8d8b549fbffe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_270b30e3-ea81-4e95-bc9f-509086ded50d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_270b30e3-ea81-4e95-bc9f-509086ded50d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f30abc44-797d-497c-a537-1d816a1bd041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f30abc44-797d-497c-a537-1d816a1bd041" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270e6b6c-610d-422f-82a3-a650c3735bce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270e6b6c-610d-422f-82a3-a650c3735bce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_eef3c5ad-f69d-4a03-ae0e-f6eea8bed8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_eef3c5ad-f69d-4a03-ae0e-f6eea8bed8b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_bac1e171-6023-4909-81b8-f94a4e3f7503" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_bac1e171-6023-4909-81b8-f94a4e3f7503" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_fc779baa-489f-499f-a074-33e02c2b0580" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_fc779baa-489f-499f-a074-33e02c2b0580" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_601de2b8-8909-4d0c-8870-07ba0e034406" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_601de2b8-8909-4d0c-8870-07ba0e034406" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_9c70ff51-d318-45c0-a689-7b7dd659ed85" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_9c70ff51-d318-45c0-a689-7b7dd659ed85" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_a356ad3b-9f3f-43ef-9eb1-726adb1645cd" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_a356ad3b-9f3f-43ef-9eb1-726adb1645cd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ab71faf7-43fd-496e-bd3c-856b1b650d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ab71faf7-43fd-496e-bd3c-856b1b650d36" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbe06cae-9309-4731-b940-781aea7a60b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbe06cae-9309-4731-b940-781aea7a60b1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c0f3a7c1-5253-4836-b2c1-0c00392e0e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c0f3a7c1-5253-4836-b2c1-0c00392e0e3a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_fea64028-8c10-445e-8da6-6d94fa7354a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_fea64028-8c10-445e-8da6-6d94fa7354a5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_729193d7-1b14-4fcd-83c1-f63db9605e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_NetIncomeLoss_729193d7-1b14-4fcd-83c1-f63db9605e04" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd5a153d-2d6d-4201-9cc7-8a2f85f3e219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0fcf96eb-6701-49ef-8678-02482cb493f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:to="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb5b867b-f29d-4a28-8545-0515eb406300_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:to="loc_us-gaap_EquityComponentDomain_bb5b867b-f29d-4a28-8545-0515eb406300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:to="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a744089a-d327-4b6a-b65e-f1b5d76e8fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_CommonStockMember_a744089a-d327-4b6a-b65e-f1b5d76e8fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_76542a91-32f7-4d7d-9657-aac704d55d78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_76542a91-32f7-4d7d-9657-aac704d55d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cee88b26-5238-41fc-aea3-b4252917bd04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cee88b26-5238-41fc-aea3-b4252917bd04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c8d12478-511a-4840-87c1-f4e38dae4237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_RetainedEarningsMember_c8d12478-511a-4840-87c1-f4e38dae4237" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a03c09d6-a376-450a-b215-92c72cac6b72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a03c09d6-a376-450a-b215-92c72cac6b72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:to="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_074edede-a0a2-4fff-9d19-81c01e75fb43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_074edede-a0a2-4fff-9d19-81c01e75fb43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_961f70c2-2671-471b-9b47-d836cfa09502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_961f70c2-2671-471b-9b47-d836cfa09502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_b2312e53-2f9e-459c-bfee-5f45f287bf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_b2312e53-2f9e-459c-bfee-5f45f287bf3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf966f0f-c359-4121-882d-4d86ef860388_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf966f0f-c359-4121-882d-4d86ef860388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_bc9e4856-fc6f-4ca0-97aa-9a90aa7f0988" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_bc9e4856-fc6f-4ca0-97aa-9a90aa7f0988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_45340bc8-db3a-40e2-8229-5d1127222776" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_45340bc8-db3a-40e2-8229-5d1127222776" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ic0551990c22c4b8f925deb846288ff99_adcbd2ca-5a93-4775-ab29-21d52aeb8860"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ieb0140a62e6843998651f68b85419124_197cb539-13bd-43c3-8389-9735053754b1"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i4f7415c93ae54c5cb75c41fcf113f719_8ec38921-0042-4597-97f8-8813a5401ea1"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="if6866a992c194305b151d59892f59a5e_74584ed8-0161-4f1a-86ee-bd842b3d41a1"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i3dc117428ac6424da8f541ba1d21edd7_4e4b5163-9f5e-4361-8420-650735e950b8">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_e7b07d7b-05bd-406a-b4b6-d6d4d7229f71" xlink:href="lgnd-20191231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_e7b07d7b-05bd-406a-b4b6-d6d4d7229f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ed246d08-cc93-46c1-a3f9-21f44646a3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_InventoryWriteDown_ed246d08-cc93-46c1-a3f9-21f44646a3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3f3c373-e033-4960-af98-87cc43ff18ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3f3c373-e033-4960-af98-87cc43ff18ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c5be1f0f-6864-4b99-b490-ebfb0923d0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c5be1f0f-6864-4b99-b490-ebfb0923d0dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_c8f9b14d-ced1-42ff-8569-59804c10fd49" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_c8f9b14d-ced1-42ff-8569-59804c10fd49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_e881df62-03b7-45fe-879e-52f59fd85c78" xlink:href="lgnd-20191231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_LicenseUpfrontPayment_e881df62-03b7-45fe-879e-52f59fd85c78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_96906aea-c1ae-495c-8ecf-026612f2f144" xlink:href="lgnd-20191231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_96906aea-c1ae-495c-8ecf-026612f2f144" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_4fb4d8ee-481e-4466-8c78-4230250d59df" xlink:href="lgnd-20191231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_ProductRoyaltyPercentage_4fb4d8ee-481e-4466-8c78-4230250d59df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_80e47863-70e0-491b-80b1-ccff84aeb7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_80e47863-70e0-491b-80b1-ccff84aeb7ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_97e4a028-86b5-44b8-b902-3bf958748ca3" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_97e4a028-86b5-44b8-b902-3bf958748ca3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_654a009a-ad0e-46ee-8bab-d5fce89054c8" xlink:href="lgnd-20191231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_654a009a-ad0e-46ee-8bab-d5fce89054c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cb9fcdae-b6f8-48bb-9387-5fac6bc3c613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cb9fcdae-b6f8-48bb-9387-5fac6bc3c613" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb8d58cd-d72a-4f19-a7c5-bc6fd5dc1f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb8d58cd-d72a-4f19-a7c5-bc6fd5dc1f0f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_32adda45-17db-425b-86b3-47b598b27c5d" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_32adda45-17db-425b-86b3-47b598b27c5d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_551862e9-c7f3-4a36-99cc-5a30d02d86bf" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_551862e9-c7f3-4a36-99cc-5a30d02d86bf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_e26b36b8-c105-470e-9764-489b7811d8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_e26b36b8-c105-470e-9764-489b7811d8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c8e659ee-9230-4f5c-84cb-e30fede3a116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c8e659ee-9230-4f5c-84cb-e30fede3a116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80410e76-bb2e-49d8-bb98-79effce61315" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80410e76-bb2e-49d8-bb98-79effce61315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_217563cd-7dee-4634-b70f-fcf806ff1020" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_217563cd-7dee-4634-b70f-fcf806ff1020" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ab5d8550-2728-4140-bfee-e3c3c313f469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ab5d8550-2728-4140-bfee-e3c3c313f469" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0c4661df-65b6-4d5c-9c47-75c66b501cca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0c4661df-65b6-4d5c-9c47-75c66b501cca" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17d3b1f3-cf86-4d65-b563-23571692db6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17d3b1f3-cf86-4d65-b563-23571692db6b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9f5dc422-6581-41c5-9c6e-65580b0015f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DerivativeAssets_9f5dc422-6581-41c5-9c6e-65580b0015f8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_982b1c41-f6e3-4a26-9607-ee5cb7c2358e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DerivativeLiabilities_982b1c41-f6e3-4a26-9607-ee5cb7c2358e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba796a7f-e85f-48ea-bd68-175e68c875e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba796a7f-e85f-48ea-bd68-175e68c875e9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f97da9c8-283c-4248-bcd2-ff15a31ecc55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f97da9c8-283c-4248-bcd2-ff15a31ecc55" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b688113-ebfd-4109-8a58-ea04ac280428_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b688113-ebfd-4109-8a58-ea04ac280428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8769802f-542b-4a22-9890-48d3e6a230fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8769802f-542b-4a22-9890-48d3e6a230fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8a00d051-72ac-48d2-891e-06df16703d5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8a00d051-72ac-48d2-891e-06df16703d5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_8383a079-b8b2-4e04-a0eb-711cf6362f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_8383a079-b8b2-4e04-a0eb-711cf6362f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d370df26-625f-4144-868a-5957aaad6842_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d370df26-625f-4144-868a-5957aaad6842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_fe85cb00-d2e6-4a0c-95cd-c93db1caf369" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_fe85cb00-d2e6-4a0c-95cd-c93db1caf369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_4d51a02a-8be6-4a0e-b5ff-65ce919620d3" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_4d51a02a-8be6-4a0e-b5ff-65ce919620d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a6843189-13c6-446f-967c-8279b058a23c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a6843189-13c6-446f-967c-8279b058a23c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aab687ee-9fb5-438e-a919-b8f1de30b644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:to="loc_us-gaap_SeniorNotesMember_aab687ee-9fb5-438e-a919-b8f1de30b644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b00ac13-dcf5-4f13-aca0-27b8c311c63f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b00ac13-dcf5-4f13-aca0-27b8c311c63f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_6e8416d4-d574-45f5-894d-c099a8a49d6a" xlink:href="lgnd-20191231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_NovanMolluscumProductsMember_6e8416d4-d574-45f5-894d-c099a8a49d6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_3d4c8e46-d383-4ddc-a1a5-b1def10a6751" xlink:href="lgnd-20191231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_3d4c8e46-d383-4ddc-a1a5-b1def10a6751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_225442d8-eb35-457a-b285-fb2a43b91569" xlink:href="lgnd-20191231.xsd#lgnd_AziyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_AziyoMember_225442d8-eb35-457a-b285-fb2a43b91569" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_e334d34f-d5f2-447a-a9d4-ef7acf7ae46c" xlink:href="lgnd-20191231.xsd#lgnd_CorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_CorMatrixMember_e334d34f-d5f2-447a-a9d4-ef7acf7ae46c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_2792fe41-e401-464f-a50c-56cd539e58e8" xlink:href="lgnd-20191231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_SelexisMember_2792fe41-e401-464f-a50c-56cd539e58e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b59669f-b148-4ff1-b8db-4908e34c7110_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b59669f-b148-4ff1-b8db-4908e34c7110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_0f6a43b8-29a7-4a44-9987-98dd3980ff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_0f6a43b8-29a7-4a44-9987-98dd3980ff6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_14643de5-9bb1-47a5-aae6-4901b8e1912f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:to="loc_us-gaap_LicensingAgreementsMember_14643de5-9bb1-47a5-aae6-4901b8e1912f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7076622b-01c7-4950-9454-237d14024dae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7076622b-01c7-4950-9454-237d14024dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_de8d9f31-f9f2-42d8-aa7b-6193563b76d1" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:to="loc_lgnd_CrystalMember_de8d9f31-f9f2-42d8-aa7b-6193563b76d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_32947c85-2ce1-49f3-b342-e98b10eb6443" xlink:href="lgnd-20191231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_32947c85-2ce1-49f3-b342-e98b10eb6443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:to="loc_srt_RangeMember_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:to="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cda9f26f-05f2-4b4e-9578-ec8be4d2872d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:to="loc_srt_MinimumMember_cda9f26f-05f2-4b4e-9578-ec8be4d2872d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_303b18b5-6eec-4507-870f-8d9f56c2786a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:to="loc_srt_MaximumMember_303b18b5-6eec-4507-870f-8d9f56c2786a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d1101ef-584a-4c9e-b33c-af506e72c325_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d1101ef-584a-4c9e-b33c-af506e72c325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4e50735d-48ea-4aad-baa6-dcff308ee432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4e50735d-48ea-4aad-baa6-dcff308ee432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:to="loc_us-gaap_VestingDomain_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:to="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_c7d4dfef-827b-4ce5-a2c6-f157ba3a0de8" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:to="loc_lgnd_VestingPeriodOneMember_c7d4dfef-827b-4ce5-a2c6-f157ba3a0de8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_648eb0bd-c54a-492a-8785-7554ce1280db" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:to="loc_lgnd_VestingPeriodTwoMember_648eb0bd-c54a-492a-8785-7554ce1280db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_763d9aed-b379-4008-8233-f9fb5aab7a50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:to="loc_us-gaap_PlanNameDomain_763d9aed-b379-4008-8233-f9fb5aab7a50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:to="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_887e3a55-e43a-45c3-b4c7-2dabd8911911" xlink:href="lgnd-20191231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_887e3a55-e43a-45c3-b4c7-2dabd8911911" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended" id="i9a4866d0b4044620900e0670f0f4c780_f979b597-4331-4e0c-b1d7-771c3b142be8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c8c29081-e186-4df1-a50a-c1bb0e29f470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c8c29081-e186-4df1-a50a-c1bb0e29f470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e7b17b47-3e85-4964-b46d-78a6ac5afbaa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e7b17b47-3e85-4964-b46d-78a6ac5afbaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_27c57552-2a93-4297-b1dc-de814f54869f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_27c57552-2a93-4297-b1dc-de814f54869f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18c08623-51a2-4951-bf18-913d3ede23f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18c08623-51a2-4951-bf18-913d3ede23f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_533ae195-c52a-4ba9-af62-f7c1ed0cffba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:to="loc_us-gaap_SalesRevenueNetMember_533ae195-c52a-4ba9-af62-f7c1ed0cffba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae2efe67-6967-4e66-91c7-af2bce5a7171_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae2efe67-6967-4e66-91c7-af2bce5a7171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:to="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_01422290-7097-41ee-8507-9f0439e273cf" xlink:href="lgnd-20191231.xsd#lgnd_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerAMember_01422290-7097-41ee-8507-9f0439e273cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_857b7ed4-f683-4800-87f9-14b77f6514f8" xlink:href="lgnd-20191231.xsd#lgnd_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerBMember_857b7ed4-f683-4800-87f9-14b77f6514f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_02402cf9-7c73-4b79-bbca-9c6f357bc691" xlink:href="lgnd-20191231.xsd#lgnd_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerCMember_02402cf9-7c73-4b79-bbca-9c6f357bc691" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended" id="i58e016a124c143fa93a20d339dd60f2d_46d3e1c6-c08f-4fee-a0d8-40a5c9874911">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ca3b253a-bc3e-4745-b567-6ca7bbf353db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ca3b253a-bc3e-4745-b567-6ca7bbf353db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c7c7ba38-370d-44b1-aff3-17d1847850a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c7c7ba38-370d-44b1-aff3-17d1847850a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277ae085-190e-4bb6-bd4c-97124692a581" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277ae085-190e-4bb6-bd4c-97124692a581" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_291f95e8-a746-4674-97f0-29143fb9f19e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_291f95e8-a746-4674-97f0-29143fb9f19e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_ac2d0fdf-f7fa-4569-9a45-d469320f145c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:to="loc_us-gaap_LicensingAgreementsMember_ac2d0fdf-f7fa-4569-9a45-d469320f145c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:to="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28795094-1e2c-4db9-94db-6e44a36d6d3c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28795094-1e2c-4db9-94db-6e44a36d6d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_63e27f1c-b563-4917-96ff-a4b389eea0f6" xlink:href="lgnd-20191231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_AziyoandCorMatrixMember_63e27f1c-b563-4917-96ff-a4b389eea0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_6de038ee-42b8-432e-bed2-b04d7d90e4ba" xlink:href="lgnd-20191231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_6de038ee-42b8-432e-bed2-b04d7d90e4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_5b84349b-1c5b-4c50-ba38-97a6a61192ee" xlink:href="lgnd-20191231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_SelexisMember_5b84349b-1c5b-4c50-ba38-97a6a61192ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DianomiMember_25d5deb5-ec87-4ad4-8809-e2dee73e5ce5" xlink:href="lgnd-20191231.xsd#lgnd_DianomiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_DianomiMember_25d5deb5-ec87-4ad4-8809-e2dee73e5ce5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended" id="i520a0de5f69b497ba16ef484a1a1c9d8_bda83975-f6ad-4e65-8211-c65f7337a868">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_640d4a49-f002-4c6e-83b7-9c7957d3e635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_640d4a49-f002-4c6e-83b7-9c7957d3e635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73fe3c30-3624-4c28-bcc1-6e033dfb62b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_73fe3c30-3624-4c28-bcc1-6e033dfb62b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_dfce1d6e-c46e-4252-8cfc-bd3fb14d4518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_dfce1d6e-c46e-4252-8cfc-bd3fb14d4518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:to="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c619e88-8741-4ba8-914e-c5f8fc6441af_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:to="loc_srt_ProductsAndServicesDomain_7c619e88-8741-4ba8-914e-c5f8fc6441af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:to="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:to="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_819018ac-d409-454d-b0cd-f8d34d0ce674" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyPromactaMember_819018ac-d409-454d-b0cd-f8d34d0ce674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_18eac395-bd27-4bff-ad5c-cd2c150ea4a1" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyKyprolisMember_18eac395-bd27-4bff-ad5c-cd2c150ea4a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_c7f4788d-dbf3-46e1-af14-fdf95ad4bd17" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyEvomelaMember_c7f4788d-dbf3-46e1-af14-fdf95ad4bd17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_c31d598a-86a6-4821-9db5-f679511f3ede" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyOtherMember_c31d598a-86a6-4821-9db5-f679511f3ede" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended" id="i2da266d4db794d02893a84c5543f94ef_b3a1d9cd-8fe9-4929-ae5e-b2134f7126e5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcb3abe-4aa5-4402-b93b-0aa0bc62977a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcb3abe-4aa5-4402-b93b-0aa0bc62977a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:to="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ec219ec-a07d-4165-aad9-b5a1b996368e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:to="loc_srt_ProductsAndServicesDomain_4ec219ec-a07d-4165-aad9-b5a1b996368e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:to="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_c2f60474-3272-4144-9f5f-f75a389aba82" xlink:href="lgnd-20191231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_c2f60474-3272-4144-9f5f-f75a389aba82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesandProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:to="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_366d82c4-b922-4e4d-b5ad-163938e8ff84" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_LicenseFeesMember_366d82c4-b922-4e4d-b5ad-163938e8ff84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_d8b98912-a7fb-4e88-845d-0521b3b002ba" xlink:href="lgnd-20191231.xsd#lgnd_MilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_MilestoneMember_d8b98912-a7fb-4e88-845d-0521b3b002ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_74403949-db96-42ea-a70a-9e1903e172ae" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_74403949-db96-42ea-a70a-9e1903e172ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended" id="if30b8a58c39949c6897571551d1c517d_71fa6d4a-ffff-41a6-957c-66f5d21a7064"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicense"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="extended" id="i6b6e2137f2db4ac1b0c7509b2a9e73eb_3ae0b10b-0e29-41f7-b0b4-4fc36c620e85"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicenseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="extended" id="i67d6a2b77ea7496d941bd01589d9d2ac_a967f99a-5609-425a-9360-635b30cb9c0c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_91115f72-db77-4163-8a17-a644eb5ab837" xlink:href="lgnd-20191231.xsd#lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_91115f72-db77-4163-8a17-a644eb5ab837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4765ad45-4c83-4986-ad05-cf93f1bbb49a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4765ad45-4c83-4986-ad05-cf93f1bbb49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_35fd7f39-f915-45a4-a58e-8a46107e4ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_35fd7f39-f915-45a4-a58e-8a46107e4ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_59e65eab-2ce8-4701-83bd-2c47446aa4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_59e65eab-2ce8-4701-83bd-2c47446aa4ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9ac783a4-6385-42ba-8296-8b44f468e502_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9ac783a4-6385-42ba-8296-8b44f468e502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8fb6fb26-74cf-4767-a730-59a947ccac09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8fb6fb26-74cf-4767-a730-59a947ccac09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:to="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21ab2cfb-be44-422c-ab93-fd9724f24d3a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:to="loc_srt_ProductsAndServicesDomain_21ab2cfb-be44-422c-ab93-fd9724f24d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:to="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_a1888e0b-26ca-4e3e-9f14-5bdf9378ea67" xlink:href="lgnd-20191231.xsd#lgnd_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:to="loc_lgnd_PromactaMember_a1888e0b-26ca-4e3e-9f14-5bdf9378ea67" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinViking" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinViking"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/InvestmentinViking" xlink:type="extended" id="i8fb28f0cfb95440aabdb1854b06a74fa_d7119c08-0c86-4ea4-adef-b8eec7995e7e"/>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinVikingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="extended" id="i745f849616e74247aeb5b3d985c7a0b4_1ee2bc90-5732-4fa1-9bd1-8d198b33a43a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_514463fa-97d5-48ac-823a-85ecd0365aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_514463fa-97d5-48ac-823a-85ecd0365aef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment_b9d2834b-1a88-41a1-9715-0093d20773aa" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseinEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment_b9d2834b-1a88-41a1-9715-0093d20773aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_a7bb683f-0656-43ad-9571-c0d213d65828" xlink:href="lgnd-20191231.xsd#lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_a7bb683f-0656-43ad-9571-c0d213d65828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_089f4b56-5aae-48ab-a9d6-d380abb2de1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_089f4b56-5aae-48ab-a9d6-d380abb2de1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_28826e68-b475-4e17-a650-76f64a3f4650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_28826e68-b475-4e17-a650-76f64a3f4650" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2e954b12-c693-43d5-adae-0d289e11f3da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2e954b12-c693-43d5-adae-0d289e11f3da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_1b9b0185-c3be-495a-9384-d2c64c0f64e2" xlink:href="lgnd-20191231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_InvestmentInVikingCurrent_1b9b0185-c3be-495a-9384-d2c64c0f64e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:to="loc_srt_OwnershipDomain_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:to="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_08998de2-b7d3-4709-a41e-3e290742828e" xlink:href="lgnd-20191231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_08998de2-b7d3-4709-a41e-3e290742828e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e560462-427b-4425-b6f0-6fd1f242edb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e560462-427b-4425-b6f0-6fd1f242edb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_056e94a0-c4da-4428-a554-255d86efd330" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:to="loc_us-gaap_WarrantMember_056e94a0-c4da-4428-a554-255d86efd330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55003a07-64b9-4290-ba36-dd2ddead4b51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:to="loc_us-gaap_RelatedPartyDomain_55003a07-64b9-4290-ba36-dd2ddead4b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:to="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_c354acc8-3a38-4207-b966-199235769b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_c354acc8-3a38-4207-b966-199235769b5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinations" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinations"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BusinessCombinations" xlink:type="extended" id="ie758c35646ea4cd2ab31f74e2a89804b_d6746b25-2cb4-4c17-8ba1-00448a912004"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="extended" id="i11fffa7773224ac484594eb80a0244d4_61f87691-85a4-4cea-a588-a8b6b2695cd5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2c14d6ee-3db0-45d2-8955-b3efd30778d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2c14d6ee-3db0-45d2-8955-b3efd30778d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_ebcfd671-ee7f-43b3-87fa-ec05ee825336" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:to="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_ebcfd671-ee7f-43b3-87fa-ec05ee825336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48c2e53a-db09-4759-b528-609fbbcb8b9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48c2e53a-db09-4759-b528-609fbbcb8b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_85e27b32-155d-4dd8-a520-2e1c51b68e59" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_AbInitioMember_85e27b32-155d-4dd8-a520-2e1c51b68e59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_1907e3d5-c2a4-46b6-9608-ae0dae63c6b7" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_VernalisMember_1907e3d5-c2a4-46b6-9608-ae0dae63c6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_1cccb1cb-877a-41aa-b6d1-b323a467b9c7" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_CrystalMember_1cccb1cb-877a-41aa-b6d1-b323a467b9c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="ifd3864e0d6704e9895a7e95273aa5b79_fe03ec49-91f1-4928-971d-ab9aa24f1a22">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5b7e946c-e4f6-4f46-8cf3-5430ea798f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5b7e946c-e4f6-4f46-8cf3-5430ea798f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5ee8af80-5c5b-432c-be31-9d951455b1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5ee8af80-5c5b-432c-be31-9d951455b1a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_a63047c7-908c-492c-9e6d-ece8103c2891" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_a63047c7-908c-492c-9e6d-ece8103c2891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_b6fd5e42-8001-451a-ba81-c71dd841e8b7" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_b6fd5e42-8001-451a-ba81-c71dd841e8b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4d133d2-87df-4769-b203-407d957f39ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4d133d2-87df-4769-b203-407d957f39ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WorkingCapitalAdjustment_97b21665-42e3-4087-b2c3-70e8a627a9b7" xlink:href="lgnd-20191231.xsd#lgnd_WorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_WorkingCapitalAdjustment_97b21665-42e3-4087-b2c3-70e8a627a9b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_b9718006-18fe-4256-a48c-710ea9e6799a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_b9718006-18fe-4256-a48c-710ea9e6799a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_4d907e4f-dc6d-48d0-99b0-ba77a4680501" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRoyaltytoAcquireeShareholdersPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_4d907e4f-dc6d-48d0-99b0-ba77a4680501" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_ac4288ab-7c2c-48e8-8374-d5eda05256c2" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_ac4288ab-7c2c-48e8-8374-d5eda05256c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberofCollaborationAgreements_ebaa3939-8b35-43ea-b186-51794673efb0" xlink:href="lgnd-20191231.xsd#lgnd_NumberofCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_NumberofCollaborationAgreements_ebaa3939-8b35-43ea-b186-51794673efb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPayable_44457989-b77a-43a6-9294-ab0ab0841ff9" xlink:href="lgnd-20191231.xsd#lgnd_CashPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_CashPayable_44457989-b77a-43a6-9294-ab0ab0841ff9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_4ea5d190-8bef-4454-a66d-68b04f1bf95c" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_4ea5d190-8bef-4454-a66d-68b04f1bf95c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_f22b5acd-93ea-41c4-a835-82dde6bd5c37" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_f22b5acd-93ea-41c4-a835-82dde6bd5c37" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b160995c-44a8-4ef1-b8de-166e3ac2241e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_Goodwill_b160995c-44a8-4ef1-b8de-166e3ac2241e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentDomain_536e7db0-1167-43fa-aa31-1488be6e8d08_default" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:to="loc_lgnd_VariableRateComponentDomain_536e7db0-1167-43fa-aa31-1488be6e8d08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:to="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_694a4be0-c57e-42a9-a28a-cc04da168e43" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:to="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_694a4be0-c57e-42a9-a28a-cc04da168e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_16513877-24fc-4b23-887e-1e2dd4e8cfd1" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:to="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_16513877-24fc-4b23-887e-1e2dd4e8cfd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d08fbd83-f175-4ee2-931b-f94b44117318_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d08fbd83-f175-4ee2-931b-f94b44117318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a6f0cd86-8ffd-42ca-b29f-93ca1e92cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a6f0cd86-8ffd-42ca-b29f-93ca1e92cf07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5e4ff18-38ff-45be-b642-8939ecda4c16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5e4ff18-38ff-45be-b642-8939ecda4c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_25ffcaf3-7b2d-4959-8fc8-7f39e50db34b" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_AbInitioMember_25ffcaf3-7b2d-4959-8fc8-7f39e50db34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_59fccb43-3670-4260-8499-0088c36bbf90" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_VernalisMember_59fccb43-3670-4260-8499-0088c36bbf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_815431a2-6119-4845-9975-ce3a739f3976" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_CrystalMember_815431a2-6119-4845-9975-ce3a739f3976" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i1118e7534a1748409b7232fdc8ba4a68_8243d6cb-1a50-42af-9223-1d0275984753">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8e6fda93-9e5b-4a4c-9303-d09ae4a0a9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8e6fda93-9e5b-4a4c-9303-d09ae4a0a9fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f02d64c6-b9bc-48a4-899c-86252d44e6ef" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f02d64c6-b9bc-48a4-899c-86252d44e6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_daa6078d-eb00-4e24-ac6a-5574292923a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_daa6078d-eb00-4e24-ac6a-5574292923a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1b04fcaa-1b8a-46aa-9b35-088873409c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1b04fcaa-1b8a-46aa-9b35-088873409c6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f4cd42ac-f23e-42fc-9d07-113e67d270c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f4cd42ac-f23e-42fc-9d07-113e67d270c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_830a62ec-1ef9-401a-a612-1860fd0c90b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_830a62ec-1ef9-401a-a612-1860fd0c90b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_923e0404-3784-4c0f-83a6-1ceacf9c8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_923e0404-3784-4c0f-83a6-1ceacf9c8acf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_4e3875dd-a23e-4ee3-9af1-357c7a425d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_4e3875dd-a23e-4ee3-9af1-357c7a425d2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7115f985-5198-4fb4-a631-95db7054c0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_RestructuringReserve_7115f985-5198-4fb4-a631-95db7054c0e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_b62b111f-7cfd-4763-85a8-15ed5839e601" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_b62b111f-7cfd-4763-85a8-15ed5839e601" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7ba8db27-37a5-4c46-813a-3e45dd751735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7ba8db27-37a5-4c46-813a-3e45dd751735" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5aed3886-d8e3-4ec4-8f7a-3c202f4b2a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5aed3886-d8e3-4ec4-8f7a-3c202f4b2a2c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a828b42a-da36-4afd-8452-61d02a572dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_Goodwill_a828b42a-da36-4afd-8452-61d02a572dc9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d57a7836-6fc1-4c8a-9ccd-46cfd11074ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d57a7836-6fc1-4c8a-9ccd-46cfd11074ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de8b0547-44d4-478f-bb27-49abce51a6cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de8b0547-44d4-478f-bb27-49abce51a6cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_83f106fe-13e8-4c14-ab6a-a9d8c4cde7f3" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_AbInitioMember_83f106fe-13e8-4c14-ab6a-a9d8c4cde7f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_38d2acde-19ff-483f-89c5-f319f1a40ea4" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_VernalisMember_38d2acde-19ff-483f-89c5-f319f1a40ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_6102564c-1de1-4226-aa53-33011a4d6a8a" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_CrystalMember_6102564c-1de1-4226-aa53-33011a4d6a8a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAggregateAcquisitionConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="extended" id="iefeafe64b6774d378a152d637caf44ae_6edd5525-7e73-4023-9241-ad5c4be75eaf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidtoAcquireBusiness_efd7e7de-7cb3-4956-99d3-263c52784d42" xlink:href="lgnd-20191231.xsd#lgnd_CashPaidtoAcquireBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_CashPaidtoAcquireBusiness_efd7e7de-7cb3-4956-99d3-263c52784d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPayable_f1c07f9f-605a-4825-87b8-d9a1a60f7a5c" xlink:href="lgnd-20191231.xsd#lgnd_CashPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_CashPayable_f1c07f9f-605a-4825-87b8-d9a1a60f7a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e43f4445-a49e-467a-812b-31afebccf703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e43f4445-a49e-467a-812b-31afebccf703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_d454b230-ba25-40c8-a3d3-02a5e83bba0e" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_d454b230-ba25-40c8-a3d3-02a5e83bba0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a57aba1-7d7c-4781-93d7-765e03f63bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a57aba1-7d7c-4781-93d7-765e03f63bc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_5a954bc9-a055-43d8-b95e-9d40432f1e55" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:to="loc_lgnd_CrystalMember_5a954bc9-a055-43d8-b95e-9d40432f1e55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended" id="i96a951d7bb074e10aadabeb21f1a057a_901fdc88-f0b0-43b3-aa3a-4f82c8a39732"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended" id="ibb353fb7a7844eeb927136a76d466392_56a16cdc-4da7-4ae5-a50d-3b8b18afdeb1"/>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i3324050fbbd54a7e9534e201fc1558ad_1f317b75-6aa6-4a76-94f5-2c6cdeba1f21">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5035367-35ea-4fe9-bd63-23ee9223e81b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f5035367-35ea-4fe9-bd63-23ee9223e81b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_83584fe3-ba24-4e2d-8c8d-50cf735574ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_83584fe3-ba24-4e2d-8c8d-50cf735574ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_58616552-6009-4572-921c-821fd3158cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_58616552-6009-4572-921c-821fd3158cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_fda0990a-4acf-4a6a-8f51-7c251910b6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_fda0990a-4acf-4a6a-8f51-7c251910b6ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9cd8c4da-a5cc-4981-b496-d6de62c1faf7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:to="loc_srt_RangeMember_9cd8c4da-a5cc-4981-b496-d6de62c1faf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:to="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_896b9475-825a-4101-94e3-f1f74b87d230" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:to="loc_srt_MaximumMember_896b9475-825a-4101-94e3-f1f74b87d230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_28314f27-c722-42af-bb76-16b7e1011832" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:to="loc_us-gaap_TransferredOverTimeMember_28314f27-c722-42af-bb76-16b7e1011832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1d40c3a-b06b-476a-9174-fdbaee2185fa_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:to="loc_srt_ProductsAndServicesDomain_a1d40c3a-b06b-476a-9174-fdbaee2185fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:to="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b31ca3b6-dac8-44c2-8690-0b9fa9f0e495" xlink:href="lgnd-20191231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b31ca3b6-dac8-44c2-8690-0b9fa9f0e495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_7439fa86-ec5b-4991-83e3-dbb340fd84f0" xlink:href="lgnd-20191231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_7439fa86-ec5b-4991-83e3-dbb340fd84f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e4ecc12-7684-45e7-b2e9-6979120b00e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e4ecc12-7684-45e7-b2e9-6979120b00e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_90f5c056-befd-476f-9fc6-4313001d54ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_90f5c056-befd-476f-9fc6-4313001d54ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51445926-99e6-4e02-963b-b87bc52fee55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51445926-99e6-4e02-963b-b87bc52fee55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9559f2aa-f7e6-4f55-900b-00c09c68a283" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9559f2aa-f7e6-4f55-900b-00c09c68a283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_13642ad0-863c-4dc8-ac80-9d51f6d3d23f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_13642ad0-863c-4dc8-ac80-9d51f6d3d23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29237339-57d3-4738-8fbe-cc2201d910b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29237339-57d3-4738-8fbe-cc2201d910b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_82a1f3df-e81d-44ed-bd26-b776e552f4bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_82a1f3df-e81d-44ed-bd26-b776e552f4bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_41fffad0-7cd6-4d7d-bfe5-dce36e4af21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_41fffad0-7cd6-4d7d-bfe5-dce36e4af21d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b4cacead-be26-49c6-89da-3326d23a939f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_EquitySecuritiesMember_b4cacead-be26-49c6-89da-3326d23a939f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_da006f90-fccc-4baf-9630-0e7b1d94331e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_WarrantMember_da006f90-fccc-4baf-9630-0e7b1d94331e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_71802db5-3fd3-4d58-8d9a-3079c46594f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_71802db5-3fd3-4d58-8d9a-3079c46594f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_de09b5b2-f948-4934-9e40-3a5411380d3c" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_de09b5b2-f948-4934-9e40-3a5411380d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_5bb13a0a-11ba-4b42-995c-6c8440a01ccb" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_5bb13a0a-11ba-4b42-995c-6c8440a01ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_8ae51d38-628b-4bf2-b863-f397aff95023" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_8ae51d38-628b-4bf2-b863-f397aff95023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_622d510d-d7e4-480e-8737-f36aece6af6f" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_622d510d-d7e4-480e-8737-f36aece6af6f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i3a82074c528d4a6e867e6e01267bf416_f0d9aa12-f72b-4318-8369-30d4ef959256">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4d4d998f-714e-4418-9b0e-f88c915b80dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4d4d998f-714e-4418-9b0e-f88c915b80dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c069f53c-5f47-4e14-b97a-82a84306328d" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c069f53c-5f47-4e14-b97a-82a84306328d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_1253dd5b-6515-4026-8bb5-558ae24849bf" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_1253dd5b-6515-4026-8bb5-558ae24849bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9820d8cc-7cd6-4130-bbd7-6fd569ab4519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_896e5f6a-2696-4b74-b948-9beecb4afd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_896e5f6a-2696-4b74-b948-9beecb4afd12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="iaed2dc4272404f6d8739f882bcfa4a11_ac1a31fb-73cf-4bc3-b0ff-a085de3f19f5"/>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20191231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended" id="ied608d8d61754378911de0aaeae58f26_ab665511-6f30-4d04-b6a0-512033da043d"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended" id="i528b8ce549d34efa95b004a533bc664a_8eec55df-280d-4966-8dd3-43c999dc24a7"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ifc1451a0bbc249a0bd8c903b3d51b0f8_7c21d32e-7935-46bf-847f-5799abae270c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_7a1d695c-2607-4d54-a402-cde6d179f07d" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_NumberOfAcquisitions_7a1d695c-2607-4d54-a402-cde6d179f07d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_c2394936-70a3-43b3-bb76-63ce547ef682" xlink:href="lgnd-20191231.xsd#lgnd_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_c2394936-70a3-43b3-bb76-63ce547ef682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9358cdc-8e02-4936-990c-de8320946eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9358cdc-8e02-4936-990c-de8320946eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets_6cc5a89a-defb-4cf2-8908-9b11c7ace78b" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets_6cc5a89a-defb-4cf2-8908-9b11c7ace78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_9dbd273d-1cab-4f81-9481-5830a77ba79a" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_9dbd273d-1cab-4f81-9481-5830a77ba79a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7beaaab-12e1-4853-a3d7-a01b85187ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7beaaab-12e1-4853-a3d7-a01b85187ba5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a36e265-3b52-4482-961e-b2da10db6ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a36e265-3b52-4482-961e-b2da10db6ab2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_881e1ab5-cc28-4dad-8838-a0869d326714" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeasePayments_881e1ab5-cc28-4dad-8838-a0869d326714" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bc1418e1-9fcc-4e31-a189-3f4ae297c526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseExpense_bc1418e1-9fcc-4e31-a189-3f4ae297c526" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_774fee12-e232-4b84-8595-041b12b8b6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_SubleaseIncome_774fee12-e232-4b84-8595-041b12b8b6f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:to="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50d0207f-5854-4891-b077-9e931e3a789d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:to="loc_srt_RangeMember_50d0207f-5854-4891-b077-9e931e3a789d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:to="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66ae8029-19c2-4115-b21c-3972a95ba2d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:to="loc_srt_MaximumMember_66ae8029-19c2-4115-b21c-3972a95ba2d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesOperatingLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="ie322c731e232420798c70e0fee1acaaf_7fd72389-2f60-43ad-bea4-8a80098204d8"/>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="i6905591c042e4a4ba3157b323cfb9ab5_38da129f-e26f-4d6c-87c6-bcd6b098b1a4"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotes"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended" id="ie3a142e4ce644a08baddcebe255a5847_b4bff21e-4561-42e6-acc6-c810ea648dc6"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" id="i35ad914784224e55995af2a8db38524f_0aecbb7d-b010-4517-8785-cc3c76ead7d5"/>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended" id="i0d248d4ce5e445eda9637ec8ea3aab38_a6a6a2ff-ced0-4080-8b1b-05936869bd36">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_215ba44b-0cdf-404c-99e9-fa9c6dfd3b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_215ba44b-0cdf-404c-99e9-fa9c6dfd3b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ed222c72-d119-4eaf-95c8-74a6e137568b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ed222c72-d119-4eaf-95c8-74a6e137568b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78ef6542-597c-4bb3-9a43-6e297b91f014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78ef6542-597c-4bb3-9a43-6e297b91f014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_49577dde-0a1a-4a8f-9d75-0615f7f80d11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_49577dde-0a1a-4a8f-9d75-0615f7f80d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1adb92bc-5909-44a0-b19f-c0a60aef884e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1adb92bc-5909-44a0-b19f-c0a60aef884e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32a27fa0-de25-4f12-8953-8f49a68805b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32a27fa0-de25-4f12-8953-8f49a68805b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e21d4be9-d271-47ac-bc18-8c66a58d963e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e21d4be9-d271-47ac-bc18-8c66a58d963e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9910dc3d-3391-470c-9fdf-5683ab09b713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9910dc3d-3391-470c-9fdf-5683ab09b713" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_57fc7e11-ae80-41f7-88c9-413680c59387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_57fc7e11-ae80-41f7-88c9-413680c59387" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_a7d618e0-b2ed-4025-b446-68c5152ef041" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_a7d618e0-b2ed-4025-b446-68c5152ef041" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4e2ebabe-e327-411a-94af-39c165375564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4e2ebabe-e327-411a-94af-39c165375564" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_00af9df7-ccff-4ec2-b8fc-ed20d3208f9c" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_00af9df7-ccff-4ec2-b8fc-ed20d3208f9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_caca6330-8e87-455b-b533-73759a6dd8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_caca6330-8e87-455b-b533-73759a6dd8eb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_eb2a6dff-8fa1-40bf-b1f7-d015e5cd70ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_eb2a6dff-8fa1-40bf-b1f7-d015e5cd70ff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_344ff276-90e1-4046-a4fb-015a6e2e868d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_344ff276-90e1-4046-a4fb-015a6e2e868d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b2ad9d84-6c1a-48df-bb20-b1f628b5c019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b2ad9d84-6c1a-48df-bb20-b1f628b5c019" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d08a27d6-d1aa-464c-ba65-720ec8920d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d08a27d6-d1aa-464c-ba65-720ec8920d6a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_6edeccbb-cf55-4fb2-8a31-aa41ddaf4a33" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_6edeccbb-cf55-4fb2-8a31-aa41ddaf4a33" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_72bdd588-2e71-4ea2-a6ad-708861a15a06" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_72bdd588-2e71-4ea2-a6ad-708861a15a06" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_c5abc545-7b5e-493e-be16-62766c2dad21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_c5abc545-7b5e-493e-be16-62766c2dad21" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4362c2f6-b512-4f6c-acf2-8d45a7364b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4362c2f6-b512-4f6c-acf2-8d45a7364b3d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_1f27da18-3af8-4d5e-9fc0-a45baa799f42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_1f27da18-3af8-4d5e-9fc0-a45baa799f42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_413645ff-29e9-48f6-bc9f-59091bb38191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_413645ff-29e9-48f6-bc9f-59091bb38191" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f50b3cf-d670-43fd-a27a-503cfaf03a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f50b3cf-d670-43fd-a27a-503cfaf03a38" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3e38cb4c-82ad-4e14-8bfc-a4dabff8b77d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3e38cb4c-82ad-4e14-8bfc-a4dabff8b77d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_002f0f92-b13d-48c5-b75f-9af67a3b7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_002f0f92-b13d-48c5-b75f-9af67a3b7c8b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_5dc1f052-4bf0-4f35-92d1-b18be900f978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_5dc1f052-4bf0-4f35-92d1-b18be900f978" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_32dd1a61-1802-4ee5-aab5-5f136b069769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_32dd1a61-1802-4ee5-aab5-5f136b069769" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_d6814906-35e4-46a4-83ac-0cd2d22c4056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_d6814906-35e4-46a4-83ac-0cd2d22c4056" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled_6a6439f7-3d08-4619-b778-5d16d546d2a4" xlink:href="lgnd-20191231.xsd#lgnd_WarrantsSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_WarrantsSettled_6a6439f7-3d08-4619-b778-5d16d546d2a4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_15af0ca7-de1d-4a3f-ad4f-e5f54029ca6b" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_15af0ca7-de1d-4a3f-ad4f-e5f54029ca6b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_62642b08-3916-4fd2-b8d5-b8724ae851e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_62642b08-3916-4fd2-b8d5-b8724ae851e1" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_09507bd8-065e-4ff2-a4ad-dacb3bd822a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4b7957f4-cb6b-4287-baa0-52f50fa9f84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4b7957f4-cb6b-4287-baa0-52f50fa9f84e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_0073627e-fd48-4b5a-b1a2-c40b1c3931e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_0073627e-fd48-4b5a-b1a2-c40b1c3931e2" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6f446d88-92c0-498c-9b74-ecf5bca22a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6f446d88-92c0-498c-9b74-ecf5bca22a09" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_790addbd-adb9-4521-baa8-f3e7537aab8b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_790addbd-adb9-4521-baa8-f3e7537aab8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_9ea5dd49-774c-45e1-9427-71db73600619" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:to="loc_us-gaap_OtherExpenseMember_9ea5dd49-774c-45e1-9427-71db73600619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4f52c560-cb22-4ecf-ac78-6530a3a278e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4f52c560-cb22-4ecf-ac78-6530a3a278e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fd9e435-4de0-4928-8cd4-6a4a6b002977_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fd9e435-4de0-4928-8cd4-6a4a6b002977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_d202a819-d97d-479f-816c-4911566d299b" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_d202a819-d97d-479f-816c-4911566d299b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_11406ee1-c4e0-497c-a163-a15aedfa6d64" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_11406ee1-c4e0-497c-a163-a15aedfa6d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_66a64a8b-c47c-4f5c-bb9b-768f88752a13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_66a64a8b-c47c-4f5c-bb9b-768f88752a13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cddfe782-ee1a-4763-a56c-3ff906a3287e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cddfe782-ee1a-4763-a56c-3ff906a3287e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d38775a6-4428-454e-9d04-5fae1bc0f1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d38775a6-4428-454e-9d04-5fae1bc0f1d2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended" id="ide5dba96b3e04da49324702c0c36a234_ff6acb61-62ee-4087-8dc9-a16e7e431289">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6a74f0fb-3da4-4396-8691-4db8a1cbd954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6a74f0fb-3da4-4396-8691-4db8a1cbd954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c9300ba2-2815-4f65-aa62-a8067ea9fcae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c9300ba2-2815-4f65-aa62-a8067ea9fcae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7b6ea465-5bf5-4676-b3e8-510feea1ff3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_NotesPayableCurrent_7b6ea465-5bf5-4676-b3e8-510feea1ff3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_3c968718-13f8-41d2-be89-979909f09c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_LongTermNotesPayable_3c968718-13f8-41d2-be89-979909f09c17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_44d2d6a9-c518-45aa-a4d0-3878382c53aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_44d2d6a9-c518-45aa-a4d0-3878382c53aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5ff7776b-9708-4ba5-9d87-4f0aac57454c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5ff7776b-9708-4ba5-9d87-4f0aac57454c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e3bc4e19-9aba-4c22-a28b-835b5ce70132_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e3bc4e19-9aba-4c22-a28b-835b5ce70132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bbc963de-40af-47ce-96a4-b1dcee887142" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bbc963de-40af-47ce-96a4-b1dcee887142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_bea20c23-61c5-4d48-b2c9-9e9d76235813" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_bea20c23-61c5-4d48-b2c9-9e9d76235813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_e03287fb-ef2a-40d8-b807-33123f3cf1e6" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_e03287fb-ef2a-40d8-b807-33123f3cf1e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended" id="i6f019106efc1478a94275120e8c2986c_e672a9e7-2b84-4e57-81ec-5de68f4f6f30"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended" id="id374aacce3f04be1aaf5b3b04f210046_071fa97e-2a15-4b81-8c4a-7aedb627d971"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended" id="ie0682d33c95d430f8424d6b54892a569_592c9d8d-8b35-4181-b1e6-f149deef98b1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f030d3-a62e-4abf-b979-a3ea03b58077" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f030d3-a62e-4abf-b979-a3ea03b58077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bc64340-8e5b-425f-95d8-2444ba2fc055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bc64340-8e5b-425f-95d8-2444ba2fc055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e347436-1114-4cfc-b5e7-8d1a4c099165" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e347436-1114-4cfc-b5e7-8d1a4c099165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_290061b8-6a1e-453a-968d-8b32d98ddd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_290061b8-6a1e-453a-968d-8b32d98ddd8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:to="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_919b5d35-ab7d-46ff-89ea-c2181022357b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_919b5d35-ab7d-46ff-89ea-c2181022357b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_51112028-f6b3-4772-979a-d2b201096e43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_DemandDepositsMember_51112028-f6b3-4772-979a-d2b201096e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e90fa806-b12e-4216-a368-c2574963a553" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e90fa806-b12e-4216-a368-c2574963a553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9499365b-a089-4abc-b6c4-f8262b11ce65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_EquitySecuritiesMember_9499365b-a089-4abc-b6c4-f8262b11ce65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1eb21c8e-aa2e-4f0f-91f6-f21000c68cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_CommercialPaperMember_1eb21c8e-aa2e-4f0f-91f6-f21000c68cfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_47163107-5c38-4377-a392-1dac25850460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_WarrantMember_47163107-5c38-4377-a392-1dac25850460" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_3fb9b643-b774-4d95-b8f4-6247f53a48ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_MutualFundMember_3fb9b643-b774-4d95-b8f4-6247f53a48ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_33191471-7d95-4959-8d3a-67d42d7f0540" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_33191471-7d95-4959-8d3a-67d42d7f0540" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2cf76a7e-72a4-463b-ada4-8ef330542dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_MunicipalBondsMember_2cf76a7e-72a4-463b-ada4-8ef330542dd6" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended" id="ia31b103d085b401a9806155d96163ce4_21489b4c-17a2-42e5-bf64-7bf06c29ceb3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1653c41b-00cb-44c7-9157-941c4f5058d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1653c41b-00cb-44c7-9157-941c4f5058d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1b72aa0-6490-4a9c-85a7-02a5cf59149e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1b72aa0-6490-4a9c-85a7-02a5cf59149e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd97315f-f332-4871-9f41-7eb9c0ef3b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd97315f-f332-4871-9f41-7eb9c0ef3b20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_75b3c8c4-765c-4ecd-8499-24b8d2398697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_75b3c8c4-765c-4ecd-8499-24b8d2398697" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e8722d6b-8c49-43e7-a259-5204069820d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_Depreciation_e8722d6b-8c49-43e7-a259-5204069820d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:to="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_508d1c20-7ab2-4580-a476-f5c7175e50fa_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:to="loc_srt_RangeMember_508d1c20-7ab2-4580-a476-f5c7175e50fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:to="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_91a30864-eb48-49d4-bc7e-1ffa8ceae86b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:to="loc_srt_MinimumMember_91a30864-eb48-49d4-bc7e-1ffa8ceae86b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6534935f-ce64-4084-b522-b3f7fb665363" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:to="loc_srt_MaximumMember_6534935f-ce64-4084-b522-b3f7fb665363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ab0eb57-e023-43ea-810a-4ddbcdad4f78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ab0eb57-e023-43ea-810a-4ddbcdad4f78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8f4e0c32-a97e-4139-a5de-c3d98d0ca1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_us-gaap_OfficeEquipmentMember_8f4e0c32-a97e-4139-a5de-c3d98d0ca1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_630ae821-b6ad-4578-a891-f01f07261e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_630ae821-b6ad-4578-a891-f01f07261e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_ad89b7c8-1014-4f40-9d9e-8aeff9be0f5f" xlink:href="lgnd-20191231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_ad89b7c8-1014-4f40-9d9e-8aeff9be0f5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended" id="i56cca0a379f842efbe7c31f2a41374f9_d99b9afc-5ba1-4492-95de-48f817de2c0b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f34524f4-f6e5-470a-8610-1f141d08f285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_Goodwill_f34524f4-f6e5-470a-8610-1f141d08f285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4bb958f-badc-4ce2-8d41-ddefcf0b1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4bb958f-badc-4ce2-8d41-ddefcf0b1cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305940a-bca7-47c1-9fcd-8614a8daa89b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305940a-bca7-47c1-9fcd-8614a8daa89b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7a57eff1-157b-4e47-86dd-cce0c6049abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7a57eff1-157b-4e47-86dd-cce0c6049abb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_073888ce-fa08-4138-b0a2-a69acc12b977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_073888ce-fa08-4138-b0a2-a69acc12b977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_75d6b16c-ea53-4c70-baed-6fb230f60d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_75d6b16c-ea53-4c70-baed-6fb230f60d5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b043607-047c-47d9-9000-4df4c7f65712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b043607-047c-47d9-9000-4df4c7f65712" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_42b6a353-44f2-4a00-988d-3e18b399536e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_42b6a353-44f2-4a00-988d-3e18b399536e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1b641bd4-0b56-482a-aebb-fdb5d772f9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1b641bd4-0b56-482a-aebb-fdb5d772f9a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d0673658-0931-4aa4-a089-6e3035234f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d0673658-0931-4aa4-a089-6e3035234f9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7826715-41b1-4271-bd6b-c74a1a51ee3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7826715-41b1-4271-bd6b-c74a1a51ee3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e342f031-4cd4-4840-ac44-1fb201c36a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e342f031-4cd4-4840-ac44-1fb201c36a6c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dd3e05f5-2df7-4535-a98d-3f167c7dda72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dd3e05f5-2df7-4535-a98d-3f167c7dda72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_48977bd9-ba75-4416-a5fd-2d48d9014a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_PatentedTechnologyMember_48977bd9-ba75-4416-a5fd-2d48d9014a0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3a10d51a-5e33-44ba-9a5a-480a50030a56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_TradeNamesMember_3a10d51a-5e33-44ba-9a5a-480a50030a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_25689187-b32b-42f8-b589-1fadb663e2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_CustomerRelationshipsMember_25689187-b32b-42f8-b589-1fadb663e2f3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended" id="iab9ef3e7ce5445a2b20525f98998a9f7_46f01824-263c-4a29-a692-9c498ffb6218"/>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended" id="i4ca2bfc750964ec49138d90a673d4aa0_aca0971f-f968-4baa-9bc4-555007ac30fd">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_15ab1de4-883f-4fcf-81c6-5763ae8af49c" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRoyaltytoAcquireeShareholdersPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_15ab1de4-883f-4fcf-81c6-5763ae8af49c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_edb5fb56-4f72-4438-99cc-95769e907702" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_edb5fb56-4f72-4438-99cc-95769e907702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:href="lgnd-20191231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_79bea372-4a95-42e9-bcd5-34f9c1f5aa69" xlink:href="lgnd-20191231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_79bea372-4a95-42e9-bcd5-34f9c1f5aa69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_2caf06f9-e541-4f71-ba7c-95b883ee0676" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_2caf06f9-e541-4f71-ba7c-95b883ee0676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_333ff0e2-0e8b-4489-8916-0d34f0df6200" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_333ff0e2-0e8b-4489-8916-0d34f0df6200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3b37cf41-91a5-47d5-aa8b-8920c08d2763" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3b37cf41-91a5-47d5-aa8b-8920c08d2763" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_5c9aeb89-5fcc-4c13-914f-a703a98ff3ba" xlink:href="lgnd-20191231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5d21b62-d808-48bc-98e8-67f6673cdf76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5d21b62-d808-48bc-98e8-67f6673cdf76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_09ff0526-6b95-46c5-8dac-8b364d8553af" xlink:href="lgnd-20191231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_09ff0526-6b95-46c5-8dac-8b364d8553af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_fe933c3e-a7fa-4dc7-9f74-33f8eb2abd8c" xlink:href="lgnd-20191231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_fe933c3e-a7fa-4dc7-9f74-33f8eb2abd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_cf0b9383-8b1f-453d-b939-11999e5f55b2" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_CrystalMember_cf0b9383-8b1f-453d-b939-11999e5f55b2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended" id="if569a363fb0547f59fb5140f183491ea_9626a9d1-f78b-470c-bb6c-c19c2b97352c"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended" id="ica9ffe24c2984b748ca030067e7f4bea_c95a5922-cdee-408a-921b-5dd4174f2a62"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended" id="ieb3b0b4a93d74645a9dda168058f2834_1c47e894-72a2-40b0-a8fe-b09f001ebeb9">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e562835c-ad20-4919-a3bb-0ddd66106a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e562835c-ad20-4919-a3bb-0ddd66106a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0767c9a2-d89b-45c1-b240-82a912595b19_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0767c9a2-d89b-45c1-b240-82a912595b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f88e75e6-5922-4a8b-aa44-73db2de56ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f88e75e6-5922-4a8b-aa44-73db2de56ef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90409547-e0eb-4a28-a2e0-296240394794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90409547-e0eb-4a28-a2e0-296240394794" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i1827b92e8a7d4d28b1b555f4c580f301_472609f5-d040-4305-893e-2fa83b9bd92c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0c0e418e-3a40-4d7b-a870-a1da745d5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0c0e418e-3a40-4d7b-a870-a1da745d5ede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81d57cf4-51f4-47e2-b0dd-2cc793002e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81d57cf4-51f4-47e2-b0dd-2cc793002e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_406f647c-25a3-4781-a096-406df91865ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_406f647c-25a3-4781-a096-406df91865ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0fdf4ae0-970c-4364-883f-4fa14d2b4f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0fdf4ae0-970c-4364-883f-4fa14d2b4f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b39f9bd0-2088-4205-81cc-d174bb4be22c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b39f9bd0-2088-4205-81cc-d174bb4be22c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9ff707d3-6ad8-43dc-9285-e0dae80964a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9ff707d3-6ad8-43dc-9285-e0dae80964a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a80798-bd27-4854-a72c-76a421e76a59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a80798-bd27-4854-a72c-76a421e76a59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a7969cd4-99e5-49f8-b9db-69f14163bf16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a7969cd4-99e5-49f8-b9db-69f14163bf16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:href="lgnd-20191231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_e7f384d8-e12a-4414-8794-1e9cac69d9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_e7f384d8-e12a-4414-8794-1e9cac69d9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_255ca3d6-566d-4192-ba9a-f5cfc708c157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_255ca3d6-566d-4192-ba9a-f5cfc708c157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_4ccaa283-7066-4ec7-9768-be3cfe8af575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_4ccaa283-7066-4ec7-9768-be3cfe8af575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:href="lgnd-20191231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb76cbc9-4bc4-47ce-9822-0b3e4a2a7b10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb76cbc9-4bc4-47ce-9822-0b3e4a2a7b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f46a9801-43c4-47e8-a506-9c4d9fdc9310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f46a9801-43c4-47e8-a506-9c4d9fdc9310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3135c637-b871-4a5e-bec0-3dba9ff4d9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3135c637-b871-4a5e-bec0-3dba9ff4d9cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_4a7b92d7-d3a6-48f3-8c4f-e57c90cbe129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_4a7b92d7-d3a6-48f3-8c4f-e57c90cbe129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_17a6d4a6-3131-47c7-944f-f36d6deea683" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_17a6d4a6-3131-47c7-944f-f36d6deea683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c7fe8aea-7a50-42f5-a358-9a3811ba43a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c7fe8aea-7a50-42f5-a358-9a3811ba43a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:to="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d1993157-2c51-47c3-bfcd-3c812a55a9b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:to="loc_us-gaap_PlanNameDomain_d1993157-2c51-47c3-bfcd-3c812a55a9b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:to="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_72b24b91-eac0-4585-afdf-7c619e800b1e" xlink:href="lgnd-20191231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_72b24b91-eac0-4585-afdf-7c619e800b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_1f4f7a1a-7aea-415f-aca7-a20858c28144" xlink:href="lgnd-20191231.xsd#lgnd_AmendedESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:to="loc_lgnd_AmendedESPPMember_1f4f7a1a-7aea-415f-aca7-a20858c28144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:to="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827f5ea0-eb5d-43f2-a018-1e60bbf422a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827f5ea0-eb5d-43f2-a018-1e60bbf422a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cdf5a0d2-5869-4dd5-a36b-bc256da8a756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cdf5a0d2-5869-4dd5-a36b-bc256da8a756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_333fec04-b1b0-48aa-beb5-f270bdcdbfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:to="loc_us-gaap_RestrictedStockMember_333fec04-b1b0-48aa-beb5-f270bdcdbfe8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended" id="i3fcee9d512a84fa5b8e955667156ec0b_2350ccc3-ed55-44f4-85a7-ea7890019dcd"/>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended" id="i7216e3a13f834fdbab83039b248a8df4_06148c1c-0e03-4980-8733-7ccc5ccab607">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1cfbcec6-b054-4b06-8cc7-585d6daf4a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1cfbcec6-b054-4b06-8cc7-585d6daf4a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b8ad664e-8f68-4774-afba-bd9272a53b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b8ad664e-8f68-4774-afba-bd9272a53b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_71cc548d-939c-48ef-a2ad-608353c5eb83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_71cc548d-939c-48ef-a2ad-608353c5eb83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_502fa27b-52b6-4eec-8bcd-9f1dd718faaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_502fa27b-52b6-4eec-8bcd-9f1dd718faaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7827ba44-9851-427d-aa2d-84b0ad309773" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7827ba44-9851-427d-aa2d-84b0ad309773" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_5eba11fd-9cd5-4bb4-bf2c-6128354b1e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_5eba11fd-9cd5-4bb4-bf2c-6128354b1e6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_af73c39f-d829-46a1-a0a8-ae6321d314a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_af73c39f-d829-46a1-a0a8-ae6321d314a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a5589199-3306-4212-926c-7c9fb2a3929f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a5589199-3306-4212-926c-7c9fb2a3929f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_66a10a52-d310-4e7a-af7b-f374823b6d6c" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_66a10a52-d310-4e7a-af7b-f374823b6d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_26be897e-2468-4f72-b3d3-9877bfb369a9" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_26be897e-2468-4f72-b3d3-9877bfb369a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_c63dbb03-841e-4ac5-9b14-c1ce97e35da4" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_c63dbb03-841e-4ac5-9b14-c1ce97e35da4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_01eb2eed-ed52-4dd1-9668-d2c752d2b9d7" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_01eb2eed-ed52-4dd1-9668-d2c752d2b9d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_7f63eff4-41ef-4ba2-a234-386f2ffcf4bb" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_7f63eff4-41ef-4ba2-a234-386f2ffcf4bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_2a659c65-e9f9-454a-876a-076dbf8fb839" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_2a659c65-e9f9-454a-876a-076dbf8fb839" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_a44524bc-48f5-4d06-89aa-11b7a1a64f44" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_a44524bc-48f5-4d06-89aa-11b7a1a64f44" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_f0025f5b-d453-481e-bfcd-52bf252fa9ea" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_f0025f5b-d453-481e-bfcd-52bf252fa9ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_475ae5aa-0f8e-48d9-899d-0514be4e5f8e" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_475ae5aa-0f8e-48d9-899d-0514be4e5f8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_5c370133-e43a-4b00-b70e-b750b46dce17" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_5c370133-e43a-4b00-b70e-b750b46dce17" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended" id="i5f2bb6a72b464cc3817c6261271560a8_de7eb9f8-6680-44a4-8a45-388464ec0608">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35d642a2-c168-44db-8005-a11097dbf7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35d642a2-c168-44db-8005-a11097dbf7b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6724070-14a4-43ed-b189-daa53723fa96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6724070-14a4-43ed-b189-daa53723fa96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3c5a6028-a44e-449e-a328-f4991ce4c1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3c5a6028-a44e-449e-a328-f4991ce4c1d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:to="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a70e3aa4-700b-4bb1-a470-8b86825514bd_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:to="loc_srt_RangeMember_a70e3aa4-700b-4bb1-a470-8b86825514bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:to="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b029a1be-e19c-4042-a4cb-c03e715c610d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:to="loc_srt_MinimumMember_b029a1be-e19c-4042-a4cb-c03e715c610d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1961b14-50ba-430e-9fe9-93ebfb9a912b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:to="loc_srt_MaximumMember_f1961b14-50ba-430e-9fe9-93ebfb9a912b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended" id="ie1fad2ce48be466287afe37285e5172c_02bfbc85-0215-4b9c-bd3e-92633b58e0db">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9a5a3e7-68a5-448f-a194-4ec9b3bfbfc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9a5a3e7-68a5-448f-a194-4ec9b3bfbfc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eae8a875-c45f-46f1-a75c-63504a3296ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eae8a875-c45f-46f1-a75c-63504a3296ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f795c81f-c0fc-4d2c-a203-b5f7c0f53c95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f795c81f-c0fc-4d2c-a203-b5f7c0f53c95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_83215486-05ba-41ba-aece-54d216702f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_83215486-05ba-41ba-aece-54d216702f7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e8fe7f5-d3b2-493c-841b-c8c474617b49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cddeb39-546b-4293-8c83-061d42a8ef16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cddeb39-546b-4293-8c83-061d42a8ef16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d68812ab-d592-4287-b2df-187361b84fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d68812ab-d592-4287-b2df-187361b84fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ddeb9b0-7f95-47c8-ba72-16860c4749c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ddeb9b0-7f95-47c8-ba72-16860c4749c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72d53577-11bd-48cd-82a9-2a55404c44f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72d53577-11bd-48cd-82a9-2a55404c44f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6af338f-c9b5-4efc-a3d8-da31ef18c9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:to="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f50843f9-400a-4673-900f-bb76ac53fe54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f50843f9-400a-4673-900f-bb76ac53fe54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d020300c-b38f-4eab-8d84-77444396e206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:to="loc_us-gaap_RestrictedStockMember_d020300c-b38f-4eab-8d84-77444396e206" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CommitmentsandContingenciesLegalProceedings"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="extended" id="i8b6caac94de94c0b81d84bfe45fd31bf_1b98c1cf-3761-4a1b-8847-9ec2f854d1a7"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended" id="i231c10da018a4f23ad059a8fa7912819_c2f28a8b-609f-46fd-b1cd-3c8475d1f9cd"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended" id="iec74283b4d7a4d8e9b6aae8416e367a6_a594875a-a1ba-496e-b692-7a2314ce6166"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i78dd9743965e4fec883afbf8b5ad7189_f85dc2c1-bcb7-4eb5-a3bb-a4c30e1083a7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a3f93ca5-a5d7-4331-9e5e-a8cae94a3b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a3f93ca5-a5d7-4331-9e5e-a8cae94a3b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_64c9a2d1-216a-4f66-886b-0b2ec97787ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_OperatingLossCarryforwards_64c9a2d1-216a-4f66-886b-0b2ec97787ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_55df0b87-e0ea-4c90-9064-f0338ddb0561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_55df0b87-e0ea-4c90-9064-f0338ddb0561" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c27dbb9f-9e65-4640-996b-468524980d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c27dbb9f-9e65-4640-996b-468524980d24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_316417e0-7393-4ed3-97b2-1d69ee1e095d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_316417e0-7393-4ed3-97b2-1d69ee1e095d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_5b25e9f1-2b1d-41ab-92a4-b99b574214ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_5b25e9f1-2b1d-41ab-92a4-b99b574214ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c97a10be-2a32-4b8d-97e9-e4f9fb3b640e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c97a10be-2a32-4b8d-97e9-e4f9fb3b640e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cd34ca42-d6e9-4fc3-bcb2-db211c421d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_ForeignCountryMember_cd34ca42-d6e9-4fc3-bcb2-db211c421d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_843a90a5-bd0f-46b5-b19f-205890d7bcf6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_843a90a5-bd0f-46b5-b19f-205890d7bcf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_efac6c00-d600-4b3f-9e3b-d30bad3aad04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_us-gaap_ResearchMember_efac6c00-d600-4b3f-9e3b-d30bad3aad04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_c8af965a-19ff-4e78-9035-11322f17b112" xlink:href="lgnd-20191231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_c8af965a-19ff-4e78-9035-11322f17b112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_d1217e01-7f96-4ce9-bb6e-5e48d71c7204" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_d1217e01-7f96-4ce9-bb6e-5e48d71c7204" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="i3c08d14ec6604be6bc45d9bd29c72129_c2573149-c628-4d93-bc8e-13fd76d0c2e6"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="i0b86b47193ae47a08ed87e2fed9b256a_cd2f7a0a-4899-47d6-a246-ff61c2601669"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended" id="i5496ac1fe45d4d70a42f7cc5120542bb_adb639ed-b9e6-4b8d-a9bf-f4887071f025"/>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i115e55a1e5c6405db76c91aae8a9cfa8_de403d29-9664-43a6-8b1c-4ebe0e7b9afb"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended" id="ibf1f3385cd9f4f598d0b8c41c2e3a904_76630fcd-9a55-4c65-8500-9a27e88da500"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended" id="i5354921e66854fbb8f57cc05a58645dd_ca34d19d-5571-4b90-9931-1934d8a47fa8"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended" id="i21a587770c094e5da32e6c9c5ab16a2f_8bc6d794-3ad3-48cc-b7c3-8b33378f89dc"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEvent" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEvent"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SubsequentEvent" xlink:type="extended" id="i98971767095e47d7b5a28264e4a2ce9e_c4cfd1c1-12b0-4e01-9e09-9bc10fcca101"/>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEventNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="extended" id="ib28af3e8664a4b0cb11053e9499904d7_c98e9042-eddb-4506-8fed-c2036e21dba2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_65087cc2-729a-4e98-8642-c38f7f8f4983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_65087cc2-729a-4e98-8642-c38f7f8f4983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a7aceea7-c3c6-4e37-939c-8dde8f14b45a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a7aceea7-c3c6-4e37-939c-8dde8f14b45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:to="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e0cd956-7ee9-421f-bf19-d27feb6c4288_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e0cd956-7ee9-421f-bf19-d27feb6c4288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_b2c8fe8d-d06b-47c8-98a2-f2b55e599432" xlink:href="lgnd-20191231.xsd#lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:to="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_b2c8fe8d-d06b-47c8-98a2-f2b55e599432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1f64d16-d713-47b4-afbd-207c8ca678c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:to="loc_us-gaap_SubsequentEventMember_e1f64d16-d713-47b4-afbd-207c8ca678c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>lgnd-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9366ce84-6569-4d32-8f05-d830f018f4e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65398032-6d21-46cd-8366-038d7714c153_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_dbeb0286-7133-48bf-9559-6a77efe8bbcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_ad2dcef0-1b68-4560-9730-eff0620bb96f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8d93b768-77d5-4cee-8a33-3cfb4c32dafe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_f0f80d21-daca-45ec-857d-d3defa723d30_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6129174e-a434-42f7-a46f-fe7f4e562e00_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of equity component of currently redeemable convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3eb9a958-8afe-4762-9ee7-75645d60c0df_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7f3a46ce-ad60-4a54-80a4-6b84c777dfe6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6ed5db91-9d3d-4435-a410-bfca40212b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1435bc4b-48ab-4860-a4d2-9571f585fb12_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_39df51ca-d8d9-45e0-b8e6-5768deed9f4b_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$159.81 - $171.28</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTenMember" xlink:to="lab_lgnd_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_efd823ce-9fdf-4a5e-b64a-3c7b47f2f043_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedStockRepurchases_16836af0-e411-46e2-ad93-225ee65d5b79_terseLabel_en-US" xlink:label="lab_lgnd_AccruedStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due to broker for share repurchases</link:label>
    <link:label id="lab_lgnd_AccruedStockRepurchases_label_en-US" xlink:label="lab_lgnd_AccruedStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Stock Repurchases</link:label>
    <link:label id="lab_lgnd_AccruedStockRepurchases_documentation_en-US" xlink:label="lab_lgnd_AccruedStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Stock Repurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedStockRepurchases" xlink:href="lgnd-20191231.xsd#lgnd_AccruedStockRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedStockRepurchases" xlink:to="lab_lgnd_AccruedStockRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cec2e706-d9c7-489d-af6a-19a37be2121b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2b363ae3-daf5-4de3-8eb5-8afcc5322feb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_eec59289-495d-418b-bf3c-b7307146fac0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e6c9472d-2b98-4d9a-939b-8af492cdd273_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_67a957dc-647f-4017-ba12-cf0a5b00fbda_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_cb954e46-09e0-4487-a199-76fa73eee4e0_terseLabel_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of cash and cash equivalents, maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_label_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Period Of Highly Liquid Securities Maximum</link:label>
    <link:label id="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_documentation_en-US" xlink:label="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of highly liquid securities maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:href="lgnd-20191231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:to="lab_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_32e77335-c628-4a25-862c-4f24171585b1_periodStartLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at beginning of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_dc569dc8-c256-4889-9dc5-e65293858b6e_periodEndLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights at end of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment At End Of Period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition contingent consideration, potential cash payment at end of period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:href="lgnd-20191231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fcb1861b-498e-4798-8aed-5b372eb32822_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0808ea21-9620-4cca-a7ed-3cdce17aa1d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_983d4427-9116-4f27-bc2d-4dfce4dd750c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_fa9e01aa-ab23-408b-a293-24abd044ae6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f65bdfa9-45e6-41da-9095-412d9289da26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PromactaMember_5475d4da-7588-4cca-8401-2d60f01a2c4a_terseLabel_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:label id="lab_lgnd_PromactaMember_label_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta [Member]</link:label>
    <link:label id="lab_lgnd_PromactaMember_documentation_en-US" xlink:label="lab_lgnd_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember" xlink:href="lgnd-20191231.xsd#lgnd_PromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PromactaMember" xlink:to="lab_lgnd_PromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a51531d4-fe24-4bb7-b321-6cae03bd09a4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, change in amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d3d09d2-c40c-48c3-9203-0844001de695_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfAcquisitions_8ed595e3-e2a7-4349-9580-293e8d67c79d_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_label_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:label id="lab_lgnd_NumberOfAcquisitions_documentation_en-US" xlink:label="lab_lgnd_NumberOfAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfAcquisitions" xlink:to="lab_lgnd_NumberOfAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_fadf9360-f038-4f8b-b670-f9d5ab2e9422_terseLabel_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_label_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products [Member]</link:label>
    <link:label id="lab_lgnd_NovanMolluscumProductsMember_documentation_en-US" xlink:label="lab_lgnd_NovanMolluscumProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan Molluscum Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember" xlink:href="lgnd-20191231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NovanMolluscumProductsMember" xlink:to="lab_lgnd_NovanMolluscumProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2ac37ad1-9d9e-4957-8e5c-e947fcda6d1a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_feb4dd21-5075-4fd4-a584-8fc64a3f0d55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1ea2c85d-8e8b-4764-aa91-5c9bb7618f37_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_06ede597-d32c-464b-bba0-6f008f9d72ea_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_69c67e23-38bd-4334-8233-6ea28a899d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b9ebc1e-4cc6-4645-a992-4d0ca2b4f396_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68af612b-42a7-4755-b827-335b89930c12_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted income per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_107834fe-9b13-4ea8-a3d5-4b95ee36e797_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares&#8212;diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_08ab3f0d-0336-440d-adee-92c83e56193c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1efdacf8-4b11-497b-863f-ed6a9a38a6a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f9d9c7b8-f8c5-469f-9053-3ecdf5853009_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_63827fbb-e0eb-4edd-9d58-eabe7879fc5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Categories</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d3f3dc1-f46a-4ec0-aad0-1130acc3113a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea05b396-6e15-43cc-94dc-b275e7faeff9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_0fef61d4-bb42-4ef8-aae5-2f73a94c0d38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_0f3847ad-f60f-4911-95b4-61f62d962cb8_terseLabel_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_label_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_documentation_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:href="lgnd-20191231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:to="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1591be18-29a8-4ad9-8762-dbea846e6ce2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b462f00e-cba4-4b03-be7a-acdf99977ef7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_02ebaf77-38c5-43d2-a4f9-dd83b9348abd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible senior notes outstanding (Level 2)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad82943c-0d72-4916-934d-d0e6974ca3c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a33ff2bf-4f24-49a2-9253-bb248e09d6fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e093307a-e685-41a8-962c-22438308a932_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_9044757b-86dd-4745-91e1-33db58459ac9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c8385c22-9fa1-49ad-bc4d-708eb151efc9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_25c4f12f-4c5a-4382-bde2-95706d9993c9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6c82c7f3-adeb-4c33-a98a-64d67700c2bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a4cb74cf-ed7a-49fb-a6b7-d05808e34a5c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_55cc2704-d186-4774-b119-47ceae28fc0f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1753bb1f-c101-4fb8-9c2f-373ac8fec7f5_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseMember_7ae4c2c7-a39f-4845-86cd-63f51a326a38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense</link:label>
    <link:label id="lab_us-gaap_OtherExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseMember" xlink:to="lab_us-gaap_OtherExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_091ac3f9-a955-4ba3-8533-bce906a27b9e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f45e2b9d-b4da-4f67-88fe-97f7be80a448_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e73de62f-8510-4b96-acb3-08554e200985_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ecc1da7e-cad9-44f1-bc1a-bc0591cc1a2d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_509e671b-4f52-46fa-845f-4537bc33b051_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets with finite lives</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_be7c84db-f55d-4c1b-ae68-9b7ed716c5f2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_2bb5828b-5910-46ec-936f-3a192a1dc736_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2023 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2023Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotes2023Member" xlink:to="lab_lgnd_ConvertibleSeniorNotes2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_a5a7147a-61ab-4681-8774-445b907d21d4_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement of Notes</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a458cc04-f0ef-4438-b30e-5ac906a3db5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_4350c7f6-8fa5-457c-b630-d6dd0f0bf8a5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_569f0527-0533-4f78-a8c8-3c9ebb4006bd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_82aa8895-a6ac-4027-9868-a3e4088b3ff5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8774987e-56c8-4a01-ba2d-9da28e5cdc22_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9fd833a5-74d1-4824-9a1c-a846a4c66ba8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_154b68ac-3203-4458-9860-f5a170e8e663_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4eae99b8-a24c-4b18-aa65-87b09aa080bd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_33acec14-4c28-4721-81c0-3c921967c0ef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_5ae32eb0-f9ac-43b8-a3bb-67bc0f2010f1_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:to="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_de23f407-5e01-42eb-b0e4-ca1ade3cbcab_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_2c0ef6da-0187-4e4c-8a6d-7f1f746d1338_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_74344311-7591-4a31-b5c7-0bb9668eafd3_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:to="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_84f7c88d-8cfa-4c68-8488-de80c5894e30_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2680e5e8-6811-4f8c-ade2-959f20882640_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3ac6236e-6bd5-4da4-8aa2-96aeaaa7e80b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03b7791e-b086-49b9-beb2-20113550ab6a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_d88beac3-824c-4a1d-963e-5632913090db_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeEightMember" xlink:to="lab_lgnd_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b59dd972-448d-4815-b545-b6ab402c5e70_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_b25ab17a-e98d-4161-89f1-9998a2fad8ad_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repurchase of warrants</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_59d5fbcd-3fd2-4078-9c90-a75455218b07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_54fc50ee-ec31-4715-ae9b-0dc47b88f8b1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_949d16e1-5b25-42fd-978d-1da680a282d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86f922ea-c21c-4400-a2b5-b8f7bef52863_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0cac35b-61bc-46bb-8952-7f790495b9fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f770989a-05ca-49a0-a774-ec14a464d19c_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_aaafd034-2dc9-44fd-b1ab-3c4caa00da7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_bf927754-2e72-47a8-a107-48e2e0bd0763_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_07392547-8317-4089-a071-c2b9230a35cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70cefe56-f421-41b0-ab4c-0ab13bf994fa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_805e196e-37fc-4ebe-ab8c-62014cfe23a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_16126c42-a216-4ae9-a305-dd85efcc6228_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$14.47</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTwoMember" xlink:to="lab_lgnd_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_540113d6-2895-4891-b3ed-f05fbb4b20a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_984c3ad4-b9f1-4f43-9adc-b9470d50f824_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_ba4096af-8b72-45e0-ba5d-d22a89780b5a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_f6239bfb-5a76-4b11-ab94-70dac4ee259e_terseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_32d2016e-2fe2-4cb1-9640-a8caafbd393c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerBMember_dfcbbc6d-ae53-448e-91f1-1b30fd424f87_terseLabel_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_lgnd_PartnerBMember_label_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_lgnd_PartnerBMember_documentation_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember" xlink:href="lgnd-20191231.xsd#lgnd_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerBMember" xlink:to="lab_lgnd_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1a4a4898-6e03-43a8-971b-bbe26fa339ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe4994c3-c379-40cd-87d7-ef37b2b97dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c3d6ee9e-7482-4a28-9287-44524548d062_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_60d2ec3d-645e-4f5f-9aba-40f64e7de3b5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ce0ac4e3-520d-4597-9b04-66f97140f32e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_41293be6-4682-4d2d-8578-2fcebfd806a1_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationLineItems" xlink:to="lab_lgnd_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8a884076-e1a0-472d-932c-456891ef5f51_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9d98e32c-2560-4480-95fd-6c1ef30f01b4_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_6a720490-3525-427e-afb6-56209fa30918_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_c584521b-3381-4fc9-830d-edb472a7c63e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and other identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5935a05f-244b-4657-a065-ef6815b07108_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8bad590-6a24-4aab-89a8-3a868dcdd24f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_8ab7c67a-ed12-482f-921e-d948ac7054f3_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment from adoption of ASU</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0a881bb6-bd67-4bb5-aeed-76a554573340_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97547de7-18b6-4e95-ba1e-1483d256cf30_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_1713f52c-135e-4812-b4a1-447ae83f886c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs related to the liability component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f3348923-f663-4003-81dc-7433e86cf7a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4b6340ec-7dd6-4baf-a32b-b517806be6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_094c260d-48a7-4f55-9c64-f87b111abd8a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_10cb224f-096a-4d6f-926b-18b6cd0a679a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reclassification of net realized gains included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1042cbc0-41f8-4e51-981e-ab0739f097a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_336a13f2-3d8d-4ff1-93d5-7c7de899bec8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50f60b8c-dc00-4eeb-b8cb-ed3baaddc9e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_52027466-ab45-4ae0-a7c8-451c17de93cc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d11dff98-d4cc-404e-8430-79f7fecc9246_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_32326b1b-83e0-4e16-a892-d1c5ff857763_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_WorkingCapitalAdjustment_fa4a1cab-3c20-4d4d-b10e-adac1ec4c01d_terseLabel_en-US" xlink:label="lab_lgnd_WorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital adjustment</link:label>
    <link:label id="lab_lgnd_WorkingCapitalAdjustment_label_en-US" xlink:label="lab_lgnd_WorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment</link:label>
    <link:label id="lab_lgnd_WorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_lgnd_WorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WorkingCapitalAdjustment" xlink:href="lgnd-20191231.xsd#lgnd_WorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_WorkingCapitalAdjustment" xlink:to="lab_lgnd_WorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1610a19f-d9e0-4596-ac9a-9b1e8b6b69df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted per share amounts:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b0c71311-5e24-4780-8231-5a58541e1159_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7ff1b0f9-3993-4b32-aa11-72eba5c3d4d5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_8fbbf610-b4a4-4b60-9b42-5164b7783beb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_fb4fc6bf-af0d-43c5-9e0f-352da11fac31_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8b2b70c5-3306-4166-8471-fa2b9c51fece_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_77b32a21-7c5b-4d5b-b486-047b48d270dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3995f981-2976-447e-aa76-e39915924288_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5079388d-8560-4b12-9ce4-f014edf59b9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorMatrixMember_2cf76336-c83b-49b9-bd37-b4172f60f88b_terseLabel_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_label_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember" xlink:href="lgnd-20191231.xsd#lgnd_CorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorMatrixMember" xlink:to="lab_lgnd_CorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fafda86-c344-441a-b536-652cca4c7393_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_d20ffd29-08f7-4c3c-9974-5a2a62966117_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_0696e34d-4e08-43eb-b5e2-56ba0e20e1cc_terseLabel_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc.</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_label_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member" xlink:href="lgnd-20191231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingTherapeuticsInc.Member" xlink:to="lab_lgnd_VikingTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1fc8eaa6-8993-4030-a876-1161c4c1d2ef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_370afa81-5087-406c-b8b6-bba50a67b9ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) - Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_86ac120f-999a-456c-b88b-0bc971ce35b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_baf6259b-6196-49b6-a75d-2011ba34dd9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodOneMember_5864a74d-7414-4f76-9491-a5e18cc155c4_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/8 on the six month anniversary of the date of grant</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodOneMember" xlink:to="lab_lgnd_VestingPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50082f88-011d-4bc9-b655-befb8a6ddba7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5fdd7dcd-130f-489a-a29e-b92430937ea1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_61952365-c755-4a08-ab87-02a1e6dddcc1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c98ccbe3-625e-4b5a-b4ba-12aabaf99b56_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_336f8e60-a5c6-4fc1-abed-75f76165ef81_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_22c764f7-f95a-4341-947d-a24cb7f24dc1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_92dac62a-0732-4d46-855b-4cc2d18a7113_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6903e79c-a94a-4090-ad9d-b43868a4d063_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dabede5c-a98e-461f-b4b7-d2ecb86ec9d4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c040212c-676c-4b17-af2b-57b1d58c84d0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_81abb7b8-8391-4865-8ce5-7c26beee65bf_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6feac0fe-c21e-4712-8e9b-8cee49bfb719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_5bce36b5-e0e2-445c-a88b-d8841896f6ef_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$101.15 - $113.76</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSixMember" xlink:to="lab_lgnd_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3875426-edca-4b23-b8b0-65a2de197619_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f689e9b-37da-4fd9-91e7-fd6cdce5ffc2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisition:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_57db574e-6cf9-42e9-b2cc-cfd1663b4970_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4f4cb392-0404-402a-99dc-3df86f2fba09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_6b7d297d-3365-4eb3-b2ab-f9162fa47ad4_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete technology</link:label>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentedTechnologyMember" xlink:to="lab_us-gaap_PatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e4bcae66-1549-488e-96cc-a08de501cb60_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_13c3c165-cb05-4558-84ea-d7e10f0b42b9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_50b97666-c6f3-467a-b6bb-39e6656e1f85_terseLabel_en-US" xlink:label="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets, Partnered Programs, and Ion Channel Technology of Icagen</link:label>
    <link:label id="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_label_en-US" xlink:label="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets, Partnered Programs, and Ion Channel Technology of Icagen [Member]</link:label>
    <link:label id="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_documentation_en-US" xlink:label="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets, Partnered Programs, and Ion Channel Technology of Icagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:href="lgnd-20191231.xsd#lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:to="lab_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d876f2db-35eb-431e-a675-b902252d2f8a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ab89e046-5902-4edd-9472-c221e1f2b0b1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock_a7b50f74-6ab2-4ad5-85a1-75d4d4605df3_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule For Share Based Compensation Expense for Awards to Employees and Directors [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule for share based compensation expense for awards to employees and directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:to="lab_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4427e2f8-2813-4140-95bf-4f61ace07acf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VariableRateComponentAxis_a99e03d9-c047-44a4-9353-65a91eaeaa2b_terseLabel_en-US" xlink:label="lab_lgnd_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_lgnd_VariableRateComponentAxis_label_en-US" xlink:label="lab_lgnd_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_lgnd_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_lgnd_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentAxis" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VariableRateComponentAxis" xlink:to="lab_lgnd_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bada4d3a-6546-4da0-a7f5-60984f6fd8d3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_17f10ee6-3222-4c0b-a65a-be25b8957893_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_39adaa8e-29b0-4eb1-8cfc-8bffd1788c73_terseLabel_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_label_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_documentation_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases" xlink:href="lgnd-20191231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedInventoryPurchases" xlink:to="lab_lgnd_AccruedInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_4f8bc934-c24c-440e-9746-88b38871c3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_511d6f9e-ed8b-407d-8cd2-877021f948ab_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_4e8f6fe5-a0a7-4cfd-b1d7-a8cb0990f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs related to obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_d65d0a5a-6bba-460e-ac3d-23083ed38899_verboseLabel_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:href="lgnd-20191231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_515a4df5-a6fc-4d18-9bc5-01161700d9e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investment in Viking</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_4dbcc08f-ec46-4b9b-b2f7-a86020638fea_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f012ac1d-85bd-49a2-9881-938677c90f92_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c52b735a-ddc2-4e2f-9611-31be07ba7f7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_21424e8f-2111-434b-a58f-08318a479d57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a5d6e562-940d-4a5f-ad8e-445dd716fd24_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f7bda587-85ce-4660-a5a3-bd2084db1e9a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Promacta License</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_299d0c86-900f-4e51-8c1d-ab537a5ccbd0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of 2023 Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ad4076e-7519-4748-a895-263c9d299665_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ef69cad3-4319-4faa-b98f-d5743c73b1bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_fcf64cdc-c140-4bc5-b691-62551bd86c02_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_label_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:href="lgnd-20191231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:to="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_df3691f7-bd3c-41cb-a913-de0c39c1dd7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d1203acd-00e2-4a61-9114-b7b2973dcf97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_57607dc1-966f-49bb-938c-787c0922b331_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_561b2969-b380-4aa9-a040-55f349e7bb16_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from commercial license rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:href="lgnd-20191231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:to="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ccd6725a-836a-452b-88ba-d8ac883c98a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_13d09c70-e33d-4278-9a4d-738e7a189651_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bf383a92-666a-486d-b68e-708e31ef4823_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_07af6bc6-a624-4970-9bdb-e15b49674f75_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_6609251c-7be8-46e2-ad56-8ec7ba94e6f1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_39fec6e9-5e53-446f-8514-13ecd80e8550_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_54b4b65f-056d-458f-a05a-02c382919bbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3bd0078a-4a34-4510-a410-408fdfb345c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5f850daa-d66e-47a4-ab76-97f643a67e9c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_f35a8f5e-f7b6-403f-a1df-d2909f021a13_negatedLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDII</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a3c7344b-37b2-49c2-ad5b-0da31d0638bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_0e6bd319-9876-457b-bc35-d652f4086aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_81c1da1f-6952-4cbb-9eb2-fdefaaa8d07a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_10f5e216-1b3f-4027-96f2-131fa0c8f683_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_64b055b1-e4a6-45d5-9f64-4ab96dfe30c3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0e0f8dda-c240-40c0-8cef-84010089a660_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government bonds</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_794497b4-90fd-4932-9548-eac3d8d9c243_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset with finite life - core technology</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3e8441eb-afdc-4f26-b2d8-2c028eb56acf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_4084fbee-5abf-4689-9a2d-e85e0f2f050b_negatedLabel_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of convertible bond hedge</link:label>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_label_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Convertible Bond Hedge</link:label>
    <link:label id="lab_lgnd_PurchaseOfConvertibleBondHedge_documentation_en-US" xlink:label="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Convertible Bond Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseOfConvertibleBondHedge" xlink:to="lab_lgnd_PurchaseOfConvertibleBondHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_8b173583-7fc9-4d03-915c-7494fe0c05ac_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$85.79 - $100.38</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFiveMember" xlink:to="lab_lgnd_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_4c767879-eba0-4ee9-ab3e-5f643fcbf2e2_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity component of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock_6b64f933-7ebf-4c5d-ab57-96f2376beab8_verboseLabel_en-US" xlink:label="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:to="lab_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4ec50c50-ecc6-4a64-b4a3-da485cbcf25f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_04e0e2f7-c268-40da-9938-181bf155f157_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fb5869a7-54f3-4e95-b23d-7ad8fa9a1822_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7ed8ec40-263c-44d0-a14c-8314d50617ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_c970d5f3-2040-4f1d-acb6-82266ba9a22d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_50393173-9f99-42a4-ad7c-79951cf7add4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0bb2c3db-ef14-4ff3-83a6-c3fdd905cde6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_90359368-e419-4240-b1d8-c1cdea2bbda3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_5155044c-87ec-407e-96ad-8f5f7d5672de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c2cd5328-daa0-4ee5-9e61-60503744dbbd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_5dc95c1f-8e9f-465d-941c-adf6e2c66f91_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4cedbcda-d205-45f4-ba0e-f94ad0b9b0da_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d0e636e7-c230-4486-8673-8ca7cc7b2bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_542eaeb0-ac4d-4a0b-80fc-a1d0dc632dff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1b6b3886-dc68-40b0-b837-80365b45fa8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5201573f-0a12-4b49-9f6a-17e364b26a44_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_2c876b75-9616-485c-929d-a98634fe30f2_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies: Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_36543165-47cd-43e5-862e-20aaf9a6df4d_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum threshold of debt trading price trigger (as a percent)</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:to="lab_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e0eb8e01-24b4-4d8f-92c3-6ea8eb3ad889_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a66f39da-62b5-42af-aa0f-62c6a4263f3f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9b33b14f-1f2e-416f-bfeb-7b3498156fdf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6ee764b7-0935-41df-85e9-b6ae432787bf_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_9316b72b-0d59-435c-9936-22675a68afa9_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_73a7cfdb-4c47-458a-9002-31d7d04ae8a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5aebefab-14ef-4ae0-947b-4ce26e67ab82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d4b283cc-8dbc-4e1e-88c8-1f7eca64ce83_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_800b2d48-c278-46fd-8d02-663e34b9b709_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2ea79fb4-a501-43cb-9ac8-e01afb2e45ed_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_1bd31004-d74e-4818-b722-e09854c0e3d3_terseLabel_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:href="lgnd-20191231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:to="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_15fee456-7429-4324-ac42-754737e7cd6a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9cc8e9c0-392a-445d-ad59-61ba56a1cbb7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_5d45fd15-c74b-4919-9ecc-e5e6ce42b798_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyPromactaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyPromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyPromactaMember" xlink:to="lab_lgnd_RoyaltyPromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_b9ff2821-bb5c-43a7-a832-5c66d0b5c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSalesReturns_9ee3dcf3-1e31-43e1-8d61-5fc21ab42ab9_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return reserve</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_label_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:label id="lab_lgnd_AccruedSalesReturns_documentation_en-US" xlink:label="lab_lgnd_AccruedSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns" xlink:href="lgnd-20191231.xsd#lgnd_AccruedSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSalesReturns" xlink:to="lab_lgnd_AccruedSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5c23059f-8179-42a4-8df9-3b7b6ad011f1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6353c04d-1325-4c16-b32d-c0ec239ef986_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_65852e04-ce86-4075-969b-28b9f3b65667_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmendedESPPMember_b57b23bb-e81e-4f98-99cb-4672cbb15e38_terseLabel_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_label_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_documentation_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember" xlink:href="lgnd-20191231.xsd#lgnd_AmendedESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmendedESPPMember" xlink:to="lab_lgnd_AmendedESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b1f60a81-0f0d-42ff-b6ec-e59c609f21c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b12bd9ae-a5b4-41ee-8749-743a99af0dc1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b5b4dfe1-e48b-4ada-8459-2be18fbeca37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_cc2aeba9-6ea6-460b-b40c-70a571f09851_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b5a6ef35-204e-44c4-8850-707514c4bba7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_eec3560d-aedf-41ef-a06b-1874ac6e1704_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_22600ece-2071-4b1d-9772-2cc20b5c785e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price trigger to classify convertible debt as current (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f4a1ad6e-a4cd-4905-83a5-5c84ad372827_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a3239a12-7523-437b-953f-c2361f63c011_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_bd35b56e-a5f6-4e7c-9e52-f96e1da12834_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_aa389296-ba12-4797-b332-01a335424686_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_959527b2-56eb-44ad-8a9f-715bde2e808a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_17e397f2-e1e3-4323-bb16-7a11bc9f1470_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other economic rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:to="lab_lgnd_IncreaseDecreaseInOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c66de363-9b8b-46c7-9900-25a66157dddf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_dc933375-18bf-441a-a39a-ea5f7bc6f169_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_42dc7102-4392-4118-b4e8-48a46a757422_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4e150834-e344-4ced-950a-dd90aa6e185d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7d9ce0a9-ad36-46a7-8bd2-dceaff7717fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3234bb14-cd53-4825-a119-b844730971d5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_aa027879-a48b-4fde-a65a-f513a3cfa5bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_3a860be0-ed12-469a-9c40-99379c8fbd5d_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share of shares repurchased (USD per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_d5b895db-4074-4cec-8bf7-d1a2679296b3_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of convertible bond hedge (USD per share)</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_label_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:label id="lab_lgnd_ExercisePriceofConvertibleBondHedge_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Convertible Bond Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceofConvertibleBondHedge" xlink:to="lab_lgnd_ExercisePriceofConvertibleBondHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5c2ae8b5-658d-4073-bf34-187651e65dea_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3e8d172e-c60a-46b2-9c17-3ad4582d8540_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cd2f88f1-db30-4bca-9a33-7e41e2fc59c0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_571483f4-6a12-499b-aa8c-2e931e540f0f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_dafc4059-f831-4ec2-b19d-ecad507902d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12b9e9d6-69f0-462a-875c-7306b2f86739_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share of stock options (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_df331bf5-a0bc-4964-9b84-95b4d5b6dc27_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4819782b-fa10-457a-97d0-539527747418_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_bf688854-422c-49df-9c62-a486f11c40e8_terseLabel_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contractual term</link:label>
    <link:label id="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="lgnd-20191231.xsd#lgnd_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_lgnd_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_186890a7-604c-4726-831d-30d95381eb15_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f0aab456-bbbd-4edc-bebd-71a1220a146d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_17dd9ed8-a3a6-405b-bc06-3334d853c2ee_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_ae7af311-42d7-4934-8cf5-c7728929d4d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity and Liability Components of the Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e7f59ba6-9120-4b7f-bd91-e069d890728c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_959fa937-60bc-4783-9483-22f4b84e1eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in public offering (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_34caa85d-1adc-474f-b582-15151853cc8e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_151c1b0c-d99f-4e9e-b5a6-fc32c06343aa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_02417ebd-56b2-401d-97b8-807e3006188f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b110464e-775a-4ee0-8bb4-f19550329752_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_79faf4eb-c3c3-4553-866c-5c1756360f30_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6c7cb166-293b-406d-87cc-38c5c8a139c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5da03ec5-103c-49d7-a81a-9ce65a6ebed5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AbInitioMember_3b9f8ffa-6859-4aba-af21-e54f52007046_terseLabel_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:label id="lab_lgnd_AbInitioMember_label_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio [Member]</link:label>
    <link:label id="lab_lgnd_AbInitioMember_documentation_en-US" xlink:label="lab_lgnd_AbInitioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ab Initio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AbInitioMember" xlink:to="lab_lgnd_AbInitioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_a143cbc8-79ce-4982-8a33-453a59ed774f_terseLabel_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals</link:label>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical Study and Clinical Trial Accruals [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:to="lab_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c1be671-cf03-447b-84f4-7a63b0369220_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_0dafe30a-6844-450d-ad13-4bdb38be6d9d_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Expired Tax Credits, Research</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Expired Tax Credits, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:to="lab_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_fa788831-f2e1-44cc-8ffb-7a6b238c2bcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_1e7a3947-1ae2-4e04-93bb-26a5fb95de9b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_fd8258fd-2a36-4122-a26c-56f2b709e97e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets_0bfb6883-b79d-434b-88f3-6c7af6bce60e_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating lease assets</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_lgnd_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_3d05a4fb-ab3a-428b-afcb-bc30efdf233b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b431c017-3c3d-4063-b3ce-a24218c9abdb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6b75535f-0b24-47a9-8333-3d322767e3f0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_00d958ae-128f-4e15-8933-0e71e4a1aca9_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_84e53053-2779-4539-bc76-f1d6f0b9a196_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_f4249f61-0b55-490f-82ee-e7f198f1def0_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_1f1470d5-8c56-4d71-b5f4-a6431c596233_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_55c1ecaf-3b92-43ff-b566-16c47cf074e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under amended ESSP (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_d3ae3521-47d4-4267-95b3-6ef1af48340d_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for restricted investments owed to former licensees</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_label_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Restricted Investments Owed to Former Licensees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:to="lab_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4922a530-e00d-4b18-9e47-391e59fc8d13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7fc75264-e47d-48e5-a623-ac6807a54ad5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets recorded in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_a1e2808b-5c73-4de1-9411-b96eedbb332c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_36119d62-1cc7-4502-a502-5d83a18b6071_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_50c48a30-c6d0-49d0-9d0e-ac637c657474_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VernalisMember_a82234fb-b4cd-4466-9997-d13058200e42_terseLabel_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:label id="lab_lgnd_VernalisMember_label_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis [Member]</link:label>
    <link:label id="lab_lgnd_VernalisMember_documentation_en-US" xlink:label="lab_lgnd_VernalisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vernalis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VernalisMember" xlink:to="lab_lgnd_VernalisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8f8247a1-94d0-440d-a566-065116bba6de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_87e4f178-75ec-46e0-bd61-f0e25e11ade7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8c2ca374-8e52-4350-9644-05deb694bf98_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c3d9c7a8-6776-472e-83cf-c966ff21d949_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssets_60ac136a-cd32-4a68-8d71-e3972901a46b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in derivative assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_2b53f0ce-c63a-4d0b-902f-83cf591ec628_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual fund</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_19b0a727-56fe-499a-8bf7-7514aa7f80af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VariableRateComponentDomain_30ddd668-5a2e-491e-af78-768b594ca705_terseLabel_en-US" xlink:label="lab_lgnd_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_lgnd_VariableRateComponentDomain_label_en-US" xlink:label="lab_lgnd_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_lgnd_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_lgnd_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Variable Rate Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentDomain" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VariableRateComponentDomain" xlink:to="lab_lgnd_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9cc5c667-d93b-4775-8b8b-55d57c28554d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_901a7547-80c6-4fce-a424-4cf4806ae636_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of royalty agreement</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_label_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_documentation_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:to="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_e98a0927-6ddf-4085-a0b8-5c3bab181cad_terseLabel_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2002 Stock Incentive Plan</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand two Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:href="lgnd-20191231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:to="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e958c6c7-a3fe-4111-9fa3-4c223261396a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ffc4d0e4-1c87-4805-bcd2-fca315ee77a0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_aa55d8c2-24b8-4b03-a674-e708dd103e0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notices for conversion</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f2ca03c4-f9cb-4658-84dc-5d6ec9aafe12_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_69440967-57db-49c1-9602-796441fac1df_terseLabel_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_label_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method Milestone Payment Received</link:label>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method Milestone Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:to="lab_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_e1d65461-eb5e-413c-8bef-2f251975f999_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - CyDex</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Cydex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCydexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_528f7d3c-f62a-4dc4-b533-310ab8b7c459_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_baba6fc2-dbc3-4300-ae5e-1a5837593663_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13c1590a-2f25-4ae0-baa1-f32ecc6fbf9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_06725622-e2ca-4d81-9835-0a3aed5af5d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_661501fe-bfdb-49a9-8835-e62f2b11fa16_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7e75022d-32a1-4bd9-adbe-d0af46364dcd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6a30d32-0c6b-4e8f-8881-bfe9616db066_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_db20ffa3-ed4d-4cf8-baf7-9e0b3e922e6d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fccbda26-7118-4ad9-a3a1-3b701b508521_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_5409c4dd-b17d-4b0e-b8f5-cc1fca40f735_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyOtherMember_ce2879ee-a7f5-44f9-89a6-7cdbd15be541_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_label_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyOtherMember" xlink:to="lab_lgnd_RoyaltyOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_934595a4-6b07-4808-a464-36a641a49430_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f1537853-d4ca-47a4-b9d0-fc74fb739773_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1bf69a77-0331-452d-a997-5813c937a45b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ef219810-bc68-4819-a4bf-43c5c7191f95_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4cff37a9-a60a-4387-8d94-38d1e6881d88_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_cbb176e6-20f5-4a8e-970b-fdee79423182_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Unaudited Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_456bef74-72f6-463c-9c98-ca899746887a_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_a519d819-0ed6-4b12-a183-054fb24fdbc3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts owed to former licensees</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_454b28c8-d905-4b6c-813f-dbc783b137fc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_c5209f62-0c07-4536-9cc4-a975c5968a93_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$21.92</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeThreeMember" xlink:to="lab_lgnd_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_00c6c316-4f3e-4ca0-8ad4-f6d35aed6c12_terseLabel_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contingent liabilities</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Portion of Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:href="lgnd-20191231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:to="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_e7c4a91e-f99e-4bf1-ac9f-f0e138173c2a_terseLabel_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $15 million with Three Collaboration Agreements</link:label>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_label_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $15 million with Three Collaboration Agreements [Member]</link:label>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_documentation_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $15 million with Three Collaboration Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:to="lab_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c72734bb-3644-4589-b719-eb96ab25f7c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_99e6f2be-bc3a-4ef1-99f9-c464d5f8de00_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f1d65bf9-dbc6-4f89-ae30-cb017ee291cc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) - Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_739e6cab-5408-4541-b6ef-29f960bd9b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment_4f07e4b6-6c4a-4e5c-97a3-44bbe4b105b2_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in equity method investment</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Method Investment</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseinEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:to="lab_lgnd_IncreaseDecreaseinEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c003af87-a92c-4c37-be78-51ae493064d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_60de36a5-9245-4201-bcd8-1b7dc38282d9_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_label_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:href="lgnd-20191231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:to="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_7c72b852-657a-4e8d-bed1-2e7d67c5094f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_6df46f25-e09e-4461-9e3c-21036b466550_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of material sales</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_d628544d-7149-4085-a629-df3521cc3c90_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share consideration</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_8fc3c39e-897f-4ffc-b699-571509943846_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share consideration</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_b68ee1f4-a422-4055-b549-612e0ce0f445_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent</link:label>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:to="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DianomiMember_b6179fbb-e52e-4e39-817f-d5cfc793b12c_terseLabel_en-US" xlink:label="lab_lgnd_DianomiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dianomi</link:label>
    <link:label id="lab_lgnd_DianomiMember_label_en-US" xlink:label="lab_lgnd_DianomiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dianomi [Member]</link:label>
    <link:label id="lab_lgnd_DianomiMember_documentation_en-US" xlink:label="lab_lgnd_DianomiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dianomi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DianomiMember" xlink:href="lgnd-20191231.xsd#lgnd_DianomiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DianomiMember" xlink:to="lab_lgnd_DianomiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fd9dcd91-b8b5-4ed7-9227-e5bac128d237_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9fb738bb-1078-46b0-b67c-98078d7841d1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_fd553167-ef51-4a0c-b424-ffb754c95081_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from derivative instrument</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4e40e5cc-d369-4982-8285-870dec05775f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_70723b71-f089-4e8c-be75-bc9234034b90_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_22091fed-bcab-4255-806b-51246ce190b6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9be06ef7-ee45-4912-8fb9-3e580fab5dc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_47eeb250-528e-49f4-b159-9dd7d46fbcd0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_fa4147cd-52ab-4227-9e1b-e419800f6197_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Promacta license</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_6de9577b-cae3-4edb-8f7d-e45da4591c0d_terseLabel_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Assets and Liabilities</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_94000db8-7a2e-4f9f-ac77-2bcb9c822543_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2648d9b3-a57c-41a9-9825-e3ee9ffc6e77_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_533eb220-e952-4be1-829f-96e5b5c0e643_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_d8763e12-bdbb-4deb-a020-8e5225809d83_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53c6ac69-9e8a-47e1-8ea2-7f1934186908_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_31be4779-b746-45a2-98cc-74284e0731ef_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8d20e72-4c37-4a37-8378-a8138b2baffb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_c9db1686-b0ff-4a14-aeb2-84b6dd56422d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76cad291-4b35-4b39-b2e2-b313cea8db83_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_0bbf16df-ad5d-4999-b8fb-e10ab8cd423f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7018f004-25ad-4648-abd1-1d1e2c96730e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c4d04f73-fb6a-4fee-9202-e3f6dbf234b0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3c320213-284b-4fbb-b57d-60d8277eaa0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_3aebb379-656d-4e04-b248-b0a89bdbc4eb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_54c35e7c-d54e-4b61-840c-1f6824322cb3_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$32.00 - $74.42</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFourMember" xlink:to="lab_lgnd_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_5aa567c0-87e2-4557-816e-40b434519126_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivatives</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Derivatives</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b974a861-4130-4fb2-9839-a38d316556ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_ce906ee4-1025-4598-8c2e-520ac6168eec_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c91abc3e-8ea3-4016-86b8-cf2c2cf107c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_b18dbf12-f680-4f4f-9acd-984d58b07812_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a3ee2f15-4137-494b-b377-caf8a372ce08_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_1ee4cd4b-0976-4925-98a9-a97f83a9ec15_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_549f38dc-b3e1-49b2-af21-adf368ff4d82_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_a0a72925-c78a-4b12-b90d-b6b49f0640e3_terseLabel_en-US" xlink:label="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex-related revenue amount that triggers royalty payments</link:label>
    <link:label id="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_label_en-US" xlink:label="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Revenue Amount to Trigger Royalty Payments</link:label>
    <link:label id="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_documentation_en-US" xlink:label="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Revenue Amount to Trigger Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:to="lab_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_ca00619c-52c6-4988-9e09-b601e4f57b84_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5334558f-93de-4070-bfe1-cb60a2d33ac0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_10520a0d-3acc-4816-a1cd-1039170c5f8d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_a9bb5a1d-bf3b-402c-9933-be15fd39a3d2_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_fb1a2937-b8d9-46de-a6e5-87ffc7752182_terseLabel_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product royalty (as a percent)</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_label_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_documentation_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage" xlink:href="lgnd-20191231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProductRoyaltyPercentage" xlink:to="lab_lgnd_ProductRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc099843-1879-487b-b16e-258da3c00cea_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e2455847-9fe7-4975-83ba-a6da0aa7389f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50e30998-6503-47a0-9c4a-64598871b278_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6939c170-8d72-45b8-b28b-890b4bd48d75_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a134eba8-5f3d-4d61-aa80-60e90afb4f9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0843da2-d7ef-49b4-96cb-3934bab78012_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_46ce831a-7dfc-4220-954e-a838cc136049_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe62864e-8979-4152-8b3e-a07a540f1b29_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8a9d288b-6ced-4aa2-9ca4-a31a8a5a801b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_be4c3475-0f54-4196-b725-358c4c8ef58a_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$9.96 - $12.81</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeOneMember" xlink:to="lab_lgnd_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9e1312b2-2629-4f5b-8921-3f152ed7bdc2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d535a5ee-0d92-46c5-a55f-e7b5cf556c95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_0fd8dff5-17ca-4e84-8bbf-ebd62cd4e6f4_negatedLabel_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of commercial license rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:to="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f77f1ab5-ba50-47a5-8071-e7fc00f3cf3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_8a424797-1c78-4f38-8ca4-3fb0b130377a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3a8b4dbf-e529-4c2e-aebd-3d70fa4c3307_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_fde3ecc3-e4e0-4002-aae8-f5e9e166dbb3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_347c5bc9-6e99-47d8-887c-990628d8251e_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrophin fair value adjustment</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_c13447d4-c8b3-4b93-9da7-9cb245270ace_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_979da6a1-6626-4257-b10e-fe9a4e436bc9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_19f99def-fd9d-4faf-ae20-fbaf4d1bc5ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion value over the principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1dd0928b-59f5-438d-85d7-dc4dba9619a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f2e481d-8878-4f25-8a28-8324f55e5e66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_e11e206a-a719-44d9-8c37-425a6cacf790_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_79280866-6628-4b02-baa3-98c698f02e7a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a6697ec5-9c63-43a9-975d-1ecb7f416afe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bb112358-3f8d-460c-a3b6-dd0e932b65ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_9faa4d23-d764-4fcb-91c3-1b2c32eb20c6_terseLabel_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-party portion of milestone payment received</link:label>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_label_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method Third-Party Portion of Milestone Payment Received</link:label>
    <link:label id="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method Third-Party Portion of Milestone Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:to="lab_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_173e9375-5fe7-46f1-ad83-fc8cb98b13b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9dcc02cd-de41-41cc-b1e2-e80056bb8c0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f05cf223-2e12-441c-96ff-20d127398687_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_60f567d1-5de3-45ab-8011-7646ee8c6574_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0117d941-126c-4396-a6d5-42702093337e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2aba451b-835a-44a2-ae50-80fe3d7f08d0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_786d8d68-be1e-4a0e-b6c1-b66ba22351aa_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1c60b09d-1646-484e-a54e-b07c14f8293a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_6330c077-29b4-49fa-81ea-ee7a1deab7f0_terseLabel_en-US" xlink:label="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded (as a percent)</link:label>
    <link:label id="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_label_en-US" xlink:label="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded</link:label>
    <link:label id="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_documentation_en-US" xlink:label="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:href="lgnd-20191231.xsd#lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:to="lab_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_01bc4dcc-3cfe-4992-b93a-cbb96ff14ec0_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Senior Notes (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4725d08b-eb42-4066-82c6-ccd8de7ee950_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate change for changes in federal or state law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_947e28c7-fc20-4f33-989f-74ed820b00d6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b65c8e82-3807-4f37-ae7f-099fb92db6be_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPayable_7cf84762-a00a-43ed-8ac6-17a935a1edce_terseLabel_en-US" xlink:label="lab_lgnd_CashPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payable to Crystal Shareholders</link:label>
    <link:label id="lab_lgnd_CashPayable_label_en-US" xlink:label="lab_lgnd_CashPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payable</link:label>
    <link:label id="lab_lgnd_CashPayable_documentation_en-US" xlink:label="lab_lgnd_CashPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPayable" xlink:href="lgnd-20191231.xsd#lgnd_CashPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPayable" xlink:to="lab_lgnd_CashPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_5f76a3c8-0c6b-462c-8e30-595e9915b857_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_ac5ff5b5-bcfe-44bc-8066-5605f7be8462_terseLabel_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year:</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year [Abstract]</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:href="lgnd-20191231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:to="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_9a61ac83-f4de-45ce-8cba-d41f0539c89c_terseLabel_en-US" xlink:label="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:label id="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:label id="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:href="lgnd-20191231.xsd#lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:to="lab_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_48256771-eeaf-4f4b-b520-aa6174c84f3b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_5d3b808b-58f7-4e8c-a61c-17f9a45c42a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7c67ad99-907a-4294-bbbb-d64aa90a045c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-Known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_f93cd55f-c6f4-4dda-892d-bbd232332d2d_negatedLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoMember_37235d8d-dda5-4640-b555-52750190a8d1_terseLabel_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo</link:label>
    <link:label id="lab_lgnd_AziyoMember_label_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:label id="lab_lgnd_AziyoMember_documentation_en-US" xlink:label="lab_lgnd_AziyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember" xlink:href="lgnd-20191231.xsd#lgnd_AziyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoMember" xlink:to="lab_lgnd_AziyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_WarrantsSettled_974dfcf5-8b5c-4160-b869-9b24427be039_terseLabel_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants settled (in shares)</link:label>
    <link:label id="lab_lgnd_WarrantsSettled_label_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Settled</link:label>
    <link:label id="lab_lgnd_WarrantsSettled_documentation_en-US" xlink:label="lab_lgnd_WarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled" xlink:href="lgnd-20191231.xsd#lgnd_WarrantsSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_WarrantsSettled" xlink:to="lab_lgnd_WarrantsSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7443af7a-ca28-45b6-befa-aa5108d89ec3_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_00583d28-ea0b-4058-864b-c24a8a8371e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerCMember_c1770303-d8cb-4715-a553-c55dc2a6ba4f_terseLabel_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_lgnd_PartnerCMember_label_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_lgnd_PartnerCMember_documentation_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember" xlink:href="lgnd-20191231.xsd#lgnd_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerCMember" xlink:to="lab_lgnd_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92a06aae-7856-4ad4-af5d-ee4d614df3f8_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b2a008a0-e8c3-45c6-a04a-6fd548cdc916_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total commercial license and other economic rights, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMilestonesandProductOtherMember_21556f48-c0bd-40fc-b975-b8ad646f1c5b_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees, milestones and other revenues</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesandProductOtherMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Product, Other [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesandProductOtherMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesandProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:to="lab_lgnd_LicenseFeesMilestonesandProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9d2a438c-9d41-49b2-93b4-eac85e86fb53_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_1815a1a9-c70d-4ab2-8cc4-8195b7828d31_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond hedge settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_be8be63f-68af-4803-afa2-3e84d2b31e2c_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$119.30 - $159.01</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeNineMember" xlink:to="lab_lgnd_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f24a120-c875-4261-8995-37ddeae7ec48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6ea5a402-55e8-4785-9f98-087e448c72bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_a3ed0c45-deb3-4f44-9bdc-5eb72256eceb_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Crystal</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_0f1e529b-e316-462d-aa2a-081bbdac0dc2_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/48 each month for forty-two months</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodTwoMember" xlink:to="lab_lgnd_VestingPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c8449f3b-74b7-4fec-85ed-7cb977c7b780_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7e8df260-a160-4d97-8b86-6d942eea88e5_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_26f13cb8-fdb5-4bd0-95a6-b10e85d887b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If-converted value in excess of principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_058b6e4e-6bb7-478f-8fb4-2a2ac0cc2740_negatedLabel_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of contingent liabilities</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_label_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash change in estimated fair value of contingent value rights</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash change in estimated fair value of contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:href="lgnd-20191231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:to="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_530ccafa-06c8-4de6-a090-f8d9dd412d89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on sale of short-term investment</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3dcb0db1-9839-497b-bddc-fdc7b580ec1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_02540324-2476-483d-b86a-9d0743b0c4c4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e26cb725-420b-4246-b1cc-9b5cd792d267_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_fb035dca-7626-4199-aef2-3dc67388fa22_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a3ba7b13-6739-425c-84e6-a42b94b46219_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_3d175084-00e1-44d2-acd3-c180cdbd3e7f_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:to="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a05ae2e1-60d7-4d9c-bfdc-880a71551bf9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2d596785-01f4-4c1e-99ff-ef4958ea33c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5fcd9c30-dee2-49ac-9f5e-b23131f7dcf8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d02c6b77-e944-4da3-9b1f-1abc957d7124_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_628965cc-19c0-4e72-90ac-6efda221ccfd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_472d29fc-6724-41c2-be84-c82ffd705bea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_621fd1b4-f8bb-46c8-a3d8-2eeb97e46260_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_f27cb6c3-89fc-4905-97af-1b87b9bcf431_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic per share amounts:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_2b8cac6f-4f02-44e3-80a9-9baaa8594e7d_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a2511f23-ea19-4df7-b324-3c3ab8f840e9_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_31a67f04-1450-4c82-8f3b-6f5bb4447284_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and product reserves</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_46f086e1-a364-4b30-ba33-6e20a4f90072_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent liabilities</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRights" xlink:to="lab_lgnd_LiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_3f60f39f-28f4-412d-8477-8cfe4c869d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from repayment of Viking note receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6653e3ac-c422-4f21-b0d2-32e23dc8e35c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_03c1c593-b400-49ce-89c6-1c8a2d146412_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6b281bba-a0fb-420c-bf50-8a2f3a0c3710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_03332712-ff75-4c6f-b4f8-510036a609dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_04887fe3-ca8d-4607-a608-19e91595420b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_30b9c6a4-ff18-4fff-b21c-302680bc37d4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fecf5db-98c9-4a79-ac8f-2dc28b329e8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated amortization attributed to principal or research and development</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed387dc1-6e37-4b4b-9194-f39997a9d5e8_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_c2def042-607c-4dca-8b0a-480139d61ad7_terseLabel_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent" xlink:href="lgnd-20191231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiabilityCurrent" xlink:to="lab_lgnd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_615c1937-460e-4ffa-9ac6-f60a3c9603a7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPaidtoAcquireBusiness_79098671-677d-4de9-86fb-29c16ef5e004_terseLabel_en-US" xlink:label="lab_lgnd_CashPaidtoAcquireBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to Crystal shareholders</link:label>
    <link:label id="lab_lgnd_CashPaidtoAcquireBusiness_label_en-US" xlink:label="lab_lgnd_CashPaidtoAcquireBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid to Acquire Business</link:label>
    <link:label id="lab_lgnd_CashPaidtoAcquireBusiness_documentation_en-US" xlink:label="lab_lgnd_CashPaidtoAcquireBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid to Acquire Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidtoAcquireBusiness" xlink:href="lgnd-20191231.xsd#lgnd_CashPaidtoAcquireBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPaidtoAcquireBusiness" xlink:to="lab_lgnd_CashPaidtoAcquireBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5c7a3479-2df4-497f-b528-56a4f7c0a732_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ce1c14b-beb2-4707-a2ce-2f33451c8df1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_173c82a2-160a-4bb8-acb9-e5ae517aecfd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CrystalMember_08837e53-ce34-431a-92de-1a4938d32d02_terseLabel_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal</link:label>
    <link:label id="lab_lgnd_CrystalMember_label_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:label id="lab_lgnd_CrystalMember_documentation_en-US" xlink:label="lab_lgnd_CrystalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Crystal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CrystalMember" xlink:to="lab_lgnd_CrystalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_78c81e4d-bfc8-4579-b83d-561cf523ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_3f094f65-457f-4a76-9d7b-d067012edc90_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1123a406-08a1-4324-ada6-e61a5d6a706c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b06c6666-2924-4ec1-9c09-ae87f51f5b26_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9742b9a7-6364-4536-8954-7eee2fe682da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f44bfb93-ac91-4925-9a09-58b4f1ad4b75_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b1c8f615-32b0-4c60-9108-cf0b6f27aca8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4846c353-0ecd-4288-ac2b-da447329e489_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_c83faa2b-5ca3-4e47-8c60-379e88b37429_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_42705e65-1578-435b-be67-d9b1c27068b9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_725421d1-4045-404c-a274-aab08dfcf02a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_71fe3b57-5bec-4e45-97a3-8c6760edda4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of level 3 financial instruments at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a35f06e9-e353-492e-9213-a27007e88087_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_74fe16d8-935a-464d-94cd-c9a543a486ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4bb2d339-02c8-455e-b1fa-6dc9611e7eed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_f21a3fee-12a4-46a9-ad6d-981998da7049_terseLabel_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_label_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember" xlink:href="lgnd-20191231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_Phase3ClinicalTrialMember" xlink:to="lab_lgnd_Phase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_31524201-7a14-4c4d-9d19-d7de0cf34ac1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7a250264-0d1b-4612-9ab7-6fec2192c472_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_20107b00-3ccc-4fc0-9444-3d7507f58852_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified indefinite lived intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e75c7a59-387f-4dae-af06-c9fcd0c9a1c2_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_6327bff5-0b13-4992-a989-27f06b7abd76_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2a3262bd-1fc2-4e0b-997c-b544bfd6024e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_afb3cb9f-05b5-4ec3-ab91-b5213607ee7e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_c743f0f2-a17a-4f3d-b2de-99b8caf6cfb0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63d67373-5672-4803-8096-9bb0b0a86e78_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_4b42fac1-67d8-41d6-876b-542d3de38f13_terseLabel_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_90c7c5e5-f304-4577-aa3b-5a1dd0fb3363_verboseLabel_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants investments in Viking</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_label_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:label id="lab_lgnd_InvestmentInVikingCurrent_documentation_en-US" xlink:label="lab_lgnd_InvestmentInVikingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent" xlink:href="lgnd-20191231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InvestmentInVikingCurrent" xlink:to="lab_lgnd_InvestmentInVikingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f5462fe1-7025-45b4-b3ce-cc92ffa7d287_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_5d6bc246-fc4d-4968-8f7b-f9437d303247_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ded34ea-2b1a-4068-8743-8e5eac0170a3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_73507348-07f2-4a31-bdf7-8c24591a6e9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_9733f47e-f24d-4b3c-8df1-d2cb866252f7_terseLabel_en-US" xlink:label="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue royalty payable on all Cydex-related revenue (as a percent)</link:label>
    <link:label id="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_label_en-US" xlink:label="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Royalty to Acquiree Shareholders, Percent</link:label>
    <link:label id="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_documentation_en-US" xlink:label="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Royalty to Acquiree Shareholders, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRoyaltytoAcquireeShareholdersPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:to="lab_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_b8a2fda7-e191-4444-a4d3-78fa66a6ed14_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_5df2341c-d352-4a83-ad19-8660a26b9994_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:to="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ec8e85b-8701-4c95-b2b3-677656f271f6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f3db1845-51de-4a3e-88b6-34a1ed95b71b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_97e362ea-0ca4-4f2b-ba44-3a3f8559b782_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_215bfde7-9ab6-4ad2-8553-a9795942478e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_eba73909-2a83-4549-b73d-ae494a7cc20f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_72edb862-0e4f-463c-af02-1b9d53a169d6_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:to="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ad585eb6-e7a8-47e2-abe2-72cae5cf0b81_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf1e35a5-da68-4b39-a2d9-bda5288827e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9cd1d12c-9712-46c0-b9c1-3e18e361f703_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_11b6c413-ea4f-4e20-b411-a3af0772f262_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material sales</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember" xlink:href="lgnd-20191231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolMember" xlink:to="lab_lgnd_MaterialSalesCaptisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_dcfdc9d5-adef-4b8e-84ac-187e08328b20_terseLabel_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $1.5 million with Four Collaboration Agreements</link:label>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_label_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $1.5 million with Four Collaboration Agreements [Member]</link:label>
    <link:label id="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_documentation_en-US" xlink:label="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Revenues above $1.5 million with Four Collaboration Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:to="lab_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_398ec4d7-b915-4aea-adc6-9634b730f9ee_terseLabel_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of forecasted cash flows (as a percent)</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_label_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:href="lgnd-20191231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:to="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_9353169a-1d93-4e69-afbc-853278314919_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9e78d541-b928-49d0-a568-ba608a5c66d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_5184972c-8179-4cfe-9e24-5c5219b7632c_verboseLabel_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:href="lgnd-20191231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:to="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_b8c7632f-55a4-405f-a5f9-97fe5ed15cb9_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period in force</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_d3694d7f-d876-434c-a36f-8c461f929eea_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_label_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyKyprolisMember" xlink:to="lab_lgnd_RoyaltyKyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e354784c-54c3-443d-a8d7-f53a650077f3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on AFS investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_dc563d6f-b355-4dac-8699-7fc890a75faa_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_c4b037e5-5817-4617-a201-07a51bd6744c_verboseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember" xlink:href="lgnd-20191231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisTherapeuticsMember" xlink:to="lab_lgnd_MetabasisTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5928d3c0-d925-49ee-b282-74fc99588358_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a0b489a8-6952-4772-b624-adb6445a620d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3b06ee49-d56f-4dfe-ae89-d234d75538d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period in which cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_471d343b-ed0b-4191-a6d2-7206a995f89c_negatedLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect for Notes transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1f7d81e3-9f15-4353-ad5e-8ab96beb8bdb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_89176f17-14df-4dda-85b2-00b68d5aff96_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ca4ebda4-2bb0-4d46-a15e-cc020906ca69_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerAMember_2ec03750-f55c-43b4-98dc-02ba6b3bc3c6_terseLabel_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_lgnd_PartnerAMember_label_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_lgnd_PartnerAMember_documentation_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember" xlink:href="lgnd-20191231.xsd#lgnd_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerAMember" xlink:to="lab_lgnd_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_302c7c42-dbf3-47fb-83db-9c9afee1733c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ecbfb94-cfa6-476e-9f4d-330b59a6f40f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a20864ed-d146-4409-a1e2-b948d1e4f4e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_81db9a0c-497d-40e0-bfa7-47381e32e499_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_4c3f1d2c-910f-4996-8aa6-dd4807a156ce_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_b508cfb9-03b1-4695-9a9b-ebd50f43d74a_terseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating lease liabilities</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fe549083-2f37-4cea-9848-4be1b84b5798_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on debt instrument (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_d78fcafb-8fba-4842-999a-2370894ac6e4_terseLabel_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo &amp; CorMatrix</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_label_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_AziyoandCorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_AziyoandCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aziyo and CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember" xlink:href="lgnd-20191231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AziyoandCorMatrixMember" xlink:to="lab_lgnd_AziyoandCorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a55fa330-7414-4309-8b98-d6ffc9ffd677_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_51a023d4-f93d-447e-80a4-ca17198bc6bf_terseLabel_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_label_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_documentation_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:href="lgnd-20191231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:to="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_bce102f1-4457-4f7d-b477-ae2f90549d1d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_1311e746-b787-4091-a762-93509096767f_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_65d96a6c-c039-43cd-a9d2-965af9812854_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3e89f382-c2a3-4569-9754-c9f4b01afaa7_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment , gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b8878eeb-88b1-4fea-b3bc-2143ebedb7fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_935bc6ec-cd87-4801-af98-241cab1e0a8b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_80197808-ae60-4515-85ad-52c7c22df48c_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff554a45-3449-4e75-8ac3-85c13ab143bf_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9abc8ac5-f506-4a51-b46f-847f082cabff_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties owed to third parties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_421732df-e75b-4691-934c-7806554ad1a4_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a207dc52-ad31-4b6e-902a-4729bb655b8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fe043126-ddf1-4898-a41b-2c709313ac5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_af26da77-5fc5-4afe-8f65-bff02b160fa1_terseLabel_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments</link:label>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3f61610d-93bd-4b1f-b13e-6c7c7e3ee665_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ae4e30f9-80bb-40c4-952d-586bf4d7ac1d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_80517f38-db5f-4c13-afb2-6d5146bfe746_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_df92dca2-7249-49ff-9f74-c667a87b1af5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:to="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28a5b197-f4df-442e-b9d4-d46d2b19e43f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_16702118-195e-4385-8a3d-2ef8a9c8501b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1a8100bf-afd5-471a-823f-009d90e5d475_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of warrants issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b396e0eb-f63d-4ba9-ab70-92918debf0a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_028da46d-3591-4838-bc29-ee3feb2dd302_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_7116dd07-4842-42ce-a472-5ce44eb3d901_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_fa48f3a1-d78a-44bc-9cbf-169a6bf34dd0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2e36a45d-ea90-4ed4-8991-3d91cf5033f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_504b67ce-7871-4dab-82e9-15cf8837494d_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties recorded in retained earnings upon adoption of ASC 606</link:label>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_label_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Recorded upon Adoption of New Accounting Pronouncement</link:label>
    <link:label id="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_documentation_en-US" xlink:label="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Recorded upon Adoption of New Accounting Pronouncement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:to="lab_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_0c71de2a-a0db-49df-be23-715150fefecf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a6b73095-8aca-48d4-ba99-9640d7c45ada_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f9a99f8c-1044-4606-8d1b-385e24e38df9_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_346fafab-8935-43a2-90ab-7854690ce401_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_1a5f841c-0412-4519-a56d-60e7334193ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_fe51e94b-4840-43c0-9797-ed5a4eadeea0_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_35c37870-0248-46b1-b6c1-49f7ed83a415_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_c9e232e1-e042-470c-9b40-fd718814ce5c_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6ee59187-e96a-432a-887d-fbe817a353fd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0d3fd767-578b-44a0-ac36-67ab87916521_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_055f5f31-e527-4a5a-aa87-a4d3a8f33f8e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_d0203a63-ef4d-4384-b992-52eb852b9802_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$117.97</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSevenMember" xlink:to="lab_lgnd_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e623211e-0d67-405b-a07e-82f0f0d233c4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain on available-for-sale securities, net of deferred tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2a3f1125-19d6-4a5a-8ebc-441298d6ac24_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_90d2cc46-439f-4d73-a0f5-2ddb42c7a3e0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0d1981da-3a08-4998-aebe-65fc0d539ff0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_e426a4f4-e0de-4622-ae9d-dc734271b75a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_83dac86d-dfeb-4ce2-9eba-271ec8fe234b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59f22500-385e-4263-8445-7a7532996535_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_72671e8e-dd4f-463a-9cc4-19935ce088bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares allowed to purchase in employee stock purchase plan per employee (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_23de1f8a-6f97-4cd4-953a-74ee6d01b022_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f572f86b-b784-48c0-9e9e-76a8c38ec32a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b51430c2-8ebb-42bf-a279-82a93a8af02e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_236ef734-fb87-40df-adb7-9466a72a081e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range of exercise prices (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a803b472-3817-4e4d-9d11-760f3a57bf58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6b498908-d30c-4d5f-a080-030ce326c8c5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_5c53bd8b-6fab-4412-b909-3678fff666f4_negatedLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant repurchase</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Repurchased</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_d03f1daf-9613-412c-83ee-19a1402baebb_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected cash flow discount rate (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_bcd631a8-01d0-4099-ac01-34a399cf89da_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average cash flow discount rate (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Average Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumptions Used Estimated Future Cash Flows, Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:to="lab_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7eb84448-6a93-4ba6-89af-06167f834636_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_eea11528-7086-4420-a2d1-de225e95b5f5_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:to="lab_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMember_86520b11-ae0f-44d0-8b99-709e24283dae_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMember" xlink:to="lab_lgnd_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ce6fb3a0-9bfe-4d74-885c-2c16de2eb01f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future option grants (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_b142f70f-a1a4-41bf-bad3-4b2c59cfff1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion price per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0d887108-8e4b-41b4-9b18-cb4461770871_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f58d32d4-0627-482e-978c-1054d4e7ccbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b8fc74ce-e092-4bf0-96a9-a12eb38efdaa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4152bbd2-0c2f-4a62-8669-3981c222befd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4025c06b-4e09-472d-9915-abd453e586bc_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_29fbec2a-69bc-4ff6-86cf-e500898f1138_terseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities - Metabasis</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis [Member]</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights Company, Metabasis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:to="lab_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_362d1197-c9dc-4c61-b198-7451c5c85746_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting right (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_840c3c0a-df55-4167-818c-6cd26f0b147a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible bond hedge and warrant transactions, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_0e53be33-9ed1-4674-946b-3484b33abfcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisMember_a68455a9-bd56-4ce9-bb0a-ee569f54e098_terseLabel_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis</link:label>
    <link:label id="lab_lgnd_SelexisMember_label_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis [Member]</link:label>
    <link:label id="lab_lgnd_SelexisMember_documentation_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember" xlink:href="lgnd-20191231.xsd#lgnd_SelexisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisMember" xlink:to="lab_lgnd_SelexisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_7f0a279a-ab90-456c-9645-5d7d262f9551_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_35d0dbb2-0fb7-4e2c-974a-2f665b864cfd_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_3e3c9f3e-e99e-45a5-b39b-8e7eff155605_terseLabel_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:href="lgnd-20191231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:to="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bcb3b5e7-5acf-49af-822a-28615c250d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_683ec0d2-b4d2-415c-90d3-cc37d89bae61_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7e5b3073-9d63-420c-9c39-3f4c282b42de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8f71e8f8-552f-4606-9778-73bfb03ab48e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8dc6681a-3663-4eb0-9a38-ea2de815ce7b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_406fbe47-8a3a-42f3-8d3c-7f38ad40f549_terseLabel_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_label_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_documentation_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:href="lgnd-20191231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:to="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a6ea9dfd-f325-474b-be6d-3dc22eb00189_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dfb523a4-5649-4995-bb50-5df03866ef04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e1e58f5-18a6-4ba4-a240-c49f3238b82a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_67dd594c-36e4-4062-b2f2-407e6296bf98_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2019 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotes2019Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotes2019Member" xlink:to="lab_lgnd_ConvertibleSeniorNotes2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fee957d2-4241-40ae-870b-62788c5dbe12_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_a0582fc4-bd0c-4faf-a564-678e4abb6c30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationTable_1ee3f464-b51c-43e9-8cf1-26bc1cdee7f8_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationTable" xlink:to="lab_lgnd_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ac8ee3f-44cc-4549-8330-178a923aece3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d6044043-0e46-46cf-88c0-1058d93cb2fd_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d92e5fd5-8510-461b-9744-6f16f54b2a38_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 60,000 shares authorized; 16,823 and 20,766 shares issued and outstanding at December&#160;31, 2019 and 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_f1cd1273-2ff8-481e-9fc9-9c96e5de772e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_7c033634-4b8c-489f-a3f8-fc3724b7a7ce_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:to="lab_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3f01aeac-32f5-41f5-bb5f-9c29a3390a16_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_afa8112d-2076-47c0-9e46-13f87e98d884_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRights_22a7032a-ac2e-4133-95c3-206d3a910fb6_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights" xlink:href="lgnd-20191231.xsd#lgnd_CommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRights" xlink:to="lab_lgnd_CommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_9d2b81b3-bedb-4a01-96d2-dd2378a59233_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deduction to additional paid-in-capital for warrants settled</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Settled</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_5377834b-ce36-41e5-96ed-dbc15eac8259_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f69028f6-fcef-46fa-8f19-33ed5c6ef5a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_67921e9f-024a-4f4b-a0b0-cd0b612a2219_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_23f9f6d4-2afe-439d-ba5a-8fe044e2b4d2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_eb731f53-1f7e-49d5-8ae7-1803dcfe9e59_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR holders and other contingency payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_710dcdd1-e9be-4a53-b8ed-52b8b0554548_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to contingent value right holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:to="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneMember_b49d8958-4d3f-4233-ab02-7fb98e71db71_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:label id="lab_lgnd_MilestoneMember_label_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Member]</link:label>
    <link:label id="lab_lgnd_MilestoneMember_documentation_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember" xlink:href="lgnd-20191231.xsd#lgnd_MilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneMember" xlink:to="lab_lgnd_MilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c1b9c7b5-c389-4300-8d3e-a5af15a03738_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b1e8685b-1d2d-4456-adfc-a6a7b42d9f91_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_4ba96357-b451-4cf5-bbca-32afd17f53aa_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_d08acca5-fed2-4acd-aa10-3f5cf3c6816e_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash holdback for potential indemnification claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_label_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:label id="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Holdback for Potential Indemnification Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:to="lab_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c289d6d0-ee78-433c-b0ef-f671505a3466_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic per share calculation (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0962f05d-10c4-47e6-af9e-857083de89ba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb82f5dd-e825-4f09-b62c-5ad5a9410e76_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares&#8212;basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_36699c58-58cd-43a6-b11d-124d95fdc47a_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_label_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward" xlink:href="lgnd-20191231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilityRollForward" xlink:to="lab_lgnd_ContingentLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_9122f0c7-5cc9-4b4c-8609-14b9e572a09d_terseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to contingent liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_27ffb772-84f4-40a9-a6ab-48708a36993c_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b331f28e-f976-4190-8b14-4a22a13e76b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0fec0b27-8de3-493a-80aa-8b0a701a8d0c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_60ddf4a9-8b25-4b8c-b0fe-59c6033f3dc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bd8d9518-f892-4026-a22f-ff8192ee72f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c578697c-59fd-46d6-9b38-2669d0d973fd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5d9cd12e-d944-4f5e-a126-965a49972aa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_e3f90c56-1f4b-4325-9fec-4b682468d9ee_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from Viking</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_c2b5bdab-363b-4611-9892-0850ee7c3158_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_920ded2b-cf58-4231-b572-772315eb5ff5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3bbc3bd1-8cd1-44c8-b32a-ce36be9d6c13_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_7da8cad2-8bf7-4caf-9b05-cd36431f03be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_47d1521e-7781-4c97-8a6a-84ddffb1a8fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_a4476c16-02c0-49fe-aef2-ae7cd8efd35c_verboseLabel_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents &amp; Short Term Investments</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:href="lgnd-20191231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:to="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_fc233512-91b4-4dbc-a743-8cce2bf10893_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0559ffe-1688-42e6-a5a8-93f2b38f8b9c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_3833309c-4073-4864-8c0c-66e04841a5e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberofCollaborationAgreements_8f907ab0-3a63-4269-99cc-137ee82de5ec_terseLabel_en-US" xlink:label="lab_lgnd_NumberofCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration agreements</link:label>
    <link:label id="lab_lgnd_NumberofCollaborationAgreements_label_en-US" xlink:label="lab_lgnd_NumberofCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Agreements</link:label>
    <link:label id="lab_lgnd_NumberofCollaborationAgreements_documentation_en-US" xlink:label="lab_lgnd_NumberofCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberofCollaborationAgreements" xlink:href="lgnd-20191231.xsd#lgnd_NumberofCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberofCollaborationAgreements" xlink:to="lab_lgnd_NumberofCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f79c6094-8be0-49c4-b2c2-04120d86462d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_57d34ae1-36de-4b46-ab59-801d0a7fa46b_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyEvomelaMember" xlink:to="lab_lgnd_RoyaltyEvomelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ac57ca0b-df65-4329-83f1-353d271e49ee_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_27200dc1-4be6-455b-bf56-53795ab7b86a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_de565a2b-aee2-42d4-ad64-c8f3f71ae1e7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to convert holders for bond conversion</link:label>
    <link:label id="lab_us-gaap_PaymentsForHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="lab_us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_57adbbbb-e769-440d-8cf0-dfb440cb4137_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c0e6b045-a320-4450-8cf6-8fe82bd8bb0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of premium (discount) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_caef4f84-c7c5-4996-8c9c-426b831eb8b3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_5bb162c1-050f-4f94-a890-32b992caf1d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_0683fcdf-a751-4243-a01a-6b04fca60ed9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6adcd545-1b41-4eda-8677-ff4c90c1ea31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1c0dfe5f-6dfa-41e5-94be-a43915cc1463_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_e300f238-3dd3-4d98-9bf6-4d6a5a2bc653_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_dc6820a5-c739-4999-adbe-c1a43ff8ff19_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a4e39fd2-90f7-483f-b8e7-fccff7b1da2d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ed314de4-6dad-4a54-807d-e64771c7451b_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_78c7c4ef-1694-4221-ac55-e9864d76ed94_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in if-converted value in excess of principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:label id="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:to="lab_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b3d48370-51f5-4d0a-9669-f7e5cff8c41e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a21414f9-5465-4ed2-91df-e71ce8fac691_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b7d86d29-d005-4b63-a71a-3a54ca21af91_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_71c7e6bc-1329-4716-b599-1badcfc2ac6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the conversion option derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_f1dfeb1d-365a-44a9-a210-5eeafad2ab89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_de4791c8-8312-447a-bebb-a133ac017672_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for convertible bond hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:to="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d7ff6385-9791-466a-acee-6c8b28fb0f20_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0e78b146-3446-4a8b-beff-e69b09da63af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2019 and 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_98cba34f-c031-44f8-bb20-20b5d2f94b4f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1a8af20b-d31a-4a25-8e3a-9828b7e0ddf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b5cff96d-cc81-4336-9448-f3bc0887baaf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2e868c5d-7f37-4636-b5b4-1aa82e4f005a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_2d527d50-6272-4aef-88cb-e10157c50fe8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f46ced66-825a-4dad-af28-a81a55cdb1eb_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3d153d9c-67c3-4e79-b278-e15e4ba47523_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_fb5bfd11-eeff-436c-adad-1827f31a6be4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_6b4d8d1c-3550-4135-9966-214662866c8a_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank deposits</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_3f2a017e-33d2-441f-bd12-99912f0f07a7_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fc6c9e40-3ebf-49f1-9c15-15f4e1817497_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c79822b9-eb8e-429c-ae97-b49c9c8ec552_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_37da5129-0d36-42c8-8284-c829281e8b08_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_c6161181-69ba-4b4d-ab0d-e9ac82db5b5e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_fe3d465f-0c67-4f74-ad21-a309da9f7886_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e9abbd19-c99d-4de2-a636-e0ab5e97041b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_53aabb09-1db3-4310-a029-23428389f2b8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_23831c48-0c50-4683-94d4-546df8474334_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_95dd2032-605e-4ebb-b6af-8a5858caf12e_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_be1e21f1-6d3d-4a5f-8322-32c5bbdd80ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b3457814-b224-45c4-b765-4e985f484d3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_ddb45f02-6350-4988-9f70-a97de511bb58_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_c9474af7-d82a-4606-b71e-54e44d56970d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_0984c34f-fef8-42b5-846b-64cbc835d96f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, noncurrent</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_f9e2257e-be82-4abf-9dd0-014a86ddd6e2_negatedTerseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_32939ad9-cdbe-4821-aa6d-d5bae0f14f0a_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$9.96 &#8211; $195.91</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeElevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember" xlink:to="lab_lgnd_ExercisePriceRangeElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b1706527-81f3-4d01-8932-925410d3081e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5670ea71-afd5-4805-87f4-029da61ec266_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_98a1e807-cf2b-405b-ada5-89fd666b4f3d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_266bacbc-1445-4ab4-9c68-93f8dcebcad0_terseLabel_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for license</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_label_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:label id="lab_lgnd_LicenseUpfrontPayment_documentation_en-US" xlink:label="lab_lgnd_LicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment" xlink:href="lgnd-20191231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseUpfrontPayment" xlink:to="lab_lgnd_LicenseUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_de662381-a1d1-4c80-b5c6-2c871cb72e6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3bec71bf-0eb5-4711-b095-946606796b95_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_8d428a7f-f523-441a-b994-bb0ae126b9bb_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>lgnd-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:5983aa56-2ed1-4014-92a8-06ce0786070c,g:154b827c-8301-4749-a4a4-fa2d7fa872ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f469ebe6-4fe6-48c3-b530-7ec168ba7742" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_AmendmentFlag_f469ebe6-4fe6-48c3-b530-7ec168ba7742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c8ec08cd-0fc5-438a-ae4f-3c399f104048" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentFiscalYearFocus_c8ec08cd-0fc5-438a-ae4f-3c399f104048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6b5e0c11-47ca-4cb6-b775-46189f93b9f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6b5e0c11-47ca-4cb6-b775-46189f93b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a371ce08-3fd3-4dcc-a21e-e47f24497ab9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityCentralIndexKey_a371ce08-3fd3-4dcc-a21e-e47f24497ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0ca02b91-82a0-44f9-8e5a-92c4a1aff4b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_CurrentFiscalYearEndDate_0ca02b91-82a0-44f9-8e5a-92c4a1aff4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3f767160-1e8c-453e-b786-e11d51600a3a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentType_3f767160-1e8c-453e-b786-e11d51600a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7f47844c-05b4-4eb9-8702-f2d3ef082f63" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentAnnualReport_7f47844c-05b4-4eb9-8702-f2d3ef082f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f41c5d12-209d-465d-84fc-68ed604e827c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentPeriodEndDate_f41c5d12-209d-465d-84fc-68ed604e827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_060227fe-9306-44f5-96f4-d7f5178add2b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_DocumentTransitionReport_060227fe-9306-44f5-96f4-d7f5178add2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a1267dbe-5f90-4e72-8ca7-8732e00971c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityFileNumber_a1267dbe-5f90-4e72-8ca7-8732e00971c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_68079e56-9866-4485-a544-023c2f7f0725" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityRegistrantName_68079e56-9866-4485-a544-023c2f7f0725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f7b3e028-4ae2-462b-ba08-9d3a71f0b512" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f7b3e028-4ae2-462b-ba08-9d3a71f0b512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0e45ddd2-ac33-4ffe-b1ce-64febdd5cef0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityTaxIdentificationNumber_0e45ddd2-ac33-4ffe-b1ce-64febdd5cef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_657b743f-c508-462e-afb1-52770079a855" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityAddressAddressLine1_657b743f-c508-462e-afb1-52770079a855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9eba518d-ce7c-41ea-96db-000f96bcf2c5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityAddressCityOrTown_9eba518d-ce7c-41ea-96db-000f96bcf2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_92cd4d54-516a-4ea7-9622-a635d92f6409" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityAddressStateOrProvince_92cd4d54-516a-4ea7-9622-a635d92f6409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_15cac384-3c3e-4e94-9a42-357b4ee3320f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityAddressPostalZipCode_15cac384-3c3e-4e94-9a42-357b4ee3320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_13728e75-6623-46eb-9399-c223a02b1239" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_CityAreaCode_13728e75-6623-46eb-9399-c223a02b1239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0234607c-c8c2-40a3-ac24-dd88992201d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_LocalPhoneNumber_0234607c-c8c2-40a3-ac24-dd88992201d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ff9272e7-fe02-4562-83a2-5d2a2b609daf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_Security12bTitle_ff9272e7-fe02-4562-83a2-5d2a2b609daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_237dbffc-8765-4a8b-ab87-83af7f07bda9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_TradingSymbol_237dbffc-8765-4a8b-ab87-83af7f07bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_23ef8fe4-811b-4f27-9eb8-07ef7e64342c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_SecurityExchangeName_23ef8fe4-811b-4f27-9eb8-07ef7e64342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_da9a3df6-f03c-4f0e-9d85-02759371d343" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_da9a3df6-f03c-4f0e-9d85-02759371d343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_8ba253c1-9c5e-45b3-9c89-65f106ee98f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityVoluntaryFilers_8ba253c1-9c5e-45b3-9c89-65f106ee98f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_01a39f6c-5245-47ff-add8-22820b592b54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityCurrentReportingStatus_01a39f6c-5245-47ff-add8-22820b592b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b9089b7d-b661-4ea4-8bd7-53976e3e3035" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityInteractiveDataCurrent_b9089b7d-b661-4ea4-8bd7-53976e3e3035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_112090ce-9a2c-49b7-b067-f61ad13a02c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityFilerCategory_112090ce-9a2c-49b7-b067-f61ad13a02c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_97c3a7a8-4586-4862-9dfc-203112272807" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntitySmallBusiness_97c3a7a8-4586-4862-9dfc-203112272807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cec21114-bda6-4048-9ae6-83e6556a2687" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityEmergingGrowthCompany_cec21114-bda6-4048-9ae6-83e6556a2687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cf8281b2-6a18-4918-9dd1-d9fa5ed9f5ff" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityShellCompany_cf8281b2-6a18-4918-9dd1-d9fa5ed9f5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_651211f4-bd1b-4d74-bb77-40965d775a7a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityPublicFloat_651211f4-bd1b-4d74-bb77-40965d775a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2308aa20-f788-4923-bdf9-ec9578818b9a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_354d6fe1-d963-489a-a35b-8edda739dc3b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2308aa20-f788-4923-bdf9-ec9578818b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_de9270ab-dbde-4295-a6d7-a0142f37cdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_de9270ab-dbde-4295-a6d7-a0142f37cdd7" xlink:to="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_735e4171-d35f-478f-8a63-c87174050113" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_735e4171-d35f-478f-8a63-c87174050113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a25dbe10-c5e9-4159-802a-647224c40ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_ShortTermInvestments_a25dbe10-c5e9-4159-802a-647224c40ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_f028784b-c465-4129-8ff8-88d077fd4dae" xlink:href="lgnd-20191231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_lgnd_InvestmentInVikingCurrent_f028784b-c465-4129-8ff8-88d077fd4dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e2cf77c2-be30-4044-92a3-051885fa8141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e2cf77c2-be30-4044-92a3-051885fa8141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ac92bc97-8ea6-430b-ab41-535b3982d361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_InventoryNet_ac92bc97-8ea6-430b-ab41-535b3982d361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_1dad428b-7e2d-4223-8417-5e7edba23507" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_1dad428b-7e2d-4223-8417-5e7edba23507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_2254db2c-f23a-4f95-b4e6-57372bdd7a80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_IncomeTaxesReceivable_2254db2c-f23a-4f95-b4e6-57372bdd7a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2ea469d1-aa9d-4a09-8c58-f431da325760" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_OtherAssetsCurrent_2ea469d1-aa9d-4a09-8c58-f431da325760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5e571e6a-c722-4e4b-a579-a534b57954f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f595ccc9-de26-4df4-af6b-12c4f1b19f9a" xlink:to="loc_us-gaap_AssetsCurrent_5e571e6a-c722-4e4b-a579-a534b57954f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e06ca1dc-57d6-46c1-b130-fa5ce3f8c9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e06ca1dc-57d6-46c1-b130-fa5ce3f8c9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_12f590fb-c50b-49df-9251-f13f28b52084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_12f590fb-c50b-49df-9251-f13f28b52084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c005ef9e-2626-4520-aa4f-8749828fcc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_Goodwill_c005ef9e-2626-4520-aa4f-8749828fcc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_925af7e6-1e2f-4390-a0d0-c0e2629fa7cf" xlink:href="lgnd-20191231.xsd#lgnd_CommercialLicenseRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_lgnd_CommercialLicenseRights_925af7e6-1e2f-4390-a0d0-c0e2629fa7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8080a3b0-1157-403f-8d37-c9e2f66623b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8080a3b0-1157-403f-8d37-c9e2f66623b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3dc89b44-7cf8-41cd-be85-b7cc6ee2411d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3dc89b44-7cf8-41cd-be85-b7cc6ee2411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2d0cdfe4-adaf-4fa6-824a-6d2dad06ff6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2d0cdfe4-adaf-4fa6-824a-6d2dad06ff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cd215691-94d2-4b2a-94b2-5a00571c6bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ee86ece8-a0a4-46c4-b35f-64a8aeeb5e6f" xlink:to="loc_us-gaap_Assets_cd215691-94d2-4b2a-94b2-5a00571c6bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_de9270ab-dbde-4295-a6d7-a0142f37cdd7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:to="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a8d467f5-0e73-4054-81b1-1f6587cb832a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_AccountsPayableCurrent_a8d467f5-0e73-4054-81b1-1f6587cb832a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e7e11da2-45e6-45a9-9503-f8b463f61041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e7e11da2-45e6-45a9-9503-f8b463f61041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_d8d010ce-f5e4-4296-88c4-4c0943cdd484" xlink:href="lgnd-20191231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_d8d010ce-f5e4-4296-88c4-4c0943cdd484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_090e5b92-a720-4f7a-a91a-5869838837c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_090e5b92-a720-4f7a-a91a-5869838837c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_52e211ae-d0b6-4fca-bd87-4e5d0e1e09f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_52e211ae-d0b6-4fca-bd87-4e5d0e1e09f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_7a4f8949-99fd-457b-b3f5-209f047e1f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_7a4f8949-99fd-457b-b3f5-209f047e1f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fe601072-94cb-489a-a65e-fa4f72f6b3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c14e530e-e2d6-48bf-8c26-97ccf2e0d9f4" xlink:to="loc_us-gaap_LiabilitiesCurrent_fe601072-94cb-489a-a65e-fa4f72f6b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_7e88862b-f2c6-48ed-bb5f-6abcef5bc62f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_7e88862b-f2c6-48ed-bb5f-6abcef5bc62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_fa3d761d-647f-4d18-b527-60e344bcb3f1" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_lgnd_LiabilityForContingentValueRights_fa3d761d-647f-4d18-b527-60e344bcb3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f28cb8b4-ce91-4c6b-a25c-24322bc46516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f28cb8b4-ce91-4c6b-a25c-24322bc46516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9b3f94a-8b40-4c44-8a2c-768f1817ba75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9b3f94a-8b40-4c44-8a2c-768f1817ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_27235627-b401-4229-9f68-820ba4c0b290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_27235627-b401-4229-9f68-820ba4c0b290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9fff1ec9-d079-4344-b835-e871406bfa83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a3f4c497-827b-4d4c-a709-41d33c1efafb" xlink:to="loc_us-gaap_Liabilities_9fff1ec9-d079-4344-b835-e871406bfa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_65e13fdb-af86-4437-bb68-0bc920781c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:to="loc_us-gaap_CommitmentsAndContingencies_65e13fdb-af86-4437-bb68-0bc920781c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:to="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_53c4824c-29f6-4795-98b6-db8ee13cae90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_PreferredStockValue_53c4824c-29f6-4795-98b6-db8ee13cae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41190d2e-597d-4af1-8a05-7ee8e7cfaf29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_CommonStockValue_41190d2e-597d-4af1-8a05-7ee8e7cfaf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3e69cc6e-de4a-47e4-b23e-dcfbf4aa515f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3e69cc6e-de4a-47e4-b23e-dcfbf4aa515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f19794ec-ebef-49f1-a39e-b4958fd1ac2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f19794ec-ebef-49f1-a39e-b4958fd1ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7a33ffa2-41d1-4459-93c8-dd181f877386" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7a33ffa2-41d1-4459-93c8-dd181f877386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9810a45-71e0-492d-b797-7faa2a827349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_404496fe-3d37-409e-9cc2-c2293bddebc6" xlink:to="loc_us-gaap_StockholdersEquity_d9810a45-71e0-492d-b797-7faa2a827349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_daeb4d8d-48d3-4431-a1bd-9deb9b28f14e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23fc2931-15ff-48c0-a53a-2aded3da78de" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_daeb4d8d-48d3-4431-a1bd-9deb9b28f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28e25d50-69d3-43f7-be3b-6b01b7440a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28e25d50-69d3-43f7-be3b-6b01b7440a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_48a54e50-f09a-4981-9593-a03329781e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_48a54e50-f09a-4981-9593-a03329781e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5942310d-5e69-4160-a5e2-7937267f8633" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5942310d-5e69-4160-a5e2-7937267f8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b37fb175-3c02-46bd-81c2-e54c53d286ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b37fb175-3c02-46bd-81c2-e54c53d286ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c745d559-f2dc-43a7-aa4a-1da7eedccc07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c745d559-f2dc-43a7-aa4a-1da7eedccc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_429f021a-0c5c-48ce-88ac-fa45a78c13cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_429f021a-0c5c-48ce-88ac-fa45a78c13cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a8a08dac-269e-4d6a-9aab-0621a51acece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_CommonStockSharesIssued_a8a08dac-269e-4d6a-9aab-0621a51acece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6c6e6758-a5e5-4b89-bf5e-aeae5773e07e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bba0931c-12a5-4f85-8858-26117797a75b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6c6e6758-a5e5-4b89-bf5e-aeae5773e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0f37b44a-e9d9-4612-a11c-97810b2fa921" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0f37b44a-e9d9-4612-a11c-97810b2fa921" xlink:to="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:to="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_114ef52c-a1f6-4a3e-a207-4382573673b5" xlink:to="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_53a10077-cc5b-4c98-a0c1-08277c6353d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_us-gaap_RoyaltyMember_53a10077-cc5b-4c98-a0c1-08277c6353d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_ead50c0f-4b6c-449c-a8fa-ed5ee0496fa1" xlink:href="lgnd-20191231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_ead50c0f-4b6c-449c-a8fa-ed5ee0496fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_952060b4-7703-4349-b743-de777a0b516a" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesandProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64a30e30-5af0-4943-87de-0ecd0950b6b0" xlink:to="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_952060b4-7703-4349-b743-de777a0b516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d99b815-f8e6-444e-bcef-b909ad037883" xlink:to="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7180df-56cb-49b6-aff2-88925851067f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_83d2c615-b662-4b1d-98f5-48443a194cb4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7180df-56cb-49b6-aff2-88925851067f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_d47c119f-c0a3-4e2f-b2bf-a912a5884658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_CostDirectMaterial_d47c119f-c0a3-4e2f-b2bf-a912a5884658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cf96b841-0a0b-409b-a9f3-0d8d2e7c5adb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cf96b841-0a0b-409b-a9f3-0d8d2e7c5adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f19631ef-2195-4066-9235-169b04c3d05f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f19631ef-2195-4066-9235-169b04c3d05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3e3a317d-336d-4b82-8353-d08dd941540d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3e3a317d-336d-4b82-8353-d08dd941540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2e7475d9-4a35-4fa0-b979-21fa12b724b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0472b0d1-f22e-4131-9db9-0687e2bd980d" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2e7475d9-4a35-4fa0-b979-21fa12b724b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1d07e2f2-79cd-4d99-a1fd-5982ee687f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_1d07e2f2-79cd-4d99-a1fd-5982ee687f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fdc48520-6c30-4ac8-ac2e-f6d723a33875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OperatingIncomeLoss_fdc48520-6c30-4ac8-ac2e-f6d723a33875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6f541688-78a6-411b-aa6d-4424d083c61a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_GainLossOnInvestments_6f541688-78a6-411b-aa6d-4424d083c61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3108d510-c62a-40ec-b021-00e472f9d6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3108d510-c62a-40ec-b021-00e472f9d6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b7e476ca-383f-402f-9959-f4afd941cdea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_InterestExpense_b7e476ca-383f-402f-9959-f4afd941cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54d8ffd0-f5e4-4780-906e-c9614a3d4eda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54d8ffd0-f5e4-4780-906e-c9614a3d4eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d4659b50-fee8-43f8-b8a2-c271dc5fbe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4c7544cc-dc68-4981-bdaa-9ef5a22b1c3d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d4659b50-fee8-43f8-b8a2-c271dc5fbe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dc473c4d-27b8-4b73-97b8-c647330c0274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dc473c4d-27b8-4b73-97b8-c647330c0274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_723d3c6c-6c97-4233-9c75-38a09481adf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_723d3c6c-6c97-4233-9c75-38a09481adf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76d790dc-845b-4eb5-a686-134b63d6f624" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_NetIncomeLoss_76d790dc-845b-4eb5-a686-134b63d6f624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16173f14-1663-4d83-b140-a6e91b07fac5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9128887a-8d00-46b6-bab0-d8ca53a47ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_EarningsPerShareBasic_9128887a-8d00-46b6-bab0-d8ca53a47ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7f132b3-041a-4322-90b4-599a55c1b904" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7f132b3-041a-4322-90b4-599a55c1b904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_46492422-716e-416a-9973-06dee132ff8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_46492422-716e-416a-9973-06dee132ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64a05b76-352c-42bc-b84a-18b338e8f3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_061ee808-6724-4ba6-aa5a-16c728c8bd6b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64a05b76-352c-42bc-b84a-18b338e8f3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d75a40d7-fcd8-4c87-b9d8-feecce5c4411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:to="loc_us-gaap_NetIncomeLoss_d75a40d7-fcd8-4c87-b9d8-feecce5c4411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_9b3dcc7d-032c-4b5b-a8b3-2a61c1db598d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_9b3dcc7d-032c-4b5b-a8b3-2a61c1db598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_990cdc0a-1a89-4f2c-92e6-37b327f7a2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_990cdc0a-1a89-4f2c-92e6-37b327f7a2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_aa37c47f-f17f-4a07-9b9d-05b0d8f377fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_aa37c47f-f17f-4a07-9b9d-05b0d8f377fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_447db7bf-2a06-4f97-9653-55ec93aaa91c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8be05be8-a31f-409f-b21f-1e2428933bdd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_447db7bf-2a06-4f97-9653-55ec93aaa91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_da8cdbec-e36d-4ddb-ac2a-312359315df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_da8cdbec-e36d-4ddb-ac2a-312359315df2" xlink:to="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb5b867b-f29d-4a28-8545-0515eb406300" xlink:to="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a744089a-d327-4b6a-b65e-f1b5d76e8fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_CommonStockMember_a744089a-d327-4b6a-b65e-f1b5d76e8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_76542a91-32f7-4d7d-9657-aac704d55d78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_76542a91-32f7-4d7d-9657-aac704d55d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cee88b26-5238-41fc-aea3-b4252917bd04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cee88b26-5238-41fc-aea3-b4252917bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c8d12478-511a-4840-87c1-f4e38dae4237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e208236a-3fb2-4bc7-be27-f5b37a59392d" xlink:to="loc_us-gaap_RetainedEarningsMember_c8d12478-511a-4840-87c1-f4e38dae4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a03c09d6-a376-450a-b215-92c72cac6b72" xlink:to="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_074edede-a0a2-4fff-9d19-81c01e75fb43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_074edede-a0a2-4fff-9d19-81c01e75fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_961f70c2-2671-471b-9b47-d836cfa09502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_961f70c2-2671-471b-9b47-d836cfa09502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_b2312e53-2f9e-459c-bfee-5f45f287bf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_58b90769-5b3c-4abe-ad19-d8c34b56a021" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_b2312e53-2f9e-459c-bfee-5f45f287bf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf966f0f-c359-4121-882d-4d86ef860388" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_bc9e4856-fc6f-4ca0-97aa-9a90aa7f0988" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_bc9e4856-fc6f-4ca0-97aa-9a90aa7f0988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_45340bc8-db3a-40e2-8229-5d1127222776" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32adf31e-f009-418a-8eda-40fd049e19e4" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_45340bc8-db3a-40e2-8229-5d1127222776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5be3a10-9dde-4a2b-bcf9-fecf0e6618d2" xlink:to="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c1d36565-4c15-4724-96f0-5fc8a8f07edd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4e376b25-d0a0-40ed-9523-9aa606e25706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_SharesOutstanding_4e376b25-d0a0-40ed-9523-9aa606e25706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_54790fa6-0069-4eff-8a66-d59671a960d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_54790fa6-0069-4eff-8a66-d59671a960d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c9625b8e-b3c7-4f2b-987b-8e58568cea6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c9625b8e-b3c7-4f2b-987b-8e58568cea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ffd806eb-22ec-4a25-a02a-99accb982c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ffd806eb-22ec-4a25-a02a-99accb982c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_72c1077c-36c5-470d-ad79-75703861fb68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_72c1077c-36c5-470d-ad79-75703861fb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b6df279-7588-43ad-a1d2-8d8b549fbffe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b6df279-7588-43ad-a1d2-8d8b549fbffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_270b30e3-ea81-4e95-bc9f-509086ded50d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_270b30e3-ea81-4e95-bc9f-509086ded50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f30abc44-797d-497c-a537-1d816a1bd041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f30abc44-797d-497c-a537-1d816a1bd041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270e6b6c-610d-422f-82a3-a650c3735bce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270e6b6c-610d-422f-82a3-a650c3735bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_eef3c5ad-f69d-4a03-ae0e-f6eea8bed8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_eef3c5ad-f69d-4a03-ae0e-f6eea8bed8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_bac1e171-6023-4909-81b8-f94a4e3f7503" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_bac1e171-6023-4909-81b8-f94a4e3f7503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_fc779baa-489f-499f-a074-33e02c2b0580" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes_fc779baa-489f-499f-a074-33e02c2b0580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_601de2b8-8909-4d0c-8870-07ba0e034406" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased_601de2b8-8909-4d0c-8870-07ba0e034406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_9c70ff51-d318-45c0-a689-7b7dd659ed85" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants_9c70ff51-d318-45c0-a689-7b7dd659ed85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_a356ad3b-9f3f-43ef-9eb1-726adb1645cd" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions_a356ad3b-9f3f-43ef-9eb1-726adb1645cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ab71faf7-43fd-496e-bd3c-856b1b650d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ab71faf7-43fd-496e-bd3c-856b1b650d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbe06cae-9309-4731-b940-781aea7a60b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbe06cae-9309-4731-b940-781aea7a60b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c0f3a7c1-5253-4836-b2c1-0c00392e0e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c0f3a7c1-5253-4836-b2c1-0c00392e0e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_fea64028-8c10-445e-8da6-6d94fa7354a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_fea64028-8c10-445e-8da6-6d94fa7354a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_729193d7-1b14-4fcd-83c1-f63db9605e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_NetIncomeLoss_729193d7-1b14-4fcd-83c1-f63db9605e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd5a153d-2d6d-4201-9cc7-8a2f85f3e219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_SharesOutstanding_cd5a153d-2d6d-4201-9cc7-8a2f85f3e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0fcf96eb-6701-49ef-8678-02482cb493f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2920f3a0-d161-4362-9aa3-ea900ab20f7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0fcf96eb-6701-49ef-8678-02482cb493f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_494e51dc-2352-4611-982c-38b70e411029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_494e51dc-2352-4611-982c-38b70e411029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_777729a1-89bd-4995-b383-3242838edb1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_494e51dc-2352-4611-982c-38b70e411029" xlink:to="loc_us-gaap_ProfitLoss_777729a1-89bd-4995-b383-3242838edb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_494e51dc-2352-4611-982c-38b70e411029" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c7ebfc5c-dc2b-4092-b19f-d115a25861f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c7ebfc5c-dc2b-4092-b19f-d115a25861f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_9bb5aa35-2632-403c-bedf-3ba8cd8a137b" xlink:href="lgnd-20191231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_9bb5aa35-2632-403c-bedf-3ba8cd8a137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_23435d9a-ae44-471c-b19e-17286551a2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_23435d9a-ae44-471c-b19e-17286551a2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_72850174-eaa1-488c-8c28-bb6a3413840c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_72850174-eaa1-488c-8c28-bb6a3413840c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_24fe0eca-10c6-409e-824b-8ca99d70ee70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_24fe0eca-10c6-409e-824b-8ca99d70ee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4684f5cc-32ea-446f-8c78-989cd634f0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4684f5cc-32ea-446f-8c78-989cd634f0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a80144e9-8d73-4bdf-8147-0041d25f7c59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a80144e9-8d73-4bdf-8147-0041d25f7c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_6f346571-f226-49e8-b5cb-cd25b28699ac" xlink:href="lgnd-20191231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_6f346571-f226-49e8-b5cb-cd25b28699ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4484027c-7c68-4ba5-b078-a1e79122d169" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_ShareBasedCompensation_4484027c-7c68-4ba5-b078-a1e79122d169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_9ac5e5d9-440f-4bb8-b386-e41f0321879d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_9ac5e5d9-440f-4bb8-b386-e41f0321879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_3eb703b8-240c-4fd3-9d74-9d703ebbadbf" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement_3eb703b8-240c-4fd3-9d74-9d703ebbadbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d595ec77-a3d4-4da3-9406-76cb2b79f05b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ad0660c-a4ea-4eab-9c49-c22396e2a40b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d595ec77-a3d4-4da3-9406-76cb2b79f05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_494e51dc-2352-4611-982c-38b70e411029" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5a2d28ef-a559-4c58-8f8f-5562008cbb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5a2d28ef-a559-4c58-8f8f-5562008cbb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d5e0dd6e-b1a2-4b4a-aa03-e1e98ca96615" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d5e0dd6e-b1a2-4b4a-aa03-e1e98ca96615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a128840f-8f3d-422e-b99e-64f111e6b0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a128840f-8f3d-422e-b99e-64f111e6b0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_542b0213-31de-4edf-80ae-cf63b5d8b43b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_542b0213-31de-4edf-80ae-cf63b5d8b43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_d3f1c21c-803e-4ec3-bb30-953f8d8413ff" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOtherEconomicRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_lgnd_IncreaseDecreaseInOtherEconomicRights_d3f1c21c-803e-4ec3-bb30-953f8d8413ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_32fc774d-950f-4899-8982-6744e2678d36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_32fc774d-950f-4899-8982-6744e2678d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91fbfe13-955c-411a-845a-cb7d7b768ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ac9d8c93-fcd6-49ad-9156-937333f4657a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91fbfe13-955c-411a-845a-cb7d7b768ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_507ea089-2335-4cef-a0d8-4ab23ae65b34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_507ea089-2335-4cef-a0d8-4ab23ae65b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_9a6bc99d-4fb6-40b2-a689-a75fe71dacaf" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_9a6bc99d-4fb6-40b2-a689-a75fe71dacaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_683e203a-82c9-41d5-9a2a-d9c4179d5caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_683e203a-82c9-41d5-9a2a-d9c4179d5caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c98988cc-6612-4ac1-a35c-f7ee4919ebd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c98988cc-6612-4ac1-a35c-f7ee4919ebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a9e796d1-f9d2-446c-9e49-a04029a5b941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a9e796d1-f9d2-446c-9e49-a04029a5b941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0f0f3c3d-4530-44fe-8ddc-388ba25f5562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0f0f3c3d-4530-44fe-8ddc-388ba25f5562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c1b93cf5-9892-435e-a47a-83b5b71c0ada" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c1b93cf5-9892-435e-a47a-83b5b71c0ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_5748ceb4-da55-483d-8982-048d3bfdf7bb" xlink:href="lgnd-20191231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_5748ceb4-da55-483d-8982-048d3bfdf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_b147a43e-b04e-488e-a304-b7cc394171eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_b147a43e-b04e-488e-a304-b7cc394171eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_df38cd5d-6a96-45a9-a142-2e497afb6c44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_df38cd5d-6a96-45a9-a142-2e497afb6c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_37660195-f3ea-41a3-a8af-e740a964bb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_37660195-f3ea-41a3-a8af-e740a964bb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_770f59f7-4401-44e5-9e52-9bea96c2967c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c880cacf-7037-480c-9524-9f651c85de62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_770f59f7-4401-44e5-9e52-9bea96c2967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7e2881d2-63ba-423d-9714-24e3d715cb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7e2881d2-63ba-423d-9714-24e3d715cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_96c23e8b-20fa-4f40-bdd5-b7438fdb4b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_96c23e8b-20fa-4f40-bdd5-b7438fdb4b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0dd7c061-57f1-4e2c-8eb6-695588c5a529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0dd7c061-57f1-4e2c-8eb6-695588c5a529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_541e36bf-93f9-4a88-8a7f-3c41fe527d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_541e36bf-93f9-4a88-8a7f-3c41fe527d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseOfConvertibleBondHedge_67bd4939-a637-4721-99bf-61f16f1d8659" xlink:href="lgnd-20191231.xsd#lgnd_PurchaseOfConvertibleBondHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_lgnd_PurchaseOfConvertibleBondHedge_67bd4939-a637-4721-99bf-61f16f1d8659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_809b6a28-9c01-4f66-b713-f1453f48ad32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_809b6a28-9c01-4f66-b713-f1453f48ad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForHedgeFinancingActivities_722e30f6-c795-4d85-a619-7779bc07ce1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_PaymentsForHedgeFinancingActivities_722e30f6-c795-4d85-a619-7779bc07ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_46a47232-dc65-4404-b4bb-f57447325c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_46a47232-dc65-4404-b4bb-f57447325c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fe7c7816-5d39-415f-b678-5bf6209ae276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fe7c7816-5d39-415f-b678-5bf6209ae276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_26a424a7-f4ab-4318-9f74-4f6dda5adb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_26a424a7-f4ab-4318-9f74-4f6dda5adb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_b3b5f9fc-baa7-4f1d-a694-09f9df984066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_b3b5f9fc-baa7-4f1d-a694-09f9df984066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_bc36047c-fef2-448d-a431-7295a122f068" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_bc36047c-fef2-448d-a431-7295a122f068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81039b9f-0ace-4fed-8e26-69d17faae058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60d27660-31f7-4985-80e0-8f6edea37049" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81039b9f-0ace-4fed-8e26-69d17faae058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_94ebf63a-ecfc-4d77-b15a-64e40b1b5bff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_94ebf63a-ecfc-4d77-b15a-64e40b1b5bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d52d21a6-d920-4db1-96d9-32ecb4c1c5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d52d21a6-d920-4db1-96d9-32ecb4c1c5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42f038e6-e03f-4d6b-a60f-26969c41d1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42f038e6-e03f-4d6b-a60f-26969c41d1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd7c0c7d-edc3-41ed-929d-ccbc095e23cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd7c0c7d-edc3-41ed-929d-ccbc095e23cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7568a606-e3b1-402f-b605-40e97af288c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7568a606-e3b1-402f-b605-40e97af288c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract_4e8be8ad-ae6d-48cd-9a8d-a210287cf001" xlink:href="lgnd-20191231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7568a606-e3b1-402f-b605-40e97af288c3" xlink:to="loc_lgnd_CashPaidDuringTheYearAbstract_4e8be8ad-ae6d-48cd-9a8d-a210287cf001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ac3244cf-a9e3-46b9-833d-c21c1e0410a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_4e8be8ad-ae6d-48cd-9a8d-a210287cf001" xlink:to="loc_us-gaap_InterestPaidNet_ac3244cf-a9e3-46b9-833d-c21c1e0410a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_4fc0ba1a-5ad6-4025-b580-7f61c9de094b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_4e8be8ad-ae6d-48cd-9a8d-a210287cf001" xlink:to="loc_us-gaap_IncomeTaxesPaid_4fc0ba1a-5ad6-4025-b580-7f61c9de094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7b4fa1b0-8264-4e18-ae29-aed3154c46df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_4e8be8ad-ae6d-48cd-9a8d-a210287cf001" xlink:to="loc_us-gaap_RestrictedCashCurrent_7b4fa1b0-8264-4e18-ae29-aed3154c46df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50d550f2-2fad-46ac-b67a-69230df5c0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a77c7054-9e6b-4ef2-aea2-b28161afaa9f" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50d550f2-2fad-46ac-b67a-69230df5c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases_dab4469b-cb6b-4de8-943d-d9a498611e32" xlink:href="lgnd-20191231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50d550f2-2fad-46ac-b67a-69230df5c0c6" xlink:to="loc_lgnd_AccruedInventoryPurchases_dab4469b-cb6b-4de8-943d-d9a498611e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8e6a63de-a142-496f-ac92-aa143db7c3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50d550f2-2fad-46ac-b67a-69230df5c0c6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8e6a63de-a142-496f-ac92-aa143db7c3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e8930935-eef0-4a04-99d2-bae45a209ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50d550f2-2fad-46ac-b67a-69230df5c0c6" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e8930935-eef0-4a04-99d2-bae45a209ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2135ba0e-a711-4934-bc33-22f7c83dc3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c8bd7ad6-2f14-4046-8641-a4bf0a2b2b82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2135ba0e-a711-4934-bc33-22f7c83dc3f9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c8bd7ad6-2f14-4046-8641-a4bf0a2b2b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6e8919ea-d5a1-41a9-aede-f707bd84abf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6e8919ea-d5a1-41a9-aede-f707bd84abf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d1cc3c1-5505-4758-9b28-f5edc95ef1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d1cc3c1-5505-4758-9b28-f5edc95ef1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_bec16d6d-4ac4-4467-bd7d-22cc56d1ebd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_bec16d6d-4ac4-4467-bd7d-22cc56d1ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_34c66188-d7c0-42cc-8e76-18e9537ef6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_UseOfEstimates_34c66188-d7c0-42cc-8e76-18e9537ef6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_000fb7ab-2cb0-452e-b8df-5f8e2fafd820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_000fb7ab-2cb0-452e-b8df-5f8e2fafd820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_85f6880d-44c1-4ba3-b1cd-85b48519f23b" xlink:href="lgnd-20191231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_85f6880d-44c1-4ba3-b1cd-85b48519f23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock_db021235-cf0a-47f4-b62d-1df725ed4b51" xlink:href="lgnd-20191231.xsd#lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock_db021235-cf0a-47f4-b62d-1df725ed4b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_fe1b29fa-02a9-4a55-88ca-5b3d6c3ad7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_fe1b29fa-02a9-4a55-88ca-5b3d6c3ad7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1b28d098-df94-431d-9b54-d33bfe20d727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1b28d098-df94-431d-9b54-d33bfe20d727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_c5fcd5f2-2ee0-49cd-85f4-89d2ed0dc19a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_c5fcd5f2-2ee0-49cd-85f4-89d2ed0dc19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8cad0ef4-473e-4c63-8e0e-fe9b7d5123f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8cad0ef4-473e-4c63-8e0e-fe9b7d5123f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_442c4974-86f6-42e5-9b11-a279a0bf8e99" xlink:href="lgnd-20191231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_442c4974-86f6-42e5-9b11-a279a0bf8e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cef5ff53-a528-4022-a7d7-f141eb6700de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cef5ff53-a528-4022-a7d7-f141eb6700de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_38886650-eb71-4b76-96e9-5cb796aec4ac" xlink:href="lgnd-20191231.xsd#lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock_38886650-eb71-4b76-96e9-5cb796aec4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_92d568fc-7146-44fd-a3c6-8b6370788eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_92d568fc-7146-44fd-a3c6-8b6370788eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_576ae669-de7b-4308-8c9a-5a55f22b93d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_576ae669-de7b-4308-8c9a-5a55f22b93d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7bcd6558-2484-4946-ba5e-491a3f5c36b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7bcd6558-2484-4946-ba5e-491a3f5c36b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4cc2dfc1-2e3d-4a5e-bdd2-fec81a91a331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4cc2dfc1-2e3d-4a5e-bdd2-fec81a91a331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_81ddd04a-89aa-4418-9143-6fb0212209de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_81ddd04a-89aa-4418-9143-6fb0212209de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cd1e8158-b687-4b65-8158-9bfdc6999c62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cd1e8158-b687-4b65-8158-9bfdc6999c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_decdd047-17fc-48af-ac1e-02d0d03b94ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c017a-7167-48cc-b819-3880a0bf0140" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_decdd047-17fc-48af-ac1e-02d0d03b94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a30f166b-16e2-4f71-8770-c40dca4347c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8d16a2cb-74db-4277-8738-e879894cfe15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a30f166b-16e2-4f71-8770-c40dca4347c5" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8d16a2cb-74db-4277-8738-e879894cfe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_25d57553-a71e-478e-88f3-8bdf00c8688b" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofCommercialLicenseRightsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a30f166b-16e2-4f71-8770-c40dca4347c5" xlink:to="loc_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock_25d57553-a71e-478e-88f3-8bdf00c8688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0f6c8f38-17ed-49b2-a644-ef3efac8c926" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a30f166b-16e2-4f71-8770-c40dca4347c5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0f6c8f38-17ed-49b2-a644-ef3efac8c926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_38ce4717-e20c-45be-940c-34c6ecde99cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a30f166b-16e2-4f71-8770-c40dca4347c5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_38ce4717-e20c-45be-940c-34c6ecde99cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46939996-778f-4a8e-9c61-fb697a79f6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46939996-778f-4a8e-9c61-fb697a79f6bf" xlink:to="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b688113-ebfd-4109-8a58-ea04ac280428" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8769802f-542b-4a22-9890-48d3e6a230fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_848826b0-be2b-46c3-a5c5-07550117ae7d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8769802f-542b-4a22-9890-48d3e6a230fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a00d051-72ac-48d2-891e-06df16703d5f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_8383a079-b8b2-4e04-a0eb-711cf6362f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2a6d6ffb-e778-4c60-a13e-264d324b8ef2" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_8383a079-b8b2-4e04-a0eb-711cf6362f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d370df26-625f-4144-868a-5957aaad6842" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_fe85cb00-d2e6-4a0c-95cd-c93db1caf369" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_fe85cb00-d2e6-4a0c-95cd-c93db1caf369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_4d51a02a-8be6-4a0e-b5ff-65ce919620d3" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26d182c7-ada3-48a0-acee-21012480cd81" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_4d51a02a-8be6-4a0e-b5ff-65ce919620d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6843189-13c6-446f-967c-8279b058a23c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aab687ee-9fb5-438e-a919-b8f1de30b644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f0184f2a-cf2f-4f79-8883-b0793111870e" xlink:to="loc_us-gaap_SeniorNotesMember_aab687ee-9fb5-438e-a919-b8f1de30b644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8b00ac13-dcf5-4f13-aca0-27b8c311c63f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanMolluscumProductsMember_6e8416d4-d574-45f5-894d-c099a8a49d6a" xlink:href="lgnd-20191231.xsd#lgnd_NovanMolluscumProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_NovanMolluscumProductsMember_6e8416d4-d574-45f5-894d-c099a8a49d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_3d4c8e46-d383-4ddc-a1a5-b1def10a6751" xlink:href="lgnd-20191231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_3d4c8e46-d383-4ddc-a1a5-b1def10a6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoMember_225442d8-eb35-457a-b285-fb2a43b91569" xlink:href="lgnd-20191231.xsd#lgnd_AziyoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_AziyoMember_225442d8-eb35-457a-b285-fb2a43b91569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_e334d34f-d5f2-447a-a9d4-ef7acf7ae46c" xlink:href="lgnd-20191231.xsd#lgnd_CorMatrixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_CorMatrixMember_e334d34f-d5f2-447a-a9d4-ef7acf7ae46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_2792fe41-e401-464f-a50c-56cd539e58e8" xlink:href="lgnd-20191231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d09cfb75-c599-4840-aee1-151660911134" xlink:to="loc_lgnd_SelexisMember_2792fe41-e401-464f-a50c-56cd539e58e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4b59669f-b148-4ff1-b8db-4908e34c7110" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_0f6a43b8-29a7-4a44-9987-98dd3980ff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_0f6a43b8-29a7-4a44-9987-98dd3980ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_14643de5-9bb1-47a5-aae6-4901b8e1912f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc28bf9-56b7-4ec7-8819-0ca278db9125" xlink:to="loc_us-gaap_LicensingAgreementsMember_14643de5-9bb1-47a5-aae6-4901b8e1912f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7076622b-01c7-4950-9454-237d14024dae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_de8d9f31-f9f2-42d8-aa7b-6193563b76d1" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:to="loc_lgnd_CrystalMember_de8d9f31-f9f2-42d8-aa7b-6193563b76d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_32947c85-2ce1-49f3-b342-e98b10eb6443" xlink:href="lgnd-20191231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8735ca06-0303-4567-956d-55bf11df856b" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_32947c85-2ce1-49f3-b342-e98b10eb6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1f92cdc7-bd30-4ff8-ac2b-8221ee46da10" xlink:to="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cda9f26f-05f2-4b4e-9578-ec8be4d2872d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:to="loc_srt_MinimumMember_cda9f26f-05f2-4b4e-9578-ec8be4d2872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_303b18b5-6eec-4507-870f-8d9f56c2786a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4c1f50c3-849c-4079-a53a-07e7dd4f4481" xlink:to="loc_srt_MaximumMember_303b18b5-6eec-4507-870f-8d9f56c2786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9d1101ef-584a-4c9e-b33c-af506e72c325" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4e50735d-48ea-4aad-baa6-dcff308ee432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed085c2b-9adf-4363-8a5a-1036728bb921" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4e50735d-48ea-4aad-baa6-dcff308ee432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_fc1143f4-a36e-4fd3-ac4e-b673e72e2ea1" xlink:to="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_c7d4dfef-827b-4ce5-a2c6-f157ba3a0de8" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:to="loc_lgnd_VestingPeriodOneMember_c7d4dfef-827b-4ce5-a2c6-f157ba3a0de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_648eb0bd-c54a-492a-8785-7554ce1280db" xlink:href="lgnd-20191231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f299cc82-2fa9-4364-ab9e-8b067ff9c88e" xlink:to="loc_lgnd_VestingPeriodTwoMember_648eb0bd-c54a-492a-8785-7554ce1280db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_763d9aed-b379-4008-8233-f9fb5aab7a50" xlink:to="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_887e3a55-e43a-45c3-b4c7-2dabd8911911" xlink:href="lgnd-20191231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4dff071b-34d2-425e-92ae-89bdb6f55e37" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_887e3a55-e43a-45c3-b4c7-2dabd8911911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:href="lgnd-20191231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_d3faca22-2639-42eb-8956-fa40a0e9a920" xlink:to="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_e7b07d7b-05bd-406a-b4b6-d6d4d7229f71" xlink:href="lgnd-20191231.xsd#lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum_e7b07d7b-05bd-406a-b4b6-d6d4d7229f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_ed246d08-cc93-46c1-a3f9-21f44646a3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_InventoryWriteDown_ed246d08-cc93-46c1-a3f9-21f44646a3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3f3c373-e033-4960-af98-87cc43ff18ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d3f3c373-e033-4960-af98-87cc43ff18ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c5be1f0f-6864-4b99-b490-ebfb0923d0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c5be1f0f-6864-4b99-b490-ebfb0923d0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_c8f9b14d-ced1-42ff-8569-59804c10fd49" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_c8f9b14d-ced1-42ff-8569-59804c10fd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseUpfrontPayment_e881df62-03b7-45fe-879e-52f59fd85c78" xlink:href="lgnd-20191231.xsd#lgnd_LicenseUpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_LicenseUpfrontPayment_e881df62-03b7-45fe-879e-52f59fd85c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_96906aea-c1ae-495c-8ecf-026612f2f144" xlink:href="lgnd-20191231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_96906aea-c1ae-495c-8ecf-026612f2f144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_4fb4d8ee-481e-4466-8c78-4230250d59df" xlink:href="lgnd-20191231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_ProductRoyaltyPercentage_4fb4d8ee-481e-4466-8c78-4230250d59df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_80e47863-70e0-491b-80b1-ccff84aeb7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_80e47863-70e0-491b-80b1-ccff84aeb7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_97e4a028-86b5-44b8-b902-3bf958748ca3" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_97e4a028-86b5-44b8-b902-3bf958748ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_654a009a-ad0e-46ee-8bab-d5fce89054c8" xlink:href="lgnd-20191231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_654a009a-ad0e-46ee-8bab-d5fce89054c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cb9fcdae-b6f8-48bb-9387-5fac6bc3c613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cb9fcdae-b6f8-48bb-9387-5fac6bc3c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb8d58cd-d72a-4f19-a7c5-bc6fd5dc1f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb8d58cd-d72a-4f19-a7c5-bc6fd5dc1f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_32adda45-17db-425b-86b3-47b598b27c5d" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived_32adda45-17db-425b-86b3-47b598b27c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_551862e9-c7f3-4a36-99cc-5a30d02d86bf" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived_551862e9-c7f3-4a36-99cc-5a30d02d86bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_e26b36b8-c105-470e-9764-489b7811d8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_e26b36b8-c105-470e-9764-489b7811d8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c8e659ee-9230-4f5c-84cb-e30fede3a116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c8e659ee-9230-4f5c-84cb-e30fede3a116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80410e76-bb2e-49d8-bb98-79effce61315" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80410e76-bb2e-49d8-bb98-79effce61315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_217563cd-7dee-4634-b70f-fcf806ff1020" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_217563cd-7dee-4634-b70f-fcf806ff1020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ab5d8550-2728-4140-bfee-e3c3c313f469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9360ab64-c321-4ed0-acdd-efae9cb85603" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ab5d8550-2728-4140-bfee-e3c3c313f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0c4661df-65b6-4d5c-9c47-75c66b501cca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0c4661df-65b6-4d5c-9c47-75c66b501cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17d3b1f3-cf86-4d65-b563-23571692db6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17d3b1f3-cf86-4d65-b563-23571692db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9f5dc422-6581-41c5-9c6e-65580b0015f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DerivativeAssets_9f5dc422-6581-41c5-9c6e-65580b0015f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_982b1c41-f6e3-4a26-9607-ee5cb7c2358e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_DerivativeLiabilities_982b1c41-f6e3-4a26-9607-ee5cb7c2358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba796a7f-e85f-48ea-bd68-175e68c875e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba796a7f-e85f-48ea-bd68-175e68c875e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f97da9c8-283c-4248-bcd2-ff15a31ecc55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_66704ff8-dc0d-4665-80c6-44dd8b94366e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f97da9c8-283c-4248-bcd2-ff15a31ecc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340dd97a-d091-4c50-80c1-fe793974ad4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340dd97a-d091-4c50-80c1-fe793974ad4b" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e7b17b47-3e85-4964-b46d-78a6ac5afbaa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_27c57552-2a93-4297-b1dc-de814f54869f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f31cc9f5-93c5-473a-9a22-f48efbc1a219" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_27c57552-2a93-4297-b1dc-de814f54869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_18c08623-51a2-4951-bf18-913d3ede23f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_533ae195-c52a-4ba9-af62-f7c1ed0cffba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c948568d-69f6-4c83-ae1b-5c82c1e511d1" xlink:to="loc_us-gaap_SalesRevenueNetMember_533ae195-c52a-4ba9-af62-f7c1ed0cffba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ae2efe67-6967-4e66-91c7-af2bce5a7171" xlink:to="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_01422290-7097-41ee-8507-9f0439e273cf" xlink:href="lgnd-20191231.xsd#lgnd_PartnerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerAMember_01422290-7097-41ee-8507-9f0439e273cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_857b7ed4-f683-4800-87f9-14b77f6514f8" xlink:href="lgnd-20191231.xsd#lgnd_PartnerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerBMember_857b7ed4-f683-4800-87f9-14b77f6514f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_02402cf9-7c73-4b79-bbca-9c6f357bc691" xlink:href="lgnd-20191231.xsd#lgnd_PartnerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77b839d3-d82d-4382-8d89-f1bd13fce3b5" xlink:to="loc_lgnd_PartnerCMember_02402cf9-7c73-4b79-bbca-9c6f357bc691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_5a3df430-8ec9-4e51-b614-b5e7e7ba93b3" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c8c29081-e186-4df1-a50a-c1bb0e29f470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_803340b3-ea52-4a40-95d2-e110b6bf63c4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c8c29081-e186-4df1-a50a-c1bb0e29f470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca212d35-af09-4bb2-af8d-294f5641f178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca212d35-af09-4bb2-af8d-294f5641f178" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_291f95e8-a746-4674-97f0-29143fb9f19e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_ac2d0fdf-f7fa-4569-9a45-d469320f145c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_731ccbb3-3034-4812-9033-b4064d763d42" xlink:to="loc_us-gaap_LicensingAgreementsMember_ac2d0fdf-f7fa-4569-9a45-d469320f145c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:to="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_28795094-1e2c-4db9-94db-6e44a36d6d3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AziyoandCorMatrixMember_63e27f1c-b563-4917-96ff-a4b389eea0f6" xlink:href="lgnd-20191231.xsd#lgnd_AziyoandCorMatrixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_AziyoandCorMatrixMember_63e27f1c-b563-4917-96ff-a4b389eea0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_6de038ee-42b8-432e-bed2-b04d7d90e4ba" xlink:href="lgnd-20191231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_6de038ee-42b8-432e-bed2-b04d7d90e4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_5b84349b-1c5b-4c50-ba38-97a6a61192ee" xlink:href="lgnd-20191231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_SelexisMember_5b84349b-1c5b-4c50-ba38-97a6a61192ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DianomiMember_25d5deb5-ec87-4ad4-8809-e2dee73e5ce5" xlink:href="lgnd-20191231.xsd#lgnd_DianomiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2244d4f8-cfa3-4be2-9dd3-a5f617b95f56" xlink:to="loc_lgnd_DianomiMember_25d5deb5-ec87-4ad4-8809-e2dee73e5ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c2f5e0fc-4c14-464c-967d-aa3c1177c8f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ca3b253a-bc3e-4745-b567-6ca7bbf353db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ca3b253a-bc3e-4745-b567-6ca7bbf353db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c7c7ba38-370d-44b1-aff3-17d1847850a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c7c7ba38-370d-44b1-aff3-17d1847850a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277ae085-190e-4bb6-bd4c-97124692a581" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3fdce1c4-815a-4fba-adc9-1bd99958c38e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277ae085-190e-4bb6-bd4c-97124692a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71fa014c-0d6d-4f6c-a132-b61eda02358a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71fa014c-0d6d-4f6c-a132-b61eda02358a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_73fe3c30-3624-4c28-bcc1-6e033dfb62b4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_dfce1d6e-c46e-4252-8cfc-bd3fb14d4518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_48662f15-4dc2-4c54-89f9-26d89c0fe3e3" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_dfce1d6e-c46e-4252-8cfc-bd3fb14d4518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:to="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7c619e88-8741-4ba8-914e-c5f8fc6441af" xlink:to="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0e671386-697c-423d-bece-a7085e54b23f" xlink:to="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyPromactaMember_819018ac-d409-454d-b0cd-f8d34d0ce674" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyPromactaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyPromactaMember_819018ac-d409-454d-b0cd-f8d34d0ce674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_18eac395-bd27-4bff-ad5c-cd2c150ea4a1" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyKyprolisMember_18eac395-bd27-4bff-ad5c-cd2c150ea4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_c7f4788d-dbf3-46e1-af14-fdf95ad4bd17" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyEvomelaMember_c7f4788d-dbf3-46e1-af14-fdf95ad4bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_c31d598a-86a6-4821-9db5-f679511f3ede" xlink:href="lgnd-20191231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_f74105f8-570b-4437-9225-3fb97de4c751" xlink:to="loc_lgnd_RoyaltyOtherMember_c31d598a-86a6-4821-9db5-f679511f3ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ffc54d5e-014b-4d05-89c5-0a9d460543ff" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_640d4a49-f002-4c6e-83b7-9c7957d3e635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4c3ae678-3291-4563-a0d4-bc2f430b9dae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_640d4a49-f002-4c6e-83b7-9c7957d3e635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dcbe08e-1d5a-4362-88d9-232649a84ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dcbe08e-1d5a-4362-88d9-232649a84ba8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:to="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4ec219ec-a07d-4165-aad9-b5a1b996368e" xlink:to="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_c2f60474-3272-4144-9f5f-f75a389aba82" xlink:href="lgnd-20191231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_c2f60474-3272-4144-9f5f-f75a389aba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesandProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2deeffde-7e81-4a45-83bd-ad1f7fdd316d" xlink:to="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_366d82c4-b922-4e4d-b5ad-163938e8ff84" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_LicenseFeesMember_366d82c4-b922-4e4d-b5ad-163938e8ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_d8b98912-a7fb-4e88-845d-0521b3b002ba" xlink:href="lgnd-20191231.xsd#lgnd_MilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_MilestoneMember_d8b98912-a7fb-4e88-845d-0521b3b002ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_74403949-db96-42ea-a70a-9e1903e172ae" xlink:href="lgnd-20191231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_LicenseFeesMilestonesandProductOtherMember_202c4b4a-1ab6-4e4a-99cb-40ae99caf57f" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_74403949-db96-42ea-a70a-9e1903e172ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9d286aa6-e300-4e79-8730-f0369641dda4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcb3abe-4aa5-4402-b93b-0aa0bc62977a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_53b63a30-56a5-495d-9183-a2918fb6ac5f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcb3abe-4aa5-4402-b93b-0aa0bc62977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d277560-0933-433f-a475-c86d889a84a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c78689e1-f4d1-47fe-ab84-003e01decc94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d277560-0933-433f-a475-c86d889a84a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c78689e1-f4d1-47fe-ab84-003e01decc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d277560-0933-433f-a475-c86d889a84a5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_e8a0fbb4-e1a7-439c-b5e9-3afbd44c63b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesRestrictedStock_e8a0fbb4-e1a7-439c-b5e9-3afbd44c63b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2122057c-5333-418a-97a4-85bfa27e04a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2122057c-5333-418a-97a4-85bfa27e04a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_a9f8f69f-27d7-4e69-ba39-762e67b65727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_a9f8f69f-27d7-4e69-ba39-762e67b65727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_25dd3adf-7b77-45da-9136-8ff45ef5604a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_25dd3adf-7b77-45da-9136-8ff45ef5604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9355a13f-3833-4c85-80a7-fac5f05079d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9f829bd9-59cf-4088-9634-b59b869b8852" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9355a13f-3833-4c85-80a7-fac5f05079d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea8a222f-8f73-42ab-a7ec-bd4f1b41c7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d277560-0933-433f-a475-c86d889a84a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea8a222f-8f73-42ab-a7ec-bd4f1b41c7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicense"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b4d05b99-8b86-4edf-81a4-fa9b792fd38c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4f2cbc48-868b-4c84-ac97-a1caf83d09e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b4d05b99-8b86-4edf-81a4-fa9b792fd38c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4f2cbc48-868b-4c84-ac97-a1caf83d09e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SaleofPromactaLicenseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b002a0fd-7063-453b-a315-4e0e7ce3b53d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b002a0fd-7063-453b-a315-4e0e7ce3b53d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ac783a4-6385-42ba-8296-8b44f468e502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8fb6fb26-74cf-4767-a730-59a947ccac09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41030c6d-5bbe-41ff-a455-2307d78f4e99" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8fb6fb26-74cf-4767-a730-59a947ccac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:to="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_21ab2cfb-be44-422c-ab93-fd9724f24d3a" xlink:to="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PromactaMember_a1888e0b-26ca-4e3e-9f14-5bdf9378ea67" xlink:href="lgnd-20191231.xsd#lgnd_PromactaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_468cec90-faa6-445e-b714-f6178733bc01" xlink:to="loc_lgnd_PromactaMember_a1888e0b-26ca-4e3e-9f14-5bdf9378ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e87b1441-edb5-4585-8092-5d1fe3a303ce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_91115f72-db77-4163-8a17-a644eb5ab837" xlink:href="lgnd-20191231.xsd#lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets_91115f72-db77-4163-8a17-a644eb5ab837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4765ad45-4c83-4986-ad05-cf93f1bbb49a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4765ad45-4c83-4986-ad05-cf93f1bbb49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_35fd7f39-f915-45a4-a58e-8a46107e4ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_35fd7f39-f915-45a4-a58e-8a46107e4ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_59e65eab-2ce8-4701-83bd-2c47446aa4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_41e0bfb4-a62d-43d6-9c89-7b47ac714f0a" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_59e65eab-2ce8-4701-83bd-2c47446aa4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinViking" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinViking"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/InvestmentinViking" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b7d3245-42b8-4f50-9d9f-4d403a46cdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ad0ee65f-b164-4d4b-9765-f9204ddb1689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b7d3245-42b8-4f50-9d9f-4d403a46cdd7" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ad0ee65f-b164-4d4b-9765-f9204ddb1689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#InvestmentinVikingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/InvestmentinVikingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22691c97-80ec-4d4f-b403-66d63d6aad1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22691c97-80ec-4d4f-b403-66d63d6aad1a" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5f4f2f6a-ab73-4df8-97df-cc0b38938f3b" xlink:to="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_08998de2-b7d3-4709-a41e-3e290742828e" xlink:href="lgnd-20191231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b4dac73d-0886-4717-b8a3-ba3552cba53d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_08998de2-b7d3-4709-a41e-3e290742828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e560462-427b-4425-b6f0-6fd1f242edb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_056e94a0-c4da-4428-a554-255d86efd330" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc6a387-ee0c-4960-95e3-d6a294ccd7bd" xlink:to="loc_us-gaap_WarrantMember_056e94a0-c4da-4428-a554-255d86efd330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55003a07-64b9-4290-ba36-dd2ddead4b51" xlink:to="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_c354acc8-3a38-4207-b966-199235769b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e137b4ef-6128-4aba-9eb8-081d45b64189" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_c354acc8-3a38-4207-b966-199235769b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3f8930d2-6600-4ec2-90fa-7c07bf8d3018" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_514463fa-97d5-48ac-823a-85ecd0365aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_514463fa-97d5-48ac-823a-85ecd0365aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment_b9d2834b-1a88-41a1-9715-0093d20773aa" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseinEquityMethodInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_IncreaseDecreaseinEquityMethodInvestment_b9d2834b-1a88-41a1-9715-0093d20773aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_a7bb683f-0656-43ad-9571-c0d213d65828" xlink:href="lgnd-20191231.xsd#lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded_a7bb683f-0656-43ad-9571-c0d213d65828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_089f4b56-5aae-48ab-a9d6-d380abb2de1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_089f4b56-5aae-48ab-a9d6-d380abb2de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_28826e68-b475-4e17-a650-76f64a3f4650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_28826e68-b475-4e17-a650-76f64a3f4650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2e954b12-c693-43d5-adae-0d289e11f3da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2e954b12-c693-43d5-adae-0d289e11f3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvestmentInVikingCurrent_1b9b0185-c3be-495a-9384-d2c64c0f64e2" xlink:href="lgnd-20191231.xsd#lgnd_InvestmentInVikingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2c0170da-db36-48c8-968e-e12b88ebde41" xlink:to="loc_lgnd_InvestmentInVikingCurrent_1b9b0185-c3be-495a-9384-d2c64c0f64e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinations" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a63e2df3-bb94-4186-9a8a-eebf23f558d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_dd409e1f-1251-482a-8513-5c4b1b3c65d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a63e2df3-bb94-4186-9a8a-eebf23f558d6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_dd409e1f-1251-482a-8513-5c4b1b3c65d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3d1eccf3-5a56-43a2-88e8-96e915d12a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3d1eccf3-5a56-43a2-88e8-96e915d12a20" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c2e53a-db09-4759-b528-609fbbcb8b9e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_85e27b32-155d-4dd8-a520-2e1c51b68e59" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_AbInitioMember_85e27b32-155d-4dd8-a520-2e1c51b68e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_1907e3d5-c2a4-46b6-9608-ae0dae63c6b7" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_VernalisMember_1907e3d5-c2a4-46b6-9608-ae0dae63c6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_1cccb1cb-877a-41aa-b6d1-b323a467b9c7" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c8be5aa-6101-47a0-9266-3109b08996e6" xlink:to="loc_lgnd_CrystalMember_1cccb1cb-877a-41aa-b6d1-b323a467b9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d85d701-79a7-43f0-9907-d5ac4493e7bf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2c14d6ee-3db0-45d2-8955-b3efd30778d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2c14d6ee-3db0-45d2-8955-b3efd30778d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_ebcfd671-ee7f-43b3-87fa-ec05ee825336" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3cdf73f2-5f3c-4a6f-ae5a-1a4e93880fb0" xlink:to="loc_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock_ebcfd671-ee7f-43b3-87fa-ec05ee825336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b2edfa8a-9844-48db-81e8-33aca8c71c74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b2edfa8a-9844-48db-81e8-33aca8c71c74" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:href="lgnd-20191231.xsd#lgnd_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_VariableRateComponentAxis_536e7db0-1167-43fa-aa31-1488be6e8d08" xlink:to="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_694a4be0-c57e-42a9-a28a-cc04da168e43" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:to="loc_lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember_694a4be0-c57e-42a9-a28a-cc04da168e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_16513877-24fc-4b23-887e-1e2dd4e8cfd1" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_VariableRateComponentDomain_9de19bb3-96a2-4d4d-99cf-50a51f2eab9d" xlink:to="loc_lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember_16513877-24fc-4b23-887e-1e2dd4e8cfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d08fbd83-f175-4ee2-931b-f94b44117318" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a6f0cd86-8ffd-42ca-b29f-93ca1e92cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc1aa100-f4ed-4b20-8271-96874c8cbd4e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a6f0cd86-8ffd-42ca-b29f-93ca1e92cf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5e4ff18-38ff-45be-b642-8939ecda4c16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_25ffcaf3-7b2d-4959-8fc8-7f39e50db34b" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_AbInitioMember_25ffcaf3-7b2d-4959-8fc8-7f39e50db34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_59fccb43-3670-4260-8499-0088c36bbf90" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_VernalisMember_59fccb43-3670-4260-8499-0088c36bbf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_815431a2-6119-4845-9975-ce3a739f3976" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0d5b4e-0689-480d-9087-a7d7e4787090" xlink:to="loc_lgnd_CrystalMember_815431a2-6119-4845-9975-ce3a739f3976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_451e9ebd-fd13-4432-a9a8-bbffa693f722" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5b7e946c-e4f6-4f46-8cf3-5430ea798f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5b7e946c-e4f6-4f46-8cf3-5430ea798f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5ee8af80-5c5b-432c-be31-9d951455b1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5ee8af80-5c5b-432c-be31-9d951455b1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_a63047c7-908c-492c-9e6d-ece8103c2891" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims_a63047c7-908c-492c-9e6d-ece8103c2891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_b6fd5e42-8001-451a-ba81-c71dd841e8b7" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate_b6fd5e42-8001-451a-ba81-c71dd841e8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4d133d2-87df-4769-b203-407d957f39ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4d133d2-87df-4769-b203-407d957f39ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WorkingCapitalAdjustment_97b21665-42e3-4087-b2c3-70e8a627a9b7" xlink:href="lgnd-20191231.xsd#lgnd_WorkingCapitalAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_WorkingCapitalAdjustment_97b21665-42e3-4087-b2c3-70e8a627a9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_b9718006-18fe-4256-a48c-710ea9e6799a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_b9718006-18fe-4256-a48c-710ea9e6799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_4d907e4f-dc6d-48d0-99b0-ba77a4680501" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRoyaltytoAcquireeShareholdersPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_4d907e4f-dc6d-48d0-99b0-ba77a4680501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_ac4288ab-7c2c-48e8-8374-d5eda05256c2" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_ac4288ab-7c2c-48e8-8374-d5eda05256c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberofCollaborationAgreements_ebaa3939-8b35-43ea-b186-51794673efb0" xlink:href="lgnd-20191231.xsd#lgnd_NumberofCollaborationAgreements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_NumberofCollaborationAgreements_ebaa3939-8b35-43ea-b186-51794673efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPayable_44457989-b77a-43a6-9294-ab0ab0841ff9" xlink:href="lgnd-20191231.xsd#lgnd_CashPayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_CashPayable_44457989-b77a-43a6-9294-ab0ab0841ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_4ea5d190-8bef-4454-a66d-68b04f1bf95c" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_4ea5d190-8bef-4454-a66d-68b04f1bf95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_f22b5acd-93ea-41c4-a835-82dde6bd5c37" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate_f22b5acd-93ea-41c4-a835-82dde6bd5c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b160995c-44a8-4ef1-b8de-166e3ac2241e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d9986094-8eb8-4cf9-a6de-7d805f723689" xlink:to="loc_us-gaap_Goodwill_b160995c-44a8-4ef1-b8de-166e3ac2241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cf10d410-84a6-462a-9372-a4bf496f8066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cf10d410-84a6-462a-9372-a4bf496f8066" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de8b0547-44d4-478f-bb27-49abce51a6cb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AbInitioMember_83f106fe-13e8-4c14-ab6a-a9d8c4cde7f3" xlink:href="lgnd-20191231.xsd#lgnd_AbInitioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_AbInitioMember_83f106fe-13e8-4c14-ab6a-a9d8c4cde7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VernalisMember_38d2acde-19ff-483f-89c5-f319f1a40ea4" xlink:href="lgnd-20191231.xsd#lgnd_VernalisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_VernalisMember_38d2acde-19ff-483f-89c5-f319f1a40ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_6102564c-1de1-4226-aa53-33011a4d6a8a" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69fc6e39-1fec-4536-a431-b3466bac5298" xlink:to="loc_lgnd_CrystalMember_6102564c-1de1-4226-aa53-33011a4d6a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ac676e61-acca-4ef4-abb8-dd649db79f30" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8e6fda93-9e5b-4a4c-9303-d09ae4a0a9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8e6fda93-9e5b-4a4c-9303-d09ae4a0a9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f02d64c6-b9bc-48a4-899c-86252d44e6ef" xlink:href="lgnd-20191231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_f02d64c6-b9bc-48a4-899c-86252d44e6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_daa6078d-eb00-4e24-ac6a-5574292923a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_daa6078d-eb00-4e24-ac6a-5574292923a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1b04fcaa-1b8a-46aa-9b35-088873409c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1b04fcaa-1b8a-46aa-9b35-088873409c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f4cd42ac-f23e-42fc-9d07-113e67d270c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f4cd42ac-f23e-42fc-9d07-113e67d270c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_830a62ec-1ef9-401a-a612-1860fd0c90b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_830a62ec-1ef9-401a-a612-1860fd0c90b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_923e0404-3784-4c0f-83a6-1ceacf9c8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_923e0404-3784-4c0f-83a6-1ceacf9c8acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_4e3875dd-a23e-4ee3-9af1-357c7a425d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_4e3875dd-a23e-4ee3-9af1-357c7a425d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7115f985-5198-4fb4-a631-95db7054c0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_RestructuringReserve_7115f985-5198-4fb4-a631-95db7054c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_b62b111f-7cfd-4763-85a8-15ed5839e601" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_b62b111f-7cfd-4763-85a8-15ed5839e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7ba8db27-37a5-4c46-813a-3e45dd751735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7ba8db27-37a5-4c46-813a-3e45dd751735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5aed3886-d8e3-4ec4-8f7a-3c202f4b2a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5aed3886-d8e3-4ec4-8f7a-3c202f4b2a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a828b42a-da36-4afd-8452-61d02a572dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_Goodwill_a828b42a-da36-4afd-8452-61d02a572dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d57a7836-6fc1-4c8a-9ccd-46cfd11074ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_581f883a-2093-4498-94ce-683440fe7643" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d57a7836-6fc1-4c8a-9ccd-46cfd11074ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BusinessCombinationsAggregateAcquisitionConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_56952ff3-cc57-4783-be54-8799799938fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_56952ff3-cc57-4783-be54-8799799938fa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8c1fc55-87a3-46c3-be4d-e54f2d0f780b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_5a954bc9-a055-43d8-b95e-9d40432f1e55" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_383dff33-b865-41b3-b284-95c4b0d90b37" xlink:to="loc_lgnd_CrystalMember_5a954bc9-a055-43d8-b95e-9d40432f1e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486397a2-4446-4921-9d08-37c6193ccdeb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidtoAcquireBusiness_efd7e7de-7cb3-4956-99d3-263c52784d42" xlink:href="lgnd-20191231.xsd#lgnd_CashPaidtoAcquireBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_CashPaidtoAcquireBusiness_efd7e7de-7cb3-4956-99d3-263c52784d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPayable_f1c07f9f-605a-4825-87b8-d9a1a60f7a5c" xlink:href="lgnd-20191231.xsd#lgnd_CashPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_CashPayable_f1c07f9f-605a-4825-87b8-d9a1a60f7a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e43f4445-a49e-467a-812b-31afebccf703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e43f4445-a49e-467a-812b-31afebccf703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_d454b230-ba25-40c8-a3d3-02a5e83bba0e" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration_d454b230-ba25-40c8-a3d3-02a5e83bba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a57aba1-7d7c-4781-93d7-765e03f63bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_46b479f7-113a-497b-acd6-cf59e18db7de" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8a57aba1-7d7c-4781-93d7-765e03f63bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_217b8b02-ec2b-470e-8aff-6411ba78d121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_5ca964bb-e5ae-4ad5-95fb-e174b9390992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_217b8b02-ec2b-470e-8aff-6411ba78d121" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_5ca964bb-e5ae-4ad5-95fb-e174b9390992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e857c85d-9e8d-4536-88d1-6b1484754228" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3bfe3e37-f720-4686-a217-3312d5adfd2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e857c85d-9e8d-4536-88d1-6b1484754228" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3bfe3e37-f720-4686-a217-3312d5adfd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_8e92818a-db67-47fe-84a5-e3ae0339888d" xlink:href="lgnd-20191231.xsd#lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e857c85d-9e8d-4536-88d1-6b1484754228" xlink:to="loc_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_8e92818a-db67-47fe-84a5-e3ae0339888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8de80099-7202-4c46-a3c2-8f2a6dc05709" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8de80099-7202-4c46-a3c2-8f2a6dc05709" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9cd8c4da-a5cc-4981-b496-d6de62c1faf7" xlink:to="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_896b9475-825a-4101-94e3-f1f74b87d230" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb7954a1-bc9b-4337-8cea-2335c3b86664" xlink:to="loc_srt_MaximumMember_896b9475-825a-4101-94e3-f1f74b87d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_e28cadb7-cac2-4c39-bc2e-73a8e2cfa3e2" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_28314f27-c722-42af-bb76-16b7e1011832" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ed49fcbd-1f47-4d4d-8fcd-ab7305b2cb73" xlink:to="loc_us-gaap_TransferredOverTimeMember_28314f27-c722-42af-bb76-16b7e1011832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a1d40c3a-b06b-476a-9174-fdbaee2185fa" xlink:to="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b31ca3b6-dac8-44c2-8690-0b9fa9f0e495" xlink:href="lgnd-20191231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b31ca3b6-dac8-44c2-8690-0b9fa9f0e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_7439fa86-ec5b-4991-83e3-dbb340fd84f0" xlink:href="lgnd-20191231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_606e700e-8104-4b58-9874-d15b3f0731d6" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_7439fa86-ec5b-4991-83e3-dbb340fd84f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e4ecc12-7684-45e7-b2e9-6979120b00e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_90f5c056-befd-476f-9fc6-4313001d54ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_df71f943-665a-4b1d-b320-bd1fe1f6465d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_90f5c056-befd-476f-9fc6-4313001d54ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51445926-99e6-4e02-963b-b87bc52fee55" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9559f2aa-f7e6-4f55-900b-00c09c68a283" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9559f2aa-f7e6-4f55-900b-00c09c68a283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_13642ad0-863c-4dc8-ac80-9d51f6d3d23f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_13642ad0-863c-4dc8-ac80-9d51f6d3d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29237339-57d3-4738-8fbe-cc2201d910b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed2ec2e-e46d-4136-83a7-9225374b89da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29237339-57d3-4738-8fbe-cc2201d910b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82a1f3df-e81d-44ed-bd26-b776e552f4bf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_41fffad0-7cd6-4d7d-bfe5-dce36e4af21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_41fffad0-7cd6-4d7d-bfe5-dce36e4af21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b4cacead-be26-49c6-89da-3326d23a939f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_EquitySecuritiesMember_b4cacead-be26-49c6-89da-3326d23a939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_da006f90-fccc-4baf-9630-0e7b1d94331e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_80e7d86f-3f5b-42cd-ad7d-64773bd26eb2" xlink:to="loc_us-gaap_WarrantMember_da006f90-fccc-4baf-9630-0e7b1d94331e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_71802db5-3fd3-4d58-8d9a-3079c46594f5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_de09b5b2-f948-4934-9e40-3a5411380d3c" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCrystalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCrystalMember_de09b5b2-f948-4934-9e40-3a5411380d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_5bb13a0a-11ba-4b42-995c-6c8440a01ccb" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyCydexMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyCydexMember_5bb13a0a-11ba-4b42-995c-6c8440a01ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_8ae51d38-628b-4bf2-b863-f397aff95023" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember_8ae51d38-628b-4bf2-b863-f397aff95023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_622d510d-d7e4-480e-8737-f36aece6af6f" xlink:href="lgnd-20191231.xsd#lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bcd2e79-d081-4f82-b93a-adc29e5c486a" xlink:to="loc_lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember_622d510d-d7e4-480e-8737-f36aece6af6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99cda35a-bdcb-4944-8657-12f07783719c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5035367-35ea-4fe9-bd63-23ee9223e81b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f5035367-35ea-4fe9-bd63-23ee9223e81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_83584fe3-ba24-4e2d-8c8d-50cf735574ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_83584fe3-ba24-4e2d-8c8d-50cf735574ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_58616552-6009-4572-921c-821fd3158cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_58616552-6009-4572-921c-821fd3158cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_fda0990a-4acf-4a6a-8f51-7c251910b6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83116a3c-f681-4089-ab99-d9ed6be277e2" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_fda0990a-4acf-4a6a-8f51-7c251910b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0e503867-2123-407b-a0bf-b396a8050a52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0e503867-2123-407b-a0bf-b396a8050a52" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc893d15-8e6d-4a2d-816a-5fc87d87c1e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_896e5f6a-2696-4b74-b948-9beecb4afd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79675a14-94f4-49b0-a80c-359169d32b23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_896e5f6a-2696-4b74-b948-9beecb4afd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_979888fa-e642-43bf-8f77-39829b6db680" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29be8bf2-bd4f-4cef-bfd1-7f9c5cfb8caf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4d4d998f-714e-4418-9b0e-f88c915b80dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4d4d998f-714e-4418-9b0e-f88c915b80dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_c069f53c-5f47-4e14-b97a-82a84306328d" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_c069f53c-5f47-4e14-b97a-82a84306328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_1253dd5b-6515-4026-8bb5-558ae24849bf" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_1253dd5b-6515-4026-8bb5-558ae24849bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9820d8cc-7cd6-4130-bbd7-6fd569ab4519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0f4c1911-620f-4dff-bab4-3cb782d43bf0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9820d8cc-7cd6-4130-bbd7-6fd569ab4519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_8c602c9d-5b99-4cdb-a625-1e94069d6035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_012a2c2a-5b0f-45bb-b71e-1e9a9ef9d5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8c602c9d-5b99-4cdb-a625-1e94069d6035" xlink:to="loc_us-gaap_AssetImpairmentCharges_012a2c2a-5b0f-45bb-b71e-1e9a9ef9d5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20191231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f50c3d26-6738-48fb-a068-1a579b637a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_16abc64b-9fcf-475d-a423-57842e24dcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f50c3d26-6738-48fb-a068-1a579b637a76" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_16abc64b-9fcf-475d-a423-57842e24dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_661b2e87-143d-46e0-927e-628908159499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_72c893ac-fe27-4784-8382-faab327ab3ef" xlink:href="lgnd-20191231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_661b2e87-143d-46e0-927e-628908159499" xlink:to="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_72c893ac-fe27-4784-8382-faab327ab3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ca32ceea-94e0-4da2-8959-0eda322c8642" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_661b2e87-143d-46e0-927e-628908159499" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ca32ceea-94e0-4da2-8959-0eda322c8642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_240bd22c-b05f-4966-af4c-9512cefe8306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_240bd22c-b05f-4966-af4c-9512cefe8306" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:to="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_50d0207f-5854-4891-b077-9e931e3a789d" xlink:to="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66ae8029-19c2-4115-b21c-3972a95ba2d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ebcebace-4072-4473-a698-33659bf60d8d" xlink:to="loc_srt_MaximumMember_66ae8029-19c2-4115-b21c-3972a95ba2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_29d4c402-4131-4fd4-aeb8-139524607957" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfAcquisitions_7a1d695c-2607-4d54-a402-cde6d179f07d" xlink:href="lgnd-20191231.xsd#lgnd_NumberOfAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_NumberOfAcquisitions_7a1d695c-2607-4d54-a402-cde6d179f07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_c2394936-70a3-43b3-bb76-63ce547ef682" xlink:href="lgnd-20191231.xsd#lgnd_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_LesseeOperatingLeaseRemainingLeaseTerm_c2394936-70a3-43b3-bb76-63ce547ef682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9358cdc-8e02-4936-990c-de8320946eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9358cdc-8e02-4936-990c-de8320946eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets_6cc5a89a-defb-4cf2-8908-9b11c7ace78b" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_IncreaseDecreaseInOperatingLeaseAssets_6cc5a89a-defb-4cf2-8908-9b11c7ace78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_9dbd273d-1cab-4f81-9481-5830a77ba79a" xlink:href="lgnd-20191231.xsd#lgnd_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities_9dbd273d-1cab-4f81-9481-5830a77ba79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7beaaab-12e1-4853-a3d7-a01b85187ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b7beaaab-12e1-4853-a3d7-a01b85187ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a36e265-3b52-4482-961e-b2da10db6ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a36e265-3b52-4482-961e-b2da10db6ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_881e1ab5-cc28-4dad-8838-a0869d326714" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeasePayments_881e1ab5-cc28-4dad-8838-a0869d326714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bc1418e1-9fcc-4e31-a189-3f4ae297c526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_OperatingLeaseExpense_bc1418e1-9fcc-4e31-a189-3f4ae297c526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_774fee12-e232-4b84-8595-041b12b8b6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42131ae6-0435-4411-8a32-39d07f36b102" xlink:to="loc_us-gaap_SubleaseIncome_774fee12-e232-4b84-8595-041b12b8b6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesOperatingLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7d29c2be-0793-4bce-a29a-23760eb0c3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9e71456-1848-44df-beff-b5e575499d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d29c2be-0793-4bce-a29a-23760eb0c3bc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9e71456-1848-44df-beff-b5e575499d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c2d6790-e433-4518-8775-a8747ffe221a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d29c2be-0793-4bce-a29a-23760eb0c3bc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c2d6790-e433-4518-8775-a8747ffe221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47203f53-0433-4bfa-bd91-ec7a8ee1b986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d29c2be-0793-4bce-a29a-23760eb0c3bc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47203f53-0433-4bfa-bd91-ec7a8ee1b986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2cb421a-260b-48ef-949f-c866be675408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d29c2be-0793-4bce-a29a-23760eb0c3bc" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2cb421a-260b-48ef-949f-c866be675408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_15a12229-683e-426e-920e-ab5ca92e3ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_15a12229-683e-426e-920e-ab5ca92e3ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cdb5a3dd-5344-4653-aa61-80d63b23714d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cdb5a3dd-5344-4653-aa61-80d63b23714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d85eb0f0-f9b6-48bf-8124-c626320e9180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d85eb0f0-f9b6-48bf-8124-c626320e9180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3a703ab-bea5-49fd-b286-53904a2a2696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3a703ab-bea5-49fd-b286-53904a2a2696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61e220e9-cdd1-4f08-8336-77afd4fcb8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61e220e9-cdd1-4f08-8336-77afd4fcb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0fe6fe04-f1d3-4e7f-adae-54420222b686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0fe6fe04-f1d3-4e7f-adae-54420222b686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4955d6ec-c94c-4d53-b17e-adf49f3763c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4955d6ec-c94c-4d53-b17e-adf49f3763c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9cbeb038-94a5-4313-aa9a-2c0d58d5932d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9cbeb038-94a5-4313-aa9a-2c0d58d5932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eef74bf1-3ecb-4ea0-8bb8-1bef4bb64701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4babe4c-f44a-4cee-8b5e-56d92ff4251e" xlink:to="loc_us-gaap_OperatingLeaseLiability_eef74bf1-3ecb-4ea0-8bb8-1bef4bb64701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6eec3f7a-e0be-488e-b393-41287059aaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cc991bae-5b88-4438-af73-a26167853650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6eec3f7a-e0be-488e-b393-41287059aaf3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cc991bae-5b88-4438-af73-a26167853650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7f8df4f8-b357-445d-85ef-2a1244de39cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_fe0768d9-2833-4af5-b98d-508ca225d1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f8df4f8-b357-445d-85ef-2a1244de39cc" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_fe0768d9-2833-4af5-b98d-508ca225d1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_43cd925a-8f10-4e24-9c35-bf32ae8927cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43cd925a-8f10-4e24-9c35-bf32ae8927cf" xlink:to="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_790addbd-adb9-4521-baa8-f3e7537aab8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_9ea5dd49-774c-45e1-9427-71db73600619" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b54dccf-a82b-4436-9b65-f65d2def3735" xlink:to="loc_us-gaap_OtherExpenseMember_9ea5dd49-774c-45e1-9427-71db73600619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8fa8c0a5-dfb9-4160-b70e-306ae9f19c60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4f52c560-cb22-4ecf-ac78-6530a3a278e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89f47523-c94f-4fac-bed0-ce2960cf21fc" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4f52c560-cb22-4ecf-ac78-6530a3a278e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fd9e435-4de0-4928-8cd4-6a4a6b002977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_d202a819-d97d-479f-816c-4911566d299b" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_d202a819-d97d-479f-816c-4911566d299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_11406ee1-c4e0-497c-a163-a15aedfa6d64" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86cd41cb-5717-4706-a21d-b6eaccec2a00" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_11406ee1-c4e0-497c-a163-a15aedfa6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66a64a8b-c47c-4f5c-bb9b-768f88752a13" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cddfe782-ee1a-4763-a56c-3ff906a3287e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cddfe782-ee1a-4763-a56c-3ff906a3287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d38775a6-4428-454e-9d04-5fae1bc0f1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_14158758-1419-44a5-b28c-df87792dcad7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_d38775a6-4428-454e-9d04-5fae1bc0f1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25dac179-9773-4a0e-a4cc-891c85a9dbc9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_215ba44b-0cdf-404c-99e9-fa9c6dfd3b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_215ba44b-0cdf-404c-99e9-fa9c6dfd3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ed222c72-d119-4eaf-95c8-74a6e137568b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ed222c72-d119-4eaf-95c8-74a6e137568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78ef6542-597c-4bb3-9a43-6e297b91f014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78ef6542-597c-4bb3-9a43-6e297b91f014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_49577dde-0a1a-4a8f-9d75-0615f7f80d11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_49577dde-0a1a-4a8f-9d75-0615f7f80d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1adb92bc-5909-44a0-b19f-c0a60aef884e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1adb92bc-5909-44a0-b19f-c0a60aef884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32a27fa0-de25-4f12-8953-8f49a68805b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32a27fa0-de25-4f12-8953-8f49a68805b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e21d4be9-d271-47ac-bc18-8c66a58d963e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e21d4be9-d271-47ac-bc18-8c66a58d963e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9910dc3d-3391-470c-9fdf-5683ab09b713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9910dc3d-3391-470c-9fdf-5683ab09b713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_57fc7e11-ae80-41f7-88c9-413680c59387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_57fc7e11-ae80-41f7-88c9-413680c59387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_a7d618e0-b2ed-4025-b446-68c5152ef041" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger_a7d618e0-b2ed-4025-b446-68c5152ef041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4e2ebabe-e327-411a-94af-39c165375564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4e2ebabe-e327-411a-94af-39c165375564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_00af9df7-ccff-4ec2-b8fc-ed20d3208f9c" xlink:href="lgnd-20191231.xsd#lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal_00af9df7-ccff-4ec2-b8fc-ed20d3208f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_caca6330-8e87-455b-b533-73759a6dd8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_caca6330-8e87-455b-b533-73759a6dd8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_eb2a6dff-8fa1-40bf-b1f7-d015e5cd70ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_eb2a6dff-8fa1-40bf-b1f7-d015e5cd70ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_344ff276-90e1-4046-a4fb-015a6e2e868d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_344ff276-90e1-4046-a4fb-015a6e2e868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b2ad9d84-6c1a-48df-bb20-b1f628b5c019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b2ad9d84-6c1a-48df-bb20-b1f628b5c019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d08a27d6-d1aa-464c-ba65-720ec8920d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d08a27d6-d1aa-464c-ba65-720ec8920d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceofConvertibleBondHedge_6edeccbb-cf55-4fb2-8a31-aa41ddaf4a33" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceofConvertibleBondHedge"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_ExercisePriceofConvertibleBondHedge_6edeccbb-cf55-4fb2-8a31-aa41ddaf4a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_72bdd588-2e71-4ea2-a6ad-708861a15a06" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_72bdd588-2e71-4ea2-a6ad-708861a15a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_c5abc545-7b5e-493e-be16-62766c2dad21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_c5abc545-7b5e-493e-be16-62766c2dad21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4362c2f6-b512-4f6c-acf2-8d45a7364b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4362c2f6-b512-4f6c-acf2-8d45a7364b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_1f27da18-3af8-4d5e-9fc0-a45baa799f42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_1f27da18-3af8-4d5e-9fc0-a45baa799f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_413645ff-29e9-48f6-bc9f-59091bb38191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_413645ff-29e9-48f6-bc9f-59091bb38191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f50b3cf-d670-43fd-a27a-503cfaf03a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f50b3cf-d670-43fd-a27a-503cfaf03a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3e38cb4c-82ad-4e14-8bfc-a4dabff8b77d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_3e38cb4c-82ad-4e14-8bfc-a4dabff8b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_002f0f92-b13d-48c5-b75f-9af67a3b7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_002f0f92-b13d-48c5-b75f-9af67a3b7c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_5dc1f052-4bf0-4f35-92d1-b18be900f978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_5dc1f052-4bf0-4f35-92d1-b18be900f978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_32dd1a61-1802-4ee5-aab5-5f136b069769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_32dd1a61-1802-4ee5-aab5-5f136b069769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_d6814906-35e4-46a4-83ac-0cd2d22c4056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_d6814906-35e4-46a4-83ac-0cd2d22c4056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_WarrantsSettled_6a6439f7-3d08-4619-b778-5d16d546d2a4" xlink:href="lgnd-20191231.xsd#lgnd_WarrantsSettled"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_WarrantsSettled_6a6439f7-3d08-4619-b778-5d16d546d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_15af0ca7-de1d-4a3f-ad4f-e5f54029ca6b" xlink:href="lgnd-20191231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled_15af0ca7-de1d-4a3f-ad4f-e5f54029ca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_62642b08-3916-4fd2-b8d5-b8724ae851e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_62642b08-3916-4fd2-b8d5-b8724ae851e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_09507bd8-065e-4ff2-a4ad-dacb3bd822a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_09507bd8-065e-4ff2-a4ad-dacb3bd822a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4b7957f4-cb6b-4287-baa0-52f50fa9f84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4b7957f4-cb6b-4287-baa0-52f50fa9f84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_0073627e-fd48-4b5a-b1a2-c40b1c3931e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssets_0073627e-fd48-4b5a-b1a2-c40b1c3931e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6f446d88-92c0-498c-9b74-ecf5bca22a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ad990cc-8d9b-4e5e-a349-60e5d9080a9b" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6f446d88-92c0-498c-9b74-ecf5bca22a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_807fccfe-1e10-4674-882e-c2f425d5d4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_807fccfe-1e10-4674-882e-c2f425d5d4f9" xlink:to="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3bc4e19-9aba-4c22-a28b-835b5ce70132" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bbc963de-40af-47ce-96a4-b1dcee887142" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_002708e5-38fa-423a-a687-0fa14fd52c61" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bbc963de-40af-47ce-96a4-b1dcee887142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d474e3f9-f07f-4542-a4b4-c9f0e567f8e9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2019Member_bea20c23-61c5-4d48-b2c9-9e9d76235813" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:to="loc_lgnd_ConvertibleSeniorNotes2019Member_bea20c23-61c5-4d48-b2c9-9e9d76235813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotes2023Member_e03287fb-ef2a-40d8-b807-33123f3cf1e6" xlink:href="lgnd-20191231.xsd#lgnd_ConvertibleSeniorNotes2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5373f7b-52f2-4fcd-aeeb-3559f0b03e7d" xlink:to="loc_lgnd_ConvertibleSeniorNotes2023Member_e03287fb-ef2a-40d8-b807-33123f3cf1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20449d35-1f51-4363-b6b6-c7c7e33af4dd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6a74f0fb-3da4-4396-8691-4db8a1cbd954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6a74f0fb-3da4-4396-8691-4db8a1cbd954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c9300ba2-2815-4f65-aa62-a8067ea9fcae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c9300ba2-2815-4f65-aa62-a8067ea9fcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7b6ea465-5bf5-4676-b3e8-510feea1ff3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_NotesPayableCurrent_7b6ea465-5bf5-4676-b3e8-510feea1ff3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_3c968718-13f8-41d2-be89-979909f09c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_d809f6e6-daad-4f27-8b79-37e845b0fbcd" xlink:to="loc_us-gaap_LongTermNotesPayable_3c968718-13f8-41d2-be89-979909f09c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_44d2d6a9-c518-45aa-a4d0-3878382c53aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_44d2d6a9-c518-45aa-a4d0-3878382c53aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5ff7776b-9708-4ba5-9d87-4f0aac57454c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b21b404f-ed30-46fc-ac91-edda0579f23e" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5ff7776b-9708-4ba5-9d87-4f0aac57454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_f2d0b3c6-d6f4-414e-9a08-3b0d1b31c365" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6a1c316f-968e-420d-a6a5-91b8e4148c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_f2d0b3c6-d6f4-414e-9a08-3b0d1b31c365" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6a1c316f-968e-420d-a6a5-91b8e4148c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2009f671-a693-46d7-8fc2-7a2ae232678d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2009f671-a693-46d7-8fc2-7a2ae232678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_94300123-286d-413a-9d15-0cdd42a0408b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_94300123-286d-413a-9d15-0cdd42a0408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ee6dac10-2c78-47c8-9470-869f96398395" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ee6dac10-2c78-47c8-9470-869f96398395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8f3f580e-ab84-448d-9145-7393d9424d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8f3f580e-ab84-448d-9145-7393d9424d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_e55c9a36-6c38-4756-ac79-84aa09164797" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c412fa4e-2a94-4f9c-a75a-2e1bce5f4fbb" xlink:to="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_e55c9a36-6c38-4756-ac79-84aa09164797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_ecfbdfd3-f9a4-475f-8516-be63dc03e825" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_ecfbdfd3-f9a4-475f-8516-be63dc03e825" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:to="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_919b5d35-ab7d-46ff-89ea-c2181022357b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fc21330-1dd3-46a8-978a-6a99c8acae47" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_51112028-f6b3-4772-979a-d2b201096e43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_DemandDepositsMember_51112028-f6b3-4772-979a-d2b201096e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e90fa806-b12e-4216-a368-c2574963a553" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e90fa806-b12e-4216-a368-c2574963a553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9499365b-a089-4abc-b6c4-f8262b11ce65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_EquitySecuritiesMember_9499365b-a089-4abc-b6c4-f8262b11ce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1eb21c8e-aa2e-4f0f-91f6-f21000c68cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_CommercialPaperMember_1eb21c8e-aa2e-4f0f-91f6-f21000c68cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_47163107-5c38-4377-a392-1dac25850460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_WarrantMember_47163107-5c38-4377-a392-1dac25850460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_3fb9b643-b774-4d95-b8f4-6247f53a48ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_MutualFundMember_3fb9b643-b774-4d95-b8f4-6247f53a48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_33191471-7d95-4959-8d3a-67d42d7f0540" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_33191471-7d95-4959-8d3a-67d42d7f0540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2cf76a7e-72a4-463b-ada4-8ef330542dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_02459580-cea2-494d-89e8-23af0f6859df" xlink:to="loc_us-gaap_MunicipalBondsMember_2cf76a7e-72a4-463b-ada4-8ef330542dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72efe37a-0117-49a2-9a5e-6e84f5d81f9e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f030d3-a62e-4abf-b979-a3ea03b58077" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f030d3-a62e-4abf-b979-a3ea03b58077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bc64340-8e5b-425f-95d8-2444ba2fc055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bc64340-8e5b-425f-95d8-2444ba2fc055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e347436-1114-4cfc-b5e7-8d1a4c099165" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e347436-1114-4cfc-b5e7-8d1a4c099165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_290061b8-6a1e-453a-968d-8b32d98ddd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b90754fd-dcae-4c7f-bfe7-97060b547eed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_290061b8-6a1e-453a-968d-8b32d98ddd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_cdf54df7-c6a6-4f40-ac30-dcf4801ebd96" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cdf54df7-c6a6-4f40-ac30-dcf4801ebd96" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:to="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_508d1c20-7ab2-4580-a476-f5c7175e50fa" xlink:to="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_91a30864-eb48-49d4-bc7e-1ffa8ceae86b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:to="loc_srt_MinimumMember_91a30864-eb48-49d4-bc7e-1ffa8ceae86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6534935f-ce64-4084-b522-b3f7fb665363" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c9b9f700-ba7e-43ce-91bd-10cc4cb05809" xlink:to="loc_srt_MaximumMember_6534935f-ce64-4084-b522-b3f7fb665363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ab0eb57-e023-43ea-810a-4ddbcdad4f78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8f4e0c32-a97e-4139-a5de-c3d98d0ca1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_us-gaap_OfficeEquipmentMember_8f4e0c32-a97e-4139-a5de-c3d98d0ca1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_630ae821-b6ad-4578-a891-f01f07261e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_630ae821-b6ad-4578-a891-f01f07261e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_ad89b7c8-1014-4f40-9d9e-8aeff9be0f5f" xlink:href="lgnd-20191231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a762c58-74a7-4247-9aea-00f559edf2f4" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_ad89b7c8-1014-4f40-9d9e-8aeff9be0f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4c7fedbd-976b-40ed-b513-939b0fe9a119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1653c41b-00cb-44c7-9157-941c4f5058d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1653c41b-00cb-44c7-9157-941c4f5058d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1b72aa0-6490-4a9c-85a7-02a5cf59149e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1b72aa0-6490-4a9c-85a7-02a5cf59149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd97315f-f332-4871-9f41-7eb9c0ef3b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd97315f-f332-4871-9f41-7eb9c0ef3b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_75b3c8c4-765c-4ecd-8499-24b8d2398697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_75b3c8c4-765c-4ecd-8499-24b8d2398697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e8722d6b-8c49-43e7-a259-5204069820d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6dc8e493-63d0-4c04-9d77-11d06ca7e9ea" xlink:to="loc_us-gaap_Depreciation_e8722d6b-8c49-43e7-a259-5204069820d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_b29432da-a9a1-4ba7-943f-0231c888d257" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_b29432da-a9a1-4ba7-943f-0231c888d257" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd3e05f5-2df7-4535-a98d-3f167c7dda72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_48977bd9-ba75-4416-a5fd-2d48d9014a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_PatentedTechnologyMember_48977bd9-ba75-4416-a5fd-2d48d9014a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3a10d51a-5e33-44ba-9a5a-480a50030a56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_TradeNamesMember_3a10d51a-5e33-44ba-9a5a-480a50030a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_25689187-b32b-42f8-b589-1fadb663e2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8609b62-ef6d-46b8-9e3e-5172715b90ee" xlink:to="loc_us-gaap_CustomerRelationshipsMember_25689187-b32b-42f8-b589-1fadb663e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0e4b211e-fe99-40e7-a50f-5d61f49ab1a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f34524f4-f6e5-470a-8610-1f141d08f285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_Goodwill_f34524f4-f6e5-470a-8610-1f141d08f285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4bb958f-badc-4ce2-8d41-ddefcf0b1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4bb958f-badc-4ce2-8d41-ddefcf0b1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305940a-bca7-47c1-9fcd-8614a8daa89b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305940a-bca7-47c1-9fcd-8614a8daa89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7a57eff1-157b-4e47-86dd-cce0c6049abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7a57eff1-157b-4e47-86dd-cce0c6049abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_073888ce-fa08-4138-b0a2-a69acc12b977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_073888ce-fa08-4138-b0a2-a69acc12b977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_75d6b16c-ea53-4c70-baed-6fb230f60d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_75d6b16c-ea53-4c70-baed-6fb230f60d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b043607-047c-47d9-9000-4df4c7f65712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b043607-047c-47d9-9000-4df4c7f65712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_42b6a353-44f2-4a00-988d-3e18b399536e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_42b6a353-44f2-4a00-988d-3e18b399536e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1b641bd4-0b56-482a-aebb-fdb5d772f9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1b641bd4-0b56-482a-aebb-fdb5d772f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d0673658-0931-4aa4-a089-6e3035234f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d0673658-0931-4aa4-a089-6e3035234f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7826715-41b1-4271-bd6b-c74a1a51ee3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7826715-41b1-4271-bd6b-c74a1a51ee3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e342f031-4cd4-4840-ac44-1fb201c36a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_01797a04-50af-416e-ab32-0aa1ced3f5e6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e342f031-4cd4-4840-ac44-1fb201c36a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0b0cf1f-5e9c-4d23-873b-b0abb640b2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0b0cf1f-5e9c-4d23-873b-b0abb640b2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6edfcce5-54c0-48e0-a4f1-fb02f29cc3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6edfcce5-54c0-48e0-a4f1-fb02f29cc3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_7f885aff-65c3-45b9-b60a-fa8791696e19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalesCommissionCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent_7f885aff-65c3-45b9-b60a-fa8791696e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3dd7645d-9efb-47e0-8501-4bc0f70daa20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3dd7645d-9efb-47e0-8501-4bc0f70daa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedStockRepurchases_36e0c157-99c0-49b8-9a09-c1736af6918a" xlink:href="lgnd-20191231.xsd#lgnd_AccruedStockRepurchases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_lgnd_AccruedStockRepurchases_36e0c157-99c0-49b8-9a09-c1736af6918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSalesReturns_e7d3a16f-a8b7-42d6-a0b7-8f0a8ec3e44b" xlink:href="lgnd-20191231.xsd#lgnd_AccruedSalesReturns"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_lgnd_AccruedSalesReturns_e7d3a16f-a8b7-42d6-a0b7-8f0a8ec3e44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_4b3f9ea7-847b-4af3-a0d0-1b8227647153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_RestructuringReserveCurrent_4b3f9ea7-847b-4af3-a0d0-1b8227647153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_0bdfe961-a240-45c5-8eb7-1aee2df8b935" xlink:href="lgnd-20191231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_lgnd_LeaseLiabilityCurrent_0bdfe961-a240-45c5-8eb7-1aee2df8b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c4b29851-ea77-402d-94d0-b4545fd25584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c4b29851-ea77-402d-94d0-b4545fd25584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eed90c14-aed8-4060-a9c7-e13d8ae2840d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fec8122e-adc0-4b42-858c-906fa18d8c01" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eed90c14-aed8-4060-a9c7-e13d8ae2840d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_a977393c-3699-4c45-924d-8ab26e262f88" xlink:href="lgnd-20191231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a977393c-3699-4c45-924d-8ab26e262f88" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5d21b62-d808-48bc-98e8-67f6673cdf76" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_09ff0526-6b95-46c5-8dac-8b364d8553af" xlink:href="lgnd-20191231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_09ff0526-6b95-46c5-8dac-8b364d8553af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_fe933c3e-a7fa-4dc7-9f74-33f8eb2abd8c" xlink:href="lgnd-20191231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_fe933c3e-a7fa-4dc7-9f74-33f8eb2abd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CrystalMember_cf0b9383-8b1f-453d-b939-11999e5f55b2" xlink:href="lgnd-20191231.xsd#lgnd_CrystalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c3ff9a46-3209-41b7-9b22-083a99963f93" xlink:to="loc_lgnd_CrystalMember_cf0b9383-8b1f-453d-b939-11999e5f55b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b424e16-05a5-4fc3-b199-b3267e612431" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_15ab1de4-883f-4fcf-81c6-5763ae8af49c" xlink:href="lgnd-20191231.xsd#lgnd_RevenueRoyaltytoAcquireeShareholdersPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent_15ab1de4-883f-4fcf-81c6-5763ae8af49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_edb5fb56-4f72-4438-99cc-95769e907702" xlink:href="lgnd-20191231.xsd#lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments_edb5fb56-4f72-4438-99cc-95769e907702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:href="lgnd-20191231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1a1415ce-2f86-4f8e-97b6-14c75a20883d" xlink:to="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_79bea372-4a95-42e9-bcd5-34f9c1f5aa69" xlink:href="lgnd-20191231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_79bea372-4a95-42e9-bcd5-34f9c1f5aa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_2caf06f9-e541-4f71-ba7c-95b883ee0676" xlink:href="lgnd-20191231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_2caf06f9-e541-4f71-ba7c-95b883ee0676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_333ff0e2-0e8b-4489-8916-0d34f0df6200" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_333ff0e2-0e8b-4489-8916-0d34f0df6200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3b37cf41-91a5-47d5-aa8b-8920c08d2763" xlink:href="lgnd-20191231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_3b37cf41-91a5-47d5-aa8b-8920c08d2763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_5c9aeb89-5fcc-4c13-914f-a703a98ff3ba" xlink:href="lgnd-20191231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_c0dfc94b-084b-47bb-ab3b-e2c536be6d25" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_5c9aeb89-5fcc-4c13-914f-a703a98ff3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8d5378a9-7163-4805-9d87-b3fea1b87c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e5d9df6e-16cd-4fff-b947-d9b36e02364c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8d5378a9-7163-4805-9d87-b3fea1b87c8c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e5d9df6e-16cd-4fff-b947-d9b36e02364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock_923d293c-4f5e-401b-8efe-91f746c15660" xlink:href="lgnd-20191231.xsd#lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:to="loc_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock_923d293c-4f5e-401b-8efe-91f746c15660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9f8235c2-2ce5-41a0-a211-8789b1b2f226" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9f8235c2-2ce5-41a0-a211-8789b1b2f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_27626be3-a20b-4ee6-be07-c2bbdc53534f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_27626be3-a20b-4ee6-be07-c2bbdc53534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8262bcc1-7dd2-453b-bcd4-497e377765b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8262bcc1-7dd2-453b-bcd4-497e377765b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_66b6ee27-1ab3-4d74-9a55-5e98aa0558be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0623-20ec-4be6-8061-5e7483f5b198" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_66b6ee27-1ab3-4d74-9a55-5e98aa0558be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec48b877-0751-4645-b607-40556cd90768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec48b877-0751-4645-b607-40556cd90768" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0767c9a2-d89b-45c1-b240-82a912595b19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f88e75e6-5922-4a8b-aa44-73db2de56ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f88e75e6-5922-4a8b-aa44-73db2de56ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90409547-e0eb-4a28-a2e0-296240394794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74692497-d68b-48dc-bc29-02551b92c061" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_90409547-e0eb-4a28-a2e0-296240394794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c8b9571-da5b-455f-97b1-12fb9b19859b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e562835c-ad20-4919-a3bb-0ddd66106a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47d38aa2-2f37-4cd3-8829-cac2ee6992f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e562835c-ad20-4919-a3bb-0ddd66106a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2e18163-db5b-4fd0-9729-2bbcae5f7763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2e18163-db5b-4fd0-9729-2bbcae5f7763" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:to="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d1993157-2c51-47c3-bfcd-3c812a55a9b6" xlink:to="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_72b24b91-eac0-4585-afdf-7c619e800b1e" xlink:href="lgnd-20191231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_72b24b91-eac0-4585-afdf-7c619e800b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_1f4f7a1a-7aea-415f-aca7-a20858c28144" xlink:href="lgnd-20191231.xsd#lgnd_AmendedESPPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6706b7ec-9075-4323-b424-0c9a8ed274c7" xlink:to="loc_lgnd_AmendedESPPMember_1f4f7a1a-7aea-415f-aca7-a20858c28144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:to="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_827f5ea0-eb5d-43f2-a018-1e60bbf422a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cdf5a0d2-5869-4dd5-a36b-bc256da8a756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cdf5a0d2-5869-4dd5-a36b-bc256da8a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_333fec04-b1b0-48aa-beb5-f270bdcdbfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5517eda-c374-4248-82d4-b116ecf91cc1" xlink:to="loc_us-gaap_RestrictedStockMember_333fec04-b1b0-48aa-beb5-f270bdcdbfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_252c8d85-f9f2-4d1b-925f-e2a81338725a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0c0e418e-3a40-4d7b-a870-a1da745d5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0c0e418e-3a40-4d7b-a870-a1da745d5ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81d57cf4-51f4-47e2-b0dd-2cc793002e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81d57cf4-51f4-47e2-b0dd-2cc793002e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_406f647c-25a3-4781-a096-406df91865ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_406f647c-25a3-4781-a096-406df91865ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0fdf4ae0-970c-4364-883f-4fa14d2b4f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0fdf4ae0-970c-4364-883f-4fa14d2b4f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b39f9bd0-2088-4205-81cc-d174bb4be22c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b39f9bd0-2088-4205-81cc-d174bb4be22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9ff707d3-6ad8-43dc-9285-e0dae80964a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9ff707d3-6ad8-43dc-9285-e0dae80964a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a80798-bd27-4854-a72c-76a421e76a59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a80798-bd27-4854-a72c-76a421e76a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a7969cd4-99e5-49f8-b9db-69f14163bf16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a7969cd4-99e5-49f8-b9db-69f14163bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:href="lgnd-20191231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_e7f384d8-e12a-4414-8794-1e9cac69d9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_e7f384d8-e12a-4414-8794-1e9cac69d9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_255ca3d6-566d-4192-ba9a-f5cfc708c157" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_255ca3d6-566d-4192-ba9a-f5cfc708c157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_4ccaa283-7066-4ec7-9768-be3cfe8af575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_e974305d-8b05-4145-8614-45349df84889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_4ccaa283-7066-4ec7-9768-be3cfe8af575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:href="lgnd-20191231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_364e9b5a-d9da-4385-a3c9-d76d9b02ad3f" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb76cbc9-4bc4-47ce-9822-0b3e4a2a7b10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb76cbc9-4bc4-47ce-9822-0b3e4a2a7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f46a9801-43c4-47e8-a506-9c4d9fdc9310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f46a9801-43c4-47e8-a506-9c4d9fdc9310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3135c637-b871-4a5e-bec0-3dba9ff4d9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3135c637-b871-4a5e-bec0-3dba9ff4d9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_4a7b92d7-d3a6-48f3-8c4f-e57c90cbe129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_4a7b92d7-d3a6-48f3-8c4f-e57c90cbe129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_17a6d4a6-3131-47c7-944f-f36d6deea683" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_17a6d4a6-3131-47c7-944f-f36d6deea683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c7fe8aea-7a50-42f5-a358-9a3811ba43a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_5c703bcf-cdba-48ed-b9ee-08334ac39936" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c7fe8aea-7a50-42f5-a358-9a3811ba43a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d312fde5-cdde-430b-9fb8-3cab6287c232" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d312fde5-cdde-430b-9fb8-3cab6287c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6f838266-4912-4647-8ba9-8384fdb9c9a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6f838266-4912-4647-8ba9-8384fdb9c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_470f8040-bf42-494a-a098-233a4000b3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_470f8040-bf42-494a-a098-233a4000b3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4d326e4-5e60-4c66-b494-1b9aa79c57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4d326e4-5e60-4c66-b494-1b9aa79c57b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_632377a5-61ac-4604-86ce-4c0eb5954379" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_775322d2-6880-42cd-934d-8179fbb5b865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_632377a5-61ac-4604-86ce-4c0eb5954379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d2493b01-2cf8-4911-b07c-fd3f16db1dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d2493b01-2cf8-4911-b07c-fd3f16db1dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e3f3c623-97ce-4286-83e8-5318fbf362fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e3f3c623-97ce-4286-83e8-5318fbf362fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e7ddbaf-8f97-48c4-b95c-55eea4a5672c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e7ddbaf-8f97-48c4-b95c-55eea4a5672c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85d2c1e9-92c8-452c-bdb3-f44c22e72c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85d2c1e9-92c8-452c-bdb3-f44c22e72c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64af9e0a-9442-40ee-9600-473251849180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64af9e0a-9442-40ee-9600-473251849180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7e46212e-ab83-4f32-bd18-f6d9d13dbe95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7e46212e-ab83-4f32-bd18-f6d9d13dbe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88988152-a6fe-4da0-809a-4c63ee21133b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2f0ae5b0-212e-421d-9787-782c66385f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88988152-a6fe-4da0-809a-4c63ee21133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2f808472-c17b-4119-a310-cbc5075df431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2f808472-c17b-4119-a310-cbc5075df431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cd2d9783-c4a1-4f97-9fc1-9eff8a2355ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cd2d9783-c4a1-4f97-9fc1-9eff8a2355ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac4fc5d2-7104-41e7-b2b4-14aa15067fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac4fc5d2-7104-41e7-b2b4-14aa15067fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c1b80e98-3aae-47f0-8eba-2baf06f34ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c1b80e98-3aae-47f0-8eba-2baf06f34ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0d05a04-3b51-43f1-9f6f-e605b0e4685a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a0d05a04-3b51-43f1-9f6f-e605b0e4685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f5341e3d-4896-446a-93c0-7063aac5ca70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f5341e3d-4896-446a-93c0-7063aac5ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1d955790-61e6-4411-98cd-1674845f9e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1d955790-61e6-4411-98cd-1674845f9e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e044a6db-b352-4068-8735-22b98117e125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a9f968e-9549-45eb-b20f-ac34dc5a5591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e044a6db-b352-4068-8735-22b98117e125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0782a5a5-edbd-410c-9d0d-b9dfc81e09cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0782a5a5-edbd-410c-9d0d-b9dfc81e09cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a5589199-3306-4212-926c-7c9fb2a3929f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeElevenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_15f8a8d3-e22e-44a2-a059-b04d38449d8c" xlink:to="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_66a10a52-d310-4e7a-af7b-f374823b6d6c" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_66a10a52-d310-4e7a-af7b-f374823b6d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_26be897e-2468-4f72-b3d3-9877bfb369a9" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_26be897e-2468-4f72-b3d3-9877bfb369a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_c63dbb03-841e-4ac5-9b14-c1ce97e35da4" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_c63dbb03-841e-4ac5-9b14-c1ce97e35da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_01eb2eed-ed52-4dd1-9668-d2c752d2b9d7" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_01eb2eed-ed52-4dd1-9668-d2c752d2b9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_7f63eff4-41ef-4ba2-a234-386f2ffcf4bb" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_7f63eff4-41ef-4ba2-a234-386f2ffcf4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_2a659c65-e9f9-454a-876a-076dbf8fb839" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_2a659c65-e9f9-454a-876a-076dbf8fb839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_a44524bc-48f5-4d06-89aa-11b7a1a64f44" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_a44524bc-48f5-4d06-89aa-11b7a1a64f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_f0025f5b-d453-481e-bfcd-52bf252fa9ea" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_f0025f5b-d453-481e-bfcd-52bf252fa9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_475ae5aa-0f8e-48d9-899d-0514be4e5f8e" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_475ae5aa-0f8e-48d9-899d-0514be4e5f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_5c370133-e43a-4b00-b70e-b750b46dce17" xlink:href="lgnd-20191231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ExercisePriceRangeElevenMember_13d6d100-ac42-41f7-a9d3-db54a0f757d1" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_5c370133-e43a-4b00-b70e-b750b46dce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91931647-3685-4f94-b364-3bdc2fd8df8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1cfbcec6-b054-4b06-8cc7-585d6daf4a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1cfbcec6-b054-4b06-8cc7-585d6daf4a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b8ad664e-8f68-4774-afba-bd9272a53b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b8ad664e-8f68-4774-afba-bd9272a53b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_71cc548d-939c-48ef-a2ad-608353c5eb83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_71cc548d-939c-48ef-a2ad-608353c5eb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_502fa27b-52b6-4eec-8bcd-9f1dd718faaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_502fa27b-52b6-4eec-8bcd-9f1dd718faaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7827ba44-9851-427d-aa2d-84b0ad309773" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7827ba44-9851-427d-aa2d-84b0ad309773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_5eba11fd-9cd5-4bb4-bf2c-6128354b1e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_5eba11fd-9cd5-4bb4-bf2c-6128354b1e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_af73c39f-d829-46a1-a0a8-ae6321d314a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_789daafa-115f-42e3-bca6-ddb2c6299cb7" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_af73c39f-d829-46a1-a0a8-ae6321d314a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63d6fbe7-d302-46d2-af99-dbf5962cc003" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63d6fbe7-d302-46d2-af99-dbf5962cc003" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:to="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a70e3aa4-700b-4bb1-a470-8b86825514bd" xlink:to="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b029a1be-e19c-4042-a4cb-c03e715c610d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:to="loc_srt_MinimumMember_b029a1be-e19c-4042-a4cb-c03e715c610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1961b14-50ba-430e-9fe9-93ebfb9a912b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_032297eb-39c4-4c8b-bcfb-e3a0cfba14fd" xlink:to="loc_srt_MaximumMember_f1961b14-50ba-430e-9fe9-93ebfb9a912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9506de72-1077-4891-a308-7dbc9a5e4837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35d642a2-c168-44db-8005-a11097dbf7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35d642a2-c168-44db-8005-a11097dbf7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6724070-14a4-43ed-b189-daa53723fa96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6724070-14a4-43ed-b189-daa53723fa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3c5a6028-a44e-449e-a328-f4991ce4c1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff0ca046-6062-4778-bb67-1daaf66e057a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3c5a6028-a44e-449e-a328-f4991ce4c1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6cad835a-3a8d-4992-abb6-a6c183823246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6cad835a-3a8d-4992-abb6-a6c183823246" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:to="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f50843f9-400a-4673-900f-bb76ac53fe54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d020300c-b38f-4eab-8d84-77444396e206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46ecf6ec-8b76-48d6-9c03-25e4ae1ba336" xlink:to="loc_us-gaap_RestrictedStockMember_d020300c-b38f-4eab-8d84-77444396e206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e212d301-2e28-4cc4-ad41-1792f5b2775a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9a5a3e7-68a5-448f-a194-4ec9b3bfbfc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9a5a3e7-68a5-448f-a194-4ec9b3bfbfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eae8a875-c45f-46f1-a75c-63504a3296ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eae8a875-c45f-46f1-a75c-63504a3296ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f795c81f-c0fc-4d2c-a203-b5f7c0f53c95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f795c81f-c0fc-4d2c-a203-b5f7c0f53c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_83215486-05ba-41ba-aece-54d216702f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_83215486-05ba-41ba-aece-54d216702f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e8fe7f5-d3b2-493c-841b-c8c474617b49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7dcd4bcd-db13-4fbd-9e9f-9f9d7b3e6dea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e8fe7f5-d3b2-493c-841b-c8c474617b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c86588-c65b-4798-961a-58f18c22f3b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cddeb39-546b-4293-8c83-061d42a8ef16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cddeb39-546b-4293-8c83-061d42a8ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d68812ab-d592-4287-b2df-187361b84fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d68812ab-d592-4287-b2df-187361b84fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ddeb9b0-7f95-47c8-ba72-16860c4749c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ddeb9b0-7f95-47c8-ba72-16860c4749c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72d53577-11bd-48cd-82a9-2a55404c44f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_72d53577-11bd-48cd-82a9-2a55404c44f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6af338f-c9b5-4efc-a3d8-da31ef18c9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_51f231b3-4462-4826-9c74-80c4a2f0cade" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6af338f-c9b5-4efc-a3d8-da31ef18c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20191231.xsd#CommitmentsandContingenciesLegalProceedings"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_649d73e3-6d64-4c7a-9340-608dc4f96d74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_ce8422e8-2bc7-455f-b301-118a53ae326b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_649d73e3-6d64-4c7a-9340-608dc4f96d74" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_ce8422e8-2bc7-455f-b301-118a53ae326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4baad5ae-ac70-4db2-ab40-e7aa4bac3fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3ebc61b0-8a88-494e-87e1-3938de94ebff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4baad5ae-ac70-4db2-ab40-e7aa4bac3fd8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3ebc61b0-8a88-494e-87e1-3938de94ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83f980b4-3100-4a5c-af8f-fbb4b6e38db4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d0950c7d-55ab-4733-9a19-ad83cc11e62c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83f980b4-3100-4a5c-af8f-fbb4b6e38db4" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d0950c7d-55ab-4733-9a19-ad83cc11e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_91135231-eabd-4aff-b7a3-25f105bd2e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83f980b4-3100-4a5c-af8f-fbb4b6e38db4" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_91135231-eabd-4aff-b7a3-25f105bd2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_93b9b885-0651-4e36-a074-c9c75528387d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83f980b4-3100-4a5c-af8f-fbb4b6e38db4" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_93b9b885-0651-4e36-a074-c9c75528387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_7b4b9f35-daa8-4299-8487-8d639e9e49c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83f980b4-3100-4a5c-af8f-fbb4b6e38db4" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_7b4b9f35-daa8-4299-8487-8d639e9e49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_54f35540-4f18-47aa-a418-a929b3472fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_54f35540-4f18-47aa-a418-a929b3472fe8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_316417e0-7393-4ed3-97b2-1d69ee1e095d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_5b25e9f1-2b1d-41ab-92a4-b99b574214ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_5b25e9f1-2b1d-41ab-92a4-b99b574214ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c97a10be-2a32-4b8d-97e9-e4f9fb3b640e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c97a10be-2a32-4b8d-97e9-e4f9fb3b640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cd34ca42-d6e9-4fc3-bcb2-db211c421d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ba29590-b566-46cb-9b43-8d3270b1e3bf" xlink:to="loc_us-gaap_ForeignCountryMember_cd34ca42-d6e9-4fc3-bcb2-db211c421d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_843a90a5-bd0f-46b5-b19f-205890d7bcf6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_efac6c00-d600-4b3f-9e3b-d30bad3aad04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_us-gaap_ResearchMember_efac6c00-d600-4b3f-9e3b-d30bad3aad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_c8af965a-19ff-4e78-9035-11322f17b112" xlink:href="lgnd-20191231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_c8af965a-19ff-4e78-9035-11322f17b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_d1217e01-7f96-4ce9-bb6e-5e48d71c7204" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ea268759-7f15-4a0e-aef4-b47c9c4a3186" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_d1217e01-7f96-4ce9-bb6e-5e48d71c7204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0a870e0e-d339-4f05-92fa-e2677cfb3f5f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a3f93ca5-a5d7-4331-9e5e-a8cae94a3b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a3f93ca5-a5d7-4331-9e5e-a8cae94a3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_64c9a2d1-216a-4f66-886b-0b2ec97787ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_OperatingLossCarryforwards_64c9a2d1-216a-4f66-886b-0b2ec97787ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_55df0b87-e0ea-4c90-9064-f0338ddb0561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_55df0b87-e0ea-4c90-9064-f0338ddb0561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c27dbb9f-9e65-4640-996b-468524980d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_53c601b8-d539-4231-9fa2-65b7840a2baf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c27dbb9f-9e65-4640-996b-468524980d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96248b58-b0f1-4c45-8174-0ff1ec67220b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96248b58-b0f1-4c45-8174-0ff1ec67220b" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_018b6a94-ee59-4713-8ca1-e0cc5538f618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_018b6a94-ee59-4713-8ca1-e0cc5538f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_90b9e98f-3634-4ca5-8b9b-a77db0b26d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_90b9e98f-3634-4ca5-8b9b-a77db0b26d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_95514bdb-77c7-4052-8814-9bbcceb770ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_95514bdb-77c7-4052-8814-9bbcceb770ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dd94dca7-62dd-4fa3-baf5-299d23949933" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a5a2da9d-71f5-41a8-bf49-b91cc7b335f1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dd94dca7-62dd-4fa3-baf5-299d23949933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82477848-2614-4a27-bca1-fb1d03c5a88d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96248b58-b0f1-4c45-8174-0ff1ec67220b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82477848-2614-4a27-bca1-fb1d03c5a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_12b939b6-f6f5-4f44-ab19-2698a5c9f5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82477848-2614-4a27-bca1-fb1d03c5a88d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_12b939b6-f6f5-4f44-ab19-2698a5c9f5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e8b6cada-6218-4c39-96f4-73470f309ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82477848-2614-4a27-bca1-fb1d03c5a88d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e8b6cada-6218-4c39-96f4-73470f309ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d6bf9851-ac75-4a17-b735-7ad165c60519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96248b58-b0f1-4c45-8174-0ff1ec67220b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d6bf9851-ac75-4a17-b735-7ad165c60519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13b31a7c-0538-4a11-aa8a-5a5be5b451ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13b31a7c-0538-4a11-aa8a-5a5be5b451ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ae5cfa29-d8cc-413a-a689-74311e8f61ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ae5cfa29-d8cc-413a-a689-74311e8f61ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c58094cc-1c2e-4322-9430-ab1339625c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c58094cc-1c2e-4322-9430-ab1339625c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_8528efcf-3697-49fa-890d-b64625551370" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_8528efcf-3697-49fa-890d-b64625551370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_86baa9e6-8d61-4f89-a814-89a9f22c13d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_86baa9e6-8d61-4f89-a814-89a9f22c13d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_abae287e-1a59-454f-ae6d-b405057db216" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount_abae287e-1a59-454f-ae6d-b405057db216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_76b8404e-ad2e-45ac-807a-901bf6e11fab" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch_76b8404e-ad2e-45ac-807a-901bf6e11fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_8787e34d-6afa-4791-a6b8-b9cf8efab52f" xlink:href="lgnd-20191231.xsd#lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions_8787e34d-6afa-4791-a6b8-b9cf8efab52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a5d23c6f-f693-4ec2-a2bb-4bc282903471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a5d23c6f-f693-4ec2-a2bb-4bc282903471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4e309ed2-a232-4c9b-b949-126471dfb558" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4e309ed2-a232-4c9b-b949-126471dfb558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_45dc3628-aeec-44e6-83cd-273a9f8c6d54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_45dc3628-aeec-44e6-83cd-273a9f8c6d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_c6366ed0-b9cc-48ce-a845-9178a20d43b1" xlink:href="lgnd-20191231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives_c6366ed0-b9cc-48ce-a845-9178a20d43b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_aaeccee4-3690-4a9c-a78b-f297d7e91944" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_aaeccee4-3690-4a9c-a78b-f297d7e91944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ead423a-e1b7-4b4b-91ab-2e983687ca3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_8873604a-aed6-4092-a7f1-08595e7d4754" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ead423a-e1b7-4b4b-91ab-2e983687ca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_966d0495-d6ce-415d-88a9-0858c24b3406" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_966d0495-d6ce-415d-88a9-0858c24b3406" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de1249dd-afa5-4f07-9fa5-51d8286cfe77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_de1249dd-afa5-4f07-9fa5-51d8286cfe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_63a3fb04-e60c-4087-b397-c139e4eab641" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_63a3fb04-e60c-4087-b397-c139e4eab641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_46079776-e1ae-4385-96a5-5f4cd3b2e27f" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_46079776-e1ae-4385-96a5-5f4cd3b2e27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ef39eaa3-4b43-48e4-a726-323e87a0287f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ef39eaa3-4b43-48e4-a726-323e87a0287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_355843be-d366-4e88-a38b-0c423be9f2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_355843be-d366-4e88-a38b-0c423be9f2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_457ca895-6e54-4902-b009-e0fe94d89c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_457ca895-6e54-4902-b009-e0fe94d89c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a765ea4c-7c72-4962-8267-14560a9a4c37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a765ea4c-7c72-4962-8267-14560a9a4c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3c1506f6-bd3b-442c-a52d-127e02d8c0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3c1506f6-bd3b-442c-a52d-127e02d8c0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9f0b4801-4c61-4fed-9239-c946144b55cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_48e52a61-3604-421f-97c9-c6e057e6936c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9f0b4801-4c61-4fed-9239-c946144b55cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_966d0495-d6ce-415d-88a9-0858c24b3406" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_18f7bdcb-e8ba-4dd1-8f11-dd1ee8f1fdbf" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFairValueAdjustment_18f7bdcb-e8ba-4dd1-8f11-dd1ee8f1fdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_4de8e3da-b2d8-4c60-a425-cf7f1644e9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_4de8e3da-b2d8-4c60-a425-cf7f1644e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_beeb23ac-cf0f-4a25-82da-22424e342fbe" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_beeb23ac-cf0f-4a25-82da-22424e342fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_151b43dc-7896-40d2-94a3-aa744c3dc4e3" xlink:href="lgnd-20191231.xsd#lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_151b43dc-7896-40d2-94a3-aa744c3dc4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_6131f37c-9d20-4557-a716-b81c3f6c1b08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_6131f37c-9d20-4557-a716-b81c3f6c1b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_1d1a0434-cb05-4194-8400-d77e34114e10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_1d1a0434-cb05-4194-8400-d77e34114e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2789fbf7-563c-49d1-b58c-3060d9134c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2789fbf7-563c-49d1-b58c-3060d9134c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7ca2bed6-3ed4-49f9-9437-a3aa8d3b5535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7ca2bed6-3ed4-49f9-9437-a3aa8d3b5535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0b2cd85b-e21e-49c1-8d26-ae14f202f329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0b2cd85b-e21e-49c1-8d26-ae14f202f329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c15527ef-d2e3-4781-af4b-444474cb94a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f96e7c59-f022-4535-85de-9bc79886620e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c15527ef-d2e3-4781-af4b-444474cb94a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9d9ac7c9-fa38-4775-9b18-1eee64ed1521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9d9ac7c9-fa38-4775-9b18-1eee64ed1521" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_241c2804-e47b-49ab-98a2-72c5df46d627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_241c2804-e47b-49ab-98a2-72c5df46d627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3274265a-9860-4dfa-be3f-4fabdd76aac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3274265a-9860-4dfa-be3f-4fabdd76aac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0a82e3ea-1a98-4143-825f-cef9bd0aaaee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0a82e3ea-1a98-4143-825f-cef9bd0aaaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ec70c476-522d-4ef1-8f11-e8c990aad05d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ec70c476-522d-4ef1-8f11-e8c990aad05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fcc0ef60-75a9-4338-814c-bfe5516fa4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aaa3d048-224f-433b-b1a2-34ab6df0516e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fcc0ef60-75a9-4338-814c-bfe5516fa4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d444ddff-5e25-4b58-b2fb-f5b9072c01fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2defa5d7-184d-4491-b669-c9cb48b6790b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d444ddff-5e25-4b58-b2fb-f5b9072c01fb" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2defa5d7-184d-4491-b669-c9cb48b6790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_88edd8a5-04b9-4ded-8417-ce41b890fbef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_78545594-d4e2-4d53-8e91-e009326ecfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_88edd8a5-04b9-4ded-8417-ce41b890fbef" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_78545594-d4e2-4d53-8e91-e009326ecfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32653169-568a-4f62-b105-d3bedd857690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32653169-568a-4f62-b105-d3bedd857690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_70daa692-f52a-46d5-9bde-d42a4cb62d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_70daa692-f52a-46d5-9bde-d42a4cb62d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c990cbe7-1ccc-4d1d-ae3a-868329db8310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c990cbe7-1ccc-4d1d-ae3a-868329db8310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54916c0e-49ca-4d6c-a297-e56e68486370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_NetIncomeLoss_54916c0e-49ca-4d6c-a297-e56e68486370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_88f1437c-215e-45ec-80a0-c123825b7651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_88f1437c-215e-45ec-80a0-c123825b7651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bc2fcdf5-cf41-4c6a-817b-6c344bab2736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_88f1437c-215e-45ec-80a0-c123825b7651" xlink:to="loc_us-gaap_EarningsPerShareBasic_bc2fcdf5-cf41-4c6a-817b-6c344bab2736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_82fb5615-0a5e-482b-bd0f-a01e0113ebe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_82fb5615-0a5e-482b-bd0f-a01e0113ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_697e6e22-f84b-4f26-96ac-adb23d25ccdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_82fb5615-0a5e-482b-bd0f-a01e0113ebe2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_697e6e22-f84b-4f26-96ac-adb23d25ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2022c0df-8f13-43d3-ab1c-87895f2f3c08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2022c0df-8f13-43d3-ab1c-87895f2f3c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b42824c0-81d9-4bfb-accf-4a0740e72370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f78e657d-b18e-4be1-85dc-80c69ef8e4ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b42824c0-81d9-4bfb-accf-4a0740e72370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEvent" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f820ce77-cea8-4b34-a092-0ac405a893db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f14ff438-05b1-40f1-89c5-b24354e11bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f820ce77-cea8-4b34-a092-0ac405a893db" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f14ff438-05b1-40f1-89c5-b24354e11bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20191231.xsd#SubsequentEventNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SubsequentEventNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0de75b34-72a1-4667-be5a-865e1df294ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0de75b34-72a1-4667-be5a-865e1df294ee" xlink:to="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e0cd956-7ee9-421f-bf19-d27feb6c4288" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_b2c8fe8d-d06b-47c8-98a2-f2b55e599432" xlink:href="lgnd-20191231.xsd#lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11547068-4bab-4aa6-a87b-1aea5e192fc4" xlink:to="loc_lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember_b2c8fe8d-d06b-47c8-98a2-f2b55e599432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3eb0a0e2-5ac8-4ed3-80d3-da6328fa7ee8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1f64d16-d713-47b4-afbd-207c8ca678c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e423bf49-9c45-458a-b817-5f7edca641cb" xlink:to="loc_us-gaap_SubsequentEventMember_e1f64d16-d713-47b4-afbd-207c8ca678c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_73ec81dd-63e5-40b2-969e-60485c3fd0dd" xlink:to="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_65087cc2-729a-4e98-8642-c38f7f8f4983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_65087cc2-729a-4e98-8642-c38f7f8f4983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a7aceea7-c3c6-4e37-939c-8dde8f14b45a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_987afe95-f1aa-4adb-ab44-8bcb27e6caa8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a7aceea7-c3c6-4e37-939c-8dde8f14b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exh43lgnddescriptionofse001.jpg
<TEXT>
begin 644 exh43lgnddescriptionofse001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "DI:* $  S@ 9ZTM%% !1110 E&T%@V!D=Z6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\,5N+.*2+6],NGG^S2(09DX."AZGCCCU'>@#N[WQ-J]]\&AXF$CV&I"#>&B
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MF*J9&4?)RV!QGFNK\07.B:QJ3:+KUBMQI<MHD\5XR'RHW+.I!D'W#@#!R.]
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M'7L?;D ]%HJGJREM)NMLDD;+$S*\;E64@9!!%>-6'BK7T^%LWB=O$5T-2@U
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M;VZ6\72OM0N!*=_FB+=GZ9[=/:M^XGATC2I)Y&EDCMHRQW,7=\=LGJ2>!]:
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M"Y)R#N/3'XUTGB;2=9UFW6UTS6VTB, EYHH]TCMV&<C:O<XY/'3N ;M%</\
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MQ;_:IS#,(IR^Y?EQU)YY/-.^*FJ:EH%QH TO4KNU6ZG,4P68G>H*8ZYYY/-
M'IE%<S86S7&N)=:9K=Y/;6-R]O>02SB2-SY6X$'KD,RCKZ^E=-0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2:KI,
M>L?&F5[[3[F72YK,P-/]G?8&,9'#XP"#T/8UZW10!Y?X 75/ VOWOA+4K*XE
MTYY#+9ZA';L4.>S,!@9'KT(/K6/IVC6NH?$#Q8=:TRY^P7Z2);W#V,CC<6&&
M0[>#W!KVBB@#B]=A?XA>'M;TBV@GM8E$:VT]U \7F2@[R0& .WA1G'K[56\'
MZFNG>#(M!UV.ZTS4+&-H65E==X!.UHW7AN,=#U!KO:* /,O!<GB*7P#K5UXF
M_M)[N5)8[=+E7W,GE\;4QW8GG%0?#JXU'P[\,[C=I=VU[#?!C:-;L))$9XP=
MH(YR"U>J44 >2^)?"&DWFKZ9JG@V">RU@WB-)'%$\:QIU9W4@>7CTXSG&#FN
MG^+,<UU\/KZRMH)KBXG:(1Q0QL[-B12> /0&NSHH Y[P0_E>!M)CF22*2WLX
MTE22,JR,JC(((S7F_A72+2;Q)XL;7-,NHXKNZ,UE<26$C$$2.P93MXZJ>V:]
MIHH XGQ%K$FO>!O$7D6%XB%7MK5'MG66<[ =P0C."6P./X37 IX,O7^'NC:[
MI5E+#KVC,S3VLEN0TJ^:Q&4(^8@8/N./05[I10!YAX\U2X\5?"P&'2[Z._FD
MB\RS-M)O1@<MQCD>A^E6M$NM.\-^';6_L=*NSJTNF06TEM%I\J^9,J\%SM &
M"3ECV]>*]%HH \K\=Q7$GQ4\-7L5G=S6UEL-Q-%;.ZQ_.3R0#5G6-#O?&_Q)
MTJ_BM)[?1]'"NUQ<1-$9G#;MJ*P!(R%&<8Z^V?2Z* *>KR+%I%VS!C^Y< *I
M8DX/  Y->>?!S0;6+PW(-5T58]1ANW=&N[/;(J[5P59ESC.>E>GT4 ><?%W2
M-0NUT+5K*TENX]+NS)/'"NYPI*G( ZCY/UKI9-4MO$4VGQZ8LTL:7"SS2M \
M:QJH) )8#YB<#;UY)[5T5% 'E'C#3_[2^,NCSSZ?/<Z9%:"&YE^SNT:G,O!(
M&/XEY[4_PE::C\._&=YH,ME<W6AZ@WFV][' S^4>P=E'X'/< \ FO5** /-]
M9T_P]XRTF=O$6G7%CJL#21Q7"VSK)(%8A&3 _> C'R\]>W!JC?\ A;Q%=_ R
M#2KB&2;4X-LHMR<R; Y(3ZA3T]L5ZM10!PVGZO#K'@&#1+6"Z.H36"V<D+VS
MIY+%-C%B1@ <G.><<9)Q6OKD[:AK=EHL4D\ 4_:I)Q;EHRR$>6F2-N<G=U_@
M'K7144 >27=EJ'@[XNPZM;17=_9ZG'MU!X+5B(RW!)"C'4*WKUKOK>YM[KQ5
MJ%NT4CQRV,$>7@;RWPTQ9<D8/##(]ZW:* /-= \$W7A'XEAK$R-H-Y')+&F2
M5AEQC:?P)P>XX[4?&^UNM1\,65G8VEQ=7 O5E*00LY"A'&3@<<D5Z510!6TZ
M59M.MW3=@QK]Y2I''<'D5-+*D,322'"J,D@$_P J?10!Y?\ !6UNM/M=8@OK
M.YM9);D21K/ \>Y<'D9%2OHMUX2^+4WB0V\LVD:K"T<TT49<VSG:?F Y +(.
M>GS>U>ET4 >8^-M+F^(?B71=.TZ*1M,L6:6]O60K'@E?D4G[S84],_>'O7H&
MM75Q8Z%J%W:1&6X@M9)(HP,EW520,=\D"KU% 'DOC;PQHOB"Q75-!L+JQ\2O
M(C);QPO%(7+#/F+C"XY._@<=32_$NSN[KQ-X1WV=Q?+8R*;YXK5Y$ W1EB<
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MCAMQM4.22H R$.!ZM76T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC0M5\3>!H/L=BYN[>X6X>U0AWV[6! QU(W#IZ'&: .AUNW9?"\8BN[N&16A
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MGTN=R")'8,N$)!Y4^]>GZ'JTVLB[G>QNK.".?RH%NH&BDD4*"7VL 0"20/\
M=H M:I?#3=-FNO+,KHN(XP<&1R<*H]RQ _&N3^%OBNY\2Z#<0ZFY.IV$[1W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC7"L&#MV/3&.!C@8XQ8AT)?[6;5[NX-Q?B$PPOLVI AY.Q<GDG&222<8X'%
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M/56XSZ?EF^=?,M_?:9I8FCMM*"VX6TA$DLLVT'8NX%4500"6[GJ .0#K:0D
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ML'ID=JLUR^OZCJ.BZ]H\5I<Q_9-1=K3[/(B[8GVY1UP Q VD$9YR!QQ4AO\
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MBV;I$544.H)4#/..3N/>MRUU+4_$<&HW6E7"6L$#R6]D2!^_D3(+N2K83=P
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M/Y8]O&=N]_XB3\@Z5U:07BZG+.]X&M&C58[;R@"C@G+;\Y.01QVQ0!:HHHH
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MG:VW<6Q]YCM'H.O'-/\ $&A)KUG!";J6UEMKF.Y@FB )21#P<$$$<G@UJT4
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M9Q<(T2*J;$W!UP,@;L#!)X/KS60OBG5X/!VJ:@;P7-W=:C)::2WE*N?G$2D
M#D!MS<YXP"3776NB00:E+JDTDES?2QB+SI,?NX\YV(  %&>?4]R<"L:#X?V$
M&E6&GC4;]ET^X6:&0N@<!=Q"<+@#+9) W$@'/ P %W?ZLWC6VT6QOV*QZ>9K
MHO$A0,6"HQXSGASC/)QVS6Y;-/I6AB35KX74MM"7N+GRPF[ ))VC@<4EEHUM
M8ZG?ZC&\KSWYC\PNP(4(NU57CIU/.>2:MW5M%>6DUK<)OAGC:.1?52,$?D:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$B%'')[C&.M '9V&JZ=JBR-I]_;7BQMM<P2K(%/H<'BDAU?3;F[-I!J%K+<
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M,25)Z9P/:NO\(V6FZ?X>AMM(EFEL%=S#)*0=P+$DK@#Y<YQ[<CC% &W1110
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M+FTGCGA?.V2-@RM@X."/<57O=:TO3I1%>ZA;V[G'$D@7&3@9STR>F: +H
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M!JO'K>ES7HLX]0MGN&+!8Q(,L5^\!ZD=P.E7J *]Q8V=W&L=S:03(GW5DC#
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M?^*M(L= N]:^TK-;VNY7$?+;Q_ 1U#>QZ=ZGAUVP?3(+Z2X14F V@9)+8R5
MZDCGH.U>>+*D_AOXA6D,TMS,TDDPW1X9E,*8;  '.#CCG'%7;W7;"VU;P_J]
MU>S)HLNG-:K>P,P2*8E&^8CL0N/JOL: /0+&_M-3M$N[&YCN('^[)&V0<<'\
M:AOM9T[3&VWEW'"P3>P/)5/[QQT7W/%9_A.WTF*QNI]%$IM;JZ>?SI&8B=V
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MO&M[G2TG,<@0$L8XPQ.&!&-Q(_#-.\)H\/C+Q?%-_K&NH)03W1HOE_D1^%8
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M6@U&;S8 Q=4NH'B5 HP.2,$8ZT >D*P90RD$$9!'>J#Z]I,=VMH]_"LK2>2
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M-Q=S+#$"!N8]23@ >I). !R:K0:YIES!=3)=HJV9(N1(#&T/&?F5@"O'/(H
MOXYS00""",@]0:J6>JV=_/-;V\C^= JM)')$T;*&SM.& .#M/Y4Z]U*TT\Q+
M<R[7F)$4:*7>0@9.U5!)P.3@4 6%144*BA5'0 8 IU93>)M#2PM[]M3MQ;74
MGEPN6_UCYQM ZYSP1V[U&OB[P^S7*KJL!:V ,B@G.#T(&/FS_LYH OP6,<-[
M/>$EYIPJEB ,*N<*,?4\]3GZ 62 2"0#CI[51M];TR[TI=5@O8I+)_NS \$Y
MQCUSGC'7/%0?\)1H@M;JYDU&*&.S(%P)@8VB)&0&5@",]N.>U &HR(RE652I
MZ@C@TH    P!T%9EIXFT6^U(:=:ZC#+=-'YBQ G++WQV..XZBL?QUXCBT_PS
MJOV+4WMKVVB.)(H]P1\9",Q4JI.1P2#R,4 =7M!.<#)&**S!K%K9:;:27L[>
M9) '(5&D<@ ;FVJ"<#/)Q@9J;^VM-.G0Z@MY%);7! ADC._S2>@4#ECUX'/%
M %ZFNBR+M=0P]",UROA76)]3\5>)8#?RW5I:O;B!9$"&+<A++C ((;CD9XYK
M4UG5GM]0T[2+5@MWJ+MA\9\J)!EWQZ] ,\98=0"* -BBL'_A)K(>)CX;5IA.
MEL)&E,;'!+!5 .,'N2>GZUC^%?%UK!I\D6NZRK73ZE/;QM-@$@2%4SM&%Z8'
M04 =H(T4Y5%!SG@=Z"BEPY4%AP#CD53U#6+#2Q_I<Y0A"Y"HSE4'5B%!(7W/
M%6;>X@N[:.YMI4FAE4,DB-E6!Z$&@!Y16(+*"5Y!(Z4H 4    < #M7)2^(-
M;32+^<Z)J9N+:^\HQQPJ6>+=]Z$?QC;CD]R3VP($\4QZ1XPUM=;U5H;&.WMI
M((IPH\HN'+* HR>GN>.M '3S:8IU6/4X&\JX">3+QD2QYS@^X.2#VR?6KN*R
MYO$VBP6]G</J$9AOV"VLB L)F/15(!R3Z=:FO;Z'S7TU+IX+V2!I(RB9(4?Q
M#(*\''7U'K0!?INQ2X<J-P& V.<5S/A+7@W@;1]0U>\+W%W&!N89>5R3P% R
M3QT [5I/XHT2+36U&2_1;5)3"\A5AY<@.-K#&5.>,'% &M15 :UIYU5=+\\B
M]:/S1"8V#;/[W3IVSZ\=::-=TUHFD6X+ 3&#:L;EFD&25"XR2 #G XP?2@"_
ML7?OVC=C&['.*"BLRL5!9>A(Y%8.J7-]JUC97?AS4S'MNPLB_9MXF"L5=&W8
M* 8.3UXP.<416FO-JNK9U4M;,$>RWVX40/SE/^FB8VY)]>"",@ Z"DQSFLWP
M]K*:]HT-^L?E.2R319SY<BDJZ_@0?PQ5ZYN(K2VDN)VVQ1*6=L$X ZGB@"6B
MLD^*-%%M9W/VT&&^;9:N(W(F;L%XY)[#O5'QAK!M_#^M1Z??26VHV-DUSE$R
M5&#MY92,'!''/!QT- '1%%9E9E!*]"1TI< D' R.AK$T7Q)IE]]ETX:C'+J)
MMED>//+<#=ST)!Z@=*ETB^LKF?4Y;;6?MZ1W&) 64I;$*,H"!T[]3UH UL#&
M,#%(R*Q!902IR"1TK-AUS3=2F-A::@4N9(C)&0FUF3IO3>,./<9%<_X(\7VE
MSX;T:+5]6235+T,/GZNV]L#@8!(' X]J .TINQ-_F;%WXQNQSCZT22)%&TDC
MJB("S,QP !U)-9]IXATF]G\F"\7S##YZAU9-\7]]2P&Y?<9% &E16/:>+?#]
M_=PVEIJUO--/O\M4;.[9G=@^V#^1J:U\0:5>7J64%XIGD0R1*RLOFJ.K(2 '
M'NN: -*BLOQ+K*Z!X>O=3*[G@@=XUVDAG"D@''0<=:YRUN5D.D:A/XPN[87A
MA1K21%'VF?*G"Y7(4YP0HQR.1B@#M514SM4+DY.!C)H"('+A%WD8+8Y-<W%>
MWJ_$V;3FO))+,Z0MPL#!0J.92I(P 3P.^>IK4;Q#I*7L=FUXJRRR&*,E6"/(
M.J!\;2W'W0<T :/TK \.:%=Z5=ZK->M;2B_OGNT\L',18*NWD<\*.>/I4/C+
MQ!!I_A[5A;:D]M>VUL[J\4>_RWVDHK$J54L<  X)R,=JU]#FDN- TZ>9R\DE
MK$[L>K$H"30!==%D4JZAE/4$9!I0 !@<"LU?$6D-=I:B]3S))3"AVML>0=4#
MXVEA@\9SP:?/KFFVUQY$MQAQ*D)(C8JLC8VH6 P&.Y>"<\B@"^0#U /UHP.>
M.O6AF"J68@ #))Z"LV#Q%I5S<FVBN]TWE&9$,; R(/XDR/G'NN: -*D*(S*S
M(I9>A(Y%94/BG1+BV6Y@OEEB:?[,K(C',O79TZ^U8LOB#^R/'NI0ZGJK+IR:
M?%-''(!A'9V!"A1D\+GN>M '8T5AZIK&ESZ5972Z\ME#=S1&WGA929_F'R $
M'.>AXXK(G\2IHGCK4XM7U<QZ<EC#+%'*!A'9G!"A1D\+GN>M '82"0QL(BH?
M'READ ^X[U3M-)BLM/DM8)&5YG:268@%W=CEF.1C)^F!P,8&*HZGK6DW&BVM
MVGB!+.WNI8_(N874F4[A\@R#G.,$8R.:<WBFR7Q6/#^)/.%OYK/Y;8R6"J <
M<]\GH,?7 !JVMK#96D5K;KLBA0(BYS@ 8%2[5YX')R>*H)KFFR7D5HEQF6:1
MHXSY;;7=02RJV-I(VMD \8-0^)_$%OX8T&YU2X1W$2_(BJ3N8] <=!GOVH U
MJ:RJZE74,IZ@C(-4I-:L([>*=YF"SL5B3RG,DA&<A4QN/0G@=.:EL-1L]4MO
MM%C<)/%N*$K_  L.JD=01Z'F@"R%"YP ,]<"C&:JWNIV>GE%N)2'DSLC1&D=
M\=2%4$D#OQQ5=_$FCIIT.HF_B-I,X1)UR4W$XP2!P<\8/?B@#3IK*KJ5=0RG
MJ",@U4;6-.349-/DNDCN8H3.\;Y7$8(!?)XQD@9JM8>*M"U2ZAM;'4X+B:=&
MDC5#G<JG:Q'XC^O2@#5Z<"EJA>Z[I6G7D-G>ZA!!<3AFCC=\,P4$D^PP#S5(
M^-/#8L7O3JT/DQR&-SAMRL.N5QD8R,G'<4 ;E%5)]5L;>UAN7N5,=QCR2F7,
MN1D; N2W'/&>*C@UO3+FPEOHKR,P0,5E8G!C8=58'E3[$9H OTTHI<.5!8<
MXY%8^H>+-+T_2[^^=YF%A&'FB\AUD&02HVD C..O3OTJ[I.HQZKID%Y&"/,0
M%@5(P2 2.1[T 7:0@,"K $'@@]ZQSXN\/"\6T_M>V,[7 M@BMG,IZ+QWZ?G4
M[>(=)2]CLVO%6660Q1DJP1Y!U0/C:6X/R@YH T%14^ZH7C' H5%4DJH!8Y)
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M)!E'P0&'J,]JL444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M("$LLB0;6^7.\D]SSDX%:\L%S<7?CS2+=)DOK]=]L/+8!U-N!G=C R1MZ]:
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M2O':!!D$MM1MV/7!VY].*P=(?26TV3PMXBL-1GU:*X<?9"]QY=T?,++(I4[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*L5/! /4&KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6?@C4[>/05DUV)O[#8K!LL@H>,H4Y^8_/@]>GL:T;3PU>6MWKUQ_:4+'6"&
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M;QY<!@F#QD*"<' )X)KJ/#U[_:&EBZ74H=1BDD8PW$0 #)G@$#HPZ'W'0=*
M+=]J%IIL FO)UB1F"+G)+L>BJ!RQ/H.:274;:WTZ34+AF@MXD+NTJ%2JCJ<$
M9_#&:XT'5M9^(^LR6C6H_L*"*"T6Z5F0/*F]FVJ1@D?+NSP.QS5VWGN_'_@^
M&6"[?1;R.Y_?;(UEV2Q.>,'@C< WX"@#:T3Q-I'B,3'2;IK@08$A,+H!G./O
M 9Z'I4^JW.G6ULC:D(V1Y D:-'YA=ST"J 23UZ#UK)\*:IJ\UUJ.BZ\(GO\
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M >@7VJV>G20Q7#N99\^5%%&TCO@9)"J"<#N?<>M(-9TXZ2=6^V1BQ"%S,3@
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MQ7<6$-U!:(E[=_:KC'SR",(I/L!T'U)H LT444 %%%% !1110 4444 %%%%
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ME:_IYU:(IKDTDKL+0YB,BA6 ^?G@#']:W-*U>'5EN/+@N+>2VE,,T5Q'M96
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MU'4(KB"VU#[; ?LVV:/YRZH'W'@9 R "0,4^+PFB:CK+RWAEL-9YGLS$/O%
MC?/G."!TP.>]=#10!S%MX0G&FV.DW^IB\T[3Y4>%#;[9'$9S&KMN((&!T49P
M/?,:>#KZSUB]N-)\02V-AJ,QGN;06ZN?,/WFC<GY"?H?Y8VK?7+.YUVYT:,2
M_:K6)99-T95=K$@8)Z]#TXK1H Y;4/!,6IZM>75U<0O:W6GBP^RFW/R(K%E8
M-N^\&.>G8=.M)/IGB73]!L;*U\0&XN[>9!YIL@3<1CC9(2Q"CIE^#QW)KJJ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7@BNEO+47=C/:;VB$T31[TX9<C&1[B@#S_1[N\\&ZPN@^(5^VZ<YMX+/4D7
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M+RUDEB$01F++L;;_  Y4'/4#UI9? JFRAM[:_6W9-5&J2%;<;7F!R %W?*G
MXY/'7KF>_P#"#:EJNHWESJ&(]1T\V$L4<.TJGS8(;<><L>V/:@#/TS7]2_X2
M72+!]0-]#J-E*\LA@"Q"5 IS$P"ED^8^O&.>M1Z-J^OS6^JZM?:M$;31KZ\B
MEMH[10;B.(''S9RO(SW[Y)SQ?MO!UW%?:1>SZ_/-/I4;PK_HZ*KHP48QV^Z,
MG//;%7-#\-'2K;4[:YNUO8-2N9;B1##LPTA^<=3E?\YH S;&]\4W,NCZA!%+
M-:W>UKV*7R%BCC=<[XBK;^,]&SD>AKL*Y?0_!]WHS16K>(;NZTJV8-;64D:
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M=Z1<W_B.:YDTEV:)EMD0N"NWYCSDX/)_3/- #OB-J-WIO@J\>P<QW,[1VZ2
MXV>8X4G/;@GGUJO;WM_X4U;1O#TL-G+IUY$\-JUO$T;0R(N[:V6.X$=QCG.1
M71ZQI-KKNDW&F7JEH+A=K;3@J<Y!![$$ CW%5(-#E?4+*^U.]%Y-8(RVY6'R
MP&889VY.6QQQ@<GCG@ X73P)?V?+J:<[I9K>XED8]3)YSG)]\@?E7=I<W?\
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MNUA@5I97#$$I(<!<*.!U)/(Q4EMX,N+:3P^ZZR7.A1-%%OMA^\5D"$'!&!M
MQWSR2:GUCPI<7>NIK>D:S-I-\8A#.R1+*DZ Y&5;C(R<&@#*O/$NMZ1I^D2^
M)HIM,CEBD6_NK*-9A#*& 0MPP5&7)Z'G XKJ]%FDN-&M9I;R*]=XP3<PXV2_
M[0QQS5,:'>0/ ;35"56%XYTNH?-%P6;<78 K@YSTXY(QC&+.@Z-;^']%M]+M
M2S10 X+=R6+$X'3DGCM0!A6^J:MXAM=:O-,O_L9T^ZEMK6'RD99&B R9-P)P
MS9^Z5P,=ZR-7U.7Q-H?@S6$GEM/MFJ6^Z) I"/MDRPRI)P0<9XQVKHU\*RV=
MYJ;Z7J1M+;57,MS"T._;(PPSQG(VDCKD,,]J34/"*3V6C65A=+96VC3QSPIY
M/F;F0$ $[AQ@G/<^M &Q=W0TO29[N=GF6T@:1V( 9PJY)X &3CM6)I;^(=0M
MM&UB+4('AO$6:\M70!$C==P\LA=VX9 ^8X//2NBDA6XMF@N%61)$*2#& P(P
M>/2N;T+P?=:+Y5H=?NKK2K9]UM921("F#E0T@^9@#R!QT'88H HQZ[K&K^%-
M0\3:=>B#[.\[VUH8E:.2.(D8<D;MS;2<@C&1Z<D7B'5M8\0:+%97B6EEJVDM
M=[# &>-OD[GJ?FX[>QJ^G@YK:WU'3K+4F@TO4G=Y;;R=SQ[_ +XC?/R@\\$'
M&>,59/AGR_$-AJEK<I!#86AM(K40Y C..^[K\HQ0!S+:SXG/A77K[^V(EGT"
MZGB#BU3_ $H1X;YQT&0<?+CUS6K=:QK-QXIT:RM;V*VM=2T^2=E\@,R, O.2
M>?O<=O7-3+X.G_L;7-,;5%*:U/+-*_V;F,R !@OS=, 8S^M3P^%[F/5]*U%]
M21VTRU:V5!;X$BMC)/S<'Y10!SW]L>)V\-^(KD:S&L_A^YG19!:)FZ$:AP''
M09!Q\H'KFMF+7[K6->L='MYC9>9I2ZC/+&JL_P Q"JB[@0.<DD@]J<G@^==+
MUZP.J*5UR6225OLV#&9%"L%^;I@#&?UIX\)20SZ7?VNHB+4M.MOLAG,&4GA_
MNNFX'L#D,.<_2@#G]5\6:]9>'?$D*W,0U+0KF)!<^2")HY"NTD= V&YXQQTK
M=@OM8L?'4&EWM_'=VM]923J@@$?D.C*,*1R00W<D^]&H^"DU#0M1T\WQ2?59
MUFO+KRLEB"N HS\H 50!SQGN<U<DT"ZF\26.MR:C'OM+=H#$MOA9 V"QSNX.
M5&/3WH /%FJ7FCZ5%=VL-Q)$+A1=/;1B22*'!W.JG(.#C/!X)/:N5\1:E)JG
M@;[=8>(GO+:34H%CFA5%9HV=!L<;1@@D\8&>,\'%=QJ=E=7@MFL[[[)+;S^;
MDQ[UD&UE*L,CCYL]>PK$N/ ]O<Z/J-G]J,-QJ%XMX\\,054E4J5VH2>/D&<D
MDY/- $C:C>7?BIO#D%_+"+2R%Q/=!(S+(S,0H&5*@  D_+W'3G.3!XQU)(9=
M*NC$=2CUE-+%T$PK*P+B3;TW; >.F<=N*VY_#,W]KVNM6NI&+4XH#;S2R0AT
MN(R=V&0%<8/(((Q[U#>>![*^T6XLI+F9+JXN_MQO8\*Z7 Z.H[    >G?/-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<I\2_#]UXD\$W=E8KOND*S1Q_P#/0J<E?J1G'OBNKHH XGP%XJTD^#;"
MTO;Z"QO-/@6VN;>YD$3QE!MY#8." #69\2Y)M0M?#>J0I,-+M]51[DNA4!=P
M"R$'HOWN3_>'K7HK6\#RK*\,;2+T<J"1^-/(!!!&0>H- 'F%BSS?$SQEJT$J
MG25TY8I)PW[MI1&F.>A( ;Z?C7!W,ML/@581AXO-.LDLH(W'Y7Y(Z],?I7T2
MD<<:!$150=%48%+L7^Z/RH \R6ZM#\?;?[/-#Y9TH(OEL,$X) &/;!^E<Q;W
M%FVE_%%_-A+273&,[AEE,LF,>HSC]*]TVKG.T9^E&Q?[H_*@#Q"XNK-(/A7Y
M<T*^7(#)M8#;EX@2?3D-^(-:MP6TKQ3\03K$BQ->::S6K2G'FQ[" %SUQE5P
M.]>M;%_NC\J1XHY"I>-6*G*[AG!]J /"]3@GT_P9\/[36,)*+\NT<W58C("-
MP/;:1UZ=*ZOPC<0-\:/%BI,AWQ)M 8?,0%!_(UZ65!Z@'ZB@*H.0!GZ4 <[X
MON]&"6>E^(((I-/U%VC=I,A8V RK$_PCJ,]B1R*XOPWX:;PI\3K:T\-:G)=Z
M1=0/+>P[PX@&#LW$<9+8VGKC/;FO5BH)R0">E-BAB@7;%&D:DYPB@#- 'D'A
M5;AM-\?Z-;,R:K-<7!A@Y$A!#<@=L] ?4CU%4D$E]X;^'VFZ6V=1M[UFDC3[
M\&U_G+#JH'?->W8 )( R>I]::L4:NSJBAV^\P')^M 'DMA=:79^-_&&@^,U"
MPZO.DT!FW!9HU8E%!'.0"N,=U(ZU'XM^T2?%O1K;0;J*QNQHS1VYF7_5,5FV
MJ0>AP0!GID'!Z5Z\T<;NKLBLR_=)'(^E.VKG.!GUQ0!QGPR\4V^O>'ELG6.#
M4M/S%=0 C)(/^L]]QY)]<UVE(%4'( 'X4M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(S!%+,< #)-+10!1LM;TO4DF>QOX+E8"1
M*8G#!".H..AI^GZG8:M ;C3[N*ZA!QYD3!ESZ9%<9X'GENM FALW*3ZGJ%U<
MRS+UAB,S+N_WCMPOOD\[2*Z!-12'55\-:);Q*;.!7GD8'R[9#]Q<#EF."<9'
M SGL0#>ICRQQ[?,=4WMM7<<9/H/>N-U'QA?R^$+VZT]((M3AU Z8H(+H\OF"
M,,GYAN>G/7'-V::3_A(-#\/W=K:WWEP-=O/)EGA,6%1QGN6;KG/6@#J**X>\
M\=:C%IFO7D&GVL@TFZ: $RMM?&!CIDL6.T#V.3TSMS:[<R^)(] LX$2X6T%W
M<32Y9(E)VJH QN)(/<  =^E &[5/4=7T[2(TEU&]@M$D;:K3.%!/ID]ZS/"6
MOWOB.PEO+BQ@MX5E>**2*=G\XHQ5FP5&T9'')_2LOQS.;G5] TA+>6Y'VHW\
M\4.TL8X!D#!('+,O?M0!U-CJFGZF'-C>P7/EG$GE2!BA]#CI^-3I+'(6".K%
M&VMM.=I]#[\UQ_AI)-8UJ[\<H8[>TO;%8+6%FY95))>7' .>,#.!3=.\2_9_
M#FFZE%I$$5_XBO,1PQ$JC,V<2.V,_<4,>,G@>] ':U3L=6L=2GN8;2<2R6CA
M)UVD;&(S@Y'7%8]GXAU!_%5[HLUM:206$237%XLK1[ ZD@>7AN>.[#@Y]JYS
MPWX@O+:RL+^"SCF'B+6&:5Y'(8!RV-@ Y"1HN23U&/6@#T>BN8M]0U2^\>WU
MJDL7]G:5;H'C4'<\L@W#)S@D*H]OGJ3PSXBO/$4-M>I%;BTF20S!2PDM9590
M(F!ZMR3G Z=.0: .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *:V[:=N-V.,],TZB@#$\)>&H/"N@0:;$YE
MD4;IICUD<\D^PST%0KH>H6.L:Q?:;-;@ZMY;&2;),#HFS(4#YQ@ XR.<UT-%
M ')R>"WMK/0[+3;I!#IUVUU.UP"S32%6_>''5@S%L=.GI5Z+1+Z/Q?>ZVUS"
MT4MK';PH5.Y0NXD$] "S9XYX%;U% ''#P5=1>%M,TB&[@,L-^EY?2R(2MPP8
MNW Z_/MZ]EQ4&H1:EKNLOJ6D065W!8"2PFBN9GMY975OG^= ?E[!6&.IQT-=
MQ5*?1M*N9VN+C3+.:9OO220*S'\2,T 5_#-[%J'AZUN(+ :?'AD%LN-L>UBN
M%*\%>,@CJ,&J=MHNHCQO/KUU);-"UH+2&)"VZ)0VXG.,$D]>G0=<5T"J%4*H
M  & !VI: .2M_"VJ6/AS6]"M+NW6"\:<V+G<#;B4D[",= 2<$?E5?5;*[N+.
MQ\*Z<UFU]81PW3&=62-8E)551E^=6RN-PY !Z9 KM:K7>FV%^4-[96]R8_N>
M=$K[?ID<4 <K:17NK:1K^@+IT&CZB4"S7$<IGCE,JD%]^ Q;:#PW(RO8UHR>
M&'35]!ELI8H+#1X9(UA*DME@J@CM]T,,_P"T:W;>V@M(A#;01PQCD)&@4#\!
M4M ',66@ZUIYU66"]M?.O=1^U*65N8]R_*Q_W$V#'3)//:[HNA'3=7U;4V\N
M)M3>-V@A)*(54@MD@99LY/ Z#ZUM44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-8O=:TNXGO\ R?.AO9[?]RI52$<J#@DGMZU?76K!M:?1UN$-W'$)70,/E!.
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M)!;ZQH<VIQ-=0'Y;FSG#(H*G^( A" ><8QQS7?0PQ6\*PP1)%&@PJ(H55'H
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MT;2[JTCL[C3;2:VB(:.&2!61#ZA2,"I8K"S@,QAM((S.<RE8P/,XQ\WKQZT
M<9JTVD-X[\%SV<EIY;172QO&5P8_)^4#';KC\:Q;FTLQ\/O'L*P0B*'5;DQH
M%&$8+'C [<UZ+;>']%LG1[72+&!HV+(8K9%*D]2,#@G _*G#1-($4D0TNR\N
M4[I%^SIASZD8YH Y.:RL[#QUX/>SMXH'N+6[65HU ,H$:,-QZMSD\]R:QI;6
M+5M$UOPV;RREFGUIY!>R7$?RXE5B64G=N4 IC&#@<XKT;^QM+W0N--M-UN,0
MMY"YC]-O''X5R5MX3U!E:WU7P[X;U.5G9GU.8'S'W$G<8S&3GGH' ]"* .VB
M@AA@6"*)(X47:L:* H'H!TQ7DUU):1_"/Q)$'A6=;^<,@(# ?:1C(Z]Q^=>J
M:=9)IVFVMC&[.EM"D2LQR2% &3^51R:-I4OG>9IEF_GN'EW0*?,8="W')]S0
M!RUW9V^F?$G21IMO#!)/IETK!%"^9@H5W>O.>36/H T37?#&D?;]=N8]2LKI
M7>V1H5G%V&PPQLWG<Q.>>0>3Q7H7]DZ;Y\4_]GVOG0@".3R5W(!TP<<4)I&F
M1ZBVHIIUJMZPPUR(5$A^K8S0!D>/YKBW\$:E-;"0E%0R"/[WE;U\S'_ -U4]
M+A\/WWB.PUC3]=DOKLVK1)'"T.TP]?WBH@( .,9Q@D"NN(!!!&0>H-4[/1]+
MTY95L=-M+59_]:(8%02?[V!S^- 'FMI>BR^'>C7$TSQ:>-=D^VRH VR/SI=K
M$$$8#[#R/2KOB2&PM-(\0ZOH>K7&HW5S;PF]$$D;((@Z@G]VHPQCW\YZ UW\
M6E:=!:R6L-A:QV\O^LB2%0C_ % &#3K+3;#3;8VUC96]K 228H(E1<GKP!B@
M#$M&\+ZIJMK?Z;);W-TUD8H_L[Y"P<'YE!P #@#(X)KA76PG_9[ Q;R300(S
M="T;>=@'U!ZC\Z]3L=*T[2Q(-/T^ULQ*=SBWA6/<?4X'--.C:4T#VYTRS,,C
M^8\9@7:S_P!XC&"?>@#GC<-_PM?[/?8\MM*S8;ONEM_[W;_M8VY[X%<CJMDD
M?A+Q%$(U_L^#7XQ89'^JS+'Y@0]EW%AQ[UZC<Z5IUY!';W5A;3PQ$&..2%65
M"/0$<42Z7IT]JEK-86TEO']R)X5*+] 1@4 <Q!9VFG?%B&*RMX;9)M#<ND2!
M0Y$RX) ZG&>:E\=7#6]SX>-QQIK:H@NR?N]#Y>[_ &=^#SQD"NB72M-6YCN5
MT^U$\:A4E$*[E &  <9 Q4\]O#=0/!<0QS12##QR*&5AZ$'K0!RHMFC^*LAM
M% MY])W7Z@?*S^9B,L/[Q&X?0&E^'"0_\(_<O&J9_M&[&Y0.GG-@5TEMIMA9
M6[6]I96\$+_>CBB55;C'( YXHM-.L=/#"RLK>V#<L(8E3/UP* .8U&^6+XJZ
M;;:@ZI:MIDC61D.%-R9 &Q_M; ,>Q/K7--%ILG@_XAP1K;LB7MQ*B+M(4^6F
M& [?-GGUKTN_TRPU2$0ZA8V]Y$K;@EQ$LB@^N"*8-&TH0R0C3+012D-(GD+M
M<CH2,<T <;J-A87GBGP0+FVAE$UG<*X=01(!"A /]X#T--_XE4'B[6M"U&]3
M2K=K2".RB(B2-[;80RKO4CA]V0/Z5VAT72BT+'3+,M  (CY"YCQR-O''X4M]
MI.FZF8SJ&GVMV8CF/SX5DV'U&1Q0!P^GW6FZ%XIT*RGOI'T@:3(FFW-ZXPTO
MF<G=@#)CVA3_ '3[\KKEMH=GIN@#2EC%@OB.(^86W1Y;>6VL3C;N)''&0:[F
M^TRPU.W%O?V-O=P@Y$<\2NH/K@BEET^RGLQ936<$EL  ('B4H .GRD8XH Y;
M2+B*Y^(NO6UV(Y$>RMCIX;!5[8J?,V=B-YY]>/2N4^PHWAG2(KF-9+./Q8L-
M@[]?LOFL  >NTX/X8KU*\TK3M0$8O;"VN1%_J_.A5]GTR.*+G2].O(XXKJPM
MIXXN(UEA5@GT!'% '+ZQH]QI^JPR^$QI\5S;VTADTN:,)%<1.X+%2/NME1ST
MZ9K4\-:[I=SH&BK'Y=@;NV M;*60;]J#!"C^( #J.V#6G<Z3IMZR-=:?:SM&
MNU#+"K%1Z#(X%0WFB6E[>V-Q)! /L+;H2(AO4]@&_A7ID#K@=N" 4/'-U86O
MA:<ZE"TUO)+%'Y8D\L,QD7;N;^%<XR?3/6N:26"?QAXG@NKFRN3<:1$72( (
M[+YG&"3D@#K_ "KT&XMH+RW>WNH(YX9!AXY4#*P]P>#5<:/I8  TVT $7D@"
M!>(\YV=/NY[=* /.+:RL[;PG\/[Z&WBCNGU"T1IU4;V#1N&!;J0< 8]AZ5HV
M5Y:W=IX[M]7:+[:ES.K).0#]F$8$.,_PXR1[DGO7:'0M',*0G2;(Q1DLB&W3
M:I/<#'%+<Z+I5Y=+=76F6<]PB[5EE@5G4>@)&<4 9W@21)/ FAE'5MMC"IVG
M."$&17')>6M]\/\ QHFIM$=22:[^TI,1N# 'R< ]@ H7Z<5Z9!;PVL"06\,<
M,2#"QQJ%51[ =*J7.A:1>7375UI5E/<.AC:62W1G*D8*DD9QCC% '':+>!_&
M6@1W+JUH_A]?L+$Y0S9'F8_VM@'X9]36GX*@>UU;Q-! -NF)J/\ HJC[JN4!
ME"^@#'H.,YKHKC2M.NK6.UN+"VF@B(*120JRH1TP","IX((;:%8;>)(HD&%2
M-0JJ/8#I0!QUUIUA<_%Z,3VD$N_0G=U= 0Y$Z $COQZ_TKFH)_L7AFQAP%TB
M'Q5)%<J/N)")6VANP3=MSVZ5Z@^EZ?+=_;)+"V>Y QYS0J7QT^]C--BTG38(
M)8(=.M8XI_\ 6QI"H63_ '@!S^- '.3VQ7XIV[V:#RY],<Z@H'RL X$18?WL
M[@#UP#Z4?"V2V;P!I:1/$95A_>JI&X'>P&[\CU]*Z:RTZQTV(Q6-G!:H3DK#
M&$!_ 4ZVLK6R5UM+:&W$CEW$487<QZDXZGWH GHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG
M?'FJZAHG@^^U/3)HXKBW"D&2/?P6 XYZ\]\_2NBKDOBDRK\.-7+, -D8R3C_
M ):+0!TD.H65S=36L%Y!+<0?ZV))59X_]X Y'XTJ7]G)=-:I=P-<+RT2R N/
MJ.M<G>PV>F?$O13;0Q0*^F72N(E +J"A XZ]S7.Q:AI[0>#+NSFMK:R_M)FA
MB:7?,B,LFYI')ZD]1C@GJ: /3(-3T^Y\W[/?6TODC,GERJVSZX/%(^JZ;'9B
M]?4+5;5C@3M,H0G_ 'LX[&N1U$7/A[QM.MBC"/Q/ $C9%R(KI."Y]O+)8^NP
MTFKW%KH/C32;6ZOWTK3/[-:"SG&S8LH8;E)=2 2@7GCI[T =M!/#<PI/;RI-
M$XRDD;!E8>H(ZTRXOK2T9%N;J&!I#A!)(%+'T&>M9'A"QTNPTN>/1[J6ZM'N
MI)%E=E9&9L%O+*@#;G/3C.:P+2\T>[UCQ=I/B::"*628+BXD"9M#&NS:3V!W
M'CH6SUH [7[=9FY>V%U#Y\:[WB\P;E7U(Z@<CFDCU"QEMOM,=Y;O!G;YJRJ5
MSTQG.*X];BQTWXC:9-),+6U?P\T4+7+[2<2H=I+=PO)SS7,3&QO/A[J1S%))
M#XC++_?CW7(Y'=<J30!ZQ]OLSYV+N#_1_P#7?O!^[_WO3\::^IV"0Q3/?6RQ
M3'$3F50KGV.>?PKD9M(TQ/BI:P+86RQ2:/(SQ",!7*RKM)7H2,G&:YZX6.W^
M'NO1H%CMK+Q,X51PL,:W2=/0#- 'J/VRWDN)+.*Z@-TB;C%O!91ZE<YQR/SK
M%\(:Q=ZCH=Q=ZK/$9(+RXA:0*(U"HY4?3@=S68FI6%Q\78&@O() VAO&&1P0
MS><AV@]SCG%8]C>Z=!X,;[;'YZ3>))(XE,OEQ^9]H+*9&[(,9/!H [ZXUS2[
M72YM3EU"W^QP EYED#*,=LCO[=:I)K4.KZ-8:AI^KVMFL\L)8R%9,YP3#U&'
M.0/4>E<>LZM??$2$W=O/+)I\9 @&U7;R) V%R>> #SVI^JS6-WX$\'S1R03-
M!?:<@=2&*-\N1GL<=10!Z!'J%E+=O:1WD#W"?>A652Z_5<Y%(-2L&MY+D7UN
M8(CMDE$J[4/H3G KEO%#OX;\5:?XF@MVFCNXSIUW'&,L['YH3]=XVY_VA5?Q
M&?\ A'9/#)O;Q[:R6YE-[=QJNU;AT)#G<" "S/R1QGVH [2TO+6_@$]G<PW,
M)) DAD#J3]13?[0L?MGV+[9;_:O^>'FKOZ9^[G/2L7PO:Z1%?ZK=Z3J4FH?:
MY$DN)0Z-%YF"/EV #=C!;ZK5+QGC0]4TKQ<D;%;-_LM]L7+-;R'&>.3M?:<>
MYH ZF.]M)O.\JZA?R#B7;(#Y9]&]/QIB:GI\EI)>)?6[VT0)DF652B8ZY.<"
MN-\3K/INC:+)>H$M[K6(9M6SRH#DG:Y[HK;%Y[**O30/#\5;26P&U9]-<Z@%
M^ZP# 1,W^UDL >N ?2@"Y'XDL]>\,SW^E:S:V/7;<S;7$(#D!F4D8R%) ..M
M;LES! =LT\<;;2^&8#Y1U/T%>3&2SN/V>&A+PR36MN-RD@M$WG$#/H>M=5JE
MA877Q3TSS[:&7S=+G+AE!$F'3;D?Q8YQG^E '7Q7$$UN+B*:.2$C<)$8%2/7
M/2FV]Y:W:EK:YAG ."8W# '\*\S,,<7@#Q-;07$-I!:Z]*L<;MLB*B9#Y7HH
M;./3GGC-='I=C;:MX[D\2+':*J6"6Z1^9%++YFXDR90D+A3MSG)R>V* .MEF
MBA4-+(D8+!068#)/ 'U-9]Y>+,;-K36+2W4W05]VU_/ R#$O(PV<=,GCI6%\
M2+:VGTS26N(T)75[4!CP5!D ;!ZCBJ_BW2M+TNX\+BQL;6T)U^(XBB5/O(^[
MIZD#\A0!V,][:6K(MS=0PL_"B20*6^F>M8?B'5[[3]>T""WGB6TOKIHKA3'E
MB!&S?>SP./3\:PM2EBB\4>*;.62VNSJ-C#&D<EQ&AMSL9=C!R/E)._*YZGCI
M4-[HUII<?@31Y/LTRI<[93&H"3,(&!;'?)QUZYYH [2?Q%HUOI$^K-J=J]E;
MY\R:.574$?PY!Y/MUI;+7=.O=)AU,7END$BJ2QF7",0#M)SC(STKB+J.*&7X
MF6MNB(@L$<11C W-:MDX'K5US<:EI?ANX\/:K9_VE:6A:*WG^:*X'EQAU)'*
ML RX(Y&3[T =Q%-%/&)(9$D0]&1@0?Q%/KFO"VN6#>'[1IH(](>:ZEMUM7D&
M//\ ,;<J'^(;@V,?2N@N;F&SM9;JXD6*&%"\CL<!5 R30!SNN>+3I'BO2M,,
M.;2Y<175P>D4D@/DK]24;/MCUKIB0H))  Y)-<)?>&M6\2>$;TF[M(Y-4/VU
M$:V8R1O@&)?,$F 0JHN=OKUJIJ'BQ=9^'.C:U(<VQOK=-751D(BMB0,!_"6"
M\=P?>@#T"VO;6]0O:7,-PJG!:*0, ?3BB"^M+F62*WNH99(CB1(Y Q3Z@=*X
MOQ5)IHT;7]4\.3+-JDVG+YTEI+N B4\$[3@-M+8/7"GTJZDWAW4!9:EH#P2Z
MC'82I8);N/D0IG#H#T!"CD<$XZF@#IA?69NS9B[@-R!DPB0;P/\ =ZTLU]:6
M[%9KJ&)EQD/( 1DX'7U->:S"*]^"UG=6>3JL+1-$X_UPO?- ;WW%BV?8UK6V
MBZ9J'Q+UJ*_T^UG#:?;2-&\892^Y\M@]^!SU_.@#<\7:\NC:!J$MMJ-G;ZA#
M;/-#',06;:I( 7()SC_]=2V=Y<W,6A3/JD$+7$&^:W=%WW1,>?EY&,'+' /'
MI7$)J-I/X!\:6VJ2PKJBRWAN(IF <M@^40#U& H7Z<5H*UI+KOP\N8FB=WMY
MT$BD$L!;=,^QH [B74+*'/FWD$>UQ&=\JC#'HO7K[5)/<P6L7FW$T<,><;I&
M"C\S7FATC2Y=(^(9>QMV,$MP8LQ@^61 K97^Z=W.1Z#TK0DO1:WG@K4;BZCE
M!T]PUO),J,2T29E4N0I(Z')SAN,\T =)XKU2YL?"&H:II5Q#YMO;M-&Y7S%(
M SQS^O-6[/5K1X+.*XO;=;R>%'\II%#L2,\+UKB)M&@TKX:^++I1:!K\W4X\
M@JWEHV=D99>N,].@+'%:7B*U>W\/:-XHLHO,N]$C28A1S+;E )5_[Y.1_NT
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M.0>* /199HK>)I9I$BC499W8  >Y-1B]M#++$+J'S(!NE7S!F,>K#M^-<O\
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M#N0<]?Z5L?#M$AT[6;:%52"WUN\BBC7A8T#\*!V'- '6T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %0W%K;W<8CN;>*= <A9$##/T-35'//#;0M-/*D42#+.[!5'U)H
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M<$C(%9/@/5;W6O!]IJ&H3K/<RO,'D5 H(69U& ..@% &^T4;HJ-&K*I!"D9
M(.0?P(%)/!#=0M!<0I-$XPR2*&5A[@UEV?BG2KWQ#>:)#=1&YM%CW#S!\S-O
MRJCN5"Y..F?:K:ZQICWOV%=0M6NB2!")5WDCJ,9ZCN* +%O;06D"P6T$<$2?
M=CC0*J_0"GR1I*A21%=3U5AD&FW%Q!:0//<S1PPQC+R2,%51ZDGI5?\ M?3/
ML27O]HVOV5V"K/YR^6QZ8#9P30!8FABN(7AGB26)QM='4,K#T(/6HK+3K'38
MS'8V<%JC<E88P@/Y4R\U?3=.95O=0MK9F&0)957C.,\GIGO5/5/%.E:3J>GZ
M?=7<,<U\6V[I H1 C-N)/ !( 'J3[4 7FTRP>)HFL;9HW?S&0Q*06_O$8Z^]
M,.C:6;B.X.FVAFB $<A@7<@'0 XR*+O6-+L)$CO-1M;=WQM6695)R<#J>YXJ
MX2 ,DX [T <[KOALR:;Y.A66F0L]PDMS!+"$CNT4D['*C/)P<X/3'0FJ^D>%
MT35+;4I/#VD:+);,S+_9[;GERI7#,$0!?FSCG) Z8K3L=4M+;3Y[J]\06EU"
M+EP+C<D:1C/$>0<$J./4U=MM6TZ\O)[.UO[:>YM_]=#'*K/'_O '(H =>Z;8
M:DBI?V5O=*ARHGB5PI]LBB;3K&X$8GL[>41#"!XE;:/;(XJ2XN;>SA,]S/'!
M$N,O(P51G@<FJZZSI;V4EZNHVIMHF*R3><NQ".H)S@'V- ',WOAS49]:O9[S
M0=!UV&XD#02WK;)+=   F#&^0,$\$9R:VM)\-:?I^GQV\EE:.4=G55A&R+<V
M[:@.< 9_KQ5N'6M*N;Q[.#4K66Y1/,:%)E+JOJ1G('(_.G6^KZ9=V\MQ;:C:
M3PP_ZV2.965/J0<#\: )(]/LH9GFBLX$E<$.ZQ*&8'KDXYJ*71M*FCABETRT
M=(,^4K0*1'GKMXXS[59@GANH$GMY4FBD&4DC8,K#U!'6JW]L:8+\6']H6WVM
MB0(/-7>2.HQG.?:@"86-HL<,8M80EN0T*B,8C(X!4=NIZ4^>WANHC%<0QS1G
MJDBA@?P-8&AZGJ%SXP\1Z==7"RV]C]F-NHC"[ Z,QYZGMU]*UK;6-,O+IK2V
MU"VFN%&XQ1RJS 9QG /3/% $Z6MO';?9DMXE@P1Y00!<'J,=*CCTS3X8I(HK
M&V2.8;9$6)0''H1CFFG6-,%\+$ZA;"Z8[1#YJ[R<9QC.<XYQ5&P\5Z1J6H7]
ME;WL&ZQ;8[&4#<<98@=P.Y^M &A8Z98:7;FWT^QM[2$G<8X(E12?7 %-L=(T
MS3&E;3].M;1ICF0P0JA<^^!S4&EW<<6@PW-WK-O?HJDO?C9'')R1G@[1Z=>U
M6(-6TZZMY;B"_MI(821*ZRJ1&?1CV_&@!$TC3([UKY-.M5NF.YIUA4.3TSNQ
MG.*5-+TY+XWZ6%LMVV<W A42'/\ M8S44.O:/<74-K#JMG)/<)YD,23J6D7K
ME1G)%:% %2;2M.N;@W$]A:RS,AC,CPJS%2,%<D9QCM3GTZQD>.1[*W9X@!&S
M1*2@'3''%1VVL:9>W!MK74+:>8#<8XY59L=,X!Z5SMUXA?6/$>H:%I>N0:?+
M:01F&5?+D\Z9BV5(;.0H4 @8/)YH Z :%HX$P&E60\__ %O^CI^\[_-QS^-8
M.M>&[E]1MGLM&T;4=+A@,8TZ[41+$Y;)=<(R\C P1VXZFNF\[[+9"6^GB0QQ
M@S2D[$!QR>3P/K7-V'B*2[\?W6GQ:E;W&FQZ8MP!&%Q&_F%3ENO09[=>E %K
M0_"]I8BZEFTK3K0780/9VJ;H5V;L'E0&8[N3M'0#MFI-4TO5;J6/3;%M/M=$
MEB*7(",)^3\RICY0"O&>HR34VG:E;6^D037NO6MZ)961+O*1K*=Y 48."1]W
MCJ15E-<TF2T>[34[1K=)#$TJS*5#CJN<]?:@!^HZ?%J.G26,D4#Q2 #;-")$
M&#D?*>#C''OBI;.UBL;*"S@!$5O&L2 G)"J,#]!3(=2L+BQ^WPWMO):8+>>L
MH,>!U.[I5*Z\3Z+:Z5=ZFVI6\EM9@^<T4@8J<<+@=SV'>@"Z^FV$HD$EE;OY
MK!I-T2G>PZ$\<FFC2].#QN+"V#18\MO)7*8Y&..*AL]<T^[T>'5#=VZ02*I9
MO.4JC$#Y2?7G&*FBU73I[)[V*_MGM4)#S+*I12.H)S@8H <=/L6O1?&SMS=
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M>8K"7M@9!MF;'RXYY'?CM3]%%[)<277]NQ:G82QJ$ 1,QR#[V&3 *^QR1ZT
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MF@L]0MKB55W%(I58A?7 /3WIBZ[H[SI NJV;2R2F%$$ZEFD !*@9Y(!''N*
M+%W9VM_ 8+RVAN8B<F.9 ZD_0U&-)TU;?[,-/M1#NW^7Y*[=WKC'7WI+?5]-
MNKG[-;W]M-/M+>6DJLV!P3@'IGC-3W-U;V<7FW,\<,>0-TC!1D]!SWH B&F:
M>)8Y18VPDBQL81+E<=,''%1)H6CQ@A-*LE!E$Q"VZ#,@Z/T^]R>>M4M4\7Z+
MI=A#>-?V\L<]PMO&8Y00SE@#ST^7.3Z8J]/K>DVL22SZG:11R)O1VF4!E_O
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M;-9?-6'89UW>8>B8S]X^G6@!S:+I+/"[:99EH!B$F!<QC_9XX_"D&A:.L,D
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MIBHH[&SB@:".T@2%CEHUC 4GU(H \X\!:K_9@T2'6WB:&_L(UTJ[SA8B% >
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MH$> &7<A4<=1UQ74_P!G6.TK]BM]I.2/*7&?RIPL;17606L(=<;6$8R,=,4
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M;/LZ?-CT]ZKH+.VTCX<31"&)C)""ZX!.ZW.[GW.,^]>C/:V\I<R01.9  ^Y
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MUV$=G:PSO/%;0QS2??D5 &;ZGO2QVEM#(9(K>)'/5E0 G\: )J*** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HK*'BGP^7=/[;L T;;7!N$&T^A
MR>#6D)(VB$H=3&5W!P>,>N?2@!]%-5E=0Z,&5AD$'((HDD2)"\CJBCJS' %
M#J*2JMAJEEJ@G-E.)OL\IAEP"-C@ E3D=>10!;HHHH **@O+RWT^TDN[J010
M1*6=R"0H'4G%.MKF&\M8KJW??#,@DC;!&Y2,@\^U $M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %1S31V\$D\K!8XU+NQ[ #)-25C>*].U'6/#MWI>FRP0R7<9B:69CA%/!P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9EAD@)02I_"=K'AO4 D5I%E7J0/J: %HJ.6XA@V^;-''O.%WL!N/H*>2!U-
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MJEOH&CVFFOIMOI=I'929WVZPKL?/7(QS^- ')VAL[FT\&V+1FXO?[+$L4$K
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M_P"C$KI+&PL],M$M+"UBM;=/NQ1(%4?@*9)I6G2Z@FH26-N]Y&,)<-$#(H]
MW44 >;E[22W\,:KIN%@N->'EW4SAKJY5VD#EF&,+VV\\;<XQBM#5K&WTWQ1J
M>EK:126_BNT'D+LRHN%^1^G;:XD)_P!D]ZZH>#_#8611HEEB243,/)&"X.0:
MU'MX9)8I7B1I(<^6Q7E,C!QZ<4 <1X+4ZC'9:7?6R&;PNSP2DQX!F&4C9?\
MMGEC[LIK<\:364>@B*^,YCN;F&%(X7"&5RXVHQ/ 4XPV>V:W(K>&%Y7BB1&F
M??(5&"[8"Y/J<*!^ J'4=-LM6LGLM0M8KFWDQNCE7(..10!P4<")JWC>RF6V
MC1M.AD-O;DB-'\N3ITYPHR<#.!Q5>STVSL=-^'NJ6T(CO9WMX99P3O=&MVRI
M/<<# Z#M7=+X7T%"Q32;5"\/D,5C )CZ[>.QR<^O>@^&=%,%M =.A\JT;=;I
MSB$^JCL?I0!Q<,EKJ_AGQR^J)%)?PSW22+* 6BC13Y(&>B@#(([Y/6NQ\)$-
MX-T4@@C^SX.A_P"F:U+=^&]$O[QKV[TFSGN638TLD*EBN,8)^E7;:UMK&V6W
MM+>."&,82*) JCZ <4 >:V7AG1M5TKQF;Z+)MM4NC"YD/^CXC0AUYX/'7T '
M2DTS34US7?#2Z[ 9Y+OP\YN5D8_O>4QN]\'/U^E;_AOPR?M>N2:SI.P7NI27
M,6Z5662(A0JNJL0<%2<$$#-=)+HNFSZE'J4MI&]Y",1SG[R#T![#VH XD6^G
MW^O^(O#^HWEO9K%'%#;PSQJ<6OE*!L9O1MQ..AIVJ:=8"X\#Q;A?Q_:3$+BX
M0,\\8A?:2<<CH?UKLM1T#1]7FBFU+2[2[EA_U;S0JY7VR1T]J?=Z-I=_-%/>
M:=:W$L'^J>6)6,?^Z2./PH XEX['5_$/B;1=6O;>T8;(XHIHDXMC$N#&6Z -
MN/'0FHSH>FWOB_0+*=Y-0M9-%F1I)R<W"*4"EL=>.?R-=MJ'A_1M5FAFU#2K
M2[D@XC>:%6*CT&1T]J?+HNFSZE%J4MG&]Y",1S'[R#T![#VH XD6^GWOB'Q!
MX>U"[M[-(H88;:&>-6_T7R@!L+^C;B<=\4U='T^3Q;X8M6EDU"V;2KA#+.<F
MX12@4MV8$?@17;:CH&CZQ-%-J6EVEY)#_JVGA5ROMR.GM3IM&TVXU"'4);2-
MKJ ;8ICG<@] >PH \W2Z71?#>HVJ$P:3!XK^RSA20L-J60LOLN3@^S'UKHO$
M%E9:/IFO:AX><Q:A/IA?R;9@$"J.) JCAL$X/?;QT-=%%X>T>&&[@33H/*O2
M3<H5R)B>I8'J?>G:1H.DZ#;O;Z5806D<C;G$2XW'W/>@#E],LM#N[_1-:L-:
MCW1Q.D$5K&B&5&3)5P.2%QGGH1ZU3\.";2-<T:PU:PM[AIDD_LW6[3_EY4H6
M(E!YW%?FSGD_C79V'A[1M+GFGT_2K2UEG&)'AA52P],@=*6QT'2]-:-K.S2+
MR5*Q $D1 ]0@)PN>^,9H P/B;%"_A5'EC1ME];?,P!V@S(#].*KZC8Z=>?$K
M2K1[>"6V72KC]S@&,XD08*]",YX/<>U=A=V=KJ%K):WEO%<02##Q2H&5A[@U
M770M(2YBN4TNS6:%!'%((%#(@Z*#C@>U ' Z<=/MO#MUILZR& >*I;6SM8G"
M1LPEW+$V00(^"2,=!W/%,FB5;3XCV3I;;(K99%AA7]W&YMB25![Y')XY&>*[
MJ3PMX?EM)K1M&LO(GD$DJ+ JAW'1C@=>3S4UOH&CVD\L]OIEK%)-$(9&6(#<
M@_A/M[4 0^%TMD\-:>+58E4VT181@ ;BBG)QWQBN0AT+2[_Q!XZ@N[2.>)/)
M94D^8*QM]Q8 ]&R3SU':N]L;"STRU6UL+6&U@3)6*% BC/7@5670-*62[E6R
M0/>C%RP)S,/]KGGTH \^BL[>+PUX$UI8_P#B92WUG%)=DDRNC*0RECR5QVZ4
MGC%[2XT'Q5J%C@R6MZBR7ERP,J3(8_DAQ@JH]2>I;C!S7?-X9T5[2WM&TZ$V
M]J^^"(@[8F'0J.Q'M23^%= N;BYN)](M));M=L[M$"9!TY_QH P/%*6WAOQ'
M8>-%B7R #9:DZ)DB-R-LG'=7 ![X.*Z#P[8&STWSI8%BNKV1KFY4  AW.=I]
M=HPO_ :J76G:E=WR:4MG96^@1>4P9'/F.%(/E[,8 R!DYZ?7CH* .&31],UG
MXD>((=4LX;N);*U(CF&Y1GS.<'C/OU&>.M<]IEU)I^F>'K6\N_)T5M3NXK>X
MN '38N?L^[=P1][&>.%/85Z9>:)I6H7"W%YI]O/,J[!(\8+;?[N>X]NE27>F
MV-_8FQN[.">U( ,,D89,#IP>.* ,?POI=CIE]JOV'43="YE2:6) HBA<@YVA
M> 2 "1]#WK)\2+8:AK.LP+&D]S;:3BX-V08;=&WD%%QDN<<G(  7GM77V&G6
M6EVBVFGVD-K GW8X4"J/P%5[K0-(OM134;K3;:>[C38LTD8+!?2@#S^WMX-5
M?X<B]9I3<6<J3$R',@%L#@\\Y[^H)]:CU#28=)M_'NEV*%-*BL$N(X0QV03F
M-B0OIG ./I70ZMX64:_X<33M$0:5IK3M,(62,*73:I4;@<AN<]1CC)K3\1Z*
MS>#M4TS1[$//>PN@4. 6=Q@LS,>?J230!S%WH=KI=SX.U?2$:/4;FZAAN'5R
M6N(6C)DW<\@!<^WY5>L(8;F\\>PSQI)&TPW*PR#_ *.M=#H&BVMC8V<K6'V>
M[BMQ'AV#&+@;@N"0H)'\.,\5:30](0W+)IEHINQBX(A4>=_O<?-^- '!:;>Q
M1:3\/K*_91IMW;,)1)_JWE6)?*5NQY+8![@>E:NKV7A_2+&:QA>X=+W5H/\
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MUO.C)C;=YVOCTVJN>.TH]*[.J&CV#Z?8[)G1[F61IKAT& TC')Q[#H/8"K]
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M1QH%,^Q1$SE@1G&_D]^<]ZS=>BT_1-$O9=-U&:[L+O5[9]58,ABCC9AY@&P
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M9=SZ@T)E@OI[?,2%%VHVT<$GT]:S]0@,/Q.T.;3@%^T65P-0\OHT2A?*+?\
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M8'YB,D#UP.M6X[VTFN7MHKJ%YX_OQ+("R_4=17GX=[2]\?\ ]G"--24J;55
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MFBP/IXN%CP5.XR(2X(W8*9 Z@5U'A&PL-,\/0V6F7DUW9Q.XAFE8-D;CD*0
M"H.0/IZ4 ;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !4<T,5S"\$\22Q2*5='4,K ]0
M0>HJ2D)"@DD #J30!2&AZ0)()!I5D'M@%A86Z9B [*<<?A3H-(TRU:9K?3K2
M$W Q,8X%7S!_M8'/XUA-XDDG\=:?IMCJ%I<V%Q:S/(L.&973;C+ G^]TP/QK
M5M+^.VAN9=0UFSF3[4ZQN"L8B'41DY.6 [\9]* );;0M'L[26TM=*LH;>?F6
M&.W54D_W@!@_C33X>T1H8X3HU@8HCNC0VR;4/J!CBK)OK-3"&NX ;C_4YD'[
MS_=]?PJ'3))7^V&;48+P+<N$\E0OD+@8C;!.6'KQU'% %W QC'%5+/1],TZ1
MI+'3K6V=\[FAA5"<G)Z#UYK#N?$COXUT;3K#4+.XLKN.X\](<.ZLB@C+ G&=
MW3 Z=ZWCJ5@MZ+%KZW%TW2 RKYA[_=SF@"*;0M(N+J:ZGTNSEGGC\N65X%+2
M)C&TG&2,=JE?3-/D^S[[&V?[*=UONB4^2?5>/E_"FSZMIMJ)#<:A:PB)@LGF
M3*NPGH#D\$U//=6]K 9[B>*&(8S)(X5>>G)H KQ:-I<%T;J'3;2.<N7,J0J&
M+'JV0.ISUIYTRP:>>X:QMC-<)Y<TAB7=*G]UCC)'L:PO#7B"?4M3U]+J]M9K
M2PG18)H0%3RS&'SG)SUZY[5OVM_9WP8VEW!<;/O>5('V_7% $$6AZ1;K$L.E
M64:P!A$$MT C#?>"X'&>^.M,_P"$=T,6QMAHNG^06WF+[*FTMZXQC-:59D%Z
MMK_:-Q>ZM:RP13<!=J?9EP/D8YY.?7'44 27.AZ1>-;M=:79SFU $!D@5O*
MZ!<CC\*1M!T9[9;5M)LF@1MZQ-;H5#>H&,9]ZQ/#&KZEXCAL-8@U&T-K.K-=
MV&T%H0<^7M8<AN!G=P><8Z5T-UJ5A8NJ7E];V[/]T2RJA;MQDT ,_L72OM1N
MO[,L_M!789?(7?MQC&<9QCBL77?#+&VM8M$TO23:Q3F6YT^>(1Q7/RD#)52
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M=:;"S:S-D;2 VI&TP&,;,>FWI3;73+"R8-:6-M;D)Y8,42IA<D[>!TR2<>]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:Q[<"M#2/$$NIZYJ>F2Z>UM]A6)PYE#%A(&(##'RG SC)ZB@#;HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV]PV@^(;36+6($ %K:V(>]#KRDC&0ECG)R02"">.: .YHHHH **** "BBB@
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MY;[S!<@@8#'..<5T88,,J0>W!KF?$.MZWX>\'2:I-%I\M[#(JR!"_E;6E"#
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MM^1V7C//:MLL%^\0,G')H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\?7\FG>'HYA((K=
MKV".[D*DA(3( Q(!!VGH>1P3735%<6T%W;R6US"DT,JE7CD4,K ]B#UH XJ]
MT"QMO[6NXK^VQ>Z1)NL[*'RH7"C*S8#'YAD#/<?2LJRTVTL=-^'NJ6T0CO9W
MMX99P3O>-K=B5)[C@8'0=J[BQ\*:#IMC<6-EI<%O;W7$Z1C'F#T)ZD=>.G)I
M3X7T1H+6 Z?'Y5FVZW3)Q"?51G@_2@#G?"VEZ:WB/Q;&UG;KF^$8VH%(5H5)
M (Y&>3Q[USME:VUS\,_ [W,$4I_M:W3,B!OE:9MPY['N.]>EG0]+-_/?_881
M=W*>7+.JX=UQC!(YZ<5$/#6BC2/[(_LV V ;<+<KE%.<Y [<\\4 8DZ11?%#
M2(X%1(DTB=55  J@2(, "L'1K6#Q)X7MM5N]4M;/4+:Z,MQ/';_Z5%.'.4+%
M\G/W0N.1@ =*[T:%I8OH;Y;.-;FWC$<4BY!C0?PC'0>W2H1X6T$:U_;(TFU&
MH9W?:/+&[=_>^OOUH Y2T%IK\'C1M6BCFN[2ZG@190"T,"H/+*_W02"V1U//
M:NC\#$'P)H6/^@?#_P"@"K-[X8T/4;\WUWIEO+<LFQI&7EE]#Z_CTJ[8V%GI
MEHEI86T5M;QC"QQ*%4?E0!YPH&CZ)X\OM)M88;ZWO95@>.-0\:^5&3MP.,#<
MV/:M#5[6UL;3PGJOA^-([F:]MX1)$.;F&127#G^+@;LG.",UV46CZ;#J,^HQ
MV,"7=RH6:8(-SCT)_ ?D*CL?#^DZ;*LEG8QPE,^6%SMCSUV \+GOC% $7BBU
MDOO#MU:0WB6<LVU(Y9!E=Q< *P]&.%/LU<5<W1'AWQA97^BQZ3JT>E%IUMR#
M!.FV0+(F.F3D8// ]#7H=[8VNHVCVEY D\$F-T;C(.""/U JJ_A_2I+6>UEM
M%EBN<"82,SF4#H&).2!V!.!0!Q\&G6FF^)?!%U:1"*>]@FCN903NG46^X!CW
MP0,9Z=JS[U[26TTO5M. $4GB2/;>3L#<S$S%7&0!M3&5 .<J!D"N_/AW2&>S
M=K)&:Q&+4EF/D_[O/'^'%0MX0\.-Y^[1;,_:9!)+F(?,V<Y_,9H YO3]!TO5
M?B'XG6\MA/'&+&:-2YVA]KG<,'KD?J?4UGZ?:P>)O#<]]>ZI:V6H6E[))<7"
MV^;JVE20X7<7Z8PH&.AP!7?6VAZ9::C)J-O9I'=RC;)*N=S = ?8=AVJ!_"V
M@R:R-9?2;5M0!W"X,8W9]?K[]: )/$423^&]2CE&5-K(3SCHI-<1:Z7H-C\/
M-'OKB&;[3J5M8V[-#+AKAB5*QL3P$SP?]G(KT.ZM8;VUDMKE/,AE7:Z$D!AW
M!QVJDWAS1GT<Z.VG0-I__/NRY0<YX';GTH XE+=%U/QS8SPVBQG3X93;0KF)
M9/+D.0#U;Y5.<#. <5/91Z3%X/\ !UG]G#7%VMO)';1E8X[B409)F.#E1UZ$
MD@=:["V\/:-9W'VBVTRUBE\KR=ZQ '9_=_4_6H6\)>'FTY-..CVGV2.7S4B$
M8 5_[P]^WTXH \[U',7@3QW9[H@D.I?)'",(F3$6"C/ R3^-=%J&AVFA^//#
MUSHL307%Z\T=ZJNQ\^()DL^3R0V.3W(KIT\.:)&+I4TFS"WBA)U\E<2*!@ C
M'3 '%2V&C:?II+6ELL;% F\DLP4=%!))"^PXH X_1M#MO$>C^,-+N@-LVN7(
M1\<QOL3:P]P:E\+7(\2-IL%[:(D_AY62[38,+<C,:[?;:&;'^TA[5OSZ>=!L
MKFX\.Z/%<7<\H>2$W'E"4D_,Q8Y&['<\FK.BV$ME;2R70C%Y>3-/<^5]W<<
M 'C(50JY[XSWH R/B5$DOP]UC>,[+<NO)&".E9FJZ=:7GCOPNEQ%YB3Z?<B5
M2QPX"QX!'<<GCOWKLM0TZTU6S>SOH%GMW^_&_P!UOJ.]5CX?THW-M=&S4SVB
M[;>0LQ:(>BG/ H P_A]#':)X@L(%V6UIK,T<$0Z1IM1MH]!DGCWJ&[LK%_B[
M;2SVMNQ.C/(6>-3\ZS( V3W Z'M73V&CZ?I<L\ME:K"]RV^9E)S(W]XYZGWH
MN](TZ_O+>\N[*&:XM23!*Z M'GT/X"@#S.[TJRNO"/CB_FA#W-IJMV]O*2<P
MLNPAD_NG/4CDUO27/]J^,4TO49+/;)I,,MK%>V_FI*6+>:5&X#=]T=S@=N<]
M*OA?1%M;FT&GQB"[<R7$>3ME8]2PSR3[TE_X5T'5+.WL[_2X+B&VXA61<^6/
M0'J![>U #/"=A'I6@Q:?#J+ZA%;.\:3..P8_*#SD*<KU[8[5QCZ%IE[-X^6Z
MM5F6!M\0<DB-OLX;</1L]^M>DV]O#:6\=O;1)##$H5(XU"JH'0 #I6>/#>CA
MKMA9(#?#%T=S?OA_M<\_CVXH XVTU"2^N_"EEJ5Q;>5>:$DT?VV+S8YK@A-W
M&X9?;TSGJ?6J^L:!8:=I>CV0N(M0CC\30( \0VVZN06A7.?D&>F3Z'I7;W/A
M70;S2HM+N=+MY;.$YBA=<B/_ '>X_"II/#^CRZ0FD/IML;"/&RW\L;%P<@@>
MN>] %B5[:RTV1P1#;00DYB& B*.P'H!7G5@L%MK/@B[LHT@M[D3A'D<-<7$1
MA+;IF& 23@D<X/>O2EAB2 0)$BQ*NP1A1M"XQC'IBLJ#PAX<MEB6'1;-!#+Y
MT>(A\K\\C\S0!RD'FZ/KUFVJ6,&H6-WJ;-8ZQ;8\Z*21F CE!Y(Y*Y'  'IP
M1^;I&O6KZG8P:C87FJL;+5[?'G0RR.P$<H/)&24R.  /08[.WT#2K6=9H;-$
M99#*HR2JN<Y<*3@,<GD#/)H@T#2K:<30V:*PE,P&2560YRX7. QR><9Y- '"
MVMI;^*='U5]1U.ULKZTU"8SW'D?Z3:%)24VN7X 0*!QC&1R<UIZ;9V"?$77I
MI(8$D6QM9!,85#*[>9N<<<,>,UT5QX6T&ZUA-7GTFUDOT((G:,;LCH3ZD=B>
M:L3:-IEQJ2ZE-8P/>)&8UG*#>%/;/XG\S0!QGAI9M(U_2M,UC3K>2>2"1;#6
M+(C;=J%W,)1U#$#=G)R<X[UK?$[_ )$#4/\ KI;_ /H^.MNQT+3-->-K2T6,
MQ(4B&21$IQD("<*#@<#'2I=2TNQUBU-KJ-LES 2"8W^Z2.F1WH Y?59EOOB"
M='OGLQ"VG+):Q7L'FI(Q=A(5&X#=@+ZG&?>L]M.&D1>&K*+46U;3[74)HY(&
MQF7Y&VA03\XB.>,G&/45U^J>&]&UNVAM]4TZ&\C@_P!7YHW%/H>OZUB>)_#S
MW+Z;!#X>L=4TBTC=38[EA:-S@*RDC&  PQD=<\X& #+ETFVT/0/$^HZI'<6%
ME?7&(([9PLR1L54*.R[G/3L&YQSBYHL9L?B;=6XBM;19='BD>VM3\BL)649Z
M9;'&<#C JWH?@[3X([I9-$AL+*[B$<FG^<9EDYSN8?=!'08_/IC7MO#.AV<T
M4UMI=M#+#$8HY$3#(IZ@'K^/6@#SU_\ D@=W_P!=Y?\ TL-=)XNMX-"U_3/&
M0A01P/\ 9=0;;TA?Y5D^J-CGK@D5N_\ "+:'_9;:7_9L7V%WWM;<^63G.=N<
M=>?K535+35+^X_L-=.@719(T\Z[>XW.R@_-&(R,\@8R3P"3UXH L>&K1$LY=
M2:!8KC5)3=2#;@A3]Q3[A N??<>]<UXI2QU"[\3)'&L]Q::6HN'NV!CM@4=E
M$2XSN/4G( PO4C%=[6==>'=&O=0_M"ZTRVFNC'Y9E>,$E?0^M '&:G$L/A;P
MMXRV">YTF&WENG(W-)"\:B0GU(W;AGI@UH:M_98\+:MK=[YT<6JNBJ]H0DCQ
M;E2)0Q[/U.>SGTKJ8=(TZVTHZ5!9PQV)C,9@5<*5/!&/?)IUWIME?Z>^GW=K
M%-:.H1H74%2!T&/; H Y#1H!!\1M4L9(;6WBGTJ%Y+:U.$#;V7GIEMO? XQQ
M6%@+\ =H.0)\ DY_Y?J]"M_#.B6DT<UMIEO#+%"84DC3:RH<Y (Y[GGKR:;_
M ,(MH?\ 9?\ 9?\ 9L7V'?O^S<^7G.<[<XZ\_7F@# \11V&HZ]J=N(UN+BWT
MK$_VL@P6\;%B"BXR7..3D  +SVK&M(TU>V^',5ZS3K+!,)<N<M_HIX)!SSW]
M1UZUW<_AS1KF]AO;C3;>:Y@3RTED3<P7L,GK^--_X1C0Q80V*Z7;I;V[[X51
M-IC;^\I'(/N#F@#C[?3H]%O_ !IIFF*8]*33EE$()*0S-&^X+Z9 !(]Q[4RW
MO-MCX#T^YEMXK*ZTH8^U1>9$\PBCV!AN S@MC)Z^^*[L:/IXT^6P%J@MIL^:
M@S^\SUW'J<]\]:@G\-:+=:0FD7&FP2V,>-D#C*ICIM]/PH J>%M)@T7^T;2W
MOQ<1M<F4PQQ[8[5F&2B#)P.AVYXS[UE:YIMA<?$[0?/LK>4S6ET9-\2G>5$>
MTG(YQVKJM.TVRTFR2RT^UBM;>/[L<2X J*XT33;K48]1GM5>\A&(YMQ#(/0'
M/'X4 <?I5M:>([#Q6VM1HUY!?SPEY!\]M&BCRBAZJ /F!'?)K-M+9]<NO 4F
MN(TL]Y8W0N [$&91&NW=ZY!R?7)]:] NO#^DWEX]W<6,;S2*$E;D>:HZ!P.'
M'LV:==:)IM[>V][<VB27%K_J)"3F+_=]/PH CNHAH7ABXCTJW"_8;1_LT(R>
M54[5YY/05Y_>V^FW7P\\,ZNBQ37DM[92379P9'E9QYFYNI^;/!]!Z"O4ZPSX
M*\,EI&.B69\R02LIC^4MG.=O0?UH R!'#;_$[5G60PA]#CDDD!)*GS'!;\ !
M^54/#T+:=KFGZ-KVDVLDTMI+%::G:@-%>QX!82J>=V #SD$D^M=E_8.EB^>^
M%F@N)(O):09R8\8V?[OMTI;'1--TYT>TM5C,2&./DL(E.,J@)^4' X&.@H \
MN%A9+\"FGC@BCN#/S(BA7.+PJ,D=< D<UTGB_0-+TFVTB2QM1"TOB"TDD(=C
MO8N 2<GDG _G72OX3T![:XMFTFV\FYD\V:,)A9&SG+ =>>?K4]WH>F7]O;V]
MW:+-%;,&A1R2$8=".>H['M0!S%UHVGZW\2]1MM2MEN8/[)@/E.3M)\R3D@=?
M;TKG;*%K:QT)"S/;VGBQ[6QGD.6-L/,"KN/)&X$?@*])N]"TR^N4N;BT5KB-
M/+$P)5]G]TL""1['BEO=#TO4-,73+JP@DLUV[8-F%7'3 '3'M0!QD\-I-XD\
M=P>5#)&=-@9X]H(W[)#DCUS@_E5.[LK*/X6>&98H8HY!+ITC&,!2S,4!+8ZD
M^]=[:>'M&L;AKBUTRVBE>,1%UC&=@_A^G\ZA_P"$4T$:>FGKI5NMHDGFK"JX
M7?\ WL#OZ'M0!BVPAUCXAZ]IVL01W$=K:V_V*&=0R^6P/F,%/&2V 3[ 5RK0
MRS^'=,M[F262&S\7):64QD;<;<3;1ALYXP0#_LCTKTR\T33;^6&:YM0\T"E8
MY0Q615/4;@<X/<9YIMUH&DWMK;VMQ80O!:L&@BQA8R.A ' (['M0!SNAV-KI
M'Q*U:QT^%;:VFTZ"X>*/A3)O==V/4CKZTOCNSM+G5_"S7%M#*6U58R9(PV5,
M;G;SVR!Q[5TD6BZ=#J9U-+51>,FPSDDL5]"<]/:GZCI5AJ]NMOJ-G%=1*XD5
M)5W ,.A'O0!RNE0V>N>+_$EAJMM#<1VJ016D$B@HENR9R@Z<G.2/0#L*N?#J
M:[E\)1K=RO,L-Q-#;S2'+21*Y5"3WX&,^@K9N]"TN]GCN)[-#-$GEI(F48)_
M<RN"5]NE7888K>%(88UCBC4*B(,*H'0 #H* //M:\W2=7N=3O[&#5M%EU"*0
MW<6!=:?(K(H!!ZH&4=.<$^O+X((K'Q9XYO+&RMS?6UM!+:XB7=YI@<\<=6/7
MUKL/[ TK[2]Q]C3?)*)I!D[7D'(9ES@L,#!(R,"I?[(T[^U?[5^Q0_;MGE_:
M-@W[?3- 'GM[%"/A?H_B'20#K*&UDCN5_P!;/.[JLBLW5MQ9@0?3VK4M(=-\
M2:MXKTW7MAN()_+CWD!H+;RU*.A/W?FW-D=\9[5U%OX>TBTN?M%O811OYAE
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M3$NX/J0RF//7YU]*] CN+7SVLXIH?-B0$PJPW(O;Y>PH EDD2)"\CJB#JS'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11534]2MM(TZ:_N
MS((($+N8XV<@ 9)PH)H MT57L+V+4=.MKZ#=Y5S$DJ;A@[6 (S[X-6* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\3<^%=7S_P ^,W_H!K4J
MIJE@-4TRYL&FDA2YB:)WC W!6!!QD$=#0!3\)_\ (G:+_P!@^#_T6M:]4])T
M\:3I5MIR3R3I:Q+$CR ;MJ@ 9P .@JY0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exh43lgnddescriptionofse002.jpg
<TEXT>
begin 644 exh43lgnddescriptionofse002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO81Y'G1.'#$=ACJ>.E20Z]I[:?:W=Q=06XN8O,"O*.  -W/HI.">@K@%>(^
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M:6RS'"C@'J30!:HHJEJ&L:?I4EK'>W*PO>3+! I!)=V. .!0!=HHHH ****
M"BBB@ HHI"0 23@#J: %HJEIFKV&LQ32Z?<"=()F@D8*1AUQD<CMD5=H ***
M* "BBB@ HJC'K&GS:O)I$=RK7L47FO$ ?E3.,YQCK[U>H **** "BJNHZC::
M39/>7TOE0(55GVEL%F"C@ GJ15J@ HHJK-J-I!J%MI\LNVYNE=H4VD[@F-W.
M,#&1UH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Q7Q)8I_PB["%IBOB"V(C7&6.'X&2!GZD5VM<]XJ\/WNO3:2UM<00+IU]'>_
MO%+&1DS\O'0<]: ,'X@7L]U9Z)%-I%W;(=;M<O,T)4_,>/E=C^E=!+K%W?\
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M/)Q@,21QC\<UB:EX<U2].CR#489)M.N_M<LDL9Q*V&&T 'Y5PQQR>@Z]3TU
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MQM>SK;P 1LVZ1C@#(&!^-7Z\TO\ 6-2U_P '>%M7NH[=;BZURU>.)$9%7YF
M!)+$@D9R.Q'%;::OKJ:AK^C75Y;-<6EDEU;74-L5VA@V04+'."O!S]<]* .O
MZTM>?Z;X@O-#^'WA^_O;@M;7*Q"XNUMRYMD*$[F&3G+ #=T&>E==H5W+?::+
MF2\MKU'D8PW%M]QX\_*>IYQP?<&@#2HKD/%/B#5M'CU:XCEM85LK=9K2$H97
MN0!ERX!RBY^4'CUSVIUUKVM3>)=*TZQ>SA@U+3WN0TL3.T3#;Z,-P^;IQ]:
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MK6>-T;;\S,I*G/R_=[@]?:@#O**Y0ZMK5OJ$6A7-Q%+>^0]S+<VMH2!'OVH
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M))5.'.<_*HX&",GKP,9PYO%>NQ^$?$^I;K+[7H]_-!'^Y;8R($[;LY^8GJ:
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MB:09VR8  (Z]SSC'0YXIW^NS^(?"_AN]NX%@NT\16T%Q&ARJR)*5;'MQG\:
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M.O=0%Z3]E(4' #(1OY! Q[>IKJJ* ,30O#T>CW^IWX\I)=2D1Y(H$VQIM7'
M[DDDD\9_GC:@UP?BW:+9RPK*NB2%EE!(93,O'!XZ9SST-=I5<V-F;G[2;6$S
M@Y\TQC=^?6@#F=0\%3W>AW=G%J$4=W?WJWMU<M 6!965E55W#"C8HY)[^M:&
ML^'I]2NM+U2"[CM]4TQF,<GEEHY PPZ,N<X/;G(K>HH R=,T5K;5;S6+N5);
MZ\1(R8U*I'&F<*N23U))/?T&*BT/PS!HFIZI>0RLRW\_FI$>D.0"P'^\^2?P
M]*VZ* .9@\-ZI;W>N74.K0Q2ZK+'+&RVY_<,@51GYOF!"\CBG0^&)5U74-7,
MEK#>WMF+8B"(B,G))D89RS<@>P&,FNDHH Y"+P//!H>AV\>HQKJ.@MFUNA"=
MK+C#*R;NC#@X-79O#5Q=RZE?W%S#_:-]9?8D=8CY<$7)P!G+$EB2<CH!VYZ*
MB@#DF\(ZB=+\.V0U.V!T*2-PYMF_?;$* 8W\<'GKS4U]X5NM6DA34KNWFCMM
M0^V6\XA(GB42;Q&&S]%SZ#IWKIZ* ,KQ-HI\1>';S25N6M6N5 $H7=M(8-R.
MX.,$=P367'X>U*#7U\07VKP2.NG-:SQQVNQ"H;>"I+';SUSG\.W4TR2*.:-H
MY461&X*L,@_A0!Y_X,T6YU[X::-87=S =-=5>14C/F2*LFX1DYP!N R?3C Z
MU<TPWS_$?Q:-/GME(CLE<3(6P?+;!X(Z>G?/45V4%M;VJ%+:".%"<E8T"C/X
M4R.QLX9S/%:PQRMG,BQ@,?QH YNX\%.NCZ-IUA?)$-,ODOGDFB+F>0,6.<$8
MR6)]JNMX=GF\73:U/<PO;SZ>+%[;RCDKN+9W;O5B.G2M^B@#E- \*ZQHJPZ<
M^O"?1[5]T$/V?$VT'*HTF>5!]!D].!Q5.[\!ZE<:;JFFIKD2VMY??;HBUIND
M5_,5]KMN^9?EQP >G.!BNWHH YU- U.SUZ]U6RU"V+ZA!#'.L]N3M:,$!UVL
M./F/RG\ZK7?@H_V-I6FZ?>K"-/OTOGEFBWM/(K%SG!&,L23^E=710!RMWX7U
M>'Q%<:QH6M1V)OU07L$UMYJ,RC:'7YA@XX]ZZ2T@-K:QP&5YBBX:20Y9SW)]
MR>>*FHH Y$^!?/TS6])O-0\RPU.YDN8E2';)!([A\[LG.& QP.^<]K\>@WUY
M>:;<:W>07)TPEXA#"4\V0KM\QLDXP">!W.<]JWZ* ,KQ/H@\1^';S2#.;?[2
M@ E"[MA!# X[\@51NO#VJ7FM:'JD^IVS2:7YID5;8@3&1=IQ\_R@#IUKHZ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "D/3BEK&\7ZROA_PGJ6I[PKPP-Y1)ZR'A/_
M !XB@#*\.ZMKNNVM[>MJ%A;VJ7\MM:N;1CYJ*VT,3Y@Y+9&*WM(EOQ:+#K$U
ML;\O)Q NP,@<A6"DD\KM)Y[UB>'_  3::;I6A*TMSYVGJLCH;F1HGD*'=\A;
M:/F;=D#J*S[J]L;?XD:EJ#A/,TO350)GYY)),N3Z[51%SV&2: .JUS44T_0-
M0OUG"?9('D+C#;2JYQCU]O>L*YU/7(-+\,0-=*NJ:E/$MT/*7&W87EP.VT C
M\JYR&6*7P'HME<W$;3>(M1%Q?.#P5+&>0?\ ?*JF/PKIC/!J7Q-\EW5ETFPV
MK&>OFS')./9(Q_WU[T =-]H@\MY/.CV(<.VX84^Y[5+7!:=8VLNI^*_"T=M'
MY-S>)(8P@V1QR0QEFQT!R./]K'8&NSU"]@TG2[B^G(6"UA:1N>RC/]* .<TW
M5?$&KZUKL%K>Z?%9Z;<""&22T9B[[ SAL2#[I('%:/A/Q%_PD/A6VUJXC2U\
MP/Y@W?("K%203_"<9K$\%^&8+SP9;3ZE)<O)JH:\ND2YD1)#*2W(4C^$@$=\
M<U-/=Z>OC)=(G:&VT[1[*.:"T "B65V(4JG\6P+@ ?Q-Z@4 =6MW;.C.EQ$R
MJ S$." #R#^-0:=<W,FE1W.HBVAE*EG\F7?&!DX(8@9&,&O-TNK:X^&^LZA&
M(DG\2:@R1J^#Y7FN(T!/0$(-WMFMY[VP;Q9;:/-*L>F:5IT4]O;MUN9&.U"%
M_BVA>!C[S#N!0!K66JW5_P"-[JSMKI)=,M;&.1PJJ?WLC': W<;5)_X$*WI9
M8X8VEED6-%&69S@#ZFN2^'+PWNFZCK**BR:I?RSLBD'8N=J*2.,X7=_P+/>B
MYU>TF\;7\6I3JMOHEO$\%LQYEED!8N%_B( "CT)- '5"ZMBC2"XB*)C<P<87
M(R,_A3EGA>3RUE1G*[]H8$[?7'I[UY6L<>H_#A+:WBB-YXIU;?Y9Y$7F/O\
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M(I9XTDD.$1G +?0=ZEKS[PY;Q>(O#VFRW^I6SM?21W=R(6WSW,JL'"$_P*A
M&T X"]0,Y]!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPP1L9P<=^15F@ HHHH **** "BBB@ HHJM=:C96+PI=W<,#W$@CA61PID8G
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M-/LH].T^"RA)*01A 6ZM@=3[GJ:Y0RW<?Q7OS:6\=Q_Q)X0ZM+L(_>/C'!H
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M4TB.6.X 8LI7RRRNAX/(Y&>E8NO6]X/A)87#1V6]+:TB201G>L3/"-H/;/\
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MIBBMIC+%$WW92V-I&,$CMGJ: .QHKF+/Q1/J6K75G9O:>;9WOV>>RDR)Q&&
M,HYY!'(&,8[YXHM?%$^HZO=6-F]H);*]$$UE+D3^7N ,HYY&#D#&,=\\4 =/
M52'5+"XU";3X;R&6Z@4-+"C@M&#TR!TKG-=\6W^B17-Y/:VT4$%VD,=M*_[Z
MYC+*IE0@X !;I@_=/(JG<OJJ?$S5!H]O:R7+:5!S=2,D:_._7:"2?\Y[$ Z^
M_P!4L-+C22_O(;99'")YC@;V/0 =S]*MUYSKVOMXB^'XN)[7[+=VVK06UU!N
MW".5)T# 'N/\:Z;4O$$ZZI<Z9IRIY]K"DLCRP22KN?.U,(..%R2>F1@'G !T
M%%9OA[5)]:T*VU"YT^?3YY5/F6TZE6C8$@]0#CC(/H16E0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML//BNQ/YOG/M*^?YV/N9SSM_7VK6AT35=*\2W^KZ:MI-%JJ1FYMIIF3RID7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  C^FVMZS2S^<+B?R]@WG&/7O7?V<VI3^'6EUBVAM;TQR>9%#)O1>N,'Z8-
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M;;PRWVH)(X>=B$0*I(&!U)(QU&*S#XX\07.M/X?L=&M!J]K8+=7,,L^49RR
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M$T86W,YW+RJX&0=N/0M77^"]&FT#2)]-EU&.]$5TYC$:E1 K8;R\9/3)/XT
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M+4;53_PC5Y,$E*#F1^%*GV'F'_@24 >G+/"TAC65"ZG!4,,@]>E/Z5Y!X/\
MMGAWQ=I.CZO:PW]O=O-/I.L0CYY R,6W'JP(;)!Y!QU&*[/XG3Z?!X)N3J5[
M=6L#.@!M0"\C9R$P>,''.?3\* .IBN()U+PS1R*IP2C @'\*&N(5VEIHQN;:
MN6')]/K7EW@Z<R?&76H]MM%%/I:/)!;.&BW?NNX #$!CSCN:XA=/LC\+?$-]
M]G0W,&LA(9<<QC*\+Z9SSCK@>@H ^B)I8X8R\DB1CIN<X&:YGP?XMNO$6K:]
MI]U:0P-H]R(-\3DB3EP3ST^Y^M<KJ,K:G\4O"-CJH$]@VF><D<PW)),4?)(/
M!/"_IZU/\*$@B\4^-XK8((4U ",(<@*'EQCVH ]-HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *J:CI=CJUM]FU"VCN8=P;RY!E<CH<5;K)\3ZE=:/X<OM4M!$TEG"TVR
M520X49(X(Q]: +5YI-AJ%C]AO+9+BUX!BDR5..F1W_&J3>$/#KZ>FGMH]JUG
M&YD2 I\BL>X7IG_&N6L_'>OR^!(O&#:997%I\QGM8G=)$17*%@QR&Z9Q@<5V
M&C:]8:YH<&LVDP%I,F_=)A=F."&]"""#]* $B\.Z/#J2ZG'I\*WJJ%%P!\^
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M]T$]ABM.B@#.A\/Z3;ZJ^JPV$27TGW[@#YV]B>XX'Y"IM1TRRU:U-KJ%LES
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MVC$A( .?7( %31HD4:QQJ%1 %50,  =J '4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M13[(L4'G7"%@WE87+#(ZXYZ=: +=%85MKNH2WVGQS:)*EKJ,;.D\<AD,&%W
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ME?+>8AFQL^\0H&WIQUK3\1RV/AKP5<D:0M[86< 4V>1M,8XP=V>!^- &^""
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MK:/*2\,OF"0>8G4E5.1TZ>E '<45G:SK$6CPV^8S-<7<ZV]O"#CS)&SU/8
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M+IR3.;;4C<8:*)F+8,>,LXR<=NE5M?\ #WB+5#XCMFL[:[6]C(L+J6XQY";
M/+5,<$G//&<\G@"N^HH Y/\ LO6T\2Z/JZV=NVS3WL[F/[1_J265@P./F^[C
M [_G5;1[#Q;X?>XT.UL[2YTYIY)+34'N-IMT=BQ#1X)<@DXQ@'U';M:* *6L
M::FL:)>Z9*Y1;NW>$N.J[E(S^M<L=!UG5O"^G^&M4M%A%K)"MQ=K*K)+'$00
M4&=VYMHZ@ 9/7H>VHH YI;'4A\19-6-BWV%M.6S$GF)G>)"^[;G.W!^OM5GQ
MGI]YJOA+4=.L(1+<74)B0%@H&>Y)[5N44 <G/IVJ3>*?#VI#3V$%C:RQ7&94
MRK.%' SR!MY^M9,OA36[NPUI8X5M+Q]9&JZ>\DBLI9=N%?:3C[I]N:[Q[NVC
MN8[5[B)9Y03'$S@.X'7 ZFEANK>Y,H@GCE,+F.0(X;8PZJ<=#R./>@#FKG3]
M<\6^'[_3]9LH=(6XMFB6..<3DR'!#D@ !01TZG)SCBH9-(UC7=.T;3=6LEM3
MI]S#/=3B5728Q=!& =WS'!.X# SUKIH]3T^:]>RBOK9[J,9>!9E,BCU*YR*B
MBUS2+B;R8=5LI)"XCV)<(6WD$A< ]< G'M0!D^&M/U&RU_7[B[LS%!J%RL\#
M^8K<!%7! /!XS7,^&[/4-;^&3Z'!:%$O)KB+[6SKL2,SON.,[MPYP,8Z<CMZ
M2Z"1&1BP##!VL0?S'(JEH^B:?H%B++3(7AMPQ81F5W ).3C<3C))- &%:Z+?
M^'?%5]J%A:-?6&I00K)$DBK)#)$NQ3\Q *E>O.<]JS;CPGJEKI6GI;6RW-U_
M;PU>["2JJ+EBQ12V,G! ''.">*[BZN[:RA,UW<16\0.-\KA5S]34U ',ZS8Z
MS<>)[&ZBLH;[3%MF5K::<((9]P(D88(; X'7')%85KX5\06W@[1K$VEN]UI&
MK"[$8N,"9!(['!QA3A^GM^%>AT4 <Q)INI3>.K;4YK(?9!I;VDK)*IP[.K'
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M>H6UJ;6SW0JJREMH\K<."@SG.2<C'3G&:W_"VF7>C>'+33[ZY-Q/"K NSEB
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MR.#S@ V)+RUANH;66XB2>XW>3$S@-)M&6VCO@=:F)"@DD #J37.W&M31^)=
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M4 7WL/#OB*^AU$QVFH3Z;(4CE5@_DOP2.#C(X//2MBN3\!JJ3>*%4 #^WY^
M/]B.M2]UJ0:['H=A%')>-;&ZD:5B$BCW;0>.22W ''0G/8@&Q5.VU?3;R[DM
M+6_MIKB-=SQ1RAF49QG [9XKF;[Q-=ZAX2\1K%;I::GI44T5S&920F(RP=&
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MVEQIRV9"RL9%(9FW8VX/WL=??VH / 5YJ&H^#["]U&1)9+B(2;USN;)).?\
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MLWEVP.&\RXCB)#L'!PI^5L#:>@YYX .MJI<ZK86=[;65Q=Q1W-VQ6"$M\TA
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M7<$'"X.<#!SM[9XN6NORP6FF:19C;<+I<-Q)*UK+<*H(VJ-L?/)5N21C'?/
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M **** "BBB@ KE/B;_R(&H\9^:#C_MLE=763XHT1O$7AVZTI+@6[S[2LA3<
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M+=)=)'O\UQ%D+LYQU !SU]JO:!H_BC3TALM2UBTNK*S $+10LDTX PHD;)
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M;=K?4DA41KNWQ^6" <XP<[C]*WJ "BBB@ HHHH **** "BBB@ HHHH ****
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MXD*/=R^3" C-N?!..!QP#R>*XC_A-]=/A])S:V2:C;:RNEWL9#;&8LHW(<\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBQX;:/S/+BB?S%9=Y'1 021CVHEDM9[CXAPW%U:7;/81R#RP C,('R57)Y!
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M5=%=7;SF&XCH3C SZ5A>)K_3Y?#?B+["]O:+#K""2.1]T\LR2QAF&3\B@+P
M#P.W2@#U"ZOK2R56N[J&W#=#+(%S^=.:ZMT@:=IXUB09:0N H'N:XR_U*SLO
M'TMS)=6MW%=Z2J"%[B-"@WMC&\@%7YSC)^7D=*R/L<7A#P[X2@N;V%+!;MC>
MWMJ%:,2%'\LDD$$ D#<1_"#P0* /2;6[MKV$3VEQ%<1$X#Q.'4_B*2ZO;2PB
M\V\NH;:/.-\T@09^IK#\-6>D0ZMJUYI>IRW[WC1R7+!XVA5P"!MV* &(Y;\"
M>M4+G5;6Q^)LD.LS100S:8HL7G8+&3O;S5!/&X_+GV H ZR2[MHK;[5)<1)!
M@-YK. F#T.>E+;75O>0+/:SQSQ-]V2)PRG\17!'^SM-U[PA:Z>I7P^)+I8&9
MRT9G(.PY).0<OL/OQQBJVN1W]IJ'CA]&5Q;FPADE6+C$Y!WE?1O+Y..>0: /
M0K?4;&[EDBMKVWGDB_UB1RJQ3Z@'BB+4;&XE6*&\MY)'4LJI*I+ '!( /0'@
M^]<GIT7AC6]6TC4K36FOIDMY(HK>,PX\EE^9945 0HP.#T8CUKG-+T^&'X+W
M&I:;9Q'48X[I1/&@\U8_/8.%;J/D!Z4 >GV^H65W+)%;7D$\D7^L2.56*?4
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M'BG07UI=.R6]U#,RJKE8Y Q"L,J>.Q'3UKAM3L?#]W;>(-3M-6.J7%QHT@G
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M)7,9]5R.#]*KV^NZ9/ID.H-?VL<,H'SM.NT,1G;G.,BLKQ;KMS9Z#::EHU[
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MSQ_VI \:P+_H(5?,C;)RY.<X/ QC'%2+JNFO>_85U"U:ZR1Y F4R<=?ESF@
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MF@"M9:9I^FAA86-M:!_O"")4W?7 J-M%TEY)Y7TNS9[D@S,8%)EP01N..<$
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MF]@Q/)Z'%>HO:6TCR.]O$S2KM=B@)<>A]131862VSVJVD @D^_$(QL;ZCH:
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M.X7ALJ$#E<[BQ)Y&2376^/%+> ]<"@D_89>G^Z:UTL;.*[>[CM($N)!AYEC
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MIZ^IK#-MI]S\5=12_AMY1_9$)19U5AC>^X@'VZUV,,$-O$(H(DBC'1$4*!^
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MXV\+S:-;P))MG,Y@48>V\OJ^.HW$ $]S65H>GQR> _$-QI-K VJ0W5^+:2-
M9(R2P 0]5.T\8]:]"L["WMXF*V-K;R3#,RPJ,,?<X&[\14EO96MIN^S6T,&[
M[WEQA<_7% ' ZBUMJ7@OPE+HI3[6EU:BT\O[R$#$H..P4-N'MS5_7#<>&_&L
M>HV,)=?$$'V-P%R!=("86;V*E@?9<UUL.GV5O<R7,%G!%/+]^5(E5G^I R:G
M:-'*ED5BAW*2,X.,9'X$T <5XKL;73I/!T$:KF#5X8E=@-Q&Q\\^YP3ZFJ>L
MS7>CWNIZK8RV^JZ4]]%_:&FRC$T$P,:AHV'4\(0I]L5WEQ96EV5-S:PS%?NF
M2,-CZ9IITVP-T+HV5O\ : <B7REW@_7&: ..G21/B'X@&F*BWKZ"C1[0 3+N
M?!/OG;^E9-R8M0^#6EIIW&JPO;I;@<2I>"10_N&SO)]B37I*V5HMR;E;6$3G
MK*(QN_/K34T^RCO&O$LX%N6X:81*'/U;&: .0L++3I_B1XH2XMK:3_0[4E70
M'JK[CCWXS]:R/#L-U>^"_"3Z5J\-IJ\%O,ULEPN^*=00KQMW'!7D<@ UZ*=-
ML&D>1K*W+R9WL8ERV>N3CFFMI&F/$(FTZT:,'<$,"D \<XQ[#\J ,[P;?G4O
M#J3O8+8R":9)88VW)Y@D8.5/=2V2*X3QAJ=A<>'?%T5I)!9O'?*)H7?=/<2J
M8_W@!/RI@<8'\).1TKU:.-(HUCC1411A548 'H!4+V%G))+(]I SS+LE8Q@E
MU]">X^M ''/;Z/J?Q6'F16EW%/H6X!E5UD_?$9QT;C//I68D^CW,_B;0?$FL
MMIS27CEK9S$@F@(7RBA9"3\H  !R,#%>B#3[(3BX%G )ATD\L;AVZXS1+8V=
MQ<1W,UI!)-%_JY'C!9/H3R* ((VBLM 1V6X:*"U!*R<RE0G0_P"UQ^=><V6I
MZ<U_X%N+>[L[>T1I1';1R;C;(T+ +(Y.2Q/!Z<@C!QFO5:K1Z?91!5CLX$"O
MYBA8E&'_ +PXZ^] '$PK97%U\08;VY,%M)(B32H>8U,"@M^'/Y50U:Y\2PZ;
MK>CSI!>ZDNCF6UU2R!5IH-X!5E'1\%B,<=<5Z*NG6*&0K96ZF4$.1$HW ]0>
M.:=:V-I9*RVEK#;ACEA%&$R??% '%:RUKJ5GX,NM!*>:+Z VYAQE;?8?-''1
M0HP1ZX%:GQ(ENH? FHO:J[8"><(_O>5O7S,?\!SGVS6_;Z?96DTDUM9P0RR_
MZQXXE5G^I YJP0",$9!H X35-3T6Y\<>#+FRO+-T*W*H\;KPC0_*/8$\ >M9
M&ES:/J_AR32=?UNYAU*WOG::P5HDF:X$I93'E-[$DC!![XZ5Z3!I>GVI4V]A
M;0E264QPJN">I&!WQ3C8V9O!>&T@-R!@3^6-X'INZT <)JTMWH][J&IV4MOJ
MVD2:C%]OT^48GMYPR*&C8=3D(0I]L5JZ:L$?Q5UE8E16?3;=G"@ D[WR3[XQ
M^E=+_9UC]J%W]BM_M .1-Y2[_P \9ILVGP-YLMO%#!=NK!;D1*75B,9]Z /,
M])&GZKX=TG0'U?3'^PZJ9S<R72;YD65V_P!63NWMG!!&,$G)Z5N:?8:9)\0?
M%L<MK;,HL[7Y61< %'W<?EFI;;PCJ,UB-.U33O#TR>7Y;WXA9YI.,%RK+]\]
M<[CR<\UU4>DZ=&N!90$E=K,T8+,/<XYH \RTC5!8Z#X%NKZ_DM-.^SSPO=+M
M*Q38 CW%@0/E#J#CC)Z"K6M?V5IFGI>Z;?2WVE7&O6\VK7&Y7A(Y+$; %QN"
M;L#&<#KD5Z-_9UC]E>U^Q6_V=SEHO*78WU&,'I3UM;9+7[*MO$MOMV^4$ 3'
MICIB@#CH[[39?C!#+;W5L[3:$Z;HY%.]O.4@9'4XR?I5KXC.L6AV$TC!(XM6
MM'=V. JB49)/85TEOIUC9E3:V=O 57:OE1*N!G.!@=,U--#%<1-%-&DL;##(
MZ@@_4&@#D+._1_BA<?:94:&ZTQ/[-DSE'4,?-"GH23M)QV /2I?A_ ]O;:TL
M?&GG5IS8@?=$>1G;_L[MV,>]=+<V%G>PK#=VD%Q&IRJ2QAE'T!J9$6- B*%5
M1@*!@ 4 <#>7]C%XVU_3M>UAM,BNX(?LQE,2QSP>7AE#2*>CE^,]S4*:;I-O
MXJ\%6MNAFMEM+L1-= %Y$ 3RR>.1W7(Z8KOKFQL[TH;NT@N#&=R>;&&VGU&>
ME+)8V<TZSRVL,DJXVR-&"PQTP: /+KF86&B^)3#'FPM/$Z27D,0_Y=\Q&08'
M8XY'U]ZZ'7[G2]5TS6=1\+RQWFL2:4T9N+.7?MCZA3@X#G+8XW<>U=?#865O
MO\BT@BWC#[(P-P]#CK2VMG:V,1BM+:&WC)R4BC"#/K@4 <+JK6NI>'O!MQH9
M3[0M[;?9?*QE(PO[T''10H(8>W-5YKZSLX/B':7-Q%%/*TC)"S .X:V&"!U.
M:] @T^RMIY+BWLX(9I?]9)'$JL_U(&32R:?933M/+9P22LAC:1HP6*'JI..G
MM0!YW FFWNJ_#LR"VG233YE;.U@Y$$> ?7!SP>]2>(;K28)?%>EV:VFFO#I:
M12A_O7 \IRB1)G"J-V"0#R>@QFN_;3K%W1WLK=FC ",8E)4#ICCBGO9VLD_V
MA[:)IMI3S"@+;3U&>N/:@#SW^U;.T/@?59-2MF5+%XVBEG5 V8D#,K,0NX'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFOKF&&7/%E<&9R&;G!#*<!OX?8$Y /1_MD3Z^J)K4&P6C.U@-A8_,/WN?O
M''IS2_\ "2Z$7@0:S8EKES'"/M"_O&!P0O/)SQ]:P99+;_A;UOAXMTFA29Y'
MS?OEQ]> :Y*7^SQ\(=;EC^SAUU20AUQD$70V\_3I[4 >J7FI6.GX^V7<,&X%
M@)' ) ZGZ#N>U/M;VTOHS)9W4-R@."T,@< _45QFKZQ8:+\0OMLNHV6+K253
MR[NX$*J!(2I5SD$-SD#IC//2MGP+I]KI?A"RL[2_MK]8PVZXMF#1LQ8D@$=0
M,X'L!0!8@\4Z5<>)+C0H[J+[5;HA8&0#<S%OD [D!<G'3-6_[:TLWHL?[0MO
MM)8H(O-&XL.JX]?;K7*BY^S_ !$\1V\<Z17MWIMO]C5V ,C 2#*CO@XSZ5B.
M\.H?!BWT^WXU>%HX4@SB=+Q91GCJ&SEB?0D]* /4NE4[76=,OK@V]IJ%M/-M
MW[(Y0Q*YQD =1GC-,U>9+3P]?3W<+7*0VDCRQ1\&0!"2!]>:X&PU6PE\2^"I
MXK^T,/V2XB2"W.8[?,:;(MQR6?MR<DCH,T >@OK.F17JV4FH6RW+-L6(R@,6
MQD+CUQSCK2WFKZ;IT@CO;^WMW(SMEE"G&<9Y[9[UPGA;5=#NO#$&AZ]Y<FLV
MEZQFL7.)I+D2E@ZCJ<DYW= ,YXJ2QUJPMIO&.G:Q<QPZE+=S%(ICAYX#&!$$
M'5A@8P,]?>@#MH]8TR::WACU&U>6[3?;QB92TRXSE1G+#'.14<VJZ?<:?>M:
MZS:1&!622X65'%L^."W. 1UP:X.QN8+"S^&U[>2I!;1V[H\TC!44M;84$G@9
M-21W]A=Q?$3;/%(K1F102/F7[, &&>HST/0\4 =O#JMC:6%B+W6+:1YXE*3N
MZI]H^7)=1G&#UXX%*?$&CBPCO_[4M/LLP)CF$RE7QUP<\X[^E<+>O8OHOPZ:
M=X"AEM\ER,8$!_KC\:OZC?67A_QZ8M0O#I%A=:>BV<R*B0A@[F1"64@$[E/;
M.![4 =Q!/#<P)/;RI-%(H9)(V#*P]01UJM=ZSIEC.L%WJ%M!(V $DE"GG@=?
M4\#UJEX2L]-L= B@T<S&PWNT+2G.X%B25_V2<D>W(X-<KINK:&I\2Z!XJ>-;
MB;4I7:WFR&NHF(\K8!RWRA0 .>!0!W-[JFGZ: ;Z]@MMP)'FR!<@=3SV&>3V
MHEU73H$MWEO[9%NF58"TJ@2D] O/S9R.E<MI-T+/XBZU#J8%N+JRMFL!,1CR
MD4^8@/3AR20/K7+M:Q6WAC2ENA&-/D\6JUBLN-HM3(VW&?X2,GTP: /2H_$>
MB36=U>0ZK:306?\ Q\213!Q']<?Y-5]+\6Z-J>E6E^NH6T2W154C>==P=NB$
M9^]R.*P,P+\1/$$$!C#2Z+$3&F,NP+CH.IP1^E8,E[I=U\,O"*/<6\BP7UC'
M-E@0A##>I]"!G(]* /2(]=TB6R^VQZG:O;%S&)5F4J7'\((/)]JK:KJ@E\*W
M^I:/?0NT5M))%/'B10RJ3].HQ6'J;0Z5\1=$FE2*#3)[6>.%PH6-;EB"23T#
M,HP#WYJEY?E2_$"\@95TR:W&Q@?D:80-YI7MU*@^_P!* .O\-W<]_P"&-*O+
ME_,GN+*&65\ ;F9 2<#@<FI;O6=+L)A#>:A;6\AQ\LDH4C/ SGID]/6J7@UU
M?P5H91@P_L^ 9!SSY:US6BW-HEEXQT_7WC2X-[<23I,0#) R@1L,]5VC ^E
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M?,!A4$9'(&<Y(Z<U8TO4K63XFV,HU2UNA/HKQ(UM@1;O-0A$ZDX&3R2>IX%
M'4Z%XITK7]*?4;6[A$,;/OW2 %%5V4,P_A!"[AGL:O66J6&I>8+&\@N3"=L@
MB<,4/;('2O,+'45M_A=IICF9ETS5/,U..##20Q"XD.2N#T.UL$=LUV/A]M U
M#Q#-JVE:E)J=U):B*>='4QJH8%5;: -W7'? .>U &_+JFGP7T5C-?VT=W,,Q
MV[S*)''LI.3TJ*'7-(N(KB6'5;*6.USY[I<(1%CKN(/R_C6)X[B:TLK+Q' A
M:;0[D3MM'+0-\LR_]\G/_ :Q(8=1MO$MQI\D+BW\6Q?:2 N!;E3B53Z$PE1G
M^]0!U_\ :%O<:Q:&WUVV,36[O]C0HQF!P1(&SD #/3@YK#U/QI;ZAX6UZ\T#
M4(4N=,678WRNS;%!+;3_  [C@'!''O3M1-O%\5M$4&-'.G7"X& 3RF!^A_6N
M>%]:Q>"/'MG)<1K<"^U!S$6^8*Q^4D>AR,>M '=Z/KMA?)!9_P!I6TNHBV22
M:!9%\P94$DJ.G7]:U'=(XVDD8(B@EF8X 'J37 RM96WB#X?F$P1!HIU!4@9!
MM_ZMC\:U?B1]H7PFTL,;R00W,,EVB#):!7!<8[C Y]LT ;UKK.EWIE%MJ%M,
M85WR!)0=B_WCZ#WZ4TZ]HXLDOCJUB+5WV)/]H3RV;.,!LX)SQBN=U,Q:EX\\
M,7FDS1S%(KAKF6%@P^SE!MW$=B^,>^<=#7(7FIV-O\*=7TR6ZB6]AU-_,M]W
MSIB[#9*]0,8Y/'(H ]0O-?T;3Y)([S5;.W>%0TBR3JI0$X!()XR35;Q;>W=A
MX2U._P!.N%AN+:U>:.0H''RJ3T/':L#;I5_\6Y%D%I<I+H*;5;:X<F9\X'<[
M?TK<\:H6\#:XB*2?[/F  '^P: )='U_3KY+>S_M.UFU'[.CS0+*OF E022HZ
M=:M7&LZ79W(MKG4;:&8D#9)*%.3T'/3/;UKB;NSL+V/P4=%2W:]AN892]MMR
MMN$/FDD?PG@>Y(J+3)[9O!'BG3-:*"_2>[^U12??D9\F-E'4Y&T+CT&* .]O
M=4L-- -[>06^X%@)'"D@=3]!W/:FRZQI<"0/-J-K&MR,PEIE E&,Y7GD8YXK
MB+&^2RO]+TS5I(K'5AH,:SWEP=TDH)P88U)P7W#)."3TP>V+IMQIT_A'X?K-
M+ _E:BJ2;R/EPLG!S[E>/<4 >G#7-*>PBODU.U:VG)$4PE!5R,YQSSC!Z>AK
M)\$:Q=ZS9ZK+=7J7BP:I-!!+&JA3$NW;C;P>N<^]9TMY::)\3XX[\PV5E+I9
M2P=L1Q"3S-TJ@] Q^4GUP*D^'-Q:2Q^(DM98F4:Y<N%C8?=.W!P.Q[&@#J;W
M4[#355KV\AMPV2OF.%SCKCZ5E^*/%%KH/A6YUF&>WF(A+6H,@VS-CY<8/S#O
MQVK-M;K['\4=434G6-;NPA_L]Y#A2B%O,52>^Y@2/3!KF+V(VGPE\5Y8)8S7
M\[:<"<+Y)D7;M_V2VXCU!SWH [W1!>2W$EV->CU2PEC4(H2/,<@^]AT !7V.
M2/6H/%^OQ:3H&I-;:I;6NH06KRQ*Y5FW!25&T^I&!GK6[!(DL$<D;JZ,H*LI
MR"*\RCU6S7P1XTTW5IX8M6$EZTL,S /(2I\ME!ZC 4#'H* .SM+][@: 9=:B
M@GN(!)):,J;[PF+/'<8.6^4=JN_\)!HIN%MQJUF9GF\A4$ZY,F,[ ,]>1Q[B
MN-%U9RZU\.IXYH6+03 .&'_/MC&?KQ]:M^$X+"X\1^+/+CM9+B/4@T>55BA$
M:X(],-GGUS0!U9UG2Q?K8'4+873$JL/FC<2.HQZ^W6BZUG3+&=8+O4+:"5B
M$DE"GGIU]>WK7G?AZZT/5O#VFZ3J^I77]K6-PN[3<JLPN48_, %W'))8MG')
MR>M7-,U70MGB/P_XJ>,74NI2N]M-G?=1L08B@'+?*%  YX% '6#Q3I1\2MH
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M!\S8SA1WH D^RV^5/D1Y7[OR#BE2W@C),<,:$C!*J!FJUMK&FWBS-:WUO/Y
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MKRZB@#DA?,<+N(&3CUXH F95=2CJ&5A@@C((H*J6#%06' ..17+^*M;FMX=
MOM+U-!:7>J00RM'L=)8F)S\W..G4'UK8T_Q%HNK13RZ?JEI<I;?ZYHY01'[G
MT'!YZ<4 7C!"T@D:)"X_B*C/YT-;P,6+0QG>06RH^;'3-<;XBU:\LOAM<ZKI
M/B'[;+%)E+U$C(D!FVE>!C@$C(]*Z*ZNX!X@LK;^V4@EV2%M/&PM.,##'/S
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MY\4:=_PE!\/^:/M"P>:Y/ !+ *H]2>?IBM>66.")YII%CC0%F=S@*!U))Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>>+-%NBCRS:M.\ELW4Q.B#)']T\\]ZB\)07YO5T"_1VB\,R,L<S=)PRX@/\
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MVD-C906=NNV&"-8T'H ,"N TN\M[+P]XGT37&5=0:YNF,,GW[M9,E&0=7SD
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MIR."'P ,C)*].*I:=J]E=:SX(O([H-"J3Q&"" B*U8PX$0XR6&,$$D\9P,T
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M$L?&?@FWO[R(W,%K<I.S./OF) "?3<0<9ZUW= !1110 4444 %%%% !1110
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M>@VRVC3:G"GVV$SVXYS(FW=N QZ?GTZTT^+M"^R+=+?^9"T N=T<3OLB/\;
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M "BBB@ HHHH **** "BBB@ KE?B+'>-X92:U@DN$M;R"XN8(QEI(D<,P []
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#$U'0)[_Q-I>LK?)$NFK*JP&#=O\ , #9;<,<
M 8XK;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQVAL\@EB<8'..>*Y^,W^D7)U>WGT+7!>W0F$:(%NAO(&V)UR'V@]2HR 2<4
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M?FP<D ;0,D>F&3^#9GT31[2WU00WFCR));3_ &?,?RILVF/=]TC_ &LYYS0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4:00QNSI$BLWWF5
M0":DHH **** "BBB@ HHHH **** "D(# @@$'@@]Z6B@!%544*H"J!@ #@4M
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%9=[;ZS<:B/LE]%:6:Q#.8!(SN2<]2,  #ZY]J -
M2BN)\'ZGXF\1^%],UUM0MMUQ(?.M_LH V"0H<-NR#@9_2K/ACQ2CV]W'KVKV
MJW(U6XM+?S&2(R!&V@*O?]>M '6T55OM3L-,0/?WL%JIR09I F<=>OI4\4L<
MT2RQ.LD;@,KJ<A@>A![T /HJD^L:9%>"SDU&U6X9P@B,RABQ&0N,]<=JP(?$
MK6'C#7+76=5MH-.M8;=X#+MB5"^_(W'J?E'?MTH ZRBLO4[V)K2TEM];MK%9
MIXRDS;'6=21\BY.#N' (YYXJ@-3OU^(_]DO<*;!M):Z$0C (<2JN2W4\9_.@
M#HZ*YRY\2V6@Z#J6KWVM0:C##/)Y?E!1M/58!MSEATR>><FM2+7=(FEAACU6
MR:6<9BC6X0L_T&>>AZ>E %^BH([RUENI+6.YA>XB ,D2N"Z ],CJ*SKSQ1I5
MCK]MHL]W$EU/&TA#R!0@&,9SW)/ ^M &Q15*YUC3+.X6WNM0M8)F( CDE53D
M].">_;UJ[0 452&L:8UZ+(:C:FY+%1")EWEAU&,]1Z4HU;32EPXU&U*6IQ.W
MG+B(_P"US\OXT 7**Q-1\7:-IMWIMO+?6Y.I$F)Q*NT(%+;RW3;Q@>I-9MEX
MF-IXH\16^M:M:PV%E]E^S-+MB5?,5F(W'J3@=^U '6T5!-?6EO:BZFNH8X&Q
MME9P%.>F#WSVJ)-7TR2P:_34+4VB9#3B9=BD=06S@4 7**Q-2UO3[C3;M++Q
M)8V,\03=<%XY/(W<C*DXY .,U?NM7TRQF$%YJ5I;RE0WERSJC8.1G!/3@_E0
M!<HJDNLZ6]D;U-2M'M0VSSEF4IN],@XS[5-9WMKJ%LMS97,5S"WW9(G#*?Q%
M $]%5AJ5@9YH!>VYEMUW31B5=T8]6&>!]:C_ +9TLVT%R-2M#!</Y<,@F4K*
MV=NU3GDYXP.] %VBJECJVG:FTRV%_;730-ME$$JOY9]#@\=ZYWQ5XG^QW6D0
M:5JUJ)9M6@MKF%=KNT;/M<>V.AXR,]J .MHJE>:QIFGRK%>ZA;6SOC"RRJI.
M3@=3W/%.O-5T[3CB]O[>V^7=^]E5>/7GM[T 6Z*S9;@-KMI$FKPQ@Q.6L,*7
MGZ8<'.X!>>@P<U+<:SI=I,8;G4;6&0$*5DF52"1D Y/7'- %VBJ$NN:1 2)=
M4LTQ%YQW3J,1\#=U^[R.?>I$U73I-.744O[9K)AD7 E7RSSC[V<=>* +=%9=
MUXET>TT>YU9]0@>TM<B5XW#88?P\?Q>W6GVFNZ==:/#J9O+>."15+,9E*HQ
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MK$*5^Q6^TG)'E+@G\O<T <5=:U:V/CFZ&L:L=.MK_3X#97!\OR9%7=O7<ZD
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M"* *?_"2Z']CEO/[7L_LT,GERS><NQ'_ +I.< ^U3MJVG(\"->P*URI:$&0
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MI')>D=$7!"NW^RK$'\JAN/)N/B(VI6<T36D6CNE],K QDE\QJQZ9QN/T^HH
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M]1]:[7PE;Z3#97<VBM+):W5V\YF=BRS.P&YD_P!G/''&0<4 ;U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %)UI:BN;F"S@:>XE6.-< LWJ3@#W))  [DT +';PQ ".&-, @;5
M P#UI?)BQCRTQ_NBLY_$FCQ6LUU-?)##;R".9I59/*8@$!LCY3R.OJ*M'4[)
M=2736N46[="ZPDX9E'4CU% %@HA0H54J1@KCC%"1I&@2-%1!P%48 J@VOZ4E
MZEFU]$)I)/*0$_*TG]P-TW?[.<^U%[K^E:=*8KR^BA92H<L?EC+?=W'HN>V<
M9H O1Q1PILBC6-<YPHP*7RTV%-B[3G*XX.>M5-0UC3]+7-Y<K%\I<C!8A1U8
M@ D*/7I22ZUIL4,,QNT>.>/S8VBS)N3C+_+GY>1STY% %I(8HXA$D2+&.B*H
M _*E\J/84V+M/48XJF^MZ<EO!.;I6CN8O.B**6+1X!WX )V\CGH,BK5M<PWE
MK%=6TBRPSHLD;KT92,@CZ@T .CBCA0)$BQH.BJ, 4XJI() )'(R.E9]UK^DV
M4[0W-]%$RL$<MG;&QZ*S=%)R, D=165XI\1+INHZ3I:7!@:_N"LTJC+)&$9C
MC@\D@#/IGZT =$T,3RK*T2-(GW7*@D?0U)6?I%M<V-BRW>IO?KO9XII4",L9
MY"L1P2/[V!FDM?$&DWLX@M[Z-W:,RH.0)$'5E)X9?<9% %[RHP"/+7!ZC:.:
M1((8X_+2)%3^ZJ@#\JR6\8^&U\LG6K/$DODH1*""^<8S]>_2KHUC3VU4Z4+N
M,WRIYAM_XPO]['I[T 6HHHX4V11K&O7:J@"D2"&/;Y<2)MSC:H&,]:CMKZUO
M))X[>99&MW\N4#^!NN#[]/S%5[[7M+TR1X[R]CB:-0\F<GRE)P&<C[H)!Y.!
MQ0!=,,1E$IC0R 8#[1D#TS536K6>_P!%O;.V,:RW,#Q*TA(5=P(R<#MGI5+4
M/%6GZ?KMAI#OF6\1Y-P!*J@'!R.I)(X_^MDTGQ38:QJNH6%NQS8R",LP(WG;
MEB,CH,X]_I0!-X<TI]'T.RLKA(#<6MM';M+$/]8$4*#R >W2M-8T4Y5%!]0*
MSX/$.D7-S]FBOXC+Y9E4$[0Z#JRD\,H]1D57'C#PX1 PUFT*W$GEQ,) 0S9Q
MUZ=01GH: -<0Q"4RB-/,(P7VC)'IFCRX]V[8N>N<<U0M?$.CWM]/8VVHV\MS
M;KODC5^54'!/N >"1TJK)XU\,1-$'UVR'G.8XSYH(8@X//3&>,]* -GR8O-\
M[RT\S&-^T9QZ9I1&BDD(H)ZX%8[>*+ >*?\ A']Q\\0>:S%3@$L%51QSGGZ8
MJ3Q+XAM?#.C2:C=!FP0D:*"=SDX ]AD]: -141/NJJY]!BD6&)'9TC17?[S!
M0"WUJI+K&GPP13/<C;.2(@%):3'7:H&3C'85-8W]IJ5JMU97$=Q"^0'C;(R.
MH^H]* )&MX7<NT,;,1M+%021Z5)5._U6QTT#[7<+&64L% +,5'4X&3@=ST%<
M[KFO-!K_ (9N+35E&E7SS&;:4,4B+$S!MV,_KB@#JD@AB=GCB1&;[Q50"?K3
MPJJ20 "3DX'6L^T\0:1?:=-J%MJ,#VEN66:;?A8R.N[/3\:(=>TJ?[1MO8T-
MLH>82YC,:GHQ#8(!]>E %V*&*$$11)&&.3M4#)]:411B4RB-?,(P7VC)'IFL
MJ#Q9X?N;FUMH-7M9);L9@0/S)]/Z>M6;W6M-T]W2ZNTC,:"23@GRD/ 9R/NC
M@\G X/I0!<\J/G]VO/7BG*JJ,*H ] *HC6]+:S6\BOX)H';8CPN) [?W5VYW
M'@\#TJ73]1LM5M1<V%S'<0EBNY#T8=0?0CT- %G W!L#(& : J@$!0 >O'6J
M=_K&GZ7_ ,?ERL1VE]N"Q"CJQ R0H[GH*675]/AM8;IKN-HKC'D-&=_FY&?D
M R6XYXSQ0!9$: $!% /4 =:/*CR#L7(Z<=*SW\1Z+'I3:H^IVR62,5:9I  &
M'53_ +7MUI;;Q%HUY?RV%MJ5O+=0IYDD2ODA1P3^!X/I0!H*B)]U%7Z#%*5#
M## $>AKGM.\<:)?6-Y?27<=K;6L[Q%YSLR%.,\^IS@=:OP>(]%N4NWAU.V=;
M(@7+!QB(GIGZ_P#UJ -(@$8/(IL4,4";(8TC7.=J* *J6NJ66J>?;V=YB>(8
MD4+MDBST)5AD>V1@UE> -0O-5\&65[J%PUQ<R/,'E8 %L2NHX' X H Z QQD
M8*+@G.,=_6CRH\Y\M<CVJI?:QI^FMMN[E8VV&0J 6(0=6( )"^YXK*\6^*(M
M&\)RZK93Q2/*J"V=?G5MS*NX8X(&[/OB@"YK^D76I6,4>FW<5G-%.DW[R+?'
M+MYV. 0=I.#P>PJO8Z)>27UO>ZJFFK):L7B%E;E3N*E<EV.<88\ #ZFK&D6\
M\<MQ=C6)K^QG"F*.:,;HF&0Q#  D'CC'&..M2GQ%HZZ?+J!U"$6D,ABEFS\L
M;CJ&/8CWH T2 001D'J#3$@BBC\J.)$3^ZJ@#\JJWFLZ?8?\?-RJ8C\UL*6V
M)_>; ^5?<X%7(Y%EC61#N1P&4^H-  JJ@PJA1[#%))%',ACEC61#U5AD&J>J
M6VH77V:.QOC9*)<SR+&KL4VGY1N! ^;;SCM7+://X@U?4/$5DGB&>)]-N!#;
M,;> @Y3.7&SGGTQ0!VVU0FP*-N,8QQBD\J/(.Q>.G'2N/M_$C:5XNUN'7-6"
M65O;6SQ+*% C9PY8+M )Z>YP*ZAM4L5L8[[[5&;:8*8I%.1)NZ;<=<]@* +*
MQHGW45<^@IJ00QQF-(D5"<E54 9^E4X-=TNYLI+R&]B>&.3RG(/*OD#85ZAL
MD#;C/(I\.L:?<6]Q<)=(([5MD[293RFP#A@V,'!!Y]: +BJJ#"J /0"D,:%M
MQ1=WKCFJECK&GZE+-#:7*R308\V(@JZ9Z$J<$ ]CWI]YJ5II_EBYF"/*2(T
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MU6V26U ,R;P63.< @=^#QUH TO)BQCRTQ_NBCRTW!MB[@, XY ]*R_\ A*]
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M;AGD9&1[UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5@>,H[&;0Q%?WTNGH]Q%Y=W&P!@E#91LG
MC&X#.?TZUOTG6@#S#6+C5[[P'XLL;[[/?S6?E8U"S3"W:_*Q) XW*HYQQT]*
MT[G6]/U7XAZ#/IMXDT<EA=)',@)0N=F!G&"1W].]=X%"C:H  ["D"JN,*!@8
M&!0!YYX0UG1Y_#^G>'-4MO,UO3YPKV,L1,BS*Y/F].G.XM[FETS6=)LIM?\
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MRL+U)W8Q]/:O4FSM.T MCC/2L+PKH5SH5I=0W<T%PTUW+<J\:%=OF-N*\^E
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MV1FAOI+=F+6[L"$9MO( Y!]F]Z]=I" 1@C(- 'G]S#X5O=-N[RQO[JSBOKR
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M_"@"%M>>Z^(VF65K?7'V66RFDEM9(C& 1MVMAE#$')YY''%;K>(M)2]BM&O
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MW/%9ESXPT^'5]+T^,2R_VC$TZ2I"Y7RPN01@<DY'T'7'%<HUA<:79:1&-?\
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M!E[J%[HCOJ44 GCN98_/MUVQW(#?ZU1Z-S]>O>LV*ZMX_BQ?,\T:*-'C4LS
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M(QU%:OAJ:UD\?^+0KQEY);8H>,N%A4''KAN#Z&@#I-5U?3]$LFO=3NX[6!2
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MOR,KJ0,#H<\DGO6KIU@MA%(#(99IY#+-*5"[W( S@<#@ ?AW/-7** "BBB@
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M=2M-)M&N[Z7R8$Y>0J2JCU.!P/<T7.I6=IIS:A/.%M%3S#* 64+C.[CMCG-
M%JBHX)DN(4FCW;'&5W*5./H>:DH ***BFN8+;R_/GCB\UQ''O8+O8]%&>I/I
M0!+1110 445%/<P6RHUQ/'$'<(ID8+N8\!1GJ3Z4 2T444 %%%% !1110 44
M57OKVWTVRFO;IF2"!"\C*C/M4<DX4$T 6**AM+J&^LX;NW8M#/&LD9*E25(R
M#@\C@]ZSI/%6BPW=Q:27NV>VP9X_*?,8/(+<< CG- &O145M<P7EM'<VLT<\
M,J[DDC8,K#U!'6I: "BBB@ HHHH ***CN)TMK=YY=VR-2S;4+' ]@"3^% $E
M%5=-U&UU;3H-0LI#);7"[XW*%=R^N" :M4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYT+6;87^=1UH@W-VT?! P @4'A N5 R3R3DU-JNC22:CH-U-JT%NMA)(-KQ
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MHTJ\-O$[(X60@JNW ;EBS8X(QC)ZBNEFU:XFU=='L4B%TD(GNI9 72W4Y"C
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M-?633VSW2,1-*,?N@01M..3UZU'%X.DDT&P\/WUW')I=EL#)'&5:Z5#E%?G
M' R!U(ZCI4]_X;N]62.#4+N*2&'4%O(9%C(EB"ON5 <_AN]"1CO0!8&K7EQJ
M2:1:K +R&W2:^F92T<!;[JA0026(; SP!GG@' N_$FHZE\.KZ^9(8[B_G>QL
M!#GYM[^2K<GKG<WTQ6E-X6U$ZGKDUMJR06^L(I8>23+&ZQ[!A]WW> >F>N".
MM1IX.NX](\/Z>FI1*NCRI(V+?ARL94;1G@@G=DYYYQCB@"2ZU-] U#2/#5GY
M%M%+9LEK-<(6222,*%B&",$C)R?P%=%9M<-90-=JB7)C4RJGW0^/F ]LYK"U
M/PW=ZS"UI?WD4D'VY+J&18R)8 C A5.<9X(W<8#'BNCH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN+6WNX
M_+N8(YTSG;(@89^AIT4,4$2Q0QI'&HPJ(H 'T I]% !1110 4444 %%%% !1
M110 4444 1PP0V\8C@B2)!T5%"C\A4E%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5'-!#<)Y<\22IG.UU##/XU)10 E+110 4444 %%%% !1110
M5')!#*R/)$CM&<H64$J?4>E244 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 5WL+.6Y6YDM('G7&V5HP6&.G/6K%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MROQ(E\_P?<Z5;+YU]JFVWM8%.6D8L"3] ,DGH,51M1;Z%\1;."\NHHDB\-I
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M5K^N7%K?PZA*UQ:(T23&82ED,>4WL2-H&"?0<5WWB.&.;PQJ<<T:R*;27*N
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MQCCFN[O;.#4+&>RN4#P7$;1R*>ZD8-1C2].%W]K%A;"YSN\[R5WY]=V,U;H
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M\T0QF1IR%:'&#9^62_3^'[N/<CO6QXNMEO-%%O\ VC_9TKW$)M[@J&590X9
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MV%S)#YKZ@\A@<C)3R4^8K_=]^E '3Z==QPZ%!<WFKV]XJI^\OQMCCDYQNX.
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M((7<89HXPI;ZD5%IFF0:9'.(50-<2F:4H@12Q 7A1T&% _#G)YKE-7\8M?\
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MFI(]FDAP1!]J5EQGMM!;Z&O4YK>"XV^=#'+M.5WJ#@^HS2O'')C>BMCIN&:
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MD&L:)?:BZQ6\@ N;"9MY;!'WE7+YSR ?QJE876BWVC7WASQ)?W2:C'>R^;8
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MWDV-K<7:B]N;99%3^-A@9;'UKE?$VJ>']0\'^)M2THPR?:+$QS7JC"S.%(1
MQ^\0#VZ9%,\(Z[!I>J_V9K%W;O-J$"7%A?[P!-#C B/. 4.0 .#R>N<@%WP[
MXK@M8]2B\0:U%YJ:Q/:V[3E4)12 HP !^..IKJ;W4[/3]@NIUC9\E$P69@.I
M"CD@=_2O+Y[S39OAYX[=)[9FDU.ZP=RY?+ I]>^/TKH++4HK3Q^E[?7,8LM0
MTB)+&Z9QY996)= W3<<[O?'M0!?\;:W+%X N]:T+4PI15>*>#8ZN"X4CD'U/
M3D&NAO=1M+!4%S<")I<B-0-S-@9.%&2<=>E>8:S&+/X<^,;@NL=C?:FTEB"<
M!U+IED]BP8C'89Z&NAN-9M=,^):WFJ7<4.GWNEK'8W;N!#N#EG7?T!/!]\#V
MH N>"]=>]TG5KW4-36Y@MM4GBBN7V*OE*0$Y4 =#^.:V5\2:*UO<SG4K>..T
M(%P97V&(GIN#8(SVSUKS:.]2/0=2O;82R6EEXLDN;M;<'>+?<?F '/!*M_P'
MVK7U.Y\,7OA_Q)K&DW3W4DNCS037CRN4)V'9'\W!;/8<COU% ';:?KFE:K/+
M!87\%S) JM(D;9*!AE<_6H[KQ'HME<36UQJEK'- GF2QF0;D7.!D=NHXZFH?
M"1LY/"NERV9A939Q*7BP1PHR,CT.?QS6(;FR7XQR;YX!(FA*.6&0?.8D?7;S
M]* -W_A+/#P6T;^V+3;>X^SGS1A\G ^G((Y[@BK5_J^GZ6N;VZ2'Y2^#DD*.
MK8'0#N>E>6SW6G#X-:\(9[8$ZA+@*RY)^T97] "/85O7NM:9IOC>^DUN_DMK
M#4[2!K"[CD(AD50VY-R\9RQ(^ON,@':RZMI\-I%=-=QF&< Q,AW>;QGY<9W<
M<\=JS-3\9Z/I]A8WJ74=Q%?W4=O"T1W EG"L21TVC).?3'6N3FETOPMJ6@SN
MM[8>'6LY[>WF+R?N':4."Y/S .!QGVZ8.%UE-&L_#]CJ6E"1--/B2VO)[F5F
M*/EQOE!;HN>,],@XH [(ZC93:_;I'KB!OLKN; %3O4X(D/\ $,#\.:0^,/#:
M^7G6[+$LIA0B8$,_3&?KWZ5AWFHV,GQ2T9UN8OGTN?&6 )RR%>OJ 2*Y:XNM
M.?X8^--D]L6?5;DC#KDYE!3\\<?2@#U2\U*SL&5+F<([@LJ %F('4[1DX&1D
M]!FDL-5T[58FETZ_MKQ%P&:"57"Y]<'BN+UC7=.T?QMI^KMJ=H!=Z08O])E*
M1,HD#!DD56!8DG(QT .>F=SP'#8VWA6"WL-3M]11))"\MNP**[,7*CT W=#_
M %H U+W6]-TYW6[NTB,:AGSDA >A8C[N<<9ZU4'BC3V\4/H"R?Z1'")')! W
M%L!1ZGKG_P#77*^*)GL-5UG4='U."2>-(UU'1;P K=KL7:8\?,&*G:,=2,5?
M^V+#\3YA,WV:>]T6);=7&2SB1\@>I&03Z#GI0!TCZ_I,=V+5[^%96D\D MQY
MG]S=TW?[.<U)?ZOI^EC_ $VZ2$[2^#DD*.K$#D*.YZ"O.8)H;GX/W'A^X'_$
M[BWV[V3']\;GS"RD#J<DAMWIDYX-:<&L6_AOQCJ=MXJN%B34+*V%M<RJ3'*$
M0K(F?7<6./\ :H V-2U6Y'C3PS%9ZAOT_48[EGC0*R2;8PRL&QG^+UQTJ/QE
MKY7P5JU]H>I^7<V*G,D2JVU@V&4[@1GK[BN=\4JCZKX4T_0KB+1YC;W@M$?Y
M3&#&NP$=5W#CU&?44NN>)])U3X1:K#%Y%C<VT7V:>QWC,,H< J/4$]#W_.@#
MN[#7M*OKU].M]0@FO(4W20HX+ ="?P/!]#3IM>TFVN?LTU_"DGF"([F^57/1
M2W0,<C@G/(KEKZ]TY/B!X1%O<VRJUG<HH1UP05CV 8]2#@5D6,\)^%FL>']4
M*G6H_M44MLW^MFG=V:-E7JVXLI!'I[4 =7J%_?6_Q!T>Q2[?[%=VMP\EOM7&
MY-N#G&?XO6H?'7B./3/#6IM8ZJ+6_MH\JR*K;7QD(<@@$CH#@],5FF4V?CCP
M?9W]U&;V+2YHYMSC)D*QC\R0<>M8!U>TB^%OB#0]4GCCUR)[G[3;RG$DKM(7
M#@=6&".1Q@4 >E-J]G8:?;RW]TL;20A^02Q  W-@<X&>3T&:27Q)H<"6[RZM
M9JMTAD@)F7]XH!)8<]  >>E<9)K5AI7BF&ZUB\FM=.U#2X$L[Q'98PR%RZ$C
MH3N!Y]*BO%T#2[OP9!9[;6P74)I85NI#G:4;#X<Y +$$?44 >AV%_::I917M
MC<)<6TPRDJ'(89Q_,56AU_2;B\CM(K^%YI2RQ@'B0K]X*>C$8.0"<8JZ0MO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M68N0!@=2>  /H*AT;6Y;[X@ZK:+?S2V<%E%(L$L?E^2Y9LC:5!' !^;G!]*
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MO0 Y!/;=746=I#8V<-I;J5B@0(@)R< 8Y/>IJ ./T[RI?B!JFO6L\?\ 9?\
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MF1OM\00?89V0?ZJ9 2DI^B;_ /OD5U6G:>FG6[1JV]Y':663:%WN>IP.!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.\\0W\*VD2(<>0&R(T5<D@#)<D]<$\ <=C4?V>$3FX\F/SBNTR;1NQZ9ZXH
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MW7]B> /[7&;UKV$2^;]\_N7X;/?D9]Z[K51 NC7@GD:& 6[[WCZHNTY(]P*
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MT_LTY!1E#'S0O8G.W..P':I/A_#);VVM0ID:>FK3BQ'\*QY&0O\ LAMV/QH
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MC]*Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFY68KA9(F&Z$?4,SGV,0KO61'*EE5MIRN1G!]10$0.9 BAV !;') Z?S/YT
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M;ZA>Z;I%C-;%B@TZ,[F)4J=SE5.W!/RXZX.>*Z"&&*WB$4$211KT1%"@?@*
M)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@N9;:TC>\G*HL:
M?-(1R!Z>O7M4]8NO>'I-<EMG&L7U@+9MZI:^7AF[,=RG)';TH 9X9TI[(:AJ
M$\1AN-5NFN7B/6-<!44^^ "?<FMVLO1M%DTEIGFU:^U*2;:-]VZG8!GA0J@#
MKSQSQZ5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh43lgnddescriptionofse003.jpg
<TEXT>
begin 644 exh43lgnddescriptionofse003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/N1.+68P2D*0%< $CD<\$=*O4 %%%% !1110 4452.L:>-9&C_:5^W&(S>2
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MR $;AZX/-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *XCQ+*]Y\3?"^DS\V2I-=^6?NR2JI
MVY]=O4?6NWK&U_P\FLR65Y#/]EU'3I3+:W&W<%R,,K#(RK#@C(^M &9\3H@?
M =_=*QCGLMEQ;RKPT<BN,$'L>H_&G:3XAU2]\10:7.MLJ3Z+'?AA$P=)&8*5
M/S8(_ 59U30K[Q'!'8ZQ);1Z>)%>>"W+,;G:<A2QQM7(!( )..HI-1T'46\5
M6^N:5=VT+"T-G/'<0LX\O?O#+@CD'L>* ,1O&>M_\(I;ZHD%B]PVK?89%VNJ
MLOG>6"OS'!X[DUV&EKJBV[C5Y+22;S6V&U1E79_#D,3S7)KX&U1/#B:2NIVS
MLFI_;UE>%N,2>8%.#SD]^/I7;INV+OQOP-VWIGVH \[TN;Q';GQ9<:$M@?(U
MB:1DNE=FF(CC)4;2-O ZG.2>W6M2/QA?3S^&[]4MHM&UL!'+QL9(9BN53=N
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M#R!3G#<G+9[#VK<O]8UP>-5T"Q^PI%+IS7233([,C!U7D C<.>G'7KQSG_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML;A=1EN$G>&W9#A$9TQECCMGZ=:SM-GUMKSQG(-53S+6;;&QM\[,0AAM&[
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MYCOHXTO=.UN&SN#$"$=DF3YE!Z @@XKJ9O#MTGB!=>L+Z*"\EMQ;W:/ 6BG
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M# <=&P.>O'!%07OB/5K"[L'>^CFDGUE+*>W@B#P1Q.Y51YFW/F ;21NZD\4
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M2NI;.P\8:=H^HS106R6\FI%,86ZNFDP !_$5RQ"\G)4\D5DP:J)O#'BO6;5
MM_K-[]C@C[C.((@<<;L[F(]\]QD ]&AU&QN)(HX+VWE>:/S8U256+ITW  \C
MGK0FHV,EW]D2]MVN!G]RLJE^.ORYSQ7'>)]-C\*>!GN=/B5+Z"".T>_5/WD4
M+,BN01R %''I@>E:FBV6EW5]9W-O?V]XNGPLEI'9#]Q & !)()RY'')Z9XZF
M@#IJYNZ\2R'QMIN@VB9B=9I+F8CCY%'R#WRRDG\/7%W5M62*YATBTNX8]3O
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M#/OCJ: .F34+*5)Y([R!TMF*SLL@(B(&2&YX('K5'4/$NE:==V-I+>0FXOW
M@C$@Y7&=W^[@=>YP!UKS9-0M9O ,T=I+%"OB'5BEPZ<+;QO)M$?'\7E)]WL/
MJ,]?%<6]Y\2O*7[ND::$@AQ@[Y?F)QV 2-1D]VQU(H Z>ZU&QLF5;N]M[=FQ
MM$LJH3DXXR?7BK->:^&'M?$WA\Q:KJD)N=1N&;4;.)<W+L'.(FYRJ* !@*,
M=1DUZ50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRX4!B,$XY-.HH 8L4:.SI&JL_P!Y@,%OK3Z** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHA((BT<RO\YZ+QGGGI0!K4456L=1M-3A::RG6>-)&B9EZ!E.&'X$4 6:***
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M\BI$BY)V+\QQPN..3SC%6K>U\1V2W<*_V=>Q37$TD/G2/&8D=RP5L*V_&?\
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MVBM]'FL8D9O](^UASYB_W?EP<'OS[5!;:1K6I6%]I_B6;3GM+BW\A(=/B9
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MC(W,_#J>F0%]<4OQ(&?AYK7_ %['^8I?#^E^*K,06FL:I97%G: !)+>-UFN
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M&93,Q#;N #C)<GVH M7.K>([&%4OUTNUD6V:1KG+/#++N(6)%+*V=H!)YZX
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MPI<,58X!!''KTK-\-ZK+%JGB+2-,DM_[4GUV>4+.I9$B"Q!G(!!/H #R?;)
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M95,NY6^3)8XRO\..<T =G17.SZQJ=OXTCT:5K2.TO+-Y;.4PL6,J$;D/SX.
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MJA#F3:&?+;L$#(' ZY':N>\0_;O^%CZ,-.^SBY.G7(5KC)1?F3D@<GZ9'UH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT=OY(!W*$+$'/3G<>*WJ0C(P>E '!^'(=2O6\7VUC-:I%/K$\1D?):$F- 6
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M&91_!OQMW=>,]B.M:A.!DT <A=>"KDZ1';6MU +E]5&J74TB':\H<-@*.@X
MZ\ =ZTHM%OAXU;7GEMQ"]@MF81N+##E]V?JV,5.GBG1I-,O=26\/V2PE>*XD
M\I_D90"PQC)QGL*TK:XBO+6&Z@;=%,BR(<8RI&1^E &1XNT6[\0Z&VFVDT,!
M>6.1I)06QL=7  'J5]:BO-%U*[\5:5K7F6L:V,,D3Q99BXDQD@X&,;1CBNAH
MH YT:!?:;XEOM8TB:W*:FB"ZM[C< )$&%=2,]N"N.?6J4O@N>'3M(M+*YB+6
M.I#49Y95(,\F6+# ^Z"7/KC ZUTNHZC;:382WUX[)!" 7949R.<=%!)ZU9H
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MX6O-<9(M0:T98;X7-M>*"+B!!)OV#CK@;<YZ=CBNJHH **** "BBB@ HHHH
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MA=VUU-:S-""$=HW*[@#G&<57FUG4[?QC-H]Q-:16L]BUS93&%L[E8!U8[\'
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M\;>5-MY5Q@Y5AT[\?G574/!,EUX5OM(@OHTN-2N_M=U<O"2&DWJYPH/ ^55
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MS;RVUK;-9&:%W3S9)IN3L$8.=H&"2!WZC%4?^$+U!O#FO:0^I6Y.LW4MP91
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-5"LIW'H5! /H.35[1M%UZT .J^(1J+0J5M_]%$8SC&]\-ESCW Y/4\CH**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCQ(Q8LH7')/)Z=^M<#IL_P!@\%^"K2+=!;ZM/#%>2(Q!8;"0F>VX@#CMD=Z
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MOH6C76J708Q6R;BJ]6/0 >Y) _&N?MVCU[QUK^F:HOF0:?!;K:P,2%PZEGD
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M#,R316:(RK:Y!!VY8_*Q7.. ,&LCQ?%+-\1/!<<-PUNY-]B15#$?N1V((]J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI#6BBZE'E$# Q\W8<?3BH[SP5X=OM8.K7&FJUVV/,8.RK+CIO4':WX@UNT4
M(0&!! (/!!K)LO"VCZ>8A;VSB.!]\,+SN\4+>J(Q*KU.,#C/&*C76[K_ (3=
MM!>VB6#^SS=I,')9CY@3!& !W]>U;= &1>>%M&O]4;4KFT+7+QB*0B5U611T
M#J#M;&>,@TR#PEHUI#9Q6MO+;K8JZ6YBN9%**V-PR&Y!VKUSTK:HH R)_"VC
M7%I:6LEHPALIA/ J3R)LDR3OR&!+9).3DY)J1?#NFIJ5SJ21S+=7:!)I%NI1
MO4=!C=@8[8Z=JTZ* ,&3P5X>ET)-#DT_?81/OBB:9R8F]58MN7OT/<^M31^%
M-&ATZ*PBM7CABF$ZE)Y!)Y@&-Y<-N)QQR:V*J[K_ /M4KY4'V#R,^9O/F^;N
MZ8QC;M[YSF@"H_AK2I(6B>"0EIQ<-*)Y!(90,!BX;=D#@<]*MV6FVNG^:;>,
MAYWWRR.Y=Y&P!DL22> ![ 5:HH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XFU@L_%6
MK>*-.U9S]HM9Q# ,X>UA,:E9(\_=8L6.[V'8"NVK&U/PCX?UG4$U#4-,BGN4
M7;YA)&Y?1@#AA['- &#:20:KXV&CWSF^L;?1XIK5;GYA<;FPTK C#-P!G'&3
MC&:YW4_M*^$==LFN+AK?2]=C@LI/.;*QF2/*$Y^8+N(&<_I7I5_HFG:E+!-<
MVY\ZVSY,T4C121@]0&0@@'TSBH[CPYI%WIJZ;-9JUHK^9Y0=@"V<[B0<DYYR
M>_/6@#EY]$L8OB3%8HLHM;[2Y)+J'SGVSLLB@%N>3AC]>]8DZE?A_J]@LD@@
ML_$GV:W!8DQQBY3:H)],\5Z,VAZ>VIQZDT3F\BC\I)C,^0G]WKT[^YYJ!?"V
MB+9W=G]@5[>]D\V>.1V<.^<[^2<-G!R.>!Z4 <ZVD0Z#\1=*BTAITAU2VN?[
M0A,[N"$"E9#DDAMS8S[_ %K!NHB/A3K6V><-;ZO*L;^<V['VE5Y.?FXXYS7I
M-GH]C8,[P1R&1T"-++,\LA4=%WL2V.3QFJA\):&=-FTTV6;2>7S983,Y5WSG
M)^;KGGZC- &$+6VT+XEP_9GDAAN]*FENBTK.'9'7#G)/(!/-9%F5AO\ P=>V
M(<0W=S(GVN:3_2+Q&C=MTH Q@D @$DCCITKNVT#37OX;]X'>Y@C\J.1IG)"=
MUY/(/?/7O5.+P1X9@CBCCTB +#+YT8)8[&YZ9/ Y/R].>E &%X8TG3Q>>+PE
MLD3#4)(U:+Y&53$A(##!'.3Q67I%_*?#?@'3[AV^PZB[+=L2?WA5&*(Q[AFZ
MCOC%=[_PCVDB^NKY;-4N;Q=L\B,REQC'8\''&1S3/^$9T;^QDT?["IL8V#1Q
M%F/ED'(*G.5(/3!&* .5O+9M/\4ZWH]D7ATRXT,WCPQ.46"8,5!3!&W< 20,
M9Q6=:645CI'@#5X&E%[<36]O+*96.^-X6)0C.,<#BO0(]#TZ.VN+<0NRW2[9
MW>9VDD&,8+DEB,<=>YJ ^%=&-I:6IM&\FQ</;()Y,0L.A7YN,=O2@"IX_P!2
MO=(\#ZI?:>66YBB&UUZH"P5F'N 2?PK)UNT@T74O#%]H $;7=]':S"(G%S Z
M,69_[Q 7=N//O7:RQ1S1/#*BR1NI5T89# ]01W%9]AX=TO3'C:TMF7R5*PAY
MGD$(/4(&)"#_ '<4 <OX-T2RO-3UN[N?/EEL-?F^S%[B0B/]V@]>>#CG/05:
M^(MG;7,/A]IX(Y"-<M$RZ@_*SX8?0]ZZ+3M$T_2IKB:R@:)[IS),?-=O,<]6
M.2>?>GZGI5CK-F;/4;=;B$L&VL2,,#D$$<@CU% ')W6DV-]\3Q8319M%T #R
M48JI G( ('4>W2L;3M2FMO"^@Z?-=B.REUFXLY);C+KL5I?+C;D$@D*.O08/
M&17?1^'M*AU :A%:F.Y$(@$B2.I$8Z+P<8[X]>:B'A/0O[)GTEM.1[&X<O)
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M&:SOY98[EY&/[PH'$4;'N"0..^W'3-=S/X6T.YN+6>7383)9Q>3#@%0L?]S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<=I8G@<<8P.I_&@#HJ*P-%UC1[?PK:W]OJ-S<V+NR0SW)>2:9C(0!@C<QSD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X6VU*3PYXFUVQU32[ZZM]4N!<VDUO;-,LP,:H8SCH1MQSQCT%=U10!
MQ:_:=%\=C4[^U>.PO],C@5XD+I:RHQ/EG:. 03@]":PM6TN[B\,ZY<BSN2NJ
M:Y'=6]LD#L_EK(F7* 9&=I;!'3%>HT4 <9XONX8_$?A"Z<.8OMDK<1L2 86Y
M*XSQU/'%9/B/P[?>(Y?%-]I$;*MU806\)92GVJ1'WMC.,C: F>AR?2NOUC0)
M=4UC2]12]$']F2-(D?E;@[,NTY.1Q@GI6U0!Q6J2'Q;-X;:RM[B&:TOX[RZ\
MV%HS;(BMN1L@<DD+COUZ#-.\*RS0KXL*6,[3/J<]Q!'- T:SJ8T"X+#!!*D5
MV=% 'F%E<7%UJ7@[46L-3WV[RI=QBR>**V=H2HC1, !0>-W(QU:M;1FEL8?&
M%E<6=VLDM]<W,9^SN5DC=%"E6QAB2",#)XKN:* /-+&WOK#3? NKO:7+6^E0
MO!?0B%O,A+QA=Y3&<*1SQT-7=3LY;W4O$VN6L,QM)M$-E$%B;-S+ASE5QDXR
MJYQW/I7?44 >>.9/[/\  (%K=YM'C^T 6LF8<0%#N&WCYCCFN@\?Z9?:MX-O
M;734\RY!CE6+./-V.K%?Q KHZ* .-U!AXJUGPW<:?#<1_8;EKJY>6%HS"NP@
MQG<!\Q) Q[$]*YO43<0>#_&.@_V??27TVH7$T2):N5>.20,K!L;3D=@<^U>K
M44 <9))+#\0=*U(V5X;:XTA[966V<[9#(C;7X^3@'EL#BL_3K>YL=<L[CP_)
M>);7EZWV_1[N%BEOG<7FC9@-@SR.S;ACTKT.B@#SJ*?4-*TKQG;PZ--=WC:A
M-=10RVK/%+&XC (XP_&X[0<_+4VF3X^(-OJ8AU::UGT9HOM5S;2+N<2JQ^7
MV<#I@ ]LYY[^B@#RJWBN4^%&BV;6-Z+F#48FDA^R2;U"W!<G;MSC:<YK>TN^
MDT+QEKL>HVMX\6JRQW%E<16SR+* @4QG:#M(QT.*[>B@#RJPCN4^''@^W>PO
M5FM=6MY)HS:R;D192S,1C[N"#GWKIK&7ROB3K%S)!<+ ]A B2_9WV,RERP#8
MP2 177T4 >4V:M8_#OPQ)/:W\-[8:EE5%F[-&=TA.Z/AF4H3]WU'/!KI_"-_
MI-YKNK745W,^IZALEEBEM)+<+'&H1=JN.<9Y.3R>W%;&MZ%)JMQ9W=MJ=QI]
MW9%S%)$%=2& #!D8$'@?45-I^ES6\PN;Z_EO[D(461T5%1202%50.I49SD\4
M 9'B6^GMO$.DPO:W(LI4E$EY:VS2RJWRXC!4$H&[D<G Y&,URD=I>K\.-0M?
M[,OQ-:ZSYS1/"Q=D%R')7J7PHSD9^IKU.B@"*VN%NK=)T21%D&5$B%&QVRIY
M'T/->:3)=1?#SQ3I#:=?&\:[NMB+:N=^^3*;3CYL@YXS@#G'&?4** .+O7,G
MC'PA.EO<M%%;W*RR"W?;&71 H8X^7)!Z^E8_A]((M-C\+ZUX=OKK4[60HN^)
MVMYP&)67?]T+T)/7T!/%>F44 9WB&"6Z\-:I;P(9)9;.5$0=68H0!^=<7?S2
M77@3PO''8WWF6UY8B6-K20,HCV[R5QG P>>A[9KT6B@#DK60K\3-1N6@N! V
MEQ(LQ@?8S*[L0&Q@G!%<RT5R?@W+8"QO?M9OMP@^RR>9C[9YF=N,XV<UZG10
M!P.HW*Z1XSO+W4M-U"ZTW5;>$V]Q:Q2/Y3H""CJO(SG(X_KCK=!MH+31K>&V
MT\:="-QCM0,>6I8D9'8G.2.Q)K1HH \XQ<6_AKQUIDEA>_:;BYO980MLY619
M5 3:0,-DGH.F#G%6IS)]M\"2+;76VV5O/(MI/W.8"GS<?+\W'-=[10!YIIBP
M6MO=^&-=\.WU[>"YE,/[IWM[M6D+JY;[JC)YSTQZ\5Z#?PO+I5S!&N7>!D4#
MN2I JU10!Y>7F;X?>%;8Z?J EL;^S^T1FSDW((V^<XVY('KT/;-=+KVH31>*
M--A>TNEL9K:0_:[2V:25G++B+<H)C4CDGC) Y&#75T4 >464=S;^"] LY=-U
M!)K+Q"LDR&UD8H@G=BW .0%(Y&1SU/-;M\R'QEK\TVFW5W:2:&(RBP/MN"ID
M+1AL8W%2!^-=U10!YYIR:MI!OK;27GU[24TN62VAOH3YD,O&V#<0"P8?PGD8
M'3O%8S2W/B7PMJ"VNJN/LMQ#/+):/&D,C*F%"8 11@C.,<=20:](HH X#PAJ
M4UAHUMX5U'1+M]4L9#&"]L3 X#DK-YA&T#!SG.<CC)K1T5Y-/\<>)EN;6Z5+
MJ2&>*40,8V180"=P&,@C&.OMUKKJ* /*],LM2@\#^%KU;&[)T?4GFO+0P,)1
M&SR#<$(RQ <' ]:Z*:+^TO&G]OVJR_8K329('F\IAYSLV0B@C+8 ).!U('7-
M=E10!Y= EQ'\//!]NUE>B>SU.U>XB^R2;XU1R6)&W. #UKNO%-A<:OX3U.PL
MVQ/<VDB1Y.,DKP/;/3\:UZ* .2T#7O[=MK.T_L:\M;^WBV3O<VI1;1MN#M8C
M!)/ "]CD]*P+:WNC\+KCP=<6$_\ ;$:/:+"8FVR$N2L@?&-F"&+9XP>]>F44
M <;9126?Q&7S$N'BAT&.W:Y,+[&D60DC=C&<<USUQ#<R?"36[)+&\^TRWTS1
MP?99-[!KC<I"XSC;SFO4Z* .02;S/BBEZL%S]F.B>6)C;N$W^;NVY(X..<5S
MEQ#<2_"WQ)9I8WGVB>_N&BA^RR;W#S;E(7&2".<UZE10!P%_=KI/C";4=0T[
M4;K3-4M(1#/;12L89$W HZ+\PSNSR.OXX6XMHK36_!WV31Y[&T@GNI&ACMV8
M0*Z,%+[00I8D$CL2?2N^HH \QU2QU*_;QHNGVEPTSW=I=6Z/"Z+<B(1E@I(P
M>5(XZUT$FI#QEHU_!INF75M<36$T#3WEL83$[J0(P2,DY()QP,?2NNHH X/P
MW=6.J#3;6Y\-W\6JV)7S?M43B.V91@NKMQSCY<<G([9-8+2W=M\*=3\)W>GW
MQUBV$D>U+61UGW2EA(K@8(.?7.:]:HH R(?$5HVKVNDM;WD<US;^=&\ENRQ]
M_D)/1L G'H*S?'MO>-IEA>V=I+>C3K^.YGMH2?,EB"LK!<<DC=G'M71FUB:[
M6Z<%I$4JF3P@/7 ]3ZU-0!R.FZGI"I=Z]8Z'?JJP;'FDM9//G.>(U4Y9@.YZ
M D<]<4/#5O<>$?$;Z=):/)8ZNGVF*6WMW9+.0DDPDXX3DE<XP2>!FN]HH \_
M\-ZC/I%C/X5U+1;RYOHKJ4P,;8O!<J\A=9"^-H +<D],>O%:EKO'Q3OI3!.(
MGTN*)93"PC+J[$J&QC.".]=910!Y) ]Q%\/=)T0Z9J+7VFZG#]JC6TD^0+.6
MR#C#9'/RYKI-+O9="\9:['J5I>-'JDL=Q97$=L\BR (%,9V@[2,=#BNWHH \
MJL([E/AQX/MWL+U9K75K>2:,VLFY$64LS$8^[@@Y]ZZ:QE\KXDZQ<R07"P/8
M0(DOV=]C,I<L V,$@$5U]% 'E-FK6/P[\,23VM_#>V&I9519NS1G=(3NCX9E
M*$_=]1SP:Z?PC?Z3>:[JUU%=S/J>H;)98I;22W"QQJ$7:KCG&>3GJ>W%;&MZ
M%)JMQ9W=MJ=QI]W9%S%)$%92& #!D8$'@?45-I^ES6\PN;Z_EO[D(461T5%1
M202%50.I49SD\4 8GQ WM::.(H)YC'J]K,XAA>0JB/EF.T'  J.9Y=*^(C:O
M<QROIFH:<D"7"QLPAD1BVU@!E002<GOQ7844 >7:OI=W'X8\07*V=R5U76HK
MFWMT@=G,:R1Y<H!D9VL>1TQ7IT<BRQ+(F=K@$9!!Q]#R*?10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<[>^.='LKJ^M"M[-<6&TSQ0V<C,H8$[L8^Z ,ENG(YYKHJXG3=1AL/B+X
ML\Z.=@T5D08H'DZ1MQ\H/// [T ;D7BS2+@:6\$[RQ:N2+254)5R 20?[I&#
MU]*)?%>EP#5?.,Z'2 K78\AF*!E+ C .1@9SV[UQL.BWWA[0O"]S-8W#+9ZG
M+<W$%O$97MTE$F!M7).W<H.,U-/]LGN/'LO]DZBBZC8QK:YM7)E/V=EP  ><
MD<=1GG&#@ Z!OB!H4=J;J7[9%;XB*S/:2"-O,^[A\8]B<X]ZMZ9XMTK5=6ET
MJ+[3!=QQ^:L=S;O"98\XWIN R*YCQ)(4^%.E[X)T>%[%'BDA9'#*Z C:P!ZC
M\:OZOILGB?Q1975BLUO%96-U')<R0O'EY5"(HW $X^9CZ?4T :Y\7:4!!*S3
M+9W,ODPWIC/DN^< ;NP)& Q ![&I[SQ!:6<MPGE7$PM"JW#PQ[A$6 (!YST(
M/ . 03BN+:SOM4^&$7@^33KF'546*T97@;RTV.O[WS,;2NU=V0>3QUJQXCL+
ME-7U#4= _M*TUJ(Q1[/(>2VU-=B8W9&WC)4MD;=IS0!UNI>(+/3//WQW$_V6
M,27'V>+?Y*=<M^ )P,G'.*0^([!UB:T\V]\VW%T!;+N/E'H_;KS@#DX/'%<I
M<YT;Q;JW]L>';K4[356CFM[BUMC<!6$:HT;#M]WC/&*=K.D0O+;&UMK_ $#4
M;2Q#6EQI\#21*"S'R'"@JV, [>Y;B@#N+2YCO+.&ZASY<\:R)D8.",C^=95S
MXMTNT26>0S&S@F\B:\6,F&-\X()ZX!X) P#P3P:N:$]_)H5B^J0I#>M AGC0
M8"OCD>U</IUM?6/P\U+P==:?=2ZDJ7%O 1 QCN/,9BD@DQM ^?G)&,<T ;7B
MC69(_$>@Z2L5R]K>R3-/Y .9E6(E5!!R1D@G'IZ5N:;8P:%I;1?:[A[>(O)O
MO)=YB0\[=QYVJ.F<X'>N8O;.?3?$'@JW,%W<IID,L=S<16TCHN8 BDD CD__
M %ZW?&6FW>L>#]4T^Q.+FXMV6,9QN/\ =_'I^- &!X@UM;S7/"KVGV^&.YOQ
MM9MZ17$6QC]W..NTC< ?3BN@U'Q5INEK-+<>>;:WD$=Q<QQ%HX6..&/7N,D
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M&6W>6!DCG  +;&(PV <\4EYXOTFQBN;F9IC:6<_V>XN8XBZ12<#:<?,>2 2
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MV\<GF8&U<DXW+G&>IJ]'%>ZCJ_C0IIEY$NI:=$EJTT)02$1.,9/0Y8<'D9Y
MH Z#2_$J76A:7>7%O,+J_C3RX%3!D<Q[VVY.-N,G)('%5M8\9)8V5A/;6-U(
M;S4DLB&BP8SYFU\CUP& QU.#TK'%M;:IX/\ #]EJ6GZQ9O;Q(BW4,$B36<R1
M@;L $A2=PR1@_3FH+R#7Y/"^FRZC#<7\FG:_%-YD=L1--;(_$AC SGVQG'-
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MIR#7-2\/W,C22V02:"1SEI(7'&?4JP*Y[C!/.:T;S5(;.XBM?+DGN9D9TAB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#C<=Q ZY  Y.#Q56;QIH\4&E3AKB2/5O^/5HX&8-P3@\=>.G7VH WZ*Q=/\
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MC7YY21G !QC !))P!CDUB>$KI[CQMXK!%W&J&U'DW3EC$2C$@<D8)YX..>*
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M*SD[LDL#R,+U]@*[BB@#S?2=)CE^'>BZ1K>DZDC1W#[W@AD6:S?<[)(-HSW
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MR]W-+(;.1-PC1@C;MQR ?ESQS5'P?IU_I=]?6T=S>SZ($C-G]O5A+&_.Y!N
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M&,<YX!]:D.OH4@6'3[R:YF@^T?9%""1$[%MS!1D\8SGKZ'&/JF@7Q\:+<6:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1ALJ!'O8*&()YY8<>O7BK4VN&-X[=-/N'O9(C*;7?&&1 <99MVT9/3!.?P.
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M=V">>3P/7KQ5N?6_*>&W6PN'O98VE^R[HPR(#C+-NVCD@#!.?P. #4HKE_\
MA/\ 2SI=EJ"VUXR7=Z+$HL0+P3;L%7 /\LY[=:MV/BRTN+K4K:\M;G3)=-B$
M\PNPH!B()#@JQ&/E.?2@#<I:X#Q)J)U'6/"-P-.N[>.;4T:*:4J R%&."H8E
M2>" 1G [$8K?U3Q?::7;W5VUI<SV5E+Y5S<Q;"(SD \%@S!2><#CGK@X .@H
MKFKOQK;P:G/IUMI6HWUQ#;I<@6T:L)(V. RY89'Y>V:Z2@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBK=M<\,^)
MM72/1+C5+'5;@75O-;.@\N0HJLLFXC ^4<^GKV[6B@#D#9:II'C4:Y+;/=VU
M]8);W7V8;C!*AR"%ZE#DCC)SUK(U3PYJA\/ZO+%82R76K:Q'>+;(5S'$CH?F
MYQN(0D\]P*]&HH Y5H+QOB3!JHL+C[%_9#6[3;1A9#(K@$9ST'IUJIH-IJ%M
MHGB>&?3;F.6\OKNXMT(4F5)/NXP< ^QQ7:T4 >=0Z3K6F6'@W5(],GGDT6W:
MVO;)2OF;715+)S@X*^O-+>:)J^O7?BY5TV>R35;6U^R2W!0 O$"<, Q(R2.Q
M[Y]*]$I"P49) &<<T <IX?N;RYEB>X\'C2);=2;B5DC.YMI&V+:<G)/4X&..
M<U@Q:3K"_#&PTDZ1<_;H+])'A^7.T7'F$YSC[OOUKTJB@#E;:WU"T^(-]J']
MG326>H64"K.I4",H6W!@3G/S#& :R+6W\2:?X7OUL].NHYY-:DGDB1E$KVKR
M[F\LYP&V\=<CZXKT&B@#AM(L+^Q\1^(+M=#N8+6_LX/)RZ,Q9%<$-AB2Y+#N
M?4FJ?]D:LOPZ\.Z;_9=P;RRN[9YX1MRJQON8YS@\=,&O1:* .3\;65XPTO6=
M(=(M4M;A88O,'$B3$(RD>V0WMM-=)86<6G6$%E#GRX(PBDG).!C)]35)/#UF
MNO2:R\MU+.V"D4D[-#$=NW<B= 2,C/N?4UJT <KXBT*_N?$NGZAIORK<PO8:
M@V<$0'YPP]P0P!]7%,\+>';O1M6U""5573+69VTQ1_"LN'<8[!2"!]6KJPZL
MQ4,"R]0#R*%=7!*,&P<'!S@T >?#2]5;PGXRLSI=RMQJ=[<R6B$+^\5U55.<
MX'0]<4^YLM2TW6;+63X=?5K2XTZ*UN;8*C36\D9)# ,<$'<1P??->@44 <7K
M%AJ;IX?U"#1-OV/43/+8VI0/'&R,H[A2>03@]^^,U8TV&_@\<ZYJ4^FW"6UQ
M:VZ1.,,'9 VX#G/5L#(&:ZRB@#R^RT+6].\,^%[LZ$;R?1A-!>:=)L+.DA'S
M)DD$C:#^=:OB.SU#5_ NHPV/AQK*6[:$06:K&LI"R*Q9\':. <#/;WP.[HH
M9#(984D,;QEAG8XPR^QKA?$&BW=WJUUJ6CV5YINO1S(EO=PG$%Y&-O\ K><$
M 9!S@_*,9X%=[10!R%I;7\7B?Q9=2:=<""]A@6V< 'S2D;*V!GCDCKBLO2[?
MQ!I^B^&-/GTF]>R@MWBO[>W=%D\T ;-QW#*=>A^OI7H=% 'F*Z+K<'A"?3!H
M4XF37!<HD3(5:(3^9E>1Q@8&<?2MWQ797ZZUI7B&ST?^UH889(+JQ8+Y@1RK
M!E#<;@5Y'_ZZ[&B@#C[^QBU70XXM0\*%+*YNANMH@HGMT"-B8[#PVX 84D@'
MOR*T/!UEJEAIMS;:A<W%Q"ERPL7NSF;R,#&\^N=W7G&,XZ#H** .6@M[R+XC
MW^HO8SBS?3HX$F !#.K,Q &<]&]*YFST'7+/PMH5R-$:YNM'O+EI].G*?OHI
M7<Y4Y() 92/?/X^GT4 <7J<%[JO@K6DM/#C:>]Y;&&WM=L:S.Q!!+;3@#D8R
M<\'UJ*6UU;2_$6C>(8=,N;NW_LO^S[NWCV^; =P8,%)YY&#@]*[FB@#E?!]O
MJ$&J^(9KS39[2.\OO/A:5D.Y=BKC"L>>/I[U!XOT:/5=1+_8+^&\M[4-8ZI8
M'#K(2^8C@].%/S<?,>178T4 <3-;Z[8Z_P"'M8O-/FU&9-->TO?L>S*3-L.[
M!(&TE3ST%9;:%KMQX4UZU;29$N9==:^BC\Q/WL?G*QVDD=E/7&>*]*HH YE[
M*?7/%NDZN;6:UM=*BF(,Z[7EDE 7:%Z@* 22>I(QFN9M])OM3\(7[:;!'<75
MGXCN+N.WE("3[)FRA)XY!->@:GIPU*W2+[7=6I219%DM9=C9'8]B/4$$&GV%
MA;Z99K:VJ;8U+-R<EF8EF8GN222?K0!R<VG7/BGP[J=G%X=&@FXLWA4SJBN\
MAP0!LS\@QR3UR..*T?#NKZ]?I;VVH:#/ITD"XNYIG0QN0,?N]I).3@Y(  SU
MKI** .7\"VFH:7I4^F7UA+ 8+N=EE9E*RAY&92N"3C![@?X+J5KJ$/C_ $W5
M8+"6ZMC8RVKO&RCRF+HP+9(^7"GID^U=/10!P>FZ=JNC^&]8\,/ILUR\KW L
M;A<&*5)<D%VS\I!8YS^&:ZW0M-_L;0;#3/,\PVEO'"7_ +Q50,_I5^B@#SF7
M2M:3P3XFT0:/<//<75RUNZLFV82R;E*_-Z')SC\:UKNUOIO%'A.\33[@P64$
MZ7+X \HNBJN>>>5/3-=A10!Y[X=L-3T> >';KPI'<RP2,L&JE8S"\98D.^?F
MW '[H&3CMUKJO%__ ")>N?\ 8.N/_1;5L53U73HM7TNXTZ>66.&YC:*0Q$!B
MI&",D'J* .0AL[CQ)X=\*626<\*V<EK=SRRJ J+&F0%/\18X QT!.<=*>;;7
M[;5/&EYIED\=S>K"VGR2!=LC)"$/4\'(XSP>*Z[3K%-,TZWL8Y9)([>,1HTF
M"VT# !P!VJU0!P6G66H+XOTK6!H-]%#_ &?+!<27$J/+O+(<O\Q)'!Q_("J/
M]CZP?A;)HW]DW0OS?>:(?EY7[3YN<[L?=]^M>ET4 -C;?&K[67< =K#!'L:X
M*;P1>7J:]H\A$>F&5[K3&!P5GD ;/L$<-C_?/I7?T4 <Q!9ZF? MXU];E]6U
M"U=YXHP,^:R;57TX 5?3C-9-SINIGPIX,M%TRX:?3;JS>[C 7,:Q(5<]<'GI
MCK7>T4 <Q!;7G_"RKC4#93"S?2X[=9R!M+K(S$=<]&ZXI_C6PO+VSTR6RMGN
M6L=4M[N2*,@,8T)+;<D GVS7244 <9JOA^Y\5:I>7ICDLH#I$UA 9EVN[R]6
M*]0JX YY))XQR4\,-J3BTLKWPA'87=J%6XO66(Q-M'WHR#N);'T&>IQ@]I10
M!SOCW3;S5O!M[9V$)GN2T3I&" 7V2HY SQG"FLC68-2B\2VOB0>&Y-2M+BR%
MK<61$;3VY5V9' )P<[B" >/6NYHH XG5[34;B/P_+#H30"#55NY;> )F"((R
M_,0<%OF!(&?3G&35UGP]J>M:EXOMH[66&/5+*WBM;A\!'>,,2#SD D@9QZUZ
M!10!P-Y-KFL2>&97\-WT,VGWJO>*QC"KB-E)4[N1DYS_ %INGV6I:)J%_I<W
MA1-42>[EGLK\"/9MD8MB4MR-I)Y )/8>OH%% '*:=:7T'Q#OKN2QE%I-80P)
M<!0$+H6)&,Y YXXK+LK+4M$U;4M/F\*+JT5W>2W-G?+Y>T"1MQ64MRNTD\X.
M>PKOZ* .+M+?5O#GC/4[EM,FU"RU>. K)9A?W,D:;"I5F&%/4'.!5[X?VE]I
M_A."SU&RDM)XIIFVNRG<&E=P1@GLPZXKIJ* .6AM[R+XC7^I-8S_ &-]-C@2
M8 $,ZNS$ 9ST/I7.P:/K$?PRTG26TFZ^W6M_'))#\N0JSF0G.['0^O6O2Z*
M*.K/?G0[M]*1?MYMW-LLF,>9M^4'/'7UKC+"QU63Q+X<U5M"OD,5O/%>S7,J
M-)O8)\S?,?ER&QC\%'&?0:* .=\=Z?>:GX1NK:P@-Q<"2&58@0"X25'(&>,X
M4UDZY;ZE'XCLO$B^''U*UFL_LMS8GRVF@PY9' )P3\Q! /XUW%% '$ZY9ZC=
M:7H[V^A- T>L07;VL 3=#$AY+$':6]AZXYQFJWB#P_J6N:[X@BAM9HH=0TA+
M:"X? 0RJS-M/.0#D#./6N_HH \_NY-=U:#PR'\-WT5QIVH1R78)C"C;&RDJ=
MW(YSG^M%E9:EHFJZEI\WA1=6BNKR6YL[Y?+V@2,6*REN5VDGG!SV%>@44 <I
M8V=]!\1+B[DL9!:/ID5L+A5"Q^8C,Q &<@8/'%=7110 4444 %%%% !1110
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MZ;:WOV6\(GOO[/>-$5C#/G&UL'GU&,YXK3M=<N+IK('0]1@%S)(DGG(H^S[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5AWGA6TN
M=5EU."]O["YN HG:TN-JS;1A=RD$9 XR!6Y10!6LK&"P@,4.\[CN=Y'+N[=,
MLQY)X ^@ Z"K-%% !1110 4444 %1M!$\R2O&K/'G8Q&=N>N/2I** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1SU'% %JBBB@ HI,C.,\U6T[4(-4LDO+;S/*<L!YD;(W#%3PP!Z@T 6J***
M"BD)P"3VJOIU_!JEA#?6WF>3,NY/,C*-CW4@$4 6:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/'OQ
M:USP_P",9]*TVVMEM[,J'\Y"QF)4,>XP.>,?6O8ZQ=5\'^'=<OX[[4])M[JY
MB "R.#D@= <?>'US0!>TF_\ [4T>RU$1&+[7;QS>6W5-R@X/TS5RD "@*H
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M1M",_-OW9#^O;'3\ZS%\ 3_V + ZULN[>_:_L[R&VV&&1F)(*ESN'S$8R.*
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MXCU74+_X=>++/4I(IKC3+H6WG1Q[!*NZ-E)7)P?FQ^%===Z!?7?B/2=9?48
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M<6R0$$B1RNX/NX(XXQ^)KIX]"NI-4.KWMU ]^EJ;: QP$11 G+':6R22!W'
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M16A3(4>.%$DD,K@8+D %CZX'%/H **** "BBB@ HHHH **** "BBB@ HHHH
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M,,YQP/?/2NJL-0CO]/BO?*GMDEZ1W49C=><8*GIS_,5:W*&"%AN() SR0/\
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M#TC3XM8N!+I%QYUO<&)"0,$;=N,8PQZ\Y_*NI*2"#9')\X7 =QNY]2!C/Z4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDR<;<8*[0#CJZU/9WVJ>)AKLECJ4EBVGWLEE:HD:,I>,#+/N!)RQZ#'&._-
M'6%E4@%@"QP 3U/7^E5HKWS-2GLOLMRGDHC^>T>(GW9X5NY&.1VR*X"'6;SQ
M1J'@74A>7%E]N6Z:2&'9M61(F!8!E/7YASG /'/-;]M?ZK+XQU_3&U#]Q!9P
MRVP\I?W);?GM\W0=: .JHKSBPUOQ%_PCWA77I]8,QU"\@MKFV\B,(ZR,5+9
MR&'7@@>WKIZKKM^-2\2V[ZB=,_LRTCFL1M3$V4+%SN!W#<-N!_,B@#M**R_#
M<M_/X>L;C5&8WD\"22JR!"C, 2N!Z=*YS_A(KI?$[:5J=]<Z5=-?#[(DD2_9
MKRWW#"J^T_,5]P=QQ[4 =L&4L5##<!DC/(I:\^L]1N=%O?&VK3WUU=KITH98
M9-FU\0@J.%R "<<8]\FK>HZMK&B:3HVNOJ+7D=S-!'>V[1H$*RX&8\#(*DC
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M=0N;J":RU>2R6,$21"%)$ESCKD9!'L:DTW38=,BE6-GDDGE,TTLF-TKG ).
M!T & ,  "J_B+7H/#6BS:K=03S0P8WK  6&3@'DCC)%:E %.RT];9;AI7\^:
MY<O-(5QN[!0.P P /QZDFLC1_"$6DW=C*UVT\6F6\EO8QE-IC1V!.XY^8X4
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M2UQYT(A?S4STS'C=SVXKB;35X];\*Q^(M0\2ZEHF6E^TM&K+&4+LJ*@92NX
M#E<GKGKP >D45E77B31M.N8K*ZU!%N'B\Q4()9E&.< =3D<=3G@5)8Z_I6I:
M4VJ6M[&]FA8/*V4V$'!#!L$'V- &C16;!X@TJX6Z*WB*;)=]PLH,;1+C.YE8
M @8[]*EL]6L[ZYDMH6E$T2*[QRP/&0K$@'# 9!P?RH NT54OM4L].>&.YE(D
MG)$42(TCR8&3A5!)P.O%+IVHV>K627MC.L\$F0K@$<@X((/((((P: +5%<6_
MB2+0_&^M)J^JR"QCM+>2&)UW;"Q?=M51D\*.<$^IKH%\2Z.\-A.E\CPZBXCM
M9%5BDK'.%R!@'@\'G@^E &I15!=<TUKF]MC=!);!!)<B12GEJ<D,20!C@\CC
MBFPZ[IT\LD0F>-XHO.<30O%A.F[Y@.* -&BN>T_7]$T[PW:7DFNO=VDTC)%>
M7)R\S%R,<*,X/'3H!]:O:=XBTG5KV>RL;Q9KBW :1-K*=IZ,,@;E]QD4 :=%
M9L'B#2;B^CLHKU#/,"8000)@.NQB,/C_ &2:6/7M-ENX;6.=VDGD>.)O)?9(
MR@E@'QM. K=^QH T:*SH]>TV6\AM4G=I)Y'BB;R7V.ZABP#XVD@*W?L:N7-S
M!9V\EQ<RI%#&-SNYP%% $M%9]GKNFW]S/;0W!6>W4/+%-$\3JIZ-M< X]^E1
MVWB32;NZ@MHKO]Y<J6MR\;HLX'),;, 'XY^4GCF@#4HK"G\:>';=;EGU-"+1
M]D_EH[^6<9.=H/ [GH.]3Q^*=$EU&#3X]0C>>Y&8=H8I)QG ?&TG'.,YH UJ
M*X73?%UIHNK^(HM?UF0QP7ZI!YJEBB&-3T1>%RW7 %=!J&I:8]_HZG6F@>YD
M\RVB@<%;L%3P>#E<'.>.G6@#:HK"NO&OARS:Z6;4TW6;!9PB.Y0GG^$'CU/0
M<9J]/K>G6Z6S-<[_ +8I>W6%&E:50,DJJ@DC!'..X]: +]%<[JOC33K'1['4
MK4R7D-_<QP0M#$[#+.%;.!P1SP>21C%63J&GS^)+.%=5GCNC;.ZV&"H=3CYW
M4KD$=LXZF@#9HK*N?$NCVDK)/>;!'*(9)?+<Q1N<?*T@&U3R."1UHO?$^BZ?
M?O87-^B720^<80K,VS(&< ')R1QU/I0!JT54TO5+'6=/CO\ 3KA;BVESM=01
MT.",'D'(Z&LX>)[=O%S^'Q!<>9';B5Y/L[E<LV%P<8QP<MT[9X- &Y165+XF
MT>&<127@7,WD>:8W\KS.FSS,; V>,9SGBM-F5$+NP55&22> * '45SMAXBT.
MQT(W[Z\]U:/<NBW,Y).XO]P849 )P.*OZ?XCTC5-0GL+*]66Y@4.\>UAE2<;
ME)&&7W&10!IT5ECQ)I!O(;3[9B2>0QPL8V$<CCJJR8VD\'@'/!K$T?6)+/6_
M%AU2_GEL]/GB*,Z[O)0Q!SPHX R><=N: .OHK..O:8);",W/.I*&M#L;;+D;
MN#C&<<X/-97C'Q!;V7A_5TM]0F@O+:V=A)!$7$4FTE S;2JY..N#R/44 =-1
M6+IFKPV_AK2I[^X9II[.-S\K222'8"QV@$GKDG'>K/\ PD&D?V?;:@-0@-K=
MR+%#*&RKNQP%'OD$?A0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %87B#4=-BNK;2M8MDEL+^&
M4R/+'NC0H4QO/10=QY/<"MVB@#S/2-&EL[[Q#IWA*\EFT2?2W,'[PO%#>-D*
ML;GKQR<$XR,FK'AR_P##.NQZ-;&&]DUC3F3-G)),#9R*,,Q!.T*!GKP>!U.*
M]$I,#.: ///"NK6EMHR>$]:TZ6?6;2X<?99;9G6=O,+K*&P5"\YW'I@GTSJZ
M3<I9?$/Q-%<K)&;I;:6)FC;8R+$0S;L8 !&.3UKKZ* /*-/6Y7P#H%Y#%)+%
MI>MM<WL*(2ZQ>=(=VWJ<!E;'ISVKIR8=4^(-EK6G7$;V5GITJ75TC QMN8%$
MW="1@L1V[]17844 >312PK\'[*$#$R:DK&/:=ZXNR^<=?N<_2O4;F^MK2P>^
MFE MT3S"ZC=E?;'7\*L44 <3IGB_1-2UB&\D:ZDOIB(+2V%G*/(1B,Y8J%W'
M +'.   ,XRS-.?\ X163Q5:72MYEW>2W]DH&3<^:H^1!_$P8$$#GD=C7<T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBO.O%OQAT_POXC;1QIDMX8
M-HN)5E";"0#A1@[C@CN* /1:*@L;R#4;"WOK9MT%S$LL;8QE6&1^AJ>@ HHK
MF==\6SZ+#J=T=)9[/3"@DEEF\HS;@"?*!4A\ CN.<B@#IJ*YV\\3W,7B*+1;
M/26N7GLFNHI3.J*V&48/!('S=>OL:HR>.IX_"DVN_P!C'=9W3VU];FXYMV5]
MK$,%.X \G@<4 =A16<^IR?VO:6$,$<JSP-/)*)?]6H( XQSDMQR.A]*K>)?$
M+^'HK&1;![L7=Y%:G9(%V%VP#SU^GZB@#:HKF$\4ZHVMW6B'0 +^.!;F ?;!
MY<D1)7+-MRI!&, -^7-%KXWM;CP]9:E) MM/>7#6JV\TP54E4L&!?&-HV,<X
M].,G% '3T5QDWQ"$&GZU,=-6:?1U61UMKH/%,C#(99,#IT(QD'UJ]+XKN[2V
M6:^T5K<75S!;6 -PK?:&EZ;L#]WCOG/MGI0!TM%<Y%XL:/6-2T_4+$6PTRW%
MS/.L^]/**DAAP#_"01CCWJO!XYC?5-.M9+:!HM2R(GM[M9GB;&0LJ  +GID$
MC/'O0!U=%<QHOBK4=;OI8H= =+>VOIK.YG:Z7]T4'4+CYLGCCID=><:FKZRF
MF365I'%Y]Y?RF*WAW;0V%+,Q.#A0H))P>W% &G17-GQ:\$^J6-WIICU'3K;[
M6((Y@RSP\_,CD#H00<@8/K4_AO7K_7K>"\ET8V=E<6D<\4S7"N69ADKM !&.
MQ[CTZ4 ;M%9-WK,W]J2Z7IEI'=W<$ GF$LWE(@8D(-P5OF.T\8Z#D],U(O%+
MSPZ5$NES0ZEJ:NRV5T?*,(3[Y<X) Z8XYR..N #H:*Y6?QL;6QULW&F,-0T1
M!)/:K,"KQE=RNKD#*D ]L@\8J2U\67,FM:78WFCM:PZM"SVL_P!H#DLJ;RK*
M!\O&2#D_0=@#IJ*Y_3/$TFKS(]E9Q2VGVJ2VE=;C,L!7<,O'MXR5Z;L_,#4,
M_B^4:9>ZQ9:9]KTRQD=)9!/MD=8SB1D3:0P!!ZL,X/MD Z%[B".>.!YHUEES
MY<;, SXY.!WI8YX99)(HYD=XB!(JL"4)&0".W'-<?J4MI>^/O!NHVFQTNK:[
M=90N"Z&)"O\ /]:N6?B73[>Y\2W%SIR:<-+=#=3#:7G_ '>0QP.3MP ,GTH
MZ.6Y@A>-)9HXWE;;&KL 7/H/4U+7 Z_/>77B?PA<W>E16OF7I*2";?(H,3'8
MXVC!YSP2,@^V=>_\83:=^_GTIH[/^T18[Y9=DKY8+YBH5PR9/][D<T =/4<4
M\,^_R9DD\MRC[&!VL.H..A'I7.6FKZO-X]U+3&@MS9VMK"Z!9FW88O\ -C;@
ML=N,9 &.IS4.G>*["VT75]1;218?9=3DMG@B*E[B?*KGC W,S 9_$F@#K:*P
M3XCGM-<M=)U33TMY;Z-VM)(9_-21D&60DJNUL<CL?6L=OB#=)HLVLMX?<65I
M=M;W;FZ7=& ^PLHQ\V#U''U/. #MJCAN(;A2\$R2JK%248, P."..X-/8E5)
M"EB!P!WKBH_&4.G>#;S7+;P^($@OGAEMHI%7Y_-"%R0.26/. : .VHKGK;Q)
M>/XCDT2ZTC[+*]JUS:.UR&$JA@I5L#Y#DCINJ/3O%DU_X>N]1_LU8KJUNFM&
MLVN,MYH<*%+;>"21CCN* .EJ*>X@ME#W$T<2LP4&1@H)/ '/<UDOKMU-J5UI
MNFV,5U=6,2/=>9<F-$9QE44[22<#/( P1Z\<UXFU>R\2^$M)U6" HZZO;(4E
M4>9 XF"NI]#D?C0!Z!4<UQ#;())YDB0L%#.P49)P!SW)XK(77YE\8?\ "/SV
M2Q*]J;F&X\[(E (!4+M^\,\C/3FL[6?$0CT..\OM"BN[>34$@C4RAE_UNU9?
MF7^]R, ]CF@#K**YR\\37L?B:?0;/13<7$=F+J-WN5C1P7*\G!P,@^IZ<=Q'
M;^-H)_#6GZK]C=)[^[%E':LX^6<N4(+8Z JQSCH.G:@#IZ*PM.\0W%WXDO-#
MGTX0S6:)(\J3AT97!VD9 /8@\<56\7ZOJNFW>AP:?' 4OM02&1I)2K'@MMX4
MX!V\G\,<T ="MS UPUNLT9F10S1AAN4'H2.N*EK@TDO+'XD:R^G:5'<W4NF6
M[O$)A$A;<^27(S[ [>?:M6W\;V5UH6E:BJ1PR:KN$45Q,(U0KG?N?'0$8R <
MDCCG@ Z>BL/PWXE37Y+^W,"PW%A*(Y/*E\V)P1E61\#<#SV&,5+=ZU/_ &G/
MIFEV:7EU;0+-,))O*1 V=BY"M\QVMQCH.O2@#7HKGXO%+W$>EPQZ9-%J.I1O
M(+.Z/E&!4^\7."0,D <<Y'OBI/XW-KIVMO/I;"_T0!KFU68%60KN5U<@94CV
MS[4 =717(7?C74=/M(+RZ\-3+;75Q;PV[K=(S.)>Y7&01Z=\]14]GXR=-;N=
M*UW2VTF6*U:\BD,XE26%?O'( P1W'/UH ZBBN7D\8R6MAI^KWFF>3I-^Z*LX
MGW21"3_5M(FW !R,X8XR*7_A*]1F\0:CH]EX?>X?3W@\QS=(@*29);D=0!G'
M?GIQD Z>BN7F\836TUB]SI+06M]J'V"(R2E9MVXJ',97[I(_O9P0>])IVL:Q
M<^.M;T^2"!K2RAM_+59SNPPD.[!7!8X (R ,#DT =+#<0W*%X)DE4,5+(P8
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M756FMX6N@C./,:8F-QG:RKGDCUZY KTFJ&K:)INN0)#J5HLZQMOC.2K(WJK
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M7)GPLB!@=S\9#8'.,Y-7]4T74-4\5:=?O:QK9Q6<]M< S?./-"YV\<XQ[=:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!30BAF<* S=2!R:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(5G( +9(P.: -2BHYI/)A>3RWDVC.Q!EF]A5/0=9M_$.BVVK6B2)!<J6190
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M^]>RM5C52 Z*I+ON!W LW3I@>O-7;GPJ;O\ LII]7NY)=+F\Y)&6/,CX*_,
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M,&4 ;=JJ".@'KZG/11*R1*KR&1@ "Y !8^O'% #Z*** "BBB@ HHHH ****
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MJ,_FZLJ+*"B$1[%VKMX]/7-4_P#A!X1H&EZ.NIW2PZ5<1SP2!4WED.4!^7!
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MN8[Z^N;P/<L\#W6/,$9 X..GS;B!V!'3H-BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F/-%&Z
M(\B*SG"AF +'V]:?7@WQ0\(>+M3\>RW=K87=];S!!:R0@LL0  VD]$PV3SCK
MF@#WFBJ>D0W=OHMC!?R^;=QV\:3R9SOD"@,?Q.:N4 %1O<0QR"-YHU=AD*S
M$CZ5)7GGB)KC2+_5-5EMK;6=$DN8FNT'%U8R*$ *Y^\!A6QUY]R2 >@>=%AC
MYB?+][YAQ]:PM<UJ]T_7-!MK;[.UKJ-RT,I927&$9@5(..WI638K9P^//&"W
M"PQQ26=H[AP K#;("3GKVR:YW38+>^\+_#NWG420R7#*ZYX;]W)D'V[$=^E
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M"TS0K*AE499 PW >XJ2O,[Z*W?X9Z!J^CA?[422U:WF3_623.RK*K'JV27W
M]<'-=EXRN+RU\':O/IY87,=I(T93[R\<D>X&30!K+<0NSJLT;-']\!@2OU]*
M/M$.W=YT>,XSN%<9IEAH5_J&B:Q8ZM"Q$3Q0PVL:+Y\;)\R2 9)"XSST/O65
M;V.FZ-XO2*2W4^&K^^9[3<B^5'?A=N/]P_,%[;@<# !H ](EFB@ ,TJ1@G +
ML!D^E+++'!&9)9%C0=6<X _&N+2;3M1\;>)-*U[R3_H\*VJ3D &W:/YRF?\
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MU>6Z.IZ^MHEVL1AABM&9DC4G+'<P!RQ"\=@H]Z -.Y$4.GS DPQ)$V3&,%%
M[?05Q/A[[9I>LZ1HVK6UIJ$$EG)'IFJ6PQOA"J2LB>X"G(X/'J:[QT61&1U#
M*PPRD9!'I56STG3=/??9:?;6S8VYAB5..N.!TS0!Y?:7,=K\*=)V&,0?VHJZ
MJ%QN%M]J?=O[X/ Y[$UT^N0SV_C_ $>XT5%$\]A="[$8&'C51Y1;_MH0 ?<U
MU<6F:? EPD-C;1K=,6G5(E E)ZEN/F)]Z2QTO3],5EL+&WM0V 1#$$SCIT]*
M .*\+3^'-8\*Z!+=3(VHVLZ.4$FV?[7DA]PSN.222#QCD\"LDWALO$.MS:E$
MLWATZULO\?\ +-_+C\MG]8PW4>N,Y'%>DPZ-I5OJ$FHPZ;:1WDN=]PD*B1L]
M<MC)IHT'1Q'-&-)L0EQ_KE%NF).<_,,<\^M %V,H8U,94H0-NWICMBO.+ 6^
MI?#CQ*=6"_VA%/=M=LWWXYE),9'<8 3;]!BO1+:VM[.!8+6"."%!A8XD"JOT
M JO+HVESWOVV73K62ZX_?-"I?CISC/';TH XB]LS=7G@%]9M8I+Z;*W9EC!9
MV%N20V>O/;UKMM6AC.AWD7EJ4%NX";>.%..*6\T;3-0N8KF\L+>XF@YBDDC#
M-']">GX5<  &.U 'EK?8Y?AKX.A1HB7O]/64(P!R6YSCG/!_*K^H0-I/BGQ-
M#H-NEM*WAU9HX[= N90T@4@#OTQ79GP_HA@6W.CV'DI(9%C^S)M5SU8#&,^]
M3)I6FQWOVZ/3[5+K&WSUA428Z8W8S0!Q>B0^']5'AS5+37&>XM@%MK>#RE?E
M<.C@+NP "3GTS6I\0KS[#H]A--G^S_[3MQJ!QD"#<<[O]G=MR.XX[UNVFBZ5
M87<MW9Z;:6]Q-_K)8H55W^I R:M30Q7,+PSQ)+%("KHZAE8>A!ZT </XM:QB
MT/Q%J?AF42:I/8)YSVDNY1&#C=\IP&V%L'KA3Z4_78K5G\&WWA]$61KZ*.$P
M@?-:,A,@..J[0#['%=?8:7I^E6YM].L;>TA)W&."((I/K@4RST?3-/E:6RTZ
MUMG;(+0PJA.3D]!Z\T <?X1\/Z+=ZIXE-QIEI,8-:D\H/$K"/]VGW1T&<G..
MOX5S$&AZ=+\%;;4;:VC&KQ2 VES&/WPE%P515;K[;>G.<9KU:'3+'3?.N-.T
MRUBGD&6,,2QM(?<@>OK6%X'\+#1/#]G;ZEIUH-1M2Y,\85\DL2"&QG.#B@"O
MHC"]\;>)[+6(HY)A' L4<HRIMBG.T'^'?G/N>:Y:WLQ/X;\)+>H)HAX@,%K)
M)RS6O[W:N>I4@#CH1BO4+W2=-U&1)+[3[:Y>,$(TT2N5!Z@$CI1=Z1IE^L:W
MFG6MR(?]6)H5?9],CB@#F;J/1M,\66FEV-M:64\6GS2AIOEMXHGD&_;&,!F)
M!SR,#/TKE=.>VE\ ^"#(\4GE:Y&CEB#M7?, #Z#@5ZE<Z7I]Y/!/=6-M/+;G
M,,DD2LT1_P!DD<?A3#HNE-9M9-IEF;5W\QH# NQFSG<5Q@G/.: .8:.W3XKP
MSV,<.^7P_(P9,8DQ*FWD=1C]*P8O)O\ X+7%U-G^U87DDDDQB=+T2\<]0Y.T
M#O@@5Z/_ &7IWVU;W[!;?:E7:L_DKY@'H&QG%-_L;2_MQO\ ^SK7[42&,_DK
MO)'0YQG/O0!Q]MI=M=_$TIJ5E;RRR>'X9+A&C!5I?-8$D=">,9-:/PTPO@N&
M)?N17-S&@_NJ)GP/RKH&TC3'O#>OIUJUTRE3.85+D$8(W8SC%/LM.L=-C:.P
MLK>T1CN98(E0$^I % ''Q;+?XA>)FA6$79T^W:V#@ M)B3&,]R<5C3"*\^"U
MK>VN?[5A:-XI1_KA>>: WON+$@^H->E-86;WR7S6D#7<:E$G,8,BJ>P;J![5
M$FC:7'?-?)IUJMTS;C,(5#EL8SG&<X[T 2W"&73Y$F16+1'<N,@G%>71FTD^
M#WA^)'BWM=68D", W^N[XYSP?R->LUGGP_HK0>0VCV!B\PR^6;9-N\]6QCK[
MT <A>6W]D^.M6BT.VCMYI/#32I% @4-*LC!#@=3VJ+0(M UBQ\-ZA%KKFZM&
M3R8(?*$N\C$B. NXCJ6]@3GO7<+I.FI>K>KI]JMTJ[5G$*AP,8P&QG&*;;:+
MI5G?2WUKIMI!=3?ZR>.%5=_7+ 9- &3\0X(9_ &M":-'"6CNNX X8#((]\UC
MZO8V5WXH\#^?;Q2>;%<*VY1\ZBWS@^HSVZ<UVUU9VM] UO>6T5Q"W6.9 ZG\
M#Q5=M$TEV@9M+LV-L,0$VZ$Q#_9XX_"@#S36[6VMO#/Q"L[:&..""YC>.)%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRBW@ +! <%B20 ,\<GGMFL^;QMHD&BKJ[2S&W,_V=P(6W12;MI5QCY"">^*
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M<"-0F>N%15&?<@GKSS6G0!R%F\__  LB]OY+"]BMWTJ*,2-;.5WJS,5R 02
MPZ'D],US-AI^IVGA/P_>OH5S>G2;VZ-YITEL1(\<KOAD5A\Q 93@>OUKU6B@
M##\-_99S<WMGX?.D1S[!F6U6":8C/+*.<#( SSU[8SN444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7-WGCC3[6]U"RCL-3N[G3@AFBM[4L=K G(R1P /U&,UTE<3INH)8_$7Q9OM
M[F4-%9$&"!I.1&W!V@XSGOQQUH TW\=:*+/2[N(W-Q#JS%;9H82V6P?E/^UD
M$8ZYJQ#XGAN$MTBTZ_-Y<1-*+%XECFC16VEG#, H)Z9//;/-<E;Z%?Z+I_A:
M%[&XD>WU.2\ND@C+BW1Q)QD<'&\#C/0UN75O>:1\06UMK:>YTZ^L5MI&@C,C
M02(Q895<G:03R <'K0!9F\<Z-!HO]JN;CR5N?LLJ>2=\$NX*5<=%()'4_3-2
MZ;XOT_4=:DT=K>]LKM8O.C6\@,7G1YP63/;V.#[<&N-\0:9<:?X9UG5)H'0Z
MEKEO<16_1@@DC5<CLS8)QVR,\YKH-6TF3Q1XDL[J".>UM[*RNHFGEA:-F>90
M@4!@"=HR2>G3WH T6\8Z<D-O=O#<IIUS*(HK\HODLQ. >NX*3P&*@=.<$4V[
M\9V-KJMUI:6&I75U:"-I([>U+DJY(W#U QR?RS7-G3=3U+X;1^#)].GAU%5C
MM'=HCY 1'7]Z)/ND;5SC.[/&*VM,AN(?B-JT[6ER+:>S@BBN&B;8S)NW#/XC
MGH: ':3XIEU,:\;W2[J&VT^YD@^3:[!51"1A&+%B6)X& ".:L:5K>D6OAG2)
M;".X-O>*L=C;L=TTG!(')[ $DDX ')K-T:&^TVX\56T^FW6VYO);J&94W)(K
MQJ %P<EL@\8X[UE6&DZK9:-X+U-;"X>30P\5Y9[") LB;"RK_%MZX'7/% '6
M+XLL!'J7GPW4%QIB>9<VKQ@RJA&0P"DA@0#R"??%0V?C;3KRYTN(6M]%'JL8
M:UN)8-L;,4W[,Y^]CVP<<$UE:AIUQJ&L:WK\-K<+"^B'3[>-H662=R68G81N
M &549 []N:JM;7HT+P-%_9UYYFFRP&[46[9B"0E&)XYY/;K0!T5SXQTZV:9V
MAN6M;>\%E-=*B^7'*2!@Y.[ + 9 (R:9%XBNI?&]QH0TV806]JDIE#1\[F(W
M?>SM&,>O7CI7*>((-=U;2]7@N=&U":\AU%'M_+ $'D+*I4H,_,Q4')P3R>@X
MK>%O?KX_N+LZ==+;ZCI<4*S*%(A=68L'.>" P/&<]J -23Q9IL,UJ)!.EM>3
M_9X+PI^YDDY 4'.>2#@D8/8UHZCJ%OI5A+>W3%8H@,X')). ![DD#\:X/PQ"
M(;"S\.ZGX,D?4K$K%]JDM%:V8*<"82GCISCKG].R\21Q3:!<PSZ<^I0R;4EM
MD&6="P#8]P"2/I0!D>*M0^V^$_$5NUM>V4]GI[S LX3.5<J0R,<\H<C-.\/^
M*+0IHVCRV]Y%+=6:FWGEBQ%.40%@ISG('/( (Z$UAG2]5L_#_B33+-]2U#2I
MM/,6GQW<3>>DKJRF-=P#% "O)X&<#H:N3079U#P1*MC=E+!'%T?(;]SF#RQG
MC^]_CTH VF\8Z<)8_P!S<FVEOOL"W81?+\[.W;UW8W C.W&>]-F\9V,6K7>E
MQV&I7-S9M$)5@M2V!(3AO]T8Y/OQGFN2U&'7M3LHI+W1-1DU"SUJ.:0( (1"
MLV1Y2[L-\N,G&>N3TKHM$2Y7Q_KUU-8W,,%Y!:K%*\1VEHU;>,]."P]CVS0!
MI:CXKT[2TFGG2X:TMI!%<74<>Z.%B0,-SDXR,D @=\5K/-%' T[R*L2J79R?
ME"XSG/IBO/;*'^R[W4]%U?PA/JC3WDT]K=):K+#.DCEP)'/"D$X.?_U]CK>D
MR:IX4O=(B:."2XLW@0H,(I*X'_ ?Z4 5T\76.^Q::WNK>VU%PEI=3(HCE8\J
M."64L.FX#-8VH7#ZUX^FT*_TRYFT]-.!$>Y  SRE3-]_/ 48/WAS@#-07%I?
M^(O"FD:#-IUS:7MO-;B[:2(JD(B(+,K_ '6SMXVD_>[<UIPK<#XG7-X;.Y%J
M^F1VRS^2VPR"1F(SCT8<]/>@";Q-JDW@[P=YUI#/>M;K' LDDBLRY(0.Y)!;
MDCIU/H,D9FL7K6OQ T&[>WO5::RNMUH&\QBPV!0%5BH/)Y!^IK3^(%A=ZEX+
MOK6QMWN+@M"ZQ)]Y@DJ.0/?"FJETUU>>.]!U$:;>Q6\5I<+*[PG]V7V[0<9P
M3M_#/.* -;3_ !3IVH:1-J6)K=+>9K>:*>/$D<H(785&<L20 !G.14MCX@M+
MW59M):*>UOHHA,8)U +1DX#J02",\=>#UKB9=)U6?1/$'V?3)GG37_[2@MYX
MRBW<2E#@9]=K<=>GK71^')K+4KX7UKX6FTMDA*23WEF()<DCY%[D=23TX'7L
M ;-]JL5E=6]H(I;BYN0[10Q;0Q5,;CEB!@;E[]ZP]4\7SV\FB+9Z5=.NIW30
MMO\ +5DV[LK@M][*_3&><\4_Q?IEGJMQ807EK?KL$LD.HV"N9;.0; ,;03\P
M)[$?+6--:>(?[+\+7NI6T]]<V&HL]QY48$IB(=4=ESC."N?3/UH ZFY\0PPW
M$]O!97=Y/:QK)<QVZH3"&&0#E@"V 3A<G\QD3Q-IEQI]C>6<C7BZB<6L<(^>
M4@$G@XQ@ YR1C'K6+IB7OA[Q3K<MY8W4MIJKQW5O+!$9BKA K1L%SM(P,'IC
MO6+;Z!K7A:U\/ZO'I\MZUG-=->V-N0TB)<'/R#."5P,@=?IS0!=\9ZW;ZSX*
MOY;;[5;7%A?PP31.Q1HW\Y 0=I*L"K>I'-=?#JR7&JSV$-M/)]GQYEP OE*2
M,[<YSN]1CC(]17+^+I-2U_P5<K#H]Y$T\\!@MVC_ 'Q5949F8 D+P#@$YX]\
M"SX6_M#0]0N- GM[NXTT'SK"_:)N%<[C'(2,[@2?F/7O@T =%J6J6VE0)+<%
MB99%BBC09>61NBJ/7]  2< 54M?$5O=7MUIYM;F'4+6(3&SE"!Y$/1E(8J03
MQ][@]<5G^,]/OYI-&U6P@>Z;2KX3RVR?>DC(*L5'=@#D#OS38K234?&\?B)8
M+B&SM-.:W!EA:-Y79]Q 0C=A0/3DGC.* ,[PI&/%!DU34+6\BN[;4YGBNA(J
MX5'*B'Y6)*X&"N,'DYR<UT]_KL%EJ"Z?';7%W>- UQY-N%R(P0,Y8@=3@#.:
MR? $-Q:Z/=6]W:7%M*;ZXF"S1%<H\A92#TZ&EUF;4_\ A+8+>33KRYTE[3Y3
M:8 :?=RLC9!"[<8&<')SGL 3R>-]'2QTJ]474L&K.$MVC@+?,03@^_!X&3Q2
MP>,;.:VU23[!J$<VDX-S:O"!*%()# ;L$$ GKGCI7'Z9I^J6WA;P=9SZ1?)+
MIFI"2Y7R2VU ) 6XSQ\P]SZ5TVCPW"?$#Q#<26EPEM=PVRPS/$0CE P89_X$
M/KVH TT\1VTNDZ=J4-O<21:DR+ BA-_SC()&['09//'?H:T;NZ@L;26[NI5B
M@@0O)(QX50,DUR/A31KJPUV]T]V5M+T>=VT\ Y*F90Q4^FP,P'M)6SXQTFXU
MWPEJ6F6C!;B>'$63@%@00#]<8_&@!8?$=K=:G#I,]K>6<UY TMN9E"^:H^]@
MJQ*D @X."*P?!>KP:3X'AFNWFE:349K>)<EY)7:=E5<D]?<GZFM;0_$&I:L(
MA=:!>Z<\*$W;7,8"[L?=BP27R><XQ@>I%<WIHUW2_!%M!;Z;>K(-6=KN-(?W
MRV[RNQ:,'J<%>G(R>AYH ZM/%>G^1J<EPD]J^E,JW,,RC<I8 IC:2#N!&,'\
MJDD\16]M'?27UK<V2V,22R><%.Y6+ ;2K$$Y4C'TKD[:PFAU#Q5]I\-7UQI^
MHK:E8I,,94"A'YW$E^K=<\<D&I+'2[NPM-6L!!J&L>'6@B$-K>QL)@2Q#QIN
M 8J%P1GH< '@F@#L;+4S=W<]J]E<VLL"(Y\X)A@Q8#!5B#]PY_"DU#5H+"XM
M[4QRSW5UN\FWA WL%&6/)  &1R2.H'4BL'PCIU]I>J7=K!<WT^A"%#;#4$82
M0R9.8U+ ,4 QUZ9 '>G:W:7MCXVTOQ%%;S75FMM)9W*0H7>(,0RN%'+#(P<<
MT 6I?&NEP:/J&HRQW2'37V7=MY69H6Z\@'&".0V<'UJ_I.M1ZNT_E6=Y D6W
M;)<0E$F##(*'^(5QNM:+?7=CXRU."SN"VLP16]I;B(B238F-[+U7))QG' YZ
MUW6FR&73;9S')&3&H*2(593CD$&@"E>>([>TEO$2TNKD6)47+0!2(BRA@""P
M)^4@\ \'ZT[4O$%KIOVC,%S<_9(Q)<_9X]WDKUR>1G@$X&3CG%<MXFTJXFUB
M_P!2T2#4;#78FC2":&-C;WZ[5P)/X, EER<8V]Z2Y5]&\6ZJ=6\-7.KV>JF.
M6"XM;7S]C"-4:-Q_"/EX)XH WKOQKI5O-8Q1)=WC:C T]K]F@+B95 .%Z9."
M..W?%-L=6TK4/%<*BTOX-3?2_.Q<(T:K"77Y2I.-VXCL<8(S6=/:3P>*O"LD
M.CR6UM9P7*S);0YCMO,";%RHQV(..._2K-Q:W,GQ,^TBWN%M6T9K7[2(CL60
MRA@,_09STH T)/%FFPS6OFB=+:[G^SP7A3]R\G("YSGD@X)&#V-2?\)%;O,5
MBM;J:%;O[(UQ&%*+)NVD'YMV W!..M<AX8A$-A:>'=4\&2/J5B5B^U26BM;,
M%/$WFGCISCKG])YM+NH_$/\ :>@V^H:=?R:EMO;9HV^R7<(<@RDGY02@SD'.
M>W.: .XO;VVTZRFO;R98;>!"\DC=%4=:S8O$UL=1M;&ZM+NQEOE+6IN44+-@
M9*C:QPV.<-@U%XXT:Z\0>#M1TRR8+<S(K19. S*P<+^.W'XUFW\=SXLN/#Q%
MA=636%ZE[=FXA9/***P\L$\/EB.5R,#.>F0"HI/BGQ=KVDZGI]Y]GMH[>.!E
MD13:%E9BX(?(8G&",G  ..E;7BC7;GP[;Z6EM9RW37=]!:E]R\!F&<[B,L0"
M!VSR2.]704GC\>>)+F6SN8[>\%L+>9X6"R;(R&YQQ@GOC/:I?'-I=W%CI<]I
M:RW1L=5MKJ6.$9<QHWS8'<\]* ,R;4&T_P")TDOV:^F:;0UD%G&?,?>9CG W
M;5X SR!QUYYZ&R\3Z=?Z);:K 93'=.8XH2F)6D!(*;?4%6SV&"<X&:R8?M3?
M$IM3DT^[BM3HRP>8T1($GFERN1GG![<9XS7-P:;JMKX;TV\.B7-TVEZM<3SZ
M>\/SRPRF0;D!X8@."!0!Z!I6NVFK7%W:Q++#=V+A+BWF7:\>1E3P2"".002*
M=>ZO%:7:64<$UW=O&91;P;=P0'&XEB !G@9//;H:H>&S9W4EQ?V7A]]*2554
MO/;"":8C/5>NT<8SUR<=.<W6&U+0?'(UR+2[O4M/O+%;69;- \L+H[,IVY&5
M(8_YZ@&K;>+=,O-,L;ZU\Z8Z@[1V]N$Q*[KG<N"0!MVG))P,=>E+'XLL&@U)
MY8KF&?2QNNK5X\RHN,@@*2&!'(()%8^KP:M)K'A[Q-_9TICLGG2XLH\/+'%*
MH ; )W,, D+GK@9QFF7>FW%[J?B'7H[:X6*XTK[#;1&%A).V&);81D<D*,@=
M">G- %M_B'I4>E_VI)8ZHED8895N&M2(V$A  #9QD$@')QZ$U=L/&&GWVN_V
M,UO>VER\9E@^U0&-;A!U*9Y/T(!]JY?Q")K?X(0036TT4]K!8PR0R)M8.DL0
M(Y]QUZ5LZGI\GB7Q/I%U##<6\&FPW)DGFA:([I4V!%# $]221QP.>: +LOC+
M38;9+YXKD:8\WDC4-J^2&W;<GG<%W<;MN/?&#2:AXSL;#5+G3!8ZE=W=O"LS
M16UJ7+(3C*CN!Z]*YJ'3=4E^&S^"Y].G74D3[()/*)@9-_$HD^[C;SC.[(QB
MMFPMI[;XBS2?9;HVO]E16J7+1'8SH[$@GZ$<]* +UQXRTZW:5VAN6M8+P64U
MTJ+Y<<I(&""=V 6 R 1DTR/Q'=2>-KG0_P"S9A!;6J2F4%#NW,1NQNSM^7&
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M9%()8ED4,H8 @.I4CZ@\B@!]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !618>'HM
M/U[4=82]NY9M1\L31R%-@V A=N%!& 3WK7K@+;5/[!\;^+'BT[4-1)%H_E6J
M>8RCRV+'YB!U/3.3V'6@#OZ*Q;7Q3I^H:;87NGB6[_M$,;>*, .VW[V=Q &W
MH<GKQR2*HR^/M,@TRXO)K6]5K2[%I<P>6I>&0D 9PV"#D8()S0!I^(?#\/B.
MQ2SN+NYMXTE27_1R@+,I!7.Y3QD UIHI5%4L7(&"S8R??CBL>P\3VUYK5QI,
MMG=V5Q#!]I7[4BJ)8LXWK@G !Z@X(STJ(^+[-)].$UK=0VNJ2"*SNW"^7(Q&
M5& VX;ATR!^% &_17!87Q/XM\0Z;J^DW,UM:Q6Z0C='NMLJSEE(?(9CC!7)X
M&<8K4\/ZUH=IX52[T^WNH+5[IX8X)<M-+,9"I'+'EFSU/'? ' !U-%8$GB6T
MFCU:TO-/O8I+" 27$!0$R1L#RA5B#P#W!&*9I^NZ9:Z+H,6G6=P4U&!?L-J,
M%@@CW?,S-@87&<D_C0!T5%<%XUU:U\0?"[6KJ!)X6MBT,D<AVO'*CA64[20?
MS(J]K:!?B)X1<%LNEX&&XX.(ACCIW/YT =?16+IOB>VU+^U%%I=6[Z4Y2X2?
M8IR%W<88C!'()P#ZUHZ?>#4-/@O!!+ )T#B.8 .H/(R 2 <>] %FBN?N?&-E
M;6DVH?9;J73;>8Q2WL:J8U(;:S8W;BH;() /0]1S5@>)+=M?_L9+6Y>9K0W<
M4@V>7-'D#Y3NY.2!T'KTYH V**P+/Q=:WVAOJL-A>E$N?LQ@(C$OF;PF,;\#
MYCCDU#/XUMXKO4[2'2-3N;C2U1IXXHE^ZREL@E@.@]<G/ /- '2T5DQ^([.X
MT_3[NT26Y.I)OMH4 #N-NXDY(  '7)]NI JM;^,M,FL;N>1)X)K.Y%I-:.H,
MOG$@*@ )#;B1@@X_(T ;]%<1;3O/\7D,EG<VC_V)(2LSA@W[Y,%=K$>Q^GXU
M8^(12&/0+IO,)BUJVXCW$D9)(VCKT':@#KZ*YVS\96]W=WM@VE:E;W]I#Y_V
M.:-!)-'G&Y/FP>>.O6IK;Q7:7GARUURWM;J2"[D2.*(!/,)9]@XW8Z]>>/PH
M W**HZSJ$FE:+=ZA':M<O;0M+Y2L%)P,]2<?YXS7$:YJ4M_H7@S6+RWN(IWU
M.T9P,'S0T98E50G()Q@$9XZ4 >BT5B:;XIM+Z;4H;BVN-.FTM5>X2["C;&P+
M!P58@C /?C%-3Q5;#4[&QNK*[M/[25C9RS!=LI SMX8E3CD!@/SXH W:*PO&
M=[IECX:GEUFTN+JQ+()(X,YSO&W)!&!NQWI;_P 4V]CKHT46%]<7;6QN(UAC
M4K( 0, D@9Y[X''7I0!N45QVJ>.C_P (DNL:787!D>[6TDCF"J]N_F!&# GD
MYZ8R.F>*W9];,<BV\6G74]X8?.:U0Q[XTR0"Q+;>2"!@G.#Z' !J45RX\?Z3
M)::9<P6][.FIR-#$$B&5D7.489X;*D=_RYJ[%XD^T0QB'2+\WC0F9[)U1)8E
MW%06W, ,E3CGG% &W16!9>,-.U.UT^;3TFN7U!9&AA 5''EX#AMQ !!(&,]_
M3FJFI^+;J&;0UM=)NMNI7312!S&'38'RF"V-V5ZYQCOF@#JJ*Q=1\2Q6$=W(
MEA=W2V"![OR-G[GY=Q!RPRP4@X&>"/44O_"2V5S]DCT]);^2]MOM,2084B+C
MYR6("C) '?/;@X -FJNI6/\ :6G36?VJYM?-7'G6LFR5/=6[&N8^&SB33M:8
M1RQ#^VKK$<QRZ#(PIY/(Z=3TK9U#Q'#8S7L,5G<WLEA )[A;?9E%()& S#)P
MI/'_ -:@"YIFFP:39+;0-+)R6>69R\DC'JS,>I/^>*N5SC>([S_A.TT)=.E-
MN+'[09 T?S;I%4-RP(5<-[G/3@5)=^+[.UMKJ]6TNY]/LY3%<7<*J40J<,<;
MMS!3P2 >AZX- &_163<>(+=)O(L;>;49OLXN2EL4XC.=IRS ?-@X&<G!KF]1
MU&TUCQ%X)UBT:40W,MP0),K@"%^"O0$'- '=45QWBS44UGX?Z[-':W4,,=M*
M89G956;:#AEVL25/4$C!%7-&\3VYN-,T:6RO+=[JTW6T\L8$<^Q06"\[@0#G
MD#- '2T5S]UXQLK:UN+\6EW-IUK*8I[V)5*(5.&.-VYE4\$@'H>N*S]3,;_$
MKPW<0N76>SNCN#DJP 3:0.G<]/6@#L**X?QWK4-_X+UU+6TN[B&W1XFNH2 B
MR+P?X@S '@D CZX.-Z+5Q:VEI9V]I/>W0LTF:& H"J8P"2S #)! YYP?0T ;
M5%<P?'VDMI^F7T,%Y-%J<WD1!(OF209RC#/!^4C S^7-:%GKSW;V"-HVIVYO
M!+GSH0!;[/\ GH03C=_#C.: ->BJVH7]KI=A/?7LHAM[="\CGL!_/Z5G)XF@
M74K2PO;&[L)+Y2;4SA-LI R5^5CAL<X.* -JBN=T[QC;ZI?O:6NE:DWE7CVD
MTIA&R%U&26.[@'IW]\9&>BH **** "BBB@ HHHH **** "BBB@#*\1:!!XET
MIM-N;JYMX7=78VY4,Q5@P^\I[@&M.-2D:JSM(0,%FQD^YP *=10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGL0W3L,?2NKJIIVFPZ;%*L3/))/(99I9""\KG W'  Z #     %6Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exh43lgnddescriptionofse004.jpg
<TEXT>
begin 644 exh43lgnddescriptionofse004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS'$HOXM4C\NYSEU4W3*5![*03D#@]:WY8(?$GB'Q-I&I75G'+&RI$ES!O>.
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M3M:_[!\__HMJY2UG\W4/ ^F7JAM/GTLR*CC*2SK$FT$=#A<D#U.>U 'H((8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-(U#3H].NM.MY+2''E0E %CQTVX^[CVHL-!TC2[B2YL=.M[>:4!7D2,!F &
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MA&$C)"C"_@H^I).!G%:M% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/VEXU(CVCL"3N.?3 SUH S_B/8Z#;Z29;NSDBN+BYB9M4CMF=K7#CYS(!D
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M %C3_$&I#Q/XD34EMH]/TI8B669B8T\LR;@-OS$YYY&,=\4^#QKYFHZ9"]K
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MS^:#P$5&CD']U@.0,_X[%_I^M:AXA\-ZH]C%&-.,S72"<'EX]GR<<@9)YQ0
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M0F8IC$!81Y"$!1D<XY( P*U]/\0W-QXFU#0[VPBM'M($GBD%R7\^-B1N V#
M!&#Z'\ZRYM UE;3PG-;V]N]UHF$GADGVJP,/EDA@#TZ]*D\7Z.=4U+1FMKH0
M7K2O:S&/K);.A,R^V  0>Q([F@#?T34)]5TF"^GMEMC.-Z(LA?*'[IR5'48.
M,=ZRYO$]U-#J=SI6G)>6^ERM%*6GV/*Z#+A!M(.,XY(R01[UT*JJ*$50JJ,
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M7><8Y&!G.3TK;.G>)M"\2:A<:+;6=_IVJR+,T<\YA:VEVA6;(4[E(4' Y_J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5>]O[/3H//OKJ&VBSC?,X49],GO5BN3^)RJ? .H$IN*O 1ZY\Y.E '
M645S$?BC4;7Q-;:3K6E16<.H([6=Q%<>8,H-Q1^!M;;SQD=@3UJK_P )V[K8
M7MO9+<6-[.L>V)F:>-&^[*5VXQT)&> >IH [&BN,G\8ZUY>O-:Z);,=$D(EW
MWA D0('.W"?>P>A 'N:T)O%L+BPCM!$LM]9B\!N&(6.,XQG )))/3V//0$ Z
M)F5%+,0J@9))P *S[?Q#HMU<K;6^K64L[/L6-)U+%L;L 9ST&?I7%^*/$5_K
M'PRO[I+'['(LZVMRDCL/^6J+E#M^=6#=3C@GK6Y>7?V#Q7HBW6AV!N]4:2)K
MR-]SQ>6C, ,H">.^1U(H ZFH3>6HO19&XB%TT9E$.\;R@.-V.N,G&:P;CQ)J
M,UO?W>C:6M_#87!MVC\TK+.RD"38,8^4DCGJ0>G!,HUACX[CTB338D+::URE
MWOS)C>JE",<<G/4]!0!OU534["26YBCO;=GM #<*)03#G.-W]WH>OI7/#Q?=
MPWVDQWVGQVRZK<- MN\O^D0_>V.RXY!V_AD<FF:!''_PL/Q>NQ=K)8Y&.#^[
M>@#0/AWPSKDW]L16T$[S];FVE91-CCDH0&Z8YS6U!;PVL"06\2111C"(B@*H
M]@*\\\.:[=>&_A7H-]%917%J&$=R[RE/(1I2N_A3D#/-=L-0G?7_ .SHH8VA
M2V$TTWF'<A8D*N,8.=K'KV]Z -&BLK5]:_L^]T_3H(EFO=1D984=MJJJ+N=V
M/H!C@=20..HS3XHOTGU;3&TV)]6TZ 7,<*S$1W41Z%3MR#D$8(ZXYH Z>BN1
M'C9ROAJ<6UM]FU["^8;@YA<KD+C;\W/R]N:EUWQ7?Z/I>J:E'ID%Q;V-PD"'
M[05,F2JL<;<<,^,9_A/- '4U7AN;/4(I1!-#<QJ[0RA&#@,.&4^X[BL:U\0:
MC_PE)T34--A@\^U:YM9([@OD*P4J_P HP?F!XR/<UDGQG/9^$-6UN+1+>-["
M_E@EMTGP&8.%+[@OS$DYZ#ZT =MTX%+7/6WB#4%\5QZ+J.G16Z75L]Q:R1S^
M8V$(#*XV@ _,#P2/<UG3^.;@:$FOVVGQ2V$EZ;55>8I)CS#&)#\IP-P^[C..
M<]J .RJ/SXC.8/-3S0NXQ[ANV],X]*6(NT2&5520J-RJVX ]P#@9_*N3L+:"
MV^+&IF")(S-I,,DFU0-S>:X)/OP* .IN;RULT#W5S% K' ,KA03^-,EU*P@M
M5NY;VWCMV.%F>50A^ASBN0\:V&KOJ2ZF^@:;K^D6L.#9S$F=3G+N@(VDX &.
M3QQU-32)#>R^&M<TBS,^C0VDP6VAC V>8B[/D_ J?3=Z9- '8A@5W @C&<TV
M.2.:))8G62-U#*ZG(8'H0>XKCM+AFT_PGI^@:K<)$EE9JVJS%_ECC[1;O4C@
M_P"R#_>4UU=C?6E]"7LY R1MY;+M*E&'\)4X*GIP1W% %FBL:YUJ:779-%TR
M**2Y@MQ//),Y"1AB0B\ DDX)]@._2L6X\?31Z VH1Z4&N;;41I]Y:F?!BDWA
M?E.,..01TZT =G15'2YM3F@D;5+.&UE$K!%AF,JLG&#D@<]>,=JYV3Q=K3IK
MWV;1;8MHLA#B2[($BA _RD)]X@]" !ZT =A17)Q^,+TS:%=2Z7''I>MLD<,G
MVC,R,Z%U++MQ@X/1L_RJQ)XDO;J/5+C1[&&ZATN5X7$DI1IW0 NJ8!QC. 3U
M.>@YH Z2BN1E\;3W,VA#1].CNXM<AED@>6?RRC(F2K#:<<GD@GH>.E23^++R
M/S;06MI'J-I;I)<Q23L5\Q@2(U(4YX&<GID=>< '5450T/5!K6BVNI?9I;4W
M";C#,N&C/0@_B#6++XMNY-(OM<T[3X[G3K&216!E*RS)&2)'08QP0V >N.V:
M .DN+F"TA::YF2&)>KR,% _$TRROK34;9;FQN8KF!L@21.&4XZ\BN.\0ZI=7
M^M>#Y]-$$MG>3M/#YDK+YA\AB-P"G  .>_-=-<Q'2=&O9]-M+6&X*O<,N,(T
MN,EC@9/3ZGVH MW5_9V)B%W=0P&9Q'$)'"EV)P%&>IR>@JQ7F5]>W]_X"\*:
MA?QI/<2:G8RJR/EY"6R<Y  )^N/>NGM_%<]MJ6K66N6D-H=/M!?"2WF,JM"=
MV>JJ<C:>W- '345REMXPN)-5TVWDL4>WU'(WV[,[6S8R!)\H&#TR#P?7K6QK
MVM1Z'91S-'YTUQ/';6\.[;YDKG"C/8=R>P!ZT :=%<^/$%Y;>(HM"U"U@2>\
M@>6RFCD)CE*??0@C((!![@CTZ5GKXXN'\%V/B,:;'_I%R()(///R9F,60=O/
M3/04 =A17*V^J:O)\1+_ $]Q ;*VLHI$0.V0&9LMC'+';TX %2Z#XGN?$-O;
M7MC#:2VMPK;PLY\RV<#*I(,<$]SV]\YH Z6BN+\-Z_KLWA.?4KBR74+DWDL<
M<<#L"3YY3D$?*BCOR<"KD/BV=[C7;06UM<7&D0).##<828,&)4G!*L-I'?MT
MH ZBH[BX@M('GN9HX8D&6DD8*JCW)Z5R5GXSU*1?#]W=Z3##8:WLC5UN2TD<
MC(7&5VXVG!'7/<XZ4[7-9N-7T'Q$FG6D$UK8QS6TK32$&5U3YPHP<;<XR>I!
M''6@#I1J=@5M&^V08O<?9CY@_?9&X;?7CGBK5<3IFKMI^D^![-M.AN$OK:&-
M;AW^:!A!G(7'< C.1WJS-XJUI]1UVPL=&M7DT<1ONDNR%D5D+]DSNQ@8Z=>>
MF0#K:*YI/%Z7=MX>-I;_ +_7U+Q+(WRQ!8][DD=2.@'<^E3^']?N]7O]3L[F
MQA@;39_(D=)RV]L @@%1@%3GKD'CWH WJ*PM;UZYT?6=)MFLXFLM1N/L[7+2
MD&*0@E1MV\[L8'/6F:EXG;2UU"::U5X+>:*VM]DGSSSOMPF", #<O.3W]* .
M@J.XN(;6WDN+B5(88E+R2.V%51R22>@K";Q!>6.OVFCZG:0(^HQNUG-#*2C2
M(,M&V1D<<@]_05BZ7XAU<^"-9U?4;.TOQ;2W1:+S2H=49@5P5/RA5XZY[T =
MQ')'-$DL3J\;J&5E.0P/0@T^N6N/%%Y;77AVSM=*AE&LP,R?Z1L$16+?MQM^
M[R.>> >#Q3(O&SVVB:[>:O8K#<:'*8YHK>3>LF5!4J2!UW#J.* .LHKFSXAU
M*#Q)I^C7%A;,;^!IUE2X8! N-ZXVG<1N!!X!]JO^(M<B\/:6+V8*$::.(O(V
MU(][!=S'LHSF@#5HKC/%6NZW:>"M4OK=+6-XW1(KB*4LLD3[!YB<<'+D>V,Y
M-:\VMW2ZK;:)%!;MJ4MN]S+^\)BAB#;0<X!8DD # [\\<@&Y4<\\-M"\]Q*D
M42#+/(P55'J2>E<S%XV1;:^BO+/RM3L;R.S:U23(EDD($15L?=;.<D9 !XXY
MEU"\U26UUC3]2TQ%@&GO+'=1/NB<D$%"" 0PZ^X]* .@M[B&[MX[FVE2:&50
M\<B'*LIY!![BI:XWP5JMQ<>&]"LM-@AN(X-/A%Y.\I40MY:D(, [F(.2.,#&
M>HST>N:Q;:!HUUJMWN,-LFXA>K'. H]R2!^- %^J=]JVFZ6%-_?VUKO^[YTH
M3/.._N163-XBO=+U33+76+*&*'5'\F*6"4OY4V,B-L@9SR P[CIWK)TE;S4O
M'?BBTU"TLY[8Q6D,T;R%P(RCD  KSDL20<=>] ';@Y&14"W]F]\UBEU"UTB;
MV@#@NJ],D=0.:Y[QGJ&HZ3;Z+%I0@CCN-4MK9PQ*_*7&%&!P#MP3Z=JS[A]0
MB^*+FRL[>2\DT!-P>4I$I\]LDL%+$=AA<_2@#N:*Y2S\;QW/A_3[Z2V6"\OK
MA[80/)\J2(6WDL!]T!">G<#O5WP_XAFU:^U"QN;3RI+)DVSQ;C#<(PR"I('(
MZ$=O6@#>HK(N]7F.L_V-IT44ETMO]HE>9RJ1J254< DDD'Z $^@-*/Q1=M!I
M-M-I36FK:F\BK:32?+$(\[W+ <KC&.,G<.G4 '25G66@:3IVI76I6EC%%>7A
MS/,!\S_CV_"LG_A++F&36;&YL(_[2TJW^TB-9B([F(@D,K;<@\$$$<'N:S[C
MQMK=KX63Q'+H-O\ 8I;>VECQ>'?F4JI^7;V+ CGD>AX !V]%<M%XJU"U\46^
MD:WI4=C%?QR26<\=QY@.P;F5^!A@O/!(]SUJ*;QI<1>'D\3C3T?1F<%L2'SU
MA+;1+MQCWVYZ=^U '75'/"ES \,NXI(-K!6*G'U'(KF;OQ/K#>(+G1]*T>VN
MI(K2.[BD>[V+(C,1S\O!X.!S]:;J_C"[T=)+JYTZ.&VCOEM5CEFVS3*653*@
MQ@C+=.X&<B@#H-+TFRT6Q2QT^$PVT>=D>]F"_3<3@>U36UY:W@D-K<13B*1H
MI/+<-L<=5..A'I7-PZIK$OQ%O=-Q;FSM[&.1$\Q@0&=@6/'+?+] /QJ*R\81
M0:'JFH3Z9';2VVJ260MX'!\^;<J@[L#EF/)QTYH Z^BN?;Q!>6&OV>D:G:0*
MVHQN;2:&4E#(@RT;9&1QR#W]!6*?'NJKH$FNOHD"V5I>-;W0^UDN )/+R@VX
M;!.><?3O0!W5%-=MJ,VTM@9P.IKE[;Q==_VOH]C?6$5L^KK(5@\[]];%5+@2
M*1W /T/'- '54G3DUQ,WC?61I>M:A%H=L8]$O)(;@->'YT15)*?)R<,3S@=.
MISC;D\0&YU.WTO3(HY+B:T%X[3,0L41.%R!DDDYX] 3GH" :EI?V=^CO9W4-
MRD;F-VB<,%88R"1WY%6*X_X=>8;77O.A2&7^W+G?&C;E4_+G!P,C\!6AKNOW
MVEM>M%91+;V=J)S<74OEI,YS^Z0XZX7KVR..: .@HKE)/&-T\_AQ;+2TF37[
M=IHR]QL,9$7F8(V].1DC/0\'C+(_%NK-HVMR_P!CPR:EHLQ2:VCN3LE7:'W(
MVW.=IZ$=J .NHK$AU^2\BT1[*&"?^U$\U_WI CB"[BXXYP2JXXY85MT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+LW,?DRLS+\JKM(*CLN<Y[T 7=9U?^S#9P11B6[O[@06Z,V%S@L6)] JD^_
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M^LZE:7'FV+3G[/&N"B2N%,Y4]P2J_0[QZUT.JI?2:?(NFF#[3E2HG)", P+
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M4K5K6_M8;J!_O1S('4_@:KZ9H6DZ*&_LS3K:T+C#&*,*6'H3U-:%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD<<CG'O0!:HJO?3SVUC-/;6K7<T:%D@5PID/ID\"IHV9HU9D*,0"5)SM/I0
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME8-\Q+.>V<*,#N2.V:[@ *H50 !P .U1QVT$5Q+<)$JRS8\QP.6P,#/T_J:
M,#7IVTV#2= TUVMGU*Y\@3 _-'&%+R,"?XR 1D\Y;/6LO3GT[_A/=0GMG$5C
MHE@(G ;Y6F<EG?\ VF"*H+=>:ZO4]'T[68XH]1LXKE89!)&)!G:P[BF)H&DQ
MO=NFGP*;V/R[C"8\Q-H7:?;  Q[4 <#/#)<_#.,>8\>H>(M05\)(1M>X?(W8
M_NQ$'!_NBM>?6E?Q==W:.SV'A_2G=4#_ .OE?)X]<)$<?7/0UTDOAS1I],M]
M-ETVW>SMG5X82GRHPZ$#\3^9J:+2-.@O9[V*RA6XN$6.60(,LH& /I@#CV%
M'):387FOZ3H^I7\\4,ES+%>R71DS*Q^^L,0'")T'7) .1DDUU6OZHFB:!?ZI
M)C%K \@![D#@?B<#\:;IGA[1]&8MIVGPVQ.<;%^[GJ!_='L*FU+2;#6+4VNH
MVRW,!.3$^=I^HZ'\: .8\-^#F_X0JRTZ_P!3OO*N(?,N[9"B!VD^9U+!=^,L
M0?F_2FOI\=[X_BT^Q0VUCI&FA)?(8IM,APJ#'0[$/(Z!CC!P:[&"".V@2&)=
ML:#"C).!^-,ALK:WN+BXAA1);E@TS@<R$  $_0 "@#DM)M(Y?$=[HKO(-'\/
M6\2)#-(6$\DBER\A/W@HX /&23V&,.?[1=?"_6=4C,D<4%]+>:2=Q4I L@*X
M_P!DX; Z8(QVKT*ZT73KV=YKBU21Y$$<G) E49PK@<,!D\'/4U/<6=M=V;V<
M\"26\B;&B8?*5],>E ')^);F$:3JWB2(.R?V?]DM@'.V=V;Y3CI@.0 >IRW;
M!J/6[.XT_P (:?#ITD=_)H:Q7%W:,^1=Q!65@3W)(9AGNO2NMOM,L=3LC97M
MM'-;$J?*8?+\I!'Y$"H9M"TR>5I'M$W/$(7VDJ'C&<(0#@KR?E/')H Y/5(]
M/GL_#&GV+.EOJ5Z;_=(Q4K  9F!YX'*+CT(%7;.YCUC5]?U#6'4:7I$QM8K>
M7_5C:@:25QT8G<,9Z <=371SZ3I]S=VMW-9Q//9@BW<K_JLXSC\A^5,FT33+
MBXDGFLXW>4JTH.=LA7[I9>C$8&"0<8'I0!Y]"=3U#PWX1TR42"\OKY[E!*QW
M1VJ,SC=SR-IC&#U'%=%X2A0^)_$EU%-(\(GCM5$DI8N\:_O'P?\ :?'''RXK
MIVLK9KY+UH$-S'&8TE(^95)!('U('Y4RRTRQTYIVL[6. W,K33%!@NY.23^)
M- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN-\4WT][XRT+PJ
MLCQ6EXLES>%&*F5$!VQY'8D<^HH [$,&S@@XX.#TI:XSQQI]OH/AF?7=$MX;
M"^TW;+&\$802*& 9' QN4@G@]\&M33O% U#5H]-6R*23::FH1.9/E9&( 4\9
M!S]: -^BN2?Q[#'H$.KG2KIDDOC9,B,I,;B39D\Y(STP#^%=!I=Y=WUN\EYI
MLNGR+*R"*61'+*.C94D<T 7:*YZ\\5F&WNKVSTN>^LK.X\B:2 YD+!@K%$QE
MPI.#R.AQG%&K^+K?39;V*&**XDL(P]PCW"Q-RN[:@/WFVX..!R.: .AHKE9/
M'4,DFE)IVEW=]_:]L\]J59%#;5!*G)X(R,YP/<TW3O$>LWOC!].GTK[-#'I\
M4[1-,I="[').."1MQ@'WSSP =4DB29V.K;25.#G!]*C-W;"1HS<1;T(#+O&5
M)Z9'O7+6FM1OX7\07VC:2;*>VNKI98V958S*,O(<9!.?<YQUK%ACTFT\(^'=
M9UCPTMW/Y5M"DZR*23)L/F/R,Y?GHQS]30!Z316/>Z[)'>75EIUBU]<6<(FG
M42; H;)50<'+D D#IZD9%1)XDDNUL%L=+N&FOK9KD)<@PK$JXR'.#ALL !@^
MO2@#=HKBM1\:W5SH.@ZGI%F?+U348K9Q*X5D_>$,G<')1AGTYK5U'Q4EC)-;
M)!#)=VT"S7$,ETL>W()"*3]YN#Z#IDC(H Z"BJ&B:Q:^(-&M=6LBQM[I-Z[A
M@CL0?<$$?A67<^+A'8WFJ6VGR76FV$CQSSI( YV'#LB?Q*O.3D=#@&@#HF94
M4LS!5 R23@ 4V*6.>,20R+(C=&0Y!_&N.\6ZI/<W'AE;&)+JQOKV.3/F +./
M+=U4@CIPK9]A72:?IMIH]G.;&P\DSN;B2WA;@R$#.W) &<>P[T 7DD21 \;J
MZGNIR*=7%V'B[3M.\&:=JECH<T%E=7;6ZV\6W]R3,R$D ]VR<*#R:UK#Q/\
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M.U1NP1O.[L/J>!56]\4Z5J/A[0]5ETF6[MM1O8%B#A/]'E+X5FR>QST!Z=J
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M9[F1F\L%2"<1Y&'( )/('09S5._\2Z@?%&A65A:+)9ZA;R7&YI K. HP,8X
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M]FLUSI5];SW"B:/!2,DG:=W).>/UQ0!KZQXXMM-%^\$=O<KIS;;A&NUCE8@
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MREM%61HBLCJQW*2K#@]B.]17OB5X]1O["PLX[RYT^!9I86N/+D<,"1L7:=W
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M.E-N/%<@L]0U"PTTWECILCQSR+-M=RG^L,:XPP7GJ5R0<=LT?"UOXLTNRM=
MO+&V%O8XC74UN 1+"IX CQD,0 O) '7GH6:?HVLZ'I^LZ);V0N[>\FFELKD2
MJJQB7JL@)W?*2>5#9'I0!H7?C&..]T6"QL);Z/6HWDMYD=5&%3?C!Y].N,?A
MBF6WC6+^S=2N-2L9+.YTVY%M+:K()2[MMV!#P#NW#'3WJE_PC5[IFH^$(K*V
M:YM=$CECGEWHI.^+9D GUR3[=,U0U'PGK>I'Q"T5N+::XOX+^P>612K-$%&U
M@"2,X- %FZ-TWQ3T&2[TV&VE:RNCYD,OF>8,+\I)53D?E\W!ZTV\\3R6_@OQ
M+JFC:1%87-E>313*[@%I %W2G:""W(XSSCK5LVWB'4_%NA:Q<:*EG%9P3QW"
MO=HQ4N%Z;<Y'''ZX[T_^$9U>Z\*>+=,>U$$^JWL]Q:[Y%(97V[02"<'Y>>W/
M6@#6U#5A;W/AZ'5-&CGFN[D)%,)%=8'V$A@2 <X!Z#\:LS>(IY9=172=.%^N
MF-Y=P3/Y9:3:&*1C:=S $=2HR0,]<9VJV.M:B_ANX.E['L+L3W$:W"-L4(RX
M!)&3\V>./>GZ;INK>&]7UK[+8F_L]3N3>PLDJ*8I6 #JX8CY<@$%<\=J 'OX
MZMY?["?3M/GO8=;#^3(KJNTJI)4@GKD8/8<\\5?\/Z_)K,NH6MU8-8WFG3B*
M:'S1(.5#*P8 9!!]*YVU\):AH@\(VMK ;N+1WFDNI5=5!:16!VAB"?F<GZ5L
M:!8:A:^*?$-Y=6;16^H2Q20.9%.0D80@@'(SC(]J &>(-9U:R\6:!IME! \%
MZT[/OF*%RD9.T_*<#D'/.2!T[S3^*)FBU*YTW3?MUMI<C17#";8[LHRXC7!W
M%<XY*Y.0*9XCTS4I_$.@:MIUM'<C3Y)Q+&\OE\21[0V<'@'KWJEINE:SX>;6
M["VL1>VVH7,MU:3"5%$32#YDD#$' /.5#9% '3Z;J-MJVFV^HV<GF6]S&)(V
MQC(/K[UAW'C![1[>6?2Y(K.XU'^STDDDVREBVT/Y97[A8==V<<XK2\-Z,OA[
MPY8Z0LGF?980A?&-S=2?S)KC+KP[XGN[-1<Z;;W-_;:LET;Q[H;KB)9=RJHQ
M\@"X&.!QP"30!WVH7;6.GW%VL#SF&,OY2$ M@9P"2!7,)X[F-EHVH2:%.MEJ
M[)%'(LZLZRNI*KMXR"1C<2/IBNDU%)Y='N8XX?,GD@91&C#!8C&,G'&>]<<=
M!UD>$_"NG#3F-QI-Y;37($L>-L0.=IW<DYX_7% &W:>+/]-U2SU>Q.G2:;;B
MZ=O.$JM"0WS9 &"-IR/YU6A\=0/JNGV<EO"5U(-Y#6]VLKHP&0LB@ (2.."1
MGC/>J^H^';[5O$FMF6V>&QU/218K/O0E'&XY*@YQ\WZ5;\/S^+_*@L=7TRV@
M%JH66]BN0_VH*.-B8^4GC)8COCKP )I/C*XU17N3H<T%A;RW$=U=/.A\DQ9_
MAZMG&..GOS2?\)I*(=&N3I#M;ZV0+0I.N\$KN4." !E>>">>*C\.6USH/AO5
MQK-K';1_:+FZW32*T;1N2V&VDXP.#Q],UAZ1'JNCV6ES:OX4NGM=,7?&ZZA%
M(EMN&"RQ\,< D $L0.!0!OZQX[M=-6^EACM[F+3Y/+N$-VJ3,1C=Y<9!W8SW
M*Y(.*6X\9W#:J=.TK0I]0E:P2^A/GI&LL;-@<GIWZ\^W<5K2T\4^'M9U*WT_
M3;;4M.U"Z>[AGDNA$;9WY<.,$LN>1M_KQ<@T[5(_B -3EMFDM#I:6;7&] 3(
M'+EMN<[3G\^V* -K4]4MM'TBXU._8Q06\9DD[D>P]3GBLQ_$L]CJ&G6VK:;]
MCCU-O+MY5F\S;+C(CD&!M8C.,%AD=:L>+="_X27PO?Z.)1$]S& CGHK AES[
M9 S67<:=JWB,Z&FJ6!LCIMVEY</YJ.LLD:D*(]I)P6.<L!@#% $VE^++[5M1
MN+:V\/SB.TOVM+F9[A!Y0"@[\?Q=>@Z<>N*Z:N:\):?J.GWNNF]LF@COM1>[
MA?S$;*LJK@@$X/RY].:Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML?E(R.0%[Y/(Z5SVAZZ_A;2_$ES!HSSV-IKERT[1R+&(DW*/E7^(CKC@8[T
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M-QO:+>P);.T;B<'^9/:M#PQ!XMLK6TT?4[:S2WL56,W\4Y9KB->% CV_*2
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M&BN-4OH;".53@Q^8WS,/<*&QZ&KM]=3:6UC8:?IZF%U<-,Q*PVJ(N1N('?@
M<=^>*S_'>GS7FD6E[;HTDFDW\%^(U&2ZQM\P [G:6X]J77;'4]1U71]1TP6E
M_80AVDMIYBB.6 V2@A6#;><9'?B@"BWCV7_A%H]9BTQ)F^W_ &*:-+G(#>9L
MW(V/F!ZCIUK4TWQ!?3>*+C0M2T^*VE6U%W \,YE#Q[MI#9488''3(YZUSC^$
M?$(\.W6F;+&21]9^W1N)F4,GF^8<C:<'C&.?K6^NEZF?'Z:XT$*VG]F?9&'G
M9<-YF_.,8([=: +NL:7?WU_IEU8ZBMH;.8M*CPB02H<!AS]UL @-VW&LR[TF
M^T_1/$YN]06[M;J*>6WB,(5HMRL6!;^+J ,] H%=35#7+>YN]#O;2TC1YKB!
MXD#OM4%E(R3@^M '(Z-KTWA[P%X1$&G+=+?_ &>U.)0A5G!.0",'H>XK3C\3
MZJTFN:?/IUK;ZCIMNMQ%BX:2*1&#8).T'(VG(QS^M9__  C6NCPQX8TT6]J9
M]&NX)IC]H(5UC!'RG;G)SW%:/]A:E+XJUB^>.%+34+!+5&$I+J5W<E<=/F]>
MU $&D>)[FU\':'=:D(7N]1CB2%C,<2$Q[V9SM^7@,>,]AWJ.X\=W5KINMSMI
M232Z0BRAXYF$-Q&PSE6*]1T*X_&H1X7\1#PIHL,3V-OJ^@NAML2,\4RJA1@Q
MV@C<IZ <>O/%S5M.\3Z_X3U*SO(+*WNKR#R8K>.<LD>>KL^WD^P'&.O/ !8D
M\47UFD;:CIT%J;R5(['-UG>"A=C)A?DVA3TSR0/>JO\ PGGV:TU62^LE0Z;)
M"HGC=C!,LC!0X8KD!2?F&#C'>I]=T36-0TO2;O3VM[;6=*E$T:2.6B?Y2CH6
M !P0>N*GV^)[O2Y9+NTTY9W:-18>:7B:/=^\W.5ZLN0!C P.N30!2\1Z_K%K
MX.UC4+2.S#00![>ZBF+I(A!RR\?>'89QT.>U79_$,FG0:=:7*VRWUY&SKNG8
MQJB@98MMR3\R\8ZGKQFL8>!9AHOB6PL$33[;5HE%M9&0LD,@!W-QD*&)' SP
M/P%K4M&\22?V/K5BME'JVG(\4MHTK&*:)PH*[\ YRH(.,?7'(!):>.#-:%)=
M/*Z@U_\ 8880Y\J=B,B17*_<V@DG&1C&#QF#3/M7_"V+W[7;P12?V-'@PL2)
M!YS?-R!@]1CGI3]9T+Q'J]I8:F7LX=7T^[6Y@M0[&'9@AHR^,DD$_-C'08[U
M8L--UV3QP=>O;2TM[>33%M6C2Y,CJPD9_P"X >OMU[T +X[LM5N+"QO-*M4O
MWT^\6YEL7.!<* 1@>X)!'N.Y %5O#6MZ#XEUJ75-/A^R:W!:O!=65S'Y4O+*
M1N]0"N,C/WOPK=UA-7\^QFTE8'$4K&XBGD*"1"I& 0#SG!'':LR+0KJ_\:6W
MB.ZLXK'[);/ %60/).6Q]\@8"J,XY)R>V* ,[0/%M]#X3N=8UF..9S>RPPI#
M(=TDAF*+& 1\HS@9R>.36S_PD%U9>(;+1]6M(HCJ*.;6>"4NI=!EHVR!@XY!
M[^U8(\$ZM-X6O-#EEM8'BOFO+"Y5V;<_FF1=ZX&T<X.">N>W.T=*U#6=;TG4
MM4MHK1=+$CB))?,\R5EVY!P,*!D^I)' QR -B\3:A>6EMJFG:3]LTV>Y\D%)
M?WWE[BOF[<8VY&<9SCGCI6/8ZBNE^-_%T=K D][/+:"VM VSS6\C)YP< =2V
M,"K/AW1?%'A^#_A'XC9/I,4C&WOC(WG1Q%B=FS&"PR0#G ]\8JIJ7@O5;W7-
M;UF$06U])+!/I=PLN6B>./85?Y?NL.HYX^E %GQ,UTGBWP?.UG$][YUR/+CE
M^7/D-QO(!QW)Q^!Z5;A\:FVTW69]9LEM[G1YUADBMY?,64N%,>PD+][<!R*+
MW3=?U'6_#>I3VEI&=-:5[I4N"02\>SY/EY')/.*H7W@S4=8'BB"Y:&U359H9
M[29)"[1O&JA=PP.I4=">#0!M2>(;O3M:T_3]7LH84U/<D$T$Q<)*!GRVRHZC
MHPZXZ"L30]4M/#T?C/4;A2L%MJK,4C'+$QQ@*!ZDD#\:U7TK4]<O]'N-7MH+
M4:7*;AUBE\SSIMI4;>!A1DGGGH,=ZRY_!FI:GI/BC3[EH;;^UKS[7:RI(6V,
MNS:&&!W09QGK0 NJMJ#_ !!\'O?V5M"6>Z(:&4N5/D-E#E1GZCWX'>Q>^/1#
M;'4+2TCN[-+@PM''(QN&4/L,BH%P1D$XSR.>.E(^G^*=2UKP]J-[8Z? VER2
MF<+=LPDWQE"5^3CKD#GZCNW2-'\6:"TVBV;6,FDM,[VUX\C":V1V+%=F,,02
M<<@>OI0!<_X2;6+CQ#J6D6.B0RMI[6Y:1[O:&CDR2?N_> '3V//0%9? FDRZ
M/>:8;6V2&\NC<%4BPL+;0N4&>&P/O>I)QVJ72M+U*T\9ZUJ<T, L]02!8V64
MEU,:L.5QCG=Z]JZ*@#F->O#HOBO0[N/B+4YC8W*CHY*EHF^H((SZ,?:NGKF/
M$=DVL>*/#]G&,I8SMJ%PP_@"J5C'U9B<>RMZ5H:+J&IW=YJ4&HVUO$MM<;8)
M+>0L'0\@-GHP&"?]X4 0ZKXC6SU,Z7;&V^TK )W:YE*(H)(4< DDE6^@'X5E
M3>.KR/PQ:^(!H;+;&41WR22E7M1NVEP-AWJ.N1C@CWQ8UG2M>M/%"^(/#ZVM
MSYULMM=V=S(8PX5B5=6 ."-Q'TJY<6.L7]M;65^+>2"X9CJ'ER$ )@XB08Y4
M\ DXR,\#/  ?\)-Y&AWVN7MLL=A"2;9HI"[W*9PK8( &XXQR<Y!S4D6JZK#J
MB6^I:6D5J]NTQNH)BZ0LO5'R!VY!'7!XK!A\(:K-X6U7PI=RQKI[$C3+@2EY
M(D#!D1QCD*0.<].*UM*A\37\'V;Q%%901+$T<AM)6=KDD;<\@;%Y)QR<XZ8Y
M **>.FD?3+B.R2:RU*58P(9&:: .,H[KMQCIGGY<]ZA?QKKDEGJ]S9^&XYET
M>[DAN ;W!=4522GR\M@DX..,=2<";PWIWB_2;>WT.Z:P?3[/:D=^CMYKPJ?E
M3R\8#8 &<\#U-4/#W]IS+XPM+&VA?S]8N$2:27 C8QH"6&,D 8/&<\CCK0!<
M;Q+J&I>)?#W]F+ =.U&RENE621D9B OWL*>F[IZ]^E=)KMVUAH5]>+:)=^1
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M215C#;LA.N#TQ[9JW:^*-3_MG1;:_P!.MXK76H6:!XYRSHZQ[R'&,8(SC!-
M'55'--%;0O-/*D42#+.[!54>I)Z5R5WXWN5LSJ=AIYO;-+@Q&"))&GD0/L,B
MX7;U!.WN!U!X%^XUJ[U*;5K328+>1-.7RYFG8@2R%=QC7'3 (RQSR<8XH W+
M2[MK^UCNK2=)X)1E)(VRK#U![TRSU*QU!IA97<-R8'V2^4X;8V,X..]8/PW_
M .2>:+_U[#^9K$L+O7++6/%LFAZ9;7ACU 22+-.8R_[E/E0 '+'WP.G7L >A
M56OM2L=,A$U_=PVT;,%5I7"AB>@&>I]JP(O&MO?Z?I$]B@$NK0O,@E#,(53
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M(BLDY:2.1HRX)7&-IP1UST/M70Z[K-OX?T2ZU6Z#-%;)G:O5B2 JCW)('XT
M:%%<Y<>(+_2=5TRUU>UMUAU1_)BE@<GR9L9"-D?,#R PQR.E0:)XCUW6M0NH
MUTJTBMK'49+.Y?[4Q;"J"&4;1GD]\=1[D '54444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>+
M=!F\0Z)]FM;D6UY!-'<VLS#(25#E<^W;\:VZ* .7EL/%NKZ%?07UU9:=>2VS
M0P?8G=E#G^-F(!'3  ' ).2<8J67AS7HM<TK4FCTJU2TL9+22"!W(3)4AE)4
M9R5Z'&/5J[.B@#C;3PE=3:_8:Q>6MG97<<,D>H26<K$7VY-N"NU>,_-D\@@#
MGJ%\/:+XLT6&+0WN["32;9ML-V-_VGR0>$*XVYQQNSP/4UV-% '':MX5OM:O
M8I[FWLH;NUOA+;:G#*1,D(DW;"-HR=ORXR1SGZ]@1D8-0WEY;:?9RWEW,L-O
M"I>21S@*!WJ5'62-9$8,C %6'0@T </_ ,*_GC\-WVGPWBBYCN?-TF0]+54D
M,D:_FS GT(]!6EXD\-WU]X7M='THVY:":%V>ZD9-PC8,3\JMDDC]:ZBB@#F9
M]!U&Z\:?VM-':?89-+:PE59V\P%G#$@;,$<8ZCU]JK>'=(\6Z3#;Z+<W>GR:
M99D+%=IO^T/$I^5"N-H.!@G/3WYKKZKS7]I;WMM937")<76_R(B?FDVC+8^@
M- &!H.@:A:R>((M32U^S:M=/.OD3LS!64(5(*#LN<@GK4'AS2?%VE0V^C7=W
MI\FFV958[M-_VB2)3\J%2-H.  3D\>_-==5>:_M+:\MK.:X2.XNRP@C8\R;1
MEL?0<T 9_BO3+_6/#EU8Z9<I;W4H7:SDA6 8$J2.0& (./6LW3-"UF#Q>FM7
M":=!;OIJVCV]NSGRBKE@%RH!'/7C'3'>NJHH Y[Q5H^HZO)HYL!:[;#48[R7
MSY60L$##:,*>3N[^E);:3JT'C/4=9,=F;:YM(X(U\]]^4+$$C9@ [O4XQWKH
MJ* . L/"/B2PT+0[/.FS-IEW++-;-</Y-RKEF4D^7D,A;(&",C-.N])U'1_"
MOC87\]FZW\5W>1B$MN^:$*00>@&WWSGM7>U1N]%TR_O(;R[L()[B$;8Y'0$J
M,YQ],T <Y;^'M1@N=!U_3Q$;JVTQ+*[MIV*"2+ ;A@#AE89Y'/M4.L>#=1U+
M1O$7EFT74M?:,.'E810QQ@*HW!26. 2>!RWMSV]% '->*-'U?7?#]K:01V4=
MRMQ#-*'G?8-CAL*P3)SC'(%22Z/J:^-XM=@-I]GDT];2X21VW)MD+Y7 PV=Q
M'.,=>>E;(O[0ZBVG"X3[6L0F,.?F"$X#8],C%3D @@C(/4&@#D&TNTU+X@Q:
MC87BR0"U62_CB(9))$8B DCN,N?^ "NKN;>.[M9;:89CF1HW'J",&H-,TG3M
M&MC;:9906<)8L4A0*"3W..]7* .)B\)ZN_A >#[R2V>Q4K%]M61O,: .& V;
M<!\#;UQWYZ5I7.C:HWCBRUB".S^PVUF]L5:=A(=S*<@;".-O3-=)10!G>(-,
M?6?#NHZ9'((WN[:2%7;HI92 3[5S\V@^(KD^&I)4TT-I$N^95GDPP\O8 IV<
M]2><>GN>IL;^TU*V^TV5PD\.YDWH<C*D@C\"#5B@#B[SP=J&J7GB@74EM!;:
MTD'D20RLTD3Q* I*E0.H!X/;'O6IH4?BQGC'B"33D2 8S9%R;AL8RVX *.^!
MWQT P>@JO+?VD%[;V4MPB7-R&,,1/S2!0"V/ID4 9?BOPX/$>G0I%<?9;VSG
M6YL[@+N\N5>F1W!Z$4^VE\2S0B&[L]/MI<8>XAN6D7ZJA0?D3Q[ULT4 <RVA
M:CIGBVXUS2_)N8K^WCANX)Y2C;X^$=6"G/!P1@>OM6;=^#-2&D1Q6;6<EY-K
M0U:[,LK(FX.&V*0C$C "Y('3/?%=Q10!S:Z+JC^.)]9D6T6SFTU;,A9V,BD,
MS;L; "/FQU]_:L=_"/B%_AJ/"Q;33/%Y4<<OG2!2B2!]Q^0G)P!C''7)Z5W3
MNL:,[L%11EF8X 'J:KZ?J-EJMH+O3[F.YMV9E66,Y4D'!P>_(H Q9-)U=O'-
MOKHBLOLR:<UHZ?:'W[F</D?N\$ KCJ.N?:L<^#M;?POJ-@S6*7<FJG4K4K,[
M(3YHDV/E 1TQD9KO** .5M-(\0-XS'B"[33T1M,^RM!',Y*-YA<88K\WUP.O
M0XR<L^#M?/@630L:=]I>_P#M._[3)LV^=YN/]7G/;I[^U=G!JEA<W\]A!=Q2
MW5L 9HD8%H\],^G3I5N@#F;BPU&#QE'XDN1916$&EO;S_P"D.73YA(S ;,$#
M;CJ/7CI7,:7!K5CH\&L'2-'OK)':_B*:A+&!N)8,L1!C1L-QCH3US7IA 92K
M $$8(/>LBU\)>';&[%W:Z+90S!MRLD(&T^H'0'Z4 :9>1K;S(HAYA7*I(VWG
MT) ./R-<GX5T;Q/X<T Z;]GTF67SI)%F^V2;1O8M]WRAG&?49]J[&B@#DH?!
MT]CX9UNVAN8[S5]:24W-U/F-&=U*C  8A5SP.:8WA[71)X4D6/3R=$0K< W+
MC?F+R_E_=^G/./3WKL** .4U/1O$%EXHDUSP[)92K>PI%>6MZS("4SM=64'D
M D8Q_P#6CU3P_P"(!J&F:]IMW:3:K:QR0W,4^Y(9XW.XJ",E=IQCZ#/OU]%
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M0J*ZN8+*UENKF58H(4,DDC'A5 R2?PH Y&?0/$=Q#X;+1Z9YND3+)*HN9 K
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M'*1,K!@^6P6.X+QQ@#W)I;+2O$NHV,UAXGN[!K=X'A;[ '#3[E*EG+<#@DX
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M%5EVCY3_ 'CS[=*U]2T;6)?%MIK%E/9M!':M;M#=!CY+%LF1 .K$<$9' ZT
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M&7;@8R23RW3BLZ^O_$$OBGPO#(\-@;NWN)9K1H_-$<J(N065QN^^<8QCKSV
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M/+=W"_WA$N4!]MY!_P" BK5UK5Y;^-M/T;R(/LMW:RR^;DF0%-O'H!R/7\*
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M* "BBB@ HHHH **** "LOQ)I]UJ_AV^TRT:))+R!X-\I("!E()X!SUZ5J44
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M;*\BRRQGR) XP\>T'(7  ')/'J<UU=4=7UC3]"L'O]3N5M[=, N03UZ< $T
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M?A6WD:W%W'K-G&""3&S#<!Z'!Q7=55O-,T_43&;ZQMKHQ-NC\^%7V'U&1P:
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M.Q>2<E1VZY[8.\/#FJ:?XGO-7TB^M8X=35#>6]Q$SA9%& Z$$=NH/_ZLRW\
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M=K?N2(Q&,_WN.>W-5U\):I;VWA@V][:?:= 5H=TD;;)4:/R\X!SD 9QG'O0
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M\\#0:A'$GE!3N3RP0#GH<[CGB@"#Q_J=QI?A&Y:TD,5Q<O':QR#JAD8*6'N
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MW,1 NH#MW,CDC+$;\ =,8P>M=#K5S<V>B7MU9F(3P0/(GFJ64E03@@$'MZT
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M[(<H57)YSG))Y]L"NHHH P;#1M7DM)X]>U=+R22!H%^SP>4JJPP6(R<L<#T
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MO[6T&(%2W\MY,# \QLG.!V'4X)-6?%6A7'B'3(K.WNX[8I<1SEY(C)G8P8#
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M'P2>1M&>>>>E+!X;U._TRZLO$VKIJ"3V[6X6W@\D -U<\G+\#'0#GCFNEHH
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MF2XD0L%*;L#!!&>>*GL_$6H:GX>T#46E@LHK^/==R*-T@;;\JQ(0=Q+9XP2
M/QJ_;>';NVUK6M33482VK)&NPVQQ%L4JISOYX//2LVS\#WVGP:$+77$6?14D
MA1VL]RRQOC(*[^&&/O _A0!0G\7ZU_PKG4]8ADMQ>Z==R6Y>2W($BK)LSMR-
MK8(/.>1TKH+G5KF]\6/X?LY_LHM[,7,\X0,Y+-M55!X'0DD@]@,5RNNZ5%I?
MA;7_  Y%K*7VH:C<"XAM&54E'FS#L/O<YY  XZ"NMO\ P]+)XCA\0:;=I:WJ
MP&VF66(R1SQ9R 0"""#R"#[4 <W>^,=<@\.:JR_95U+1]1CM)F,1V3H[J%=1
MGY"0_/WNE:FJZCXCT'^S?M%[8W:WVL16S%;5D*1/V'SGD$'DYZTZ_P#!+7FA
M7EA'J*Q7&H7BWEU<FWW;G5E8!5W#:HV* ,G@>O-7O$&A7NMPZ6J7L$,EC>Q7
M;L8"1(R?P@;OE!SZF@#)L1J<_P 1]>A&J,L<5I;^6IB4A WF$ ?0\Y[TFF^(
M=7N- O+6YN(AX@M[_P"Q%5B 0,6&Q@O4H4^?Z!O2M9M%:R\377B(:D(8)K9$
MNX3"#GR]Q#!L_*,$Y&#]16?H\&E:_P",)?%&F2&:W2U2'S5R(YIOF&X ]65"
M5S_MD=C0!T6I7Z:/HUUJ%R6D2SMVED(&"P5<G\3BN6O?$6L:3X=TSQ/<S13V
MURT)N[18P!%'+@ QMU)4LN<YSSTKK[NUAOK*>SN4$D%Q&T<B'^)6&"/R-<Y;
M>#[@:39Z)?:FMWI=E(C1H8-LLBH<QH[;L$ @=%&0!TYR 53!>'XN-B^PHT</
MCR@?D\\_)^G6K/Q*DNH? M_+:736[+L5RJ@EU9U4K[ @U>_L&Z'C(^(!?Q;#
M9BT^S?9S]P/OSNW]<GTQ[58\2Z(OB+P_=Z2T[6_VA0!*J[BA#!@<=^0.* .>
MUZ*_3QOX5CBN(I+LP7X\^6/"CB/G:I&<#MD9]126WB_4H-(OH[Q8)]1M=772
MXY(HRJ2EBFURI;CASQGDC&1G-:<OA[4Y_$&CZM/JD,K:;',CK]FV^:9  Q&&
M^4#:,#GW)JDW@5[JQUNTO=07;J=[]MBDMXBCVTHV[2"6.<;1Z=Z +^DW/B >
M()K6]MI)=+:W$D5U*L:.DN<&,A3R,<@X]N:R/%\C7/Q!\'Z5/_QY233W#*>C
MR1IE,_0_SK>T32=7LW\W6=;.IRHFR/9;K J@XR2 3EC@<]NPY-.\1>'+?Q#;
M0!IY+6[M)1-:746-\+CO@\$'N#UH T;RT@O[22UN4#Q2KA@?Y_7O6#%JFH:[
MJVL6>FW:62:6ZP(YB#F64KN);/\ ",@8&">>:OP6.M2H(=2U.VDB'#FUM6B>
M0>Y+M@'O@?0BJH\.75EK]]JND7\5O_:*K]J@G@,BEU& ZX9<''4=#0!@Q>,]
M9U+3O#MU:K:VTE_?/97<4D98+(H?)4Y^[E,XZ]LBI)]7UU;'QAIMQJ*&YTFV
M6>WO(8 C%7B9\;<D @J1GWK1?P5Y-KHMMI]^L":3<FYS+!YC3R'=N+$,N,[V
M/%3'PI++J>OW,^H*T&N6RV\D20;6B"HR AMQSPQSQZ=* ,F/5-6T/P=X6EAG
M@G6[FLK>7S8CN6.0*,*0>HYY.>M7)=0\0WGC'4]#M+^TM88;.*>&4VI=D+%A
M@@M@GCKP/;N%G\(ZC-X>TG2FUB)VTRY@F$K6N PBQM7:&XZ<G)_"K\.@7D/B
MF[UU=0AS=6R0&$VQ.W:20=V_GECGC\J ,&S\7:K=:#X4U,M$CZI?BSNXPF5/
M^L!9>X.8_P!:UK;5=4E\3Z_I:S0LEG;P36IDB^Z7#Y#8(R/E'I5*+P)<V_A;
M3M(BU=!<:7>B\M;G[+QNW,<.F_D?.PX([5>L?#6H6>M:CJSZNL\]_;QQ.AM@
MJAD!P1ALX^8\=?4F@#&'BW79_"7A?5H6M$GU6^A@N$:(XP[-]TYX'RXZ$\]:
MU-*U?5K?Q%K.D:E-%?\ V2VCNX'A@\IB&W IC)[KQ]:KP^![R+PUH>CC5H0=
M&NTN4E^RDB4H25!&\8ZG//Y5<N=,GTC6=5\4R79F1K$(UM!:DR8CW,-IW')R
M3V]* ,>/Q-KMQI7AO4K2[M6DURX$,L#V_F)!D,V5"LK?+MPV6/KQTKM;_P#Y
M!US_ -<7_D:\TT.:XLK2WNM(\5:!JEXR;A:BR7[3.QY92ZONW$]6*^Y[UZ7?
M02W-C-!!*D4DB%0[IO"Y&,XR,_G0!SGPU19/AMHZ.H9&MR&5AD$;FX-<EHNK
MZAX:\(>,#I#0M;Z-JDJV@G4NBINY08(Z9S^/O78:1X7UC1_#MOH=OKT*00(8
MUGCL2)@"2>"9"H//7;1?>"+;_A![CPOI4HM([@8>>53*S$G+,W(RQQUH BUG
M5->_X2K3M'TZ[M+>*_LII?,DMR[1NFWG[WS?>Z<?CTJ.36-?O!J-II[%KO2P
MD.^*!"EQ<>6KMN#-E4)8  <CDY-:4OAZ]G\1Z9K+:A IL('A:$6Q(D#XW'._
MC[HQP<>]5KSPIJ*>(KC6-"UTZ:;X*+R![99DD*C =<D;6QQWH +36M5U;4H=
M(=1I5W'IZ75Y@+(R2,2H1<Y& 58D\\$=*RM;?Q'N\*1:C>PVUU+J)CN%M5W1
MN0KE6YYZ ';TR?88U-1\'W3:G::MHNLO87\%O]FEEFA$ZW,>=WSC(^;<2<CU
MJ?4O"T]]::;LU5UOM/NQ=_:I80XE?!# H",##8 !X % $<&IZAK>KZMI]A>K
M:+I6R'S?)#F69EW$L#T49 P,$\\BL9?&>M7^DZ#=6JVEM/>:F=/O(GC9@LB[
M\E3G[OR9QUYQD=:WE\-W5CKMUJVE:C'$]_&BW<=Q!YBR.@PL@VLNUL=1T/M5
M:;P24L='M-/U!8%TR\^V%Y;?S&GE.[<6PRXR7;I[>E %34?$&H>'[NTT_7M6
M6V2:%BFJ): 0O-O.U'!R$ 7:>HSD\C'/6V#3/I]LUPZ23-$ID>,Y5FP,D>V:
MS]5TB]U"><+>6QL[FV$$EK<VIE7(+'>/F'][&,=AS1INB7&DQZ59V>HL-/L+
M8P20/$&:<@ *V_JN,'@=<T :KQ1R-&SH&:-MR$C[IP1D?@2/QKD/"?\ R/GC
M3_KXM?\ T578U@Z+X<NM*\0:MJLFHQ3C571Y(EMBFPHNT8.\]NO'Y4 8IM[\
M?$C4K;2);:T9=(MU62:(R! '? " C/Y\>AJ33O&5[J>A: PA"7^K-,LAA4-L
M$6X.5#'&20,9/&<\XP=>+0KV'Q=>:ZMY 4N;5+=8#"<H%)(.[=SR3VK'A^']
MS%X:T_3TUGR-0TJX>>SOX8,;"[,65D+'<#N((SZ?B ;7AVYUV2:_M]9MBL4,
MJ_9+E@BM.A'.Y5) *GC/ .1Q5.^U+6V\=)HEK=6L-K-IKW"NT!9XV$BKG[V&
MZ\=.O.<<ZVCZ??6<3R:GJ1O[N7 :01")% S@*@)QU/)))S] *TVA7$GB^+7T
MOHU6*S:U%N8"<JS!B=V[KE1VH Y=_$?BA?"6K:K]MLA-H5U-!(/LQ(N_*?!)
M^;Y,CTSSW[5OW>NW\7BW0;"/R!9:I;SR,"A\Q61%(YSC'S#MVJL?!=TWAW6]
M';5HB-8N99VE%H1Y?F'+ #?S[?UJU+X<OI=<T/4FOX#_ &3#+$4%N1YN]54G
M[_R_='K0!@2^(?%+:'XEU&.^L4;0[Z9%7[*2)DC1&VG+?+P3SR<GMCG=N=?O
MT\3>'+.,0"RU:&:212A,BE(PP ;.,?,.W:H!X,N_['\0:<=6B*ZY/+,[BT.8
MC(H5@/WG/"C'X]:L/X:OGU;P_?-J$!_L:*2-E%N1YV] I/WSMP /6@#'?6_$
M\VE^)[F._LHGT2YE$>+4D2JD:N%(+<9R<G)//;'-I=>UJ+4/#EW//;-9:X0C
M6B0D&$F(NI#YR3Q@\ 5:C\)7:6'B"U.J1'^W))'9OLI_<ET"''S\\ ?C2R^%
M+N6#P_&-4A!T1E8$VA/G$(4Y^?C@^_/Y4 54U[539>+0;E/-T9V^S2>4.0(A
M)AAT/)QQBH_^$AUV>\\)0PSVB+K5D\LVZ DJZPJ^1\W(RW3CIUJU>>#[V6\U
MMK36!;VFM1_OX3;!G5_+V95]W0C&1C/H1UI]OX1NH+KP[-_:J.-"@>%0UK_K
M@R!#DA^.%'KS0!F1ZMXHFM/$5N-2M%GT.5MMQ]DR9QY8D52N["]<$C.?;'/6
M:'J#:OX?T_4F18WO+6.8J.BEE!(_6LF'PM=Q-X@;^TX2=;.3_HI_<G8$_O\
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MIWFFC@,;,T>,8&X@###\JFO?"]W<W&C3QZL/,TN9IV>>W\PSNP(8G#*%'S'
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MTXMX3;K&^!PN]P26Q^'(!/I5WQ5H4OB/1CIT=XMH&ECD,AA\S[C!@,;AW44
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M(4$_-D Y/H, <Y6#PU=S#3(]8U&.^BTJ02P[+?RVDD52J,YW') )/ &3S[4
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M8D\4R2&T)\TQJ54$;^.#S_2@""[UW7]1BU.?087:2QNGMX(?+0QS-&0'#LS
MC)R!C&.#S3Y-6\0W7C"/1HIK:QCGTC[60\'F/ ^]5(/S88C)'8<]\5(?".I6
MFMWEYHWB%]/L]1E\ZZM3;++B0C#/&Q/RDX[@\^M7!X<GB\51:W!?1JD5A]A6
MW> L=FX-G?OZY [=/SH QM,\8ZA-H^GVTWD/JUWJ4NGB781'^[9MTNW/]U>F
M>I["J[WMQH?CW7=0U&5+I;/05F4QIL+(KN<'DC.01GZ5:/P_NDTY$AUA%OK7
M47U"TN!;$!'<DLC+O.Y3G'8_6KB>$[Z[UR[U'6+ZUGBOM-^PW%M#;L@*Y8G#
M%R1][W_"@!+74?$W]HZ9,;9KBQN5/VT,D<:V^5R&C(;)&>"#DXKGO%^JZAXB
M^%.I:U#+!%8W /E6YB)8Q"4*"6SPQQNZ8 X]ZZ70?"^K:4(;2]\1R7^G6N!;
MP-;JCX'W0[@DL!]!G SZ5E2> -47PQ?>%K76;==(F8FW\RV+30J7W%-VX @'
M/.,_3L =O<W$=I:S7,I(CA1I'(] ,FN+N?$^LV_@N#QF)(G@8)/+I_EC @9@
M,*_7> 0<G@X/ KLUA:2T\F[*3%DVR$)M5\C!XR<#\:YF#P3+'H7_  C<NI";
M1%D!6)H3YWEA]PB+[L$9XSMSCCWH BEU/Q'J'BV_TC3M0LK:"&TAN89'M2Y
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M5+@;L9'R[3_P,>G-:WO/$\6IV%Q)!--ITL;&_,WV=5A^7(>+8Q8C/&#N..]
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M"NF>9<//NM(67>JC:-B\# ''UYK&T);Q_'_BD2ZC/+';_9@L;*F-K1LP7ID
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MC+&V#TX./KF@#MJ*XRWU?7;;7?#2W=_%<6VM0N)(%@">4RQ>8&#=3G&#GCT
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M@12QR2 ,<GN:P+7PO=:-?7,V@:FEI:W<IFEL[BV\Z)9#U9,.I7/IDCVKI**
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M.#2C9V0"S7MFC6]RS'JH<X#*$&3NS\W'>O0U97&58,,D9!SR.#2E0PP0#]:
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M_:L4RPK^ZG).>#PR\]#^= &7=ZQJ=WI'C>Q:_NT_LNU$UM.T:1S;6A+[6PH
M&1Z!L'L:ZOPK"\/A?31)<RSEK6)@9 H*C8/E&T#@>_/O5&/P9']HUJ6XU2ZN
M%UJV$%RK*BYPA3<"!QP>!T^M-?1-7L+#1[.QUNZ=[2=!(3"FV6(;5*M@?* H
M/N3^@!N:H\\>E73VLHBF2)F1V3<%(&>G>N+/B'7I/#?@Z]BU"-)M5N(8;HM
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MM./EQH9(Y/E0#"X+>9\I)&,D<59N-1U-=9@\/+<W4L\6GBYN+FV2 22,7*#
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M^6!<"(Y7<."1]>M<C#JGB?7='BUK1?-$K7#-'#(\(MVB60J4;^/.T=>N[T%
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M.>JHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N3^*'_).=7_ .N:?^C%KK*R_$6@
MP>)=%FTFZN+B""?;YC6Y4,0"#C+ ]P* ,99M2TWQ]9Z?+JL]W;ZE932/'(B!
M8I$*X*8' PQ&"3[DUG0:[K\/@OQ1=P327]_I^HW,%NSQJ6"(RC.U0 =JY.,<
MXKIIO#D<^NV6L2:C>&XLHFB11Y>Q@V-VX;,Y.!T(Z5AZUH*:%X5U:"VDU6]3
M5+LRW)BVM)#YC#S'4(H) '.WG\LT .LKRZNO&=I!I6M7%WI!L?/N"K)*HDW
M+ERI(W GY01TR,5S4$VIZ7X(U;7+'5)H&L=7G=+=%7RY ;C#!\@DY!/0C%;^
MB&[FU"W.E>)M8U&#?B=+VR"1JF#D[S&OS9Q@#)SU&,UH'P'9-X;O- ;4]1-K
M>3F>5]T7F;BV\X.SH3[4 1WE]J.K^(=6TFSEFA73X8@I@F6-M\BEMYR#D#@
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M\+M[=VYJI=7_ (HT;1M.?6HIKV.&65=0DTP@S;,?NW( '3/S;<= >F0=._\
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M<S7$#19D.%"J#]X<%L]BJ^M=70!Y;!;R)\._&TCWES-MN;^+$KA@=IP#TSG
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MMR6&JR6%Q8W\EG:A0"B&/&2XQ\VXD]> ,8&>3D>(=<_L+X@K=S$,9=#CA-P
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M82@Y#@C.[/OUH GHKSZ'5=0AO?#D\6I7-Z+V^>WNKK[MM<@JY C0G@+M&&
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MG=WFG(S_ &Z.Q<K.!@;6&""0#G(!';M5&'5(;W3-$>SUZ>\MKJ:8^7&"+F\
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MOQ)-KL>F7'V::QN3:VK"[:(1.J*=S($(<%CWXQP #DD [:BJ5M/<PZ+%/?\
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M,P("+D@NWHV.?;&CX9ANAJ0EM=8UJ_TXQL)?[5@\OY\C;LRB-ZYX(_&NLHH
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M=,.;.>TDV2PGOACG.>^<YI;KP=9WFC#3)K^_93,L\L[2JTLSJ05+,5/3:.
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$S/_"
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MO*$:)VD(P#CCISQD^N.*1#KOBBSU.XTV]%K=VU_+;V\GVV1%A\I]H#Q!2K9
MR=V?O=L#'3IX?@3Q(^O"ZN?M+PB!DW+Y9C!)"XQV))SG-4+CP-I4^LSZG'/?
MVINR#=V]M<M'#<GU=1USWP1GGU- &M=7<UOH4UX#')-':M+F,Y5F"YX]1FLG
MX>+CP%I#;BS2P>:['JSN2S$^^2:Z+8I3R]HV8QMQQCTK&\,:=)H-C_8C(S06
MK,;6;J&B+$A2>S+G;[@ CO@ S_"?_(U>+O\ K_B_]$I3-1E>U^*NC^43B]TZ
M>*8>H1@RG\"3^9K9TO0(-)U"^O8;JYEDOW$DXE*D,P  (PHQP,<<5#;:8UWX
MHDUZX0HL5M]EM$88.TMN=R.V2% '7"^] &3\1+=)X= +/,O_ !/+1/W<K(,%
M^>A'/'!ZCM4%UIWVKXH"S6\NK>,:  SQ2D2,///&\Y(^O7WKI];T2TUZQ6UN
MS*@CE2:.2%]KQNIRK ^HJO'X9MH=<&L1WEX+H6OV0%I P\O.<<@Y.[G)YS[<
M4 <EI?B#4V\/:+82W;S376JSV+W,TI1W2,R%07 )#-M5<@9Z]#S73Z!8:OIV
MIWZ7MY'+93;9+2W:Y>>6$XP_SN 2I.",YQ4)\!Z/)H4NC3O<S6TEP;E&>0!X
M9222Z, "#DD_C6EHVAP:+$ZI=7EY-)@/<7DYED8#.!D] ,G@>I]: *&M.9O$
M%M9"]N7W6LC?V?:.8G)W*!*T@8;5'(QGDGC)%<I!J^LWO@WP=>-JUS%<7>JI
M:W#H5_>+ND&6XY/R#KP>X-=KJ'AJRU#6H=7::[@NHH3 S6\YC\V/.=C8[9YX
MP:HQ^ ]+AT^RL8+F^B@L;K[7;J)@=DF21C(/ W-QTYYS0!E1R7]CJOBO28]6
MOI(H+".ZMY)I=\D+LK[@K$=,J..W;%5;2?4K6Q\$:NVL7T\NI-!;W,4LN8Y%
M>$MDK_>!7.[K74S>%;6;4-0OC>WBRZC +>?:R8*#(  V\8R>>O-1'P;9FPTN
MR^W7PBTAUDM,.F4*C"Y.WG )'- &583W7BBQ\07?]H75G<6=]/:V@AF9%@\H
M#:64<,2>3N!ZXJKH_B#4-5U/P7>2RRQ?VI9737<*L1'(R*NUMO0<DG\:Z67P
MK9->WMS;W-U:#4!_ID,#@).<8R<@E21P2I4GZTNH^%M/U!=.\MY[%],R+62S
M?RVC4KM*]"-I  Q[4 <;J>I:G#X3\:O!JEY$^G7[+;2"4ED3;&=H8Y./F/O[
MUM%[W2/'6CQ?VG>74.IV=P9X9GW(&C",&1>BGYB.*NOX#TA[#4[$37JPZK)Y
MER/M!)8\>N>N!D]3ZU<D\-P2ZIIVI27UX]QIR,D)+)@AL!MPV\Y 'Y<8H Q-
M!^V>)?#>F>(UUN:SN9)OM$V'+0^6&(:$QY"@ #&[&<C.:C=]8\4/KJ6%U]EN
M+*\>UM76]DB\@HJD,T:J0X))/S9R#@8Q6K9^!M)T_4GNK::]C@>;SS8"Y/V;
MS,YW;/KSCIP..!2WW@G3+W6I-62YO[*>X 6Y6SNFB6Y X&\#KQQD8H R8QJ=
MYXZM].N]9N/*FT$3S):2[8S+YBJ60@9 /8]<=QFL6>XU:/X?:KJO]NZ@;O1+
MR>*V?S<;UCEP/,'_ "TR.#N_QSW:^&[6/74UB*>>*>.U^R(B%1&L6<[0NWU
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M[2EO+U;?3)UGML.FY'4Y7G;S@D]?QS1>^"-,O-9DU5+G4+.>=56Z6SNFA6Y
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MJ74)O.G8=VVA>/RS]2?6LH^!]..A7NBM=WK6E_,9IP9%W,S'<W.W(R<'_)H
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M<L.YX'6M_P *&>T\4^)='-Y=7-K:/;R0"YF:5D\R,EAN8DXR.E &CXD\1_\
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M4="Z@*PP3D=1]*K?#>UN;WPWI>O7NJZA=7,ULZ/'+<%HC\YYVG^(8Z]>3[8
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M=06</G7$@CCW*NX^K$*!^)('XU-0 5DZOX=L]:NK.YNY;@/8RB:W$<FT(_\
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MQ$(78.-NP9V@+C'&:IIX)TB/0[?1U-T+:TN!<VY$[!X9 2<JPYZLWYFNAHH
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MJ,8BN2+B0F0 ;<\G[Q'5NI]:2X\'Z/<Z58Z<\<RQZ<0;.5)W66# P-K@Y'
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M34.LZ=%)\0- LA-<I#]@NPQ6=M[#*9&_.X?4'/O75:KI5GK>F3:=J$7FVTX
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M+1(Q()*@DCH:PIO ^@SZS+JK6TBS3L&GCCG=8IV'=T!PWXC![YKH* "BBB@
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M\!:X!GBPE')S_ :YJXTUM#G\)ZMIMW>&YOKF"UNXGN'=)XGC)8E2<#:%R,
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MB D*FV6-2%4 'C/4_P![)!R.*D4O'+\.WCGF59(0CQK*P1P+8D97."0>^,T
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M86^GRB:U07<W[IQT(.[/&3CTR:VZK07]M<W5S;0RAY;4JLP'\!(R!]<8/XT
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MB2&)(HU"HBA54=@.E<_KWB'4]$\'C69-,A6Z01B>V>?(C+,%." =V"WM71T
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MKJU39#*UQ(2JGJ/O<Y[YZ]ZJP>#/#MMK+:Q!I<27C/YA<,VW?_>V9VAO?&:
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MM.]>/P7XONY8;59+?Q!;XMDQQ]K7@1^P?<#]0: .^HJCHVEQ:-I%MI\."(4
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MM[=@T4;RN0I'0]>H[>G:F:OX7T37HH(]5T^.[%O_ *II"Q=?^!9S^M:@=20
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MBJU[J=II\UK#<2A9;R80PIW=L$_D "30!&-#TU=2CU%;4+=11^4DBLPVI_=
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M-L-*BMK60QV.$9&DC<,8QT#'"U9TVUCMOB/%9O;6=O!<:"1):PX92!*H7>>
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M8)XZ9]<>] ')P:187_Q$A@O%^WQ2^'(WD,P.+@^;C<Z]"3P<'OCTK&2VMY/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***Y;XA7K6'AV*9RPLS?6ZWQ7M;F0;\^Q'!]B:
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M-$I6-@C;1P&..O4[<U1L9K.2Q\$6A027QTP26XF?$" 0H&=A_$P!X QU/(H
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MXTGO+.*9P.!N9 3@'MDUBZE::%%!K=[ILD?VFYTE_-6!P8]BJ=K$#@$YP#W
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M* $5510JJ%51@ #  I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **0D*,D@#U-+0 4444 %%%% !14
M,MW;02QQ37$4<DIPB.X!<^P[U-0 4444 %%%% !1110 45%+=6\#I'-/'&\A
MPBNX!8],#UZBI: "BH4N[:1F6.XB<H0&"N#@G@ T1W=M-.\$5Q$\L?WXU<%E
M^H[4 34444 %%%% !1110 44QI(U.&=0?0FG @C(.10 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGC6!X-%F^P7"KJX8IDC*!02>.ISQC'7<OK6SI5]/J%E]HN-/GL'\QU\F?&\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1169>ZAJ4>H_9
M+#2UN5$0D>:2X\I5)) 4?*23P30!IT5RFA^+]0UW1['6+?0@+*\DV!OM8+Q_
M.4W%=O3(['IS6EX9UV77K2\FFM5MGM;V6T*+)O!,9P3G ZGVH V:*** "BBB
M@ HHHH **** "BL6YUV:W\7V6AFT4Q7=O),MQYO(V8R-N/\ :ZYK:H ****
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M3/\ $S'  K,M-=FN/%U]H4EHL:VMM'<),)=QD#,1TP,=/4T ;5%%% !1110
M4444 %%%5;:6]>[NTN+6.*"-E%O(LNXRKM!)(Q\N#D=Z +5%-<L$8HH9@. 3
MC)^M0V$EW-80R7UNEM<L@,L22;PC>@; S0!8HHHH **** "BBF2F18F,2*[@
M?*K-M!/N<''Y4 /HK'\*ZXWB3PY:ZN]L+9KC?F(/OV[79>N!G[M7A+>_VHT)
MM8Q9"$,MQYOS&3)RNW'3&#G- %JBBB@ HHJK'+>G4IHI+6-;-8U,4XERSL<[
M@5QQCCG/>@"U14-I=P7UNMQ;2"6)B0KKT."0<?B*FH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHYX4N(6A<N%<8.QRA
M_ @@C\* .1^$G_),M(^DO_HYZY:XM#'X)\4ZQ%=745Y8ZS=RVS1SLBQL)ASM
M! .>G.:]*T;0=.\/Z>-/TN&2"U7)6,SNX7)).-Q..23Q5/\ X0S0?[*N]+^R
MS&SO93+<1&[F/F.3DG.[/)ZXZT 95Q-+KWB_4-'F>,1V]E#)#!([KNW[M\@V
MD9(.T9[=L9-;OAFUN['0;>SOM3&IW%ONC>ZQ@OAB.>3R.A/J*KZIX,T/6&M7
MO+:4S6:[(9TN)%E"_P!TN&W$?4FM>TM8+&UCM;6)8H8EVHB] * /.M=NG6RN
M-5TZZN+AHM;C7[<\I39F54,,:C[T8&5.< G)YK5&GIJ/Q%UFPNKF\>T;3X)/
M(%U(JABS@XP<@<=!@>U:LW@3PY.MTDEBY2[F\^2,7$@42;@V]0&PC9'5<'MT
MJ[#X<TNWU*748894N981 [BYEY0=!C=@8[8% 'GD(N/^%8:?XA?4+Y]2M+Q(
MXIFN7P$%UY6TKG# KUR"370W"S^)/$OB#2'G1#9+%' K2.K1J\8;S5VD<[B1
MG_9 K9_X0O0?[$&B_99O[/$GF"'[7-C=NW9SOS][GKUYHU3P9H6L7D%Y>6TA
MN8$$:S1W$B.R?W696!8?6@#FWL[H^*/"^GWFLW-YYEE=1W4L,[QK.8]H!P#P
M>2"1@GUJ@NK76B^'=6L(;N=((_$@TZ.=Y2SVT#["V&// + $],UWC^&])>_L
MK[[.Z36$?EVQCGD18EX!4*K!<8 [=JA'A#0OLNH6K6;20:FYDNHY9Y)!(YQ\
MWS,<'@<C'0>E &%=:5:V7Q.T9;<21I-IUT&42MC@IR.>"<\D<G KFY8IH_AA
MJ&M#4+\W^GW\IMIFNY"4VW&WD9PV1D'=FN^M?!NC6MW;7BI=R7%HC1PRRWDK
MLBG&1DMTXZ=*#X,T$Z+-HQM9C83R&22$W<V&8G<3G=GKSC- &3+;G1OB+IJ6
MD]TZZA97+7*2SLXE9"A5L$X!Y/0#@XZ5G:/!?^(_#FF>(HM7BM+M91//<[G8
M\,=\++NQM[;>V!78R>'M-EU.TU.2.=KNS4I#(;J7Y0>HQNP<X&<@YJG!X(\/
M6VL/JL-B4G>3SF02OY1D_O\ EYV[O?'7GK0!RLNG"^E\<)/>Z@5LF#VP%Y(/
M*;R X((.3@] <@>E*84UC6?A[>7V^6>\TZ5IG\Q@6/V=&['CDD\5V \+:0KZ
MBXAG!U08N_\ 2YOWO&/[W'''&..*:_A'1'M-/M6M9/+TS_CT_P!)DW1#&TKN
MW9*XXVDXQQ0!'XXU6[T3P9JFHV(_TF"',9QG:20-WX9S^%8VLQ'0I_#6H://
M,QN[^&TN TK.+J*13EFR>6&-P;KU[5V<T$5Q \$T:R12*4=&&592,$$>E9NG
M^&=,TUK<P1RL+0$6R33O(L (Q\@8G'''L.!Q0!@:%IMJOQ,\2,$?,4-FZ?O6
MX)63/?G\:U_%DT*6MC#+=7$1GO8T2"WQNNCR?*)R,*<9)R.![U<MO#^FVFKW
M&K01S+>70432&YD8.%X *EMO';BG:QH>GZ];1P:A"SK#*)HF21HWC<=&5E((
M/)[T <#<RWD.A>/;4S36HL")+>."Z<B F$,0K<';GG'3DUHI;'3O%?A.2&ZN
MV.J6\\=X);AW64+"'7Y2<#!] *WV\%>'V%\#9/C4$5+H"XE'F@#'.&ZD=3U/
M?-3MX7TEI]/G:*X,FF BT8W<V8P1@_Q<Y''.>.* .42670-2UOPNTTTDVIE9
MM*DEE9VVR81ER3G$;9;'7;S7<PPKI^G+# KR+!'A0S%F; [D\DGUK%TZ.[US
M6H-6U'1GTX:>DL=NL[(TC,Y 9AM)PNU<>^X^@)Z.@#S,7$U]\*3XN2]E3641
M[L7*R-PZN<Q[<XV8&W;C'X\UIZS9PW_C7PC-=0NDEU!<M,@E9<$1(<<'C'M7
M0)X3T>.64I;NL,TWGR6PF?R&DSG<8\[>H!QC&1G&:GO?#^FZAJEKJ=S',UW9
MAA!(MS(@CW##8"L!R.O'- $'B^WBN/!NL1RJ6064K8W$<A"1T]Q7(7]E%'X2
M\"10M)$)M2LF9E<E@3 ^2"<X_"O1)X(KFWD@F0212J4=#T92,$5BKX+T%+6R
MMA;3^782B6V'VN;,;@8!SNR<#@9Z#B@#EKB]N?#$_C:'39IS%9V4%S;I+*TW
ME.ZN&8%B3V!Y]*V['1YXM9TO5[35HH[62-DEB1Y)!?!ERA)9OO#!;=U(SVK9
M3P[I::E=ZA]G=KB]C$5P9)Y'61 ,!2A8KC!/;N:K:+X-T+P]<&?3;1XVP0@>
M9Y%B!ZA Q(7/M0 WQ7-"MO8027-Q&T][&J6]OPUV0"?+)R,*<9)ST&.^*XO4
M9;E/"GC^PF^2*U8>5")3(L0:-6*J2!QGG&,#->A:QH6GZ];Q0ZA"SB"431/'
M(T;QN.C*RD$'D]ZJ1^#]!B-]ML 1J*!+I6D=A(  .03U.!DCDGDG- '/7NGR
M:!XD\.7VG7M[))J-Q]FO();AI%F0QEB^TG"E=N?E  ],53MII=;^&NH>)I;J
M>#6(OM5PLJ2L#;-$S;8P,X"[54%<<Y)/)KMK'0;&PFCFC$TTL*&.)[B=Y3&I
MZA2Q..@R>IP,U WA31VGN9/L[JEW)YMQ;K,XAF?^\R9VDG SQSWS0!S=Y>36
M&H>&/%EX\D-O?0I;ZA$9&$<,DB H^W.!ALJ3Z$5)JEU-I^FZ;.)6MQKVJJ)F
MDD8".-E9D3KE,[4!QCDMZUUVI:99ZO826%_ L]M+C?&W0X((_4"FZKI%AKFG
M2Z=J5LEQ;2CYHVR/H01R#[B@#+T/1[K2-;O2^H1FUNT5X[!=Q$+#AF4L3@'/
M(Z9K-\26K7?C_0K,WEY%;W=K=>?%#<NBOM"8Z'CJ>1@^]=!HOA[3?#\#Q:?$
MX\S&^265I';'0%F).!DX'09/K6'X@T^>_P#'NA3BVO/LMI#<"2YAW*(W<+MY
M'/\ "<]1SS0!S-^EYI?A_P <Z/%?WK6NE>5+92FX?S(]Z;F3?G) XX/K6SJ<
M(T:XT.UBNKP1:[>QI>RR7+L6VQDA5R?DWG&0N.!@<5TTWAC2;C2;C2YK=WMK
MIR]P//<-,QZEG!W'H._0 =!4MUH&FWNDII=U TUM'M*;Y7+H5^ZP<G<".QSF
M@#G5MFM?'TV@PO,=*U#2VN)(!(V()%<+N0YRF0>@[C-4_#CRW5BGA&\FF>_T
MZ_=;J4RL)'A0AUDSG.'#1K]"WI796.DVEA+)/$)))Y557GFD:1V49P,D]!D\
M#CDGO3XM,LX-3N-2C@5;JY1(Y9!U8)G;_P"A']/2@#E8/M">-_%-O#?RQ#^S
MH7B::5G2W<B3Y@"< 9 .!Q4/AFY9=<32-9T^ZTS5A9.A*3L\%ZN5S*CYSO&/
M][YN372OX:TI[Z^O6@D,^H0^1<L;B3$B8(QMW8'!.,#C-/M= L+259E$\DD<
M)@B>:=W:-#C(4DY&<#GKP.>* .!TW5[R#P)X=@>[N-NHZT]I<W+2L9/+,\O&
M_J"=H7.<XS6])"^F?$"VTJSDF73M4L)7GMTE8"%T(Q(ISE"=V#C&>O6MF+PC
MH<.AOHBV1:P=BYA>:1\,3NR"S$J<\Y!'-6+70[*U:21?/DFEC$33RSNTFP=%
M#$Y [\8YYZT >;Z8D\?@/POKWV^^?4/[1AC:1[ER&1YRK*5S@@@\DC/O6QXB
MNY]*U:^NM8MIKC1YIHS%J5G*2^GD!04= >$W DD==QSG( Z,>"M 72(-)6UG
M%E;2B:&(7DWR.#D$'?G@\XSC-3R>%]+EDN#(D[I=.LD\+7#F.5@  2I./X1G
MUQSF@#7KE_$]]-_PD6A:.)$C@O\ SV<2,RK*R*NU"1S@[F..^T5H6VA1P>*[
MO7(PT;W, BD'FLPE(VX8J>%VA<#'7<V:FUSP_IGB.R%IJEL)XT<.A#%61AT9
M6&"#0!SDGAEXM#UK3[[7Y(HLFXMGADD5K $'@-NR5R/N^F147A+49YM+U34;
MY)!KNGP^3/9,S!8]B90A2?X\;MWOCM710^%=(@T^*Q2"80QS+/\ \?,FYY%(
M(9VW9;&!U)' ]*F&@::NNOKBPR+?R1B)Y1/( RCH"F[:?RH Y_0+.#5=!T#Q
M#_:UQ'=L(Y;B9921<,XPT3 \;=YP!VQQBLVU@O\ Q7H5WJ4>JQV%]!?39N=[
M[K3RY3A"N0NW8!D'@YR>:Z;3?!6@:3J+7UE9&*0N9%C\US%&QZLJ$[5/N!]*
M27P1X>FUI]7:Q(N96#RA976.5AT+(#M8_44 8%OHZ:]XT\3Z?>W^H&UCALW2
M**[D0*S(Y)'.0 >0O3GD' QBVJS:KI7@]]6DDNIXM9EM!<-(P:6-1* <@]3M
M'/4XKI;'2)+KQ]XAN[F"_M[>YBMH[>>-WB64*K!QD$=R,$X/'!K>N_#6D7NG
M6FGRVFRWLG62W6&1HC$RC *LI!'!/?O0!H-!&]L;=@?+*;"-Q!QC'7K7EUG<
MMX?^'.J:C8M)#,VJ2V[3AV/E1M<;2V"< @'KZUZD(4$ A4;(PNT!25P,8X(Z
M5F6?A;1K'3;G3H;1FM+HL9H9II)5<M]X_.QZT 8FK0-H/BKP]_9;S+#J,LEK
M=V_FLRRKL+"3D_>7&=W4YY-0>!]+6[FOM0N;V_FFL-8O(H!)=R,H0';@@GYN
M.YR>!72V/A[3]/>)XEFD>",Q0M/.\AA0XR%+$XZ#GKP.:?I.A:?H8N!I\4L8
MN93-*'N)) SGDM\S'!/?'6@#G_'ME;W.H>%VF5B3K"1Y#L/E,<A(X/L.?:J[
M:1;:E\2=2LKAIQ;C2+<%(IVC+?.X&64ACCZ_7-=5JVBV&N6\4&H0M(L,JS1E
M)&C9'7HP92"#R>A[U##X;TJWU.74H898[J:(0NZW,@!0= !NP,=L"@#B-%UJ
M^NO#O@^QN;LL-0DN(Y99W8>:8BP1&8')S@=^2N.<D'K?#>E76CW>HP3:BL\$
MKI-!:C<?LH(((!8D[21D#H,&AO!'AY] &A-8,U@DGF1QM/(QC?).Y6+%E.2>
MA[GUK0TC1;'0[0VUC$RJS;G:21I'<],LS$DT <QJ.GC4_B:VG3WEZMG+HIED
M@BNI$5F\X+V.5XQG;C..>^>=NGU&V\$ZW9'4KUAI6MI:VESY[;S$9(_E8Y^?
M <CG(_*NGN]-FO/B<EZ]O>QVB:5]G6ZBW(!+YN[;D=1M]>/QK9N?"NC7FD#2
M9[5S9^9YI19Y%+ONW;F8,"QW<Y)//- &!?VT>E>*M$T".>[^PZK-<W-QYUR[
MF5T083<3D+_$5S@_3(I+>REE\3Z_X62YN%TV2RCN(665MUG(^Y<(V<@97<!G
M QZ5U&H:'I^J6D%O=Q.XMG5X9/-821N.C!\[L^^>>]2V.F6NG&5H$8RSL&EE
MD<N\A P,L>>!T'0=J .0\*W3ZWIVEZ5<EUO-'D=-1Q(V?,CRBACG)WD[^>#M
M--M$OY;WQQ8V6HR13B6*.UDN)V81,\0( ))*C<W&.F>*[&UTRSLKN[NK>!8Y
MKUUDG<=78*%'Z#^?K5(^%-'+:BQMY<ZGC[63<RGS,=/XOE(QC(Q0!SVAWD=U
M<:KIUYI]YHNJK9*9;99V\ME!;$L+J>Y."1@\#KBL[2=5NI=#\!Z;<7$OV?50
MYNYO,(:0I&65"W7YFQGUQCH37<1Z!8(9G83RRSPB!Y9)W,GEC)VALY Y/3KW
MJ#_A$]%&B0:.+1A9VSAX%\YRT+#D,CD[E([8- ',WPN--\1:]HMK/<)I\FAF
M_14F<&VF#,N$8'*@XS@'&0:IVD4EE8> ]6CO+QKN]:""X:2X=EDC> DJ5)V\
M$#MGN<GFNX7P_IXMKN!TED^VH$N)7F<R2*!@ OG(&"> 0.3ZFJY\(:*UI86I
M@N/)TUP]HHO)OW1 P,'?G@<#/04 )XUWCP5K,D<TT,D5E+(CPR,C*RH2.00>
MHKEIK)K>]\&SPWU\DFI+Y-VPNG_>H8"V,9PO(X*@$?7FN[U'3[75K":PO4:2
MWG0I(BR,FY3U&5(.*I/X7TF3^S]T,Y_LS_CT_P!+E_=\8_O<\<<YXH Y2.6/
M1G\;6!U6ZL+"T6!X9=[2O;F2/YMFXDY+8P,]3Q5S1FN+3XC?85ADL[6;1O/-
MLTYD)=90H=AT#X)!P3GU-;D_A#0[F349)[1Y3JB*EX'N)")0OW>"V 1V(QCM
M3;?P?HEM=PWD=O-]IAA,*S-=2LY0D'!8MDXP,9Z8&,8% '#_  ^NX[ZTT?1=
M3$MM%''-<6.V0JMZWFR!P6!'W?[G?J<C%=/%&P^)]Y:?:+@V\NBQR>5Y[[48
MRLI*\_+PHZ8J\/!'AY=-M-/6SE6WL9O/ME%W,#$_)RK;\CDGO5P>'M-75FU8
M1S_;7@^SM+]JER8^NW&['7G/7/- 'G-M'/#\.M(U_P#M"^?4(-2"K*]TY!4W
M3(5*YPP()SD$^^.*Z;5#++XKU2VU*.ZGM&TY&L5M4=_*;+!SA.5<G&UCC@'!
MX-:H\%: -&31Q:SBQ27S5A^V38#[MV0=^?O<XSUYKGM6T59_$UW/J7A_5IU9
M8XK2[TR\*[HU7I)^\4[MQ;DYXQ[D@'2>#[+4+#PO91:M)-)J#1AKDS3M*V\C
MD98G';@<9SBLFUA\_P"(/B&RFFGEMI-/@8Q/,Y5=Q<-M&?E!QT%;?ARPN-.T
MPPSR7+*9"T4=S-YTD*$#",_.3G)ZG&<9.,U-#H>GV^LSZQ'%(+VX0)+(9Y"&
M4=!M)V\?2@#!^%]M%#X TJ6,$-- "Y+DY()[$\?A775G:/H.FZ!;-;Z9 T,3
M-G89&<+R3A=Q.T9)X'')K1H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***Y/XG;U\!W\T<TL,D;1%6BD9#S*H.<'D8)X/% '645P=_IK>&O'6BW&DRW
M4AU);A+V"2=Y!/LCWJ_S$X.[ X]0!BLSS3>_"8^*UN736XT:Z^V*Q#B19#F/
M_<XV[.F.U 'I]%>=^)9;Z"2ZU/4],.H:5+:1I<&V?%QI3A,L54]OF#$@@^O
MI_BJ>9+B\U6:Q_M?09K5%>2V?%QIWR[BZJ>Q#!B1@^O H [:634!J")#;P-:
M&%BTC2D.),C:,8/!&>:H>%=<F\0:5)>7%LEO)'=2P&-'+@;'*]2!GIZ"LEYE
MF^)VEW$$\KP76D2R!3(Q0_.F"%)P#@]A7+PZ+;3_  _UO6#=75O?6%W?3VLT
M=PZ")DD8@!0<<D8.1DY]A@ [VXURX@\96>AFUC\BZM9)Q/YA+90J,;<<?>ZY
M-;=<3'-<7'CKPO/=ILN)-&F>5<8PY\LD8^N:S-,M+KQ1X:CUS^V;>POH;EY9
M;H0,TT#(YS$W[P?+MXVXQC''>@#TFN=TS7]2UG[)?V%A#+I5Q-+$SF7;+&J,
MRB3!X()7H.0"#Z@;TT,=Q"T,R!XW&&4]Z\KTJ?\ LCX5Z--;9MQ?ZBEM>7$;
M%62%KAPQSVX&,^] 'K%%<;>VW]C^/M%M=,5H;358+F.\MXF*H!&@*R #[K9.
M-PP>14'PXTFWFT6VUB>6ZFO(I[J-'DN'8!?.<8(S@],Y.3G\* .YHKE?$EX[
M^,/#NC3DBPO?M#RKG"S.B JC>HY)QWP*YKQ"LVG'QCI5JS_8(-,2]@4,<6DQ
MW#"'^$':6P.G.* /3Z*XJ]<CQ=X**R,#<07 EVN1Y@$ (SZX))%1>"M'MKN^
MU:]N);N6:PUVZ2W+W4A"+@#!&?FX/?/04 ;^OZY<:->:1%':QRQ:C?):/(TA
M!C+!CD+CGA3W%;=<CX_A%P?#<)=T#ZY"I:-BK >7+T(Y'U'-8.I&Z\&:UKT.
M@O.UK_8;7WD22-*L$X?:&&XG&1N..^V@#TRBO/\ 5(ETS1?#6MZ-(_VR:YM8
MY) Y)O4EP&$G]XG.<GICC%4O$TRG2-:U73I99IK358Q]OEDVO XDC0Q1 #[@
MR0<X!R>O6@#TVJ.M7TVF:+>7\$"3R6T+RB-Y"@;:"2,X/IZ5R5]HUMJ_Q,O=
M/O);MK631XY6B6ZD4;_.89&#Q]T<#CVJLGD^(_#GC"[U &2ZM)[NWB!8[K9(
MTP@7^[GJ3_%DYR* .VT2_;5="T_4701O=VL<[(IR%+*&P/SJ]6/X0_Y$O0_^
MP=;_ /HM:Y&SQX@\#:WK5W*\6K0373+.KE7LVB)V(I_A  7([Y.>M '9ZUK
MTK[%"B"2XO[E;:!6.%#$$DGV 4GWX'&<U)I,^IS02C5;.*VFCF9%,,F])4XP
MX[C.>AYXKB]37^V(? E_J=NOVN[GC\_(QG,#L1CMR<XKM-5N&TK0+VZM8@SV
MEK))%'ZE4) _2@"GXGURXT&WLIH;6.=;F]AMG+R%2@=@N0,'/YBM%7OCJ<D;
M00BQ$2E)1(=YDR<@KC&,8YS7G6HVEI=>"/"VLES->W%]8RSW1;YI'=P7#'N
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MN[B[TG5;UK-7N9& *QC (S\V>G.>@JSHVER7]GX?\10:Y;PMF-IIHX6+WF_
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M?MLEI)=[[@$QJJLJ@8!!R6;\ #UZ5HZ=+>3:?!)?VZ6UTR RQ(^]4;N >XH
MJ0>'-*MM575(;=TNUB$(<3R8V#HNW=C'?&.O/6H+SP=H-]?7-[/9'SKM/+N/
M+FDC688Q\ZJP#''<BMNB@"MI^GVNEV,5E90B&WA4+&@). /KS5&7POH\UU<7
M#6A#71#7"),ZQSD=WC!VM[Y'/>M>HYIHK:"2>>18XHU+.[' 4#DDF@"EJ.@Z
M=JMQ:W%Y#(\EHV^ K.Z>6WJ I S[UH;1MV]1C'/-<]JOB6:TET![.WBEM-8N
M4B,DC$,@9"P(7'H/7\*Z*@#G1X!\,B,Q#32(?.$RP_:)/+1P<Y5-VU>?0"M
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M=D_NL58%Q[-FHO\ A"_#AT-M$.EQ&P9]_DEF.&SG(;.0>3T/<UN44 8@\':
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M<%K#'IZHEF_F6X61QY;?W@0>N,#/IQ5J'1-.@U"YU".W_P!)NE"SN78^8!P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$\0*;P4;:Q'.",^]2ZEXM^P:VVCPZ-?7EU]C-W&(=F)%#!< EN.IZXZ<9)%
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M -8,&&5((SCBEKD?A9C_ (5YIVU2@\RXPK=1^_DXKKJ "BBB@ HHHH ****
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M3)Y30[LAMN=V[!QMQUZD"FPVFMZ#KVJ0)X<36++4+IKJWN1+&AB9\;DDW<@
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M6?1G1;F&"9'7#_<=7R,J?ID>E7YO%DUOKL>DRZ'=K)=1/)9-O3]_LQN!Y^3
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MO]GK*N?)=-C*'X4OCGL.2,\9-^QTNYN_&4OB2YMGM%6P%E##(REVR^]F.TD
M?= &?7I0 MAXJ_M+PU::S:V)8W<PB2V,H#@E]A!XZ@@DCL ?2J^K^.K/2XKR
MX6)+BWL)?+N=MPJR9&-VQ#][;GG)'0XS1HWAN[TWQ5J,I9?[):8WEI'W6>1=
MLGT PV/^NAJG96_B?P]J^I6=KHT.IV%]>27=O=&Y6/R#(=S*ZGD@,2?E!_P
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M?A[[+:OI9MY$^U1M*)/,#98Y^9CCKDY[D4 3VGQ!6ZT_2]4.BW4>G:C.MO\
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M4CH:R-;L/$<5_I/B&RLX+Z\MHY8;NQ64('CD(;".V!E2HY.,X[5<O=:UW3=
MEU:705>0."UBET@:&(#YF+]&;K\H]AZT =)124M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\\XJUINEZO9V'B))=&CN/[0U1KJ.":2,K+"YC5E/) ;:K'GCI79T4 >>/X
MN9]'US3+ RZ98W7DRV%I<2B003(VYB,%@JDA1C)[GTK:GT[4O$5_HD^HZ>=/
M73)OM4P:5'\R4*54)M)^7))R<'@<<\=310!B^+[&[U/PGJ6GV,/G7%U;M$B[
M@H!88R23TK,N].U676?"EXFG.8]-67[5^]CRI>+RQCYN<'GZ>_%=;10!YWK'
MAS7;W3O%]K!IA+:S-&UJS3Q@8"JIW?-Q]TGO6Y>V.I7/C+0M433I!;6=O-'.
M3)'E3(% XW<XV\_IFNHI@FB,QA$B&4+N*;AN ]<>E '!OX7UB]\)^*]*:V6W
MGU6_FN;8R2J5*L5(!*DX/RGVY'-;<^GWVOZSI%Y>6+Z?!ICM.8Y)$=Y92I50
M-A(VC).3@GCBNDHH X5/#6K7/ASQ?ILEJ()=7NY[BU+R*00ZJ%!P3@Y7]:ZS
M1S>?V5;B^MEMIU0*T2R!]N!CJ.*O44 <5+X7U*[;Q7IDT<<=GK+F6&[$N2I,
M:J 4QGAES]*T-"N_%TRQ0:UI5O:_9E_?7$5RLANB!@;%Q\N3@DL?;OD=+10!
MYXWAO76^&M]H0T[%]/=O(BF9-NUI_,R3GTX^M;MY8ZC<^.-(U5+"06MM:S13
M,TB94R;<<;N<;>?TS734UU#HR$D!AC*G!_,4 >;^';74-8^'5YHEO9$"\N;J
M$7;.GEHC3,&8C.[(YP .>.1SC=M-$OO#?BJ[U#3[1[ZPU"V@BEC21%EA>%=B
MGYR 5*]><Y[5NZ-H=AH%F;/38Y(H"Q?8\SR8).21N)QDG-:% ' 7/A/5;;2;
M46]JMQ=R^(!K%TB2JJI\^XH"Q&3C ^H/2MC6[/6;GQ'I]Q'8QW^EBW99+26<
M1B.8D$2,.0X !&.<9)%=/3))HHB@DD1"[;5W,!N/H/4T >=V_AKQ#;>%]'TU
MM-C>73M:%XWEW"X>,2N_&<8)## _/%=-XWL4O_"-VQ<V]Q;*+FVDZM',AW)C
M'<GY>/6M]W2-&>1@B*,EF. !6;<:!H^I:K:ZU/:I/=6Z 03;R5"YW XSM/)R
M#B@"31+*6PTF&*Y97NFS+<.O1I6.YR/;<3CVQ63XCL-1N_$?A^\M+%IX-/N)
M)9V$B+PR%  "1D\YKIJ* .;@T_4%^(ESJS6;+92Z<ELLGF+G>KLW(SG'S8^M
M<RGAOQ/'X.M/#JZ7"3IU^DJSFZ7$Z"8N"!U7@\YYXX!SQZ54:S1,\B+*A:+&
M]0PRG&>?3B@#D5LO$N@^)]1NM-TR#4K'5V29E:Z$1MI@H5LDCYE.!T&?:K-[
MI6LKXJT;5XHH;SR;26VNCYGEA"Y4[@,'*Y4\=>E=-%+'-&LL4BR(PRK*<@_0
MT^@#@;S0O$,5IXMTJUTZ*>'6'FG@NC<*HR\04H5ZYRO7ISUJV=,\0K?Z-YVG
M6][8P:>(9;5KD!(;@$8D;(^<8&!P<<D5V=% 'G=GX8\06O@W1+$V4#W6CZJM
MUY2W _?1AW)P<8!PXX/I^%;DFF:E/X\M]4FLL6G]E-:2NDJG#LZL<<@D#&,X
MS[5TJS1/*\2R(TD8!= P)7/3([9P:?0!P5IX<UNW\$7'@M[8.A#V\.HB1/+\
MEF)W,N=P< D8 QD#GO6G%I%[9>.+:]@L7?3K?2/L*R>8F[=O##@G.,+C/K[<
MUU5% '!:=H&H)HDVF:KX=2^M;G4IYIH6EC)\MRS*RG<,,#@'D=>#6]X/TB\T
M329K.YEE:+[2[6D4TGF/! <;4+<YQ@GJ<9QGBM^B@#FFL=17XAOJXLF:R_LO
M[*'$B;C()"_0GICC/K[<U@?\(YKI^&XT(Z:1>B^\['GQ[2OVCSNN?3CZUZ)1
M0 Q29(060QEEY5L97V../RKSU/#OB*/X>V'A]M,C:XLKF$[DN5(=(Y=Y;G&,
M@  =>N<5Z+10!R-_HE]J?C*>ZDLY(]/NM%?3WE\Q-R,S[L[=W3''U]N:7PT/
M%]K;VNC:EI]K'%9!8VU)+D,)XUZ8CQD,0 "21CD^U=;10!S_ (ZTR]UGP=J&
MF:?!YUS=($0%PH'S Y))Z<57U"QU*[\7^'M333Y!;V,5PLY,D>5,BJ!@;N<;
M>?TS7444 <#+HWB9+7Q)]AM6@EO]02YA_P!(5#+$ BNFX$E&(4\^_6I;?1-8
MM]=U.]BT2WM[:]TM8$AAN%S&X+\$8 ).X$GIUY)KN:* .%N-!UF;X1CPX+#&
MHBT2UV&5-N1CYMV>G'U]JMZ%I6JZ!J\MK:V+MH-ZGFF)I4#64QSO51NY0]<#
MH3Q77TA(4$D@ =2: .+\-VGB[0[6+PX]C;26=LVR#5?M XASQF+&2X''I^7.
MCH^F:GIWB_7+A[:-K'49(YDG$O(VQA2NW&<Y'TQ^5;G]H67_ #^0?]_!_C3O
MM=L55A<1;7;8IWC#-Z#U/M0!RWC:26+6O"KPPF9UU)B(PP!8>4^<$\9QGKC\
M*;J&A:AJ%SKNK_8VCN+S2SIUI;&1-V/F)9R#M&68=">!ZG%;^I:!I^K7EI=W
MD<K363[[=DG=-C>N%(!/UK2H X[5-&U6^^%?]A1V)&H&RCMC&94VAE"@MNSC
M''U]J-1L-?L?$MKXCTG3DO/.L5L[RQDG6-UPQ975N5X)(/\ G'8T4 <CKFF>
M)+A=*URSCMGU73YG=K$R8C>*1=K1A\=0 /F/&<]L"MS1YM6NHGN-5LX[%GP(
M[5)1*4 SDLX !)ST' P.>:TJ* .7GTO4=,\;3:]96S7MK?VJP7,,;JLD;H?E
M==Q (P2",@]^:S[WPMJ(\'^(K>&W$NHZ]/+,8ED4+#NP%!8D9PH&2.Y/;FNX
MHH K:>9?[/@$\#02K& R,0<$#U!(KE].TG6?#XUO3K:Q^VVU_<2W-I.)441-
M(.4D!(. ><J&R/RKL:9)-%%L\R1$WL%7<P&YO0>IH XH^%M1T!O"LFEVPU$:
M-#-;SIYJQ,WF*N7&[C 93QZ&J5YX:\17'AOQ98-80F;6+PS0;+@$8(0<YQP-
MG7J?05Z+3/.B,QA\Q/-"[BFX;@.F<>G% #;5Y)+:-I86@D*C=&Q!*GTR"17)
MFQ\1Z!XIU.ZTK38=3T_5F24J]R(6MI0H4DY!RI !X!/]>QHH Y272-7T_P 6
MV_B&&,:AYUB+.^AB948,&W*Z;B 1DD8)!QZFLO6/">J77AW7S!:A]0UN]BG\
MGS% A2-DVAB3C.$.<9Y..@S7?T4 <S=V.HS^.M+U9+"06EO9RPRL9$RK.5(X
MW<XV\_IFL"]\-Z[<>%O%&FIIA$^JZHUU;[IH]NPLA^8[N#A#Z]17HM% ',WU
MCJ-UXVT;54L)!:VMM-',S2)E3)MQQNYQMY_3-8<_A/6-0T[78O(%I<RZP-4L
M'DD5D8J$ 5MI)&=I_,5Z%10!S,NGWVMZ]I&JWFGR6*:2LLGE/(CM+*Z[0%*D
MC:!DY)!)QQUK D\-Z[)\.M1T+^S2+RXO6FC!FCV[6G$G)SQ@#'UKT6B@"O,]
MP^GR/#$4N#$2D;D'#XX!P<=?>N4T3PU-9>)X-5LM-?1(9(7_ +2M5F5H9Y#C
M:4520,')SA>,<<FNP>:*-T221$:0X168 L<9P/7BGT >=V_A#7?^$*M-*,,$
M-[HNH"\LW,VY+EEE=QG ^4$-CGOV%;=WHESXEURQU#4+.33X;&UN(Q&\B,[O
M,H1ON$C:%![Y)/3BNIHH X[PM;^+-+LK30+VQMA;V.V-=26X!$L*GY0(\9#$
M +R0!UYZ5DGPKKL.IZGK]A9&#5AJ)N+3=*FRX@8(K128;@';GV.,5Z)'-%*7
M$<B.8VVN%8':>N#Z'D4^@"&UEEFMDDGMVMI6'S1,P;:?J#@UP\GA_7H_#?BG
M1DL(Y/[1N;F6UE%PHWB8Y&0>F!G/X8S7?44 <A<:9JLNL^$[M=.?R]+24769
M8\J7B\L8^;G!Y^GOQ6/+X=\47-G:F[TRWN-0L]8CNY+QKH;KF-92P"\?(H4@
M8XQC@'->CT4 <UINF:K8^-]6OVMHFL]3CMV,PFYC:-"I7;C)R2.>!C\J=XJT
M:^O;S2-8TQ5EN])N&D$#MM$T;KM=0>@;'3/%=!YT7G"#S$\TKN";ANV],X].
M13Z .<M=,NI_%DWB:YM)(#'8"S@MF9#(WS[V8D,5'. !N]<XK"A\+ZS<?"W4
M?#DUHMO?2F5H]TJLC[I3(!D'CKCD5Z!10!QVIVGB:/6+#Q-IVFP2W(MFM;S3
M6N0"8RP92LA&-P/7ZTNNV7B#5;+297T]#<0:K#>26\<RD0Q)_#N.-S'KTQR1
MG@$]A10!S=G8:@GC^^U22R9+*XLHH$D,B$AD9F.0#G'S8_"NDHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *QO%>O/X9\/7.KK9F[%N 6C$@3@D#.<'N1VK9KG_'.E7NN>
M$;W2]/C5[BY"JN]PJKA@Q)/X4 ,F\3W5DZQ:CIL5C+<SF.S$UXH61 NXNY ^
M3'3'/)&,]:J)X^@2SOY+NVCAEL;J*W9UGW6[B0@+()=OW>N>.,8J?Q+I>LWW
M]E:SI"0IJ>FR,_V6=_DE1UVNFX=^F#[5)*OB"_TMGU#2;)_.D19-,,PE7RN=
M^7*@%CD$#&/E'/)H 9J_BB_T70+[5KC289$M)$ $=V2LT;;<.K;/5L8QV/-7
MI];>+Q7;Z%)9J8[JUDG2<2Y/R%05*[?]KUKF)/ UY_PBGB'2=/!M+:^='L+*
M>7>("NUF&02 &8= 3C\<#1CL?$5[XOTO6[K3K6UA@M)H9H1=;V3<5.00N"?E
MZ=/?G  .>BU"[\/^ O&%WI$<,;V^LW:ID[1$I8+E0!U&1@<#\L'TBS:Y>U1K
MN*.*8CE8I#(OYE5_E7$_\(MJ][X/\4Z3);K;3ZI?3W-L7D4J5=@R@E2<'C!^
MO>NTT][N2RC>^@CMYR/FBCDWA?;=@9_+_&@#CXVO]0\?Z]:76G6EW;K801&%
M[DD>6QD/ *8);N.,8')J31_&S'PS'K,VA?8-$@MI"91<JS(8VV+&J8!.<8!]
M>.F";]EI^IVOC;5]6>RW6EY;PQ1;95WYCW=1V!W>M9EAX.OKKX72^$]2"6UP
M5<++&^]<F0R*>QZXR* -B7Q)=:?J.FVVKZ:EK%J;^5#+%/YFR7&1&XVC!/."
M"1D?C6<_C?43INM7L'A\,NBW,D5PKW@7<B*&9EPIR<$\<#CKGBK$VEZMXA;1
M$U>T2T_LRZ2[G=90XFE12%V8YVDMD[L'C&#UJG%H&KKH?BZR:T42ZU/<26W[
MU< 21A!N]",9.,T :$?BVX.JZ3#-I1BL-8!%K<&<%PP3> Z < @'&&/N!6SJ
M]_)IFESWD5G->R1@;8(%R[DD  ?GR>PR:YNXT75I%\)[+-<Z0RM<@S*.D1C^
M7UZY[<5L>*[/5+_PY<VVC3".\;:5RY3>H8%EW#E<KD9]Z *T'BQ(]5U/3]3A
MAMFTVT%W)+#/YJ>7SG/R@@C;TQZ4^WU[5);G3]VA.+7449DF28L8#MW+YHVX
M7(XR"<'CFL,^$]2O]8O6GL+/3]/U'1OL+)!-N-N=SG@!0&/S9[#Z]]/PTGBV
M&WM=-U>ULX8K)0CWD,^]KD*,+A-ORYXR2?7 YX ,RP\7ZU;>&=;UR_L;6X6P
MO)U*)=,O"-MVJ#'T&.O?T%=!/XADM_$.D:6UFICU6*5TF$W*%%#$%=O^T.<U
MA+X5UB3PUXET&5+9$OY[F:UG$I.\R-N4,N/EQT/6I4TWQ)?>(/#>IW6G6EM'
MIL<\<\?VK<1O15R"%YZ<#VY(S0!;NO&$]G+:/<Z48+6[U+[!'YLI68DMM$GE
ME>5)'KT(/M45A!%#\5=6,4:H9-+@=]HQN;S'&3[\"LB7PUXHFL4CGL[*>]M]
M6CO&O'N3NND67<J_=^0!<#'08X'-=!9Z?J2>/KO5)K3;:36$5N)5D4_.K,QX
MSG'S8'':@#1UC64THVD"Q>?=WTX@MH=VT,V"22><* "2<'Z5GCQ3-#J-_I5Y
MIP34;6U^UQ1QS[DN(LXRK$#!!X((_.E\5:)>:C/I6IZ:8S>Z3<^<D4C;5F0C
M:Z9[$CH:@ET:]O\ 6KO7IK0PR_V:UC;6K2*6)9MS,Q!P.< 8)X!/M0!9\,>(
M=0\0VUO>R:-]CL;FU6:.8W(<EB>5VX!QCD'OZ"F:QXFOK#Q#%HMEHQO)[BUD
MGB8W(C5BI VG(.!SU_2K'@^PO-)\*:?IM_$L=Q:0K$VQ]RM@=0:KWVFZC)X]
MT[5HK96L[>TDMY&,@#9=E.0.X&V@!VF^([Z^O]5T^72X[>[TV&"78;K<KF16
M.TL$XQM(R :I)XZDETOP_?Q:.[KK<@C"B=?W3$,0.0,_=/I4CZ9K=CXQU._L
M;6WN+75K>%&EDFV&W>,,.5QE@0V>,>G'6LFP\,Z];:!X3LIK2$RZ-=":?RYP
M<H%88&0/F^;ITXZT :T'BG6;F_U/2H_#\1U+3PCE/MW[ET<$J=^S.>",;?QJ
M6U\9V]]HNC7MK:LUSK3;+:V=]N& )?<V.%4*><'MQS18Z=J-IXSUO5GM-UM>
M001P[9%W$QALY'8'=Q6'I_A#6[+P]X;=8X1JOA^:1O*,OR7$;Y#@-C@D'C(Z
MB@#=_P"$KFAN]3TZ[TX)J-A:_:TBCFW)<0]-RL0,8(P01U]:KV?C6YDT>#6+
MW1Q:6-U!"UM(UTI,DLA "$8&T9.=Q[<X'2EN-$OK_5M0UV2U\J>32SI]K:M(
MI;!8LS.0<#DCH3P#W.*KMX9U:Y^'FG:2K16FK:6('MW+;XS+#C:21V./PS0!
M;MO&MNNHWMIJ,<$26EH;S[5:W'GPM&#A@6VC#C^[W'-8_B.ZN;_5O"%Y/I26
MR3:FC12F4-(JE&.QQCY2>#@%AP?;.G=:?XC\5>'=0T[6+6UTKS[5H42*?SM\
MAQAR<#:HQTY/)].:%Q9^*]3@\.)<Z''%/I5]'+<2&\39(%1E++C)P<YP1D9'
M!Z@ W?'4,4_@37%EC60+83.H89PP0D'Z@U0T/Q)- ^@:1=:7)!#J%F!:W)E4
M[V2,,04'*@C)'/X"M?Q5:76H>%=3L+*'SKB[M9((UW!1EE*Y)/89K$ETG56O
M?"$ZZ>Y725870\V/*YB\OCYN>>?I[\4 6Y_%T_\ 9=[K%CI@N]-L9'61Q/MD
MD6,XD9%VD$ @]6&<'VS+)XLBGOX++2TM[F:YL5OH!-<>3YR,3M"?*<GY3GIC
M(]>,NQ\/ZSI&AZKX;M[>.>UNGF^QW9E $*2YR)%ZY4DGY<Y]J75?"*3Z;;Z(
M^D+?V=G81Q65TDJQSP3KN!;)((! 0\9Y!X- $]QKNMMXRT>PBM(([>YL'N9(
MI)V5MWR AOD/W=QP._?%36EW8:M=^)[%M&2VE@*)=-($8W.8\J6QGHN,9)_"
MH!H.NVNL>'K\20W\MG8-9WDLLI0EFV?O!P=W*GCK4FG:;J=MK?BF\DL&\O43
M&UMB1,MMB"8//&2,_2@"GX6UR#2/ /AJ%C%Y]Y;A(A-*(D&U26+-@X 'L>2*
MV_#GB,:[+?V\ENL,]A*$<Q2>;%(",JR/@9!Y[<$5SD'AKQ#9^&O#<UC%"FL:
M"&1K>:0>7<(R[7 9<XR ""?2NNT>35YXGN-7MX;-WP$M8I?-\L#.27P,DYZ
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MWG0S(PX*O@<CH1CCWK>K*T6;6[I6N-8M(+#@*EK#-YQSW9GP/P Z<Y)SQJT
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M/IR ;M%8_AG7GU_3I9Y;-K2:"=X)$))5BO\ $C$#<I!!!Q6Q0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5B>+-$N==T7R+&Y6VOK>:.YM97&565&RN?8]/QK;J&ZNK>RM9;
MJZF2&")2TDCG"J!W)H R=(D\33*T^LVME;M'&52WMIBXE?CYBQ VCC@<]3GM
M61I7A_6K/X<77AZ:"V-[)#<1(RSDQGS6<Y)VY&-_IVKL4=)8UDC8.C@,K*<@
M@]"*=0!QEYX>U[^R/#]UIYM8M8T-!'Y4DA:&="@1UW 9&< @XXQ4VKZ'KWB3
MP](MY+:V&I)-%<6<<3&2.&2-MP+,0"23P<# XZ]^MHH Y^TA\1:I87,>M16=
MB9+9X5BMI#*&9A@N20, =E&>IR>E3>$K+4M,\-V6G:G';I+9P) /(D+A@BA=
MQ) QG'3MZUM44 <O:Z1JNA>(]6O+"&&\L]599C&\WEM!,%VGL<J>#D<C'0UG
MW?@W4+;P98:)I_D7%Q%>I=SRRR&-682^8V.">3P/:NXHH ;&6:-2Z;&(Y7.<
M?C7G/AJSU+6/ 6H:/!#$D5[=W</VII.(T:5@Y*XR6ZX'3IR*[V:_L%O$TV6\
MB6ZN%)2 2XD8 <D '/3O570;/1;"&YM-%,:QPS%9HXY2XCDZD$$G!YR: ,RU
MT*^LO'$6HP00_P!FQ:4FGKF8^8-KE@V-N,=NM5XM*\4:%KNHG1DL+O3=3N#<
MXNI61[:5@ YX!W*<9QQ^'6NB36M+EOS8)J%NUT 6\H2#=@<-Q[=_2H8O$VA3
M7*VL>KV;3NZQK&)EW,S E0!WR <>M %'Q-X?O=6TFQ%E>"/5-/GBF@NG4#D?
M*Y(]"I;CZ4SQ'X<N[C2M-&@S107NCS)+:"?)1P%*%&(YP5)YKI:* .2U33_$
M^O>%-3M+R"QMKJ\@,$-O',61,]79]O)] !QZG/#[C1]7GU[PSJ MK=4TN.5;
ME?/.<N@3Y?EYQC/.*Z&^U*QTN#S[^[AM8L[0\SA03Z#/4^U6: ..M/#VM6>F
M>)M.$=I)'J4]U/;2><P),W0,-ORA<GG)S_-@\/:TMOX0006Q;0PHN?WY ;$7
ME_+\O/KSBNTHH X?4+.]TB7Q?JUZEDEKJD,:V_G2;QO$?E*KK@##,1W[U%I4
M&KZ%<Z:^I>'8'2$)91W2:HTS0JY5?E1U'&<9P<X'<#%=O=VEM?VLEK>01W$$
MHVO%*H96'N#5#3?#.BZ1*)K'3HH9%&%;EB@]%R3C\* (_%FAOXB\.7.FPW'V
M>=BLD$I&0DB,&4GVR*I0+XLOM,N4U2VT^WE%N\:1P3LPFD(QN8E?D4>G)_+G
MIJ* .&_X1G6U\-^%=/6"U,VBW<,TY,Y"NL:,N%.WJ=W?TJ#5O"GB2_LO$%GL
ML)FO[H36]Y+,V_R@ZLL.W;\H7;C.<<].2:] HH YF'3-87QN^MS6UMY#Z8MH
M52<E@X=GXRO(^;&>/7':L&;2=0TSP - O8M/-[>:@5MXWF8I+OF,I ; *L%W
M8/8C(YQ7HE5-2TJPUBT-IJ5I%=0$AMDJY (Z$>A]Q0!RMC!?_P!H26.LZ!';
MG5X6MFO8M1-R^U48[2&4$+C/(XR1GDYJQX;L?%^G06VCZ@U@UE9;46^C=C+-
M$OW5V$8!( !.>F>IYK=TW0M+T<L;"RCA9AAGY9B/3<<G'M4T^I6-M>064]W#
M'<W.?)A9P'DP"3@=3T- '+1>%[VXU[3-8EL[?3]2MI2;V\MI>+N/:1M*@#))
MVDYZ8X)XK:\6Z;=ZQX6U#3+)8S/=PM$ID?:HSW)P:THKVUFNY[.*XC>XM@IF
MB5@6C##*Y';.#3YYX;6!Y[B5(8D&7DD8*JCU)/2@#F)M&U>7Q!X:U 6]N(M+
MMY8K@&<Y)D55^7Y><;<\XZU9\,:5J.FZCK<U[%"L>H7IN8C'*6(!55PPP,'Y
M<]^M;EK=V]]:QW5I,DT$J[DD0Y5AZ@U-0!S5YHVH6?C(>(M-2.X2XM1:W=L\
MFQOE;*NIQ@GJ"#CBLZ_\&WUQX>U<1/ -4U&_2^VECY:E'0K'NQD\)C..I/:N
MVHH Y.WT[Q#)XRB\07-G91Q_V:UJUNERS,C&0.,-MPWW?0=>^*N>"-*U#0_#
M$&F:E'"LT#R8:&0NK!G9NX&/O8_"N@HH Y[6M*U"\\6:!J5M%"UMIK3F;?+M
M8^8FP;1@YQUZBJ<&AZO%>>*IV@M\:P%^S 3G@B(1_-\O'KQFNMHH X:S\/>(
MK.+PVA@L;J+3+3[//:RW#",2 *%F!V') !X(XSQUS59/"/B&+P[;:9LL9)+;
M61?!Q,RAT$ID_NG!.<8YQZUZ%2,P12S$!0,DGH* .3O]#URY\4:AJ=H8;5;G
M1S8PS>:2\4H+,'QMZ98=^U4K#PYK\6H^&[V6TTVV&EQS17"I<,Q?S%4&7.T9
M)*YP?7EN>.TM+RVO[2.[LYXYX)5W))&V58>QJ:@#S6RMM4NX[O4;;0].U32[
MN^>\CVZDT,<@#_*QC*E<_*"<]3R>:UFM?$ UB/Q1X>@MI8=7LX?M=C>RF-D8
M#*,& /(#8(_GVV8_!OAR*Y:XCT>V5V;>5"_(6]=GW<_A6W0!RM]HVMW.M>';
M^3[-.=.DFENB'*#,B%0J#!R%SU.,XI+71M6@UCQ1>FW@*:LL?V8"<Y!2+R_F
M^7C/7C-=756XU*QM+B"VN;N&*>Y;;#$[@-(?]D=30!QD?A?Q%I^C^';G3S9C
M5=$A:VD@DD)BN8F"AANQD'Y01Q5[7=)\2:[X<,$T5DEY)<PR^0LQ\N%(W#XW
M[<LQQUP!T],GKZ* .<&F:FWCV'6S! MH---HX\[YPY</D#&".,=:J^'=+\1^
M'/"(TN*WT^:YM)"MN6G;;*AD+%F^7Y3M;@<\C\*ZVB@!&)"D@9..!ZUQ^B^'
M-6MX/$]M>I;Q+K-Q--"\<I?9O7: PP.G7BNQHH Q_"MIJ.G^'+&PU..WCFM(
M$@'D2%PP10N[) ZXSC''K5 Z3K">,-4U>%($BN-/6VMV,F6$BEB"5QC&6]>U
M=/5:?4K&VNX+.>[ACN;DD0PLX#R8&3@=3T- '-:5X8FM_%,.N1V,&DLUNZ7\
M5M+NCNY#C:0H & =QW$ G/3O2?$,RK%X=,"H\HUZVV*[;0QP_!.#C\JZB\O;
M73[9[F]N8K:!/O22N%4?B:JWNDZ7KT=I/=1?:$A99[=A(RA6ZJXP1SSP: ,6
M_P#"TGB/4;Z\U-!:I-IKZ?#&KAW4.<M(2.,Y"X'/0YZX$(\/:QJ>@Z9H.KQV
MZ16,L+3W,<I;[0D1!7:N 06P,YZ<XS78 8 'IZU7?4;&._CL'NX5NY062 N-
M[ #)(7KCWH Y76?"][K5^ER]G;VVH6UXLEKJL$NUU@#YVL  2=N5QR.<Y'-&
MM^%[W6[U9WL[>VU"WO%>TU6&7;(D(<':P !)VY4#D<]1S767E[::=;/=7MS%
M;0)]Z25PJC\34D<B31)+&P9'4,K#H0>AH YZ#1]1'C'5M1DCA6SO;2.WC82$
MN"F[DKCH=WKVK+M/"NJS^#['PGJ$5O%:V[1K<7,<Q;SHT<. BX!!8@ YZ#/6
MNXHH Y>7P_>WGBO5[FYCB&G:CIRV6Y9?W@QNR<8QSO/?M4?ANS\7V$-MI&HG
M3S9V6U!?1.QEFC7[J[", D  G/KCGFNLHH Q/&.BS^(?"6HZ3;.B37,6V-I,
M[<@@C./I5&[TS7;_ ,2^'M6FM;2--/6?[1&EP6(,BA0%)49QC)Z=:ZFB@#@[
MCPSXC:T\0K;&VA?4;]+J(?:&'F1C:&B<A<KN"]1GKBKEEX?U@>(;Z\FM["UM
M+[34MO*@D9C 5WX4#: 1\V<\>F.]=A10!B>$+#4M*\-V>FZG';I)9Q+ I@D+
MAPHQN)(&,^G;U]*Z:3JEGXVOM7MX[::SOK6)'WRE71H]W &,'.[KD8]^AZ.B
M@#S]/"6O+\.K?P\8;0WD5V)F87!\LKYYEZ[<YYQTK0DTOQ/I/B2\U'18K&ZM
M-5\M[BWN9FC-O*JA2RL%.00!GC/%=-::E8W[S)9W<-PUNVR41.&V-Z''0^U6
MJ .4UW0+O68?L6J:=:ZM;FV&V7?Y4D-QEMS+QE5P5Z'(QT-4V\.^)M'NM*U3
M2[FWU*\@T]+"^BNI&03JIW!U;!P02>O4&NWHH J::M^+0-J3Q&Y<EF2'.R/T
M52>3CU/4YX'0<GH\VH1>./&/V*SCN-TUMM+3;-K>0N,\'Y?<9/L:[>LFTL=$
MTO6Y?LY2+4;]3+(AG8O,%P-Q4GG&<9[4 <[#X/U#2O\ A%H;$07$>C22RW+R
M2&,R-(K!MHP>[$\^PK3FT;4-.\93:_IT<=S#?6RPW=NTFQ@R?<=21@\$@@X]
M?:NEHH Y_1_#*6VEZI;Z@$E?6;B:>[1"2H\P8V GJ H S@9.3Q2^$M%O=!T(
M6]].+N\4;/,!QE$&V-<_[H!/NQK?JM=:E8V,D$=W=PP27#B.%)' :1B< *.Y
MY[4 <KH^@:QIOA.#2;JPL+P?;)7NH'EW)+"[.V 2OW@67@CMU%4[GP1J">!]
M:T+3A'$FH7&ZTMIIR4M(\J2-V#W4G X&?J:[^B@#F+G1]3MO%L7B6QABE,]F
M+6]M&EVGAMRNC8P2#D$''%9FJ>#M3NM U:.!;=M1U>_CNI0TI$<2HZ%4!VY/
M"=<=2:[JB@#F+G2M8E\:0:U%# D*::]J<S999&8-D#;@@%<56TSPQ<1^*+/7
M?L,&ESB%UU$6LN8[QB!CY0!P#ELD ].O4=A10!SWB_0[_5;>QN](FBCU+3+H
M7, FSY<G!#(V.0"#UJIJNA:UXK\-7=IJK6VG7,FQK:.!S*L+HVX,S$#.2 ,
M<#U-=95:_P!1LM+M6NM0NX;6!>LDSA5^F30!AOI6I:YJ6CW6K6T-HNENT[)%
M+YGFS;=HV\#"C)///08K!O\ PGXCD\/^(O#]M%8FWU&[EN8+EYVW8D<-L*;>
M".?FS^!KT($$ @Y!Z4M '-7&EZM/XNT;56@MA!9VLL,X6<D[GV\KE1D#;WQU
MK!_X13Q)9>$=5\(VL-E<64WF_8[I[@HR([%MK)M.2"3SG'/X5Z"S*B%W8*JC
M)). !4=I=V]_:QW5I.D\$J[HY(VRK#U!H 99+<1:="EPD?GI$ ZQN64L!V)
M_E7%2>%-=D^'VJ:!Y5H+N\N9)4;SSL"O+YG)VYR.G2N^HH YJ_TO5;SQ?HVK
M)! D%E!-',#-\P,@7E1MYQM]LUA0^%O% T[2H9XM-DNM/U1;N:Y:X<M>XWC<
MQV?*</TYZ=@,'N+?4K&[N[BTMKR&:>VQY\<;AFBSG&X#H>#^56J //KWP7K%
MSJ^L:S +>VU)[F*YTRX64Y0J@1D<8^ZP'(Y_2M+5-,\3-J6G>(M.ALEU*&W:
MVO+*28^5-&2&^5\9!##(R/\ Z_47M[:Z=:27=[<1V]O&,O+*P55YQR3[FIJ
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M;^#3(/[-$ZSK%<._F;U"[ER@QTS@_G4FE:'K-A#XC$L=BSZI=27%N%N'PNY
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MXN-4NYYHV%P^Q%E;<<_N\Y'TY]J -5/$6HP^)[#3+ZQ@CMM4BE>U>.8M(AC
M8AQ@#D'L3@\<]:K7'B^]LKO3A>64,":AJ'V-;5Y,7"*695E(Z$$KG&.A')J:
M]T;6+KQ%X=U(1V2QZ8DJW"FX?<3(@7Y?W?.,9YQGVK%7PAXF_LVSMI)=,EGL
M=62_-RTDF^\PY.7^7Y2 <?Q= . .0#H;'Q!<OXEU/1M0@@M?L<"W$$@D)\^)
ML@OR!@*1@^YK1T6\N=0TFWO+N!())T$@C4D[5/*YSCG&,CMTKGO%&F6VN:UH
M\5O>H+U)9(;I82"7MBG[Y&&> 2%'/0L/6NO P,"@#F9/$U_=6>J:AI%G!<6V
MF321%)'*O<F/[^T@87!R!G.2.U4)O$M_J?B+PNVDO#_9^IVTURJ2%@S%4'#8
M]-_3U'TJQ9>'M8T5=8L-.^RS66HS23P22RLK6SR#Y@5"G<H/(Y!['UI&\(7>
MFW'AE]&DMV318);=Q<EEWJZJ"XV@Y.5SCC.>HH RK?4-4TK5O&MYIEC;SBVN
MEGE\^4H"JP*2J@ Y8X/7 ^O;H)/%B3C3XK)%6:_LA>YE5F6*,XQD*,DDG'8<
M'GH#3B\.ZV@\5[DL"=:R;?%P_P G[ORQN_=\<#/&?2JR^&/$FFQ:'J&ER6']
MI:=8+I]U;RR.8;B(8P0VT$'(ST[_ )@$C^.-432["Y;0MD]QJBZ=+')(R?,3
MP\>Y1N4CH3C'OBKK>(-;T_4](L]7T^RA34IY(#-#.SK&X!9!RHSN X]ZBUK1
M/$6JV6ELSZ?)=VNIQ7TJ&5TC4)TC0[&)^IQSDX[#3\4Z+-KV@/;6\B07T;I/
M:RGD1S(P93GTR,?0F@#.L_%US<1^((Y+>V%WH\OE)$DI83$CY.<<;C\N.<$&
MK1UBZC\96.D76GVP:>QDF^TI(68%2H9 "HP,D=^>.!5<>#1#XDT[48;C]Q#;
M>7>(W6Y=6#QN?<.68GUQ5B[T?4IO'5CK,8M?L=M:20,&E82$N5.0NW'&WU[T
M 1:'XHFUZ:*2T%J\'GR174(<B>TVAMI<>Y4#H,9[]:J3>-[DVT.IV.GF\L7N
M/+,44<C3&/=M\T87:?7;Z=\\41>%;ZYUW2]8N[:RL]1LW)NKRTE.;M-I&UEV
MCJ<$YZ8XZ\-T70?%6A!M$MKJP?11(Q@N7+_:88V8DH%QM)&3@D\=>>E '67U
MY!IUA<7UR^R"VB:61O15&3^@KAO$E[J6HV_A2^GM8(K:YUFTE1 Y,D.<E=W8
MY!YQC!XYZUV>L:;%K.C7FF3,4CNX'A9EZKN&,CZ5R+>'O%MSI&BZ;<C2R='O
M8)A<"=_](2+.,KL^4D8SR>?2@"[J7C&ZBBOKG2[%;Q+"=H6@"R&2<J</L*J0
M,'(&<YQVJ>]\5S/+<P:7 IEM8$E=;A),LSKN$>%!VG&,D],C@\XJVNB>*M$U
M:_CTB?39=,U"Y:YS=;_,M9'Y?  PXSR!D?A3KG0_$>E>))]5T">RN8=0BC2\
M@OW93O1=JR*R@_PXR,?_ %@ 7QCJ4]YH-O#H@B.LP3/LNI6C>%XURRL-O R1
MSSD=JB7Q;K[Z?K+)I5C]KT21Q<[KEO+D4('&SY<Y*GO@#CKGBY=:'K,WB3P_
MJ32VDZ::D_VEFD9&=I0 =BA2 !C@$]._>H(?#NM)'XJ#)89UHL8,7#_)F,1_
M-^[]L\9]/>@#I=,ODU32;34(E*I=P),JMU 90P!_.N1T?Q1?65EXIU;7'A:U
MTW4)8\1$Y&U(PJ*#Q@Y]>I-=+X<LKK3/#FG:?>B$3VEM' QA<LK;5"Y!(!YQ
MGI7//X+O+NS\3:1=S6XT_6;E[J*5"QE1V"8!7 &%* ]3GVH T+CQ%J&D7VE)
MK%G EMJDRVZO Y)MYF&51LCY@<$;ACD=*9\25#?#O6@1G_1B?U%-;1-7UA-'
MAUQ;5%TNX2YDD@E9S<21@A, J-HR=QZ],>]:?BG1Y-?\,:AI,,JQ274)17<9
M /O0!E)XEU;3]>TZPU?2X(++4\QVL\,Y=D<+D+(,  D#L2,]SUJ&;QO<FVAU
M*QT\WEC)<>68HHY&F,>XKYHPNT^NWT[YXJ^='U#5]0TJYU:*WMH]+<S+%!,9
M?-EVE0<E5PH!)]22.F.<[1-!\5:$K:);75@^BK(Q@N6+_:88V))0+C:2,D D
M\=>>E '5WTLL%A/-!"DTD<998W?8&('0G!Q^5<G%XQNX_#?AJ_MM(MRFKSQV
M_E)+L$)8,0 ,8(PIYR,>AKK;U)I+&>.W5&E:,J@D8JN2.Y ./RKC(O">O0^&
M?#.F*NG--HMY'/*QN7"R*@884^7G)W=QQCO0!MZ%KM_>:WJFCZI:007-B(I%
M:WE+I)'(#CJ <C:0>*K>*=1U:U\0^';2P>!8+NY=9 Y8%RL;D D=%[^YQ^,]
MAI.IV_C74]7F6T^QWEO%$FR9C(ICW<E=@'.[UXQ3O$NCZAJ%]H]_IIMC-IMT
M93'<.RJZLC(>0#R,YZ4 8,4^J6WCSQ6^EVEM-<?9;-V\^4H@PC\< DD]N@XY
M/8ZD'C2.]TO1I[>$1W&KP-,J2;F6%5 WD[1EL%@!TSGM2V>BZU;>)=>U1TL7
MBU&"&.$+.ZL#&K#+#8<9+'H3C'>LBV\'^(M-T30)+&>P35]$22'8TCM!<Q/C
M<"=H(/ (XZB@"?4/&=]#X1U:_N="1Y=.F$3I,72*="0%D3<N2.1P?3K6EK'B
M'5[7Q-%H>G:;;3R7%G)<12S7!494@88!>!SVSGCIR:@U_0_$7B#P;?:=/)8+
M?WNP!!(XA@4,#][:2QX/.!U'IS8GTG6)O&VGZWY5D+>"S>WF3[0Y?+LI)4>7
M@XV]R,^U '06[3-;1-<(L<Q0&1$;<%;'(![C/>I:** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "JFHZI8:1;?:=1NXK6+(4-*P&2>@'J?85;KE/B;_R(&H\9PT!Q_VV2@#J
MZ*Y5?$>L:?XHM-+URQM(K74ED-I/;2LWELB[BDF0.<=Q5=/&>HW$6G:C9Z7-
M=6-[,JM#'93^9%$W27?C:1C!(QQGJ: .RHKE[3Q1/J6L75C9O9B:SO?(FLI0
M1/Y08 R@YP1CYAQC'?/%,\,WNK7GBGQ%'>7$$D-K<I$B*A&U?+# #G_:Y]3Z
M=* .CO+^TL!";NX2'[1,L$6\XWR-]U1[FK%87B;6;G2)-($5I!/%>ZC#:R-(
MQS'O/WE&.3P>XQ[U4N->UV7Q3?:%865B&@M$N(IIY7VG<S#Y@!G^'H/KGM0!
MU%%>?7/BC5M8T?PI?VAALQJ6HB&XB(+992_&<CY=T?3J>.?78U'Q-?+/J%KI
ML FGTU5$@^R32K-*4#[%*#Y."O)SR>G&2 =317'2>+-<N-0TJRLM&AMYM3L9
M+A4OG=&A=<95QMR ">V2?:GW7BG5=EY#:6D;WNG1H)XTMIYTEG*!VC1D'R@;
M@ 3D\]!CD ZZBN2?QD[W=A9,D6D75[9"YCCU-&7?(208>HPPQSWY& :CO-0U
MUO&N@69DMX(Y[*6>6 H3B0!0V2#SC<0/QZ]@#L:*Y>P\43ZIJMQ:6DEF);2]
M:WN+*0$3I&&V^:.<$'AA@8P>N>*ZB@ HHHH **** "BBB@ HHHH **** "BB
MB@"E8:/I^F33S65LL,ERV^9E)_>-_>;)Y/OUJ[110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 4K32--L+NYN[2Q@@N+MMT\J( TA]2>]7:** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\5Z++XA\-7>EP
MS)#)-L*.ZDJ"KJPSCL=N/QK8HH Y\Z+>:MK%CJ.LQVT0T])/*M[>5I [NNUF
M9BJ\!<@#'?.:S] \/^*=$C311J5C)HL#8AGVO]K$6<B/^[[;O3MTQV%% '(:
MCX5OM9OK>XO8K%)[._\ /M]1A=A.L(D+",C:/X?E/S$=\5?TK1-0TSQ/J]Z)
MK9K'4I$FVX;S58($*^F.,Y_#'>N@HH P?%.CW^L#2Q9&W'V+4(KQ_.=EW!"3
MM&%/7/7M3(M(U2+QI=ZWMM&MY[)+94\Y@X*EF!/R8Y+8]O?I70T4 <):^#-:
MM?#.BV*S6/VO1]1-VA+N8Y5)<D'Y<J?WGOT]^+LV@^)=.\176J:%>:<\6I+&
M;R"\5PJRJH7?'MR>0!P3^/IUU% ',RZ#JQ\4Z1JOG6\\=C;R0S-([*\ADVEF
M "D#!7@9]N*AN-"\1Z=XEO-3\/76GFVU/8UU;WP?]W(JA=Z%>N0!D''3KZ=9
M10!S&L>'[_5+=["\@L-5LI+55/VMFC=)\MND7"M@'*\ C&.*A7PKJ=G>^';F
MTOH9WTJT>TG>Z#9D5@HWC'<%>A/XUUM% '(WWA6^U;4K.[O8K&.YLK_SXM0@
M=A.80Y(C(VCJN%.6(ZG%=%9C4OM5Y]M-J8/,'V3R0VX)@9WYXSG/3M5RB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBD)"@DD #DDT +16;H>O6/B&SEN]/=G@CG>'>PQN*G!(]
MO2M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?Q5K^GVE[!I
M&HRRPVTR>;<,D$DGF)G C&U3]X@Y_P!D$?Q9'444 <1\--6L;ZWUB"UD9G_M
M6ZG ,3J-C2':<D ?AU'<5V]9VCZ-!HL5U';R2.+J[ENG\PCAI&W$# Z>E:-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exh43lgnddescriptionofse005.jpg
<TEXT>
begin 644 exh43lgnddescriptionofse005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !28&<]Z6B@ I*6B@ HHHH
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M)/%)$\;QDC(RK $9'0XYJ_0 4451U'6-/TEK9;ZY6%KN98(0027=C@#@>IH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3W$ML]O$+>%HXQN&"[C)+-[# '/KQI>'-.N-'\/V.F7,L<SV<*0B2-2H95
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8\HE A/#<C X''U--C\):C$WAEEU.VSH$9C&;9OWX,?E_P!_Y?E^O/Y5UE%
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MI.Y9_.DD2(S-'!$9&6,'!8@=OY\XZ&KEK=0WMI#=VT@D@GC62-QT92,@_D:
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MI&=I]@ZHWX>] &;=ZGKNFZAX8M;FXMW.H2M'>@0X.X1L^%.<  C'3/'6H/\
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MY_X1&9;SRO.U.WRHC!PYCD.[_P"M5H>"+LZ-K^G2:RK?VW,\KO\ 9?\ 5E@
MV!NYX48YX]ZN:GX9O=1AT5/[3AC.DSQW&?LI/FNBE1QOX&"?6@#+U:WOS\2M
M"0:C@_8;@J?)7C'EAN/<\^U3/XKO-,O/%SZCY4UOHL<,END2;"P="V"23SG
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MLTGFRC2[D.^W;N.Z/G':JUUXFU6QO--,]S!))=:L+*XM88]\4,;,P7]X!_K
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M3[;5+^"^T[55E "6_E-;.B%^,$EE(!'/-59/$>M2>!1XTM[A< &X.GM&OEF
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MEFT>SDGN8KJ5H$+SPXV2M@99<<8/6N2U3Q%JVG3QRF^CE?\ MA+62VAB#PI
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M-%;)L5GZGN3^9-<XW@"?^S7TY-?F6V6^%[;)]G0F)_,\S#'J_.<=.O>NSHH
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M3^&9SJ]KK5KJ7EZG% ;>>62 /'<1D[L,@*XP>00>.^:Z"FNZQHSNP55&2Q.
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M(1;W-Y/%#Y\L-J@9TCSC<02,\@X R3@X'% &-?\ @5[S^W($UJ:"RUGYY8!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(B%HHXX@Q50%"Y)( )!P,]>*@O-=UG3+WQ#HS7OFRVFF'4;*[DA7<%^8%7
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MZ /2:*Y?P[=ZC%XKUO1+W4);^*UC@G@EF1%=?,#;E.P $97CCO5S7KFXBO\
M3H8[_P"SP2F020PKNN)R%&T(,' ')8\8XY S0!N45YP_B/7W\$6]ZNH-%>1:
MQ]BD=X4)D3S]GS <9QUVXK9M)M6@\:WN@3:U//%/I@O(9FBB#V[^84(7"X(Z
M'# ]/S .NHKA](UK5[O1!I-SJ4B^((M2^QSRB*,$ '>7"[=NTQ D<=<"NMU&
M2:#2;J2">&*>.!S'+<G$:L%.&?'\.>3[4 6Z*XG3-8U'_A*].T_[?<W-K?:;
M)(TLT*J&E0K^\C& <'<>",'C%8\FM^(X_ %WXC.NR-<Z?>R*(Q!&(YE6?9AQ
MMSTZ;2,>_6@#TZBN3-WJFD^.K*QN-4EO;74;2>5XGB11"\94Y3: <88C!)^I
MJA8ZGXGUO2],US3/,!GE666&5X1;F DY0?QA@,<]<@]N  =W17 37?B"ZD\7
M1Q^()K<:0P>V,<$6?]2'VME3E<_C[]JO6/B.\UN]T#3%F-J][I"ZG=21 ;B"
M% 1<@@99B2>N!Q0!O:3KMMK-Q?P013QOI\_D2^<H7+;0W'/3!'7%:=>:1S:C
MI&D>/;FUU%Q>6ET9$N&C0L<0H1D8QG&!G%:4]WKMMK?AR-=<D9-:BD29&@C*
MQ%8MX:/C(/!^\6'/3M0!W-%<#_PDNIZ':>*(+B\:_?2KFWBMIYU0-B8)C=M"
M@[2^>U:L$7B=-:QY\ZZ;-;LLC730M)%,.59 @P0>X/% '4TT.AD,88%U 8KG
MD YP?T/Y5YMI^N>(?^$7\,>(I]:DE>]O8;>XMO(C$<B22%2>!D,/4$#CIZ[6
MA07!^(_B8MJ%RZ1):$1ML*D%9"%^[D $G&".O.: .QHKG_$NL3V>H:-I-K)Y
M$NJW+1M/M!,:*I9L9XW'  R#U-9LVIZKIWB74- -_)-')I;7UG<NB&2!E;:R
M'C##H02/;F@#LJ*Y?P2=7O\ 1M/UG4M8>Y%W8H6MO)155SSO! SG'4=.>W J
M#Q7KUQHNKH+V6]L='EM@$U"UA6189]QSY@(.!C;CC')SGL =?17)V^IZ@/&.
ME6']I_:+2[TAIWV*A1Y%* .K;<X.2>N.:P[OQ%K\7A'6;N/5&-S8ZZUG'(\,
M>6B\U$"G"@=&/(&: /2**XMKC7]&\;:?IEUK#7]GK4,^TM B&UEC7=E<#[I!
MP <_4]\)-9\6#X=P>,!KOF36I=Y;0V\8CGC$K*P8XR#CH1@  <9YH [U->MG
M\3/X?\F<7*6OVK>R 1E-P7@YR3D^G:M2N->Y1?BA]K*ML'APR$8YQYP-0Z??
M^*-6L-'UNP,F+EDFNH97A$!@8995Q\X9<C!/H<^E '<45Y^;SQ!=6WBXC7YH
M6TB=S;-'!%G"Q!PK94Y7Z8/OVJ5-7UF)_">K2:F\D>MO''<6?E((E#Q%P5XW
M @CJ6.?8<4 =W17#R:EXCUVUU&YT-YHKBVO9(+9<P^1^[?:1(&^8[L$]L9&.
MF3*)]=U'QG>:0=8DLH/[,BN L$4;-$[,P(5BIR..I!]L=: .Q=TC7<[!02%R
M3CDG 'XD@4ZO,9=1U+7/"'A&^NM0F2XEUJ."9H0JB0K*ZAR,$9^0''3/;I7H
M=Y=+I>DSW<S/,MI TCL<;G"KDG@ 9..PH KZYKUMH%O!/=0SR)/.D"^4@.UG
M8 9R1@9-:=>:Z^]_J?@G0]:N=1D9KR]LYY+=57RE5Y%(4<9&W(YSSSGVZ&PO
M]1N/%GB73)-0E,%K!;26V(X]T)=7+8.WG[H^]F@#5UG7K;0VL5N89W^W7<=I
M&8D!"NYP-Q)&!_A6I7FT^I7>L>!/!FH7\WG7-QK-DTDFT+N/FGL  *WI]4O=
M%\="WU/4G;2;^U>2T#I&JPRQ\NA8*"?E^89/8]: .KHK,\/F^DTB*XU">66:
MX)F"R(JF)&.43Y0.0I /OFN4\7:[JVDV.N7]KJ9DFL)(V@@MHU:*%/ERLQ8?
M>;)X!R 5(Q0!WK-M4M@G S@#)-9VA:Y;>(+![RUBFC1)I(2LRA6W(VT\ GN*
MS3J-SJ_B^_T2&[ELX--MHGD:$+ODDDR1RP.%4+^)//'%<OH&K7>E>'K/3XKC
M%UJ7B"XM6N2@^4>8Y=P.FXXP!C&3TXQ0!Z917'W&HZII?BM]#-_)/;WNGR7-
MM-(B&2WD0X(X #*00>><U@G6O%%IX&TKQD^M&X"^2;JQ-N@26-W"GD#(;)!R
M./;U /3!(AD,8=2Z@,5SR <X./P/Y&G5PEE/-IWC3QGJ$E[=316%M;S>22A#
MKY4C;?NY !SC&.O.:LZ?<>*+PZ+J=N\CP7.Q[Z.=H1"8W7.8]OS C/ )Y'7)
MH Z+7=9M_#^CW&J744TD-NNYUA7<V/Q(JVDZR6JW"JQ5D#A0,G&,X^M>=ZS?
M7GB?X8:UKHOY8(I%G$-LBKL$2,4PV1DLP4G.>,C'OZ#I_P#R#K;_ *XI_(4
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MTT,[2ZC(T<3H@V A2QW'/H/>M.N*\56URFM^$8%OG>?[;(/M$J*6_P!2W.%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <C=^!8+K6+[4+A--O
MS>.'']HV/G/" H&U6W#Y>.F!U/)K9\-Z!;>&=&CTVU)9%=W)Q@;F8DX'8<X
M]!WZUJT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5]7L="TZ34-2F\FVB^^^QFQ^ !-7%8,H8=",B@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KA_$DCW?Q0\+:9/S9JD]T(S]V255.TGU*]
M1]:[BL?7O#\>LO9W4<YM=0T^7S;6Y"[MA(PRD<95AP1D?44 9?Q/C4^ =0N
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M9H5[?6ELUS/!"SQQ*"2Q ]!R?H.M<\/!NI+X?T#2UU&VW:+<Q3B0V[8E\L$
M$;N,YY.:Z;4H+NYT^2*RNA:W)P8YBNX*00>1D9''3- '+_\ "0W.J>&-9U'2
M-<M+B&&Q,D$T<.)89 KEU="W!P%QD#'/6FZ5K5[9:'X3TE9H9+W5[=/*E:,A
M8HDA5V)&[YFZ#J!ELXXYO+X06>_U6_N6@@FU.Q-G*MHA"G.<R-GJW(^@'4U
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MDRC;(HQ\ZGJI]B...:!8P_VA]N.6F$1B3.,(I() ^I5<Y]!0!9HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBU9-,&I%/+>8*/,A7.T*S<# *X'?GTH ]6FUK2K>^^PSZG9Q7>TOY#SJLFT
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M_P#"4^'?^@]IG_@9'_C0!JT5#:WEK?0"XL[F*XA;($D3AU..O(XJ:@ HHHH
M***JWFJ:?IQ07M];VQD^X)954M],GF@"U15>VOK.]!-I=0W  #$Q2!N#D \?
M0_D:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR?\ ?.TK[G'3-=)7)>$]&@M];UG4+2X,MBURZV:#!2,MM:?8?0R #V*&NMH
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M **** "BBB@ HHHH **** "LS4O#FB:Q.D^HZ5:74J#"R2Q L!Z9ZX]JTZ*
M(K>V@M+=+>VAC@AC&$CC4*JCT '2I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *I7VCZ=J4T$U[:I/);MNA9LYC/JOH?>KM% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4A&00>]+10!2T_2-/THS&PM4M_/
M<R2[.-['JQ]3[U=HHH *@O;&UU*SDL[VWCN+>48>*10RMSGD?6IZ* ([>WAM
M+>.WMH4AAC4*D<:A54#L .E2444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>lgnd-20191231_g1.jpg
<TEXT>
begin 644 lgnd-20191231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)O8F)Y+E9I
M9V%R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S$S  "2
MD@ "     S$S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O#/BA_R/ES_P!<H_\ T$5[G7AGQ0_Y'RY_ZY1_^@B@#D*FL_\
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M0#+P/\LB?4?U&10!L5X9\4/^1\N?^N4?_H(KW.O#/BA_R/ES_P!<H_\ T$4
M<A4UG_Q_V_\ UU7^=0U-9_\ '_;_ /75?YTQGTY1112$%%%% !1110 4444
M%%%% !1110 4444 >"_$G_DH6I?]LO\ T4E<O74?$G_DH6I?]LO_ $4E<O3&
M%?3UO_QZQ?[@_E7S#7T];_\ 'K%_N#^5 $E%%%(04444 %%%% !1110 5\^^
M.O\ D>=5_P"NW]!7T%7S[XZ_Y'G5?^NW]!0!S]:GAC_D;M'_ .OZ#_T8*RZU
M/#'_ "-VC_\ 7]!_Z,%,9]'4444A!5;4=0MM*T^:]OI1%!"NYF/\AZGVJS7B
M?Q*\4MK.M'3K63-C9,5X/$DG0M^'0?CZT 4_%WCN_P#$LSPQ,UKIP/RP*<%_
M=R.OTZ#]:Y6BBF,**[[PS\+;S5(4N]9E:QMW&5B5?WK#\>%_')]J[JU^&OA>
MV4!K!IVQC=-,Q)_ $#]* /!Z*]\F^'?A:9,'2U0]BDKJ1^M<QK?PAB,;2Z!>
M.KCD07/(/L&'3\0?K0!Y56AHVNZAH%\+K3)VB?\ B7JL@]&'<57OK&ZTV\DM
M+^!X)XSAD<<C_$>]5Z /H+PEXMM/%.G[XL17<8'GVY/*^X]5-=!7S9HFL7.@
MZQ!J%DV'B/S+GAU[J?8U]$Z9J,&K:7;W]HVZ&= Z^WJ#[@\4A%JBBB@#GO%O
MB^T\*62M*OGW4N?)@!QN]R>PKQC7O%NK^(Y#_:%R1#G*V\?RQK^'?ZG)K9^*
MDS2^.)$;I%!&B_3&[^9-<93&%%36EG<W]PL%E;RW$K=$B0L?R%=GI7PHUR]"
MO?O#I\9[.=[_ )#C]: .&HKU^V^#VE(H^UZC>2MW,05 ?P(-7?\ A4_ASUO/
M^_P_PH \3HKUV[^#NFO&?L&IW43]C,JR#] M<-XC\"ZQX;4S7$:W%IG_ (^(
M,E1_O#JO\O>@#FZTM$U[4/#]\MUIDYC;(WH>4D'HP[_YQ6;10!]#^%?$]KXH
MTD74 \N9/EGA)R8V_J#V-;=?/G@OQ"_ASQ)!<,Q%M(1'<+G@H>_X=?\ ]=?0
M8.1D<BD(*HZW_P B_J'_ %ZR?^@FKU4=;_Y%_4/^O63_ -!- 'S71113&>V?
M"?\ Y$L_]?3_ ,EJ+QK\1H=$:33]'V3WX^5Y#RD'^+>W0=_2N#L/&DVC^"/[
M(TPM'=33.TLXXV(0!A3ZG'7M]>G*$EF)8Y)Y)/>@">]OKK4;M[J^G>>=SEG<
MY)_SZ5!1UZ5UFB?#?7M8C69X5L8&Y#W)P2/91S^>* .3HKU!/@R=G[S7,-[6
MF0/_ !^L_4OA%JUM$SZ==P7NW^ CRF;Z9R/S(H \_HJ:[L[FPNGMKV"2"9#A
MDD7!%0T =7X,\<7?AJZ6"X9Y]-<_/#G)C_VE]/IT/ZU[E:W4-[:17-K(LL,J
MAD=3P0:^8J],^$WB1DN)-!NG^20&6VR>C=67\1S^!]: /5J***0@HHILLJ00
MO+,X2.-2SLQP% Y)- %'6];LM TN2^U&39&O"J/O.W90.YKPWQ1XQU'Q/='S
MW,-FK9CMD/RCW/\ >/O^6*=XT\4R^)]::169;*$E;:/V_O$>I_P':N=IC"BB
MM31/#>J>(9S'I=JTBJ</*?E1/JQ_EUH RZ*],L_@W.R*VH:O'&W=(82__CQ(
M_E4UQ\&ALS:ZR=WI);\'\0W% 'EM26US-9W"7%K*\,T9RDB-@J?8UT.N> ==
MT)&FFMQ<VZ\F:W.X >XZC\L5S5 'L/@CXCIJKQZ;KI6*\;Y8I^BS'T/HWZ'V
M[\;\4/\ D?+G_KE'_P"@BN0JQ>7USJ$RS7LS32JBIO;J0!@9/?B@"O4UG_Q_
MV_\ UU7^=0U-9_\ '_;_ /75?YT ?3E%%%(04444 %%%% !1110 4444 %%%
M% !1110!X+\2?^2A:E_VR_\ 125R]=1\2?\ DH6I?]LO_125R],85]/6_P#Q
MZQ?[@_E7S#7T];_\>L7^X/Y4 24444A!1110 4444 %%%% !7S[XZ_Y'G5?^
MNW]!7T%7S[XZ_P"1YU7_ *[?T% '/UJ>&/\ D;M'_P"OZ#_T8*RZU/#'_(W:
M/_U_0?\ HP4QGT=1112$8WBW5CHGA6^OHSME2/;$?1V^4'\"<_A7SL2223R3
MU->Q_%^Y:/PS:0*<>== M[@*>/S(_*O'*8PKT+X6^%H]2O'UB_C#P6K[8489
M#2=<_AQ^)]J\]KZ%\$V"Z=X+TR%5P7@$K9Z[G^8Y_/% &[1112$%%%% ''?$
M;PO'KF@R7D$?^G62%T8=70<LOOZCW^M>'5]1$9&#R*^:];LQI^O7]FHPL%Q)
M&H]@Q _2F,HUZY\(-5:?2[W3)&S]F<2QY_NMG(_ C/\ P*O(Z[?X37!A\9M'
MGB:V=<9ZX(;^E 'M=%%%(1YC\2O!NIZIK,6IZ1;FY#Q".5$(W*0>#SU!!_2J
MOASX33S,MQXCE\A.OV:%@6/^\W0?AGZBO6** *>F:18:/:BWTRTCMH^X0<M[
MD]2?K5RBB@ HHHH *;)&DT31RHKHX*LK#(8'J"*=10!X-X_\,+X:UX"U!%E=
M R0 _P ']Y/PR/P(KEJ]J^+%B+GP@MSCYK6=6S[-\I'YD?E7BM,85]">"=0.
MI^#--N')+B+RW)ZDH=N?TS7SW7L_PCG,OA&:)O\ EC=L%^A53_,F@#NZHZW_
M ,B_J'_7K)_Z":O51UO_ )%_4/\ KUD_]!-(1\UT444QA4]E97.HWL5I8PM-
M/*VU$7J3_GO3;:VFO+F.WM8VEFE8*B*,EB>U>Z^"O!L'A>P#S!9=1F7]]*.0
MH_N+[?S/X8 *O@[X?6?A^-+O4 EUJ. =Q&5A/HOO[_EBNRHHI""BBB@#GO%_
MA2V\4:4R,JI>QJ3;SXY!_ND_W3_]>O 9X9+:XD@G0I+$Q1U/52#@BOI^O%OB
MMI"V'BA+V)=L=]'O./[Z\-^FT_C3&<-5K3+^32]5MKZ#_66\JR#WP>GX]*JT
M4 ?3\,J3PI+$<I(H93Z@C(I]8/@>[^V>!]*ESG$ C_[X)3_V6MZD(*X#XKZ\
M;'1(M+MWQ+?',F.T8ZC\3@?0&N_KP'Q_JO\ :OC2]=6S';M]GC]@G!_\>W'\
M: .;HHI54NP5068G  ')-,9T?@KPG+XIU;8^Z.R@PUQ*.OLH]S^@S7NUC86N
MFV<=I80)!!&,*B#@?_7]ZSO">A)X=\.6UD /.V[YV'\4AZ_ET'L!6S2$%%%%
M !7 ^,OAM;ZJLE]H2);WWWGA'"3?_$M[]#W]:[ZB@#YAG@EMKAX+B-HI8V*N
MC#!4CL:CKV[Q[X'C\06K7VGHJ:G$O;@3@?PGW]#^'T\3='BD:.161U)5E88(
M(Z@BF,;4UG_Q_P!O_P!=5_G4-36?_'_;_P#75?YT ?3E%%%(04444 %%%% !
M1110 4444 %%%% !1110!X+\2?\ DH6I?]LO_125R]=1\2?^2A:E_P!LO_12
M5R],85]/6_\ QZQ?[@_E7S#7T];_ /'K%_N#^5 $E%%%(04444 %%%% !111
M0 5\^^.O^1YU7_KM_05]!5\^^.O^1YU7_KM_04 <_6IX8_Y&[1_^OZ#_ -&"
MLNM3PQ_R-VC_ /7]!_Z,%,9]'4444A'FOQD!_L_2SCCS9.?P%>3U[/\ %NT:
M?PG#<(,_9[E2WLI!'\RM>,4QA7TMI!5M$L3&,(;>,J/0;17S37OOP^U--3\%
M6)!!>V7[/(,]"G _\=VG\: .EHHHI""BBB@ KYV\7NLGC+5F0Y'VN0?B&P?Y
M5] :C?1:9IEQ>W!Q%;QF1O? Z5\U7$[W5U+<3',DKEW/J2<FF,CKK_A>C-X[
MMBN<+%(3CTVD?UKD*]!^$%F9?$=Y=D96"VV].C,PQ^BM0![#1112$%%%% !1
M110 45'-<06Z[KB:.(>KL%_G6=+XHT&%MLFLV .<$?:4)'ZT :M%89\:^&U8
M@ZS:<>CYI/\ A-O#?_09M?\ ON@"#XA1B3P#J:MT"(W'LZG^E> U[3XS\5:%
M?^#M0MK/5+>:>2,!(U;)8[A7BU,85Z[\'6/]AZ@N>!<@@?\  17D5>N_!W_D
M"ZC_ -?"_P#H- 'HM4=;_P"1?U#_ *]9/_035ZJ.M_\ (OZA_P!>LG_H)I"/
MFNBBBF,[_P"$,$4GB6[EDC5GBMLHQ'W26 )'X5['7D'P=_Y&"_\ ^O7_ -F%
M>OTA!1110 4444 %>>?&*W#>'["XQ\T=UL!_WD)_]EKT.N)^+'_(EC_KZ3^3
M4 >)T444QGN?PO<OX$M@?X)9 /\ OHG^M=?7$_"?_D2S_P!?3_R6NVI"(+^Z
M6QTVYNWQM@B:4Y]%!/\ 2OF:21I9&DD)9W)9B>Y-?0'CNX^R^!=5DSC,/E_]
M],%_K7S[3&%=)\/]-&I^-K%'7='"QG?/^R,C_P >Q7-UZ-\';4/K&HW1',4"
MQ@^FYL_^R4 >N4444A!1110 4444 %>$_$R)(O'=WY:*FY(V;:,9)49->[5X
M9\4/^1\N?^N4?_H(H Y"IK/_ (_[?_KJO\ZAJ:S_ ./^W_ZZK_.F,^G****0
M@HHHH **** "BBB@ HHHH **** "BBB@#P7XD_\ )0M2_P"V7_HI*Y>NH^)/
M_)0M2_[9?^BDKEZ8PKZ>M_\ CUB_W!_*OF&OIZW_ ./6+_<'\J )****0@HH
MHH **** "BBB@ KY]\=?\CSJO_7;^@KZ"KY]\=?\CSJO_7;^@H Y^M3PQ_R-
MVC_]?T'_ *,%9=:GAC_D;M'_ .OZ#_T8*8SZ.HHHI"*.M:9'K.B7>G3<+<1E
M0?[IZ@_@<'\*^<;NUFL;R6UND,<T+E'4]B#BOIRO'/BU'I:Z_"]H_P#Q,&3_
M $I%'&,?*2>S8[>F/Q . KJ/ _BYO"VJ-YX:2QN,"9%ZJ>SCW'ZUR]%,9].6
MEY;W]K'<V4R3PR#*NAR#4U?-^C^(=5T&4OI5Y)!DY9!RC?53P:Z^U^+^L1KB
MZL;.?'\2AD)^O)%(1[#2,P12S$*H&22>E>1R_&+4FC(@TRU1_5V9A^7%<OK?
MC/6]?4QW]X1 ?^6$(V(?J!U_'- '2_$?QO%J_P#Q*-(E\RS1LSS*>)6!X ]5
M'7/<_3GSVBBF,*]P^&.C-I?A-;B9=LU\WG'(Y"8PH_+G_@5>=>!/"$GB751-
M<(5TZW8&9B/]8>NP?7OZ#\*]V50BA5 50,  =* %HHHI""JFI:K8Z/:&YU.Y
MCMXA_$YZGT ZD^PK*\7>++7PKIOFR 2W4H(@@S]X^I] *\,UC6K_ %V_:[U.
M=I9#]T?PH/11V% 'H>M?%\*S1:#8AAT$]SW^BC^I_"N+U#QOXCU(G[1JLZ*3
M]R ^4/I\N,_C6#13&.DD>60O*[.[=68Y)_&FU/:V-W?2;+*UFN7_ +L,9<_I
M6S#X#\3W"ADT>< _\]"J?^A$4 <_174?\*V\6?\ 0*_\F8O_ (JC_A6WBS_H
M%?\ DS%_\50!R]%=!J'@;Q%I=A+>WVG>5;PC+OY\;8&<= Q/>N?H *]=^#O_
M "!=1_Z^%_\ 0:\BKUWX._\ (%U'_KX7_P!!H ]%JCK?_(OZA_UZR?\ H)J]
M5'6_^1?U#_KUD_\ 032$?-=%%%,9Z'\'?^1@O_\ KU_]F%>OUY!\'?\ D8+_
M /Z]?_9A7K](04444 %%%% !7$_%C_D2Q_U])_)J[:N)^+'_ ")8_P"OI/Y-
M0!XG1113&>V?"?\ Y$L_]?3_ ,EKMJXGX3_\B6?^OI_Y+7;4A')?$Y]G@*[&
M2-\D:_7YP?Z5X57N7Q14GP+.0.DT9/M\U>&TQA7JWP:11::LX'S%X@3[ -_B
M:\IKU;X-,#9ZLN?F$D1(]B&_PH ],HHHI""BBB@ HHHH *\,^*'_ "/ES_UR
MC_\ 017N=>&?%#_D?+G_ *Y1_P#H(H Y"IK/_C_M_P#KJO\ .H:FL_\ C_M_
M^NJ_SIC/IRBBBD(**** "BBB@ HHHH **** "BBB@ HHHH \%^)/_)0M2_[9
M?^BDKEZZCXD_\E"U+_ME_P"BDKEZ8PKZ>M_^/6+_ '!_*OF&OIZW_P"/6+_<
M'\J )****0@HHHH **** "BBB@ KY]\=?\CSJO\ UV_H*^@J^??'7_(\ZK_U
MV_H* .?K4\,?\C=H_P#U_0?^C!676IX8_P"1NT?_ *_H/_1@IC/HZBBBD(QO
M%?B"/PWX?FOGPTOW($/\;GI^'4GV%?/=S<S7EU)<W4C2S2L7=VZL3WKO/B[J
M;3^(+;3E;]U:P[R,_P ;?_6 _,UY]3&%:.I>']5TB&&;4;&:".90R.R\<]B>
MQ]CS6U\.-'CUCQA"+A=\-JAN&4]&(("C\R#^%>Z2Q1SQ-%/&LD;##(ZY!'N#
M0!\P45[KJ?PS\.:BQ=+:2R<]6M7VC_ODY'Y"L"?X-6[-_HVLRQCTDMP_\F%
M'E-%>I)\&5##?KI*]P+3!_\ 0ZT[/X1:)"P:[N;NY(_AW!%/Y#/ZT >-HC2.
M$12S,<  9)KO/"_PPO\ 4W2YUP/8VG7RB,2R#Z?P_CS[5ZEI7AO1]$_Y!FGP
MP/C'F;=SG_@1R?UK3H$06-C;:;91VEC"L$$8PJ(.!4]%%( J.XN(K2UEN+AP
MD4*%W8]%4#)-25R/Q-OVL?!%PJ-M:ZD2 $>AY(_)2* /'_$6N3^(=<GU"XR
MYQ$A/^K0?=7_ #W)K+HHIC);:VFO+J.WM8FEFE8*B(,EC7KOACX6V%C$EQKX
M%Y=$9\G/[N/V_P!H_I[5F?"#18Y&O-9F4,T;?9X2?X3C+'ZX*C\Z]3H C@@A
MMH5BMHDBC7[J1J% _ 5)112$%%%% '.^/O\ D0]4_P"N0_\ 0A7S_7T!X^_Y
M$/5/^N0_]"%?/],85Z[\'?\ D"ZC_P!?"_\ H->15Z[\'?\ D"ZC_P!?"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (+NQM+^'RKZUAN8_P"[+&&'ZUS5[\-/#-X2RV;V
MS'O!*1^AR/TKK** /.YO@[I;9^SZE=Q^GF!6_D!51_@RI8^7KI5>P:TR?SWB
MO3Z* /+O^%,>NO?^2?\ ]G5N'X.:<I_?ZI=./]A%7^>:]&HH X^S^%_AFTP9
M+>:[([SS'^2X%=-8Z98Z9%Y>G6<%LG<11A<_7'6K5% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>lgnd-20191231_g2.jpg
<TEXT>
begin 644 lgnd-20191231_g2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 Z17AI9@  34T *@    @  U$0  $
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M]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\
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MX9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\
MH>_&G_?O3?\ Y"KU"B@#R?3_ -EM-,NK^6W\;>,DDOY_/GPNG?._EI'_ ,^O
M]R-!5C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_
MX9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\
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M]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\
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M]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\
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M* /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R_\
MX9PF_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\
MH>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W
M[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R?3_ -EM-,NK^6W\;>,DDOY_
M/GPNG?._EI'_ ,^O]R-!5C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\
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MC_Y]?[D:"O6** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\
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M]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\
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MX9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\
MH>_&G_?O3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W
M[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D
M*O4** /)]/\ V6TTRZOY;?QMXR22_G\^?"Z=\[^6D?\ SZ_W(T%6/^&<)O\
MH>_&G_?O3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W
M[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D
M*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#
MR_\ X9PF_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<
M)O\ H>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'O
MQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-
M_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"JO
MI_[+::9=7\MOXV\9))?S^?/A=.^=_+2/_GU_N1H*]8HH \O_ .&<)O\ H>_&
MG_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_
M .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-_P#D*C_A
MG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A
M[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O
M3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J
M]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+
M_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R?3_ -EM
M-,NK^6W\;>,DDOY_/GPNG?._EI'_ ,^O]R-!5C_AG";_ *'OQI_W[TW_ .0J
M]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+
M_P#AG";_ *'OQI_W[TW_ .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R_\ X9PF
M_P"A[\:?]^]-_P#D*C_AG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&
MG_?O3?\ Y"H_X9PF_P"A[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_
M .0J/^&<)O\ H>_&G_?O3?\ Y"KU"B@#R_\ X9PF_P"A[\:?]^]-_P#D*C_A
MG";_ *'OQI_W[TW_ .0J]0HH \O_ .&<)O\ H>_&G_?O3?\ Y"H_X9PF_P"A
M[\:?]^]-_P#D*O4** /+_P#AG";_ *'OQI_W[TW_ .0J_GW_ ."W'_!6OXF?
ML4?\%/OB?\,M"L?"OB#2_#;:68;_ %JUE-]<&XTJSNG,GDR11\/,RC9&HVA>
M.]?TL5_(+_P=%_\ *=7XY?\ < _]1_3: /ZK/V</^/CQU_V,*?\ IML*].KS
M']G#_CX\=?\ 8PI_Z;;"O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME:O//LD_>220?Z(_F(Z1ILWR9'Z[4 %%?D[\+_%O[8G_  4O_:-_:&U;X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OY!?^#HO_ )3J_'+_ +@'_J/Z;7]?5?R"
M_P#!T7_RG5^.7_< _P#4?TV@#^JS]G#_ (^/'7_8PI_Z;;"O3J\Q_9P_X^/'
M7_8PI_Z;;"O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ]G^#7A"?X>?"+PKX?O)+=KW1=(M+"9HCB-WA@CC?9G^'*4 ?FCXM^"N@?\
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M&&XNGL8"]P\<*('DDS\[^W->S?N?V)O^#BO_ )86?A?]L?P+_M^9<^)M _\
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ML;3IIIOAOHFI>%O!%Y\+]$MH(('TZ!X=-.IOYCYCB(C2>2,;W0%RF\NG9_\
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MQ&\:?LC^-OA3;^$?BY>OX@U[P+\2;6^?2-/UMWC\^^L7L?WD?GHAWH?3^/\
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MT/3M1C\6>(-+A@D@M;&\=U^SV\<R)#'.\:32>7O^>?+^8 >"_MX_#^'XL?\
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M_>26[7NBZ1:6$S1'$;O#!'&^S/\ #E* .KHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K^07_@Z+_Y3J_'+_N ?^H_IM?U
M]5_(+_P=%_\ *=7XY?\ < _]1_3: /ZHOV6]7AUR#QQ=0+=1QR>(?D6YM9+>
M0?\ $NL/X)/GKUBO,?V</^/CQU_V,*?^FVPKTZ@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOXP?&#XC6.FIK6I>'?AOX2FUZ\T>T=T6.2Y^=(TW[\CYST^?9YD>_KOV$/\
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M6/2_VP/^"-WPU_:V^/,7Q6M?%'Q7^$/Q2:R72+WQ7\./%4FA:EJ=B@REM/\
M))&R B/D(C_NXP7(1!78_L+?\$SOAS^P$?$VH>%;OQAXG\8>.IX9_$_B[Q=K
MDFL:[XA>'>(S<3/A/D#O_JT3KSF@#T_]J3_DV;XB_P#8L:E_Z2R5^'W_ #HI
M_A_[T&OWA\?>#[7XA>"-9\/WC316>N6,]A.\3;9$2:,H^T]F^>OES_ARQ\+?
M^'4W_#'G]O?$#_A6?_01^VVG]N?\A?\ M?\ UWV7R/\ CX^3_4?ZOC[_ ,]
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M,?ND8%6?^#4+PMIMG_P11\%[;.%?[<UG6I]0)3B\?[;)!E_^V<<:?1*^P/V
M/V%O"G_!.']EW1?A+X%U+Q%JOAW09[JXMI]<GAGO&>>=YWWO##&GWW/\ XH_
M8 _86\*?\$X?V7=%^$O@74O$6J^'=!GNKBVGUR>&>\9YYWG?>\,,:??<_P
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MBBB@ HHHH **** "BBB@ K^07_@Z+_Y3J_'+_N ?^H_IM?U]5_(+_P '1?\
MRG5^.7_< _\ 4?TV@#^JS]G#_CX\=?\ 8PI_Z;;"O3J\G_9:T6S\.0>.+/3[
M.VL;6#Q#A(;:'RHT_P")=8?P5ZQ0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?'/[3W_!>']E/]C3XY:[\-
M_B1\5&\,^-O#GDC4=._X1?6+OR/.@CN8_P![!:R1MF&:-_D<_?\ 7@;/[)O_
M  6D_9?_ &WOB%#X7^&OQ>T#7/$ET7^R:5=VUUI-Y>[$WD0Q7L,,DQ"#?^[#
M\(YZ(37S#^QCX<TOQ-_P<T_MO#4M-L=26W\,>$S&+F!)/+SI5AG[]=Y_P<&_
ML*^!_B[_ ,$X_'/CJTTG3_#OQ#^#=@_B_P *^)M+7[#J&E3VKI.ZI-#B38Z(
M?DZ;Q&_#HC@ _0^BOSO\3_\ !9F^^$W_  3%_9W^(!\-_P#"POCC^T%I6E:=
MX8\*Z5*D$.N:W/!&)G=_N06\<C9?^X9$3CETP/'/_!1?]K;]@'5?"OBO]JCX
M<_!2X^#/BC5K72M2UWX=ZI>BZ\!M=/Y<;Z@EZ^R6/S&C1Y(B(T^?YWWHA /T
MOHKX1_;#_P""E/Q/M?VT;?\ 9I_9I\$>%_&GQ8M](3Q#XBU;Q9>3V_AWP98O
M\D;77D8GF=R\#;(SOQ(.O.S/_9,_X*B_$[PO^T_XY^!?[5WA+P-X'\;^$?"4
MGCJR\4^#KZ[G\-Z]I"/()'CCGS/"\?DS\2/OD\B?Y$"#> ??U%?F-\*_^"AO
M[:/[?G@^Z^+/[//PC^"VG_!7[=,/#UM\0=3OX/%'C6U@D,;SVPM7^SVN]XY$
M'V@XZ?ZQ>6T_C+_P7#UI/^"(WCW]I;P/X5TW1_B/\.=2M?#FO>$O$X>[M]#U
MA=4LK*]M9_(FCD;8ESOCR\;X>-W09*4 ?I-17Y4_M.?\%<OVK_V9_@;I/[2>
MN?!3X:V/[..H7.GO/H$VI7TGCZTTV\F_<7MQLQ8VKNDD*>02[QS2HCN>UC]I
M[_@K#^UC^R[\#K/]I+Q!\&OA78?LYFYL9+GP^VM7<_CRTT^\NHXX+R9H_P#0
M(WD2>']P/,V2. 7H ^^_BC^UMX ^"GQJ^'OP[\3^(#IOC+XMW%_#X3L/L-U-
M_:KV2))= 2)&\</EQR)_K70.3\F3FO4Z_)G_ (+S_%W7_@]_P4P_X)_^)? _
MA5OB!XF_M/Q=;Z)HT%V((]3NKJUTRWA+S?.(X \P=Y,'9&COVKT*U_X*-_M/
M?L0?'WX6Z)^UYX*^"]O\/_BYK*>&+#QA\.;W4!;>'-6G3-M:WL=Z3Q(4<>8F
M$1 [[SY;Y /TDHKX5_;3_P""DGQ(@_;&M/V:_P!FGP7X9\:?%Y-)'B#Q-JWB
MZZGM?#7@RP; A>Y\C]_-(Y>/Y(^0DB??R_EP_LC?\%#OC3X8_;+T[]GG]J+P
M5X'\-^.O%>D76M>#?$W@F_GD\.^*X[;>]W!&ETWVB.XBCV/Y9Y*)(_R)LW@'
MWA17Y9_!/_@IA^V-^VE\;?V@/!OP=\!_ *&/X$_$[5?#,VK^+KG5;2#5M,@G
MEAM;2".V>0F_/D2/).[I#B2$",<FOU,H ^3/VM/^"V7[+?[$/Q,F\'_$KXN:
M/H7BJU2-KG2[2QO-6N+'?DJLR6<,WDN4^;9)L?9)&<8="?>O@/\ 'SP;^TS\
M,].\:> ?$NC^+O"NJ&1;34M-N1/;S%)"CKD?QHZ%<'D&O /V!/\ @G)X7_X)
MK?"KQ]?^)/$6A^,/$WC/7]7\8>+_ !SJVFQZ9->)=/Y\RSN\TFR"-$R_[SR\
MAWV N]?GO^P)\1F_9X_X)U_\%$OC1\(;";P)\(-8U/6[OX4RVA\N.*>"TGM?
MMMK'A]D?G_9MG\&8]F$$= 'WU\3/^"\O[(OPC^.4OPY\0_&_PS9^++:Z^Q7"
M);74]G93I(\;QSWD<+VL+HZ/O\R1-G>OKVSO(=2MHYH9(YH9DW(ZMO1UKXB_
MX)+_ +"GPPC_ ."*'PH^'^I>#=#UKPO\2O .G:UXFMKBV&=9GU&".]F>9_OL
MZ23?NWSOC\N/9LV)CR'_ (('_$WXF_%+_@A_-X;\%:WH/_"POASJVK>"?#FK
M>(8)Y=/C\B?? \R1L[LD<,X1$Z#RD3WH ^^-<_:H\ ^&?VE- ^#]UXGLHOB5
MXDTF?Q!I^@B*1[F33H'V/.Y1-D:;]R(9'3S#&^S?L?&A\?/VB/ _[,'PYNO%
MWQ#\4:+X-\-V+I'/J6JW2V]N'?(1,_Q.>R#D_A7Y4?L\?L7ZA^Q__P ''WPS
M_P"$B^)7BWXL^./''PHU36/$WB76UCM_M]TD[P+Y%LG%M D<<:)"'?9Y?XUW
MW_!;:?09O^"J?[#EK\9)[&']GV;6-:EU :MG^R'UU+5/L/VW_EE_KC B>:-F
MQ[G/[OS* /KW]C7_ (*X?L[?\%"/%.H:#\(_B=IOBG6].MOM<^GR6-[IEX(>
M,R)#=0PO(@\Q/GCS][J*^F*_)S_@Y:^+O@W]EV']FSQIH-UI.D_'#PK\1].;
MPZ;62"/5!HICN$OHRA_Y<7_=HXV;-\B#^_7ZQT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_(+_P=%_\IU?CE_W /_4?
MTVOZ^J_D%_X.B_\ E.K\<O\ N ?^H_IM ']5G[.'_'QXZ_[&%/\ TVV%>G5Y
MC^SA_P ?'CK_ +&%/_3;85Z=0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=+NKK3K*"UNM.U"]>-XPX^S"9-^Q/G3G,B5U7[+/P;_9L\4_\%:OA/I/@_\
M:0_:N_:@^('P_M;[Q'9:Y=>-=/\ &?@WPA#+;/%,EU=^2/+\_P#=QXM\GS#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\
MRB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H
M_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_
M *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.
MVG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\
M_AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H
M>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_
M ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B
M? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-?
M'_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8
MKO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"
M_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A
M.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_
M (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\
M1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/
M_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_A
MZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-?
M '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\
MQBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X
M6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\
M*)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H
MX#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G
M_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HF
MH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\
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M /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\
MZ'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI
M_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'
MHGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37
MP!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\
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M (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\
MH>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:
M?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^
M&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ
M_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\
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M:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\
MAZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$
MU\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__
M !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'H
MGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\
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MX6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\
MRB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H
M_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_
M *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.
MVG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\
M_AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H
M>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_
M ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B
M? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-?
M'_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8
MKO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"
M_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A
M.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_
M (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\
M1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/
M_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_A
MZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-?
M '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\
MQBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X
M6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\
M*)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H
MX#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G
M_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HF
MH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\
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M /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\
MZ'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI
M_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'
MHGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37
MP!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\
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M (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\
MH>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:
M?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^
M&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ
M_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\
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M:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\
MAZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$
MU\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__
M !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'H
MGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\
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MX6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H>O\
MRB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_ ,;H
M_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B? O_
M *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-? '_A.
MVG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8KO\
M_AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"_P#H
M>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A.VG_
M ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_ (>B
M? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\ 1-?
M'_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/_P 8
MKO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_AZ)\"
M_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-? '_A
M.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\ QBC_
M (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X6?\
M1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\ *)J/
M_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H X#_A
MZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G_1-?
M '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HFH_\
MQBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\ AD_X
M6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'HGP+_P"AZ_\
M*)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37P!_X3MI_\;H
MX#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\ &*[_ /X9/^%G
M_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\ Z'K_ ,HF
MH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI_P#&Z/\
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M /X9/^%G_1-? '_A.VG_ ,;H_P"&3_A9_P!$U\ ?^$[:?_&Z . _X>B? O\
MZ'K_ ,HFH_\ QBC_ (>B? O_ *'K_P HFH__ !BN_P#^&3_A9_T37P!_X3MI
M_P#&Z/\ AD_X6?\ 1-? '_A.VG_QN@#@/^'HGP+_ .AZ_P#*)J/_ ,8H_P"'
MHGP+_P"AZ_\ *)J/_P 8KO\ _AD_X6?]$U\ ?^$[:?\ QNC_ (9/^%G_ $37
MP!_X3MI_\;H X#_AZ)\"_P#H>O\ RB:C_P#&*/\ AZ)\"_\ H>O_ "B:C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \]_:Q_Y-;^)/_8J:I_Z225Y__P $O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \]_:Q_Y-;^)/_8J:I_Z225Y__P $O_\ DQ7P+];[_P!.-Q7H'[6/_)K?
MQ)_[%35/_222O/\ _@E__P F*^!?K??^G&XH ^@J*** "OY!?^#HO_E.K\<O
M^X!_ZC^FU_7U7\@O_!T7_P IU?CE_P!P#_U']-H _JB_9:T6S\.0>.+/3[.V
ML;6#Q#A(;:'RHT_XEUA_!7K%>8_LX?\ 'QXZ_P"QA3_TVV%>G4 %%%% !111
M0 4444 %%%% !1110 4444 ? '_!('_D^O\ ;R_[*K:_^FZ.OO\ KX _X) _
M\GU_MY?]E5M?_3='7W_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%!.* $#9-*3BN#_X7_X/_P"%Q_\ " _V]I__  E_
MV?[9_9GF_O/+SG_<WX^?R\[]GSXQ7=@Y%')*/Q +11FC- !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%&ZC=0 449HS0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >>_M8_\FM_$G_L5-4_]))*\_P#^"7__ "8KX%^M]_Z<;BO0/VL?^36_B3_V
M*FJ?^DDE>?\ _!+_ /Y,5\"_6^_].-Q0!]!4444 %?R"_P#!T7_RG5^.7_<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW4/:8IOC\M.\8]*^CSC#8&4/]JT.ZO3I\GOGUM%_P6O^#<GWH_%T?^_IB_\
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MG_Y&JK+_ ,$-_BY']W6_A^W^[J-U_P#(M']GY.W_ !G_ %\A^QPW\Y]R1?\
M!3_X%./E^(%A_P #LKI/_:-7(_\ @I1\#YE^7XB:+_P)9D_FE? LO_!$;XQ0
M_=O? [?[NH3C_P!H54?_ ((M_&B,?*GA5_\ =U,C_P!IT?V7E/\ S_\ R%]7
MH?SGZ'P?\%#O@K,/^2C>&E_WKC;_ $JW%^WK\&YE^7XD^#_^!ZE&E?FU)_P1
MK^-L8^73= ;_ '=6051D_P""//QTC'R^']';_=U>'_XNC^R<K_Y__D'U>A_,
M?I]'^VS\(9Q\OQ.\"#_>UNW3_P!GJU%^V)\)9_N_$_X>M_W,-I_\<K\K9/\
M@D9\>HQ\O@^S?_=UJQ'_ +/567_@DU^T!$/^1#W_ .[K6G?_ !^C^Q<MZ8E$
M?5Z/\Y^LT'[4_P ,;G_5_$3P+)_NZ[:G_P!GJU'^T5\/[G_5^./",G^YK-L?
M_9Z_(63_ ()9?'J/[WP]N/\ @&J6,G_M>JLO_!,KXZ1?>^'>J?\  +JUD_\
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M2(/^W6^CH\WXM6'\?Q(@_P# Z.E_JNO^?R_KYA]07\Q^\_GKZT>>OK7X,?\
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M%ZG/S8K8TP^#]_WS]QOV2?VMO#/[7GPVCUK176&\A"QZEI\C?O[&;J0?5#_
M_<5[!NXK\!_V?OV@O$O[-?Q(M?$GAF[\FY@^2>%_^/?4(?XX73^Y[U^U7[,7
M[06D_M-_!K1_%VF1K;-J"?Z39B9)9;*8.4:-]I/0K_WS7GYWD[PD^>'P'/B,
M.X'IU%%%>"<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_8%^$UUX4\"ZHOB3Q)KURVL>+/$VH7R76M^*+YW)>ZNI<E_OR'8G1-_=W=W
M/S#\=?'3X*_$S_@LW^UYJGQ:^!_BS]HVY\,R>'O"_A+PIX9^'_\ PENH6$5I
M:R)?3?PP0K]H#O\ O)/,.73_ )9[*^J/@O\ M>?LT_"O_@F9^T1\9OV4_"WA
M#X?^(/"/A^^&M:.GA^/1]2TW5[2WN/L,&HVIV9Q.[^6,X?S)$0[]XKWC]@?]
MNOX'_'_XO?'3P?X%\-V/PW\?^ ?%UXGC?1KRPLM.U/5ITV1SZP_V5W2Y1Y$>
M,S[W?]VF_8)(\_GU\0?@I#^WU_P4/_X*(77PC2+6/#-Y\&X_!MU<Z<GGZ?XB
M\5^1!/ (YH'(DDC^RF!_XP[G*'^, ]U_X)P?\$/?V?\ X[_\$F? \GQ'\"Z/
MXP\:_&CPI;^*_$/C>^A6X\3->:J@OO.AU"13)#)'YR)\G#^7^\$F]R_JW_!N
MU^TYXH_:6_X)?>%9/&FJ3Z]XL\"ZG?\ @_5-4EN6N7OGLY?W+O(WSN_D20(7
M.\N4WD_/BC_@E/\ M^?"O3O^")/PE^(&J>,-$TWPS\-_ .GZ+X@EN+M(Y-/N
MM.M1:30NKX.^1[8^6A ,F]-F_>A//_\ !LI\,-2\!_\ !)_PWK6IZ;/H]Y\1
M=>U7Q>MO-@L(;JY(@<<_ZMX(HW'W<YZ<T ?HA117D'Q;_8S\*?&WQ<^N:QK7
MQ6L;YX$@\KP_\3?$>@VGR=Q;6-]!!O\ ]K9D]Z /E_\ X) _\GU_MY?]E5M?
M_3='7W_7Y-_\$NOV'_!_CO\ ;,_;0TZ\U[XPVUOX:^),%G:/IOQ4\3:;<3QF
MR1\W,\&H))=2<_ZR>1Y,=Q7W#%_P35^'T2?\C1^T _\ O_'+QI_\M* /H.BO
MG_\ X=K?#W_H9_V@/_#X^-/_ ):4?\.UOA[_ -#/^T!_X?'QI_\ +2@#Z HK
MY_\ ^':WP]_Z&?\ : _\/CXT_P#EI1_P[6^'O_0S_M ?^'Q\:?\ RTH ^@**
M^?\ _AVM\/?^AG_: _\ #X^-/_EI1_P[6^'O_0S_ +0'_A\?&G_RTH ^@**^
M?_\ AVM\/?\ H9_V@/\ P^/C3_Y:4?\ #M;X>_\ 0S_M ?\ A\?&G_RTH ^@
M**^?_P#AVM\/?^AG_: _\/CXT_\ EI1_P[6^'O\ T,_[0'_A\?&G_P M* /H
M"BOG_P#X=K?#W_H9_P!H#_P^/C3_ .6E'_#M;X>_]#/^T!_X?'QI_P#+2@#Z
M HKY_P#^':WP]_Z&?]H#_P /CXT_^6E'_#M;X>_]#/\ M ?^'Q\:?_+2@#Z
MHKY__P"':WP]_P"AG_: _P##X^-/_EI1_P .UOA[_P!#/^T!_P"'Q\:?_+2@
M#Z HKY__ .':WP]_Z&?]H#_P^/C3_P"6E'_#M;X>_P#0S_M ?^'Q\:?_ "TH
M ^@**^?_ /AVM\/?^AG_ &@/_#X^-/\ Y:4?\.UOA[_T,_[0'_A\?&G_ ,M*
M /H"BOG_ /X=K?#W_H9_V@/_  ^/C3_Y:4?\.UOA[_T,_P"T!_X?'QI_\M*
M/H"BOG__ (=K?#W_ *&?]H#_ ,/CXT_^6E'_  [6^'O_ $,_[0'_ (?'QI_\
MM* /H"BOG_\ X=K?#W_H9_V@/_#X^-/_ ):4?\.UOA[_ -#/^T!_X?'QI_\
M+2@#Z HKY_\ ^':WP]_Z&?\ : _\/CXT_P#EI1_P[6^'O_0S_M ?^'Q\:?\
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MT!_X?'QI_P#+2@#Z HKY_P#^':WP]_Z&?]H#_P /CXT_^6E'_#M;X>_]#/\
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M4?\ #M;X>_\ 0S_M ?\ A\?&G_RTH ^@**^?_P#AVM\/?^AG_: _\/CXT_\
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M/CXT_P#EI1_P[6^'O_0S_M ?^'Q\:?\ RTH ^@**^?\ _AVM\/?^AG_: _\
M#X^-/_EI1_P[6^'O_0S_ +0'_A\?&G_RTH ^@**^?_\ AVM\/?\ H9_V@/\
MP^/C3_Y:4?\ #M;X>_\ 0S_M ?\ A\?&G_RTH ^@.M&VOGX?\$U_A[CGQ/\
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M/_#X^-/_ ):4?\.UOA[_ -#/^T!_X?'QI_\ +2@#Z HKY_\ ^':WP]_Z&?\
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M_P!ZU0_TJG+\)O#-Q_K/#N@R_P"_I\)_]EKR'_AVM\/?^AG_ &@/_#X^-/\
MY:4?\.UOA[_T,_[0'_A\?&G_ ,M*?M)CNSU*?X%^"[G_ %G@_P +R?[^E0?_
M !%59?V;?A[<?ZWP'X-D_P!_1+4_^R5YO_P[6^'O_0S_ +0'_A\?&G_RTH_X
M=K?#W_H9_P!H#_P^/C3_ .6E'MI]V',SO)OV3_A?<_ZWX<^ W_WO#]K_ /$5
M5?\ 8S^$MP/F^&/P]/T\/6G_ ,;KC?\ AVM\/?\ H9_V@/\ P^/C3_Y:4?\
M#M;X>_\ 0S_M ?\ A\?&G_RTJE7J_P Q7M)G3S?L._!^8?-\,_ Z_P"[HT"_
MR2JD_P"P)\&I/O?#;PG_ , L$6L/_AVM\/?^AG_: _\ #X^-/_EI1_P[6^'O
M_0S_ +0'_A\?&G_RTJOK5;^=_>Q^UF:$O_!.CX*R#Y_AWX=_X#&R?^S56F_X
M)H_ ^4?-\/=''^[+.G\GJ#_AVM\/?^AG_: _\/CXT_\ EI0?^":WP]_Z&?\
M: _\/CXT_P#EI5?7<3_._O8>VF07/_!+CX$W,;JW@"S7S.NR_NT_E-7YO?M\
M?L#ZQ^Q[XT^UVPN-2\%ZE/\ Z!J&S_CV_P"F$_\ M_\ HROTF7_@FQ\/S_S,
MWQ__ /#X^-/_ ):UF^(_^"5WPK\8Z3)I^L:I\;]5T^X'[RUO/C5XQN()/JCZ
MH:]#+LZQ.&J<\IN?J:T\1.$KGP#\'/\ @D_\3/C1\%U\76?]FZ=)=8DL-.U%
MI()[^ _Q_P"Q_L>97EFL^$_BK^Q;XZ6:ZM_$W@75X^$N4=X([C_<=/W<\?\
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MT!_X?'QI_P#+2@#Z HKY_P#^':WP]_Z&?]H#_P /CXT_^6E'_#M;X>_]#/\
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M_LJMK_Z;HZ^_Z^ /^"0/_)]?[>7_ &56U_\ 3='7W_0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=R9XOE]RF?-/[-'_  2Z^&?[.Q@OIM/7Q7XB0<ZCJT:2+$^/^6</W$^IWO\
M[9KZ648& *7(S2]J^;Q&(JUI\]25SEG4E/XAU%%%9F88Q1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //?VL?\ DUOXD_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %#5M)M=9T^:UN[>&YMKA-CQ
M2IYD<B^ZU\L_M#_\$A/A?\81->:%#+X%UB3K)I<>ZSD_W[4_N_\ OWLKZS ]
MZ#@&ML/C*]&7/1E8TIU)0^$_&#]H7_@EI\5O@(9KN'2?^$LT13O%]HN^>1$]
M'@_UB?3YT_VZQ_@#_P %%OBQ^S9<PVFGZ]<:OI-N/+_LG6M]U!'Z(G_+1/\
M@$E?MNR;E^:O'?CY^PE\,_VD(YIO$OANV_M20?\ (4L?]%OT/_71/O\ T?</
M:OI,/Q%"K'DQT.='5]:Y_P"(>'_L]?\ !9[X??$HPV/C"VN/ ^J2?)YLQ^U6
M,C\?QI\Z=_\ 6(!_MU]>>&O%NF>,]'AU#2=0LM4L+@;X;FTG2:"3Z.N0:_,O
M]H?_ ((E>+O!OG7WP_UBW\6649WQV%YLM+]/^VG^KD_\AU\R^&?'_P 4OV,_
M'+0V-WXF\#:O')F:SFC=(KCTWP2?NWCJY9+@\7[^!G\F5]7A/X#]YLYI#7YO
M?L]?\%QI87@L?B5X;\W^#^U-$^]_VT@?C_OA\_[%?;_P1_:9\#?M$:.MYX1\
M3:;K&U \D$<FRXA_WX6Q(GX@5X&,RO$X;^) Y:F'G#<]#HH!S17"8A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Y[^UC_P FM_$G_L5-4_\ 222O/_\ @E__ ,F*^!?K??\ IQN*] _:Q_Y-
M;^)/_8J:I_Z225Y__P $O_\ DQ7P+];[_P!.-Q0!]!4444 %?R"_\'1?_*=7
MXY?]P#_U']-K^OJOY!?^#HO_ )3J_'+_ +@'_J/Z;0!_59^SA_Q\>.O^QA3_
M --MA7IU>3_LM:+9^'(/'%GI]G;6-K!XAPD-M#Y4:?\ $NL/X*]8H **** "
MBBB@ HHHH **** "BBB@ HHHH ^ /^"0/_)]?[>7_95;7_TW1U]_U\ ?\$@?
M^3Z_V\O^RJVO_INCK[_H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &J^Z@L,UY#
M^UQ^UGX9_9"^&KZUK4BS7L^Z/3M/C;]_?3=0 .R#^-^@%?E!_P /"OB5_P -
M*_\ "S_[8_XFG_'O]@S_ ,2_[+_SZ[/[G_[S_65ZV R6OBX\]-:&]'#RF?MZ
M..M#+S7D/[)/[6OAG]KWX;)K6BNL-Y"$CU+3Y&_?V,W4@CNA_@?H17KV<'UK
MRZE.=*?)/<Q:Y1U%&<T5(@HHHH **-U&Z@ HHHH **,T9H **** "BC-&: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **,T$XH 0&ES7!_&C]H+P;\!/#AU/Q?XBL=#M=I"":3]]/
M[)&N7<_[@-?!G[2/_!;_ %'5%GTWX8:.=/A/[O\ MK5$1YP/[Z0_<3ZR;_\
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M[GW<FNTZ4TG93@<BOG)5)3?-,XKW"BBB@ HHHH **** "BBB@ HHHH ****
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M\^97W!%\/OVJMG[SXO?L^[O]CX1:Q_\ -+0!]"45\^_\*^_:H_Z*[^S_ /\
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M^_:H_P"BN_L__P#AHM8_^:6C_A7W[5'_ $5W]G__ ,-%K'_S2T ?05%?/O\
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M%?/O_"OOVJ/^BN_L_P#_ (:+6/\ YI:/^%??M4?]%=_9_P#_  T6L?\ S2T
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MQ_\ -+0!]!45\^_\*^_:H_Z*[^S_ /\ AHM8_P#FEH_X5]^U1_T5W]G_ /\
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M36/#6J>(- GD3R'O--NI[3S/]C>E>BZ#_P %"?C3X<_X]_B-XFD_Z^9OM?\
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M)_M)>"-"M],T7XF?LYZ5I]JFR&WM/@WJD$$8]$1/$F!6D?A]^U-_T5WX ?\
MAHM7_P#FDKAQG$5>K^[H>Y YZF,G+X#VCP1X!T/X<>&X=)T#2-/T/2[<8CMK
M.%((T_!*W*^??^%??M4?]%=_9_\ _#1:Q_\ -+1_PK[]JC_HKO[/_P#X:+6/
M_FEKY^]]3E/H*BOGW_A7W[5'_17?V?\ _P -%K'_ ,TM'_"OOVJ/^BN_L_\
M_AHM8_\ FEH ^@J*^??^%??M4?\ 17?V?_\ PT6L?_-+1_PK[]JC_HKO[/\
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M%K'_ ,TM'_"OOVJ/^BN_L_\ _AHM8_\ FEH ^@J*^??^%??M4?\ 17?V?_\
MPT6L?_-+1_PK[]JC_HKO[/\ _P"&BUC_ .:6@#Z"HKY]_P"%??M4?]%=_9__
M /#1:Q_\TM'_  K[]JC_ **[^S__ .&BUC_YI: /H*BOGW_A7W[5'_17?V?_
M /PT6L?_ #2T?\*^_:H_Z*[^S_\ ^&BUC_YI: /H*BOGW_A7W[5'_17?V?\
M_P -%K'_ ,TM'_"OOVJ/^BN_L_\ _AHM8_\ FEH ^@J*^??^%??M4?\ 17?V
M?_\ PT6L?_-+1_PK[]JC_HKO[/\ _P"&BUC_ .:6@#Z"HKY]_P"%??M4?]%=
M_9__ /#1:Q_\TM'_  K[]JC_ **[^S__ .&BUC_YI: /H*BOGW_A7W[5'_17
M?V?_ /PT6L?_ #2T?\*^_:H_Z*[^S_\ ^&BUC_YI: /H*BOGW_A7W[5'_17?
MV?\ _P -%K'_ ,TM'_"OOVJ/^BN_L_\ _AHM8_\ FEH ^@J*^??^%??M4?\
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M*BOGW_A7W[5'_17?V?\ _P -%K'_ ,TM'_"OOVJ/^BN_L_\ _AHM8_\ FEH
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MAJEK>30>1)YB0S2:_(D;E/N2/')L//EO]RNX_P""7_\ R8KX%^M]_P"G&XH
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MC'F7=\_/R1I^'WONC\J\:_;G_P""GOAW]EV*Z\/^'F@\3>.?N&V#XM--//\
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MYF]SA#%&*** "BBB@ HHHH **** "C%%% ";1Z#\J9);I<1;6164]F%2447
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ0['-6KRF/HHHKR3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &ELT;LCTK-\2
M>)-/\':'=:EJ=Y;Z?I]C&9KBXN)/+CA0=69CQVK\V?VZO^"O5]XQ>^\*?"N:
M?3]+R8+GQ /DGNO^N'_/-/\ ;^__ +G6NS 9?6Q<^2FC6G1E,^A?VY/^"GGA
MW]F&"[\/^'6@\2>.%^0VPDQ9Z:>?]>_]_I\@YXY*5^:44/Q(_;N^.'_+]XL\
M4:N_SO\ \L[-/_1<$$==A^QQ^P#XR_;'UO[>OF:/X32?_3-:N8_]9_?2!/\
MEL_O_JZ_6O\ 9V_9C\(_LO>!H]!\)Z:+6$_/<W$I\R[OI/[\TG5S7TE2OA<I
MAR4/?J=SK]I##_ >,?L0_P#!,3PW^R[!;:YKGD^)/'7W_MTD?^CZ:?2W3_VH
M?G.?X.E?5@4;<#I2&E#5\IB,35KS]I49QU*DIN\AU%%%9&84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449HS
M0 4'FC.:* & #9^-)P@]/QISNJ#YB!7@O[0'_!1'X5_L]RS0:QXBM]2U2'.=
M/TK_ $RZS_=;9\D9_P"NCH*BI4A!<TSIPN!Q.*GR8:#G+R1[R>!TK"\9_$#0
M_AUH4VI:]K&FZ+I]N/GN;VY6&)/J[\5^9GQ^_P""X'B_QB+BR\!Z+:>%K,C"
M7M[_ *5??]^_]6G_ )$KYBCMOBA^V5XUWJOBKQYJ^?O_ #S?9S_Z+@3_ +XC
MKQ*^=4_@H>^?HN6^&.-E#V^9S5"'GN?HM\>O^"T_P_\ AV]Q9>#[2]\;7\?'
MGQC[)8HW/\;_ #O_ , 0C_:%?$OQX_X*<?%SX[O<0R>(#X;TF0Y^PZ&3:X3_
M &W/[QOH)*]I^ O_  0V\5>*/)N_B#KUKX;M<9>QT[_2KL_]M/\ 5I_Y$K[;
M^ ?[ 'PK_9V2&;0?"]G/JL//]J7Y^U7F?[RN^=G_ &SVBL?8YABW^\]R!ZG]
MI<)Y'_NL/;U.[_KE_P# 3\K?@9_P3I^+G[1<T<]CX<N=+TVX(?\ M/61]E@?
M_;._]XWU2-Q7VM\"/^"(/@GP0L%YXZU>_P#%]]&=[V=M_H5AGTX_>-_WVOTK
M[FC/R=%X["CJ,D#\Z[,/DN'I?'[WJ?-YOXD9MBU[.A+V,.T-/_)CF_AO\*?#
M?PGT)=-\-:#I>A:='RL-C:I!&WOA!\U=03P*"1FE R*]C2VA\)4J3J2YYN[%
M'2C&***" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH \]_:Q_Y-;^)/\ V*FJ?^DDE>?_ /!+_P#Y,5\"_6^_
M].-Q7H'[6/\ R:W\2?\ L5-4_P#222O/_P#@E_\ \F*^!?K??^G&XH ^@J**
M* "OY!?^#HO_ )3J_'+_ +@'_J/Z;7]?5?R"_P#!T7_RG5^.7_< _P#4?TV@
M#^JS]G#_ (^/'7_8PI_Z;;"O3J\Q_9P_X^/'7_8PI_Z;;"O3J "BBB@ HHHH
M **** "BBB@ HHHH **** /@#_@D#_R?7^WE_P!E5M?_ $W1U]_U\ ?\$@?^
M3Z_V\O\ LJMK_P"FZ.OO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ H/2C.*">* &CE:\P_:/\ VJ_"/[+7@>36?%6I>3NXM;&(
M>9=WS_W(T_#[WW!W[5XY^W-_P4]\._LPQ7?A_P .M;^)/'$?R/;!\6FFGG_7
MO_?Z?)U]=E?FC%:_$G]N_P"./_+_ .+/%&KOAW_Y9V:?^BX((Z^@RS)95E[?
M$>Y3.JAA^;WYG7?MB?MZ^-/VR?$GV.3[1I?A;SO^)?H5F_F>8_\ RS>?_GL_
M^4KZ!_84_P""/]UXD:Q\5_%>VN+"Q#B6W\.D>7/./^GK^XG^Q]__ '.E?0O[
M#W_!,3PS^RY;6^N:T(?$GCG[_P!O>/\ T?3/]BW3_P!J$;S_ +'2OJIVVJ*V
MS#.H0A]5P"Y8&E3$)>Y2*6B>'[/PQHUO8Z?:6]G8V<?EPP6\8CCA0?PJHXK1
MH%%?,[G"&**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHS10 449HSF@ H/2C.*AFN8[>)FD=45?O,QH#5Z(%(*^OTI
MP;'^ KYO^//_  5"^$?P&,UM)KP\1ZM&<&PT0?:SN_VW'[M/Q>OB7X^?\%HO
MB'\1WFM?"%K8^"M-<[1(G^E7SI_OO\B_\ 0_]=*\_$9IAJ6[/KLGX%S;,??I
MT^2'\TM$?J!\1?C+X7^$.@MJ/B?7M)T*R_YZWERL0;_=_O5\<_'S_@N)X1\*
M&:S\ :/=>*[CF-+ZZ'V6QSZA?]8_TPE? WA#X4_%3]L;Q:]UI^G>)O&VJ3OY
M<U_<N[QQ_P"_,_[M/^_E?7?P(_X(8:G?^3>?$?Q-'91_??3-'.]S_O3/\B?1
M(V'O7EO,,9B/]U@?;+A'AS)ESYQB?:3_ )%_P/>/F?XZ_P#!0?XM?M)7,EIJ
MGB.\M=/N)-B:7I'^B02?['R?O'_X'(];GP)_X):_%SXY-!<-HK>%=)D.[[5K
M8\D[/]B'[X_%!7ZJ_ ?]C+X;_LY6\?\ PBOA73[.\48-[,GGWC_69\O^M>HD
M&/'\C5T\EG/W\5.YQXSQ,IX:'L,CPZIP[_\ VI\9_ C_ ((N_#OX=-;WGBJ\
MO/&NI1C)2<?9K%&]HD.YO^VCM7UQX/\ !.C^ M"ATS1-)T_2=/MQB.WL[9((
M4^B)@5L=?2G!:]FCAZ-)?NXGYWF6>9AF$_:8VJYCL4445T'EABC%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'GO[6/_)K?Q)_[%35/_222O/_ /@E_P#\F*^!?K??^G&X
MKT#]K'_DUOXD_P#8J:I_Z225Y_\ \$O_ /DQ7P+];[_TXW% 'T%1110 5_(+
M_P '1?\ RG5^.7_< _\ 4?TVOZ^J_D%_X.B_^4ZOQR_[@'_J/Z;0!_59^SA_
MQ\>.O^QA3_TVV%>G5Y/^RWJ\.N0>.+J!;J..3Q#\BW-K);R#_B76'\$GSUZQ
M0 4444 %%%% !1110 4444 %%%% !1110!\ ?\$@?^3Z_P!O+_LJMK_Z;HZ^
M_P"O@#_@D#_R?7^WE_V56U_]-T=??] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 '6C;2+PM>8?M(?M5>$?V6O!$FM>*-2\G?Q9V,0WW=_
M)S\D:?A]X_(/YNG3G.7) -SO/$GB73O!VB76I:I>6]AI]C&9KBXGD$<<*#JS
M,>*_-?\ ;L_X*]WOC%[[PK\*YKC3M+SY%SX@'R7%U_UP_N)_M_?_ -SJ?!?V
MPOV\_&G[9'B3[)-]HTSPN9L:?H=H_F)*_P#RS>3_ )[O_E*^@/V%O^"0MUXC
M-CXL^*UK<6-B'$MMX>^Y/< _\_/]Q.G[O[_/S[",5]7A\MP^!A[?'[]CT:="
M%)<\SP;]CG_@G[XR_;'UF/4%\S1_":3_ .F:U<I_K/[Z0I_RV?W_ -77ZT?L
MY_LQ^$?V7? \>A>$].%K"?GN;B4^9=WTG]^:3JYKM-"T*S\+:/;V.GVEO9V-
MI'Y<,%O&(TA0?PJHXK0"YKR<RSBMBW;:'8YJU>4Q]%%%>2<X4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BC-!.10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG[.'_'QXZ_[&%/\ TVV%>G5YC^SA_P ?'CK_ +&%/_3;85Z=0 4444 ?,_\
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M[E\_/OH _3"BBO'?B[^T/XJ^&GC%M,T?X%?%;Q]:>0DIU7P_=^'8[1R?X/\
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M]&J_M ?^#'P=_P#+Z@#Z HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\
M1JO[0'_@Q\'?_+Z@#Z HKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_
MM ?^#'P=_P#+Z@#Z HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\ 1JO[
M0'_@Q\'?_+Z@#Z HKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_M ?^
M#'P=_P#+Z@#Z HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\ 1JO[0'_@
MQ\'?_+Z@#Z HKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_M ?^#'P=
M_P#+Z@#Z HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\ 1JO[0'_@Q\'?
M_+Z@#Z HKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_M ?^#'P=_P#+
MZ@#Z HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\ 1JO[0'_@Q\'?_+Z@
M#Z HKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_M ?^#'P=_P#+Z@#Z
M HKY_P#^&S?'W_1JO[0'_@Q\'?\ R^H_X;-\??\ 1JO[0'_@Q\'?_+Z@#Z H
MKY__ .&S?'W_ $:K^T!_X,?!W_R^H_X;-\??]&J_M ?^#'P=_P#+Z@#Z H/2
MOG__ (;-\?#_ )M6_: _\&/@[_Y?4A_;.\?#_FU;X_\ _@Q\'?\ R^H ]_'*
MUYA^T?\ M5^$?V6O!,FL^*-2\DOQ:640WW=])_<C3\/O?='?MGY:^/O_  6C
MC^'\6N>'K7X5^-O#/CBP"QI#XBNM&N+2!SUWG3M0NL.G78^P^]?!ER/B9^W!
M\7+JXCM]8\;>++Z/?LB*?NX_[G\$<,?_ 'PE?099D<ZR]MB/<@=6'P_-[\SM
M/VQ/V]?&O[97B7[)-]HTOPOYV-/T.T?S$E?_ )9O)_SW?_*5] _L+?\ !(.Z
M\0FQ\6?%>UN+&Q#B6V\.GY)[@'_GZ_N)_P!,_O\ /S[,8JY^Q!\#M6_9;M8=
M9UK]EGXY>)O'>=YOGOO!WV?3_:U1]>_\?^__ +G2OJ9OVS/'H'_)JWQ^_P#!
MCX._^7U;9AG4(0^JX%<D#2IB/L43W'1-#L_#&CV]CI]I;V=C9Q^7#!;Q"..%
M!T54'%:-?/\ _P -F^/O^C5?V@/_  8^#O\ Y?4?\-F^/O\ HU7]H#_P8^#O
M_E]7S)PGT!BBOG__ (;-\??]&J_M ?\ @Q\'?_+ZC_ALWQ]_T:K^T!_X,?!W
M_P OJ /H"BOG_P#X;-\??]&J_M ?^#'P=_\ +ZC_ (;-\??]&J_M ?\ @Q\'
M?_+Z@#Z HKY__P"&S?'W_1JO[0'_ (,?!W_R^H_X;-\??]&J_M ?^#'P=_\
M+Z@#Z HKY_\ ^&S?'W_1JO[0'_@Q\'?_ "^H_P"&S?'W_1JO[0'_ (,?!W_R
M^H ^@**^?_\ ALWQ]_T:K^T!_P"#'P=_\OJ/^&S?'W_1JO[0'_@Q\'?_ "^H
M ^@**^?_ /ALWQ]_T:K^T!_X,?!W_P OJ/\ ALWQ]_T:K^T!_P"#'P=_\OJ
M/H"BOG__ (;-\??]&J_M ?\ @Q\'?_+ZC_ALWQ]_T:K^T!_X,?!W_P OJ /H
M"BOG_P#X;-\??]&J_M ?^#'P=_\ +ZC_ (;-\??]&J_M ?\ @Q\'?_+Z@#Z
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M,?!W_P OJ/\ ALWQ]_T:K^T!_P"#'P=_\OJ /H"BOG__ (;-\??]&J_M ?\
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M=^'L?3X/?'*3_<A\/G_W+5?]H8;^<R?"N<1WPT__  %GZ!;O\YH))_A'YU\
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M /PV;X^_Z-5_: _\&/@[_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\
MPV;X^_Z-5_: _P#!CX._^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV
M;X^_Z-5_: _\&/@[_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X
M^_Z-5_: _P#!CX._^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_
MZ-5_: _\&/@[_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-
M5_: _P#!CX._^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_
M: _\&/@[_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_:
M_P#!CX._^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\
M&/@[_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!
MCX._^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[
M_P"7U'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!CX._
M^7U'_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[_P"7
MU'_#9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!CX._^7U'
M_#9OC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[_P"7U'_#
M9OC[_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!CX._^7U'_#9O
MC[_HU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[_P"7U'_#9OC[
M_HU7]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!CX._^7U'_#9OC[_H
MU7]H#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[_P"7U'_#9OC[_HU7
M]H#_ ,&/@[_Y?4 ?0%%?/_\ PV;X^_Z-5_: _P#!CX._^7U'_#9OC[_HU7]H
M#_P8^#O_ )?4 ?0%%?/_ /PV;X^_Z-5_: _\&/@[_P"7U'_#9OC[_HU7]H#_
M ,&/@[_Y?4 =]^UC_P FM_$G_L5-4_\ 222O/_\ @E__ ,F*^!?K??\ IQN*
MXO\ :"_:Q\<>(?@-XTTV\_9M^-FB6NH>'[Z";4M0O_"KVFGI)!(AGF\G6I)-
MD?WW$<;R8^XDE=I_P2__ .3%? OUOO\ TXW% 'T%1110 5_(+_P=%_\ *=7X
MY?\ < _]1_3:_KZK^07_ (.B_P#E.K\<O^X!_P"H_IM ']47[+6BV?AR#QQ9
MZ?9VUC:P>(<)#;0^5&G_ !+K#^"O6*\Q_9P_X^/'7_8PI_Z;;"O3J "BBB@#
MX3_X*Q0?M(?![XN_!SXT? NS\0_$+P_X!O+VW\=?#.QOS;_\)-8W,>R.>&$?
MZZ:#?(<'?^\,#B,B-Z^!?!4WQ0_X*[>"=%^"_A'X$_$CPI\.X_V@]?\ B!X^
M\6^-]/318])L3XBO[O\ LZU7>[R7Z>=)#.D?SP3Q[#^[=Y$_>:L'P=X'TGP1
M97$.BZ3IFCP7M]<:G<QV-HEO'/=7$SSSS.$QNEDDD=W<Y+NY?J30 GQ)MI;O
MX?:]# CS33Z?/%$B)N=W,;@"OC?_ (-T/A/XI^"/_!&WX.>%?&?AGQ!X/\2:
M2=9%YI.M:?-87]H9-;OY4+PS(DB;XY$<9'*./6ON>B@#\S8?VY_VH/\ @GE^
MT=\5/#OQD^#OQC_:,^'NM:S/K'PY\5_#7PW!JUY9V4A_<Z7?6UND")Y:)S/L
MW^9O_P!8CH4K_LS_ /!/+QY^VW\:/VGOC9\>/",OPPD^/7A"3X8^&/"MU+!J
M&J>'M!^SHDES-)"=@DGG1)_+^_&Z8WXV5^G5% 'Y%?LV_MO_ +4G["_[(&C?
MLVZC^R?\7/&OQH^'ND_\(QX<\3Z):)<>!=4M84=+*ZDU1V"0^7 D.87Y<Q['
M\AW\N/[-_P""/W[#>I_\$[?V!/!/PSU[48=8\46?VG4M?NXG,D<FH74\EQ-L
M<H'=4W^6'?E_+'KBOJBB@ HHHH ^ /\ @D#_ ,GU_MY?]E5M?_3='7W_ %\
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M9Q6Q;MM#L<U:O*8^BBBO).<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS10 449HH **
M,YHH *#THSFD+ =Q0!$&;/)6G!P*Y_QG\1=!^'&D_;M>UK2-%M5X\Z]O$@C_
M .^W(KP'XF_\%<_@K\.%D2+Q!=>)+J/_ )8Z/:-/G_@;;(__ !^L*F(HTOCD
M=^!RG&XMVPM&4_1'TVKY/WA4G '6OS2^)O\ P7?U*99(?!O@BW@_N76L78<_
M]^8MI_\ (E?.GQ-_X*>_&KXHB2.7QA<Z+:R?\N^CQ)9F/_MHO[S_ ,B5Y]3.
ML-'X&?:Y?X7YUB-:W+3]7_D?LOXO^(VA?#?2/MFOZYI.BVJ_\MKZ[2",?\#8
MUX#\3O\ @KE\%?ALLB0^(KCQ-=1_\L-&LGG/_?;;(_\ Q^ORU\(?L\?%?]HW
M5A?:?X;\7>)9+GIJ-U"[QR?]MY/W?_D2O?\ X6_\$0OBEXP\N;Q%J7AWPG;M
M]]'E-]<1_P# $_=_^1*Y/[2QE;^! ]Q<#Y!E[MFF-U\K?_;2._\ B;_P7DU&
M5)(/!O@>WA_N76LWGF?^08=O_HROG+XG?\%/OC5\4Q)'-XPN-%M9/^7;1X4L
MO+_[:+^\_P#(E?;7PS_X(<_#GPOY4WB37?$/BBX3[Z*ZV-O)_P  C^?_ ,B5
M]%_#+]C7X7_!Q%D\-^!_#UG<0_<N7M1-<?\ ?Y]S_K3C@\?57[Z8O]9>$\O_
M -QPOM)]WM_Y-K^!^-/@_P#9W^+'[1VJ_;M/\,^+O$LES_S$KJ%WCD_[;R?N
M_P#R)7OOPP_X(C?%+Q:8IO$.H>'_  G WWD>7[=<1_\  $_=_P#D2OUIBA6,
M?= I60-V!_&M*>0T?MGG8[Q4S.:Y,)"%/T7]?D?$7PT_X(=?#GPQY4OB+7?$
M/BBZ4?.@=;&VD_X!'\__ )$KY%_;E_88\4>!_P!IGQ!8>!?AMXLF\'QI;?V9
M)I>F75];_P#'K!O^?Y_^6V^OV60D]P:5U$A_A/U%=-?*:$Z?LX>Z>/EOB!F^
M&Q7UNM4]J^SV^X_ _P#X9'^+&/\ DE_Q$_\ "<O?_B*[W]EC]E+XHZ?^TY\.
M[NZ^'GCBRM;+Q)875Q<W>A74-O;PI=([R.[IL3Y$K]LRF1\JK^5*$ ' 'X5R
MT<AITZGM.8][%>+&88BA4HRI0]_0(X%$:_*O0=J=Y$?]Q?RIPH)Q7NV/RSF9
M3GTJUO!^\AMY/]Y!6;??#O0]1YFT;29O]^S1_P"E;@>G=:.5%QK5([-G&7GP
M'\%WP_TCPGX:F_W]*@?_ -DK,NOV4?AGJ(_?_#_P/-_OZ%:O_P"R5Z)R*.#4
M^S@:?7,0OMO[V>57/[$WP@G'S?#+P'_P'0[9?_9*H3_L#?!>]7YOAOX2'LE@
MD?\ Z"!7L6XD]_SI=K?WC4?5Z/6)T1S?'P^&M/\ \"9X7/\ \$UO@==#YOAW
MHO\ P%ID_D]9MS_P2K^ EROS> ;?_@.I7J_RFKZ% )_B'Y4NW_.*GZG0_E1M
M_;V9K;$3_P# Y?YGS1<?\$B?@'<?=\%W$7^YK5\/_:U9=U_P1M^!UQ]W0=7A
M_P!S5IQ_6OJK:/\ (H\O!^[6?]GX;^0WCQ3G$=L3/_P.1\A77_!%7X,W:YC7
MQ3!_NZE_\6IK.N_^"&GPCN?N:MXVA_W-0A_^,U]G\4A!S]VI_LS#?R&W^N&<
MQ_YB9_>?#UQ_P0E^&DG^J\5>.H_]Z[MG_G!6?>?\$'_!#G]SXT\51_[Z6\G_
M +3K[QPP/:C<!W_2I_LO"_R&\>.,\AMB7^!^?UW_ ,$$?#[_ .I^(6M1_P"_
MIT<G_L]9MU_P0(MW_P!3\4)H_P#?T'S/_;FOT3V\]:7D5/\ 9.$_D.A>(7$$
M?^8C_P EA_\ (GYL7/\ P0&OH?\ 5?%*W;_>\/%?_;FL^Z_X((>)(1^X^(FB
MO_OZ4Z?^SU^FYB^GY4>5]/RJ?[%P?\IT+Q)X@7_+[_R6/^1^6EQ_P0?\>1_Z
MCQEX7?\ WX)D_DE9EW_P0J^*4 _<^)/ K?[]Q=)_*&OU;S[?K0#ST_6I_L/#
M=C3_ (B9GW_/S_R5'Y)S_P#!#[XQ6_W=2\#S?[E]/_[/!5"X_P""+/QJMQ\D
M?A6;_=U$C_VG7Z_X-&#[UG_8.&.B/BEG2WY/_ 3\;;K_ ((Z?'*U^YH6DW'^
MYJT/_L]9=S_P20^/EORO@F*;_=UBR'_M:OVGVBC:*/["PQT?\18SC^2'W2_^
M2/Q(G_X)8_'R#[WP^O/^ :I8O_[7K/NO^";7QQM?O?#C6_\ @$D$G_H#U^X^
MWZ?E1M^GY5E_8=+^9FR\6<RZT:?W2_\ DC\([G]@OXR6WWOAMXL_X!8O)6=<
M_L;_ !<LA\WPS\>?\ T.ZD_]DK]ZL?[M&/\ =J?]7Z7\S-/^(M8__GQ3^X_!
M%?@!\7-$'R^!_B-:_31;Z/\ ]DH_L'XNZ#_RY_$BU_[87T=?O>8P1]U?RIAM
MU/\ "M+^P8_SLT_XBQ6E\>%A_7R/P3_X6#\7=!_YC?Q(M?\ M]OHZ8W[3GQ8
MTG[WQ"^(MM]=<O4_]GK][S%_L_K1Y0'\*_E1_853I68/Q.P\OXF7P?\ V]_]
MJ?@]:_MK?%ZU^[\3?''_  /69I/_ &>M.U_X*#_&BV^[\2/$W_ [GS*_<*Z\
M.:??#]]86<W^_"K5DW7PE\+Z@?\ 2/#NA3?[]A$W_LM']BU_^?S#_B(V62^/
M+X?^2_\ R)^&_P 7OVMOB)\>_#D&C^+_ !5?:]IMO<I>PQW$4>8YD21-_P"[
M3^X[UYO7Z=?\%KOAAX;\&_LTZ!=Z/H.C:9>3>)H(7DM+%(9'3[+=_)O1,_PU
M^8M>#F&%J4:W).?.?K'!F;X3,, ZV%HJG"_P!7V3^P[_ ,$F9?VG?ASIOCCQ
M!XH32?#NJ23^59V$/F7DGES/#('=_D0[T?M)7QM7[1?\$ESM_P""?O@/C/.H
ML/\ P8W0KJR?#PJUN2H>/XD9[B\ORR%? SY)SGROTM(ZCX"?L$_"_P#9R\FX
M\/>&K-]2@'_(3OA]JO,_W_,?[G_;/;7MBJJCY:CYQ\Q_ 4XXV=\5]G3IP@N6
M)_->*QE?$3YZ\W.7FR2C% .:*LYPZT8HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //?VL?\ DUOX
MD_\ 8J:I_P"DDE>?_P#!+_\ Y,5\"_6^_P#3C<5Z!^UC_P FM_$G_L5-4_\
M222O/_\ @E__ ,F*^!?K??\ IQN* /H*BBB@ K^07_@Z+_Y3J_'+_N ?^H_I
MM?U]5_(+_P '1?\ RG5^.7_< _\ 4?TV@#^JS]G#_CX\=?\ 8PI_Z;;"O3J\
MQ_9P_P"/CQU_V,*?^FVPKTZ@ HHHH **** "BBB@ HHHH **** "BBB@#X _
MX) _\GU_MY?]E5M?_3='7W_7P!_P2!_Y/K_;R_[*K:_^FZ.OO^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BB@G% #<K3B<"LGQ+XHT_P5H%WJFJWEKI^GV,?G7%Q<2"..%!U9F/
M%?FO^W3_ ,%>;[QJU_X5^%L\^G:1GR+G7Q\EW=?]</\ GFG^W]__ '.M=F R
M^MBY\E-&U.A*>Q]#?MR_\%/_  [^S)!?>'_#;0^)/'"#8\ /^AZ:_/\ KY/[
M_3Y!SQR4K\U;>W^)'[=WQQ^7[?XK\4:N_P [_P#+.S3_ -%P01UV?[&O_!/W
MQG^V%K<>I?O-(\)I/_IFM7,?^M_OI"G_ "V?W_U=?K1^SS^S'X1_9>\#QZ%X
M3TU;2$D/<W#_ +R[OI/[\TG5S7TE3$87*8<E'WZG<ZO:0P^D#QK]B'_@F3X:
M_9<MK?6=<\CQ)XX^_P#;WB_T?3/]BU0]/]\_.?\ 8Z5]5!1MP.E(:4-7RF(Q
M-6O/VE1G'4J2F[R'4445D9A1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#(E<G]I8RM_ @>XN!\@R]VS3&Z^5O_ +:1W_Q-_P""\FHRI)!X-\#V\/\
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M4 &,4444 %%%% !1110 8HHHH **** "BBB@ HHHH ,4444 &**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<C3\/O?='<^OC/[<_P#P5!\._LQQ7OASPW)#XC\=1C8\(.ZSTQ^3^_D'\?\
MTS'ISLK\U;:R^)/[=WQPD*F^\6>*-8?YW_Y9V:?^BX($KZ#+,DE67M\1[E,Z
MJ&'YO?F=9^U]^WGXU_;.\4?8Y7N-+\-^=C3] M'\Q"__ "S>3_GO)_E*^AOV
M$O\ @D'<>(#8^+/BO;SV5KN$MKX=^Y/< _\ /UC[B?\ 3/\ UA_CV<QU]#?L
M/?\ !,KPS^RW!!K&M^1XF\=9$GV]X_\ 1],[[+5'Z?[Y^<_['2OJ<\ 8K;,,
M[A"'U; KE@74Q%ER0*&B:'9^&=*M[&PM;>SL[2/RX8((Q''"@Z*J#BM*BBOF
M3B#%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU+P[X3MV^^CRF^N(_P#@"?N__(E<G]I8RM_ @>XN!\@R]VS3&Z^5O_MI'?\
MQ-_X+R:C*DD'@WP/;P_W+K6;SS/_ "##M_\ 1E?.7Q._X*??&KXIB2.;QA<:
M+:R?\NVCPI9>7_VT7]Y_Y$K[:^&?_!#GX<^%_*F\2:[XA\47"??176QMY/\
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M5.Z4"BND\4,4444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_B-X*TW6[%C]EU*!)X_50<?+_,5OKTK]*HU8SA[2&QW"T445L 4444 %%%%
M!1110 4444 %%%% !1110 4444 >>_M8_P#)K?Q)_P"Q4U3_ -))*\__ ."7
M_P#R8KX%^M]_Z<;BO0/VL?\ DUOXD_\ 8J:I_P"DDE>?_P#!+_\ Y,5\"_6^
M_P#3C<4 ?05%%% !7\@O_!T7_P IU?CE_P!P#_U']-K^OJOY!?\ @Z+_ .4Z
MOQR_[@'_ *C^FT ?U1?LMS7TL/CAKZWM;6Z_X2']Y%;W'GQQG^SK#^/RX_\
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M44 %%%% !11FB@ HHHH **,T4 %%&<4;J "BBC- !12;U]1^=)YJ_P!Y?SH
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M^8E=0N\<G_;>3]W_ .1*]]^&'_!$;XI>+?*F\0ZAX?\ "D#?>1Y?MUQ'_P
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MB,XP5#^-5BOF1[2/<]L48/2@L?2OE/Q'_P %,[2-Y%TGPO<3_P!Q[N\\K/\
MP"-)#7 ^(/\ @H?XZU;?]CBT735_@\NW,DA_!WQ7A8CCC*J6T^;T,OK5,^ZB
M=O4\50U;7+'0X#-=W5O:PKQOEF$:#\Z_.CQ%^TO\0/%AVW7BS5LO_!;3?9_,
M_P" )Y=5=-^#_CKXAW'G0^'_ !'J$DG_ "\R6S^7_P!]R5X]3Q <WR83#3F9
MO%W^ ^Z/$/[5GP]\,(WVCQ9I<C+R1:R?:C^4>^N \1?\%%O!NF/(MC:ZWJ;
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M/)_XY7'/Q(PGV*,V1]=AV/TQ+ ?Q+67J/C72=&'^E:IIMM_UUNDC_F:_-_\
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M<UJ:4Z,__ 3UW4/^"G=L@_T3PA<2?]=K\1_^TZQ-0_X*8Z[+_P >OAG2;?\
MZ[7$DG_Q%>=_VK^R[HR_Z?\ %O4+D]OLL3M_Z!"]2Q_'?]D'21^\\3:YJ?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44;J-U
M!1110 44;L5')<)#'N:154=R:ER2W8#MWO2 9KE-<^-GA/PY*5OO$N@VK?W7
MOXP__?.<UQ7B;]M_X=^'[2X:/7%U"ZCC+)%;03.)3_=#A-GZUY>(SC!45^^K
M1^\GVD>YUQ^,^@CXP_\ "&^>W]M?9?M6W;\G^YG_ )Z;/GQ_<KL2.*_,<?%W
M5Q\6O^$R\[_B;_VA]NW?^T_^N?\ RSK[(TC]OWX?7UI"UQ>7UE)(N61[.1]G
MUV U\SDO&N%Q3G]9DH:^[_A,:>(A/XCW '%.#5Y79?MI?#.]'R^)H%_ZZ6TR
M?S05J6'[37P_O1\GB[0E_P"NUT(__0S7U$,XP$OAK0_\"1K[2/<]"SFCO7*V
M7QF\(ZD/]&\4>'9O^N>I0O\ R:MJRUVQU3_CWO+6?_KE,K_RKJIXJA/X9HLT
M**3>/44;QZBNCF7<!:*-U&:JX!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 44;J,T %%&:,XH 0<]:0C!J"^U""PMS+<2QPQ+U9WV@5P_B/]I7P'
MX5#_ &[Q5HWF*/G2"X$[C_@";C7'B,90HK]]-1 ] S_G-*37@/B'_@H;X%T<
M,MF=6U9OX/(M/+4_C(4K@_$/_!36>0R+I/A>-#_RSDN[W?\ ^.1I_P"SUX>(
MXNRFC\=8Q^L0/K@#W%&['\0KX(\0?M]_$+6]_P!GO--TE!_SZVB-_P"C/,KA
MM7^-GCOQ]<>3-XC\07CR?\L8+I_+D_X!'7BU_$+!P_@4YS^1C]<@?HQK_C?2
M?"D7F:GJ^FZ:O9KFY2'_ -"-<'XC_;)^'?AAV#^)+>[91RMG"]QG_@: I^M?
M%6A?LV_$#QA)NM?"VMOYG.^YA^S^9_P.3RZ[WP[_ ,$\O'VM;/MC:3HZ?Q^=
M<[Y#^*;Q7+_K9G.(_P!UPG]?^2D_6*TO@@>L>(O^"DGABR5O[+T76;^0=?-V
MP)^>7_E7!^(O^"EGB.^+?V7H6D:=&/\ GYDDG?\ +]W70>&_^"9L*-$^J^)I
MI%Q^\2TM/+/_ 'VSG_T"O0/#O[ ?P]T-%^T6NIZLW8W=Z^?_ !S94_5^*L7\
M4U3'_M,CYA\1_MI?$;Q(N'\1R6,1_P"6=I D'_C^S?7)^;XV^+#??\3^)F?_
M *[W>*_0C0/@+X.\)\Z?X7T6%@/O"S1I/^^VYKK!!Y8PNU1["J_U(QV(_P!]
MQ;^0OJDY_',_//PY^QG\1O%"QLGAV>UB_P">EW.D'_CC_O*[[P]_P3:\37I0
M:IKFC:>G_3!9+B3_ -IU]J8P*2N^AP!EL/XG-/U9K]4@?-7AO_@FGX;LE4ZI
MKFKZBV./)1+=/R.^N\\.?L7_  \\.O&5\.PWC==]W*\__CA.S]*]:PU&&KW\
M/PSEE'X*,?N-51@8_AOP'HOA6+&EZ/I>F^UK:QPY_P"^!6UM [4W&VG$X%>Q
M3I4X+E@C0****V **** #&**** "BBB@ HHHH *,9HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#SW]K'_DUOXD_]BIJG_I))7G_ /P2_P#^
M3%? OUOO_3C<5Z!^UC_R:W\2?^Q4U3_TDDKS_P#X)?\ _)BO@7ZWW_IQN* /
MH*BBB@ K^07_ (.B_P#E.K\<O^X!_P"H_IM?U]5_(+_P=%_\IU?CE_W /_4?
MTV@#^J+]EO5X=<@\<74"W4<<GB'Y%N;62WD'_$NL/X)/GKUBO,?V</\ CX\=
M?]C"G_IML*].H **** /.?VBOVF?A_\ LH?#2Z\8?$GQAHG@KPS9MY;W^J7'
MEH\ASL1/XI)#M;Y$RYP>*\+_ &%_^"U7[.?_  4;\67GAKX:^.XY_$\-S>I;
MZ+JEO)I]_?PV[G_2H8Y/]9')'B9 /WB1G]Y'&Z2(GA/_  7=\":MH?[0G[+/
MQKUGX?\ BKXJ?!CX,Z]K%_XW\/Z)8_VE-:>?:1FSU1K/81)':O#)([O_ *L#
M *;R]>9_L$Z3^RK_ ,%//%.CW7_"?Z;;_&'X7_''Q=\0?"L-C<QZ3XCN;2;7
M]2OX87MKJ'SYK62-HYY(0@=/+0/L!>-P#]:]8UJUT#3;B\OKB"UL[2%YIKB9
M_+CA1!EW=SPJ@"N*_9J_::\#_M@?!K2/B)\.]:7Q)X-U]KF/3]26UFMUN/)N
M'MIODF1)/]="Z<I_!Z$5\Y?\%-/V(?B=^W+/J'AF\^*EUX%_9^M?#HFUO0O#
MD'E^(/&%YNNO/MKB]?Y(+#R1;#8@=Y-\X< ",UR7_!KG_P H*?@9_P!Q[_U(
M-2H ]J_;+_X*U?L[_P#!/WQ!9:+\7?BAHWA'7M0@2>+3DM;K4K\POYFR1X+6
M&22./*/\[H$R.N:]7_9^_:+\%_M3_"_2/&OP]\2:;XL\+ZTC26>HV$F^.3:V
MQT/&4='!1T<!T((.#7P%_P $#M+TOX^?'3]L+]H+5$77/&GB+XS:GX4LM1NH
MQ)<6&CZ=#!]BM89,#8@@N4C.-A<0Q[\[!CP?Q!\7S_P3/_:S_P""EW@?X:+#
MX/\ #T'PTM/B+X<L]/A,-MX<UJ;3HX))H$^=$\RZNDFV;-G[N-/W<:4 ?=WQ
M,_X+R_LB_"/XY2_#GQ#\;_#-GXLMKK[%<(EM=3V=E.DCQO'/>1PO:PNCH^_S
M)$V=Z^O;.\AU*VCFADCFAF3<CJV]'6OB+_@DO^PI\,(_^"*'PH^'^I>#=#UK
MPO\ $KP#IVM>)K:XMAG69]1@CO9GF?[[.DDW[M\[X_+CV;-B8Y+_ (-B_B[J
MWQ&_X)4^']!U:\;4)_ACXAU/P;!>.@5[BUMI_,A! =\;(YDC'HD:#G[Y /T3
MHHHH ^ /^"0/_)]?[>7_ &56U_\ 3='7W_7P!_P2!_Y/K_;R_P"RJVO_ *;H
MZ^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/2@#'\7>+-/\$^
M%M2UC4KJ.ST[1[>2ZN[B3I!%&F]V/T49KP.T_P""KWP%U*YC@A\<2332R>6B
MKH6H'>WI_J*[C]M_48-,_9#^)DUS<0VZ'PQ?PJ9G$:EWMW1%S_M.R+^-?CI^
MR_X#_MGQ1)K%PG[C2_\ 4?\ 32>OF>(\[EEM/G1]ADN29?7RO$YGCIS7L=N7
MJ?JM<?\ !4_X+Z"(X]<\1:AH-])'YGV2ZTBZ>2-?4O"DD?Y/7R9^W-_P6 O?
MB'%>>%_A7-<:;HK#R[GQ!M>"\N_^N"?ZR%/]O[_^Y7DOQI^$/_"T+>U>WFCM
M;ZS?[[I_K$J'X(_LW>'O!'C2#4O%MM)XNL;?]XFFI/\ 9+>X?_;?]Y(\?^Q\
ME>1PSXC8&%:,\S_]N,:/^KKR?ZW[:?UG^3^H_P#MQ3_8S_X)\^,?VPM9CU#]
MYI'A!9\7NM7"?\?']](4_P"6S_\ D-*_6S]GK]F;PC^S!X'CT/PCIJV4&?,N
M;B3Y[B^DY^>:3J[5\SP_\%$=6T#3(;'0_"?AW2K.U39%;IO*0H/X$1-GZ5FW
MW_!0WX@WX_=KH-K[PV<@S_WV[U[F;>*F Q.\Y<A\E6S*$]C[L!]_TH/U%?GG
MJ7[;/Q+O/^9C\E?[L5E I_/96#J'[3OQ U7_ %WB_6D_ZXW/D?\ H%?-2\1\
M!]B$W\C#ZTNS/TH! _NBH;K48;*+=--'$@_B9]HK\N=9^-.MW7_(2\6ZI)_U
M\ZH__L[URNJ?%#1(I-]UXATN23_;O4DDKE_XB'*?\'#LWIQQ53^#1G+Y'ZIW
MWQA\+:2/]*\1:#9_]=;^)/YM6)J/[4OP_P!,7]YXOT1O^N,XG_\ 0,U^6-U\
M<_"5K][6[?\ X CR5G77[2WA6U^[<W$_^Y:O6/\ KSF<_P"'ACOIY)G57X,+
M+_P&1^H-]^W'\-+,?+X@:X;TBL9S_P"R5S^I?\%#_ %FO[J+Q!=>\-JG_LT@
MK\UXOVA[/5/^/#0?$E]_UQM:O1_$CQ?J0_XE_P ,O&E[_N64_P#[(E1_K-Q'
M5_AT8_U_V\=W^J.>R_Y<?C'_ .2/OS4?^"E_A^%-MGX=UB;_ *[3)'_+?6'J
M'_!3B5DQ9^$(U_VY=3W?R2OB56^,>J_\>7P>\8+_ +<FCWO_ ,15N+X5_M%Z
MS_Q[_"_4(/\ ?L'C_P#0Y*S^N\55>G_I)I_J=FCTG4A#_M^)]7WO_!2;Q;(/
M]&T?P['_ -=(YG_DXK#U#_@H+\1-1_U5QH]I_P!<++_XO?7SNG[)?[5&L?\
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MXL*V_L+#'/+Q8S9[0A]TO_DC\AK'_@B?\9[X?O7\(VO_ %UU*3_VG'6Q8?\
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MJ77O^"=?@?4US:W.M:6_\(@N$=!^#H:X/7/^"9EZ(_,TOQ1;RM_#'=V13'_
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M5N'_ -RZ@D_] >G_ *U9Y#X\'_Z4'UBM_(?H-9>(K'4Q_H]]:3_]<YE?^57
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M\7^-?BE,]N^H>)]>9_\ E@)IY\?]LZW/#O[(_P 1O%&S[/X7OX5_O7>RT/\
MX_7G?Z]XJO\ [EAG(R^MS?P0/K;Q+^W!\.O#HD$>L3:@_P#=M+:1\?\  V 3
M]:X7Q%_P4QTFV#?V5X:O[K^ZUW<QP _]\>97 ^'O^"<7C/4V5M0U#1=/C/\
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M];[_ -.-Q7H'[6/_ ":W\2?^Q4U3_P!))*\__P""7_\ R8KX%^M]_P"G&XH
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M#P_8^%M(AT_3;*TTZQM4V0VUM"L,4"?["(,"@#\P?^">'_!<GX _L_?\$EO
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M\#__  B=-_\ C-'_  ZA_9?_ .C=?@?_ .$3IO\ \9KZ"HH ^??^'4/[+_\
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MN/P_DCY]MO\ @F9\*2O^E6'B2]_ZZ^([Z/\ ]%R)4\?_  3(^"H7+>"S<?\
M7QJM[/\ ^AS&O?!'GM1793RK!0^"E'[D=$<RQ4?AJR^\\1TW_@GA\$K'_5_#
MCPZW_7:W:3_T/-:A_8:^#?D[&^%_@21/1M$@?_V2O6@#_M4N&S71]5H+:"*E
MFF-E\56?_@3/&+G_ ()X_ >_'^D?!GX7S_\ 73PM8M_[3K.N/^"7O[-M^/\
M2/@#\&[C_?\ !FG-_P"T:]Y^:D_&M/8T^QC+%XB6\W][/ /^'4/[+_\ T;K\
M#_\ PB=-_P#C-'_#J']E_P#Z-U^!_P#X1.F__&:^@J*OE1E[2?=GS[_PZA_9
M?_Z-U^!__A$Z;_\ &:/^'4/[+_\ T;K\#_\ PB=-_P#C-?05%.R%S/N?/O\
MPZA_9?\ ^C=?@?\ ^$3IO_QFC_AU#^R__P!&Z_ __P (G3?_ (S7T%102?/O
M_#J']E__ *-U^!__ (1.F_\ QFC_ (=0_LO_ /1NOP/_ /")TW_XS7T%10!\
M^_\ #J']E_\ Z-U^!_\ X1.F_P#QFC_AU#^R_P#]&Z_ _P#\(G3?_C-?05%
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M(G3?_C-?05% 'S[_ ,.H?V7_ /HW7X'_ /A$Z;_\9H_X=0_LO_\ 1NOP/_\
M")TW_P",U]!44 ?/O_#J']E__HW7X'_^$3IO_P 9H_X=0_LO_P#1NOP/_P#"
M)TW_ .,U]!44 ?/O_#J']E__ *-U^!__ (1.F_\ QFC_ (=0_LO_ /1NOP/_
M /")TW_XS7T%10!\^_\ #J']E_\ Z-U^!_\ X1.F_P#QFC_AU#^R_P#]&Z_
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MWD/_ (__ .R5W4/$'+I?Q.:!K];@>N?\.H?V8?\ HW7X'_\ A$Z;_P#&:/\
MAU#^S#_T;K\#_P#PB=-_^,USWA[_ (*8Z7,%_M;POJ%K_>:TNH[@#_OORZ[O
MP]^WG\.];4>=J5WIK]DNK1]Q_P"^ X_6O<P_%&55O@K1+5>#,<?\$H?V7_\
MHW7X'_\ A$Z;_P#&:/\ AU%^R_\ ]&Z? _\ \(G3?_C->J^'/C5X2\6MMT_Q
M)HETW]V.]C\S_OG.:ZD$,/O#\Z]NGBJ=7WJ<[FQX#_PZA_9?_P"C=?@?_P"$
M3IO_ ,9H_P"'4/[+_P#T;K\#_P#PB=-_^,U]!9S16X'S[_PZA_9?_P"C=?@?
M_P"$3IO_ ,9H_P"'4/[+_P#T;K\#_P#PB=-_^,U]!9HW4 ?/O_#J']E__HW7
MX'_^$3IO_P 9H_X=0_LO_P#1NOP/_P#")TW_ .,U]!9HS0!\^_\ #J']E_\
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M\#__  B=-_\ C-'_  ZA_9?_ .C=?@?_ .$3IO\ \9KZ"HH ^??^'4/[+_\
MT;K\#_\ PB=-_P#C-'_#J']E_P#Z-U^!_P#X1.F__&:^@J* /GW_ (=0_LO_
M /1NOP/_ /")TW_XS1_PZA_9?_Z-U^!__A$Z;_\ &:^@J* /GW_AU#^R_P#]
M&Z_ _P#\(G3?_C-'_#J']E__ *-U^!__ (1.F_\ QFOH*B@#Y]_X=0_LO_\
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M-_\ C-'_  ZA_9?_ .C=?@?_ .$3IO\ \9KZ"HH ^??^'4/[+_\ T;K\#_\
MPB=-_P#C-'_#J']E_P#Z-U^!_P#X1.F__&:^@J* /GW_ (=0_LO_ /1NOP/_
M /")TW_XS1_PZA_9?_Z-U^!__A$Z;_\ &:^@J* /GW_AU#^R_P#]&Z_ _P#\
M(G3?_C-'_#J']E__ *-U^!__ (1.F_\ QFOH*B@#Y]_X=0_LO_\ 1NOP/_\
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M4 %%%% !1110 4444 %%%% !1110 8HQ110 48S110 4444 %&*** "BBB@
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MYC^IP/C#0/\ @FGXCN_^0CX@T6U_Z]HI)_\ XW77Z)_P3/TF/_D)>*-4NO\
MKVMXX/\ T/S*^H,T'::]:CP3D\/^71I]5IGB&B_L ?#S3!_I%KJFI?\ 7S?/
M_P"T]E=7I'[+OP_T%/\ 1_"&C2'_ *>8?M'_ *'OKT3;0%KV*&2X"E\%&'_@
M)K[.'8S=(\*Z;X?BVV.GV5F/^G>!(_Y5IA !TI F#3J]"-&$%[B+#I1116P!
M1UHHH .E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #?O+
M7F7[5/B#7-"^#NHKX;TV^U35;[%DB6EN]Q)"C_??8G/"?S%>F[LBDVE37)C*
M'MJ,J2ERWZ@?F3_PH7QO_P!"=XJ_\%,__P 11_PH7QO_ -"=XJ_\%,__ ,17
MZ<8'H*,#VK\^_P"(;X6]_;3.+ZC3/,?V5O$&N:[\'=.3Q)IM]I>JV.;)TN[=
M[=YD3[C['YY3^1KT[[JTW:6-+NP*_0,'1]C1C1<N:W4[1V*,445V %&,T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GO[6/\ R:W\2?\ L5-4
M_P#222O/_P#@E_\ \F*^!?K??^G&XKT#]K'_ )-;^)/_ &*FJ?\ I))7G_\
MP2__ .3%? OUOO\ TXW% 'T%1110 5_(+_P=%_\ *=7XY?\ < _]1_3:_KZK
M^07_ (.B_P#E.K\<O^X!_P"H_IM ']5G[.'_ !\>.O\ L84_]-MA7IU>8_LX
M?\?'CK_L84_]-MA7IU !1110 4444 %%%% !1110 4444 %%%% 'P!_P2!_Y
M/K_;R_[*K:_^FZ.OO^O@#_@D#_R?7^WE_P!E5M?_ $W1U]_T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^QA3_P!-MA7IU>3_ ++<U]+#XX:^M[6UNO\ A(?WD5O<>?'&?[.L/X_+C_\
M0*]8H **** "BBB@ HHHH **** "BBB@ HHHH ^ /^"0/_)]?[>7_95;7_TW
M1U]_U\ ?\$@?^3Z_V\O^RJVO_INCK[_H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \]_
M:Q_Y-;^)/_8J:I_Z225Y_P#\$O\ _DQ7P+];[_TXW%>@?M8_\FM_$G_L5-4_
M]))*\_\ ^"7_ /R8KX%^M]_Z<;B@#Z"HHHH *_D%_P"#HO\ Y3J_'+_N ?\
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M_INCK[_KX _X) _\GU_MY?\ 95;7_P!-T=??] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'S_ /\ #(/Q,_Z.J^-7_@B\'?\ RDH_X9!^)G_1U7QJ_P#!%X._^4E?0%%
M'S__ ,,@_$S_ *.J^-7_ ((O!W_RDH_X9!^)G_1U7QJ_\$7@[_Y25] 44 ?/
M_P#PR#\3/^CJOC5_X(O!W_RDH_X9!^)G_1U7QJ_\$7@[_P"4E?0%% 'S_P#\
M,@_$S_HZKXU?^"+P=_\ *2C_ (9!^)G_ $=5\:O_  1>#O\ Y25] 44 ?/\
M_P ,@_$S_HZKXU?^"+P=_P#*2C_AD'XF?]'5?&K_ ,$7@[_Y25] 44 ?/_\
MPR#\3/\ HZKXU?\ @B\'?_*2C_AD'XF?]'5?&K_P1>#O_E)7T!10!\__ /#(
M/Q,_Z.J^-7_@B\'?_*2C_AD'XF?]'5?&K_P1>#O_ )25] 44 ?/_ /PR#\3/
M^CJOC5_X(O!W_P I*/\ AD'XF?\ 1U7QJ_\ !%X._P#E)7T!10!\_P#_  R#
M\3/^CJOC5_X(O!W_ ,I*/^&0?B9_T=5\:O\ P1>#O_E)7T!10!\__P##(/Q,
M_P"CJOC5_P""+P=_\I*/^&0?B9_T=5\:O_!%X._^4E?0%% 'S_\ \,@_$S_H
MZKXU?^"+P=_\I*/^&0?B9_T=5\:O_!%X._\ E)7T!10!\_\ _#(/Q,_Z.J^-
M7_@B\'?_ "DH_P"&0?B9_P!'5?&K_P $7@[_ .4E?0%% 'S_ /\ #(/Q,_Z.
MJ^-7_@B\'?\ RDH_X9!^)G_1U7QJ_P#!%X._^4E?0%% 'S__ ,,@_$S_ *.J
M^-7_ ((O!W_RDH_X9!^)G_1U7QJ_\$7@[_Y25] 44 ?/_P#PR#\3/^CJOC5_
MX(O!W_RDH_X9!^)G_1U7QJ_\$7@[_P"4E?0%% 'S_P#\,@_$S_HZKXU?^"+P
M=_\ *2C_ (9!^)G_ $=5\:O_  1>#O\ Y25] 44 ?/\ _P ,@_$S_HZKXU?^
M"+P=_P#*2C_AD'XF?]'5?&K_ ,$7@[_Y25] 44 ?/_\ PR#\3/\ HZKXU?\
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ME?0%% 'S_P#\,@_$S_HZKXU?^"+P=_\ *2C_ (9!^)G_ $=5\:O_  1>#O\
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MS_\ \,@_$S_HZKXU?^"+P=_\I*/^&0?B9_T=5\:O_!%X._\ E)7T!10!\_\
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MW_RDH_X9!^)G_1U7QJ_\$7@[_P"4E?0%% 'S_P#\,@_$S_HZKXU?^"+P=_\
M*2C_ (9!^)G_ $=5\:O_  1>#O\ Y25] 44 ?/\ _P ,@_$S_HZKXU?^"+P=
M_P#*2C_AD'XF?]'5?&K_ ,$7@[_Y25] 44 ?/_\ PR#\3/\ HZKXU?\ @B\'
M?_*2C_AD'XF?]'5?&K_P1>#O_E)7T!10!\__ /#(/Q,_Z.J^-7_@B\'?_*2C
M_AD'XF?]'5?&K_P1>#O_ )25] 44 ?/_ /PR#\3/^CJOC5_X(O!W_P I*/\
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M>#O_ )25] 44 ?/_ /PR#\3/^CJOC5_X(O!W_P I*/\ AD'XF?\ 1U7QJ_\
M!%X._P#E)7T!10!\_P#_  R#\3/^CJOC5_X(O!W_ ,I*/^&0?B9_T=5\:O\
MP1>#O_E)7T!10!\__P##(/Q,_P"CJOC5_P""+P=_\I*/^&0?B9_T=5\:O_!%
MX._^4E?0%% 'S_\ \,@_$S_HZKXU?^"+P=_\I*/^&0?B9_T=5\:O_!%X._\
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M 44 ?/\ _P ,@_$S_HZKXU?^"+P=_P#*2C_AD'XF?]'5?&K_ ,$7@[_Y25]
M44 ?/_\ PR#\3/\ HZKXU?\ @B\'?_*2C_AD'XF?]'5?&K_P1>#O_E)7T!10
M!\__ /#(/Q,_Z.J^-7_@B\'?_*2C_AD'XF?]'5?&K_P1>#O_ )25] 44 ?/_
M /PR#\3/^CJOC5_X(O!W_P I*/\ AD'XF?\ 1U7QJ_\ !%X._P#E)7T!10!\
M_P#_  R#\3/^CJOC5_X(O!W_ ,I*/^&0?B9_T=5\:O\ P1>#O_E)7T!10!\_
M_P##(/Q,_P"CJOC5_P""+P=_\I*/^&0?B9_T=5\:O_!%X._^4E?0%% 'S_\
M\,@_$S_HZKXU?^"+P=_\I*/^&0?B9_T=5\:O_!%X._\ E)7T!10!\_\ _#(/
MQ,_Z.J^-7_@B\'?_ "DH_P"&0?B9_P!'5?&K_P $7@[_ .4E?0%% 'S_ /\
M#(/Q,_Z.J^-7_@B\'?\ RDH_X9!^)G_1U7QJ_P#!%X._^4E?0%% 'S__ ,,@
M_$S_ *.J^-7_ ((O!W_RDH_X9!^)G_1U7QJ_\$7@[_Y25] 44 ?/_P#PR#\3
M/^CJOC5_X(O!W_RDH_X9!^)G_1U7QJ_\$7@[_P"4E?0%% 'S_P#\,@_$S_HZ
MKXU?^"+P=_\ *2C_ (9!^)G_ $=5\:O_  1>#O\ Y25] 44 ?/\ _P ,@_$S
M_HZKXU?^"+P=_P#*2C_AD'XF?]'5?&K_ ,$7@[_Y25] 44 ?/_\ PR#\3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //?VL?\ DUOX
MD_\ 8J:I_P"DDE>?_P#!+_\ Y,5\"_6^_P#3C<5Z!^UC_P FM_$G_L5-4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'GO[6/\ R:W\2?\ L5-4_P#222O/_P#@E_\ \F*^!?K??^G&XKT#]K'_ )-;
M^)/_ &*FJ?\ I))7G_\ P2__ .3%? OUOO\ TXW% 'T%1110 5_(+_P=%_\
M*=7XY?\ < _]1_3:_KZK^07_ (.B_P#E.K\<O^X!_P"H_IM ']5G[.'_ !\>
M.O\ L84_]-MA7IU>8_LX?\?'CK_L84_]-MA7IU !1110 4444 %%%% !1110
M 4444 %%%% 'P!_P2!_Y/K_;R_[*K:_^FZ.OO^O@#_@D#_R?7^WE_P!E5M?_
M $W1U]_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_Y/K_;R_P"RJVO_ *;HZ^_Z^ /^"0/_ "?7^WE_V56U_P#3='7W_0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_\ _A?S_P#Q%?H!10!^?_\ PT/_ ,%&_P#HW7]G_P#\+^?_ .(H_P"&A_\
M@HW_ -&Z_L__ /A?S_\ Q%?H!10!^?\ _P -#_\ !1O_ *-U_9__ /"_G_\
MB*/^&A_^"C?_ $;K^S__ .%_/_\ $5^@%% 'Y_\ _#0__!1O_HW7]G__ ,+^
M?_XBC_AH?_@HW_T;K^S_ /\ A?S_ /Q%?H!10!^?_P#PT/\ \%&_^C=?V?\
M_P +^?\ ^(H_X:'_ ."C?_1NO[/_ /X7\_\ \17Z 44 ?G__ ,-#_P#!1O\
MZ-U_9_\ _"_G_P#B*/\ AH?_ (*-_P#1NO[/_P#X7\__ ,17Z 44 ?G_ /\
M#0__  4;_P"C=?V?_P#POY__ (BC_AH?_@HW_P!&Z_L__P#A?S__ !%?H!10
M!^?_ /PT/_P4;_Z-U_9__P#"_G_^(H_X:'_X*-_]&Z_L_P#_ (7\_P#\17Z
M44 ?G_\ \-#_ /!1O_HW7]G_ /\ "_G_ /B*/^&A_P#@HW_T;K^S_P#^%_/_
M /$5^@%% 'YC_LTZQ_P4,_9D_9U\ ?#FQ^ _P)U6Q\!>&]/\.07DWCF:.2[C
MLK6.W1W&SAY-@/I7<?\ #0__  4;_P"C=?V?_P#POY__ (BOT HH _/_ /X:
M'_X*-_\ 1NO[/_\ X7\__P 11_PT/_P4;_Z-U_9__P#"_G_^(K] ** /S_\
M^&A_^"C?_1NO[/\ _P"%_/\ _$4?\-#_ /!1O_HW7]G_ /\ "_G_ /B*_0"B
M@#\__P#AH?\ X*-_]&Z_L_\ _A?S_P#Q%'_#0_\ P4;_ .C=?V?_ /POY_\
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M/_\ $4?\-#_\%&_^C=?V?_\ POY__B*_0"B@#\__ /AH?_@HW_T;K^S_ /\
MA?S_ /Q%'_#0_P#P4;_Z-U_9_P#_  OY_P#XBOT HH _/_\ X:'_ ."C?_1N
MO[/_ /X7\_\ \17"^(]8_P""AGB#]H?PE\1I/@/\"8[[PCX?U?P[!9KX[G\N
MYCU*?39WD<[.L9TR,#_KH]?IU10!^?\ _P -#_\ !1O_ *-U_9__ /"_G_\
MB*/^&A_^"C?_ $;K^S__ .%_/_\ $5^@%% 'Y_\ _#0__!1O_HW7]G__ ,+^
M?_XBC_AH?_@HW_T;K^S_ /\ A?S_ /Q%?H!10!^?_P#PT/\ \%&_^C=?V?\
M_P +^?\ ^(H_X:'_ ."C?_1NO[/_ /X7\_\ \17Z 44 ?G__ ,-#_P#!1O\
MZ-U_9_\ _"_G_P#B*/\ AH?_ (*-_P#1NO[/_P#X7\__ ,17Z 44 ?G_ /\
M#0__  4;_P"C=?V?_P#POY__ (BC_AH?_@HW_P!&Z_L__P#A?S__ !%?H!10
M!^?_ /PT/_P4;_Z-U_9__P#"_G_^(H_X:'_X*-_]&Z_L_P#_ (7\_P#\17Z
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MT/\ \%&_^C=?V?\ _P +^?\ ^(H_X:'_ ."C?_1NO[/_ /X7\_\ \17Z 44
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M(K] ** /S_\ ^&A_^"C?_1NO[/\ _P"%_/\ _$4?\-#_ /!1O_HW7]G_ /\
M"_G_ /B*_0"B@#\__P#AH?\ X*-_]&Z_L_\ _A?S_P#Q%'_#0_\ P4;_ .C=
M?V?_ /POY_\ XBOT HH _/\ _P"&A_\ @HW_ -&Z_L__ /A?S_\ Q%'_  T/
M_P %&_\ HW7]G_\ \+^?_P"(K] ** /S_P#^&A_^"C?_ $;K^S__ .%_/_\
M$4?\-#_\%&_^C=?V?_\ POY__B*_0"B@#\__ /AH?_@HW_T;K^S_ /\ A?S_
M /Q%'_#0_P#P4;_Z-U_9_P#_  OY_P#XBOT HH _/_\ X:'_ ."C?_1NO[/_
M /X7\_\ \11_PT/_ ,%&_P#HW7]G_P#\+^?_ .(K] ** /S_ /\ AH?_ (*-
M_P#1NO[/_P#X7\__ ,11_P -#_\ !1O_ *-U_9__ /"_G_\ B*_0"B@#\_\
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M?_\ PT/_ ,%&_P#HW7]G_P#\+^?_ .(H_P"&A_\ @HW_ -&Z_L__ /A?S_\
MQ%?H!10!^?\ _P -#_\ !1O_ *-U_9__ /"_G_\ B*/^&A_^"C?_ $;K^S__
M .%_/_\ $5^@%% 'Y_\ _#0__!1O_HW7]G__ ,+^?_XBC_AH?_@HW_T;K^S_
M /\ A?S_ /Q%?H!10!^?_P#PT/\ \%&_^C=?V?\ _P +^?\ ^(H_X:'_ ."C
M?_1NO[/_ /X7\_\ \17Z 44 ?G__ ,-#_P#!1O\ Z-U_9_\ _"_G_P#B*/\
MAH?_ (*-_P#1NO[/_P#X7\__ ,17Z 44 ?G_ /\ #0__  4;_P"C=?V?_P#P
MOY__ (BC_AH?_@HW_P!&Z_L__P#A?S__ !%?H!10!^?_ /PT/_P4;_Z-U_9_
M_P#"_G_^(H_X:'_X*-_]&Z_L_P#_ (7\_P#\17Z 44 ?G_\ \-#_ /!1O_HW
M7]G_ /\ "_G_ /B*/^&A_P#@HW_T;K^S_P#^%_/_ /$5^@%% 'Y__P##0_\
MP4;_ .C=?V?_ /POY_\ XBC_ (:'_P""C?\ T;K^S_\ ^%_/_P#$5^@%% 'Y
M_P#_  T/_P %&_\ HW7]G_\ \+^?_P"(H_X:'_X*-_\ 1NO[/_\ X7\__P 1
M7Z 44 ?G_P#\-#_\%&_^C=?V?_\ POY__B*/^&A_^"C?_1NO[/\ _P"%_/\
M_$5^@%% 'Y__ /#0_P#P4;_Z-U_9_P#_  OY_P#XBC_AH?\ X*-_]&Z_L_\
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M(K] ** /S_\ ^&A_^"C?_1NO[/\ _P"%_/\ _$4?\-#_ /!1O_HW7]G_ /\
M"_G_ /B*_0"B@#\__P#AH?\ X*-_]&Z_L_\ _A?S_P#Q%'_#0_\ P4;_ .C=
M?V?_ /POY_\ XBOT HH _/\ _P"&A_\ @HW_ -&Z_L__ /A?S_\ Q%'_  T/
M_P %&_\ HW7]G_\ \+^?_P"(K] ** /S_P#^&A_^"C?_ $;K^S__ .%_/_\
M$4?\-#_\%&_^C=?V?_\ POY__B*_0"B@#\__ /AH?_@HW_T;K^S_ /\ A?S_
M /Q%'_#0_P#P4;_Z-U_9_P#_  OY_P#XBOT HH _/_\ X:'_ ."C?_1NO[/_
M /X7\_\ \11_PT/_ ,%&_P#HW7]G_P#\+^?_ .(K] ** /S_ /\ AH?_ (*-
M_P#1NO[/_P#X7\__ ,11_P -#_\ !1O_ *-U_9__ /"_G_\ B*_0"B@#\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)[FUN;SY//M9(-FPXWB1XT1$3>7_ $IH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@G]D+X*:]\0OB)KUKX9\)^&X/M%[>7!SG/W$1/OO([X1$0;W<@ &O2*^$?\
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MI)_X)N?&CQ$M]"VCR_#C6KZ.Z',;POIL[HX^N?UKDO@7^PIXRE_90\??"O\
M:)^,$_[15CX\\^SFOKSPS#X?DM;">!(7M42"5_G#;Y$GWAT=QCE,U\WV7_!
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MGP^-/^#ISX(QVEPDEUX/^#.J:I?1C_EG'-=7=NF?J9Z]D_;:_P""5FH_'_\
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M1JB  ]EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS(KE 3R@V;/GW_7U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7\@O\ P=%_\IU?CE_W /\ U']-K^OJOY!?^#HO_E.K\<O^X!_ZC^FT
M ?U6?LX?\?'CK_L84_\ 3;85Z=7F/[.'_'QXZ_[&%/\ TVV%>G4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?R"_P#!T7_RG5^.7_< _P#4?TVOZ^J_D%_X.B_^4ZOQR_[@'_J/Z;0!
M_59^SA_Q\>.O^QA3_P!-MA7IU>3_ ++6BV?AR#QQ9Z?9VUC:P>(<)#;0^5&G
M_$NL/X*]8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQO\ $0?\W8_M ?\ @H\$?_,]1_PQQ\1/^CLOC_\ ^"CP/_\ ,]0!] 45\_\
M_#&WQ%_Z.Q_: _\ !1X(_P#F>H_X8V^(O_1V/[0'_@H\$?\ S/4 ?0%%?/\
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M17S_ /\ #&WQ%_Z.Q_: _P#!1X(_^9ZC_AC;XB_]'8_M ?\ @H\$?_,]0!]
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M] 45\_\ _#&WQ%_Z.Q_: _\ !1X(_P#F>H_X8V^(O_1V/[0'_@H\$?\ S/4
M?0%%?/\ _P ,;?$7_H[']H#_ ,%'@C_YGJ/^&-OB+_T=C^T!_P""CP1_\SU
M'T!17S__ ,,;?$7_ *.Q_: _\%'@C_YGJ/\ AC;XB_\ 1V/[0'_@H\$?_,]0
M!] 45\__ /#&WQ%_Z.Q_: _\%'@C_P"9ZC_AC;XB_P#1V/[0'_@H\$?_ #/4
M ?0%%?/_ /PQM\1?^CL?V@/_  4>"/\ YGJ/^&-OB+_T=C^T!_X*/!'_ ,SU
M 'T!17S_ /\ #&WQ%_Z.Q_: _P#!1X(_^9ZC_AC;XB_]'8_M ?\ @H\$?_,]
M0!] 45\__P##&WQ%_P"CL?V@/_!1X(_^9ZC_ (8V^(O_ $=C^T!_X*/!'_S/
M4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\ F>H_X8V^(O\ T=C^T!_X*/!'_P S
MU 'T!17S_P#\,;?$7_H[']H#_P %'@C_ .9ZC_AC?XB_]'8_M ?^"CP1_P#,
M]0!] 45\_P#_  QM\1?^CL?V@/\ P4>"/_F>H_X8V^(O_1V/[0'_ (*/!'_S
M/4 ?0%%?/_\ PQM\1?\ H[']H#_P4>"/_F>H_P"&-OB+_P!'8_M ?^"CP1_\
MSU 'T!17S_\ \,;?$7_H[']H#_P4>"/_ )GJ/^&-OB+_ -'8_M ?^"CP1_\
M,]0!] 45\_\ _#&WQ%_Z.Q_: _\ !1X(_P#F>H_X8V^(O_1V/[0'_@H\$?\
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M/!'_ ,SU 'T!17S_ /\ #&WQ%_Z.Q_: _P#!1X(_^9ZC_AC;XB_]'8_M ?\
M@H\$?_,]0!] 45\__P##&WQ%_P"CL?V@/_!1X(_^9ZC_ (8V^(O_ $=C^T!_
MX*/!'_S/4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\ F>H_X8V^(O\ T=C^T!_X
M*/!'_P SU 'T!17S_P#\,;?$7_H[']H#_P %'@C_ .9ZC_AC;XB_]'8_M ?^
M"CP1_P#,]0!] 45\_P#_  QM\1?^CL?V@/\ P4>"/_F>H_X8V^(O_1V/[0'_
M (*/!'_S/4 ?0%%?/_\ PQM\1?\ H[']H#_P4>"/_F>H_P"&-OB+_P!'8_M
M?^"CP1_\SU 'T!17S_\ \,;?$7_H[']H#_P4>"/_ )GJ/^&-OB+_ -'8_M ?
M^"CP1_\ ,]0!] 45\_\ _#&WQ%_Z.Q_: _\ !1X(_P#F>H_X8V^(O_1V/[0'
M_@H\$?\ S/4 ?0%%?/\ _P ,;?$7_H[']H#_ ,%'@C_YGJU/^">OQ-U_XZ?L
M%?!/QIXJOO[5\3>,/ 6A:WJUZ88X/MEW=:?;SSR>7&B1IOD=SL1 @[8Z4 >V
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_(+_P '1?\
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M176[C[+=0P)&Z!X;-XWP1U1R/Z6_^"8'CO4/^"DG_!;7XH?M:>"?#_B+P_\
M O3? B^ ]$UK5[6>UD\;S"[C=YX$?Y/(22UG! ?,>RWWHDDCI& ?97_!(_\
MX*,?\/3OV-M.^+G_  AJ^!?[0U.\TT:5_:W]I[/(DV;_ #O)A^_Z;.*^HJ_
M;_@WE_X)V?$K]LK_ ()FK?7'[2GQ?^%/@J'6;Z#PKHGPVU-=%FAND>3SKK4)
M]GF3[Y' $$;H@2 '?O?Y/M/_ ((L_M?_ !L\??LP?M$> ?%UW;_%OXM?LV^,
M-:\&:1J%Q.+$^,)+1'%K'<3/G8\D\;Q^?)SY;QE][H[N ?I-17Y.P?\ !.#X
MX>-_@ OQ._:6_;>^,7P1^*&H6KZC=:?X>\6VNA^$/!\:.9/(FACD$%UY:.-\
MGGH.<;W2/+^.ZU_P4C^+'QR_X-2OB1\2KGX@:O'\6?!.LVOAN?Q?X>O7TZ\N
M?)U_3D$R3P"/[]K.L;NG^L0G?R[T ?N)17Y9V7[)/Q8_9Z_X)L_%3X]>+/VG
MOCCXV^)&L_ K7-6U'39-?^S^']+U632?M$%SI<$*)]E>WV%$DCY=_P!Y\A^2
MO$_@7^RC^T)^U1_P1QM?C]XL_;"^.WA_QIHO@J;Q!X7L/"VNR6>D1VEE;91=
M4Z3ZC=3_ &5WDDDG^1[@\.@^< _;BBOQW_9S^!G[1/\ P5J_X)GZ/^T-XN_:
M@^+GPU^(=]H=W<>%]#^'MY'H/A]/L3R0(^H6L?SWLUU):O,Y\^-$^T;$C1$V
M5Z=\"OVN_P!JC]NG_@@Y\(?&GP;M=)U#XX>/I$\/:OXAO)+:TCT2V@O;JQNM
M<\F8^7--_HJN8T[SNZ1_((" ?IU17XG_ /!47]G3Q]_P2C_9EOOC%X=_;R^-
M6J?%3PS/!<MX:\:^+H+O1_%MP]U 7@M-+D_U>(6FD\G$_P B;,HGSCWS_@I/
M^W5\3/B3'^RO\&?@7XHA\!_$']JB-=9N_$<.G_;)/#&BPVD5W=3P1NZ'S#&S
M[ XY2"1-\)(DH _32BOSAT/_ ()[_M*_L+?'SX9>(/A'\=?BU\=/ E]K,.F_
M$7PU\4_$D&K26^GR?Z[4M/FD\ORY(-GR0#DR%,[T,E?-\O[:>E_\%0/VL?C)
M#\1?VSIOV6?A'\+_ !*_A?PGX9\+^.M.\&^)/$$\ D2ZU&YNIG>1[=WP$1-\
M;X^Y&\>^0 _:ZBORW_X)2?M\ZQH7_!0CQA^S'K'QZT']I;PFOA2'QCX(\>V>
MJ6%[>1QK*(;O2[N2S=UFG#OYB;SY@CC.04DB">E_\&T_QA\6?'G_ ()%^ /%
M'CCQ-XB\9>(KW4-72?5-=U.;4KVY1-1G1-TTSL[;$ 0>PQ0!]V:]K</A[0KZ
M_F5FAT^!YW"_>VHF\U\A:=_P5@G^,7_!*&;]J#X0_"#QS\2)-0F?^QO D8,>
MMZFD>M?V6[?Z+'=;71$DN=L:281",]7'SW^Q!;>+/VX/@Q^W]X*\5?%;XN:7
M#I_QP\2:7HNKZ+XFG@U;P[8V=S%<1V5C/)YGV:WPGDM#&@3RY)$'W^/B+]G+
MX?\ BC]E?_@TV\5?'+P7\8_CAI'B3Q%;6]M9Z7!XNGM]'\*F/QM]ED?2X80C
MVLD\>_SB)#YAFD_OD4 ?T(>!O$-YXK\#Z/JEYIEUHU[J5E#=3V$YS+8R21AV
M@?A?G3[F?4?6M^OS'_X*"_M>?%;4O#_[)7[._P '?&DO@_XJ?M$6L,^J>+IK
M9=3O=!TBTLH)[VZ1'D^>9QYA']_R)OGC)\P;6A_\$]_VE?V%OCY\,O$'PC^.
MOQ:^.G@2^UF'3?B+X:^*?B2#5I+?3Y/]=J6GS2>7Y<D&SY(!R9"F=Z&2@#]'
MJ*_.+XC_ +&/[1W[<G[3?Q.UGXN_&;XE?LY_!7PSJXTWP'I'PT\4VNFWFO6J
M90:K=:@F^1//,G_'K)'P<)QY:22<9_P1;_:-\5>&_P#@H+\?OV:=9^/5Q^T1
MX1\ Z9IVL^&?%%[?1ZEJ$>_9'>VTUU&7WR1S2(CH\C_/'_ 7=* /KO\ X)2_
MM^G_ (*:_L4^&_C#_P (F?!2^(+J^@&D#4_[2^S?9KJ2#/G>3#N+^7O^YQG'
M-?2M?A#^Q1^U/\0?V,O^#273_'7PSDM;+Q)9:OJ%E_:L]J]S'H,%QK<\#WWE
MXZQ[QCY'&2,H_P!RO4O@C\(/$GQ+NO"/BC]D_P#X*0ZQ\7/B7)J4=_XB\-_$
M#QC#J6CZO9>8_P!J6/2! \^GY42;$V?<^X\>Q)  ?L97RW^V7_P48;]DG]LK
M]F_X1_\ "&_\) O[06IZIIHU7^UC:_V ;%+63?Y'DOY^_P"TC^./9L[YX^I*
M_,/_ (+,_P#*9;_@FU_V-'BC_P!$:30!^GE%?CW?Z#\<OVR/^"^?[4?P=TG]
MH+XB?#'X0^']+\/:CJ5IH.J/_:ENCZ):#[/I3S>9!I_F37+SS3Q1^87CC[N7
M';?L,>)_BI^P)_P6HU7]EGQ1\7/&WQJ^&_CKX>GQ[X8OO&5X^I:]H$D=W) 8
M)+MOOH?(N<Y&S_4%/+/F!P#]3J*_)?X06?Q2_P""Y/[7'QOU@?'KXK?!O]G_
M .#WBF7P)X<T[X::A_8.J>(]0M1FZO9[W]X=@\Q"$V$2)-"=D+Q_O/6OA?\
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M?L ?%Z\^&=Q"E]!J?_"26O\ ;QM73?YCZ0D#RH__ $S,E>Q_\%NO^"=FO?\
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M0#I/ ?\ P7&UKX;?M)>$?AG^U#^S_P"*OV;-4\?SBS\.ZW<^(;7Q#H%_=?\
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MSN(W^2:U=/D=T_Y:9._[@Q6/^RM_P40_9:_X*?\ [='P]N]>\&^-OAW^T_\
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MNIG>1[=WP$1-\;X^Y&\>^0 _:ZBORM_X)??\%$KGX??MX^//V=?%'[0'AO\
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M9L39LD=XW0 ^RO@+_P % &^./_!0OX^? ;_A%%TMO@;:Z#<?VZ=4\_\ MO\
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M0-?/W_!)S_E%I^S5_P!DJ\+_ /IHM* /H&BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OY!?\ @Z+_ .4ZOQR_[@'_ *C^FU_7U7\@O_!T
M7_RG5^.7_< _]1_3: /ZK/V</^/CQU_V,*?^FVPKTZO,?V</^/CQU_V,*?\
MIML*].H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?\
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M_P $</ 6AZS_ ,$H_P!G6ZNM%TBYN9/A[H^^2:RCD=_]%C[XKZVHHH _,/\
MX-&/^4-?A_\ [&?6/_1XKQO_ ()_:A\1M+^''_!52Z^$2W4GQ,M_B[XHF\.I
M;P+/.;I)KLIY*-D/-P=B$'Y]G'.*_:"B@#^>?]C3Q+^P7-\!M(NO$'PG^)G[
M1?[8EWH=N_B?PCXBT+7M:\0:AK<:HDJ2/-&]C#:^<4Q)RZ0.F_>X,=<K\-=/
MNM _X-#/VI-)U&UMM-UC1_BC'9:A8VY3987":UH.Z'Y./DX_"OZ0J* /D/\
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MB@ HHHH **** "BBB@ HHHH **** .#^/'P7L?CQX%DT6^E>V_?)<0W$:AS
MZ=#_ ./,/QKP3_AV"^?^1V7_ ,$__P!NKZT[4BQX->%C^'<!CI^VQ,+R(J48
M3^(^33_P3 ;'_([+_P"";_[=7SW\8_ %K\+?B'>:':ZLNM-8/LGN%MO)&_\
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M"B@#Y_\ ^'EGP[_Z%OX_?^&*\<?_ "HH_P"'EGP[_P"A;^/W_ABO''_RHKZ
MHH ^?_\ AY9\._\ H6_C]_X8KQQ_\J*/^'EGP[_Z%OX_?^&*\<?_ "HKZ HH
M ^?_ /AY9\._^A;^/W_ABO''_P J*/\ AY9\._\ H6_C]_X8KQQ_\J*^@**
M/G__ (>6?#O_ *%OX_?^&*\<?_*BC_AY9\._^A;^/W_ABO''_P J*^@** /G
M_P#X>6?#O_H6_C]_X8KQQ_\ *BC_ (>6?#O_ *%OX_?^&*\<?_*BOH"B@#Y_
M_P"'EGP[_P"A;^/W_ABO''_RHH_X>6?#O_H6_C]_X8KQQ_\ *BOH"B@#Y_\
M^'EGP[_Z%OX_?^&*\<?_ "HH_P"'EGP[_P"A;^/W_ABO''_RHKZ HH ^?_\
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M%OX_?^&*\<?_ "HH_P"'EGP[_P"A;^/W_ABO''_RHKZ HH ^?_\ AY9\._\
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M?_*BC_AY9\._^A;^/W_ABO''_P J*^@** /G_P#X>6?#O_H6_C]_X8KQQ_\
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M_H6_C]_X8KQQ_P#*BOH"B@#Y_P#^'EGP[_Z%OX_?^&*\<?\ RHH_X>6?#O\
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M8KQQ_P#*BOH"B@#Y_P#^'EGP[_Z%OX_?^&*\<?\ RHH_X>6?#O\ Z%OX_?\
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M_*BOH"B@#Y__ .'EGP[_ .A;^/W_ (8KQQ_\J*/^'EGP[_Z%OX_?^&*\<?\
MRHKZ HH ^?\ _AY9\.Q_S+?Q^_\ #%>./_E11_P\L^'9_P"9;^/W_ABO''_R
MHKZ HH ^?O\ AY9\._\ H6_C]_X8KQQ_\J*7_AY9\.Q_S+?Q^_\ #%>./_E1
M7T!10!\__P##RSX=_P#0M_'[_P ,5XX_^5%)_P /*_AW_P!"W\?O_#%>./\
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M7CC_ .5%?0%% 'S_ /\ #RSX=_\ 0M_'[_PQ7CC_ .5%'_#RSX=_]"W\?O\
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M+?Q^_P##%>./_E17T!10!\__ /#RSX=_]"W\?O\ PQ7CC_Y44?\ #RSX=_\
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MZ/R".?2O>J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OY!?^#HO_E.K\<O^X!_ZC^FU_7U7\@O_!T7_P IU?CE_P!P#_U']-H _JL_
M9P_X^/'7_8PI_P"FVPKTZO,?V</^/CQU_P!C"G_IML*].H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_87_ .BX'_PC/$'_ ,@T?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\
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MQ!_\@T?\11?["_\ T7 _^$9X@_\ D&@#[_HKX _XBB_V%_\ HN!_\(SQ!_\
M(-'_ !%%_L+_ /1<#_X1GB#_ .0: /O^BO@#_B*+_87_ .BX'_PC/$'_ ,@T
M?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\ 87_Z+@?_  C/$'_R#1_Q
M%%_L+_\ 1<#_ .$9X@_^0: /O^BO@#_B*+_87_Z+@?\ PC/$'_R#1_Q%%_L+
M_P#1<#_X1GB#_P"0: /O^BO@#_B*+_87_P"BX'_PC/$'_P @T?\ $47^PO\
M]%P/_A&>(/\ Y!H ^_Z*^ /^(HO]A?\ Z+@?_",\0?\ R#1_Q%%_L+_]%P/_
M (1GB#_Y!H ^_P"BO@#_ (BB_P!A?_HN!_\ ",\0?_(-'_$47^PO_P!%P/\
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M_87_ .BX'_PC/$'_ ,@T?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\
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MQ!_\@T?\11?["_\ T7 _^$9X@_\ D&@#[_HKX _XBB_V%_\ HN!_\(SQ!_\
M(-'_ !%%_L+_ /1<#_X1GB#_ .0: /O^BO@#_B*+_87_ .BX'_PC/$'_ ,@T
M?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\ 87_Z+@?_  C/$'_R#1_Q
M%%_L+_\ 1<#_ .$9X@_^0: /O^BO@#_B*+_87_Z+@?\ PC/$'_R#1_Q%%_L+
M_P#1<#_X1GB#_P"0: /O^BO@#_B*+_87_P"BX'_PC/$'_P @T?\ $47^PO\
M]%P/_A&>(/\ Y!H ^_Z*^ /^(HO]A?\ Z+@?_",\0?\ R#1_Q%%_L+_]%P/_
M (1GB#_Y!H ^_P"BO@#_ (BB_P!A?_HN!_\ ",\0?_(-'_$47^PO_P!%P/\
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M_87_ .BX'_PC/$'_ ,@T?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\
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MQ!_\@T?\11?["_\ T7 _^$9X@_\ D&@#[_HKX _XBB_V%_\ HN!_\(SQ!_\
M(-'_ !%%_L+_ /1<#_X1GB#_ .0: /O^BO@#_B*+_87_ .BX'_PC/$'_ ,@T
M?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\ 87_Z+@?_  C/$'_R#1_Q
M%%_L+_\ 1<#_ .$9X@_^0: /O^BO@#_B*+_87_Z+@?\ PC/$'_R#1_Q%%_L+
M_P#1<#_X1GB#_P"0: /O^BO@#_B*+_87_P"BX'_PC/$'_P @T?\ $47^PO\
M]%P/_A&>(/\ Y!H ^_Z*^ /^(HO]A?\ Z+@?_",\0?\ R#1_Q%%_L+_]%P/_
M (1GB#_Y!H ^_P"BO@#_ (BB_P!A?_HN!_\ ",\0?_(-'_$47^PO_P!%P/\
MX1GB#_Y!H ^_Z*^ /^(HO]A?_HN!_P#",\0?_(-'_$47^PO_ -%P/_A&>(/_
M )!H ^_Z*^ /^(HO]A?_ *+@?_",\0?_ "#1_P 11?["_P#T7 _^$9X@_P#D
M&@#[_HKX _XBB_V%_P#HN!_\(SQ!_P#(-'_$47^PO_T7 _\ A&>(/_D&@#[_
M **^ /\ B*+_ &%_^BX'_P (SQ!_\@T?\11?["__ $7 _P#A&>(/_D&@#[_H
MKX _XBB_V%_^BX'_ ,(SQ!_\@T?\11?["_\ T7 _^$9X@_\ D&@#[_HKX _X
MBB_V%_\ HN!_\(SQ!_\ (-'_ !%%_L+_ /1<#_X1GB#_ .0: /O^BO@#_B*+
M_87_ .BX'_PC/$'_ ,@T?\11?["__1<#_P"$9X@_^0: /O\ HKX _P"(HO\
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+K\R@G&>A!H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827037168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Equity and Liability Components of the Convertible Senior Notes</a></td>
<td class="text">The following table summarizes information about the equity and liability components of the 2019 Notes and 2023 Notes (in thousands).<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:57.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.768%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.292%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2019 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(893)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2023 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(111,041)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(140,136)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">638,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">609,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of equity component of 2023 Notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">647,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>lgnd-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgnd="http://www.ligand.com/20191231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgnd-20191231.xsd" xlink:type="simple"/>
    <context id="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3db79f26c0544fc6a26a782c03095534_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i52984fc7f6524de3bd553513b238634b_I20200221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1845b3a0c00f4faf86884050f553c2a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i675b454e2a4246a5976716630c08343b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesandProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i869489dbc2cb4d108beb10a315c6229a_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i8cf4dc97e05a4c57ab75939e7f4190ad_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5489d8e2a3154e579e1950596bad4e83_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="idf5608c1b3e145d7b634848e84a0417e_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i70090b4fce044e77b235ddf8a74bbb7e_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1c39c6b8d84c41cca43833810fbc7ae2_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idae4fa193bce41988665297c8c87cd90_I20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="ifcb933ddf4a24744b8334b58adba6068_I20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="i942f3b02c5b94bd68a645167798076c7_I20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="i52155cd9acaf404eadf5b7e3d980852d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iba785669817e4bca8806263b74bbb109_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idc1374cff04f4a8a9e7ff2371b8b8aed_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i04273cf057274bd7ba4eb19b16af0d81_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibac644851be347358be4803ad12d0c11_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7a9bcb91841d44d6ba7d80ded777ad08_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i1e5aa84c1f894416941ae3fb3370a0e7_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i01597458c3654e7d814509dc1fe6a346_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i4ecf11d232574f23813a8e1cac3990ee_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i352af84d1ae44bb8a22c67271354ceae_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ef94475465245018ed0c204e8bd7fda_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic339114ab562486b8927a1f3fd53be85_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iafd33958a305462b9dded4123ec458ad_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9508f9f000dd4ad0b0d754524aee17b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i58b3cbeb39e14feb8ab2224143dffb5a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45ef1d23069649bc84d61c935c800a92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2870d56eba64b3dbd7901fdf1a45b5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice4b9c573b6e48dcb989d7ab948495c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53e345f65cef494a89a25239fa967bbb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c0def0efae44a5ea9424174e127e04f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad8277e193464fc0bfc5035fabc271f6_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8112712360b5447cbcf4086b3a12a30f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97f46503b54b4c4581f7af547a5f1819_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i36e85343882a43ef806ab5bd3ca04f8b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3790f97128f2494d8984195c0fc58a83_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7c3e0f45fa04308991b331a1b1cdec4_I20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-06</instant>
        </period>
    </context>
    <context id="i4d5cb59bf92840e6a385702bbe7c55ba_I20100131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="i76f6da162c3e4716b198d45ef10746a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59fc29cee5074164b3c15d239382aa22_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoandCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ac076f1e57a4636b9b7a8d17ac9c624_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i503b6946954c46afa717c2fcf22da428_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1677d2b07ff14a8dbc63ada1e73e55b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10ee583771d143e48147fc04de5f46c1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i96448a01fb3f40a096e5d761e2c099b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:DianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2287a9c538514d76aadb3ec1766fe149_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:DianomiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id883dd6370374636a72ea85102571215_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="ia8345e8c12e54d5aaee35fd1453902c0_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i22c27966fa7a47b48404cf82d0835b4b_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="iabe93206950f4a5ca90a7c38545f68fa_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:NovanMolluscumProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="id5b9fd1011fc45cb824aa53afa55ee70_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic25cc6cea36649299a866a8aefa35559_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1a7529b75a8a4febb9932e1ac827bae4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i04c56e43b6e44052bafac504dcd95284_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5df91a43747141109e40628d6c3e1602_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i5c0bcf32476240a69acc2df358c66283_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ia434c2f1e4fd4242bc042dcec9b0f76c_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ibcbe0bbeae724e1d93328ffcae8742d7_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ibf9680e99f8b49b19bbd0708cf2b886f_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ieaa465d6d40c45fba9d4e1bdc39e4cd8_D20170531-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i00b84867fefc461a891bb0fd73e18725_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AziyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id365704cf3b84c6ab7c5a47ec6bdff70_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i014e836b51b047e8b7d0a0a06fb58ea5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia82f8b0071ba419db2fd44d139c75921_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i752660ce777040a3bf4a197f34a8a7ae_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i48b6c33518324d248216b8fc59601e1e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyPromactaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8fd9ffdb575642bc99960b6a0f220f7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbf94a70bfff4f93bc6e7bb11e783a03_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9e64ad3b9590426a946af951ece864ce_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ifdbe7a966e324982b84d652d014786ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ff65fe494c14a35b1dd9f4bd1dc538c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9612324a089e4c32998e3a6d952592f8_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i146808219fd64e048cff80065bea6f1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i960ac618c48c4ce3b0502dead45bbb2a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if187e8fde5214e529fe79103581b53a1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i194607164d454958b0723749de9579e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5ff0c9eca02e4a2f9b35491141d683f0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iffdb648378694003ae22ea717992f96b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i554d97702ee847d8a57c46340addad5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05a2217af97e477b903d2d5d4edab90b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd04a9173f544a62859a7935f7ae3658_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7d72465b58ad4e67b216c687373c6ff8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd9941b5f3154326bcadc3bdd7cdd3b7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iee06435e8cf54fa7aa9127b85e72920f_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i40f1b30e9315498090c3a5d490662303_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0993a0ffdc9416e8eae6352f6f762b9_D20070101-20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="i59e2fe191ffb414da27578a719a56920_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i5b883a1064da430e9dc11a5b03492ca1_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="id36623c1d9734d28ae32c58d9b90c026_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="i7411d3bb032347e6a6b92e42a6d29132_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="i879ae176b2124f789573e2512496d9a0_D20190101-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="id432212c910f45cb9fd439930be6a10c_D20190101-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="i42d16a6431d94f848413960849cb7def_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i627d466bba7d41ddbcecee653a9fcb3e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ia866a9721849422ea2aa6ef8a644c3b6_I20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="i6365b125a6f9462a9020457fd59be296_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if127a97e90a74b089bee82f5b9537b9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i4ee653649d66402981113f680d933493_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-23</instant>
        </period>
    </context>
    <context id="i6a285f7cae6847cbb84e55f9cc40ae24_D20190723-20190723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:AbInitioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-23</startDate>
            <endDate>2019-07-23</endDate>
        </period>
    </context>
    <context id="i063eb253ae3b4c25a99074736166eeb7_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="idffee5590e9a4dc7b62742af7e16dc82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icde9c31e86024dd0ae2c8ea70643ce67_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i814ece52582942738ba79ba1e26c7405_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:VernalisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-06</startDate>
            <endDate>2017-10-06</endDate>
        </period>
    </context>
    <context id="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-06</startDate>
            <endDate>2017-10-06</endDate>
        </period>
    </context>
    <context id="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-06</startDate>
            <endDate>2017-10-06</endDate>
        </period>
    </context>
    <context id="i1697e6f29f434232b75e818f4ca2eca0_I20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:VariableRateComponentAxis">lgnd:ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-06</instant>
        </period>
    </context>
    <context id="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-06</instant>
        </period>
    </context>
    <context id="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8cf89aa90cf34ae8b88f29189cdd661b_D20171006-20171006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-06</startDate>
            <endDate>2017-10-06</endDate>
        </period>
    </context>
    <context id="i4b00d8919174418ebe287cc12594d727_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if66e23507a484f19a663af8fe0d1ac56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b560e54f4ba43f09c2f8005e045a4b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia520b2b8a01f4302905c89f3b3631aba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if13f24dbd7b94cdd98bce8907218b098_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib0c1b7515d834b96ba399542082661b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if65edf5940434c65862432001f7fca40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2641b53d2baa4c3fa22b49a8cd48329e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a384419cf554229afda13595299df80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie86a62fed86e4561b271030c70bfbe6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1065d4ab29524f959cf02e2235084e47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0795ba3ab21f49fcbe79b88fea60278d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f894f3d17b245c480e3f32580adbf3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic92a6ee4b08740648c5cc02eb96d8312_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7cf3fc5e9b14c01b5883261d2ebf84e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if88fbc1c8f9440599dc1210a3215a18f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ee3f1bbedd04ef0a2d097ae36f3fcfb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i333307bd30ca43dabd171c81f9a061c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9e55472ecafa4bd8b817bfd8cea90435_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a96b9c75a6a4db4a42908340754361e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dd10b3dca034733bcf105cef8c3fe1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i053fc7c14c3a4fcca4e9518b3b0aa792_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie765c2c1580b4b668660efe86db75615_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a73bc52ddbc49a0ae7ab3c3890665fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id30791cf6bd640898b2c76820ef15a1f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib14e95be5980439b89d0be5d5cf9c38f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e3d2af9fb0b4d51a38451c771ddbcbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2210269696b54388859b9c440a7e5ffa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie876dd3bfe4948ecb026d413a211825c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4a4220bf4b8433f97d84d75a7a15ec3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6148de9bc6314d7db99b0174ac32270f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if4219c1edadf45ef9ebabf21e48f42bc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie62d7c10b74b402c87f6a4746c4edc9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i687289d5249341bea56d56f06881a316_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i12332e287c1448f0ae90bd926ae81019_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i88287563b1f84464879d94daa8496cb9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie9166e07465648fc897dff070b433978_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i240c26f07d684902a2a5a2aa13ff4522_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie1db864c137e4884a0d080828544685a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if50c2885177f46b9a3b8e52be036553c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib62050c02be84bc68a5fe4449b65fc5c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i39ec9979e10e4655be2956189114b459_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i440e6011a4b240eea401a947eb82807d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id50232e03fcd40198b29f681ccae378c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i270207e77dc041c3a631393297a9d666_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i376e8b7a95ec4903a952f0e1a98b9ca6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2c435e953ccb4fea8d4665b2ee78d8aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic3ff8fdbb91347e4bd610fe51e004636_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21d8f620ea2f4486b9f6948e67e4eb7d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i35fc6c1c2c364e28b41de2556a16e837_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id4405cd949e5464d859260401ea0db00_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCydexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibdc8f1e296044e74bbcefba8f0616310_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib784ac7bf6464a7d884b4167b4e99ee0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4ac90e5d89444162acf3bc0b9b6480fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia5f4d39a9f964e3f99fac70fd3f35100_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyMetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6ce4b41fbdca463599bc3cef217fef45_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i79709122c16343dcbc74ae3a46e989b4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i088931a8204941488973e380b4de1025_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b3229ad3f5f439fa27e10965c78eea1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i727f5a67038e4448b546d9073616f76a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77529a8905b14bc3bc8add865edf0f75_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">lgnd:LiabilityForContingentValueRightsCompanyCrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i62d2f834fa2244ceac78756b0afb44a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c826c5ec76f4cfabdff851267a7e696_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92d6816bd05c485785171f05859f970c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0feee4e225cd43f6b19d270f81f68e54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice1e4b995b8f493ca3f05d0880c4ed18_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i9174105094b344fdaf382f6d88a00492_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="ia69c2295fad14d86b0c1d0d33d08fd9d_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i41c98ddc8ed6424e97637ef827414c85_D20181231-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ic8bcea58a1cc45ad91cd2cfd6e88fb72_D20181001-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i42d47e48e8714a4a85ce5692e87edc2a_D20190815-20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-15</startDate>
            <endDate>2019-08-15</endDate>
        </period>
    </context>
    <context id="i183d237079bf442793fe6653077b02d1_I20190815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-15</instant>
        </period>
    </context>
    <context id="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i018f28bd405f4e8e80369ec4e6ebaf93_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad13e0c01d0342d4a22d93e03d73bdec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if15033c4ceb44752bec11bcc6b5a4535_D20140801-20140831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="ia44b7731c223433ebd2d48a7da02b9fd_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i677af219811f4afea5707d272137352f_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i4087e5834f3f43f7b9dcd9f3bc7ad89f_D20180522-20180619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-06-19</endDate>
        </period>
    </context>
    <context id="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95d01d0ac3874584a772c93ae9343d59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad33a1fd7a4d4bb4b58891b708e03689_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic695d6dc03fe4a25b48518725b03cc3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c0a208cee4646039870279eaed26fbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id951cc41dcda47b79a7837e8a9cac151_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i777f42855f6b42b5815a6e77f13da34f_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotes2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ib9cf631831404b3ab0a176b30ff1cf61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4adf86c26c74eebbff052e6408a24bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0997e7cf40f4560bfc2d3b81a693374_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i159e354578674c4980944fd7e84d264b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b0f02512c784ca8a96f7587ae1fa695_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i512fa91ade644f0f8d1e64336cafc646_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb0f673df80c43e6ae301f9b370879d9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i187f37e52b0046fbbddd2f4c14993bbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i19269a85c84b42aab38f5fac2f97aa03_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia19b9a02facb489a95e3193c4f7ac238_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie4e8496488c64c268cd3de6924f039d0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6e41a03cf4b245ecae999cdd0f89c769_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6737d944593c47919db533223783d735_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id8397721ad934a4fb6b8e4182e177246_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3da08223a8214656b754f9367925b52a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9d5e8e38535841d0a6ebe69742fcb55b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cff8def88d547cca5ed63725081c9f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic92c2bb9b787480489b39a01bb366f35_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if268533fff3b4793a31072861a742a93_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44726d215cc14202aa7482a959d9f789_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i29175925b83b4f7db955ba48c6e95710_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4900b9ff94548d4902c449b76d44e10_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia139119e13424a1bbb83b3bd29c3eb9f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e84a7b813d74048b025e392263824ce_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60511aae828945a397611be17e7b185e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib238a21ed8404ddeba140fd318f30bb2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i82abd5a9777940b08fc61c5d462259e1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie1979f3d940c419ea3a725a37ea9e014_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33ebdb404a3245379c9d5860ed4ac8ba_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i391b93678af74f27899b8002cc987285_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3a6da7b97a744bc9c0497857d795d5f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CrystalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i84123edc447641828fe3e7279992698e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia262ce3b54954a979aceac7f234989a3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i36c58245200747a5b667564d502af59e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i164955ed1d7f4491869eb2cbafa3cc29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e964f748c5942548018f2246cc35730_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id1c406d933204c55979cce5e2f3e220b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8f9c362671564a50b0f69033777e2901_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifaf7c83e118d4acf95a3663f3661d169_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14280bd3deb24f1abb91beb0987cdc1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i863a470ced3a418db7a073687288d252_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i03b1c1acedea452c8463bc86fcb2b913_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d741a769aee4da4af5556260a102804_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53406fa840174f8093916463e6389023_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5af0404808a345a382abe78ab35beb37_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7da0cebd72844cccbc3578ab39bffc76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12002ca5921748508b192203c7a9d235_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i903cd103982640959896b8b7ba2c6e13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd44dfbec8d944479851c647f8b7ccdc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice16507fcb4e413ea981ad6098db588e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2831464859c14cdc9755d96fcee5dab1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4872587a0b7b4d018481b6594f32290f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i06c0ce63eae94a5eb3fcba29f768110d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i6341c256477e4429836844da17a32b5e_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="icf64fbf8a55e465ba26faa70a391914c_I20190123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-01-23</instant>
        </period>
    </context>
    <context id="i1ea985b507f54962867ac2d46fb5c542_I20190911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2019-09-11</instant>
        </period>
    </context>
    <context id="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i70b9c37a13cc461ab7f396a30c812ca3_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i2b493974b1c542688ad91b9e471e0124_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb372575aafc4ed3b9445394ffcccb29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1894d5ffb9e46e1bd0855a3f66e9ffa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b4fae611a5c4181ac378c7ecc937744_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife0bb7031f9647efa3364ba02afec1e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia54d651574f64756a24c8e91f44996a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i666408c546004c06983d164938ebb335_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i385d806689a94eb697a22d2f0a119715_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i29f487b559ca433687df3df3c64d6816_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lgnd:right</measure>
    </unit>
    <unit id="acquisition">
        <measure>lgnd:acquisition</measure>
    </unit>
    <unit id="numberofcollaborationagreements">
        <measure>lgnd:numberOfCollaborationAgreements</measure>
    </unit>
    <unit id="trading_day">
        <measure>lgnd:trading_day</measure>
    </unit>
    <unit id="day">
        <measure>lgnd:day</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF80LTEtMS0xLTA_80f7abce-4229-4266-8477-0012788a5ca7">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF81LTEtMS0xLTA_27660fbe-2d05-47b5-b738-3a84b196e735">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGFibGU6Y2ZkZDQ4OWQ1ZDgyNDE2NGFhNjI5ZjVhNGNkZjgwMTAvdGFibGVyYW5nZTpjZmRkNDg5ZDVkODI0MTY0YWE2MjlmNWE0Y2RmODAxMF82LTEtMS0xLTA_928ab552-700f-4271-9d69-2bf45cdf315b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGV4dHJlZ2lvbjo4ZDQ1MTMwNDE3Mjk0NTBlYWRlOGM5YTg2NmRiN2FlYl82Mg_205d6a5d-3baf-435e-87f4-d731ac93a7a3">0000886163</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M180L2ZyYWc6OGQ0NTEzMDQxNzI5NDUwZWFkZThjOWE4NjZkYjdhZWIvdGV4dHJlZ2lvbjo4ZDQ1MTMwNDE3Mjk0NTBlYWRlOGM5YTg2NmRiN2FlYl82Mw_ecfa12b1-07b8-42a9-a5eb-ca2d0d60736e">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RhYmxlOjg3OWE5NTMxNGJhYzQzZDg5OGFmYTUzZDAxNThjNDAzL3RhYmxlcmFuZ2U6ODc5YTk1MzE0YmFjNDNkODk4YWZhNTNkMDE1OGM0MDNfMS0xLTEtMS0w_70a6c102-ebf9-49bc-a760-f68b6a814ad8"
      unitRef="number">0.1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RhYmxlOjg3OWE5NTMxNGJhYzQzZDg5OGFmYTUzZDAxNThjNDAzL3RhYmxlcmFuZ2U6ODc5YTk1MzE0YmFjNDNkODk4YWZhNTNkMDE1OGM0MDNfMi0xLTEtMS0w_2f93776e-d45b-4136-8a42-a1eabc2ea123"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2Mg_d4d29f6d-132f-4dc2-b098-95f72fab738d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE1OQ_d031b37f-7abd-4e75-9dbc-e2609faa8890">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6dab41fdf68142f6b945f9ea4789f513_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2Mw_9a207cf4-1833-4ab3-be76-ab0fc99f1b93">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ieb9557158cef4e81999208f6dd2dead8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184OC9mcmFnOmMzMDE2MjM3OGJiZjQ2YzJiOTA1YjRjOWEwM2RkOTBiL3RleHRyZWdpb246YzMwMTYyMzc4YmJmNDZjMmI5MDViNGM5YTAzZGQ5MGJfMTE2NA_8520ed79-2606-452f-a2a5-cecf6fcdf469">P42M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lgnd:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODE_ffef5594-a0f1-449a-ba9a-61a27ea72532">P7Y</lgnd:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ice1e4b995b8f493ca3f05d0880c4ed18_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODc_303e6841-ce99-40a8-b295-685264827d3d">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDYvZnJhZzplOGUzZjQ4MWRjMjY0NjQyOWZlNDcyOGIxMzFkZGNkZS90YWJsZTo4OTI1ZjQwODE3MWY0ZTdjOGNlNTJkYzY5YWEyMjEzNy90YWJsZXJhbmdlOjg5MjVmNDA4MTcxZjRlN2M4Y2U1MmRjNjlhYTIyMTM3XzItMS0xLTEtMA_5d8e2a5b-c485-4948-b8ea-a6a62c1f058e"
      unitRef="number">0.0133251</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i777f42855f6b42b5815a6e77f13da34f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDYvZnJhZzplOGUzZjQ4MWRjMjY0NjQyOWZlNDcyOGIxMzFkZGNkZS90YWJsZTo4OTI1ZjQwODE3MWY0ZTdjOGNlNTJkYzY5YWEyMjEzNy90YWJsZXJhbmdlOjg5MjVmNDA4MTcxZjRlN2M4Y2U1MmRjNjlhYTIyMTM3XzItMi0xLTEtMA_27bc89bd-ac27-4de5-8000-b947ff154de5"
      unitRef="number">0.0040244</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTIvZnJhZzo4YzU4ODIyOTcwMDg0NDliYjM5MTE1ZWY0MjJmMGVhOS90ZXh0cmVnaW9uOjhjNTg4MjI5NzAwODQ0OWJiMzkxMTVlZjQyMmYwZWE5XzE2NA_644d97ae-6fb7-4538-8240-8aea62cbe311">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTIvZnJhZzo4YzU4ODIyOTcwMDg0NDliYjM5MTE1ZWY0MjJmMGVhOS90ZXh0cmVnaW9uOjhjNTg4MjI5NzAwODQ0OWJiMzkxMTVlZjQyMmYwZWE5XzE2NQ_4e027a84-6ba7-4386-9829-ab30502f40c3">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMS0xLTEtMA_97c79f67-2c96-48f5-9338-a9519f29e4f2"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMi0xLTEtMA_dda99e59-baaa-467c-bfc7-dd31d72e85dd"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzMtMy0xLTEtMA_0fe598a4-0685-462d-98ea-8b581dde66db"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMS0xLTEtMA_79ea4123-c66a-49ec-8477-7471e848465e"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMi0xLTEtMA_23cbd5ab-407a-49f4-8a23-119aadd7f53f"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzQtMy0xLTEtMA_f0a3c5ef-302b-4310-97bf-dcdbc32f2600"
      unitRef="number">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMS0xLTEtMA_e557bb29-b244-45c9-808b-b7bfb3013224"
      unitRef="number">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMi0xLTEtMA_4c8f23ab-a4e4-4730-8035-6430bc20ca9c"
      unitRef="number">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzUtMy0xLTEtMA_2e94d433-9b01-4390-ba82-b61d051a93e7"
      unitRef="number">0.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMS0xLTEtMA_d4486ce7-eb12-4166-8c8d-54bf975c8284"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMi0xLTEtMA_f2f97fac-e32b-45f1-972a-efd83d8f0c18"
      unitRef="number">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzYtMy0xLTEtMA_44f66bf9-e1de-4890-897c-04349e6762d2"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i311860ef9ff344fcb1814625650f0c87_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMS0xLTEtMA_86adeddc-2fa6-4ccc-bc4c-fda6ef4b6b85">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iefa85f732d7040c3b5973ec23e1e8a9e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMi0xLTEtMA_bf3f8564-54d1-4d19-bdd7-0781cf0092c7">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0f947a18f7ff4077800a5f7aec88e692_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzgtMy0xLTEtMA_b8923c77-13a3-4559-8d4a-0a979a5f4186">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7da00701f3a4493d914b7d09b174ff63_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMS0xLTEtMA_0ff933bf-3b43-4e6d-9db7-e351c92def90">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie0b8fd7c9dc04f4f857f2fb5b65c9653_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMi0xLTEtMA_4c1c7006-f4cd-4dae-86a9-42102f515d82">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3cab4b715bc84c9db16be5c9aecffb5e_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTpiMWJlMTBmYmI2MjQ0NGUwOWU2M2RmNWI3YjllNDA5Mi90YWJsZXJhbmdlOmIxYmUxMGZiYjYyNDQ0ZTA5ZTYzZGY1YjdiOWU0MDkyXzktMy0xLTEtMA_f9b1acc6-ea70-4d58-a72b-e87da2d9989f">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEtMi0xLTEtMA_a69d3950-4678-49a5-afc7-7d6ffcfc138a"
      unitRef="usdPerShare">9.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEtNC0xLTEtMA_1ba2a1d4-a704-4c9b-b0a1-d7520338360d"
      unitRef="usdPerShare">12.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzItMi0xLTEtMA_70da67f6-a8b2-45a8-b765-c9482475e765"
      unitRef="usdPerShare">14.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzItNC0xLTEtMA_17dff686-47c7-4ca0-bb41-963e0e6b4d41"
      unitRef="usdPerShare">14.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzMtMi0xLTEtMA_9314ada2-f9d7-48d8-91b3-a18d2de38c39"
      unitRef="usdPerShare">21.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzMtNC0xLTEtMA_60f31d11-50c0-420d-ac3a-dbdcc2291ae3"
      unitRef="usdPerShare">21.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzQtMi0xLTEtMA_35d9b861-7e8b-4586-b032-b03f737db72d"
      unitRef="usdPerShare">32</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzQtNC0xLTEtMA_f9333f4f-1ef1-46dd-8567-b9069fe22fad"
      unitRef="usdPerShare">74.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzUtMi0xLTEtMA_76fbb955-f8dd-426b-968a-39a94e3fa436"
      unitRef="usdPerShare">85.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzUtNC0xLTEtMA_e76a4347-5fc2-4003-b35c-c1101e3510a8"
      unitRef="usdPerShare">100.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzYtMi0xLTEtMA_e2b9f087-c40f-4d33-b770-d21bb80fae31"
      unitRef="usdPerShare">101.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzYtNC0xLTEtMA_a6538900-b19d-4dad-9c35-7b3ca41d198f"
      unitRef="usdPerShare">113.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzctMi0xLTEtMA_034e3464-c00b-4600-9986-7a3a9adf2f21"
      unitRef="usdPerShare">117.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzctNC0xLTEtMA_455b5bb9-43e2-447a-886f-e4eac0665eab"
      unitRef="usdPerShare">117.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzgtMi0xLTEtMA_26f000ed-29a7-4a47-b7ee-dfb41fa15c5a"
      unitRef="usdPerShare">119.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzgtNC0xLTEtMA_cb52f911-3126-4e4d-8d20-9f308d413448"
      unitRef="usdPerShare">159.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzktMi0xLTEtMA_0cccab06-1761-4efd-a130-cfc123d79009"
      unitRef="usdPerShare">159.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzktNC0xLTEtMA_aa2bb725-b775-417d-8d55-be78f1c1aaf6"
      unitRef="usdPerShare">171.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEwLTItMS0xLTA_b66d27aa-6cbc-4596-a416-a3f31142e382"
      unitRef="usdPerShare">195.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzEwLTQtMS0xLTA_ceb54b8a-3538-4551-b83c-0fcad7f27df6"
      unitRef="usdPerShare">195.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzExLTItMS0xLTA_7e33c279-2f1b-471e-8cb9-07e0978f667d"
      unitRef="usdPerShare">9.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90YWJsZTo1OTU1OTYxZDJhYzE0ODc2YTg2ZTJmZjA0MTAwNWJkZS90YWJsZXJhbmdlOjU5NTU5NjFkMmFjMTQ4NzZhODZlMmZmMDQxMDA1YmRlXzExLTQtMS0xLTA_ba40b462-5777-4e85-8499-c4d741b52ef2"
      unitRef="usdPerShare">195.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i70b9c37a13cc461ab7f396a30c812ca3_D20150901-20150930"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTgvZnJhZzpjYjM5ZmQ1NTU2OTc0NTI3YWRhZjJmMzIwNGE0MjE4MC90ZXh0cmVnaW9uOmNiMzlmZDU1NTY5NzQ1MjdhZGFmMmYzMjA0YTQyMTgwXzI4Mw_dd5ee4fc-162e-4f0d-a9ec-912163fc61d9">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <dei:DocumentType
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN180MDI5_c764b2ad-e141-406b-b7bb-530e3678bc91">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6Njc3NGM1ZTYwMjdlNDU4MTlkZmM1NDQwNzQ0ZTliMGYvdGFibGVyYW5nZTo2Nzc0YzVlNjAyN2U0NTgxOWRmYzU0NDA3NDRlOWIwZl8wLTAtMS0xLTEzOTI_2f4d10f2-e374-4317-a7fe-0d6bd22b8495">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTkx_39c3d824-15f0-4a4b-98d9-011a1bdfd3cc">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6YWIzNjFhMDQ3MzE4NDgyYWJlYThmNmJkNTcwZGIxNmEvdGFibGVyYW5nZTphYjM2MWEwNDczMTg0ODJhYmVhOGY2YmQ1NzBkYjE2YV8wLTAtMS0xLTEzOTQ_b00f124e-c1c2-4c8d-a87b-3a81dbd5840c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDc1_63b4de35-33e7-4797-b5ef-4dc43c547dfe">001-33093</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNjA5_e96d2723-cd6b-480b-9bfe-a958218d7474">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18wLTAtMS0xLTEzMDU_94f05c65-4def-4acb-9a0e-47a008625cee">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18wLTItMS0xLTEzMDc_7ac4db62-c1b8-4f76-bdfb-de2aa4e84ce5">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM18zLTAtMS0xLTEzMTE_5ce208c9-2d6b-4650-9359-118ed268900d">3911 Sorrento Valley Boulevard, Suite 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM180LTAtMS0xLTE1MzE_7ddd9392-5a18-4e3c-be66-a2357fed538d">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM181LTAtMS0xLTE1MzM_2a4e401a-6dd1-4824-9e58-3042a99320ed">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NTAwZDVhZTBhM2NjNDQ5MWFhOTZmMjEzMDRhOWQyMjMvdGFibGVyYW5nZTo1MDBkNWFlMGEzY2M0NDkxYWE5NmYyMTMwNGE5ZDIyM181LTItMS0xLTE1MzU_32a4b4ef-f39b-4c92-989d-fcce922ec729">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDcz_a413bd51-1a1d-4cc4-b09e-763091392b3f">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNDc0_a7ad22c8-a45e-479b-a97a-845ec5dae946">550-7500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTAtMS0xLTEzNzY_83119400-2933-40ac-be17-f44eb95e4b77">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTEtMS0xLTE1NDA_bd9fb10c-ba3d-4876-8f39-533a3d3a9f9f">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6MTAwMzEwMDQ5YTBkNDI0MmI5ODgxN2Y4MjA1MGY2ZDcvdGFibGVyYW5nZToxMDAzMTAwNDlhMGQ0MjQyYjk4ODE3ZjgyMDUwZjZkN18xLTEtMS0xLTEzNzg_fbc153d4-c07a-477f-8b22-324248c7d52a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY3_5e4b2d14-d18a-4b5c-9109-15c8738149b6">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY2_760a4dbf-a09a-4a82-97de-9a8356d7a734">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY4_867edb9e-a719-4783-b308-ed809b96a193">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTY5_aa6b7d2a-84fd-4f26-8ab0-d7cbbab3a5cb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTAtMS0xLTEzNzA_1f799722-0f93-4cfb-9828-b9379becb7be">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTUtMS0xLTEzNzQ_dfbf836e-904c-4532-843a-3b43d277f402">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGFibGU6NzEyMmZlNTQ1MzgxNGU1Mjg5NTg4MzQxOWRiYjgyZTYvdGFibGVyYW5nZTo3MTIyZmU1NDUzODE0ZTUyODk1ODgzNDE5ZGJiODJlNl8wLTEwLTEtMS0xNTQy_2ff3f3b5-1dfe-4674-94df-e95b19220d55">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yNzQ4Nzc5MDczNTU1_ce9b42dc-6955-4c78-8a7e-d217ccd2a8a5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i3db79f26c0544fc6a26a782c03095534_I20190628"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18yODkw_a127d378-b307-475d-8eea-1c330af2ff81"
      unitRef="usd">1800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i52984fc7f6524de3bd553513b238634b_I20200221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xL2ZyYWc6ZDJhNjg2MTk2NmEyNDcwYTlhOGUzYTk2ZThlYzQ1ZDcvdGV4dHJlZ2lvbjpkMmE2ODYxOTY2YTI0NzBhOWE4ZTNhOTZlOGVjNDVkN18zNTAz_394aba13-c713-454d-b440-d50ad98481d1"
      unitRef="shares">16505197</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNC0xLTEtMS0w_131bf674-19dd-412b-9c47-a46e283c3903"
      unitRef="usd">71543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNC0zLTEtMS0w_200d757f-7fd3-4998-99c3-9e86ba1a2598"
      unitRef="usd">117164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNS0xLTEtMS0w_47c57ddf-beb4-41fc-b09e-f53f4e12dcaa"
      unitRef="usd">939989000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNS0zLTEtMS0w_5f5e4a9e-4126-44c1-99b8-d0f37141a49e"
      unitRef="usd">601217000</us-gaap:ShortTermInvestments>
    <lgnd:InvestmentInVikingCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNi0xLTEtMS0w_f483fadd-00ff-490e-8c44-2cf18b2e2759"
      unitRef="usd">58335000</lgnd:InvestmentInVikingCurrent>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNi0zLTEtMS0w_71e93bcf-34d3-47db-9c9f-349c9c604648"
      unitRef="usd">55448000</lgnd:InvestmentInVikingCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNy0xLTEtMS0w_32c34022-b63f-46b2-8b34-aa1caa6437fe"
      unitRef="usd">30387000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNy0zLTEtMS0w_b24b2fa0-b21e-499c-8882-c1f05930fa1a"
      unitRef="usd">55850000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfOS0xLTEtMS0w_22d94322-902d-48a6-a4ac-6f67e365019e"
      unitRef="usd">7296000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfOS0zLTEtMS0w_0810913d-1b06-4e78-9bc6-437c4f7b90ed"
      unitRef="usd">7124000</us-gaap:InventoryNet>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMS0xLTEtMA_fe7d3ade-e38b-44c0-ad26-554cfd17ccb0"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtMA_9f63d875-5a45-469f-992f-74cca1d37bb0"
      unitRef="usd">22576000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtMA_a960a01f-66e5-4a26-8dd6-4c0b5ebc4526"
      unitRef="usd">22576000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMS0xLTEtNTg1OA_e0cb32e6-2b82-45bc-80fd-eb8d131cfc4d"
      unitRef="usd">11361000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTAtMy0xLTEtNTg2MA_28c6c9b2-54a8-4b27-91d1-376bb441d959"
      unitRef="usd">142000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTEtMS0xLTEtMA_122b8462-e775-42f8-8a6f-d3eb6d2f60c4"
      unitRef="usd">4734000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTEtMy0xLTEtMA_18b93eaf-8c3b-4166-8b04-d9b90847d6a5"
      unitRef="usd">11019000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTItMS0xLTEtMA_0256d628-a7df-4823-8711-8a6ddf3ea57c"
      unitRef="usd">1123645000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTItMy0xLTEtMA_5be84c9b-a9bb-44ab-9ecb-60658cff8846"
      unitRef="usd">870540000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTMtMS0xLTEtMA_b347a2b8-9426-4fc4-9514-1d4be5433031"
      unitRef="usd">25608000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTMtMy0xLTEtMA_52455c76-7206-476f-8a5e-bfed1a0c2f43"
      unitRef="usd">46521000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTUtMS0xLTEtMA_93bdb691-98c4-4c66-9b7c-2a66149c65e1"
      unitRef="usd">210448000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTUtMy0xLTEtMA_c8c67a94-8e3d-4385-a3c5-d8147ef1fb33"
      unitRef="usd">219793000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTYtMS0xLTEtMA_6dd22ffd-c61a-4533-8ca5-e0c90d4c0af6"
      unitRef="usd">95229000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTYtMy0xLTEtMA_c72e84dd-6df9-48ce-a251-03dbb24bd6eb"
      unitRef="usd">86646000</us-gaap:Goodwill>
    <lgnd:CommercialLicenseRights
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTctMS0xLTEtMA_bce703a8-957c-4d30-a007-816af34dfe27"
      unitRef="usd">20090000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRights
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTctMy0xLTEtMA_e2467a61-6fd0-490d-877a-09fb31a30378"
      unitRef="usd">31460000</lgnd:CommercialLicenseRights>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMS0xLTEtMA_e1edbb94-1bdd-4b55-8040-3552cdc81d11"
      unitRef="usd">7185000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMy0xLTEtMA_997d1782-4e8d-41fd-895a-66e7956ff631"
      unitRef="usd">5372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMS0xLTEtNTg2NA_51823956-d533-4557-adfe-c09b3ed917fb"
      unitRef="usd">10353000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTgtMy0xLTEtNTg2Ng_91d24c8e-e866-4a0b-ad45-c1f1de2a8880"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTktMS0xLTEtMA_0f53ec6a-3752-4c54-ab20-eee0c79d683b"
      unitRef="usd">2357000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMTktMy0xLTEtMA_1b184c16-5a3b-4780-b168-af0cc5cf3f07"
      unitRef="usd">471000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjAtMS0xLTEtMA_23fe458c-152f-4a75-9971-d885d8065ead"
      unitRef="usd">1494915000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjAtMy0xLTEtMA_295e1812-8fb4-4981-aa64-d173461e9993"
      unitRef="usd">1260803000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjMtMS0xLTEtMA_201975a5-0f7d-4fd9-9f4d-40dcfbf1c5b2"
      unitRef="usd">2420000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjMtMy0xLTEtMA_cfb8512e-e51b-4f0c-a77a-16b5361277ef"
      unitRef="usd">4183000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjQtMS0xLTEtMA_1f8b6582-2ae3-420c-bc21-b8cd51e6def3"
      unitRef="usd">9836000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjQtMy0xLTEtMA_f3aea7aa-afee-4d47-946b-60727e6d2552"
      unitRef="usd">19200000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjUtMS0xLTEtMA_7d0a81c6-27ef-4097-91f2-e9d6cef19bff"
      unitRef="usd">2607000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjUtMy0xLTEtMA_33aca06a-94e1-4c7f-9258-dc4f7ee8e665"
      unitRef="usd">5717000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjYtMS0xLTEtMA_7492c6d7-9dc3-4d59-adef-658be914321f"
      unitRef="usd">2139000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjYtMy0xLTEtMA_9c4785a9-8c74-443b-af11-ee199647becb"
      unitRef="usd">3286000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjctMS0xLTEtMA_489693f0-10dd-44b3-b66b-320a1af49139"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjctMy0xLTEtMA_96274a68-ed5a-44b9-9a0f-6f4367eabe08"
      unitRef="usd">23430000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjgtMS0xLTEtMA_11fd20f8-dfd3-43e5-baa4-cde62bd7005b"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjgtMy0xLTEtMA_fd636643-8a1d-47c0-bf3f-fd0f57837308"
      unitRef="usd">26433000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjktMS0xLTEtMA_48531a17-c40f-49e8-8fe6-c112db3303a8"
      unitRef="usd">17002000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMjktMy0xLTEtMA_5a0cda33-f33b-4339-b0f9-7b034a52a64f"
      unitRef="usd">82249000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzAtMS0xLTEtMA_603fdbdf-faf7-4a9c-b9c3-b6718ecc8dda"
      unitRef="usd">638959000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzAtMy0xLTEtMA_ef2eaeda-6b32-420a-9e4a-44eee47e64a8"
      unitRef="usd">609864000</us-gaap:ConvertibleDebtNoncurrent>
    <lgnd:LiabilityForContingentValueRights
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzEtMS0xLTEtMA_b07867e8-a13f-4ed7-835d-b707c4b1e635"
      unitRef="usd">6335000</lgnd:LiabilityForContingentValueRights>
    <lgnd:LiabilityForContingentValueRights
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzEtMy0xLTEtMA_148a6d69-46f0-4924-a0b3-deb55b7d91bc"
      unitRef="usd">6825000</lgnd:LiabilityForContingentValueRights>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMS0xLTEtNTg3MA_31d17ab6-615c-413d-a831-eca315d3bd01"
      unitRef="usd">32937000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMy0xLTEtNTg3Mg_06daa613-716f-4108-9ddb-32c4a05e61dc"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMS0xLTEtNTg3OQ_cf10e05a-bf0d-4312-a55b-0fc904e4b0bd"
      unitRef="usd">9970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMy0xLTEtNTg4MQ_3d5355e6-a374-4a32-92cd-0ff51d21510c"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMS0xLTEtMA_e85d37f8-8f5d-42ed-93f5-89254d108e3c"
      unitRef="usd">22480000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzItMy0xLTEtMA_2792db1a-3ac6-4cc3-bba5-2c13ed0d748a"
      unitRef="usd">951000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMS0xLTEtMA_993726c4-d3c0-4d23-969c-dc84a06b2bb0"
      unitRef="usd">727683000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzMtMy0xLTEtMA_7c5533bc-c830-4275-958f-20a57c11fc73"
      unitRef="usd">699889000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzQtMS0xLTEtMA_39b92e8d-f33a-48d1-bf2f-836d7b8a3b8d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzQtMy0xLTEtMA_506dd6af-4b41-4900-b3d1-8b420c6550ba"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTA4_0f0bb658-1c9d-4f16-9d8d-64ea70afa836"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTA4_1f8c2af1-0e75-4f32-a32a-dd2963db6886"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTE3_c4021d57-bc45-42c8-bd26-a5c994d23282"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTE3_f6e33ac3-545f-4bf1-a90b-dba7ba67f886"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_00654d4c-25a7-49ae-ba7f-7b1e92a65b41"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_1f776f9b-761f-45cc-99ba-94cb7132bc77"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_7ec69f95-86e0-42de-9a18-3520fba9b573"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMC0xLTEtMTA0NDkvdGV4dHJlZ2lvbjo0YjU0NWIyZjEwN2Q0MmMyOGMwOGU3MmU0ZTA0OTY2N18xMDk5NTExNjI3OTM0_d5c882c0-f992-45c6-b748-fd241346753c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMS0xLTEtMTAwOTM_fe9ff155-634a-42ee-a82f-b35d9cc5a081"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMy0xLTEtMTAwOTY_0bd94bf5-8e13-41f2-aad7-65f15c9e03b8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMjA_288272f9-f775-4694-a0d6-47a5fbe87d35"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMjA_5d49be42-1df1-4917-a9e5-23f56246fe99"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMzQ_4e213de1-cc19-4c2e-843b-8679deae2d77"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwMzQ_c21ebeb7-b9fb-43c8-8053-8750d6455f45"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNDg_469bbcde-4b91-4854-a552-5b81904b1301"
      unitRef="shares">16823000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNDg_a3777c8c-971c-4cc7-866c-36965c027f79"
      unitRef="shares">16823000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNjI_8a1bc324-4331-4ff2-adcd-ed4f526abf70"
      unitRef="shares">20766000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjI1YzE2ZWI2NGQzYzQ1OTc4MjViMjE1MzZlYjljYTI3XzEwOTk1MTE2MjgwNjI_8ccbe489-f883-4d6a-b3f6-f32d47f508cd"
      unitRef="shares">20766000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMS0xLTEtMA_96671af5-f7b3-49c0-accb-46bcdb191975"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzctMy0xLTEtMA_3ef199d1-8609-43d6-9fbd-33a0516b172f"
      unitRef="usd">21000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMS0xLTEtMA_7028e871-0556-42a7-8201-1208b8d6e6c8"
      unitRef="usd">367326000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzgtMy0xLTEtMA_05ba4ed7-85e7-4669-8517-d24a8a6ae1cf"
      unitRef="usd">791114000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzktMS0xLTEtMA_ac9e07b9-3988-4669-bc09-b8ea9a559381"
      unitRef="usd">-216000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfMzktMy0xLTEtMA_47d34871-c31e-4956-9275-b20dd582b870"
      unitRef="usd">-1024000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDAtMS0xLTEtMA_a0db480c-04a2-4140-befc-67f7be0712b2"
      unitRef="usd">400105000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDAtMy0xLTEtMA_8301ff43-557e-4525-afae-a6f35d8968c9"
      unitRef="usd">-229197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDEtMS0xLTEtMA_1006ea54-db41-4550-a73c-593a35c84f17"
      unitRef="usd">767232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDEtMy0xLTEtMA_15ad1e2d-a35b-470d-930f-25136976ed59"
      unitRef="usd">560914000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDQtMS0xLTEtMA_e41e159f-8a3e-4bbf-9e01-4a25de22b441"
      unitRef="usd">1494915000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M182NC9mcmFnOjQxMzg5MjdiNjMyYzQxMzhhZDE1YmRmOTgxOGUwYjJkL3RhYmxlOjVhNzhjNDYwMTYzNzQxYjZhYTU0NDliZDlhYmVlN2NjL3RhYmxlcmFuZ2U6NWE3OGM0NjAxNjM3NDFiNmFhNTQ0OWJkOWFiZWU3Y2NfNDQtMy0xLTEtMA_8e74848a-8150-495f-af12-9c58704af5df"
      unitRef="usd">1260803000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy0xLTEtMS0w_ea762e07-d4fe-40aa-85e0-7eb1bb4499b9"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy0zLTEtMS0w_1a45c5eb-def8-4506-ae1c-c16199b7ec6d"
      unitRef="usd">128556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMy01LTEtMS0w_63168171-c9a5-4923-85ce-fc3c571a109e"
      unitRef="usd">88685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC0xLTEtMS0w_bd7cf525-f58b-4120-a3b7-1f7ed8dd79c1"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i675b454e2a4246a5976716630c08343b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC0zLTEtMS0w_3cfbbba8-0794-4533-ac6f-5b041d5b0562"
      unitRef="usd">29123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNC01LTEtMS0w_d38a3785-1468-4e6f-95c3-bf94c04dfcfb"
      unitRef="usd">22070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS0xLTEtMS0w_c98f41a7-3eeb-4ab3-8d93-f9787a365d18"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS0zLTEtMS0w_ace98bdd-86cb-4bc8-9b06-0c608f91c4b9"
      unitRef="usd">93774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNS01LTEtMS0w_3ebf739a-9dde-4429-8f3c-8768ac71abc3"
      unitRef="usd">30347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi0xLTEtMS0w_23f06a75-f48c-44be-a7bf-a55dd1ccde12"
      unitRef="usd">120282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi0zLTEtMS0w_c1604332-e585-41f9-b4b2-ee547763121f"
      unitRef="usd">251453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNi01LTEtMS0w_7af7dff3-4891-4aaf-9ff8-20fbd918292a"
      unitRef="usd">141102000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostDirectMaterial
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC0xLTEtMS0w_b5e90310-a196-436a-97e8-999e4975e495"
      unitRef="usd">11347000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC0zLTEtMS0w_615c8b64-5b8b-442c-847d-292ad1d44f7e"
      unitRef="usd">6337000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOC01LTEtMS0w_47abc8c7-f646-4e04-9336-aa2dbfc0b6d6"
      unitRef="usd">5366000</us-gaap:CostDirectMaterial>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS0xLTEtMS0w_0981528c-90aa-4615-a35a-1bbf470f7844"
      unitRef="usd">16864000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS0zLTEtMS0w_14c2620c-4cfd-43dd-b23f-81d7ae98a097"
      unitRef="usd">15792000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfOS01LTEtMS0w_c5add2f1-f7c4-48bf-9ba0-ec159f0555b8"
      unitRef="usd">12120000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtMS0xLTEtMA_13dc3985-0eb5-45f4-980d-3abc2fda516f"
      unitRef="usd">55908000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtMy0xLTEtMA_7c1b6d04-041f-41bd-b7cf-082da34c2d6e"
      unitRef="usd">27863000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTAtNS0xLTEtMA_92b599af-848c-4991-9f90-3b9ce66e2d02"
      unitRef="usd">26887000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtMS0xLTEtMA_187e632f-b98d-4fbd-9c28-a0be11f6fba5"
      unitRef="usd">41884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtMy0xLTEtMA_02b82b1d-9782-4b20-93fd-d4f397901139"
      unitRef="usd">37734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTEtNS0xLTEtMA_784b6dcf-db56-43ad-84ed-c20b081f1257"
      unitRef="usd">28653000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItMS0xLTEtMA_6fee3b66-502d-4c45-97ab-57d28fb1d810"
      unitRef="usd">126003000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItMy0xLTEtMA_74a4a4c6-e68b-4c91-a4a2-b5ec87a6c2c5"
      unitRef="usd">87726000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTItNS0xLTEtMA_2006fa4c-46ba-465b-b2cb-c548d6255b8e"
      unitRef="usd">73026000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMS0xLTEtNDE4_a7bc024a-7ef8-42de-a4dc-50227c909f9f"
      unitRef="usd">812797000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMy0xLTEtMTA0NTU_03dd2c2a-14f7-4167-8fbc-731034916e08"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtNS0xLTEtMTA1MTI_2d46821c-a2e9-462c-a5da-a0c3fc939d43"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMS0xLTEtMA_d0a4266d-278b-40bf-acfb-13a05aadd40f"
      unitRef="usd">807076000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtMy0xLTEtMA_8c86536f-e779-4609-8fa8-43f5b275d107"
      unitRef="usd">163727000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTMtNS0xLTEtMA_ff64ca7b-518f-47fa-9d26-902f8c24d225"
      unitRef="usd">68076000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtMS0xLTEtMA_55128711-5661-495b-afad-13e57eb13899"
      unitRef="usd">2888000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtMy0xLTEtMA_5e24eaac-d352-45ec-a01e-699397c336fb"
      unitRef="usd">50187000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTUtNS0xLTEtMA_74377f4d-9ebd-4b9d-abdd-c00de8653a23"
      unitRef="usd">-2048000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtMS0xLTEtMA_05c8e7b4-419c-46ed-8af1-637cb3793180"
      unitRef="usd">28430000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtMy0xLTEtMA_fe26a59d-1e83-45d0-bfb2-1728dd3a327c"
      unitRef="usd">13999000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTYtNS0xLTEtMA_f64ed375-2179-4da0-aeba-0cc2aae81181"
      unitRef="usd">2060000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctMS0xLTEtMA_b33f6d0d-4072-4a59-9275-f86a6d9f02bc"
      unitRef="usd">35745000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctMy0xLTEtMA_2c311601-00be-4e00-8cf9-d2b866516aa9"
      unitRef="usd">48276000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTctNS0xLTEtMA_856519b5-20eb-49ea-a7a2-959ed3f48446"
      unitRef="usd">13460000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtMS0xLTEtMA_d1a7dd50-72f1-45fc-95b1-a438dea2a7ef"
      unitRef="usd">-6010000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtMy0xLTEtMA_e98ddeb2-0c61-4832-80b0-654f38e01c68"
      unitRef="usd">-6307000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTgtNS0xLTEtMA_1d36995b-6d4a-4a89-815f-4642a2836d33"
      unitRef="usd">2603000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktMS0xLTEtMA_ffcbe99f-ee38-4d46-a3a4-ab94e65a48b1"
      unitRef="usd">-10437000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktMy0xLTEtMA_4e14b220-d0a8-44f1-bdd6-cfd2ff3d3de4"
      unitRef="usd">9603000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMTktNS0xLTEtMA_f511c50d-ca57-4372-a1e4-d6e34556ddf1"
      unitRef="usd">-10845000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtMS0xLTEtMA_e5b47caa-5e38-419e-a3d4-4c9da94468fe"
      unitRef="usd">796639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtMy0xLTEtMA_65bf9e40-a240-47f5-a9d1-22bd66130f92"
      unitRef="usd">173330000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjAtNS0xLTEtMA_15a1e18c-cb7d-4d28-88dd-384b8b6c82b8"
      unitRef="usd">57231000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtMS0xLTEtMA_a00303e1-29dc-40a3-9f7b-d944f7721c7b"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtMy0xLTEtMA_c59f2c60-6cf8-4118-a086-055c2068becb"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjEtNS0xLTEtMA_601f1f0a-9b56-4e6d-9b89-9f47cf01d7fc"
      unitRef="usd">44675000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItMS0xLTEtMA_e6944805-cef7-4c52-a176-a201d90fda1b"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItMy0xLTEtMA_4bfd28e5-6d4c-4d3c-b9d2-4aa6ff585dc0"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjItNS0xLTEtMA_50e9203a-d827-44d5-93dc-11a340b97dbb"
      unitRef="usd">12556000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtMS0xLTEtMA_ad394f90-c1da-4039-b63d-16a9a22863a2"
      unitRef="usdPerShare">33.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtMy0xLTEtMA_25b346ff-0c8d-4b71-bdcb-02ab9bbe1ea7"
      unitRef="usdPerShare">6.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzAtNS0xLTEtMA_1595e0d3-259f-4506-8602-d0ccdab1247f"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtMS0xLTEtNDU4_b714ee0e-3e05-436d-800c-4bcc64fd4729"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtMy0xLTEtNDY4_c7b1a67f-418f-4afc-9ab3-46062298ca57"
      unitRef="shares">21160000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMjYtNS0xLTEtNDcw_ef81a807-c7f8-4204-979f-4d6e4303fd9f"
      unitRef="shares">21032000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtMS0xLTEtMA_ce952db2-8223-46c9-8445-43c77f4c3532"
      unitRef="usdPerShare">31.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtMy0xLTEtMA_52e7ac39-ac72-4c1e-878f-2960c791a7fe"
      unitRef="usdPerShare">5.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfMzUtNS0xLTEtMA_02778382-2579-41b6-9be7-fc02c3a910a8"
      unitRef="usdPerShare">0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtMS0xLTEtMA_325f618e-0042-4891-98f8-daf4173331df"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtMy0xLTEtMA_8448ff89-a910-4df0-8c55-6062717f1105"
      unitRef="shares">24067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183MC9mcmFnOmMwNjRhOTA4NjUyNzQ0Y2I5NmE3OWNlYmQ2ZGVlYTYwL3RhYmxlOjFkNTZjNTc2NDhkYzQ3ZGE5ODE0MTJmNzIzMzFhMWNkL3RhYmxlcmFuZ2U6MWQ1NmM1NzY0OGRjNDdkYTk4MTQxMmY3MjMzMWExY2RfNDEtNS0xLTEtMA_9aed5d65-6eaf-4eeb-b08e-d3238489b7c9"
      unitRef="shares">23481000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi0xLTEtMS0w_33fcd6dc-0a1f-4e7c-8c63-e3ebeb45bed6"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi0zLTEtMS0w_395c4808-20ef-4557-9d40-dfc19c84f149"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMi01LTEtMS0w_3aadf4bc-a26e-406b-91ae-106e867cd11f"
      unitRef="usd">12556000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy0xLTEtMS0w_8e7c556c-84a2-47a8-bbf4-def178a34978"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy0zLTEtMS0w_773a69c2-e7ec-4e89-9a25-d049e8be11d7"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfMy01LTEtMS0w_c739c069-fe4d-4682-bcd8-72a3c6515d19"
      unitRef="usd">143000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC0xLTEtMS0w_12175b3b-094a-4137-b2fb-a61b89929550"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC0zLTEtMS0w_303caa37-b89f-4d7e-861e-ccb74e1b566b"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNC01LTEtMS0w_6190d2ed-a263-459a-8807-eba8ed972640"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS0xLTEtMS0w_de5406e0-2774-4f56-a306-b0704363edd5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS0zLTEtMS0w_7b955b65-4b21-431a-b260-6c210cf59a9c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNS01LTEtMS0w_3eb11f36-5512-4c60-80c5-1e5beca68acd"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi0xLTEtMS0w_670794bb-9c95-406a-b69b-7c9262455ed5"
      unitRef="usd">630110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi0zLTEtMS0w_91e1a56c-e312-4b3d-b74d-46b14309c3c7"
      unitRef="usd">142473000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183My9mcmFnOjYzMDQ3NDc4Yzk2ODRhZmFhM2Q1OWUwODQzNTE4ZTYzL3RhYmxlOjgxOWYyOTJhNDA5OTQ3MDlhYWJiOWRjNzI4ZTUxMmIxL3RhYmxlcmFuZ2U6ODE5ZjI5MmE0MDk5NDcwOWFhYmI5ZGM3MjhlNTEyYjFfNi01LTEtMS0w_1292fbef-d2ee-4603-9cf9-0a50e26bb801"
      unitRef="usd">12299000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i869489dbc2cb4d108beb10a315c6229a_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMS0xLTEtMA_2c640e9d-248d-4543-a9a5-fb1090e59e72"
      unitRef="shares">20909301</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i869489dbc2cb4d108beb10a315c6229a_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMy0xLTEtMA_18469952-02ed-4909-994b-ad10d586fc70"
      unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cf4dc97e05a4c57ab75939e7f4190ad_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtNS0xLTEtMA_b3520f04-719b-4bd6-ac68-626229d03307"
      unitRef="usd">769653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5489d8e2a3154e579e1950596bad4e83_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtNy0xLTEtMA_c9d234b4-ecb2-41e8-b1c2-d3fd31d66995"
      unitRef="usd">2743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf5608c1b3e145d7b634848e84a0417e_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtOS0xLTEtMA_c3ffa310-a2c5-4105-ab77-f369d315ad06"
      unitRef="usd">-431127000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTAtMTItMS0xLTA_8e9ead1f-279a-4334-8699-6cc62ca1d7fb"
      unitRef="usd">341290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtMS0xLTEtMA_f75f7698-0c49-4ca6-ac28-f42f1253a71d"
      unitRef="shares">253364</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtNS0xLTEtMA_a872d060-e339-454b-b6dd-939dd7d77e45"
      unitRef="usd">-5558000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTEtMTItMS0xLTA_21fec43c-3dfc-45fc-972c-3e249189fc72"
      unitRef="usd">-5558000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTItNS0xLTEtMA_fd39e8c2-15ba-4ee6-a937-7602a264c890"
      unitRef="usd">10704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTItMTItMS0xLTA_3ea2671c-a9d8-46af-83ff-875e36c3adf2"
      unitRef="usd">10704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTMtNS0xLTEtMA_e6f33cf9-4652-4cb9-b096-6e5663837403"
      unitRef="usd">24916000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTMtMTItMS0xLTA_f69f47a7-b9f8-4a69-8313-230c4b828a81"
      unitRef="usd">24916000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0752af0959664888aba41bd16b0d0aed_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtMS0xLTEtMA_e160df71-024a-456b-aa55-c28c9dba9428"
      unitRef="shares">14000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i348bda80edfd4a1fb760becabf2322da_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtNS0xLTEtMA_ce71ca33-4f68-49f9-acb4-473c8d57c6e1"
      unitRef="usd">1966000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTQtMTItMS0xLTA_d8c5ccbf-5880-4001-8e02-513dbdf00a75"
      unitRef="usd">1966000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c39c6b8d84c41cca43833810fbc7ae2_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTUtNy0xLTEtMA_28b6c96d-893f-448e-98a3-d3d4bbe45bbd"
      unitRef="usd">-257000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTUtMTItMS0xLTA_6bef2feb-4e32-4522-99e6-4ed2513cad63"
      unitRef="usd">-257000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="idae4fa193bce41988665297c8c87cd90_I20170101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtNS0xLTEtMA_952b8f0c-69e0-4706-b0de-3f107a4f38dc"
      unitRef="usd">456000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="ifcb933ddf4a24744b8334b58adba6068_I20170101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtOS0xLTEtMA_6cd7878d-5bae-404a-aef8-4b7c561023af"
      unitRef="usd">17647000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i942f3b02c5b94bd68a645167798076c7_I20170101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTYtMTItMS0xLTA_8fc1628a-bf21-4384-8c9a-5105c3dd1355"
      unitRef="usd">18103000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="i52155cd9acaf404eadf5b7e3d980852d_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTctOS0xLTEtMA_db36737d-f05a-42a7-9a7f-1cf6d619f62a"
      unitRef="usd">12556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTctMTItMS0xLTA_7d380d9f-e481-438c-b72b-810746eda575"
      unitRef="usd">12556000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMS0xLTEtMA_3091596e-e9a9-4ba9-8697-e00168dcb96d"
      unitRef="shares">21148665</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9ec385cfcdc4e57abbc99bbb0aaf3b7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMy0xLTEtMA_7d97ffe1-06c5-4737-8645-fad23cde578a"
      unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba785669817e4bca8806263b74bbb109_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtNS0xLTEtMA_8ffe7c28-5279-4707-893a-37c32a8b944e"
      unitRef="usd">798205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc1374cff04f4a8a9e7ff2371b8b8aed_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtNy0xLTEtMA_e6af111d-ae77-47f4-8772-b06d18d89358"
      unitRef="usd">2486000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04273cf057274bd7ba4eb19b16af0d81_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtOS0xLTEtMA_16a99aff-6047-41e2-a759-faaac2459f1a"
      unitRef="usd">-400924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTgtMTItMS0xLTA_3327aa53-588c-4fe3-acce-6dab116f01a1"
      unitRef="usd">399788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibac644851be347358be4803ad12d0c11_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktMS0xLTEtMA_96434695-5421-4b4a-8b85-2e1b2926772e"
      unitRef="shares">399116</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktNS0xLTEtMA_a1f3afdd-c5d2-4aea-a843-6e467b74628a"
      unitRef="usd">16417000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMTktMTItMS0xLTA_297716f7-2a1a-468a-986d-e184dc913383"
      unitRef="usd">16417000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjAtNS0xLTEtMA_b02a75df-3fa4-4e06-977f-d320358d959a"
      unitRef="usd">18859000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjAtMTItMS0xLTA_e20ca037-0a74-48cf-b872-38bf76e5d7c5"
      unitRef="usd">18859000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjEtNS0xLTEtMA_e0f0ec79-4a90-434c-87dd-e214da61b37e"
      unitRef="usd">20846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjEtMTItMS0xLTA_2dc13e6b-5a2d-468b-80c6-62041e96df9d"
      unitRef="usd">20846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ibac644851be347358be4803ad12d0c11_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItMS0xLTEtMA_b8e4aac9-5416-4805-8767-6317afc2812a"
      unitRef="shares">782248</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItNS0xLTEtMA_652e5af1-4c8c-4e79-9d63-290cb6909bd6"
      unitRef="usd">127481000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjItMTItMS0xLTA_172c9713-8e8c-4fe6-a749-de64cd65f8ed"
      unitRef="usd">127481000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjMtNy0xLTEtMA_8d012e70-f3cb-437a-9f18-6c3b416f5928"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjMtMTItMS0xLTA_f39ea132-7d0a-4474-811a-0bdc2fc7a3c8"
      unitRef="usd">73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i7a9bcb91841d44d6ba7d80ded777ad08_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtNy0xLTEtMA_47a308c4-982b-48b8-baf8-e03521535743"
      unitRef="usd">-2662000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i1e5aa84c1f894416941ae3fb3370a0e7_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtOS0xLTEtMA_66af54ce-c591-4496-a332-343a90d7554b"
      unitRef="usd">2662000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i01597458c3654e7d814509dc1fe6a346_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjQtMTItMS0xLTA_9f2f3543-b1dc-401f-98db-ffa9909ae932"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i4ecf11d232574f23813a8e1cac3990ee_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjUtOS0xLTEtMA_bad03e6d-871c-4e6d-959b-aa3f6929127f"
      unitRef="usd">25581000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i352af84d1ae44bb8a22c67271354ceae_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjUtMTItMS0xLTA_5f88ce62-913d-404f-99e6-442ac659729b"
      unitRef="usd">25581000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjYtNS0xLTEtMA_2468427f-b963-4052-bd68-26c00623ffb9"
      unitRef="usd">-1559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjYtMTItMS0xLTA_ca191cfe-92ee-41fd-99a4-26a816928f2b"
      unitRef="usd">-1559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes
      contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjctNS0xLTEtMA_cdee5b67-4f90-48cd-b296-cf6a429c2f04"
      unitRef="usd">3187000</lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes
      contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjctMTItMS0xLTA_96c0f1a6-fadc-426f-a6ae-1ef86a1512d7"
      unitRef="usd">3187000</lgnd:AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased
      contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjgtNS0xLTEtMA_5ae6f8f0-81de-4619-a8a4-2ce663d2600f"
      unitRef="usd">30472000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased
      contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjgtMTItMS0xLTA_303fc475-0b02-496c-a9c6-e76693b52ed9"
      unitRef="usd">30472000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants
      contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjktNS0xLTEtMA_f25a6ccd-f410-4dac-b1a1-2962b5b4313e"
      unitRef="usd">1792000</lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants
      contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMjktMTItMS0xLTA_5a805f41-be4d-4c5c-a1cd-9576cf37caec"
      unitRef="usd">1792000</lgnd:AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="i4e83d395a31848489f532fb88fcb5444_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtNS0xLTEtMA_86f328ec-aff2-4113-a02b-5465a31c22a8"
      unitRef="usd">1680000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="ifab6c24820e8484dac6b1bf522e92aa6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMTItMS0xLTA_c5ab3dac-90d5-4e85-b165-0bafcc2f2661"
      unitRef="usd">1680000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtNS0xLTEtMA_66a72cd4-71ca-4f7b-a5cb-709ef5959c4a"
      unitRef="usd">-1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtMTItMS0xLTA_ff14ae8b-b22b-467f-98ca-80d770a9695a"
      unitRef="usd">-1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItNS0xLTEtMA_8ce0d423-238f-4afd-96e6-1a0c790a8378"
      unitRef="usd">97805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMTItMS0xLTA_b4b180d7-b9f5-4077-a479-425cde2de6ec"
      unitRef="usd">97805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="ia7fcb2c97a41452194c8ba701747b1e4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtNS0xLTEtMA_5096bbbc-b4a1-459c-8c0d-5adc3ae5346b"
      unitRef="usd">3181000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions
      contextRef="i1f00312ea37c45a4be2ad468bfb0c53a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtMTItMS0xLTA_c07b1a59-c161-47d0-9061-5f3e59506b28"
      unitRef="usd">3181000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8aafb43ba3304595bae374d92387c2fc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtNy0xLTEtMA_3b91a4cd-e686-4b0d-b628-72eaf649c0cd"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtMTItMS0xLTA_c196f14b-c9aa-44b7-bc63-498070cc3188"
      unitRef="usd">-921000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i24a563ed36b343c48b0d245e8ab13985_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtNS0xLTEtMA_4fd0dd1b-f9b5-4c63-829e-55e3a6ad36b2"
      unitRef="usd">183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtOS0xLTEtMA_3b357f42-7e3c-40f9-9bc7-7057852d9462"
      unitRef="usd">163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtMTItMS0xLTA_c0205616-9268-4454-b089-93c59bbb671e"
      unitRef="usd">346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="ia290703daec7409aafd60f7dddf9b5b5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtOS0xLTEtMA_bbc02d37-77d6-4e8c-b0ef-6e0b703aa76e"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtMTItMS0xLTA_57328a3a-b8e8-4372-858a-ae2c524e189f"
      unitRef="usd">143321000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7ef94475465245018ed0c204e8bd7fda_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMS0xLTEtMA_49cf8d7f-d9bd-43eb-a5bc-0a54d59a580a"
      unitRef="shares">20765533</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ef94475465245018ed0c204e8bd7fda_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMy0xLTEtMA_d1d0a0b4-8410-4d6b-92a9-674dc1da649b"
      unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic339114ab562486b8927a1f3fd53be85_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNS0xLTEtMA_00f13ee8-f5f8-4446-9f1f-656fb5071041"
      unitRef="usd">791114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafd33958a305462b9dded4123ec458ad_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNy0xLTEtMA_6e89f484-24b1-47fd-9625-37015eca85cb"
      unitRef="usd">-1024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9508f9f000dd4ad0b0d754524aee17b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctOS0xLTEtMA_7f08cfc2-ed28-4344-b581-a9d79fad5b08"
      unitRef="usd">-229197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMTItMS0xLTA_5f4e35cd-be2f-4741-a189-122dd705f209"
      unitRef="usd">560914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMS0xLTEtNjg3Ng_ede1d42b-528a-40d6-a26c-a8ac16b4ec4f"
      unitRef="shares">179838</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtNS0xLTEtNjg4OA_a36363dd-6464-42f1-85ba-9084074f7ace"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzAtMTItMS0xLTEwNTM1_40f224d6-bf03-4886-ae1b-2e711075f797"
      unitRef="usd">-1421000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtNS0xLTEtNjg5MQ_9c8a056f-96c5-4164-80b3-90c5500e6ed3"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzEtMTItMS0xLTEwNTM3_bb393a6b-fd05-4d23-820b-31ff8911f521"
      unitRef="usd">24515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMS0xLTEtNjg3OQ_a635109c-2dc7-4004-aa3f-ffc070a5ce1b"
      unitRef="shares">4122133</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i484f533e1170410699a1b9eae24d5fc0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMy0xLTEtNjg4NQ_88860a74-f34f-4fa1-b27b-82b5fbcb6c51"
      unitRef="usd">4000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItNS0xLTEtNjg5NA_0a5e972d-776d-4dea-85a0-20545bf864f7"
      unitRef="usd">448429000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzItMTItMS0xLTEwNTM5_1a4bd047-6649-45b8-bf66-4cd648ae4f5c"
      unitRef="usd">448433000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtNy0xLTEtNjkwMA_4124fe0d-5cba-4cea-8fd5-5dcf395d361c"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzMtMTItMS0xLTEwNjA2_7591eeb3-e8ad-4943-bc10-031ed81be109"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i95ffdb1c678e42e6ac3a759e65fffe3f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtNy0xLTEtNjkwMw_4c44a684-dbb1-4efc-a8d2-cb26b588dd96"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzQtMTItMS0xLTEwNTQx_0a6a223f-9b9a-4471-99a5-f2f1b68e7e86"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i6da59b23aa5e41a19c655cfc0bb70f12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtNS0xLTEtNjg5Nw_953a85a0-16ad-474e-b3e3-b0e6139f8504"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzUtMTItMS0xLTEwNTQx_2aec8885-5653-4fda-95df-f678f112bece"
      unitRef="usd">1547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="i58b3cbeb39e14feb8ab2224143dffb5a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtOS0xLTEtNjkwNg_050f5ac9-6d11-4ef5-8b33-9ca2f3e6ffa8"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzYtMTItMS0xLTEwNTQx_3243bfd3-9255-4c57-8af1-383746df0435"
      unitRef="usd">629302000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMS0xLTEtMTA1MTQ_d46699ed-ca00-4bbb-9272-3c5c037de095"
      unitRef="shares">16823238</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81e50e75f7bd4126acf89240d2a4ebb7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMy0xLTEtMTA1MTQ_3d2f043c-fe09-4fad-8b61-9a315fc458b5"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45ef1d23069649bc84d61c935c800a92_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNS0xLTEtMTA1MTQ_3aa15158-6ec9-4872-8876-58902e99a168"
      unitRef="usd">367326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2870d56eba64b3dbd7901fdf1a45b5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctNy0xLTEtMTA1MTQ_e7ee12cc-69f8-41f8-ad33-0e0ba1d2427d"
      unitRef="usd">-216000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice4b9c573b6e48dcb989d7ab948495c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctOS0xLTEtMTA1MTQ_e28012eb-06c7-471c-84b4-d617301e6940"
      unitRef="usd">400105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183Ni9mcmFnOjdiZWVlOTEwZWY1NzRhYWNhYTBlZWIyMDYyZjA5NjM0L3RhYmxlOjgzZjI3ZDgzNzJlMDRhMDg4NWE3NzhiMDZlMDJjNzIyL3RhYmxlcmFuZ2U6ODNmMjdkODM3MmUwNGEwODg1YTc3OGIwNmUwMmM3MjJfMzctMTItMS0xLTEwNTE0_0db830dd-9159-4413-a434-afba03769e01"
      unitRef="usd">767232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC0xLTEtMS0w_92d7029f-ee1a-44b8-ae2d-f80d944568f5"
      unitRef="usd">629302000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC0zLTEtMS0w_32744d46-cdeb-452c-861b-03718b99f3a6"
      unitRef="usd">143321000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNC01LTEtMS0w_fe87a58d-9b64-44a5-9517-e82d90ddc7b5"
      unitRef="usd">12556000</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC0xLTEtMS03MDIx_147d01ed-9c6f-4846-8701-451ff64a2fc2"
      unitRef="usd">812797000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC0zLTEtMS03MDI1_3c8cf9b2-66fa-4bb6-9368-21ffa93faa3a"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOC01LTEtMS03MDI4_9f24c184-c3ab-49ac-af86-295c7fcad3a0"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS0xLTEtMS0w_23e1eb1d-163a-4f91-9d99-1451333e8bd6"
      unitRef="usd">30000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS0zLTEtMS0w_da328cad-a2d6-4246-af7f-441f980bc1ab"
      unitRef="usd">-3448000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfOS01LTEtMS0w_afe4a2ca-7039-42f3-b8e0-448fb6703508"
      unitRef="usd">-2580000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtMS0xLTEtMA_c16b80c6-7e58-4f9b-ab10-edb2629ae1fc"
      unitRef="usd">41000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtMy0xLTEtMA_94b65b2b-2da6-4ee7-8c6f-93977826b690"
      unitRef="usd">2611000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTAtNS0xLTEtMA_55e30685-ce71-42c0-961e-5b323b92cd67"
      unitRef="usd">831000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtMS0xLTEtMA_076220b5-d85c-4739-a3bd-7af717081021"
      unitRef="usd">18361000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtMy0xLTEtMA_342d9a2c-8e53-4587-9bc0-c10f9aca7608"
      unitRef="usd">12784000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTEtNS0xLTEtMA_d69b7ff2-5cb5-4f3c-bd19-71cdef7a1bc5"
      unitRef="usd">10955000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItMS0xLTEtMA_d451fe15-dea9-4a40-a1c7-5f23f8b31fb3"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItMy0xLTEtMA_718f028b-a1ba-4812-be7c-193872ca2dd9"
      unitRef="usd">47658000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTItNS0xLTEtMA_6b5b9706-a4d3-4fcf-86ef-61414861da38"
      unitRef="usd">1114000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtMS0xLTEtMA_0790ef77-3312-4452-ba88-bf80e40bb9eb"
      unitRef="usd">10274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtMy0xLTEtMA_76d8974a-18b8-4b54-9f34-3cc124b8ac41"
      unitRef="usd">5452000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTQtNS0xLTEtMA_30e6de59-5555-480d-9507-0fb17227cec1"
      unitRef="usd">81000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtMS0xLTEtMA_9b16ab71-273e-4c88-ad8c-c2c683642148"
      unitRef="usd">29988000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtMy0xLTEtMA_c6e57bd9-b894-4c77-8aa3-ba50d1405677"
      unitRef="usd">43954000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTUtNS0xLTEtMA_d862a964-6e0f-4cb1-bb2b-b80258e1a9df"
      unitRef="usd">11619000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtMS0xLTEtNzA3Ng_d90292e2-dd09-4c95-ac4b-dd878430a33b"
      unitRef="usd">25370000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtMy0xLTEtNzA4MA_19120b62-da66-4aef-8429-2f62b59b8af8"
      unitRef="usd">1934000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTYtNS0xLTEtNzA3OA_37942908-c537-4960-a8a0-2e292004fc00"
      unitRef="usd">759000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <us-gaap:ShareBasedCompensation
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctMS0xLTEtMA_1f22bf61-2297-4e44-8ad3-5a7ee56be688"
      unitRef="usd">24515000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctMy0xLTEtMA_d551a58b-a39d-46f1-bb60-b644b278dbda"
      unitRef="usd">20846000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTctNS0xLTEtMA_3f442455-ac20-44f0-b5bd-0763bbac6c1a"
      unitRef="usd">24915000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtMS0xLTEtMA_8a512b3d-a329-412b-87de-1bd460f50f9e"
      unitRef="usd">-74829000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtMy0xLTEtMA_6845c236-3b8d-4c8d-aa22-08f87f78e1d0"
      unitRef="usd">-29739000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTgtNS0xLTEtMA_6e6d29a6-8c8a-4525-ba9e-3f8bdc141ee0"
      unitRef="usd">-44518000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktMS0xLTEtMA_bead9a24-0b74-4a82-9edf-43f6994eb337"
      unitRef="usd">0</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktMy0xLTEtMA_bb931ae3-6a4c-4bd8-aa10-dd7958fe17a1"
      unitRef="usd">32707000</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMTktNS0xLTEtMA_4751ae5f-7138-4787-bbe1-8ad1a80920eb"
      unitRef="usd">0</lgnd:RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMS0xLTEtNzI0Nw_1de9a1c5-279c-4c7e-bd2a-02c2a984081d"
      unitRef="usd">-1456000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMy0xLTEtNzI1MA_b120e828-d150-4794-9c23-775a3e9928fc"
      unitRef="usd">2832000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtNS0xLTEtNzI1Mw_85cf44b1-6f51-4ac4-8897-2fd01cbc7d0a"
      unitRef="usd">-870000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMS0xLTEtMA_0a9bd300-05aa-41a9-a6a6-7bbb9d88c33a"
      unitRef="usd">-25463000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMy0xLTEtMA_1ee53fb0-ad29-4e72-9a58-e4e89aebb052"
      unitRef="usd">29544000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItNS0xLTEtMA_8cc4297f-388f-450a-92fd-07e4ba7ea64e"
      unitRef="usd">8358000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtMS0xLTEtMA_4890637a-325e-458e-b8d0-52904a931f64"
      unitRef="usd">2061000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtMy0xLTEtMA_adcbccf5-5b9c-4acb-8ad6-0a657d674444"
      unitRef="usd">2559000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjMtNS0xLTEtMA_9622e2aa-1315-4416-943d-be3445ff865e"
      unitRef="usd">843000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMS0xLTEtMA_cda48493-0c36-4f58-88ce-d2c8671efe69"
      unitRef="usd">-6826000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMy0xLTEtMA_4da55e04-3fdb-4124-a2a7-42743f4af21f"
      unitRef="usd">-4542000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtNS0xLTEtMA_097206b8-9d30-4411-9c57-61c02588710e"
      unitRef="usd">-1713000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMS0xLTEtOTUyNg_d9f2da77-d636-46f8-83ac-0b8448cf5711"
      unitRef="usd">11219000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtMy0xLTEtOTUxOQ_5dd7f259-5f23-43c6-9d64-b46681a72d6f"
      unitRef="usd">-318000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjEtNS0xLTEtOTUyMg_dde5d9d7-aab1-475a-898a-fb2ba5152f72"
      unitRef="usd">460000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMS0xLTEtMTAwMjQ_6d6b2046-09e4-41f6-9df0-0de0b2ccdfa6"
      unitRef="usd">-12000000</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItMy0xLTEtMTAwMjY_24bd6b2b-d4b4-4cfb-b311-0fb333cade36"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <lgnd:IncreaseDecreaseInOtherEconomicRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjItNS0xLTEtMTAwMjg_fc4607d8-de78-4300-a1ee-caf8597dfb92"
      unitRef="usd">0</lgnd:IncreaseDecreaseInOtherEconomicRights>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktMS0xLTEtNzIzNg_ff377ccd-0e0e-4fac-a3e8-62fe43cd548b"
      unitRef="usd">2428000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktMy0xLTEtNzIzOQ_30aa3040-548f-4b0e-9fde-9cda07b8b026"
      unitRef="usd">-5458000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjktNS0xLTEtNzI0Mg_1180cc1d-2b22-4dd1-8ec6-b6126f0b9d5d"
      unitRef="usd">-5062000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtMS0xLTEtMA_9b099f0d-83cd-42a0-b3f3-1c475ea70c83"
      unitRef="usd">-29336000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtMy0xLTEtMA_ad48d719-bd70-4ce3-90e9-c07cea712055"
      unitRef="usd">194059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzEtNS0xLTEtMA_507efff2-89e4-4a11-a432-05dadc1edc8a"
      unitRef="usd">88570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItMS0xLTEtNzE0NA_643a4736-7263-46d6-b4d7-15286cd0fbf6"
      unitRef="usd">812797000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItMy0xLTEtNzE0Nw_82cb5cd7-814b-43b8-bf19-a273e7135f30"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzItNS0xLTEtNzE1MA_b5a25caf-4001-4ee0-b388-51dd417427d2"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMS0xLTEtODcyNg_b6498f89-85d2-4524-a38e-8994e6055613"
      unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtMy0xLTEtODcyMw_8627ef90-acc7-4ebe-ae47-ed51b3dd7161"
      unitRef="usd">10000000</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMjYtNS0xLTEtODcyOQ_cef47b31-2e66-40fe-b1af-be528ddfe517"
      unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtMS0xLTEtMA_2a5895e7-8028-40b9-9496-88d3b701341f"
      unitRef="usd">11840000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtMy0xLTEtMA_c5e7b8d4-97e2-4821-9a2f-d045a3f8440d"
      unitRef="usd">5856000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzYtNS0xLTEtMA_652aac80-a96a-419c-90b6-d99637f068dc"
      unitRef="usd">26653000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtMS0xLTEtMA_a8987184-db1a-493d-a1a6-8e9ec210f099"
      unitRef="usd">2553000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtMy0xLTEtMA_a4f399fb-1741-4d7a-a61e-ddfbf6a2c2fb"
      unitRef="usd">887000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzgtNS0xLTEtMA_644058c6-34ea-4f29-9ca2-d711c640be62"
      unitRef="usd">2156000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktMS0xLTEtMA_939468f1-403f-4504-941e-3692b64b4eb8"
      unitRef="usd">2356545000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktMy0xLTEtMA_857076c6-9de4-4f39-ac46-4b42acb9b370"
      unitRef="usd">1434255000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfMzktNS0xLTEtMA_051bf1fc-8d56-42c4-8505-395d928e8eed"
      unitRef="usd">254258000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtMS0xLTEtMA_2c82689b-6ec7-4aea-84f6-ca646254e545"
      unitRef="usd">535877000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtMy0xLTEtMA_399761a8-1d49-457d-b715-57c8baca924d"
      unitRef="usd">131942000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDAtNS0xLTEtMA_d4384ce1-9afc-42d1-ad24-c2473bb5a965"
      unitRef="usd">86985000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMS0xLTEtMA_77562661-d2ba-428f-9d63-42b5210a9d85"
      unitRef="usd">1494851000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMy0xLTEtMA_35dca859-47d8-4ae4-ab01-d79345e75b78"
      unitRef="usd">892873000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtNS0xLTEtMA_0a048527-87d8-4e18-81e2-6f81124ad8b2"
      unitRef="usd">109649000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItMS0xLTEtMA_019d4879-a65c-443b-8c18-22d77cb8d230"
      unitRef="usd">0</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItMy0xLTEtMA_758dc999-2260-46d6-9abf-297c860bf716"
      unitRef="usd">0</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDItNS0xLTEtMA_56f77c4d-fa0e-4be5-927c-3609e5e8260c"
      unitRef="usd">7054000</lgnd:ProceedsFromCommercialLicenseRights>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtMS0xLTEtMA_5016d61c-d48f-4cd8-ac38-c4a79ee7aab3"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtMy0xLTEtMA_2f8a5afd-c518-4fff-be4e-2c3e66ba0f77"
      unitRef="usd">3914000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDMtNS0xLTEtMA_8a808cbd-33dd-4ebe-a3c4-c255e79a6543"
      unitRef="usd">200000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMS0xLTEtNzE5MA_53222fd4-ff3b-4dda-9e10-15255213be59"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtMy0xLTEtNzE5Mw_e52b443d-536e-4e3a-882d-03639e4862db"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDEtNS0xLTEtNzE5Ng_84bb022d-f104-44ef-be5d-2bd936b0286a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtMS0xLTEtMA_8c456f82-ebb7-4ca8-a463-8a7aa4f6cd54"
      unitRef="usd">4669000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtMy0xLTEtMA_2c2b51b1-4b00-4215-82ae-ba1ccce7bf38"
      unitRef="usd">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDQtNS0xLTEtMA_f7075f22-b841-437e-a6ad-0b8c7c5fd841"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtMS0xLTEtMA_05082f5d-39c1-407e-985d-1b1d48d9f203"
      unitRef="usd">466918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtMy0xLTEtMA_b86fda81-5927-4178-94c0-a730528f1ad2"
      unitRef="usd">-423269000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDUtNS0xLTEtMA_a56414bf-fc27-495d-92e4-f29ea6059c68"
      unitRef="usd">-79179000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctMS0xLTEtMA_91ee6133-5fb0-4a65-b4bd-fb7ad13c10a9"
      unitRef="usd">27323000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctMy0xLTEtMA_38f89eef-18de-41d2-8302-0df95b73d127"
      unitRef="usd">217674000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDctNS0xLTEtMA_b1371645-038e-4b61-bd64-030e48946085"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtMS0xLTEtMA_b8aed288-182e-4500-90a2-1cefe0a65c11"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtMy0xLTEtMA_c02e6a30-99b1-452d-be7c-2500fb8c4d74"
      unitRef="usd">750000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDgtNS0xLTEtMA_1f62f3c5-eb3c-4ec6-b371-a728b0c8cf36"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktMS0xLTEtMA_2ae3694c-0b68-4959-a0f1-a95bf1b4960e"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktMy0xLTEtMA_6a8cf861-fb04-45d5-8b6b-724834c6a733"
      unitRef="usd">16900000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNDktNS0xLTEtMA_a5cb2348-f9e6-4038-b9be-521b0cbec9ef"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtMS0xLTEtMA_17620021-158c-450c-b799-c426338b2baf"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtMy0xLTEtMA_c51b4726-0d0e-482b-9ea0-82033bfb95c9"
      unitRef="usd">90000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTAtNS0xLTEtMA_6cb93442-6a4c-40b6-af7c-cd141d9ff99b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtMS0xLTEtMA_3fa09d0f-faff-4beb-92bb-13bb3c939a1d"
      unitRef="usd">0</lgnd:PurchaseOfConvertibleBondHedge>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtMy0xLTEtMA_d318c3ec-01e4-461e-b13a-162414873282"
      unitRef="usd">140250000</lgnd:PurchaseOfConvertibleBondHedge>
    <lgnd:PurchaseOfConvertibleBondHedge
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTEtNS0xLTEtMA_6e456214-ba0b-456d-a76d-d885de60d242"
      unitRef="usd">0</lgnd:PurchaseOfConvertibleBondHedge>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItMS0xLTEtMA_13d5500c-fbe8-410a-a1bf-b103de223618"
      unitRef="usd">12401000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItMy0xLTEtMA_1ab56191-f9a9-4cbc-a027-ce16029894e0"
      unitRef="usd">439559000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTItNS0xLTEtMA_558ba17b-7532-4a27-9aa9-c2964a03d7fd"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtMS0xLTEtMA_20b31d3c-7587-4e10-98b5-8749502011cb"
      unitRef="usd">12401000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtMy0xLTEtMA_f5c106b3-3df4-4f4b-8fd9-0e5f597b1fb6"
      unitRef="usd">439581000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTMtNS0xLTEtMA_89a18869-c3d6-45de-9491-9c76568d96d8"
      unitRef="usd">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMS0xLTEtMA_ffc1ef5a-9e4b-4b13-8bd0-7cf928d4c60f"
      unitRef="usd">2997000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMy0xLTEtMA_efb96c21-b83c-40e3-9a47-63ffc1c81e5a"
      unitRef="usd">20183000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtNS0xLTEtMA_53776a9b-c6db-4969-a83e-8dc476541664"
      unitRef="usd">4517000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtMS0xLTEtMA_efebfcdc-5330-428c-941e-3ced6453dc8a"
      unitRef="usd">4418000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtMy0xLTEtMA_58460992-e26b-4a6f-ab44-9aac60526645"
      unitRef="usd">3765000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTUtNS0xLTEtMA_17fae675-711c-4600-9a0d-a30e61325ee6"
      unitRef="usd">10074000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtMS0xLTEtMA_65771813-554c-4862-af9f-71384df1f78a"
      unitRef="usd">453048000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtMy0xLTEtMA_01df278c-818e-4a2a-ae24-e873d6cf87b2"
      unitRef="usd">122868000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTYtNS0xLTEtMA_8488237c-f9de-4349-9791-2bfd1fa6ce86"
      unitRef="usd">1966000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctMS0xLTEtMA_cf0ef9e3-b9a3-4891-879a-9ed5a6fafbc1"
      unitRef="usd">380000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctMy0xLTEtMA_beaa63aa-bde0-405a-8078-f7895b86d203"
      unitRef="usd">30094000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTctNS0xLTEtMA_7ab7fbe2-2b82-4164-8e8d-8aa83a296a6a"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMS0xLTEtMA_3a2517dc-c882-4118-938f-37082d3e5fbc"
      unitRef="usd">3000000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMy0xLTEtMA_d2b6c1c0-2f06-4a82-8067-933cfaba14a1"
      unitRef="usd">25000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtNS0xLTEtMA_8d59564b-5099-4bd9-9dcb-82ae60443ae3"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktMS0xLTEtMA_46324161-c3de-4bc7-8f27-c743b23282b5"
      unitRef="usd">-485172000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktMy0xLTEtMA_5885dd5c-b8b0-4313-8255-08d1e1fdd890"
      unitRef="usd">328585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTktNS0xLTEtMA_11601fc2-d7c7-408c-bab3-050a43a556b8"
      unitRef="usd">-7523000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtMS0xLTEtMA_c06b6b57-994c-4652-b1ba-09f508111fb1"
      unitRef="usd">-47590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtMy0xLTEtMA_71f383a9-21e0-4709-ada8-30958e39eddc"
      unitRef="usd">99375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjAtNS0xLTEtMA_41ee70c8-7c04-441c-963d-f95a4234289f"
      unitRef="usd">1868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMS0xLTEtODA4MQ_57243fdb-d43c-43b6-bed6-524b4798ad95"
      unitRef="usd">83000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtMy0xLTEtODA4Mw_ac733b8e-dcc3-4f9b-aa67-d69881fbb6d3"
      unitRef="usd">-215000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTQtNS0xLTEtODA4NQ_8968128c-5e45-4cb5-a62f-003d3a1922fa"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItMS0xLTEtMA_fd84b0a7-4b94-4221-8a5a-df89a39c0b07"
      unitRef="usd">119780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItMy0xLTEtMA_823cc5dd-2e52-4a2c-9e56-291dc41a73c3"
      unitRef="usd">20620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjItNS0xLTEtMA_1212fc8a-ba6e-49ca-89e5-d9b99b437a89"
      unitRef="usd">18752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtMS0xLTEtMA_867306db-2866-4a81-839f-0ebad713204f"
      unitRef="usd">72273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtMy0xLTEtMA_226d7992-d5c8-4acc-995e-042593db6b06"
      unitRef="usd">119780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjMtNS0xLTEtMA_018304b6-87d2-479e-bf94-3ce442c60843"
      unitRef="usd">20620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtMS0xLTEtMA_7a2e85a0-f00c-4cb6-8a67-fb13891dcc3a"
      unitRef="usd">5827000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtMy0xLTEtMA_76b28a51-54e4-4c02-845b-91137f09df15"
      unitRef="usd">1513000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjYtNS0xLTEtMA_d1e4e0a6-6faa-4608-832b-ce5cea0f9a61"
      unitRef="usd">1838000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctMS0xLTEtMA_7d6ddd78-c03e-4c1e-81eb-a44bb7ab8fbe"
      unitRef="usd">103817000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctMy0xLTEtMA_e6ff4812-b6b5-4ed9-a8e3-b81b32871391"
      unitRef="usd">341000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjctNS0xLTEtMA_0ff76732-5bf6-451b-a6eb-ea2b5d517f2a"
      unitRef="usd">157000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RestrictedCashCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMS0xLTEtODE2Mg_9fe7efc5-8e9e-4181-8d3c-722876a862cf"
      unitRef="usd">730000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtMy0xLTEtODIwOQ_3012a497-f5f8-433a-830e-5467104d1386"
      unitRef="usd">2616000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNTgtNS0xLTEtODIxNg_0df0465c-44b1-40cc-b0fe-eade02e6de59"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <lgnd:AccruedInventoryPurchases
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtMS0xLTEtMA_a52c18f5-07a1-4c69-b5fd-5e5fd9e91dda"
      unitRef="usd">170000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtMy0xLTEtMA_9c4ce64f-4e58-4992-8453-c08eb31be6c1"
      unitRef="usd">2059000</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzEtNS0xLTEtMA_8f596d48-09f0-4109-bcc6-90cd3565db43"
      unitRef="usd">1007000</lgnd:AccruedInventoryPurchases>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItMS0xLTEtMA_7a7b225c-bcf7-4dda-b72f-8b04949d5611"
      unitRef="usd">256000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItMy0xLTEtMA_c739081f-e273-4d02-a76f-d7c6bf17b77d"
      unitRef="usd">48000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNzItNS0xLTEtMA_4b089504-432a-4496-8b64-8d67a3218fc5"
      unitRef="usd">144000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtMS0xLTEtMTMyMzE_7f55abc0-b6a2-476c-998f-2e22b4db1910"
      unitRef="usd">495000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtMy0xLTEtMTMyMzY_95b37611-ae3e-4277-8773-2a9f3ce531a8"
      unitRef="usd">15000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183OS9mcmFnOjVkM2FmMTczNjA2MjRiNmE5NWQ2ZGViY2YzMzRhZDU3L3RhYmxlOmQzYzAxMjNiMjE2YjRiYTliMGM4YWI4MDM4NjIwN2YzL3RhYmxlcmFuZ2U6ZDNjMDEyM2IyMTZiNGJhOWIwYzhhYjgwMzg2MjA3ZjNfNjQtNS0xLTEtMTMyMzk_db5a8418-f63c-47b9-9bec-ebde9a4e19ef"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzI_5201a9a8-b604-48b7-8f1f-2f02e56ed285">Basis of Presentation and Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking warrants was reclassified from &#x201c;other current assets&#x201d; to &#x201c;investment in Viking&#x201d; in the audited consolidated balance sheet as of December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&amp;lt; 10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&amp;lt; 10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash Equivalents &amp;amp; Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms which range from 30 to 90 days. We reserve specific receivables if collectability is no longer reasonably assured. We re-evaluate such reserves on a regular basis and adjust the reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2019, 2018 and 2017.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in other income (expense), net. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;amp;D is capitalized and assessed for impairment annually. IPR&amp;amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $10.5 million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.&#x201d;   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2019, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.542%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.856%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aziyo &amp;amp; CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selexis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated amortization attributed to principal or research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial license and other economic rights as of December&#160;31, 2019 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Arrangement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and reduce our asset as the funds are expended by Novan. As of December&#160;31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan has been fully amortized as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congentia. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and will reduce our asset as the funds are expended by Palvella. We will evaluate the remaining asset basis for impairment on an ongoing basis. It is anticipated that the cost basis of the asset will be reduced to zero prior to the receipt of any payments from Palvella. Therefore, we will recognize milestones and royalties as revenue when earned. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Receivables&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2019 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2019 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. We recorded a $5.1&#160;million reduction in the carrying value of the Selexis asset which was reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See additional information in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; subsection below. Our accounting policies under the new standard were applied prospectively and are noted below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalties, License Fees and Milestones&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For R&amp;amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Material Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenue when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at prior year-end was $3.3 million. During the twelve months ended December&#160;31, 2018, the amount recognized as revenue that was previously deferred at prior year-end was $2.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have revenue sharing arrangements whereby certain revenue proceeds are shared with a third party. The revenue standard requires an entity to determine whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. We received $4.6 million royalty payments from a license partner during 2019 of which $4.0&#160;million was paid to a third-party in-licensor. We recorded net revenue of $0.6 million as we believe we are an agent in the transaction. We recorded an immaterial amount due to third-party in-licensors as general and administrative expenses as we are the principal in the transaction during 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Royalty revenue for 2019, 2018 and 2017 are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.654%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.115%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.397%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2019&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2018&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2017&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;128,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;1) Royalty revenue for 2019 and 2018 was reported under the current revenue recognition guidance (ASC 606).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2) Royalty revenue for 2017 was reported under the legacy revenue recognition guidance (ASC 605).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands), which are not affected by the adoption of ASC 606:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Material Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;License fees, milestones and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preclinical Study and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;,&#x201d; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (7), Convertible Senior Notes.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income (loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.289%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.749%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Warrants associated with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;2019 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Standards Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In 2018, the FASB issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in ASC 840,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt; Leases (Topic 840),&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; including its disclosure requirements, in the comparative periods presented. We adopted this standard on January 1, 2019 by applying this optional transition method. For leases with a term of 12 months or less, we elected to not recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. In addition, we elected the available package of practical expedients upon adoption, which allowed us to carry forward our historical assessment of whether existing agreements contained a lease and the classification of our existing operating leases. We did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases. We continue to report our financial position as of December 31, 2018 under Topic 840 in our audited consolidated balance sheet. The adoption of this standard update resulted in the recognition of right-of-use assets of approximately $5.2 million and lease liabilities of approximately $5.9 million on our consolidated balance as of January 1, 2019, with no material impact to our consolidated statement of operations. See "&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Note (6), Leases"&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; for further information regarding the impact of the adoption of ASU 2016-02 on our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for us beginning in the first quarter of 2020, with early adoption permitted. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We will adopt this standard effective January 1, 2020, and we currently do not expect the adoption to result in a  material impact to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Simplifying the Test for Goodwill Impairment,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. This standard is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement: Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020, and will include the required disclosure beginning in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In November 2018, the FASB issued ASU 2018-18&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;recognized from contracts with customers. The new standard is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted in any interim period for entities that have adopted ASC 606. The standard should be applied retrospectively to the period when we initially adopted ASC 606. We will adopt this standard effective January 1, 2020, and do not expect the adoption will result in material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjQ_aae531a3-9e6d-4395-8009-cbf31df32ce6">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjU_29d8e016-23d1-43ad-9079-6376d90d6955">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDM_4a223010-db64-4f67-8469-60f31118e829">ReclassificationsCertain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking warrants was reclassified from &#x201c;other current assets&#x201d; to &#x201c;investment in Viking&#x201d; in the audited consolidated balance sheet as of December 31, 2018.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDQ_f5921a20-a303-492c-8455-c47b8931cf81">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTE_adb5c6dc-e67d-447b-ac30-e8d306e130d2">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTM_b1464dfc-080f-47c0-b785-d4271da03fcf">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.678%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&amp;lt; 10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&amp;lt; 10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53e345f65cef494a89a25239fa967bbb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi0xLTEtMS0w_ad2929f9-a66c-49d5-9c87-645c3e3775f4"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c0def0efae44a5ea9424174e127e04f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi0zLTEtMS0w_db3e4a24-a532-4581-9c43-f31ae2367135"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iad8277e193464fc0bfc5035fabc271f6_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMi01LTEtMS0w_16ec8d5c-6853-4ac5-b2b9-989c078ec60b"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8112712360b5447cbcf4086b3a12a30f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy0xLTEtMS0w_9fcaeb8a-647d-4c3c-b161-56ad338ad548"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97f46503b54b4c4581f7af547a5f1819_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy0zLTEtMS0w_02e7282b-7fe1-412d-af13-0af5848df0e5"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36e85343882a43ef806ab5bd3ca04f8b_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfMy01LTEtMS0w_3f5d7d0a-39ec-4f82-91d8-b570da9181e9"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3790f97128f2494d8984195c0fc58a83_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQyYjg3OTM4NTQ2MTQ5NDA5MWI1MTE5ODU2ZmRkMjI4L3RhYmxlcmFuZ2U6ZDJiODc5Mzg1NDYxNDk0MDkxYjUxMTk4NTZmZGQyMjhfNC0zLTEtMS0w_fa42eba0-7062-4942-a32e-89c786532cad"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjY_fbe8a8d6-7075-4cad-a9b6-496f739261e7">Cash Equivalents &amp;amp; Short-term InvestmentsCash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method.</lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock>
    <lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjg5NA_1a1687ae-a9eb-4a6c-baa2-84d66f1a8fda">P3M</lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum>
    <lgnd:AllowanceForDoubtfulAccountsPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTQ_6eebb4c1-41c4-4e54-9215-60a283f09735">&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms which range from 30 to 90 days. We reserve specific receivables if collectability is no longer reasonably assured. We re-evaluate such reserves on a regular basis and adjust the reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.&lt;/span&gt;&lt;/div&gt;</lgnd:AllowanceForDoubtfulAccountsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDU_29842245-6124-4164-93c1-c1af0dd09728">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_005688c4-03b4-4186-a6bc-f4e12ada5cee"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_919aada0-6a4c-4e53-a54f-9673872cca2a"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDI5MQ_d988ff46-c053-4c91-af5a-c01b30ca9a57"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjc_b3339588-2447-475d-8e8e-c975bdc3cf2d">&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzc_45c7d04e-58fb-46f7-91a3-3cb6a6cce268">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in other income (expense), net. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;amp;D is capitalized and assessed for impairment annually. IPR&amp;amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfODAzMQ_aa2918a1-6dc0-4586-9760-bcb0e0525cb8"
      unitRef="usd">10500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <lgnd:NumberOfContingentValueRightsIssued
      contextRef="i4d5cb59bf92840e6a385702bbe7c55ba_I20100131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfODU1OA_b6278794-6a91-4d97-8db3-85a51b8eeaa2"
      unitRef="right">4</lgnd:NumberOfContingentValueRightsIssued>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzg_5df585d6-25b7-4215-a3a7-67591cbbd24f">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2019, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <lgnd:CommercialLicenseRightsPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjA_3c3884e8-d768-451e-899a-cdc1d998c9e8">Commercial license and other economic rights&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.542%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.856%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aziyo &amp;amp; CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selexis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated amortization attributed to principal or research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial license and other economic rights as of December&#160;31, 2019 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#x201c;Novan Molluscum Products&#x201d;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Arrangement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and reduce our asset as the funds are expended by Novan. As of December&#160;31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan has been fully amortized as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congentia. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#x2019;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and will reduce our asset as the funds are expended by Palvella. We will evaluate the remaining asset basis for impairment on an ongoing basis. It is anticipated that the cost basis of the asset will be reduced to zero prior to the receipt of any payments from Palvella. Therefore, we will recognize milestones and royalties as revenue when earned. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase Agreement&#x201d;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Receivables&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2019 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2019 were accordingly allocated between revenue and the amortization of the commercial license rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. We recorded a $5.1&#160;million reduction in the carrying value of the Selexis asset which was reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</lgnd:CommercialLicenseRightsPolicyTextBlock>
    <lgnd:ScheduleofCommercialLicenseRightsTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDY_bfd69c2e-11b5-4277-a3a9-14b0e1fe9c8f">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.542%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.856%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aziyo &amp;amp; CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selexis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated amortization attributed to principal or research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofCommercialLicenseRightsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i76f6da162c3e4716b198d45ef10746a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMi0xLTEtMS0w_51a87776-dbe9-4ff1-a052-391c00c0c85d"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i59fc29cee5074164b3c15d239382aa22_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMi0zLTEtMS0w_7821327c-dd70-433b-8c1b-35949852e8a6"
      unitRef="usd">17696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ac076f1e57a4636b9b7a8d17ac9c624_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMy0xLTEtMS0w_59ae37ac-946a-4fa5-bfec-0cbd933520cf"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i503b6946954c46afa717c2fcf22da428_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfMy0zLTEtMS0w_99135142-34d7-4d06-aee2-71e1c8e1ab0b"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1677d2b07ff14a8dbc63ada1e73e55b0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNC0xLTEtMS0w_b188c691-6f8b-4d93-b3bd-cd9d9fdaef1c"
      unitRef="usd">8602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i10ee583771d143e48147fc04de5f46c1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNC0zLTEtMS0w_9d3e4534-cddd-43d5-ab20-104ace780e98"
      unitRef="usd">8602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i96448a01fb3f40a096e5d761e2c099b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0xLTEtMS0xNzQ2_49fb88f9-0ab6-491c-9616-dcc273133c33"
      unitRef="usd">2000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2287a9c538514d76aadb3ec1766fe149_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0zLTEtMS0xMDc4MA_c13d6d8d-94a0-47eb-a3b4-cbbcc1dfc001"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0xLTEtMS0w_f6fd51fd-fde2-4c70-bc7a-c7c183843c47"
      unitRef="usd">38298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNS0zLTEtMS0w_e4fdf3c8-85a9-4717-ba0c-59154405b9c4"
      unitRef="usd">36298000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0xLTEtMS0w_1fd31aaa-83b9-4e5f-acb0-7d220ef25f85"
      unitRef="usd">18208000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNi0zLTEtMS0w_24cfbad8-0bc2-4470-9dad-d588f80c6dda"
      unitRef="usd">4838000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if8ac8b2184b2414ba9a6ed927b533c8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNy0xLTEtMS0w_395eab8d-0f09-458a-91b9-fbcc19d927b9"
      unitRef="usd">20090000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6838bb2e0eeb48ca929a8a31bb077daf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwZmNiZGM2ODdmNzRlMDI4YzNmODUyNGYwNzVkMDg2L3RhYmxlcmFuZ2U6MjBmY2JkYzY4N2Y3NGUwMjhjM2Y4NTI0ZjA3NWQwODZfNy0zLTEtMS0w_c365dd7a-50db-48e7-8f83-aca286d4acff"
      unitRef="usd">31460000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <lgnd:LicenseUpfrontPayment
      contextRef="id883dd6370374636a72ea85102571215_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY5NTkxMQ_7f9a01a3-119b-4a05-acf7-8b41ae1cebf5"
      unitRef="usd">12000000.0</lgnd:LicenseUpfrontPayment>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="ia8345e8c12e54d5aaee35fd1453902c0_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ3MA_21d26fa0-0241-4901-80fa-b89bdc65d4e0"
      unitRef="usd">20000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i22c27966fa7a47b48404cf82d0835b4b_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ4OQ_bdcd76af-6fe7-493d-95ad-4e498d0eb0cb"
      unitRef="number">0.070</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="iabe93206950f4a5ca90a7c38545f68fa_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTY4OTQ5Ng_3c9e6e45-2362-4a37-aec6-93941b12f130"
      unitRef="number">0.100</lgnd:ProductRoyaltyPercentage>
    <lgnd:LicenseUpfrontPayment
      contextRef="id883dd6370374636a72ea85102571215_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTczMjk3MQ_7f9a01a3-119b-4a05-acf7-8b41ae1cebf5"
      unitRef="usd">12000000.0</lgnd:LicenseUpfrontPayment>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="id5b9fd1011fc45cb824aa53afa55ee70_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTIzNzk_cc9fa361-c789-4278-9cdb-8a8d734a9233"
      unitRef="usd">8000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="ic25cc6cea36649299a866a8aefa35559_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI2NzQ_608ee05a-b26e-4321-8b54-6441221ada4e"
      unitRef="number">0.050</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i1a7529b75a8a4febb9932e1ac827bae4_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI2ODA_d327fd93-e5e8-4625-8d7a-82fc3234dec3"
      unitRef="number">0.098</lgnd:ProductRoyaltyPercentage>
    <lgnd:LicenseUpfrontPayment
      contextRef="i04c56e43b6e44052bafac504dcd95284_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTI5MDc_7d82f1a6-31c6-44f3-aea9-14b4057f35a4"
      unitRef="usd">10000000.0</lgnd:LicenseUpfrontPayment>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="i5df91a43747141109e40628d6c3e1602_D20170531-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTM2Mzk_b65cad6c-cc29-4714-b0c1-a167ba292020"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <lgnd:ProductRoyaltyPercentage
      contextRef="i5c0bcf32476240a69acc2df358c66283_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTM5MDk_56adc76a-b670-4d59-b99d-250c3e8ca9ac"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="ia434c2f1e4fd4242bc042dcec9b0f76c_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQwMDY_cf8ac407-284b-44b0-9434-baa29ec659ab"
      unitRef="number">0.20</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
      contextRef="ibcbe0bbeae724e1d93328ffcae8742d7_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQyMzM_bb34f4b1-a19d-4c3f-9fa2-c3bb623b92e7"
      unitRef="usd">10000000.0</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="ibf9680e99f8b49b19bbd0708cf2b886f_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTQ5MzE_b4866d86-37bc-4651-99a2-29d3ace7976f"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:RoyaltyAgreementExpirationPeriod
      contextRef="ieaa465d6d40c45fba9d4e1bdc39e4cd8_D20170531-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTUwMTY_4c0790c1-2c11-4da0-927d-beb71d02f25f">P10Y</lgnd:RoyaltyAgreementExpirationPeriod>
    <lgnd:ForecastedCashFlowsEffectiveInterestRatePercent
      contextRef="i00b84867fefc461a891bb0fd73e18725_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTU1MTU_32b74630-81ad-4196-89ac-eb0960bb5209"
      unitRef="number">0.23</lgnd:ForecastedCashFlowsEffectiveInterestRatePercent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id365704cf3b84c6ab7c5a47ec6bdff70_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjE5OTAyMzM1MzEyMA_105ae137-e851-450f-88c4-5f8d6bbdc69a"
      unitRef="usd">-5100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjk_a7fd1fc5-ca5b-4478-a3df-97694f458a95">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See additional information in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; subsection below. Our accounting policies under the new standard were applied prospectively and are noted below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalties, License Fees and Milestones&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For R&amp;amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Material Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize revenue when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at prior year-end was $3.3 million. During the twelve months ended December&#160;31, 2018, the amount recognized as revenue that was previously deferred at prior year-end was $2.3 million.&lt;/span&gt;&lt;/div&gt;We have revenue sharing arrangements whereby certain revenue proceeds are shared with a third party. The revenue standard requires an entity to determine whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. We received $4.6 million royalty payments from a license partner during 2019 of which $4.0&#160;million was paid to a third-party in-licensor. We recorded net revenue of $0.6 million as we believe we are an agent in the transaction. We recorded an immaterial amount due to third-party in-licensors as general and administrative expenses as we are the principal in the transaction during 2019.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfOTg5NTYwNDc0NDA1MA_5936d94d-f22e-4022-8b81-f9362ee2ae03"
      unitRef="usd">3300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfOTg5NTYwNDc0NDEwNQ_87f9018d-513a-4798-bbfb-fe6ac57dc8a8"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <lgnd:RevenueRecognitionMilestoneMethodMilestonePaymentReceived
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjM0MzI_fe4b6ea1-660d-425e-bbbf-d293b88340a9"
      unitRef="usd">4600000</lgnd:RevenueRecognitionMilestoneMethodMilestonePaymentReceived>
    <lgnd:RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcyMzE3NQ_842e3577-df90-4d8e-905a-5dd5aa47a4ac"
      unitRef="usd">4000000.0</lgnd:RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i014e836b51b047e8b7d0a0a06fb58ea5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjM1NjY_ae2f2776-ba3a-40fb-b4b1-a9e4be98ce79"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE3MzE3OQ_3f96d075-eaba-4491-b91f-8c0e93acf9a8">Royalty revenue for 2019, 2018 and 2017 are reported as below (in thousands):&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.789%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.654%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.115%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.397%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2019&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2018&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;2017&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;99,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;128,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;1) Royalty revenue for 2019 and 2018 was reported under the current revenue recognition guidance (ASC 606).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2) Royalty revenue for 2017 was reported under the legacy revenue recognition guidance (ASC 605).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands), which are not affected by the adoption of ASC 606:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.976%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Material Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;License fees, milestones and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia82f8b0071ba419db2fd44d139c75921_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy0yLTEtMS0xMTk4Mw_55513136-7ecf-4fab-b432-b5a0971b145b"
      unitRef="usd">14193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i752660ce777040a3bf4a197f34a8a7ae_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy00LTEtMS0xMjAwNA_882ebcc9-5050-4069-a6b7-adbb25d0cbfe"
      unitRef="usd">99260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48b6c33518324d248216b8fc59601e1e_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfMy02LTEtMS0xMjAxNQ_adf0ff9f-edc1-44ae-b661-b26b39c10f3f"
      unitRef="usd">62918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fd9ffdb575642bc99960b6a0f220f7e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC0yLTEtMS0xMTk5NA_39c24535-37e0-49ff-a620-35b8cc1d7da7"
      unitRef="usd">25046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbf94a70bfff4f93bc6e7bb11e783a03_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC00LTEtMS0xMjAwNA_89157734-0882-4b6f-bde6-b9a4124f8032"
      unitRef="usd">21686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e64ad3b9590426a946af951ece864ce_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNC02LTEtMS0xMjAxNQ_4021e80a-2ec9-463c-9720-e066e4f8366b"
      unitRef="usd">16413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdbe7a966e324982b84d652d014786ac_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS0yLTEtMS0xMTk5NA_b669dee6-18d9-4405-921e-e86a18448be0"
      unitRef="usd">5171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ff65fe494c14a35b1dd9f4bd1dc538c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS00LTEtMS0xMjAwNA_c14206ec-c1e9-49dd-8136-7f8c543219db"
      unitRef="usd">5658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9612324a089e4c32998e3a6d952592f8_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNS02LTEtMS0xMjAxNQ_d30f4b67-df9d-4c76-b361-b3b368ca64f1"
      unitRef="usd">7155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i146808219fd64e048cff80065bea6f1b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi0yLTEtMS0xMTk5NA_dc1bb883-4458-4b20-b12e-652ceb6f4030"
      unitRef="usd">2566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i960ac618c48c4ce3b0502dead45bbb2a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi00LTEtMS0xMjAwNA_cdaa7570-9f54-4c2a-b8be-ea027207bce1"
      unitRef="usd">1952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if187e8fde5214e529fe79103581b53a1_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNi02LTEtMS0xMjAxNQ_f5813717-c657-4cfa-a59e-b4699650752d"
      unitRef="usd">2199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcf81d10b48b4bfe9fa77f4a59eb3a7c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy0yLTEtMS0xMjMyOQ_7a98b21a-ca03-4e35-9dd7-28ab0f732f82"
      unitRef="usd">46976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4dbcf6a76aa417dbf8f6bddc23a57b3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy00LTEtMS0xMjMzMA_9bfb9dc5-b517-4302-b2a0-a67ffa0da55d"
      unitRef="usd">128556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0845150ee3d8408f8aaef7ffb7acab4d_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOmQzMWYyMTA3MDAxNjQ2NTBhNDc3MmYwMDYwY2MxODE1L3RhYmxlcmFuZ2U6ZDMxZjIxMDcwMDE2NDY1MGE0NzcyZjAwNjBjYzE4MTVfNy02LTEtMS0xMjMzMg_2a9f8d14-9f84-4f78-b4b1-7f3006062473"
      unitRef="usd">88685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i300135f7b3cb4b7ba9b2a36a2a1df4da_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy0yLTEtMS0w_bd7cf525-f58b-4120-a3b7-1f7ed8dd79c1"
      unitRef="usd">31489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i675b454e2a4246a5976716630c08343b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy00LTEtMS0w_a4608a2a-6071-42f7-a819-86791953668a"
      unitRef="usd">29123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72df125d1c2340aaa61ccc90d1ebcf13_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfMy02LTEtMS0w_11bd1dab-96c5-4d33-a743-5a4abcc5cdd2"
      unitRef="usd">22070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i194607164d454958b0723749de9579e2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS0yLTEtMS0w_6cb3fd65-4b51-4bd2-9c71-5740c7aa3495"
      unitRef="usd">6199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ff0c9eca02e4a2f9b35491141d683f0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS00LTEtMS0w_7254e4ad-e3e6-48ff-87ce-d4f84d299041"
      unitRef="usd">78195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffdb648378694003ae22ea717992f96b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNS02LTEtMS0w_95c348ef-51e3-4283-851d-0cb78d0419e9"
      unitRef="usd">13665000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i554d97702ee847d8a57c46340addad5d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi0yLTEtMS0w_ec027014-12f8-443a-aab1-695502fce16c"
      unitRef="usd">23451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05a2217af97e477b903d2d5d4edab90b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi00LTEtMS0w_17710779-142a-48fa-b2a3-931bfa7eeb24"
      unitRef="usd">6577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd04a9173f544a62859a7935f7ae3658_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNi02LTEtMS0w_86677d53-03ad-4e5d-965d-102a5374a669"
      unitRef="usd">11093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d72465b58ad4e67b216c687373c6ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy0yLTEtMS0w_b961dc1d-a554-4fb2-b0f7-ca9cc3b87b80"
      unitRef="usd">12167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd9941b5f3154326bcadc3bdd7cdd3b7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy00LTEtMS0w_ae3c20bd-bcd7-4c8b-bbb2-ed2f38a4e908"
      unitRef="usd">9002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee06435e8cf54fa7aa9127b85e72920f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfNy02LTEtMS0w_6700825a-c9b9-4c16-9d78-00a035aa7479"
      unitRef="usd">5589000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i931a0da031a240d4907cedb7675e6b32_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC0yLTEtMS0w_49e30556-2a72-4915-98db-a4ad4c926463"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ccc3f98d0d4f2ba9a8c509ad29453f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC00LTEtMS0w_475879ba-17d5-4028-b6ad-ee8d331fe4b9"
      unitRef="usd">93774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ab772db91d340699594bd2dcf068ecb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjFmYTI2ZTc4Yzk0OTQ2MDRiY2E4ZmNjMmZlMmM5NDVkL3RhYmxlcmFuZ2U6MWZhMjZlNzhjOTQ5NDYwNGJjYThmY2MyZmUyYzk0NWRfOC02LTEtMS0w_559168d3-b8e3-44c4-bff5-87a18b437326"
      unitRef="usd">30347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDA_b89e5376-f37f-4927-b8cc-903b366fc6e6">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preclinical Study and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.&lt;/span&gt;&lt;/div&gt;</lgnd:PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjg_288dc1d5-b584-4ac6-8157-2a3777a3454f">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzM_859df81f-7ec9-4306-bb2c-70fae4491f30">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i40f1b30e9315498090c3a5d490662303_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjgyMDA_38a99079-8558-4555-ae5d-1fa987712ba0"
      unitRef="number">0</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie0993a0ffdc9416e8eae6352f6f762b9_D20070101-20071231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjgyOTU_124f8a32-a9ad-49ea-9c10-f76e5e13b6e5"
      unitRef="usdPerShare">2.50</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i59e2fe191ffb414da27578a719a56920_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjkwODI_2fca8384-0ab5-47d9-adc9-9c59cc9648ef">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjkzMjU_b9fcf26d-b9c4-4195-86d4-e1a1c43e3149"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3f0605d8c3b74b0aa10699fe578b6e43_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjk0MDU_0d408b4b-2ec3-4a25-bc52-6b3f4aee74b0"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMzA5NDY_bcf997a4-8b9d-4822-8194-7ed87b204b68"
      unitRef="usd">245000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeAssets
      contextRef="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE2OTcyMQ_0f96d7c3-231c-491d-b15c-4ffece2106fd"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i244bb56d758c4eaf8ecbd3d30e45a013_I20190815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMjc0ODc3OTE2OTcyMQ_7be812fe-5ba8-4f51-8f4c-7191473e4ee2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNDk_086c4739-6228-4570-805d-9103c34fca73">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzE_658fff9c-c6ab-47ff-9da7-8f1c0553f085">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income (loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMzQ_bca81617-c7b0-4abd-9b23-32fd30514357">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.289%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.749%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Warrants associated with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;2019 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi0xLTEtMS0w_b714ee0e-3e05-436d-800c-4bcc64fd4729"
      unitRef="shares">18995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi0zLTEtMS0w_c7b1a67f-418f-4afc-9ab3-46062298ca57"
      unitRef="shares">21160000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfMi01LTEtMS0w_4700684a-aeb2-4c57-92b5-7ebb64c1d9c4"
      unitRef="shares">21032000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC0xLTEtMS0w_5fa46a17-1eba-4840-b27b-f736fa0abe54"
      unitRef="shares">43000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC0zLTEtMS0w_befe4a02-76c2-4b05-9c72-0e70979a871b"
      unitRef="shares">72000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC01LTEtMS0w_2eff0143-f711-4fc6-83ef-2aa1f686ac03"
      unitRef="shares">141000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNC01LTEtMS0w_9da4b67d-acf6-4171-b421-b2fb8ba7c8ac"
      unitRef="shares">141000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS0xLTEtMS0w_862e417c-24bf-404c-bdaf-08f511fa0715"
      unitRef="shares">719000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS0zLTEtMS0w_8bf2e12f-09f6-4771-921c-0c66660c72ca"
      unitRef="shares">1125000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS01LTEtMS0w_6945c21a-56ed-48e9-98f6-1ba6941e4aa1"
      unitRef="shares">1000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNS01LTEtMS0w_e032b521-a7e5-46ec-bdec-bada29a8a93f"
      unitRef="shares">1000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi0xLTEtMS0w_5a2f45bd-fe2d-4579-a1c2-94e0d0862556"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi0zLTEtMS0w_8b0085ff-b5a7-4f48-a970-d27651a886d1"
      unitRef="shares">1017000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNi01LTEtMS0w_97af1849-eb2f-4604-9170-51acce54022d"
      unitRef="shares">94000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy0xLTEtMS0w_b7ddf039-e487-413c-b975-df3bcf57ea74"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy0zLTEtMS0w_ce793e47-b6d9-4f42-9864-fdde003e887a"
      unitRef="shares">693000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy01LTEtMS0w_1f47ab30-488b-46a0-a05a-15b777b05828"
      unitRef="shares">1214000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfNy01LTEtMS0w_2957f5e0-ebfa-40f9-8400-e53e7eefe191"
      unitRef="shares">1214000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC0xLTEtMS0w_465c2087-02e5-4bb4-a442-1c7a273eedc7"
      unitRef="shares">19757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC0zLTEtMS0w_bb2207a1-a66b-4fcd-a903-d6ef773e4b88"
      unitRef="shares">24067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOC01LTEtMS0w_db7cf6c3-6ac6-4810-9324-ce1fda59b2d5"
      unitRef="shares">23481000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS0xLTEtMS0w_21532399-3f38-462f-94e2-a861368d55ce"
      unitRef="shares">8926000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS0zLTEtMS0w_6765e738-fbde-4e2b-b4c1-ac0e5c5670aa"
      unitRef="shares">2845000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS01LTEtMS0w_b3d919f3-c821-4db4-8a73-e591e25e94d4"
      unitRef="shares">335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RhYmxlOjIwOWE1NWEwOTA5ZjRkYmY5MTJmMmVkYTgxNmE5MDdiL3RhYmxlcmFuZ2U6MjA5YTU1YTA5MDlmNGRiZjkxMmYyZWRhODE2YTkwN2JfOS01LTEtMS0w_b552faf1-3494-4b5e-9966-27076f4590e3"
      unitRef="shares">335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwMjM_f491ab91-4cd1-4f77-b4c5-d57af5978546">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTA_a94f2e0b-466c-46a6-a412-b2dfebaea9fb">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfNDUwNTU_f650397c-24b2-402a-b1aa-67ebc160e7dc">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Standards Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In 2018, the FASB issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in ASC 840,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt; Leases (Topic 840),&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; including its disclosure requirements, in the comparative periods presented. We adopted this standard on January 1, 2019 by applying this optional transition method. For leases with a term of 12 months or less, we elected to not recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. In addition, we elected the available package of practical expedients upon adoption, which allowed us to carry forward our historical assessment of whether existing agreements contained a lease and the classification of our existing operating leases. We did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases. We continue to report our financial position as of December 31, 2018 under Topic 840 in our audited consolidated balance sheet. The adoption of this standard update resulted in the recognition of right-of-use assets of approximately $5.2 million and lease liabilities of approximately $5.9 million on our consolidated balance as of January 1, 2019, with no material impact to our consolidated statement of operations. See "&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Note (6), Leases"&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; for further information regarding the impact of the adoption of ASU 2016-02 on our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for us beginning in the first quarter of 2020, with early adoption permitted. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We will adopt this standard effective January 1, 2020, and we currently do not expect the adoption to result in a  material impact to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In January 2017, the FASB issued ASU 2017-04, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Simplifying the Test for Goodwill Impairment,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. This standard is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement: Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020, and will include the required disclosure beginning in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; - In November 2018, the FASB issued ASU 2018-18&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;recognized from contracts with customers. The new standard is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted in any interim period for entities that have adopted ASC 606. The standard should be applied retrospectively to the period when we initially adopted ASC 606. We will adopt this standard effective January 1, 2020, and do not expect the adoption will result in material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id36623c1d9734d28ae32c58d9b90c026_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcxMjk5Mw_dbf5f070-5646-4bef-9534-7269a4ddfec0"
      unitRef="usd">5200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="id36623c1d9734d28ae32c58d9b90c026_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M184NS9mcmFnOmQ5NzQ4MmMxNmVhMjQ3YmFhYjJhN2MzMzVmNmM5NGQ4L3RleHRyZWdpb246ZDk3NDgyYzE2ZWEyNDdiYWFiMmE3YzMzNWY2Yzk0ZDhfMTA5OTUxMTcxMzAxMA_4a3628a7-59dc-4269-a82e-dd736852247d"
      unitRef="usd">5900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzI3NDg3NzkwNzEwNjk_56fd045c-b404-4f97-916e-aa3a9152353d">Sale of Promacta License&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On March 5, 2019, we entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with RPI Finance Trust (&#x201c;RPI&#x201d;), doing business as &#x201c;Royalty Pharma&#x201d;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#x201c;Purchased Assets&#x201d;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets&lt;/span&gt;.</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <lgnd:RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets
      contextRef="i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNDE_350eee67-75b3-4e6c-85c4-dc6b7a062d79"
      unitRef="usd">827000000.0</lgnd:RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7411d3bb032347e6a6b92e42a6d29132_I20190306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNjA_029aa10d-803c-4fc5-8996-8ba12301b4ad"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i879ae176b2124f789573e2512496d9a0_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzNjY_cb67970a-60f2-4520-97eb-5d7a47d9962a"
      unitRef="usd">14200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id432212c910f45cb9fd439930be6a10c_D20190101-20190306"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M183NjgvZnJhZzpjN2QzMGI2NmNkYWY0MGFhYmQzZjViN2ZhZDcxMWM4MC90ZXh0cmVnaW9uOmM3ZDMwYjY2Y2RhZjQwYWFiZDNmNWI3ZmFkNzExYzgwXzEwOTk1MTE2MjkzODQ_c6af926a-1a6e-4459-8f6c-495604fc2b5a"
      unitRef="usd">812800000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjc0ODc3OTA3NjY3Mw_eaf7a96d-87e7-480a-a752-c33bc92d7471">Investment in Viking&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our ownership in Viking was approximately 10.3% as of December&#160;31, 2019, and we account for it as investment in an available-for-sale security, which is measured at fair value, with changes in fair value recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to February 2018, we accounted for our investment in Viking under the equity method. As a result of Viking's public stock offerings, we recorded a dilution gain of $2.7 million for the year ended December 31, 2017. These amounts were recognized in Loss from Viking in our consolidated statement of operations. Our equity ownership interest in Viking decreased during the first quarter of 2018 to approximately 12.4% due to Viking's financing events in February 2018. As a result, in February 2018, we concluded that we did not exert significant influence over Viking and discontinued accounting for our investment in Viking under the equity method. Viking is considered a related party as we maintain a seat on Viking's board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and December&#160;31, 2018, we recorded our common stock in Viking at fair value of $48.4 million and $46.2 million, respectively. We also have outstanding warrants to purchase 1.5 million shares of Viking's common stock at an exercise price of $1.50 per share. We recorded the warrants in "investment in Viking" in our consolidated balance sheets at fair value of $9.9 million and $9.3 million at December&#160;31, 2019 and 2018, respectively. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (5), Fair Value Measurement.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subsequent to the adoption of ASU 2016-01, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Overall (Subtopic 825-10), &lt;/span&gt;on January 1, 2018, we no longer account for our investment in Viking under the equity method; instead, it is measured at fair value, with changes in fair value recognized in net income (loss).</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i42d16a6431d94f848413960849cb7def_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfODA_588250c9-f2e3-4abc-a267-119d1c49a69c"
      unitRef="number">0.103</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <lgnd:IncreaseDecreaseinEquityMethodInvestment
      contextRef="i627d466bba7d41ddbcecee653a9fcb3e_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfNjcx_5060365e-1ff3-42d0-8ddf-ab961b2896af"
      unitRef="usd">2700000</lgnd:IncreaseDecreaseinEquityMethodInvestment>
    <lgnd:VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfOTU3_5217b4b1-76a6-4816-9538-3f380e15d4dc"
      unitRef="number">0.124</lgnd:VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIwMA_b85c6aa1-f822-461e-9894-67177ef8b70c"
      unitRef="usd">48400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIwOQ_9cc64fa5-d132-470c-892c-6a56ff4fea12"
      unitRef="usd">46200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMTA5OTUxMTYzNDIyOA_3be83385-e9c2-4f23-a031-1f92e50e21ea"
      unitRef="usd">1500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia866a9721849422ea2aa6ef8a644c3b6_I20160430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjc1MA_8591e775-ca42-4287-872f-7e94bf2846e2"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgnd:InvestmentInVikingCurrent
      contextRef="i6365b125a6f9462a9020457fd59be296_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjg2NQ_8d14be8c-e381-476b-9863-dd092d7b168e"
      unitRef="usd">9900000</lgnd:InvestmentInVikingCurrent>
    <lgnd:InvestmentInVikingCurrent
      contextRef="if127a97e90a74b089bee82f5b9537b9f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185MS9mcmFnOjRkMTM1OGQyZjlkNjQwMzJhYTUwZTU1MzhkNTYzZDFlL3RleHRyZWdpb246NGQxMzU4ZDJmOWQ2NDAzMmFhNTBlNTUzOGQ1NjNkMWVfMjg3Mg_f0035d4e-4797-47eb-9caf-6a58544721da"
      unitRef="usd">9300000</lgnd:InvestmentInVikingCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1Mw_759a52ab-7169-48c5-b569-7a5851b8dfbd">Business Combinations&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As set forth below, we completed three acquisitions from January 1, 2017 through December 31, 2019, and all were accounted for as business combinations. We applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, we did not incur any material acquisition related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Ab Initio Acquisition&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae; &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The purchase price of $12.0 million included $11.84 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.482%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles assets with finite life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Vernalis Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018, we acquired Vernalis, a structure-based drug discovery biotechnology company for $43.0 million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.482%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restructuring and product reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles assets with finite life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies.  These projected cash flows were discounted to present value using a discount rate of 34.0%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately nine years.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Crystal Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 6, 2017, we acquired all of the assets and liabilities of Crystal. Crystal is a biotechnology company focused in avian genetics and the generation of fully-human therapeutic engineering of animals for the generation of fully-human therapeutic antibodies through its OmniChicken&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; technology. Under the terms of the agreement, we were to pay Crystal selling shareholders $27.2 million in cash including a $2.2 million working capital adjustment, and up to an additional $10.5 million&#160;of cash consideration based on Crystal&#x2019;s achievement of certain research and business milestones prior to December&#160;31, 2019. In addition, Crystal&#x2019;s selling shareholders will receive 10% of revenues realized by Ligand above&#160;$15 million between the closing date and December&#160;31, 2022 from&#160;existing collaboration agreements between Crystal and&#160;three&#160;of its collaborators, and Crystal&#x2019;s selling shareholders will receive 20% of revenues above&#160;$1.5 million&#160;generated between the closing date and December&#160;31, 2022 pursuant to a fourth existing collaboration agreement with a large pharmaceutical company. As of December&#160;31, 2019, $0.02 million of the initial $27.2 million of cash consideration remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the closing of the acquisition, we recorded an $8.4 million contingent liability for amounts potentially due to Crystal shareholders. The initial fair value of the liability was determined using a probability weighted income approach incorporating the estimated future cash flows from potential milestones and revenue sharing. These cash flows were then discounted to present value using discount rates based on our estimated corporate credit rating, and averaged to approximately 4.6%. Refer to &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 5 Fair Value Measurement &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for further discussion. The liability has been periodically assessed based on events and circumstances related to the underlying milestones, and any changes in fair value are recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (8), Balance Sheet Account Details&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The final aggregate acquisition consideration was determined to be $35.7 million, consisting of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.411%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.589%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid to Crystal shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payable to Crystal Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assumed liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Current liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the core technology, or OmniChicken technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniChicken technology. These projected cash flows were discounted to present value using a discount rate of 10.8%.  The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 20 years.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was $10.7 million and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to Crystal&#x2019;s potential revenue growth from combining the Crystal and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <lgnd:NumberOfAcquisitions
      contextRef="i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTA5OTUxMTY0MjM4Ng_090e2d5f-e574-44f9-8b0b-25e6b03c661b"
      unitRef="acquisition">3</lgnd:NumberOfAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMDI_1cea1e43-b9a4-4af8-a704-59d91545be19"
      unitRef="usd">12000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMTI_9dcb7db9-7182-4036-aebb-cdc03f0b304c"
      unitRef="usd">11840000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims
      contextRef="i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTcyMTk_9eee0029-b876-4d77-ad18-15a9d87d2df2"
      unitRef="usd">150000</lgnd:BusinessCombinationCashHoldbackForPotentialIndemnificationClaims>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i4ee653649d66402981113f680d933493_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjc0ODc3OTA4NDQ2MA_510a5e2d-b770-456e-b771-16f08b4c85a1">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.482%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles assets with finite life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfMC0xLTEtMS00NDQ3_370c23b9-76cb-4c6a-8edf-477a42b30fcd"
      unitRef="usd">28000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfMy0xLTEtMS00NDQ3_f9fc24c4-5840-4655-9f14-255a042ccff6"
      unitRef="usd">83000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNC0xLTEtMS00NDQ3_36f6a2f3-0b0c-4e14-8205-d1862739d5c4"
      unitRef="usd">1609000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNi0xLTEtMS00NDQ3_eb505c55-fada-4e9f-ac53-8b172d79b5dc"
      unitRef="usd">7400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNy0xLTEtMS00NDQ3_59c84023-1d52-4ebf-88b9-a3cf0f298ed4"
      unitRef="usd">6275000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOmQwODNjY2MwYTMzYzQwNWY5MzFiYmUwOTU4N2QzMTVhL3RhYmxlcmFuZ2U6ZDA4M2NjYzBhMzNjNDA1ZjkzMWJiZTA5NTg3ZDMxNWFfNS0xLTEtMS0xMDg0Mw_366da8ab-4910-4ee0-842b-5cffaa46f75d"
      unitRef="usd">12011000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTgxMzU_ad4438c0-776b-48e9-bc0e-edb5f065187b"
      unitRef="number">0.120</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6a285f7cae6847cbb84e55f9cc40ae24_D20190723-20190723"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTIwOTQ2Mjc5MTgyODc_31fcca57-3585-485c-b7dd-4e94d1bb24ef">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i063eb253ae3b4c25a99074736166eeb7_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjAw_6a5b8434-6b75-4089-8223-8eac65991bc0"
      unitRef="usd">43000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="idffee5590e9a4dc7b62742af7e16dc82_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU2MQ_517b35ab-f7f5-4aed-8e46-20ae535cd2b7">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.518%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.482%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restructuring and product reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangibles assets with finite life - core technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMC0xLTEtMS0w_665546d0-b113-439c-ab59-de80bd7ce28a"
      unitRef="usd">34286000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMS0xLTEtMS0w_59469b80-8291-4730-aac7-a608bd4f2fff"
      unitRef="usd">2836000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMi0xLTEtMS0w_6e260e2e-f2b8-481f-9799-22ca1edd8618"
      unitRef="usd">6383000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfMy0xLTEtMS0w_e3dcca15-8f8a-4966-a01e-1c12b9d0d426"
      unitRef="usd">3479000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:RestructuringReserve
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNC0xLTEtMS0w_ea3490a5-3207-4a0e-bc2b-5e90a0b8cc34"
      unitRef="usd">9241000</us-gaap:RestructuringReserve>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNS0xLTEtMS0w_868ea12d-cf84-419f-abf1-4ea98c022e38"
      unitRef="usd">746000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNi0xLTEtMS0w_1225c331-bbbf-4472-9d91-f0e35309eef8"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfNy0xLTEtMS0w_638ef3b1-767b-4454-897c-7de1ba52e912"
      unitRef="usd">5939000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjlmOGIxYTdmZWVmNjQ4N2NhYmY2NWNmNzUzMGQ4ZjBkL3RhYmxlcmFuZ2U6OWY4YjFhN2ZlZWY2NDg3Y2FiZjY1Y2Y3NTMwZDhmMGRfOC0xLTEtMS0w_00d30377-21f6-4627-9e46-d6d0b666d25e"
      unitRef="usd">42978000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="icde9c31e86024dd0ae2c8ea70643ce67_I20181031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTM0NA_52a5db4a-3dcb-43f9-99b6-38110bac6d88"
      unitRef="number">0.340</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i814ece52582942738ba79ba1e26c7405_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMTQ5NQ_b94932d0-e62b-4b91-a87e-302e80bc86e6">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjMxMQ_54d3c941-fabb-4ddf-99b6-27b79763e3f0"
      unitRef="usd">27200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:WorkingCapitalAdjustment
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjMzNA_034d2fd3-9b21-4d33-81f1-7c22fcf290d3"
      unitRef="usd">2200000</lgnd:WorkingCapitalAdjustment>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjM4OQ_e0c909bf-22af-4fd4-b7ba-21b8a2d23841"
      unitRef="usd">10500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <lgnd:RevenueRoyaltytoAcquireeShareholdersPercent
      contextRef="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjU3NA_e2e469ed-0188-4442-bda1-92f4cccc44fb"
      unitRef="number">0.10</lgnd:RevenueRoyaltytoAcquireeShareholdersPercent>
    <lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments
      contextRef="iaf0ae53bd7984c9eb4aba338f8ed96a6_D20171006-20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjYxNA_43ee8901-cf4a-48a0-9125-fbf61c32fc1d"
      unitRef="usd">15000000</lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments>
    <lgnd:RevenueRoyaltytoAcquireeShareholdersPercent
      contextRef="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjc5OQ_9feae559-ec32-46b8-ae15-793defe4e16a"
      unitRef="number">0.20</lgnd:RevenueRoyaltytoAcquireeShareholdersPercent>
    <lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments
      contextRef="i7f552f6ae3704a4fab13d22fd9780292_D20171006-20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjgyMA_c7696f0c-00df-4a63-a49f-cd730ac57837"
      unitRef="usd">1500000</lgnd:ThresholdRevenueAmounttoTriggerRoyaltyPayments>
    <lgnd:NumberofCollaborationAgreements
      contextRef="i1697e6f29f434232b75e818f4ca2eca0_I20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjg5NA_3703db2f-1218-465e-950a-9f703a0cbd99"
      unitRef="numberofcollaborationagreements">4</lgnd:NumberofCollaborationAgreements>
    <lgnd:CashPayable
      contextRef="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjk3OQ_b2c3e75d-83dc-4d20-abce-8974abc7b0b5"
      unitRef="usd">20000.00</lgnd:CashPayable>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMjk5Nw_b3d8a5f8-522c-4257-9146-4ed4818d8daf"
      unitRef="usd">27200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMzA5NQ_eaf7769f-d5de-4a65-b448-5b6bc334343b"
      unitRef="usd">8400000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate
      contextRef="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfMzUxOQ_b5bb4382-e9cc-454c-aa2a-89c29c47d0de"
      unitRef="number">0.046</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate>
    <lgnd:ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock
      contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1Nw_09a9ca95-5fdd-4e90-b166-c46782056353">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The final aggregate acquisition consideration was determined to be $35.7 million, consisting of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:77.411%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.589%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid to Crystal shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payable to Crystal Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assumed liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDEyMQ_bba8f22d-e935-4249-858a-ca06edb8a970"
      unitRef="usd">35700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:CashPaidtoAcquireBusiness
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMC0xLTEtMS0w_ded8a8a7-464f-413a-a263-fffc41f24ee6"
      unitRef="usd">26877000</lgnd:CashPaidtoAcquireBusiness>
    <lgnd:CashPayable
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMS0xLTEtMS0w_3d1cc96a-64c6-4bbf-99f3-d95ee7785b89"
      unitRef="usd">336000</lgnd:CashPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMi0xLTEtMS0w_9d567600-a0bb-45bb-b3e6-a5ac30d5be98"
      unitRef="usd">129000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration
      contextRef="i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfMy0xLTEtMS0w_c5c776d1-2a17-4878-a2ec-63ee271bd289"
      unitRef="usd">8401000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjM0MmM4ZGY1NTk0ZDRlOGE4NGViYmI2M2U5N2E2ZmU5L3RhYmxlcmFuZ2U6MzQyYzhkZjU1OTRkNGU4YTg0ZWJiYjYzZTk3YTZmZTlfNC0xLTEtMS0w_7a3d089b-fdda-4684-93af-9978ea9684da"
      unitRef="usd">35743000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNjU1MQ_5eec17c4-ef92-4f32-9455-ab0b0a5e5dd1">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.498%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Current liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMC0xLTEtMS0w_1dd1c05c-dca2-40e8-9b85-c82f056fb6cd"
      unitRef="usd">224000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMS0xLTEtMS0w_e0c9cb3d-0200-4ad7-a9c3-02d4ba9f2a44"
      unitRef="usd">2513000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMi0xLTEtMS0w_0fcc8c30-b709-4ebe-b3ee-95c4376c2132"
      unitRef="usd">201000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfMy0xLTEtMS0w_cd4818b0-02d5-468f-a30e-725dd01ec0e9"
      unitRef="usd">589000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNC0xLTEtMS0w_ed13badd-483c-429e-8650-d14c0b11f76b"
      unitRef="usd">354000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNS0xLTEtMS0w_e1c2a1d2-e39e-41ad-9761-3d9e02840287"
      unitRef="usd">4624000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNi0xLTEtMS0w_8c8089c5-d275-4be7-b263-9b976d3ca0d8"
      unitRef="usd">9503000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfNy0xLTEtMS0w_a3a7e531-0424-48bf-9936-af495b860985"
      unitRef="usd">36000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfOC0xLTEtMS0w_17cd1086-8ac9-4abc-82ba-0bc3121343fe"
      unitRef="usd">10697000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RhYmxlOjA0OTlhZWE0YjAxMTRmNzdhZjM0MmMxYmUwMjY0YjJhL3RhYmxlcmFuZ2U6MDQ5OWFlYTRiMDExNGY3N2FmMzQyYzFiZTAyNjRiMmFfOS0xLTEtMS0w_285ade63-af68-4678-9d8e-22de9fd9ed0a"
      unitRef="usd">35743000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate
      contextRef="i244fcac88b0c4c6a9c93b9832417b4dd_I20171006"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDYzMg_e3f84f82-22b5-49ab-8b19-b7fdf81067e6"
      unitRef="number">0.108</lgnd:BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8cf89aa90cf34ae8b88f29189cdd661b_D20171006-20171006"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDc1Mw_f06f0b78-b3e7-4c98-8f5f-86c2c1b52d66">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:Goodwill
      contextRef="id7c3e0f45fa04308991b331a1b1cdec4_I20171006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185NC9mcmFnOjM1ZDQzZjhlMDBmODQwNzY5ZGUyOTJlNzgwNDBjOThhL3RleHRyZWdpb246MzVkNDNmOGUwMGY4NDA3NjlkZTI5MmU3ODA0MGM5OGFfNDg5NA_beeafc14-ad1e-4cbe-b86e-48c058409d10"
      unitRef="usd">10700000</us-gaap:Goodwill>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI3MQ_64af6131-d793-4e2b-a203-51248e5fec74">Fair Value Measurement&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 - Observable inputs such as quoted prices in active markets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Short-term investments&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Investment in Viking warrants &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;998,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Short-term investments&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;601,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Investment in Viking warrants &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;656,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;(1) Short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on black scholes value estimated by management as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;Gain (loss) from Viking&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (3), Investment in Viking.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2019, we paid $3.0 million contingent liability on development milestones to former Crystal shareholders. At  December&#160;31, 2019, $1.8 million of the development and regulatory milestones were considered to be achieved and will be paid to former Crystal shareholders during the first half of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. Another Metabasis drug development program, RVT-1502, has been outlicensed to Metavant. RVT-1502 is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist or &#x201c;GRA.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2019 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:81.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.716%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of level 3 financial instruments as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Assets Measured on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other than a reduction in the value of our Selexis commercial license right disclosed in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial license and other economic rights&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; and a GRA intangible asset, there were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the current fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (7), Convertible Senior Notes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; for additional information related to the fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI3Mg_1bbd2f73-3b76-4004-aeaf-af53c0382884">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Short-term investments&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Investment in Viking warrants &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;998,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Short-term investments&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;601,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Investment in Viking warrants &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;656,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Crystal &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent liabilities - Cydex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent liabilities - Metabasis &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;(1) Short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;"&gt;short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on black scholes value estimated by management as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(2) Investment in Viking warrants, which we received as a result of Viking&#x2019;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#x201c;Gain (loss) from Viking&#x201d; in our consolidated statement of operations. See further discussion in &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (3), Investment in Viking.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#x2019;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2019, we paid $3.0 million contingent liability on development milestones to former Crystal shareholders. At  December&#160;31, 2019, $1.8 million of the development and regulatory milestones were considered to be achieved and will be paid to former Crystal shareholders during the first half of 2020. &lt;/span&gt;&lt;/div&gt;(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. Another Metabasis drug development program, RVT-1502, has been outlicensed to Metavant. RVT-1502 is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist or &#x201c;GRA.&#x201d;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b00d8919174418ebe287cc12594d727_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC0xLTEtMS0w_22b03f30-a3dd-4f4e-b1f7-48e1bfb347a9"
      unitRef="usd">939989000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if66e23507a484f19a663af8fe0d1ac56_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC0zLTEtMS0w_97a941c6-2c87-4fda-8c36-122d4dbe0396"
      unitRef="usd">3073000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b560e54f4ba43f09c2f8005e045a4b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC01LTEtMS0w_98c93640-5412-4b00-9c4a-c964800770e4"
      unitRef="usd">936791000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia520b2b8a01f4302905c89f3b3631aba_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNC03LTEtMS0w_cf51080c-db57-4eb4-977c-82a9087bdcaf"
      unitRef="usd">125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if13f24dbd7b94cdd98bce8907218b098_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0xLTEtMS0xMzI3Mg_62eb5ee8-f993-40c3-9660-ff843cb6b817"
      unitRef="usd">48425000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0c1b7515d834b96ba399542082661b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0zLTEtMS01MjQ4_a7c38d16-f499-4266-9a05-bfa84915440d"
      unitRef="usd">48425000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if65edf5940434c65862432001f7fca40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS01LTEtMS01MjUx_43f42b35-f77a-4cc9-8be5-2d0bdec51bf6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2641b53d2baa4c3fa22b49a8cd48329e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS03LTEtMS01MjU0_58cc9d5d-c68a-416d-96bd-7897fe1aecb8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a384419cf554229afda13595299df80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0xLTEtMS0w_3d7cf599-f088-448e-a46f-04dff5b7038f"
      unitRef="usd">9910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie86a62fed86e4561b271030c70bfbe6b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS0zLTEtMS0w_0ad0def7-3638-408f-a3a2-3f193cfc0df5"
      unitRef="usd">9910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1065d4ab29524f959cf02e2235084e47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS01LTEtMS0w_abd3c7fe-7dec-4d86-b437-bdddccc0f0c4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0795ba3ab21f49fcbe79b88fea60278d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNS03LTEtMS0w_2714d26d-e3db-4e3b-a90c-c944a5c52bd5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f894f3d17b245c480e3f32580adbf3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0xLTEtMS0w_129b3cf6-5339-4d7f-92cc-fb7ad59be822"
      unitRef="usd">998324000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi0zLTEtMS0w_1213d771-916e-428f-ae1d-9a57fb0963d4"
      unitRef="usd">61408000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi01LTEtMS0w_2be332cb-7f09-44de-80bd-8161f20db5bf"
      unitRef="usd">936791000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfNi03LTEtMS0w_d1430cb0-77e8-4056-90f6-6c88c93b4b06"
      unitRef="usd">125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic92a6ee4b08740648c5cc02eb96d8312_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC0xLTEtMS0w_c0737b71-d679-46f5-a838-3ecd1eeeea6f"
      unitRef="usd">2659000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if7cf3fc5e9b14c01b5883261d2ebf84e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC0zLTEtMS0w_917b19c3-1fdd-4387-8829-8a60d98a2a11"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if88fbc1c8f9440599dc1210a3215a18f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC01LTEtMS0w_11c2c16b-41e7-446f-bfe9-83e16b1488b4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4ee3f1bbedd04ef0a2d097ae36f3fcfb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOC03LTEtMS0w_9b21fa90-e9b5-4381-99a4-1720558189fe"
      unitRef="usd">2659000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i333307bd30ca43dabd171c81f9a061c7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS0xLTEtMS0w_bda652bb-4dff-478d-a404-bed669fe572a"
      unitRef="usd">348000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9e55472ecafa4bd8b817bfd8cea90435_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS0zLTEtMS0w_272d0598-388d-493f-a687-fd0bcd6bd704"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9a96b9c75a6a4db4a42908340754361e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS01LTEtMS0w_e65aa4af-9de7-43a2-936c-52be0e90da61"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4dd10b3dca034733bcf105cef8c3fe1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfOS03LTEtMS0w_f8f823ee-2dee-48c5-83da-fa366da9e3cc"
      unitRef="usd">348000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i053fc7c14c3a4fcca4e9518b3b0aa792_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtMS0xLTEtMA_e04b988f-97c3-45c2-a92c-2cc9c2602273"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie765c2c1580b4b668660efe86db75615_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtMy0xLTEtMA_7920061c-d062-40df-a26d-4f227bfa3518"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1a73bc52ddbc49a0ae7ab3c3890665fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtNS0xLTEtMA_cd7a2f13-94ab-43de-92ae-430fb9d3a380"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id30791cf6bd640898b2c76820ef15a1f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTAtNy0xLTEtMA_ce197a3e-c27e-48f1-9ede-7adf5c83cab7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib14e95be5980439b89d0be5d5cf9c38f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtMS0xLTEtMA_3324602b-bd20-4fbf-8342-1c4fcbb689e1"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6e3d2af9fb0b4d51a38451c771ddbcbc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtMy0xLTEtMA_35430515-70c7-4324-bf41-72a5b5fe2a69"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2210269696b54388859b9c440a7e5ffa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtNS0xLTEtMA_51b8177d-6074-4f12-9b36-19c89f143f4d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie876dd3bfe4948ecb026d413a211825c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTEtNy0xLTEtMA_440dc110-3e34-4593-9293-1475aaa0b42e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2f894f3d17b245c480e3f32580adbf3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItMS0xLTEtMA_80cf7d9d-e808-4fe6-a211-f979e3047565"
      unitRef="usd">9017000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i105e3f5a6d6346b69ae4b1ec7e09ab45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItMy0xLTEtMA_e4157beb-3d87-49e7-9b64-e1858e0949f6"
      unitRef="usd">75000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5136a3ba0ad1414aac4859f0ba4eef69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItNS0xLTEtMA_bbbe7df3-36a5-4323-b013-971379c63c7f"
      unitRef="usd">5935000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i59cd86e8dadd4d92ad4eea3a591088d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjAwNzQ1Zjc1YTllMTQ0MGU4OTM3ODk3OWFkZmY5MjkyL3RhYmxlcmFuZ2U6MDA3NDVmNzVhOWUxNDQwZTg5Mzc4OTc5YWRmZjkyOTJfMTItNy0xLTEtMA_9b1de086-5877-4b38-912e-558441ebd315"
      unitRef="usd">3007000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4a4220bf4b8433f97d84d75a7a15ec3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC0xLTEtMS0w_ca48bcc9-c195-4b9d-9a49-c4a92efc807f"
      unitRef="usd">601217000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6148de9bc6314d7db99b0174ac32270f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC0zLTEtMS0w_1b9e1bbb-5e13-43ee-99b2-1a9a4ee38626"
      unitRef="usd">1326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4219c1edadf45ef9ebabf21e48f42bc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC01LTEtMS0w_2e08bea2-cd21-46f8-a6e5-762fdf11fbcc"
      unitRef="usd">599891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie62d7c10b74b402c87f6a4746c4edc9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNC03LTEtMS0w_0b24b8cd-b8cb-4ef2-b1ca-9dcad1095f8c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i687289d5249341bea56d56f06881a316_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS0xLTEtMS0xMDg1Nw_b2adb528-ecf1-4006-9cbb-73c10709ce1b"
      unitRef="usd">46191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12332e287c1448f0ae90bd926ae81019_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS0zLTEtMS03NjYz_9afa174a-f6f9-4da1-bf43-abe9e189f0e9"
      unitRef="usd">46191000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88287563b1f84464879d94daa8496cb9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS01LTEtMS03NjY2_81b489d6-449a-4072-a64a-9dbf61aefaaf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9166e07465648fc897dff070b433978_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNS03LTEtMS03NjY5_b7011eba-0002-493f-bdd2-dc3005d2606f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i240c26f07d684902a2a5a2aa13ff4522_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi0xLTEtMS0w_eab394df-a8a6-4260-b56f-2d1e9088365d"
      unitRef="usd">9257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1db864c137e4884a0d080828544685a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi0zLTEtMS0w_9565d7c9-eb6d-4e40-b81d-418fd0e2791f"
      unitRef="usd">9257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if50c2885177f46b9a3b8e52be036553c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi01LTEtMS0w_1e02c3c4-2a51-415c-93ba-dd2c4eddd2fe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib62050c02be84bc68a5fe4449b65fc5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNi03LTEtMS0w_7ed77d04-5fdd-4065-a0b5-fe3732d391c7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i39ec9979e10e4655be2956189114b459_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy0xLTEtMS0w_d33e5920-94f5-47f9-94ee-b1819addfda1"
      unitRef="usd">656665000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i440e6011a4b240eea401a947eb82807d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy0zLTEtMS0w_29a1d079-fbdb-4492-9b6c-28ebf015a44d"
      unitRef="usd">56774000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy01LTEtMS0w_695c826e-3eb2-4068-a332-a30692021c24"
      unitRef="usd">599891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfNy03LTEtMS0w_16fe159e-dea2-43f4-8ea6-39856e21f077"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id50232e03fcd40198b29f681ccae378c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS0xLTEtMS0w_28b7e40a-a0a7-4da7-9f95-cabf6217d524"
      unitRef="usd">6477000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i270207e77dc041c3a631393297a9d666_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS0zLTEtMS0w_53029e4a-9e5f-472e-ab98-5f21e7ccf03f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i376e8b7a95ec4903a952f0e1a98b9ca6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS01LTEtMS0w_ab7c89e6-3431-4f7c-b423-0876ac85ca3d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2c435e953ccb4fea8d4665b2ee78d8aa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfOS03LTEtMS0w_3dd44c8f-ac68-4f33-9ba5-e51a7fda9fa9"
      unitRef="usd">6477000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic3ff8fdbb91347e4bd610fe51e004636_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtMS0xLTEtMA_d38e7f73-be91-4498-99b2-6ebaab7318e7"
      unitRef="usd">514000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i21d8f620ea2f4486b9f6948e67e4eb7d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtMy0xLTEtMA_f73005c8-2475-4cac-a926-68fa97001a8e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i35fc6c1c2c364e28b41de2556a16e837_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtNS0xLTEtMA_5e878d23-a912-4d0c-abd7-b3e975e13820"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id4405cd949e5464d859260401ea0db00_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTAtNy0xLTEtMA_8cd3bbdf-42d3-4997-adb8-f211e3ce9c00"
      unitRef="usd">514000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibdc8f1e296044e74bbcefba8f0616310_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtMS0xLTEtMA_f0ae8d65-52de-4d54-a69a-a0fcca009ab8"
      unitRef="usd">5551000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib784ac7bf6464a7d884b4167b4e99ee0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtMy0xLTEtMA_b540fcb0-f732-4c43-8b76-14c95a2a8c1f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4ac90e5d89444162acf3bc0b9b6480fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtNS0xLTEtMA_f472f91c-4f97-4345-bac3-0a3c843ab0f3"
      unitRef="usd">5551000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia5f4d39a9f964e3f99fac70fd3f35100_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTEtNy0xLTEtMA_18a2d98d-1bd6-4124-88bb-7edaf72c1c99"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6ce4b41fbdca463599bc3cef217fef45_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItMS0xLTEtMA_25f46257-9017-4624-a6a6-fdce598a28af"
      unitRef="usd">199000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i79709122c16343dcbc74ae3a46e989b4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItMy0xLTEtMA_11c38ebf-6d0e-4e00-ac67-22713586d241"
      unitRef="usd">199000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i088931a8204941488973e380b4de1025_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItNS0xLTEtMA_a1d8496b-7333-40f3-bdbb-66aed7f60f61"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4b3229ad3f5f439fa27e10965c78eea1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTItNy0xLTEtMA_c9a8acdf-8ba6-4875-bb8a-bdf1076945e5"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i39ec9979e10e4655be2956189114b459_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtMS0xLTEtMA_f8373e59-c48c-40f6-a812-911935757542"
      unitRef="usd">12741000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i440e6011a4b240eea401a947eb82807d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtMy0xLTEtMA_f6457dc0-49ce-4170-8797-d2d9f4c1a2a5"
      unitRef="usd">199000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1c8d1794353c4ab2b2c546ff11fb3dc4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtNS0xLTEtMA_7ae277be-5c86-49ba-9a08-cd44836cbcff"
      unitRef="usd">5551000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie9bbc3e2990a4abfaaa5bfec789a87e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjI0ZmZhZjU0YTFlMjRlYmI5NTA3Mjg4MWY5MDYxZGY4L3RhYmxlcmFuZ2U6MjRmZmFmNTRhMWUyNGViYjk1MDcyODgxZjkwNjFkZjhfMTMtNy0xLTEtMA_92fe3261-0bc9-48d2-a651-c6b27b7de888"
      unitRef="usd">6991000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i727f5a67038e4448b546d9073616f76a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMTA5OTUxMTYzODgwMw_37478a49-5ece-47f4-b5e9-a4fe0484f3c1"
      unitRef="usd">3000000.0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i77529a8905b14bc3bc8add865edf0f75_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMTA5OTUxMTYzOTEyNQ_a819821a-3cd2-4c97-933b-2e79e295c0f5"
      unitRef="usd">1800000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="i62d2f834fa2244ceac78756b0afb44a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNTA5OA_82150991-8de4-418e-b586-6566daf95678"
      unitRef="usd">375000000.0</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="i9c826c5ec76f4cfabdff851267a7e696_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNTIxMw_64cdf720-54d2-445d-947e-4ee9241ef80b"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerAssetGross>
    <lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfNzI2OQ_39cf2945-ca90-4457-83ad-337e61bbc82c">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2019 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:81.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.716%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of level 3 financial instruments as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i92d6816bd05c485785171f05859f970c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfNi0xLTEtMS0w_258ba189-3c29-4fce-8c2b-b6bbbd26d45b"
      unitRef="usd">6991000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfNy0xLTEtMS0w_4c5117db-4155-4a65-bcfd-41092da691bb"
      unitRef="usd">3050000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfOC0xLTEtMS0w_271267db-b950-40e4-bcfa-dd8db556f8d2"
      unitRef="usd">934000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0feee4e225cd43f6b19d270f81f68e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RhYmxlOjE0ZTY1NWU3ZTE4MDRiN2I5MTc4MDZjZDU0MGRhZjVmL3RhYmxlcmFuZ2U6MTRlNjU1ZTdlMTgwNGI3YjkxNzgwNmNkNTQwZGFmNWZfOS0xLTEtMS0w_328dd5bb-9328-40e5-a883-3ec13053da87"
      unitRef="usd">3007000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetImpairmentCharges
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_6b3129ac-c86f-4482-99bf-bd4c4518199c"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_eea54642-dc7a-45a5-bace-5ec68ca7ba4d"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185Ny9mcmFnOjg2ZmU4MzAzZjNjMTQzOGQ5NTQzYTNjYzhmY2E0MWZmL3RleHRyZWdpb246ODZmZTgzMDNmM2MxNDM4ZDk1NDNhM2NjOGZjYTQxZmZfMjc0ODc3OTA4MTc0OQ_f0104f51-bb9a-475d-9c1d-3a20bcea616f"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzM4Nw_c658a3aa-8d53-40b3-a306-15cd265bfa5c">Leases&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our leases have remaining contractual terms up to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODE_ffef5594-a0f1-449a-ba9a-61a27ea72532"&gt;seven&lt;/span&gt; years, some of which include options to extend the leases for up to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODc_303e6841-ce99-40a8-b295-685264827d3d"&gt;seven&lt;/span&gt; years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Operating Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.122%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.912%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.556%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.210%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the twelve months ended December&#160;31, 2019, we entered into several new lease agreements including our San Diego headquarter expansion, opening new Las Vegas office and a new United Kingdom office lease, which resulted an increase in lease assets and liabilities of $6.1 million and $6.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Maturity of Operating Lease Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.281%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.410%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, our operating leases have a weighted-average remaining lease term of 6 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.8 million for the twelve months ended December&#160;31, 2019. Operating lease expense was $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <lgnd:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzI3NDg3NzkwNzM5ODc_ce74165b-77ae-485f-8cb9-0d9ab5df3f7b">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Operating Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.122%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.912%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.556%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.210%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzEtMS0xLTEtNTMyOA_fe44200b-5761-4a13-96b2-e186cf27616e"
      unitRef="usd">10353000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzMtMS0xLTEtNTMyOA_8e2811a7-775f-4f2e-bd17-87f677f8ab29"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzQtMS0xLTEtNTMyOA_0289e077-b7e8-423a-84ad-4879ed4519df"
      unitRef="usd">9970000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpmNTU3OGI1OTBjY2U0M2Q1ODg2ZTViNTJlMGI4Zjk4Ni90YWJsZXJhbmdlOmY1NTc4YjU5MGNjZTQzZDU4ODZlNWI1MmUwYjhmOTg2XzUtMS0xLTEtMTA4ODc_b5cd6320-02f9-44ec-aebf-d0a6263e20f3"
      unitRef="usd">11212000</us-gaap:OperatingLeaseLiability>
    <lgnd:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5MDM_73c3788c-29de-4c65-931b-426cdb878e0b"
      unitRef="usd">6100000</lgnd:IncreaseDecreaseInOperatingLeaseAssets>
    <lgnd:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5MTA_3905ed52-1264-48f8-aede-17b50a0a155b"
      unitRef="usd">6000000.0</lgnd:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4XzI3NDg3NzkwNzM5ODg_1d3cb110-a8a5-4a2e-ac8d-d80365a92a4c">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Maturity of Operating Lease Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.281%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.410%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzEtMi0xLTEtNTMyOA_31209d87-0beb-4e8d-9d88-fbf7bd7becce"
      unitRef="usd">1914000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzItMi0xLTEtNTMyOA_e7454f95-1503-4cb4-96aa-9b3c4bc23fdb"
      unitRef="usd">2221000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzMtMi0xLTEtNTMyOA_e9ac6848-6f9a-4fb4-acaa-baa368b69261"
      unitRef="usd">2261000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzQtMi0xLTEtNTMyOA_e2ed00d6-e068-4ab6-bb38-f0527da1c7fd"
      unitRef="usd">1988000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzUtMi0xLTEtNTMyOA_3756c640-d7e9-42d8-87f1-6a591bcd7e3b"
      unitRef="usd">1989000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzYtMi0xLTEtNTMyOA_631aef3c-2611-4bab-932a-07944f821c7d"
      unitRef="usd">3493000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzctMi0xLTEtMTA4NzQ_cea0637b-85ac-457a-84d7-e1f2d2c268f1"
      unitRef="usd">13866000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzgtMi0xLTEtNTMyOA_6fa05762-82bc-4c81-bfaf-39e39ca221bf"
      unitRef="usd">2654000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90YWJsZTpjMzc5OTY3NmY3ZGM0MDdlYmY0YWNkYzM2ZTg0YWRhNi90YWJsZXJhbmdlOmMzNzk5Njc2ZjdkYzQwN2ViZjRhY2RjMzZlODRhZGE2XzktMi0xLTEtMTA4NzQ_0aa6a53d-5bb0-4f81-9eaa-c91ef90766c0"
      unitRef="usd">11212000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5NjU_cacd2661-390e-492c-ae52-61e40bbf2c46">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM5NzQ_4dc56dcc-8728-4abd-8732-80c89547416f"
      unitRef="number">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQwMTQ_47220de2-067a-4ed1-b68b-fcd774bb8fdf"
      unitRef="usd">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQyNzU_3fcef12a-5824-4670-8b08-ffaa528761f7"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTQyOTQ_8308157b-3732-4cc8-bb5f-436c88ee14bd"
      unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE2MDI2_4acd0952-7189-42cc-9364-efb2f13ebef1">Convertible Senior Notes&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;0.75% Convertible Senior Notes due 2019&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;   &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;                                                                                                                               &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $340.0 million and marked it to market as of December 31, 2018 to $22.6 million with the resulting $119.4 million increase, net of $471.2 million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $11.6 million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants. We continue to have the ability to avoid settling the warrants associated with the 2019 Notes in cash after May 22, 2018. Accordingly, the warrants continue to be classified in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of 525,000 warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#x2019; equity to a derivative liability on the modification dates, resulting in a $28.3 million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $30.1 million and recorded a $1.8 million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December 31, 2019 and 2018, 1,890,359 and 2,739,643 warrants remain outstanding, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;0.75% Convertible Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Embedded Derivatives&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $144.0 million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $13.5 million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. As of December 31, 2019, the debt discount remains and continues to be amortized to interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December 31, 2019, the &#x201c;if-converted value&#x201d; did not exceed the principal amount of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $3.2 million was recorded as interest expense for the twelve months ended December&#160;31, 2018. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $19.2 million and $7.5 million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information about the equity and liability components of the 2019 Notes and 2023 Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.768%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.292%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principle amount of 2019 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principle amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(111,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(140,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;638,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;609,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;647,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMQ_bcf997a4-8b9d-4822-8194-7ed87b204b68"
      unitRef="usd">245000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE3NQ_ce16b1bf-656a-488a-bdc3-174b61b4f7eb"
      unitRef="usd">239300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzI2NQ_90d0cc8c-37a8-4b19-b48a-32415d3a08d8"
      unitRef="number">0.0583</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzUyMg_36c0d214-9d43-459e-9dd8-140b1e0d194e"
      unitRef="usdPerShare">75.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b883a1064da430e9dc11a5b03492ca1_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU5NA_04287bd8-6ab6-4aaf-b192-fd2f105a4079"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk0NA_89e92ac8-822a-4f72-8c3e-771bdc3977f4"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMDA_f23bc31f-dd3d-418d-a00b-bbb06d33d8b5"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i98fe214fadde4f73b64d85fc5c3d1873_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExOTU_0f17fb24-e5b6-45b5-ae3b-0d96f871ae41"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNjA_115d57bf-c637-4da4-9af9-72dd0800a7d6"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzMDk_3cb4a193-2efc-40d3-ae46-64885fe18f38"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i9174105094b344fdaf382f6d88a00492_D20140801-20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0MjI_09c8fa29-0751-4ad2-9dd2-bd4bf0a3b07f"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="ia69c2295fad14d86b0c1d0d33d08fd9d_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzI5Mzg_dab17c2f-5167-40dd-9060-e3d21797eb8c"
      unitRef="usd">341600000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i41c98ddc8ed6424e97637ef827414c85_D20181231-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzMwNjg_4872166b-51e6-4414-9d84-16cd60ef3567"
      unitRef="usd">23400000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal
      contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzMwOTA_89819ce7-4754-4d94-b1a9-0978174fa145"
      unitRef="usd">118700000</lgnd:DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM0Mzc_d8218202-23d8-44a5-9a23-571df2c9137a"
      unitRef="usd">21800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i6f0e9fbd71bb4bab9e88b7da9034946c_D20180301-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM3MDM_db05c320-8435-4f14-a7e0-35937c268139"
      unitRef="usd">31600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM4MDY_c41924ab-8f26-4d46-8668-ad6d8003d293"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i431a4662d0c94709acc11135ef5587ee_D20180701-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzM5MjQ_6d2840c4-a917-4d75-90fa-2ec919ad61e3"
      unitRef="usd">195900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="ic8bcea58a1cc45ad91cd2cfd6e88fb72_D20181001-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzQwMTU_49ff71cb-8397-4862-b3f6-a60f853129ff"
      unitRef="usd">439600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzQzMjk_0ec08079-5ed7-4015-9f15-9bc4e5bb94cd"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDYzOTU_7f703151-d5f0-42db-a421-8fb046a66a61"
      unitRef="usd">1000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0MTE_fa3a2c59-8969-400f-9274-16f731027524"
      unitRef="usd">1000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="iff4c9237c7ba45b18cca0704bbcb0539_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0MjY_51ac38cd-0438-4e25-bcd0-e8fa89405072"
      unitRef="usd">500000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i42d47e48e8714a4a85ce5692e87edc2a_D20190815-20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0NTM_d465e09c-193c-4751-8344-cccd80649668"
      unitRef="usd">26300000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i183d237079bf442793fe6653077b02d1_I20190815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0Njk_8713ee08-c3d9-4b8c-a8f4-37d3364c0186"
      unitRef="usd">11900000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i87aa5c347671496aa3cdde3c294e882e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDY0ODQ_ff4f449c-7c40-4534-a731-757abb0f7fbb"
      unitRef="usd">-11000000.0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU4MzE_7a4a8577-3f34-45fa-882c-df83608bce05"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgnd:ExercisePriceofConvertibleBondHedge
      contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzU5MTY_430fc6a4-3db2-47f5-802d-40decad714f4"
      unitRef="usdPerShare">75.05</lgnd:ExercisePriceofConvertibleBondHedge>
    <lgnd:PaymentsforConvertibleBondHedges
      contextRef="icc4e79015c2f490db32124b22dedcd99_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzY3MTU_59a079da-5cfb-4478-8c43-8f84b72a262a"
      unitRef="usd">48100000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i018f28bd405f4e8e80369ec4e6ebaf93_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyMDU_fbfc6770-d01a-4750-b653-cc3aa0dcf97a"
      unitRef="usd">340000000.0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyNTk_83334f9e-d47f-4b66-93eb-3e3283046d72"
      unitRef="usd">22600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzcyODE_fbb6ff8e-1486-4e3b-aa81-a8db1b5fbb31"
      unitRef="usd">119400000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities
      contextRef="idb267eaaf4f04c55a8b254a290680020_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzczMDE_53787291-1db2-4782-97f3-2f4d08268c89"
      unitRef="usd">471200000</us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iad13e0c01d0342d4a22d93e03d73bdec_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDc4NjM_a1de70ef-3931-41f4-b548-29a2bbd9d5bd"
      unitRef="usd">-10200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc1NzU_46fd1052-6f56-4586-ba49-30034e913af3"
      unitRef="shares">3264643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc2Mjc_8029f3b1-1e5a-4b86-978e-689b8bc1de95"
      unitRef="usdPerShare">125.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if15033c4ceb44752bec11bcc6b5a4535_D20140801-20140831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzc5ODg_a5ec87c1-ae35-49ba-ae61-9b4464a4d3fe"
      unitRef="usd">11600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgnd:WarrantsSettled
      contextRef="ia44b7731c223433ebd2d48a7da02b9fd_D20181101-20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg2Mjg_c87df07d-4a05-47f7-821a-54899de4e118"
      unitRef="shares">525000</lgnd:WarrantsSettled>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg4NDY_ca7bc328-9fc3-404b-a584-8b5243d9df30"
      unitRef="usd">28300000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantsSettled>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg5NTg_6960137a-7155-494a-878a-7eb33202a927"
      unitRef="usd">30100000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzg5NzY_ec632a3f-4a47-40d1-8be6-6cf4cb293917"
      unitRef="usd">-1800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzgyNDYzMzcyMjU4ODg_f27c04a2-0196-43b6-b764-9276027a34e9"
      unitRef="shares">1890359</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwOTk1MTE2NDc4NzY_1a303165-d8e4-4aac-8094-1c74778f4540"
      unitRef="shares">2739643</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzkzNDI_9fff6f5d-681d-45b5-9ff5-030ebcd82222"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk0MjI_d88d1350-8334-4391-a809-e1fb97396343"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk1ODU_e9098073-c548-4c7b-8558-173d72bbdd83"
      unitRef="usd">733100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0Xzk5MTQ_6e38ed1f-0377-4ae6-986b-eb6d3562e365"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMjQ2_eb07d7c1-bb9a-4786-a500-0a734bbc8044"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwMzAy_24a46271-b5e0-491c-a01c-8e3c26e9ad51"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i677af219811f4afea5707d272137352f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNDk3_f9c70fac-c4cd-4a98-9971-cf780297b099"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNTYx_8cbd8137-2058-4f1c-9000-1c4bae8ad195"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNjEw_73a87268-4d23-4318-9bd7-783c295a6199"
      unitRef="trading_day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger
      contextRef="i62c768441c624c9fa3632d03d7cbbf0f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEwNzIz_21125c0e-1d67-4efe-b716-1101584ba4bc"
      unitRef="number">0.98</lgnd:DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExNTM4_431c5a1b-44d2-4c9a-81aa-33b6ad66f12b"
      unitRef="usd">144000000.0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i4087e5834f3f43f7b9dcd9f3bc7ad89f_D20180522-20180619"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzExOTYz_4b9214ea-8061-42be-b9fe-584d21bcd458"
      unitRef="usd">13500000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyMzY4_432d167a-faba-4672-bcd3-26495297fd2e"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNTQx_e61f33e7-bbd7-4edc-8032-d8e31ba2003d"
      unitRef="usd">16900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyNzEy_6b854987-44e9-467c-8e2d-1794dd52dce2"
      unitRef="usd">3200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEyODM2_a7896c36-73b6-4a95-9c16-561a58d3add8"
      unitRef="usd">13700000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzMzg5_6e87d551-a0c7-40fe-a338-e66de698dbcc"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzNjYz_7a5d6a30-7687-4a9a-b30f-c74440571ca5"
      unitRef="usdPerShare">248.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lgnd:PaymentsforConvertibleBondHedges
      contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzEzNzQ2_178af0b4-4e88-4213-ac5d-ce46b97b803c"
      unitRef="usd">140300000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0NjMx_b5c183c5-6c14-4119-95a0-e8468e9779fb"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7d28f5c6a3d64e3da8a48dd4c4fd1b05_I20180522"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0Njgz_d18bb851-eac4-4a16-aa11-a18ab3df36ff"
      unitRef="usdPerShare">315.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ie562c20066384609b6d4e35155e67ba5_D20180522-20180522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE0NzQx_b5a6dffc-22ce-460b-b050-8d51fa215540"
      unitRef="usd">90000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE1Njg3_dfc4e826-5404-4689-b235-ac4261c62f17"
      unitRef="usd">19200000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ia110cbf5a9944b03aa20016d325e3688_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE1Njk0_2f085692-37e0-49db-988f-c80be955cfa7"
      unitRef="usd">7500000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90ZXh0cmVnaW9uOjBhZGI0ODg0MDJjODRhYzI5OWY5MzVlOTFhNmNkZTk0XzE2MDMw_2abb15d9-1e93-4482-b6b1-6c063e2a7797">The following table summarizes information about the equity and liability components of the 2019 Notes and 2023 Notes (in thousands).&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.768%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.292%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principle amount of 2019 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principle amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(111,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(140,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;638,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;609,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying value of equity component of 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;647,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i95d01d0ac3874584a772c93ae9343d59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzEtMS0xLTEtMA_78f2c0b6-9efa-415b-85b1-604ffa46a3ae"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzEtMy0xLTEtMA_66df80b7-b45d-4044-8f99-2de047a4cf5d"
      unitRef="usd">27326000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i95d01d0ac3874584a772c93ae9343d59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzItMS0xLTEtMA_178bf018-aae0-4334-af00-37cb7625a9ed"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ieb24a00e5dce4beeb4b0b94bcad01c83_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzItMy0xLTEtMA_5b482f9b-72f8-47d0-b1a5-d757bddc669a"
      unitRef="usd">893000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableCurrent
      contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzMtMy0xLTEtMA_6436cfab-d467-4817-8780-50b92bac2d8f"
      unitRef="usd">26433000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzUtMS0xLTEtMA_56b3285c-665d-46ee-8f32-25a5f3306669"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzUtMy0xLTEtMA_6681d760-90c6-4ea9-ac9a-4d6eba986225"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzYtMS0xLTEtMA_3f4b3846-a21d-482c-9d62-231e09721d3c"
      unitRef="usd">111041000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzYtMy0xLTEtMA_9150f3fc-8a09-4eb0-9c41-40bd069f064a"
      unitRef="usd">140136000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="id951cc41dcda47b79a7837e8a9cac151_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzctMS0xLTEtMA_ea597f7c-e5c8-42db-ae94-88c79bd7de85"
      unitRef="usd">638959000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzctMy0xLTEtMA_14920b8a-bed5-497c-9454-6a12810f93b1"
      unitRef="usd">609864000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ic695d6dc03fe4a25b48518725b03cc3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzgtMS0xLTEtMA_a53645a2-5aff-4aef-801e-c45bbc6954a8"
      unitRef="usd">101422000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i4c0a208cee4646039870279eaed26fbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzgtMy0xLTEtMA_f71814d6-1fb3-44b9-9e26-e575db3f8bec"
      unitRef="usd">127997000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="id951cc41dcda47b79a7837e8a9cac151_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzktMS0xLTEtMA_2bac3a1c-962b-405b-8459-e8b280ba7523"
      unitRef="usd">647280000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="iad33a1fd7a4d4bb4b58891b708e03689_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDMvZnJhZzowYWRiNDg4NDAyYzg0YWMyOTlmOTM1ZTkxYTZjZGU5NC90YWJsZTo4ZjVkOTFhMmIyOGU0MjU5YWI2N2QyOWYzOGU2YzdlNy90YWJsZXJhbmdlOjhmNWQ5MWEyYjI4ZTQyNTlhYjY3ZDI5ZjM4ZTZjN2U3XzktMy0xLTEtMA_4133bc97-6a5b-4f7f-86aa-00a72f67395a"
      unitRef="usd">713533000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDA_fe93370b-1ae2-4f9c-b542-79884591907a">Balance Sheet Account Details&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the various investment categories at December&#160;31, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;411,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;411,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;941,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;600,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;601,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;margin-top:5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $1.5 million, $0.9 million, and $0.4 million was recognized for the twelve months ended ended December&#160;31, 2019, 2018, and 2017, respectively, and was included in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;margin-top:5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;305,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $16.9 million, $15.8 million, and $12.1 million was recognized for the years ended December&#160;31, 2019 and 2018, and 2017, respectively. Estimated amortization expense for the years ending December&#160;31, 2020 through 2024 is $14.1 million per year. For each of the years ended December&#160;31, 2019, 2018, and 2017, there was no material impairment of intangible assets with finite lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments due to broker for share repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Return reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingent liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal. See &#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note (4), Business Combinations&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; for more information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.509%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.453%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.225%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.010%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDE_555a76dc-37fc-4a7a-9a96-e1f35c82bf2c">&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the various investment categories at December&#160;31, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;411,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;411,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;210,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Mutual fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;250,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;941,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;311,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;600,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;601,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtMS0xLTEtMA_7a699109-1977-4142-a6f3-c3a7242c92e0"
      unitRef="usd">411690000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtMy0xLTEtMA_0f5f9e9b-525a-411f-8819-2935e8de5626"
      unitRef="usd">188000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtNS0xLTEtMA_4557f8e3-f42c-4864-8116-e14847b0c7fb"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9cf631831404b3ab0a176b30ff1cf61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzMtNy0xLTEtMA_ed1c67b4-09e2-4573-9062-fb76c96f8991"
      unitRef="usd">411875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtMS0xLTEtMA_8d7e8873-bd41-41c0-8308-fca39d48a656"
      unitRef="usd">63818000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtMy0xLTEtMA_094f51c3-bda8-4c02-8a38-d60a751b325d"
      unitRef="usd">161000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtNS0xLTEtMA_793d265a-ab1d-4ca2-996b-717434e4ae79"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4adf86c26c74eebbff052e6408a24bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzQtNy0xLTEtMA_96a96fdc-ea80-4a68-9f7b-2eac49a000ce"
      unitRef="usd">63979000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtMS0xLTEtMA_cfaf99ce-a953-4ebe-ac32-0b59c3b279f3"
      unitRef="usd">4506000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtMy0xLTEtMA_222aee7a-e425-4dd0-a6f2-97e24878d668"
      unitRef="usd">416000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtNS0xLTEtMA_176209cf-44c6-4841-bdcd-a13d54b4c9dd"
      unitRef="usd">1850000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53a1d6e6b22a4e688442ab222c22bfc7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzUtNy0xLTEtMA_dcc9580e-0c0c-413a-b523-468ea9cc0c8c"
      unitRef="usd">3072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtMS0xLTEtMA_606b5a21-e023-4720-8b8a-961c233eb912"
      unitRef="usd">210525000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtMy0xLTEtMA_4d802e42-a6d9-4ce5-8b20-6fa462c7fd12"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtNS0xLTEtMA_1285eca7-7ae2-426a-8515-27679b16a5c9"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3edd354ce74e4dca903c8d87d72f9fbe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzYtNy0xLTEtMA_88aa270a-0b51-4d56-9c83-f6c4f001888e"
      unitRef="usd">210552000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctMS0xLTEtMA_a481c960-d26f-43e1-bd32-82838846c887"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctMy0xLTEtMA_68a4bb9f-2391-4d43-a291-c1c07a322a52"
      unitRef="usd">125000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctNS0xLTEtMA_e484c14f-f2fb-4610-9b7b-28c4d92bc570"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0997e7cf40f4560bfc2d3b81a693374_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzctNy0xLTEtMA_ce932c75-4e95-4ace-864b-bb84b4013f11"
      unitRef="usd">125000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i159e354578674c4980944fd7e84d264b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtMS0xLTEtMA_74026afc-d950-4d41-bdca-338e77b5c189"
      unitRef="usd">250635000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i159e354578674c4980944fd7e84d264b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtMy0xLTEtMA_f567e79c-3f48-4053-8acc-46fd856b804b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i159e354578674c4980944fd7e84d264b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtNS0xLTEtMA_bd1af22f-ccbc-459f-90ba-5d8935ad4d4f"
      unitRef="usd">249000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i159e354578674c4980944fd7e84d264b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzgtNy0xLTEtMA_e1843763-3bdb-45b0-b161-1bb2ce5861b6"
      unitRef="usd">250386000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktMS0xLTEtMA_f990702b-9df0-40f8-9bb7-19b654824c8b"
      unitRef="usd">941174000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktMy0xLTEtMA_e9a33031-a902-4629-bdd4-91c9a0b8cbe7"
      unitRef="usd">933000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktNS0xLTEtMA_8cf9659b-be63-4126-b05c-9b27ec026e51"
      unitRef="usd">2118000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b0f02512c784ca8a96f7587ae1fa695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzktNy0xLTEtMA_f07dfbd3-d398-4067-bf3e-e58a791b4a0c"
      unitRef="usd">939989000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTEtMS0xLTA_0a59c5fc-18c4-4629-9650-dd3675a8e927"
      unitRef="usd">311066000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTMtMS0xLTA_35f31fa5-a314-4e75-bf7e-bc0c07f8f28a"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTUtMS0xLTA_223f9978-8ba2-43e6-a72c-205be3498e9b"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i512fa91ade644f0f8d1e64336cafc646_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEyLTctMS0xLTA_15b2e920-4e63-4cdd-a89f-b2bc5474bb2f"
      unitRef="usd">311063000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTEtMS0xLTA_c426b463-a12a-40ff-9bf9-ea97f95d9039"
      unitRef="usd">53223000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTMtMS0xLTA_914e1943-7a03-489b-a842-d98193952b5d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTUtMS0xLTA_f39074b9-a0ca-4794-be6f-74ad8f84bdf4"
      unitRef="usd">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb0f673df80c43e6ae301f9b370879d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzEzLTctMS0xLTA_95a7e26d-ccee-4230-9028-a978be99a276"
      unitRef="usd">53179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTEtMS0xLTA_b5928b70-c11f-48c6-87cc-cc434060066a"
      unitRef="usd">135000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTMtMS0xLTA_ef75b9e5-77c2-4cc2-8048-1b96c49c03f7"
      unitRef="usd">1191000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTUtMS0xLTA_53dde29f-1dad-4384-9333-60966ef79ca6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i187f37e52b0046fbbddd2f4c14993bbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE0LTctMS0xLTA_1b59a14d-7663-48bf-bd38-e0df2f1f9cdc"
      unitRef="usd">1326000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTEtMS0xLTA_f7874b40-c6ee-40da-829d-738605064690"
      unitRef="usd">225731000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTMtMS0xLTA_a12e5f62-a4d0-41c4-a9b1-b52b811c347f"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTUtMS0xLTA_21795da9-33a2-47d9-92a6-b10385f98358"
      unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ba7d38dbb624cb08b11681c3feadf4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE1LTctMS0xLTA_9d90e326-536a-4590-9099-f962bb055cd8"
      unitRef="usd">225663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTEtMS0xLTA_b4a3cdb8-af3b-4104-a0d4-36ea956c2c1a"
      unitRef="usd">7982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTMtMS0xLTA_64fe1bf4-2d14-47dd-89b5-446460fcf869"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTUtMS0xLTA_2011e68b-9319-4dd5-ba7a-4325c66ef57b"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19269a85c84b42aab38f5fac2f97aa03_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE3LTctMS0xLTA_e71ebde9-aab8-4a06-aae2-c885f8563119"
      unitRef="usd">7973000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTEtMS0xLTA_da54f540-0ae2-4a1e-9fdc-24ed1a5d841f"
      unitRef="usd">2017000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTMtMS0xLTA_79d660c3-5a7c-440c-9054-136f482003f8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTUtMS0xLTA_abcea190-e71a-4227-ad9c-01e46035a4fd"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia19b9a02facb489a95e3193c4f7ac238_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE4LTctMS0xLTA_5d53dac2-921d-4efe-8858-be33b5bcf6ac"
      unitRef="usd">2013000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTEtMS0xLTA_d6c180f1-e8a9-471f-91e8-74d72fee26d5"
      unitRef="usd">600154000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTMtMS0xLTA_0962949f-56dd-4be5-aaf6-91739ab03142"
      unitRef="usd">1226000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTUtMS0xLTA_bdb35e4d-d54f-47ec-95ac-0d353485bc69"
      unitRef="usd">163000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4e8496488c64c268cd3de6924f039d0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjYzg3ZmExNTkwYWY0ZWEwYWE3MjBhODI0NjNhMGJlYS90YWJsZXJhbmdlOmNjODdmYTE1OTBhZjRlYTBhYTcyMGE4MjQ2M2EwYmVhXzE5LTctMS0xLTA_1f57f5ad-b227-40db-b16b-da3c724e60d9"
      unitRef="usd">601217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDQ_64f4f53d-2134-451f-a31e-d68754a3b4f1">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e41a03cf4b245ecae999cdd0f89c769_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzItMS0xLTEtMA_b0a19a90-10d2-4c32-bc31-9cd7241d14af"
      unitRef="usd">6307000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6737d944593c47919db533223783d735_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzItMy0xLTEtMA_f03e804a-500e-4dce-8621-4537a056c004"
      unitRef="usd">4183000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8397721ad934a4fb6b8e4182e177246_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzMtMS0xLTEtMA_e6a54aa3-58aa-4ba8-9fbc-2dcb0d8c57c7"
      unitRef="usd">2729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3da08223a8214656b754f9367925b52a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzMtMy0xLTEtMA_97acbc8c-c4d0-42fd-9211-0d211c332351"
      unitRef="usd">2418000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d5e8e38535841d0a6ebe69742fcb55b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzQtMS0xLTEtMA_f08c1937-4bed-465b-896c-f893358d981e"
      unitRef="usd">999000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8cff8def88d547cca5ed63725081c9f3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzQtMy0xLTEtMA_0a3d4dc2-6086-4dcb-bbc4-4fa1f3fd472c"
      unitRef="usd">936000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzUtMS0xLTEtMA_f79138aa-881d-4ed6-ac84-d0e60c413374"
      unitRef="usd">10035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzUtMy0xLTEtMA_6e6436c1-d61c-434f-9249-2a498e69bb63"
      unitRef="usd">7537000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzYtMS0xLTEtMA_8e190f65-e023-4ca6-890c-1d8917e28e07"
      unitRef="usd">2850000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzYtMy0xLTEtMA_077bbfc7-fc49-4131-b266-c0424a114679"
      unitRef="usd">2165000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzctMS0xLTEtMA_a50d2742-92f8-4f91-b9a9-eba120dbf086"
      unitRef="usd">7185000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZToyZjRhN2RiOTJhOWE0YTMwYjYwNDk0OGViMTZkZjc0NS90YWJsZXJhbmdlOjJmNGE3ZGI5MmE5YTRhMzBiNjA0OTQ4ZWIxNmRmNzQ1XzctMy0xLTEtMA_cb973c88-2703-40ce-bc7f-4d655e127622"
      unitRef="usd">5372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY0Mw_517c0c36-72b7-4810-a5ef-d9f93520db92"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY0Nw_455b154f-b9e8-4aaa-b301-8019e810770d"
      unitRef="usd">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzY1NQ_a76fca9f-ef6f-4321-b836-0065bb80e97b"
      unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI3NDg3NzkwNzMyMTY_6ade4d2e-8d93-496f-bfb3-1ae221eecd8f">&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Complete technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;305,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzQtMS0xLTEtMA_4648462d-52cf-47cc-90a8-bd8d6bbd26a6"
      unitRef="usd">95229000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzQtMy0xLTEtMA_cde8a661-08d1-4d7b-a07b-0e8dfc1eb0e2"
      unitRef="usd">86646000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzYtMS0xLTEtMA_609bc68b-d367-41f6-95a7-a35a23acb83a"
      unitRef="usd">242813000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic92c2bb9b787480489b39a01bb366f35_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzYtMy0xLTEtMA_54ea0cfb-56b4-4365-9010-3ef808ec0391"
      unitRef="usd">235413000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ieffc1cb16f5e482bac76699c9a80cdc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzctMS0xLTEtMA_953de17c-2e8c-4b6b-b1ed-b107577a2474"
      unitRef="usd">50203000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic92c2bb9b787480489b39a01bb366f35_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzctMy0xLTEtMA_c3f6798f-c364-4cb4-944d-7675f9c84e97"
      unitRef="usd">35070000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if268533fff3b4793a31072861a742a93_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzgtMS0xLTEtMA_1704d68e-e5b5-4583-aa26-d40275f2810e"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i44726d215cc14202aa7482a959d9f789_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzgtMy0xLTEtMA_cb16a63e-5c69-411f-8edd-4bd895a76295"
      unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if268533fff3b4793a31072861a742a93_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzktMS0xLTEtMA_22d594a7-127a-4e3f-bf62-2887a1885dc4"
      unitRef="usd">1180000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i44726d215cc14202aa7482a959d9f789_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzktMy0xLTEtMA_5b74447c-b5a5-4f81-998a-6e45aaeca92a"
      unitRef="usd">1048000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i29175925b83b4f7db955ba48c6e95710_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEwLTEtMS0xLTA_1321dbdd-1f9d-4db4-893a-97f25f342c91"
      unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id4900b9ff94548d4902c449b76d44e10_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEwLTMtMS0xLTA_123b26d1-f7db-4812-a4bb-4161fc95a765"
      unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i29175925b83b4f7db955ba48c6e95710_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzExLTEtMS0xLTA_73c9a881-34b2-4b44-84a0-ab77970e6506"
      unitRef="usd">13224000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id4900b9ff94548d4902c449b76d44e10_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzExLTMtMS0xLTA_16aa23e0-7a53-4117-ba06-c94daed7810b"
      unitRef="usd">11744000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEyLTEtMS0xLTA_a65ea29e-1b51-4113-bb63-1b2ba5281559"
      unitRef="usd">305677000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTpjNWQ3ZGJiMWUxYTA0NjJhYmJmNGY1NDA5NjdkNmJmZC90YWJsZXJhbmdlOmM1ZDdkYmIxZTFhMDQ2MmFiYmY0ZjU0MDk2N2Q2YmZkXzEyLTMtMS0xLTA_18e36c3d-0faa-41b3-ba7c-75a42dd11276"
      unitRef="usd">306439000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzk4OA_16938e39-7610-4c99-a58e-64748b5ca343">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMTY_e24d8cda-52cb-41d0-96bb-75ca8aa04a9d"
      unitRef="usd">16900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMjA_94d64d25-6e4c-4a06-b745-846005bd86a5"
      unitRef="usd">15800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEwMjg_05b90958-f5a2-43ee-b65b-19a1b6b0d4b1"
      unitRef="usd">12100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_2e6cff1b-d06f-4df5-88ac-bc5cdf47d476"
      unitRef="usd">14100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_5952335c-b046-498f-b077-fc7eda72cf45"
      unitRef="usd">14100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_6854faba-8d26-43cc-b441-b1c8d5738aaf"
      unitRef="usd">14100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_c702df3b-a0d8-4491-a11c-df4753d8f0b8"
      unitRef="usd">14100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzExODU_d48dd972-39d8-40cb-a1e7-a13418e029ce"
      unitRef="usd">14100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_3631cb1e-ffd2-4f70-ab83-45b33a1451d0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_54a26f81-1edd-4bb2-a5cb-94fa9441513d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzEyNTI_ec9587df-f110-41e0-a28f-0534053e8193"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1NDU_33d035c4-bed2-434a-b9c6-731d1f2ad141">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.628%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments due to broker for share repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Return reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzItMS0xLTEtMA_69dfeb7c-e70a-4815-836f-86b8ce502be7"
      unitRef="usd">1986000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzItMy0xLTEtMA_57acf224-c7d3-4da9-9315-f2c0c7c6d30f"
      unitRef="usd">4045000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzMtMS0xLTEtMA_17f29bf5-1ce0-41f0-bb73-1d8293498227"
      unitRef="usd">1135000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzMtMy0xLTEtMA_0d6353cb-5db7-4755-983d-4baadea5fa73"
      unitRef="usd">942000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzQtMS0xLTEtMA_86c7fbf5-8ef7-401d-b91e-1234eea7af14"
      unitRef="usd">381000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedSalesCommissionCurrentAndNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzQtMy0xLTEtMA_2f59202a-25a7-4918-8079-d92c7d27165d"
      unitRef="usd">428000</us-gaap:AccruedSalesCommissionCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzUtMS0xLTEtMA_8e282e33-f59a-4dea-be1a-83691c73b793"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzUtMy0xLTEtMA_23abd581-c520-464e-b6f6-ad9e3a2f20d0"
      unitRef="usd">1025000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <lgnd:AccruedStockRepurchases
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzctMS0xLTEtMA_bb3f14fe-9908-41c8-9652-2bdc20daa614"
      unitRef="usd">0</lgnd:AccruedStockRepurchases>
    <lgnd:AccruedStockRepurchases
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzctMy0xLTEtMA_d7fd8bed-8f15-497b-9c1d-053df23ea38a"
      unitRef="usd">4613000</lgnd:AccruedStockRepurchases>
    <lgnd:AccruedSalesReturns
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzgtMS0xLTEtMA_819e3661-fc49-4540-8c46-5ab01bc280a5"
      unitRef="usd">3027000</lgnd:AccruedSalesReturns>
    <lgnd:AccruedSalesReturns
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzgtMy0xLTEtMA_ecc4250a-4e92-4670-98fa-8e8ad26a91d7"
      unitRef="usd">3590000</lgnd:AccruedSalesReturns>
    <us-gaap:RestructuringReserveCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzktMS0xLTEtMA_e7957013-2dc4-469c-9351-aeb327272875"
      unitRef="usd">0</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzktMy0xLTEtMA_9f5d4dd3-1d9a-4933-97f5-85c38519d0d8"
      unitRef="usd">1093000</us-gaap:RestructuringReserveCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTEtMS0xLTczMDk_389020f9-8191-4bed-bfb4-4138a7183b77"
      unitRef="usd">1242000</lgnd:LeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTMtMS0xLTczMTI_ced5ed44-9a00-4e7c-8d84-e6c1d046fc7f"
      unitRef="usd">0</lgnd:LeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTEtMS0xLTA_fd461561-1f3c-498c-bd0c-ac1ba4d635d0"
      unitRef="usd">2065000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzEwLTMtMS0xLTA_7e3f5055-5c51-42ab-974c-3686dadaf6bc"
      unitRef="usd">3464000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzExLTEtMS0xLTA_c87dc6d6-c518-4a7c-a1eb-bb2d3e6ddaf0"
      unitRef="usd">9836000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo4ODQ2ZjBkYTJlYjI0OTQ1ODk4MTcxNjYwZmY1OWYxNS90YWJsZXJhbmdlOjg4NDZmMGRhMmViMjQ5NDU4OTgxNzE2NjBmZjU5ZjE1XzExLTMtMS0xLTA_d48881df-b6a2-41c3-81ab-2e3e9fae9d49"
      unitRef="usd">19200000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:ScheduleofContingentLiabilitiesTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90ZXh0cmVnaW9uOmNjMDdkODUxYWIwNTQzOWJhYTRmZGViYmNiNmY3NmZmXzI1Mzk_b6907b47-e267-4ef1-9a67-129f327ae92a">&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.509%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.782%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.453%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.225%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.010%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Crystal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofContingentLiabilitiesTableTextBlock>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ia139119e13424a1bbb83b3bd29c3eb9f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMS0xLTEtMA_6bb5fea5-7019-47dc-869d-41268a3ce5ba"
      unitRef="usd">1589000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMi0xLTEtMA_30d21b3f-ecf6-4989-9839-345eda2a858b"
      unitRef="usd">25000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i7bdf1a6a42f842598be277d115fdc741_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtMy0xLTEtMA_365c0433-a605-49b3-a692-4a412e7f270d"
      unitRef="usd">-1050000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i6e84a7b813d74048b025e392263824ce_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtNi0xLTEtMA_5a6f1882-9beb-4ebc-a3ae-5f1351660801"
      unitRef="usd">514000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtNy0xLTEtMA_6a987b2d-fd43-4ce3-9e01-abb3d32cf8e1"
      unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOC0xLTEtMA_41e56f68-1aec-4e4b-b14d-843748791f8a"
      unitRef="usd">-116000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="i7968c60734f3443b988a68f2b3746e62_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOS0xLTEtMTA5MzA_18457750-3507-4548-8d95-74815d87ed0e"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i60511aae828945a397611be17e7b185e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzEtOS0xLTEtMA_e4bba4c5-f97a-4f24-9048-437e84587bc0"
      unitRef="usd">348000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ib238a21ed8404ddeba140fd318f30bb2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMS0xLTEtMA_0154c413-ef1e-4aec-9ece-76d2e19e0b7b"
      unitRef="usd">3971000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMi0xLTEtMA_30baf226-2fe4-4475-bd16-050311192b83"
      unitRef="usd">3860000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ie179d26413044f59aed5eb2c4f99ddf8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItMy0xLTEtMA_dd79d703-77a2-4b0a-9ad7-38737823ad9d"
      unitRef="usd">5440000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i82abd5a9777940b08fc61c5d462259e1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItNi0xLTEtMA_11821c35-e7ae-4876-942c-22e7eb7d9286"
      unitRef="usd">5551000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItNy0xLTEtMA_0bb75a0b-a919-4558-aea9-24c6328d7e85"
      unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOC0xLTEtMA_2b263455-1ec5-49b6-ac01-51f25b208047"
      unitRef="usd">904000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="iedcd3f52dadc454f96e5cd6e59bd35fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOS0xLTEtMTA5MzA_f1f55aeb-a5e8-4b45-ba8c-dc275d5f8622"
      unitRef="usd">520000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ie1979f3d940c419ea3a725a37ea9e014_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzItOS0xLTEtMA_2f7a1267-0e82-4854-83c9-3426b860a418"
      unitRef="usd">5935000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i33ebdb404a3245379c9d5860ed4ac8ba_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMS0xLTEtMA_716d1234-a095-4e28-a785-3abc940de7cd"
      unitRef="usd">8401000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i391b93678af74f27899b8002cc987285_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMi0xLTEtMA_970ec303-9a24-4c0a-a96d-5ecedf2c4b9b"
      unitRef="usd">1000000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i391b93678af74f27899b8002cc987285_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtMy0xLTEtMA_01d5f341-98c4-4f8c-816e-bea5f9c65f6b"
      unitRef="usd">-924000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ia3a6da7b97a744bc9c0497857d795d5f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtNi0xLTEtMA_34ea4105-2106-49aa-b5dc-c05be921345f"
      unitRef="usd">6477000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtNy0xLTEtMA_6ef1e249-6742-4475-bbf6-1dad3e552726"
      unitRef="usd">3000000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOC0xLTEtMA_34b04d09-1218-4f0f-a226-7ec03db3c6fd"
      unitRef="usd">-818000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="if21e0066c15642debe44b1b8bf8dafbc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOS0xLTEtMTA5MzA_3c475a74-2960-406d-bca3-15a967289819"
      unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i8215f01222a94ee6a007f5c2f49f0ff8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzMtOS0xLTEtMA_99ebca5a-423e-430b-9365-9235b0187e48"
      unitRef="usd">2659000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMS0xLTEtMA_a5a66cc7-4f17-40a4-9744-18942475ca31"
      unitRef="usd">13961000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMi0xLTEtMA_fe3d6fb6-27e6-4e61-8b7f-be67e17420af"
      unitRef="usd">4885000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtMy0xLTEtMA_9adb3e59-c36f-4a8d-838c-eb436d505fc6"
      unitRef="usd">3466000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtNi0xLTEtMA_8e36fa39-4713-4bda-b54f-e3e26852c5ee"
      unitRef="usd">12542000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtNy0xLTEtMA_5c2fb125-1ef2-4278-9503-6d9ddb82e063"
      unitRef="usd">3050000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOC0xLTEtMA_8764cd83-3852-4ab2-a092-66b539987b94"
      unitRef="usd">-30000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOS0xLTEtMTA5MzA_e8302636-cc37-4158-99f1-23e563b925ed"
      unitRef="usd">520000</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDkvZnJhZzpjYzA3ZDg1MWFiMDU0MzliYWE0ZmRlYmJjYjZmNzZmZi90YWJsZTo0OTU0MmU4YTllZGE0ZDQ3YjczYjAzZjkyYTU3Y2U3OC90YWJsZXJhbmdlOjQ5NTQyZThhOWVkYTRkNDdiNzNiMDNmOTJhNTdjZTc4XzQtOS0xLTEtMA_98ff474b-f42e-44a9-ba11-8ce463cfd218"
      unitRef="usd">8942000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTI_bb2726a7-a15f-4e3d-bf90-75c43b82767c">Stockholders&#x2019; Equity&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.143%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.143%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.146%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2019, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 0.8 million shares. As of December&#160;31, 2019, there were 0.9 million shares available for future option grants or direct issuance under the Amended 2002 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;(In&#160; thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted-average grant-date fair value of all stock options granted during 2019, 2018 and 2017 was $48.65, $58.85 and $53.17 per share, respectively. The total intrinsic value of all options exercised during 2019, 2018 and 2017 was approximately $10.4 million, $51.9 million and $13.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash received from options exercised, net of fees paid, in 2019, 2018 and 2017 was $2.6 million, $19.8 million and $4.7 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.366%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.391%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.574%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.96 - $12.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$32.00 - $74.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;374,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;374,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$85.79 - $100.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;301,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$93.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$92.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$101.15 - $113.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$109.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$107.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$119.30 - $159.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$151.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$149.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$159.81 - $171.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$166.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$164.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.709%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.986%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.544%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4%-2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7%-3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0%-2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40%-49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33%-36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43%-47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.1 to 5.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.5 to 6.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, there was $23.2 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.413%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.893%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, unrecognized compensation cost related to non-vested stock awards amounted to $11.2&#160;million. That cost is expected to be recognized over a weighted average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, 59,263 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 4,745, 3,386 and 3,061 shares issued under the ESPP in 2019, 2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share Repurchases &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased 260,000 shares of our common stock at a cost of $191.14 per share. In September 2018, the board of directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years (the &#x201c;Repurchase Program&#x201d;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $350.0 million of our outstanding common stock under the Repurchase Program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $326.8 million of our common stock remained available as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;During the twelve months ended December&#160;31, 2019, 2018 and 2017, we repurchased 4,122,133 shares for $448.4 million, 782,248 shares for $127.5 million, and 14,000 shares for $2.0 million, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTM_fbd8cc2e-5e74-422e-8bce-ff99e1a63fde">&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.143%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.143%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.146%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i84123edc447641828fe3e7279992698e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtMS0xLTEtMA_d174f912-8938-4b54-9cbe-b5e9df8a9043"
      unitRef="usd">9641000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ia262ce3b54954a979aceac7f234989a3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtMy0xLTEtMA_78071b3c-3c30-4cfe-8524-c56397d0e352"
      unitRef="usd">8352000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i36c58245200747a5b667564d502af59e_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzMtNS0xLTEtMA_a2f736af-8926-4e3a-935c-a509bef82e7a"
      unitRef="usd">14235000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i164955ed1d7f4491869eb2cbafa3cc29_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtMS0xLTEtMA_7faa8475-86b2-4db6-8b04-e4e5a4a49fda"
      unitRef="usd">14874000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i8e964f748c5942548018f2246cc35730_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtMy0xLTEtMA_c028bd8b-80c7-442f-9af9-1b2e68e7c91f"
      unitRef="usd">12494000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="id1c406d933204c55979cce5e2f3e220b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzQtNS0xLTEtMA_4e20df2e-3284-4de0-8a14-ad4f7fc01a70"
      unitRef="usd">10680000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtMS0xLTEtMA_c1569ffc-0fd7-4e91-9b5e-ca5e02f9525e"
      unitRef="usd">24515000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtMy0xLTEtMA_138ad582-4b2c-4b53-b073-b41d375a866b"
      unitRef="usd">20846000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTozYzEyZTc4NmQzYTk0NTQxODc5YzZhNTJkMWZhN2E4OC90YWJsZXJhbmdlOjNjMTJlNzg2ZDNhOTQ1NDE4NzljNmE1MmQxZmE3YTg4XzUtNS0xLTEtMA_99112b70-949c-43af-b323-b09d903e5eb4"
      unitRef="usd">24915000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8f9c362671564a50b0f69033777e2901_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI4OQ_4dcb4d4a-fe94-4ea3-b7a0-47a9d874ab3e"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ifaf7c83e118d4acf95a3663f3661d169_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzM0NA_6ca74006-9997-4e68-9ed4-bc00af723760"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTY_88190619-b771-4076-b5f9-0380f280503c">&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.220%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;(In&#160; thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,736,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;139.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options vested and expected to vest as of December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtMS0xLTEtMA_93ef1981-4927-499d-82fb-4439cba9e27f"
      unitRef="shares">1736304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtMy0xLTEtMA_6ba830d2-399c-4eec-a987-dbc30cdaeb1b"
      unitRef="usdPerShare">66.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtNS0xLTEtMA_fdcf3d5b-dea2-49e1-bd21-95c3b21ce75e">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzEtNy0xLTEtMA_e1c70596-271f-459e-8f1d-681734bd2257"
      unitRef="usd">125858000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzItMS0xLTEtMA_caaf48a9-1052-4aec-8187-4f5e3d2eadc1"
      unitRef="shares">338617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzItMy0xLTEtMA_356bbb59-7323-458d-9537-9039cb7f6929"
      unitRef="usdPerShare">116.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzMtMS0xLTEtMA_5102de39-4a91-4bbd-8856-a937d5312922"
      unitRef="shares">112011</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzMtMy0xLTEtMA_b59b42be-e012-40c7-8d0a-347e0dd5a8a4"
      unitRef="usdPerShare">23.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzQtMS0xLTEtMA_103944fb-e424-4a47-8e2a-9a2343eb835c"
      unitRef="shares">6531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzQtMy0xLTEtMA_451edcbb-9de8-4669-ae71-9e19c42ff21b"
      unitRef="usdPerShare">139.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtMS0xLTEtMA_346cd3ea-4ee4-4103-bd84-1f6996f5a3cd"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtMy0xLTEtMA_5d52bcdd-14c1-424d-a61b-55734788cd5f"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtNS0xLTEtMA_0bb1ff63-fd8c-4f75-88e2-5f50085a4143">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzUtNy0xLTEtMA_115d1018-81bd-4b22-9cf0-4b058aca251a"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtMS0xLTEtMA_c31ba1db-cafb-4242-b416-dd1101bae462"
      unitRef="shares">1454726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtMy0xLTEtMA_fd67e798-0c13-41c6-a2cf-48e9d2bf11c8"
      unitRef="usdPerShare">61.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtNS0xLTEtMA_11d06353-1095-418c-9a33-aeb257bc65d7">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzYtNy0xLTEtMA_6c110efd-f2d3-45bd-b5d4-750862aafeb7"
      unitRef="usd">70345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctMS0xLTEtMA_21df61c5-85b0-4251-806d-d2633681133e"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctMy0xLTEtMA_b8a732d8-936d-4f39-8000-fe29023c9b8a"
      unitRef="usdPerShare">77.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctNS0xLTEtMA_f7ce9227-b2ac-4087-b653-7e273a926ff2">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNDExODFhNmEzNzc0MWE2YWZjODM5MmFlYjQ0NzM3OS90YWJsZXJhbmdlOmY0MTE4MWE2YTM3NzQxYTZhZmM4MzkyYWViNDQ3Mzc5XzctNy0xLTEtMA_d4bcd58b-7398-4d41-8595-698a46cdd13a"
      unitRef="usd">72002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYyMQ_1dc10b46-c07a-49eb-ae61-dafbd212ee18"
      unitRef="usdPerShare">48.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYyNQ_2d8abf76-19b7-46ce-a8fb-9f691eb45430"
      unitRef="usdPerShare">58.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzYzMg_0755faa0-4755-4c98-8851-d160249c76f1"
      unitRef="usdPerShare">53.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc1MA_6fdb8075-c5eb-4c56-b7a1-85366e7d649a"
      unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc1NA_4e48ef0a-5587-4844-b973-918d81fa3346"
      unitRef="usd">51900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzc2MQ_30693994-f902-4a73-9e07-58a4b6a4d4d7"
      unitRef="usd">13300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg1Nw_9f97fcf7-1ca6-41b7-9a73-3cf1104358e3"
      unitRef="usd">2600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i82055d1b8fca49509d627692bc5330e5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg2MQ_d6066a86-e360-4071-a53f-e17cd8ae91e9"
      unitRef="usd">19800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie7ad24ee387a4d6dbd7d44adc8c18136_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0Xzg2OA_d860c630-742b-4f57-b7a3-9334eced5aa6"
      unitRef="usd">4700000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTA_d530ee99-50ef-4f3d-801d-1481537147af">&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.366%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.391%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.313%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.574%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.96 - $12.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$14.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$21.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$32.00 - $74.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;374,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;374,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$85.79 - $100.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;301,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$93.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;239,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$92.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$101.15 - $113.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$109.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$107.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;272,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$117.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$119.30 - $159.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$151.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$149.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$159.81 - $171.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$166.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$164.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$195.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,956,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$77.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,454,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$61.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtMS0xLTEtMA_b3f35b78-0e27-48e0-a875-5a96ac44505d"
      unitRef="shares">195148</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibcf7708847b943269baab2b8cdefb406_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtMy0xLTEtMA_8da1d33c-9b55-4f5e-9562-34716e9360ed">P1Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtNS0xLTEtMA_e2b639c8-7b7b-478c-b5fe-340b424bb0d1"
      unitRef="usdPerShare">10.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtNy0xLTEtMA_f84b5409-5c69-4807-a3d0-91525d64cee9"
      unitRef="shares">195148</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i4fd4cb909dbb47838f386d03cf6e79f5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEtOS0xLTEtMA_fe07c437-3b6b-4f98-b5cf-222b0a8d20bb"
      unitRef="usdPerShare">10.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItMS0xLTEtMA_741cdd09-6606-4a61-a877-8d03da7b0927"
      unitRef="shares">212116</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iabce026c73264362b4fd2ae612d6c246_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItMy0xLTEtMA_224afc2f-8ded-455a-bf8b-27d9e9dc45d8">P2Y1M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItNS0xLTEtMA_f083f026-dd5f-4c3e-b62d-10507209b3f8"
      unitRef="usdPerShare">14.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItNy0xLTEtMA_780fa3f0-94a8-4581-9085-70bdc64adcc4"
      unitRef="shares">198116</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i14280bd3deb24f1abb91beb0987cdc1e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzItOS0xLTEtMA_01be4fcb-9fc8-4961-b00b-eaa764a9781b"
      unitRef="usdPerShare">14.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtMS0xLTEtMA_20c67744-d6f7-405b-9194-9178cd1320fa"
      unitRef="shares">195955</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i863a470ced3a418db7a073687288d252_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtMy0xLTEtMA_42858111-bc8c-41f8-85e1-da5ce6e6ee15">P3Y1M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtNS0xLTEtMA_205c28fb-4c61-4649-bd0a-a8dfaff87832"
      unitRef="usdPerShare">21.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtNy0xLTEtMA_1bfb19d9-219a-4d9e-b553-3242f256727b"
      unitRef="shares">195955</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i3f4fd2c6c4624064bc3154bb52d73b9a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzMtOS0xLTEtMA_79820924-5202-43b5-bef7-d934c35f863e"
      unitRef="usdPerShare">21.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtMS0xLTEtMA_c9ae39e8-1e41-4fad-b75f-36134cadd7f8"
      unitRef="shares">374059</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2e510b02efe440c28d46a496c7a3ab9c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtMy0xLTEtMA_672f75c2-fb51-42a9-be77-548420252637">P4Y5M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtNS0xLTEtMA_b153bbb7-79f7-4149-b5b7-22fea306ac64"
      unitRef="usdPerShare">63.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtNy0xLTEtMA_884294dc-e88d-4787-8aee-966a33ec78c8"
      unitRef="shares">374059</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i03b1c1acedea452c8463bc86fcb2b913_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzQtOS0xLTEtMA_e4bbc923-fc2a-4a74-831d-9420039cfa5d"
      unitRef="usdPerShare">63.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i2d741a769aee4da4af5556260a102804_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtMS0xLTEtMA_fca196e1-1292-44a8-b031-d462804a561c"
      unitRef="shares">301459</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i53406fa840174f8093916463e6389023_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtMy0xLTEtMA_0fc23ef5-d479-4a0f-9c59-c205fe3fb26c">P6Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i2d741a769aee4da4af5556260a102804_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtNS0xLTEtMA_8cfa0ca2-4102-4b8e-9b4e-49ac4815a318"
      unitRef="usdPerShare">93.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i2d741a769aee4da4af5556260a102804_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtNy0xLTEtMA_02a00b7a-ad89-4d0f-ae7a-2c4e4e3512ee"
      unitRef="shares">239220</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i2d741a769aee4da4af5556260a102804_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzUtOS0xLTEtMA_3ec3d5f9-f700-4a0e-b8ee-89fa212ffcbf"
      unitRef="usdPerShare">92.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtMS0xLTEtMA_3768f49f-7413-4e0f-8183-8fd206abbea9"
      unitRef="shares">98112</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5af0404808a345a382abe78ab35beb37_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtMy0xLTEtMA_ea6e2a5d-f359-478f-b9ca-2f477219bb3b">P7Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtNS0xLTEtMA_c023b803-afa5-4c53-8cfc-bdbf8b93d85c"
      unitRef="usdPerShare">109.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtNy0xLTEtMA_9ba312fa-200f-4e39-8432-ddc448cce279"
      unitRef="shares">46066</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic3a630f9e2ca4548af0a20a4c70d2297_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzYtOS0xLTEtMA_c6e39eff-1db5-49d5-80c2-fc246d245f15"
      unitRef="usdPerShare">107.65</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctMS0xLTEtMA_18cddea9-1b11-4d65-a4c8-605d2559c226"
      unitRef="shares">272687</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i78b7e93e24294f65b35f7e9d7b6c25b9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctMy0xLTEtMA_44420bfc-63d2-45ff-a015-301c6fcd37d2">P9Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctNS0xLTEtMA_24ddde83-1aa9-479a-a965-edc0c230a3f1"
      unitRef="usdPerShare">117.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctNy0xLTEtMA_d01b7012-3e89-4a31-a834-bfe0880a96d6"
      unitRef="shares">56830</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ia6fcbb1f4d4149b2881dacc180a3be44_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzctOS0xLTEtMA_0a8a2524-13ac-47a4-b9b7-8baa537f978a"
      unitRef="usdPerShare">117.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtMS0xLTEtMA_30ce2f68-e693-40a9-86d3-47dc3dd23df0"
      unitRef="shares">282475</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="if02d99896fd14ceb8c645034d1c0dde1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtMy0xLTEtMA_0dbcd1d9-3242-43c9-8bf9-674d8656395f">P8Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtNS0xLTEtMA_bc2f0d6e-6326-4756-a28d-5c7a15e58965"
      unitRef="usdPerShare">151.55</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtNy0xLTEtMA_3a6930fd-6d07-4439-b6a3-95b1986cd306"
      unitRef="shares">129541</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i78f2ad2f01184be8b4d40ef89f4a91ea_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzgtOS0xLTEtMA_eeb28777-2061-4bac-8e23-93e8535eb521"
      unitRef="usdPerShare">149.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktMS0xLTEtMA_0ce93644-6717-40d0-a75c-d4a7c346fdef"
      unitRef="shares">7050</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibef83b92b4f74a809d2b7427ab985d7f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktMy0xLTEtMA_f8ec6344-1e05-4633-a5a9-4e165380491d">P8Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktNS0xLTEtMA_2c7f85ba-8754-4d1e-82c8-c86c90bf29e4"
      unitRef="usdPerShare">166.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktNy0xLTEtMA_303af075-2ff8-41e1-ae2d-9cde6f6a9cbb"
      unitRef="shares">2473</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iaac4f9c38d8b44439baea6ee0a050b4e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzktOS0xLTEtMA_bc2b301e-d9fd-40dd-93e5-f5606796cc12"
      unitRef="usdPerShare">164.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTEtMS0xLTA_cabd126e-0157-49f1-bb5e-b34622cc9d2c"
      unitRef="shares">17318</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i331ee32d8ae94446ad141d463c34fd45_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTMtMS0xLTA_4de63d57-be6a-4086-8f10-9a574f7c6152">P8Y5M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTUtMS0xLTA_5b242f34-3681-4583-a32c-d0dd009fb0d6"
      unitRef="usdPerShare">195.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTctMS0xLTA_58af4be4-97a7-4a45-adb7-91289e7ca6c9"
      unitRef="shares">17318</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7da0cebd72844cccbc3578ab39bffc76_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzEwLTktMS0xLTA_69bdc9dc-d90f-4696-8fda-fc10f778e49e"
      unitRef="usdPerShare">195.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i12002ca5921748508b192203c7a9d235_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTEtMS0xLTA_377a151c-c495-4d93-b94b-acc331a58f9e"
      unitRef="shares">1956379</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i3fc1967286cf446aa67efcdb33bbfc4a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTMtMS0xLTA_b8cc6e86-25a1-4a4e-acfc-91da56f1f766">P5Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i12002ca5921748508b192203c7a9d235_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTUtMS0xLTA_c5956973-c13b-482b-9a3a-1357951084a9"
      unitRef="usdPerShare">77.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i12002ca5921748508b192203c7a9d235_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTctMS0xLTA_8535a76a-1305-4ece-9f92-1ef0983985e3"
      unitRef="shares">1454726</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i12002ca5921748508b192203c7a9d235_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTo0NDM1OWY1MTgxNzk0MGFkOGRhYmUxZDY2Nzg4MTIyMC90YWJsZXJhbmdlOjQ0MzU5ZjUxODE3OTQwYWQ4ZGFiZTFkNjY3ODgxMjIwXzExLTktMS0xLTA_73f080c6-6022-49c2-a9c0-fc9279c5a0be"
      unitRef="usdPerShare">61.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNDc_5d290495-d770-4873-af47-bfbe3f282171">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.709%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.986%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.540%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.544%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4%-2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7%-3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0%-2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40%-49%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33%-36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43%-47%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.6 to 5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.1 to 5.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.5 to 6.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i903cd103982640959896b8b7ba2c6e13_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzExNDM_558f5bc7-f06b-46ba-9c0a-31023a64ae54"
      unitRef="usd">23200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib6a66cef40314c6aa309503a8512152a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEyOTc_84e00f15-e4ed-4f59-a504-e8d56d735d97">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyNTE_4c74306d-fd3d-41e3-8533-33ee702c3bcc">&lt;div style="margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.413%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.893%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$130.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;118,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$115.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(102,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$121.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(666)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$134.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$125.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibd44dfbec8d944479851c647f8b7ccdc_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzEtMS0xLTEtMA_94258295-4521-4196-b58c-b56282caa495"
      unitRef="shares">132273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibd44dfbec8d944479851c647f8b7ccdc_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzEtMy0xLTEtMA_6bbdcba4-6a28-4cb4-b10e-b41fa0e4ce46"
      unitRef="usdPerShare">130.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzItMS0xLTEtMA_cbe68b6e-d69e-49a5-86ec-61e1dd8aeffb"
      unitRef="shares">118498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzItMy0xLTEtMA_2b6111d8-f0be-47ee-977c-b34ac13c5660"
      unitRef="usdPerShare">115.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzMtMS0xLTEtMA_281a6dad-55f6-43c0-aa2c-f7960ff1e866"
      unitRef="shares">102846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzMtMy0xLTEtMA_a9e570f2-1e83-478b-9205-d6d0a5401b44"
      unitRef="usdPerShare">121.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzQtMS0xLTEtMA_bfa971cb-976c-4a52-94d6-82521515b4c8"
      unitRef="shares">666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzQtMy0xLTEtMA_0cc01f67-796f-48d4-9094-c2ab0043750f"
      unitRef="usdPerShare">134.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzUtMS0xLTEtMA_f865d4c0-84b1-4e2b-8976-fa95f8e4ad8f"
      unitRef="shares">147259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90YWJsZTpmNjY2Y2JmODUzZDE0Yzc0OTQxMTNlYTY1MWQ2Yjc4OS90YWJsZXJhbmdlOmY2NjZjYmY4NTNkMTRjNzQ5NDExM2VhNjUxZDZiNzg5XzUtMy0xLTEtMA_39a7531c-7e8a-4d25-a025-34fd28a3dff7"
      unitRef="usdPerShare">125.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ice16507fcb4e413ea981ad6098db588e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE1MDQ_3e86ae7c-b30b-4c1f-b072-5b02ccb7d184"
      unitRef="usd">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if03a39e46faa4ddbbda6682b94725807_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE1ODE_0f95f3d9-671d-4e85-869c-8faeb50a56e0">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2831464859c14cdc9755d96fcee5dab1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE2NDc_7e5c57fd-80ac-4d1b-ad14-71d71e1428bf"
      unitRef="shares">59263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE4MjM_d8896112-61ef-4dd1-8cec-defc3b36d794"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzE5ODE_26f30ac1-9e74-424c-a9e2-394fa722888a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ied72345d69394ba88607a84eb7f6c8a4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMjI_123c2d8e-26b8-4bcc-a43e-6e25ce7800f5"
      unitRef="shares">4745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i4872587a0b7b4d018481b6594f32290f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMjY_f14bb0c7-659a-4028-9d52-64a9ca697462"
      unitRef="shares">3386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i06c0ce63eae94a5eb3fcba29f768110d_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIxMzM_608fe47c-7dfb-43a1-a233-67c63c73899b"
      unitRef="shares">3061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIzMDM_be7dc864-5280-442b-9fcc-5ac2a06fd7f0"
      unitRef="shares">260000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="i8d459ba1e80a400fb8140039e5009443_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzIzNDY_d46a1fe3-1973-4b5a-81cb-17ba938a1b1e"
      unitRef="usdPerShare">191.14</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6341c256477e4429836844da17a32b5e_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI0MzY_19748376-e343-472b-af12-430427d41a64"
      unitRef="usd">200000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="icf64fbf8a55e465ba26faa70a391914c_I20190123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzI3Njc_a51e5e47-ca7d-4a20-97aa-5b8e38683f26"
      unitRef="usd">350000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i1ea985b507f54962867ac2d46fb5c542_I20190911"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTA0_d8b6a61e-83e7-4126-8d80-79df8c897fb9"
      unitRef="usd">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="icf64fbf8a55e465ba26faa70a391914c_I20190123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTIz_a51e5e47-ca7d-4a20-97aa-5b8e38683f26"
      unitRef="usd">350000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzEwNDQ1MzYwNDY4NTQz_9a8589ec-5cb5-438e-825a-92a17819c22d"
      unitRef="usd">326800000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxNzU_0739448d-5034-4f1b-9a68-35405f5969c7"
      unitRef="shares">4122133</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxODk_de151c5e-1095-486d-b12c-a2245ef62524"
      unitRef="usd">448400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMxOTM_e4daa8c1-9c79-4c54-8f03-a85b6fa042c5"
      unitRef="shares">782248</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMDc_3580cba7-c72a-4cad-8dca-25c95d1ffd73"
      unitRef="usd">127500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMTU_d1883955-10de-44c4-8f69-bd6ed5c6db96"
      unitRef="shares">14000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMTUvZnJhZzpiMmQxYzliZDhjMDM0MmU0YTQ0MGYzMDNjYWZlM2ExNC90ZXh0cmVnaW9uOmIyZDFjOWJkOGMwMzQyZTRhNDQwZjMwM2NhZmUzYTE0XzMyMjk_2a8bde35-b566-43e1-8827-b1281d1a1cf9"
      unitRef="usd">2000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjEvZnJhZzo3OTI4ZmU3ZGJhNmY0MDM1YTBhMGNiYzRkYmVmYTE4Ni90ZXh0cmVnaW9uOjc5MjhmZTdkYmE2ZjQwMzVhMGEwY2JjNGRiZWZhMTg2XzI0MDY_810826d2-6e6d-4927-a8ca-92432f749022">Commitment and Contingencies: Legal Proceedings&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ASC 450, Contingencies&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On July 27, 2018, AG Oncon, LLC, AG Ofcon, Ltd., Calamos Market Neutral Income Fund, Capital Ventures International, Citadel Equity Fund Ltd., Opti Opportunity Master Fund, Polygon Convertible Opportunity Master Fund, Wolverine Flagship Fund Trading Limited, as plaintiffs, filed a complaint in the Court of Chancery of the State of Delaware (AG Oncon, LLC v. Ligand Pharmaceuticals Inc.) alleging claims for violation of the Trust Indenture Act, breach of contract, and others against us.  On May 24, 2019, the Court granted our motion to dismiss and the Delaware Supreme Court subsequently affirmed the decision of the Court of Chancery dismissing this case with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Teva stating that Teva had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#xae; prior to the expiration of any of U.S. Patent Nos. 8,410,077 (&#x201c;the &#x2019;077 patent&#x201d;); 9,200,088 (&#x201c;the &#x2019;088 patent&#x201d;), or 9,493,582 (&#x201c;the &#x2019;582 patent&#x201d;), and alleging that these patents, each of which relates to Captisol&#xae;, are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s ANDA product.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 20, 2017, CyDex filed a complaint against Teva in the U.S. District Court for the District of Delaware, asserting that the filing of Teva&#x2019;s ANDA constitutes infringement of each of the &#x2019;077 patent, the &#x2019;088 patent, and the &#x2019;582 patent. On March 22, 2018, Teva filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on April 12, 2018, CyDex filed an answer to Teva&#x2019;s counterclaims. On October 31, 2019, CyDex, Teva, and Acrotech Biopharma L.L.C. (the holder of the NDA for EVOMELA&#xae;) entered into a Confidential Settlement Agreement, settling this patent litigation. As a result of the settlement, Teva will be permitted to market a generic version of EVOMELA&#xae; in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 9, 2019, CyDex received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#x201c;Alembic&#x201d;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#xae; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or U.S. Patent No. 10,040,872 (&#x201c;the &#x2019;872 patent&#x201d;), and alleging that these patents, each of which relates to Captisol&#xae;, are invalid, unenforceable, and/or would not be infringed by Alembic&#x2019;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#x2019;s ANDA constitutes infringement of each of the &#x2019;088 patent and the &#x2019;582 patent. On July &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#x2019;s counterclaims. On December 16, 2019, the Court entered a Scheduling Order, setting October 2, 2020, as the fact discovery cut off, March 5, 2021, as the close of expect discovery, and May 17, 2021, as the first day of a five to six day bench trial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#xae; prior to the expiration of any of the &#x2019;077 patent; the &#x2019;088 patent, the &#x2019;582 patent, or the &#x2019;872 patent, and alleging that these patents, each of which relates to Captisol&#xae;, are invalid, unenforceable, and/or would not be infringed by Lupin&#x2019;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin's counterclaims on January 2, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 31, 2019, we received three civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#x201c;JPML&#x201d;) has assigned several hundred civil cases which have been designated as a Multi-District Litigation (&#x201c;MDL&#x201d;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NTY_7d06eb6f-f171-4e9e-b68d-5598e1a5f1ec">Income Taxes&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Tax Act was enacted on December 22, 2017 and includes a number of changes to existing tax laws that impact us, most notably it reduces the US federal corporate tax rate from 35% to 21%, for tax years beginning after December 31, 2017. The Tax Act made modifications to allowable tax depreciation, the deductability of compensation for officers, the deductibility of meals and entertainment expenses, and the deductibility of interest expense. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.192%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.833%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.192%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.686%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.194%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.682%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.148%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rate change for changes in federal or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2019 and 2018 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2019, 2018 and 2017. The valuation allowance increased $136.9 million in 2019, decreased $2.5 million in 2018 and decreased $8.4 million in 2017.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.578%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.762%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.913%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(141,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Retrophin fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Identified indefinite lived intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, we had federal net operating loss carryforwards set to expire through 2037 of $31.5 million and $119.1 million of state net operating loss carryforwards that begin to expire in 2028. We also have $0.6 million of federal research and development credit carryforwards, which expire through 2038. We have $22.9 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $713.8 million of non-U.S. net operating loss carryovers and approximately $14.6 million of non-U.S. capital loss carryovers that have no expiration date. We have a full valuation allowance against these non-U.S. tax attributes. &#160;&#160; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2019 are net of any previous limitations due to Section 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2019, 2018 and 2017 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="14" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2019 is $27.1 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and December&#160;31, 2018, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2016 tax year to the present.&#160;The state income tax returns generally remain open for the 2015 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2019, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2015 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NjA_a1cb91ca-a56d-404d-bccc-7c5a7c10cfc9">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.192%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.833%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.192%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.686%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.194%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtMS0xLTEtMA_0eb40d00-0426-409e-888a-541eeffce9d1"
      unitRef="usd">89471000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtMy0xLTEtMA_17b9d3cc-a4fe-4b08-97dc-45f824800709"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzMtNS0xLTEtMA_91b79ebc-2c3c-458d-b533-38b532cf91b7"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtMS0xLTEtMA_881bed4b-fb8e-49d8-927c-91bb4d5790bb"
      unitRef="usd">3103000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtMy0xLTEtMA_2857ae3f-8115-461b-ad69-48d9ba57f5c1"
      unitRef="usd">424000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzQtNS0xLTEtMA_d3271067-d0f3-49d0-b6fd-cd441c17a1c9"
      unitRef="usd">111000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtMS0xLTEtMA_0c4459ab-385e-4558-82d5-bba275eea4ba"
      unitRef="usd">-66000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtMy0xLTEtMA_58710640-9c56-4350-8b3b-c67772266d5b"
      unitRef="usd">-158000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzUtNS0xLTEtMA_82e0f6db-5e7f-42b7-8925-644ca01092d8"
      unitRef="usd">261000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtMS0xLTEtMA_1671a909-c92b-4cc7-9af5-75db3741dc6a"
      unitRef="usd">92508000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtMy0xLTEtMA_e78e3bd4-0471-468c-9b70-cf9151db4717"
      unitRef="usd">266000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzYtNS0xLTEtMA_2554f6c6-948c-4290-b98c-96ec58349f4e"
      unitRef="usd">372000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtMS0xLTEtMA_c73bffff-e44c-4c05-989d-f7639770dd8e"
      unitRef="usd">74627000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtMy0xLTEtMA_af21feac-2c3c-41a8-9b47-3fb78730ecf1"
      unitRef="usd">29928000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzgtNS0xLTEtMA_3f4500fe-40fa-48ae-98c0-7b854545eee9"
      unitRef="usd">44075000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktMS0xLTEtMA_15aa22fd-2712-4927-9e3f-84e89dc06699"
      unitRef="usd">202000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktMy0xLTEtMA_4bded98f-d368-401b-850d-779c4a1a1300"
      unitRef="usd">-185000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzktNS0xLTEtMA_66de0fc4-a20f-4772-9f0e-abc9bd5fa197"
      unitRef="usd">228000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTEtMS0xLTA_84284f5d-636c-4f72-8a82-127a77eb2fec"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTMtMS0xLTA_12b3ecc9-d50a-4ab8-b78f-0885c90e6bf3"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo0NjRiYTc5ZWZlOWI0MTJiYWY0OWI2OTEwODgyNDI5Zi90YWJsZXJhbmdlOjQ2NGJhNzllZmU5YjQxMmJhZjQ5YjY5MTA4ODI0MjlmXzExLTUtMS0xLTA_43777042-d40c-40ad-938a-aca7a470443b"
      unitRef="usd">44675000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NjI_b4f72973-6fdf-4f98-acfa-3ea643567707">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.682%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.148%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rate change for changes in federal or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItMS0xLTEtMA_09109b65-5ea6-4fae-b37d-e3be9b7c843b"
      unitRef="usd">167294000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItMy0xLTEtMA_adc5180d-9953-41ba-bd6a-a48ec9b2b8fc"
      unitRef="usd">36400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzItNS0xLTEtMA_867b232c-aae5-4c45-b8b9-9fbebf9abfaa"
      unitRef="usd">20031000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtMS0xLTEtMA_ff625fa5-76bd-4685-9c33-ec231209d9ef"
      unitRef="usd">2466000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtMy0xLTEtMA_63bc5b16-5e94-4b18-80f9-591d3b3f3e8c"
      unitRef="usd">1635000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzMtNS0xLTEtMA_d7d12347-2ec2-4281-9010-68e10aec872b"
      unitRef="usd">622000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtMS0xLTEtMA_bea00cd2-5e79-4417-a4e1-9800ce7a6782"
      unitRef="usd">18000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtMy0xLTEtMA_d1a1cd66-4645-4057-a1a2-9e0113e2bd47"
      unitRef="usd">948000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzQtNS0xLTEtMA_a9f64b83-64cc-4fdb-8af6-0b9d28fdb9e5"
      unitRef="usd">903000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtMS0xLTEtMA_87619a50-a212-4aa3-9ca9-63a9c55ece16"
      unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtMy0xLTEtMA_37e852ab-453a-41cd-825f-ccba6b0f45ab"
      unitRef="usd">-8131000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzUtNS0xLTEtMA_6d7c492c-7884-414a-887b-39efd6f71c81"
      unitRef="usd">-4019000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMS0xLTEtNzM3OA_2f4f1eef-7813-464f-8d82-677ff2bb44b5"
      unitRef="usd">402000</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMy0xLTEtMTA5ODk_adc02bde-b74e-4443-9e33-c3c539d069ab"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtNS0xLTEtMTA5ODk_020a6d4c-8a3b-42da-bb2d-286fe6f53878"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount>
    <lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMS0xLTEtMA_dcf631b2-6971-4b45-b85b-6a1cc2621382"
      unitRef="usd">-879000</lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch>
    <lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtMy0xLTEtMA_b3947e3c-16e4-48ca-95c5-6ba0d154be18"
      unitRef="usd">-2758000</lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch>
    <lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzYtNS0xLTEtMA_f5da5a53-6e7a-4998-8503-aa298239206b"
      unitRef="usd">-2821000</lgnd:IncomeTaxReconciliationExpiredTaxCreditsResearch>
    <lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctMS0xLTEtMA_3ce9c546-f1be-41da-963b-757aaa002397"
      unitRef="usd">-441000</lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions>
    <lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctMy0xLTEtMA_9fba0cd2-500f-4b95-a03f-bc596b6ccac4"
      unitRef="usd">-858000</lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions>
    <lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzctNS0xLTEtMA_6f2affa4-cf0d-400d-85d0-1cfd9c9f9bcf"
      unitRef="usd">-1308000</lgnd:IncomeTaxReconciliationChangeInUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtMS0xLTEtMA_bcb13eaf-edf8-43b1-8901-3195e584230a"
      unitRef="usd">-210000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtMy0xLTEtMA_3c771c66-0dde-4bbe-8d67-0c696b622095"
      unitRef="usd">178000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzgtNS0xLTEtMA_5868410f-2002-4ada-ab5c-9fb939b556a7"
      unitRef="usd">32429000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktMS0xLTEtMA_7b9dec92-2ad3-4887-b025-cb59775e272c"
      unitRef="usd">-1193000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktMy0xLTEtMA_a2c3ee67-0953-4733-b49c-1c6d49a9a73c"
      unitRef="usd">-4225000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzktNS0xLTEtMA_5d6d3340-79cb-43ae-b536-b0d6dd5d19db"
      unitRef="usd">-4169000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTEtMS0xLTA_6bfb1436-abf4-476d-be3a-b11c716f483f"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTMtMS0xLTA_ad990bcc-8534-4b8a-ba97-fe2b512c9b59"
      unitRef="usd">-3054000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEwLTUtMS0xLTA_9098aff8-0361-4471-9879-ff293b77de0d"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTEtMS0xLTA_5aaea13d-31d7-4511-aa7f-ef97fee464f8"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTMtMS0xLTA_16d7e3ec-5406-4060-b2c1-6c986cc1c384"
      unitRef="usd">615000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzExLTUtMS0xLTA_628478be-c6a7-477d-aac8-fff7f41d0fcb"
      unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationChangeInDerivatives>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTEtMS0xLTA_2c6978de-2fa5-484f-8e6e-ed7d5b77f891"
      unitRef="usd">621000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTMtMS0xLTA_ad08402c-2446-49d6-a564-072c96ea3763"
      unitRef="usd">1435000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEyLTUtMS0xLTA_afdfb2e2-fdfc-48c9-bf16-99d5fe28c6b4"
      unitRef="usd">391000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTEtMS0xLTA_da4d85a9-d137-46b3-bb8e-8e44a4e791d9"
      unitRef="usd">167337000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTMtMS0xLTA_ad4a9f96-f2ca-43f2-a047-5fc993a23207"
      unitRef="usd">30009000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphOTYyOGJjYzIyNWE0MmExYTNhMWQ4YmEyNmFmN2I5Ny90YWJsZXJhbmdlOmE5NjI4YmNjMjI1YTQyYTFhM2ExZDhiYTI2YWY3Yjk3XzEzLTUtMS0xLTA_8ba34e78-4cfb-4bad-8bbf-a6b2bff7cb42"
      unitRef="usd">44675000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzE5NTQ_9a456730-7ee5-4302-aaa1-73a0b50f7890"
      unitRef="usd">-136900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzE5NzY_e548790f-cd16-40d7-ac45-363c563ad0d6"
      unitRef="usd">-2500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIwMDE_a227a968-ea77-4e2f-8d18-358cfc869bec"
      unitRef="usd">8400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzI3NDg3NzkwNzc5ODY_1e25a612-a312-4057-bb3d-6fd3726b99e1">Deferred tax assets (liabilities) are comprised of the following:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.578%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.762%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.913%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(141,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Retrophin fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Identified indefinite lived intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investment in Viking&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzQtMS0xLTEtMA_fec0945e-cc33-45e2-8626-4eeaea9c9783"
      unitRef="usd">150727000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzQtMy0xLTEtMA_4c2f9464-2117-40e8-9fba-e592d5326c2b"
      unitRef="usd">57181000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzUtMS0xLTEtMA_be77ca28-98ef-41bd-9284-5df07e555ac6"
      unitRef="usd">14843000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzUtMy0xLTEtMA_a1f9cc73-e47e-4e9f-ae76-291c76d70025"
      unitRef="usd">31101000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzYtMS0xLTEtMA_bbc41c71-dfc0-47c8-bb09-e9db689a983c"
      unitRef="usd">419000</lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets>
    <lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzYtMy0xLTEtMA_80e57c4e-78aa-4fbe-b4c2-7df5a52c54ed"
      unitRef="usd">1637000</lgnd:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzctMS0xLTEtMA_f7e04924-3cfd-46ea-8fb7-0508bf10dfc4"
      unitRef="usd">171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzctMy0xLTEtMA_04e4794c-1635-4f23-b02f-047282f5ef41"
      unitRef="usd">657000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzgtMS0xLTEtMA_a350cf3d-2f15-4b2f-b608-c8df13403500"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzgtMy0xLTEtMA_4dbb22cd-7f90-4fe8-86f3-60383812f505"
      unitRef="usd">957000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzExLTEtMS0xLTA_60aaae1f-673b-4f3c-8038-3d035f5726b1"
      unitRef="usd">17960000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzExLTMtMS0xLTA_68b2ca5c-36d6-4c17-9f12-9c05334b8312"
      unitRef="usd">11430000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEyLTEtMS0xLTA_43572b19-1d42-4074-99ed-c6790b7e4b4d"
      unitRef="usd">184120000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEyLTMtMS0xLTA_cdb96180-0d8a-4df3-8f56-869ddc0c1a5a"
      unitRef="usd">102963000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEzLTEtMS0xLTA_214a7c3f-3c86-43a6-a893-c481b2d81205"
      unitRef="usd">141338000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzEzLTMtMS0xLTA_74bdd6b3-36d6-49f9-9e95-94e837da1e0b"
      unitRef="usd">4476000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE0LTEtMS0xLTA_adc3c325-3468-4b4a-9e26-187f403bdb63"
      unitRef="usd">42782000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE0LTMtMS0xLTA_f313bb5d-ad54-4f7c-8fe3-b5c76c9e12b0"
      unitRef="usd">98487000</us-gaap:DeferredTaxAssetsNet>
    <lgnd:DeferredTaxLiabilitiesFairValueAdjustment
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE3LTEtMS0xLTA_0a99adaa-1ba4-4065-b459-c1c9034b4367"
      unitRef="usd">18000</lgnd:DeferredTaxLiabilitiesFairValueAdjustment>
    <lgnd:DeferredTaxLiabilitiesFairValueAdjustment
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE3LTMtMS0xLTA_2c2302ca-9249-4f71-9913-0358029c9e33"
      unitRef="usd">179000</lgnd:DeferredTaxLiabilitiesFairValueAdjustment>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE4LTEtMS0xLTA_3cd26b56-41d6-4012-813d-a294960d5fc0"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE4LTMtMS0xLTA_4f012b1f-d08d-4eb8-b4f1-8863948cda86"
      unitRef="usd">2905000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE5LTEtMS0xLTA_838176b7-8cce-4764-a354-780214f173cd"
      unitRef="usd">41664000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzE5LTMtMS0xLTA_b32e4f34-3158-469d-93bd-ac25833f59a1"
      unitRef="usd">44643000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTEtMS0xLTA_10a74620-f6fb-4dd9-b95a-60eb0bce0d56"
      unitRef="usd">1040000</lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTMtMS0xLTA_dbd22d2e-d061-4145-b3ca-9da2b9c6d859"
      unitRef="usd">1759000</lgnd:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTEtMS0xLTA_fed0c85a-fc45-45ec-bdb8-3219913e5a04"
      unitRef="usd">2937000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTMtMS0xLTA_ba23743f-01d9-432d-970a-77ba7157c7d6"
      unitRef="usd">2480000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTc0Mjg_2f247a1e-d1da-4544-856b-fe43f407cbf6"
      unitRef="usd">3488000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIwLTMtMS0xLTExMDE5_979111de-b111-4fdf-ae39-1caed4dc509d"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTc0MTQ_421b6f15-0e43-441b-b8dd-3b5242e0e6f3"
      unitRef="usd">964000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIxLTMtMS0xLTExMDE5_835c1d9e-cf53-436b-9f21-d9c5d63864a4"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTEtMS0xLTA_f9ee9775-a32f-4c1d-9a89-6e81d4b5c7a7"
      unitRef="usd">50111000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIyLTMtMS0xLTA_050f80d4-f2d5-454f-ada3-d9e312bdd0c3"
      unitRef="usd">51966000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIzLTEtMS0xLTA_0417060c-04db-4a59-9e44-9d73ace5e3ad"
      unitRef="usd">7329000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTphNzIwN2U2NWFjZmI0OWZhODdkODczZDEzNTk5N2QzZC90YWJsZXJhbmdlOmE3MjA3ZTY1YWNmYjQ5ZmE4N2Q4NzNkMTM1OTk3ZDNkXzIzLTMtMS0xLTA_ffa72a87-4249-4165-a4cb-5274e4e52ec1"
      unitRef="usd">46521000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2b493974b1c542688ad91b9e471e0124_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxMDI_b47b0438-5cb7-4170-9f58-6bf58cee2402"
      unitRef="usd">31500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idb372575aafc4ed3b9445394ffcccb29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxMDk_965e58b6-99c2-4e89-8985-20236f69f6bb"
      unitRef="usd">119100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic1894d5ffb9e46e1bd0855a3f66e9ffa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIxNjg_86b1d1a8-a460-4b62-a585-9b31224c110e"
      unitRef="usd">600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4b4fae611a5c4181ac378c7ecc937744_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzIyNjI_6bc159e9-ee94-4924-b673-e31f8edd0e2f"
      unitRef="usd">22900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ife0bb7031f9647efa3364ba02afec1e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzgyNDYzMzcyMjAwNTY_60702799-b4c1-4c15-8fb5-b8a220c92d04"
      unitRef="usd">713800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia54d651574f64756a24c8e91f44996a2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzgyNDYzMzcyMjAwMzc_debdadfd-e8eb-4199-841b-5e8ddb563cd0"
      unitRef="usd">14600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzQ3NTg_6c5fca81-f937-4d7b-8569-c405570c73a9">&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2019, 2018 and 2017 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.547%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="14" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItMS0xLTEtMA_8daedd4c-63cd-424c-a68c-4bf93b775728"
      unitRef="usd">30289000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItMy0xLTEtMA_1d4575ad-167a-402e-a706-3a200adc9031"
      unitRef="usd">29363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i70090b4fce044e77b235ddf8a74bbb7e_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzItNS0xLTEtMA_d4438552-bf48-406a-b88b-ce526546bfe7"
      unitRef="usd">38770000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtMS0xLTEtMA_330eab64-3ce0-4275-970d-a18b0f5c378f"
      unitRef="usd">543000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtMy0xLTEtMA_980f8d5a-8e03-4157-be9c-4b004b6f5cc0"
      unitRef="usd">1247000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzMtNS0xLTEtMA_f5c28d5e-f6e8-439e-a556-cd38c3210ab8"
      unitRef="usd">1067000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtMS0xLTEtMA_320559af-1585-4208-9bee-3b4a62b19c8e"
      unitRef="usd">-54000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtMy0xLTEtMA_007d5af4-0fbf-4724-862f-f80c86f3769b"
      unitRef="usd">336000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzQtNS0xLTEtMA_0d74d71a-522a-4f6a-bb5a-3d82244502f6"
      unitRef="usd">109000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtMS0xLTEtMA_e56e870c-8e92-43aa-b2e5-435e394283d3"
      unitRef="usd">2042000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i41210e99b1f64bd0a8ce80ef5c05030a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtMy0xLTEtMA_a070d1a2-8cf1-4550-928b-1f00f0f7f167"
      unitRef="usd">657000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="idec9bf5d6dc04d06a0d4a2f4f0d1de84_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzUtNS0xLTEtMA_e5385c8d-4762-471c-bc2f-1c6326a49856"
      unitRef="usd">10583000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtMS0xLTEtMA_23e87d5e-ea8e-4b2b-84ff-4970e6590ff2"
      unitRef="usd">28736000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1845b3a0c00f4faf86884050f553c2a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtMy0xLTEtMA_929e85a2-20dc-4034-91cd-92116fca4920"
      unitRef="usd">30289000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iff71220a9b5a4125a61ea2bfa763a1d0_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90YWJsZTo5ZjUxNDdmMWZmZjE0OGExOWZhYTA1ZTE0NzI5Njc3NC90YWJsZXJhbmdlOjlmNTE0N2YxZmZmMTQ4YTE5ZmFhMDVlMTQ3Mjk2Nzc0XzYtNS0xLTEtMA_dba57545-1797-45b1-bdbf-ead5db465e88"
      unitRef="usd">29363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjQvZnJhZzpmZjA3MTY3ODkzNzY0MDcyYWQ2MGVjYzljMjk4ZDZjNC90ZXh0cmVnaW9uOmZmMDcxNjc4OTM3NjQwNzJhZDYwZWNjOWMyOThkNmM0XzM1NjA_a2333431-104b-4c96-b128-fb9522aa7f93"
      unitRef="usd">27100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90ZXh0cmVnaW9uOjdhZmQ4NTA3ZGU3ZTQ5NjU5YTcyOThkMTI3NDVmMGRhXzM2NA_30abb94a-59dc-41ba-9ec3-3713d2608608">Summary of Unaudited Quarterly Financial Information&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2019 and 2018 are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;First Quarter*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(176,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;666,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;*includes pre-tax gain from sale of Promacta license of $812,797.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,071&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,071&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90ZXh0cmVnaW9uOjdhZmQ4NTA3ZGU3ZTQ5NjU5YTcyOThkMTI3NDVmMGRhXzM2NQ_a571b89c-7566-4273-ad93-c228d2b73fa9">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2019 and 2018 are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.665%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.669%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;First Quarter*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(176,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;666,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,558&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;&#160;&#160;*includes pre-tax gain from sale of Promacta license of $812,797.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diluted per share amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,071&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,071&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItMS0xLTEtMA_8c8ffaa7-e088-47c7-a763-b5495904f247"
      unitRef="usd">43484000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItMy0xLTEtMA_4a0ca207-603a-426b-b733-2864be538537"
      unitRef="usd">24987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItNS0xLTEtMA_f176bd78-84d1-4f2a-88e7-d42b2a711909"
      unitRef="usd">24808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzItNy0xLTEtMA_0a6a0960-55bd-45e3-9009-2e05a983582f"
      unitRef="usd">27003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtMS0xLTEtMA_87c3c796-ab6d-4910-8ad9-677df354a5a7"
      unitRef="usd">29738000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtMy0xLTEtMA_75c4deb9-dbe8-48bb-aef4-7c4318a58092"
      unitRef="usd">29117000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtNS0xLTEtMA_69b6ec56-1388-41c2-b95a-0b410f02fefa"
      unitRef="usd">29966000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzMtNy0xLTEtMA_6f70bbc0-6d2c-4a93-b817-58014437df61"
      unitRef="usd">37182000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtMS0xLTEtMA_4842a541-e871-4047-8dfd-a899912cd1ff"
      unitRef="usd">176376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtMy0xLTEtMA_1cecd271-cce4-46fb-9873-8f7a79f54de9"
      unitRef="usd">-3609000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtNS0xLTEtMA_fcb71c29-8faa-4c5d-8ef1-085f40a148c6"
      unitRef="usd">-4620000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzQtNy0xLTEtMA_9c92f6e4-489c-4440-846f-94826ee3fcf8"
      unitRef="usd">-810000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtMS0xLTEtMA_7e11c500-4b56-4d35-9c5e-47c23c55ddec"
      unitRef="usd">666337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtMy0xLTEtMA_884bf0cc-8078-4b50-a874-e8db750404c8"
      unitRef="usd">-14419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtNS0xLTEtMA_9edb5ab2-7a3f-41b4-a4fc-8753c5f8bbe0"
      unitRef="usd">-15251000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzgtNy0xLTEtMA_4c26e320-62c5-47a9-bb6b-43b532e9952c"
      unitRef="usd">-7365000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTEtMS0xLTA_c5d79871-9208-46d3-8423-a0bc079ff724"
      unitRef="usdPerShare">32.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTMtMS0xLTA_cae295a5-b6a1-4cb3-80be-6954568d0acd"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTUtMS0xLTA_8ad51ef5-28ea-4dc0-a5e8-115eca6a9e1d"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEwLTctMS0xLTA_9b52d230-947e-4506-8334-519ad48d8b41"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTEtMS0xLTA_28dad269-f85f-4f60-ab14-f2e1cdce1f4a"
      unitRef="usdPerShare">31.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTMtMS0xLTA_5caa6fb3-a3bd-466b-9f47-b12a0908631b"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTUtMS0xLTA_d3f3332d-05bc-4b14-978b-0a9c693a19a4"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzEyLTctMS0xLTA_297ea957-ad26-4923-acd1-ec0a9895d02e"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTEtMS0xLTA_66900692-9876-4254-b152-3675ec895b47"
      unitRef="shares">20447000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTMtMS0xLTA_d492a0eb-eda3-4607-badd-117efe7117f7"
      unitRef="shares">19558000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTUtMS0xLTA_e1813efd-7753-4c82-81f3-585a12a02b66"
      unitRef="shares">18770000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE0LTctMS0xLTA_475fd25f-4d6a-4e58-8b30-c0651c4ba43e"
      unitRef="shares">17243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ida0301a86087477c92ee0bb52ead3e1c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTEtMS0xLTA_7e464f7f-b275-4dcc-89fa-03038f2f8db9"
      unitRef="shares">21277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i666408c546004c06983d164938ebb335_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTMtMS0xLTA_8896ba2c-3395-4f31-901e-64d6dd14cf80"
      unitRef="shares">19558000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cc820e7099844dc86ac37707e8ae200_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTUtMS0xLTA_7e06d0af-c311-43da-9f22-c7a30dc27e0a"
      unitRef="shares">18770000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE1LTctMS0xLTA_decc7e47-dd27-4f96-bea3-2cd6b6ec8116"
      unitRef="shares">17243000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTEtMS0xLTA_3450ebdd-29c5-4d0c-b222-56d4895b578d"
      unitRef="usd">56157000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTMtMS0xLTA_45721839-1dbb-40ec-8143-ba446dbb299b"
      unitRef="usd">90043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTUtMS0xLTA_4d4a583c-8e55-49fa-8c6e-8d6d471c3914"
      unitRef="usd">45663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE4LTctMS0xLTA_7ede12df-2499-4d58-a214-abcbf9506a73"
      unitRef="usd">59590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTEtMS0xLTA_65e6fbd4-956f-4fde-b0d3-a27ee9bffcba"
      unitRef="usd">19116000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTMtMS0xLTA_5e77c6df-d0ae-4c44-833a-5ab17c26e8ca"
      unitRef="usd">19868000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTUtMS0xLTA_f422a400-1fd7-4337-82d2-75041025db02"
      unitRef="usd">22301000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzE5LTctMS0xLTA_24b11954-5cf5-4136-9747-05c5490eac44"
      unitRef="usd">26441000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTEtMS0xLTA_06ceacf0-8cfe-4db4-921a-c1a82751a3da"
      unitRef="usd">10033000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTMtMS0xLTA_32885a69-a718-41e9-b2e3-310cf80afb37"
      unitRef="usd">22419000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTUtMS0xLTA_042f28a4-d925-40f3-bd94-fedf3ae7c612"
      unitRef="usd">11864000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIwLTctMS0xLTA_22bbf5bb-1c68-4b00-8f81-8acabb81f5b3"
      unitRef="usd">-14307000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTEtMS0xLTA_e20ae0ec-edc7-425a-a613-8547a7840d03"
      unitRef="usd">45279000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTMtMS0xLTA_06055076-5264-46c9-8253-3c08f6a8b87e"
      unitRef="usd">73160000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTUtMS0xLTA_ed22171e-b23c-4ef8-8d09-f3ffe65e4e5c"
      unitRef="usd">67362000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIxLTctMS0xLTA_ad80827d-084f-4422-99f1-c30d8034ceeb"
      unitRef="usd">-42482000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTEtMS0xLTA_822f3a7b-d134-4f62-a527-bc33ac99d6f7"
      unitRef="usdPerShare">2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTMtMS0xLTA_874ece80-c477-41d2-9b91-8c3d9915ef11"
      unitRef="usdPerShare">3.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTUtMS0xLTA_023afc0d-8a23-46f4-8cf9-ab35d3254847"
      unitRef="usdPerShare">3.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzIzLTctMS0xLTA_eaeca46d-29aa-4b71-a02b-cdbceed0de01"
      unitRef="usdPerShare">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTEtMS0xLTA_d3cca1b5-f99c-46f3-9c3a-31587bb09ab0"
      unitRef="usdPerShare">1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTMtMS0xLTA_f2cd1efd-280e-43a8-b3f3-4e7c2d68c672"
      unitRef="usdPerShare">2.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTUtMS0xLTA_b133ebcf-7bc1-4dee-80cb-f9ccd39ec205"
      unitRef="usdPerShare">2.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI1LTctMS0xLTA_e5eb99f0-c185-4f1d-93fc-d1d0aff5576e"
      unitRef="usdPerShare">-2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTEtMS0xLTA_42c35c5f-c1fd-4982-9d45-99d10093197b"
      unitRef="shares">21209000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTMtMS0xLTA_acdd5416-b7be-46cf-b076-aa41c9f13d26"
      unitRef="shares">21212000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTUtMS0xLTA_94f2efcb-4533-4c77-8e6f-446056446a5c"
      unitRef="shares">21148000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI3LTctMS0xLTA_f824ca97-ee1f-4674-b0bb-d2f2937029d0"
      unitRef="shares">21071000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTEtMS0xLTA_6fc6cd34-f09d-42b8-a0a5-3f3a95700978"
      unitRef="shares">24800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf0a51aa88f84c278825ffe30d237c60_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTMtMS0xLTA_1e7db22f-dd13-489c-90b1-87e6636b5bac"
      unitRef="shares">24438000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i385d806689a94eb697a22d2f0a119715_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTUtMS0xLTA_e8533788-d8a5-4380-a9be-99da28113c05"
      unitRef="shares">24052000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i896ac395635a4bb1ae871e9256c0d189_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMjcvZnJhZzo3YWZkODUwN2RlN2U0OTY1OWE3Mjk4ZDEyNzQ1ZjBkYS90YWJsZToyOGJjZDI5NDY3ZTM0ZDMxOThiZjExNzJhZjVlMDUyMy90YWJsZXJhbmdlOjI4YmNkMjk0NjdlMzRkMzE5OGJmMTE3MmFmNWUwNTIzXzI4LTctMS0xLTA_60e158ad-1b9a-421b-a7e4-57cd97eaa643"
      unitRef="shares">21071000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5MzE_6b7e862a-4a6e-415e-9a72-62108f89f255">Subsequent EventOn February 11, 2020, we announced the signing of an agreement to acquire the core assets, partnered programs and ion channel technology from Icagen for $15&#160;million in cash. Icagen will also be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements. The transaction is subject to certain closing conditions, including a vote of Icagen stockholders, and is expected to close in April 2020.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5MzM_0d9ef2ff-d262-40e5-a02e-649d58f8c2c9"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i29f487b559ca433687df3df3c64d6816_I20200211"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M185OTUvZnJhZzo2YmIyZTdiNDgyNWU0ZDNjYmFlODUxMDU3ZjYyMDQwYi90ZXh0cmVnaW9uOjZiYjJlN2I0ODI1ZTRkM2NiYWU4NTEwNTdmNjIwNDBiXzI3NDg3NzkwNjk5NDY_be3a9684-a94a-4516-a261-ca0ed295fec5"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606681936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customers</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner A</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner B</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner C</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock', window );">Schedule of Commercial License Rights</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights consist of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:71.542%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.856%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo &amp; CorMatrix</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization attributed to principal or research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,208)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,838)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">Royalty revenue for 2019, 2018 and 2017 are reported as below (in thousands):<div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.654%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.274%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.115%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.397%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.548%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2018</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2017</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promacta</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">1) Royalty revenue for 2019 and 2018 was reported under the current revenue recognition guidance (ASC 606).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Royalty revenue for 2017 was reported under the legacy revenue recognition guidance (ASC 605).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands), which are not affected by the adoption of ASC 606:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:35.976%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.944%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material Sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones and other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;License fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,451&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.289%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.749%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">693&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used to compute diluted income per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,926&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofCommercialLicenseRightsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Commercial License Rights [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofCommercialLicenseRightsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6827039632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">$ (3,050)<span></span>
</td>
<td class="num">$ (4,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">3,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at beginning of period</a></td>
<td class="nump">6,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">(3,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of level 3 financial instruments at end of period</a></td>
<td class="nump">$ 3,007<span></span>
</td>
<td class="nump">$ 6,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624817776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">2,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">13,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(2,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 11,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6723831808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 150,727<span></span>
</td>
<td class="nump">$ 57,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">14,843<span></span>
</td>
<td class="nump">31,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets', window );">Fixed assets and intangibles</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">17,960<span></span>
</td>
<td class="nump">11,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">184,120<span></span>
</td>
<td class="nump">102,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(141,338)<span></span>
</td>
<td class="num">(4,476)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">42,782<span></span>
</td>
<td class="nump">98,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFairValueAdjustment', window );">Retrophin fair value adjustment</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(41,664)<span></span>
</td>
<td class="num">(44,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets', window );">Identified indefinite lived intangibles</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investment in Viking</a></td>
<td class="num">(2,937)<span></span>
</td>
<td class="num">(2,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Deferred revenue</a></td>
<td class="num">(3,488)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(964)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(50,111)<span></span>
</td>
<td class="num">(51,966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="num">$ (7,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606757024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (shares) | shares</a></td>
<td class="nump">132,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">118,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(102,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (shares) | shares</a></td>
<td class="nump">147,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 130.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (USD per share) | $ / shares</a></td>
<td class="nump">115.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (USD per share) | $ / shares</a></td>
<td class="nump">121.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (USD per share) | $ / shares</a></td>
<td class="nump">134.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 125.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6906059776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 11, 2019</div></th>
<th class="th"><div>Jan. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased in period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,122,133<span></span>
</td>
<td class="nump">782,248<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Price per share of shares repurchased (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,433,000<span></span>
</td>
<td class="nump">$ 127,481,000<span></span>
</td>
<td class="nump">$ 1,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
<td class="nump">$ 58.85<span></span>
</td>
<td class="nump">$ 53.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="nump">$ 51,900,000<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase the number of shares under the 2002 Stock Incentive Plan (shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember', window );">Amended ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EmployeeStockPurchasePlanAbstract', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Shares allowed to purchase in employee stock purchase plan per employee (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued under amended ESSP (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CorporateShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CorporateShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EmployeeStockPurchasePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EmployeeStockPurchasePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_AmendedESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828660256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 95,229<span></span>
</td>
<td class="nump">$ 86,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total goodwill and other identifiable intangible assets, net</a></td>
<td class="nump">$ 305,677<span></span>
</td>
<td class="nump">306,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expense, 2020</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense, 2021</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense, 2022</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense, 2023</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense, 2024</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets with finite lives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Complete technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">242,813<span></span>
</td>
<td class="nump">235,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(50,203)<span></span>
</td>
<td class="num">(35,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">2,642<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(1,180)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (13,224)<span></span>
</td>
<td class="num">$ (11,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6923974560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3911 Sorrento Valley Boulevard, Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,505,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643192704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
<td class="nump">$ 12,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized net gain on available-for-sale securities, net of tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">608<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: Reclassification of net realized gains included in net income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 630,110<span></span>
</td>
<td class="nump">$ 142,473<span></span>
</td>
<td class="nump">$ 12,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912775120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Promacta License<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Promacta License</a></td>
<td class="text">Sale of Promacta License<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On March 5, 2019, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with RPI Finance Trust (&#8220;RPI&#8221;), doing business as &#8220;Royalty Pharma&#8221;, who is not an affiliate. Under the Asset Purchase Agreement, we sold, transferred, assigned and conveyed to RPI, and RPI purchased, acquired and accepted from us, all of our rights, title and interest in and to the Purchased Assets, which include among other things the intellectual property and related know-how generated by us in connection with the license agreement (collectively, the &#8220;Purchased Assets&#8221;), dated December 29, 1994, by and between Novartis (as successor in interest to SmithKline Beecham Corporation) and Ligand, which allowed us to receive a royalty on net sales of Promacta. We concluded the sale does not qualify as a sale of a business, but as a sale of a non-financial asset. At the closing on March 6, 2019, RPI paid us $827.0&#160;million in cash and we do not have any remaining performance obligations related to Novartis or RPI for Promacta. The carrying value of our Promacta asset as of March 6, 2019 was zero. Of the total cash proceeds from the sale, $14.2&#160;million was recorded to revenue related to the Promacta royalty for the period between January 1, 2019 and March 6, 2019, and the remaining $812.8&#160;million was recorded to income from operations in accordance with ASC 610-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912755936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">0.75% Convertible Senior Notes due 2019</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, we issued $245.0 million aggregate principal amount of 2019 Notes, resulting in net proceeds of $239.3 million. The implied estimated effective rate of the liability component of the 2019 Notes was 5.83%. The 2019 Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the 2019 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December&#160;31, 2014, if,</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day; </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 22, 2018, we entered into a supplemental indenture whereby we made an irrevocable election to settle the entire 2019 Notes in cash. As such, we would have been required to deliver cash to settle the principal and any premium due upon conversion. As a result of the requirement to deliver cash to settle any premium due upon conversion, on May 22, 2018, we reclassified from equity to liability the conversion option (a derivative) fair value of $341.6 million. In accordance with ASC 815, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the derivative was adjusted to its fair value as of December 31, 2018 to $23.4 million with the resulting $118.7 million increase, net of payments made, reflected in other expense, net, in our consolidated statements of operations for the year ended December 31, 2018.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">                                                                                                                               </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March and April 2018, we received notices for conversion of $21.8 million of principal amount of the 2019 Notes which were settled in May and June 2018. We paid the noteholders the conversion value of the notes in cash, up to the principal amount of the 2019 Notes. The excess of the conversion value over the principal amount, totaling $31.6 million, was paid in shares of common stock. In July and August 2018, we received notices for conversion of $195.9 million of principal amount of the 2019 Notes which were settled in October and November 2018. We paid the noteholders the $195.9 million principal amount and the excess of conversion value over the principal amount, totaling $439.6 million, in cash. The equity dilution and cash conversion premium payment upon conversion of the 2019 Notes was offset by the reacquisition of the shares and cash under the convertible bond hedge transactions entered into in connection with the offering of the 2019 Notes. As a result of the conversions, we recorded a $3.2 million loss on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the carrying value of the 2019 Notes as of the settlement dates. To measure the fair value of the converted 2019 Notes as of the settlement dates, the applicable interest rates were estimated using Level 2 observable inputs and applied to the converted notes using the same methodology as in the issuance date valuation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, we received notices for conversion of $1.0 million of principal amount of the 2019 Notes, which were settled in cash upon the 2019 Notes' maturity date in August 2019. As a result, we paid the noteholders (1) the $1.0 million principal amount, and (2) the excess of conversion value over the principal portion in an amount of $0.5 million in cash.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 15, 2019, the 2019 Notes maturity date, we paid the noteholders the remaining $26.3 million principal amount and $11.9 million bond premium, which was classified as a derivative liability, in cash. We recorded the decrease in fair value of the derivative liability of $11.0 million in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2019.                                                             </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Bond Hedge and Warrant Transactions</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014, we entered into convertible bond hedges and sold warrants covering 3,264,643 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we were required to make in excess of the principal amount upon conversion of the 2019 Notes. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The convertible bond hedges had an exercise price of $75.05 per share and are exercisable when and if the 2019 Notes were converted. If upon conversion of the 2019 Notes, the price of our common stock was above the exercise price of the convertible bond hedges, the counterparties would have delivered shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below were separate transactions entered into by us and were not part of the terms of the 2019 Notes. Holders of the 2019 Notes and warrants did not have any rights with respect to the convertible bond hedges. We paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the irrevocable cash election, conversion notices received relating to the 2019 Notes after May 22, 2018 must be fully settled in cash and amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the convertible bond hedge. We have accounted for the bond hedge as a derivative asset and market it to market at the end of each reporting period. We reclassified from equity to derivative asset the remaining bond hedge fair value of $340.0 million and marked it to market as of December 31, 2018 to $22.6 million with the resulting $119.4 million increase, net of $471.2 million in payments received, reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. Upon the 2019 Notes payoff on August 15, 2019, the bond hedge was settled, with the remaining $10.2 million fair value decrease reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire 3,264,643 shares of common stock with an exercise price of $125.08 per share, subject to certain adjustments. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. We received $11.6 million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants. We continue to have the ability to avoid settling the warrants associated with the 2019 Notes in cash after May 22, 2018. Accordingly, the warrants continue to be classified in additional paid in capital.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, we modified agreements with one of the bond hedge counterparties to cash settle a total of 525,000 warrants. As the modifications required the warrants to be cash settled, the fair value of the warrants was reclassified from stockholders&#8217; equity to a derivative liability on the modification dates, resulting in a $28.3 million deduction to additional paid-in-capital during 2018. We settled these repurchases for total consideration of $30.1 million and recorded a $1.8 million loss during 2018 on the change in the fair value of the derivative liabilities between their modification and settlement dates, which was included in other expense, net in the consolidated statement of operations for the twelve months ended December&#160;31, 2018. As of December 31, 2019 and 2018, 1,890,359 and 2,739,643 warrants remain outstanding, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">0.75% Convertible Senior Notes due 2023</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. The 2023 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 4.0244 shares per $1,000 principal amount of the 2023 Notes which represents an initial conversion price of approximately $248.48 per share.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the 2023 Notes may convert the notes at any time prior to the close of business on the business day immediately preceding November 15, 2022, under any of the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than 130% of the conversion price on such trading day;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the May 22, 2018 issuance date of the 2023 Notes, we did not have the necessary number of authorized but unissued shares of our common stock available to settle the conversion option of the 2023 Notes in shares. Therefore, in accordance with guidance found in ASC 815-15 &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Embedded Derivatives</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the conversion option of the Notes was deemed an embedded derivative requiring bifurcation from the 2023 Notes (host contract) and separate accounting as a derivative liability. The fair value of the conversion option derivative liability at May 22, 2018 was $144.0 million, which was recorded as a reduction to the carrying value of the debt. This debt discount is amortized to interest expense over the term of the debt using the effective interest method. Up to the date in which we received shareholder approval on June 19, 2018 to increase the authorized number of shares of our common stock, the conversion option was accounted for as a liability with the resulting change in fair value of $13.5 million during that period reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December 31, 2018. As of December 31, 2019, the debt discount remains and continues to be amortized to interest expense.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $248.48. As of December 31, 2019, the &#8220;if-converted value&#8221; did not exceed the principal amount of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portion of these costs allocated to the conversion option totaling $3.2 million was recorded as interest expense for the twelve months ended December&#160;31, 2018. The portion of these costs allocated to the liability component totaling $13.7 million is amortized to interest expense using the effective interest method over the five year expected life of the 2023 Notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Bond Hedge and Warrant Transactions</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $248.48 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants will not have any rights with respect to the convertible bond hedges.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the period from May 22, 2018, the issuance date of the bond hedge and warrant transactions, to June 19, 2018, the date shareholders approved an increase in our authorized shares of common stock, the bond hedges and warrants required cash settlement and were accounted for as a derivative asset and liability, respectively, with the resulting increase in fair value of $19.2 million and $7.5 million reflected in other expense, net, in our consolidated statements of operations for twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information about the equity and liability components of the 2019 Notes and 2023 Notes (in thousands).</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:57.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.768%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.292%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2019 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(893)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principle amount of 2023 Notes outstanding</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(111,041)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(140,136)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">638,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">609,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying value of equity component of 2023 Notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">647,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there were no events of default or violation of any covenants under our financing obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624960304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Viking<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investment in Viking</a></td>
<td class="text">Investment in Viking<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ownership in Viking was approximately 10.3% as of December&#160;31, 2019, and we account for it as investment in an available-for-sale security, which is measured at fair value, with changes in fair value recognized in net income.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to February 2018, we accounted for our investment in Viking under the equity method. As a result of Viking's public stock offerings, we recorded a dilution gain of $2.7 million for the year ended December 31, 2017. These amounts were recognized in Loss from Viking in our consolidated statement of operations. Our equity ownership interest in Viking decreased during the first quarter of 2018 to approximately 12.4% due to Viking's financing events in February 2018. As a result, in February 2018, we concluded that we did not exert significant influence over Viking and discontinued accounting for our investment in Viking under the equity method. Viking is considered a related party as we maintain a seat on Viking's board of directors.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and December&#160;31, 2018, we recorded our common stock in Viking at fair value of $48.4 million and $46.2 million, respectively. We also have outstanding warrants to purchase 1.5 million shares of Viking's common stock at an exercise price of $1.50 per share. We recorded the warrants in "investment in Viking" in our consolidated balance sheets at fair value of $9.9 million and $9.3 million at December&#160;31, 2019 and 2018, respectively. See further discussion in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (5), Fair Value Measurement.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to the adoption of ASU 2016-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Overall (Subtopic 825-10), </span>on January 1, 2018, we no longer account for our investment in Viking under the equity method; instead, it is measured at fair value, with changes in fair value recognized in net income (loss).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912313456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Act was enacted on December 22, 2017 and includes a number of changes to existing tax laws that impact us, most notably it reduces the US federal corporate tax rate from 35% to 21%, for tax years beginning after December 31, 2017. The Tax Act made modifications to allowable tax depreciation, the deductability of compensation for officers, the deductibility of meals and entertainment expenses, and the deductibility of interest expense. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:65.503%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.192%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.833%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.192%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.686%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.194%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(185)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:65.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.682%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.148%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(819)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,131)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,019)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FDII</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(402)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(879)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,758)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,821)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in uncertain tax positions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate change for changes in federal or state law</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(210)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,193)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,225)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,169)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired NOLs and credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%.  Significant components of our deferred tax assets and liabilities as of December&#160;31, 2019 and 2018 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized.  However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2019, 2018 and 2017. The valuation allowance increased $136.9 million in 2019, decreased $2.5 million in 2018 and decreased $8.4 million in 2017.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:75.578%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.762%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.913%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(141,338)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,476)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(179)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,905)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,643)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified indefinite lived intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,040)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,759)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,937)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,480)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,488)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(964)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,111)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,966)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,329)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had federal net operating loss carryforwards set to expire through 2037 of $31.5 million and $119.1 million of state net operating loss carryforwards that begin to expire in 2028. We also have $0.6 million of federal research and development credit carryforwards, which expire through 2038. We have $22.9 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $713.8 million of non-U.S. net operating loss carryovers and approximately $14.6 million of non-U.S. capital loss carryovers that have no expiration date. We have a full valuation allowance against these non-U.S. tax attributes. &#160;&#160; </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2019 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2019, 2018 and 2017 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:65.713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.164%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.164%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="14" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,247&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,042)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(657)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,583)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Included in the balance of unrecognized tax benefits at December&#160;31, 2019 is $27.1 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and December&#160;31, 2018, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, United Kingdom, and Canada with varying statutes of limitations. The federal statute of limitation remains open for the 2016 tax year to the present.&#160;The state income tax returns generally remain open for the 2015 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of December 31, 2019, we are no longer subject to state, local or foreign examinations by tax authorities for tax years before 2015 and we are no longer subject to U.S. federal income or payroll tax examinations for tax years before 2017. No tax returns are currently under examination by any tax authorities. Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608696816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details) - Licensing Agreements - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">$ 38,298<span></span>
</td>
<td class="nump">$ 36,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization attributed to principal or research and development</a></td>
<td class="num">(18,208)<span></span>
</td>
<td class="num">(4,838)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total commercial license and other economic rights, net</a></td>
<td class="nump">20,090<span></span>
</td>
<td class="nump">31,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Aziyo &amp; CorMatrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">17,696<span></span>
</td>
<td class="nump">17,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">8,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Dianomi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite lived intangible assets</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoandCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_DianomiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_DianomiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624950224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Promacta License - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets', window );">Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets</a></td>
<td class="nump">$ 827,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,448,000<span></span>
</td>
<td class="nump">$ 219,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of Promacta license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,800,000<span></span>
</td>
<td class="nump">$ 812,797,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_PromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829373536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares [Rollforward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period (shares)</a></td>
<td class="nump">1,736,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">338,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(112,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(6,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period (shares)</a></td>
<td class="nump">1,956,379<span></span>
</td>
<td class="nump">1,736,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (shares)</a></td>
<td class="nump">1,454,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (shares)</a></td>
<td class="nump">1,956,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (USD per share)</a></td>
<td class="nump">$ 66.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">116.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">23.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (USD per share)</a></td>
<td class="nump">139.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (USD per share)</a></td>
<td class="nump">77.54<span></span>
</td>
<td class="nump">$ 66.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">61.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (USD per share)</a></td>
<td class="nump">$ 77.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="nump">$ 125,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">70,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 72,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6625603168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">$ 4,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent', window );">Amounts owed to former licensees</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedStockRepurchases', window );">Payments due to broker for share repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedSalesReturns', window );">Return reserve</a></td>
<td class="nump">3,027<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 9,836<span></span>
</td>
<td class="nump">$ 19,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedStockRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Stock Repurchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedStockRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6625270048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company with a business model primarily based on developing or acquiring assets which generate royalty, milestone or other passive revenue for us using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking warrants was reclassified from &#8220;other current assets&#8221; to &#8220;investment in Viking&#8221; in the audited consolidated balance sheet as of December 31, 2018. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Business Risk</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.678%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.624%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner A</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner B</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Partner C</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&lt; 10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We obtain Captisol primarily from two sites at a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents &amp; Short-term Investments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method.  </span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms which range from 30 to 90 days. We reserve specific receivables if collectability is no longer reasonably assured. We re-evaluate such reserves on a regular basis and adjust the reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventory</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December&#160;31, 2019, 2018 and 2017.  </span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in other income (expense), net. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Liabilities</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Crystal in October 2017, we may be required to pay up to an additional $10.5 million in purchase consideration upon achievement of certain commercial and development milestones to the Crystal shareholders. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (5), Fair Value Measurement and Note (8), Balance Sheet Account Details</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;   </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2019, noting no impairment. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commercial license and other economic rights</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights consist of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:71.542%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.856%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo &amp; CorMatrix</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization attributed to principal or research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,208)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,838)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights as of December&#160;31, 2019 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Arrangement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and reduce our asset as the funds are expended by Novan. As of December&#160;31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan has been fully amortized as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congentia. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and will reduce our asset as the funds are expended by Palvella. We will evaluate the remaining asset basis for impairment on an ongoing basis. It is anticipated that the cost basis of the asset will be reduced to zero prior to the receipt of any payments from Palvella. Therefore, we will recognize milestones and royalties as revenue when earned. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Receivables</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2019 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2019 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. We recorded a $5.1&#160;million reduction in the carrying value of the Selexis asset which was reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See additional information in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disaggregation of Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> subsection below. Our accounting policies under the new standard were applied prospectively and are noted below.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalties, License Fees and Milestones</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Material Sales</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at prior year-end was $3.3 million. During the twelve months ended December&#160;31, 2018, the amount recognized as revenue that was previously deferred at prior year-end was $2.3 million.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have revenue sharing arrangements whereby certain revenue proceeds are shared with a third party. The revenue standard requires an entity to determine whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. We received $4.6 million royalty payments from a license partner during 2019 of which $4.0&#160;million was paid to a third-party in-licensor. We recorded net revenue of $0.6 million as we believe we are an agent in the transaction. We recorded an immaterial amount due to third-party in-licensors as general and administrative expenses as we are the principal in the transaction during 2019. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Royalty revenue for 2019, 2018 and 2017 are reported as below (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.789%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.654%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.274%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.115%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.397%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.548%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2019</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2018</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">2017</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promacta</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evomela</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">1) Royalty revenue for 2019 and 2018 was reported under the current revenue recognition guidance (ASC 606).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Royalty revenue for 2017 was reported under the legacy revenue recognition guidance (ASC 605).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands), which are not affected by the adoption of ASC 606:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:35.976%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.944%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material Sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Captisol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License fees, milestones and other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;License fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,451&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,817&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Derivatives</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we issued $750.0 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually, as further described in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; Concurrently with the issuance of the notes, we entered into a series of convertible note hedge and warrant transactions which in combination are designed to reduce the potential dilution to our stockholders and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the notes. The conversion option associated with the 2023 Notes temporarily met the criteria for an embedded derivative liability which required bifurcation and separate accounting. In addition, the note hedge and warrants were also temporarily classified as a derivative asset and liability, respectively, on our consolidated balance sheet. As a result of shareholder approval to increase the number of authorized shares of our common stock on June 19, 2018, as discussed in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; the derivative asset and liabilities were reclassified to additional paid-in capital. Changes in the fair value of these derivatives prior to being classified in equity were reflected in other expense, net, in our consolidated statements of operations for the twelve months ended December&#160;31, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our 2019 Notes, which we issued in August 2014 for $245.0 million aggregate principal amount, on May 22, 2018, we amended it making an irrevocable election to settle the entire note in cash. As a result, we reclassified from equity to derivative liability the fair value of the conversion premium as of May 22, 2018. Amounts paid in excess of the principal amount would be offset by an equal receipt of cash under the corresponding convertible bond hedge. As a result, we reclassified from equity to derivative asset the fair value of the bond hedge as of May 22, 2018. Changes in the fair value of these derivatives are reflected in other expense, net, in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the payoff of the 2019 Notes in August 15, 2019, the bond hedge was settled and accordingly, the derivative asset and derivative liability were settled to zero. See detail in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income (loss) Per Share</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.289%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.749%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding:</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Warrants associated with 2019 Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;2019 Convertible Senior Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">693&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used to compute diluted income per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,926&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Translation of Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In 2018, the FASB issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in ASC 840,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> Leases (Topic 840),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> including its disclosure requirements, in the comparative periods presented. We adopted this standard on January 1, 2019 by applying this optional transition method. For leases with a term of 12 months or less, we elected to not recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. In addition, we elected the available package of practical expedients upon adoption, which allowed us to carry forward our historical assessment of whether existing agreements contained a lease and the classification of our existing operating leases. We did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases. We continue to report our financial position as of December 31, 2018 under Topic 840 in our audited consolidated balance sheet. The adoption of this standard update resulted in the recognition of right-of-use assets of approximately $5.2 million and lease liabilities of approximately $5.9 million on our consolidated balance as of January 1, 2019, with no material impact to our consolidated statement of operations. See "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Note (6), Leases"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> for further information regarding the impact of the adoption of ASU 2016-02 on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Not Yet Adopted</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for us beginning in the first quarter of 2020, with early adoption permitted. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We will adopt this standard effective January 1, 2020, and we currently do not expect the adoption to result in a  material impact to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Goodwill Impairment Testing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Simplifying the Test for Goodwill Impairment,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. This standard is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020, and will include the required disclosure beginning in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In November 2018, the FASB issued ASU 2018-18</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">recognized from contracts with customers. The new standard is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted in any interim period for entities that have adopted ASC 606. The standard should be applied retrospectively to the period when we initially adopted ASC 606. We will adopt this standard effective January 1, 2020, and do not expect the adoption will result in material impact to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6923847600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
<td class="nump">$ 141,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost of material sales</a></td>
<td class="nump">11,347<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
<td class="nump">5,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">16,864<span></span>
</td>
<td class="nump">15,792<span></span>
</td>
<td class="nump">12,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,908<span></span>
</td>
<td class="nump">27,863<span></span>
</td>
<td class="nump">26,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">41,884<span></span>
</td>
<td class="nump">37,734<span></span>
</td>
<td class="nump">28,653<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">126,003<span></span>
</td>
<td class="nump">87,726<span></span>
</td>
<td class="nump">73,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain from sale of Promacta license</a></td>
<td class="nump">812,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">807,076<span></span>
</td>
<td class="nump">163,727<span></span>
</td>
<td class="nump">68,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from Viking</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">50,187<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">28,430<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(35,745)<span></span>
</td>
<td class="num">(48,276)<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(6,010)<span></span>
</td>
<td class="num">(6,307)<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(10,437)<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
<td class="num">(10,845)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense</a></td>
<td class="nump">796,639<span></span>
</td>
<td class="nump">173,330<span></span>
</td>
<td class="nump">57,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(167,337)<span></span>
</td>
<td class="num">(30,009)<span></span>
</td>
<td class="num">(44,675)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
<td class="nump">$ 12,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (USD per share)</a></td>
<td class="nump">$ 33.13<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic per share calculation (shares)</a></td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
<td class="nump">21,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (USD per share)</a></td>
<td class="nump">$ 31.85<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted per share calculation (shares)</a></td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
<td class="nump">23,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 46,976<span></span>
</td>
<td class="nump">$ 128,556<span></span>
</td>
<td class="nump">$ 88,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Material sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31,489<span></span>
</td>
<td class="nump">29,123<span></span>
</td>
<td class="nump">22,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember', window );">License fees, milestones and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 41,817<span></span>
</td>
<td class="nump">$ 93,774<span></span>
</td>
<td class="nump">$ 30,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624950512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Summary of Unaudited Quarterly Financial Information</a></td>
<td class="text">Summary of Unaudited Quarterly Financial Information<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2019 and 2018 are as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(176,376)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">666,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,365)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,447</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,558</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,770</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,243</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,558</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,770</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,243</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;*includes pre-tax gain from sale of Promacta license of $812,797.</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,157&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,663&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,033)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,864)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,362&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,482)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.02)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.02)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,209</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,212</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,148</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,071</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,800</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,438</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,052</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,071</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912775120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account Details<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Short-term Investments</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the various investment categories at December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">fair value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,072&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(249)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">941,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,663&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">600,154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab and office equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,165)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $1.5 million, $0.9 million, and $0.4 million was recognized for the twelve months ended ended December&#160;31, 2019, 2018, and 2017, respectively, and was included in operating expenses.</span></div><div style="text-indent:24pt;margin-top:5pt;"><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,203)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,070)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,224)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,744)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total goodwill and other identifiable intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $16.9 million, $15.8 million, and $12.1 million was recognized for the years ended December&#160;31, 2019 and 2018, and 2017, respectively. Estimated amortization expense for the years ending December&#160;31, 2020 through 2024 is $14.1 million per year. For each of the years ended December&#160;31, 2019, 2018, and 2017, there was no material impairment of intangible assets with finite lives.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts owed to former licensees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties owed to third parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments due to broker for share repurchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Return reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent liabilities:</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (4), Business Combinations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for more information. </span></div><div><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:13.509%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.782%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.453%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.225%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.010%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cydex</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,860)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(924)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(818)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,885)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912753296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As set forth below, we completed three acquisitions from January 1, 2017 through December 31, 2019, and all were accounted for as business combinations. We applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. For each acquisition, we did not incur any material acquisition related costs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ab Initio Acquisition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 23, 2019, we acquired privately-held Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has a patented antigen technology that is synergistic with the OmniAb</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">therapeutic antibody discovery platform, providing our current and potential new partners enhanced capabilities for the discovery of therapeutic antibodies </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purchase price of $12.0 million included $11.84 million cash consideration paid upon acquisition, net of cash acquired, and $0.15 million cash holdback for potential indemnification claims. As the acquisition is not considered significant, pro forma information has not been provided.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:77.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.482%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and other assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,609)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/ milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20 years.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair values of assets acquired and liabilities assumed, including deferred tax assets and liabilities, and purchased intangibles are provisional. The accounting for these amounts falls within the measurement period and therefore we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Vernalis Acquisition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, we acquired Vernalis, a structure-based drug discovery biotechnology company for $43.0 million, funded through cash on hand. The acquisition of Vernalis increases our overall portfolio of fully-funded programs. As Vernalis' operations are not considered material, pro forma information is not provided.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:77.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.482%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,479)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and product reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,241)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(746)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams derived from the licensing of the related technologies.  These projected cash flows were discounted to present value using a discount rate of 34.0%. The fair value of the core technology is being amortized on a straight-line basis over the weighted average estimated useful life of approximately nine years.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Crystal Acquisition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 6, 2017, we acquired all of the assets and liabilities of Crystal. Crystal is a biotechnology company focused in avian genetics and the generation of fully-human therapeutic engineering of animals for the generation of fully-human therapeutic antibodies through its OmniChicken</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> technology. Under the terms of the agreement, we were to pay Crystal selling shareholders $27.2 million in cash including a $2.2 million working capital adjustment, and up to an additional $10.5 million&#160;of cash consideration based on Crystal&#8217;s achievement of certain research and business milestones prior to December&#160;31, 2019. In addition, Crystal&#8217;s selling shareholders will receive 10% of revenues realized by Ligand above&#160;$15 million between the closing date and December&#160;31, 2022 from&#160;existing collaboration agreements between Crystal and&#160;three&#160;of its collaborators, and Crystal&#8217;s selling shareholders will receive 20% of revenues above&#160;$1.5 million&#160;generated between the closing date and December&#160;31, 2022 pursuant to a fourth existing collaboration agreement with a large pharmaceutical company. As of December&#160;31, 2019, $0.02 million of the initial $27.2 million of cash consideration remained outstanding.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the closing of the acquisition, we recorded an $8.4 million contingent liability for amounts potentially due to Crystal shareholders. The initial fair value of the liability was determined using a probability weighted income approach incorporating the estimated future cash flows from potential milestones and revenue sharing. These cash flows were then discounted to present value using discount rates based on our estimated corporate credit rating, and averaged to approximately 4.6%. Refer to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 5 Fair Value Measurement </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for further discussion. The liability has been periodically assessed based on events and circumstances related to the underlying milestones, and any changes in fair value are recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability. For additional information, see &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (8), Balance Sheet Account Details</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#8221;  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final aggregate acquisition consideration was determined to be $35.7 million, consisting of (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"><tr><td style="width:1.0%;"/><td style="width:77.411%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.589%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid to Crystal shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payable to Crystal Shareholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Current liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(354)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,624)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the core technology, or OmniChicken technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniChicken technology. These projected cash flows were discounted to present value using a discount rate of 10.8%.  The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 20 years.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was $10.7 million and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to Crystal&#8217;s potential revenue growth from combining the Crystal and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606530224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details) - Customer Concentration Risk - Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828290192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (shares)</a></td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">20,447<span></span>
</td>
<td class="nump">21,071<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
<td class="nump">21,212<span></span>
</td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
<td class="nump">21,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Dilutive potential common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Restricted stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">2019 Convertible Senior Notes (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted income per share (shares)</a></td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">21,277<span></span>
</td>
<td class="nump">21,071<span></span>
</td>
<td class="nump">24,052<span></span>
</td>
<td class="nump">24,438<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
<td class="nump">23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
<td class="nump">2,845<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1930-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606687264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investment Categories</a></td>
<td class="text"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the various investment categories at December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Gross unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">fair value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,072&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">210,552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Mutual fund</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(249)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">941,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,663&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">600,154&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment are stated at cost and consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab and office equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,850)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,165)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Definite lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Complete technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,203)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,070)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,180)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,224)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,744)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total goodwill and other identifiable intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:72.008%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.628%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.630%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts owed to former licensees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties owed to third parties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments due to broker for share repurchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Return reserve</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock', window );">Schedule of Contingent Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:13.509%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.782%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.453%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.225%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.010%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.930%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Adjustment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cydex</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Metabasis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,860)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Crystal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(924)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(818)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,885)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Contingent Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofContingentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624994720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preliminary allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:77.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.482%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and other assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,609)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:77.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.482%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,479)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and product reserves</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,241)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(746)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangibles assets with finite life - core technologies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:78.498%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Current liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(354)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,624)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology</span></div><div><span><br/></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final aggregate acquisition consideration was determined to be $35.7 million, consisting of (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.444%;"><tr><td style="width:1.0%;"/><td style="width:77.411%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.589%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid to Crystal shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payable to Crystal Shareholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6929249360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember', window );">Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for contingent consideration liabilities</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">998,324<span></span>
</td>
<td class="nump">656,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">9,017<span></span>
</td>
<td class="nump">12,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">939,989<span></span>
</td>
<td class="nump">601,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">48,425<span></span>
</td>
<td class="nump">46,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">9,910<span></span>
</td>
<td class="nump">9,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">61,408<span></span>
</td>
<td class="nump">56,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">48,425<span></span>
</td>
<td class="nump">46,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">9,910<span></span>
</td>
<td class="nump">9,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">936,791<span></span>
</td>
<td class="nump">599,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">936,791<span></span>
</td>
<td class="nump">599,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="nump">6,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Contingent liabilities - Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time | Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transferred over Time | Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyCydexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6910471680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 10,353<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="num">(1,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="num">(9,970)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="num">$ (11,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826942336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 30,289<span></span>
</td>
<td class="nump">$ 29,363<span></span>
</td>
<td class="nump">$ 38,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(2,042)<span></span>
</td>
<td class="num">(657)<span></span>
</td>
<td class="num">(10,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 28,736<span></span>
</td>
<td class="nump">$ 30,289<span></span>
</td>
<td class="nump">$ 29,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6906220704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, change in amount</a></td>
<td class="num">$ (136.9)<span></span>
</td>
<td class="num">$ (2.5)<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">119.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California and New Jersey Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">713.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US | Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6925211536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 71,543<span></span>
</td>
<td class="nump">$ 117,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">939,989<span></span>
</td>
<td class="nump">601,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Investment in Viking</a></td>
<td class="nump">58,335<span></span>
</td>
<td class="nump">55,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">30,387<span></span>
</td>
<td class="nump">55,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,296<span></span>
</td>
<td class="nump">7,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">11,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,123,645<span></span>
</td>
<td class="nump">870,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">25,608<span></span>
</td>
<td class="nump">46,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">210,448<span></span>
</td>
<td class="nump">219,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">95,229<span></span>
</td>
<td class="nump">86,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Commercial license and other economic rights</a></td>
<td class="nump">20,090<span></span>
</td>
<td class="nump">31,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">5,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,357<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,494,915<span></span>
</td>
<td class="nump">1,260,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,836<span></span>
</td>
<td class="nump">19,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights', window );">Current contingent liabilities</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">5,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">2019 convertible senior notes, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,002<span></span>
</td>
<td class="nump">82,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">2023 convertible senior notes, net</a></td>
<td class="nump">638,959<span></span>
</td>
<td class="nump">609,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LiabilityForContingentValueRights', window );">Long-term contingent liabilities</a></td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">6,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">32,937<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">9,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">22,480<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">727,683<span></span>
</td>
<td class="nump">699,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2019 and 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 60,000 shares authorized; 16,823 and 20,766 shares issued and outstanding at December&#160;31, 2019 and 2018, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">367,326<span></span>
</td>
<td class="nump">791,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">400,105<span></span>
</td>
<td class="num">(229,197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">767,232<span></span>
</td>
<td class="nump">560,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,494,915<span></span>
</td>
<td class="nump">$ 1,260,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentPortionOfLiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InvestmentInVikingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Viking, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InvestmentInVikingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6925693184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>2019 Convertible Senior Notes</div></th>
<th class="th"><div>2023 Convertible Senior Notes</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>2019 Convertible Senior Notes</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>2023 Convertible Senior Notes</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,909,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2016</a></td>
<td class="nump">$ 341,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 769,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,743<span></span>
</td>
<td class="num">$ (431,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="num">(5,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reclassification of equity component of currently redeemable convertible notes</a></td>
<td class="nump">10,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 24,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (1,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">12,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,556<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,148,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2017</a></td>
<td class="nump">399,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">798,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="num">(400,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="nump">16,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reclassification of equity component of currently redeemable convertible notes</a></td>
<td class="nump">18,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 20,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(782,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (127,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Convertible bond hedge and warrant transactions, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,559)<span></span>
</td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,559)<span></span>
</td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes', window );">Loss on settlement of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased', window );">Warrant repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants', window );">Loss on repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions', window );">Tax effect for Notes transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,680)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,680)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">143,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,321<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,765,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2018</a></td>
<td class="nump">560,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">791,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(229,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock compensation plans, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="num">(4,122,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,122,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (448,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(448,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized net gain on available-for-sale securities, net of deferred tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other tax adjustments</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">629,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,302<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,823,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">$ 767,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 367,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (216)<span></span>
</td>
<td class="nump">$ 400,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6625013296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 24,515<span></span>
</td>
<td class="nump">$ 20,846<span></span>
</td>
<td class="nump">$ 24,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">9,641<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
<td class="nump">14,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 14,874<span></span>
</td>
<td class="nump">$ 12,494<span></span>
</td>
<td class="nump">$ 10,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830282064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 10,035<span></span>
</td>
<td class="nump">$ 7,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(2,850)<span></span>
</td>
<td class="num">(2,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">5,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830902912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830942608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Viking - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded', window );">Loss recorded (as a percent)</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Warrants investments in Viking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseinEquityMethodInvestment', window );">Increase (decrease) in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_InvestmentInVikingCurrent', window );">Warrants investments in Viking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member', window );">Viking Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseinEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseinEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InvestmentInVikingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Viking, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InvestmentInVikingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6599889136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for 2019 and 2018 are as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(176,376)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">666,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,365)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,447</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,558</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,770</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,243</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,558</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,770</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,243</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;*includes pre-tax gain from sale of Promacta license of $812,797.</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">First Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Second Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Quarter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fourth Quarter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,157&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,043&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,663&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,033)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,419)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,864)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,362&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,482)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.02)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted per share amounts:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.02)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,209</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,212</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,148</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,071</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares&#8212;diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,800</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,438</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,052</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,071</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6923833920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 59,590<span></span>
</td>
<td class="nump">$ 45,663<span></span>
</td>
<td class="nump">$ 90,043<span></span>
</td>
<td class="nump">$ 56,157<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
<td class="nump">$ 141,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,976<span></span>
</td>
<td class="nump">128,556<span></span>
</td>
<td class="nump">88,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember', window );">Royalty, Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,193<span></span>
</td>
<td class="nump">99,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember', window );">Royalty, Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">21,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember', window );">Royalty, Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">5,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember', window );">Royalty, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,566<span></span>
</td>
<td class="nump">$ 1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 | Royalty, Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 | Royalty, Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 | Royalty, Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 | Royalty, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyPromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606448864">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 25,581,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">25,581,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">2,662,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(2,662,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">18,103,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">17,647,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 456,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0000886163-20-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-20-000025-xbrl.zip
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MJTKG+'LG20J2;J#42'2TFT,1%9?(A!L!ZQ825?1X:C@]Q\IAZH,<3M6M$T%
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M\"S\Y:GRXQ/?ZZ:Z'VM&N%S&2#^R=Z%!)H@$BUI??TPL<_R)Y2_K,5$_A!<
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M2M2;"6D:J@8^GXX#U,LAFPE.JI.%R%0(R>?6OH"9O38&(E6834KOXHO^B:H
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MJ\J),RK#@*8FL@*DUJ"+C[:J_CN JP-P.?9?@G$/T4K@G4 IBVP,MW1Z22*
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M&+]'L7S_B._QZ"Z7;<Z[H_%P_/KPV>#U[E4DK;UZ<ZV\93+.(EN"+.%"$OI
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M K:@BM)],!H-WGD*#FJR/B3CR!F\9OWIZJ%:7*]*Q7%D&YUU$=HZ1<\DNB&
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M5NW=HS8@$Z_M%IRGK,Z<XM.ZN/C8.B?7)U>7US?DZN-UYV/KXH;<7!)P_&_
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MDW+PG'1=>SJUOS'>Q++"S1>M9XTBSC5:2LY OS@PVJ[]?27=? 1_O(QNPOM
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M<^>AWU5JYUE&PK&JCGM#S/9@XZ%H0$R=)"9T '^\8RZQAV+8]H?C%K%I#!_
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ME<*GGHMNP($5"*V3M$^.V2#S)I5B7(BFG8]*)<Y#-Q9Y(3B.@8.@#Z%S2]*
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M,PEH/_.#X;YWZ&R)KS%JETK2)6CGP7Z-ZZ(BVY<.7ON%:P?5Y[SQQ$E/$@Z
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MP!AD2J"D9C[,HD4.>W//9.Y$*E:R%_="S&0$I!M2?W\O2Q6'$D(G^\T8FL,
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ML%5 %")GI_,Y%PI8_[?/HF!%;Y3*,T6]IE7=+**.[+]1>[?^-G*\-M8ZD"F
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MG;4_W51T2S+;N!! !'@WZO\"+@)Y]/LA7-0;'I1_".8XJPWMI7U,3>0G(D*
MRP>\P,ING+>%\:#';2YF!*(O$@*7PU(_."+3/ "!4XRZGDN=S:BM0<+NPC&W
M+U=\HK(PSTM)UM2EGX8*K'7UZ=(R:]*O M>P3>UQ_ZU<92>]A3$OKN#EXS0\
M!+:3=N3!JNB'AUL=LQ55':6 9">"->D\9N84607#-2SD\N4A6H XNU,U+W(4
MZB@#EKGQXW$1+++X8<%WJ6R4+6(C;*5-!Z*7=:)DOSR1&N^5^[ZE0ZJWT['3
M.])FD7-+_CJE+:PN^R0&*8Z)TCO2^9N<!6@)T!=X1PY9X-+KAW<$_O00P]40
M/(DJ>2SN^41]&M@\?#<JX=G2V$/R1(YXG!W/<U$LV>KC"6!>-RALD8@"?[!2
M%34.#)/GUGE-H>Q8H5%0JK+"TF4_M L>@MW-'YD5O\6C ]*BJBJ,)G@/W$(\
M4.^ =1.9UXP1Y4++3F(V!C=W#X]:%\>7UT#\%(QJGR5BR4556. .0B[=OUQ!
MPFM4/"P=B],( FB<MXO'JQ'K MF#;-:MG-I-B5G_/UG>EV3GP;+?/+Z=N*/H
M%0=?L_=L?[F(B_M#" V%6XSO?PG?/O[VE,1%/<UX>X9XU"'C8"-$)P1LBR.T
M7B7/@,SJBLD#@X" EJ!YR,X#6&51>XMO=-0#/UNTZ6<9'RZ*+9PLT2/R"TY1
M9XND1%XIV("7.T-D5W^I3%1F HK'"-XHB"9+\1ZGVA8+[D5)WU980$7[18$G
M($X;BDP:UL6(G2DKZR[#\H=!CY<UN\Q4M4Y/LA^C$_'UX_GU2:=SF>7A9.@D
M2@Y*X1,X*0FJ[+0/G#[(^3[;\H\=:3..6IVSTHTSI.I<]60[O,V;=LI]1EW2
MD6UV<4EV@5A_TD 4O)A9P4NAS8:B/AZ[Z:1/%\88$8BMRG1K#X)4E-0TZ879
MD&"1*<(PWLWQ,V3RU DCB!?N>)3&Y,W1Y:>SXXK>_(V$:2).V8L&C@PM0U2>
M8A9 5#7S[.0WE77R$>MC%R'<C+PY[52J==/Z[8!<CS[E(_L [RA6G//L <F(
M 9H:]AX6+:XI/ <1?N%K=)FHHY4_[F&E'!M[T3&5VLM*J&V&<YM%(UOQX.Q=
M1<TM ^/2QTQN/HPY.]X530?4&4Z\'399EFI?1YR?RX*@Y]BKW^-OT+@5#KFT
M&FA-D)U.@JZ/3_Q3)CCQ@>VL56^4G,ASL!Z/L,622K(7;Y*+%U"/83$E^J^C
M-C9,EP<5]@#>4RS.F2<<KRQ6%;NP7^2%&<3"85^$(,!T=LK]1.J,1[S"^8M^
MUZ((Z/EU:%B!5M2AC;F^=$2;CS'[O2/IW!JGL[1>URP&(J/H'X<IJ.S*440#
M-C7V^2@\V"?G"6P+>9-/G+[.?D+$3[+YT;_MRUI1*JO>BB8R46^0;7BQ.-S$
M\;L436\H1."%Y<(GZC'ROZ#SQ*7K5A()5"JBEQ0Y4)QR3.F7??%Y)3@*/XV*
M("9\O5*1F] X?=C\9*SP7B!ER*Z@B=7/7P.Y :9B^E"@H$AQ+%!$<^7POBAK
M%"XJ=BRSXO1&I#XIEC_L9V<%P\>/!53-VO2NF&M?LZ:2>NN1U&N#X 5IV<4K
M\G@RB,PZD"9/5,111$ ?8.V!T,O7H_@&+3S<\F0 -AMT@8,NQ_-TH.**->&*
M(EM58HR< 0J^ */<KM70U<!DS,TU <>?"BLM\OYAM%\ZW),^(C;1YDUEZ$KB
MS]%&=UG?P895="L%<![&@%<?.@6^)_Q*E*0]@.N9#*<3%'C0#XS<K\#J.!BB
M($>/4&<,Z[G4V8PGTZ4EILN9K72:JD\WX\O$6<D=*U(--ZV_*DVCBJ=HQ3D5
M^&KL 8.2X8!5C.(TBKRY_*]Q_1O!RA5@(8'ZB!"0=]Q-T=L5?!;0" C$!O%0
M_)SHBK_6<ZFS^4ODC$JV#F);J<CPBTJMT=P?CZ!+Q_ N\%4D8 9H+"K%BY#]
MM'78(KWA(/3@KC+#+)-3L@\E X7H]R5F4<'%16G"2WI2UH)%7GJ.E4]@)<<"
MS&E4>?CFT_'5;[MQI)771KFE!+0H<"L#4P YBL/.,10I5Z)2R>PG7.Z']WG7
M GS6&.N+Q/OD!,>GP$VG2[3<4HW6""QLU&D(49IRVM9UJ;-U&VQZ&.0UF+,<
M>G$@+\)M"V[/;D=%)$>75\>9/I)6CMFIA!I V"*/(:@7>&8""6 @@G0>)E$X
MX&D_UY' +3<]-GUHA0E&/-%"S\_WB1O&>4?_V*WED4 IL^K+3">X<HEHU!6?
MB$Y*3'T& FL8H<.*$E8_13R,D0;.R"&QBH4.EG59^9E;T:NBF'PMESJ;R4MU
MSG2ZECG+8:;]U$^E7?]T<FU4M8:E%779B(R%1^A'O5M]*F*1#=T1/,3G78XI
MO%)C;#\4G;I L'_6:^5VV )00RI<B$MP?:/3Y2P!WN=N)0DKF&DG6 4(=W?A
M*=@;JWAP+9?Z4Q[,$NMH8F<<95_U@&-$BXPH11');NRB&V65)RX+)<Y\UOZ?
ML?=3[+&&6_]2Y[ UZC*_RB!?2"FK'!/\YY>RBC'OJY$5_?-\3[F4KOZ>@AGU
MAING+; S9(1?F+,('B%,8R2,N;=9>T%6+E#JX1@[E\@Z=,<.E4J%'27/.!9]
MK;X\K"W.2T>="TJ+K^=2'W&7^6T.]"O[BB14U,R<=Y%?^O27T= @!,/2(7F0
M*.!;*Z/<4M(;1B$'_H#X%E/C17;)9N!]EW-+XPE,/ 2GOA/VL ^:>#1)AN/0
ML-)G]MF=2#Q   B1(GC0XK)!"!*0,&PG@-\C$$T49A!@S^E/*,K(IU:%2-/Q
M$/-L'H^P*?BBU?E#I;S6<ZFS^?R*^G?8@_=4_>& WXG^<J$/I4\K&(71OH_G
MM1F;_&Z23ZWSRY$X7-W\MZ(9QB.U5N,)>NKTAF$P='H<6WB"+@LX]O%1M\B-
MN8LQUC;8N@WGM6N&68$>+Y=[HEJ5K0"H4T=<9Y#CCR<WDI?VP<##(H.\D$CB
M<B 3 04BU,^B&)3\+Z5YDZ?//3:MKSYT3CM*/:WG4A_)R#.TD_Q!6B41UD^=
M-/LT#KWP ;-%8L^Q:"$>P<,+,U?P&SB"4O]\P&MN(J!!EG=^ =*RXHXUX0[1
MC5YRTB:ZC$RI6E!1I GO^[Q/[6FMX""N'>UV?;@&=$SN42E66,^E/E:3D%#1
M)2DQA( 7,LS'4?UQ$()?'" D,1[L!?D4/UFT*V&QQ\^-I89![^4:FQVKFB%J
M7\7!;C'*H73>$K'_I2S.XX,/QRTYQ&*4P4 O?K(B\8",EAZ7.S4QB!@[>"E.
M(S.@;XQI56YP39<ZFTN/*>?@XB*,QNUP,O"2/06B\.7LXN+D\/HR:RIXPV+Z
M@) 4$#'^1@0X@CS4^)/"^V_UV;!,J)"K#-3] T< -=EVL0C*[EK0XFE.;T\E
MI')D Y=X!1G8W1A&"R@TG,DQ/J?"RU1A93HC=D#(A:R@W<\1"Q#J"*X0F>@X
MKVC^XZ]3F?FB'.N<_VG41B<<7"@NB67WR/,EGH'$??/#\IM0D>P&'Y[TF4"+
MEZ-WQ!+@WA<T=NG_!-HX*.7OV?%=,=VD#!BZG]\\A]A'7R^,!<J\PY@KBH3^
MJ3>*=>=K%<UT6=X08=("Q$!+G3"2 P;*$IJCCXKDR#]'F*?@I>)!SF%I8\0\
M5C&N(?-%RB016'?P6-$ZDNT%//3HLJ)KNB:^[C%T4A*@["%N4OY5T<$X@8]X
M?G-5U$WD+4YE(-_3E 9=%^<$_<DKAS2<*-8G1UFO'+R9N/1'+TSWLW+_$7BQ
M-4):#@H#._I:+Z/*(KT*,A8$$@*VW2<69_E\A.*\0D&KSE6F;JU]F?IF6I9'
MX<Z*R1[7_Z+]P;OCD9X58VE0I>$ /"8&[ B(IK$JI$SHY?'D!';XC'J3)!Q4
MA'C,S*KKH_A^;.C(5 GGFZ.3W\A9V&,/H3_RBB6:M$#5D2C3;N8U3]2?V,.)
M(N1L5DQX"RM#>'>;AXC&#F\LZO/0F)U4\L?QX+L<,I=#M><3P\GT%6\NVQ=G
M5ZV_/YYD^ODW(AB6G'V"$ &S6W(-4GO*7L@A?(.D.9C]4"R>N4?<H23TI<G+
MLAVN-*F9<R#::+$$!HE=;.EM@$,YLJY!,1%(S@HIEBEAX_)167%J]SF>5).S
MBQ)C8)!#@\E(:OQ@)&_P.^@<E"!@<VC\O)Y,N#5W;+33.8Q,1:C$\C%>-K,G
M+W$KP>1-P?G?LU);)CP<BRRP).X@*T<J348LP>C)"7YQ:3R9'.TX1$]'$&Z?
M.*-#?O%Z1:LXB+XS(WFPZ'#N7W>N_32@^$UI\LJSW'&S-E*16S9/L#76J39K
MJH5@2JFZBGD^HW%'!;JC@%H8\Q=E;MRF,2_P>A\?3C@V<.]@5% [-B5'X"WG
M]>MR(D^Q MFIF$_-$"4I4@9%/8L=A>"W(IR"!%9#D?4Q3DLE2 ].CLK':<C#
M[[@\CC*?0YF-I7SA.,IGL,^O9I+G>XQ9"<,$KN@L2=HL>=%_)B\9ZNQZYW'D
M(M/1H,V11(_X.OOZFB;[X@_M,,4I6OC'#[#_^V/F"<4I1X2=K2!*O<SEF5HS
M\-5$[O F@\&:?'S^(%Q"Z>[9<#'1G\>$@X.%L^!+@3%E0NQ%1(VGKX@@"\Z2
MG^FLK (WEWY_.#8Y,&(H\R'.*A$(3/D"LTI>H>YD08344Q- <1/:;W+X<#9K
M> )/-!]"*N^5?5EZM)SUF,&(RKER.%6QC!K+LS%!,Q;%\\&_<O(=F'D!Q"<H
M(^8$R'%AO@!F'YO^"\PG!I-E@_7B)"MHIH[#,C<MH\7TZ*#1AL[DF#DWTI'W
MBC-?)ML/X=>/\(<1L:J\*K%[7<K!-2[\H6+,91 F98((SXKV!;?X_!9K6;/Y
MVW!S">90C&^"QP)[3TP9+Z%UC+<J7+9O9*(SR. +])H$88F&<2)+4DIP0O4#
MTA+F\9@Y$F%)PI!D00A6$XR59CX#_5@6AQ6EO9;VR,SH\A@:8\1A!99'-B I
M?]4R&T+P)!_S.?TOE],T)Z%SA0N?8Z=@N(&8)@_Y4$F]H9%L#$-IP*^7;;=N
M%!' C,G?$T@E=#;Y=M8TS\#8VUTG=P)VD,<9&\O98OLD#?C_4F#(2A_4A[ +
MSM#Q0Q=Q<W-5BV.=,HART;/ABK-WZ5GV*; T+"6+2O>S@::RE2,O_L D5SZK
M!0&])*XWZ@2(T>@=Y7[^&3!RZ^H,@^<"T0]1P*3V\RB6P<EI*"C=HT&]8V=N
M-.E)FUP6V'W2!5F3R'$RC"Y5A**:'R1RS,O$D$Q8 G=+"!CAO8L%"O<LF_4[
M9IOP/G(TJG/:OL)!LZE'!5H9F!(@,\KQZ,7PQ#(0N&EH0GA<X-Z).XOYNR#:
MXPAH0F/*#@9AVG&SF+!?&3ZK&#%2ANR0]Q1H]12B7"0RTD;.2K^#C>EG4VES
M""^A^HMI,W8(2DX<GV+. QXA_OR)'+<_Q&,I!6$&X<GB"\Q546%@<@KDPW:R
MY$5Y:HQ,G\K\^P@R!AE/#'67^AV$ 3EAE*VYQTG=I9&E4TDF$1V-QOE)9"*I
M<<4:\[.X/&4N3!0-J$N?L$BSGR*5M<UP'7T:W;(\<U'8H#K:H!0[H_)>*1%<
M6=J(>=#2/7)['LPY5G=;%/MSFD[G"[]4$G_:@%8W(XF_YC87HP+L(BJ%C/G@
M<FF$\20Q<R4YOD4&;%GIIMS-1+\48,$ETC?,Z\*+'^S+2SVXLS" ,=@ 5DPW
M$[-=Q5\BF:CM1J,^][X$?D.@^1[K<S%N'IN91]%&1 >\/,.D"#DR]9J_I?!N
M*48JA;V*BR4*IW^D\.\X)0\5'%;ER)# EX"0TB6X:%]C>VDO=.-R5(G-'3Z7
M0R;B&'X;PT]97UC;! ]#L+"]-XPEFF[>-9I#BC'?!V,?Y9FN(@['I2,.H&@\
M%4/=A 47Q)&3ZBI.CR+V;[=TTI"?P.8Q%CX"[S(ZQLX3;D6^+VM9$5J_N@^L
M5R+C[_(^V1'[ XM',(%NV59HLA(R^W#  A&Y9*FYJ8AMDOG*8<QCS>6ET P^
MQJ3[_OCP.9$_Q'HK>$ %>PZRL"J,LJ[((]JW(^YV@2L__O6ST.YN.FS32Q;1
MRT=%B/,F1B.G-Q')R0J&B1?%6"N;K@;/!G=I(LZ:*\^_"592:N\_V$ .ZOH=
M"PQF3(?:\#SE,_/Z*-T%*4;I CGY0*!:EA(ILN5'BJ%L(0J%3BUQ53GH08V*
M(IE/N!WTPAC^'Z5Q)?-\\2;2=\LP4.4/[&'&LJ)R<8#G#I@B$<H7%8H,PAPZ
MFH8=(7!2),&QK\ZR,ZTL#@/%+3D;'$N.V.>,WLE3 )HW,>63I5CP8]AG4N<5
M5)DN.@%!'^9M^&+9!2PI:('?01PS]QVS$-F[R[<42A;6: OL5I_GP6'F"\,O
M1=- .<X8 3F.-46)0X[BSPZ5(-%#@C-40/O@60KOVPB6+H]V'1XY:19 ]$.?
MP5^8#$"RN1KV<+0!2W.=-T\JLNP]*']4"^/R(&U5C BL[@O%0C IVCY,PSIR
MCBK\LL]PEBF/^R3F\!Y4P':.Q-%.L\9^\62,Z9%I)-_'F<4)"DYTB<=P=D]N
MM'\J.G'.BX)YI*>#]RLN=GPQN"<_Q9.0E:6H?[9 HWW&K<P-/@((%!/("O\I
MAT+'0*^L-'*Q\L#$\U(*)/<Y(@FB6TY [&<]6Y/[4J(_:*(^#AMB<B8+GB7&
M/!)NDCVL%+(&OA.3T^BR4'RT55EGV)1.S#8[?F%^=MS\C*:U3=CYF#^4<C.(
M(R*2GV%?W''28D\7GVV5R>Y\O#Y)9HQQ?!/>!U*#84WM X_G#'+'M%3MH&:M
MOZ(J.[,Y,G21D ^+K#A2;CT.)!_=\T=>,)E*3J_S=HQXLJB_$:5?&5]*O:PV
MXY4W8S\/CO,X<4)=[$OS+B/-2:.=V2-I-^YI]BE&RK*V*BM;+HJERCGVS$*7
M<KL"HSN;?"<1QS!)D47P/S<C J 'YP/ZTECFWN4,T7],63YV$*A;HXBRE"_&
M>FUZEYGU/HMP4+QX7<-<+%+\B2Z>P*+7?J$J?F:UV%5QO"$*R+-T_-SH^[_R
MC5]0;5L,AA%^WEC1K.QWF,UMLF;*T"931=EAU]2H&Y&)FCAS$ET2TH4#;KV7
M E*<88P.%;"W(,#4' [F<$O'4*/U/34F0:6^IW>^MI:I[]D2)%ED_!+1ND;3
M),RE3NA-^8DMP$XK(H,VB-G;_ ]EF 7\_;NR!..S@,7 CQ^^Y8&@F'AN]C[-
MYH$EC=*_DPC^[^;KR5[W0+[N[XD[_:6A'=2;UN/?/_GC)[]L'!ASWU@[T)_Z
M9;7VQ(U_\MNG7J=Y4'_JSO/3HGF@UVNKH45=?^+K!6A1.Z@:S=70HEYK//.W
MOPM^ECP-DH+R^9\]<V^D V2O:!(.WAJ#AZ)W-)-1_.B9"FU2^N[P? ),1O:9
MO.%$;VJI,5@*N#YM5)\P>_67F,]QA?O,E]I[?\B[6<-:H=PRFBMJOIR:-U@-
M&#V#DK^ 3&I?Y]]7G(L8<0<BM0+G3HF+$A>UKX\9%1%!*6E9M;2LP/OYA^,P
MYGG/)&(6K. #=!P'(LHP_R%>2WZ34[?\U5(I;[T"Y5NV_8FS%?'PL@B^>50]
M//STVKI_8:Y<T\W?)FG[@]^N+!K966'[X^PO)6M*UB;9HGURMFF2EEU:4'36
MQ6M,[JN5.W">^.>UA'2-J-O"FIZO$*H[*S,?+Z+MYA'PZ\7.&XF=E9XK^IQ,
MC)*::<)%6*/WG/!02<Y62DX;.W>2-;4Y&^TNG5_<K&6^:RO8]I ^),_*OJ^>
MK)M'N]9_=U[?[ZS@?!VZ B' Y?YZY*DVCH)'K>.S\]8?1TJ&=E6&VBR@$0_X
M>LK/)CM-L\(1E69:INT/60^+Z1%@%O[M]QCOKZ?OO^Z45)'S_**TZD.I5ZP3
M60OAV2*R[E!9U>Y:H3;\V.6PG'-JQVLA0<J+4@' "W1_N[.>OO_Z$^[+SCM,
MJI)C5C5=:RT$:HN*IE1\LN-&*I\?N1:"I?PK%1\\G\#C\S#7,T!8>QIV_E*^
MULY*4.OPG!QR)3IS$<]H-LR&IH1G5X6GS2(<".C<KJ?X;++KU&X=_:7R4JNB
M[HG/R3GW_>%Z^OSK3K[S<^4Q[:SLM.P[?K<RAVF[!4?EFG9<>"[".QJLI^QL
MLK=T<?GI0F695N8M\9BNK(9ONR-DJVJ8.Z_M=U9P6K[+AM&:]@RM/?'.CU7[
MQ<Z*#CA*.!MW/45GHUVE3Z>K=Y5VUK\_[3P'@45%QG,2;KN5_<Y*3:N_0E6_
MW7+3:I\J.(^=%9R+U DC'JZI[&RRFZ1*EU9,X#_A#O&Z.OAK3[R+/W=>Z>^L
MY+0B)UW39J!U)]WUT<?G-*0HP=E*P;D<)#VVIMG83?:5+J\4@-,J:^Q65U^W
MW;%Q^UKEE'96;EHQ[7'R%XW9FL+/K#L!34NK*_'95?&Y3!,_#-?4\&RTLW1S
MOOK"[IUU\86W1/XZI2MKD][N !E<IH/CDYU7^SLK/ZT8AXY3HJ1'E7<K\9D#
M7M^_0_E93_'99+=)036]0F<"O./*#A:V.UB^^*3.%796= Y9X-+K!R4YRF=2
MTO-R!NB%+. /Y(;'<;H>\U>5YZ2<_A=D] (%'S-O<UQCY_7^SHK-(7N(PP#!
ME_K,Q5=50J3\)R5'<S  <WC,I2CY89<[:UH<J)PH%04\[D0E<7JK!FW-YT?5
M:\J/VEG)L?V4V3QRB;TZ&,OMEI_#\X_JR'MGY>>:)5$XZ''51+=\TMY<_U?E
MG5;FDWKP:#7.?3[:?5 :?V<%YX@&\-)*<%2Z20G/'.[2G<PVK:?\;+*[I)),
M*R9PAP:AI]J!YJ/=A<+\WEG!.6)^EP5K6IRQ]L0[.3]5HK.KHM-IG3XGU%29
MI<6HJC)+RYPM3F^9NZ9-#.M..ZNJ&3NO[7=6<H["Z$Z!,\U)NVO51+&[DM-A
M-$E\1DXASDA4#=,J*'QZLG+D[R7(XJIGBM=?@]0#YG#J)T-RU:-1?U6NE**V
M=%>Y<_NL@]"E$E#%T:_K'7224&6@YJ.=4=-K!W\H,+2=%9X.8WZXIJW=&^U2
MG9R<;Z9+M4W<W7*B,&%.;W>]+%7YH2+TU7M@:?__L_?M36WL2-]?1;7/7LA;
MMO$-C).M4V4(23@)"0]PLGGV/WE&MK6,1]ZY&'P^_=LMS8QGC&V,88QFK*W:
M$V!N4JO[UQ>UND/'!+>,]!CIV<H$\Z9<UW3=(MM@)FLJ;_-J%H1XMM2W.',M
MXX)O1\3_N_UC[\%_;T7H+/1T;=*E.^F,X;3GLG,3NOZ(NXQ\HW>:*A]C/AG#
M?[7F_Y//3($H@_U&=K:PF_[(KZRF$1TC.B46G9O0&]#\O/7]C3?=_'']R02;
M\JL*Z.!>GJD$95#?B,\6SL8D8%-3!FH[VEW]_&$D9U\EYV8VGHS$,+^.]";$
M9$),>;G)O9L+/0W]DE"NW)B_MW)S[C K\,Q!5^-K&.G9YI2XP\9ZRHZQEHRE
MO^Z,]B4-/&X:=AG<-_*SA=7TP!S^8#I%;DF]7PM'AHSL[)'LW#*7"6T+]1NS
MR9C[J\VFVPO, I_D6="@Y"XSD/!L[[%_;P7H$Y\R C UUC0I0WOZ75_],M*S
MK])S^YG<CIA')RPTY:'R(?!M_LU:]M;P/POS*ZA9;H?9Q)OV7'0^56\"FMO!
M:2,\1GA*+#RW_$_A:JIYBFPMF7!3WJC// _&IZ>=KSOQ#.SON?1\9NZ8]HWP
M;$6[A3+)1G#V2'#^<'DPTU-NBFPN_7%J8DOY 19<Y)K:^+K3KMEN=?8>[?=7
M<IA+AZ8RDW$RC/1LP0 _J4-=D\QDHDO%8]UO<$N?67=Z6OK:4^\/XR'OK>A@
M@ZX[-L-<P!R+[I=<@HSMM.=2]),^/%"3Q518RVEOC?XK3SSP,=6V4(;^]#/(
MO]<"]-G!O3DO-]=C,\*.N6T[[$74.WD+XGT[_W[9NS:M[/96?'ZRH:9;'<9L
M,O;^FO8_MM"T^8_NI#,6TY[+SF<^I)_S\S>,]!CI*;'T_&3N:7Y[=";29")-
M^75,' O7E&DRN&_$9RNKR6'4)C>J:Z.IUK0=$2^^?30BM*\B!*93P//K0&3"
M32;<E)?M-.*>*3.S'>F^7'W>>\C?6\'Y0MV>XQC)V89VW7:S;B1G7R7G)_-R
MK#2POW&FG]??>R;(E)NV_U]RX;H"K%%NS@&92).1H:UL)J\O0E.AR4B/D9ZM
M[":8M)["4VR[:0?U+/?6VK]E_#_<I&1L1[N+[]\^[3W@[ZWH7)R>$3Q$Y_%0
MT_99NE/0V$Q[+D(_^1W7M39@H6VFKZ8&>)Y<ZS%!OC#J!+D=FS;.\CX _]Z*
M$+]D >W#!"PC0$: C !MHX."4/BF9M->Y33A!_+DW,XN4C&ERZQ)YY\2T?66
M6W=LD\V;5]4(QF'>;<QI/ YQE]L-M!"?XM'O\N?MWAM->RL]#V?,<4QJ4V%-
MIFVL_26JO4PLW7.F0I<:3CLRIHQ_;?SKW!G@]^I5K@VR37C*B$^)Q><7_P>,
MY1=W Y'?_IZ)4>D8HRH%_YYR<49M/3T%W6EGP'_/A><K]S1ULG6GG!&=/1>=
M7[??B*GRE ]A3[6,3Y6";<_$B'FAJ4VS'?&^7-_L/>+OK>A\O?E?(S;&5C*2
M\VP&^%?XB^LI.D4VE([KK>915\O(4O3"$N_F?68V$RZYYM8HV"B7YXUI7SP"
MGW^\,4?VC/ MXXU+ZG$W/R=FCZ7N\OJ[\7",T"UCC7^/N'-'W2'Y(MSA+#=[
M+D?A*[*QMW(?\3"@?8?!OS:?_O9/^1]U2]\[_"VY_>47DT45/L?*3>\]YM"
M3]F'>VX'(Z!*_6\?1A%!FK7.D2+ALB=I'P@?!NQ#M&[U]"NRSZ38P&(N6%J+
MR[(A ;-4SRQ6S^/4R2S1?*F[2U;:X2ZK1A-M-.6(.UEJI?\[\N;2,&35OL?H
M794.8";OJ7-/9_Y?#C,37J#@(\*L7J.%97P] JWCYI14-)=DTB^AU9D8CYEG
M <T)=6UR!K>@7).; .A#KJ@7N,QC-KD27C  ^13;L:ED'.[:P#3OFYW'XKPS
MLBP#BR5D^1<C(SIEA!*'>D"(23Q](@;$"CT/)B()-@B#T,/K 99*!L)Y;,K<
MD%6'>%H#)!(0>N*)H4?'?H5PUW)"!#8B $%)LUZ'%SC.K#J F0.5^S,B0H],
M%-G]&B$7+D$H1$$E@2#!B!&),*3/''%?(?<P1L<7:K1C 4,)1D!68%$"K^2^
MY0@?7CSQF!4O;3R<VK-7ZXE%'@.IN!O#_[%Z3HTV>X=4 30,Q(?H#PKFY5\B
MK0 K[=")S]['/SQ20>E!XJK"9"<.G;WGKEQ/^=VYP-;JD=!&[G@TH.AZ35V+
ME6?F8JM1:[5:JZ^O??@MW]S>\.&E48KNB\R&)^W/2'ODF8"<EWFQBR-)O0D(
MZ91MDD<3L[TK7/:$];WTUAQB5#JLONXK'&E6\IV.\RI3GM<R%(_62N$5G<Q%
M!K3;$1A#$Q8"!4@/C.[GA,DCRPR[[>81Z,@#:-:PV.YG4X8A/YOW3:K*J]LD
ME@=.CC4Z/.O=7.BY?:@["<^G8LSR.T>YOWNO9]2U%K;]=-E[+8?LYWM8LMRY
MR3^%QRWATC^%HVE'HB*+_H4[8%; 1>B3C]QGU-?S-'4Y8& ,('#XP]6T>)+N
MY/LZFWBP^IIF^Q89!(S^SUGP9T&HI^K2G7*WX9_<#W0]UE5DF3>*?X?R_R>?
M&:6_G<]_=CG?/=:3A$5&@4MFRTUMFTVYQ0[/J&=S>& X,\9 ;D?\Z8,N.=:%
MH]UWAK03K@D$Y. #H.A/J6^%#LW?%]A;6^"4"RN_"A_E-@9N61\?UY-X119^
M< 8<.A[30'BSP^4E\HT-\)I6[0-S^ /W#S]2SJT1K]Y0]RX_%Z'<1L$E=UW6
M]S2E7I%AP=@$.VJ R^],Q4=]=P?WVB[8=9!P;VV";W!+GUEW>JHQW:D'JLIE
M#WRJ)_6*C %GS T\ZL!+O2D"P<W,#]C8& /YA60=[@;&'-@VN&J;%$%C"10<
M 5PL":''H?3"4>^3!QYKX/%)0#7-N"PR#AAK8-=8X.7G$I3;%O@N'NB .]6+
MGWK2K\@P8,R!'19+H29;8#O""9^:DP,E@H"]M0*N!O#IW%"@W&; 3S[EU T.
MSX3;]_B?)C9@L@<,&NRM3? QI%-FK(&R8("Q"#349;K3[N> P3TF+% *GV!O
MK8";WN=S/?68[I3[=^AXS/=-PJ#9'2@X!OQ[9@.5SZC-==WSUIV"&!W(\7SQ
M_IH"IJ9 \46_W&; J3=[".CAOV>GS*0-%E7^C>HWJG]+"IX_L/$DX)I2K\BR
M;S8$RH<%Y;8%?@HO"!\TS;C<;RB(.XM@ YD-/ZM+R>==COD5.K>5<T*F/\>S
M0&$G'05&U&>D=7C%IR*@#A$>N6;#T)$H06["_IC[/K;LD6V43!</T\5#NV4H
M'JU-%X^W7H)7Z.*Q>_V[/= \;4X4T*1[RR&;+AYO[L[T')O-=-TNTIUXUVSB
MB0?JT(F>]"NRG_TC .5R^,>\9Z6)MA6S@E^YXVRG9Q^K]>-C/8E79/D_=82P
M,>E.SL$W^VZY[6O>!#G6GRVW 7!VTZC7&WK2KLC";W)M<M[$.#TCG[$A.0_S
M"J"47.]__GY=K==/]"1>D47_AL$D&:&N3:ZI9X[@YEA-8II?/9ERJ_V;TV8]
M-Y-_?[6^.6RSP_!*&("#=4=2(?S<^M"5VQ+X\?VF>E1OU/6D7I'Q8/<AP+TU
M!JY9X(G)B!N#8#N#8$(]G[DY%NC;7ZM@UP[!WIH$-]05 TTS1K6G'1A08X>/
M:5]/^A49 ,Q.P,Z0UA:F L=V >OSZB?A3T;,G05"5RNJR"#P1@?Q]]<8"%T?
MW %&OM$[3:M+Z4["G]RA?PK;-/<L#QSLK6EP"RA@FRS![1+5V10PP.9^0 ,]
M*5AH)'AVJH Y?V?&'#')84#[#H-_;3[][9_PGT0(A<\#+MSW'G-HP*?LPSVW
M@Q&P>/UO'Z*)M9NUSI%ZX[(G:1\&%@;L0R2X]?0KLL\\/E:R(&,;DB\K0AG)
MZWF<.AEYF\MM=XG8.F#[5>,5;,H1SY,=)+72_QUY<_0:LFK?8_2N2@<PD_?4
MN:<S_R^'F0DO4/ 18=3L?_MGWX/GEGPU]:HQ]8;<C='Q6*V'7-:%.R1/T# 0
M'Z(_*)Z0?XDX"NCGT(G/WL<_/&)(^3MW;5BE]XAV\>$[[DJ"R>_.IU.K1U.*
MP"@:4'2]IJ[%$I2YV&K46JW6ZNMK'W[+-[<W?'@SC&Z]-G2\%JB]^L!V<MI9
MVU&;(\W/LJMV=Z2Y:<XJF[/*VBU#\6AMSBJ_]1*\PEGEX]TY,CLXJ[S#V91A
MR.:LL@ZA'IBTGB$T[6GWJVH.*ND0?33;D,^CKV=S\3!S#D\O;_3<1M.=A$"X
M[LEQLY6;]._Q+J3DSBGUK="AIC1P?G2^O2"G7$Q&U!N;3<CMW!_,GQ=F"](8
M <7CW7/N4Y.7O!7I/OW?V8_+JYZ>Q"NTS)L$I-V>M^<.RZ]&4;EU_^>;ZE&G
MU=:3>$4& 7-@>8=,#!?S:VU1;BO@\[<;<T"YN(;_WBK]B_$X=+%,B:9.J_;T
MN_QY6VVT3>!?QS8@1OT_A]Z_5Z]RC?Z5VP#X_>I+M5EOZ4F\(L. L0#RI>\E
M];@;YE:9J-SJ_S-UZ0-UA,O(Q4\]25AHV3='DG>+!<RS[O148=J3[OBX:?Q_
MH_V+QK;@5QGO?^N:;N#[']4W.<%A%+_Q_36F-U8JACF:^J1;4>_KM\OV\9&>
MM"LR"JBR9+8I2U9T\2^W%7!V7KWUZ)@%W.6Y%2?<7UO Y/X56_C+K?O/SSZ=
MM$W8ORP>P-Z: #\FP8B9S/_M:'=U6VV9,$ 9VA/LK15P19TI<QRS^[\=]6Y_
M5>O-W!!@?\T TZ!D=SSL,8O[7+AX$- 1PQS;%97;'/A^=59MG.E)NR)C@0D$
MY$O?7)L3E%O_GYU73T.;^<+EMJE%;H(!A4<"!L:6GAI,=]KU)@YW 4@U[?=>
M9!@PZ8"[A@%O#!HMMWI@Y;8)OE%?#,0#'S#3GJ2PSL#>F@ _ 6OYM2D%N!WQ
M;G]5FZU61T_J&;$W*G^UV'O"-9L VZ4"N#XJ^\#C1N&;&$#AD8#?P?#TU&#:
MT^[K4;-A2@*4!0/VUQK(%0/*;0W\_-H\J7?UI)W! &,'Z($!9;<#ZLV&J0I8
M%@PP=H"&NDQ[VGVM'S=,9F!9,&!O[8!?_!\PEE_<#80Q![;-L*0V&X@ISRW+
M:J]- E,H>%=0</L-<X3UU&FZ$V]T]O':- K*(5<%)LD(=6UR3;UG"7_<@QW[
MI&_X/5W:->YRS#OIGUW$"9G6VL]"@]VUUMX$9DUK[5<W04QK;=-:6T,R%QG/
M7J&U]LDRQ;J5#_,VS;1S'7\Q!VD:9K^YV]$;#YFK9S1'>])=?JZV6KG5S-W?
M4)C)D<W[A%? IB;ZM1WMKG[^:+>.]22>$7JCZ%<RKF>9)AE;DNZTD5]I'*/F
MC9K/B;["F^8G\N56\V=\@)S@YMA9P*AZH^ISHN_--SVU50$(5VTU3;YK425^
M?U5]:)LSKUM3;B </8E7:)%_FUHW>ZOT/U5O JII7J;VM+NI-DSY:Z/VB\:W
MGYG-A$NNN34*F*E\N14-3]F46OS/<$QS:WVSQT: \?1+  #E5O[7GT^K^?6]
MWU_E;\ZX[AH+7';'9GBP)6#62$]EICL1K\YNOE9-T8LW X-#N.(P^-?FT]_^
M"?])Z"U\'G#AOO>80P,^91_NN1V,8#;UOWV(DA?;S5KG2$U]V9.T#P0+ _8A
M6J-Z^A799QYG[RZ0<\.)9ZF5(7+/X]3)D':^1-TE*^1PEU7C0R9-.>(YGTIJ
MI?\[\N:,.F35OL?H794.8";OJ7-/9_Y?#C,37J#@(\*HV?_VS[X'SRWY:NI5
M8^H-N1L+PK%:#[FL"W=(QJ9A(#Y$?U#,*_\2\3K0SZ$3G[V/?W@D._)W[MJP
M2N^1L>,S#MR5!)/?G4^G5H^F%"F=:$#1]9JZ%DM]YF*K46NU6JNOKWWX+=_<
MWO!A8Y>_KB[.T9\LMST.M&O4V[EEV.VO06ZB<3DSKO!].F:>.5J^M?7]Z6NU
M<72B)_&,Z!M]OXJ^7ZC;<YS#+]3KB]#$X;:CX;?&L2DY:\)P!8>"W^$-?GY'
MZLIM /S^_?=C^$ZG>Y1;ZPEC!!@CH)"27V[MCY+?:74:S;9)ORVJY.^MSK\\
MOR!7(^J-31+NEO2KMO*3>Z/QC<;/B6_A89M3H_*WH]ZW:MUX_(65^KW5]M_%
ME,(<S<G:[:3^XFOU^/A(3^(9L3?*_JW$OMS*_O3L6[59-]J^J&*_M]K^:B28
MRQ_(+??]4-.VJ-K3\/:ZFI_L[Z_*_Q&,F'?XAVMSWW*$SVRC_7.L(?S Q]04
MR]Q63?TZNS:1?:/]"\:V-\R;<G.T=DOB'1UUVL>'-\?M5L,X_$65_;U5^3>S
M\60DC,;?EGS_=UEO-@_E/^9X;5&E?V\U_RV]8Z:HUI:TZWVMUINY5<;?7Y5O
M>L:6"03*K?\1!+K-W.S^_=7\+^@4:4R 9W$PFQH#8"O*]=R 5R^^&:??E-4L
M. ;\I \/U.SY;Y<Q05TQH4%^M8CVUP8PW>)W" $ N?SZP63XOX2&M[^JC?9Q
M;G' /38(]-T%B%ZX0- R0<,O_@\8RR_N!L(=:J'E7J$GO$;TO3RM=QHM/78/
MGD?9,D+*RN)\Z2)LS<Y\/LOJQ;W\L6R!N4;S,?U>7IUO'577K ZVTEY2J.^&
M.6"M,9N<B?&8>18'!RYJ2NYO3AV-Y[VB0.&_&!G1*2/CT GXQ&%D$DV:P!"9
M1QQN,==GY)X'(R(PF0U$>PP3XC"(8$0#]3@\98=6$/V)8NS+\1BU9Z3/0([P
MF8BJ,#B[1FY'C R$XXA[O)I\TV,3C_E 3OD1X<)//A$#(D+X;.AY>&4BO  >
MY0(O>&S*W)!5A\QE'@WP9=3W&3R%L;>)"- PA*4<"(^XC'K5@'EC @MP#]/A
M+O'$C#K!3-ZM9A>]L48^P2/<A0?'%&M3$MH780#S8]%#2 !Q#QP3" (V/GX!
M+OIS"E:(SQCY^_^<-)OU#]?Q,_+WQ@?B4!@*#B$8<9_T0Q_6QO?A$?09W%JA
M1$M^^#T/8'6M380-!&M,K8"2@SAC_]VS$4A7@;IP)8\,N.<'Y+\AS Z6&3BU
M66]T*^2>H9:Q)4,G5)#U4H&1P$9A#L)0"!P+7#0!)3<C4@7YL2!*=HNI5H%'
M+"=$395BS!F0!F1O3(!I[X7GV/?<9L#]H."HPZ0\)9^&EUU'#RG?2?+Q7T^:
MG5J= 'D<Y'Q@4HOZHQJY 7ZV64"Y@W^+.#M>.4U9<-4R!6Q,3D#*N0NJ%"'B
M)H!%&$O$032X"2< A_@[]6;D(PTHSK?1_/ =0,5'PIT)5UH,<NV6O2?U #EH
MOJN0&Z!_AOS?U*+6]*#A>HK%P$7(1K+:.M[*R$@_IBLEKCR.8"^DS*%,5>8K
M2BT+!HH<$:L<9T:.ZG_#90\$L.=<P8#J146)&BIPE&"[@@S"(/3FHAS=30;P
M@>0KJ[7#*Z_ $X^9BL^/F:-1SY+KC4L^O[4D;6X:-(YP6E]GH/@<L(@.>F,P
MZA[;!2]R6_1#%#5K@ (?]<V,G-$)*';A(!I("D@<"6,+?$X>BWH#[OPIQKP/
MF@4U%AB=$GC48S!9]@#&@<_GYGG5GS"+#[B5F/7*R$=K9$+15HZM#?DQ,,7A
M_D#JNFA8M?D(N+1YP6^0^D\^\(T/82!2[74^^*FY,&OD BV'RM"&)^D$WC*5
M-H]$T3]<CF^1NC.QI><>PON7LT&U<9**IL@@@-ZZ1G&&U+K'FAA9ZX::#:^T
M:PKSP1H&3ZX/QI'TH227V.R!CADXBCXX>$1XC^]PF MX80-O@^$Z 1Y>>";F
M#S1S S2U4+L" W-IO46\*XO1V_A^CPT\4)L"[+C$S1W/F -S)O<CH3Q8CUF,
M(T?B!Z1N]\#:Q6E*BQE]0SJ9;:9Y#:^]!:_U %8(N-%#6%X\!1;DSR?PT%AX
MSV$3;5LO=$]JS?;1=IT7FJU:I[UI%P--WMPXJ9WDT].AT:FUN[F,^;C6.#EZ
M2;.([E_ L;A7/Q^]*#"_7/Z?"-,#GMO <)OM<138G$O;2-3Q1<;<2:!%.HJ>
M#".&@8^J3EI"M9N:M)*4&6?!US@X@#+BP-TI\P/ N*&+5AR8>V QPBN3[P7H
M/WHRCLD>)M+6PM 1[3-'F8@,0Y.3T:RF7I^8:J(/"Z0T,+QC0F>I(*<MX#^N
M"/"5W$.;,> 8406C<0;^+4P1/1@Y>'F'>HT"0_BV'P!C5:-G(RO3 F)X&+6:
MVY4_$AM4Q5^ 9&"DRG?Y*D(FHUS*Z4XLRR1,C-]+R(!N=31@%=2'QS*#;]9;
MK=I"'&/-SE4,FRY\*BU]V]QZG*_819[Q<L&+](;Z8'J_:W'3]_'5];MGJ^_?
M9@.ML\4&VF!P?/R<#;25?N8SE_:)C?S7Y)RM;MTUMK\FB^F^"?MW)_A _MH\
M2B+E*YFHJ:O0/T%S94]H1/)&[>AO?_^?QO%\VV'!$LJ%OI(8+V#X/$!R)PS^
MF-)EQ+L-DTRR"UX6$)/X!?;17X_J>>/8$CJO1:ZB@5,3_*]7!Z<E1-L C@SB
M:(TXKV!AE09_$'<0?SJ:VU'%0R--326#35ICTU;64/+"E7GD)8"JOP^##SN
MJ>>:26N7H&BHU=+'AEK+TV4#L6<GCNL:>\<X,AUZ3*;@J3T^%4D?4TQ&)I@
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M@%=L0[$92&4"HZ]M.$1=*7;JOZ\Q'%Y>W^8U)K1^^(EQ\[+N+*]7F;4(HE'
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MLKE/(+N-'BV'*Z+/QOI+R*H;/!]7ZB>-2E>;RFCKB:HI:^IG.I=#Y-<!^V%
M^PZ#?VT^_>V?\)]XR(\C.-&<?OMGWSO\+7G3XG-CZ@VYFU"N&1$CG,0W;#CL
M[%PW)M&<TD>UY@*M._ BA[NL.E*_-YH (POK#RPE.?&DV3Q"5@PGV97<U>A/
MEO#)H['_Y;?SAPGW:,"%2VP:P'O%@)R'GI@P&#)U;2+AGOF,3."R&_B$>HS
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MD9=@&04VE.G&/A=TNNBL):D)RZ)!),?*E7.P<0%+3:D7!7DHY(4=U4=I!NR
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M#-C5< O3#4-6'?<AB&?JZG8">HQP4";VJ. PSJV^J5QMT,TL4)'<CUU('?'
M5Y*0N8,YX^)(,!+,!G24ODH7#)L'4I4X(9S1-Q59.*8R77#JG'R-W*A\DRU9
M]$).(?7T: VVM]>]L3\O/I]3:9'0A:&51@\2:))ST%I?_UZI'2IQQMP"4Y1&
M_]W=8*LS#O*TL';S! CHG6N>RC#2,+,U#E*Q0+/:;!E$I*[$\+!FR#\+#$-J
MI!RVJ/A[*SC!8.)%TE6#2&LD2.=Z$3]+\+XF.C]/*B?:UQ62UJ2EN+VDK!B?
M)=<8N4X8"&]^2Q7J9%+)83%K>&QF;K/]-=G^2:.R_<<J=_Y!0(M8$5T5'A&.
MUG4]/NG*NS%X/M,TH E?1LF*:_N.^BF]'Y/D,W=;E5Q+Q!E \4,@VXB8KL&V
M;;<^Y4AUC((>FRI*'8?H]2&^'&?U>*2825%LCBR3]S$SRO2C:M?/KI6[5)*^
MIA,M83!*BCJG>;A8:R<=8UZX2E\3 *U24\I$R&OFGKYC?&1$8S6OH9N1N]4W
MJ*Q9C[]$'QPQ7 1>GD'T-.Z*V O:_#&!T5UV5X44YOEU6P2.?XEL3!Z9(<L4
M"%Q$5KLJ8Y$YKWXF1#$R6D<?2K*Z]-Y85 >Z4\UYS%Q  '?>V[]K;51:D "$
MEG>:436S?:YW=AVG#\-KA Y^[)U74PDGX9;&)LI#)P';IHQ2Y]]LN8(]@#5!
MHKL?JA<9"ZXEO?I9>6?=XXBQ.[(<I5]5QM+;@#IN>13<@NG'H)XY=CY.-9Q(
MKN,!"Z5KG77P:\X5*);I>6E<3"F/X4(??@_-(613ZB=*D.U\Z,VQ5L)4#!J,
M4+LI^VPH3O9#_-290+)QEZ0YVHQK29%N;>CJ4^#2C-%5*,TGM8"R+D)-<4J8
M!MVS)0BJ:Q2\83+W:[[DD$P^UH#_I2$'-(P0@].VR-<EMG-&=(36R !D78P+
MTZP"V8H2K0G[1*/<E[)QAF/EQ04^/V:,-CJEV36"]%-<6$I-^%VI19"Z$HM4
M4+'Q%41+[-IR,U52\Y<3:#5.U_GP;(Z1 X>N=W&Z*R KQ\KL$Q#X\?)YQV<H
MR,0>:>2Q!#5EM[-K%+["592)M]6#;N.N;ASD+Y<UH>D=V4/IE5*&]2.;RIU-
M+D*>"5A+BZFC,XT?5<D!YS5@9>SZ=[1+SK%KC/(@\^!_9:()JQ<RI]S&5JD*
MP\((-:>L>Y"5 N?O7:E5$E?5#JO*A90U<$0$IZCT<-L<(^(TNT1W^[#U)Q)[
MCVDF9JI$L7IJ5AUUAOOP:LT8RV]^ ,]L?/X:%E^LFGW.]IH6<Z]A,5Q0L<D:
M=D0.#>(Q?7[N*!,]\R4@\8L&UA0.:CL#YMAFP+P\K54#37-+'9,4X<%V2>6M
MDT*,:BOH74!O*_2II0Z]31=LGQLG ^X>R6@Z*)X0,X"=9E(ANK8,6OV,C!16
MP"_QIJ9CCXN00Z[I9  P7A6I&S*:T3:%AY^Y 'V[\AQNO$_.J/ Z!]C,\5K@
MKI$EQHZ6>66"9!*T[2!V,K[69',"P^9OI!(Q*6)J$)$8L4S;JR[$P#=5@W82
M6'=LLW(X 9Y[AD^AYE=RXS*ML>PK"&G+,O6]+ *>^RD-$(4[_>R]P[9P<$=T
M&%&3;UYI9Z!L#]<ORC=+[BF'239+M8U)LSM=X=<83MKTK5H2*QWC$QP0JG)&
MF'H@#!H)@ASGLX3@TF">"^$_[XBH!\\V#AE>'FBCLF:\P>[U&G+'P#K6[:2Z
MS32\L7@^[(JQ<T3X9M1FJL\8<2;'0W1YE6M :L-:^ZAT2D.,.%4-7.P$258D
M6URFW8XJ7;)YI6,A#M(TN64@(*<(Q)>&MXAZ5%T>YB+6"IK:ED:&TNP/74HQ
M!Q]OAF4>#EI0I5W:%  )B+29Y5S^&D'I8,R3DE9%G=^M(_].UFJ;A'7R DXE
M>=8JW[_=X?(XXS#I+%"TZ$ZXUV0!^X..R=JDD(!-:8"$,C-WZ>/=S6I4&1>B
MLR#PY'' 5I.1T>@NQ4Z-$%73I,J!'M?U,/:XN#,P=7NH!,[+'<7.I :G:4IK
MT?+1T6"U4CU3G4^PH508/4KC=,"!F,F,=TGM[MZ6JM=< JQ*2RD!%@5D_SJ!
MIDH8VO7%:SNJG?<OZ5CU1<T*Z5W3-+=80P&A4UQ1/JQ,3XOLC[T.G(=DK 33
M3VUKTCO>?X$8H[X?A+UD@5?$TBRMEQ;&U]P\5(*H<DU*W5T-[W]5!*AEE:0-
M+/FY&H[=< 9JP3HMV@![TX[W =Z*H!QHJ=SM[UY(B<^(9XN0E<H94+_R-3D*
MV/F!:>4:-"Q"L EFKAEICT%YXZ3MWXSSN@,$YJ6+OI+?P?%(\"@I":]B,E47
MBB?IQNH6ZZ<5(X/$U-&!O]$&W00TW$QXQ,[3DRN\I)+/3\NVO<'L*TS@UA2E
MZEOKMK*RE8'.L_[&*@FI6D42?S10B$)<%;UHBG%J7(]7E:51X(Q[]M=9CJAM
MF,Z+L$Z3BJ.6B#W# \]6G%[(E"'2G*$P&2B:K C!$M=NA9 1-N\FY#N6;V*
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MST9=,.Y6NFQ*('=+5*RV60>(J4LPIDFQI635S353\H'SU%'X&?R@ZR29<Z8
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MPE [I&!C)5FN&55,&?)G@B_*8+M*T3FUWX@+[^\X2/H<,:RNI(]3<@4"MQ[
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MZI_Z%T ZC;_\XD'R$8^[#+LM&S9=>S1M#[;YV_EW2/L/ZJJ(^%L?S_Z*HQ"
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M<\?MYI[NYD[:S3W=S;TX= ']GDTK&/!^3"(^15G*W\*K()X_Y'0\20_=(8)
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M^22;Y&E<%OR%#/88[2:>?(>A<>NZ>II%+%XS[:MB/2L4U+&ZXFK_.<L:"[Z
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M:&2<XGZ[;,!LC:IJX'2BO<5;]&G[FJ]V@E*6A+P5[4OX3'%()@W!7F-:JRB
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M(R2L*4LO,(0K=]P,0T^+LI#[:Q&H;_\FQP9(+]IP*7U%]%KDX2""8D9S2D\
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M3?D4K:Y0U*M.9VN2:#H,9:LFIB)/ *T3H3]!BM#E-6"7:02;&%X4<97?7,N
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MA[P@&D;K*N6*5*#3\U?:V#0&EJ%K9Y3!(FD^!]JOLF!QJ"'C)V])Y35ON^6
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M.?4FXY%G#2S&[0&XY\%@$ECF8.(%X<CDXY!/[2<O?=VS'X+ \-@O$.P[ZJ6
M[T"]5P5\VP&^QH&=VHPSE[$!FW(^<$+''?C.& O#NI8+N ?J8#UY:?JZ]?_9
M^]*F-I*LW;^B4+P?9B)T/+DOW>]5! UT#W,;\$*WK_V%R-7(%I)'$K;QK[]9
M8I$PQD8@I))TIB<PBZ2JRCSYG.?L!!M=U9/!KK&__2I^5$%-N<UO0DE83+6R
M9/:B;^'%[C[O#ZH[.<Q7R'[^>W^P?;WC?[ON&78T? C0WQB@I2-QA@8%!=8S
M"&(+T-/,(-FH0LK4^IPKUW0!?O14K(-K&M%P91@NHN%BT'!">SEWP1'E"ME-
M%$30&2R3!F(06:=DDE*RZH>E*:)A/5GO^B9-72S@C[]>S8YN#-*GU#M+C<;=
M*8;HX:@[&[[R<%0P7]W)Z\[H9/ML6-8S#:[5 #H['H+Z-P9R:6%94+$PWQ@X
MB"@MN%C8L)+&)TL%9W3,@2E?Q#RN=?=UH)=W[3!P 5Y>Q,"GP,"I3K!!:".=
M!1.T "&X!Y<IA92HM4IHGX)OMGF+&8QTU9/Y/M3?NR[,=]#YY$:=3^G:%7R.
MCN!5H+YW]4:<["B&]AZ)]#<&=PECE>69 "75O /A.7BE/'!&''59V$)S%]D6
M<=V]'.CS73O@6P#?1?2;)_I-\5S%M'#*0(K25>AGP3I2;/TLN-+)^41,L?5Y
M2W"LQ:@GT9VWBS=V/EW=S_@S.[U8#ME%(L0WZWO/I;BY?O=>]A_O7K?32W!R
M\3,E8_2LZ%6%3.-'KRJ7AZG7Z0\:O?XH#6_._2H/>:\G;?^O'_RK??-MZ#99
M1?Z\/9&+G>1'J#L>HCMN3 JC-$=&LH&8(P?!DP3OG( 0DV(^:D*DQX;BZ"E&
MR%NRIQAQ;PZX-Y4,'!572G PCD80.A#PF6?(L>R;-ESS,6=6A3/7KQ_3ZL%>
MC9S#J].R-MQN*5,/]^]L#0G7!N@7D!:!CI%'@OR'FVYAR:FC&H(@&81-!DQ.
M"@*E+'K."7<%Y*EN$5*_69!KUG1O8UW&&PJ6"V#%"):/!\L)(Y9EKZ+C'#*O
M)CAP;L&3;$%[PH63S"F1FVW#6DPL(F5LH\&R3B[F%:B=8X3Q>_J,T0>RJM3X
M&Q\(CNUY&.A_O3'50!&>HX^YB%'6()P-X&VHLB<T-2D$$Z-KMA4W+2LQ41C=
MOPA]-7#_(O0]'/HF?#=EEER*#I3GK.J#X\ F4>5/I)2$3DI4S@%%;,LH@=!7
M2TZ[QOT@_NQ7BY$&I]@18MT8[;@&&FN>YXOMN].TUA-ME$X&'.491(H:#)<1
MO"8Z"$^3XK)@>XOS10SJ6O>$N(UU[:XO^CUU!PA$O[FCW]0L7F&<BLJ"4)F
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M#:;L$U!&C#=1)15,L\V5;G%VVV;$'"),G-QXX%M )T@$OCEG4&X=$^F=2+'
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M? :;2#%O'),Q,>9%-;:!MH0515'7SYD_SU-8.W1;5"A@#H-F4:NA5ELCK;8
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MM=4(XS/!^)MI:Y[(8)+V @2U5=%IBF!<IJ"X#IYKRXLE,NYL)3C.K,*4>D3
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ME*?BL4KF;A_U[X/^Z=;A]MZEF_LP3QS=J&<>HF=>3;DP8I*"J$2 :2U 9*G
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MRJ<>RB=D$8/5B4@G@M3.:VEY(<194$M<O%OYW-^40;VT#+UT,+%_/)>,9")
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M;S@%JS^:[</121J,ZSX&Z23UAIU/J='IE9\3UG_4GH-M7$P5DUGP..!QP..
MQP&/ QZ']3P.,YC2QKGL!?>.<R*DE=XEKD6TC!L=6 [W,*5OVLMC-KP]38;W
MQESXS_YP>)!&A_G(?4&3>2:3>7]T<'X=B#*14)8T@<R#!\&U YNI 16X%U1E
M:9EIMC7'=$0$1P1'Y J;>!SJ=3=X..M:I(',Y<F9R[2S/W.;'.4,=-DM$$(+
M,)0Z(#Y65%,['I"ZK(SK?S,K*;;/3L^Z;E3  <K#IS!JN.L"KD8>]$_+S_V/
M5U,;ME[]U2C@HX!0++2H(6?;@* ?9D"@D*.0HY#79O-0R%'(UUS(9\EET\[Z
MX"TU@D8AHO).1T-BBEIK%XDYWKLR8[^U7H=EB<IW,^2R3<CK[IB['N;RV%LA
ME$<:54EM@TXO=#YVB]U[D=]VF+<NR2S:O3/9O2^F/?:B&+;$! '6, _"> />
M90.)<,FHY%(+WFRSEE(,,]P0(C<#(F= 2)JD<T8$FHT5@BHKJ$L\>\XU<23I
MNQ$2@;%^P'@X55.G7)8B) C24A#"*G"<,^"".TNBEE+XNX 1">1JH^.RKX_H
M/"=T)E1:+:0)7$F1"G>E0A(;"UHGY;A0]T/GKVG0CVYX@L"\-&">CM38S#*7
M@H.G,8 @-!?R&CWD[*PEUB7+V;4MC]A<SP -UF8\,%PC@-A6HY?&0[9'[@N6
M<=3>_;=Q 5U,=\'C@,<!CP,>!SP.>!SP..!QP..PYL=AEMS@%#*ED7$FM<B,
M&\J=232XP*TE*6'(8'4\4W]-APR\BX0G%<%H6K7A*]]9:3TXQ[.RS%*F<[/-
M9$M^IUT( NGZ FF][@9A_4E@G4OFLA&1NB2$]\8Q%I1FFO(JC.@0UE<*UJ<#
M#C(;$Y)B8"F/((C(8&U2( 1S04FKF?6(ZZL4?7B*\I ZK>).>?.G,5 TW'#8
M#QTW2K'QN3,ZJ4((MG'0'Y5+NEYL_-8O7_Z=XKMTIR[%:#3F#*]]R@<*.0HY
M"OE&"_E,35Z3X9%;Z3@UHOQGL^0L>V-R\%((<8_Z[MDSY.\SC6^[WQMOA^^F
MG>1'KXO*O_C5L+SV]^1&9P-L"CN;,?!F>M0"$\H(IC-XJWBQ!20#'Y4!I@(A
MBO&<O6VV:4M*B_GRB)R;@9Q(#U#(4<A1R%=!R)=]?3QD\^+@V7D5F#",I(J#
M1Q>4ISY+QI)ESBGDX.O$P:<=\L%12T-.8%E*(&B.8*T3A80[0Y5E)C./)+RN
MSO>G3_VOTYI6#=H:U4#K-!IUTSBUOY^GO/!/Y';?K# M)J.M?0X%'@<\#G@<
M\#@\=6[FH_WZ/S4ENN]Z\5YV1$4=#GNOKHG#89ZR+%ZE7J<_&%,(M"5FLB7"
MM#\_Q)2D5QI$M@2$"1$\LPI"5DXP&U@FHMGF+6HTIO8@OB*^(MW XX#' 8_#
M1A^'>MT-'LXGL07F$%] 6Z#VML"-SD(JD$R=*@)8=19B*H-3+@%-V2A')651
MHS&P0J&&=<_S?^T& ]<;-0;7(^ ;G5Z%8KUT 6_?I/QCCG^M&-T&Q \Q]0*%
M'(4<A;PFF[?@'/_Y\?]+33]\>:WI(U+]F:C^NVFWOW1)99,)&!H3"$4M.%-E
M$(6D%(],$9(+TR<MH;'O/:+CAJ C4@ 4<A1R%/)5$/)E7Q\/68WR^)%GUXEG
M3[O4.>$Y""V!>,) 6!7 V: @::4L]Y*E:)%HU]:!OIFY^E/N]'YN?+Z$A*6X
MUC<K.HNI$VN?.H'' 8\#'@<\#AN4Q_^'Z_0N\G<F5L5AOK(TT+R8R;SX,.W&
MSTPZ%4*$+"B!RG0$3UW94ZN8EUYPRE-5"*SM H8T(JHBJJX@JB+)P.. QP&/
MP^8<AWK=#1[.]<_>1PM@KA; C>;\SA!9Z#_X)"*(( ,X&JK)*UJ%S'5P*: )
ML$(AAW7/V3]R7QJ7XWX+@DVUXQ\5,!A>2"8FZM>+O&U \!!S*U#(4<A1R&NR
M>2N;J%_4^]5PKN]7Z!Y-J7ED_K,P_Z];T[Y_HS)G)A6ZGS,#02D'1Y@'*50E
M"8$Q9RKBKPS!Q"*$S<V 3>0&*.0HY"CDJR#DR[X^'K*US.!' OZ4!/Q&&W[I
M/*]R;BR)$HH5)L%35:7ZNQP"RTPIB@R\KG[VS4KM_^%$7,87.1%WLT*VF$^Q
M]OD4>!SP..!QP./PQ%:&TSEX%JQV@@K)J!7!>*<)U4)[FG#F[AH9&KO3GGZE
MG&8A"M T.!!9>W R>-#$IBRMM$&XRLXPY'9;SGG:&8BQB+$KB+%(.? XX''
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M^!#XZK-YJ-U1R-=<R&<IGF.6:,*C2T$+8IW+49&L8XR5XO"HW>NCW0]?344
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M,86(G700;'"1@JL. C\Z.8ECW[>#>0O"VDLPFA['<97;EHY.^KZJ;Z:4*]@
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MJUC93P&(*]X?55BX.A9>M%AX?JBI=\(#_#3A#G'F-'*)&&2I8E$1)A+#94=
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MTN<NT[D27V(&6<\E @Y2ZYUQ3.&M;=+CC.<%4VA8:%AHV!E'0*'A/="PY0/
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M)1*ER.G<&):IB*RT 6&GO?(B!7B[I(9VVP/PG7D!3';?!; ?IY6ODP/&HT^
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M)1CX%/"8$FC*%%OCA.6$"BM)M-0EJR2H5@'7>'S 2%_!XUWQN$RBT)1Y+T)
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MV(\!4R^B!>)[8<TMST#Y0NT 1@R*6-CE:'#4ZP=X[.KXA<0I<<]C4_<,1A/
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M&K?NRRY4K^A+/Q$D\,$E00TZ-MZ+40V;EUVUNB!Z9,:303T!*8Z[*&O>/GS
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M&P']M$S/O8!^AH ^OSS^XQ1A T;?$)YFDC!1%D0IIXBSN=1<&%W(8N\IO4E
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M7?F1@]LO? %P7[C;#FI R=B!@:S#1TW;)UHO9ON#@WJ L]B,%C0#OO2#!^V
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M_7%U!(L9!@47Y(OQ=#%O@[D(_<$,NZ.W9U='AP>G62'+,A$E0=I"&.><2$Q
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M#<)R(U]?X^F92_*$FT)G2C"52)GB(1]G <N!*[)@WA4)WT+/[WRNY] J,/!
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M!&$A\6HPQK_^KJPJ225F;, "9^_86""I*BMSY?.LM7(-,2$C&$>*2F-Y"$#
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M'=:PPE'3)!R89,J9]!W*2EGKZ]::;1T>)(P9F+H1EMDH^!%AK;U-6471@G-
M]6#S6E]V$<_7>GR3Y5/;.8M*3*XE.RUMFLW5R6C4A+0UL:?/[2"\M@+K.K/B
MU]5KRD&L+<=CW?P039COLXM%N+(VZOTS<*[+/+SM-/#"Z2$8?-H%#,PL ^<!
M.P8*/V&:"JF2#&IITPGJ:?Q[XD;Q?R:M_B!75Q8FSR]FI>GG>$V1TYW/527'
MSB\P ^.F=HM !/\Z?]#G$IE2/^C5XGR[>%[J[U$[J_J#3F_0/\S56%I'?_=U
M*_Y>E8Z,-JSF4\.'/?Z;=\U[HL@:_GPB:_CC1];\N\F5>#4X<;F"'4S\\H75
M;+^:ZEI;9'\SQQD>];8V_WVRL_GN;/OKGMA_\^%\9_<_O>VOAV?;F_\^WMD]
M.KJH:VU]_>?3]N;VR<Z;#V=;;_*U<\A,[]/^[ENQ=?*![6QN8!BKV'GS.L%X
MR-;9@1+&"FH=4D0:Q+47R EXI;*N19P.R5U*LDM6&,F5HIH0CIEW*5CBX4(N
M12&,NAA*,YW_3FL!1@\=2W/[H!8?(KA@,'P6,_B:25X;RE,,2H+:& (7SR&6
M9F/4R3D. '< 22[V!F?-F<W):2]6[0BOLW:JA+(Z'O>"U4.QCX3#N@L/\P(V
MK<.!.>TT!4,(&[]X#G[)U+UCVD-E &U7QY,[:6,^F-'2N$Z>>C^V?&YXZWB+
M;Q\>8(,C#2*A*!1'^9@6:8<=HB)*!R(N)7$KZ^.C88R7+:'6"C?'UXO<J8 "
MAU59R8N'XDTH358YJN/PQ: ..YKG3OK6?J[=P$W1@[K%[6P T\YS\_(M0,1K
MG8TJ[!A>5G6N+SA[IB'BTQS&V:]-5ZUV1N1"8ZW1:')2LS9<!JAY6BTZM)AZ
MU(025>/,8_95W>:J3U(UR-G0ZZY@,1=';_UUM7T06A7'KA*<9DG\[6>?'DOZ
MP>C9U4NX=V<+![IK?NQ.:T\OAS;^;?TKEG1=;@FQS.T@>N<=REJ)U[,-<SKL
M?J[B1N!;O="9+5E5/3Z':AS&/JH.[,'N:&KH@FQ/B\F"8OOW8 )\\S=\'. &
M+!;XZ&KG54Y3'0S[7;LVOV;GJ,I,/85O5@#27+XSCOZHGVN^G\^**XW.^W%X
MF*L]^7EN\,Y)O[OA9@(T.7WJ*9=KXBYS#C-5U3MNZBF!E59Y+8CBE=-B<KK<
M I.=7J"O3?+<YR5R@W#>F8O *0!8IO35IL-HE3Z<O>Q-J?P,P:>#O,09^W*9
MG],F^+43^T?9]P[H9T_G&#V-S)K?HL;BBX/(G[V#\Z34S[JA?I:^,('+5C_K
M5CW\@MXNHA:"$:.%IYPYJCW8PE%C*FQ,R2U)=_&;%\7F -71&.0_I:Z?],9H
M/$"VJD70\;'7F_0L;)!<5KPJ7'L!35L%';.G>U8VH4+-OQ(,I(K.G6XNT%$^
MQ]YUVVLZ%)N-@Z:04-; JIM/*^&^^>O5^]S@(@[K^7AF6LS-BY%3R2^4J;_G
MH2 V('?1.RYRF((*AGJ)'7>1D.A)-(V+0E&&IB\NGAC=ZK!XU:Y;N#LO)D*6
MYK#HZ0VFMV<[N^_HUK$7,.;SK<VW!\1'2R)GR!D+%I--&EF%>6YMF*M3"%@2
M4\5/7G'P/"]BT 0\/J4(\(LB\)<]K_R_NX.-6G&;RD0<O1D.1DN3,_OCEWWW
M[8$).<?'&:2(IHAC)I&-SB$?/&8).X9Y#ILE:_J&6+:J#,!B>="Z&DK5$[EM
M^V7'[K1K^U2M7KWW\?*#B4SE2[D*,F!\_V?0"QEPP8C]:ZJAO>V'>-*?=5A^
MU;/=DR)/<WGZ=&!BC!A3@YQ6$L'B*&1#KJTMK E:!1H275G':^2&:*=*.HZ:
MZ:\TWKF*W%U<@5S@&9:@"L>^Z#EI*D^U IU;$=>50EY[VQ:Z7&4]H2YCF"M"
M5SI[#/<A[1O\\;Q*B@%5+4C)88Y =2,L28V#88P;=@=__-_^*(9)+^ZD][,#
MD[=UR[ N:'F5@Z=!O;#1GZ7@@;JR43MW=K.WYF=UW+?R8>%S(+@;!X)@*R(-
MR"F%$1<RYE<$$9FP=MQK8<E%I_PS4<R&3=LAL!%;S8,:U]TB6E<9I(M-;Q;W
M4N7>:SL!IZZ^RH_8^!7[8>9"7'0KPC[+-;Y&G5_J$K,3>+@P^O6W>Y[@-9-]
M @IVMX\:,U/6%FG=/6[Q$[V8QK_9R7CP>_.'JL);_1>7W:5#5!D$IZ/XV_3%
M[RW;-'^__CVC3G_\6YY]4/3!J#__K=NOYKVZ;V//&;6&E:Q,NO$0_A^FXVG,
MO;7:W/O7.%Q^4ZDU0?3U[]_XY9O?U&M<TSM^^5_5P.O!PY3D%:CREF;&;L@N
M#+"Y3G^CIU]^G_[>K$7^TZ6M\+_ . /S\M+$7G#\U)>87;%:.P+S/?U#O7:D
M7NWVWKME=]QYERUNSCONZ)7U5].J776]/[M8]F)QPG_ ]"W79/T_CSLQE8S<
M,C.U'-4BOT0S<Y]:6311SYU(#OZQ/&A,<O)!"%I;T#!L4U3MHM)[*4W_"KWW
MLE)A9Z6&;E0K\BZ -W(&"1!$MKYF6C%[GDK&T=[)E][.R;NSG<WMXSVZ=;:W
M"U?]"M_YN">VOK[N[IU\ .WW Z^J'>W^,_L.W&NR3S_(_<T-#F,YWOOZ[Z,\
M2E!,R/[QIZ];'__3W=_=$-N[A[G:T9?MCZ"8O,)?_MS]8[SU-\:@F+ #IK"G
M+)METCO$O;1(QY 05\IR"E99\F%EG5Y7QVA9MMGR(= 5\_,8G)>J_UXJYVU,
M^SF?VG,[/6BVW@\GBZK?13&<S2Y]Z-F]BTA>,[U+1P6_/'<NJ,^VVF\T\O)7
M+2Z%&NY##><7J"&9Y"GW' G-P6*50B"3"$<@0A9SZGU*<F5=7X[P__4A6>';
MMN"R MH3L<++MH0V8WVNTAG;+VT6J+R^CT4%WZ:=%"IH4\&=,WX?DB6FTK)K
MO[3>+-1P#VK8OF0UR"0M30QAASWB$5A!4YSSU;6DBID@/%]9)ZL27\[U>U!V
M*#9#L1DN3.*\<O%HZC"NHBY2[M^56UFD7&W6#X9Q'N)63(AE]B;]$-IHB5'A
MBOMP1?<"5T0GL/!@/"0;+'"%2<AZP9!V1.6V%4[D>EEJ%<3U"9Q,Q9PHYL2%
M29RV[BB6P_-G@$MM6 IDWP&R+WI^A/&:8\H0"8("9+N$M'8&6>833M3H&$"]
MEZM470ZN*><"#PW93Z+ /PZWWC"L)BXBWP"&T*E* 75FLUF_V=R-P?MA,,G^
M_^D'?J;CY_NI+ \SKX5LGMC<V([CPEGWX:R_9YSU96L3GO7L@$D9K+8.<4,P
ML%;$2'/JD/ I6<ME4B+DP/)53,C261H/N6V7#P^O([U_55%M[<2Q=K6!YYVS
MLCWHQVD0Y&&CEN90X1##!&0N+U^58V>_Y-26T\$HCNJ>B8N5[^H8R@O.JBJ.
M,L1Q')YT^U7YO)P0-.C/,_;J9/ JP#GU!F?3[.XJDW.>;3VNPS='.35IX8Y'
MYZ<YS*P2U&D[M'_EN&GX;GZNT7@8[4FK1U/=(;;*.FQ2MB]EJ;822NN>NE>F
M2$VKO9\.!\?1+SQ$4_J]]7RY9NG"\"?5$.SL,YUADRY^O_KKWT8>[+9H_PKK
MJW)(HP^P8'],U^'U9#P9QAS:]#H_YF8S^/?PWO(46_^Q0?^'N4#=@0V<,^TQ
M4KFX(-?1(.=Q1#' 6F$IB%;NFMRA_[K[YH)-ZF(E1R<#P.JO]=:R6>AMWN&H
M:CH,>RYW/OW<%"JJP2 '*>=24(>QM<LFHY@FO=KSG,.9KVH,<&4<O[14BZ2\
MC5)SY9W3/ J1C/<<VTCYE>DG%PM[A,DP=U>XJ+R\KMSA?W8_MUV=E:+RH1KN
MGS#:GUOBSG<V_0$CR7LK%&)""Y"XW.I>A9#]F#P0![>(N<<%ODA>54>+YU9*
MXO98_ZL+=62AOEO)C]4F=:]NI]$ZQF^%]B^<Z%=YZ[..XMWVV<XPUGDSN0:D
M[=7;^T+?@O%"XY!D>[WZ,*C)F3V9UUB<]OAL&G<.8\JP4'4G +H*Q[E5_7A*
M3--[SJY<]11-N1]ZE5K?SO,9N-S;(,^(&TQRE3+?/*;O#OWD)->Q]G'4$/.7
M[JB"D'GADPNI$<],H.Y;F^2?.(1I!5B]HC3)\WCBF[?0VWYGQX\'N9!/JQ]3
MLV6F#[]:4PTHB2";J%;MPG!RV"K%X+J#EC8U+?^1)?Y>V8V214<%LY$Y[JFP
M!BB$*R:)E#&ZILL,P4V7&8*_HX9[R96]ML;;QMF!M *XG7$DG0*6P=H@38'5
M=;1>"F,(:#DKZYS=D!.]VDF3?EV8J2X95:G-5:)A/TS!<0XFN<+[=+-UFVY7
MHZIBR* I97D*ND\",W20/PL*0>\<-7< !#P<VB89<GJ5_V[WJ\W8?"$E<EIW
MZ;I\R":)\H$S(4-*,9>6P]& &N^5DU1Q:I.*1 :O:<F$?/P2AG3KW8$@RC%A
M'4HJ@8#;&$"VN81)SP4BA0_472I)N/QP7AD4W:P(S(I3E'3'DNY8TAT?,MVQ
MXK$XS_<J*8\EY?'13HU\B,8S$K7$E(>0O2P>E#"%)6<^2M7TD[BH"?^H4Z.7
MF@UYW /EXNV7O=UPLO_QGY/MXW=\FV[#>WMT^^/VR?;7#U^WWKSC^\?__G3Q
M$&GGXQ[?.WY]M$WW>_L?X?.;AVR/ON[N'^^1/;K'MG>WSO8WCTZVWKQO9T."
M#BZ%X#)@Y AAB#/CD77"H%RXS 7E(]5V99WQ5:IEB7I8SD"UEQW9_#Z.QF#A
M3,]$2L3R\R6#ZTZ(OID)YK*1.:&PP'U8X.\6"PC#I7$:(TU-[F'%,++6*V0E
MUB[P1&%KK*S35<V>@@1*M'*QBRY,XLX-U5]*Q/+S88#', <JV=@>])NBS_4W
M"A?<APNZ;8L@4HDCC2A1IW.G]X2,,@91ZBW)P2"2Z!P&S:[(@2\&P5)PP<LV
M"$IYE&7)B7]F1/&35$YY*M(X;Y%&9,$#/0BDD[:(&RF1Q20BX@EU)N# J5Q9
M9ZM</7)J?+$=BNUPE0.IBBNIHAO[U5%^CD;.?7;C\//C,<7+MBB6C"D6EOE]
MO;(%T.\!Z-OM<X%H&3?8"L0H5HA;')'S.:TD-QW'3GO/^,JZ6:7\<E9)J77R
MHP']91L LTI8P_@Y]B>Q*/K+"]]/J<U/Y>)]+18%_.\#_NWC "UA<0D%"4J:
M(TYR\1*7".+1&NTQI9'IE77%+Q\&%%W^1T/_R];EEZS,U<M6\)=+OR]EKI:
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M>QKVSC.VS(&K 8K^><<?64#MW#VJ#;:Y\]-,3>C6Z)-UJ1P"7ET<;C9NW(\
MS/.>4?73>#L<GC>1CI/ZA&81NW,[OM3+Q8TRAN6CM&Z")^V/>^=-]4-X9]Z8
M[]1V0_4=%V<=J#*-=!.(=%[^\9%MW ^WW'FM\SISTOPXLM6\:K4SBK&3':%T
M'A[^##?)+_K7U<Z_;2^+0^?OHQC'G:8N(%C%8]OMC9;CX6Y^E+5J(<CO%T,>
MO[6'6*(D E5)3X3D-$07.7?$:9>R0>'\#3W$*B:;-A ;I"M.C$?NO/7;@FZY
M.X19J.NX_.PMQ A8=]B 'F&-0"+5_5=SIPXID>=2:8J%9((]YQ9B]O!P& \K
MYV>K0=CE?F(MS16 &G#M\>,B[N6E>*P4LI_-PH+[GF^!YN:L3I0&T-R80)QR
M@[30%GF+90Q.6Z/PRCH3:^J&UI"5%-4>4N"UV[K%71][O;PMXO@:Y_R;6\1Q
M0AZI19S0IK2(>\P6<96&=XU+H+2*6[HL[I>3C?V]3LT[MPFJ#WL ,"ZZ_5](
M=O46WCK9XOMO]LCV[B>\O_F^M_/F#[[]YI_NWLE;ND4_B&WZ!]T_^2 N9E=O
M?7UW#N/\M \:XL[N^T_;;S[PO=U#O/_Q/]V]X[VO^[N?V-[N_LG^;F^QUQL8
MI]IJJQ"7/"%.F$662H922IZ31/.9W<HZE:M:7:;5'YU=O>RP_#05FZZ^^\MF
MNKK)0XOL_KZ![!ZHMM.M\_R35GKZ1DN*W7J.7\#\#F#>KM'* O'>2(LD]Q+Q
M7(+/F,10,")&I;1PVH"%]!0-VQYDLRPK")6RK0_1LN=R(_=2DG7)H?HQ/%NM
MOQ3DOP_RM^NNFB"DDA@CBW,VHH ?CD6)K+">X2!<-'IEG="G*.-7=/BBP]\X
MI:\7(E):42\++OZBQ;],)\Z/BTPKK'('5FF7A_7"*R4#0=02A;A6&N4D "19
MC%01%VBV)_0JQY<;_A2+8OE8YH5;%+N#<97$< .)_/BJM[?6?FR7?RRG)H\S
MK\^?KK_=DOOAX0N%AF^GX86^>\JR "OL4 K!(BXU1X;9[-M3.EH#OP>; Q]6
M%5^^]ML/N6&7#PF_N0[N0F1)$]G!Y/SYGBXR;[K=I\%Y.^GR+H==??L>_^E#
M\W)5J!@]49ZCF Q%/#&*#!<"68<=MB**$,CS#,V[.13/]F#-VR'3[8]7><SS
MR.@JW'E>NF]>K\]>]@C#WX"P>E4*R&W!6G>JV?F<(KG,FL+J&R.Y]!HW^E$B
MN=2:P+1$<CTJH5SWLSK]KM(5\HL(6PAV5,X@*/%=2V>I%%OC43N]P@: -_Z8
M;X$78E]LX)W=WM'^QS_PWO'&EZW=]R?;7\/1?FUW?-D[ 57D> _>^\_1)?MB
M\YW8^?BZM[?[OKNU^<>7[3=[;)N^/JGMCM?=_=V-\^UC>._D]6(,& &EQ&/A
M4? 6E!8<-3)."^0U35C(Y*0/*^N47DY=_='&Q?- \W)X]&0$V21IC9I"6QE,
MRCG2,R&+'^*8:CJ&UY]\/Q.:PB;W8I-V$%HN9^H="PA3C!&W02%K/(-? W?6
M)&HY!S99%>0)G%7ET*@87-_#)W\-8Y56$[^<QOZHJ58QJ-+/:\=%"5E;6CYY
M(M)H1.2/6D+@\SM9/.KW"HO<AT7: 6TX>:\]P\@I;!"/+N: MEP*SW.FI*>$
MT5QW\PD"#XI-4FR2[^.07-MC7%?ER#Z[T[JZ?S^.BVWRTW/)5#K^ZEE@E-JC
M=;K06Z-PQQVX8R%LK2IRZ' V.40^+T_(,AR1HB($3*+'T:RL"_T$P=#%_BCV
MQW<=^-2:YH4CT0HXBN7Q+=/]RS.GBT8@7E[2S-/PQ$)<50R$.9M+*&F6J^2:
MB+04& 7"/7:$)"5=CJNZ?.[Q:S$OBGFQ)!2Q&>O*:-,BJL6F>"XL\2,//%IO
M3 6HZ?Q1^.0^?+)P\D$\M210%!E0"2<V(*,D02R8B*GF\'^ULLY7Y14GZ0_)
M*,7H6$JC8XG#/.N>VG?DF;']TK9'%AU9MP=C%GNE,%'%1%.!VK5?BCGSC?33
M/C+17L.:>X$"50)Q%Q5RN927<<!"@7F+@UY9-ZL"7SYX+P;-BS=HGCG]O.V/
M;?^PF\/RJY/WNI%5RETN<FWR%#LHMW2(K5;M/XZ4?BICZ>4RU%SF"BW=BY;:
MIS&6614%(PASRA'755$R)I%-W BG)39:K*PSN0I"5PYDG@%5_=0',F\&@Y [
M^9;3E^=/%=.U+-A^#VS?6<@<43X0K"72UAN4NTPB39U%V'E&*&&<I9@[P*]*
M4ZH'+R>:_U0G*8];(>9[IK+4BWD*!:Y4CWF6=MC+J1[S1!S=/I6B6M@0<X?Z
M)',_<:61"3HB2D,T*9@8\!-6CUF:[;M\*/G-M62><;?EJNG7I0:U%_QXJYW!
ML+-STN^^.NKZ3[&_\%:N/C)KZ)B_W.H/.^L?VSF)XZ-!R#T.QZT6L/GCBPUD
M<V62SM'Y:4[QJ02P,QR<V][X'"9P&.T)H.&P^SEWN,W];.NVB#[VVZVBKQ[H
MM*7MZ7!P'/W"X)KFMK?WM;6+G6WS#9^B&^W;[=</U(^V-**MVYG!4QP>1)8T
M3YH"$#N!N+$.:4<,<BJ%I F6*G=>(7A-7]6)MG.GG=/IYD:HW;J7)R#JUWJ;
MV"S--N]#E/=DWC_PP<'GW-MVH8_S9!33I%>[U^?2=F4%*NV3-M8:[!/C-FJG
M=:*&:.-#D)*X*^O'MK0)@!#_6Y@,SZ,=7M0E7E=>_C_SQIN[9"N]X4,UP#]A
M?#^=$'FR=7:0L$S8 :4[%A7BWFBDDTA(2T\]<8+"W.<TJ8NTT<G3/%J[5V/0
M9T$F\8L':)INATM5J!8K5\TDOEV<RHYR+]U6):NF0-6L8%4_+/3#;85D5V2T
M9$TH+SFY?K[ND8=B>^/ Q6B3)QS90"+LE)Q0J"6\TAX+S;$)!%=P>WWWR&KI
M\Q+/VCK#Z\-F?D$3 =(_RHC;'X#N&<,$OIWUS]RS.L?,G$Z&IX-I#C%\['0(
MZS7LYG;-X_&PZR;C"TV-<O=>HGZ'3P[&V5[*VD@=H]>!;7>6CS^S%N(K'LX@
MG\5RVA IW^3/[F'^QS6$W=SZ;##\!&/R<36/_RSV>OG?_%T7^S%UQTV!MFHC
MP6CF+:)AN)^FQ=K\9 1Z=@00N7"2"I-7EW2?5)OLKJ!R7=VV2E:-U\X'9SR3
M@@O8+<Y$[)F/3&K07=B!42M7%'N#Z:[V_F]5/V^@CZ:R6G7@W& 'IVM*S$[(
M+WW3.K R)N/X>V-7X/8E5FXI+;?RT'BYD;MV7X.2YFX@J?"%]6K]/!K.3;M#
MV!^@\7X"LQ$>Y3?;.[/GHY5_+3SQA2F\-#,WG+<O&:.HJR=+K-VH\UC%$V8D
M12\-=])JE8S@T7"J;10LW*'J)J@VMN]A5=_V02>;5.W@LYK<&^3:^$M33?-\
MBMF'N;0MW_JZ ;B]?;RU^^[KSIMW N[W=6]W^QBN>;)'_\!;'_=/+F+VSF8N
M;7OX=0MP>XMN?=G>W.+[FY\(X/@1W _&OW^\M_ON"WPJ;7]]R[;>'4ANDR2,
MH* ,0SQ2ARS%# E"N8X"YEWQE::!Q"2&C<R'G!-LA,!8@WJM+=':>T9(=%@+
MSXF^6'VS:D91-1#HM!H27#*S[]4_O8U_]<+=/JK%IQ":   K;.!?;@R'KS$N
ML4K)&4>=6>YXGGKS?(Q@=E<SVO%Q.+;=?M7?NY+V=MG/!45JO&#49%-E..W[
M4)LIH+.V^H< C=J&EE#M!3B9+V)M[H^.!I->R.W!6_W"&X-Z;K;6GZVOU#FU
MV?O4A;F%(9Y57P=+J ,/ )SMJV_VFR@DX/;I^,'&_U@93T#CW5RG$:XYC!'U
M@+-[G:,N:)U#?W1>6_?=P;";[;&*=[M5NXM\CY!O4C]"OLU\+BK_0:>Z%#QR
M=A> &(/24'^C)N_LZ*BBHNH[DLZ1_3Q5"XY@96!HTSO7R>CUYUC[<W -^-@M
MG;#;]8J;6JC9)R?FOS9L*2X[V99-2O]LY@IU=F;M1Z8+,IJ 0@>ZT?],!MD:
MSHL/=X;YSHKAYSC3AWZVV:(P6W6+EJ86#FR>6@AOFZEJEV7QG?=ZZ<1N=8T
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M_Y#8/S_L-CD9U1J,P%(36>4GR!C+$5$4"Z&)-BD6/\_/?:+]C ]ISD/\,EN
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M(6I,%.Q_2.R?'T"S$#CW.B'KI0;L9PP99P6*@EB5@C7)FN+G*2?,/VP2KS^
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MZ9P+5 8NW+JF=*\[M[\;^*2U48SN8DK_G&3/#4H@8APB*/E3Q9$PB:WZ\TG
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ME-8>41,BXEX*9!AQ8$A+'YQ6.N:FUG)KOK/9I*=UIHX'20Z+FE@\>9K8?W[
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M"JCNY1</ISX_SM]:0;22(#J<,X"2Q4))BC1U((>\)L@EFQ SD1EO*24NY6P
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M\,54-G*5?)+/6&1!S]]L55%_+SZ<:;)B]N9D9\Y>?_K;;GS*/IQ9^MS;_NL
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MLW.E7/;K-LOCCNW'HD;/)N[-&7/?#/I>K(!<B/5_M5K3%M)_'HR>KP^D_T+
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MZ'0E+=-G-[$<E@K7MUHIN2K5:I.6,9!QM]-N,FE7F[0<2,OE*I,VVWVWDV_
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MCH+RHO22":]EBE#Q\S#?F$CM[^7<UR$ZOJQ4/CZXUR]^4P%_5&XI)>8"N/\
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M95HAL*Z2-)$*G+:E6"K3-;O3V&&_,QZ%GR9V-%Y\Q*.7]EHNPG_CJHX*GYO
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M)#]9"TSF+(M>436O9^!]K(L"M.JDG'Z<.2$G>4&YR-?+]Z-=7!4B#+- N)%
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M6QC$KH!OV->&BU(RC&0( @Q%#(:B,01)9K 5.$JE\=HZ865[V4XL ' [B0N
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M=?THZNJ+Q[CLE;W9%#YH3_3L?7C*+76)LAFW;X3;;[\N=B(KL3$FD(A*R2P
M-W-( 68CYD$WC2+5[R/)Z=K2)<ZNANQWS<BW&OFT&?ENAWSS1E:ELM09X1 K
M?8FX(Q+I2"C2#@O&N%6,4$"^U/X\(]_#:ZVOP$2_M%[02P;'IU +_SWH#W/T
MZ8;@>+JH%G(&JI\E&A'/4TUGR9'6 =BBE!I;&3C0$L!1\1:ACX&.][W0GA%N
M9KA\37#Y%+IDALO;P>5<EW3>ZI(HC+!7!H&88TA%42)5:N\==L0( W")*9C1
MC[$M]17#Y2HY1Y^!;_2O"[IR 9)<U$HD>U!O55=SQ77EY5Y$61+<3!)\6U2<
M*>%&.A81<ZI$G)D2&:49<EP12SU([A0((YRT&%-+DF"I[FKV*&1?ZNO"P*=0
M@#,&W@,&SK5AR:WWI643SZJ.&NF@!=(\*":](2#0UM9YB\LR(^#**;NW35Q]
M!LKN]L6]<)^LTO#-"LBOUEP^8>W):TW;BHK"%;<&8(5DT7<ST8<7U7_C'7.,
M"L1XJ1"WW(#HHR4B2D:.F?6V9"#Z:$LJ^GS\0,_4%;0"GO,L2K(H60%1\A1&
M518EMQ$E<RLJ,L*L%1X9+SCB43JD8F#("B=+IP.A%J^M:]7B:O6RJE^:*/F.
MH35MCLM@M$_=\2:/997&DBWT&RV],UVN%OI[WZ[5U6.D1+S&]Z]2C/4Y;$#Y
M$$:#_O%AU2NBJ0;%%],9A\+XH_%PE&J$Y<#JZ@96+R[ZME#DXE>@:(H?A(T9
M/;/:>S.UERUZ4+#1VGAC$+$&U%Y<"F2YT,@1IS'CEK-2ILS#'#G(L=,,<_>[
M43K#W /#W-RZIXXR3)U!FG*=K'N"M"8,8284IAKL>Y;:ULGE$K\9YYYKA/0Y
MJ*J_]'OU=]A. (BP#Z:;YN(6CUW:9Q',JY[I.9B_C<' ] Y"0O.< 'Y#..>+
M6BMSG@+I2L1)2GG!A")%F$>&:JY+[$5TN<[/"XOM92A<'?WU-F&J#(CW#HAS
M_99'P$!+(O)8><2#56#&1X*4*IGFRGFCRK5UVM)8/*R&^^*1,#MC;S:%[SPL
M[BI6X5$Z$F7GQ".DLUWEMZA@1.&WZDO(?3CNB.]B4>%-5=UD:252P.&(RY(C
MPP1'4F%* .@E:,2I15&K+'EV8617;4;#)^M0E-'P@=!PKNU:!I(L,HX8$0KQ
M4GNDF07SWU&A&(M"&P)HR%OE!5V),QH^M;K[DAVZ9]1='V*- $4G04#NR/GR
M]=]W,YIGU+\[ZK\[6=2!"3:2EQ2C6$:+N/<:62T,*G&PV+J O4B]Z%N8+Y=(
MRCZ.[.U]Y8#X-"IP!L3[!L2Y&NRMI]33@#PN">*$"V19RG'PAEKM2J^$3H H
MQ0.G-;QX0,Q.WQMJP;TOH<E: J6W^*OZ#(/-+M]GK/)>'<^;DSL#^@T!_4QU
M^!@\=@I4VN@ R[D(#EEO%6*4I&RU( SF=13O@G;+V:V1G;RO'/^>+)\AX]]=
M\&_!KVLHDYQ%A D8]YQ1C[3$!DEIC21".NGK+ :N'MC"?_'XMTINW6>@SS8S
M>-G/W)_SU6BZ"ZV9<Q>[V^#]0ME[A[>.#O9II%P:$I GWH#.RSE2HK0H!A $
M'$MG(V ^ \Q_X#UH+]Z)D;VZSP0)'UWEO=EVAHR!]^?$??MU:_.MV-=2$T)\
M0!;^03SZB$Q@&A%G@N?>":Q]WL^PXOKO"RY;?[7^FQM^KKC2>QU4SQWN[JS-
M[K[?YY38,O6>QZ"^(LZ)159YCY@5E-. 0QG9VKK.2;K9?_LZ &[%==F,>G?S
MV4[T5\6$(UX'Y*( V&-@O^M("?+:"5\R57+#'U-_??'XE_VW-YK!I4KT"[7N
M5J\<_?+\KM9LKF(!X567@ROJW6X<.&=E8A:'MS8"-O:C#D%+*9!A-*8VUQYI
MHS0J@R*>IV+"1JZM"]PBA*R2/_M%-25< 4]WEB)9BKR:;)@L1>Y%BLP381*9
M%/8<1>I3(B"/R'C#P)X*C%#K/78,I AIZ?*!>WJ]8BF2B]#GL:Q,O>X7;)S/
MTJ>J6HPD^SP,6T4O+%5#7 &E:G)F\BK@J\+WQZEZ8U:Y;BD9KC>C+T A>[*D
MM:R*W4P5.]-A&G,B<8D=PMQ;Q(U(W54Y1]I+9EP0@1F_MBY;C*[4)KO[66^K
M!V'9VL^":047RLH)IM5T%,RZU2U(I]RX[C8":J%Q7322&B41KTO;DU(@PYU%
M@H)2P8.@P:5B2&5+T&6/\U.G#KXB,55;A3^.#'S#>DV'M BKWMC4A/C7C[[Z
MLOZO^D=SDQW\N#Y[P-F3E\JXBX=S]ANN_>G?F<).U0MH:F#3&@ WAD4_%IO!
MA:X-@V8.&&D52:]M%2>A.#2^B 'H:CK)OBOZQ_ K3,)!T>D/AX4S@\$I@,J)
M&?AA 3A1C/I%^'I<#< J/(0//3B$9S&9WO(_-T X:KEF6G)+G. 4X,UX32RH
M<9($3"B_1/,6-T"XG>F7_ 8?\LOB=\S K7RFX/;I[T/LNG_US$<]WNE^ZL*U
M7[>/'-_9W6+;1^]/MK_!,S?W3CY]W#Z"<9SN[!Y^WNYNX90ILK7Y;M]R:3%G
M"@EG :5 G48Z"H5*"S]=")1CNK;.2'NY-'$!7-I)Q#4]?R.*>\LD%5(8$QT/
MGEG-N6":Q^B<LU1GBC\<Q3_OZU($H6R)M'84\: T4EH)1#%E92PUV+YV;9T0
MW5Z62#.2PQH?CLPH?!\H1H=F5-AP4/46\ +^@->I=O$Q%$#</F#/EW C'G)$
M:>Y%C DIRD"LQTH(PV)9!@U2]QYX"/2A7T MJD:+_+/1!40?O6HF@O'NJ](2
M3XP";:;$B-N2(B. B;1EA%+N",%A;1VWEP,@BRPTE3:#, QFX YK)/'A2^CT
MC^OZ)*Z>_[,<!;+JL()KET5/PT\W9B5N0;$.)2%&. ZZM'%,*B>#<YI)R>]#
M &56NI"53K>/WNV7UA&A@T8A:(ZXIAS94C(4&(DJ>(\#C6OKE+:773B+O/0+
MJ*XPL;W*W(R=&H"JF:8WP:=:Z2L\P%N[> ?B#;39=&2B),&%YOAXT/\*A!Z%
MSNF->"TFAZ+$\&FZY#)$PUC)K<'41+ $0IE%W\.PVL'I]B9\R3=W"I;<R?;N
MWGZ)):92:V0!K5(ND$ J6H&L,I1BIZE/Y5PD8>WEK:V+? ?'T9_M/]J72L(^
M&%?#FA5OSS9&<%\*(B2/P#:B- "Q*F@2.=<:_LH0]2A\ __N^V"]\=&CH((%
MA1DX2*6=)"(H[ZTHF?,8U"?^'=$W8QMGCJL1R,#S#',U+$WEG"GBN-.IN^@V
MITVGTS\Q/0>G#DS5&X*5=@AP.']?2K UH]&@LN-1&+:+Q;UBQ24F[;.T=W\?
M#X9CTZO-U#]"L\28HO5*9(HE(L#4 ,"/PJ '!/C0U(<H?NG[D$X2K<I686#I
M@NSPP;>*\:CJ5-^:>88+^N/!!8L^-&N]$37#HFM.0?LMAF-[!&-(8S&]WCC1
MN^H"W=.SADD=3D-) QBE)YO>:3&L#GI5K%SZ@C@>C4'5<8>I'T]]>7IT_Z0'
MC')8'0,%!F.7+FD7NS6U+WA'&@@(QG%G-'O=G*D20W[O2XX'57^0/F!A&NKW
MG4W>-K4+,<W;I=Z&P@PFAD/SJ<>#\*7JCX=GQNN!%!=3KKW$B%,6[)H!V!FU
MPTHO>YU6C4&3[>-< MB$TF<"[(4]!6YH%C50P\ 4]6WCE#U-&F\8'O8[OL$(
M4T_[<7]8*RE%=PQKOAM",KK@L35$-!V=@"%JFZU6A6SHA0BZ4#4$KG!]X+5O
MP3?D[%:]JCON+KP'+CKWEOK-<+B;WM"I/B>!!L=Z@#,UD]<L#V^#K_;%^!CN
M"%]A$GL-N]G3F@%!'G: P9/?$!Y>?^AX=-@?P$>VTG1TQLF-F+BVWQE/^30Q
MS"!TX#MJ@1I TA4P>\E=?= \'>;*A<2^K<*:(5S6;_A]%-QA+WDY87H&]0)J
M$&#Z4>UB!U;T('1AU/4:F+O!:P*- 54'Z9/.3,6PYN;CI'/VTI@F?#VZ<%W
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MJ:;'5^<$(5%9 /['A7[3=(:% E(5"@RJQA$#6OO<"<$.V[+=S"F"AJ A:!*
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M$"H."0R/F$?O3*MGV^A3T*>@3Y%HB.^S3W$]OFS7LVS#HJ;O$\I<AS!/M^Q
M"XGK53ZE6<OG/FDM'_J47?B4H+62-V1$#R-5-SU/-4/+5:E.3)7Z@1]YEF93
MQSAZ9WD]RUM<R8L^9;L;^^]3-GUWN:!LQ'):0CL!LJ(L%)J&"OLQXLMZ%O)#
M4U!UB=9V[[,OV&4>Y*+IZ%/>SR=I^+'N9;3XFUE\:VX;:XO9D1^:*CAT?L!R
MR%1?"PTP^PYCGA]%@4_%KBV$V-NW^(^<6;):J,?KAIV41J 5W+_(/5K![JQ@
MZXA?YD!' >\--<I4,S!-U34,JEK4)TZ@V\P-*BOHVHM[5Z$51"N(5G"GL6:T
M@MU9P5E$.3)UG<*H4DD4.JII&([J0@^JCJ691-.MT-?THW>ZWC.TQ<-FT0JB
M%40KN-/H*%K![JQ@Z\A3TP>'99FJ%426:A+#5CW'=%3-"BS3TQ@%=@A6T.Z9
M)EI!.:.>+Z<>_BP-LB%3^#9'K^JHYVO%9RF+XG)+T<]M'M<AG>5?><#U,P9#
MJWZ_HC]JD_^^ZG(T_!L9_K/;=BA4LP,P[I&FND'$5#/T3=73"54#0EW=L0@U
M0AX$T'K0<_*>=BV[Q=J'6@JTE-NUE+L,F**E[,I2SL*EANZZ%K4]E3K$!8K,
M/-77F:$:1..[_-/(-QP1*#")AY82+25:RL=:RET&5=%2=F4I9R%5S=0CW:6F
M&GJZI9I:9*A^Z)EJQ,+(H R<'=&!4Y*>:YMH*=%2HJ5\OKAK 4C!3V@QG\%B
MML*ONN]'EN^K)+"!6_H:Z/'():I+ ^K[+H'/#+"89L_0</GU/@1C#[D$]9R5
M2ER%8%\E65$L>&S,K^UQQ2GT;F7A/T/7HE'?S*C_:(=6F:Y1QE<]LS!P5%.W
MJ$IM8JBN93K4<4TMU RQ5DUW%@,&F%/#R@*T?#L-FJ+E>YKE^])**FF6I3FV
M:NFVJ9IVX*G0;X9J!)H;V=3U78<=O7.,'LQAM'QH^=#R/6\0%"W?TRS?+/3)
M0ETG#F&JKQN!"OS<5=U0\]3( *]E6\#8K>#HG>WT#%M'RX>6[\58ODWR/\\2
MUD0;^#0;. MF4O!;KNZ$JN::D6J:NJYZ7D34 %B[JQDFC',?=*_>,]U%&]AE
M^N?PS1^6D3X!S_>TB -EQ')%'-^MT"%<5!9O]B2EAJW!UF!KMGX>W4ZS/_H>
MF,T'TS_;!^Y1AQ/(A6*7>W1MR'/6@DU2&;%*17QE^25WY-TFS_2[0N$CS5-
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M-P3V9'P]+DK%$^[!11:(+% .%)$%=BADY^8X HH44+[.10JX]Q30XS^;!E!
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M*Q8,4GCD]:0W6U[_^_B?L7(R&L&'ROLX&PUH/J0!&PL "ZX<>\KG,NPC.>R
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MXQ-7^;5_V3_M3[TX,2SM05?O:3:Z>FP-NGI93<8!N'IYP"3:.C6"B.)J%*_
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M%GO6/%QS__I9.('_#<IA\N[_ U!+ P04    " !*BEM0X#MSST,8  "L# $
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M&A$7($QDW8.F+FP(BGQ?I&\A<Y$]5KLCKNV8#19+BZPP'KM@#48>U>;@>8^
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MX98@.T(:E3CF;R$FVM=V >6EC%O![VG.,BJ$J5QF'U4H36+'S3>VBCZ]9%O
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MB]%5 L)'10B%-)M1/$,NWCQ0&QVCW5T-9"F(E> 2/'YI)0A)*C&:R@;1@U2
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M.1$9C42SQH $GRT)VB@E& .,+MI$\@\3UR>WO+))J:Z;:JAY#M/A%Y3(%]C
MLHHV2I<<<<PB14HG8@,PDBE5Z$UZ!K()6NXCJD_^=V645--%39OR!=#LH6/T
M',+\BI;L=$R*1X) 1;AFH9%)E1&XR+6//CAH=#>VB9Q=$*$?)R(JR+]%%#8P
M*0JI0B8*@L'72D8LQZ@PL!RIIMY)UCH3H$%0J05&R%)%D@5*5 (Z_B%'083&
M6-I+1C5K$G,=9N1.$&_MI?=[;OL/$7@KF_9Z,HXK<J(R8#+-N)A<659E[P6/
MY/CD1.+.1]/D$F\K13T-LCK!H([XZT17#WOR&4VW8S&1)#AR&@J3T3J"*"TN
M?J+,WHF[MT13CS5Z.DC7#81;T>%=7K(N#\,_^&]KS+X&]+-LL"!]N6S-&.,G
MHXB'X(C'V"T8W*X%-+GJ>H"NG@9'G4Q!3554P\>;SS#U!:ROP,^N'?'+-3OE
M>4*_"UWO&"DZ=!+ME$>>2=:!039&VC:9/P]2UM/0J!-&ZJJC'DK*Y=HZ7&_H
M<3('325ZXUPA:B7ZY0$=?L)D"(%*EZEJ<C6QG:2>!DC=<%%' ?6.[F<SP"V-
MX:X5E++$0% EV"LGQ#D1S1,3,6DE3)-,F>7KZS!QY9W31)5T@A/J2VX=HXD$
MFQTQ/"(7*5F:73M>>A@)':#C[^X6#I9P.P=H25/9<*7SGN."(9YK7) 2/*Y%
M'8G(7@43L["VB<:WD]2G"*B"^BO)OAH67H[G?ORQQ&+7A)Q]BZ.+4OKUU\DD
M?1V.1@,IK8P\4Z(80\I20H:-%40'&:.-#*/X)H<]NQ#7IZBI CZJZZ,:4J[?
M[I3/&*D%(C1U&+0%35S >-TF&[,'%EW0+="PC\:/%0A5T/A!<JUTMSPY/X=I
M'/K1JV&$\>PJ+)<(HBS*$0R/FLAL)%JB4I/I3(S*:*] [':#O/D%?0I3.FBP
MF@RKK=&WTPE&2_/+MR,_GC\=IY(2]KE4T93]Q5(; 8,APABH4GAAB*,(M\"U
MM,8!>LU-#K?O(ZI/@4F%M5Q-_HT.,Q;8?)-_FRUWEP&8$)T5F6B:!))4+J6L
M4R0I"I3*Q-'TM#_(N$/5+I@PCP<3]310]^QBY5_<1,W,*Q&=SH0J@4PR0TDH
M3J@!&@W2B00V\?TW4K,+".PC D%GB5<^I[@*0$723C*+_H;7N$U1),8##82B
MKI)-CDK;),'CGA#_@ L]/_M4RD3Q/\7B?O&C1>'H_)F?3B]QY2WK:20&6%(H
M19!CC+651],;,=S2@I8&$IP)WR;S:1?J^G?*<0A"OKOJJZZ8>B6<GR;3^0>8
MGK\<?X'9LM1XP'7$P,IYXL!R=,$9Q:\4QN%"I)B2T,ZU*>G=0$S_#CYJ(**S
MV.M$/C=O?SG^^_!WA.)U1H)T*46M2/3HK:,7GXDUZ*I!,)0:FIB[:Q"WQ#Y;
M7]&_$XLNBJTHSII9](N,_G<0 8U.& 'ZWU<40?!62,U(=#PCD\ZAQV4B<:4#
M4;+*,Y^;['CW$-6_(XT::[V:&BJ>=G[!=T^FER4>"SH8Q:@BU'&$IE>&>.26
M)/PT<5".TR;Q\#H1_3L)J:'X@\7<(*GY-E<1I V>!1)%P'!+&D<"%99XQ:4Q
ME(GL1 N=;Z&G?\<?-=1?0_@5E_SJH@76[-# E>I%AP241%HBC?;$JF@)9\P(
M%R)/LLDM[49J^G?@4<<(=!5\B_..:\Z<#3)IC-ZA'+9SI8G58 BRJVWDPAO)
M&A]V[&$#CGO244/['45^1_7_\O-=X;S"[ROW_GOK"YF?8#[$]]PFI&,CP-M/
M;M@5\!X6:K9,?/\!__WU[/6']V]>O'E[]N[IAY?XTZXBV_+4NN+:A?1*W11?
M3\:3J[/?I3$\^_:YW! -LG<A1(JA$!5 I' :%U;&H#>KK)3(4K7IDK&5HLYW
MPWXX+ETEWHS7P_J0TZ(O"7I^);F?E[H7 Y* I=8EIC,Z!$TNBC=1TZ<#MCK(
M^.XBN;,2JL995^<!A;V7XSE,\9.!"XY& %IN.I :#Y[XF!PQ5#I%+5/.-ZEB
MWT90GP[9VJ"BBBIJIALMWG[%&8\N<!,<T2%YY(Q:= >]) :<3@JAJ4*3@IL[
M=.QY)$<>)0X.EWQ=1WP[?X(ER4!08A:VRD5'/%6"&&L%PM%ZPYH<S=U/5I\.
MY]I@HZ):JD'E-<QONE4--.28P7#"M#-HK(0B&#]: BS@+A8DC[:)*W&+BFI'
M$2O!_@)CR,/Y0!?>2ISE6%&=-@R5F#,Q,F;E4Q2F3=+M%GKV])0:&\.#8;#U
M/**#]"N?2A6>7B#+R^*X"UQXJV21R7CV"^3)%-8.47X=CB?3X?SRRI _':?;
M3UGV__H5YI\F:=T#](%&%E@F-!MD,(A(@K*)4!Z$4=DX:IO4LQV1QUZY<941
MVS^0/,I58+RS(7A/(FY@N(G)C QF39S71CA(3.2&)[XG6 4=<@77\%O$P@,%
MHA !B%^47;"1$:ZCCYGEP&.3"Y,-M/0I@N\K<K<F'QZHTGKNW%;ODCN:P-!(
MN$@!'5?@Q):RAE#Z9WD',LLFU["=_/UC;2:/!6=UU%L_ZWD-]B()Z[FER)0L
M5QHJ$<],)MY84-)2IV*3]+\'+=G^[+V#+S"^@"M(W.TK=ETP5.Y?\/]2Z?.;
M6?!<0B39"T9DBI1XB<I(+CG#K5.9-JGA.H#6/AGZKDCZOL-N6]757T+/)K/%
M$);5@IX-+,BHF:(D*U.N\9DO)@)(9 *_%HIJ%YHNI+L4[6FPVP:LM0%31P_U
MJ@"O+QF>#V>?)[/ALB/FW;+%@7994ZLPGI"^U$ %=#)0G@1BSD%8:3-O8FYV
MI*]/.9BU$=-"14<P*TI$)"9+D@);%$-$9)D;X@QU$:A7D)I<#>UH5@ZH2L#G
M/1].(<Y_]>B*#?UH($VPP7I)6.%,&@C$4LN)DC*!*ZTO6)-CS.])Z>4>VPD3
MW[<9ZR3^BMWF9O,WN53Y+@9BP?3+,,+L_624GIZ7AL+_7(AHP"QX[YPE/$JD
MS1E5LN$5T3XQE9,'#-%:0>-A\OH4$[6#2V4U51R7,0-\3"FE>8[^XVBRJ"F]
MBK"<IN I[A!9QI))#8;8&!P!%Z+C02O3)LWB7JIZN<%6!4P]I=1SSF",G(Z0
MHJ?I?#@>SN;311KN%5$4^<U!HK-H3(GP%XUH2_<]:;)R40I)FVRQ#]#5IPO6
M-EBIJ9@CI4:N)\H]>_/KVW=G?SM[_?[EW\]>OL9OSVHF^VUZ?+NLOP>9J93^
MMV'PTO70)9 Y.:44@5)%++.0&+KQ3$R*3!H%*H16HV6WT53WOCY+C?LA]81E
M7ZZ]4BGII+%,E<H&P#HJCWU??UH?MQ8:OCMX/5CL=9-ZMHP9>_K%#T<E\?_%
M9/K>C^ ]Q(OI<CAL^J^+Y<GS\@3['<21G\V&>1B7.KK^^<VL,FECRA ML3R5
M(0DJH*#*: VOC4J+CFEM+J..Q6&?W.Q6B.TG7(ZR&I KU-QX61 1+S],_7CF
MXX+\<5I\-[K#S#4OZ&3(R TER11>%!4D* =$J(QQK$VBU>E($W;Z%!V< N='
M L)10+U])99+CJ=OGKU<+>8W^68Y7[.3,TB6J2/&,8U>-4CBA=7$:^:L*J/7
M9+NF,RTXVC.8:7L9<0IL'P\/QXZ$WKQX_^'-LW_[VYM7S\_>O3_[]]]>?OC/
M:G'0QH<WBH(>9J15M=BSI^__]N+5FW]4+1:[>6C#J'$SX;5*Q6!>>N2\G4Z^
M#/%IOUS^-BLM8J\/(Y[BWO!EU3([""VC"80I9XD,N%2\SX8D)TU@UE(I6D56
M.Y+8Z(IQ>6O%!DYK1YFF!%VXB'8+OW(:OT)K)EV";'1L<OU\/UE]2YIN :<=
M+QH/452=KCZO)^/"][-/?OP1=Z2SV7QX7F87O_##Z:+5U)N\>0X)!LTL1:])
MTJ41FY<8,SAAB'(NE]GJ,M]-D=[2].=0"GJ5PM 8/L=35<4+&#\:_A/6TN4*
M]F<%_"@$+I4UT4EB?4"77.A,G$F4:' 212),2$VN[NZEJE\E;<<Q2/745+$1
M#?K(<;@0$GX]@E60=^M2D0H9"G\8R:52HQL%.KU!$6U#HI93&]HT8=R%N#Y=
MSAP)1M5UUJA@8ELB+_7:>A^0(%L2>T 9XKACQ$D%,@E*@VWB(54KU5$_F%VJ
MK[:J ^>7^%X#]YN,#MVR=QO"_NT4SH<7Y[-;N>)1688+@%#/&9%*>.+*S&(;
M68RZM"T.3:*0P\C=L\W6#X&Y(RBV'@AOD?AB./;CN'8%?TWS0',JM*>)L/*/
M5*P4.>M % /<SXWA5K7I5KPC@7WJY'4LG+7079UP\#9IWPUJ0.H6YYAG<3*>
MG _C*L#@,>M(M2?:<XINH@%B*42BC)'>1N[ W-D]M\2"![V^3]W CA$'MM=1
MQ8[1?@J_>)1!.?E&ZE:.( U))$L)T\DN1WAYJP7AP0N'O"O5IK!F,SF[X,?]
M&/BIJ)>:#OJTC'EX#LO_OAQ_-_ +N=4L^. I$!.4)S)9AS$I1A&@#62-_TMU
MHWE:.U"WTTDF_<&\I?IZJ[.%O9M<^E'A[AW$(OOTV^=RHS;YO+27K^'KJLDR
MB@)E-,8O(Q1/;I!Y-,"$)!D,6P["#!*W6ZD2]8%G_=TQ^99M[& 2=@+2T5JN
M'6$O.XZRZE[J;Q! D=.+T>3K^[F?+\D3E-F0%"/4((TR\U*-E!@)F7FF(*O$
MFO1.V)G"G:!VQ 8@QS!9;=37<"?\OAW\P)HH0SG,EU*6P0] B>.ELY2V(@4,
M"%R;A/1=B-L)4S_:"7IUK37$TU67^<)SF91E.#*I %T\J:P@P8J &W76)CB6
M)6^24'TO53LAZ&BY0"=#T*%Z.H(I>NLO"Z++V7Z,TPM(MX:3@Y'&2D:XRE#:
MW@5B(0L2HTTI>.,@']DXW4?N3F [UBB)DUNK:HIM:K\V-<A/3%J>,R? ;!F7
MD03Q"87"00-5U"O.CX2Z@V<5L!_M++V%[FK-L;I+V:;C,HSHG.7>$YZ2P[A5
M O(>,D&_CSEGLPEZM_26G5ZW$T1^D%/P1DIH:'66J;O+D0SK1M%)X8UF@205
M%O.8/ 8)61/(-&KN5*1M1M_M3.%.L/I!CL;;JJ_FN.D\G"\JSU*6-.+>23+B
MO%3')F(]:"(X\XKQ)$ T&0I_0\).^/C!CKX/5$#-)LV;V+R^!5QCTR9M4D#2
MRNP8!&@L1US2$PV,Z2!820T]8M[R!A*[)PE^]I>+6_0W^=5D_+%,N7P.83XP
MAC/C?"3H'2#K5AA<FZ7Q?HY&208QI28->+<1]!ARE;M"Z/O4P K*J6DX(T!:
MI .]GLSA*EX9Z$ Q0$Z*,.M=J>YRQ(8@B>%2*:NC;]0*?!M!?2I(/1)2JNBF
M'E*N45O0^G(VNT!F89%=,4@4'&/2$>>"P9TC:.*2L43IJ%AP3J8VC5_NH>DQ
M9!U7!TPE%36Q+E?DO,G_\-.I7R3B!)TT%^@?+,8P"HVNHN"4X'?,^Y(-[9K<
M/M]/UB/(,VYI:3KJJ<YIPMN+:?R$8<:B]N(+3.>E6^ ODW'Z&Z2/, @J,.E%
M)(R'0$H70F(QMB"@LJ9!)A'LG6O +<<(][_G,60(UX)";;$WL2$+,C9QK$7T
MN /B9AAU&9UA-;&V1)Z.:R3*@LY-'-M=B.O3:-T3V),J.JONQ;R83+<21I.2
M-H,G-)4)%$(!&KZ"=0=:!N5C;A,E[4#;GFF]C]HBM5)9$\OT?CZ)O[]9Y-?,
MSKZ5S%&4Q<"I[#73C&@3D"RN)7%EJ@GC/-J074"LMS9+&RE[!,F]+6U2=VU5
M-TCO8%2J3C],/OAOI0_[I\FH=%\O'2HV9Y4*JEP":D@.FA-9K@VM5Y1X&H2*
M3B<(3:W4O@3OF0_\0YFNILIML3>^@\]KKN#Y^62\6#(#$;50KGB 1C*DR^@2
M$TB2/43*!4AKFXQ(>9BT1Y$LW'!KK*&QUDBZ#BC1T#(A/.[/^#]ENV;$Q\ (
M;M16&*9L-$WJU!^@:]\\X1\90P?IJE+POZ+HPV13XX6_H>V$Z>RN&"X'S#HI
MLO?$*"Y0"#83GW0B-E@C(HU4P(.-?3J\?]_,WT<-GF/IJ?7]X++@]+8\("#(
M@T."K"RY,QE#4B,3;L4Y+.JY*&V2?[ [B54#ET7_L^]'<G 69<J6J,QRZ<G&
MB&,,B %J94I4*=?\^F<S:7WJI=L(5?>&+MWU5?>(-D^FWQ5+KA*-%%! %T,0
M91WZ'M%'XE0946",C]$RK7/<S2(_^*['T+:H%BQ:B+^ZZ_=A\C3^]\40@YN+
MV7!<)H@M6RL6P:Q^D@:4*N-+ZQ*A2XU_DJ7E!'<8<9<)\#(IYIN8VGV(? P7
MB=4-3BLEMH,9BN0S3.>7;T?HM99I"?CI8@[&@$F><JG)-DZA((SR!!T02F)T
M+AF/9+(VMXP[D]BK3JVG@E@=!;8#V/M/D^F\).O<;E)B,I-9$O"E#M=S1;P4
MH?BR,=DDDF--<N1WHNXQ7%\VAU5GM;6Y+EAV'=Y$FPO> L7X*[N$YI0A;<YJ
M1I+G,8'SX.]V@&SE>1^*J1-?9K;WOCOKK0FF?O7S50_KM]/K'$,TI,_\:#1;
M$3V_NQ"4R%(&3VPL!;E*E![NJDRD,U:4P"';-@Y8-[H?07>CEBALK>E* >(:
MQ=M"%$]3AE*[JXH<,("-Q#LTQ"Z5N:-@M;I[G[ M0GSX98_@SK-NA%A9_DV,
MUK/): 1QU9:BY+BN%;$YS400)A 5&0)5.TH<('BM-*STHC"R_>WY/?0]@@9'
M+8U0+<VU\]BWM;=DU'!K%"? RY58P$TZ*(Q?68HTEO:""HYSZM"A,>G)KS*;
M.^XUM-?B0G-]#2QJX#9)@CFAG0^..,]BL:NAM/PRA);$?9!6<MHZA6P7.A_%
MA6<KI+709;U9S:4E/?Y_605?,.A8))',YM-AG$-:'+^-T^T/UG[S+4R'9='<
M+MD\^Q9'%R7M!+]8-+M_Y^=PEC,:\8&QT@:9+(%8FCU1+4KPDHG05$29J!&Z
M2:/FX[+9Z!)Q4RTEQ^V..H=F*>LR/2A($GATA$DKO#-2*WG,(L,'AZ.<>"9E
M?]&^8<QE"PR<XJ([,W3%.#BBH S\%3X3'V@D20'WD+R3K$DRUZ$7W2>>0OGH
M,=H5 Z<HUH[,"RZX)L9B;"I]<B0DPTC*TF8O->C8Y/+FT&+M$T^0?/08[8J!
MAI/X?O&SX6R2WTYAAN):/ Q__KZH9GHYR>^''\>+48/C^5ISS<EH& M(;I&W
MVY"Y3N_K/G^N'KM=1_AUH>14"NB)(OJGD _E@.CHZEB]];3*V,3Z*57QNJ3X
MHI5%6S_WP]'1E?+=^T^KGOO%<4I%O8,O,+Z LM^O_=Y;/YV/83H[D?9V(^JT
M*CU <*?4\Y9;FA,I^ %J3JO9?415:30NNJ;H?;]" Y'NIM^B,SO0.O' .4;[
M'",*2;,D&$ %8JCE0LMDJ,XM(I7[R>H:JMWS]+].2[<OKYD%I2@Q/% B#0K
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M"B1:6@Z8&: _5H9S S/1<D,I[?U&L\;/OI-J_W=='!$_U1;#7R>3]'4X&@U
MJ.3+T!>:2\-\*C)Q)AI"!;,^1Z=2;%(_=T7 3G#[GW@%?9"&6K9-V916^?'C
M%#[Z.2PD,1N6#Y_AY\.TZ'<]&=?.(]WU?8VR2 ]BMVL*[PL_G"X&9_\*?G:Q
MK!DZ1* ;G]-=4 ^3UT( A^?!W_.T-L)HD0>_Z3U+FW0[MWGUX^3GUW^Q,&D8
MT*R*'+OT#VQ 11L5U!1-"]65368<D;!5OY97&%:.Q*K;M1^]')<CG$4_B,K:
MVO_%;13440 M=%*EKF2W![>1:>/*DE>E__M!0EG]97>N-Y%0AZW#MY=;?U^+
MQ19;R/+)-4"^Y4FUF#\&C*\'M"R^W;1==);/[J^H);@#F:I4\W3[[5<OO1QH
MZ:.7I0:"<DZDLHS8E V)4E O:(Q"-;D,W4)/UT!ZRV-71\:#;+.0$321V1@B
M&<O$TF1)X!*,B!2H9D?D=D56GVJ :N#D;NQ<42G53ERVT'23A3<(H!)XEXCQ
M4"[E:&GU)35ACGN1--=1'!,K-Y3UJ9;FB' Y4#4-SV"6=OUFP/,D;R:]QGZU
MUUMJ;5F'LU9IUWH%N$W"%D!<S89\?@$#D;B(!@2)(A0;8B2Q3"<2<[9"1 O"
M-AD]M2N!7<W5KN]YC8+_\!5&7^#7R7C^:3;P3DO%;<$4=40&(X@+,A)6>BD)
M7$BTS=RX0PGNTU[8!'UWK=U1-%MMV]R5VO\$/_WP=3)P,DBM@R*0D#X)UA,O
MJ2"49ZF<C(&+DZ[+%9U]VE)[A;I#]'@:L"%ZH(P:!E4&3(=D2PM]%X@%&Q$=
M5&?.+7C;Y/IL;TK[5.G9/\#MK<N30.[%Y&(Z"!8@TW(_G)4G4B,VO(H)J=0\
M>)E3%$U*6?8EM$]5D+T#W-Z:/ W>AE]@H!--,H,ARB>&@569#L,S_A.C%99!
M@C:3B_8EM$]U@_W#V[Z:/#K>GN8Y3*])Y31Q:T 1EE(JLV,ML:@)$J,'RI/+
MF<$I07>+VC[5W_4*>8?KM%=G*(,[1SNM3E'P/:<X1[G+WK%/4ESB685<9I!I
M3:0M8:7R"$<M@@K2@@/^F$]2MIU86I&0UQQ("C00*260H!1^"\"] $X;.7([
M780\DG.0?;"SXZGO7GHYSC;YVS@-9XLR24AGWR+^ZM/S\MT@&) 6XV&2RNPV
M"6")RR(33WV@B888[O;A.L+2V4;MHSSRZ *P]CIMN$TN9S#,2XKR>Q@/)]/7
MD_EA&1%;GM1]J]N%Q*[I 9O?<7AZR+W/:R62%NDCF]]4(YUDQR>W$E;;=)/-
M[RS=).:7:[D9E\\FYY\GXV*%)GF5!C?^N#X8JKJ .]#02A6UQ-)]?.$(WP3O
M/P%<3=KK-'APZ]-JC S<C=1V(NG0H?RA9[843Y-NY5O?=M-+_YF?P\?)M-N-
M_6$O:BG.G1FL%&T^_8*/+BI\,9F6B1:WQT:MQA!#>C:9S1>IW0/)A>?4NE*Q
MZ]'-"J6+@I,DNB"#3E)2:5JXSOL2VC6P>.!]-Z.:%P/!?QM/P8\* 7_UP_$O
MD"=3^."_#5SP7D.DQ+ER=F-$F4?(&(&H4F#96J.;#.FL0OV>D6W;2M^F0+T;
M@1Q?^=4"XD-)?X7?W9!N@^>+0T:K2BPOP!&7&"6@#3 =0@37Y&RI"O5]"I@?
M!6P/UWTSV-Z0?6>0H07K@#I*3!GI*E,H9PH2",O2*BE5#&U&..Q*8)_R!4X*
MOBH:;%F7N]4'N^I9Z-?:%39Q,N][44LG<V<&*SF96YM EEIO 0#"1X<;9$E8
M"AJ(XSP1$(O$$6!,-G&1[B.JJS7;^NR%X1V88$/R,1"M$_)M+26A^ G&4>^]
M,E::)J4<]Y/5IXN,:HBY:Z4J:J;>WG>S,3^'SU.(PU51/!J7A?S':66K%Y]O
M;ZG*9;0Q(LU&.RAC5TM[&"$(#]S)*%)FQC?9&RLQL*?CUC;@: ;!DZC[)!OI
M52L.O^HL?].]95E4UV13W?6E+3?8@QBOM-G>?1?"]>4XCB[*X-WKWB@J1@@F
M:5*FWA))4R8A,4"_CWFNDU=!-IIW_#!Q7<WIB^$85_:KX9?U=D'+URV-/'4:
M !<IB2FJ98 37,PD<6\A6ZZ]:)(D]1!A?=J JZ/HKA6LJJ5J6_$]5*V9[77S
M/(BE@(Z*TKVP="^G6:$0T(/(I5I2R^2":+*4]B>U5]OK*0%60Y4GV5#QN^D%
M5"JO/^0U+3?-'9FK=?'QW=NNJIQ],#ER <0;RHGDAA'K?:F(]5[P&$)L,_-B
M*T5=C=H9HF%R"8B_!>0WL.R"-4%81Y3@Z$D&H8C37I'HF8L!,/J)38J_'J2L
M3UMB'<3<-5-UE5,S)BW,8O"1839#X?C1"[BAB5'.# 8Y)&6#EC*7OKU*,>(=
M5RIR2"RTN1^XEZQ>'?PW04M%M=2&2CGS+5W_SH<+PJX&C8W36CL 8PU5C@OB
MP5F,G<O5 GY$A&1..,:L-$W:(N].8J^.[UM"J+:Z:L/IW>32C]9XODU9L&4Z
MG?:$:X<"$#03JVT@5"L-3@4!JDGYZ"[$]:F KRF$ZJFHSN#F*V3/)_'W=_#Y
M8AH_E9J.@79&R80PMDR4/B?2$1L]AI,!,DC#K0_Q(6?YOA?TJ8*NKL*KB;6N
M@HOI>@?SB^EX-G Q^BA\),D)@3"+0%P"0P(:)_25'*5W*]X>4.[:P_M4H-90
ML8>*L^F0G"ON#%BF$D;BS)=BWX#_!!T-83:[H),W-C2Y*[N'ICTGGCTB6-16
M2)UEO[D96<#-Q)N424Y4$XFFB'A&%3':)!F<4S+KG1;^P9W>[*/4<261UNOO
MMI@YO)5%D81B-!>:=&DN832Q&3AA/(+5 ";H)D<3]Y.UY]2L1P2/!FHYR5'I
ML\FX%(_='3_4X+3TWC>U/##=G<6N"?D+W^_39(2X7A67'"+"#4_I+IZ'2*O/
M^N&%&EN?U4(,+0HSOG_+^T]^"K_@9I)*B1&,9[[C^(I]7]%"='LP55^B-4H!
M=WAJ"[FU+0'<H*?RR9O/BRP9-))/([X;/ZZ+OOO?T01^>[!57ZB_3,'_GB9?
MQZ4#QF)\RYN+^6R.?X5[3571[O2F%@+>G\7Z8EY,.UJ^O*I0-SRWA0@?(K^^
MP!8QZ3#.5R=131;[ ^]H(<A]V.I>1'U^/EP4%Y9^]M?N8T2W\15\]*.WTTD$
M*(O@P/KHW1]?H_3Y0&:Z2O'E&+\LE3*'.8'K?]Y="EN)J<CEX0[O]P^IRG$+
M%W?M\34\L?L>5U46;7VOM1>MMQ*X_OCL6W&3X1<80QYV*98Y[$55)7DH@Y42
MDU8G+%O>/-#!6>VH)5%)260TF@2G%(DL"NFH\UPU25Z]GZRNAX"KI[^ ,A%P
M]#W7D5-G$J4$D5)::/N,7[%$;  ; V4RLR;--!^@JT_I215Q<_<LL*9VJIT;
MKXAZ/R]S)<?I%?[!!M(8C\HD00FWPA+IHR).(:5!"!,%4AVE; B<^ZGK4[Y2
M>_A4U%1M$+V83%'&XPUL W,N>4H$59E(&P7QBE-"=>DUYGBBN<GMXP-T]2E+
MZ0AVIX9VJD%F&Z,N<PG*>))8#D1JSXE-*1*GN3<A\,Q,DY2DMCOR-FY3LK@B
M54E*+55P*@A4*PT$DLI(J%7*-)E6LH\;<NH*FNXXV;(@:BBEVGIX#AF0JK3R
M#K;2%H0%336QM%P8@N0D@(HD4Q>U,%G'U"2K?C?R^K03MP!. R55!] M_V ;
MA2HYBMZD(]Q0())92X)4FAB.6P&C7"K7)!U@'R+[M#NW!%-UA35,%%B+[^_.
M3&YZB+'GRZH>9'1AM%HQ\A9#PTNW?"F(\[8D!R]&QBA*6."<22=IUDVZR#5R
MEJX?>UOD6][V]"J2+@OH I]\>?/WN*(&+.+RHR83]&H3NLS4$9>1'1T49Z!4
M#+&M<&IP\1A<L7U0>-<(GD[E]2.9VRQL-NLP&S@5)1-689#%!)'9 ?&<16+0
MO$.@-.4VA9%[TOD8?+D&R*NBMCH)NULHO,E7^[L?7<"[(O_90* ;$IW3)8NX
M5%X+%$6$0#2/ G1R@;GTT(:[]UL?@XMV"$;:BK^UY7D]*2['15STLUY)8W,N
M5FE9-W#46N&$(IHZ))UCH.($,.*HB:"5"]8?TQ[M1WV?JL2.:*4:JKB.[3K+
M&4H.!MS:H&\SL3J0? [3V]TEEG^RFD?AD^!9ADABYAF%)SS&TB5#.@FEO!=,
MW$U<WV+7:E&T9YE:Z_8?E8W>2?36=+M$R0PQRL;/G^%_AO-9*<3!=WT:6"8@
MHF>(1MIZC*FC(E9K3RB&[N S1MIW6\[LMV5N?7.?"N*.M6W644-;Q^I3F>/P
M<OS;.,(4@_ER5?)V,ALNTO,&V6@9 A<D*@M$EI%,-JE$O(!RKF>DR[M52![R
M]CUKY1Z9T6FNC]8>UQ6E9V-?4A"OPE&>G8:H)8FV(-OI2*R4FHAL$U428U71
MI)'D7E3VJ43OB!Y4!94="U57!\7X"\O&6R7P6*IH-)I\+65- ZL$2QDR\3[C
M:O BDJ"<139,0%?/ZY":=)+I3GJ?:@!/@+_:RFT-RIL-?%':.*":@J"@2,B>
M$JD-QP5C!1%4)ZTC=TP>,WJ\0]Y.QZ?T,6Z<#=5TO CP9A%@*+%(NYT-HHDJ
M"L:(9IPAI9823[DG246'E HC?=[)SSJ0@)T@\QB/W(^FE=8F:%E3G?[K8CGA
M:3;PV7FI.(* ,XO$:4JL84 <& K14)\T.Z(-NDO?3HCZ 8_2.^GI.)?8:[MO
MI[+VAQY9]4+Z8:(K73M?O>CZW6L%\@-&G?;,.\*#,412+E&9*1/CL@7M$F.^
MB<=Y'U&=-JPUL:X]\H4?3A<'_3= '@2!I(%Q1.: _P@4@D\F$AYC<,&$B"MI
MIRUJYU?VZ1JX&BIN;4QMI%\]N^H.>9MF@ Y,,@XD^EHN9EZ:>@ )3&$@"66P
M-[-&MTD\V(/&/EWN5L=3:YW5\8^W4K>MW39NGT8I%RG)+*,/9ITG00HH<RN<
M#""%UKNU:MK[U7VZYSVJ^:FDC9:(>8D;?;Z'3AL#5]EHDFBQF4X9XA)BW*=D
M4!Z9Y\P[H.:!U_?I?O:8R*FIE<:;V,VLW-E R1B\U@)!+121J'_B718D"2D-
MC3(E%X^W=:U1UJ?FH$?>L [53V/8X'>W!3'@V0N=A"<^EHF$1=-!>$F<4RGE
MZ+6!IK4)#]#7IUO7(T.HFZX: VEY0!FI#A(6#3 -.F N2T1V1*;!@P6C4PI-
M*DSOH:E/#4J/#)C]==(")-<C;08N*V99C,1K5X:=YM(?61@2=3+4"*D5:U(5
MN(F8Z@PN!S4YK2#KB*8]RE)UYCD)IDB<2\EY=(%!DT/,S>3T\<#A8$3<@_E#
M-= .[AON_S0U64O<Z[4.NG23]FBGJ2>1L\2LDPR:;ZQ=;F^/-@RK/5 Z*J<=
M:I8(5M%9Y0TK\R60EL0#L4H)(H1@2AHO!6U29[^+#:G Y)O/4)KSC#^62>O/
M_'1ZF2?3KWZ:9@-PANHL,_HS#AUC&ASQ4HI2@8EA%4 VM$D_ESUH[+5)W1\_
M#ZZ52MIJMV:N[\AO$R=]A,C0AV)"^M+N&85@;2+>8YC.5>0B-YFDO2-]?3RZ
M;0FC"EJJ?ORVI&SK2&'\^KL#'VYDE%H;XK,IX\>RQFW")Z*Y9)R*!$;=,<T/
M'\/M3T8?#W(K@.?(^FEJDJX^6]W/K\9&S,HXZ])&WF^:\#C(PH>8$Y"@&$:
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M\&^_LK_07W^!86Q2?WC^MU]___R:V%__]W_\V[_]^_\@Y/\]__CVEY=-O+J
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MM[[Y:#V2/_QHY/$#MXS8GJ8L <?)8LNTD8E&8JVAA)K@*5 AY?)][@X:MP+
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M3T&'^KKQ$,33U);.2*G1U>PEKF=?IZD^S\9C*'U1LTI1<HX*;7%]95&A0FO
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MNM<T$J=B(M&)%%CT62P'!#[]4OL;$;)1J?U-I+FOK@HW+1]D4LQ3[HD-,W!
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M F7:,RYC23-!D]N7CK>HBTG3S%-/:G3;6=0$W?K2:@]7;4^3)9)Z%9TULL3
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M"-%1DDN^@Y0E']"4)&#-C#5"A$C;5*4X1NHWC0+OGOE-A-MU9.%2G07/K+5
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MFTBP\\.MJ0VRU(O]+_/+071XG4W 23!)E#0)1[QD0 1P1XWDEB_72EQW4/7
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M70ZG$IL(OH(JW ^H@D4!V2B4]#%:(G"/Q8'BD(/3FC#GN%!&NZ"JE(=8#^D
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M4B([+B)52,V"+$):LKEX4;N,2=D%[.GPJ:N:UG!K[SC\!_IR58[VOBZ3._[
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MR+87&MTZ>\L0@>5OM5>:S="7-9)R\[7]>"&.S)>7-,KRJ26V,B4YTMFB$RH
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M7;7U- =V$/6V?1ZOOMW^2#BG__?_^?\!4$L#!!0    ( $J*6U X4.6\"2T
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M*QVP_N(I"6@9+HE$6S3KU(<-X]K4SSUONABLP'W$FW6:[D O]LXP DT"7$B
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M/K0F 9D)5;XK<KPDH%-QL&$]F1AUX]MRM,#R*@*+>4)HQ!<NL.%\IXBR%B3
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MD?*G/:42TZ?)W3 B1;RN9VU*.VW&4A%:QJP>:G=1B')'US>#@P6A/;6%<A[
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ML/E*Q@']Y21I*U/35[84[[SHE)GAQIZ%=_XE,_JE_W,52OKROP!02P,$%
M  @ 2HI;4,=LFI:EM0$ _ L# !0   !L9VYD+3(P,3DQ,C,Q7V<R+FIP9^R[
M>503:=0W6(K(ID1 1$&(LFJCIE4$A9"X XT8EVY1$**B+-(8$9 @(5$0 1$B
MT(I"2U04M!$CLBE@(@2(-&)D438E&XH((1664)!*9<KWS#??.>_Y_IAYS\Q\
M7\]TP9/4@:<J]S[W=^_]_9(GFAZ-"%CTRVZOW<"<.7. U^@/H!$#KKNH8<$
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MH*1=JCU1?3WJJR>8&P7SA*?4C05'(_LYTZL72.K<$/VRAS0[!1DV26D\"*]
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MGV881J>7:C5>]V_^[E3;\TEO16RT_OA*#]7M9L*-#EJ0!KAQMNXWE(WTQVB
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M+"\2P/N<W]3E7-$3(H811+J:Q^!]!/E-I*MDDTT+B:HPO"4HYQF'US2ZGM<
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MXZ,8NU(JJ.4/-@)RP@.N-4K&_;K-07X<7% IOXLM(ZHI@+(R1"C;XN.V_ZZ
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MS:(EMW5]\3[(VG/%NC756S;89\![0Q<Q:YC'/T8SE^/-5D:=D12Q$S8;LHQ
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M+'K7_8 *)7'-IR%2V1FLUG,1<A ?XD-(=)?958HN:0.C-E4-&1?(UPV4>6Z
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MG-E!<W?.@9N_+O"97#/BYI"_%F6M6):@ >\8HR)X9PX6*(#M];"2 E#[GJ
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M3I;15_)[#EZ;(\@_9/G6EA(BLJL-$A<"?%#0RYJN 'HOXAG-, W7?:OPH?Z
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MQSC%RP5GILM:/)<SY7)S!2 .X(] I3,M/C!$7:;7>:(^//56KW[&@K>P-15
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M:(U>6#YK1EG 0A=<D7BX<_@GF2K46L+B)J93T=G[%VJ-%5U[$DU/UX/=*^K
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MW.8Q:.KT(>$65\W:W.CUN=35.0>.6[Z</%(@ ^;$P2J9N\R#;:JS11G>MAA
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M*JC):AJTKMK!ZT$GSH[*IPN^,F^0LIGENJTC]NY%*A;U.AF9) /#\5?C#S
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M62\JP%Z\AU:KK@4+__[P?3&CAK1"*A]>[W-7?9%4U<T)Z:[;-IF]4XDD:E)
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MEN[&)_6W6\3UZ\ ?JE'294%MI--M[1<"TXSEQ_;.TS/[9H1!R:KD?R#MAT;
M/Q IB_ZAL6#Y.F,,UTB?=*7J*C)@<P.,!;K+.,1\JA5EI/W>+JN]^ ;GOTD
MYT#\!]*)_EV(A6>C"V;+ *TFB1_4<C(/,\S+6X109LEC"5:%$:20.?JJ508,
M?3"4H/^C&Q95;?4O?9I*YRSSC2'RKX5ZOW3S>2"FTAU7QW.Y7*+.[J/>3HXL
M-WG@9&)QL_//<1.TK P:*)O=FS2"OH/8^C* S),![QL+?E@=>-%N9G.RC=<%
MO4%26PRZT*^;TQ*BR,3!WH\%6M$JO;M*#I\92J5/\Q"4OG8@^I!U_R]'I0>1
M L9NZ&]'!^U#1Z]( +A*R&I$.QE.M&Y].J)G\YZ&.(MJYV!ZC\U#,W^-D^06
M&A8G13>2OU&TGD><)K(]KV!QDO<,E=9Z>Y(LCC-4-H=NQ%%3/;-:37%\C>V2
M)9AC;#<VD.@4>V2Z)Q'#C;U%:,<&:%#L.I5/1%Y0/>E=0Z13<]4N&QY7/=HP
M\3#2RF92>'\UZ_BSYSQYMK3S3O_J3 C_GE>\WMZY"O%Z\=_/NJY$C]*:;P*J
M>GYX/!.VHHN9JR!=;MY-&A5M_>:NL3Z_/N^@9R)X2 8<_L 6V3I7KL9$4730
MTY2#^SP/#Y5T7=G]<N+LXP'=#0&575[INJNE>[^AZBXGW&R$V<\'/P2^FQDG
M7SJU*F:85TYUHE"Q$-'ERZQ8SZWZZ+\M]5;ZIQ('3"^ED" .4YZAXZYV__=C
MC.^I+0X[.].X61IN,Q(98,QQ!L4ZF!LQ-+.6,;R)74]X]*=]C%4]%W#DN.JC
MH4D#@_FL+'@;6(J%=_*5"UT22XX:B<6BKY)LO&T 5L@ (QGP<0E->(MB*>A!
M%UX1>/84M)MJA>%"IN(64TN?Q+C?E $>;)[:X(8L5UB^67&7P/JV<0(SS' Z
M*V3L2FQV';,VDXWD_FEI9!NL( $HVDCBO=6Y>,46]JM2MC!E1G*R'RK,G,%4
MVD7A;59S_ZI\"?NJPDLDI<0/+TDW*3K"$V,(]I'XF7.#SC]"CZ#GVM6P';NK
M$G6MWJV3 ;G3=X6G\4@.4Q0U?;#=NI7S'=@51EC WU_LUY/A@-$444TBS]D#
MO766?@3TY8A:$>UQ%W9EC>_H]\,[]DI'<G#WNH<H5-'+23]F^.JWVP(,EPE_
M&%,")QP38#(_M11:,+6QCK+S\9#_RD2\ME+4JWUJ =T*U?;[C!<N6)TR>WU1
MU+8G_/M;CCQ[WS]>KOY]Q?=/@_YOF,0?<NJ?,*D#NLB UBP,*)MN]#923K[T
M,WJ7EQTFG]5!/M7Q)9S+/F,.>R2>4#&18B3YH=P'"WJ+\YCAQE?PGX3% M?G
M25 34R2F) ;*)W5.,9=!EV1 -(C5@<M>[L8+A6:<G>ABG?F:68^K=IPYY<!9
M.G["\,79F:*91)^Q<(D_7">L%&@U]TK,8KO)1NA&\8J$F21'&5!E0$<#P)E#
M8@7A<JPC@QV^=],IU@*'5FY)V>X'G-)G?IY?P:'_,JVC*,']:5K'UG8D_EMH
M6=(>K#^3?65 S11;^.N\SM)"S EJ&:^NM3Y]^T7OQ7[\R8\ZIU5_*MLX?GRS
M2Q(^AU\1179,;;5M:6YA]97.+3RWNWN?= NFFQX?(^F]+_E_F1+Y/^.*K,&8
MF%-D__6%N$-ZMT/<'XYQG>XVK*!.;G^\TW_M\85B9'-Q-OH=@PQ/RH"Y^V%S
M_JIJCTV%QN9I9I<OZN\3YA0@^?@"8OD(ET2C\VUTPZ"EG>ZD^3;-L+:59^Y!
M^I#U5SJ/^8G)GP-.UQ9*S5Q#4@H(!5I==FW;14-UO:&3EC]2'U,.P%7=T$U#
M13>"5E-NXL(JU+_3+GT?LP.=IG@*)E'%\&[\PM7ITEG)';Z9/0]KQ8.!#UB$
M)U C6+> --O7M)M83FQ3*\_R3AWJW"1X^])HQI/47E!X108P]= QD-<7Z,/7
M1.>??<F9,: OE5JI_P(%3E6OX7FB4^P)K1K-LSP'VR_;'])$I_$7WYF'[KC
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M#6)^@W5H^X$5V27_$T.#_TYI.__.>2YX^0J?'V5 US,-/&9:H MU:1YY$9S
M52G3#?=/&.Q4XON$-A Z,NW7]YNU#RPMUH"EE3^@I#C\)_=^?',;JEC7@U\N
M]>#+@!N02U:0"D>A'^L'47FTN;!UF>JU%_$545=>V;CM.*.TWH<V;F^^WD_C
M,M+.6WUWV6Y.[S0(;V&-Z@G,>[3*<4&D-=0YU5TCM A2#H*F>IY-]DTQ+L M
M:W&PF?%LC5NZ(P8=W;#AEQ_U"N*6=(_T,9L-T(5[NM@+AN](]R#/"7/=DA82
M-L$=W (9H.2;=OIMK@!W4U\&+*O.=+LD#'_QLY_!98L-PIHOFC.LN$V.4=4
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M]67G5?.H$=,H+=Q\V9]-^+W"*-R@5I$<S]LR7IF6;3@&%VN*9%HE4)E?*S1
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M\UQ7<WCFD2JMQ^,/!B9K;/L?,'$%>.V+I-G(J=C&_DNP8$DMXB;%R<%?8[D
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MD]VQFK]/G-7=2!.)#*"!&A^'KE2]>/JL;B_,W)T0#4ANSF(/CLK(1>:/M;R
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M5K:3BJ>?=2>]"'SQV.)[V^C8C_$7,EM+IKD>0D@8 KSH",58\A+;?#Y.O]F
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MS<NMT@&A#;UHLC%#-1U6'S8:T%@F?"M;^RX]#9QLG+A_E_J9:@M=2CO*BK&
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M=X#QII:-1GH21.7R4N(8N 3UPW'.;C2Y^NX;VE!,_X*N%;0 1::VJZI%,!Q
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MIV8^\@Y%N<Q]N8.()NLR6!3\XK.BE40/R" _EF.&#WOJF^9\E"[ OQ2:#I5
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MOR7*^=9]!D^@BU:L.=M/:O3@ W<,UD.%W:'Y=-0>:HN+('5]:6YISA(OC?;
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M($Z9Y6FO1>"!*MZ[#600U#/V](4IO)(T^"9 +8^86_.V:8?D2?%LA3U2)!W
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M@/PZKGK_2SGFK(@@2[$8UC9L=0MX=[99CJF^!?*6B];B@_[X27F0*M@G7&&
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M ERLB/4"*-V$>P,E\8E2;$EA()I)-.K)N_DU5ZBZ=K^D:4&,2U(C7?9DU^?
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M^\+KQ\[_[%OQB-^F/<KW_303=#J*K<'-IS;359F6;YS*@S77H?AP>"'J$KC
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MK:6>85'>K.6[HJ*%?I"80Q%L._O4LBS*[N?9'.MFVD>&/]/1S3*7##9QN/O
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M@#)%J2@2Y]9:]#1TP7)D2=#+@;^JC!-DE#[=^WZCBQ;W.!A-'= &4/._;'Z
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MV$:)J_.*CUN0@ K'RA;*#P0UU,C*>@UFR_!9L8D'#3UG,0_1;1""L$63-$Q
MBG,LBPF06\<5%^Q\"E?X)'LJ;52K+A^?&/ SZ:KI!5BCQ2R;CRDP:?*GU154
M;/TZ+'PVW8B4-AB4LZJL#"T#AI<"OJ4][ *;*UT5&]3I@!#BO^!)!^39AUY&
M)#,[PXY6?*Z<,\+<:%OP\[$&HQ^.@!5(FLF+O;A >Z J"Z-^RFYB)0"0E\R
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M9E,==M$P^>R/TH=HN>E@"JWFAB@9W3ET?S9L-XZU%ZT40C1V!/".(TD5 [>
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M/8%VUQ)0 SRW6;^7$LHB,;?6;R81_45]8L./8R2JOW>*$Z&]P>SD_0%V98C
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M,80@@S;%?5"4P;+$7 )@4 [ ^G+Z460/YQ 4_Z>*BTV7;PB?+CMDO*WQZ\=
MTI 5AYDDFKB_]:_*&M\\BBDC3J:!^?>5I+Z,-$3?#M7@RG? PR)N*;C<'2'"
MNB]J7P\+5_J'6 S1.JH$<6E''<1?PP0QSMUX0=%1LG.]T=<^P$?0*10+$=UT
M5.M.*RE02OFIR9J]M <QSZT_]*VCQ#5SS;B+X7.XKUJB*)V4<;LTL(3!5J&?
ML'"2B?PX,D]*OPZ>IBU#]L%54L_R0T#;L>#S+(./N9G0EX3;IL"EO)1>P,HZ
M; R%+I@;)NO6^$EIG>XR<JNJK!W>T"IYJNKK"0DBG] C.4;(@?@>LZ*;)*G[
ML0U\6<S+'5>-X9,IYZZI=9P-[:'&!7YF]1W<2> <XD$^7,DVGPM1YL7;K0QL
M.L;M[OHKQN#-@X14YL=_G5<3'C.-X1GY.8P)(A=R#Y'Q4I,>F/WI[0G"#I>L
M$S_.6U"PC;RK=ADQ+>]DW%>*@]C8CMNA2H8$F8FJ _HP!]K-"8T79HZ-W'[*
MB"J6I<P+M!:H,=T:"QS\7\&T,H,C5A<#"E\YW&[\PJYN(YR*J%DB[T9-%6G8
M<G)T 3JW/<X%-I12#S5RR0M\4FP:K86ZK/H\\.94--&YQ6_PC/S@7?>0R/4>
M@76>ACK?0Y[5SM-_<1J2/>&HTGCC+9!"EO#J:(?WCK,9R^)SXQ,.O)9-7\Y;
MP?BRI_*TG[UEE__C9;0;QWCA_H(PC^5YD,=+K]<,LMOZ3KG>;,/ B';/L<"-
M7RK9R,F*>;6L0]@>/0=X<Q:AF)-ZT-LF>B/*-O]XD8!A*BCW-DL8L#*]VV5U
MRN=O+<#]>0&*+_4QCCY3 DK]13]-VYZ_*GJ6NCLX_[3JHIAJ97]P\?+E:AJ/
M->H?XS\3.N)0+3=%"NK(JO4@0=1B&RFW7'C;8Q,T)8M^#'NZ09>>7NZ(;F["
M:P1&#JUF+.\*C(P(W"=97'15U7O\#$&752:$?A"TT<2Y=S,Z!.4&!+Z1WO!/
MV0YV1VN#S;*9)V=6UQ6 WNTI$:>&:(48J.\?&VE\S0A#U6]CR>)ZHQ+G'>U:
M2OY.2BG&$V M8#[\UX138TRJK]AG<+0L/H&J\YM3;L@]"F]@IN>'Z9Z%9$^Y
M!ZO%@(BLF2=W0N;!GG*'\^@&:1H6 B,\R.^E8VQ2B.^?)X;RC!_(K"_'6TQO
MY5MVDZX*QID<UO=%)R>,\>TJ[P=ER8H7!1M4K:^+/Q^CL8LLW5XQ:)]XVD4:
MI:):0IGF<X%_6M7+G)RX&;RIA9SLK$6!Z-'"W\BS$"V<O$Q5&[4P6I&.;F<8
MRDI@=7&AEWCL;H%G2!^ 0]Q;601*;[![E&L&1VJ9XI>3Z!3K>%O^H9'L^==H
M9.R>,7DV!A*P>%J\/9MW@Y!C7LXUK(+H,DH=:L3<;&P@U^24GT,,SXBCV#HV
MWWY/;*D@O'\V-B\W!&4A:T[5G?T>5573J:Z!>P!;HDM N76Y_'NT>3DC2<R)
M+-(7?HO8W8R!></"H@;FB5/^P39=VSJH%V(C)HQ];E0Z4<T]>YU\:>\Q'B_B
M("O2>P?XM Y=F17L+K7LT^.$B$/P%6"VWBU5"VYU[Z!]0:Q4L6+1VN:;A(L[
M0ZE9+H]X?XR5G1MZ"P#7P.)ZSG@H)P:<QLS8%.;&K5.9EBB;4N+B4$R]O4I<
M%TV)<\NS"0#^.5$CA8H\?[8V6+P5$+TU $<.OF1XE7M8P.OZE+AY?!%M=<^Y
M1-^F-Z3-(49ML0U#O?N<X\?>+YG&\))#)5G^*:(&]!%TE.[& MEUX!SG.K ,
M]+H(E!59PS1HF-_BX2@=8+^QMBRTV]505!&C4V[\U;X_."TF$*7&C54<KC'V
M+):OPY;B-*O20SL;CL <LD]UIP.#-?5F_?M6DJ,H7SW%O$/ZK&/^'CE^NNA2
M=C\!VL^#OR/<!$51A,Q?:)FTD9,I%G! +_=6@%W+K%8V%NYK1WKB>KNM7--2
M6H*/9ORTL[^Z)FR=KO:%@!XN[1UF]0FYU$0V'U:]H&4&^\M_8;4<H]Y@[A8)
M5\#Y9:BQ%"@EJ ]?,][#36\[M\23DM()5DYTS%RZ+ZZ)I=P,<-&A3 L[Y*C6
M%I@NWZ7RH:(-F.,:&\ W J6"8Y#92^-<T7.H6Y@L<I);IDY-3567Q&-&SZ4$
M+L3BMV2'V7C4+ ;-%NDI[F2IVE 0)7&8]K/AV8'BP.RRZ,F1:\W+X@:G[W]@
M>#E//T<'APKM^*:W[Z>0*?!MN:[J4)GGC0^;Y18+(T$#GI?"4,R+M&Z?/.%9
M;KP&DCWU[<VX5$'OKEU:O-W5&:DT=B(:!OF;?L"-\D1_<#)[DN1NF(A"H2;9
MD!%]S&@;GZ9I2$GNO^E<MZ'IROI]D>!MNZ=I]99]--@NK+1GB^(YX#VR>+C7
ML>A9M%P;UAD0G]:;ENW,*"HDOPQ94$7?AO'SJZGN/_BL+5G^J>TVFCD9U3<F
M&9)&B;B2\R(P GQ/?@E-E^3Q;S144[*-=[A&16,!=JG+VC:/)3W4++J<E/39
MZ*N=<'K84]6Q5@<L56/5#(E#=I7I,/@5*:;-7.:O?00=DCK=/-(FOU7H[[=3
MB;N^AR/9\_ Q_HGEA'[O&)+Q$N*AM3)0L>.;_ZP_YDZ_@<6%G/&K!.@ 7FZ_
M&4.S>]]8&LI^@:)SRPBP?:D,@13#QW>?><,@ENKIDJC9?2Y9/JN$YR5"1]8K
M+#'&$" W#KR1'0Z(HL#,:(XD5[Z_':XN ;7)1M\2<E+T;'L,"ILR$##M!(TD
MRQQJW&E*F1E@R)A)MJ;@L([3*NSS1#4LPFIPY!C_*MYCG>&ZMXFDWTN,ZK',
M-V ]?&G>/E#_);8ZY*Z^"_M^7YDZ(%4H<1]\:=F8=XH)DHOR@V@%D*DO&19S
M;PFSO21<,3X")!3HTNGBJ,)MA^ =B84#T6DW3=6#SU\U>AW:/Z#HS"^X[F)Z
M\VEE3 SK90,H^C-EJ>(&3Y109 ;7IJ+50:!$GL$H/1%B64S0>CW9Z69W6)I=
M_3:"FMC;TK+*8SOA>V<(&3<]0.;',3%[[1M\C"]QW";;":ONJ=P+!93R.GT\
MFK.)>HR!LM888=;9N,LDP39J\Z@XCKEQ25M<6]7-*Q'5$QH7YF^1*W$7BU8R
M#]:Q;!#K.B9-G+Q7> 0:N_UZ7;-UYR"ON;MSWXT^WZD?+9__0R>W&3FJOEV)
ML\A2)/(D#QBJV*7W8%*3B9EGX2.,=!]CU=)D>PLP5/H\:B]N=O&_E7G]X_.W
MEH;9BI!_O+;Z.O!*\.\-Z HX,O?$V2/,RZTMLIQ<&G0/';<,9I/M!3+_".D,
M!BX'5P[_E_JASYL 1J2]ZB2\=*GLFO1T'B%JJE ?LZZ.%3&;#5-(=B\8X6/4
M4*HZ'%YO%NQC8?XHC>._\$P9<W6<S3LE#K\)#E#B?A3RQY"M'O9*7/_ND'F[
M<?^Z[_OO0P1H7! !3FY&6$I<Z<H^-OK+X;K_N"7[;P,'_]\1;8Z0,L7M&)NB
M]TVCJ[AKP/$G13>>7">#&+"(9SHH<7_^KP$V'.A5RIO50P%0?$?*5^*^LQS$
M4I^J1="_#UC\P\>+KL_)G9,[)W=.[IS<.;G_1;E88HMX@/SO PFH\5%H#+W%
M8POAWPHP./#YSNS\?U6K_WT $/=SM## X YC:";<DD] 7G ?6SS&JYK@_6WD
MZ9S@.<%S@N<$SPG^OR=8 M;D2C%^NNQP##!SD/(/?.-_QOE_3P )?_\X;>?!
MG015WZ=JLI$25_>?1EPP=F/Y-^*SX/\SNC8G>D[TG.@YT?]YX!<AY$94_]:C
MNHSL"C*OSK_62HFCM&2!$<;&;YLNT$=.Y^2]_<#>E^NR-M%\IL')KV,0"=T^
MR0WZAZ/ ?WK^UE6N=6J*5DE$C/25N(W-<+\2=QFOH$QVX-!TX-]?,YT@_/O9
MWG_M.^>>__^>_XX?P0M^Q;R[AU4#O,ME%[C\R72&'S/M7@TG^ ['Q_>5)F:(
M4QHEUUK02\/!AYV,SQ149SI CZ=7@&4'P;<\A?X")>ZF5R0PL_@Z68E[4H3M
MN,@G2MPI<-9*354UK@V.:Q*D*V@2HA*W^Q,&<5;WXM$?'N-Y@]SK0*\%KXV&
M1MU0XDJVE1&0, JR6U^^5(FKOPS >QAA2MR]<PO&9BU%>/@.489-Y8D(A.Y*
M,;EKZY6XY;O1$B5N\C@>79ZR5HG[8H"3HW?@!>CZ*,4M#$1](" FI!^4N$KK
M.4WG-)W3=$[3.4WG-)W3=$[3.4WG-)W3=$[3.4WG-)W3=$[3.4WG-)W3=$[3
M_S--_W[D.B;\VQ_ZS)0I<:&3K$;6(L5[4)2NQ*TDFR+;6P'Q>HAV>W&,7[=3
MN\!+=E\KVI.^;CPMVO2XBRZWYO$CKS\77P>4[?\#4$L#!!0    ( $J*6U"W
MD8_E 68! %#^#@ 5    ;&=N9"TR,#$Y,3(S,5]L86(N>&ULW+U[<]PXEB_X
M_WP*;,_$WNJ(1!4?( GVSLP-6;;[.L)E^]JJ[CM;L9&!I\2I5%*=9*JL^?0+
MD,Q,YHL),$&*-1$S7;)$$N?\0/YP<' >__H_OS\NP+-8%5F^_+<_^3]Z?P)B
MR7*>+>__[4^_W+V'^$__\]__Z9_^]?^"\/^\^?H1O,W9^E$L2W"[$J04'/R>
ME0_@[UP4OP&YRA_!W_/5;]DS@?#?JYMN\Z>757;_4(+ "[S#OZ[^$J4X)"2*
M82"X#Y'G(Y@&!$,O9L)+<.PE'IO=_\6/$,5!PB ./759@E)($$%0DH GDN D
M$/5#%]GRM[_H_Z&D$$ IMRRJ?_[;GQ[*\NDO/_WT^^^___B=KA8_YJO[GP+/
M"W_:7/VGYO+O1]?_'E97^VF:_E3]=7MID9VZ4#W6_^G__/SQ&WL0CP1FRZ(D
M2Z8'*+*_%-4O/^:,E!7F%^4"9Z_0_X*;RZ#^%?0#&/H_?B_XG_[]GP"HX5CE
M"_%52*#_^\O7#V>'3'_25_RT%/=Z9K^(59;S;R59E1\)%0LE??6T\N5)_-N?
MBNSQ:2$VOWM8"7GZL8O5:N^I6LI42^G'6LI_/C?83U>([TC>\EA6!\)5ZGYR
M)6,7II^<B7NG^$$,+W!KF*M%KE^H=TL^UKN['>IJT8>7V-5KD9=D,<)KL1NF
M)?)"_^*C^JD91C^H@TRK<1KJ;HDJOI=BR47-EGN/!AG_MS^IG^;K MX3\C3_
M5N;LMX=\P=5;^NX?ZZQ\^;!DB[5>*;_D*\WE-V6YRNBZ)'0A[O)/N5I'EZ4:
M6#WT_L.R%"M1E/,TC-72AA&,HSB%B(<!Q-*+(%<KF_1\+)'PYD\'=#@72_C+
MMXWHE7Q#"/<G"RP/1=S'53TM7Z_8;DU]7)Q:*-4:J5=5_-.2/(KBB30W* VU
M^5$K_>]OR$*OGH"4@(K[;+E4$H-<@EJ"?_UIA\EHDQA'88H]-74Q#Y0Y$C.N
M#),XAEZ(>9+XB/E1V$SBAA<F.X6G.7*@"50?VRM/W6*BD[$8=@[:"OT/4*LT
M UNE0*,5:*L%RASL*P8VFIV=NISMJ;#09FZ^.D0Z9P,AO;?85"A+4M *IF9
M!;F?_B069;'Y#=2_@6I;41O._^Q8LI^.7NV;U08DLF(7WHWFBI_4DYEX*N'>
M:Z(W7$.B6>9#?A7U&Z(4_!/(5^J1:OMY JPC'G@KI%BME%E OM\4A2B+OY'%
MNMI+W2P6^>^::>:<"NH%.(:)'X8082IA&D4IC$F2J-LQI4S.CZS.BZQ@,+31
M)V]F7;O\_+>" K*1%,A\!7BC$2C)=T JG>Q8V60VS"C7%;CC\.E&6J#$!;6\
M,[!#>2NR.Z*TP,<E"YH,.RK%6>!PR%\VMUY-3A\S0K-%5F:B4/_:_$$19OXH
MYH0'G GI09_&&*(H]F":A!X44GIQX%&:QEN"LN:FKI%[\-/ U+3]DE;B62S7
MY[^8JP"WYJ"K07P%'FK)/*M^L?UK+?<@9&0"U$"$U#GT:Y&2"1X=Q&1T>S]R
M>D^RE68\T1KC9T&*M1K@\_*K8.O52MEI;TB1%;\L<UJ(U;,VY#XLG]:E^K."
M0MU5\>6;E\TS7FX7RFYXFS^2;#G'/ UIHA@M27@$$1,"8J(LL)!)BE@8<"+%
MO#0WN :7V.9++D>PT[3"E1DA 'W9?L\OH!(9_%H+_?_94>3PTVY&KI.:S(%I
M^<IYM.;CT;!UR>3#"SWJ&C#:'!RN'N,-W&_=^4)>])%Q\5F^%;3\4!1K;6G?
MYD59S*4GL:>=J)PPH@QAP2".$@YYJ+:F) E"'GIVAG#':-,S?AMAM4^4*VE!
MUH@+F);7CN>[8#9CZ&NA&X=;-U)JT+2<8",HN.T$S9I4#>!P28==PXU*9 9Z
M'U*0R2W]R..&_^>Z**N'W^4WG&>:ILCB"\F447Q+GK*2+&I?Y&W^^)0OU86?
MY6V^?!:K,E,DI^69QWZ0^@D2D* 0013(1/T42RA%(I&(XD!XGHU=ZD*HJ9F>
M:B'0C)_)K(Y,T9^7J'109-0HH7^G5Q/UX^)%;=BY$(_520';Z0:6>2DLJ<O)
M)(>"IB2-L-IR2 %1$@<P%2*!212CB,<>\[B<JSMH/M5I;@LWI,O@:*%14[FH
MHKG*')0/XO2\MZ98KU6O,,-FJ]C8LS;P<M=21T_/3B&@-0+9$C0ZS9IC/7#;
MGK:68M5JZ6YY=(FSRW74B5RC+K@ND3Q<F9T^^TJ_4[7A*#Z*9[$(?Q:/5*SF
MB0S52LS4RJP8&B(2(8@]@F!,,6))DG I8CO2[AAM>ES\+;M?5BNN^EC;6S-0
M"P]^J,0'X9][NGQ.(!X+'G&:^C!5>RR(4!@I6\CW()6,("_P ^K37CZZZ_ >
MP\1IP'2'I:7CZSJ$1G-9S9JW;P8:P,"OM;1#.*S.8S*(J^G$<*_C)#JO]UGW
M3L<MP^VM/BM[<#7W%4U0ABA$F.C_45Q-$%<&=I3X,L*1I'[@>@-5C3PU"JF$
MJJ,E=BJX-X5KU-W9N]983L>HK40?UVK=0VMLT[0>?'+VYQXF?8S,_0?8$=;B
M?LGG[[Z+%<L*\665,?%5O4WB3BR;A3A,N8Q\1B#'/-5N9&7/8!'#*(DQ%X*G
M$AD9-9<&FAH=_8L?I3]B'T#P+W[B_QA@,RJZB&<W\[A$:6"BV4@)*C%!)2=0
M@EXV:>P XTU>7.4Z&P6XO1&G"* Q-9NB4C.QOKKB5S]HV/7B_:.0J:D6&^XT
MOGXXV^[; UD)G3O(]=Y?+(OJ7?JJO7]%5HIO:C.JQ*KSF_0YH=JKZ@LJ8W0N
M),=!J';NJ>12[]P%I#$B,&0)18D,I(="UR;A-0)/C;HK76"E3.5HW6CCWIB\
M:IK=V:!C3=[0INN7#[<ST)Z]S2'NS6JEOV#]<Y5:L1(Z>U>'6>N#,-#2:5QS
MU@7P8UO!5\D\.>/9Q0STL;F=C-O#5+]A;+46O,H7^2J>U*?WH(0HYGZ,PYA(
M#PKDZ[PY$4#"TQ &021$'/&()JFQF7YFD*GQ_#9<@:^KC"JZRG\3JXH6"CT]
M8+63W<(8/0>Q@>7N +BA.;:6$%0B@J]. ;*PU!T -9*5;@^8G75^ 8E.R_S<
MO>-9Y1>DW[/(+UW;\P@L7XGL?GE;Q4ZPESME*!2$Z7>BN%GRZI^+ZA4ION2+
M3%T@OI=OE/R_S9E@@4B\&/*4)1#AE$,B8P+]E(0)%8$?6![7])5D:KS:* (V
MFH"6[)8G/+TGQ_#\9PS(ASX=.HEVHP4@2]Z&OP"U(N#7YK]:(U"IY/((Z5I8
MG1XP]19FW..G:S$[.IRZ^H']"/66% _Z_W7HPC-9: /KJRC*5<9*9>RJ/ZC1
M]W_1NK(V>#<[M+>B_N^[[TTNL_KA06_DOI)2O)-2L'(>T# .B0@A)S*"B*N?
ML*"1#C5C+ J#0 K%PMM")1<I85SQK:C[3%$7EV3R290@V^R/?^"- G_6QSY,
MJ5K12?6#V"EM1^DCOQYFZ\!T)WW@Q4.K,@/Z?T%+HQG8*5O_4<_[X>_V;JA!
MV/E6?MC@\.<9V$(!-E@ #0:HT7"W[+S.++I<JT;68-0%[G5FYW!5?"4I>NY-
MLF56BH_9LTXS+=6C==A?G1]_\ZC+>OQ7M8"_^ZX=2.*36L#O?A>+9_%SOBP?
MBKD0+$H#G$*41APB'U-(9<@@34(O\5$L"?,L(_BN$FAZ07YMH8&HI9Y5]3 M
M]RG7393A9F4T\(?>L52*P$H3L%-E6ZQC;U;>;69%*P1JC4"MDL,-BQ-HG>Y:
MKI-HW*V+$_2.]B]NGMIS$Z.+(ZG=TM^S\N%V793YHUAM\R^_UN4P&K?\?PD^
M%S%+41)P&- 4JTU(2F :IE1O0E :,,Z#Q.K$U6[XJ?E_&@'!:BNAY1;!#GQ#
M$W\P2(<VT1O!ZWK.&]%GN]1U;:W7@'^]#+B]4=T+-Z=&L9T$XQJUO= Y,DK[
M/:4?M;52T6O?4#F/$Y)&"6<P1HG4I;X32(D?0"8]$E'/DY03&Q_*\1!3\W-4
ME6LW"9-@L9/7CJE.8&G&1M<A-##C[!4K:L1S1RCG57=)&B=&&948SFMY^/%W
M7-GC?/]G4JY7BC7JK>IG^;^R^X?%R\=,;6+Y-UUOHJY!0;YGC^O'.:-IA 2*
MH9<*#R*$$TC4ZP$3M3=,0B&$+GEL>NIO-?34;):-\$T!W"JM]IS#<P8>:R4L
MSKSMYL4@5& PM <FERW0C<?PLP2UZ*"6'>R$!S\/#+-%P,%@<(\4AG#B_7ZH
M85_4L!<[V)NW^T='$0J]H.N,6[![XGC1#+TTW8MQZ/>$'NO$FW61+451W+ Z
MXDR]?-H*S9;WZEU4/Q69>E#U3G[)2_6KC"RT,[0)F;HIWRV5=+64\S 021*&
M$61QH':_)(@@C@,&D0R0G_@1CJAO7CC?M7@V'^-XI?-O\\=''6"NK-"J"4]Q
M51%]YU/*612GG&'(@BB&".,4JG]&4,11D(8XPC06IF7T7W]"AR^D?W(Z>Y34
M=SZ1!I;$*TW-P';&1BO04@OL] )[BH&M9O71YC9NO 1*.VVC?'G5K]'<3GFE
MR1S)BME.*FE-*MM-*FLK. -/VUFM3/BG9E8//TU7ALX V'>:02['&\](&@"E
M/1-JB.?W\[3]LMQYP._(]S=B*62F*RLRZN/8IQ"E6)?#2G5A+,%A1,,D$#0,
M<!#8-QHZ,]HTS1^7G8/.P>QA#PL2^#"- P\BQ@@DB8(Y9)P)/R'$Y[%M*R!G
M(/]1>ON< ]?,S>D KH'-A+:$56'VC8SN')X70'#I]3PWU*BNSPOZ'OH_+UW>
MCWL_Z5*'BM-UR::-:S[%(4<H2&#J^['>G2:0LH!#Q"43B/,D\IC-*>V),:;F
MUMP_YWAJ6DDI+JA*06J+2 MO1PFGH#6C@RL!&Y@**NE (]X !Q\=VKOD@%/#
MC/K]=^AY^.UW77IE1;LW+U6L2%4K^^9[IJPND@K/)\H(H$$(D8<I)('.<$2$
M<@\A(F+>J[K:X4A3XX!*NDU]>RU@WRX%1Y":??5.@!KXV[? J']!M7/Z#U).
M[6BPURFF=D[GLZ74SM[0L\+]*E=F;_GR14UW>;/D.IKW26_TWKS<J2?6S!!'
ME"MZT-6)E%W@<P)3+XW43P'7\;.<!+$-,QB,.36.V(@\ Y70U;'G5NP9T&+W
MX@X3^,U8Q#&H _.) SSMB^*;(^2T.+[!L.,6R3?'X:A8OL6M/0[=U.,?"2M)
M4YDJ0DG$D6*;),*X=E!@I  .>*P;3I. (6(<?;'_[ GR2R6=A0/] "R#@XS^
M$ S/!I5@?4J;'<!@<130'XZ1O/D77PH[]_MI?3L]Z >WC.<$/RWKGA_[S"7]
MS*#C=IJ''3=OJ]2E#\N;QWRM-O0D\J/0YPA*$2"(*$T@#0,?QHP(+U0;II0@
M&YO(5H"I$=B)-KTST"0S9NJ7E=!VMI'UG)@92D,B/3!/GNC2.P-OC_KYSDZG
MF=YTSX&U/=472)?&E;4,HUI:?1$Z-+MZ/Z<?&5:UM]X<UMYJU8A[\[*[9',N
M^#M9\4UG]:)<K>NF2KIR[IV2[?-354GAK^H19?%AV9S;ZSK^7LH#R)#'(,(L
MA&G@A=##"'F>ST6<1G8)F&.);D,*XZ1J5O(I%OBA*LU56+9=&&W*S3AZBM,X
M,+>WRS*VE6[79M0=.4^6;]2J;YOHM+0'3=%WI3]H )B!&@*]*E\(VK%>$<:>
M-I<KR6BRC[H"C3TCARO7Z./W\#I\6NL-Q&?9"H@IYECP*(U$"$5 $HA"E,(T
MPAX,TE!@'B<L28U.0\Z.,#4#OI91'WVV8L=LJA:>A-' *W$M.$.?>FYQN7&(
MBX6;XEI\1G)66.)DY[KHPJ#3@7'RQO'<&%UR[SDS.B_LPVGY,UG^G"\6ZT+-
M_I=5SM>L+!H?F21<IF'L0>F%&"*IZY[$B?IGRB-" Y&BP*@ESL61)L=Q6E:;
M3[<+11-J<X3-T!2GQ01;.<%&T#[NV$[(;%C/$71CL=\9"%WQGP$:W3S8]8 1
M^=! CWU>-+FA9P2<^/V&,>TNR9;WZLE+]2.K;-*FX.-AR=2 L# A7+<?3(6N
M&95 +"(&%5\FDG$2<]_H.*JO %-CTYWPX%M)EEQ9[84NL2&J%LLW/'_2_@A]
MLGORRD]Y"?Y#E)L++6/L;"?/S.\PY)0,3>+B]S;.^\+/1BEKVQ<]I]%]MC*,
M&_K7$Z&CN,"^S^G9D6<[UO;S_>6)DU*H24!>NC$K!46<!SZ,O"129B5'D$08
M02Q9C$@H/1Y%5FUU3$;]0Y!B+3;0<D,OM6R38X2]&;TY1W1@3C, <X &KU8H
M.>TN8S3PN"UB;+ XZO-B=?/4SJK^)HI2E]9K#BY\00*&(ZYL/K5?1DFLV(VD
MBNQ82FD2^UB&R7PI[I5ZAKE28XEN]$&G]0?=5F# <^Q*OLD=51W,^&L?5?68
MQ?]N1U7-B_*'.JHZ/6U_C*.J ]G_FQQ5G9Z1\8ZJSHQOM^!QD<V;%*#W6<'(
MXC\$6;U;\K>*K^=>++B(T@3R4->5B1&%E!(/QM+SL$QY$@@CUT37(%.SM!LY
M02THT))6Q2BTK&8K2B>DW>SO"JB!F;H71L9<:@+"CO>*#?$5@OUXGS__I&ZO
M.4_]<$AUG8\>A99,E-M0B-&U+NW;ZK?%S;I\R%<Z+_B7I7IBU?BKIAP=GU\<
M=^C]F/\N5O5/V6-6SN.4Q8D(0AABRB$*0[59#\(0QLK6Q02G*0^M$GZ'%'9J
M]%.)!ZK%01]ZBDVSZ2>M0 %^^.7;6UU0H.Z4Z,3$=33IUYBUXT_EB*;LR6:X
MM5ZZ1\MQ,_$9J%^"NK-XI=K0!JK;"1C>*'4D[P0,4;?(FQF?CL?LMP+]7>B"
M;8+?/(L5N1>;2(6WV6*M?EN+^'E=%MK%DRWOYQ%-!66^T E;L;9%(TC2-("(
M>XP$%,DPC>=+85BUQW)T.U_'T%5\:O' NJCWL+P6>K<L &4JL'7=9:ZG-\1V
M=F),9.P'%*(JKBV)(DAQD, PC*A:\$./^8%-*?,AYF?$.N?M&2KSJIN]DGL[
M4]E2_4:T)FR<2?*]!(=("IA2/X1($ Q)R".(:!H)$<8B21.[N/@!IVF<\/:-
M H#4&M3S4?S?_XP#/_A_-O,USO2865 #0CZP4;3%NA$=[&+[FN^E)?<,-!JY
M,WUZ(N?2FK$5850#I2<^AS9'W\?8^ZW>+<NL?+GA7#VQ^)*K)R[^W^SI-N=B
M[F%"]=$P],)060M(_42X4,P7,!R**/93LRUH]S!3VSS6DH)&5!V=H84%2EJ@
MQ35W7W4@>]F!Y0:O@<FH+U167JS+2%SAQ^IX^&B>K,L*MGU9!E?WVTN\%;3<
M.<IO\Z6BGE+W+;M3^!8/^8+K J2"K<OL6=RMB.:=M^2E\.>^D)PPB94-Y/L0
MI0F%. XE%#PF*0DQB8E5!['>DDR-2G9K,]L)#,I:8L"5R';&4/\I,C.+1@%^
M8$[2.K3.+F>@I<8,;!4!+4U HPIXVS4CUJ;2U6BZ-)KZ"S.J^70U9H>&U/4/
M[,>FFTK.M_DCS9:5%V'7!>T#U[6;949V72%U;LE*V7M+WNJII/ZFQ.9G*_O,
M9<I3EE ,)69J"QJG$J9>%,)0,"XC'(6>E]HP[RA23XVE-X)6X=!B5^AJ*2R+
M8HPSYV94/KF9')CVM]7U6PK/6DTE05OGIELOV&A=S7Q+;] H/@,'M=!F^\70
MW*T5HTZ7RW5E',%'78-&G8O#]6K<P?OO%'8-G6Z>2;;0$KW/5]^(6ECUS[OD
MCCC$02(IA<(3%"+!.4QYA*%0CTYPDDH669UCVPP^M97F&WL0?+VH#J4_*$ND
M**M#S5M2BOM\9=W!TVH>S'< 0Z [AM&_DWL&MI)#F:]@H60'OU;2#Y-=TP<V
MU]:]\?BC&_2VR)RRX:V?,7+(>A-.V/+)UIO_><A#&7+F0XEBHOB/>9 0[D'?
M#SW"6*C^2^P;ICB7T^9CGDJKE;&#U,_.L2!>1,,TAK'PU38L9 RFB#-(@R02
MB21"RM2V6\L$9OCU^KQ,9F;-5LU7G:N!EU8'"07;E(&]H\E:TPED#5R:A$FD
M!YP5<@+A5PXP=A;P?W&@GG9!8[E_EO][K98]L5J\O%?;LZ7NFOEAJ6S,QTK
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MCW#(@RAF,C1BBR&$FQK);"5M[7WZ5JQT.HEF%MAK3<W I-9S5JS-K2'@<VF
M.95O5)-L"&0/C;1!QG#ANOM%O=OYJM0GYE]6XC%;/\[]Q ]E%##HASKK'ZN=
M,$7$AP@E1.!08AQ;516^-.#4>+9R+V5%L5;XBRI]H@ KL="G/Z#,0?D@P*+I
MS?52I5KD2VW4J$T6T['&2C=]SLK54ZYQZ)V8F#[.O.O@'MN1UY(6-.(.Y< [
M#\QPSKL38[ZBX^X\ MU.NX[[>IX_ZRB=#^J#$_QMU56D-E:K>KVGCS[F4FTC
M<1J$4,9Q")'" F*?,YB@,!2*GV1"K&HAV8LP-=;ZL"&LBH?JRB1:*;#6@5!
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M2193"8G415="%L%4>%*W$^;*&)&$A;Y=K&J?MH'CA(IN)+/CD2U4F 8T\11
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M^\'/ FOL_G8!U_!>[Q92>X0\ SK&1FT"E,0S<%.6JXRNRRH;H,R5A;ARTJ;
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MT@]".#V1<UQ=VTJ$L>ML]\'G1,7M7H_I47QB_\/5//!MVWPGHDR$,8V@\$0
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MHTV/'/[W.M?O?75$5?D.;UBIBZ3]3%:_:<^AL@[!!ZXF)6-D 6YJ=^(/E4[
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M\OEV*;/Y6#NOZ9D==S)/KRZQ?K-61L9*9^C_LE1/;*7IZZC0XKA391-2S**
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M-\CO)+LN>,77Y0]CW6HN/9?$U7$A#?]!6"Z=DQKF$1?+W1JXYXSM2G@ID7+
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MAR^BQ=0HLI5UE[6KMM671E[ #S(:N]'DRWPA=M0[^7$/3.=;_4$' ',WNH4
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ME2*3LA!GL<29D-3M>/ER9],[4OYZL>2'X[%R#\*6IQM>4 M]'M$1\O]MJWR
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M<JGWO"B)"TXH$\PQ;[!EURYS:YS@CJV\=Z"6N,GCNI6YS=?M&$!J/0Z6.^$
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MU)9*O55>\/([G0-:RP>6%FD=W:"UNX[S 5C@-:I.3[>7\0X8*4$CIK\+N&M
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MP@QF<8(PES&)F)/3UR IID9D74F!W(;%)E$2N_'8L"&Q([7@0 =FN$9^6"L
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M7S\DN5(:31$G14IPCAU+,=D,.[5MRD;JI@/JE=Z6=,4)+HJ+LYP$.YX(#^W
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M- ;(P3NI>E"/V8M!QO5LG=+QA0?JY(67%D)HMJ#_*(5L6T&^??Z%_O=RU76
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M=(8@P8+#*&$T9RGC*;=OMKG_[*F142L=N'9PAAZ@9>&C]L=@8-;8J.\367N
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MIO1FD2>0I%E$(I(7>>&4DG)LD*GQRT9&P(R0;CQR%$4[ZK@4FX'98@M++=\
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M&59*I6FJD$-[DIYB] AZ#$Q)M9!@O172H8Q5W\GHIJ/! 1[IO,]. Q-"VND
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MO:8H^I)MW!1%SX@>I2CZ?G[O9'13:DDO)9\WFG5,C]C?'@7=2#V9:1#5F_-
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M.PEU:I2I?:NU?([1A)/X648#KD5EX(^V%@V\DDM^_T#7?PZP;^C$P*L3_>1
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M=7-W=(XW/=_'N?+N'JNZ^ZCG/J%U\%(E]Y$*N ^Q?^@><#I%V\_M$NQNZIO
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M+]? )'ZL'G(.UJ7L3N?K3D-LX>/Q -P(4;,:LUI$\,D70$[G#J\&:K3CAJZ
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MD,584UMO6OE>NPIW?QB!02VQ2RK#!9PMMK#^T!LZ[#DF<$XUK'P!.%HIJ_Y
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M? Z9K^]C^K'A^]7RJ]F@?EAM9'%'GTO_>8SC. X(ARC(8HAPBK3U%'"8IC)
M&(4TD4Z'-TX-,C5>J\*7"RUIM2%Y-/Z7RC6V-&*#QTIN-QH[":\=5UT+VL"$
M5(H%:KG*'']3O\MKX+(+ 9^L<G*<4:FC2]-#?NB\MH<_L"H]OU*WJX7^MU5E
M<=U\7<NZJRE6),@H"V!,4TT&44H@(9S#,,ZDQ)&0B;2R?VP&FQHI['HN\+;
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MB-(@U89!*&&")$(B24D6"#<GUMFQIN?(BH(HWFMZ7<BE*>^Q7&UZM?XY#W-
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M,J*$"L)9GH2N IZ;1(S3%:H>6'86<!/^RBM8(,++"?@MR4Q8\DER&X@!GC#
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M0#9B:1%B/772,I]RE193C]#3R/7S(>&XG\R;<!??P^I&IM#H9!Q-D5A9KH5
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MYZMB^S_/W\]GL0SF1"FNVUINNS@K:1S-7A-*-;H1D#.Q7FN2E-.&>:=IJI(
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MR5_W)'#D^U9C!S%#J*VI</K-?'%SR:T/TQ^0YD08K1$YBF11KDRP,N#=^DS
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ME$9P%47U(I8'*6NR>N 0QF]_/35D^3["=%T^./_LO_[1K4[*8%@4'RZR1_J
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M>2W)M@H3YK;,R*28I]P3&S;,  DJ9Z)5!,><YC2)O6!R^:1QBSL.!Y.=)-O
M7O1N/CLN71B+I*ZR<![MJ&#6$59NGDJI,W':1&*Y<8$JZ[F(-?:AAX@9YPB[
MGONRM\ ;!,UV467*K,P(_9AY+B?UCEAK!0GHR0O&F#6TR@6AA\D9=X/:7\W?
MP,T.,F\ .3=LYM9>>E_N:Z#I=3DH(H4%XM%.8N2760)!@Y95NF#=HZ0MO.RB
MWKO%+WO)>D2P+!<KW&?/9_A)*+S51=FW-^DL=+]\9(*DF)'^C*_0#E/"3; 1
MQ1&UZ)-MQL^_@1/\[BY&'B-@G&;BP^]%@PAX9(!\A+/M&-\7QPM8YSSOLK1=
M0XFZF(-1)"J'$K(2?3T 1IAB6E.'JTCTL3"]4-.;JG&LS3"*G]?6PMCAT_OY
M%S_[;3Z=GB_C^>F'Q3R=Q]6E$=5@)=-)DJ2,)%*AO*R3& =2Y[SUTB5]Y\3U
MD=#IJ:>,!X]*&IW7$._8./G@IU]@.O6?3V#AS^!\U<4R2W?+B4@R6I":)($[
MMDPI$L^\(@'WVLRHUZ9GC_<G'S-.@'T@I PGX+&A\N*?W<7\\OR$*REYL@2"
M0&.KC">!6T5RX%Z*X)CJF:.[\:'C9/D/!(-=A3>VTE_.%[_YU:+[NJ4=A)!)
MR$S6_8RE1-J]2^62A/$1_X]8[M<D\,X'CY,C.9#R]Q'BV #X!%- ]^H2NL;Q
M#)(1D.@U2HT\>$4C43HF)1PH"[:7^F]][#A!R8&4O[L &TAVO.EFW0K>=5_@
M7OOH7R]^\_\]7[PL0^?6#K@,RFGM,FY>TJ(#GEF9Q12(=-2"D-$P5J5MXS-H
M'&>(4;U,;"WUM(V\:\9NK$\(D=N0':ZD8(B$:(@M[2XHRM8@GVA_JMQ:?R:=
MXZ;HJN&E/R[W5EX#V/PXO_#3U<75EG%IW&G6Q8&SA#N/;'@IB7/6$&=3$L[2
MG.\Z1P,UKGV8GF:QMC\&[G:E'4 A#>!J<VN^FQW?8X2AIR#2NE=^0+?!8(CH
M?3F<=90%"\6[JE*D_"A%XQZ*'Q);PRBE 71=#JAY$?_GO%MV:UT50V^HT9KS
M@.I'N4BG*'%22<*%24Q2+I.O<N;Y"#WCS/BKYZ,-(?9&T5->XIJXO(QBA(J>
M:D(%%40JC796Z424"IFQE"TNOD/AZ!9EX^Z#@^B_!Z9V5\;8*8:7BXOERD^W
M5C6!32X+1K(KR9&2)_/>!**9$TJ+8/3=UNJ/99AN?FQ[&-A#7_-!A#>VVG^#
ME0_%XMY,C5_FQ;F3)EI%> 3<6I$E$H3D!)P-C$(YY>]7W/?$0\9U82I"8BC!
MCGT\CG[=YFB79<=C0BL9DJ E%$541[2<EG,&('7RO3)+_8Z_+Y\ZSJ#7.I42
MNXFR!?U?EJ1&EA6-@ECI(I'E7HU7PA-JP*0DLY2]KA7T1\#H9]B[:>RNSG<0
MW\A:_PU#N]/STRWA,7G<R'0F='U2$B2@#3260+0!9.+6\#Y=!WKI_=:31];\
M+GJ;#R'$L;7OO]X@'/>]P&Q01 .4'E:TM*JDF10?1^F(H?O=.I4]M'_SR2-6
M) RA_9V%V$"<^>)/OTA7Y<8N,4899**L]$1&!^BNB$@\"D:#X5'4R>K?HF*<
M^=H5+]_O+.(&\/'P-*<7BT59..OLW*\7U^_YX"_6-^\*Q]=LSU*9]70S/YBH
M5653=3YE(D69?>N5)XP*;;@-P?$JMQ9K,#/RY?[=L=5K;-<!%=T V%^?GDWG
M%P"?5O/XCZ.;%]@EH"$7*A%I 27K?2+!>UV*7[.@%AU#4>5R]J,4C0N[\<%R
M=\;2()IK ()_AV5I=;!>SCDR)D66Q L-&(JD4F*-WF301N!J!@Z^BIF\04,_
MF T^7:;>9KRK?-N!QN4]'^Y<C!:%D+TKJP79"&CP;:#:Y.RBM56.D6Y1,:X5
MVEF7#V-B!\&.G=/=4OX!%MT\'<TN(YEHDDP9_0#+RSC-"(IX'G&!,&6"%YZF
MGF6##W]^$UK?15OS8477E/8__WE9[ZQEF?@;$HFJ>(&NW"PW5A&C%/+#N*6I
MWU2&AS]_W#Q^#>WO)KH&=H1+!VISP*E%<A[0O1$&94'+#%TN1#F:"LK[8+RJ
M4@]ZDXA^EN$[ZC2[LX0;0L=VK:!9R]2P0(1,Y:Q2 4%\XUIQ(06=E0)A:N*C
M!8]A=W4^@HL=9#OVKH'6[O/)_'SI9\7PK0.F6S.Y+QNJ60/"*T4P0$)3J*(@
M049#>/(A6<=PL^A7%]#O>6W@8A=USNO*=FRX/&!6WW4S>+N"T^5$:T/71V0I
M4HRP=9F@2=>-*E*RP>&&K+\Y]>&;3^D'C>^@&^NP\AP;&+_YU?FB6UUL/>C\
MM^[X9'KQKON?\RY]@EA^U\%R>S@R 1.H2>A24X7NE:3:(^2#)DFCOVTX=]GT
M,R?/>FQ;C>]WU//\($)OP&%Y._N"HIHO+OY -M 6_UER@ESJA#MSC$Z4CML,
M _SL"&=92BVU%ZF*4WN?E+9:0N\'I8$$W@!D/BSF9[# ]3 M4WAFZ34NA+.2
M;/Y]"?E\^J[+:U,MHC"" $7O3KK2?#8[=/9,C%+DS&R=,<@]:&NKT^HPH!I:
M)0V@[('BP<+5ZN)MN;H*R]7;Y?(<TM&B_%O<@[_[Z7FY(-$=SR!-H@K ,LU$
M6RV)#,ZA&7:T3*P(U'%<4:G*+(_]R&ZKC=XPV#R@(@<<\K9K3YKS$FRL1]66
M7!=*<LW-9DCHAM%)M-D%5IJE0&+HQN9,K-*.*&>IC(SF)/LUENCQL+9Z80W@
MC TMX+$]^NT4V=_/4'JSU?;4=@+6LI0U)U24RUPJ8QQL'!#%LW(Y615-O\.$
M!S^^K2OB X!B?R&.#8,7*:TMHY]N[GEB0/$1(G1?BD'\?88:^>2GL SE:/^W
M#E^MYFA3)TX[### D\@\E LVD5B(F5"N->.99W:W+>-C/6IV>GY;]]@& -(!
MU# VTK:-O+;7B3&F+:DR?PP3F8-,%I!^6V96H]2(C65R!!>4*YJ42[D7EAY[
M0ENW#09 RR"B;,#51CXB0%J^0:'=P3WNII:"-%8+8BA0!#<+*)[ ,%A%F4D/
MP?@J-_Z?I*JM>M7!@KB!U#"VC;G;J^#UU[-NL9;4)H<V<0:DIQR#3UU:W,I@
M27"4$Q&R4]9(#$7[W7W[UI,:JZ4:P.@,*MNQ@?)FOH#HERM(+_WRY,UT_N?R
M=<X0R]G-97A8AO1M;>M$*V2-.D]\HFA8-92R Q]*D[$(UE$E8S^_^)D/;NR,
M?0 8U91\ UO:T>H$%N_GLY(6\R50?#N+\U,H R Q4)C$X'),OI2JH>RD#8$X
M80U1V4<=HHB:B1I[VM-D-7;H-LRN-J F1DWO7/)3$@]E%/<?W>KDY3D& *>P
M>-?YT$V[U<5'^ *S<\!->WX\Z_Z)VW8.-BD;$TF&^]*RV1%OHB(AZIQ4BB6U
M50-ISR.S'_*^LZ1X14V-O6_>IGY=>7\9C?X&JY/Y=7"Z389<N9&"^Y2\5(29
MTNB,JU#\!$&D"<K9P)'CU,_SVI6$?EC[3I+<!]1&\YC[?-(MTH?24_3#?%%^
M?Y0?95PI9C4'1Z+)R*X7FI2J4J*\H(GRA%+HEVP8DJI^R/R>LN6CZ:P!%_"1
M^U)AN=X4)DYHZH.6) K.B(149HNE1"![<#%8I6D5%_!ILOI!\#O)S5?01 .X
MVAQ>7A?^O/GROKL[:'X"',VXQM [,HI!N,&8R9ER?FE=,)8QE%F5^H<^Q#5Y
MC7$G,-R]D#BT9AI &PKI=#Y;5[6^ZKYT"69IB3'Y6HJO($[QGW+@"5JY,C&*
MK_NGE/,'&0,!03,D$)ZQ*J.Q^Q W[M65BF@;7#,-H.V;=XR?O&)\ZX(/FU@J
M&06C20B\G(HEBZ^<)<9!SA$PL&=5&EL,R<0XQ6('0.]HFFX%Y>';O(>G>-]4
MG-PX]./,*"UB(B:5DS\M) FE"4V.V5*=,Z.\2MEL%6[&*40[%.Y'U?WWO #N
M'3;YH))5JHR@X[:,>J<D9!0!B(C_92++NT.21@;]3@>$@X?\+0-]+QTW .[;
MT\3?^ @O3LN\FPF-&+:R5(9\!PQ<$_IB+DI#C(I:!T59K%.3_AA!_>*P[Z1\
M:E#I-X>BFR>BGU!<N&*NC3\S2026!4%C7SA#<07<#0@7RC#M> IUFH+W)[$?
MTKZ3TJO*&FH">XONBR\G\9MY#Q.758J2<UP[%O<!%A6N'0WXK;(T4,I4MG40
M=IN0?CCZSLJN]I)V4VBY/-SL2DFJY8%%R4C64)+U7!.GJ2$ *@83$?EU6A4]
M2$V_'-!W4H4UG-P; ,_1957&.T _<!W7'.7?EYNE, G>..U-)F!5WC1S"TE;
M@M$.:!LM_E/%NW^2JGY@^DYJL8;70W.@NBJYF&1GDG?1$FY%)))+2T),G&!\
MK+Q@$*.JDA!\A)Y^0/K>RJT&D/U@$/JW7^Z)%KG\Q_I7Z]^4O_H(^:?R[^\?
MW][Z_&EW[&?I+W%^NOGPM<CFMT2&O_]T?GKJ%Q?S_*D[GG6YB^4";(PEY"@)
MROFTB^LJZO4Y>%'"C?>5<^\9DOP*5KZ;+F^SO^Q.SZ;?;*11GZA?KJ5U5XY;
MVNZA<F3)P=<5S!*DG_>T(@ODHOOGFMR7\]D2"4J;U3E+-UDYRF\ZY"=V?KIV
M_->M4*]2*$+2E)SQ)%&'SEQ4M*PEW)[!..&,]$E6"<X&H7[O/%\\@70^A:/\
M&I6ZNOBC2[!5Z.4LS&U=W/+7BX]P5DI 9L>?X'A-Q:;I"EJ'E*6@Y4:3(Q(4
M(T$SB0$4&##!.Q'JU$GL3_NX!]V'Q^^]%."!U=^ ZX&"+D'_)G_YL5O^X]>+
MJT[=2"XS01HBT(TJ#1"0"ZD3,=9K'Y7/P5?)_SU!T\BE&(?&Q_T"W4&4U2+N
M"B.7#3,%B]%E19R(I>)$>.)*%ZN,CGP.D7G.JD113] T+NX&T_NW\+2C$EK
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M*#*BE:@3ZD&BO_?8::*8)Q+]X0SLP%%^PF*_#:S)DA/R1"OANHYGB'443?+
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MV[O<7,AUR 8A*5/#.%J 2R61E2]+Y"HKS9LD11].\DM#\2&0>EBY<1KY3IQ
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MA(\F1^.&] B=Y+:@]T;7^R"O8:/K/23<@14PL+XQ)^=EYAH<UAJ-4*UX.KQ
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M( ,O+-:Z5,\<UU[Y)H['.$IBX[CNBC%<X7;#QENT6E'3&T*"@L(26IT")YV
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M;76&9U:KDB&G0'9;L@5B05N+*0R+6EG$UHDESU,Y?4E5RTA(.X%U@,:'2WK
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MP$L)+F% ]W N^>%RO_?FB25_B-R68S!Q:NF'O^\0;K147NH""8EZQ1P1KH6
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M[E=MCL5+'_O,NNGE^JKVX<W'[1J!J^JV/-&.%\\U9[6U&!&JH9:%>B95;67
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M<WK,^73U8\T4L$YJ3AZXT.25:X691>$I^ <PRDE5()PP8WA0VEY]^F,WZC0
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M<2#85D;]VLV/\QIT7*;5-)[CEO6/3ZIY-U\2:VT$"&AKUSX*=@OM$U OSGR
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M087$?,YU"):.VC2Y:#E@K5VY[2W1.)S$VE_.;']1_XFPQ/_Y/_X_4$L#!!0
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MG=NI$S#2@>>+)%GB58C_<#[#/.^7WE6B$+]TBJ 2P)$_RXP>#3?-8_ZS2+C
M3VJ^B!-*-,5\+QF&&ORRA(>*MZ-2T'5IT-=9]=+@#CX$%'LA11I'Y/8;33$?
M<R-@&^_)!%N)<U;.N]*%3"6V0^BY-S*,%\2=@(?4A*?+"3%)JU?4'REZ^QML
M*^X)@2 3C)V+1C;P[CG(<"+^R!G1;B8R+"1#E%B""J,RLE:M0F>*/:A4JU4#
M[0I%8!7<)JYMNT:\\MC>]$O[2$N[B2O;J@$_4U]67_S66R]-ULM"9FICH78*
MD(A6C;HSTH9T?;6!T9-VC7C%ZN91B%E6!7Q]JP;=&<%NN[P4.<NM&G=G%KKC
M&E1?\OMM+?"NJ%#15.')QM31<32-D_G&106U&@7,,4NP)6@J_42B1W>1Q-AC
M4<*?.+$\%%B3*S(QL#U4*$B4Q#?<K0 ;']S@8L3H2O9G<DX1HCCQ)@IF=4V?
M8($D!:(082 52W0=2W\6J3]R?),-3"&0.3XFS1" YEKACWZ> LN0"8&APV?,
MO*547U4L/;LH$2-A@HTQ=2-OBFU1&TC\&^X+V#6M,W;9H4D_X)WTT%N52GB&
M#R_43?T80\M>"1\Y?5@WDB$T=WHI3$Q=1QS5LW? <V\EK+)P@<V<@0_<O@\H
ML>Q*::]K(F'4\#NU!BF.'8P$MF"1*)EAGU;L99(XDW* R&B3W:4JOX4!V-BS
M^W9_[\V[U"ZX[DMAAWTU4TF@GZ];6:B$>E[D889]++:I"0;U42.4J6(&L V8
M#$WKSJAK]!3=5T7#O?&*)?):) &I2=3:0M*/-(I:/XU$\M$)'!PUNT;U +BS
M8J5&8O-Y'BG._2Z-" :+'_3H\8T\;(5]5$4X\&X3E642-I$ -Y1/)X10N)(8
MGD@4M'M?;ZR-3P'O"\U[/T.3D-2(ANV?2">391@#L_W3L(L_0&8?,8HE<%CJ
MQ"D1NP-X,C9[IG:/.2>?+"3)B@)E/02I$9KZG(P*?K@Y6R'?-,:1MQ5;<8)-
MJ"UL:KI=M.["SK'<SHU0CVQS-[RG:2A&&R 8E9(X8Y6AT"UZP$6<2 ^XZ)Q_
MHQV5-#H\-XYF7E9V8U:B2@?M5D?[<0?\F0GW,\HL$D&T+%1-#8?C:G1T4N<J
MI7PR&(6P&0/KCHHHS7EBURO?>AR-7NUID+L)=MNC]J,7)!/:/Z&FKB7<094M
M0-U-55>X<G-*:]KI#F4=ZG/P?2O^'M;G@/9G2VQ@@D"[1GQ7,*Q5 ^W,TA9\
MHR \<ZA;-?ZNQ&J(5;1JH)TYRUN3/"MY/D&9CL)E+:^Z57/IS.KW&LCWU$"V
M!][69)N"#*T:=6>.MPUWM&JP79&* ^#+UQQB8I](?XX?39<&?A%/O5Y8?E>N
MW8O)[R,FNYXJU>,Z]M[0!F_HC4S:/P=0 XP'M$/KWD?>O]_:MTU=_[HZ<.WX
MY]CV@'W^W*_C,Q40(VBHA8S0Z6SQ= JZ-';VX)8=B6W=(:(B4]#S0Z'F;+53
M*+/T*D_W!?'C".O,J;:<[M>5XTL:RL!T/A*3E/($* !I(O6T)0W/AEG&>8@O
MGN(NR:)Y71Q)[U\B5(%WB(.SC=+*0S,):0M8)_R:&J1X*DUS:2,EU"@/03-J
M@1-/8=*!N1R3 LU%V-13@WW06VF!.JXT[/?@H7U^=9V#.@ 2[9])-7B*355]
MN(K2GM'E;C\$27YM,I 9NJ? P4@,^@*V6@K=3-32#5C1DD_FP#YTPD4E*T0T
MMEP:>$4R<!9_4;@RU_"MQO2A3_1LSB<Q.=/\'?"Y8CZ2D2$P>1L8YAPX81S4
M1YB)B0J)2\-5)"%*N$8FQ=R]T2:;TTQ*/P0R5#2:=)EF<E[^\8]<T)L$,-2$
M&CWA",RWIE%RZ984)56:Z?T1X3)5F&1NIIAFL% R+75RQC703333;,>VO#*7
MTJ1!9JHI/@&V4'XQR^WTS5J!__0@C*=M1/6P27(D/F!I)H-N$7[[9U'+F(@]
M&5V+:^S"Z.+?=%U^]^#(O=%_E_CVSD.Q>651Z[5&Q,9C?CP'V0 ,.041!6(N
M#S.ULY0BH3HF+126)I%2@.GCJP5+=S4WO)X+H4A#D" +N";GJ%E/(+L*S8/Z
M:!P93]U@@R)7*\8VKADP&$E%43A_74R3B 4H C 8B5_R\W%2(5=C?9:NW"*-
M(=766$FF@NB:8WJHC()%K*@HS ?- TN,]"-AZE%.,W8>AP(4Y#ILU(#>*A(4
ME:0HI?2-!2'67Y4'BE5I*)OI/E/9A,G</$)']A9*$S[$JD LTUTMR!7I]RHM
M+/A]-&_S!4CF8800:,[JVIZ\59) T:TO&8&][!,:PQ&V7%>UGKQX;?M):#V/
M_?=%U^V+FDEH]XCOO='=(+7C,!0;X:OOG,?XO]H__J84\5#<3O/0\_,$R[1L
M>>XGD'D@O"XS+*GJ.B_MX>)[ ZA&SV65KOV3*8@;81 HP -$3I$(24W:P1C2
MH1:CT*+*337O3/6@M0Y-;5G72;['!.])OD[R)Z-A^Z?0),5'.98P@TDZO"8I
M/M6QU]&-"'-;V'DB W1. ^47V-^ZC#K-?32,\1,_(6.[M>M\H$?7[/E G0]0
MY$?J%(+V3Z;>2?5(I8L\T]@]?ASY,H'OL<00N<(-YD=H? 630<% _U.;RC#@
M$G$$YF%XG<520S$D7"J E>A1IK(D3]&+"G_NS.,H7L3A4N/Q,$(IL!ZP,0C*
M@5UYE&!B$C#@:\3UPW!>CDZ^/X.SLQD<IT>C>RHRULQH]$7Z.2KR[9].E9!1
MC#,&)C?I.)PI.?7LA+RSZ53Y2$53 Y6Y94(+&#JX44'."%J$"!9(@C:3V^QB
MARLO9 9ZPTQ%]S[>7KG>&X",QU-/*DZRTN FZ!:_$;[@W*KJCT$L4^(%\HM"
MCI)AA)R*V&62PN\S<6/"(O,XS;Q(B@2C]'_D"O@9<B_[J/46@5%%)Q:930=8
M4&NR*Z"](8D,Y0V.^QY(C![]Y=N@OW2#T_>(:KUNV:!;JLR[2N#I&$/=0+C1
M#6X=U''-LH<RZOE-C=]\.-I0E]:GW<M=[T,<!Z2M'F':[3"8JT@1JC!7*3QO
MWU5?K-?3>YW>E0PWJF2LH/A B>LHID3N12)UC1'ZH:3(3!]*DPRNL1!G.0R$
M^8":8^Z=2B45H\,?<1*P@PD+D,B^ZCB6X4%?B-,SA :&D*29TR74NQ3AYKG"
MULWF)6AYFC$5+**3*V?\7T*XGR_(0:0AX4%;D G&P0D:V)8*5I_*U8%8B)(#
M\UF:*/J53!+%12'H*D$$-*XH6?D<V]F X(EU-P.ZM&B=0-FH.'3E]C)8R&2.
M(/5PBQY[4XF0?;,>:<<5H(.^<*'G=S5^]\MP>-[^*53U'\V*0LS4]^4"<^_@
M#R1C7506^6H1RM0PG^>4GW?0YSKW=%ZC\_'I4?MG4.]XZ8VC&RRHO:8I@;:
M+V+O1@$P0!V' CE5$8,K(,4/4;V9JA"^(57HNTY^;VVT,._#T9#R##(*9\+/
M$:LG,EF().L\[^ISBWO>5>==\/<\HDISLD<V+L_HSA3C2TF1+6]O?_>@Z^3=
MYQ'WY+V*O#.Y47Z6GJ8U3?<YP3U-KZ3I>*.J*]>GZ:[GW1[T>;<]5=>H^I^G
MFY@>(1J=!JYS &G^USB5*IW%7H(YLHGDE%\GTF#B%:982",<3D+9& +YIUB(
M/Q%"W0PNT>=L]ERBD4O8\%[[Y]*46R&<X*3P:$(ZD&C91,\&"C;0IU+V;*"9
M#7P@9*KVSZ2)"3BHHQJ7U!)_P1:>A@UL1D)5GV'9LX$:&_@UBF]W/L:W[9]&
ME0>T:L1=Z3W5<1[XLD\J[8'F&IB@5AS:/XTF18B4%YE*[X3K22AS\J,4(?:.
MBP+O-QE.12*?>X7)RS[!LM=_:J1_+&[3]D^AYC,-0\0A20<::P21BY,\I'\L
M+@GA(04JPAX$J=-,89'$$4S,)Y24U(4BD(02A^R#0$ZX*F4J TSF''B13O+2
MH-+%1QR#Q#*7^ 8S._$K2HI:PK\:F$6_.0X5=SD XPW!#%).#V,V9"^;Q '<
M&L1S3"WS\7N=:]5U#M6GAO8<JLZAV%_1_EG4TT.70-H:@A$!F*)TBE4FV(,$
M[TKOKH(YC.<+G)I16VI^F\FR N2"B'%3!%M'U'(7YF7;//QJII* <4],5R[I
MPM3C-?K[ ?(H^[<?[Y30Y>$SL+MYS/FM :I=:I+SIW\CW+R'%7\Y:EU5=';?
M%B^I_W"HRT><XXG>?*JB4; [(N$U8V0%[%,6A\2IA5U+@I1?L93-"UE=Q%VO
M(RK\!E()0_:(,(WU"90L;_.$I*"[R50'I7<:CKUH/,CFD+,0=:[H-_G[;3)M
M;R)A'U/CIH:Y(:%B'2]2<P+[K!'KC+>:*NK*_*V@=)PI/NK]R27Q$XV5564
MV#H0(^2@.=59P5:ZK>\MLP/\?I$G:8[OAX<,$U# 0NEU/4ON99_8WFM>J]A-
M03:;9RDROE$/\883Z2'>[CHV6V*[YX'?<D%1D+=JG%V)40%/^ZG3Z&=;DYX4
MO^F"HE74JG'VI+@II.CWI-B38JL&?!<IHE'?:7(,>G+LR;%5 _[FB50;0(9[
MNR_[4O'>8;;:8:;=R>V?3E/,4G=?ECFG*BQTN!'!.H6*. )7#ZYMB5"[W,D3
MST$8P3WWX)Y$!@K3+;8'!, 74J':G,%!4_C!9&S@MR9_@UST09R*:\E7=YVI
M]+7J/5-I8"IIMM$^>"^;Q:FD'E(T 4\AF:JI8CBL]L]GO4;JWU<CZ-4RXJ ]
M+D#/0>L<-$Y3G0%*V%P;Q4+7!?W8ZSII]\7\/6G72/MDN,FU_+:.7U?O8\MB
M+MYU@#T8#URG2@H'(62K,UO8_AG8G=NN K/0GJU39DUSY@0X8,0)IK_"K[;7
M,YP$7P9Y(KG;8NTZ>@V5JQ>7(JP\-EG,4\22=VFAZ(<H_)F2-_"$?!%'#J+^
M\(& ,>@9R&YCTT1Q&H=A?(NC87AZ)76NS8<$ZRT&WB\R@45?#KQQ)D+XYW(A
M%"7W.H#7O\+]03SONN3J\2=ZR=4HN;H%/U%(K_;/J L2J3U2A\_Q_3)'/VEM
M#:<738\MFGI,E%XTU?F?^#<0PPD1J'=H:*C]DVH04ZT:=&=B^UVIIVHXZ,OV
M3ZDXYJT::V=.=[=%_JL> J@7^35.V&'D9&Q9](U DTTGZXYSB!XHJ.<031QB
M@R,M==1D!S3YP_I J<^$ _1 /#T':.0 W?)84S=#PPS6X !=)_L>!:(G^SK9
MRXRZS&^> ["YS7RKIM$5IPD%6+K,'7MXB/Z(8X%I.T9*+_Y990(TE77&3M"D
M 89K9_&MO)$;T?9N .J8R+Q;1&<VP,W?N5/V\SC;G>3?/:9(?\9[K([^B'?^
MB/<8&/TQ[_8Q[W23'NMN*=(I YG)9 Z7!KWV^TCY3&,.[?@BE:;OPV$\G^@F
M#S8"E,9A8,) 5XCEGL7)<N 5>X9.9#)3&N\V&^J+T$>0 ]C02>^0ZGG$G^41
MF(WM0JBW:H,Z<Z*\'D>8)O(=<80W@#;W=E_UV%!]&*T61CM+%C,1U4+*[9]5
M/>NNEAA#?MI$^A(X7^K%/-, \_("F0(KT'EY23RW87>WR\+^GG>X^V'W8I?:
M=7@'>Z^I5Q]=+[P+;N@%BI8WY$JA;%FZ71"TC$@H9(]=P/#FH@T850B9#EK>
MO_-$I8'RN55-T?D&QZ4'#OQ'IQ*F9;0%O.;(Z69S'HKH+JG0#6[6@U+UW*S.
MS0C>[1Q,&!C^!=ZT>>D!WI;:WCQ5N5TC7ATM;]<X.[.R(-JV)OWB/A8:< !,
M07U?__*:J^MMH '=<4VI!Y_K-:6:IK3A.A+:/(?80Z\T#\+2PY\:],!.>UZ!
MRGL<NI[*ZU0NDS2.VC^))KQO]'?<J"#'ON53E<RQNV^RT-,<> N19!%,;Z86
M R]4<X)'"968J! ],>1[03"5+,G3;.!-\A1>FJ;F<ZD;<''U=7PCDPC=*"(T
M"##8,%VD:>PKVPF88<01+CA;=KWZHH<)ZQE+G;',,"2][UTE:A/K+H4WR^&9
MG@]74C>!#.?!15=5-_* -(I%HB)?+;#Q0 Y<B./QMS/ESQ!W2MAD",TBIEXJ
MIA+X$&HD<CJ%E_A+XZS-@ W(##A8AKT'O$6\T#YAY#/HF_83-6$4\L('?;"W
MO[N_!T8V.:&%;49NIY!F>;"DO@7Z=EU&VN"H5K"P)?<S(U)A1^H/\' ]PY21
MJV!Z0],N?F 05N"=F;)S%5[I/)BUGM) :V[Y0H-C^*T@3C7\%J4H-$)IZ?TR
M2T9?E=[Y9QS>F\&'>TRL;PM3UR5&?/ <&+&','S (Y";$A>(\OD$U#!B')-_
M2S]+.>2G4AW@@WNSV)-I)B:A2F?\JUC5209N0Z;MLFP5YYP\I3+DF&!.!@@?
MF,H!FYIQD03GW8H$D="Y=XP/NB-WCL'K1 !:)6Q3(H7/ 3P>"1:0:,720(,0
M"UPU0!8?NO4,]:?'(4RDP_4'6BCQ.BIGU'!EFB] @79 =E<(O'NED/\$4LB'
MY[+N#<9 XRF9BZ7W!]@':KK$(1N)H(G!4U/8-C/G])Y)T^K'>4:#C22OEQ]'
M]%OER7]63!Y\!S%Y\$S$Y.L>1ZHW5U9(R9<=DY(K&(<?SX$)^? -Y<QQ!LPB
M0\YA>: 6)9KCTI-8;A!OL<)C(AFOEM@@/I#\JRQBBV^1=>H'8K[+'$5B:F!O
M:X#N-?0*SRMM3TI\W>2-RH4*Y%S!NE];^0*"8^#-XT 2;"^.20O,&+8_BN?*
M+RY3T0W(?W6-HL=+%R![8P3<*J^D'6QM+>GA<9KM%.A<:9[<2!6&"-IKWM-Q
M']#K'GJK9ZIUIIK$BT3)3"3+HM\B$-+[DTM4#H^!Z(J2K_;.L6"VCO/9M_,Q
MSEY0N6$&S! #SK:3]#,67PP\3"T1EH^<B 38Z/Z;@;?_XL5K4I4SQ@.'@>,5
M8 D@;QZ@>JS7"TV,X12QR,$:2 <:^%LEU.$R <,A1J:*'X'W3'!'X NZ##,O
MBG>/IE/)_2V/X$'T[A4OYAWZZG=WG>GU:&.]PZ7.]9KR?ML_I:8 &_NJT2#&
MXK!%(NP7JZ)@Y;SD#T?#@>ZND7B_@B6LTEGL;:E=N<L^\W^*A8@D:'8GH&RE
MJ&<"B_HH19C-2+'Z3893D<B!X5&@>_HR36-FMOZ2^546;VO(#>PYAZA)H,0I
M'>934=%-H58!Y^$T:NG1\.:__N7EFW?PFD/4E!-?85L):Z77>@AS6D%5->P\
M^^M1UWJ=K\;]+O-)R(30KAX&:S.]JYE* BKH6**'[W86S[U$)P\EH"$!%TRG
MP$",/[:"TE9O,$Z:;M6!ZC)*6([K&=VL5VZ [FK[MQ_O! 5WXL\J]9%U+>D3
MF,_SF*.# 7)1-<GY4RF%8=!7 3YV%>#F<?&*V&N0=X5"KS-;C$.?"(&C%6#T
M9+=2DB^9Z&:+Y'5A,&C?-OZVS?$.E\PZTY9C0WD?UV*+,(U+Q=A-C)"<?RNX
MH6%DTSPA>[C@86A*"L]9G7['V[#C*S=;^V\%I= MN511BS!0O'4(J^O:;5\,
MW6NW-7JWEF/[Y]&DVYIHCK:#;^,D#+I.QWT9<$_'=3HNQ%W[9])$R9RWKR,/
M&5;_7\@LB1<S!7:?=MOK6A>5&!L57?Z%$[_KA-]7M?6$7R=\E872V_N^X>H'
M4CUZM5%<(_53?H&+[7$IV03?.]A]TW6*[BO8>HJN4;3N>WV9H4QK_UP*LHZ3
MCCA!W+YB[9U"4X%PZ>Q0^ML<GNT+4ITPY2'3]AX&#W6F5RJI%1.BL%@?_GDN
MDRSV+I0?;W>\C/AU7^WWS.$D.ZYD]%54O9)1$W'_$J$*O,-0J'G[9U)/#O=Q
MX"C?$#D,D0+3--?)VGDDORRHQ?""P3"X:B=?+$)R\V/NYB*),VUF^"#H%%8^
M9=(4$O'#T4A!.-\)Q@%GDN"F;VC5X('PD@@L%E\2U"%%@_PX3[(B>;)(*#*I
M/3!:S+&4-"@7_9#Q%?G=48QM#Z4(/5]@&!(?B".A463B,\8D89+UP>$L@[G*
M,J[C@3M7#M?$M1*Y([^(HH(WP6@[31ZS)>.%"8?C<ODRH)![E(>4A93FJICL
MK4IIH(C8A$$6&9$2H==?%!VAN]"YJ1VCOZ]A4SM&^= UWKR>6&KJ<J.[SKZ#
M$#X3-]*P+%U)TJHI=P=&CJJ!T#"2 B2?3#/L24_Y[)C$X?!=R@/@?40NFR+Z
M@4X!=7XJMM '@RE360Y/$9XC3&W-S^I22>#&(<*RL+#*5$AQ:3HN="92IRR6
M7GN/@LK9/3[<+Y,V:Z@K3M7PXFI\>#SR]K^OR?T@/;6>>=;N-3X>'XY.+T?>
M+Q?#TZO+]>V=A0B0F^V$<IK]O/]F(RV@_=V^E.N[0.P1@_LUBF]W/L:W[9_8
MNHZ -_M5POAI4^FBIXPGHXP5R(T;11X>9CS^6Z>&$ZJ33.8\#ZR,5HU _27-
M9ZM<3I-(&,N-+4/1:9A.#'!_]]6VC?YC90Q8VM>)B-"1'1<) J! 17&T8W(W
MR<C=DE]\N6! "!_V)*#B9=*L;(3QU>Y+>#Q<&.8IIA*X2>IT)0T21X6O:T@#
MO>/A^[O[ SX!=R%WFOW'DDH9+LW"PDG""Q,ITCB"Z2R]2&*=$/HNLGC@S4%%
M'2 HB[NB-)A,W3#,2* 2R07LF5UK*M'$U[I9THWU/[ L9*3,18#)^S(,]1=<
M^AE/ISBO6/\BOR#>R,!3<\):H0I+ZQ> '\.8G05N,K9<N^K()'=]4+*AY]?S
M8]I]D6;?6^%9,FJ\]4F8=<.^/X!!H[\UE=,\Q(N_"Z=N9,\< OX.''I3G9'&
MX0L+S&[)03OF<4_-.;DEH]@M:B%*1!0W?<*!U(N3#P*%RIN*\^!<9CG"=F-M
MX%IX&"ZXV50[0P??;(1]#>#UX]8 =D!K<DXQ0=SM@-B;4]M7S:RYJ+[H$RL:
MJE[I_#_DT%\9>93:XUT@D)2DXLI3;PJ:2J*-18K#]!]7NM2E!^(K)G,94-(U
M_9#"8A!2U!R^8GBI1M%HG..PI?D4!HE Y(WOM6"3"X1B@9^]N<QF<? =GEL\
MDZ&P$/YXC05 _'7$[PR7C2&!TE-Q"^D?7F#"/$STPN.'!CE\MTWT (ZKM02*
MY;IJ@X&GJ,X6"V8;)JOI:-T;&,@M6A;0TD7>_[W+U; >#^EH<Z]3>P/2UO9[
M*_ [E,1NBO7WS%PB?83G&R]IH9EPP)MTC9(.0M+#,:[3FGF0%=I/:-AU@]*C
M]9V4%)X]DJ6L^F@+HX2X4-P\)10Z+XP1#3-EL5-<FLBY4%17MN+^+N0A;:)9
MBMEZE;W26 VHH:,><XLHV>AUHA2V">G6$^XID:[ATZHG6VC=*!5S4@\CQ#5D
M%=!^K9TY<(X<1Y5N0.A5:8'/5@'*%<I"89$)&A;D7JH/A*9 C_"%596*=2##
M9+X ==$ZL]:;(?#[,8PWX L&M0%_)^(M"E+7!HOMDD3JU;,GEDB4_H2F1R.V
MA[;>75207@8\O0PH.<^M@5G?+1TZT"QH+50RV,ZW[]9B,WLOWFZDS;?UG=OA
M=HZIK#A\S&$FDG(\59I9]K&^3!XXTAZS1:E9G[<UW'95T+?[>V_>P;,TKB<Z
MI5B!H$*]&*3SM>#G-SGD!][6^VWM3;3/T@2SXOK#OEOUX[4"/^I[57_'I+S-
MY>D]4_^V*XHJ8B-?9X!F!]]N'=.S9/1@7Z<F]F\[6X%)E6:@N2AX[K+ E8S)
M/4XY_U-Q$W/:@]:%W/&@]WM0+JJ"!\6WSA HLP$?;D0%MS1)V!SE?(VU)!1I
MOUTGK9ZVGE!A<KT7)HKY=G?OQ>X^)01AVI"\%@F=T;F*U#R?>TF\%"'H/@NQ
MQ">E99NLH\?RIC^5WW1%$2UZD<'1<ZJ]OD@_MVUI5XB#JD]!&]54RKM8KKX3
MF3#KW3KQ;*HB$6'.5)%7A;QWJO"@*NXVL'"2!GR;9*69=2(#03'Z)HMC01+"
MU*V9487-'@X2*3!WW6L0QS/ZXL^H;R+F=BF"^O"VNE'$?CDZ;/\,;/$Z-9 <
M8,4HFH2PGP9PG39M=$@*2O2MC]16V>E"N@J=(//0RHVHQ^#X5N9#% DL12/0
MNE5+TD 5F9:5;#(G2-F*G>L*ELDS4.MZ\?FXKO6O#G"Y*6B-#BP;+GIEPT6O
M=_>V=;=Y5@&IBAY&T:=U/G):Y^91OC$2O""75 *%)RV1W.H8#]-G*1?XW22.
M/_,W"2H..FN=3S=&7@N9!\+-RCF)';#I69AC&4>*VF>BI'1L]#ODF_$-5_3&
MY\"1>SO[&\-64&3,%J[4DX@+GJV<9.6JKD?'L'A.L"+]L_2P:M8_4PWK>91%
M$S'4$:*N[TR6.P: O:DN!'^OM9>="+!PD-0T?'.^0'M$;5L*,CG8)9F!:+#[
MIMVC61>"[VC*IZX&#%<MA($L^LI78\*WM077?6D?=OX^J4>KSD 1I"L.N9H.
MG.ZBQ5D-=!X9=XQV#DR1U[_JZ)0T)3AW>'96'[-/BS0#P32WE#U<[<56C 0&
MQ]YD5WNH7:"%-ZTI8@U)/'A)@W?$'.D>F^B1CF4 2E_C8:IN,&U*NBI"P?4=
M7)E8JD"A(TSA >PTC@W&)](4.8H&_]&JX$7U\+9J;;MBMS=OUAUI>2XG0_<Z
M[>N -Q%AJ6RMBGN2T(XKR/_.D\)B"IE UW777GE]A""1<^K2>_)0ZY7:S?FH
MI5JU^QK9FLKD@?'J!XX6T/1&F_334"5>23[&"[6<OC/6ZA27UY,8VKV'?-H>
M^E^L.7.+MBKU9^3E 6$E&2 1]R5=N6#[CF*&((I+UK1K=7#5D\)H?@63:Q7%
M=$9W,?UXS(ZL.M\-CJAGD/O=MY'^IDLZKG-D9"6@S,CKF*MG&5#3G$K6EXLD
MFD)S'KBYPYK#M&H)NJ+//K^"C[Z[YK<E>B</6_0T^OUH]/7!1AIVO11^NC2<
MT]B[2D0@X91\-L*U_5.B2OE3C8E!";H&34Q^ 3,EI?" PB@?.KQ5VAPR@0\8
M4D2U(C-K,. _O4C,I?D[,$]$(#7"'<'%BF\C&; U&\$3PY##.^]/+BV8FL;)
M8(-S9>=+S^V6B;#T&K$,[-*42T]A4CP[RU:;(ORI#-D(&V"VIDJS1 /BP!,P
M+2"3D8G^4US(3#G5AI?*/ E+%B]3AM2)(FW3D=J&HW*@:=!FSBE)":S&-!=1
M5G<W4KX4+(!;40.K9FQN7#3M0;5#Z3A?ZQ6-)^1K8Z9_P]4V!0 $1FX<_+8A
M#?,YQ4S(EK@E4F3,@@Q[L]YDY$3$_XP#1Z99O%C(L%2B &\;AF$I*57G7A3!
M9O>-YC6$C"12PVS#9>&IJX6A']"AJQN(]7V+[Z>B<1";(-;@T&T0O.LSLZU?
M]? ^CY7Q292 45^=(Z==9Q0JP6"RR0A%&BE%'T$%55/%O-K! +X_?^'Y'=X>
M">2;+FD%V?JN3!DZNWQ@,8Q4:!IEM%D'<I.T%0:[+J%ULOF#<7&T]MQ?*CB&
MH WI'XJWZ>>9C-2,H*F*0"CEOM50/;D[5-J(P6S>23B+D0@+3$\;?7-RL1&&
MTF(0L/F*#^@3K!\YP;H#[,L-YJ9@*LA(X\MB-TU$@J60>PF!HN%,)C'0VQRA
M9#G9,K:W4QB'Z]JH%W4"+ROJ]NHM]#1\*U7VWD4SC0 Q!L%]JJ%*!>'#N5BE
MC5"E!D"L BV+K_ M-##[/IC--& '/S^AUSM?'U/H%4T0*JGAJU"EAW"F_5!Z
M^TU >D"I6:)T:0YF/Z=5L$1-VX=N >(XHE(@)U_:O&1OKUUIP=V!0F%8YUJ*
M#3:I!,XST\RY%!POHQEE2<ZG1.LD3OIZ!4SM&H2H>1AV!<9NQO :-PF+V/[+
M-^]6)6,-V4M=Z"V'^!#6GE:T1+('&_AT,_"@]4ZM"W/;Y.?="";ZNF>A3^0#
M6FU#M']BCCNH%8-<Q6Q;-<@5*WD:9QBF(G\(ZZ1+9JI:4%*\"<O@:P[J057L
MUGTJ7.)$31C*^+24RQTC+HJ&@;W;K/4,LW8*Q.X5_^[;C!V(:KP?+V0EL=QY
MEI8,6@JL'A+GBNM*JM+KM,UL*VL"C.;=,S]X@',]Z_H*X2TJ&#,6LL-)(KWS
MP6#/RAL=9*Q$(M$6*&7*;\$W@9R29_C>^6^;!;C91J^9UI<0A 1$(BM3*JN!
M\]TYUA6-IG5ACQ6"^L4WQ0I1(1.8162@"%\7E,"QNXWS$-T/:1YRKRVG2FB=
M[27#ZZ:T%W!X$CRS-DE:I(A>XI3DS:7,5J(9WNDFU'V6'4!F_W,4WX8RN#8.
M2H6-U%,X7S(J8D<:Y]4@N-SSEGM4B(YTUC[H.VL_VAH?CW\9GAYY%^-?/EYY
M9Q^\#^.+RROO=/3+V=5X>#4^.^VRDGK01V:>3$G%<,P%IRI-O0\*- QXZW4,
MMCA>V_[)D?DZ9E$*1J2!(BH8?"!3E<AT-99WDB",58%U=1\B=%=0KMYC<RC,
M'CLCKVD>@<'?_BFYL%=%*-%) ,&#L/I E[N3&M?2P3HRO0;LUMQ7H?0""TUS
M8*%I\*^#'?SOZ[7>^J&A;56IK D>-?#TD3R?B60N4/U60J^3FYBW"(5OE!E]
M1\D=AY>O&/7@8:/^EGVS-D)B]>'8I^);V@RP- ZG-8;/FR:UGE7LYJ!OIO4(
MY6L/UGF:1/X 1 .Z]?E*]O7#Q5%!3FG1H]3I<\*6.4&C3F.$DS9-O<%F!B&#
M\<PF48@RQ1.3^*8!A\#%MZKCJ$8QALK=U F#K.HBY2@G?K2B=W;A1Y W(LS)
M/<;C1@$;-&J&'='Y1CQA7!PGT-;^215:GVZ JQM F:.A#RN%EJ[C./"FHJR5
MN94 '%;7IP!=B?&$$M'H^#61"&?&($RABJDE;ZL6K#/5WX1<4^8E)60D9 "^
M]+;H@]Z,1$YEDK!?6:.-=(-2]?%T39=SFG+[Y^42Z[/3<GH[X)LNZ2<NP7<Z
M5Z"1&8#.DMVB@SXK9,&@74RN,^6\SZSO[T&/M/&MEW3H@&,4P'!D;U <%''G
MEE6<S5)3Q6_1/,VI].1>-Y+A>>_H@J,AF59'&HN'LU*I(YA1IJ)<]KG0?2[T
MO;0!QXZ!0+'@L=E[C,!5C#!3[S+E-C/^D]V+G3;%]SBG.A*_?MG'KQ]MC:\N
MAJ>7'T87&+O^]?3LMYV/9[]]?6+E!A30O^S]FT]F&Q_%?HYL;&.<5\#;S\%V
M3TQ.W,A"/Q^)3%I,#DP[*G EW:2[.)+>UMZV1S :21PIGSKUB 6UVN&<)!0'
M@5X9,(8"D8FB2M]UBY9!08P_U::ZE0=7::Y<H%U67\4I?<5;L.0-DQ,;&_X4
M_EB#$.+4P0S6PN3$FXY1$W1+V)SZM,OAA3N>[:82A5^C^';G8WQK40T:*O>X
M,&A;E_#9N8@;H4+3<=%Q0,=YAD_)T?N-=4HPE"Y LV\D,GMIKT.1PG>HL[AM
M9LQ6O\0@>E.% Q!?%.LH2R+_R%4BG0""B4  #2H.S1?GF-J(Y)%M%H)00&*"
M#"T&"HCB3&)#$?/S)A\2 WQK#DL[9K'.&5'34M1,]QU+,0<TDA(SK0-6HD4C
M;W7YW9]D9+5JW#M8F148Z_>>V7+C@TZWF3**TW:Y_=KM3++PX(Q88OO.@I2X
M?40YV(X@HZN=2P;XF')'Q.HE99FWUHA!LEZZTD@G^1C;*$![)]# ]EP<M*+6
MS):<5EJL.Z79Q= JU=E:QF*?77?'!^7BSONPI8NM;VIZDC8A2%?@;+QU\IH1
M*5EA&;K;YF0MB;Y8K<+ 5T#;US,<(?IKC=)0J"OTQ"2&5\HT@Z.ITEFMX+U!
MI.NR!)&Y1XNZ%R.VBNNY@=%%5=6D*)MWL,*!G1?.'"Y:XSE66R1C:!N^FL<!
MQIVY>0X\W53PIM13&>YGL*/B>]PI9^;X\(%'P/CD-BJD!KQK7CKS;1("7ZV=
M;Y(4&#@*K7O4%=*)"(B%5OLBH3?0SY,$>3K>@8Z;2*=#&,2JXBP$,E1<GEAB
M;C5D.D<1(56S.+3<.(^:*31&/<B1@YA\F, @T5EJ>1E!=I6+CRH0QXB"ES',
M("RL%[#:8CQ)#9XC9RF(C4Y1[UG@6/P<&WO<(R4=J7:',J1+FG ==*\85UL?
M$/;$K=0=11>)O%%QCI 8S8L]*)A(18F_RR Q7MS@X1*]H52?NV)4>E8YBU$<
M&%0R9:HKJ:I(AR!@!-R0N88=ZJ1+/*4"IGP-FT!+.LS!%L$:7FH/N\[$5P(H
MF&K<9AP%77Y$1;CF[#3(M(;YIQ4]QC9<+ND'%C"A7(6&[;WT4JTT454F=>=9
MN*,"* %R.Y7<M9@H%TG.FG0K#+E.(T"^[$/73R8B3PRUMW\>Y+Q:0XDR-%N)
MXJ5BO@C9,G:A3=*"@16<;\M1HY&>R[JG]D.4/30@+;<;*U+;D@SPM?Z6=HQ^
M'1.:.#'V00#F:SFRJS,-"O<8G![!<ND_;OL$UC<2&,N4X4%;-?O.Y->5/<KL
M,)9?P-["+?#A!N6+D'2 4#NS:AJ+47+M;>[5N(N";<(%UZ%(4!9\\A0 709*
M]V&^2P^J\@0Z8KK<V_* ":DMY:;Q=ZC6E2:'W<@/O-+D@LKN1HD3)Y&WFN'=
M !XN',MJBG@'/IRL:SX#K9IM5]*]FJR.$GO6A-YX_DJ$J.WBY@M1W[;TK"ER
M>.F-+_7Q:#X=G)U3/2-*]^G&?POL>JWI#TH]XPR&PIT-"/OLG&^3G;-Y-A C
ML?A@0-N3DE-O _@&UA0Q :/ X@H&*C5[?B=5P%G^1"HJ*,V^2OQ\CMX8WU8O
M:"$VP3;09'[&2>V,USWA^N _X,"O/SMX]KJ38^>*XW=.TQRWA#Q2=A8P1%-&
M@59 *-0<[L3IXB_DQ@K$7%QK--.0C',M_*G.3R1*8RL:K)%&*+FO8 -_9E7$
M"O[6P+W0.3"/@((&"  CM6=[%H?HTD[FI49CM4D8#U:E44<,%_@RP<6C;KTQ
M_LE],B3==,V..)XW_=KXG#0GKSU=@+^E%G7E.C+PLH@ZR_&5&WPT!0\8A@AQ
M9[.2H-9;6=E@WM0!A7!2-X;CQKH&UO=">$+"] RQ :U07HO0WFF>!GN!K[DN
M@E'.+0+X3Q+)I3TEJ$ALTY'2T'9U-UMQ2--<Z7Z?OJ06D_#!!,:F%!Z 1]O3
M"U]@D#BC%X/\4'(Z,"?ELZ*>N/JU.$?X@6@=Q0S.W39=)J^I^32HQ AX%@.G
MA<L#CGR</-:);Q;T5%^%/1E<!;[LG:V>]5*3UPJ)ZO*OYG=9/:$>L7- 6DOH
ML^SP-#9HR;F[,C+;&)Y['BF3K_J4R4=;XZ/1OT;'9^<GH].KYP6>T#=B>,+4
MR3+0:HGCG8=B,[(IGU4]TBO$8.GIXXGHX]#-H[HH=,@1YU&U?W84KRGTGBUM
M)KHZ%:42:/A[F-NVDT:6@I7/?8ON60A4X33OP 2"4&)V)68IUR/?3>H2YL,8
MEV].ZO :[T.EGY+/*-;OBP3#USE'JZW[.G 86I%3M&:*E>.(+K^,?,J4T%E$
MV#E SH\:+E"W)<<680HDGR4IE2;:H0O'R !^^&IM-^=^R1KW?GZ<L8]9?P_-
M86,T!;86@350OF=U"ICF);),^#/=GY!!)-H_LSLW"GB1C +UQ?N^5<QK!Y'C
M<B7MGP'@WP 7<]^XZ_NPK NYV$@%CI(FFH"NM@0H;G*N=D04Y<#<3 J&JP E
M/&F31-FJR7<FK:("6_3//)+:M/;E?,(14T)$;]5D.K/\5* WV?;^R$62 >DO
MO4R&<C'CJH.>&+XK,9Q0JS;<HDNYR#:<'%HUX)4%#5A\@LOKBQ0C+A2U(U,4
MC/OYG%*^IS7CT>U9X1.NL:W/<>KCBN* PGN@@=A<@[[D7?#R!8*XV9*@J@[.
M(4F,-*HIW$%TBO'==%"K+Z-Z@FL947>(H(8>N7:DQO,^<?:X=3(X:8LL8NOH
MDV#;F[X3T0[,.36QPB(%#>L0<!MK4>D5*_U0]P0#G9L"O$%1CU6,M8SAZ8"<
M%S@U-6R=@4FFOVLYN-NG-T>@4$K0C=$1@>7GK:**[I!Q]?QI2BZJS0?-!9)3
MX=N(.Q.\SL[<,O=P;S[>85LII,%8;1WS=N%1 ^4SBV'F1)$W<!>&V>'@39+8
MG^4)OLCQBJ7Y9*Y2[IW#L=N$LT "JKNFO 'G<DQ1\/&5]U)S(TUPB@AEI.M^
M+7(A,"A,875=Z%AB8@7.00E;LG;D.UWKT3?2?#HC]()+VMH_BXKAR6P'2P\)
M')>4 IFQ:0,Z0DXMFBRV 6>3W\;)9P*> M+D C8-#2 LYH*L]GI\4%%\L]O>
MY!W94C&K0M@Z9L<02+FIKV,"]!F@?09HD0&*9XI+&]!TL>J:01HP1]XF&QD2
MD5A&CQEY5.<08$/V4-?0,R9U2K^@FFLQUS!L!&H<DA*E)NG6U)2_9F6D25A"
M_6]:9(N&2F+W]RKB=0D('K.O-(H!=RO!B3%.^@I,0Z<4&:1$O4*3_%#&UZ01
MF9'")1*MJXKJ\N"E,1DF(E6I4[1A-9:)SI(KYY$:K1L,2>ZG'4AT:^/RN+B0
M6OZG%*]+,DP259'6Q.V;X_BS26/DO2/  14!5U)E'(M!:4ULFT5F&UCSFL@=
MJQB1>F/+9C+L;#M1\4XF_5D$Y_6:R]U$I'3(U4*/.VUG!3;W=G7OF$!K:"B%
M29&Z!P]V9B)A=:8.9@5<BN6WTV7U *BTNO'5+2[.-;_* =K4;-SH_5-2DB+,
M3RR; %0^?BO#&P2IVM_&E,AL9@U#B]U0!_&H&AXBN"%)H<\59O_F64XA88W[
M2W=D1/+:'(UP[V#$!K=]%N?)1J/IF"S)@<5<:LE$[@&RG.JBS69"=<!UZD<4
M6931,50%WL0YJA46P:TG88ULXK0)K>^]^-]\9)$7Q$L1DKUM2TX78JDA"JK\
M)I%J/H'S8Q])$7O"=*TE+9-NP,FL=TS<'GJFK\Y'MU[VAL5WB6XYA19*ITT?
MXIEM_R0;[0XRZ5?4D P<<)2)% :N@]T9A0(W(,)U5ZGJ8_B&^=V;3K:O>K)]
M,G^ 5>P[1+6M&G!7O,#KE4AC4,*8.AJATMHKVG.\(W1^(F@I7/6%YHV^F!RD
MJ,(WH >QW3OZXLM%AB9,(SSYWL'N2U>5JE8FXA=UY/+X-J+AC4^/0!$[/1K"
M?\MIE*XKN5RD109GT1X<GE+<:=>)NSJ9Z=E^ZQ%BGKO%@_>-M^.<_W7/^9^(
M\\.9,I5L0*_MGPPQH,L"1=>%.*;J3,(F=7L4E!U/MHL&EH8684_JM,8X8[IT
M<1U,M;6=P0:),BVM-HV_9) 6185N321PN.0&?0]Q O:??G^GO GMF,9]Y/[J
M[3N/4MRJ M#M9QF5'*C&*5F-=1O<SE([F>)PP.;3S^25("S%\F^U-AODEW3R
M'W"!TQ5]-K2107TV-#R=VV?#L]BK#L1IX3' )4D;X:WHQO<GEZ9^MW+I7<V9
M"7H#'2XB@-.08E6L("Q7&? YQV2J-1:-O)GQW,T/4:D?4F7M&BB[#]]-XYDU
MKOF2&S@N;9'KQ&6;T Y'Z<ZEH$5EB=*:$(P,JU],,'CE\"V&9!1[5+%OGW(C
M"]PR]^VD=+@[I]?8WZ[F>.J[9./D:!5*B%FQKL\G6'&]QUNV,(3. UY$7=%Q
MY_0UZ78%9!DV&J/Z$0]WB_$'EA5P1]^ .VJ@5'/]-H?2)@V'!8&8F/_;^S1K
M3:N %K@@E,47U,D=UQO^88]O@_)+C5OY/2;&R.]RS^KSJ,U^O4&UV:T20BO6
M==/JQP_/3DY&%X?CX?'X_QU>C<].NVRWO.YK8I_08V5X\EDAV=H_IR>LA'4M
M%EF$H5JU1IU),:_E &K'SI5,0#F*DZ6;BXP_G(A_P]Z?4%$N;%4.:@'[M7ZK
M&K,5</2*,L)629\T],A)0UTL57[=@SA\ZR5%)KT&:V8OL.,?1J.GB24L:^'!
MS>7CK1KPJL+?1G!AA'D@;P3QX@\J23-GE[U+$1;I9N1(Q$H7O7\8GXAC2O%V
M6ATLR /(OAIB:YP8OLBLK6C/1MG/]VP84U^0_$V7=$QH T4OD/,95F+M>U>4
MFER" &G5=+JG(-K2$73786XX^^A:-8>NL/-GRCO[.IIONJ0?E/;K&IG<\\O'
M7_2S9(%LL::/]5SSB;@F*+[/CG'V><(]X]QTQEGCF)4&5E,R7WOV^OT" -T.
M@?6&^]/!PIIFH$-N$DG%".V?%,7 /E@XGM4^M7+74B>RLL)76HVY<#D?+%*H
M6W$N5*)]((G'E5].;7>Y*5<UYV--SRZU'N,7?Y9RP;Z\VA0<3V#1WU.G92TH
M%%CU(W:<:?06Z]-U^4P^;TZB[T@TD4\ILEV!4FE,3'3*XH%A!-Y6N3DO-VR.
M9VJB,IV:7Z12'HO;=)NCK%MJVT 5V2)ST]:WSJ:HW9#I#2IL/AR!S;P_N=29
MPK:YSI:R3W?R.(O:>]-9.9,AMG'/&02'>VOS:%+;M,7PDD,L-SWG9UQPUISA
M*\*6^Z>FE6&I]**T !WG/KW9]W19.YL)>%I&FG 13YO03GM0QZ<'=21VCFQR
MVH.=/O%.:$2W_U!.M8.9Z!?JO OEB' %-U0+N!)>S=;-..B.F+2#.XR(-NI+
M"<[C>:12O^E3J9]U*O7)\/33A^'AU:>+D3<\/?(N/YV?'__>9<WL39^>]H1V
M891/@4WG"<O.2W)DM']2JPK2=6]%MS0'3#7,M=98.5RF+C[KEI(S<8-_4>D0
M58)S%6BU=KWOOE@52V\W2"QM&LO_,#X=GF+QC'<UNCBY[#*O?]OS^J<,'*1@
MQ_)/[9\+L?AQY"U$0L6OOCM\PY1U42B5EK(+JT A+,0#M4P3I@;Z;H\_R ;)
M'GF-S%; 7*/3S/8-GE)?9/TX&*$/HN;M>AZSSG1+?=N'_;X+Q-J)"F6:8=.^
M<WU(VS^YY]8K%6BCEVT]=?P9>X9$T=S.ID$@$02M\&<(OVPZQ9/+4XO'XF;M
M>].Q<C''^+*+H361B&X,/U]1]&=/MRODM*':& J#"[Z@&TK1N&* O2_\$8\,
M^<)QQ[](/W>U(K>!X6F<X2:D&6R'"Y*T]VKW)5K B+"AH6@->@SUGU2(^@S/
M"L6?.@ ,DHQ!R3"FYKHNW)F%EQE]49EW!4I<*FAT9; G,V1DJ?L##2Z'4.<!
M._G+)]V22?5P$[1)?V1;<62)"97Y%H$3+:2OI@K4ZPKGXJ!!7^^,$WG$>N<.
MZ%U.8$F6TDB,VTY+MB:&03Q-]RA(Y!0N9AQ\K-/,\H33OC12$1W+ 4*^Z_O@
M_%(^A9]@LVZN\;P&)@7L\P[<[]U[ZI3N<A>VR;_3R*'N5-FTHK&:IMVS^.;U
M[JO:<7S-\^>UUG?I*^@FD6>QN84<!?S-)$Y@%+@^H5BD\F?SQSMGP?'^=ZY9
M@D07J'01BN7/*J*9TGLU);[9WWW[^C418P94E@5F/)I0=YE0?\R"^H\OW^Z^
M>OMJ]>]WWGSWD]_LOMQ;]\D_TL!Y\+ DZ4)$__W#P0_5[<CBQ<_[BR_61--[
M@5^M>?BJRWR#S3)\$>KOX 5FB_!=<,C1JZ\"CX^K,#_2%M=_+1V;/<>6Y!.P
M5Q,"FTUF+ $*DV>$;*G"Y?76=VE3]>5V3U=<_SSV7)NY#;O^7&FZQ;M94UMX
M-T>N#6?MMYZ0NT3(*[;^O_9V]UZA/AHZ<9F>B-M,Q"M8<F-16D^[7:#=%3O^
M7_=M>4^\F[*5/?'VQ-L3;T^\F["!/?'VQ-L3[X9N8$^\/?'VQ+NA&]@3;T^\
MI<UU=^J>M5Q[3\I;N>9BK"+%G@A[(NS0WO=$V)*-Z(FP)\*>"'LB[(FP)\*>
M"'LB[!81FK7OB?29;%1/Q&L2\8^4][Q.B?/J%6BH1?BZ!WWWI;RSJ'+]_XZY
M2(IK7;BU<ZT$1J6F9";0'<+A,%[+!+[V J?^L5ZL)=QB*#&);^3 4UQQTZJB
MH<Y@?2/0<>+)+V*^"&&M6S7FSBSRMRLGWP"&0K6/?3GY\S[QWC=L:K4A9[Z'
M"'_F9_ZY(>KT!_[)4*FI*G>Y62@ASPQ#YZ#'T/FV2UH#-Q=+!_L"OO9%.M/-
MYPW(=J()Q1;*:TB/+,X0Y/GZ.I'7(D, 4<)#/P53$QNYI/7.+-C:!5Y:1WRF
M[BZ$].;GH4@VSV)JUXA7;+Z+>#(@H-/A=*I"!9N7#C3^ZT1WK&C8/FJ'L9(!
MM;8V?^\%K+)&RGAP<?[KE[MO]O<?HSC_8&]W_\W;#2O.YP=VO,A^19WFT#*Z
M(3.ZW^(D#&ZQ-43!\K!Z=S6':Q63V,R$SN=\ HW&>H&'$ %(.WS,VL+Q[HE#
MO>A4CO>*<_=I@3KBQIVJ=HUXQ=H>H8:3I-[6?[5JM ^AVE8,>,7R;K=/@GU[
MCK)1LJTSE/N_6RZUGH%@.L%.AQO0LWI3CW@OG)ZC<.KEST80YTKY\RTRM-HW
MZ:]+K'J_]&[%DE&R=38.F<C7ZD:V76IL:,C6YI;5(@.W#0XS=&.LB FD7LO%
MSL9N$$&HEZ,Z;@OM G#]8'</=BT/ T0V]D!,8'@&.^T@$?D^6#$B\B6C<Y>#
M1K"O<[B66VBW:E4Z$\XY8<A 3VMISRTA[J!/B'OR7(DKF<S;/Q7NIF)!UVN]
M*N+V.\DWE2>!HK6EMMLUU.XL;@*+VZ_NHZ[N)BYOJP;\X,RUOGG+'<-[0/.6
MKF8 ]AFQSYQS>#U'?J1U/4\42+U2KUQL:YNE;B(@]I=+?$7=V_"G5LVM,]K'
M"O?+0;U#L6Y![/:K:]<,.T0@V"GL'-.2K1D9J-3/TY2\71.99IX?YTDJ*;69
MMPW(*9&@DMQ(+\W]F;>(,Q#)V,*Z59/NRBX-BI[<5!5-:ZYW";;#;>L6JKG*
MD,,%H&DN&_I0UIF?_8EB7^U/@]K037Q F=?FN2I'7WRY:*[";]7>/*_#U"43
MZ65O(CVQ(_PPC@)R/VQ&V2!K,D4?4M8VRW$^ZR9/B];+Y9B>;R=]=RG0_63V
M($=,6U=5;/=D]RW7D]2W. J7'H+7F/BT/99!K@/-3HM?:AHMYA(.M*(NTM4T
M CBH/SW[@SKI#^JW/ZA1[/#3TB&U/>]3P=VCN>5SAOWMI_"'F,? 3.^HQ(1;
MW$+,@3?),\RX(-/&%ZE,2QD<I9>C2\#)TZ"QK#1T[$O='YJLGU*!6Y7&K*!0
M28KC#.1"$DV!T%%)0 ;TD@@11_?<B='OB?&;KF<#'0K?3W)IRM2Q-%C'BAI/
M+Q!6(D4:<WOW/W(198H>=E>Y=)5&T;K#^G7R T6>_+* HPXO@:'(-$47Q74B
MY@.\K!V+2B_^665 3OY:,@36!R@\D.T8_MV#19U@$5)1>[$MYS/@G-Y+[RI1
M(J0-A!\#F!9IM,C$HCC:@9V:*CP4P%^RG'^"2Z_!7$\B1M.[EI&O=.HBWN+'
M\SEZR$7H+?($SII,F=NU8ZD>NM/&G39HQ_#OV>EV#/*A:SR+;R4<J,U88F"0
M4FC-8\!.UD@JTFE6\<<:>TRD+]4-\LFH2#E% B*=ILJ3U_/@O#[82'?@V]Y=
M\V3NFA,117!,D?OSF6O_?,A;,V1H'H;; <D$ROU<!+*DDGA @)(=.=8"H(N4
M30G&ZV\5UL@9VP-60H&T"I!(P= 6-T*%I/=,X4GT*B+(3V!. SE>9J3K3$3T
MF=*]<PTF:PT.F8(R3H8&O(D#DC#Z8^0 =OCF:@$V!Q8'8= ,T6O1@J$+3?@&
MQEUXI'[J. ]XU?. )^(!;+=>R$6<9"G9QQN)_ 9, 9/+B&X^D*5]6.B=E^1I
M -.C;M[@A(,\0?\M@7;)9(Y74J;!\#J1$I>@GF4PS9-((128!0<3WFVBLDRB
MN81K.2!OG-K *JIVC7C%A@=B":?5;KF$'< J-E3$6C7\SBSX%FBC>*X5^PT2
M&4]U*9M+*41 *B*YJ,EJ VL)6C7@%?NQ/0!6Q($GJB:<D_H!-&#\GNCNM"9$
MJV;499K8MK4U#B(D;D//FAYM&\H>_JP(>V7P&M+(D03*XIGVI&_Q\'CJV&\8
MB]S,0]^J :_,ZZNJI($,U8U,2BKI-$=_?T2.]IS,26VGDMB(P:;TPSP@H@FE
M2+-*1H.*L$Z9C(:[4QI*L:BW>^TV.A]R!/J9]C/M9[J!,^U 8NQX6F11+#%D
M8 (#*K7*/<8++%0%O"<."K]G742DL=9^.NX]?-U[#Y_8>XA8)]XP#]2FA!"J
MI/%9R@6#O/-G7^2I9/T5@P+W@,&3)P1H<8!*%3^JKGI-XOASRI4P5@=K (KY
M93@\1Z-E+I9HT]CDBZ472<R6$,G2&B\ZH(X/-5E-QB%09'T87 >K&,+T+]$B
M:AK0%JN$_!3]Z'J"5%^MC!-YQ&KES>.ZZY#'=A$;^TPU'V1P*)!L"1P[M< 4
MD5#X=.@F>0HO22DDP;YT L(J:"#-%^1[@9,:B$P,C!FDO8[PIY.WE-%<-];F
M;]>(5YR I<28:@3GWC$A'>=\O_*/EG$;>[<SY6M_BZZ#E4DF,/,$B"U>R(@.
MOXHH-QS]E4![-?J@=%CC)XOB#.BWB%RS,,OT)RL*@%]+SX_3;(#:ZMQ"SL8H
MT!:25=16+6)GMGT.E\RTVC_ C8)E=_.+.7</#L,2$XSBZP@>'G@^0II.%?RU
M(!;M2O^I2N9>*D,X(V[2 JHC]HPY&1;P-5HHQ3&*J30&7CIH4E%N<)Y+MV=2
MBAD4A8_<C^<+D"$.9IX;6S)JBQZO@!G.0;+",&X031&NHB0)/+_:O34' D B
M(&G@.+/0V95$?+D?1YBW">\<>-*6(A9B!AZ#Y;(ASJ%PK7&N>3%<SG5TOG!3
M44Q]D4SS,$MMG+(@QD)]-/*Q5<>O*SY3S+W1VV>[>]D(6;$;J3T(E,RGRLVG
MP;JF7M/ U?+%K0"S1P2HX+%E'CFPGG4-O-<_'G-[M?\#R*NRH?C5?$.PT#=U
M\;5^I\/0"Z&"!F@.45BNKM#(LYUXNK.(_<\R(U4B;=A$S/!!FD/G0RUYCEY8
M3O_KLV\>=[=1/9PJ7Q@"R\H2KGGWL$R@OGGH*EEZ?B(#Q1WQQ+7 "@-]F@K^
M245>DU3^D4LZ9.P.9;K'.@22HY%.TC0W3T#UF1?HEOVY>,1SX61E5<\'[8D^
M((6> ]]@:JT,.NZ1?M-[I)_((WV8)PEH\TMO],4'<7_=+E7ZGGP)IW;;[1-[
M$X,E'CB9ZXQ17ER".FTA?CD\5!@K#9GP\LL"WI66'KKV((3GFT76M;NH5ZT8
M6O,KJ?(0V'*:@0%:/&VJ_469 N-P+CX;#Q*6"J-O_5K2^RR@.K_3 X&@;N 2
MS-1UJWM3FQT'-N%L+O%E8"PFXEJ:=Z6+.*-$>]NWETT]UP.I?P@Q0>*]^?*(
M^R:TZG1U1HZ@_D;.AO)9ND7C"XLXM$6-3JC]%^]PQW"GYRH +1),?MY0^G7O
M':B<>60/G;XEX(-#NP\J*=MQ6NO@LXF_FR>P5D+NDG3&CI$KRC./P-;'!'.:
M/56FHUW(1,'>%99_13A'^RFP:&5);S+X:87GPI&..9*+X'KV-,X3=HT[9Q:>
M8P\\GW1]O+%X4TY55)#; HO,*+"38A>:R)?52II5=3(=E\UO>]G\1++Y2GPA
M$3.+0SR([9\-2>9QV0$D,B+RVV(>P!^^<,U[JF ,P%= \TBN42X#OPKE#3I;
MJ: Z90%(KMHEWD:AJCR;Q0E*O%I'^"J@BR75>KE;(>X=K,P[*EC0&">=?.7@
M-6[% F[#YU4&6XJA(W,#)9[0+DK)Z'>_H6ZUFPJ[VM),DWC.SUXLD*TB0RX<
M;!9%Q-B$].E6I;(>_1ZL1'!J2 N R<\7&5BG3;"B\H8=Q^Y$BQ$ ][\6&O+2
MU5LP-I(HX)(BY+K?A5/JZSPA]3"]7#C^>C]>+&W[(/L,E1)ZHZU5W"9MD)<C
MB/T<GV6ED!Z^DU002"[9D-12*$%5"@SQ)O=])?"#0TUDEB=1ZBY<#0JB&@PV
M"18Q'BL46[0J>F"P)5)'I$@5$W!BX!Q0[59"!XS,R011=V%C\ .=C 9JC(J%
M9(I DG-.CQ]'2-'TO$C+SEAQ(@:\+XAS&H;X(LP[S?$5MMI%45C-ET[BB#DH
M!3UJ G)/BQT9_%T9.H?9TE2E)M2&%!)/,(Y!2Y'H5YCTD=2;"@)K@'U*E5DZ
MNY'E(_#5VUI X!3G^D:E.V('_LNE<SAV3:\%V$@B,0@#.R"F4QM5TFP%[F0
MB6D5V?=MQU6.GWJ5XXE4CK&IJ3[*-\D3$.<:CY>DH+4I"&:7Q!W0%2CSR%YM
MC;HCX9J$O68FML@<!4+D%"FQ9@,*"TH3DLS,]29RRK$3B7DV??#J2>I9::49
M']OL#VX-X:<UJ'>8ER$8+P"8*>(#XE:W:MZ=V2F4Y9QYH67I''35>3YW=8M0
M7J-V!_M!^EH(:G_),Z45CBS.X+(HGT\8>X(.@9OE+>']%.SH^\,\=L9EK6"@
M5"NQ_Z:N:6P FM[;W;T7O:KQW)->5O*.S3O0#VUPS/]%,MC=X[_'H/8$C--L
M' "$-N_!<$$M,K*STO\U;=:I"B.O7#C9JH/1E9/<HVKWJ-H]%?1(P3UL=T\)
MK-FL3P*;Z"0$G66_/S[?29TH'YC7?%XX#Z!\!3%5D6>Q.6/DH^-O)G$2R 2G
M&XI%*G\V?[@,&.]_YYY79"P(RAV*Y<\JHH'3>PO#=_>%-GXSL&JSP Q(_[[+
MO_V8!?4?7[_<?;._O_KW.V^^\\>#O=W]-V_7O/E'&C@/'M8D78CHOW\X^*&*
M4I#%BY_W%U^L_-*;@5^M>9BJZWR#L31?A/H[?F!9/NXY I.W<J_F/'$>ZV,N
M1=)F_E*CUQ?WP2B8#>RWIIU;TQ;R@1<8%H?O@I7%:D 5>&:-'KQ[W=NKSFU1
M3V!/NWL]#6WD+CP;,OF1E--N(C!]E9_Y@/^^W$C8U58->'5$8S,7MUTC7HTE
M42J2=EH+]F5SCYG\T4>/6M#V^#D)JI?\]P?,*-6-N1I2,?=>;& ?[I8->54$
M(\^\():<OVV@>+?4=KL&WQDN"^=\2ZGO&S5:<W&]KK'7NRRA-L4:5^S'\.)J
M?'@\\HJV2]]EM)V+.=8C>.T>[\7H_&)T.3J]&EZ-STXOO>'ID??;\.)B>'HU
M'EUR:/YH?'EX/!R?C"[X\Z;-\7A\,N;Y>6<?O./Q\/WX>'SU>Y<+,G[:W>OI
M^JEZ#N99+D)L.);(U-0E<978;R))L+VPW)268R.$<:/^W8BKS?/AJ=SR5&P1
M)9=O\*54:(%JGLH(0H_+I/[(5:HR+$L#59P[_\6W5+46.&605!^'10(JHB>7
MBP"X@&XA$T2ZHSJ\HEHK75$7BBH15M/Y>8'D4W_J3)K'&G0[*D[@"6F 9/==
M!>0$H?--I(R\(,>6BCR5_\B 7@WOKKP./E#V/%P[ :["]2\!S)H*[1@P*G+?
MW@"AC*/!JD;>BRUULUV;07V>,"?EZ.-^(JE?AC>'?[ GLH<YZCYE_=NO CD5
M>9@Y!8:\T46%H(5-5#0UP8/^^O*V-BE+*[GI?L]-GXB;5MCHP.&A=/8/XQL9
M"5UIRGZ]]L_816HL^.J@8*KX@V]GQH5KJ4%T&5&AJ0*N<P1D2ED^Q&TM=&,4
M>Z'*3!$K@J42Z$:<&&;].8IO0QE<.^6Q\#WQ@PCY%A,TL"AY[:!^&-Q<['>>
M1Q;Y Z^BY],P*\6V @?*Y;+54G_&!LF0AUS8JC_\TK:P/(SG"]RRE'FLBJ:(
M?,U0 W.5B@46'B>*"HZ(-?'Z8 %@B BO*(:Y-AGEEWX'X9!Z5S.5!,RJM(2@
MII=8O>T Q'.5$WZ[7=0;<SM>4]EOBPX]"D*70%GK,RQD!=V/T*M40L6"0HM+
M*D],Y(V*\Q2$Q#4>"=P5K)F^IOTQ[7P3_$!EWDO\2T8^55KAW_,XR:[%-?ZY
MH*V&/V;+!7+OE%!R80U#L]!8AZ]?0]7["U,\P*\L7FC>5KRK>)-Y4>D]SFNV
M26K1-L #519R'8(MUVQ<,'TD?H4#N_,QOAVPK,.]TC)9,**I1\5AO#OX=9Y:
M *3R _&5YFE6\A_)&QG&"ZL-%)U5U7]*^'\-1Q.OKS9=335RK@P*7/=Z\1P?
MJ+DL"%[?H_%\K1#61),6#TOD-1;:(8)&Z3%;&M?55,&;U:E7P?O E# $C ^7
M(B&Q#Q?H^0Z\0T1-B$&+Y5\')81DPD0NJ[?PPEN',VL8HT)-VH:M0RUE-0/:
M&F[?NU^))'Q$E3*,T(W 3(^J]L0[PL!@FIQT^WEF$QKWFR 7"(#!\K "_*3Q
M[!@&5,!Q$  '$&JH@2"6*Y@/8QH KY(90BX3$32SHO?;NN0RRJ>P>WD"]%0]
MGGVIY".72FZ>2GH'QTHSAU\Y(BL TF&_/"ST%%4'BSIWGP0MCJQ"_6#KL"2[
MFHC-$M:Y3%(8G;+49!#LZF2_=;3F8T&8TKV:Q=+T=3BW@8@UV)B&R-%$J)6D
M8C$(+CU>&-+ XF;X*@PU>X1%R0ACP.#R^!A+EM$U23P1W, T!3%ON-*7DC6P
MK9M"RI<EA&G-;21!Q 5\5N?[M$@S((NY$36N/;E*6A@&B/<7<.\U <Q6..$2
M&0R;M03QC:.R((!\C C[.8HO8I4P&@3O"9+\FG^&)5ER-W*'G<'J@.(Q+SJ7
M5,\KBVA$*3<G@75*6;RB]HSB=?"%^[85-,&GC>;CP#WBE8<(#%%:B($E'V-'
M'\+$DSC46!-XZ1:HB]3-K'HJ\0>+0M'8]PAN ]5EFH=V,B[SAZ\:"1U?79T4
MW0ZO(@G'AP"/G#[/A!@NLHS+\E?<+[RYS&:,..X()#W(%3=V&MCFI]V#WO)O
MH^5O:Y?;/^F[*];OKVW</.4$J*://WS;)2UJ]2MNHBU5,X^U_^5K+.3!XYG(
M \S)27,1:6=0R55M$/1 15K>84*S_ZS9%&;'.*LH_#@4UFAX C7!4T%70QA9
MQ2!1SCJQ'0I+F3<J0F1$OWSS#H1@89@29C3L:B2UU(79Q'F6$DX>:IL^Z-!F
MA8R2I?5IXWBA?7'B"IC-\7[;M&AAR_-K_%OK">2'UE%3L<6&\)[>6_](O$>;
M9@/0N,$Z0Q11:L%F/H$!-9VR.Q)A1E5*?U'GE")*AK=<@SX?,:^Y59I2M?$V
MS=D'0D^RS\''+)VGF(>@-S*22^VQ1@N0H#5O1)C+U:-$1R?0S"]H,T3$?\ZF
M4T6XUUL.S/0$&. M:?9G9"6@ H(.88[2-5Q9QZ(LG/5 T3"FR#?P=\+/V%KQ
M"3/2\(JF,34/@',QF.-%P&&-7;W^$\@='9-).U>9_B0B&IJ*M)O+6!Q>*&[1
M3 ERY]7P[E3ZNC\E.L/F&AH4#&)@<L!O^5)*5+OY4P,UZR>-G[.Z>L*[+AZ(
MQZ/XA"#H"6.&A@J];J[WGH%(&8&0_C(H^10'X4-3(.=G\4#[#\BM@;BMA.T_
M,(+E5BQ=R5MK^-:8G&HO*,Z+AG5O/W^X4Z=OV./VSPAY,\/DSZ6(4NT?YM$/
M^"]D31*4E7@I)1^=PG:Y<0A_N$UW3R4L"=Y,[0$'#!4;\?.H]1^Q* JR4<_8
M\DG&)P1R 91@O[FF[A(4 *1W(3F^YW?I'HC:6\+]$DN^_O4?B61[R$]%U8S6
MP?B_=$N+^#9BENZS5R0LP,"+25B$%V97W3C:#7RJ_3-J.MJ+&(/'&!I:"!.[
MT%DP]LSSB?%A"Q4!>:*D*^YCDNCUSMY7]$AZIXFPIPXL>=$*U4N7:2;G9 (;
M'['3 E9SIM1+<SK0.HG)P)H[??M$FN8)NOT=VYHBX2:LBFY<SBS34=M*FA;,
M&?@HLSP==P6VBJR?T-87H*Y,L6./5F.)JSAZ7.U=V.06])2@UL!U@0CWE#4
MI&J5M*EMW^*TH=4=86.\0=O6OPR'YR:WKEA&W81VHD)J3Z#;.Z#A7B1(\(#2
M$N*[UJ8SLD 7)D;4(/EY]^I\4V%GFT*CA(&PIJ7?C[8USY>!9L/&#+FO7_I2
M1EVQXJN6 X=#TC QL1SYA>/3YH)R(VHZDC=F]DX.BP[64X!*?)91+6&&A+2:
MZNA4NLN4VT>#'SL:_%S$U<M>7#V1KC@$2;1S&"=)SIE6A[:M=OLG]L,_[F<\
M:]#':OI;07E[+][>^:2VKA915A_^^+:+.HY,KCO*V?OZ05&:8:5G#UY'S>56
MQQ@PU@C3M50:BMN2\O,A3F!02+UTB7>>H 1';7'(B25[/[UY0XES D:$2L16
M-TS=#X?GP_9/P=JVW"\*-Q=W$-LO^2;> GNOJQA USL;'1YA-H?3- D8\T20
M+O<^41/**)G:?2_T6#ACXY)_Q3;1O')4^'OY9L\F^TC--UW48<D. RXWB]TZ
MKH)#8D"DS"#93(PT2@*R1W+[X!,H1#.1U#$WO&'+M^#&@VHL5SN+C!-<1UJ7
MI@DH=W];6EZL"AMN#7YLX]-N;19876B@89U45$9[P%/V"LQDQ;40G+!+LS"I
M=.L-?JUB\&=*P[W7ZY&\7J8/XBVZ@G2<_P%!LYFX,7&YPC%4K;XP:;%%;F"=
M()S(%H>]N)911G*JV_NN"K3J'I>E$%A/22LIJ3?(O^FBGL9.C(*\P&J2V^H5
M;-FJ&/\ZB",C20Q"F,Y0J.4S<'0$BU RVY62\L(?3)XF;6B=N/%JF7JK6^M5
MJGU8XID"/G(ZWHBPI[W5M/>JI[UO;+!76DP7<LW63^$5:%N:XWVW[D>M&ZEB
M79=>V8:K36J?S=MGDJ9"3")8*L4""LLCA:-(2)AQQV!N.5^25D]APE%N?.N)
MI!=.3^5N.5(I%7'(I/T38=20_SD<G5]YPTOX"^&$+H]_]RY'5]Z'LXNKC][X
MU+OZ.+[TAK]<C$8GH].K@7<Z&E]]'%UXY\.+J]^]D^&O(T0>^MVKHA&=73A@
M1 C>@Q?].CX]&GCZ"?J%>.7XY/QX/(*?QJ>'QY^.QJ>_T.7U*RK//!E=''Z$
MCQH6""_\,+XZQ7M@ MZ01CD^_'0\A %_NC@_NQQYO\';8;27YZ/#*^_JC%YT
M/KR"D7L7XU\^7ET.O,.STP_C(_AF/#R&(<&C3C0&T87WZ^G9;SL?SW[#UU]^
M.ORH%P+?!@\Z'A^.3N$EO^ @8;CO?W<O@EF//IT>C2X&M#P- SD\.SD_@TLN
MW:5X_^G*.SV[\@@,"1X*U\(">E?PCLL/HXL+^ K&-[J T5[2D\\OSHX^'5Y=
M8L[:IPM<[).SB]'@J3;[ZN/PREG6@5G>X3GLX2'=0L,\XV=?G)U?C$=7PXO?
M]0;HJ<.T8$A?LS5Z%ZK+K]?MS)F2W1%O>#'R_C4\'A_ADT;XX,/1\/WQ"#_2
MA#[!MA9[_O!!P457(SC%0]S"XKU'9[!BN+MPWP7L]JA^((NU&L,CCH_AO'R"
M%^'"C7 2YBJF,=C#BR.>7EUI_"KYMHFU7[U.^%0B[Q@[@]L\EF.ETR[:/RN2
M?T!YR(<OKX:G1NP  <$?-6YHJ?"W\>6HRAHO/PZ/C[WW(X*H Z918C5-C/[R
MT_M_XD=@%,"YD7:KO/>WCR.Z6[,G$@ZGP/,/B2__<CS^971Z" .YO+H8'UX5
MV'@%MS@>_0)L MG9__TTON)Q?1R=7?P^8.D(CP1.2XQK>(P"YVA\,<+'XTC'
M^-7H?XACX1WGGT['5^-_P0M//AU?C<^/1\3#84R7\'C-^_K\EJ=%.]@ 5GPT
M/!G^ B)NJ]!GRF?&7(#?CB^O\ *$>CR[O$()!^H<"%CX1/+M$U(>WX"$],O9
MV=%OX^-C.HGFFO>?+L>H 6XC(":>:J:=(=X*1(,HF4RM*'0+BJ7KO.$):%]7
MH+Z-4*%"P7]*A,S?7P*UCTFKN!A=@?3]B$SBS#S5Z!&,SOJV3M.<L]8.QD@O
M_EEA586_SC;"5OP+.,51.T9_]UC; KC]T#4&+7'TK]%%.P9_WQ*33HRD :)D
M],L9DFU!5JCI_VY$W7L@)M"92U1#M#$RBOJEM9?@EO&5IJ2*^*47XC>G5E5F
ML?RAHBVS,EU8$/BB\A76/H#7%6,J6V?ED9>$O25L \3LT0WZT]X>/>GLP_-
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MJ_'*B9'6(&U9L=:LV^>^K_Q*=FX[W.QD86TQE\GO-?K#7'9&?(+O7W/N)UB
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M5B^TR<+.P!!(#2S.#!VLUDO>3Q$8.2X(=J$V83WVYEI('_@?)8M9T!IO.*U
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M"0.S-??\"+O^%0NO8!YE[S96@G+  ;IQ&S?.YH[]Q@#6J-:RK5.U>@!6NK2
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ML$+WU#&;,R_VWV6"L>V^:XU<X(IC!G3%2F8;7NH))3WZPU!"MO>;VMY&3W(
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MK1^YP\IGWC!BDOZC6]HQK*R@]:R+V6A48G8)*A&>J\?%-*D8EW!0 ]\H8<?
MSTYW>@JZTS?$#GHDK&61@AK$2X-HR?5%M*+)8ID7E;$"0"$EQ [XDS3<V8J,
ME9BU8JP[NE)%+ ?OMR+8O^HD^I2N#H+C*,IIH;&U0S*CW1SL)?O6U!O=\H]A
M];D*;R^!99;U_9;K*PO\+1<8G1W)]0B7F(<_AH4F3XH')&W\.84N\_1:8U.G
MN3TT44=1),U5%FE;1PL'KZ_K'/CJI&L T[FH<1JA3[&.J@9VEJ!I85H9W">
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ML)27?:;M%),M<4^0]RD,=$:I4;%_FK2D16\]C<8CHG1-Z2H3U\"1_S,O/KD
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M02WH[5NCOV)V1-MBNC(9?=4-0HZ9BLP/J$RJ2-?4Y*L,SC*+94#Y'"UD@[R
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M"GM$I,&.2P-T]6I5I GC^NVI?:S0C>;!T<2D?&,/F>E^0 [<=D0I*<H*<^?
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M0QG, G; .(_.-C=SY%X*!DK!B0-<JWR&Z,3D):2W="'/?6EA_ "@,;+?F;T
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MP^[M8-@M!Q=(6$*,?P8FAJ0Q0KH\V!)X14C\LB!3?.%[/L<\<K =$,>/@*.
M25)0K"HUL":A9"2H"J7P$8H4J)()K@-"!0(+/0\PX?0D'V!"H9@GJRU#$:HX
M<C)ZAZ\L#Q8<#5%L'?!K2SER+G"=<(*,V-"E4B-@3\FXQ.(8[XE 34PQ)<Y.
M-:^0U1IX3:+T) ")%<;9+J?+Z^'K9HGXNB"HXKD9.E_I&\6#G@4T4P;^"B!Z
M1T&WD?-ZHRZ]N_BWT]U&BR,") '8Y6!#VQ?*?!UK.DFN*2UD:^="6FZPCH';
M'O9Z";+T(Y&0RK"8RG-R:\W)JF+M%6X4G/#GT1F#-?L>E>(=-8[9P%G-.#JX
M:85-=N_8IF]XI7+ A#,$5E%0 84:]CY'W-)6^) >DB+1H:Q4= "60ZO[!L00
MKQ9JR'MH(#T(H44EH=OB0)3BFW ,.I9@/*6+:"@$23%8R30F[H:FVT2 ]CFN
MR193J,%2ZQ(ZN@T;C#KL^I4DN:6JC#:Y&M7>%.0Z':04$J^%0ILF)90.Q8,_
MESC&C'))6;.!SOL)EO6RCZ5BJW#4A1KL/J%6;=82I*WMH2T>!01L/Q8A'=/A
M=9/<X7+(?FS4TE$"&$H.I0^D&;06H1DB2&B9M4PTM;(E*\3AHZ4.4+@UJ -6
MG)!QE9<L21[%2\ HOHANJDFX9I?Z J+"4L^J=HEN3?ZZ]#$9@:"19F!_DE=-
MG4H9]65((NZ*O]'9 A])#H'TF^R<*%,UD<O@=.KP!Q%8:IB<IZ!S$59V*H&K
M9NFO$0 Z,#8<;8_.CIGG<'+6F+  JNMAX+Z9H:?FJ)6XQPVZ/B;9''FAI&PL
M);108\X;/"K$8 ]O,*.3R$N:/:R3R'42>2F2R%^'WR9H@%"&[>!&/,*Y;$6R
M$C6?[CZ6Q_M*\02/TF@6X00(T1\C &-JC](@J^NWI.T6)E8%OC)I)2*<IMAP
MF.W8-:O*QLIJ3"S:WE;0I8^?9,A)T)ZU:*U/\XI)H0:999H6:I!%ZGQ:6;$*
M6IT6!^94"]3/Q@.H!,II924T $LN#&2H%M!?*Z _"7FUL,"KF8G@(?A]420Z
M*\.8+/IB<!Y]^ ]*!3/RC'T$RRX[6-ZCA_U6GM"*,9=]IRDX/OV@\O(,;!#+
M_/<;:]JX$.8E-R>-YM7I29-?&:=-HW$UO9R<7DZ;C:O_NWBC7<&5<@6/8<1L
MH%RBJ-YN*5@Z$J!"P0+"OB2@H:OB]"3+#GOTRM["U,SUFS'CRP<,_R]4&#F7
M.B_#=#M@G!)*%GJPQ\#?'FW*0_&W+UPD^&>L2*O*;!L7K%._K0_K+,PK;)Z<
MU"]/CB;'1Z>R5J\)UG;S=/*V63_  UT="(^"P1;GKGBH%FQQP9ED.[#P=V,)
M%WS6<>#@//"+072J>=9,AZ?D3R\/TE@U<,?JHN=ZH"N>V)]U.'.(F5.6"58=
MU7CD"5#7;1=.*0]"0ZQN!S7>SKQ;(7<3ZUFA%4D#QX9@L\1&G<$@OB8;*+/=
MP3,P/-$=]"N@0(OYJEP.!>DV__4NA<J_2OM,M,]$^TRTSR2?SZ12T*^G&OHU
M"_IU[](48CX:^O57Y0+F@'Z%#=,CE$_6T-BO&OLUC?W* MC76NS1OEUGS<.0
M7VLIV%A\16O/*[:@$I=,8VCXV&*@>6KXV%U<JN%C-7RLAH_]"?"QC2;,DW7G
MK ,S6MKP54R"&_$EJ _Q8",# ?\T6B>E4A\:-K9P)-&PL<7GQ!>$C4V8^T\S
MRY@%+W?#NRE9/OH.^<7<F#J[RS#"/W$'7B<M\)/ST!*DG0J_<.U8KF?/WWY:
M"\=EH[]]:X(>2=J*X^;ZYY7K.8(O@@\E 6LTY&T1AOK3(&]5!G?($QH--QX+
MUFBX&@WWN<P3H.%JI%F--)N79P*DV:A &D4LPA:XY^ORE$UK;-=W$;9KH2AV
M$)Y%J7BN4(/<BR)5B%%F97TI\ \*3$D,W<MZL]X(4[]W .>BCQ94%V8-.,);
MY[<%=*)3@5ZE$YUTHI-.=-*)3GL3G9+&&RJ5I)XYEVK&HQU%/:/NH$>X[]G!
M([1X\I<)X=#B<LWYRA5_!'^)&X;X_+NX.8DJQ[3<U9RO_["6-'/ZKM)#E^?U
MDY-S4D4>Z#O/#,:CU%1=JJG?/7/SXNE%_?3D-/OZSH=WO_FR?G9UGO/AWVG@
M<O"P).Z*+__]IO4F30R90OTMM*R#I#/X*2<OII?Y43@4+5._P0<"$E'U_@IX
MW9Y;)I/<RX.+1.+-JPFF:<2. )(#&AM[_)Y# _VR.Z.\#.<%Q.UE:32YE/PI
M%JD2\=7M(>TS[G_EO#%)\H8ZF6WA#JTC*LT'!O)!EVI^E8<WPV>F5<5K91$3
M6>2W1KUQALB>\Q@:N%83KX4'!/( ^O$%=^:6!.Q'^R+,*&VIC-*P&P ZZ)-1
M(\MQ/<R6<@5KPK'("IK^;+3WT8I',QTRW50IGE:@=V3N0:%<GAF'8I4? 2=B
M&XZ_H9V5PNTMQ PR5C_5=*@6=AU2SIS$O-!QJQI[$,B]2BV@SB')SBY!!GDK
MS$!/=QU9\*^8=L>0HU%_@)KX[>RD!M/%+B02G-):^'./+X5,IPF1[H+K=L8H
MCTC?P*L?'A!KTDL\@8P6[G#'-=)BY)9,C[G%)KZ7GE>4UGX9Y,;GF5CC!&?V
MPR=V&IL7$<8(YK8Q[FV3D^E"P?1SSBQ%LV<//:*)%/_81]2=.*<RI=.VHQFH
M<U>9]$(P2-=?_>PQ7M33/LFM@]RR>;]YW_B?WV'$VF:-'*9!Z*919%/@)$!M
MC,#OM7F8QSS<E>Q< 8IKV:T*)2M&0"V[6G:U[):3@%IVM>QJV2TG ;7L:MG=
M3]LR9G]K<=;BK,59BW.9::K%68NS%N?*T%2+LQ9G+<Z5H:D69RW.6IPK0U,M
MSI43YV#IM;B_'G%_*9IK=9!/'?Q.U9U[BU*?@2BRIR=+ H(F@"3X!>EU<F8[
ME[-QMB>][I=PP4F>8;]YSWH9.:@2!FW--A,S,;$9@8FV)#<3@BB;"$3#VLB0
M#9#ZDNA%)&*$WBV<A;7$9-<D_D4<\B^ RFBTZLUZ4^8"6XN%,"U\+NKG;4]3
M7\<QRK1MQ-5Z<A!D8(FSL R1P NLX8_X7M?C$H0+$[9Q1 :V=E[!,MLFU6A0
M_0:WYKZ$AI/YOF&B[M,,WF_Z@D#>;-]#T Z76V9Z"D?7CN#&[#BH$:',9ARH
M2U7C,7@0>N"4'=U8[HJ:4:HGZXSUHC1CF<N,XS/F'*:YKNU^);Q0XLGC[V-%
M DHL#M%Y[15AG3T*A"8SYCZN2HW6'N=%^,1<?GKS2P@]'53 'QG'M:.O0;;U
MXI@1#(G$:^0+;*5.J/!RV? >6$O4/O54)G!.99%#R6@\E *]2N.A:#P4C8>B
M\5 .Q$,YSZ_O7Q$NWD3AXD788HV3G4BU$<J8*>;"VT09VX$W6%F\R%: ,1I'
M?"U#01+8A.EZ-#"FPA)$ZYC]=JEJT38 ;0/;ED<@F1%0,<&)QGN@*VO.PE<&
MY6W!&\ >AX?<"#@Y 86\B<.-H*>& 2=SO@2KG(S[@']/)?,FOPSWHP7,#"R?
M=GWX6U@S&-BN2WOYUA%3( RA(T7G#[A&S:+P*_">,V:"58$?$7'<AU2_]PF"
M\'KX&8+JS=Z,*BL1ITHBNA%I:7EVD+44\E*H068!6^;:V.3Y)\& )40,SX9O
MDORG--F3!:+L [<!Z[GVDF1\@JV+8JK'GA!8.V=/'(YX3NS\Z[)6O4$Z@<[6
M9RC?UY]&H?YJNQ9G]]RPII8!^O0![<^@IG;+-75,90L!4V3_X2L.1^(.:!=>
M8Z,Z^Z\-@ZRQ,;>>\,)XQJUY@#7_Q1+>DB_R <!7F\*39U,82(<D:%R\DQCI
M0?,WPLA&;PZ0-S!\0GQL^"W88YKHD#EZ1)P.U5M"/-(^LW'#D^W/L5=8B,B*
M;@[X AKS<"Q3F-LPOD4$#X_XK.A. IH_^-01_NSR74Z;ZNRT*N15TH/_USIY
MEP124' *M)''VWFH#AYRWT;'8^0IM*8UY>Y3]H;J'(@=/>C7R*$5"+=L!!)W
MJM525K$(')Q QP6\B%!93#'E_MQ3CZ-A'+!2Q&MDL2B^#7F(C)/XRXFCN>OZ
M"W@6_@K#E,\HYG6#"9-#%9Y[D.,/.IC X#)[30!+4I< 9H+-;GC B\#_.&MB
M4,L#PP98,#X:U'6QIA=PW_]#9Z 2F\">@G\&'MXI#=JQUWP>'M07@=<XWF<E
M(N&F. (KT[]F8@U_-X0P@T^YY/U3H\XSY=@0\9&\XX-7;C;EV.MIC*OAJPHK
M8>,%E+"[2?9("\8.%^I:7%23/N3M#53R[95O-ZATV:@*E:QZ\HPOO?F3X^PU
M"_<K6'.X8B:;T$P$$.> ;B+564D6;DNQD.@ANF"3S0BGMQ*+8VWC,\2A"IA)
M,U'<M(FKS 0_';2YO&TTZLT-,[]*3+65JZSCP/V83[U7>0\VU1Y\&_CC'FU+
M>L9 OYNV/R'?VUK:R\%&'(7BR;NUSX"*;&I'_.UCDS/U-&P0Z#!$BPJ_,05+
M$4/*-GP^Z+#^S7+)FI36:HTPLAR.S8K4:UU[+N@T]&C/5; ?;0@8_=Q^@%,S
MOD4:%/@Y,$:_TF<%AOOA(_#MG'O\P6A_162##*?/V=:6165MM_UL@E8I-L-S
M"/824W V? >;5O/V8Q'(L6PB)TT]@Z/<<3:AA)%=YJ'*^0F_(T_DTMT1]2&3
M[R.]$[XT\KC[>+R%%^&L&)](U%-[AZ]<9V$4Z%4Z"T-G8>@L#)V%L3<+XQ5M
MV.EDBD;.3(J8MT4F3HKD?GY("*!*ZZE.RHWZQ<F/#:<==N*N- \;*1YNRNSC
M1SAQ1PR+W=C=[_7H9*]:P9=H>VR*S>PG\2B<'Q^=4D=O>69O8ST!=HALO6QX
M*DH+.BA"%3[VHX)4:O*.<%=RE>;KW4&K:"*[XU;1?3\M=)4@9.[HU8$!MJRW
M/B_"MC7"HM5GJ!O,E/IL@?(\S CXP59 P==/Z599PC+.*DC!A)RF2LF1Y3&1
M6N6KE3IKJ?2*;=DY!U6*[%U,G4VLJ"?2!G"KW@ R;;5T80T8)\4#BA[FN43E
MG6AWXV+%)+J[@H8@D>Z.?>!"[<-:"85DF&Z2H5D_WTS=UEY6&-S#YF*ULCDV
M;.ZQR:8O$,PL^%(I.8PLI05?)\HQ,0DZW-JF,A#T*)862;&_LI?)2"<[2OSS
M6.96RR7>++V,91\I8W-/P2*9IZ[O/*(M';>APX3MK;6CTF2*<<-AN\4>VNJ]
M0C'33,G=."MR0>2;Q,]#&/:%<])$>$\"6"/&$#$C'RP YL%(964MQB+402B(
M0!AS#I?-9)[?=LN6BA;^^8_3BW=8=8NU"_CZY5I^@!@Z,X])5C(@)W-+1371
M-+$,V7XY,&04&V=D-2D39G-DU&#JV5'/1K,Z?,2WY0=,CK>H<)U_DG1?/#>'
MJ>(,-=%I3,\R!KX[DZG:;&4\-X])Q[V+]"H=]]9Q;QWWUG'OP] 'JE3:>ZXV
MLEO?H23.\$SBEBJSL!"#_*X*WFT6TTGY$EKW9#^J4_Y4<1N=L5W54-F31N?2
MAI,Z'O00G<IAMM+"-96 F#Y?9^<UIF.Y48[T.@4[MN5A]'<]V+:IOIJ,HH8^
M@J1W"Q$5R,]  6$;W1W^,BR>DEOG3,S-.GP01DY(:BLO#J0V)7^$\I)A7J@*
M\%)CX+6L3)6K95!VYMSZBGOR'*MZ8F!J.]<EA&2CU89%6JPP&HL?G:Y3 =8G
MV_F:CB##=Q3D&F&CJ>_$1DKYXD0S^>AWI7171P2"?*)Q(E1+99I1N N)%#BD
M8]XSH!+8_Q*>)0+'X!,;X=EBY*RE L$@4Z8M9.) D ^<3!K(XI%ME(?_DDA,
M.?XNORGAX )Y3F**Q.^0<!S(+6% FFH5T*NC1F*#R,\LH=QK-H6'X(#DXEL]
ML5A)V#B0EDU\C@7_BO[&8!BQ D4J,(A<>5-@]]T,6=F=_D+M]'V;#>16'_)7
MH7;12FSUA1ADQDK"$4>L"# SVB%!"JUE.N=HHV0(!=%:^EAG +(&/X"8&:HP
MB+8$7;KS_E*)V0?0S0Z%P>_X4QG80@O82ZWD.+D_A44R#\02M(?5F%B2\)BU
M)#P5[J">X\NM/HV+A>(YYT]AG&GDJ9Q"'/E?P8XMM]L'[L@<9(\VT"G(M$</
MP@MB02DML>^O0KPW'T&]$>9+[XBO66#Q@(BA:L*$DY)H2-YX2\P1":,+-GH,
M@-J:2J2X>XD4QV9P+'-!.(09W6W:AD]YEJQ-"0T8PXXQ7J0)3-QZT0D+9RH+
M1(J#=;]%37CV@Y!GZ5"-T$7,H 7=H#"]P\];]%P.*(UM./<$TE\DB<Y&=KB*
M E6_=J3TX3\L#];3R#/V$2P[]_!D?<\?!+NE9(I2Z*,M+04RMI.<]?J7>\-
MEOGO-]:T<2',2VY.&LVKTY,FOS).FT;C:GHY.;V<-AM7_]<X>:,C<05_U?='
MX@@F0X?B2CIA'8K3H;C#2U /WTA^^>:9L42]/ONS-^YW1R/VY\?NL#NX+<.6
M+SU&D;G[&+.:4U[:#/P2N WF\T#FM.4PTP>]QGTXQ#HP#JP,6SD"@RI<NH)E
M5"5*(HT*[:(O=<.K-Z G-U5&098T@Q'N>A_:_1MV_[$]_-3N=#^/>YWVW4B>
M4(?=\7!P_['7K[%>OU/_M6>KO:V&LJ*?Q5Y_6-C!\'XP;(^[-W+5\WE(FF?-
MM(M$_O1=V>,O^MPO7_(,%KE>4\YE<K6+.V!:8%,8M@QS_2$C:7@;'8).+]ZY
M]"?KS+@SA\]>"^<K?+0L\\-)X$BK2I8[[CN<=>;\P1=Y)/Q5R&"?+T1UR)V2
M/,986:85"%^UZ*%%;IO7V?+F<1J7P%6^D\A?[FOL@U@*!XZT&$MQ!580M"[?
MX:G/$1YWUN63PS21BC_R/8K1$E-V:RWYTD#7PV ZA1.9<[A,QB("S_$1;N^?
MN_]-.1V^K><Z?"^:VMU;27=O@<+2Z8-SQD&T^VUF32R/-4[JS8,=@;FI]TO=
MAU<OYPRORER#_F=['.%5F>X^/WA5YDGN?':0'SQP;.9?@N+HN)RK$N/SD,?;
MLBEUXZIU2CAJJE W5U0@IVWQR^VVC.5H?^KV;^!_8]8?U-D9&P_8Z//U7:_3
M[8^ZK/UAV.WBU6?;5^<'[>Z'A5A*L+SCC[T12Z[Q_D4NQ(2R7.M'J!]4Z7:A
M!IS%X$&,IE"#W542WWA'V!-4JD!ISBA6E!*&Y0H4?/K$'6,&>KP&_VM<(@I.
M^>B1BID5:NS[R$.H,3@1-SM]/1TPO!43QT=_1..<R-:,;S4I_" LMA(.M;G:
M'\TTJ4;E1AAB,<$-OQ&\/GJT;]=9<\\+_L.7-+P+>KR5?KRUY_%P>DWY@C-:
MI.0[3O>\ TQK3TTB>$G9U$U9^V6$K(U5D 2=FH!(NI]Q9\$-X7N6P><NZRT-
MVUFANX>RR5GP+ZH"=. 1BJ1'Y5Y!!OF-@+]AUPA\Z8P_$F(36\VYK#V<^"X,
MS741):E0JY;5MONJT6"CP7 (N_> ?6G?W77_8M>#SW?=+^WA30UV^=ZX"Q()
MBGK4[K.;7O?#H,8Z;7;5;#0;A9IAUGY/+28Q_WAF8\=1^VFINI!:I@7B7@M8
MPUX)B]?8W5V''2' C6]@0:;M4'=WVL%<4F'QV]F-XS^P&\LUL$IAC5Q5/R[5
M;G;?&=P7:IQ[Q!ME=6XM+-2V<XM/K+GEK4%Z%RNL]=626R7)/8)/S0.(ZUH>
M34ZT19:.DOZ_+D'BT5 ID5#*F19JI'D,RJCH&?7@C]A5V^-RR.9%LQ&()!R1
MQ\,NNQGVOG0#J6R>;$@EBF7KI%"3RQ3+$DE2R)*%&NP>87I&D5&)/$K7[<Y_
M/PP'G_LWK\R51BG*[5$9.'$[L"RE*J^P\XGMNV!*)_PZF6Z$N&- =M%0+X^W
M!DETGU#],J)MXB[CN*V\2'34/CD/CWQD . 7KAW+]>SYVT]KX;AL]+=O33 <
M1*9B_%P>8GFH#P6"2!"S++85:TXM&J?6MK.J*5QLT1J"$ ?.* 3[<7>VHTA@
MFTJ(AWSEWM4A?W_P9XV-D0=N!\-N.;C 6J9P=,*.H(YXL-&>!,6UL%P5'<9+
M"]_S.1;^/HHE7\J*?V22%+3'2A9JU%2?4'R5+*B8BP>.'@7JT%-3,$3 /A+*
MV]T-B;L'*.#LM'3,E$&:1KV .6!9@76^HIIC/*2,45,4:M!9B ;4),:(#5TJ
M.=\-&9E8'N&LHL:TII@2I\MS,NWL4;4]7K-DJ#T.>*.@V+>IS6<C8E2'T9LE
M8O22H5BQ9Z-!7NPN)BKJC'FJ(\MYO5%O'=Y*TT&(P[P[4F+=KDZ^HP@K"?=^
M5NX^7'+I*76.\"W;*]2'G&"\T%<\%]SU"#+DJ'',!LYJQI?!.<)D]XYM^H97
M*I]).$-@M%3F7"&&O<\5N;09HA[BT1%(489RSP(AK^P>Z+_^]:^2K&>K%.M9
M*KT *A //S>PJ>#50@UYCT[(Z!64LS#BO#B%$?MR5@],82^0E9TSP1\TT&'I
MSS^Q:&*_D?1=1E=1A2QG0]:2SB[9SN<G6,_5/-%,4B>:2^I>^Q-/-)F@Z(<?
M:4K+R61JR)4O5AS]\)K,&_$HYO:*..53T/*;W2N8].)/CKP:4;Q"NN$6_*N(
M&IA'H.^Q1NG8 T$AOM/<08*HI:.2I.AA:GL0MD_D"X3+W&C;AI?'U(VQ <,9
MAPU=-\80Y=/ #_3 9)UL;Q "ZJNNTY;CK=E1ZT2U-,5Q$LA1S#<?>0\9Z]L>
M/NIZ7+K8PQYA9_73H),#>2\C&-Z$EW[.OVO8M*[XGLX<##39AGFS<T7WF^6!
MQ0%4YS0Z&/>6CLPH8$TY*D<LN$5AS WZA,1-D:06 :4*PAR/+=CF_- )T4-?
M;3+H042\GW%0J"T8L*7<%=&UM(.B%O8:?3Y]B<^2K$DNY97 QN/PK11SRHDZ
M F^@!21&#D>&@5J45L68T<,O->=#IRR6[*B1FF^"IY.YXF?XOCBR[<9$(A8(
M>UE,A&KZ0 ."X3O"\YTE_8O\^*J?";9+<=1S, Z"WC4<85H>W<H?.&+6,L=>
M\SF5BF%3&"D^ZJ,Y39D7W#8W7J526(JR;6X]<>S<A)3JS)Y^(<^(O_QHE[$A
MGE_J@VLY#ZZG5^3CWUHX*162>DK=00]QW[.#1XBH\I>)[8" (<WF?.6*/X*_
MQ!4'/O\N?DY"&IB6NYKS]1_6DE:?OJMF?WE5;YXW:0$\F)EG!N-1BU.7B_.[
M9VY>A+E=G)QE7]_Y\.XWG]>;5WG?_#L-7 X>EL1=\>6_W[3>I"C>PAKBG)R?
M7L]'X5!&M?K-LU<!+0C!? 629<\MDTE9X<%%J=HWKB8U?^P0*TG=V%!Z/P9G
MH_A9DAO*4$IJ=*;I/L8JL)0T*G8I)2.HVT,^R+A?\\F!?*+.OELX98_N"%9<
MPA)]"RF@5@%_*B8GO2BK%)7 W<0)(UV1N5<?E):X/U--%)7VOS7JC3,\,,XW
MT&NT8)>=N.@+$!R.DM([=,2/HQ+XEBJ!QV/[T>2863O='<V8NX-ON#FTJG@-
MW/0;9BDI35$BS(&3 -+(7IJ1'[]08\Y8\&2-2) C6U-MF55<*S4OC&E1 ^-'
MV9-5.1A1]&539,\F1]TRQ+)HA5@86V,%?,F0N5$Q@/S_=G92@UE'SF]KX<\]
MOA2R7"?T*P?7[8Q1'I$B@5<_/&!+/"_Q!#):N"<=UT@]D2<B/>86F_A>>EX1
MR,9E@-*19V*PYC]E9J>QB1%EC&!R&P/?-CM9CQ3,/^?44D1[]M CHDCYCWU$
MW8ES*I-::$<S2!UN"C'J/8HA&*OKKW[V4"_JZ1XS6\>Z95M^\[[Y/[_#B+69
M617#H$WMY4-%]1*!,VU1O@;&^>VT?J[/GM6D;2*I38NS)KF6YTH3MV(TU?*L
MY?E5$[=B--7RK.7Y51.W8C35\JSE^543MV(TU?*LY?E5$[=B--7RK.7Y51.W
M8C35\JSE^543MV(TU?*LY?E5$[=B--7R7#UY#I9>R_OKD?>7HKG6!SGUP>]4
MQ;VO_'P/AC22-'<77PW9<!!DPY6&;(@S;GD@&TAFWOR2[/1S HO8R5V-LSW9
MZ85@FZW#?O.^EU'!(;N4K-EF60/6!2'ZSY;:(&J<QB8"^UALU)<$C722&/XD
M;M2&5S@+:XFE(@FTK41'GA!GJX6H5;*2QEHLA&GA<[(%<*)G<U3=LU953PB7
M]>18'@(DP2PL0R3:^2!441+;"^N=<$2&#W-:P2K;9I1QSJVY+SNWR&J9L,SE
M:0;O-WU!@%FV[R$>DLLM,SV%HVL'@:2.@]I)J@L*,,/<C3F?LJ,;RUWYV$](
M/5EGO:A&1Q8"X?",.8=9KFOI-\+2Q-X([Y-]H?'WL:( 5>6$6&3VBIJ4/ KL
M*6+,?5P4"?N%TZ+NEEQ^>O-+V+A4?LS%ZJ0:._H:U"HMCAEM6A(I,4!\\X)E
MPWL4TE5=U:CDPVT*5$6.S?. 7;D(^T!.I+Z>A(:3H&54W\<WL,Q @A7VF2EO
M\4 ,'[#M%&=F#*MP$\(MT7"(3VQBBZDB/2@$$ID-7#^2=FKI88 8.=32UIBI
M3\^B-EV[/QY[SP0[9\6:>ZU M("Q@&/IQ7G?%S"Y86,CD23;;44OI+>GIE=G
M[!8$3GSCB]5<+@=/5:A8;E 4_0(+'LH>3U54PUZS@MN0 C3.Y!@FPI)]A8(U
MBT9TA-/&AD1H*"P]N$8E>:O5'+8T">86K\-)?G5SR' YDT@14MTQM4$*%!=3
M3=FV@P;BE<VJ\L3\-NL7^=RU\2TQ<+S4M/)^++70>Q72J^DBTRI1%YF^S0:$
M*5BV=C)= M9,]#:*8XENA2.6$H MPJRE3V",4W].E7*&5'+25M*-D-Z?EHB%
M/V#?]B6J\3O^5*@![^CV!7M?!#4:6I4/-!4Z/-286!)CFM(T#._!'<ES?-G+
MBQN&[9A\:8BH@#YHR$QBX.$1 /Z!8__+=KZ&VR06H#NT\5BR;=X4Y,6C!^$%
M,8M52\/[LQ))0P>/#,+!CH<ET>0I85AP0L*5J+R2RPTYI[<TJ8C1J=%==+P%
M"S,.U0L&%T@-,)XP8VWQ;,-7:-7MP"PV8BL6B9F)>P8>]N$,:@&_HBVU108]
M^T'0_AG)*%VT/!\%3[D,PN];]%R.;GNE$9D,-NSUV9^]<;\[&C'J1#NX+0,S
M2MLA8J#'&!]Z239%'\0V&\.;P7P>B$$M!TY/8.%S'U2N0VT='0&6OPOWD>_
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M1&=$@YDP):<K&!C9J33@DX-3LQA.AI1AF,Y@I<3 30Y./:,:CW'$(OA'Z_]
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MDXAPV):W$DB+!"!_BN=R>I2DCI_/KJ%#E("C@I ,')A&0*@$ F46H+T@,%S
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M97-C<FEP=&EO;F]F<V4N:'1M4$L! A0#%     @ 2HI;4#L'8L+;$   A7H
M !,              ( !^A$  &5X:&EB:70Q,#EF:6YA;"YH=&U02P$"% ,4
M    " !*BEM0TW3=8+QR! #SM#\ $0              @ $&(P  ;&=N9"TR
M,#$Y,3(S,2YH=&U02P$"% ,4    " !*BEM0X#MSST,8  "L# $ $0
M        @ 'QE00 ;&=N9"TR,#$Y,3(S,2YX<V102P$"% ,4    " !*BEM0
MCDP,][(R   @(P( %0              @ %CK@0 ;&=N9"TR,#$Y,3(S,5]C
M86PN>&UL4$L! A0#%     @ 2HI;4"+ 'Q9^D@  90X& !4
M ( !2.$$ &QG;F0M,C Q.3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( $J*6U X
M4.6\"2T  -U3   4              "  ?ES!0!L9VYD+3(P,3DQ,C,Q7V<Q
M+FIP9U!+ 0(4 Q0    ( $J*6U#';)J6I;4! /P+ P 4              "
M 32A!0!L9VYD+3(P,3DQ,C,Q7V<R+FIP9U!+ 0(4 Q0    ( $J*6U"WD8_E
M 68! %#^#@ 5              "  0M7!P!L9VYD+3(P,3DQ,C,Q7VQA8BYX
M;6Q02P$"% ,4    " !*BEM0E7<8"^_1  "SD@D %0              @ $_
MO0@ ;&=N9"TR,#$Y,3(S,5]P<F4N>&UL4$L! A0#%     @ 2HI;4 *_NPI\
M"@$ G)\- !H              ( !88\) &QG;F0Q,C,Q,3EE>&AI8FET,3 T
M,FXN:'1M4$L! A0#%     @ 2HI;4$#L,HHO!0  NF4  !@
M ( !%9H* &QG;F0Q,C,Q,3EE>&AI8FET,C$Q+FAT;5!+ 0(4 Q0    ( $J*
M6U"Q]\L!S0,  "D4   8              "  7J?"@!L9VYD,3(S,3$Y97AH
M:6)I=#(S,2YH=&U02P$"% ,4    " !*BEM0+ &V!L((  #23@  &
M        @ %]HPH ;&=N9#$R,S$Q.65X:&EB:70S,3$N:'1M4$L! A0#%
M  @ 2HI;4!_S?(/%"   !4\  !@              ( !=:P* &QG;F0Q,C,Q
M,3EE>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( $J*6U"BU&J6M <  -5%   8
M              "  7"U"@!L9VYD,3(S,3$Y97AH:6)I=#,R,2YH=&U02P4&
2     !  $  _!   6KT*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624950512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Commitments and Contingencies: Legal Proceedings</a></td>
<td class="text">Commitment and Contingencies: Legal Proceedings<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ASC 450, Contingencies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On July 27, 2018, AG Oncon, LLC, AG Ofcon, Ltd., Calamos Market Neutral Income Fund, Capital Ventures International, Citadel Equity Fund Ltd., Opti Opportunity Master Fund, Polygon Convertible Opportunity Master Fund, Wolverine Flagship Fund Trading Limited, as plaintiffs, filed a complaint in the Court of Chancery of the State of Delaware (AG Oncon, LLC v. Ligand Pharmaceuticals Inc.) alleging claims for violation of the Trust Indenture Act, breach of contract, and others against us.  On May 24, 2019, the Court granted our motion to dismiss and the Delaware Supreme Court subsequently affirmed the decision of the Court of Chancery dismissing this case with prejudice.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, CyDex, our wholly-owned subsidiary, received a Paragraph IV certification Notice Letter from Teva stating that Teva had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of U.S. Patent Nos. 8,410,077 (&#8220;the &#8217;077 patent&#8221;); 9,200,088 (&#8220;the &#8217;088 patent&#8221;), or 9,493,582 (&#8220;the &#8217;582 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or will not be infringed by Teva&#8217;s ANDA product.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 20, 2017, CyDex filed a complaint against Teva in the U.S. District Court for the District of Delaware, asserting that the filing of Teva&#8217;s ANDA constitutes infringement of each of the &#8217;077 patent, the &#8217;088 patent, and the &#8217;582 patent. On March 22, 2018, Teva filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on April 12, 2018, CyDex filed an answer to Teva&#8217;s counterclaims. On October 31, 2019, CyDex, Teva, and Acrotech Biopharma L.L.C. (the holder of the NDA for EVOMELA&#174;) entered into a Confidential Settlement Agreement, settling this patent litigation. As a result of the settlement, Teva will be permitted to market a generic version of EVOMELA&#174; in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2019, CyDex received a Paragraph IV certification Notice Letter from Alembic Global Holdings SA (&#8220;Alembic&#8221;) stating that Alembic had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or U.S. Patent No. 10,040,872 (&#8220;the &#8217;872 patent&#8221;), and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Alembic&#8217;s ANDA product. On May 23, 2019, CyDex filed a complaint against Alembic, Alembic Pharmaceuticals, Ltd., and Alembic Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, asserting that the filing of Alembic&#8217;s ANDA constitutes infringement of each of the &#8217;088 patent and the &#8217;582 patent. On July </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29, 2019, Alembic filed an answer and counterclaims seeking declarations of non-infringement and invalidity as to each of the asserted patents and, on August 19, 2019, CyDex filed an answer to Alembic&#8217;s counterclaims. On December 16, 2019, the Court entered a Scheduling Order, setting October 2, 2020, as the fact discovery cut off, March 5, 2021, as the close of expect discovery, and May 17, 2021, as the first day of a five to six day bench trial.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 16, 2019, CyDex received a Paragraph IV certification Notice Letter from Lupin Ltd. (&#8220;Lupin&#8221;) stating that Lupin had submitted an ANDA to the FDA, seeking approval to manufacture, offer to sell, and sell a generic version of EVOMELA&#174; prior to the expiration of any of the &#8217;077 patent; the &#8217;088 patent, the &#8217;582 patent, or the &#8217;872 patent, and alleging that these patents, each of which relates to Captisol&#174;, are invalid, unenforceable, and/or would not be infringed by Lupin&#8217;s ANDA product. CyDex filed a complaint on October 29, 2019, alleging patent infringement against Lupin. Lupin filed an answer on December 11, 2019 and counterclaimed for declaratory judgments of invalidity and non-infringement as to all four patents and CyDex filed its answer to Lupin's counterclaims on January 2, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 31, 2019, we received three civil complaints filed in the US District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned several hundred civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624950512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease certain office facilities and equipment primarily under various operating leases. Our leases have remaining contractual terms up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODE_ffef5594-a0f1-449a-ba9a-61a27ea72532">seven</span> years, some of which include options to extend the leases for up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjljOGJjZGI5YzM2NTQ1NWZhYjllMGMzY2UzNjg0MTczL3NlYzo5YzhiY2RiOWMzNjU0NTVmYWI5ZTBjM2NlMzY4NDE3M18xMDAvZnJhZzo5Yzg1YzllOWJmMWY0YjMwOGFiNGFiMjM3OTVjZjY4OC90ZXh0cmVnaW9uOjljODVjOWU5YmYxZjRiMzA4YWI0YWIyMzc5NWNmNjg4Xzk4OTU2MDQ2NTM4ODc_303e6841-ce99-40a8-b295-685264827d3d">seven</span> years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:50.122%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.912%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.556%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.210%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,242)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,970)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,212)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the twelve months ended December&#160;31, 2019, we entered into several new lease agreements including our San Diego headquarter expansion, opening new Las Vegas office and a new United Kingdom office lease, which resulted an increase in lease assets and liabilities of $6.1 million and $6.0 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Maturity of Operating Lease Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:74.281%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.410%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.109%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity Dates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, our operating leases have a weighted-average remaining lease term of 6 years and a weighted-average discount rate of 6%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.8 million for the twelve months ended December&#160;31, 2019. Operating lease expense was $2.1 million (net of sublease income of $0.7 million) for the twelve months ended December&#160;31, 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624933376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating Lease Assets and Liabilities</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Lease Assets and Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:50.122%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.912%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.556%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.210%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,242)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,970)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,212)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Maturity of Operating Lease Liabilities (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:74.281%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.410%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.109%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity Dates</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,988&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lgnd-20191231.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 360,
   "dts": {
    "calculationLink": {
     "local": [
      "lgnd-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lgnd-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 751,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 52,
    "http://www.ligand.com/20191231": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 58
   },
   "keyCustom": 76,
   "keyStandard": 472,
   "memberCustom": 54,
   "memberStandard": 54,
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.ligand.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Investment in Viking",
     "role": "http://www.ligand.com/role/InvestmentinViking",
     "shortName": "Investment in Viking",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Business Combinations",
     "role": "http://www.ligand.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - Fair Value Measurement",
     "role": "http://www.ligand.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Leases",
     "role": "http://www.ligand.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Convertible Senior Notes",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Balance Sheet Account Details",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetails",
     "shortName": "Balance Sheet Account Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Stockholders' Equity",
     "role": "http://www.ligand.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148110 - Disclosure - Commitments and Contingencies: Legal Proceedings",
     "role": "http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings",
     "shortName": "Commitments and Contingencies: Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - Income Taxes",
     "role": "http://www.ligand.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156112 - Disclosure - Summary of Unaudited Quarterly Financial Information",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation",
     "shortName": "Summary of Unaudited Quarterly Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159113 - Disclosure - Subsequent Event",
     "role": "http://www.ligand.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i4ee653649d66402981113f680d933493_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.ligand.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i4ee653649d66402981113f680d933493_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.ligand.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Leases (Tables)",
     "role": "http://www.ligand.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Balance Sheet Account Details (Tables)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsTables",
     "shortName": "Balance Sheet Account Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.ligand.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.ligand.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables",
     "shortName": "Summary of Unaudited Quarterly Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lgnd:MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i53e345f65cef494a89a25239fa967bbb_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i53e345f65cef494a89a25239fa967bbb_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "if8ac8b2184b2414ba9a6ed927b533c8d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofCommercialLicenseRightsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "if8ac8b2184b2414ba9a6ed927b533c8d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia82f8b0071ba419db2fd44d139c75921_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i194607164d454958b0723749de9579e2_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lgnd:RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Sale of Promacta License - Narrative (Details)",
     "role": "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails",
     "shortName": "Sale of Promacta License - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i4d4f084e91544b0e8c00e376ba1b8806_D20190306-20190306",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lgnd:RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "lgnd:VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Investment in Viking - Narrative (Details)",
     "role": "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails",
     "shortName": "Investment in Viking - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "if00e0f012d59428b944f9bce4efc1b67_D20180101-20180331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "lgnd:VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Business Combinations - Narrative (Details)",
     "role": "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i09fbeecb457b4d7d92c60b4be11ec1e9_D20190723-20190723",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostDirectMaterial",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Business Combinations - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i82f2c4b5fb2c4a4d801f4fedd88aee6a_I20190723",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lgnd:CashPaidtoAcquireBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Business Combinations - Aggregate Acquisition Consideration (Details)",
     "role": "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
     "shortName": "Business Combinations - Aggregate Acquisition Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i003080e24fa44a03a98f01cd886ef3ce_D20171006-20171006",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lgnd:CashPaidtoAcquireBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i727f5a67038e4448b546d9073616f76a_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i727f5a67038e4448b546d9073616f76a_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lgnd:PaymentsToContingentValueRightHolders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i0a70d920271041ac9dcd34bf4a232117_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "lgnd:PaymentsToContingentValueRightHolders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ligand.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i20ce148df5c649e29b0d3b8b82e9009c_D20170101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "lgnd:NumberOfAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "acquisition",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Leases - Operating Lease Assets and Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Operating Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Convertible Senior Notes - Narrative (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
     "shortName": "Convertible Senior Notes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i82e955d1fb6e4902bf8f82d24fa0a7d3_I20140831",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "iad33a1fd7a4d4bb4b58891b708e03689_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "role": "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
     "shortName": "Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "iad33a1fd7a4d4bb4b58891b708e03689_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i5b0f02512c784ca8a96f7587ae1fa695_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
     "shortName": "Balance Sheet Account Details - Investment Categories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i5b0f02512c784ca8a96f7587ae1fa695_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
     "shortName": "Balance Sheet Account Details - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
     "shortName": "Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i1845b3a0c00f4faf86884050f553c2a5_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)",
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
     "shortName": "Balance Sheet Account Details - Contingent Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "iff71220a9b5a4125a61ea2bfa763a1d0_I20171231",
      "decimals": "-3",
      "lang": null,
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails",
     "shortName": "Stockholders' Equity - Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i8d459ba1e80a400fb8140039e5009443_D20180501-20180531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i8d459ba1e80a400fb8140039e5009443_D20180501-20180531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i1845b3a0c00f4faf86884050f553c2a5_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i12002ca5921748508b192203c7a9d235_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i12002ca5921748508b192203c7a9d235_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Stockholders' Equity - Assumptions (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
     "shortName": "Stockholders' Equity - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i869489dbc2cb4d108beb10a315c6229a_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i869489dbc2cb4d108beb10a315c6229a_I20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibd44dfbec8d944479851c647f8b7ccdc_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)",
     "role": "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibd44dfbec8d944479851c647f8b7ccdc_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452432 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453433 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454434 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ibcb09fc55e7b4df6b5b62e4e0bbf74e2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i1845b3a0c00f4faf86884050f553c2a5_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455435 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i70090b4fce044e77b235ddf8a74bbb7e_I20161231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)",
     "role": "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails",
     "shortName": "Summary of Unaudited Quarterly Financial Information - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia4b8adf74a90430babe95d39d453c7b8_D20191001-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - Subsequent Event - Narrative (Details)",
     "role": "http://www.ligand.com/role/SubsequentEventNarrativeDetails",
     "shortName": "Subsequent Event - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia0679186eee548b3bda2848515c0d2cc_D20200211-20200211",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Sale of Promacta License",
     "role": "http://www.ligand.com/role/SaleofPromactaLicense",
     "shortName": "Sale of Promacta License",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "ia74f031fec694b6a87f954e9428ae53d_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20191231.htm",
      "contextRef": "i352af84d1ae44bb8a22c67271354ceae_I20180101",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - lgnd-20191231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - lgnd-20191231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 112,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lgnd_AbInitioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ab Initio",
        "label": "Ab Initio [Member]",
        "terseLabel": "Ab Initio"
       }
      }
     },
     "localname": "AbInitioMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AccruedInventoryPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Inventory Purchases",
        "label": "Accrued Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedInventoryPurchases",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedSalesReturns": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Sales Returns",
        "label": "Accrued Sales Returns",
        "terseLabel": "Return reserve"
       }
      }
     },
     "localname": "AccruedSalesReturns",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AccruedStockRepurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Stock Repurchases",
        "label": "Accrued Stock Repurchases",
        "terseLabel": "Payments due to broker for share repurchases"
       }
      }
     },
     "localname": "AccruedStockRepurchases",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Royalties Receivable Under Sales-based Milestones",
        "label": "Additional Royalties Receivable Under Sales-based Milestones",
        "terseLabel": "Additional royalties receivable under sales-based milestones"
       }
      }
     },
     "localname": "AdditionalRoyaltiesReceivableUnderSalesbasedMilestones",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants",
        "label": "Adjustments to Additional Paid in Capital, (Gain) Loss on Repurchase of Warrants",
        "terseLabel": "Loss on repurchase of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalGainLossOnRepurchaseOfWarrants",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes",
        "label": "Adjustments to Additional Paid in Capital, Loss on Settlement of Convertible Senior Notes",
        "terseLabel": "Loss on settlement of Notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalLossOnSettlementOfConvertibleSeniorNotes",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions",
        "label": "Adjustments to Additional Paid in Capital, Tax Effect of Convertible Senior Notes Transactions",
        "negatedLabel": "Tax effect for Notes transactions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Repurchased",
        "label": "Adjustments to Additional Paid in Capital, Warrants Repurchased",
        "negatedLabel": "Warrant repurchase"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsRepurchased",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Settled",
        "label": "Adjustments to Additional Paid in Capital, Warrants Settled",
        "terseLabel": "Deduction to additional paid-in-capital for warrants settled"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsSettled",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for doubtful accounts.",
        "label": "Allowance For Doubtful Accounts [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_AmendedESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended ESPP [Member]",
        "label": "Amended ESPP [Member]",
        "terseLabel": "Amended ESPP"
       }
      }
     },
     "localname": "AmendedESPPMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of Commercial License and Other Economic Rights",
        "label": "Amortization of Commercial License and Other Economic Rights",
        "terseLabel": "Amortization of commercial license and other economic rights"
       }
      }
     },
     "localname": "AmortizationOfCommercialLicenseAndOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_AziyoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aziyo [Member]",
        "label": "Aziyo [Member]",
        "terseLabel": "Aziyo"
       }
      }
     },
     "localname": "AziyoMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_AziyoandCorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aziyo and CorMatrix [Member]",
        "label": "Aziyo and CorMatrix [Member]",
        "terseLabel": "Aziyo &amp; CorMatrix"
       }
      }
     },
     "localname": "AziyoandCorMatrixMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basis of presentation.",
        "label": "Basis of Presentation [Line Items]",
        "terseLabel": "Basis of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basis of Presentation.",
        "label": "Basis of Presentation [Table]",
        "terseLabel": "Basis of Presentation [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationTable",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition contingent consideration, potential cash payment at end of period.",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment At End Of Period",
        "periodEndLabel": "Commercial rights at end of period",
        "periodStartLabel": "Commercial rights at beginning of period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Assumptions Used Estimated Future Cash Flows, Average Discount Rate",
        "label": "Business Combination, Assumptions Used Estimated Future Cash Flows, Average Discount Rate",
        "terseLabel": "Average cash flow discount rate (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "label": "Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate",
        "terseLabel": "Projected cash flow discount rate (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "label": "Business Combination, Cash Holdback for Potential Indemnification Claims",
        "terseLabel": "Cash holdback for potential indemnification claims"
       }
      }
     },
     "localname": "BusinessCombinationCashHoldbackForPotentialIndemnificationClaims",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "label": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "terseLabel": "California and New Jersey Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "verboseLabel": "Cash Equivalents &amp; Short Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Paid During the Year",
        "label": "Cash Paid During the Year [Abstract]",
        "terseLabel": "Cash paid during the year:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CashPaidtoAcquireBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Paid to Acquire Business",
        "label": "Cash Paid to Acquire Business",
        "terseLabel": "Cash paid to Crystal shareholders"
       }
      }
     },
     "localname": "CashPaidtoAcquireBusiness",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CashPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Payable",
        "label": "Cash Payable",
        "terseLabel": "Cash payable to Crystal Shareholders"
       }
      }
     },
     "localname": "CashPayable",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial License Rights",
        "label": "Commercial License Rights",
        "terseLabel": "Commercial license and other economic rights"
       }
      }
     },
     "localname": "CommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CommercialLicenseRightsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial License Rights [Policy Text Block]",
        "label": "Commercial License Rights [Policy Text Block]",
        "terseLabel": "Commercial license rights"
       }
      }
     },
     "localname": "CommercialLicenseRightsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "verboseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ContingentLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability [Roll Forward]",
        "label": "Contingent Liability [Roll Forward]",
        "terseLabel": "Contingent Liability [Roll Forward]"
       }
      }
     },
     "localname": "ContingentLiabilityRollForward",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ConvertibleSeniorNotes2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes, 2019 [Member]",
        "label": "Convertible Senior Notes, 2019 [Member]",
        "terseLabel": "2019 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2019Member",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ConvertibleSeniorNotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes, 2023",
        "label": "Convertible Senior Notes, 2023 [Member]",
        "terseLabel": "2023 Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2023Member",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorMatrixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CorMatrix [Member]",
        "label": "CorMatrix [Member]",
        "terseLabel": "CorMatrix"
       }
      }
     },
     "localname": "CorMatrixMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Core Assets, Partnered Programs, and Ion Channel Technology of Icagen",
        "label": "Core Assets, Partnered Programs, and Ion Channel Technology of Icagen [Member]",
        "terseLabel": "Core Assets, Partnered Programs, and Ion Channel Technology of Icagen"
       }
      }
     },
     "localname": "CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CorporateShareRepurchaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Share Repurchase [Abstract]",
        "label": "Corporate Share Repurchase [Abstract]",
        "terseLabel": "Corporate Share Repurchase"
       }
      }
     },
     "localname": "CorporateShareRepurchaseAbstract",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_CrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Crystal [Member]",
        "label": "Crystal [Member]",
        "terseLabel": "Crystal"
       }
      }
     },
     "localname": "CrystalMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_CurrentPortionOfLiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current portion of liability for contingent value rights.",
        "label": "Current Portion of Liability for Contingent Value Rights",
        "terseLabel": "Current contingent liabilities"
       }
      }
     },
     "localname": "CurrentPortionOfLiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_CydexPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cydex Pharmaceuticals, Inc.",
        "label": "Cydex Pharmaceuticals, Inc [Member]",
        "verboseLabel": "Cydex"
       }
      }
     },
     "localname": "CydexPharmaceuticalsIncMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "label": "Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal",
        "terseLabel": "Increase (decrease) in if-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "label": "Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger",
        "terseLabel": "Maximum threshold of debt trading price trigger (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets",
        "terseLabel": "Fixed assets and intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DeferredTaxLiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Fair Value Adjustment",
        "label": "Deferred Tax Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Retrophin fair value adjustment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFairValueAdjustment",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "label": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "negatedTerseLabel": "Identified intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFiniteLivedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Indefinite-Lived Intangible Assets",
        "label": "Deferred Tax Liabilities, Indefinite-Lived Intangible Assets",
        "negatedTerseLabel": "Identified indefinite lived intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties",
        "label": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]",
        "terseLabel": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties"
       }
      }
     },
     "localname": "DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_DianomiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dianomi",
        "label": "Dianomi [Member]",
        "terseLabel": "Dianomi"
       }
      }
     },
     "localname": "DianomiMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Derivatives",
        "label": "Effective Income Tax Rate Reconciliation, Change in Derivatives",
        "terseLabel": "Change in derivatives"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDerivatives",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount",
        "negatedLabel": "FDII"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_EmployeeStockPurchasePlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Abstract]",
        "label": "Employee Stock Purchase Plan [Abstract]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanAbstract",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_ExercisePriceRangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Eight [Member]",
        "label": "Exercise Price Range Eight [Member]",
        "terseLabel": "$195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeEightMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Eleven [Member]",
        "label": "Exercise Price Range Eleven [Member]",
        "terseLabel": "$9.96 \u2013 $195.91"
       }
      }
     },
     "localname": "ExercisePriceRangeElevenMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$85.79 - $100.38"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$32.00 - $74.42"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Nine [Member]",
        "label": "Exercise Price Range Nine [Member]",
        "terseLabel": "$119.30 - $159.01"
       }
      }
     },
     "localname": "ExercisePriceRangeNineMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$9.96 - $12.81"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Seven [Member]",
        "label": "Exercise Price Range Seven [Member]",
        "terseLabel": "$117.97"
       }
      }
     },
     "localname": "ExercisePriceRangeSevenMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Six [Member]",
        "label": "Exercise Price Range Six [Member]",
        "terseLabel": "$101.15 - $113.76"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Ten [Member]",
        "label": "Exercise Price Range Ten [Member]",
        "terseLabel": "$159.81 - $171.28"
       }
      }
     },
     "localname": "ExercisePriceRangeTenMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$21.92"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$14.47"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ExercisePriceofConvertibleBondHedge": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price of Convertible Bond Hedge",
        "label": "Exercise Price of Convertible Bond Hedge",
        "terseLabel": "Exercise price of convertible bond hedge (USD per share)"
       }
      }
     },
     "localname": "ExercisePriceofConvertibleBondHedge",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "negatedLabel": "Repurchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "terseLabel": "Fair value adjustments to contingent liabilities",
        "verboseLabel": "Fair Value Adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration",
        "verboseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ForecastedCashFlowsEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "label": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "terseLabel": "Effective interest rate of forecasted cash flows (as a percent)"
       }
      }
     },
     "localname": "ForecastedCashFlowsEffectiveInterestRatePercent",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Reconciliation, Change in Uncertain Tax Positions",
        "label": "Income Tax Reconciliation, Change in Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncomeTaxReconciliationContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Reconciliation, Contingent Value Rights",
        "label": "Income Tax Reconciliation, Contingent Value Rights",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "IncomeTaxReconciliationContingentValueRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Reconciliation, Expired Tax Credits, Research",
        "label": "Income Tax Reconciliation, Expired Tax Credits, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationExpiredTaxCreditsResearch",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Assets",
        "label": "Increase (Decrease) in Operating Lease Assets",
        "terseLabel": "Increase (decrease) in operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Increase (decrease) in operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseInOtherEconomicRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Other Economic Rights",
        "label": "Increase (Decrease) in Other Economic Rights",
        "terseLabel": "Other economic rights"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherEconomicRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_IncreaseDecreaseinEquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Equity Method Investment",
        "label": "Increase (Decrease) in Equity Method Investment",
        "terseLabel": "Increase (decrease) in equity method investment"
       }
      }
     },
     "localname": "IncreaseDecreaseinEquityMethodInvestment",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_InvestmentInVikingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in Viking, Current",
        "label": "Investment in Viking, Current",
        "terseLabel": "Investment in Viking",
        "verboseLabel": "Warrants investments in Viking"
       }
      }
     },
     "localname": "InvestmentInVikingCurrent",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability, Current",
        "label": "Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Remaining Lease Term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining contractual term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_LiabilityForContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability for contingent value rights.",
        "label": "Liability for Contingent Value Rights",
        "verboseLabel": "Long-term contingent liabilities"
       }
      }
     },
     "localname": "LiabilityForContingentValueRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCrystalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "label": "Liability For Contingent Value Rights Company, Crystal [Member]",
        "terseLabel": "Contingent liabilities - Crystal"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCrystalMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyCydexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Cydex",
        "label": "Liability For Contingent Value Rights Company, Cydex [Member]",
        "verboseLabel": "Contingent liabilities - CyDex"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyCydexMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForContingentValueRightsCompanyMetabasisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability For Contingent Value Rights Company, Metabasis",
        "label": "Liability For Contingent Value Rights Company, Metabasis [Member]",
        "terseLabel": "Contingent liabilities - Metabasis"
       }
      }
     },
     "localname": "LiabilityForContingentValueRightsCompanyMetabasisMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "label": "Liability for Restricted Investments Owed to Former Licensees [Member]",
        "terseLabel": "Liability for restricted investments owed to former licensees"
       }
      }
     },
     "localname": "LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fees",
        "label": "License Fees [Member]",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseFeesMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMilestonesAndOtherProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fees, Milestones, and Other Product, Other",
        "label": "License Fees, Milestones, and Other Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LicenseFeesMilestonesAndOtherProductOtherMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseFeesMilestonesandProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fees, Milestones, and Product, Other [Member]",
        "label": "License Fees, Milestones, and Product, Other [Member]",
        "terseLabel": "License fees, milestones and other revenues"
       }
      }
     },
     "localname": "LicenseFeesMilestonesandProductOtherMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_LicenseUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Upfront Payment",
        "label": "License Upfront Payment",
        "terseLabel": "Upfront payment for license"
       }
      }
     },
     "localname": "LicenseUpfrontPayment",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_MaterialSalesCaptisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Material Sales, Captisol [Member]",
        "label": "Material Sales, Captisol [Member]",
        "terseLabel": "Material sales"
       }
      }
     },
     "localname": "MaterialSalesCaptisolMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maturity period of highly liquid securities maximum.",
        "label": "Maturity Period Of Highly Liquid Securities Maximum",
        "terseLabel": "Maturity period of cash and cash equivalents, maximum"
       }
      }
     },
     "localname": "MaturityPeriodOfHighlyLiquidSecuritiesMaximum",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_MetabasisTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Metabasis Therapeutics [Member]",
        "label": "Metabasis Therapeutics [Member]",
        "terseLabel": "Metabasis Therapeutics",
        "verboseLabel": "Metabasis"
       }
      }
     },
     "localname": "MetabasisTherapeuticsMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_MilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Member]",
        "terseLabel": "Milestones"
       }
      }
     },
     "localname": "MilestoneMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash change in estimated fair value of contingent value rights.",
        "label": "Non-cash change in estimated fair value of contingent value rights",
        "negatedLabel": "Change in estimated fair value of contingent liabilities"
       }
      }
     },
     "localname": "NonCashChangeInEstimatedFairValueOfContingentValueRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_NovanMolluscumProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novan Molluscum Products",
        "label": "Novan Molluscum Products [Member]",
        "terseLabel": "Novan"
       }
      }
     },
     "localname": "NovanMolluscumProductsMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_NumberOfAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Acquisitions",
        "label": "Number of Acquisitions",
        "terseLabel": "Number of acquisitions"
       }
      }
     },
     "localname": "NumberOfAcquisitions",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberOfContingentValueRightsIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Contingent Value Rights Issued",
        "label": "Number of Contingent Value Rights Issued",
        "terseLabel": "Number of contingent value rights"
       }
      }
     },
     "localname": "NumberOfContingentValueRightsIssued",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_NumberofCollaborationAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Collaboration Agreements",
        "label": "Number of Collaboration Agreements",
        "terseLabel": "Number of collaboration agreements"
       }
      }
     },
     "localname": "NumberofCollaborationAgreements",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lgnd_OtherBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Balance Sheet Details [Abstract]",
        "label": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "localname": "OtherBalanceSheetDetailsAbstract",
     "nsuri": "http://www.ligand.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lgnd_PalvellaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Palvella Therapeutics, Inc.",
        "label": "Palvella Therapeutics, Inc. [Member]",
        "terseLabel": "Palvella"
       }
      }
     },
     "localname": "PalvellaTherapeuticsIncMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Partner A [Member]",
        "label": "Partner A [Member]",
        "terseLabel": "Partner A"
       }
      }
     },
     "localname": "PartnerAMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Partner B [Member]",
        "label": "Partner B [Member]",
        "terseLabel": "Partner B"
       }
      }
     },
     "localname": "PartnerBMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PartnerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Partner C [Member]",
        "label": "Partner C [Member]",
        "terseLabel": "Partner C"
       }
      }
     },
     "localname": "PartnerCMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PaymentsToContingentValueRightHolders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments to contingent value right holders",
        "label": "Payments to Contingent Value Right Holders",
        "negatedLabel": "Payments to CVR holders and other contingency payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHolders",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsToContingentValueRightHoldersFinancingActivity": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments to Contingent Value Right Holders, Financing Activity",
        "label": "Payments to Contingent Value Right Holders, Financing Activity",
        "negatedLabel": "Payments to CVR Holders"
       }
      }
     },
     "localname": "PaymentsToContingentValueRightHoldersFinancingActivity",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PaymentsforConvertibleBondHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Convertible Bond Hedges",
        "label": "Payments for Convertible Bond Hedges",
        "terseLabel": "Payments for convertible bond hedges"
       }
      }
     },
     "localname": "PaymentsforConvertibleBondHedges",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_Phase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 3 Clinical Trial",
        "label": "Phase 3 Clinical Trial [Member]",
        "terseLabel": "Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "Phase3ClinicalTrialMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preclinical Study and Clinical Trial Accruals [Policy Text Block]",
        "label": "Preclinical Study and Clinical Trial Accruals [Policy Text Block]",
        "terseLabel": "Preclinical Study and Clinical Trial Accruals"
       }
      }
     },
     "localname": "PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ProceedsFromCommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Commercial License Rights",
        "label": "Proceeds from Commercial License Rights",
        "terseLabel": "Proceeds from commercial license rights"
       }
      }
     },
     "localname": "ProceedsFromCommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ProductRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Royalty Percentage",
        "label": "Product Royalty Percentage",
        "terseLabel": "Product royalty (as a percent)"
       }
      }
     },
     "localname": "ProductRoyaltyPercentage",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_PromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Promacta",
        "label": "Promacta [Member]",
        "terseLabel": "Promacta"
       }
      }
     },
     "localname": "PromactaMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_PurchaseOfConvertibleBondHedge": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase of Convertible Bond Hedge",
        "label": "Purchase of Convertible Bond Hedge",
        "negatedLabel": "Purchase of convertible bond hedge"
       }
      }
     },
     "localname": "PurchaseOfConvertibleBondHedge",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_PurchaseforCommercialLicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase for Commercial License Rights",
        "label": "Purchase for Commercial License Rights",
        "negatedLabel": "Purchase of commercial license rights"
       }
      }
     },
     "localname": "PurchaseforCommercialLicenseRights",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets",
        "label": "Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Revenue from Contract with Customers and Gain (Loss) on Disposition of Intangible Assets"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomersAndGainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method Milestone Payment Received",
        "label": "Revenue Recognition, Milestone Method Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMilestonePaymentReceived",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method Third-Party Portion of Milestone Payment Received",
        "label": "Revenue Recognition, Milestone Method Third-Party Portion of Milestone Payment Received",
        "terseLabel": "Third-party portion of milestone payment received"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RevenueRoyaltytoAcquireeShareholdersPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Royalty to Acquiree Shareholders, Percent",
        "label": "Revenue Royalty to Acquiree Shareholders, Percent",
        "terseLabel": "Revenue royalty payable on all Cydex-related revenue (as a percent)"
       }
      }
     },
     "localname": "RevenueRoyaltytoAcquireeShareholdersPercent",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalties Recorded upon Adoption of New Accounting Pronouncement",
        "label": "Royalties Recorded upon Adoption of New Accounting Pronouncement",
        "terseLabel": "Royalties recorded in retained earnings upon adoption of ASC 606"
       }
      }
     },
     "localname": "RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_RoyaltyAgreementExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Agreement, Expiration Period",
        "label": "Royalty Agreement, Expiration Period",
        "terseLabel": "Expiration period of royalty agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementExpirationPeriod",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lgnd_RoyaltyEvomelaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty, Evomela",
        "label": "Royalty, Evomela [Member]",
        "terseLabel": "Royalty, Evomela"
       }
      }
     },
     "localname": "RoyaltyEvomelaMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyKyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty, Kyprolis",
        "label": "Royalty, Kyprolis [Member]",
        "terseLabel": "Royalty, Kyprolis"
       }
      }
     },
     "localname": "RoyaltyKyprolisMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty, Other",
        "label": "Royalty, Other [Member]",
        "terseLabel": "Royalty, Other"
       }
      }
     },
     "localname": "RoyaltyOtherMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_RoyaltyPromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty, Promacta",
        "label": "Royalty, Promacta [Member]",
        "terseLabel": "Royalty, Promacta"
       }
      }
     },
     "localname": "RoyaltyPromactaMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for share based compensation expense for awards to employees and directors.",
        "label": "Schedule For Share Based Compensation Expense for Awards to Employees and Directors [Table Text Block]",
        "terseLabel": "Schedule of Accounting for Share-Based Compensation"
       }
      }
     },
     "localname": "ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block]",
        "label": "Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleofBusinessAcquisitionsbyAcquisitionConsiderationTransferredTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ScheduleofCommercialLicenseRightsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Commercial License Rights [Table Text Block]",
        "label": "Schedule of Commercial License Rights [Table Text Block]",
        "terseLabel": "Schedule of Commercial License Rights"
       }
      }
     },
     "localname": "ScheduleofCommercialLicenseRightsTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_ScheduleofContingentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Contingent Liabilities [Table Text Block]",
        "label": "Schedule of Contingent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Contingent Liabilities"
       }
      }
     },
     "localname": "ScheduleofContingentLiabilitiesTableTextBlock",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lgnd_SelexisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selexis [Member]",
        "label": "Selexis [Member]",
        "terseLabel": "Selexis"
       }
      }
     },
     "localname": "SelexisMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold Revenue Amount to Trigger Royalty Payments",
        "label": "Threshold Revenue Amount to Trigger Royalty Payments",
        "terseLabel": "Cydex-related revenue amount that triggers royalty payments"
       }
      }
     },
     "localname": "ThresholdRevenueAmounttoTriggerRoyaltyPayments",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold of Revenues above $1.5 million with Four Collaboration Agreements [Member]",
        "label": "Threshold of Revenues above $1.5 million with Four Collaboration Agreements [Member]",
        "terseLabel": "Threshold of Revenues above $1.5 million with Four Collaboration Agreements"
       }
      }
     },
     "localname": "ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold of Revenues above $15 million with Three Collaboration Agreements [Member]",
        "label": "Threshold of Revenues above $15 million with Three Collaboration Agreements [Member]",
        "terseLabel": "Threshold of Revenues above $15 million with Three Collaboration Agreements"
       }
      }
     },
     "localname": "ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_TwoThousandTwoStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand two Stock Incentive Plan.",
        "label": "Two thousand Two Stock Incentive Plan [Member]",
        "terseLabel": "2002 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwoStockIncentivePlanMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded",
        "terseLabel": "Loss recorded (as a percent)"
       }
      }
     },
     "localname": "VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lgnd_VariableRateComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Rate Component [Axis]",
        "label": "Variable Rate Component [Axis]",
        "terseLabel": "Variable Rate Component [Axis]"
       }
      }
     },
     "localname": "VariableRateComponentAxis",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lgnd_VariableRateComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Variable Rate Component [Axis]",
        "label": "Variable Rate Component [Domain]",
        "terseLabel": "Variable Rate Component [Domain]"
       }
      }
     },
     "localname": "VariableRateComponentDomain",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VernalisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vernalis",
        "label": "Vernalis [Member]",
        "terseLabel": "Vernalis"
       }
      }
     },
     "localname": "VernalisMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting Period One [Member]",
        "label": "Vesting Period One [Member]",
        "terseLabel": "Vest 1/8 on the six month anniversary of the date of grant"
       }
      }
     },
     "localname": "VestingPeriodOneMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VestingPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting Period Two [Member]",
        "label": "Vesting Period Two [Member]",
        "terseLabel": "Vest 1/48 each month for forty-two months"
       }
      }
     },
     "localname": "VestingPeriodTwoMember",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_VikingTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Viking Therapeutics, Inc. [Member]",
        "label": "Viking Therapeutics, Inc. [Member]",
        "terseLabel": "Viking Therapeutics, Inc."
       }
      }
     },
     "localname": "VikingTherapeuticsInc.Member",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lgnd_WarrantsSettled": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Settled",
        "label": "Warrants Settled",
        "terseLabel": "Warrants settled (in shares)"
       }
      }
     },
     "localname": "WarrantsSettled",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lgnd_WorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Working Capital Adjustment",
        "label": "Working Capital Adjustment",
        "terseLabel": "Working capital adjustment"
       }
      }
     },
     "localname": "WorkingCapitalAdjustment",
     "nsuri": "http://www.ligand.com/20191231",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r65",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r181",
      "r262",
      "r266",
      "r503"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r180",
      "r262",
      "r265",
      "r501",
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "terseLabel": "Price per share of shares repurchased (USD per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201609Member": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2016-09 [Member]",
        "terseLabel": "Accounting Standards Update 2016-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r36",
      "r182",
      "r183",
      "r263"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization/accretion of premium (discount) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r50"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r476",
      "r495"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties owed to third parties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": {
     "auth_ref": [
      "r29",
      "r31",
      "r468",
      "r490"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.",
        "label": "Accrued Sales Commission",
        "terseLabel": "Amounts owed to former licensees"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r226"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r73",
      "r76",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r249",
      "r255",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Convertible bond hedge and warrant transactions, net of tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Reclassification of equity component of currently redeemable convertible notes",
        "verboseLabel": "Debt issuance costs related to the equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Other tax adjustments"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r275",
      "r277",
      "r321",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r240",
      "r249",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant derivative",
        "verboseLabel": "Value of warrants issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r119",
      "r426"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r119",
      "r213",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r119",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r178",
      "r465",
      "r489"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r62"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r187",
      "r200"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r185",
      "r188",
      "r200"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r279",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables",
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables",
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Total share consideration",
        "verboseLabel": "Value of share consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r373",
      "r374",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r372",
      "r375",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedTerseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r331",
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible asset with finite life - core technology"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "verboseLabel": "Assumed liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r127",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.",
        "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]",
        "terseLabel": "Calculated under Revenue Guidance in Effect before Topic 606"
       }
      }
     },
     "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of fixed assets recorded in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r42",
      "r121"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r112",
      "r121",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r112",
      "r420"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (USD per share)",
        "verboseLabel": "Warrant exercise price (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued in public offering (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r56",
      "r236",
      "r477",
      "r494"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend declared (USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; 16,823 and 20,766 shares issued and outstanding at December\u00a031, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r82"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r415",
      "r416",
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r415",
      "r416",
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r161",
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Business Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r166",
      "r167",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Total revenues (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r384",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r258",
      "r260",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "terseLabel": "Gross contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r258",
      "r259",
      "r263"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "2019 convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "verboseLabel": "Fair value of convertible senior notes outstanding (Level 2)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible debt, noncurrent",
        "verboseLabel": "2023 convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r27",
      "r466",
      "r486",
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r271",
      "r274",
      "r504"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Cost of material sales"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative-effect adjustment from adoption of ASU"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r353",
      "r357"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r355"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r353",
      "r357"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total Current Income Tax Benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r353",
      "r357"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r123",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notices for conversion"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r29",
      "r30",
      "r466",
      "r469",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Conversion value over the principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "netLabel": "Carrying value of equity component of 2023 Notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt conversion price per share (USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r53",
      "r250",
      "r251",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible debt conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "If-converted value in excess of principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger to classify convertible debt as current (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r425",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r52",
      "r245",
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest on debt instrument (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r54",
      "r132",
      "r250",
      "r252",
      "r253",
      "r254",
      "r424",
      "r425",
      "r427",
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r424",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r424",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt issuance costs related to the liability component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Investment Categories"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r354",
      "r357"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r32",
      "r33",
      "r343",
      "r467",
      "r485"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r332",
      "r347"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r354",
      "r357"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r325",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r324",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r325",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r349",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r324",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r332",
      "r347"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r325",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Investment in Viking"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r325",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r325",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Bank deposits"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r119",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r119",
      "r175"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r63",
      "r64",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Net change in fair value of derivatives",
        "terseLabel": "Gain (loss) on derivative liabilities"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r63",
      "r64",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Core Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r12",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Promacta License"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r88",
      "r141",
      "r145",
      "r148",
      "r149",
      "r150",
      "r154",
      "r480",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) - Basic (USD per share)",
        "verboseLabel": "Basic net income per share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic per share amounts:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Dilutive potential common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r88",
      "r141",
      "r145",
      "r148",
      "r149",
      "r150",
      "r154",
      "r480",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted net income per share (USD per share)",
        "terseLabel": "Net income (loss) - Diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted per share amounts:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of the conversion option derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average period in which cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost, restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r193",
      "r454",
      "r456",
      "r458",
      "r460",
      "r462",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r24",
      "r28",
      "r192",
      "r474",
      "r487",
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities",
        "verboseLabel": "Investment in Viking common stock"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r410",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r402",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r403",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r409",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r402",
      "r403",
      "r406",
      "r407",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r403",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r403",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r403",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of level 3 financial instruments at end of period",
        "periodStartLabel": "Fair value of level 3 financial instruments at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r409",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      },
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization",
        "negatedTerseLabel": "Less: accumulated amortization attributed to principal or research and development"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "verboseLabel": "Amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r218",
      "r221",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r218",
      "r452"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      },
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Definite lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r214",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total commercial license and other economic rights, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r419",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain from sale of Promacta license"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain from sale of Promacta license"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r93",
      "r119",
      "r186"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) from Viking"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r119",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r127",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r119",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets with finite lives"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r86",
      "r119",
      "r176",
      "r194",
      "r478",
      "r497"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "(Gain) loss on equity investment in Viking"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Condensed Statement of Operations:"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r177",
      "r358"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "negatedTerseLabel": "Income tax (expense) benefit",
        "totalLabel": "Income tax expense from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r127",
      "r329",
      "r330",
      "r341",
      "r342",
      "r348",
      "r359",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r328",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r327",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Rate change for changes in federal or state law"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r129",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r129",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Expired NOLs and credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r115",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r58",
      "r475",
      "r496"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssets": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Assets",
        "terseLabel": "Increase (decrease) in derivative assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Increase (decrease) in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisition:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Warrants (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "2019 Convertible Senior Notes (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r152"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r212",
      "r216"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total goodwill and other identifiable intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r85",
      "r174",
      "r423",
      "r426",
      "r481"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r109",
      "r114",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r15",
      "r59",
      "r205"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r60",
      "r127",
      "r155",
      "r206",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-downs related to obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r92",
      "r173"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Commitments and Contingencies: Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r470",
      "r492"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "verboseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Total long-term portion of notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes Payable, Current and Noncurrent [Abstract]",
        "terseLabel": "Notes Payable, Current and Noncurrent"
       }
      }
     },
     "localname": "LongtermNotesPayableCurrentAndNoncurrentTotalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual fund"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r112",
      "r116",
      "r120"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r77",
      "r80",
      "r87",
      "r120",
      "r152",
      "r479",
      "r498"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Total current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "verboseLabel": "Lab and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "terseLabel": "Total operating costs and expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "verboseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "negatedTotalLabel": "Total lease liabilities",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Long-term operating lease liabilities",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r437",
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r13",
      "r139",
      "r172",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r50"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax",
        "terseLabel": "Unrealized net gain on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r68",
      "r69",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized net gain on available-for-sale securities, net of deferred tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r67",
      "r421"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r84",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r191"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: Reclassification of net realized gains included in net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentedTechnologyMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.",
        "label": "Patented Technology [Member]",
        "verboseLabel": "Complete technology"
       }
      }
     },
     "localname": "PatentedTechnologyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Payment for contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForHedgeFinancingActivities": {
     "auth_ref": [
      "r108",
      "r117"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for Hedge, Financing Activities",
        "negatedLabel": "Payments to convert holders for bond conversion"
       }
      }
     },
     "localname": "PaymentsForHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r98",
      "r101",
      "r138"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Share repurchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedLabel": "Repurchase of warrants",
        "terseLabel": "Payments for repurchase of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r99",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Gross payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Cash paid for acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Cash paid for equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r279",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2019 and 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds received from repayment of Viking note receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from debt issuance"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Investing Activities",
        "terseLabel": "Proceeds from derivative instrument"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "auth_ref": [
      "r104",
      "r117"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Proceeds from Hedge, Financing Activities",
        "terseLabel": "Proceeds from bond hedge settlement"
       }
      }
     },
     "localname": "ProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r102",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Cash received from options exercised"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Proceeds from maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Gross proceeds from issuance of 2023 Convertible Senior Notes"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of Promacta license"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r102",
      "r309"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Net proceeds from stock option exercises and ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r77",
      "r80",
      "r111",
      "r178",
      "r179",
      "r383",
      "r385",
      "r386",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r45",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r44",
      "r225"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property and equipment , gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r25",
      "r26",
      "r227",
      "r493"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r127",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r25",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r25",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Summary of Unaudited Quarterly Financial Information"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "Realized gain on sale of short-term investment"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r273",
      "r442",
      "r443",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of notes"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r323",
      "r513"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r127",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r14",
      "r23",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash in other current assets"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "calculation": {
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedLabel": "Restructuring and product reserves"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r232",
      "r235"
     ],
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r255",
      "r491"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "terseLabel": "Royalty Agreements"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails",
      "http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Equity and Liability Components of the Convertible Senior Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r214",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r45",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r279",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Plan Activity by Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r284",
      "r296",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Weighted-Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r164",
      "r166",
      "r167",
      "r168",
      "r415",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Major Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (shares)",
        "periodStartLabel": "Outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Shares [Rollforward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "periodStartLabel": "Outstanding at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "verboseLabel": "Shares allowed to purchase in employee stock purchase plan per employee (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase the number of shares under the 2002 Stock Incentive Plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for future option grants (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant date fair value per share of stock options (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r286",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares [Rollforward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end of period (USD per share)",
        "periodStartLabel": "Balance at beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Options vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Options vested and expected to vest at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Common stock issued under amended ESSP (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r276",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r127",
      "r279",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range of exercise prices (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting right (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r303",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining life in years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r28",
      "r471",
      "r472",
      "r474",
      "r488"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r57",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Condensed Balance Sheet:"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r34",
      "r35",
      "r249",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r249",
      "r255",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r255",
      "r278",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r34",
      "r35",
      "r249",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (shares)",
        "terseLabel": "Shares repurchased in period (shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r34",
      "r35",
      "r249",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Shares repurchased in period"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r39",
      "r40",
      "r184"
     ],
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r381",
      "r382",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r435",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r271",
      "r274",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Government bonds"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on AFS investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r326",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r163",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, change in amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Investment in Viking"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinViking"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Investment in warrants",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/InvestmentinVikingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r150"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "netLabel": "Shares used in diluted per share calculation (shares)",
        "totalLabel": "Shares used to compute diluted income per share (shares)",
        "verboseLabel": "Weighted average shares\u2014diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r142",
      "r150"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "netLabel": "Shares used in basic per share calculation (shares)",
        "terseLabel": "Weighted-average common shares outstanding - basic (shares)",
        "verboseLabel": "Weighted average shares\u2014basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.",
        "label": "Weighted Average Number of Shares, Restricted Stock",
        "verboseLabel": "Restricted stock (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3581-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27405-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e34017-109320"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r516": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r517": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r518": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r519": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6746853808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying consolidated financial statements include Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain reclassifications have been made to the previously issued financial statements to conform with the current period presentation. Specifically, our investment in Viking warrants was reclassified from &#8220;other current assets&#8221; to &#8220;investment in Viking&#8221; in the audited consolidated balance sheet as of December 31, 2018.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Business Risk</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock', window );">Cash Equivalents &amp; Short Term Investments</a></td>
<td class="text">Cash Equivalents &amp; Short-term InvestmentsCash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt and equity securities and mutual funds. Debt securities have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. We classify our short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss) and unrealized gains and losses on equity securities and mutual funds included the consolidated statement of operations. Mutual funds are valued at their net asset value (NAV) on the last day of the period.&#160;We determine the cost of investments based on the specific identification method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms which range from 30 to 90 days. We reserve specific receivables if collectability is no longer reasonably assured. We re-evaluate such reserves on a regular basis and adjust the reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryInventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the first-in, first-out method or the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in other income (expense), net. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. In addition, IPR&amp;D is capitalized and assessed for impairment annually. IPR&amp;D is amortized upon product commercialization or upon out-licensing the underlying intellectual property where we have no active involvement in the licensee's development activities. IPR&amp;D is amortized over the estimated life of the commercial product or licensing arrangement.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div>Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2019, noting no impairment. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsPolicyTextBlock', window );">Commercial license rights</a></td>
<td class="text">Commercial license and other economic rights<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights consist of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:71.542%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.856%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aziyo &amp; CorMatrix</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Palvella</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selexis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dianomi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated amortization attributed to principal or research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,208)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,838)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total commercial license and other economic rights, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial license and other economic rights as of December&#160;31, 2019 represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015, CorMatrix in May 2016, Palvella in December 2018, and Dianomi in January 2019. Commercial license rights acquired are accounted for as financial assets, and other economic rights are accounted for as funded research and developments as further discussed below. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, we entered into a development funding and royalties agreement with Novan, pursuant to which we would receive certain payments at specified milestones, as well as royalties on any future net sales of SB206, a product candidate being developed to treat molluscum contagiosum, and any other Novan products used for the treatment of molluscum (&#8220;Novan Molluscum Products&#8221;). We paid Novan an upfront payment of $12.0 million, which Novan is required to use to fund the development of SB206. We are not obligated to provide additional funding to Novan for the development or commercialization of SB206. Pursuant to the agreement, we would receive up to $20.0 million of milestone payments upon the achievement by Novan of certain regulatory milestones for SB206 or any other Novan Molluscum Product and commercial milestones. In addition to the milestone payments, Novan will pay us tiered royalties from 7.0% to 10.0% based on aggregate annual net sales of SB206 or any other Novan Molluscum Product in North America. We determined the economic rights related to Novan should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Arrangement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and reduce our asset as the funds are expended by Novan. As of December&#160;31, 2019, Novan had used up the $12.0 million upfront payment provided by us. As such, our other economic rights related to Novan has been fully amortized as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, we entered into a development funding and royalties agreement with Palvella. Pursuant to the agreement, we will receive up to $8.0 million of milestone payments upon the achievement by Palvella of certain corporate, financing and regulatory milestones for PTX-022, a product candidate being developed to treat pachyonychia congentia. In addition to the milestone payments, Palvella will pay us tiered royalties from 5.0% to 9.8% based on aggregate annual worldwide net sales of any PTX-022 products, if approved, subject to Palvella&#8217;s right to reduce the royalty rates by making payments in certain circumstances. We made an upfront payment of $10.0 million, which Palvella is required to use to fund the development of PTX-022. We are not obligated to provide additional funding to Palvella for development or commercialization of PTX-022. We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for it in accordance with ASC 730-20, and will reduce our asset as the funds are expended by Palvella. We will evaluate the remaining asset basis for impairment on an ongoing basis. It is anticipated that the cost basis of the asset will be reduced to zero prior to the receipt of any payments from Palvella. Therefore, we will recognize milestones and royalties as revenue when earned. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, we entered into a royalty agreement with Aziyo pursuant to which we will receive royalties from certain marketed products that Aziyo acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Aziyo to buydown the royalty rates on the products CorMatrix sold to Aziyo. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Aziyo (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Aziyo acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase Agreement&#8221;) between CorMatrix and us. In addition, Aziyo has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Aziyo acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Aziyo in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for the Aziyo commercial license right as a financial asset in accordance with ASC 310, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Receivables</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and amortize the commercial license right using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Aziyo as of December&#160;31, 2019 is 23%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in 2019 were accordingly allocated between revenue and the amortization of the commercial license rights.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160; In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for commercial license rights related to developmental pipeline products such as Selexis and Dianomi on a non-accrual basis. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The developmental pipeline products are on a non-accrual basis as we are not yet able to forecast future cash flows given their pre-commercial stages of development. We will prospectively update the yield model under the effective interest method once the underlying products are commercialized and we can reliably forecast expected cash flows. Income will be calculated by multiplying the carrying value of the commercial license right by the effective interest rate. We regularly perform reviews to determine if any event has occurred that may indicate the carrying value of these commercial license rights are potentially impaired. If the affected commercial license rights are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. We recorded a $5.1&#160;million reduction in the carrying value of the Selexis asset which was reflected in other expense, net, in our consolidated statement of operations for the twelve months ended December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, license fees and development, regulatory and sales based milestone payments.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which amends the guidance for recognition of revenue from contracts with customers by using the modified-retrospective method applied to those contracts that were not completed as of January 1, 2018. The results for reporting periods beginning January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See additional information in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disaggregation of Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> subsection below. Our accounting policies under the new standard were applied prospectively and are noted below.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalties, License Fees and Milestones</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under the contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when it is probable to estimate the amount of the payment. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received because we have to satisfy a future obligation. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Material Sales</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost for freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of material sales. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the twelve months ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at prior year-end was $3.3 million. During the twelve months ended December&#160;31, 2018, the amount recognized as revenue that was previously deferred at prior year-end was $2.3 million.</span></div>We have revenue sharing arrangements whereby certain revenue proceeds are shared with a third party. The revenue standard requires an entity to determine whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. We received $4.6 million royalty payments from a license partner during 2019 of which $4.0&#160;million was paid to a third-party in-licensor. We recorded net revenue of $0.6 million as we believe we are an agent in the transaction. We recorded an immaterial amount due to third-party in-licensors as general and administrative expenses as we are the principal in the transaction during 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock', window );">Preclinical Study and Clinical Trial Accruals</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preclinical Study and Clinical Trial Accruals</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Substantial portions of our preclinical studies and all of our clinical trials have been performed by third-party laboratories, CROs.&#160;We account for a significant portion of the clinical study costs according to the terms of our contracts with CROs. The terms of the CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. Our objective is to reflect the appropriate preclinical and clinical trial expenses in our financial statements in the same period as the services occur. As part of the process of preparing our financial statements, we rely on cost information provided by our CROs. We are also required to estimate certain of our expenses resulting from the obligations under the CRO contracts. Accordingly, our preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development ExpensesResearch and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. In addition, the amortization of the above mentioned other economic rights such as Palvella and Novan are included in research and development expenses in accordance with ASC 730-20.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-Based Compensation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div>Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income (loss) Per Share</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Potentially dilutive common shares consist of shares issuable under 2019 and 2023 convertible senior notes, stock options and restricted stock. 2019 and 2023 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. In addition, post May 22, 2018, the 2019 Notes can only be settled in cash and therefore there will be no further impact on income (loss) per share of these notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The British Pound Sterling is the functional currency of Vernalis and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Translation of Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Recently Adopted and Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Recently Adopted </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In February 2016, the FASB issued ASU 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases (Topic 842)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. This standard requires organizations that lease assets to recognize the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In 2018, the FASB issued guidance that provides an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in ASC 840,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> Leases (Topic 840),</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> including its disclosure requirements, in the comparative periods presented. We adopted this standard on January 1, 2019 by applying this optional transition method. For leases with a term of 12 months or less, we elected to not recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. In addition, we elected the available package of practical expedients upon adoption, which allowed us to carry forward our historical assessment of whether existing agreements contained a lease and the classification of our existing operating leases. We did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases. We continue to report our financial position as of December 31, 2018 under Topic 840 in our audited consolidated balance sheet. The adoption of this standard update resulted in the recognition of right-of-use assets of approximately $5.2 million and lease liabilities of approximately $5.9 million on our consolidated balance as of January 1, 2019, with no material impact to our consolidated statement of operations. See "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Note (6), Leases"</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> for further information regarding the impact of the adoption of ASU 2016-02 on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Standards Not Yet Adopted</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for us beginning in the first quarter of 2020, with early adoption permitted. This standard includes our financial instruments, such as accounts receivable, investments that are generally of high credit quality, and commercial license rights. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We will adopt this standard effective January 1, 2020, and we currently do not expect the adoption to result in a  material impact to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Goodwill Impairment Testing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In January 2017, the FASB issued ASU 2017-04, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Simplifying the Test for Goodwill Impairment,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new standard the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. This standard is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement: Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, which modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for us beginning in the first quarter of 2020, with earlier adoption permitted. We will adopt this standard effective January 1, 2020, and will include the required disclosure beginning in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - In November 2018, the FASB issued ASU 2018-18</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (Topic 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The new standard clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, when the counterparty is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">recognized from contracts with customers. The new standard is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted in any interim period for entities that have adopted ASC 606. The standard should be applied retrospectively to the period when we initially adopted ASC 606. We will adopt this standard effective January 1, 2020, and do not expect the adoption will result in material impact to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AllowanceForDoubtfulAccountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical Study and Clinical Trial Accruals [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6925713472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:65.503%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.192%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.833%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.192%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.686%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.194%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(185)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:65.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.682%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.148%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at federal statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(819)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,131)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,019)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FDII</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(402)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(879)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,758)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,821)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in uncertain tax positions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate change for changes in federal or state law</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(210)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,193)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,225)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,169)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired NOLs and credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in derivatives</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Deferred tax assets (liabilities) are comprised of the following:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:75.578%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.762%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.913%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(141,338)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,476)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retrophin fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(179)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,905)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,664)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,643)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identified indefinite lived intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,040)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,759)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,937)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,480)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,488)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(964)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,111)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,966)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,329)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2019, 2018 and 2017 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.807%;"><tr><td style="width:1.0%;"/><td style="width:65.713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.164%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.164%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.547%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="14" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at beginning of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,247&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,042)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(657)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,583)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912842784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Narrative (Details) - Core Assets, Partnered Programs, and Ion Channel Technology of Icagen - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CoreAssetsPartneredProgramsAndIonChannelTechnologyOfIcagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6829668400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,294<span></span>
</td>
<td class="nump">$ 36,400<span></span>
</td>
<td class="nump">$ 20,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationContingentValueRights', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(819)<span></span>
</td>
<td class="num">(8,131)<span></span>
</td>
<td class="num">(4,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount', window );">FDII</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(879)<span></span>
</td>
<td class="num">(2,758)<span></span>
</td>
<td class="num">(2,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change for changes in federal or state law</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">32,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(4,225)<span></span>
</td>
<td class="num">(4,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Expired NOLs and credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,054<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives', window );">Change in derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense from continuing operations</a></td>
<td class="num">$ (810)<span></span>
</td>
<td class="num">$ (4,620)<span></span>
</td>
<td class="num">$ (3,609)<span></span>
</td>
<td class="nump">$ 176,376<span></span>
</td>
<td class="num">$ (14,307)<span></span>
</td>
<td class="nump">$ 11,864<span></span>
</td>
<td class="nump">$ 22,419<span></span>
</td>
<td class="nump">$ 10,033<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
<td class="nump">$ 30,009<span></span>
</td>
<td class="nump">$ 44,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Derived Intangible Income, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Change in Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Expired Tax Credits, Research</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationExpiredTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6926274432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 19, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>trading_day</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ExercisePriceofConvertibleBondHedge', window );">Exercise price of convertible bond hedge (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,576,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,576,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,859,000<span></span>
</td>
<td class="nump">$ 10,704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,959,000<span></span>
</td>
<td class="nump">609,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_WarrantsSettled', window );">Warrants settled (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled', window );">Deduction to additional paid-in-capital for warrants settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="nump">30,094,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890,359<span></span>
</td>
<td class="nump">2,739,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member', window );">2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0133251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">If-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,400,000<span></span>
</td>
<td class="nump">$ 341,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal', window );">Increase (decrease) in if-converted value in excess of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notices for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,900,000<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion value over the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="nump">$ 26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="nump">340,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
<td class="num">(119,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities', window );">Proceeds from derivative instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000,000.0)<span></span>
</td>
<td class="nump">119,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2019 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible debt conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0040244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of the conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs related to the equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt issuance costs related to the liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Increase (decrease) in derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) in derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger to classify convertible debt as current (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 2023 Convertible Senior Notes | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger', window );">Maximum threshold of debt trading price trigger (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense | Convertible Notes | 2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Settled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantsSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Increase (Decrease) If-Converted Value in Excess of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleIncreaseDecreaseIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentConvertibleMaximumThresholdPercentageofDebtTradingPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ExercisePriceofConvertibleBondHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Convertible Bond Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ExercisePriceofConvertibleBondHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsforConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsforConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_WarrantsSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Settled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_WarrantsSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912963456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 23, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 06, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 95,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring and product reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible asset with finite life - core technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6826738528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624930928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock', window );">Schedule of Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.102%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.143%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.143%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.146%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,846&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:48.220%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.344%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Term in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,736,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,617&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,531)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,454,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.42</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Option Plan Activity by Exercise Price Range</a></td>
<td class="text"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a further breakdown of the options outstanding as of December&#160;31, 2019:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:25.366%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.391%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.574%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range of exercise prices</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">remaining&#160; life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">in&#160;years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.96 - $12.81</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.01</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.13</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$32.00 - $74.42</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">374,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.43</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$63.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">374,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$63.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$85.79 - $100.38</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.66</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$93.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$92.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$101.15 - $113.76</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.98</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$109.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$107.65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.12</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$119.30 - $159.01</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.01</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$151.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,541&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$149.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$159.81 - $171.28</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$166.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$164.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.47</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,454,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$61.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:51.709%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.986%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.544%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4%-2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7%-3.0%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%-2.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40%-49%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33%-36%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43%-47%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 to 5.9 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 to 5.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 to 6.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of our restricted stock activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514%;"><tr><td style="width:1.0%;"/><td style="width:70.413%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.893%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.549%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$130.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$115.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(102,846)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$121.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(666)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$134.36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$125.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule for share based compensation expense for awards to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleForShareBasedCompensationExpenseForAwardsToEmployeesAndDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624793728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">998,324&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">599,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">656,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">599,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities - Cydex</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1) Short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on black scholes value estimated by management as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;Gain (loss) from Viking&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note (3), Investment in Viking.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#8221;  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2019, we paid $3.0 million contingent liability on development milestones to former Crystal shareholders. At  December&#160;31, 2019, $1.8 million of the development and regulatory milestones were considered to be achieved and will be paid to former Crystal shareholders during the first half of 2020. </span></div>(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. Another Metabasis drug development program, RVT-1502, has been outlicensed to Metavant. RVT-1502 is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist or &#8220;GRA.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2019 is as follows (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:81.284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.716%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December&#160;31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912266912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventOn February 11, 2020, we announced the signing of an agreement to acquire the core assets, partnered programs and ion channel technology from Icagen for $15&#160;million in cash. Icagen will also be entitled to receive up to an additional $25&#160;million of cash payments based on certain revenue achievements. The transaction is subject to certain closing conditions, including a vote of Icagen stockholders, and is expected to close in April 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830510048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Unaudited Quarterly Financial Information - Summary (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 59,590<span></span>
</td>
<td class="nump">$ 45,663<span></span>
</td>
<td class="nump">$ 90,043<span></span>
</td>
<td class="nump">$ 56,157<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
<td class="nump">$ 141,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">37,182<span></span>
</td>
<td class="nump">29,966<span></span>
</td>
<td class="nump">29,117<span></span>
</td>
<td class="nump">29,738<span></span>
</td>
<td class="nump">26,441<span></span>
</td>
<td class="nump">22,301<span></span>
</td>
<td class="nump">19,868<span></span>
</td>
<td class="nump">19,116<span></span>
</td>
<td class="nump">126,003<span></span>
</td>
<td class="nump">87,726<span></span>
</td>
<td class="nump">73,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="num">(176,376)<span></span>
</td>
<td class="nump">14,307<span></span>
</td>
<td class="num">(11,864)<span></span>
</td>
<td class="num">(22,419)<span></span>
</td>
<td class="num">(10,033)<span></span>
</td>
<td class="num">(167,337)<span></span>
</td>
<td class="num">(30,009)<span></span>
</td>
<td class="num">(44,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (7,365)<span></span>
</td>
<td class="num">$ (15,251)<span></span>
</td>
<td class="num">$ (14,419)<span></span>
</td>
<td class="nump">$ 666,337<span></span>
</td>
<td class="num">$ (42,482)<span></span>
</td>
<td class="nump">$ 67,362<span></span>
</td>
<td class="nump">$ 73,160<span></span>
</td>
<td class="nump">$ 45,279<span></span>
</td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
<td class="nump">$ 12,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic per share amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) - Basic (USD per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 32.59<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 33.13<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted per share amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) - Diluted (USD per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 31.32<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 31.85<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares&#8212;basic (shares)</a></td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">20,447<span></span>
</td>
<td class="nump">21,071<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
<td class="nump">21,212<span></span>
</td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">21,160<span></span>
</td>
<td class="nump">21,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares&#8212;diluted (shares)</a></td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
<td class="nump">21,277<span></span>
</td>
<td class="nump">21,071<span></span>
</td>
<td class="nump">24,052<span></span>
</td>
<td class="nump">24,438<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="nump">19,757<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
<td class="nump">23,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828299232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,471<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Income Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,508<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,627<span></span>
</td>
<td class="nump">29,928<span></span>
</td>
<td class="nump">44,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense from continuing operations</a></td>
<td class="num">$ (810)<span></span>
</td>
<td class="num">$ (4,620)<span></span>
</td>
<td class="num">$ (3,609)<span></span>
</td>
<td class="nump">$ 176,376<span></span>
</td>
<td class="num">$ (14,307)<span></span>
</td>
<td class="nump">$ 11,864<span></span>
</td>
<td class="nump">$ 22,419<span></span>
</td>
<td class="nump">$ 10,033<span></span>
</td>
<td class="nump">$ 167,337<span></span>
</td>
<td class="nump">$ 30,009<span></span>
</td>
<td class="nump">$ 44,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>360</ContextCount>
  <ElementCount>548</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>112</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Sale of Promacta License</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPromactaLicense</Role>
      <ShortName>Sale of Promacta License</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Investment in Viking</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/InvestmentinViking</Role>
      <ShortName>Investment in Viking</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2148110 - Disclosure - Commitments and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentsandContingenciesLegalProceedings</Role>
      <ShortName>Commitments and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2156112 - Disclosure - Summary of Unaudited Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2159113 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BusinessCombinations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FairValueMeasurement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2357309 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCommercialLicenseRightsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Commercial License Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuebySourceDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Sale of Promacta License - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPromactaLicenseNarrativeDetails</Role>
      <ShortName>Sale of Promacta License - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Investment in Viking - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/InvestmentinVikingNarrativeDetails</Role>
      <ShortName>Investment in Viking - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Business Combinations - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Business Combinations - Aggregate Acquisition Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BusinessCombinationsAggregateAcquisitionConsiderationDetails</Role>
      <ShortName>Business Combinations - Aggregate Acquisition Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Leases - Operating Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesOperatingLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Operating Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Convertible Senior Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesNarrativeDetails</Role>
      <ShortName>Convertible Senior Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ligand.com/role/ConvertibleSeniorNotesEquityandLiabilityComponentsofFinancingArrangementsDetails</Role>
      <ShortName>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Investment Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Breakdown of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Stockholders' Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2452432 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2453433 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2454434 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2455435 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Summary of Unaudited Quarterly Financial Information - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationSummaryDetails</Role>
      <ShortName>Summary of Unaudited Quarterly Financial Information - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SummaryofUnauditedQuarterlyFinancialInformationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - Subsequent Event - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SubsequentEventNarrativeDetails</Role>
      <ShortName>Subsequent Event - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lgnd-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - lgnd-20191231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - lgnd-20191231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lgnd-20191231.htm">lgnd-20191231.htm</File>
    <File>exh43lgnddescriptionofse.htm</File>
    <File>exhibit109final.htm</File>
    <File>lgnd-20191231.xsd</File>
    <File>lgnd-20191231_cal.xml</File>
    <File>lgnd-20191231_def.xml</File>
    <File>lgnd-20191231_lab.xml</File>
    <File>lgnd-20191231_pre.xml</File>
    <File>lgnd123119exhibit1042n.htm</File>
    <File>lgnd123119exhibit211.htm</File>
    <File>lgnd123119exhibit231.htm</File>
    <File>lgnd123119exhibit311.htm</File>
    <File>lgnd123119exhibit312.htm</File>
    <File>lgnd123119exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lgnd-20191231_g1.jpg</File>
    <File>lgnd-20191231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6606686112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Aggregate Acquisition Consideration (Details) - Crystal - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 06, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPaidtoAcquireBusiness', window );">Cash paid to Crystal shareholders</a></td>
<td class="nump">$ 26,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPayable', window );">Cash payable to Crystal Shareholders</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Assumed liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration', window );">Fair value of contingent consideration</a></td>
<td class="nump">8,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="nump">$ 35,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPaidtoAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid to Acquire Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPaidtoAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624921424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>acquisition</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfAcquisitions', window );">Number of acquisitions | acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInOperatingLeaseAssets', window );">Increase (decrease) in operating lease assets</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Increase (decrease) in operating lease liabilities</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining contractual term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6625238512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Equity and Liability Components of Financing Arrangements (Details) - Convertible Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 22, 2018</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Total current portion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term portion of notes payable</a></td>
<td class="nump">$ 638,959,000<span></span>
</td>
<td class="nump">609,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible senior notes outstanding (Level 2)</a></td>
<td class="nump">647,280,000<span></span>
</td>
<td class="nump">713,533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(893,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2023 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(111,041,000)<span></span>
</td>
<td class="num">(140,136,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of equity component of 2023 Notes</a></td>
<td class="nump">$ 101,422,000<span></span>
</td>
<td class="nump">$ 127,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912805296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">16,823,000<span></span>
</td>
<td class="nump">20,766,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">16,823,000<span></span>
</td>
<td class="nump">20,766,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6920982000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 629,302<span></span>
</td>
<td class="nump">$ 143,321<span></span>
</td>
<td class="nump">$ 12,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain from sale of Promacta license</a></td>
<td class="num">(812,797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain on sale of short-term investment</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(2,611)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">18,361<span></span>
</td>
<td class="nump">12,784<span></span>
</td>
<td class="nump">10,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity investment in Viking</a></td>
<td class="num">(2,888)<span></span>
</td>
<td class="num">(47,658)<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of premium (discount) on investments, net</a></td>
<td class="num">(10,274)<span></span>
</td>
<td class="num">(5,452)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance fees</a></td>
<td class="nump">29,988<span></span>
</td>
<td class="nump">43,954<span></span>
</td>
<td class="nump">11,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights', window );">Amortization of commercial license and other economic rights</a></td>
<td class="nump">25,370<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">24,515<span></span>
</td>
<td class="nump">20,846<span></span>
</td>
<td class="nump">24,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes, net</a></td>
<td class="nump">74,829<span></span>
</td>
<td class="nump">29,739<span></span>
</td>
<td class="nump">44,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement', window );">Royalties recorded in retained earnings upon adoption of ASC 606</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(1,456)<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
<td class="num">(870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">25,463<span></span>
</td>
<td class="num">(29,544)<span></span>
</td>
<td class="num">(8,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(2,559)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(6,826)<span></span>
</td>
<td class="num">(4,542)<span></span>
</td>
<td class="num">(1,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="num">(11,219)<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInOtherEconomicRights', window );">Other economic rights</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="num">(5,458)<span></span>
</td>
<td class="num">(5,062)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(29,336)<span></span>
</td>
<td class="nump">194,059<span></span>
</td>
<td class="nump">88,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of Promacta license</a></td>
<td class="nump">812,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseforCommercialLicenseRights', window );">Purchase of commercial license rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition, net of cash acquired</a></td>
<td class="num">(11,840)<span></span>
</td>
<td class="num">(5,856)<span></span>
</td>
<td class="num">(26,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,553)<span></span>
</td>
<td class="num">(887)<span></span>
</td>
<td class="num">(2,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(2,356,545)<span></span>
</td>
<td class="num">(1,434,255)<span></span>
</td>
<td class="num">(254,258)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">535,877<span></span>
</td>
<td class="nump">131,942<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">1,494,851<span></span>
</td>
<td class="nump">892,873<span></span>
</td>
<td class="nump">109,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProceedsFromCommercialLicenseRights', window );">Proceeds from commercial license rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds received from repayment of Viking note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(4,669)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">466,918<span></span>
</td>
<td class="num">(423,269)<span></span>
</td>
<td class="num">(79,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(27,323)<span></span>
</td>
<td class="num">(217,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds from issuance of 2023 Convertible Senior Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,900)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PurchaseOfConvertibleBondHedge', window );">Purchase of convertible bond hedge</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Proceeds from bond hedge settlement</a></td>
<td class="nump">12,401<span></span>
</td>
<td class="nump">439,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Payments to convert holders for bond conversion</a></td>
<td class="num">(12,401)<span></span>
</td>
<td class="num">(439,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock option exercises and ESPP</a></td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(4,418)<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
<td class="num">(10,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchases</a></td>
<td class="num">(453,048)<span></span>
</td>
<td class="num">(122,868)<span></span>
</td>
<td class="num">(1,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(30,094)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(485,172)<span></span>
</td>
<td class="nump">328,585<span></span>
</td>
<td class="num">(7,523)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(47,590)<span></span>
</td>
<td class="nump">99,375<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">119,780<span></span>
</td>
<td class="nump">20,620<span></span>
</td>
<td class="nump">18,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">72,273<span></span>
</td>
<td class="nump">119,780<span></span>
</td>
<td class="nump">20,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">5,827<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="nump">103,817<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash in other current assets</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AccruedInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on AFS investments</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of fixed assets recorded in accounts payable</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Commercial License and Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During the Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash change in estimated fair value of contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseOfConvertibleBondHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Convertible Bond Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseOfConvertibleBondHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseforCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase for Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseforCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Recorded upon Adoption of New Accounting Pronouncement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltiesRecordedUponAdoptionOfNewAccountingPronouncement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6924381904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Breakdown of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember', window );">$9.96 &#8211; $195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">1,956,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 77.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">1,454,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 61.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember', window );">$9.96 - $12.81</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">9.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 12.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">195,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">1 year 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">195,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember', window );">$14.47</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">14.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 14.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">212,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">2 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 14.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">198,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 14.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember', window );">$21.92</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">21.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 21.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">195,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 21.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">195,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 21.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember', window );">$32.00 - $74.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 74.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">374,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 63.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">374,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 63.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember', window );">$85.79 - $100.38</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">85.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 100.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">301,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 93.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">239,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 92.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember', window );">$101.15 - $113.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">101.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 113.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">98,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 109.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">46,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 107.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember', window );">$117.97</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">117.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">272,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">9 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">56,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 117.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember', window );">$119.30 - $159.01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">119.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 159.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">282,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 151.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">129,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 149.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember', window );">$159.81 - $171.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">159.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 171.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">7,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 166.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 164.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember', window );">$195.91</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (USD per share)</a></td>
<td class="nump">195.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">17,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">17,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 195.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828951120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">$ 12,542<span></span>
</td>
<td class="nump">$ 13,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(3,050)<span></span>
</td>
<td class="num">(4,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">3,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="num">(520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="nump">12,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember', window );">Cydex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">5,551<span></span>
</td>
<td class="nump">3,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,860)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="num">(520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at beginning of period</a></td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">8,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(818)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights at end of period</a></td>
<td class="nump">$ 2,659<span></span>
</td>
<td class="nump">$ 6,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration, potential cash payment at end of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6906645168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Investment Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 941,174<span></span>
</td>
<td class="nump">$ 600,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,118)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">939,989<span></span>
</td>
<td class="nump">601,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">411,690<span></span>
</td>
<td class="nump">311,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">411,875<span></span>
</td>
<td class="nump">311,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">63,818<span></span>
</td>
<td class="nump">53,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">63,979<span></span>
</td>
<td class="nump">53,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1,850)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">210,525<span></span>
</td>
<td class="nump">225,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">210,552<span></span>
</td>
<td class="nump">225,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember', window );">Mutual fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">250,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 250,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6931442240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>right</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum', window );">Maturity period of cash and cash equivalents, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs related to obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,010,000)<span></span>
</td>
<td class="num">(6,307,000)<span></span>
</td>
<td class="nump">$ 2,603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived', window );">Third-party portion of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,353,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsIssued', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember', window );">Novan | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_LicenseUpfrontPayment', window );">Upfront payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent', window );">Effective interest rate of forecasted cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AziyoMember', window );">Aziyo | Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember', window );">CorMatrix | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RoyaltyAgreementExpirationPeriod', window );">Expiration period of royalty agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member', window );">2023 Convertible Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member', window );">2019 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forecasted Cash Flows, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ForecastedCashFlowsEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of highly liquid securities maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProductRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProductRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RevenueRecognitionMilestoneMethodMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method Third-Party Portion of Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RevenueRecognitionMilestoneMethodThirdPartyPortionOfMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltyAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltyAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_NovanMolluscumProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AziyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AziyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_CorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6924191328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,003<span></span>
</td>
<td class="nump">$ 24,808<span></span>
</td>
<td class="nump">$ 24,987<span></span>
</td>
<td class="nump">$ 43,484<span></span>
</td>
<td class="nump">$ 59,590<span></span>
</td>
<td class="nump">$ 45,663<span></span>
</td>
<td class="nump">$ 90,043<span></span>
</td>
<td class="nump">$ 56,157<span></span>
</td>
<td class="nump">$ 120,282<span></span>
</td>
<td class="nump">$ 251,453<span></span>
</td>
<td class="nump">$ 141,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Material sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
<td class="nump">29,123<span></span>
</td>
<td class="nump">22,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember', window );">License fees, milestones and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
<td class="nump">93,774<span></span>
</td>
<td class="nump">30,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
<td class="nump">78,195<span></span>
</td>
<td class="nump">13,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,451<span></span>
</td>
<td class="nump">6,577<span></span>
</td>
<td class="nump">11,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,167<span></span>
</td>
<td class="nump">$ 9,002<span></span>
</td>
<td class="nump">$ 5,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesandProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)FR]-@?SCXVO@ET+O^ZB^P)02P,$%     @ 2HI;4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MJ6GZ-!1J/@\ V:9J<[VITU,_7OKANCT?OY]O^N9X^6MA<?U_8_4?4$L#!!0
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M'IM3\\28!.6*9^KK*-1%.@PHG*3NIJK/N]ND&TC6]#<E&J[K]7]02P,$%
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M8N@%-!5"MA,D(7G+D^^A9+P$H@7P%8> F87E,UR@U&)*M&Q@*!@8<0/#T'/
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M!N6T:?"1RV4FUE2/"[WAI!\G83"-X_(?4$L#!!0    ( $J*6U#JV*-=YP4
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M ("S :H/4,< )<X&Z#Y 7QJ0]0'9+TKJ;(#I \PQ0-JS ;8/L,> S)P-<'V
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MN4<</\'<SSM*YN:_P 643P]*?(T2E8U?4@[6H9Y9O!0M7J93=O$<9_XK;!O
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M][89EVQT'';3^V'S(\[_ E!+ P04    " !*BEM0F"B^!K4!  #2 P  &0
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MZ/S+QO[7B Z\E-V5'Z'6?[#%4%"[</SLSV8:L\EPV,\_B"W?N/@-4$L#!!0
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MG&ZB(%!0^L@@PG:#)U J$@49/R9..J>,P.7YC?U]JCW4<A4.GE!]EY5O<_I
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M;'.6^WX#0;$ZP&9 PDYG>5 '"!2I XKM@().+_TZ ""6+R(ZV YHV.HL]_T
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MCY: 0:7M-C%[.4WE%&C1SP\.7EZ]_"]02P,$%     @ 2HI;4'H^TZL* @
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M5_V(ZPTCVV%\D_$?DO\%4$L#!!0    ( $J*6U >'8^KQ0$  #<$   9
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M=V:25\9[*Z(XR,C-$LV8TX0)5YC=@B"&?9$(,8E3^"$\Q,,C-,/(A4?K\"3
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M,;6]2_KWM0TAE$Q?L&=\YIP9FYEL%/)%M0#:>^6L5[G?:CT<"5%E"YRJ.S%
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M9;JQ[HOV.&\'BM?=507U]Z7L'U!+ P04    " !*BEM023_(_.@#  !C$@
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M'FZEK(0*/ORB.G0ODDW_D(IM5=_&ZKYHCSW:ATH>NR.=H#]7FO\/4$L#!!0
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MT@#/D8?7BE='\"YML"M99G@$5D=@O6H#E31NF*!FBL9GZ#(PF@E"16$($O"
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M9MUEU4T$;<Q%#/JO@?PO4$L#!!0    ( $J*6U#D(CXXV@(  /<*   9
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MEC%)E<=PHE*R5UUH.RCI5NK73+WSIA5K!I(=;)L9M+WN\A]02P,$%     @
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M8?['$^E\CTE3F#0='+"Q@U&P)PX8=, &!WR<"8NM3!"&8!(.2;CC(+56YNX
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M+0L*M=331,WY]/=/"\F&^6)#R^V:_P-02P,$%     @ 2HI;4/9(>;N-!@
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M=J/VW$Z:-20;W"."YI>L^ =02P,$%     @ 2HI;4$<)I2R  @  UP@  !D
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MMI0CYXII+]%$>SGKKXQ^4;*C,M.9G@O7:MU"\:;[C$#]M\SJ'U!+ P04
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MI=#^-SA>M9'MI&)3:=G[.#:='X=Q)Z-3&!Q I@ R!Y"QEA'D,__"#*M*)8=
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M<=/,SM5X48X+(_OI$4#S2U3]!U!+ P04    " !*BEM0HG^^9!<'  !A*0
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M];CKKQ;]1(G679N2\]UM\0]02P,$%     @ 2HI;4#43>2&<!   4AD  !D
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M>CM$3#X-$7>VW%Y.*OO2CX=F.&[/;_G/)WUSG/_!B"]_HZS_ U!+ P04
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M\%"SG3*WN;X7W:+8/2A^[)?@:-C$%_\!4$L#!!0    ( $J*6U#N22;R3 ,
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M,K%3]6VH[\OVI-(.E#QVIS"O/PHN_@-02P,$%     @ 2HI;4*H#&-A] @
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MNT=L10C#D)EG8J-X&L_\?S"L&PP)A]4DZ1MU,'"Q(>]X$LV4"V$)(O^&)AE
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MU_W<V2^4/ TSM7<=[%?_ %!+ P04    " !*BEM05/S6_%("  !/!P  &0
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M3"=*!<@LG2=YGTLYW88-@9-0RUBN6=?BNXV@;3^^T#!#LW]02P,$%     @
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M^8U7QMQ&8A@'42GW] Y7I47=JYA0:O;>O<O&O>_=EXSV;K #Z1W(X! Y#NI
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MW4)80,U\O@,P%-' _);>0^$0"<QQ?X#BH9@:>\LC@&%,D.'N"8KF^T%@3C:
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M-D51*^V>?-'INE/)NK])U:9N+@-]778'_^ZF+@[FHX;7?UF9_0]02P,$%
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MJQC4RHQU61$3V'05RL "B2GJANVJD)%SV\#C!!'8GLB+GSY%?^/3>"9(WYX
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M6"123VGDSL?[?'$?W9'G"GDSR<$'8U+'MQA4MVA.>LC4L$YT>H_V?QH.XS$
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M7I1 =_ L*-0+X*>7NP(KAQ!D@X9)S1AVV,,XO#<^H""CH5'[]Q8D$1*_="$
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M+O3*[PK0:+78KR3&2[/];:.CFZ(L.7Z!XLY\+QU3ID%@OI[*O?(7@-V(5EH
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M9M(!54-QA1,#8U&L1F+)7F?/ <N/]$;\K*3V4PIFS^@(W[DB)"Z:T-TC1ZH
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MX51NQS76A/$_3*2?8$8L#]@V:ZCWXKY([G.;JVW+Q;3E&#$)XA0V,O!RF&O
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M5)L/UJ(^/H3'2$CSU#MG\]Y\$EV2@0+4U&0^CA.07)(>"!U4GF'LOI./: \
M<@'"1@QD(1KTDD2_2^8S^DX^8N7+^8#>GX]!0>RA/R#\3CZ>#0<]T!5A&5-"
MW^$45&T08^ #O#(9]J;^._EX-AOW #=QY?T^1@P-T6<*OP.E@A7,ASU@L(,A
M**'806 ^X*7WDQZP1'P)@W@G$2T8R$5O3ON#PP!5?<)NFJ0_1<(&C\+/L&'
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MHP\H7OIC2@E\[PNX[UD\PC!?],R*"*W2=#+]#K_>TL,J17\748!,W)_-6E^
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MF!!B'D .$.,HX8X3J@(R&0PZ$A0C6,9\!/\#R.E, CF?)7/,OXD3C'<_!P#
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M*7?0_'QI@<CI4+V]AOEB%?A%-?BW_P.VS)],R LOE(X^Q,#LJ(-<S14'5X+
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MG%)]?<*<*O8"0F A/2C.57_8/6U=<B77SF;#_05CA05#*,L;%2.@!8$X0(.
MSOOZ:;J$3:XQ5&U<[T#RZ^KLF\S2JD>ONW\.2K.L"T?G-BS]BBX"[@ L$*2Z
M05G%A0'^1 *BU&0T.T=YW-=.'4,/S=;8$QI7:IG#9 -[@CO+;0 N A;F8137
M>W*\"7Z39[+CPK-Y"&IO-Q)^1RFQ>!G(^>>2I^EB_'G]!?FZ'@RZ@7-2LA=$
M\YDUJ=BE*H.H]4RP;M6W :*/_^Z:02]ED^#^Q-0/VF.7/]1=Q$;P?D+H,N5'
MP*@9,(I&)5(6$UG QEHN]S W#$ WO5VL014N74R)EX,&IZTV2&RI&77D^-84
MEI1??>=^_D$:\;1WJ'=.%S/Y"/QO_P";&7U@LM6Q$J.J/;67^D3XA86+,GF0
MK#6M&6?9F(74*7+%CG@%K\$4N9TZR;)&L"QK$.KJPV_Y@SKPH.5-RB?K/F<Q
M+^C&\M0(T?9P7(0A?YV7!F[?D,.7W7 NI1WU&^XF.G]<4BWJB!0O]]N+QD']
MP]XWUSI:,"GA<T?=-Q2XOW6$<7=+:9EL!_@AA007=.;\YB8I-D(B8>0![>)?
MG&DWO859NV4_(!DF\=X_;B2+%0,!(YLIVG=AI@-OFZ8 ,K78W.R6G=!7'"Y!
M2%8'T3@]))FL.QN=$/LM^:PL?L8NE1..?%^C7O<<2SL"T,,?3=L7ONVB%%41
MX5M)%V.52)'374H4Q7&PQ[I[LB7DNHH(,$1B +<KM!4<T.@$R[&B]I'$Z6)+
MFC4G6*<E?C3AG,N!527[T*[*,>/AMFS<8]] SNLM>?!0XS9OG.GQLX^TNYO-
MJ7;ILJ5>I=KW[''_\.G_.N\B6/!)5\0#=.9IO7J"+J&WA^*OB^G1Q][U_?#)
M'\C)GW3&;0?_<;U9SAY13@<B $^^C-#=5>S?%U;1(#5&N^7@WVGC<:R$S@O9
ME*)U,6@E45O^RC#O3S[1/4T10_X>O$HR%UHWOM"\!G;2G29C?NZMYK[*,'&'
M+S7[O>/%IOO,_]N2DZ)(?#I/D8O^X*L3U_EOV?N@4#L*CH.NG89#EW0W^._M
M&A^D1^ 8D5<#O79HT^S4)>,RA*ZTULC9[P9Y$T= T_N/^68=\CJ0\'GPD$ZZ
M9>FD^=%\PO O.C<#L26)(T9^-*3BUA74$3X K-9*(N&B5H]2XE;/4T.HLM&9
MUIVM'&V("SUY[%&8S[R&RHQ&U&IH(3G;YY#\=IP%P4E5P$ZA7*(/H!MW_T1Y
MB;'($''N.N9MKRV!7JVY$0'==[-"!8(D_' V%1U=*;<C<EJM3PPV"54VAX-V
MWPLXJ?VO*?A87,*+7CW_H,[)_/4V+0;?N7$W1]Q8!<="&7^S=/O9Y;BM08XL
M4%[57?^%QI@>&NMH2L-FC-XP-V44+F_(C(<SR&FF2P:"L=/S7OOP5MMP=/>.
MXLPQ+US-=X^HI/CN4>+[MI$CPI-"05UL@J4TWXRB*U0-_=_(;G,H=U),(FX3
M7(S@2GSF2FCFW/RWG3 ?2$ZE,D'X@WCUY/+>>!.GCCA&O)1A.=S4]:@Q,XM6
M ;)2U#\%/ME)06)V=8.EO)"7CUE).EQN<O2*WNX?$)EZYN'^4!G:S'><3'+,
M7I$8(H<E*:M38R=Q%LPV%!/QFO&YT05R:W[$0!6L:+]B=^HL@E\)OV1N8>S?
MXH$JGJRB%806K1C$7H&$T$2VZ%W>.,?TN;&5JJ[@V$1%-3O-4;>3JE@/W OW
M\09V(<T?S7;"5<A*(JLJH?\JIW;T*K+6?-V".%?$?FDN?/@AGSKM:Y'<9I?$
M3\K?@F/X.'<Q2A^2L-@M&F;BHRQ7A;$6\8!M-B30=W342-LFW2S^NMQ8K) G
M.F="R^Z:,B%4TR^W=JW*0<Z+"JI1W?NNXV!"*>=N>2U.9-38D3G'\#2DXR+9
M%= LL<P$.*W*Z0N""@[+(3[+#9X)M%B7"%Y%O9)+PD$2:&%J(Q&^K6.P;]\$
M"GKCUQYCEB+&*#%QR[N0H@N=$_2#W_TFMN*CCF:UL*];WZ3L038=@K#:JA&;
M>E2M/X":FQ5WZT>B-I,<3L=%HR'BMPW+2O(5&>7U,>"+3^WZ15BQ9[4#?=PK
M-/L'EA_0-I5@VAFCW,RO[HM/2$ETA$OOT3_-CA&]3/Q"<*]\#EPPQ= _$YH+
M,NFNGEBW\N4[H>S2NY6V 2U!(Z-,0Q5!O@WQ!.'&-ZG\N;&;>*D<*3^\6'IL
M%#+Y]YQN3IQB7KA#<TY[Y-#V:%PDV;-IS>(#UZI+_=;0C@W%4$8! BU/$4X>
MV5C8HOQ$.MJAEME5L#JW-OZ<BAJ@0?&8-"PJ<4H@0:&K;;'N)N4JU*#J7@II
M/7REC8U_NCNND^EA<G3$.3R>T'XGV,ZUOP:C@'QQ"TM%.M1B0V!05CO .FPI
M)G>=\M9^L-:Z%7 ?\U:X7\_F2\'R:[^OURMQ+IG,[&"\X8*XK'S2%C']?/G4
M>M%W%/Q)O03_>^Y#.;._5TI*IJ/;EANR/?DD2,MH;^-?,5/C%UO(6[P8&.#<
MC0(!.VB,Y ><1&&7$CM<R*]S(]>[JV>1.@\*AY>:UW%,^;6/$@8U\/,T3U4"
M1X85I(]\DZ60>!*/"/2UTP<]B8Z'#2"E,PBJ.IO9G<7&.;QZ4K@=A,,"!4NI
M2 L'EDMMN.0SJ;X)/9AE("]1F:+OLK,[=I\S"['$VRU@[W2V?L A&=2G2[@E
M9X3Y^9FET]G%Y>>7^$K_O#LIG8HL_A.NR9*\KE>2&+<MSCZM'Q;7Q; [?%DX
M6,E[0J:@_,']8N9(139FTM<W;LX=GYGYP+7[ ,6 7,V#(&*<;Y UQ&FG(BH)
M5%US@M;;N6E4JJA<:1,7=6@TJ#%CXID0<!?N>5CL8;D)H^D.0=$3=AXG+#WB
M*: 50$)8S+BYO=.L5Q&5OO "!1ZK'F0(: VOPTG=,UGCE2;V8JC-E/^Y1=^Z
M12=89@7^0O6=,7/X!.+D><3.>1 +L-U:$.2I1EQD777C((J4N!XEBP)/FNF,
M^[SOJIT6L8ED4<,+U6 .^"2-CWI R^(G.5-O]$R]\UZP7YR[UKL=I,ON8#=.
M;^.@?R$?T]63H\35(CW4<H+7'E=F<+:PT5FM[%&8K6EY2?T1-<2DS6M\AF2D
M:V\[]^E$WB[G]GQ&*=+D;04>Q#=#>6X;14>+J[SD.A/OK+^^K<-$AQ,2>1'+
M8>C3,<>>F-<WQ(SL0E9^@@)I00LAC']>]"K#LQ0*3Q.//;F3(!?>:EULU[#T
MAEO6*%/80!#7^"HY[S SQ)22.U43G(V'E8 6ULL9'POWOH4'IQHQ[H$]=13C
M8ST7A;^VO9S>XCCVVUCC\(@#FA?&Z> &;X0\.-/EDT2/3#H[OKQ9S+7471%]
M";/7ANJ#:0C<>Z@]:PZ_1YBD@75 @"!PUIPL-G5UZ"'!#'9G634.JZ1Y44&7
M)!B%55NNK'J'Q:8"[""59CY%/$Q^E+GL*#A?^DY:W^P4BE)S6M5V\"7'_G;F
M.?9W-"%C\6M'/*^C\A-A$2@Y498<*%S#PG0I;-D$>\"G*>^\)TJM/U/GOC&0
M+,E=4 ;11PO]C#O@"I5[I1G7&D-H?.[4Z,-CIJ/AS_5I<L4HT4',,7'LZ5I%
M9"V8Q^44RY,L0J;G2B=BF2N)T!-6E/==<5);<T%NY"9PXB,I9CO%#V"7":8=
M#0WQUABX3<4-?<Y'M&DG!B>-MB';'.B@LP\WU,0M)\#*U9>RPX-Z'1_71</+
MK)K;F7SMJ:=."'_V)B_%=L:O]3KI!4!4+8R?4V12:6M,D"*(Y3^:\ACBFI&L
MV, 5:NO!G</U2F9<_9T(A2=7Y%1/L;\GZ;!2X1(6OR+,#E<DT2+OFJ5/I+F<
M3Y<XR"TLMP#IZX4FL K9FYU*D2F(_[#<(ZK@!KG/G.N5=C$V+?5N#M&+?;M:
M2(V=7+@JW #8@7WZ<!9Y L6'2KL)L7K1^\6Z-M6./CB0'E:([4_(F4+SLFD@
M.(&N@+?6HZ9#<%X(ECL9$ /D&N 9HZF7HZ,(I<GIH97("+3F-YO1)1QR<"<J
M(0NAZNVW$:R"+U$O$_VG(BMV#6GAM04*; AK2B.7'KJVS*Z3&RLYY$]WY)AE
M":NU7>A G=[.W?JJBT:=+;$TBC:JGSHG(NT^(4$BV&7<![<)&Q M]SB!(2X+
M[@H4G1*]?,N+ZI^!.7"_WBI$AHLV@7&PV1H5<PD[?+WQ?.U/?.X]P.<.<69O
M-4C6&%5\!-3'H2BKJYG1M]G>>:?V^24)[X![)[A12#\ @QYACB/CGM21E&K=
M\!C!Y!JL"BU*][K&8A7[VH7F(99RCZKJ641LLJ^C1N>_&7)JL?A,@)4U":H+
M%V2'K9:V>5^@Z$=\*4U=^V5T0>8DG@=CI8;B%]TG:".7&A5+_UH/WXP(CZ]W
MQW]6=09<9.9=:R@.N98\W# ?YP6Z"R\RCU.TT:.JN&[R I'KK-'+J9EC4?%$
MXT;31P'Z'4N85"O.%]R6(Q@DD+7U+=>NL08AOO@M[ MW5[#I,IVAQ\M=+E'K
M E!N0((6EDVU81I:^+]I;E[<W+&WVUW-YER8LV9LJ!(O,;]9M(MWDIKG: /7
M<H?/!,&"?JO3)TT^]PAWTA*"35@=5_;*7RV?>&D;E>V&A\R%0X3FZW9*,>(&
M/B(NL<R7H.'@?'5$B!$YD*N78:+%Q[DB(A( L$A$2>N@09SS-)-\=3>BI#H*
M6!A[1OEQ Z>[-.3L.C,[35'$J;G9S#DW GV:=XN'!Q<'=BN-5T*\*+2VH< ,
MMR<A7RC4$&7 <95;Z'9E=<(]=<WH(E3P);B(O%,8L;]Q"@6S2#WR/B!K(_(>
M.\3YY]U]9(!.K*]@ZY*C'-ZM.,1%_F.QEB-;8\?18B; FZB9H*)^_&!,';:Z
M-=5[*%0'?+>:"]787&5QM2 5U]#^*'0E@[DYM04?G,]2$*,E[&[YK07K/'-]
MY+C&2Q;1?I$1"/G:N<NI4-.^%?"#>VC1+,7D:Z82(E=OZ&6(;2*Z4_7LB7W[
ML$;+\W&>\[:A+%BCD^6&G N?@B1:\?WYCU  QBY40* )]PL6=*%C4V8.+PJ>
M$,(_H,1\SK!M(+AN/2^G.[(&)>6HJ$MI]V.(OA-J7=-MD%NI'R;;5JDES]%
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MD=F<+IJU!>N B2=(B9G_-KUW+!U/^'42LGN0-TH!&]ANA.I,>BU"N'GZ%NU
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MDV-5S"F1>*HE,8I88YL_&_=>AM5?05D/*C!G<#]W)R_1O8$0/(1G9^J;T-)
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M/ @I67PTJC#U4D$2*OCKG;85VQ/'PLT>DTW-P+D@8K$A/9N5:I[&LY\O_N;
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M/ D8@]WT3Y0R08@)GBLG\XUGNY#9;[SXQSQD(Y]>K?=2M.X[YJ_)ZZAC)C'
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M>#+V\=Z81_&S++0[[#U4U6*_WW?9 Y32_646H/V>F;&EK/RFG??=PH+,W0-
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MBJSFB+).Q[*W[?!=D@?G-N_SV?07P:O_4$L! A0#%     @ 2HI;4!\CSP/
M    $P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%
M  @ 2HI;4"?HAPZ"    L0   !               ( !Z0   &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " !*BEM0Q%;TJ.\    K @  $0
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M=#(N>&UL4$L! A0#%     @ 2HI;4#]MMNX_ @  N@<  !@
M ( !NQ$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $J*
M6U!8%G]@W@0  /D6   8              "  3 4  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " !*BEM0.(H*!60"  ":!P  &
M        @ %$&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ 2HI;4.K8HUWG!0  BQ\  !@              ( !WAL  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $J*6U"<;-J+R0<  *<L   8
M              "  ?LA  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " !*BEM0]'(JC*\!  #2 P  &               @ 'Z*0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 2HI;4*B$H_FU 0
MT@,  !@              ( !WRL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( $J*6U![Q9DKL@$  - #   9              "  <HM
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 2HI;4)@H
MO@:U 0  T@,  !D              ( !LR\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " !*BEM0ZAS]DK,!  #2 P  &0
M    @ &?,0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M $J*6U#=+4C2M $  -(#   9              "  8DS  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ 2HI;4$ ";_"U 0  T@,  !D
M             ( !=#4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " !*BEM0"!AFQ+4!  #2 P  &0              @ %@-P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $J*6U#F,?5DM $
M -(#   9              "  4PY  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ 2HI;4.P;^ BU 0  T@,  !D              ( !
M-SL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !*BEM0
MK7\9 ;8!  #2 P  &0              @ $C/0  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( $J*6U#Q'(K.M $  -(#   9
M      "  1 _  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ 2HI;4)G42;JU 0  T@,  !D              ( !^T   'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !*BEM0PF6'3<L"  #C"P
M&0              @ 'G0@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( $J*6U#0K[DSW $   $%   9              "  >E%  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 2HI;4'H^TZL*
M @  3P8  !D              ( !_$<  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " !*BEM0'AV/J\4!   W!   &0
M@ $]2@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $J*
M6U!VE6Q,Q $  #<$   9              "  3E,  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ 2HI;4,Z]]$>X 0  T@,  !D
M         ( !-$X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " !*BEM05,2%-^T!  !F!0  &0              @ $C4   >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $J*6U!D/2&;[0$  &8%
M   9              "  4=2  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ 2HI;4*77+RK? 0   04  !D              ( !:U0
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !*BEM0R_*@
MHK8!  #2 P  &0              @ &!5@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( $J*6U#-?Y1%+ 8  (PF   9
M  "  6Y8  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M2HI;4"++5_\T @  . <  !D              ( !T5X  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " !*BEM0","D&W@"   ["0  &0
M            @ $\80  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( $J*6U!)/\C\Z ,  &,2   9              "  >MC  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 2HI;4)9,05.& P
M- \  !D              ( !"F@  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " !*BEM0>7YX(VL#  ":#@  &0              @ ''
M:P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $J*6U"S
MB=EA5P(  !D(   9              "  6EO  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ 2HI;4.0B/CC: @  ]PH  !D
M     ( !]W$  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M" !*BEM0-9_61.$#  "#$P  &0              @ $(=0  >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $J*6U FW\U?J@,  )$0   9
M              "  2!Y  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ 2HI;4,K$62GV 0  :04  !D              ( ! 7T  'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !*BEM0]DAYNXT&
M   P*P  &0              @ $N?P  >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+ 0(4 Q0    ( $J*6U#FK*E"3 (  #<'   9              "
M ?*%  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 2HI;
M4!W__@GI 0  U00  !D              ( !=8@  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " !*BEM01PFE+( "  #7"   &0
M        @ &5B@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( $J*6U"*&;";\0$  "4%   9              "  4R-  !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 2HI;4%X*6;XA @  E08
M !D              ( !=(\  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " !*BEM0HG^^9!<'  !A*0  &0              @ ',D0
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $J*6U 6*'P7
MJP(  ,<)   9              "  1J9  !X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ 2HI;4#43>2&<!   4AD  !D
M ( !_)L  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !*
MBEM0Y^ZX5N8"  "5"P  &0              @ '/H   >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $J*6U#N22;R3 ,  !8.   9
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M970U-BYX;6Q02P$"% ,4    " !*BEM0[9A15D(#   K#0  &0
M    @ '*M   >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M $J*6U!JWYMGF 8   @I   9              "  4.X  !X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ 2HI;4,DY'S!V @  #PD  !D
M             ( !$K\  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " !*BEM0^:+QSV\"  #1!P  &0              @ &_P0  >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $J*6U!-P'\(S (
M -X*   9              "  67$  !X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ 2HI;4/ (DWI1 P  < T  !D              ( !
M:,<  'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !*BEM0
ME!560N0#  !E$0  &0              @ 'PR@  >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( $J*6U"9)<?#10,  ,L-   9
M      "  0O/  !X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ 2HI;4$$)3H-I @  HP<  !D              ( !A](  'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !*BEM0X],!V]P$   %%P
M&0              @ $GU0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( $J*6U"\X.8KK0$  +T#   9              "  3K:  !X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 2HI;4*[!#"5J
M @  D D  !D              ( !'MP  'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " !*BEM0'.Q70:W.  "F)0, %
M@ &_W@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !*BEM0R7J7
MV68"  !&#0  #0              @ &>K0$ >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( $J*6U L4ANO604  #0M   /              "  2^P 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !*BEM0\ACRL$ "  #Q*   &@
M        @ &UM0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !*BEM0 E!J^/X!   J*   $P              @ $MN $ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     30!-  T5  !<N@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6931617280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2017 </div>
<div>USD ($) </div>
<div>numberOfCollaborationAgreements</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,229,000<span></span>
</td>
<td class="nump">$ 86,646,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember', window );">Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="nump">11,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims', window );">Cash holdback for potential indemnification claims</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember', window );">Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember', window );">Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_WorkingCapitalAdjustment', window );">Working capital adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Total share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_CashPayable', window );">Cash payable to Crystal Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Core Technology | Ab Initio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Core Technology | Vernalis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Core Technology | Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate', window );">Projected cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate', window );">Average cash flow discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember', window );">Threshold of Revenues above $15 million with Three Collaboration Agreements | Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent', window );">Revenue royalty payable on all Cydex-related revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments', window );">Cydex-related revenue amount that triggers royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember', window );">Threshold of Revenues above $1.5 million with Four Collaboration Agreements | Crystal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent', window );">Revenue royalty payable on all Cydex-related revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments', window );">Cydex-related revenue amount that triggers royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lgnd_NumberofCollaborationAgreements', window );">Number of collaboration agreements | numberOfCollaborationAgreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumptions Used Estimated Future Cash Flows, Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAssumptionsUsedEstimatedFutureCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Cash Holdback for Potential Indemnification Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationCashHoldbackForPotentialIndemnificationClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueofContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberofCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberofCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RevenueRoyaltytoAcquireeShareholdersPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Royalty to Acquiree Shareholders, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RevenueRoyaltytoAcquireeShareholdersPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold Revenue Amount to Trigger Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ThresholdRevenueAmounttoTriggerRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_WorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_WorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_AbInitioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_VernalisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CrystalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove15millionwithThreeCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_VariableRateComponentAxis=lgnd_ThresholdofRevenuesabove1.5millionwithFourCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830901408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><div><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.102%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.143%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.143%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.146%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,846&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,915&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Plans</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, our 2002 Stock Incentive Plan was amended to increase the number of shares available for issuance by 0.8 million shares. As of December&#160;31, 2019, there were 0.9 million shares available for future option grants or direct issuance under the Amended 2002 Plan.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:48.220%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.344%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Term in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(In&#160; thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,736,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.47</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,858&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,617&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,531)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,454,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.42</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options vested and expected to vest as of December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant-date fair value of all stock options granted during 2019, 2018 and 2017 was $48.65, $58.85 and $53.17 per share, respectively. The total intrinsic value of all options exercised during 2019, 2018 and 2017 was approximately $10.4 million, $51.9 million and $13.3 million, respectively. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash received from options exercised, net of fees paid, in 2019, 2018 and 2017 was $2.6 million, $19.8 million and $4.7 million, respectively. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following is a further breakdown of the options outstanding as of December&#160;31, 2019:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:25.366%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.391%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.313%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.574%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range of exercise prices</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">remaining&#160; life</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">in&#160;years</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercisable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted&#160;average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.96 - $12.81</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.01</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$14.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92 </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.13</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$32.00 - $74.42</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">374,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.43</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$63.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">374,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$63.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$85.79 - $100.38</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301,459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.66</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$93.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239,220&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$92.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$101.15 - $113.76</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.98</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$109.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$107.65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.12</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$117.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$119.30 - $159.01</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.01</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$151.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,541&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$149.80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$159.81 - $171.28</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$166.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$164.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.47</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$195.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,956,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$77.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,454,726&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$61.82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538%;"><tr><td style="width:1.0%;"/><td style="width:51.709%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.986%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.540%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.544%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4%-2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7%-3.0%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%-2.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40%-49%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33%-36%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43%-47%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 to 5.9 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 to 5.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 to 6.8 years</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:27pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there was $23.2 million of total unrecognized compensation cost related to non-vested stock options.  That cost is expected to be recognized over a weighted average period of 2.4 years.</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Activity</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of our restricted stock activity and related information:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.514%;"><tr><td style="width:1.0%;"/><td style="width:70.413%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.893%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.549%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Grant&#160;Date Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$130.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$115.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(102,846)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$121.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(666)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$134.36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$125.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, unrecognized compensation cost related to non-vested stock awards amounted to $11.2&#160;million. That cost is expected to be recognized over a weighted average period of 1.5 years.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, 59,263 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 4,745, 3,386 and 3,061 shares issued under the ESPP in 2019, 2018 and 2017, respectively. </span></div><div style="text-indent:24pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchases </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, in conjunction with our 2023 Notes debt offering, we repurchased 260,000 shares of our common stock at a cost of $191.14 per share. In September 2018, the board of directors authorized us to repurchase up to $200.0 million of our common stock from time to time over a period of up to three years (the &#8220;Repurchase Program&#8221;). On January 23, 2019, the board of directors elected to increase the Repurchase Program, authorizing us to repurchase up to a maximum of $350.0 million of our outstanding common stock under the Repurchase Program.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 11, 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over the next three years. We expect to acquire shares primarily through open-market transactions and have entered into a Rule 10b5-1 trading plan, and may enter into additional Rule 10b5-1 trading plans in the future, to facilitate open-market repurchases. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Our prior $350.0 million stock repurchase program mentioned above was terminated in connection with the approval of the new stock repurchase program. Authorization to repurchase $326.8 million of our common stock remained available as of December&#160;31, 2019.</span></div>During the twelve months ended December&#160;31, 2019, 2018 and 2017, we repurchased 4,122,133 shares for $448.4 million, 782,248 shares for $127.5 million, and 14,000 shares for $2.0 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6912785840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We measure certain financial assets and liabilities at fair value on a recurring basis.  Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="padding-left:36pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">998,324&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">936,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Cydex</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Liability for amounts owed to a former licensor</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,935&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:45.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.669%;"/><td style="width:1.0%;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Active Markets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">for Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Short-term investments</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">599,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in Viking common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Investment in Viking warrants </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">656,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,774&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">599,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Crystal </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent liabilities - Cydex</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent liabilities - Metabasis </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,551&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">(1) Short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in mutual funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on black scholes value estimated by management as of December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) Investment in Viking warrants, which we received as a result of Viking&#8217;s partial repayment of the Viking note receivable and our purchase of Viking common stock and warrants in April 2016, is classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The change of the fair value is recorded in &#8220;Gain (loss) from Viking&#8221; in our consolidated statement of operations. See further discussion in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note (3), Investment in Viking.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#8221;  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3) The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. During the twelve months ended December&#160;31, 2019, we paid $3.0 million contingent liability on development milestones to former Crystal shareholders. At  December&#160;31, 2019, $1.8 million of the development and regulatory milestones were considered to be achieved and will be paid to former Crystal shareholders during the first half of 2020. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(4) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially differ than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. Another Metabasis drug development program, RVT-1502, has been outlicensed to Metavant. RVT-1502 is a novel, orally-bioavailable, small molecule, glucagon receptor antagonist or &#8220;GRA.&#8221; </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the level 3 financial instruments as of December&#160;31, 2019 is as follows (in thousands):</span></div><div style="text-indent:45pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:81.284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.716%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,050)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of level 3 financial instruments as of December&#160;31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Assets Measured on a Non-Recurring Basis</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than a reduction in the value of our Selexis commercial license right disclosed in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (1), Basis of Presentation and Summary of Significant Accounting Policies - Commercial license and other economic rights</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and a GRA intangible asset, there were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the twelve months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2014 and May 2018, we issued the 2019 Notes and 2023 Notes, respectively. We use quoted market rates in an inactive market, which are classified as a Level 2 input, to estimate the current fair value of our 2019 and 2023 Notes. The carrying value of the notes does not reflect the market rate. See &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note (7), Convertible Senior Notes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for additional information related to the fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
